PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Nakkazi, E				Nakkazi, Esther			A dose of reality about fakes	NATURE MEDICINE			English	News Item																			0	0	0	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2010	16	4					358	358		10.1038/nm0410-358b	http://dx.doi.org/10.1038/nm0410-358b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376020	Bronze			2023-01-03	WOS:000276446800013
J	Dunn, D; Lynn, T				Dunn, Dan; Lynn, Thomas			Physician Cost Profiling	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Dunn, Dan; Lynn, Thomas] Ingenix Eden, Prairie, MN USA		Dunn, D (corresponding author), Ingenix Eden, Prairie, MN USA.							Adams JL, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-57	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					491	491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830831				2023-01-03	WOS:000280411300023
J	Kang, J; Salmon, R				Kang, Jeffrey; Salmon, Richard			Physician Cost Profiling	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Kang, Jeffrey; Salmon, Richard] Cigna, Bloomfield, CT USA		Kang, J (corresponding author), Cigna, Bloomfield, CT USA.	dick.salmon@cigna.com							0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					492	492						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830831				2023-01-03	WOS:000280411300025
J	Luft, HS; Eaton, LJ				Luft, Harold S.; Eaton, Laura J.			Physician Cost Profiling.	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Luft, Harold S.; Eaton, Laura J.] Palo Alto Med Fdn Res Inst, Palo Alto, CA USA	Palo Alto Medical Foundation Research Institute	Luft, HS (corresponding author), Palo Alto Med Fdn Res Inst, Palo Alto, CA USA.	lufth@pamfri.org						Adams JL, 2010, NEW ENGL J MED, V362, P1014, DOI 10.1056/NEJMsa0906323	1	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					491	491						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830831				2023-01-03	WOS:000280411300022
J	Mitchell, DL				Mitchell, Dolores L.			Physician Cost Profiling	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									Grp Insurance Commiss, Boston, MA USA		Mitchell, DL (corresponding author), Grp Insurance Commiss, Boston, MA USA.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					491	492						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20830831				2023-01-03	WOS:000280411300024
J	Higginson, IJ				Higginson, Irene J.			Refractory breathlessness: oxygen or room air?	LANCET			English	Editorial Material							OBSTRUCTIVE PULMONARY-DISEASE; SYMPTOM PREVALENCE; DYSPNEA; MANAGEMENT; CANCER; RELIEF		Kings Coll London, Cicely Saunders Inst, London SE5 9PJ, England	University of London; King's College London	Higginson, IJ (corresponding author), Kings Coll London, Cicely Saunders Inst, London SE5 9PJ, England.	irene.higginson@kcl.ac.uk	Higginson, Irene J/C-7309-2012	Higginson, Irene J/0000-0002-3687-1313				Abernethy AP, 2010, LANCET, V376, P784, DOI 10.1016/S0140-6736(10)61115-4; BAUSEWEIN C, 2008, COCHRANE DB SYST REV, V2, P5623; CRANSTON JM, 2010, COCHRANE DB SYST REV, V3, P4769; Galbraith S, 2010, J PAIN SYMPTOM MANAG, V39, P831, DOI 10.1016/j.jpainsymman.2009.09.024; Gallagher Romayne, 2004, J Pain Palliat Care Pharmacother, V18, P3; Gysels M, 2010, J PAIN SYMPTOM MANAG, V39, P555, DOI 10.1016/j.jpainsymman.2009.08.009; Gysels M, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-216; Higginson IJ, 2006, J PALLIATIVE CARE, V22, P158, DOI 10.1177/082585970602200306; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Murtagh FE, 2010, J PAIN SYMPTOM MANAG, V40, P342, DOI 10.1016/j.jpainsymman.2010.01.021; Saleem T, 2007, J PALLIAT CARE, V23, P291, DOI 10.1177/082585970702300408; Simon ST, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007354.pub2; Solano JP, 2006, J PAIN SYMPTOM MANAG, V31, P58, DOI 10.1016/j.jpainsymman.2005.06.007; Uronis HE, 2008, BRIT J CANCER, V98, P294, DOI 10.1038/sj.bjc.6604161; Wilt TJ, 2007, ANN INTERN MED, V147, P639, DOI 10.7326/0003-4819-147-9-200711060-00009	16	5	5	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					746	748		10.1016/S0140-6736(10)61346-3	http://dx.doi.org/10.1016/S0140-6736(10)61346-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816528				2023-01-03	WOS:000281831000005
J	Gao, ZB; Zhang, TZ; Wu, M; Xiong, QJ; Sun, HY; Zhang, YA; Zu, LS; Wang, W; Li, M				Gao, Zhaobing; Zhang, Tangzhi; Wu, Meng; Xiong, Qiaojie; Sun, Haiyan; Zhang, Yinan; Zu, Liansuo; Wang, Wei; Li, Min			Isoform-specific Prolongation of Kv7 (KCNQ) Potassium Channel Opening Mediated by New Molecular Determinants for Drug-Channel Interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KCNQ2/KCNQ3 K+ CHANNELS; I-KS; ANTICONVULSANT RETIGABINE; ION CHANNELS; ACTIVATION; ICA-27243; BINDING; ASSAY; N-(6-CHLORO-PYRIDIN-3-YL)-3,4-DIFLUORO-BENZAMIDE; SENSITIVITY	Kv7 channels, especially Kv7.2 (KCNQ2) and Kv7.3 (KCNQ3), are key determinants for membrane excitability in the brain. Some chemical modulators of KCNQ channels are in development for use as anti-epileptic drugs, such as retigabine (D-23129, N-(2-amino-4-(4-fluorobenzylamino)-phenyl)), which was recently approved for clinical use. In addition, several other compounds were also reported to potentiate activity of the Kv7 channels. It is therefore of interest to investigate compound-channel interactions, so that more insights may be gained to aid future development of therapeutics. We have conducted a screen of 20,000 compounds for KCNQ2 potentiators using rubidium flux combined with atomic absorption spectrometry. Here, we report the characterization of a series of new structures that display isoform specificity and induce a marked reduction of deactivation distinct from that of retigabine. Furthermore, KCNQ2(W236L), a previously reported mutation that abolishes sensitivity to retigabine, remains fully sensitive to these compounds. This result, together with mutagenesis and other studies, suggests that the reported compounds confer a unique mode of action and involve new molecular determinants on the channel protein, consistent with the idea of recognizing a new site on channel protein.	[Zhang, Tangzhi; Zhang, Yinan; Zu, Liansuo; Wang, Wei] Univ New Mexico, Dept Chem & Chem Biol, Albuquerque, NM 87131 USA; [Gao, Zhaobing; Wu, Meng; Xiong, Qiaojie; Sun, Haiyan; Li, Min] Johns Hopkins Univ, Sch Med, High Throughput Biol Ctr, Dept Neurosci, Baltimore, MD 21205 USA; [Gao, Zhaobing; Wu, Meng; Xiong, Qiaojie; Sun, Haiyan; Li, Min] Johns Hopkins Univ, Sch Med, Johns Hopkins Ion Channel Ctr, Baltimore, MD 21205 USA	University of New Mexico; Johns Hopkins University; Johns Hopkins University	Wang, W (corresponding author), Univ New Mexico, Dept Chem & Chem Biol, Albuquerque, NM 87131 USA.	wwang@unm.edu; minli@jhmi.edu	Wu, Meng/F-3958-2010	Wu, Meng/0000-0003-2222-0736	National Institutes of Health [GM078579, MH084691]; American Heart Association; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH084691] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported, in whole or in part, by National Institutes of Health Grants GM078579 and MH084691 (to M. L.). This work was also supported by a postdoctoral fellowship award from the American Heart Association (to Z. G.).	Ashcroft FM, 2006, NATURE, V440, P440, DOI 10.1038/nature04707; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BEZANILLA F, 1994, ANNU REV BIOPH BIOM, V23, P819, DOI 10.1146/annurev.bb.23.060194.004131; Brown DA, 2008, J PHYSIOL-LONDON, V586, P1781, DOI 10.1113/jphysiol.2008.153007; Doyle DA, 2004, TRENDS NEUROSCI, V27, P298, DOI 10.1016/j.tins.2004.04.004; Dunlop J, 2008, NAT REV DRUG DISCOV, V7, P358, DOI 10.1038/nrd2552; Horrigan FT, 2002, J GEN PHYSIOL, V120, P267, DOI 10.1085/jgp.20028605; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lange W, 2009, MOL PHARMACOL, V75, P272, DOI 10.1124/mol.108.052282; Lawson K, 2006, CURR PHARM DESIGN, V12, P459, DOI 10.2174/138161206775474477; Muller K, 2007, SCIENCE, V317, P1881, DOI 10.1126/science.1131943; Padilla K, 2009, NEUROSCI LETT, V465, P138, DOI 10.1016/j.neulet.2009.08.071; RAE JL, 1990, CURR EYE RES, V9, P847, DOI 10.3109/02713689008999557; Redrobe JP, 2009, BEHAV BRAIN RES, V198, P481, DOI 10.1016/j.bbr.2008.12.027; Roeloffs R, 2008, J PHARMACOL EXP THER, V326, P818, DOI 10.1124/jpet.108.137794; Rogawski MA, 2000, TRENDS NEUROSCI, V23, P393, DOI 10.1016/S0166-2236(00)01629-5; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schenzer A, 2005, J NEUROSCI, V25, P5051, DOI 10.1523/JNEUROSCI.0128-05.2005; Schroeder BC, 2000, J BIOL CHEM, V275, P24089, DOI 10.1074/jbc.M003245200; Schwarz JR, 2006, J PHYSIOL-LONDON, V573, P17, DOI 10.1113/jphysiol.2006.106815; Seebohm G, 2003, CIRC RES, V93, P941, DOI 10.1161/01.RES.0000102866.67863.2B; Seebohm G, 2006, BIOPHYS J, V90, P2235, DOI 10.1529/biophysj.105.067165; Shapiro MS, 2000, J NEUROSCI, V20, P1710; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; Singh NA, 2003, BRAIN, V126, P2726, DOI 10.1093/brain/awg286; Sun HY, 2006, J BIOL CHEM, V281, P5877, DOI 10.1074/jbc.M600072200; Sun HY, 2004, P NATL ACAD SCI USA, V101, P16964, DOI 10.1073/pnas.0404178101; Surti Toral S, 2005, Curr Opin Investig Drugs, V6, P704; Tatulian L, 2001, J NEUROSCI, V21, P5535, DOI 10.1523/JNEUROSCI.21-15-05535.2001; Terstappen GC, 1999, ANAL BIOCHEM, V272, P149, DOI 10.1006/abio.1999.4179; TOPLISS JG, 1977, J MED CHEM, V20, P463, DOI 10.1021/jm00214a001; TOPLISS JG, 1972, J MED CHEM, V15, P1006, DOI 10.1021/jm00280a002; Wang HS, 2000, MOL PHARMACOL, V57, P1218; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Weaver CD, 2004, J BIOMOL SCREEN, V9, P671, DOI 10.1177/1087057104268749; Webster SM, 2004, NATURE, V428, P864, DOI 10.1038/nature02468; Wickenden AD, 2008, MOL PHARMACOL, V73, P977, DOI 10.1124/mol.107.043216; Wuttke TV, 2005, MOL PHARMACOL, V67, P1009, DOI 10.1124/mol.104.010793; Xiong QJ, 2008, TRENDS PHARMACOL SCI, V29, P99, DOI 10.1016/j.tips.2007.11.010; Xiong QJ, 2007, NAT CHEM BIOL, V3, P287, DOI 10.1038/nchembio874; Xu J, 2001, DRUG DISCOV TODAY, V6, P1278, DOI 10.1016/S1359-6446(01)02095-5	43	46	48	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 3	2010	285	36					28322	28332		10.1074/jbc.M110.116392	http://dx.doi.org/10.1074/jbc.M110.116392			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	644TL	20584905	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000281404100074
J	Safren, SA; Sprich, S; Mimiaga, MJ; Surman, C; Knouse, L; Groves, M; Otto, MW				Safren, Steven A.; Sprich, Susan; Mimiaga, Matthew J.; Surman, Craig; Knouse, Laura; Groves, Meghan; Otto, Michael W.			Cognitive Behavioral Therapy vs Relaxation With Educational Support for Medication-Treated Adults With ADHD and Persistent Symptoms A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; PLACEBO	Context Attention-deficit/hyperactivity disorder (ADHD) in adulthood is a prevalent, distressing, and impairing condition that is not fully treated by pharmacotherapy alone and lacks evidence-based psychosocial treatments. Objective To test cognitive behavioral therapy for ADHD in adults treated with medication but who still have clinically significant symptoms. Design, Setting, and Patients Randomized controlled trial assessing the efficacy of cognitive behavioral therapy for 86 symptomatic adults with ADHD who were already being treated with medication. The study was conducted at a US hospital between November 2004 and June 2008 (follow-up was conducted through July 2009). Of the 86 patients randomized, 79 completed treatment and 70 completed the follow-up assessments. Interventions Patients were randomized to 12 individual sessions of either cognitive behavioral therapy or relaxation with educational support (which is an attention-matched comparison). Main Outcome Measures The primary measures were ADHD symptoms rated by an assessor (ADHD rating scale and Clinical Global Impression scale) at baseline, post-treatment, and at 6- and 12-month follow-up. The assessor was blinded to treatment condition assignment. The secondary outcome measure was self-report of ADHD symptoms. Results Cognitive behavioral therapy achieved lower posttreatment scores on both the Clinical Global Impression scale (magnitude -0.0531; 95% confidence interval [CI], -1.01 to -0.05; P=.03) and the ADHD rating scale (magnitude -4.631; 95% CI, -8.30 to -0.963; P=.02) compared with relaxation with educational support. Throughout treatment, self-reported symptoms were also significantly more improved for cognitive behavioral therapy (beta=-0.41; 95% Cl, -0.64 to -0.17; P<001), and there were more treatment responders in cognitive behavioral therapy for both the Clinical Global Impression scale (53% vs 23%; odds ratio [OR], 3.80; 95% CI, 1.50 to 9.59; P=.01) and the ADHD rating scale (67% vs 33%; OR, 4.29; 95% Cl, 1.74 to 10.58; P=.002). Responders and partial responders in the cognitive behavioral therapy condition maintained their gains over 6 and 12 months. Conclusion Among adults with persistent ADHD symptoms treated with medication, the use of cognitive behavioral therapy compared with relaxation with educational support resulted in improved ADHD symptoms, which were maintained at 12 months.	[Safren, Steven A.; Sprich, Susan; Mimiaga, Matthew J.; Surman, Craig; Knouse, Laura; Groves, Meghan; Otto, Michael W.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Safren, Steven A.; Sprich, Susan; Mimiaga, Matthew J.; Surman, Craig; Knouse, Laura] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA; [Otto, Michael W.] Boston Univ, Dept Psychol, Boston, MA 02215 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University	Safren, SA (corresponding author), Massachusetts Gen Hosp Behav Med, 1 Bowdoin Sq,7th Floor, Boston, MA 02114 USA.	ssafren@partners.org		Otto, Michael/0000-0002-8915-7578	Abbott; Alza; Cephalon; Eli Lilly; ElMinda the Hilda and Preston Davis Foundation; McNeil; Merck; New River; National Institutes of Health; Organon; Pfizer; Shire; Takeda; Jazz Pharmaceuticals; Organon (Schering-Plough); Sanofi-Aventis; National Institutes of Health [5R01MH69812]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH069812] Funding Source: NIH RePORTER	Abbott(Abbott Laboratories); Alza; Cephalon; Eli Lilly(Eli Lilly); ElMinda the Hilda and Preston Davis Foundation; McNeil; Merck(Merck & Company); New River; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Organon; Pfizer(Pfizer); Shire; Takeda(Takeda Pharmaceutical Company Ltd); Jazz Pharmaceuticals(Jazz Pharmaceuticals); Organon (Schering-Plough)(Merck & CompanySchering Plough Corporation); Sanofi-Aventis(Sanofi-Aventis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Drs Safren, Sprich, and Otto reported receiving royalty payments from Oxford University Press. Dr Surman reported receiving research support from Abbott, Alza, Cephalon, Eli Lilly, ElMinda the Hilda and Preston Davis Foundation, McNeil, Merck, New River, National Institutes of Health, Organon, Pfizer, Shire, and Takeda; being a speaker for Janssen-Ortho, McNeil, Novartis, Shire, and MGH Academy/Reed Medical Education (which receives funding from multiple pharmaceutical companies); and being a consultant or advisor for McNeil, Shire, and Takeda. Dr Knouse reported receiving consulting income from Eli Lilly. Dr Otto reported receiving consulting income from Jazz Pharmaceuticals, Organon (Schering-Plough), Pfizer, and Sanofi-Aventis; research support from Organon (Schering-Plough); and royalty payments for use of the SIGH-A from Lilly.; This study was funded by National Institutes of Health grant 5R01MH69812.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barkley R.A, 2006, ATTENTION DEFICIT HY, V3rd; Biederman J, 2006, ATTENTION DEFICIT HY, P704; DuPaul G. J., 1998, ADHD RATING SCALE 4; Faries D.E., 2001, J ATTEN DISORD, V5, P107, DOI [DOI 10.1177/108705470100500204, 10.1177/108705470100500204]; First M, 2016, STRUCTURED CLIN INTE; Kessler RC, 2006, AM J PSYCHIAT, V163, P716, DOI 10.1176/appi.ajp.163.4.716; Knouse Laura E, 2008, Expert Rev Neurother, V8, P1537, DOI 10.1586/14737175.8.10.1537; National Institute of Mental Health, 1985, PSYCHOPHARMACOL BULL, V21, P839; ORVASCHEL H, 1985, PSYCHOPHARMACOL BULL, V21, P737; Safren S. A., 2005, MASTERING YOUR ADULT; Safren SA, 2005, BEHAV RES THER, V43, P831, DOI 10.1016/j.brat.2004.07.001; Solanto MV, 2010, AM J PSYCHIAT, V167, P958, DOI 10.1176/appi.ajp.2009.09081123; SPENCER T, 1995, ARCH GEN PSYCHIAT, V52, P434; Steele M, 2006, CLIN THER, V28, P1892, DOI 10.1016/j.clinthera.2006.11.006; Wilens TE, 1996, AM J PSYCHIAT, V153, P1147; Zylowska L, 2008, J ATTEN DISORD, V11, P737, DOI 10.1177/1087054707308502	17	213	219	0	51	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2010	304	8					875	880		10.1001/jama.2010.1192	http://dx.doi.org/10.1001/jama.2010.1192			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	644OY	20736471	Green Accepted, Bronze			2023-01-03	WOS:000281389900025
J	Madar-Balakirski, N; Tempel-Brami, C; Kalchenko, V; Brenner, O; Varon, D; Scherz, A; Salomon, Y				Madar-Balakirski, Noa; Tempel-Brami, Catherine; Kalchenko, Vyacheslav; Brenner, Ori; Varon, David; Scherz, Avigdor; Salomon, Yoram			Permanent Occlusion of Feeding Arteries and Draining Veins in Solid Mouse Tumors by Vascular Targeted Photodynamic Therapy (VTP) with Tookad	PLOS ONE			English	Article							NITRIC-OXIDE; SYSTEMIC HYPOXIA; MELANOMA TUMORS; PROSTATE-CANCER; BLOOD-VESSELS; PD-BACTERIOPHEOPHORBIDE; OXYGEN-CONSUMPTION; ANGIOGENESIS; RAT; PHOTOSENSITIZER	Background: Antiangiogenic and anti-vascular therapies present intriguing alternatives to cancer therapy. However, despite promising preclinical results and significant delays in tumor progression, none have demonstrated long-term curative features to date. Here, we show that a single treatment session of Tookad-based vascular targeted photodynamic therapy (VTP) promotes permanent arrest of tumor blood supply by rapid occlusion of the tumor feeding arteries (FA) and draining veins (DV), leading to tumor necrosis and eradication within 24-48 h. Methodology/Principal Findings: A mouse earlobe MADB106 tumor model was subjected to Tookad-VTP and monitored by three complementary, non-invasive online imaging techniques: Fluorescent intravital microscopy, Dynamic Light Scattering Imaging and photosensitized MRI. Tookad-VTP led to prompt tumor FA vasodilatation (a mean volume increase of 70%) with a transient increase (60%) in blood-flow rate. Rapid vasoconstriction, simultaneous blood clotting, vessel permeabilization and a sharp decline in the flow rates then followed, culminating in FA occlusion at 63.2 sec+/-1.5SEM. This blockage was deemed irreversible after 10 minutes of VTP treatment. A decrease in DV blood flow was demonstrated, with a slight lag from FA response, accompanied by frequent changes in flow direction before reaching a complete standstill. In contrast, neighboring, healthy tissue vessels of similar sizes remained intact and functional after Tookad-VTP. Conclusion/Significance: Tookad-VTP selectively targets the tumor feeding and draining vessels. To the best of our knowledge, this is the first mono-therapeutic modality that primarily aims at the larger tumor vessels and leads to high cure rates, both in the preclinical and clinical arenas.	[Madar-Balakirski, Noa; Tempel-Brami, Catherine; Salomon, Yoram] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Kalchenko, Vyacheslav; Brenner, Ori] Weizmann Inst Sci, Dept Vet Resources, IL-76100 Rehovot, Israel; [Scherz, Avigdor] Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel; [Varon, David] Hadassah Hebrew Univ, Med Ctr, Dept Hematol, Jerusalem, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Hebrew University of Jerusalem; Hadassah University Medical Center	Madar-Balakirski, N (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	yoram.salomon@weizmann.ac.il	Kalchenko, Vyacheslav/F-2924-2012	Kalchenko, Vyacheslav/0000-0002-3166-7049	STEBA Biotech, France	STEBA Biotech, France	This study was funded solely by STEBA Biotech, France. YS and AS are the incumbents of the Tillie and Charles Lubin Professorial Chair in Biochemical Endocrinology, and the Robert and Yaddele Sklare Professorial Chair in Biochemistry, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashur I, 2009, J PHYS CHEM A, V113, P8027, DOI 10.1021/jp900580e; BAATZ H, 1995, INT J MICROCIRC, V15, P85, DOI 10.1159/000178955; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Berdugo M, 2008, INVEST OPHTH VIS SCI, V49, P1633, DOI 10.1167/iovs.07-0767; Brandis A, 2005, PHOTOCHEM PHOTOBIOL, V81, P983, DOI 10.1562/2004-12-01-RA-389R1.1; Bryan PT, 1999, J PHYSIOL-LONDON, V514, P163, DOI 10.1111/j.1469-7793.1999.163af.x; CHAPLIN DJ, 1987, CANCER RES, V47, P597; Chen B, 2006, CLIN CANCER RES, V12, P917, DOI 10.1158/1078-0432.CCR-05-1673; Chen B, 2008, INT J CANCER, V123, P695, DOI 10.1002/ijc.23538; Chen B, 2006, CRIT REV EUKAR GENE, V16, P279, DOI 10.1615/CritRevEukarGeneExpr.v16.i4.10; Cooney MM, 2006, NAT CLIN PRACT ONCOL, V3, P682, DOI 10.1038/ncponc0663; Cosby K, 2003, NAT MED, V9, P1498, DOI 10.1038/nm954; Dolmans DEJGJ, 2002, CANCER RES, V62, P2151; Dvorak HF, 2005, J THROMB HAEMOST, V3, P1835, DOI 10.1111/j.1538-7836.2005.01361.x; DVORAK HF, 1988, AM J PATHOL, V133, P95; Eberhard A, 2000, CANCER RES, V60, P1388; Edmunds NJ, 2001, J PHYSIOL-LONDON, V532, P251, DOI 10.1111/j.1469-7793.2001.0251g.x; Eggener SE, 2008, THESCIENTIFICWORLDJO, V8, P963, DOI 10.1100/tsw.2008.127; Fleshker S, 2008, PHOTOCHEM PHOTOBIOL, V84, P1231, DOI 10.1111/j.1751-1097.2008.00340.x; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; GERTNER MRW, 2003, CAPCURE SCI RETREAT; Gross S, 2003, NAT MED, V9, P1327, DOI 10.1038/nm940; Hathcock JJ, 2006, ARTERIOSCL THROM VAS, V26, P1729, DOI 10.1161/01.ATV.0000229658.76797.30; He C, 2008, PHARM RES-DORDR, V25, P1873, DOI 10.1007/s11095-008-9604-5; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jung O, 2007, ARTERIOSCL THROM VAS, V27, P470, DOI 10.1161/01.ATV.0000254823.15843.1f; Kalchenko V, 2007, J MICROSC-OXFORD, V228, P118, DOI 10.1111/j.1365-2818.2007.01832.x; Kawamura Y, 2009, J ATHEROSCLER THROMB, V16, P807; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kim-Shapiro DB, 2006, ARTERIOSCL THROM VAS, V26, P697, DOI 10.1161/01.ATV.0000204350.44226.9a; Koudinova NV, 2003, INT J CANCER, V104, P782, DOI 10.1002/ijc.11002; Lepor Herbert, 2008, Rev Urol, V10, P254; MARSHALL JM, 1988, J PHYSIOL-LONDON, V407, P385, DOI 10.1113/jphysiol.1988.sp017422; Mazor O, 2005, PHOTOCHEM PHOTOBIOL, V81, P342, DOI 10.1562/2004-06-14-RA-199.1; Moncada S., 2006, V176, P213; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moore CM, 2009, NAT CLIN PRACT UROL, V6, P18, DOI 10.1038/ncpuro1274; Nagy JA, 2009, BRIT J CANCER, V100, P865, DOI 10.1038/sj.bjc.6604929; Scherz A., 2003, U.S. Patent, Patent No. [6569846, 6,569,846]; SCHERZ A, 2004, Patent No. 04045492; Takaya T, 2007, ARTERIOSCL THROM VAS, V27, P1632, DOI 10.1161/ATVBAHA.107.142182; Tempel-Brami C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001191; Tozer GM, 2004, SEMIN RADIAT ONCOL, V14, P222, DOI 10.1016/j.semradonc.2004.04.009; Tozer GM, 2005, ADV DRUG DELIVER REV, V57, P135, DOI 10.1016/j.addr.2004.07.015; Trachtenberg J, 2007, J UROLOGY, V178, P1974, DOI 10.1016/j.juro.2007.07.036; TRACHTENBERG J, 2008, BJU INT; Vakrat-Haglili Y, 2005, J AM CHEM SOC, V127, P6487, DOI 10.1021/ja046210j; Zangari M, 2003, SEMIN THROMB HEMOST, V29, P275; Zilberstein J, 1997, PHOTOCHEM PHOTOBIOL, V65, P1012, DOI 10.1111/j.1751-1097.1997.tb07962.x; Zilberstein J, 2001, PHOTOCHEM PHOTOBIOL, V73, P257, DOI 10.1562/0031-8655(2001)073<0257:ATOSMT>2.0.CO;2	50	53	55	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2010	5	4							e10282	10.1371/journal.pone.0010282	http://dx.doi.org/10.1371/journal.pone.0010282			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	586YT	20421983	Green Published, gold, Green Submitted			2023-01-03	WOS:000276952600006
J	Knowles, SM				Knowles, Sherry M.			Fixing the Legal Framework for Pharmaceutical Research	SCIENCE			English	Editorial Material							INNOVATION		GlaxoSmithKline, King Of Prussia, PA 19406 USA	GlaxoSmithKline	Knowles, SM (corresponding author), GlaxoSmithKline, King Of Prussia, PA 19406 USA.	sherry.m.knowles@gsk.com						Bunch JN, 2005, TEX LAW REV, V83, P1747; Cahoy DR, 2003, AM BUS LAW J, V41, P1, DOI 10.1111/j.1744-1714.2003.tb00001.x; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; DiMasi JA, 2002, PHARMACOECONOMICS, V20, P1, DOI 10.2165/00019053-200220003-00001; DIMASI JA, 1991, J HEALTH ECON, V10, P107, DOI 10.1016/0167-6296(91)90001-4; DiMasi JA, 2007, MANAG DECIS ECON, V28, P469, DOI 10.1002/mde.1360; Higgins MJ, 2009, SCIENCE, V326, P370, DOI 10.1126/science.1176116; 1995, Patent No. 6410516	8	8	8	2	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 26	2010	327	5969					1083	1084		10.1126/science.1184188	http://dx.doi.org/10.1126/science.1184188			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	560KJ	20150445				2023-01-03	WOS:000274901100018
J	Corn, BW				Corn, Benjamin W.			Ending End-of-Life Phobia - A Prescription for Enlightened Health Care Reform	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Corn, Benjamin W.] Tel Aviv Med Ctr & Sch Med, Inst Radiotherapy, Tel Aviv, Israel; [Corn, Benjamin W.] Tel Aviv Univ, Sch Med, IL-69978 Tel Aviv, Israel; [Corn, Benjamin W.] Thomas Jefferson Univ, Jefferson Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Jefferson University	Corn, BW (corresponding author), Tel Aviv Med Ctr & Sch Med, Inst Radiotherapy, Tel Aviv, Israel.							BLUMENAUER E, 2009, NY TIMES        1115; Burns JP, 2007, CHEST, V132, P1987, DOI 10.1378/chest.07-1441; Rosenbaum ME, 2005, J PALLIAT MED, V8, P1186, DOI 10.1089/jpm.2005.8.1186; Shanafelt T, 2003, J CLIN ONCOL, V21, P2616, DOI 10.1200/JCO.2003.06.075; Yalom I.D., 2008, STARING SUN OVERCOMI	5	13	13	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	2009	361	27					E63	E63		10.1056/NEJMp0909740	http://dx.doi.org/10.1056/NEJMp0909740			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	538JV	20018960				2023-01-03	WOS:000273181300005
J	Honigman, B				Honigman, Benjamin			The Heart of the Matter	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												benjamin.honigman@ucdenver.edu						Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	2009	302	24					2638	2639		10.1001/jama.2009.1808	http://dx.doi.org/10.1001/jama.2009.1808			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535JU	20040544				2023-01-03	WOS:000272965300001
J	Umetsu, Y; Aizawa, T; Muto, K; Yamamoto, H; Kamiya, M; Kumaki, Y; Mizuguchi, M; Demura, M; Hayakawa, Y; Kawano, K				Umetsu, Yoshitaka; Aizawa, Tomoyasu; Muto, Kaori; Yamamoto, Hiroko; Kamiya, Masakatsu; Kumaki, Yasuhiro; Mizuguchi, Mineyuki; Demura, Makoto; Hayakawa, Yoichi; Kawano, Keiichi			C-terminal Elongation of Growth-blocking Peptide Enhances Its Biological Activity and Micelle Binding Affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMATOCYTE-SPREADING PEPTIDE; RECEPTOR-BINDING; DOPAMINE LEVELS; TMV RNA; INSECT; NMR; CYTOKINE; SYSTEM; RESIDUES; IDENTIFICATION	Growth-blocking peptide (GBP) is a hormone-like peptide that suppresses the growth of the host armyworm. Although the 23-amino acid GBP (1-23 GBP) is expressed in nonparasitized armyworm plasma, the parasitization by wasp produces the 28-amino acid GBP (1-28 GBP) through an elongation of the C-terminal amino acid sequence. In this study, we characterized the GBP variants, which consist of various lengths of the C-terminal region, by comparing their biological activities and three-dimensional structures. The results of an injection study indicate that 1-28 GBP most strongly suppresses larval growth. NMR analysis shows that these peptides have basically the same tertiary structures and that the extension of the C-terminal region is disordered. However, the C-terminal region of 1-28 GBP undergoes a conformational transition from a random coiled state to an alpha-helical state in the presence of dodecylphosphocholine micelles. This suggests that binding of the C-terminal region would affect larval growth activity.	[Kumaki, Yasuhiro; Demura, Makoto; Kawano, Keiichi] Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan; [Aizawa, Tomoyasu; Kamiya, Masakatsu; Kumaki, Yasuhiro; Demura, Makoto; Kawano, Keiichi] Hokkaido Univ, Grad Sch Life Sci, Div Mol Life Sci, Sapporo, Hokkaido 0600810, Japan; [Muto, Kaori; Mizuguchi, Mineyuki] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Toyama 9300194, Japan; [Hayakawa, Yoichi] Saga Univ, Dept Appl Biol Sci, Saga 8408502, Japan	Hokkaido University; Hokkaido University; University of Toyama; Saga University	Kawano, K (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Kita Ku, Kita 10,Nishi 8, Sapporo, Hokkaido 0600810, Japan.	kawano@sci.hokudai.ac.jp	Demura, Makoto/F-5272-2011; Aizawa, Tomoyasu/F-5278-2011; Kamiya, Masakatsu/F-5274-2011	Demura, Makoto/0000-0003-0912-9284; Aizawa, Tomoyasu/0000-0001-9134-7576; 	KAKENHI [19770123]; Program for the Promotion of Basic Research Activities for Innovative Biosciences	KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Program for the Promotion of Basic Research Activities for Innovative Biosciences	This work was supported in part by KAKENHI Grant 19770123 and the Program for the Promotion of Basic Research Activities for Innovative Biosciences.	Aizawa T, 2001, J BIOL CHEM, V276, P31813, DOI 10.1074/jbc.M105251200; Aizawa T, 1999, J BIOL CHEM, V274, P1887, DOI 10.1074/jbc.274.4.1887; BEIER H, 1984, EMBO J, V3, P351, DOI 10.1002/j.1460-2075.1984.tb01810.x; BEIER H, 1984, EMBO J, V3, P1091, DOI 10.1002/j.1460-2075.1984.tb01934.x; Besenicar M, 2006, CHEM PHYS LIPIDS, V141, P169, DOI 10.1016/j.chemphyslip.2006.02.010; BRAUNSCHWEILER L, 1983, J MAGN RESON, V53, P521, DOI 10.1016/0022-2364(83)90226-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Clark KD, 2004, J BIOL CHEM, V279, P33246, DOI 10.1074/jbc.M401157200; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 2001, J BIOL CHEM, V276, P37431, DOI 10.1074/jbc.M105235200; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Farmer BT, 1996, NAT STRUCT BIOL, V3, P995, DOI 10.1038/nsb1296-995; Goddard T., 2001, SPARKY; Gololobov G, 1998, J PHARMACOL EXP THER, V285, P753; HAARER BK, 1993, MOL CELL BIOL, V13, P7864, DOI 10.1128/MCB.13.12.7864; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HAYAKAWA Y, 1995, J INSECT PHYSIOL, V41, P1, DOI 10.1016/0022-1910(94)00077-T; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; HAYAKAWA Y, 1995, FEBS LETT, V376, P185, DOI 10.1016/0014-5793(95)01273-7; HAYAKAWA Y, 1993, INSECT BIOCHEM MOLEC, V23, P225, DOI 10.1016/0965-1748(93)90003-B; Hayakawa Y, 1998, J INSECT PHYSIOL, V44, P859, DOI 10.1016/S0022-1910(98)00017-1; Hayakawa Y, 1998, EUR J BIOCHEM, V253, P810, DOI 10.1046/j.1432-1327.1998.2530810.x; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lerch M, 2005, BIOCHEMISTRY-US, V44, P9255, DOI 10.1021/bi0501232; Lerch M, 2004, J MOL BIOL, V339, P1153, DOI 10.1016/j.jmb.2004.04.032; Linge JP, 2003, BIOINFORMATICS, V19, P315, DOI 10.1093/bioinformatics/19.2.315; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; Matsumoto Y, 2003, J BIOL CHEM, V278, P38579, DOI 10.1074/jbc.M305986200; Mozsolits H, 2001, BBA-BIOMEMBRANES, V1512, P64, DOI 10.1016/S0005-2736(01)00303-0; Noguchi H, 1996, INSECT BIOCHEM MOLEC, V26, P659, DOI 10.1016/S0965-1748(96)00016-1; NOGUCHI H, 1995, INSECT BIOCHEM MOLEC, V25, P197, DOI 10.1016/0965-1748(94)00054-L; Ohnishi A, 1995, INSECT BIOCHEM MOLEC, V25, P1121, DOI 10.1016/0965-1748(95)00054-2; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; SARGENT DF, 1986, P NATL ACAD SCI USA, V83, P5774, DOI 10.1073/pnas.83.16.5774; SCHWYZER R, 1995, J MOL RECOGNIT, V8, P3, DOI 10.1002/jmr.300080103; Sekiya T, 1990, Tanpakushitsu Kakusan Koso, V35, P2977; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; Tada M, 2003, J BIOL CHEM, V278, P10778, DOI 10.1074/jbc.M211251200; WAGNER G, 1982, J MOL BIOL, V160, P343, DOI 10.1016/0022-2836(82)90180-2; Yoshida M, 2004, J BIOL CHEM, V279, P51331, DOI 10.1074/jbc.M409382200	48	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	2009	284	43					29625	29634		10.1074/jbc.M109.011148	http://dx.doi.org/10.1074/jbc.M109.011148			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	507ZW	19710009	Green Published, hybrid			2023-01-03	WOS:000270896800044
J	Pavet, V; Portal, MM; Moulin, JC; Herbrecht, R; Gronemeyer, H				Pavet, V.; Portal, M. M.; Moulin, J. C.; Herbrecht, R.; Gronemeyer, H.			Towards novel paradigms for cancer therapy	ONCOGENE			English	Review						apoptosis; TRAIL/Apo2L/TNFSF10; epigenetic drug; tumor-initiating cell; dependence receptor; non-coding RNA	APOPTOSIS-INDUCING LIGAND; ACUTE PROMYELOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR-RECEPTOR; METASTATIC COLORECTAL-CANCER; SESQUITERPENE LACTONE PARTHENOLIDE; HISTONE DEACETYLASE INHIBITORS; AGONISTIC MONOCLONAL-ANTIBODY; ACUTE MYELOGENOUS LEUKEMIA; TRAIL-INDUCED APOPTOSIS	Cancer is a complex progressive multistep disorder that results from the accumulation of genetic and epigenetic abnormalities, which lead to the transformation of normal cells into malignant derivatives. Despite enormous progress in the understanding of cancer biology including the decryption of multiple regulatory networks governing cell growth and death, and despite the possibility of analyzing (epi)genetic deregulation at the genome-wide scale, cancer-targeted therapy is still the exception. In fact, to date there are still far too few examples of therapies leading to cure; treatment-derived toxicity is a major issue, and cancer remains to be one of the largest causes of death worldwide. The purpose of this review is to discuss the state of the art of cancer therapy with respect to the key issue of any treatment, namely its target selectivity. Therefore, we recapitulate and discuss current concepts and therapies targeting tumor-specific features, including oncofusion proteins, aberrant kinase activities and epigenetic tumor makeup. We analyze strategies designed to induce tumor-selective death such as the use of oncolytic virus, tumoricidal proteins (NS1, Eorf4, apoptin, HAMLET (human alpha-lactalbumin made lethal to tumor cells)) and activation of signaling pathways involved in tumor surveillance. We emphasize the potential of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway, an essential component of the evolutionary developed defense systems that eradicate malignant cells. Finally, we discuss the necessity of targeting tumor-initiating cells (TICs) to avoid relapse and increase the chances of complete remission, and describe emerging concepts that might provide novel avenues for cancer therapy. Oncogene (2011) 30, 1-20; doi: 10.1038/onc.2010.460; published online 11 October 2010	[Pavet, V.; Portal, M. M.; Moulin, J. C.; Gronemeyer, H.] IGBMC, Dept Canc Biol, F-67404 Illkirch Graffenstaden, Alsace, France; [Moulin, J. C.; Herbrecht, R.] Hop Univ Strasbourg, Dept Hematol & Oncol, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Pavet, V (corresponding author), IGBMC, Dept Canc Biol, 1 Rue Laurent Fries,BP10142, F-67404 Illkirch Graffenstaden, Alsace, France.	vpavet@igbmc.fr; hg@igbmc.fr	Gronemeyer, Hinrich/AAH-5575-2019; Herbrecht, Raoul/D-3471-2013; Herbrecht, Raoul/AAT-1763-2021; Gronemeyer, Hinrich/H-7002-2016; Gronemeyer, Hinrich/G-6240-2011; Herbrecht, Raoul/GVU-1333-2022	Gronemeyer, Hinrich/0000-0001-9454-2449; Herbrecht, Raoul/0000-0002-9381-4876; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; PORTAL, Maximiliano/0000-0002-2884-6900	Agence Nationale de la Recherche [ANR-07-PCVI-0031-01]; European Commission [LSHC-CT-2005-518417, HEALTH-F4-2007-200767]; La Ligue Contre le Cancer; Fondation pour la Recherche Medicale	Agence Nationale de la Recherche(French National Research Agency (ANR)); European Commission(European CommissionEuropean Commission Joint Research Centre); La Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	Work in our laboratory is supported by Agence Nationale de la Recherche (ANR-07-PCVI-0031-01), the European Commission (LSHC-CT-2005-518417 'Epitron,' HEALTH-F4-2007-200767 'Apo-Sys,' H Gronemeyer laboratory), La Ligue Contre le Cancer (H Gronemeyer, laboratoire labellisee; MMP post-doctoral fellow) and Fondation pour la Recherche Medicale (JCM master fellow).	Aits S, 2009, INT J CANCER, V124, P1008, DOI 10.1002/ijc.24076; Alemany R, 2000, NAT BIOTECHNOL, V18, P723, DOI 10.1038/77283; Altucci L, 2005, CANCER RES, V65, P8754, DOI 10.1158/0008-5472.CAN-04-3569; Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Backendorf C, 2008, ANNU REV PHARMACOL, V48, P143, DOI 10.1146/annurev.pharmtox.48.121806.154910; Bedikian AY, 2006, J CLIN ONCOL, V24, P4738, DOI 10.1200/JCO.2006.06.0483; Belyanskaya LL, 2008, LUNG CANCER, V60, P355, DOI 10.1016/j.lungcan.2007.11.005; Berdis AJ, 2008, BIOCHEMISTRY-US, V47, P8253, DOI 10.1021/bi801179f; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bianco R, 2007, INT J BIOCHEM CELL B, V39, P1416, DOI 10.1016/j.biocel.2007.05.008; Blundell TL, 2002, NAT REV DRUG DISCOV, V1, P45, DOI 10.1038/nrd706; Cai XZ, 2007, RNA, V13, P313, DOI 10.1261/rna.351707; Castets M, 2009, DEV CELL, V16, P614, DOI 10.1016/j.devcel.2009.02.006; Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94; Clarke N, 2004, EMBO J, V23, P3051, DOI 10.1038/sj.emboj.7600302; Cortes J, 2007, CANCER, V110, P1295, DOI 10.1002/cncr.22901; Costa FF, 2008, GENE, V410, P9, DOI 10.1016/j.gene.2007.12.008; Cretney E, 2002, J IMMUNOL, V168, P1356, DOI 10.4049/jimmunol.168.3.1356; Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Dorer DE, 2009, ADV DRUG DELIVER REV, V61, P554, DOI 10.1016/j.addr.2009.03.013; Druker B, 2001, SEMIN HEMATOL, V38, P9, DOI 10.1016/S0037-1963(01)90112-X; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Duringer C, 2003, J BIOL CHEM, V278, P42131, DOI 10.1074/jbc.M306462200; Eager R, 2008, EXPERT OPIN BIOL TH, V8, P1633, DOI [10.1517/14712598.8.10.1633, 10.1517/14712598.8.10.1633 ]; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Ekmekcioglu S, 2008, CYTOKINE, V43, P34, DOI 10.1016/j.cyto.2008.04.010; Ellerhorst JA, 2002, J CLIN ONCOL, V20, P1069, DOI 10.1200/JCO.2002.20.4.1069; Emdad L, 2009, CANCER BIOL THER, V8, P402, DOI 10.4161/cbt.8.5.7581; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Flygare JA, 2010, EXPERT OPIN THER PAT, V20, P251, DOI 10.1517/13543770903567077; Fraga MF, 2005, CELL CYCLE, V4, P1377, DOI 10.4161/cc.4.10.2113; Fukuhara H, 2005, CLIN CANCER RES, V11, P7886, DOI 10.1158/1078-0432.CCR-05-1090; Fukuhara H, 2010, INT J UROL, V17, P20, DOI 10.1111/j.1442-2042.2009.02383.x; Fulda S, 2009, LEUKEMIA, V23, P467, DOI 10.1038/leu.2008.329; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Georgakis GV, 2005, BRIT J HAEMATOL, V130, P501, DOI 10.1111/j.1365-2141.2005.05656.x; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Gopal YV, 2007, CHEM BIOL, V14, P813, DOI 10.1016/j.chembiol.2007.06.007; Gopalan B, 2005, CANCER RES, V65, P3017, DOI 10.1158/0008-5472.CAN-04-3758; Granchi C, 2010, CURR MED CHEM, V17, P672, DOI 10.2174/092986710790416263; Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227; Greco FA, 2008, LUNG CANCER, V61, P82, DOI 10.1016/j.lungcan.2007.12.011; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gustafsson L, 2004, NEW ENGL J MED, V350, P2663, DOI 10.1056/NEJMoa032454; Gustafsson L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005229; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Guzman ML, 2007, BLOOD, V110, P4427, DOI 10.1182/blood-2007-05-090621; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hallgren O, 2008, ADV EXP MED BIOL, V606, P217, DOI 10.1007/978-0-387-74087-4_8; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Hasegawa H, 2005, BRIT J HAEMATOL, V128, P253, DOI 10.1111/j.1365-2141.2004.05289.x; Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Holoch PA, 2009, EUR J PHARMACOL, V625, P63, DOI 10.1016/j.ejphar.2009.06.066; Holyoake TL, 2001, BLOOD, V97, P720, DOI 10.1182/blood.V97.3.720; Hotte SJ, 2008, CLIN CANCER RES, V14, P3450, DOI 10.1158/1078-0432.CCR-07-1416; Huang EY, 2001, ONCOGENE, V20, P7051, DOI 10.1038/sj.onc.1204897; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Idogawa M, 2009, CLIN CANCER RES, V15, P3725, DOI 10.1158/1078-0432.CCR-08-2396; Insinga A, 2005, CELL CYCLE, V4, P741, DOI 10.4161/cc.4.6.1717; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Jain RK, 2009, NAT REV CLIN ONCOL, V6, P327, DOI 10.1038/nrclinonc.2009.63; Jiang HP, 1995, ONCOGENE, V11, P2477; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kantarjian HM, 2006, INT J HEMATOL, V83, P289, DOI 10.1532/IJH97.06024; Kantarjian HM, 2006, ANN INTERN MED, V145, P913, DOI 10.7326/0003-4819-145-12-200612190-00008; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kasuya H, 2005, CANCER GENE THER, V12, P725, DOI 10.1038/sj.cgt.7700830; Kawasaki BT, 2009, PROSTATE, V69, P827, DOI 10.1002/pros.20931; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; Kirn D, 2000, ONCOGENE, V19, P6660, DOI 10.1038/sj.onc.1204094; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kogan SC, 2009, CANCER CELL, V15, P7, DOI 10.1016/j.ccr.2008.12.012; Kohler C, 1999, EXP CELL RES, V249, P260, DOI 10.1006/excr.1999.4472; Landry MC, 2006, B CANCER, V93, P921; Lane AA, 2009, J CLIN ONCOL, V27, P5459, DOI 10.1200/JCO.2009.22.1291; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; le Coutre P, 2008, BLOOD, V111, P1834, DOI 10.1182/blood-2007-04-083196; Lebedeva IV, 2007, INT J ONCOL, V31, P985; Leong S, 2009, J CLIN ONCOL, V27, P4413, DOI 10.1200/JCO.2008.21.7422; Lessene G, 2008, NAT REV DRUG DISCOV, V7, P989, DOI 10.1038/nrd2658; Leverkus M, 2000, CANCER RES, V60, P553; Li JH, 2003, J IMMUNOL, V171, P1526, DOI 10.4049/jimmunol.171.3.1526; Li S, 2009, ONCOGENE, V28, P390, DOI 10.1038/onc.2008.393; Li SY, 2009, J VIROL, V83, P8340, DOI 10.1128/JVI.00711-09; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu TC, 2008, GENE THER, V15, P877, DOI 10.1038/gt.2008.72; Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Lurje G, 2008, CLIN CANCER RES, V14, P7884, DOI 10.1158/1078-0432.CCR-07-5165; Maddika S, 2006, CANCER BIOL THER, V5, P10, DOI 10.4161/cbt.5.1.2400; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x; MASUI H, 1986, CANCER RES, V46, P5592; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehlen P, 2010, CURR OPIN ONCOL, V22, P46, DOI 10.1097/CCO.0b013e328333dcd1; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mitrus I, 2005, ANTICANCER RES, V25, P1087; Mitsiades CS, 2001, BLOOD, V98, P795, DOI 10.1182/blood.V98.3.795; Mom CH, 2009, CLIN CANCER RES, V15, P5584, DOI 10.1158/1078-0432.CCR-09-0996; Morel J, 2005, J BIOL CHEM, V280, P15709, DOI 10.1074/jbc.M414469200; Mossberg AK, 2007, INT J CANCER, V121, P1352, DOI 10.1002/ijc.22810; Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867; Naka T, 2002, CANCER RES, V62, P5800; Nasr R, 2009, CLIN CANCER RES, V15, P6321, DOI 10.1158/1078-0432.CCR-09-0209; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Newsom-Davis T, 2009, APOPTOSIS, V14, P607, DOI 10.1007/s10495-009-0321-2; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Noteborn MHM, 2009, EUR J PHARMACOL, V625, P165, DOI 10.1016/j.ejphar.2009.06.068; Nuesch JPF, 2008, CANCER BIOL THER, V7, P1376; Nuesch JPF, 2007, P NATL ACAD SCI USA, V104, P12482, DOI 10.1073/pnas.0705533104; Nuesch JPF, 2006, J VIROL, V80, P4729, DOI 10.1128/JVI.80.10.4729-4739.2006; O'Brien S, 2007, J CLIN ONCOL, V25, P1114, DOI 10.1200/JCO.2006.07.1191; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Ozoren N, 2000, CANCER RES, V60, P6259; Pallasch CP, 2009, BLOOD, V114, P3255, DOI 10.1182/blood-2009-06-229898; Pavet V, 2010, CANCER RES, V70, P1101, DOI 10.1158/0008-5472.CAN-09-2889; Peng DJ, 2007, CANCER GENE THER, V14, P66, DOI 10.1038/sj.cgt.7700985; Persson H, 2009, NAT CELL BIOL, V11, P1268, DOI 10.1038/ncb1972; Plummer R, 2007, CLIN CANCER RES, V13, P6187, DOI 10.1158/1078-0432.CCR-07-0950; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Qin JZ, 2001, NAT MED, V7, P385, DOI 10.1038/86401; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rohn JL, 2004, APOPTOSIS, V9, P315, DOI 10.1023/B:APPT.0000025808.48885.9c; Sarkar D, 2008, CANCER BIOL THER, V7, P109, DOI 10.4161/cbt.7.1.5693; Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489; Schessl C, 2005, J CLIN INVEST, V115, P2159, DOI 10.1172/JCI24225; Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489; Shankaranarayanan P, 2009, CANCER CELL, V16, P220, DOI 10.1016/j.ccr.2009.07.029; Shanker M, 2007, CANCER LETT, V254, P217, DOI 10.1016/j.canlet.2007.03.004; Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Shipley JL, 2009, EXP HEMATOL, V37, P649, DOI 10.1016/j.exphem.2009.04.002; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sieger KA, 2004, MOL THER, V9, P355, DOI 10.1016/j.ymthe.2003.11.014; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Spannhoff A, 2009, CHEMMEDCHEM, V4, P1568, DOI 10.1002/cmdc.200900301; Srikantan V, 2000, P NATL ACAD SCI USA, V97, P12216, DOI 10.1073/pnas.97.22.12216; Steele AJ, 2006, LEUKEMIA, V20, P1073, DOI 10.1038/sj.leu.2404230; Sun J, 2009, INT J CANCER, V124, P2973, DOI 10.1002/ijc.24279; Sun Y, 2008, CANCER BIOL THER, V7, P1420; Svanborg C, 2003, ADV CANCER RES, V88, P1; Takeda K, 2004, J EXP MED, V199, P437, DOI 10.1084/jem.20031457; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Tan ML, 2009, PHARM RES-DORDR, V26, P1547, DOI 10.1007/s11095-009-9895-1; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; Thibert C, 2010, CELL CYCLE, V9, P2085, DOI 10.4161/cc.9.11.11809; Thorburn A, 2008, DRUG RESIST UPDATE, V11, P17, DOI 10.1016/j.drup.2008.02.001; Tolcher AW, 2007, J CLIN ONCOL, V25, P1390, DOI 10.1200/JCO.2006.08.8898; Trarbach T, 2010, BRIT J CANCER, V102, P506, DOI 10.1038/sj.bjc.6605507; Trauzold A, 2006, ONCOGENE, V25, P7434, DOI 10.1038/sj.onc.1209719; Tsimberidou AM, 2006, LEUKEMIA LYMPHOMA, V47, P1062, DOI 10.1080/10428190500463932; Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620; van Rhenen A, 2005, CLIN CANCER RES, V11, P6520, DOI 10.1158/1078-0432.CCR-05-0468; Varfolomeev E, 2005, J BIOL CHEM, V280, P40599, DOI 10.1074/jbc.M509560200; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Vilimanovich U, 2008, CELL MOL LIFE SCI, V65, P814, DOI 10.1007/s00018-008-7513-8; Volkmann X, 2007, HEPATOLOGY, V46, P1498, DOI 10.1002/hep.21846; Wakelee HA, 2010, ANN ONCOL, V21, P376, DOI 10.1093/annonc/mdp292; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang M, 2005, IMMUNOLOGY, V114, P166, DOI 10.1111/j.1365-2567.2005.02094.x; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yamashita N, 2005, BRIT J HAEMATOL, V131, P495, DOI 10.1111/j.1365-2141.2005.05793.x; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006; Zerafa N, 2005, J IMMUNOL, V175, P5586, DOI 10.4049/jimmunol.175.9.5586; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792; Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871; Zhang W, 2007, J CLIN ONCOL, V25, P3712, DOI 10.1200/JCO.2006.08.8021; Zhenchuk A, 2009, BIOCHEM PHARMACOL, V78, P1351, DOI 10.1016/j.bcp.2009.06.094; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137	209	88	93	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					1	20		10.1038/onc.2010.460	http://dx.doi.org/10.1038/onc.2010.460			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20935674				2023-01-03	WOS:000285959300001
J	Ahn, AC; Park, M; Shaw, JR; McManus, CA; Kaptchuk, TJ; Langevin, HM				Ahn, Andrew C.; Park, Min; Shaw, Jessica R.; McManus, Claire A.; Kaptchuk, Ted J.; Langevin, Helene M.			Electrical Impedance of Acupuncture Meridians: The Relevance of Subcutaneous Collagenous Bands	PLOS ONE			English	Article							HYPODERMICALLY INJECTED TC-99M; LAPLACE PLANE ANALYSIS; CONNECTIVE-TISSUE; RADIOACTIVE PATHWAYS; TRIGGER POINTS; INVASION; MECHANISMS; ULTRASOUND; NETWORK; HUMANS	Background: The scientific basis for acupuncture meridians is unknown. Past studies have suggested that acupuncture meridians are physiologically characterized by low electrical impedance and anatomically associated with connective tissue planes. We are interested in seeing whether acupuncture meridians are associated with lower electrical impedance and whether ultrasound-derived measures-specifically echogenic collagenous bands - can account for these impedance differences. Methods/Results: In 28 healthy subjects, we assessed electrical impedance of skin and underlying subcutaneous connective tissue using a four needle-electrode approach. The impedances were obtained at 10 kHz and 100 kHz frequencies and at three body sites - upper arm (Large Intestine meridian), thigh (Liver), and lower leg (Bladder). Meridian locations were determined by acupuncturists. Ultrasound images were obtained to characterize the anatomical features at each measured site. We found significantly reduced electrical impedance at the Large Intestine meridian compared to adjacent control for both frequencies. No significant decrease in impedance was found at the Liver or Bladder meridian. Greater subcutaneous echogenic densities were significantly associated with reduced impedances in both within-site (meridian vs. adjacent control) and between-site (arm vs. thigh vs. lower leg) analyses. This relationship remained significant in multivariable analyses which also accounted for gender, needle penetration depth, subcutaneous layer thickness, and other ultrasound-derived measures. Conclusion/Significance: Collagenous bands, represented by increased ultrasound echogenicity, are significantly associated with lower electrical impedance and may account for reduced impedances previously reported at acupuncture meridians. This finding may provide important insights into the nature of acupuncture meridians and the relevance of collagen in bioelectrical measurements.	[Ahn, Andrew C.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA USA; [Ahn, Andrew C.; Kaptchuk, Ted J.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; [Park, Min] P Pro Korea Co Ltd, Seoul, South Korea; [Shaw, Jessica R.] AltThera Hlth, Boston, MA USA; [McManus, Claire A.] Spaulding Rehabil Hosp, Dept Res & Training, Boston, MA USA; [Kaptchuk, Ted J.] Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Boston, MA USA; [Langevin, Helene M.] Univ Vermont, Dept Neurol, Burlington, VT USA	Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Spaulding Rehabilitation Hospital; Harvard University; Harvard Medical School; University of Vermont	Ahn, AC (corresponding author), Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Charlestown, MA USA.	aahn1@partners.org			National Center for Complementary Alternative Medicine (NCCAM) [K23-AT003238, P30AT005895, K24-AT004095]; Clinical Translational Science Award [UL1RR025758]; Bernard Osher Foundation; Beth Israel Deaconess Medical Center from the National Center for Research Resources; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K23AT003238, P30AT005895] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT004095] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025758] Funding Source: NIH RePORTER	National Center for Complementary Alternative Medicine (NCCAM)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Clinical Translational Science Award; Bernard Osher Foundation; Beth Israel Deaconess Medical Center from the National Center for Research Resources; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This research was supported by grant number K23-AT003238, P30AT005895, and K24-AT004095 of the National Center for Complementary Alternative Medicine (NCCAM) and supported in part by a gift from The Bernard Osher Foundation. The project described was supported by Clinical Translational Science Award UL1RR025758 to Harvard University and Beth Israel Deaconess Medical Center from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Complementary Alternative Medicine or the National Center for Research Resources or the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahn AC, 2008, BIOELECTROMAGNETICS, V29, P245, DOI 10.1002/bem.20403; Ahn Andrew C, 2005, BMC Complement Altern Med, V5, P10, DOI 10.1186/1472-6882-5-10; Cairns RA, 2003, CURR MOL MED, V3, P659, DOI 10.2174/1566524033479447; CHENG XM, 1995, ACUPUNCTURE REFERENC; Deadman P., 1998, J CHINESE MED PUBLIC; DEVERNEJOUL P, 1992, J NUCL MED, V33, P409; Grimnes S, 2007, J PHYS D APPL PHYS, V40, P9, DOI 10.1088/0022-3727/40/1/S02; HEINE H, 1988, Journal of Traditional Chinese Medicine, V8, P207; Ho MW, 1998, AM J CHINESE MED, V26, P251, DOI 10.1142/S0192415X98000294; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; KIM HJ, 2009, IEEE T MED IMAGING; KOVACS FM, 1993, EUR J NUCL MED, V20, P585; KOVACS FM, 1992, J NUCL MED, V33, P403; Kovacs FM, 2000, EUR RADIOL, V10, P1019, DOI 10.1007/s003300051056; Kovacs FM, 1996, AM J CHINESE MED, V24, P101; Langevin Helene M., 2002, Anatomical Record, V269, P257, DOI 10.1002/ar.10185; Langevin HM, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-25; Langevin HM, 2002, FASEB J, V16, P872, DOI 10.1096/fj.01-0925fje; Langevin HM, 2004, ULTRASOUND MED BIOL, V30, P1173, DOI 10.1016/j.ultrasmedbio.2004.07.010; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Langevin HM, 2001, J APPL PHYSIOL, V91, P2471, DOI 10.1152/jappl.2001.91.6.2471; MELZACK R, 1977, PAIN, V3, P3, DOI 10.1016/0304-3959(77)90032-X; MELZACK R, 1981, ARCH PHYS MED REHAB, V62, P114; Oschman J. L., 2000, ENERGY MED SCI BASIS; Osterman KS, 1999, ANN NY ACAD SCI, V873, P21, DOI 10.1111/j.1749-6632.1999.tb09445.x; RABISCHONG P, 1975, NOUV PRESSE MED, V4, P2021; Regling G, 2000, ELECTRO MAGNETOBIOL, V19, P149, DOI 10.3109/15368370009167833; REICHMANIS M, 1977, COMP MED EAST WEST, V5, P289, DOI 10.1142/S0147291777000416; REICHMANIS M, 1979, AM J CHINESE MED, V7, P188, DOI 10.1142/S0192415X79000167; REICHMANIS M, 1977, IEEE T BIO-MED ENG, V24, P402, DOI 10.1109/TBME.1977.326154; Schwartzman D, 1999, J INTERV CARD ELECTR, V3, P213, DOI 10.1023/A:1009887306055; SENELAR R, 1979, CHARACTERISTIQUES MO; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Tabel GM, 2006, ECHOCARDIOGR-J CARD, V23, P103, DOI 10.1111/j.1540-8175.2006.00178.x; TIBERIU R, 1981, AM J ACUPUNCTURE, V9, P251; VANDERSCHOT L, 1976, American Journal of Acupuncture, V4, P233	36	46	49	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2010	5	7							e11907	10.1371/journal.pone.0011907	http://dx.doi.org/10.1371/journal.pone.0011907			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	633QZ	20689594	Green Published, gold, Green Submitted			2023-01-03	WOS:000280520300021
J	Rajapaksa, TE; Bennett, KM; Hamer, M; Lytle, C; Rodgers, VGJ; Lo, DD				Rajapaksa, Thejani E.; Bennett, Kaila M.; Hamer, Mary; Lytle, Christian; Rodgers, Victor G. J.; Lo, David D.			Intranasal M Cell Uptake of Nanoparticles Is Independently Influenced by Targeting Ligands and Buffer Ionic Strength	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEYERS PATCH; HUMAN MUCUS; POLOXAMER; DELIVERY; PLGA; DRUG; IMMUNIZATION; MUCOSAL; PROTEIN; SURFACE	In mucosal tissues, epithelial M cells capture and transport microbes across the barrier to underlying immune cells. Previous studies suggested that high affinity ligands targeting M cells may be used to deliver mucosal vaccines; here, we show that particle composition and dispersion buffer ionic strength can independently influence their uptake in vivo. First, addition of a poloxamer 188 to nanoparticle formulations increased uptake of intranasally administered nanoparticles in vivo, but the effect was dependent on the presence of the M cell-targeting ligand. Second, solvent ionic strength is known to effect electrostatic interactions; accordingly, reduced ionic strength increased the electrostatic potential between the epithelium and the particles. Interestingly, below a critical ionic strength, intranasal particle uptake in vivo significantly was increased even when controlled for osmolarity. Similar results were obtained for uptake of bacterial particles. Surprisingly, at low ionic strength, the specific enhancement effect by the targeting peptide was negligible. Modeling of the electrostatic forces predicted that the enhancing effects of the M cell-targeting ligand only are enabled at high ionic strength, as particle electrostatic forces are reduced through Debye screening. Thus, electrostatic forces can have a dramatic effect on the in vivo M cell particle uptake independent of the action of targeting ligands. Examination of these forces will be helpful to optimizing mucosal vaccine and drug delivery.	[Lo, David D.] Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA; [Bennett, Kaila M.; Rodgers, Victor G. J.] Univ Calif Riverside, Dept Bioengn, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Lo, DD (corresponding author), Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.	david.lo@ucr.edu	Lytle, Christian/X-2836-2019; Rodgers, Victor G. J./AAF-3838-2021; Rodgers, Victor G/G-3652-2016	Lytle, Christian/0000-0001-5442-1546; Rodgers, Victor G. J./0000-0002-1857-8025; Rodgers, Victor G/0000-0002-1857-8025	National Institutes of Health [AI63426, AI73689]; Foundation for the National Institutes of Health; Grand Challenges in Global Health; Bill and Melinda Gates Foundation; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI073689, R01AI063426] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation for the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Grand Challenges in Global Health; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grants AI63426 and AI73689 and the Foundation for the National Institutes of Health. This work was also supported by an award from the Grand Challenges in Global Health and the Bill and Melinda Gates Foundation.	Al Haushey L, 2007, INT J PHARMACEUT, V344, P16, DOI 10.1016/j.ijpharm.2007.05.067; Allen MJ, 2004, INT J FOOD MICROBIOL, V92, P265, DOI 10.1016/j.ijfoodmicro.2003.08.017; BESHEER A, 2009, MOL PHARM IN PRESS; Bielinska AU, 2008, AIDS RES HUM RETROV, V24, P271, DOI 10.1089/aid.2007.0148; Bonferoni M C, 2000, AAPS PharmSciTech, V1, pE15, DOI 10.1208/pt010215; Busscher HJ, 2008, LANGMUIR, V24, P10968, DOI 10.1021/la8016968; Busscher HJ, 2006, ENVIRON SCI TECHNOL, V40, P6799, DOI 10.1021/es061282r; Clark MA, 2001, ADV DRUG DELIVER REV, V50, P81, DOI 10.1016/S0169-409X(01)00149-1; Csaba N, 2006, J CONTROL RELEASE, V113, P164, DOI 10.1016/j.jconrel.2006.03.017; Cu Y, 2009, MOL PHARMACEUT, V6, P173, DOI 10.1021/mp8001254; Doble MA, 2002, J GASTROINTEST SURG, V6, P387, DOI 10.1016/S1091-255X(01)00049-X; ELDRIDGE JH, 1989, CURR TOP MICROBIOL, V146, P59; Florence Alexander T, 2005, Drug Discov Today Technol, V2, P75, DOI 10.1016/j.ddtec.2005.05.019; Florence AT, 2004, J DRUG TARGET, V12, P65, DOI 10.1080/10611860410001693706; Foster N, 1998, VACCINE, V16, P536, DOI 10.1016/S0264-410X(97)00222-3; Gregory J, 2005, PARTICLES WATER PROP, DOI DOI 10.1201/9780203508459; Gupta PN, 2007, J DRUG TARGET, V15, P701, DOI 10.1080/10611860701637982; Gurtovenko AA, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2166396; Helander A, 2003, J VIROL, V77, P7964, DOI 10.1128/JVI.77.14.7964-7977.2003; Hillery AM, 1996, INT J PHARM, V132, P123, DOI 10.1016/0378-5173(95)04353-5; Jepson MA, 1996, J ANAT, V189, P507; Kharenko EA, 2009, PHARM CHEM J, V43, P200, DOI 10.1007/s11094-009-0271-6; Kimura J, 2010, J BIOL CHEM, V285, P401, DOI 10.1074/jbc.M109.051417; Kondoh M, 2006, BIOL PHARM BULL, V29, P1783, DOI 10.1248/bpb.29.1783; Lai SK, 2007, P NATL ACAD SCI USA, V104, P1482, DOI 10.1073/pnas.0608611104; Lai SK, 2009, ADV DRUG DELIVER REV, V61, P158, DOI 10.1016/j.addr.2008.11.002; Lavelle EC, 1999, VACCINE, V17, P512, DOI 10.1016/S0264-410X(98)00229-1; Li Q, 1999, WATER RES, V33, P1090, DOI 10.1016/S0043-1354(98)00291-7; Ling J, 2008, J BIOL CHEM, V283, P30585, DOI 10.1074/jbc.M803548200; Lo D, 2004, INT IMMUNOL, V16, P91, DOI 10.1093/intimm/dxh011; Manocha M, 2005, VACCINE, V23, P5599, DOI 10.1016/j.vaccine.2005.06.031; Moghimi SM, 2000, TRENDS BIOTECHNOL, V18, P412, DOI 10.1016/S0167-7799(00)01485-2; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Neutra MR, 1999, SEMIN IMMUNOL, V11, P171, DOI 10.1006/smim.1999.0173; Rajapaksa TE, 2010, J CONTROL RELEASE, V142, P196, DOI 10.1016/j.jconrel.2009.10.033; Rajapaksa Thejani E., 2010, Current Immunology Reviews, V6, P29; RYAN JN, 1994, J COLLOID INTERF SCI, V165, P536; Santander-Ortega MJ, 2007, COLLOID SURFACE A, V296, P132, DOI 10.1016/j.colsurfa.2006.09.036; Shahiwala Aliasgar, 2007, Recent Pat Drug Deliv Formul, V1, P1, DOI 10.2174/187221107779814140; Shakweh Monjed, 2004, Expert Opin Drug Deliv, V1, P141, DOI 10.1517/17425247.1.1.141; Sleator RD, 2002, FEMS MICROBIOL REV, V26, P49, DOI 10.1111/j.1574-6976.2002.tb00598.x; Suzuki H, 2008, GASTROENTEROLOGY, V135, P917, DOI 10.1053/j.gastro.2008.05.037; Tang BC, 2009, P NATL ACAD SCI USA, V106, P19268, DOI 10.1073/pnas.0905998106; Tobio M, 1999, PHARMACEUT RES, V16, P682, DOI 10.1023/A:1018820507379; Tsao HK, 2001, J COLLOID INTERF SCI, V233, P124, DOI 10.1006/jcis.2000.7261; van Merode AEJ, 2008, COLLOID SURFACE B, V64, P302, DOI 10.1016/j.colsurfb.2008.02.004; Wu YP, 2001, P NATL ACAD SCI USA, V98, P9318, DOI 10.1073/pnas.161204098; Zhang Y, 2008, BIOMED MICRODEVICES, V10, P321, DOI 10.1007/s10544-007-9139-2	48	43	48	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 30	2010	285	31					23739	23746		10.1074/jbc.M110.126359	http://dx.doi.org/10.1074/jbc.M110.126359			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	630RT	20511224	Green Published, hybrid			2023-01-03	WOS:000280291400024
J	Collins, F				Collins, Francis			Has the revolution arrived?	NATURE			English	Editorial Material									[Collins, Francis] NIH, Bethesda, MD 20892 USA; [Collins, Francis] NHGRI, Bethesda, MD USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Collins, F (corresponding author), NIH, Bldg 10, Bethesda, MD 20892 USA.	francis.collins@nih.gov							0	184	191	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 1	2010	464	7289					674	675		10.1038/464674a	http://dx.doi.org/10.1038/464674a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	577EO	20360716	Green Published, Bronze			2023-01-03	WOS:000276205000018
J	Giroud, S; Perret, M; Stein, P; Goudable, J; Aujard, F; Gilbert, C; Robin, JP; Le Maho, Y; Zahariev, A; Blanc, S; Momken, I				Giroud, Sylvain; Perret, Martine; Stein, Peter; Goudable, Joelle; Aujard, Fabienne; Gilbert, Caroline; Robin, Jean Patrice; Le Maho, Yvon; Zahariev, Alexandre; Blanc, Stephane; Momken, Iman			The Grey Mouse Lemur Uses Season-Dependent Fat or Protein Sparing Strategies to Face Chronic Food Restriction	PLOS ONE			English	Article							MICROCEBUS-MURINUS; GROUND-SQUIRRELS; METABOLIC-RATE; BODY-MASS; TORPOR; WATER; SUPPRESSION; PHOTOPERIOD; HIBERNATION; INHIBITION	During moderate calorie restriction (CR) the heterotherm Microcebus murinus is able to maintain a stable energy balance whatever the season, even if only wintering animals enter into torpor. To understand its energy saving strategies to respond to food shortages, we assessed protein and energy metabolisms associated with wintering torpor expression or summering torpor avoidance. We investigated body composition, whole body protein turnover, and daily energy expenditure (DEE), during a graded (40 and 80%) 35-day CR in short-days (winter; SD40 and SD80, respectively) and long-days (summer; LD40 and LD80, respectively) acclimated animals. LD40 animals showed no change in fat mass (FM) but a 12% fat free mass (FFM) reduction. Protein balance being positive after CR, the FFM loss was early and rapid. The 25% DEE reduction, in LD40 group was mainly explained by FFM changes. LD80 animals showed a steady body mass loss and were excluded from the CR trial at day 22, reaching a survival-threatened body mass. No data were available for this group. SD40 animals significantly decreased their FM level by 21%, but maintained FFM. Protein sparing was achieved through a 35 and 39% decrease in protein synthesis and catabolism (protein turnover), respectively, overall maintaining nitrogen balance. The 21% reduction in energy requirement was explained by the 30% nitrogen flux drop but also by torpor as DEE FFM-adjusted remained 13% lower compared to ad-libitum. SD80 animals were unable to maintain energy and nitrogen balances, losing both FM and FFM. Thus summering mouse lemurs equilibrate energy balance by a rapid loss of active metabolic mass without using torpor, whereas wintering animals spare protein and energy through increased torpor expression. Both strategies have direct fitness implication: 1) to maintain activities at a lower body size during the mating season and 2) to preserve an optimal wintering muscle mass and function.	[Giroud, Sylvain; Gilbert, Caroline; Robin, Jean Patrice; Le Maho, Yvon; Zahariev, Alexandre; Blanc, Stephane; Momken, Iman] Univ Strasbourg, UMR 7178, Dept Ecol Physiol Ethol, Inst Pluridisciplinaire Hubert Curien,CNRS, Strasbourg, France; [Giroud, Sylvain; Perret, Martine; Aujard, Fabienne] Museum Natl Hist Nat, CNRS, UMR 7179, Brunoy, France; [Stein, Peter] Univ Med & Dent New Jersey, Dept Surg, Stratford, NJ USA; [Goudable, Joelle] Hop Edouard Herriot, Inst Sci Pharmaceut & Biol, Fac Pharm, Lyon, France; [Gilbert, Caroline] Nancy Univ, Univ Henri Poincare, Vandoeuvre Les Nancy, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Museum National d'Histoire Naturelle (MNHN); Rutgers State University New Brunswick; Rutgers State University Medical Center; CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Universite de Lorraine	Giroud, S (corresponding author), Univ Strasbourg, UMR 7178, Dept Ecol Physiol Ethol, Inst Pluridisciplinaire Hubert Curien,CNRS, Strasbourg, France.	stephane.blanc@c-strasbourg.fr		Giroud, Sylvain/0000-0001-6621-7462; Gilbert, Caroline/0000-0002-9957-405X	MNRT; ANR AlimH	MNRT; ANR AlimH(French National Research Agency (ANR))	S. Giroud is supported by an MNRT fellowship. This work was supported by ANR AlimH (http://www.agence-nationale-recherche.fr), the FRM (http://www.frm.org) and the GIS Longevite (http://www.gis-longevite.cnrs.fr). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aujard F, 1998, J COMP PHYSIOL B, V168, P540, DOI 10.1007/s003600050175; BACHMAN GC, 1994, PHYSIOL ZOOL, V67, P756, DOI 10.1086/physzool.67.3.30163769; Blanc S, 2005, J MED PRIMATOL, V34, P130, DOI 10.1111/j.1600-0684.2005.00106.x; Bozinovic F, 2007, J COMP PHYSIOL B, V177, P393, DOI 10.1007/s00360-006-0137-0; CONCON JM, 1973, ANAL BIOCHEM, V53, P35, DOI 10.1016/0003-2697(73)90405-3; Coward WA, 1990, DOUBLY LABELLED WATE, P48; Crawford FIJ, 2007, PHYSIOL GENOMICS, V31, P521, DOI 10.1152/physiolgenomics.00131.2007; Dark J, 2005, ANNU REV NUTR, V25, P469, DOI 10.1146/annurev.nutr.25.050304.092514; Evans MC, 2007, RESUSCITATION, V73, P296, DOI 10.1016/j.resuscitation.2006.08.029; Fietz J, 1998, FOLIA PRIMATOL, V69, P183, DOI 10.1159/000052712; Filaire E, 2002, INT J SPORTS MED, V23, P588, DOI 10.1055/s-2002-35531; French Alan R., 1992, P105; Frerichs KU, 1998, P NATL ACAD SCI USA, V95, P14511, DOI 10.1073/pnas.95.24.14511; Genin F, 2000, PHYSIOL BEHAV, V71, P315, DOI 10.1016/S0031-9384(00)00335-8; Genin F, 2003, AM J PHYSIOL-REG I, V284, pR811, DOI 10.1152/ajpregu.00525.2002; GIROUD S, 2008, AMERICAN J PHYSL REG, V294, P1958; Giroud S, 2009, AM J PHYSIOL-REG I, V297, pR950, DOI 10.1152/ajpregu.00214.2009; Grigg G, 2000, LIFE IN THE COLD, P5; HOWELL RR, 1961, J CLIN INVEST, V40, P2076, DOI 10.1172/JCI104433; KARMANN H, 1994, INT J OBESITY, V18, P351; Kunz TH, 1998, ECOSCIENCE, V5, P8, DOI 10.1080/11956860.1998.11682443; LINDGARD K, 1992, J COMP PHYSIOL B, V162, P607, DOI 10.1007/BF00296641; Lohuis TD, 2007, COMP BIOCHEM PHYS B, V147, P20, DOI 10.1016/j.cbpb.2006.12.020; MCBRIDE BW, 1990, J ANIM SCI, V68, P2997; MICHENER GR, 1992, OECOLOGIA, V89, P397, DOI 10.1007/BF00317418; Migliorini RH, 1997, AM J PHYSIOL-REG I, V272, pR656, DOI 10.1152/ajpregu.1997.272.2.R656; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; MROSOVSKY N, 1985, INT J OBESITY, V9, P93; NELSON RA, 1978, KIDNEY INT, pS177; NELSON RA, 1980, FED PROC, V39, P2955; Orr AL, 2009, COMP BIOCHEM PHYS A, V153, P213, DOI 10.1016/j.cbpa.2009.02.016; Perret M, 1995, CREATURES OF THE DARK, P377; PERRET M, 1987, J CHEM ECOL, V13, P495, DOI 10.1007/BF01880095; Perret M, 1998, COMP BIOCHEM PHYS A, V119, P981, DOI 10.1016/S1095-6433(98)00015-4; PERRET M, 1998, P INT C CHRON PAR FR, P415; Petter-Rousseaux A, 1980, NOCTURNAL MALAGASY P; RACETTE SB, 1994, AM J PHYSIOL-ENDOC M, V267, pE585, DOI 10.1152/ajpendo.1994.267.4.E585; Radespiel U, 2000, AM J PRIMATOL, V51, P21, DOI 10.1002/(SICI)1098-2345(200005)51:1<21::AID-AJP3>3.0.CO;2-C; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; RUF T, 1992, PHYSIOL ZOOL, V65, P994, DOI 10.1086/physzool.65.5.30158554; Schmid J, 1999, J MAMMAL, V80, P749, DOI 10.2307/1383244; Schmid J, 2000, BASIC APPL ECOL, V1, P133, DOI 10.1078/1439-1791-00019; Schmid Jutta, 1996, P47; SCHOELLER DA, 1986, AM J PHYSIOL, V250, pR823, DOI 10.1152/ajpregu.1986.250.5.R823; Speakman JR, 2000, ADV ECOL RES, V30, P177; Speakman JR, 1997, DOUBLY LABELED WATER; van Breukelen F, 2004, AM J PHYSIOL-REG I, V287, pR349, DOI 10.1152/ajpregu.00728.2003; Van Breukelen F, 2001, AM J PHYSIOL-REG I, V281, pR1374, DOI 10.1152/ajpregu.2001.281.5.R1374; Velickovska V, 2005, J COMP PHYSIOL B, V175, P329, DOI 10.1007/s00360-005-0489-x; Wang T, 2006, ANNU REV PHYSIOL, V68, P223, DOI 10.1146/annurev.physiol.68.040104.105739; Wang ZM, 2001, J NUTR, V131, P2967, DOI 10.1093/jn/131.11.2967; WATERLOW JC, 1984, Q J EXP PHYSIOL CMS, V69, P409, DOI 10.1113/expphysiol.1984.sp002829; WATERLOW JC, 1978, AM J PHYSIOL, V235, pE165, DOI 10.1152/ajpendo.1978.235.2.E165; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; Williams JB, 2001, J EXP BIOL, V204, P2301; WONG WW, 1987, AM J CLIN NUTR, V45, P905, DOI 10.1093/ajcn/45.5.905; Wunder Bruce A., 1996, P131; YOUNG JB, 1977, SCIENCE, V196, P1473, DOI 10.1126/science.867049	58	17	18	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2010	5	1							e8823	10.1371/journal.pone.0008823	http://dx.doi.org/10.1371/journal.pone.0008823			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546AJ	20098678	Green Published, gold, Green Submitted			2023-01-03	WOS:000273779100015
J	Maynard, A; Bloor, K				Maynard, Alan; Bloor, Karen			Will financial incentives and penalties improve hospital care?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PERFORMANCE; QUALITY; PAY; MEDICARE		[Maynard, Alan] Univ York, York Hlth Policy Grp, York YO10 5DD, N Yorkshire, England	University of York - UK	Maynard, A (corresponding author), Univ York, York Hlth Policy Grp, York YO10 5DD, N Yorkshire, England.	akm3@york.ac.uk		Bloor, Karen/0000-0003-4852-9854				Baker G., 2005, PROVIDER PAY FOR PER; Campbell SM, 2009, NEW ENGL J MED, V361, P368, DOI 10.1056/NEJMsa0807651; *DEP HLTH, IMP ASS COMM QUAL IN; *DEP HLTH, 2009, FIG YOU CAN TRUST BR; Department of Health, 2008, US COMM QUAL INN CQU; Department of Health, 2008, GUID ROUT COLL PAT R; Doran T, 2008, LANCET, V372, P728, DOI 10.1016/S0140-6736(08)61123-X; Fleetcroft Robert, 2006, J Health Serv Res Policy, V11, P27, DOI 10.1258/135581906775094316; Grossbart SR, 2006, MED CARE RES REV, V63, p29S, DOI 10.1177/1077558705283643; *HOUS COMM HLTH CO, 2008, PUBL EXP HLTH PERS S; Hughes D, 1999, SOCIOL HEALTH ILL, V21, P71, DOI 10.1111/1467-9566.00143; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Mehrotra A, 2009, AM J MED QUAL, V24, P19, DOI 10.1177/1062860608326634; Milstein A, 2009, NEW ENGL J MED, V360, P2388, DOI 10.1056/NEJMp0809125; National Patient Safety Agency. National Patient Safety Agency, 2009, NEV EV FRAM 2009 10; *NHS NW, ADV QUAL; *PREM, P4P POND; *PREM, ADV QUAL N W ENGL; Rosenthal MB, 2007, NEW ENGL J MED, V357, P1573, DOI 10.1056/NEJMp078184; Ryan AM, 2009, HEALTH SERV RES, V44, P821, DOI 10.1111/j.1475-6773.2009.00956.x; [No title captured]	22	19	19	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 21	2010	340								c88	10.1136/bmj.c88	http://dx.doi.org/10.1136/bmj.c88			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	548HP	20093280				2023-01-03	WOS:000273951400011
J	Bhalla, R; Kalkut, G				Bhalla, Rohit; Kalkut, Gary			Could Medicare Readmission Policy Exacerbate Health Care System Inequity?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HEART-FAILURE	The Centers for Medicare & Medicaid Services recently started publicly reporting hospital readmission rates. Health care reform proposals include readmission provisions as vehicles to promote care coordination and achieve savings. Current approaches ascribe variability in hospital readmission primarily to differences in patient medical risk and hospital performance. These approaches do not adequately account for the effect of patient sociodemographic and community factors that influence health care utilization and outcomes. The evidence base on cost-effective and generalizable care management techniques to reduce readmission is still evolving. Although readmission-related policies may prove to be a transformational force in health care reform, their incorrect application in facilities serving vulnerable communities may increase health care system inequity. Policy options can mitigate this potential.	[Bhalla, Rohit] Montefiore Med Ctr, Orange Zone Res Ctr, Bronx, NY 10467 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Bhalla, R (corresponding author), Montefiore Med Ctr, Orange Zone Res Ctr, Room 131,111 E 210th St, Bronx, NY 10467 USA.	rbhalla@montefiore.org		Kalkut, Gary/0000-0002-6160-2262				*AG HEALTHC RES QU, 2007, NAT HLTH CAR DISP RE; Casalino LP, 2007, HEALTH AFFAIR, V26, pW405, DOI 10.1377/hlthaff.26.3.w405; Centers for Medicare &amp Medicaid Services, 2009, ROADM IMPL VAL HEALT; *CTR MED MED SERV, 2009, PAT MIX COEFF MARCH; *CTR MED MED SERV, 2009, HOSP COMP; Egerter S, 2009, REACHING AM HLTH POT; Fisher ES, 2009, HEALTH AFFAIR, V28, pW219, DOI 10.1377/hlthaff.28.2.w219; Gawande A., 2009, NEW YORKER; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Krumholz H., 2008, HOSP 30 DAY HEART FA; KRUMHOLZ HM, 2009, CIRC CARDIOVASC QUAL; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Rathore SS, 2006, AM HEART J, V152, P371, DOI 10.1016/j.ahj.2005.12.002; Ross JS, 2008, ARCH INTERN MED, V168, P1371, DOI 10.1001/archinte.168.13.1371; Sochalski J, 2009, HEALTH AFFAIR, V28, P179, DOI 10.1377/hlthaff.28.1.179; Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care (full printed version), 2003, UN TREATM CONFR RAC; *US HR, 2009, HOUS TRIC HLTH REF D; *US SEN FIN COMM, 2009, DESCR POL OPT TRANSF; 2009, NY TIMES        0416, pA28	19	69	69	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	2010	152	2					114	117		10.7326/0003-4819-152-2-201001190-00185	http://dx.doi.org/10.7326/0003-4819-152-2-201001190-00185			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548IE	19949133				2023-01-03	WOS:000273953000006
J	Hawkes, N				Hawkes, Nigel			Health Policy Handing over the prescription pad	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							NURSES VIEWS; DOCTORS					nigel.hawkes1@btinternet.com						Courtenay M, 2009, J CLIN NURS, V18, P2668, DOI 10.1111/j.1365-2702.2009.02799.x; Marks D, 2009, ALLIED HLTH PROFESSI; Stenner K, 2009, J ADV NURS, V65, P851, DOI 10.1111/j.1365-2648.2008.04944.x; WATTERSON A, EVALUATION EXPANSION	4	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	2009	339								b4835	10.1136/bmj.b4835	http://dx.doi.org/10.1136/bmj.b4835			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	525AX	19945998				2023-01-03	WOS:000272186600003
J	Soussain, C; Ricard, D; Fike, JR; Mazeron, JJ; Psimaras, D; Delattre, JY				Soussain, Carole; Ricard, Damien; Fike, John R.; Mazeron, Jean-Jacques; Psimaras, Dimitri; Delattre, Jean-Yves			CNS complications of radiotherapy and chemotherapy	LANCET			English	Review							CENTRAL-NERVOUS-SYSTEM; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; WHOLE-BRAIN IRRADIATION; MAGNETIC-RESONANCE-SPECTROSCOPY; INDUCED COGNITIVE DYSFUNCTION; HIGH-DOSE METHOTREXATE; LONG-TERM SURVIVORS; LOW-GRADE GLIOMAS; RADIATION-THERAPY; SPINAL-CORD	Treatment-induced CNS toxicity remains a major cause of morbidity in patients with cancer. Advances in the design of safe radiation procedures have been counterbalanced by widespread use of combined radiotherapy and chemotherapy, development of radiosurgery, and the increasing number of long-term survivors. Although classic radionecrosis and chemonecrosis have become less common, subtle changes such as progressive cognitive dysfunction are increasingly reported after radiotherapy (radiation-induced leukoencephalopathy) or chemotherapy (given alone or in combination). We review the most important and controversial complications of radiotherapy, chemotherapy, and combined treatments in the CNS, and discuss new diagnostic tools, practical management, prevention, and pathophysiological data that will affect future management of patients with cancer.	[Psimaras, Dimitri] Grp Hosp Pitie Salpetriere, AP HP, Serv Neurol Mazarin, F-75634 Paris, France; [Soussain, Carole; Ricard, Damien; Delattre, Jean-Yves] INSERM, U975, Paris, France; [Soussain, Carole; Ricard, Damien; Delattre, Jean-Yves] Univ Paris 06, Fac Med Pitie Salpetriere, CNRS, UMR 7225, Paris, France; [Soussain, Carole; Ricard, Damien; Delattre, Jean-Yves] Univ Paris 06, UMR S975, Paris, France; [Soussain, Carole] Serv Hematol, Ctr Lutte Canc Rene Huguenin, St Cloud, France; [Ricard, Damien] Hop Val de Grace, Serv Neurol, F-75005 Paris, France; [Fike, John R.] Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Mazeron, Jean-Jacques] Grp Hosp Pitie Salpetriere, Serv Radiotherapie, AP HP, F-75634 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Rene Huguenin Hospital; Val-de-Grace Hospital; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Ricard, D (corresponding author), Hop Val de Grace, Serv Neurol, 74 Blvd Port Royal, F-75005 Paris, France.	damien.ricard@m4x.org						Abbott NJ, 2005, CELL MOL NEUROBIOL, V25, P5, DOI 10.1007/s10571-004-1374-y; Ahles TA, 2008, BREAST CANCER RES TR, V110, P143, DOI 10.1007/s10549-007-9686-5; ALLEN JC, 1991, NEUROLOGY, V41, P148, DOI 10.1212/WNL.41.1.148; Amirjamshidi A, 2000, CHILD NERV SYST, V16, P390, DOI 10.1007/s003819900125; Armstrong CL, 2002, NEUROLOGY, V59, P40, DOI 10.1212/WNL.59.1.40; Armstrong CL, 2000, NEUROPSY NEUROPSY BE, V13, P101; Atkinson S, 2003, INT J RADIAT ONCOL, V57, P1093, DOI 10.1016/S0360-3016(03)00735-1; Baumgartner JE, 2003, PEDIATR NEUROSURG, V39, P201, DOI 10.1159/000072472; Behin A, 2004, SEMIN NEUROL, V24, P405, DOI 10.1055/s-2004-861535; BERNSTEIN M, 1993, J NEURO-ONCOL, V17, P253, DOI 10.1007/BF01049980; Brandes AA, 2008, NEURO-ONCOLOGY, V10, P361, DOI 10.1215/15228517-2008-008; Brandes AA, 2008, J CLIN ONCOL, V26, P2192, DOI 10.1200/JCO.2007.14.8163; Brandsma D, 2008, LANCET ONCOL, V9, P453, DOI 10.1016/S1470-2045(08)70125-6; Brown WR, 2005, RADIAT RES, V164, P662, DOI 10.1667/RR3453.1; Chan AS, 2004, CANCER, V100, P398, DOI 10.1002/cncr.11885; Chuba PJ, 1997, CANCER-AM CANCER SOC, V80, P2005, DOI 10.1002/(SICI)1097-0142(19971115)80:10<2005::AID-CNCR19>3.0.CO;2-0; Cohen IJ, 2004, J PEDIAT HEMATOL ONC, V26, P156, DOI 10.1097/00043426-200403000-00004; Correa DD, 2007, ANN ONCOL, V18, P1145, DOI 10.1093/annonc/mdl464; Correa DD, 2004, NEUROLOGY, V62, P548, DOI 10.1212/01.WNL.0000109673.75316.D8; Daigle JL, 2001, CANCER RES, V61, P8859; DeAngelis LM, 2002, J CLIN ONCOL, V20, P4643, DOI 10.1200/JCO.2002.11.013; del Rio MS, 2009, ONCOLOGIST, V14, P526, DOI 10.1634/theoncologist.2008-0236; Dietrich Joerg, 2006, J Biol, V5, P22, DOI 10.1186/jbiol50; Ducray F, 2008, NEURO-ONCOLOGY, V10, P1035, DOI 10.1215/15228517-2008-069; Eberly AL, 2008, PHARMACOTHERAPY, V28, P1502, DOI 10.1592/phco.28.12.1502; Erbayraktar S, 2006, MOL MED, V12, P74, DOI 10.2119/2006-00042.Erbayraktar; Esik O, 2003, PATHOL ONCOL RES, V9, P115, DOI 10.1007/BF03033755; Faithfull S, 1998, Clin Oncol (R Coll Radiol), V10, P250, DOI 10.1016/S0936-6555(98)80011-3; Feldmeier JJ, 2002, UNDERSEA HYPERBAR M, V29, P4; Ferguson RJ, 2007, J CLIN ONCOL, V25, P3866, DOI 10.1200/JCO.2007.10.8639; Fike JR, 2007, NEUROSURG CLIN N AM, V18, P115, DOI 10.1016/j.nec.2006.10.010; FIKE JR, 1994, RADIAT RES, V138, P99, DOI 10.2307/3578852; Flickinger JC, 2000, INT J RADIAT ONCOL, V46, P1143, DOI 10.1016/S0360-3016(99)00513-1; Gavrilovic IT, 2006, J CLIN ONCOL, V24, P4570, DOI 10.1200/JCO.2006.06.6910; GLANTZ MJ, 1994, NEUROLOGY, V44, P2020, DOI 10.1212/WNL.44.11.2020; Gonzalez J, 2007, INT J RADIAT ONCOL, V67, P323, DOI 10.1016/j.ijrobp.2006.10.010; Graus F, 1990, NEUROLOGICAL ADVERSE, P87; Grill J, 1999, ANN NEUROL, V45, P393, DOI 10.1002/1531-8249(199903)45:3<393::AID-ANA17>3.0.CO;2-B; Gutierrez AN, 2007, INT J RADIAT ONCOL, V69, P589, DOI 10.1016/j.ijrobp.2007.05.038; Heckl S, 2002, CANCER, V94, P3285, DOI 10.1002/cncr.10596; HORNSEY S, 1990, INT J RADIAT ONCOL, V18, P1437, DOI 10.1016/0360-3016(90)90319-F; Hunault-Berger M, 2008, HAEMATOL-HEMATOL J, V93, P1488, DOI 10.3324/haematol.12948; Hustinx R, 2005, RADIOL CLIN N AM, V43, P35, DOI 10.1016/j.rcl.2004.09.009; IMPERATO JP, 1990, ANN NEUROL, V28, P818, DOI 10.1002/ana.410280614; Inagaki M, 2007, CANCER, V109, P146, DOI 10.1002/cncr.22368; Ishii J, 2007, NEUROSCI LETT, V423, P225, DOI 10.1016/j.neulet.2007.07.029; Jagannathan J, 2004, AM J CLIN ONCOL-CANC, V27, P441, DOI 10.1097/01.coc.0000128721.94095.e4; Jensen FK, 1997, ACTA RADIOL, V38, P37, DOI 10.1080/02841859709171239; Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813; Kastrup O, 2008, J NEUROL, V255, P452, DOI 10.1007/s00415-008-0732-y; Klein M, 2002, LANCET, V360, P1361, DOI 10.1016/S0140-6736(02)11398-5; Klein M, 2003, ANN NEUROL, V54, P514, DOI 10.1002/ana.10712; Kleinschmidt-DeMasters BK, 2006, J NEUROPATH EXP NEUR, V65, P204, DOI 10.1097/01.jnen.0000205146.62081.29; Kremer JM, 2006, ANN RHEUM DIS, V65, P1121, DOI 10.1136/ard.2006.051789; Kumar AJ, 2000, RADIOLOGY, V217, P377, DOI 10.1148/radiology.217.2.r00nv36377; Lamproglou I, 2003, INT J RADIAT ONCOL, V57, P1109, DOI 10.1016/S0360-3016(03)00775-2; Lamproglou I, 1998, INT J RADIAT ONCOL, V42, P179, DOI 10.1016/S0360-3016(98)00202-8; Lee AWM, 1998, INT J RADIAT ONCOL, V40, P35, DOI 10.1016/S0360-3016(97)00580-4; Li YQ, 2004, RADIAT RES, V161, P143, DOI 10.1667/RR3117; Maccormick RE, 2006, MED HYPOTHESES, V67, P212, DOI 10.1016/j.mehy.2006.01.045; Malone S, 2000, INT J RADIAT ONCOL, V47, P185, DOI 10.1016/S0360-3016(99)00554-4; MANDELL LR, 1989, CANCER, V63, P1975, DOI 10.1002/1097-0142(19890515)63:10<1975::AID-CNCR2820631017>3.0.CO;2-I; Martin G, 2007, J CLIN ONCOL, V25, P3559, DOI 10.1200/JCO.2007.12.8710; MASTAGLIA FL, 1976, BRAIN, V99, P101, DOI 10.1093/brain/99.1.101; Meyers CA, 1998, J CLIN ONCOL, V16, P2522, DOI 10.1200/JCO.1998.16.7.2522; Mizumatsu S, 2003, CANCER RES, V63, P4021; Monje ML, 2007, ANN NEUROL, V62, P515, DOI 10.1002/ana.21214; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monje ML, 2002, NAT MED, V8, P955, DOI 10.1038/nm749; Moore-Maxwell CA, 2004, MODERN PATHOL, V17, P241, DOI 10.1038/modpathol.3800049; Moretti R, 2005, J NEUROL SCI, V229, P195, DOI 10.1016/j.jns.2004.11.027; Muldoon LL, 2007, J CLIN ONCOL, V25, P2295, DOI 10.1200/JCO.2006.09.9861; MURROS KE, 1989, ARCH NEUROL-CHICAGO, V46, P449, DOI 10.1001/archneur.1989.00520400109029; NAGAT AT, 1991, CRYST RES TECHNOL, V26, P19, DOI 10.1002/crat.2170260105; Nicholson HS, 2007, CANCER, V110, P1542, DOI 10.1002/cncr.22961; Nordal RA, 2004, J NEUROPATH EXP NEUR, V63, P474, DOI 10.1093/jnen/63.5.474; Nordal RA, 2004, CLIN CANCER RES, V10, P3342, DOI 10.1158/1078-0432.CCR-03-0426; Omuro AMP, 2005, ARCH NEUROL-CHICAGO, V62, P1595, DOI 10.1001/archneur.62.10.1595; Onujiogu N, 2008, GYNECOL ONCOL, V111, P537, DOI 10.1016/j.ygyno.2008.04.032; Panagiotakos G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000588; Papadakis V, 2000, BONE MARROW TRANSPL, V26, P153, DOI 10.1038/sj.bmt.1702475; Patel PN, 2006, ANN PHARMACOTHER, V40, P299, DOI 10.1345/aph.1G114; PELLMAR TC, 1990, RADIAT RES, V122, P209, DOI 10.2307/3577608; Pelosini M, 2008, ANN HEMATOL, V87, P405, DOI 10.1007/s00277-007-0411-6; Pels H, 2003, J CLIN ONCOL, V21, P4489, DOI 10.1200/JCO.2003.04.056; Pena LA, 2000, CANCER RES, V60, P321; Perry A, 2006, ACTA NEUROPATHOL, V111, P197, DOI 10.1007/s00401-005-0023-y; POSNER JB, 1995, NEUROLOGIC COMPLICAT, P311; Prigent-Le Jeune F, 2006, J NEURO-ONCOL, V77, P177, DOI 10.1007/s11060-005-9018-8; Proescholdt MA, 1999, J NEUROPATH EXP NEUR, V58, P613, DOI 10.1097/00005072-199906000-00006; Rajasekhar A, 2007, ONCOLOGIST, V12, P1332, DOI 10.1634/theoncologist.12-11-1332; Remsen LG, 1995, CLIN CANCER RES, V1, P731; Robbins ME, 2006, INT J RADIAT ONCOL, V64, P6, DOI 10.1016/j.ijrobp.2005.08.033; Rock JP, 2004, NEUROSURGERY, V54, P1111, DOI 10.1227/01.NEU.0000119328.56431.A7; Rola R, 2007, FREE RADICAL BIO MED, V42, P1133, DOI 10.1016/j.freeradbiomed.2007.01.020; Rosi S, 2008, CANCER RES, V68, P9763, DOI 10.1158/0008-5472.CAN-08-1861; ROWLAND JH, 1984, J CLIN ONCOL, V2, P1327, DOI 10.1200/JCO.1984.2.12.1327; Ruben JD, 2006, INT J RADIAT ONCOL, V65, P499, DOI 10.1016/j.ijrobp.2005.12.002; Shah GD, 2007, J CLIN ONCOL, V25, P4730, DOI 10.1200/JCO.2007.12.5062; Shaw EG, 2006, J CLIN ONCOL, V24, P1415, DOI 10.1200/JCO.2005.03.3001; SHELINE GE, 1977, CANCER, V39, P873, DOI 10.1002/1097-0142(197702)39:2+<873::AID-CNCR2820390725>3.0.CO;2-Y; Shi L, 2006, RADIAT RES, V166, P892, DOI 10.1667/RR0588.1; Sibtain NA, 2007, CLIN RADIOL, V62, P109, DOI 10.1016/j.crad.2006.09.012; Silverman DHS, 2007, BREAST CANCER RES TR, V103, P303, DOI 10.1007/s10549-006-9380-z; SIMONIAN NA, 1993, NEUROLOGY, V43, P2700, DOI 10.1212/WNL.43.12.2700; Slotman B, 2007, NEW ENGL J MED, V357, P664, DOI 10.1056/NEJMoa071780; SUGIMOTO S, 1995, J NEURO-ONCOL, V24, P229, DOI 10.1007/BF01052839; Tangpong J, 2007, J NEUROCHEM, V100, P191, DOI 10.1111/j.1471-4159.2006.04179.x; Tilly H, 2003, BLOOD, V102, P4284, DOI 10.1182/blood-2003-02-0542; Tofilon PJ, 2000, RADIAT RES, V153, P357, DOI 10.1667/0033-7587(2000)153[0357:TROTCN]2.0.CO;2; Torcuator R, 2009, J NEURO-ONCOL, V94, P63, DOI 10.1007/s11060-009-9801-z; Troy L, 2000, PSYCHO-ONCOL, V9, P29, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<29::AID-PON428>3.0.CO;2-Z; Vardy J, 2008, ANN ONCOL, V19, P623, DOI 10.1093/annonc/mdm500; Verdecchia A, 2008, EUR J PUBLIC HEALTH, V18, P527, DOI 10.1093/eurpub/ckn022; Verstappen CCP, 2003, DRUGS, V63, P1549, DOI 10.2165/00003495-200363150-00003; Vigliani MC, 1999, J NEURO-ONCOL, V41, P137, DOI 10.1023/A:1006183730847; Vigliani MC, 1996, INT J RADIAT ONCOL, V35, P527, DOI 10.1016/0360-3016(96)00097-1; VIGLIANI MC, 1997, HDB CLIN NEUROLOGY, P371; Wassenberg MWM, 2001, J NEURO-ONCOL, V52, P73, DOI 10.1023/A:1010676807228; Wick A, 2007, J CLIN ONCOL, V25, P3357, DOI 10.1200/JCO.2007.10.7722; Winocur G, 2006, PHARMACOL BIOCHEM BE, V85, P66, DOI 10.1016/j.pbb.2006.07.010; Wong CS, 2004, MOL INTERV, V4, P273, DOI 10.1124/mi.4.5.7; Yoneoka Y, 1999, BRIT J RADIOL, V72, P1196, DOI 10.1259/bjr.72.864.10703477; Yoshikawa E, 2005, BREAST CANCER RES TR, V92, P81, DOI 10.1007/s10549-005-1412-6; YOUNG DF, 1974, CANCER, V34, P1069, DOI 10.1002/1097-0142(197410)34:4<1069::AID-CNCR2820340416>3.0.CO;2-4; Zakarija A, 2005, SEMIN THROMB HEMOST, V31, P681, DOI 10.1055/s-2005-925474; Zhao WL, 2006, CLIN CANCER RES, V12, P3823, DOI 10.1158/1078-0432.CCR-05-2418	127	259	280	1	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 7	2009	374	9701					1639	1651		10.1016/S0140-6736(09)61299-X	http://dx.doi.org/10.1016/S0140-6736(09)61299-X			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	518EZ	19897130				2023-01-03	WOS:000271674600038
J	Quill, TE; Lo, B; Brock, DW; Meisel, A				Quill, Timothy E.; Lo, Bernard; Brock, Dan W.; Meisel, Alan			Last-Resort Options for Palliative Sedation	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICIAN-ASSISTED SUICIDE; TERMINAL SEDATION; CARE; LIFE; REFUSAL; END	Despite receiving state-of-the-art palliative care, some patients still experience severe suffering toward the end of life. Palliative sedation is a potential way to respond to such suffering, but access is uneven and unpredictable, in part because of confusion about different kinds of sedation. Proportionate palliative sedation (PPS) uses the minimum amount of sedation necessary to relieve refractory physical symptoms at the very end of life. To relieve suffering may require progressive increases in sedation, sometimes to the point of unconsciousness, but consciousness is maintained if possible. Palliative sedation with the intended end point of unconsciousness (PSU) is a more controversial practice that may be considered for much fewer refractory cases. There is more ethical consensus about PPS than PSU. In this article, the authors explore the clinical, ethical, and legal issues associated with these practices. They recommend that palliative care and hospice programs develop clear policies about PPS and PSU, including mechanisms for training and ensuring competency for clinicians, and approaching situations where individuals or institutions may conscientiously object.	[Quill, Timothy E.] Univ Rochester, Ctr Eth Humanities & Palliat Care, Med Ctr, Rochester, NY 14642 USA; Univ Calif San Francisco, Program Med Eth, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Pittsburgh, Ctr Bioeth & Hlth Law, Pittsburgh, PA USA	University of Rochester; University of California System; University of California San Francisco; Harvard University; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Quill, TE (corresponding author), Univ Rochester, Ctr Eth Humanities & Palliat Care, Med Ctr, Box 687,601 Elmwood Ave, Rochester, NY 14642 USA.				National Institutes of Health [MH062246]; Greenwall Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH062246] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Greenwall Foundation; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Dr. Lo has received financial support from the National Institutes of Health (grant MH062246) and the Greenwall Foundation.	*AM MED ASS, 2008, SED UNC END OF LIF C; American Academy of Hospice and Palliative Medicine, 2006, POS STAT STAT PALL S; Brock DW, 2008, THEOR MED BIOETH, V29, P187, DOI 10.1007/s11017-008-9076-y; Burt RA, 1997, NEW ENGL J MED, V337, P1234, DOI 10.1056/NEJM199710233371712; Callahan D., 2000, TROUBLED DREAM LIFE; Cellarius V, 2008, J MED ETHICS, V34, P69, DOI 10.1136/jme.2006.019224; Chater S, 1998, PALLIATIVE MED, V12, P255, DOI 10.1191/026921698671831786; Claessens P, 2008, J PAIN SYMPTOM MANAG, V36, P310, DOI 10.1016/j.jpainsymman.2007.10.004; Curlin FA, 2008, AM J HOSP PALLIAT ME, V25, P112, DOI 10.1177/1049909107310141; Curlin FA, 2007, NEW ENGL J MED, V356, P593, DOI 10.1056/NEJMsa065316; Hospice and Palliative Nurses Association, 2008, HPNA POS STAT PALL S; Jansen LA, 2002, ANN INTERN MED, V136, P845, DOI 10.7326/0003-4819-136-11-200206040-00014; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; Morrison RS, 2005, J PALLIAT MED, V8, P1127, DOI 10.1089/jpm.2005.8.1127; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; *NAT HOSP PALL CAR, TOT SED HOSP PALL CA; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Ventafridda V, 1990, J Palliat Care, V6, P7	21	89	92	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	2009	151	6					421	W134		10.7326/0003-4819-151-6-200909150-00007	http://dx.doi.org/10.7326/0003-4819-151-6-200909150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	501OB	19755367				2023-01-03	WOS:000270390100007
J	Ingemarsdotter, CK; Baird, SK; Connell, CM; Oberg, D; Hallden, G; McNeish, IA				Ingemarsdotter, C. K.; Baird, S. K.; Connell, C. M.; Oeberg, D.; Hallden, G.; McNeish, I. A.			Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer	ONCOGENE			English	Article						oncolytic adenovirus; paclitaxel; mitosis; apoptosis; microtubule	CELL-CYCLE PROGRESSION; E4ORF4 PROTEIN; GROWTH ARREST; MICROTUBULE; INFECTION; MITOSIS; DEATH; BIOLUMINESCENCE; INSTABILITY; CHECKPOINTS	The microtubule-stabilizing drug paclitaxel has activity in relapsed ovarian cancer. dl922-947, an oncolytic adenovirus with a 24-bp deletion in E1A CR2, replicates selectively within and lyses cells with a dysregulated Rb pathway and has efficacy in ovarian cancer. In the aggressive A2780CP xenograft, combination treatment with weekly dl922-947 and paclitaxel has significantly greater efficacy than either treatment alone and can produce complete tumor eradication in some animals. We investigated the mechanisms of paclitaxel's synergy with dl922-947 in ovarian cancer. The host-cell microtubule network is grossly rearranged and stabilized following adenovirus infection, but paclitaxel does not increase this significantly. Paclitaxel does not synergize by increasing infectivity, viral protein expression or virus release. However, destabilizing the microtubule network with nocodazole reduces viral exit, revealing a novel microtubule-dependent pathway for non-lytic adenoviral exit. dl922-947 can override multiple cell cycle checkpoints but induces cell death by a non-apoptotic mechanism. In combination, dl922-947 and low-dose paclitaxel induces aberrant, multipolar mitoses, mitotic slippage and multinucleation, triggering an apoptotic cell death. Oncogene (2010) 29, 6051-6063; doi:10.1038/onc.2010.335; published online 23 August 2010	[McNeish, I. A.] Queen Mary Univ London, Barts & London Sch Med, John Vane Sci Ctr, Ctr Mol Oncol & Imaging,Inst Canc, London EC1M 6BQ, England	University of London; Queen Mary University London	McNeish, IA (corresponding author), Queen Mary Univ London, Barts & London Sch Med, John Vane Sci Ctr, Ctr Mol Oncol & Imaging,Inst Canc, Charterhouse Sq, London EC1M 6BQ, England.	i.a.mcneish@qmul.ac.uk		McNeish, Iain/0000-0002-9387-7586	Medical Research Council [G0601891] Funding Source: Medline; MRC [G0601891] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Akhmanova A, 2001, CELL, V104, P923, DOI 10.1016/S0092-8674(01)00288-4; Baird SK, 2008, ONCOGENE, V27, P3081, DOI 10.1038/sj.onc.1210977; BELIN MT, 1987, J VIROL, V61, P2559, DOI 10.1128/JVI.61.8.2559-2566.1987; Chang YC, 2008, MOL BIOL CELL, V19, P2147, DOI 10.1091/mbc.E07-12-1269; Chen JG, 2002, CANCER RES, V62, P1935; Cheong SC, 2008, CANCER GENE THER, V15, P40, DOI 10.1038/sj.cgt.7701099; Cherubini G, 2006, CELL CYCLE, V5, P2244, DOI 10.4161/cc.5.19.3263; Connell CM, 2008, CANCER RES, V68, P7923, DOI 10.1158/0008-5472.CAN-08-0817; De Luca A, 2003, CANCER RES, V63, P1430; Decordier I, 2008, MUTAT RES-GEN TOX EN, V651, P30, DOI 10.1016/j.mrgentox.2007.10.016; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Felsani A, 2006, ONCOGENE, V25, P5277, DOI 10.1038/sj.onc.1209621; Flak MB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-175; Gartner M, 2005, CHEMBIOCHEM, V6, P1173, DOI 10.1002/cbic.200500005; Giannakakou P, 1998, INT J CANCER, V75, P57, DOI 10.1002/(SICI)1097-0215(19980105)75:1<57::AID-IJC10>3.3.CO;2-V; Hassan MAIA, 2006, CANCER GENE THER, V13, P1105, DOI 10.1038/sj.cgt.7700984; Hecht JR, 2003, CLIN CANCER RES, V9, P555; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; Kornitzer D, 2001, J CELL BIOL, V154, P331, DOI 10.1083/jcb.200104104; Le LP, 2004, MOL IMAGING, V3, P105, DOI 10.1162/1535350041464874; Le T, 2006, GYNECOL ONCOL, V102, P49, DOI 10.1016/j.ygyno.2005.11.025; Leopold PL, 2007, ADV DRUG DELIVER REV, V59, P810, DOI 10.1016/j.addr.2007.06.007; Leyton J, 2006, CANCER RES, V66, P9178, DOI 10.1158/0008-5472.CAN-06-1539; Li S, 2009, ONCOGENE, V28, P390, DOI 10.1038/onc.2008.393; Lockley M, 2006, CANCER RES, V66, P989, DOI 10.1158/0008-5472.CAN-05-2691; Markman M, 2002, J CLIN ONCOL, V20, P2365, DOI 10.1200/JCO.2002.09.130; McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101; Meulenbroek RA, 2004, MOL THER, V9, P617, DOI 10.1016/j.ymthe.2004.01.012; Mimori-Kiyosue Y, 2005, J CELL BIOL, V168, P141, DOI 10.1083/jcb.200405094; MURRAY JD, 1982, J CELL PHYSIOL, V111, P89, DOI 10.1002/jcp.1041110114; Paoletti A, 1997, J CELL SCI, V110, P2403; Pines J, 2006, TRENDS CELL BIOL, V16, P55, DOI 10.1016/j.tcb.2005.11.006; Reed JC, 2006, NAT CLIN PRACT ONCOL, V3, P388, DOI 10.1038/ncponc0538; Seidman MA, 2001, MOL THER, V4, P13, DOI 10.1006/mthe.2001.0414; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; STAUFENBIEL M, 1986, J VIROL, V60, P1186, DOI 10.1128/JVI.60.3.1186-1191.1986; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Warren JC, 2006, MOL BIOL CELL, V17, P3557, DOI 10.1091/mbc.E05-09-0850; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; Ying BL, 2003, VIROLOGY, V313, P224, DOI 10.1016/S0042-6822(03)00287-3	45	43	46	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6051	6063		10.1038/onc.2010.335	http://dx.doi.org/10.1038/onc.2010.335			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20729921	Green Published, hybrid			2023-01-03	WOS:000284108700007
J	Boyd, K; Murray, SA				Boyd, Kirsty; Murray, Scott A.			Spotlight: Palliative Care Beyond Cancer Recognising and managing key transitions in end of life care	BRITISH MEDICAL JOURNAL			English	Article							HEART-FAILURE; PREDICTION; DISEASE; INDEX		[Boyd, Kirsty; Murray, Scott A.] Univ Edinburgh, Ctr Pop Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Scotland	University of Edinburgh	Boyd, K (corresponding author), Univ Edinburgh, Ctr Pop Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Scotland.	Kirsty.Boyd@luht.scot.nhs.uk		Boyd, Kirsty/0000-0002-5526-1078				Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Department of Health, 2008, END LIF CAR STRAT AD; Fortin M, 2007, BMJ-BRIT MED J, V334, P1016, DOI 10.1136/bmj.39201.463819.2C; Glare PA, 2008, J PALLIAT MED, V11, P84, DOI 10.1089/jpm.2008.9992; Larson AM, 2006, JAMA-J AM MED ASSOC, V295, P2168, DOI 10.1001/jama.295.18.2168; Lau F, 2009, J PAIN SYMPTOM MANAG, V38, P134, DOI 10.1016/j.jpainsymman.2008.05.017; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; Luhrs CA, 2005, J PAIN SYMPTOM MANAG, V29, P544, DOI 10.1016/j.jpainsymman.2005.02.010; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Munday D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2391; Murray SA, 2008, FAM PRACT, V25, P78, DOI 10.1093/fampra/cmn011; National Gold Standards Framework Centre, 2008, PROGN IND GUID PAP; NORTON SA, PROACTIVE PALLIATIVE; *ROYAL COLL PHYS, 2008, ADV CAR PLANN CONC E; *ROYAL COLL PHYS L, 2007, PALL CAR SERV M NEED; *SCOTT GOV HLTH DE, 2008, LIV DYING WELL NAT A; Selman L, 2007, HEART, V93, P963, DOI 10.1136/hrt.2006.106518; Shipman C, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1720; Stone CA, 2008, J PAIN SYMPTOM MANAG, V35, P617, DOI 10.1016/j.jpainsymman.2007.07.006	21	126	127	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c4863	10.1136/bmj.c4863	http://dx.doi.org/10.1136/bmj.c4863			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847023				2023-01-03	WOS:000282095800011
J	Gandhi, TK; Lee, TH				Gandhi, Tejal K.; Lee, Thomas H.			Patient Safety beyond the Hospital	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Gandhi, Tejal K.; Lee, Thomas H.] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Gandhi, Tejal K.; Lee, Thomas H.] Partners Healthcare Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Gandhi, TK (corresponding author), Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA.							Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; McKinsey and Company Global Institute, 2008, ACC COST US HEALTHC; National Center for Health Statistics, FASTSTATS A Z; Roy CL, 2005, ANN INTERN MED, V143, P121, DOI 10.7326/0003-4819-143-2-200507190-00011; Wachter RM, 2006, ANN INTERN MED, V145, P547, DOI 10.7326/0003-4819-145-7-200610030-00014	5	72	72	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2010	363	11					1001	1003		10.1056/NEJMp1003294	http://dx.doi.org/10.1056/NEJMp1003294			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	647HS	20825311				2023-01-03	WOS:000281609700003
J	Akech, S; Ledermann, H; Maitland, K				Akech, Samuel; Ledermann, Hannah; Maitland, Kathryn			Choice of fluids for resuscitation in children with severe infection and shock: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CRITICALLY-ILL PATIENTS; HUMAN ALBUMIN; VOLUME EXPANSION; CIRCULATORY SHOCK; HYPOVOLEMIC SHOCK; RANDOMIZED-TRIAL; SEVERE MALARIA; SEVERE SEPSIS; SEPTIC SHOCK; SALINE	Objective To systemically review the evidence from clinical trials comparing the use of crystalloids and colloids for fluid resuscitation in children with severe infection. Data sources Medline (1950-2008), PubMed, the Cochrane Library, Embase (1980-2008), and reference lists. Eligibility criteria Published studies comparing fluid resuscitation with crystalloid or colloidal solutions in severe infectious illness in children aged >1 month to <= 12 years. Controlled trials and randomised controlled trials were separately selected by two unblinded investigators who also independently extracted data. Main outcome measures Efficacy in the treatment of shock, mortality, and reported adverse events. Results Nine trials fulfilled criteria, eight of which compared crystalloids with colloids. All trials were conducted in settings with poor resources and predominantly included patients with malaria or dengue haemorrhagic shock. None of the trials had mortality as a primary outcome. Three out of six studies that reported at least one death showed better survival in children resuscitated with colloids compared with crystalloids (Peto fixed odds ratio ranging from 0.18 (95% confidence interval 0.02 to 1.42) to 0.48 (0.06 to 3.99)). Studies contributing data on mortality had some methodological limitations so caution is recommended when interpreting this finding. Studies were heterogeneous so combined estimates were not calculated. The review was limited by inclusion of only published studies. Conclusions The current evidence on choice of fluids for resuscitation in children with infections is weak. While existing trials have provided important evidence in malaria and dengue, resuscitation in children with paediatric sepsis, for which colloids could theoretically be of benefit, has not been studied. The evidence from existing studies is not robust enough to make any definitive recommendations over the choice of resuscitation fluid and a definitive trial is required to address this.	[Akech, Samuel; Ledermann, Hannah; Maitland, Kathryn] Kenya Med Res Inst Wellcome Trust Programme, Ctr Geog Med Res Coast, Kilifi, Kenya; [Maitland, Kathryn] Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Paediat, London W2 1PG, England; [Maitland, Kathryn] Univ London Imperial Coll Sci Technol & Med, Fac Med, Wellcome Trust Ctr Clin Trop Med, London W2 1PG, England	Kenya Medical Research Institute; Imperial College London; Imperial College London; University of London; London School of Hygiene & Tropical Medicine	Maitland, K (corresponding author), Kenya Med Res Inst Wellcome Trust Programme, Ctr Geog Med Res Coast, POB 230, Kilifi, Kenya.	kmaitland@kilifi.kemri-wellcome.org		Maitland, Kathryn/0000-0002-0007-0645	Wellcome Trust [084538]; Medical Research Council; Medical Research Council [G0601027, G0801439] Funding Source: researchfish; MRC [G0601027, G0801439] Funding Source: UKRI	Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was funded indirectly through programme support by the Wellcome Trust and Medical Research Council. SA is supported by a grant from the Wellcome Trust (No 084538). The Wellcome Trust had no role in the review and in the preparation of this manuscript.	Akech S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010021; Alderson P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000196.pub2; ALDERSON P, 2000, COCHRANE DB SYST REV, V2; ALDERSON P, 2002, COCHRANE DB SYST REV, V1; Alpar EK, 2004, INJURY, V35, P500, DOI 10.1016/S0020-1383(03)00196-7; [Anonymous], 2008, REV MAN REVMAN COMP; BEARDS SC, 1994, CRIT CARE MED, V22, P600, DOI 10.1097/00003246-199404000-00015; Brierley J, 2008, PEDIATRICS, V122, P752, DOI 10.1542/peds.2007-1979; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; BUNN F, 2000, COCHRANE DB SYST REV, V2; BUNN F, 2008, COCHRANE DB SYST REV, V1; CARCILLO JA, 1991, JAMA-J AM MED ASSOC, V266, P1242, DOI 10.1001/jama.266.9.1242; Carcillo JA, 2002, CRIT CARE MED, V30, P1365, DOI 10.1097/00003246-200206000-00040; Carcillo JA, 2006, INTENS CARE MED, V32, P958, DOI 10.1007/s00134-006-0189-3; *CFRAD, 2001, UND SYST REV RES EFF; Cifra H, 2003, CRIT CARE SHOCK, V6, P95; Cole RP, 1999, BURNS, V25, P565; de Jonge E, 2001, CRIT CARE MED, V29, P1261, DOI 10.1097/00003246-200106000-00038; Deeks J J, 2003, Health Technol Assess, V7, piii; Dung NM, 1999, CLIN INFECT DIS, V29, P787, DOI 10.1086/520435; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; HAIBACH L, 1976, ANESTH ANALG REANIM, V33, P673; Han YY, 2003, PEDIATRICS, V112, P793, DOI 10.1542/peds.112.4.793; Haynes GR, 2003, EUR J ANAESTH, V20, P771, DOI 10.1097/00003643-200310000-00003; Haynes RB, 2005, BMJ-BRIT MED J, V330, P1179, DOI 10.1136/bmj.38446.498542.8F; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Hung NT, 2006, AM J TROP MED HYG, V74, P684, DOI 10.4269/ajtmh.2006.74.684; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Kunz R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000012.pub2; Liberati A, 2006, INTERN EMERG MED, V1, P243, DOI 10.1007/BF02934748; Maitland K, 2005, CLIN INFECT DIS, V40, P538, DOI 10.1086/427505; Maitland K, 2005, BRIT J HAEMATOL, V128, P393, DOI 10.1111/j.1365-2141.2004.05312.x; Maitland Kathryn, 2003, Pediatr Crit Care Med, V4, P426, DOI 10.1097/01.PCC.0000090293.32810.4E; McKiernan CA, 2005, PEDIATR REV, V26, P451, DOI 10.1542/pir.26-12-451; Mecham Nancy, 2006, J Trauma Nurs, V13, P17; Nhan NT, 2001, CLIN INFECT DIS, V32, P204, DOI 10.1086/318479; Ochocka M, 1984, Pediatr Pol, V59, P873; Perel P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000567.pub3; POCKAJ BA, 1994, J IMMUNOTHER, V15, P22, DOI 10.1097/00002371-199401000-00003; RACKOW EC, 1983, CRIT CARE MED, V11, P839, DOI 10.1097/00003246-198311000-00001; RAHMAN O, 1988, J PEDIATR-US, V113, P654, DOI 10.1016/S0022-3476(88)80374-3; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; ROBERTS I, 2004, COCHRANE DB SYST REV, V4; Roberts JS, 1998, DRUGS, V55, P621, DOI 10.2165/00003495-199855050-00002; Schortgen F, 2001, LANCET, V357, P911, DOI 10.1016/S0140-6736(00)04211-2; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sparrow A, 2002, EMERG MED J, V19, P114, DOI 10.1136/emj.19.2.114; Tanaka R, 1975, Masui, V24, P873; Upadhyay M, 2005, INDIAN PEDIATR, V42, P223; Veneman TF, 2004, WIEN KLIN WOCHENSCHR, V116, P305, DOI 10.1007/BF03040900; Vincent JL, 2006, BMJ-BRIT MED J, V333, P1029, DOI 10.1136/bmj.39029.490081.80; Vincent JL, 2004, CRIT CARE MED, V32, P2029, DOI 10.1097/01.CCM.0000142574.00425.E9; WEIS KH, 1983, ANAESTHESIST, V32, P488; Wiedermann CJ, 2008, BMC EMERG MED, V8, DOI 10.1186/1471-227X-8-1; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; Wills BA, 2005, NEW ENGL J MED, V353, P877, DOI 10.1056/NEJMoa044057; Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754; World Health Organization, 2000, MAN CHILD SER INF SE; World Health Organization, 2005, EM TRIAG ASS TREATM; World Health Organization (WHO), 2005, POCK BOOK HOSP CAR C	61	56	61	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 2	2010	341								c4416	10.1136/bmj.c4416	http://dx.doi.org/10.1136/bmj.c4416			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	647JV	20813823	Green Published, hybrid			2023-01-03	WOS:000281615700001
J	Tobin, MJ; Laghi, F; Jubran, A				Tobin, Martin J.; Laghi, Franco; Jubran, Amal			Narrative Review: Ventilator-Induced Respiratory Muscle Weakness	ANNALS OF INTERNAL MEDICINE			English	Review							DIAPHRAGMATIC CONTRACTILITY; PRESSURE; DYSFUNCTION; STIMULATION; ATROPHY	Clinicians have long been aware that substantial lung injury results when mechanical ventilation imposes too much stress on the pulmonary parenchyma. Evidence is accruing that substantial injury may also result when the ventilator imposes too little stress on the respiratory muscles. Through adjustment of ventilator settings and administration of pharmacotherapy, the respiratory muscles may be rendered almost (or completely) inactive. Research in animals has shown that diaphragmatic inactivity produces severe injury and atrophy of muscle fibers. Human data have recently revealed that 18 to 69 hours of complete diaphragmatic inactivity associated with mechanical ventilation decreased the cross-sectional areas of diaphragmatic fibers by half or more. The atrophic injury seems to result from increased oxidative stress leading to activation of protein-degradation pathways. Scientific understanding of ventilator-induced respiratory muscle injury has not reached the stage where meaningful controlled trials can be done, and thus, it is not possible to give concrete recommendations for patient management. In the meantime, clinicians are advised to select ventilator settings that avoid both excessive patient effort and excessive respiratory muscle rest. The contour of the airway pressure waveform on a ventilator screen provides the most practical indication of patient effort, and clinicians are advised to pay close attention to the waveform as they titrate ventilator settings. Research on ventilator-induced respiratory muscle injury is in its infancy and portends to be an exciting area to follow.	[Tobin, Martin J.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA; Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	Tobin, MJ (corresponding author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, 111 N 5th Ave & Roosevelt Rd, Hines, IL 60141 USA.	mtobin2@lumc.edu			Veterans Affairs Health Services Research and Development Service; National Institutes of Health [RO1 NR008782]; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR008782] Funding Source: NIH RePORTER	Veterans Affairs Health Services Research and Development Service(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Grant Support: By a Merit Review grant from the Veterans Affairs Health Services Research and Development Service and by a grant from the National Institutes of Health (RO1 NR008782).	ANZUETO A, 1987, American Review of Respiratory Disease, V135, pA201; Ayas NT, 1999, AM J RESP CRIT CARE, V159, P2018, DOI 10.1164/ajrccm.159.6.9806147; Betters JL, 2004, AM J RESP CRIT CARE, V170, P1179, DOI 10.1164/rccm.200407-939OC; Cattapan SE, 2003, THORAX, V58, P58, DOI 10.1136/thorax.58.1.58; Cholette J, 2009, CRIT CARE MED, V37, pA434, DOI 10.1097/CCM.0b013e3181b6e760; DECRAMER M, 1994, AM J RESP CRIT CARE, V150, P11, DOI 10.1164/ajrccm.150.1.8025735; DREYFUSS D, 2006, PRINCIPLES PRACTICE, P903; Gayan-Ramirez G, 2005, CRIT CARE MED, V33, P2804, DOI 10.1097/01.CCM.0000191250.32988.A3; Jubran A, 1997, AM J RESP CRIT CARE, V155, P906, DOI 10.1164/ajrccm.155.3.9117025; KNISELY AS, 1988, J PEDIATR-US, V113, P1074, DOI 10.1016/S0022-3476(88)80585-7; Laghi F, 1998, J APPL PHYSIOL, V85, P1103, DOI 10.1152/jappl.1998.85.3.1103; Laghi F, 2003, AM J RESP CRIT CARE, V168, P10, DOI 10.1164/rccm.2206020; Laghi F, 2006, PRINCIPLES PRACTICE, V2nd, P129; Lee SI, 2008, J ANESTH, V22, P385, DOI 10.1007/s00540-008-0646-y; Leung P, 1997, AM J RESP CRIT CARE, V155, P1940, DOI 10.1164/ajrccm.155.6.9196100; Levine S, 2008, NEW ENGL J MED, V358, P1327, DOI 10.1056/NEJMoa070447; Maes K, 2007, AM J RESP CRIT CARE, V175, P1134, DOI 10.1164/rccm.200609-1342OC; Mancebo J., 2006, PRINCIPLES PRACTICE, P183; MARINI JJ, 1985, CHEST, V87, P612, DOI 10.1378/chest.87.5.612; McClung JM, 2007, AM J RESP CRIT CARE, V175, P150, DOI 10.1164/rccm.200601-142OC; Powers SK, 2002, J APPL PHYSIOL, V92, P1851, DOI 10.1152/japplphysiol.00881.2001; Sassoon CSH, 2002, J APPL PHYSIOL, V92, P2585, DOI 10.1152/japplphysiol.01213.2001; Sassoon CSH, 2004, AM J RESP CRIT CARE, V170, P626, DOI 10.1164/rccm.200401-042OC; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; Shanely RA, 2004, AM J RESP CRIT CARE, V170, P994, DOI 10.1164/rccm.200304-575OC; Smith HK, 2000, CELL TISSUE RES, V302, P235, DOI 10.1007/s004410000280; Tobin MJ, 2001, NEW ENGL J MED, V344, P1986, DOI 10.1056/NEJM200106283442606; Topeli A, 1999, AM J RESP CRIT CARE, V160, P1369, DOI 10.1164/ajrccm.160.4.9806041; VASSILAKOPOULOS T, 2006, PRINCIPLES PRACTICE, P931; WARD ME, 1988, ANESTHESIOLOGY, V69, P29, DOI 10.1097/00000542-198807000-00005; Watson AC, 2001, CRIT CARE MED, V29, P1325, DOI 10.1097/00003246-200107000-00005; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; Whidden MA, 2010, J APPL PHYSIOL, V108, P1376, DOI 10.1152/japplphysiol.00098.2010; Yang LY, 2002, AM J RESP CRIT CARE, V166, P1135, DOI 10.1164/rccm.2202020; Younes M, 1995, THORAX, P2367; Zhang XJ, 2009, BRIT J ANAESTH, V102, P61, DOI 10.1093/bja/aen327	36	50	55	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	2010	153	4					240	245		10.7326/0003-4819-153-4-201008170-00006	http://dx.doi.org/10.7326/0003-4819-153-4-201008170-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639KF	20713792	Green Accepted			2023-01-03	WOS:000280973000004
J	Wong, A				Wong, Albert			Quantitative Modeling of the High-Throughput Production and In Vivo Kinetics of (Drug-Encapsulating) Liposomes	PLOS ONE			English	Article							EGF	In developing liposomes for in vivo use, it is important to design the liposomes to have optimal in vivo kinetics, and it is also necessary to identify optimal high-throughput production conditions for these liposomes. Previous work has not definitively established the general relationship between liposomes' configuration and composition, and their in vivo kinetics. Also, no straightforward method exists to calculate optimal liposome high-throughput production conditions for specific liposome compositions. This work presents first-principles quantitative correlations describing liposomes' in vivo drug leakage and vascular mass transfer kinetics. This work further presents a simple quantitative model relating specific liposome compositions to ideal high-throughput production parameters. The results have implications for the identification of promising liposome compositions via high-throughput screening methodologies, as well as the design and optimization of high-throughput reactors for liposome production.	Yale Univ, Program Biol & Biomed Sci, New Haven, CT 06520 USA	Yale University	Wong, A (corresponding author), Yale Univ, Program Biol & Biomed Sci, New Haven, CT 06520 USA.	albert.wong@yale.edu			MIT Office of the Provost; MIT Portugal	MIT Office of the Provost; MIT Portugal	This work was supported by funding from the MIT Office of the Provost and the MIT Portugal Program. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carneiro AL, 2004, PROG COLL POL SCI S, V128, P273, DOI 10.1007/b97107; COLTON CK, 1971, AICHE J, V17, P773, DOI 10.1002/aic.690170404; Deen W.M., 1998, ANAL TRANSPORT PHENO; Fogler H. Scott., 2006, ELEMENTS CHEM REACTI, V4th; Ishida O, 2001, PHARMACEUT RES, V18, P1042, DOI 10.1023/A:1010960900254; Johnston MJW, 2006, BBA-BIOMEMBRANES, V1758, P55, DOI 10.1016/j.bbamem.2006.01.009; Kullberg EB, 2002, BIOCONJUGATE CHEM, V13, P737, DOI 10.1021/bc0100713; ROSS SM, 1974, J FLUID MECH, V63, P157, DOI 10.1017/S0022112074001066; Semple SC, 2005, J PHARMACOL EXP THER, V312, P1020, DOI 10.1124/jpet.104.078113; Suita T, 1997, ANAL SCI, V13, P577, DOI 10.2116/analsci.13.577; Wong A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007391	11	4	4	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2010	5	4							e10280	10.1371/journal.pone.0010280	http://dx.doi.org/10.1371/journal.pone.0010280			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	588NU	20428243	Green Published, Green Submitted, gold			2023-01-03	WOS:000277079300005
J	Hui, D; Elsayem, A; De La Cruz, M; Berger, A; Zhukovsky, DS; Palla, S; Evans, A; Fadul, N; Palmer, JL; Bruera, E				Hui, David; Elsayem, Ahmed; De La Cruz, Maxine; Berger, Ann; Zhukovsky, Donna S.; Palla, Shana; Evans, Avery; Fadul, Nada; Palmer, J. Lynn; Bruera, Eduardo			Availability and Integration of Palliative Care at US Cancer Centers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SUPPORTIVE CARE; MEDICAL-CARE; DATA-BASE; LIFE; ONCOLOGY; QUALITY; END; HOSPITALS; SOCIETY	Context The current state of palliative care in cancer centers is not known. Objectives To determine the availability and degree of integration of palliative care services and to compare between National Cancer Institute (NCI) and non-NCI cancer centers in the United States. Design, Setting, and Participants A survey of 71 NCI-designated cancer centers and a random sample of 71 non-NCI cancer centers of both executives and palliative care clinical program leaders, where applicable, regarding their palliative care services between June and October 2009. Survey questions were generated after a comprehensive literature search, review of guidelines from the National Quality Forum, and discussions among 7 physicians with research interest in palliative oncology. Executives were also asked about their attitudes toward palliative care. Main Outcome Measure Availability of palliative care services in the cancer center, defined as the presence of at least 1 palliative care physician. Results A total of 142 and 120 surveys were sent to executives and program leaders, with response rates of 71% and 82%, respectively. National Cancer Institute cancer centers were significantly more likely to have a palliative care program (50/51 [98%] vs 39/50 [78%]; P=.002), at least 1 palliative care physician (46/50 [92%] vs 28/38 [74%]; P=.04), an inpatient palliative care consultation team (47/51 [92%] vs 28/50 [56%]; P<.001), and an outpatient palliative care clinic (30/51 [59%] vs 11/50 [22%]; P<.001). Few centers had dedicated palliative care beds (23/101 [23%]) or an institution-operated hospice (37/101 [37%]). The median (interquartile range) reported durations from referral to death were 7 (4-16), 7 (5-10), and 90 (30-120) days for inpatient consultation teams, inpatient units, and outpatient clinics, respectively. Research programs, palliative care fellowships, and mandatory rotations for oncology fellows were uncommon. Executives were supportive of stronger integration and increasing palliative care resources. Conclusion Most cancer centers reported a palliative care program, although the scope of services and the degree of integration varied widely. JAMA. 2010; 303(11): 1054-1061	[Hui, David; Elsayem, Ahmed; De La Cruz, Maxine; Zhukovsky, Donna S.; Evans, Avery; Fadul, Nada; Bruera, Eduardo] Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Houston, TX 77030 USA; [Palla, Shana; Palmer, J. Lynn] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Berger, Ann] NCI, Dept Palliat Care, Ctr Clin Canc, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Elsayem, A (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Palliat Care & Rehabil Med, Unit 1414,1515 Holcombe Blvd, Houston, TX 77030 USA.	aelsayem@mdanderson.org	Bruera, Eduardo/AAA-1550-2022		National Institutes of Health [RO1NR010162-01A1, RO1CA122292-01, RO1CA124481-01]; National Cancer Institute [CA16672]; Royal College of Physicians and Surgeons of Canada; NATIONAL CANCER INSTITUTE [R01CA122292, R01CA124481, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010162] Funding Source: NIH RePORTER; CLINICAL CENTER [ZIACL000785] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Royal College of Physicians and Surgeons of Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); CLINICAL CENTER	Funding/Support: This work was supported in part by grants RO1NR010162-01A1, RO1CA122292-01, and RO1CA124481-01 from the National Institutes of Health (Dr Bruera); grant CA16672 from the National Cancer Institute (Patient- Reported Outcomes, Survey and Population Research Shared Resources); and the Clinician Investigator Program, Royal College of Physicians and Surgeons of Canada (Dr Hui).	[Anonymous], 2006, NAT FRAM PREF PRACT; Baker JN, 2008, PEDIATR CLIN N AM, V55, P223, DOI 10.1016/j.pcl.2007.10.011; Bilimoria KY, 2008, ANN SURG ONCOL, V15, P683, DOI 10.1245/s10434-007-9747-3; Bilimoria KY, 2009, J CLIN ONCOL, V27, P4177, DOI 10.1200/JCO.2008.21.7018; Billings J A, 2001, J Palliat Med, V4, P309, DOI 10.1089/109662101753123913; Byock I, 2000, CA-CANCER J CLIN, V50, P123, DOI 10.3322/canjclin.50.2.123; Cheng Wen-Wu, 2005, J Palliat Med, V8, P1025, DOI 10.1089/jpm.2005.8.1025; Cherny NI, 2003, CANCER-AM CANCER SOC, V98, P2502, DOI 10.1002/cncr.11815; COLUZZI PH, 1995, J CLIN ONCOL, V13, P756, DOI 10.1200/JCO.1995.13.3.756; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; El Osta B, 2008, J PALLIAT MED, V11, P51, DOI 10.1089/jpm.2007.0103; Elsayem A, 2004, J CLIN ONCOL, V22, P2008, DOI 10.1200/JCO.2004.11.003; Ferrell B, 2008, J CLIN ONCOL, V26, P3824, DOI 10.1200/JCO.2007.15.7552; Ferris FD, 2009, J CLIN ONCOL, V27, P3052, DOI 10.1200/JCO.2008.20.1558; Goldsmith B, 2008, J PALLIAT MED, V11, P1094, DOI 10.1089/jpm.2008.0053; Higginson IJ, 2003, J PAIN SYMPTOM MANAG, V25, P150, DOI 10.1016/S0885-3924(02)00599-7; Hui D, 2010, J PALLIAT MED, V13, P49, DOI 10.1089/jpm.2009.0166; INGHAM J, 1998, PRINCIPLES PRACTICE, P749; *IOM NAT CANC POL, 2001, IMPR PALL CAR CANC; Johnson CE, 2008, PALLIATIVE MED, V22, P51, DOI 10.1177/0269216307085181; Lagman R, 2005, SEMIN ONCOL, V32, P134, DOI 10.1053/j.seminoncol.2004.11.015; LENEXA KS, 2009, STANDARD DEFINITIONS; Levy MH, 2009, J NATL COMPR CANC NE, V7, P436, DOI 10.6004/jnccn.2009.0031; Meyers FJ, 2004, J PAIN SYMPTOM MANAG, V28, P548, DOI 10.1016/j.jpainsymman.2004.03.002; Meyers FJ, 2003, J CLIN ONCOL, V21, P1412, DOI 10.1200/JCO.2003.01.104; Morita T, 2005, J CLIN ONCOL, V23, P2637, DOI 10.1200/JCO.2005.12.107; Morrison RS, 2005, J PALLIAT MED, V8, P1127, DOI 10.1089/jpm.2005.8.1127; Pan C X, 2001, J Palliat Med, V4, P315, DOI 10.1089/109662101753123922; Schnipper L, 1998, J CLIN ONCOL, V16, P1986; Temel JS, 2007, J CLIN ONCOL, V25, P2377, DOI 10.1200/JCO.2006.09.2627; World Health Organization, 2002, NAT CANC CONTR PROGR, V2nd, P83; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	33	350	354	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2010	303	11					1054	1061		10.1001/jama.2010.258	http://dx.doi.org/10.1001/jama.2010.258			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569KC	20233823	Green Accepted			2023-01-03	WOS:000275594100018
J	Nout, RA; Smit, VTHBM; Putter, H; Juergenliemk-Schulz, IM; Jobsen, JJ; Lutgens, LCHW; van der Steen-Banasik, EM; Mens, JWM; Slot, A; Kroese, MCS; van Bunningen, BNFM; Ansink, AC; van Putten, WLJ; Creutzberg, CL				Nout, R. A.; Smit, V. T. H. B. M.; Putter, H.; Juergenliemk-Schulz, I. M.; Jobsen, J. J.; Lutgens, L. C. H. W.; van der Steen-Banasik, E. M.; Mens, J. W. M.; Slot, A.; Kroese, M. C. Stenfert; van Bunningen, B. N. F. M.; Ansink, A. C.; van Putten, W. L. J.; Creutzberg, C. L.		PORTEC Study Grp	Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial	LANCET			English	Article							POSTOPERATIVE RADIOTHERAPY; RADIATION-THERAPY; GRADING SYSTEM; STAGE IB; CARCINOMA; IRRADIATION; PATTERNS; SURGERY; VAULT	Background After surgery for intermediate-risk endometrial carcinoma, the vagina is the most frequent site of recurrence. This study established whether vaginal brachytherapy (VBT) is as effective as pelvic external beam radiotherapy (EBRT) in prevention of vaginal recurrence, with fewer adverse effects and improved quality of life. Methods In this open-label, non-inferiority, randomised trial undertaken in 19 Dutch radiation oncology centres, 427 patients with stage I or IIA endometrial carcinoma with features of high-intermediate risk were randomly assigned by a computer-generated, biased coin minimisation procedure to pelvic EBRT (46 Gy in 23 fractions; n=214) or VBT (21 Gy high-dose rate in three fractions, or 30 Gy low-dose rate; n=213). All investigators were masked to the assignment of treatment group. The primary endpoint was vaginal recurrence. The predefined non-inferiority margin was an absolute difference of 6% in vaginal recurrence. Analysis was by intention to treat, with competing risk methods. The study is registered, number ISRCTN16228756. Findings At median follow-up of 45 months (range 18-78), three vaginal recurrences had been diagnosed after VBT and four after EBRT. Estimated 5-year rates of vaginal recurrence were 1.8% (95% CI 0.6-5.9) for VBT and 1.6% (0.5-4-9) for EBRT (hazard ratio [HR] 0.78, 95% CI 0-17-3.49; p=0.74). 5-year rates of locoregional relapse (vaginal or pelvic recurrence, or both) were 5.1% (2.8-9.6) for VBT and 2.1% (0.8-5.8) for EBRT (HR 2.08,0.71-6.09; p=0.17). 1.5% (0.5-4.5) versus 0.5% (0.1-3.4) of patients presented with isolated pelvic recurrence (HR 3.10, 0.32-29.9; p=0.30), and rates of distant metastases were similar (8.3% [5.1-13.4] vs 5.7% [3.3-9.9]; HR 1.32, 0.63-2.74; p=0.46). We recorded no differences in overall (84-8% [95% CI 79.3-90.3] vs 79.6% [71.2-88.0]; HR 1.17, 0.69-1.98; p=0.57) or disease-free survival (82.7% [76.9-88.6] vs 78.1% [69.7-86.5]; HR 1.09, 0.66-1.78; p=0.74). Rates of acute grade 1-2 gastrointestinal toxicity were significantly lower in the VBT group than in the EBRT group at completion of radiotherapy (12.6% [27/215] vs 53.8% [112/208]). Interpretation VBT is effective in ensuring vaginal control, with fewer gastrointestinal toxic effects than with EBRT. VBT should be the adjuvant treatment of choice for patients with endometrial carcinoma of high-intermediate risk.	[Nout, R. A.; Creutzberg, C. L.] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands; [Smit, V. T. H. B. M.] Leiden Univ, Med Ctr, Dept Pathol, NL-2300 RC Leiden, Netherlands; [Putter, H.] Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands; [Juergenliemk-Schulz, I. M.] Univ Med Ctr Utrecht, Dept Radiat Oncol, Utrecht, Netherlands; [Jobsen, J. J.] Med Spectrum Twente, Dept Radiotherapy, Enschede, Netherlands; [Lutgens, L. C. H. W.] MAASTricht Radiat Oncol Clin, Maastricht, Netherlands; [van der Steen-Banasik, E. M.] Arnhem Radiotherapy Inst, Arnhem, Netherlands; [Mens, J. W. M.] ErasmusMC, Dr Daniel Den Hoed Canc Ctr, Dept Radiat Oncol, Rotterdam, Netherlands; [van Putten, W. L. J.] ErasmusMC, Dr Daniel Den Hoed Canc Ctr, Dept Biostat, Rotterdam, Netherlands; [Ansink, A. C.] ErasmusMC, Dr Daniel Den Hoed Canc Ctr, Dept Gynecol, Rotterdam, Netherlands; [Slot, A.] Radiotherapy Inst Friesland, Leeuwarden, Netherlands; [Kroese, M. C. Stenfert] Radiotherapy Inst Stedendriehoek & Omstreken, Deventer, Netherlands; [van Bunningen, B. N. F. M.] Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; Utrecht University Medical Center; Medical Spectrum Twente; Maastricht University; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Netherlands Cancer Institute	Nout, RA (corresponding author), Leiden Univ, Med Ctr, Dept Clin Oncol, POB 9600, NL-2300 RC Leiden, Netherlands.	r.a.nout@lumc.nl	Leer, J.W.H./H-8067-2014; Smit, Vincent/AAD-1811-2022; Putter, Hein/C-2244-2018; Creutzberg, Carien L/E-2253-2018	Smit, Vincent/0000-0003-3730-5652; Putter, Hein/0000-0001-5395-1422; Creutzberg, Carien L/0000-0002-7008-4321; Nout, Remi/0000-0001-8011-2982	Dutch Cancer Society [CKTO 2001-04]	Dutch Cancer Society(KWF Kankerbestrijding)	The PORTEC-2 study was supported by a grant from the Dutch Cancer Society (CKTO 2001-04). Part of this research has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 June 3, 2008, Chicago IL, USA. We thank Philine van den Tol and Chantal te Marvelde, central data managers, for all their meticulous work and extra efforts to obtain compete follow up; the radiation oncologists, gynaecologists, and data managers at the participating centres; and the patients who greatly contributed by repeatedly filling in questionnaires throughout the study.	AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Alektiar KM, 2005, INT J RADIAT ONCOL, V62, P111, DOI 10.1016/j.ijrobp.2004.09.054; Anderson JM, 2000, INT J RADIAT ONCOL, V46, P417, DOI 10.1016/S0360-3016(99)00427-7; Blake P, 2009, LANCET, V373, P137, DOI 10.1016/S0140-6736(08)61767-5; Bray F, 2005, INT J CANCER, V117, P123, DOI 10.1002/ijc.21099; Chadha M, 1999, GYNECOL ONCOL, V75, P103, DOI 10.1006/gyno.1999.5526; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; Creutzberg CL, 2001, INT J RADIAT ONCOL, V51, P1246, DOI 10.1016/S0360-3016(01)01765-5; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048; Kitchener H, 2009, LANCET, V373, P125, DOI 10.1016/S0140-6736(08)61766-3; Lax SF, 2000, AM J SURG PATHOL, V24, P1201, DOI 10.1097/00000478-200009000-00002; Lindau ST, 2007, NEW ENGL J MED, V357, P762, DOI 10.1056/NEJMoa067423; National Cancer Institute, 2006, CANC THER EV PROGR C; Nout RA, 2009, J CLIN ONCOL, V27, P3547, DOI 10.1200/JCO.2008.20.2424; Panici PB, 2008, JNCI-J NATL CANCER I, V100, P1707, DOI 10.1093/jnci/djn397; Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712; Rittenberg PVC, 2005, GYNECOL ONCOL, V98, P434, DOI 10.1016/j.ygyno.2005.04.030; Scholten AN, 2005, INT J RADIAT ONCOL, V63, P834, DOI 10.1016/j.ijrobp.2005.03.007; Scholten AN, 2004, CANCER, V100, P764, DOI 10.1002/cncr.20040; SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6; Weiss E, 1998, GYNECOL ONCOL, V71, P72, DOI 10.1006/gyno.1998.5155	23	751	769	0	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2010	375	9717					816	823		10.1016/S0140-6736(09)62163-2	http://dx.doi.org/10.1016/S0140-6736(09)62163-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570MO	20206777				2023-01-03	WOS:000275682600031
J	Edwards, AD; Brocklehurst, P; Gunn, AJ; Halliday, H; Juszczak, E; Levene, M; Strohm, B; Thoresen, M; Whitelaw, A; Azzopardi, D				Edwards, A. David; Brocklehurst, Peter; Gunn, Alistair J.; Halliday, Henry; Juszczak, Edmund; Levene, Malcolm; Strohm, Brenda; Thoresen, Marianne; Whitelaw, Andrew; Azzopardi, Denis			Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WHOLE-BODY HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; THERAPEUTIC HYPOTHERMIA; NEUROPROTECTIVE THERAPY; MILD HYPOTHERMIA; NEWBORN-INFANTS; TERM INFANTS; ASPHYXIA; SAFETY; BIRTH	Objective To determine whether moderate hypothermia after hypoxic-ischaemic encephalopathy in neonates improves survival and neurological outcome at 18 months of age. Design A meta-analysis was performed using a fixed effect model. Risk ratios, risk difference, and number needed to treat, plus 95% confidence intervals, were measured. Data sources Studies were identified from the Cochrane central register of controlled trials, the Oxford database of perinatal trials, PubMed, previous reviews, and abstracts. Review methods Reports that compared whole body cooling or selective head cooling with normal care in neonates with hypoxic-ischaemic encephalopathy and that included data on death or disability and on specific neurological outcomes of interest to patients and clinicians were selected. Results We found three trials, encompassing 767 infants, that included information on death and major neurodevelopmental disability after at least 18 months' follow-up. We also identified seven other trials with mortality information but no appropriate neurodevelopmental data. Therapeutic hypothermia significantly reduced the combined rate of death and severe disability in the three trials with 18 month outcomes ( risk ratio 0.81, 95% confidence interval 0.71 to 0.93, P=0.002; risk difference -0.11, 95% CI -0.18 to -0.04), with a number needed to treat of nine ( 95% CI 5 to 25). Hypothermia increased survival with normal neurological function ( risk ratio 1.53,95% CI 1.22 to 1.93, P<0.001; risk difference 0.12, 95% CI 0.06 to 0.18), with a number needed to treat of eight ( 95% CI 5 to 17), and in survivors reduced the rates of severe disability (P=0.006), cerebral palsy (P=0.004), and mental and the psychomotor developmental index of less than 70 (P=0.01 and P=0.02, respectively). No significant interaction between severity of encephalopathy and treatment effect was detected. Mortality was significantly reduced when we assessed all 10 trials (1320 infants; relative risk 0.78, 95% CI 0.66 to 0.93, P=0.005; risk difference -0.07, 95% CI -0.12 to -0.02), with a number needed to treat of 14 ( 95% CI 8 to 47). Conclusions In infants with hypoxic-ischaemic encephalopathy, moderate hypothermia is associated with a consistent reduction in death and neurological impairment at 18 months.	[Edwards, A. David; Azzopardi, Denis] Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Clin Sci, London SW7 2AZ, England; [Edwards, A. David; Azzopardi, Denis] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Ctr Clin Sci, MRC, London W12 0NN, England; [Brocklehurst, Peter; Juszczak, Edmund; Strohm, Brenda] Univ Oxford, Dept Publ Hlth, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England; [Gunn, Alistair J.] Univ Auckland, Sch Med Sci, Dept Physiol, Auckland 1142, New Zealand; [Halliday, Henry] Royal Matern Hosp, Royal Jubilee Matern Serv, Belfast BT12 6BA, Antrim, North Ireland; [Halliday, Henry] Queens Univ Belfast, Dept Child Hlth, Belfast BT12 6BL, Antrim, North Ireland; [Levene, Malcolm] Univ Leeds, Leeds LS1 3BR, W Yorkshire, England; [Levene, Malcolm] Leeds Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; [Thoresen, Marianne; Whitelaw, Andrew] Univ Bristol, St Michaels Hosp, Fac Med & Dent, Dept Clin Sci S Bristol, Bristol BS2 8EG, Avon, England	Imperial College London; Imperial College London; University of Oxford; University of Auckland; Queens University Belfast; University of Leeds; Leeds General Infirmary; University of Leeds; University of Bristol	Azzopardi, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Inst Clin Sci, London SW7 2AZ, England.	d.azzopardi@imperial.ac.uk	Brocklehurst, Peter/B-5804-2011; Edwards, Anthony/HCI-9626-2022	Halliday, Henry/0000-0001-7978-4992; Edwards, Anthony David/0000-0003-4801-7066; Gunn, Alistair/0000-0003-0656-7035	Health Research Council of New Zealand; MRC [G0100126, MC_U120081323, G0200270] Funding Source: UKRI; Medical Research Council [MC_U120081323, G0200270, G0100126] Funding Source: researchfish	Health Research Council of New Zealand(Health Research Council of New Zealand); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	AJG was supported by the Health Research Council of New Zealand. Imperial College London (ADE and DA) and University of Oxford (PB, EJ, and BS) are Comprehensive Biomedical Research Centres.	Akisu M, 2003, PROSTAG LEUKOTR ESS, V69, P45, DOI 10.1016/S0952-3278(03)00055-3; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; BARKS J, 2005, NEONATAL HYPOTHERMIA; Barnett AL, 2004, ARCH DIS CHILD, V89, P637, DOI 10.1136/adc.2002.019349; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Blackmon LR, 2006, PEDIATRICS, V117, P942, DOI 10.1542/peds.2005-2950; *COCHR NEON REV GR, 2009, GUID REV ED; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1998, EARLY HUM DEV, V53, P19, DOI 10.1016/S0378-3782(98)00033-4; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Gunn AJ, 2008, PEDIATRICS, V121, P648, DOI 10.1542/peds.2007-3310; Higgins RD, 2006, J PEDIATR-US, V148, P170, DOI 10.1016/j.jpeds.2005.12.009; Hoehn T, 2008, RESUSCITATION, V78, P7, DOI 10.1016/j.resuscitation.2008.04.027; JACOBS SE, 2008, P HOT TOP NEON C WAS; Jacobs SE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub3; Kirpalani H, 2007, PEDIATRICS, V120, P1126, DOI 10.1542/peds.2006-2776; Lawn J, 2005, B WORLD HEALTH ORGAN, V83, P409; Lin ZL, 2006, J PERINATOL, V26, P180, DOI 10.1038/sj.jp.7211412; Robertson NJ, 2008, LANCET, V372, P801, DOI 10.1016/S0140-6736(08)61329-X; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2002, PEDIATRICS, V110, P377, DOI 10.1542/peds.110.2.377; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; SIMBRUNER G, 2008, P HOT TOP NEON C WAS; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839; Zhou Wen-hao, 2003, Zhonghua Er Ke Za Zhi, V41, P460	29	618	645	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 9	2010	340								c363	10.1136/bmj.c363	http://dx.doi.org/10.1136/bmj.c363			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554ZS	20144981	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000274476800002
J	Trivedi, AN; Moloo, H; Mor, V				Trivedi, Amal N.; Moloo, Husein; Mor, Vincent			Increased Ambulatory Care Copayments and Hospitalizations among the Elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH MAINTENANCE ORGANIZATION; EMERGENCY-DEPARTMENT; SERVICES; BENEFITS; INSURANCE; PLAN; EVENTS	BACKGROUND When copayments for ambulatory care are increased, elderly patients may forgo important outpatient care, leading to increased use of hospital care. METHODS We compared longitudinal changes in the use of outpatient and inpatient care between enrollees in Medicare plans that increased copayments for ambulatory care and enrollees in matched control plans-similar plans that made no changes in these copayments. The study population included 899,060 beneficiaries enrolled in 36 Medicare plans during the period from 2001 through 2006. RESULTS In plans that increased copayments for ambulatory care, mean copayments nearly doubled for both primary care ($7.38 to $14.38) and specialty care ($12.66 to $22.05). In control plans, mean copayments for primary care and specialty care remained unchanged at $8.33 and $11.38, respectively. In the year after the rise in copayments, plans that increased cost sharing had 19.8 fewer annual outpatient visits per 100 enrollees (95% confidence interval [CI], 16.6 to 23.1), 2.2 additional annual hospital admissions per 100 enrollees (95% CI, 1.8 to 2.6), 13.4 more annual inpatient days per 100 enrollees (95% CI, 10.2 to 16.6), and an increase of 0.7 percentage points in the proportion of enrollees who were hospitalized (95% CI, 0.51 to 0.95), as compared with concurrent trends in control plans. These estimates were consistent among a cohort of continuously enrolled beneficiaries. The effects of increases in copayments for ambulatory care were magnified among enrollees living in areas of lower income and education and among enrollees who had hypertension, diabetes, or a history of myocardial infarction. CONCLUSIONS Raising cost sharing for ambulatory care among elderly patients may have adverse health consequences and may increase total spending on health care.	[Trivedi, Amal N.; Moloo, Husein; Mor, Vincent] Brown Univ, Alpert Med Sch, Dept Community Hlth, Providence, RI 02912 USA; [Trivedi, Amal N.] Providence VA Med Ctr, Res Enhancement Award Program, Providence, RI USA	Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Trivedi, AN (corresponding author), Brown Univ, Alpert Med Sch, Dept Community Hlth, Box G-S121, Providence, RI 02912 USA.	amal_trivedi@brown.edu			Veterans Affairs Health Services Research and Development Service	Veterans Affairs Health Services Research and Development Service(US Department of Veterans Affairs)	Dr. Trivedi is the recipient of a Pfizer Health Policy Scholars Award and a career development award from the Veterans Affairs Health Services Research and Development Service.	Agency for Healthcare Research and Quality Healthcare Cost and Utilization Project, HCUPNET; [Anonymous], 2001, INTERSTUDY COMPETITI; BECK RG, 1980, MED CARE, V18, P787, DOI 10.1097/00005650-198008000-00001; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; CHANDRA A, 2007, 12972 NBER; CHERKIN DC, 1989, MED CARE, V27, P1036, DOI 10.1097/00005650-198911000-00005; Claxton G, 2006, HEALTH AFFAIR, V25, pW476, DOI 10.1377/hlthaff.25.w476; *COMM FUND, 2003, MED CHOIC PLANS CONT; CULYER AJ, 2000, HDB HLTH EC, P409; CUTLER DM, 1997, 6107 NBER; Diehr P, 1999, ANNU REV PUBL HEALTH, V20, P125, DOI 10.1146/annurev.publhealth.20.1.125; Eichner MJ, 1998, AM ECON REV, V88, P117; Freiberg L Jr, 1976, Inquiry, V13, P54; Ginsburg PB, 2007, NEW ENGL J MED, V356, P1201, DOI 10.1056/NEJMp068272; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; GRUBER J, ROLE CONSUMER COPAY; Helms LJ, 1978, COPAYMENTS DEMAND ME; Hsu J, 2006, HEALTH SERV RES, V41, P1801, DOI 10.1111/j.1475-6773.2006.00562.x; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; Magid DJ, 1997, NEW ENGL J MED, V336, P1722, DOI 10.1056/NEJM199706123362406; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; Rice T, 2004, MED CARE RES REV, V61, P415, DOI 10.1177/1077558704269498; RODDY PC, 1986, MED CARE, V24, P873, DOI 10.1097/00005650-198609000-00009; SCHEFFLER RM, 1984, MED CARE, V22, P247, DOI 10.1097/00005650-198403000-00008; SCITOVSKY AA, 1972, SOC SECUR BULL, V35, P3; Selby JV, 1996, NEW ENGL J MED, V334, P635, DOI 10.1056/NEJM199603073341006; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Trivedi AN, 2008, NEW ENGL J MED, V358, P375, DOI 10.1056/NEJMsa070929; Trivedi AN, 2008, JAMA-J AM MED ASSOC, V300, P2879, DOI 10.1001/jama.2008.888; Trivedi AN, 2005, NEW ENGL J MED, V353, P692, DOI 10.1056/NEJMsa051207; Wharam JF, 2007, JAMA-J AM MED ASSOC, V297, P1093, DOI 10.1001/jama.297.10.1093; MEDICARE HEDIS3 0 19; MEDICAID SCHIP STATE	34	118	118	3	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 28	2010	362	4					320	328		10.1056/NEJMsa0904533	http://dx.doi.org/10.1056/NEJMsa0904533			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	548OT	20107218				2023-01-03	WOS:000273975000008
J	Edes, K; Cassidy, P; Shami, PJ; Moos, PJ				Edes, Kornelia; Cassidy, Pamela; Shami, Paul J.; Moos, Philip J.			JS-K, a Nitric Oxide Prodrug, Has Enhanced Cytotoxicity in Colon Cancer Cells with Knockdown of Thioredoxin Reductase 1	PLOS ONE			English	Article							DNA-BINDING ACTIVITY; MOTEXAFIN GADOLINIUM; IN-VIVO; LIPOIC ACID; ELECTROPHILIC PROSTAGLANDINS; ANTICANCER AGENTS; TUMOR-SUPPRESSOR; LEUKEMIA CELLS; SYSTEM; EXPRESSION	Background: The selenoenzyme thioredoxin reductase 1 has a complex role relating to cell growth. It is induced as a component of the cellular response to potentially mutagenic oxidants, but also appears to provide growth advantages to transformed cells by inhibiting apoptosis. In addition, selenocysteine-deficient or alkylated forms of thioredoxin reductase 1 have also demonstrated oxidative, pro-apoptotic activity. Therefore, a greater understanding of the role of thioredoxin reductase in redox initiated apoptotic processes is warranted. Methodology: The role of thioredoxin reductase 1 in RKO cells was evaluated by attenuating endogenous thioredoxin reductase 1 expression with siRNA and then either inducing a selenium-deficient thioredoxin reductase or treatment with distinct redox challenges including, hydrogen peroxide, an oxidized lipid, 4-hydroxy-2-nonenol, and a nitric oxide donating prodrug. Thioredoxin redox status, cellular viability, and effector caspase activity were measured. Conclusions/Significance: In cells with attenuated endogenous thioredoxin reductase 1, a stably integrated selenocysteine-deficient form of the enzyme was induced but did not alter either the thioredoxin redox status or the cellular growth kinetics. The oxidized lipid and the nitric oxide donor demonstrated enhanced cytotoxicity when thioredoxin reductase 1 was knocked-down; however, the effect was more pronounced with the nitric oxide prodrug. These results are consistent with the hypothesis that attenuation of the thioredoxin-system can promote apoptosis in a nitric oxide-dependent manner.	[Edes, Kornelia; Cassidy, Pamela] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA; [Cassidy, Pamela] Univ Utah, Dept Dermatol, Salt Lake City, UT USA; [Shami, Paul J.] Univ Utah, Dept Med Oncol, Salt Lake City, UT USA; [Moos, Philip J.] Univ Utah, Dept Pharmacol & Toxicol, Salt Lake City, UT 84112 USA; [Cassidy, Pamela] Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Edes, K (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.	philip.moos@utah.edu		Moos, Philip/0000-0002-8223-442X	USPHS [CA115616];  [P30 CA042014]; NATIONAL CANCER INSTITUTE [P30CA042014, R01CA115616] Funding Source: NIH RePORTER	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This project was supported by a USPHS Grant CA115616 (PJM). We also acknowledge the use of core facilities supported by P30 CA042014 awarded to the Huntsman Cancer Institute. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Amato RJ, 2008, CLIN GENITOURIN CANC, V6, P73, DOI 10.3816/CGC.2008.n.011; Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Anestal K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001846; Arivarasu NA, 2007, LIFE SCI, V81, P393, DOI 10.1016/j.lfs.2007.06.001; Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; Benhar M, 2008, SCIENCE, V320, P1050, DOI 10.1126/science.1158265; Bersani NA, 2002, METHOD ENZYMOL, V347, P317; Biaglow JE, 2005, CANCER BIOL THER, V4, P6; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; Bleys J, 2008, ARCH INTERN MED, V168, P404, DOI 10.1001/archinternmed.2007.74; Bracht K, 2007, ANTI-CANCER DRUG, V18, P389, DOI 10.1097/CAD.0b013e3280140001; Cassidy PB, 2006, CARCINOGENESIS, V27, P2538, DOI 10.1093/carcin/bgl111; Fang JG, 2006, J AM CHEM SOC, V128, P1879, DOI 10.1021/ja057358l; Ford JM, 2007, INT J RADIAT ONCOL, V69, P831, DOI 10.1016/j.ijrobp.2007.04.017; Grogan TM, 2000, HUM PATHOL, V31, P475, DOI 10.1053/hp.2000.6546; Hashemy SI, 2006, J BIOL CHEM, V281, P10691, DOI 10.1074/jbc.M511373200; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Kakolyris S, 2001, CLIN CANCER RES, V7, P3087; Kim KM, 2002, J BIOCHEM MOL BIOL, V35, P127; Kiziltepe T, 2007, BLOOD, V110, P709, DOI 10.1182/blood-2006-10-052845; Lamas S., 1998, Trends in Pharmacological Sciences, V19, P436, DOI 10.1016/S0165-6147(98)01265-6; Lincoln DT, 2003, ANTICANCER RES, V23, P2425; Lothrop AP, 2009, BIOCHEMISTRY-US, V48, P6213, DOI 10.1021/bi802146w; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; May JM, 2007, CLIN BIOCHEM, V40, P1135, DOI 10.1016/j.clinbiochem.2007.06.009; Moncada S, 2006, BRIT J PHARMACOL, V147, pS193, DOI 10.1038/sj.bjp.0706458; MONCADA S, 1991, PHARMACOL REV, V43, P109; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Mullally JE, 2001, J BIOL CHEM, V276, P30366, DOI 10.1074/jbc.M102198200; Nilsson J, 2000, BLOOD, V95, P1420, DOI 10.1182/blood.V95.4.1420.004k12_1420_1426; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Ravi D, 2004, CANCER CHEMOTH PHARM, V54, P449, DOI 10.1007/s00280-004-0833-y; Richards GM, 2007, EXPERT OPIN PHARMACO, V8, P351, DOI 10.1517/14656566.8.3.351; Rosenberg A, 2006, INT J RADIAT ONCOL, V64, P343, DOI 10.1016/j.ijrobp.2005.10.013; Rundlof AK, 2004, ANTIOXID REDOX SIGN, V6, P41, DOI 10.1089/152308604771978336; Saavedra JE, 2001, J ORG CHEM, V66, P3090, DOI 10.1021/jo0016529; Seemann S, 2005, ONCOGENE, V24, P3853, DOI 10.1038/sj.onc.1208549; Shami PJ, 2006, J MED CHEM, V49, P4356, DOI 10.1021/jm060022h; Shami PJ, 2003, MOL CANCER THER, V2, P409; Shao LE, 2001, CANCER RES, V61, P7333; Spyrou G, 1996, BIOCHEM BIOPH RES CO, V220, P42, DOI 10.1006/bbrc.1996.0353; SPYROU G, 1995, FEBS LETT, V368, P59, DOI 10.1016/0014-5793(95)00599-5; Stoyanovsky DA, 2005, J AM CHEM SOC, V127, P15815, DOI 10.1021/ja0529135; Sun Y, 2008, CANCER RES, V68, P8269, DOI 10.1158/0008-5472.CAN-08-2010; Udupi V, 2006, LEUKEMIA RES, V30, P1279, DOI 10.1016/j.leukres.2005.12.007; Wang XF, 2007, TOXICOL APPL PHARM, V218, P88, DOI 10.1016/j.taap.2006.10.029; Watson WH, 2008, BIOCHEM BIOPH RES CO, V368, P832, DOI 10.1016/j.bbrc.2008.02.006; William WN, 2007, J THORAC ONCOL, V2, P745, DOI 10.1097/JTO.0b013e31811f4719; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Yoo MH, 2006, J BIOL CHEM, V281, P13005, DOI 10.1074/jbc.C600012200; Yoo MH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001112	56	14	15	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2010	5	1							e8786	10.1371/journal.pone.0008786	http://dx.doi.org/10.1371/journal.pone.0008786			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546AI	20098717	Green Published, gold, Green Submitted			2023-01-03	WOS:000273779000015
J	Onken, B; Driscoll, M				Onken, Brian; Driscoll, Monica			Metformin Induces a Dietary Restriction-Like State and the Oxidative Stress Response to Extend C. elegans Healthspan via AMPK, LKB1, and SKN-1	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; NEMATODE CAENORHABDITIS-ELEGANS; LIFE-SPAN EXTENSION; CALORIE RESTRICTION; CYTOPLASMIC LOCALIZATION; SIGNALING PATHWAY; INDUCED LONGEVITY; SKELETAL-MUSCLE; MAMMARY-TUMORS; FAMILY-MEMBER	Metformin, a biguanide drug commonly used to treat type-2 diabetes, has been noted to extend healthspan of nondiabetic mice, but this outcome, and the molecular mechanisms that underlie it, have received relatively little experimental attention. To develop a genetic model for study of biguanide effects on healthspan, we investigated metformin impact on aging Caenorhabditis elegans. We found that metformin increases nematode healthspan, slowing lipofuscin accumulation, extending median lifespan, and prolonging youthful locomotory ability in a dose-dependent manner. Genetic data suggest that metformin acts through a mechanism similar to that operative in eating-impaired dietary restriction (DR) mutants, but independent of the insulin signaling pathway. Energy sensor AMPK and AMPK-activating kinase LKB1, which are activated in mammals by metformin treatment, are essential for health benefits in C. elegans, suggesting that metformin engages a metabolic loop conserved across phyla. We also show that the conserved oxidative stress-responsive transcription factor SKN-1/Nrf2 is essential for metformin healthspan benefits in C. elegans, a mechanistic requirement not previously described in mammals. skn-1, which functions in nematode sensory neurons to promote DR longevity benefits and in intestines for oxidative stress resistance lifespan benefits, must be expressed in both neurons and intestines for metformin-promoted healthspan extension, supporting that metformin improves healthy middle-life aging by activating both DR and antioxidant defense longevity pathways. In addition to defining molecular players operative in metformin healthspan benefits, our data suggest that metformin may be a plausible pharmacological intervention to promote healthy human aging.	[Onken, Brian; Driscoll, Monica] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA	Rutgers State University New Brunswick	Onken, B (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08855 USA.	driscoll@biology.rutgers.edu			National Institutes of Health [R01AG024882]; Ellison Medical Foundation; National Institutes of Health Center for Dietary Supplements Research on Botanicals and Metabolic Syndrome [1-P50 AT002776-01]; New Jersey Commission on Cancer Research; Ellison Medical Foundation/American Federation of Aging Research; National Center for Complementary & Integrative Health [P50AT002776] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024882] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); National Institutes of Health Center for Dietary Supplements Research on Botanicals and Metabolic Syndrome(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); New Jersey Commission on Cancer Research; Ellison Medical Foundation/American Federation of Aging Research(Lawrence Ellison Foundation); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Work was supported by National Institutes of Health funding R01AG024882, the Ellison Medical Foundation, and the National Institutes of Health Center for Dietary Supplements Research on Botanicals and Metabolic Syndrome, grant # 1-P50 AT002776-01. BO was supported by a grant from the New Jersey Commission on Cancer Research and by a Postdoctoral Fellowship in Aging Research from the Ellison Medical Foundation/American Federation of Aging Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	An JH, 2003, GENE DEV, V17, P1882, DOI 10.1101/gad.1107803; Anedda A, 2008, J ENDOCRINOL, V199, P33, DOI 10.1677/JOE-08-0278; Anisimov VN, 2008, CELL CYCLE, V7, P2769, DOI 10.4161/cc.7.17.6625; Anisimov VN, 2005, B EXP BIOL MED+, V139, P721, DOI 10.1007/s10517-005-0389-9; Anisimov VN, 2005, EXP GERONTOL, V40, P685, DOI 10.1016/j.exger.2005.07.007; Anisimov VN, 2003, EXP GERONTOL, V38, P1041, DOI 10.1016/S0531-5565(03)00169-4; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Barbieri M, 2003, AM J PHYSIOL-ENDOC M, V285, pE1064, DOI 10.1152/ajpendo.00296.2003; Barzilai N, 2001, J NUTR, V131, p903S, DOI 10.1093/jn/131.3.903S; Beale EG, 2008, EXP BIOL MED, V233, P12, DOI 10.3181/0705-MR-117; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; BOLANOWSKI MA, 1981, MECH AGEING DEV, V15, P279, DOI 10.1016/0047-6374(81)90136-6; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BRENNER S, 1974, GENETICS, V77, P71; CARLING D, 1989, BIOCHIM BIOPHYS ACTA, V1012, P81, DOI 10.1016/0167-4889(89)90014-1; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Curtis R, 2006, AGING CELL, V5, P119, DOI 10.1111/j.1474-9726.2006.00205.x; DeFronzo RA, 2000, ANN INTERN MED, V133, P73, DOI 10.7326/0003-4819-133-1-200007040-00016; Dhahbi JM, 2005, PHYSIOL GENOMICS, V23, P343, DOI 10.1152/physiolgenomics.00069.2005; Dirkswager E., 2002, TEACHERS OWNERS KEY; DORMAN JB, 1995, GENETICS, V141, P1399; DUHON SA, 1995, J GERONTOL A-BIOL, V50, pB254, DOI 10.1093/gerona/50A.5.B254; Eckel RH, 2005, LANCET, V365, P1415, DOI 10.1016/S0140-6736(05)66378-7; FRIEDMAN DB, 1988, GENETICS, V118, P75; Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200; Gami MS, 2006, AGING CELL, V5, P31, DOI 10.1111/j.1474-9726.2006.00188.x; Gerstbrein B, 2005, AGING CELL, V4, P127, DOI 10.1111/j.1474-9726.2005.00153.x; Glenn CF, 2004, J GERONTOL A-BIOL, V59, P1251, DOI 10.1093/gerona/59.12.1251; Greene AE, 2001, EPILEPSIA, V42, P1371, DOI 10.1046/j.1528-1157.2001.17601.x; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Hawley SA, 2002, DIABETES, V51, P2420, DOI 10.2337/diabetes.51.8.2420; HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hayes JD, 2001, CANCER LETT, V174, P103, DOI 10.1016/S0304-3835(01)00695-4; Herndon LA, 2002, NATURE, V419, P808, DOI 10.1038/nature01135; Holden-Dye Lindy, 2007, WormBook, P1, DOI 10.1895/wormbook.1.143.1; Houthoofd K, 2003, EXP GERONTOL, V38, P947, DOI 10.1016/S0531-5565(03)00161-X; Houthoofd K, 2002, EXP GERONTOL, V37, P1359, DOI 10.1016/S0531-5565(02)00172-9; Huang C, 2004, P NATL ACAD SCI USA, V101, P8084, DOI 10.1073/pnas.0400848101; Hughes SE, 2007, PLOS GENET, V3, P254, DOI 10.1371/journal.pgen.0030025; HYUNG J, 2003, GENE DEV, V17, P1882; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Kaeberlein TL, 2006, AGING CELL, V5, P487, DOI 10.1111/j.1474-9726.2006.00238.x; Kahn NW, 2008, BIOCHEM J, V409, P205, DOI 10.1042/BJ20070521; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; Koo SH, 2005, NATURE, V437, P1109, DOI 10.1038/nature03967; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091; Lane MA, 2004, J GERONTOL A-BIOL, V59, P405; Lee GD, 2006, AGING CELL, V5, P515, DOI 10.1111/j.1474-9726.2006.00241.x; Lee HJ, 2008, J BIOL CHEM, V283, P14988, DOI 10.1074/jbc.M709115200; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Link CD, 2002, METHOD ENZYMOL, V353, P497; Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044; Marsin AS, 2000, CURR BIOL, V10, P1247, DOI 10.1016/S0960-9822(00)00742-9; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; McBride A, 2009, CELL METAB, V9, P23, DOI 10.1016/j.cmet.2008.11.008; Morck C, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-39; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; MORTON DG, 1992, GENETICS, V130, P771; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Narbonne P, 2006, DEVELOPMENT, V133, P611, DOI 10.1242/dev.02232; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837; Partridge L, 2005, MECH AGEING DEV, V126, P938, DOI 10.1016/j.mad.2005.03.023; Rand JB, 1995, METHOD CELL BIOL, V48, P187; Sakamoto K, 2005, EMBO J, V24, P1810, DOI 10.1038/sj.emboj.7600667; Scarpello JHB, 2003, DIABETES METAB, V29, pS36; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; Scott MP, 2002, J BIOL CHEM, V277, P28238, DOI 10.1074/jbc.M202783200; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Siegfried Z, 2003, PHYSIOL BEHAV, V79, P39, DOI 10.1016/S0031-9384(03)00103-3; Teale KFH, 1998, ANAESTHESIA, V53, P698, DOI 10.1046/j.1365-2044.1998.436-az0549.x; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; VOWELS JJ, 1992, GENETICS, V130, P105; Walker G, 2005, MECH AGEING DEV, V126, P929, DOI 10.1016/j.mad.2005.03.014; Watt MJ, 2006, AM J PHYSIOL-ENDOC M, V290, pE500, DOI 10.1152/ajpendo.00361.2005; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xue BZ, 2006, J PHYSIOL-LONDON, V574, P73, DOI 10.1113/jphysiol.2006.113217; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505	96	440	470	4	82	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 18	2010	5	1							e8758	10.1371/journal.pone.0008758	http://dx.doi.org/10.1371/journal.pone.0008758			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	545EJ	20090912	Green Submitted, gold, Green Published			2023-01-03	WOS:000273715000016
J	Krishna, ADS; Mandraju, RK; Kishore, G; Kondapi, AK				Krishna, Athuluri Divakar Sai; Mandraju, Raj Kumar; Kishore, Golla; Kondapi, Anand Kumar			An Efficient Targeted Drug Delivery through Apotransferrin Loaded Nanoparticles	PLOS ONE			English	Article								Background: Cancerous state is a highly stimulated environment of metabolically active cells. The cells under these conditions over express selective receptors for assimilation of factors essential for growth and transformation. Such receptors would serve as potential targets for the specific ligand mediated transport of pharmaceutically active molecules. The present study demonstrates the specificity and efficacy of protein nanoparticle of apotransferrin for targeted delivery of doxorubicin. Methodology/Principal Findings: Apotransferrin nanoparticles were developed by sol-oil chemistry. A comparative analysis of efficiency of drug delivery in conjugated and non-conjugated forms of doxorubicin to apotransferrin nanoparticle is presented. The spherical shaped apotransferrin nanoparticles (nano) have diameters of 25-50 eta m, which increase to 60-80 eta m upon direct loading of drug (direct-nano), and showed further increase in dimension (75-95 eta m) in conjugated nanoparticles (conj-nano). The competitive experiments with the transferrin receptor specific antibody showed the entry of both conj-nano and direct-nano into the cells through transferrin receptor mediated endocytosis. Results of various studies conducted clearly establish the superiority of the direct-nano over conj-nano viz. ( a) localization studies showed complete release of drug very early, even as early as 30 min after treatment, with the drug localizing in the target organelle ( nucleus) (b) pharmacokinetic studies showed enhanced drug concentrations, in circulation with sustainable half-life ( c) the studies also demonstrated efficient drug delivery, and an enhanced inhibition of proliferation in cancer cells. Tissue distribution analysis showed intravenous administration of direct nano lead to higher drug localization in liver, and blood as compared to relatively lesser localization in heart, kidney and spleen. Experiments using rat cancer model confirmed the efficacy of the formulation in regression of hepatocellular carcinoma with negligible toxicity to kidney and liver. Conclusions: The present study thus demonstrates that the direct-nano is highly efficacious in delivery of drug in a target specific manner with lower toxicity to heart, liver and kidney.			Krishna, ADS (corresponding author), Univ Hyderabad, Dept Biochem, Hyderabad 500134, Andhra Pradesh, India.	akondapi@yahoo.com		A. DIVAKAR, SAI KRISHNA/0000-0003-0232-4052				Ali SA, 1999, J BIOL CHEM, V274, P24066, DOI 10.1074/jbc.274.34.24066; Anhorn MG, 2008, BIOCONJUGATE CHEM, V19, P2321, DOI 10.1021/bc8002452; Aravalli RN, 2008, HEPATOLOGY, V48, P2047, DOI 10.1002/hep.22580; Baalousha M, 2005, MICROSC RES TECHNIQ, V66, P299, DOI 10.1002/jemt.20173; BABSON AL, 1973, CLIN CHEM, V19, P766; Berthelot MPE., 1859, REPORT CHIM APPL, V384, P2884; Beyer U, 1998, J MED CHEM, V41, P2701, DOI 10.1021/jm9704661; Bills CE, 1926, J BIOL CHEM, V67, P279; Bowers GN, 1972, CLIN CHEM, V18, P97; BOWERS LD, 1980, CLIN CHEM, V26, P555; BRASLAWSKY GR, 1991, CANCER IMMUNOL IMMUN, V33, P367, DOI 10.1007/BF01741596; Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3; Chen BA, 2008, INT J NANOMED, V3, P277; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; ENNS CA, 1982, P NATL ACAD SCI-BIOL, V79, P3241, DOI 10.1073/pnas.79.10.3241; Erickson B, 2008, LANGMUIR, V24, P11003, DOI 10.1021/la801497d; GATTER KC, 1983, J CLIN PATHOL, V36, P539, DOI 10.1136/jcp.36.5.539; Gaur U, 2000, INT J PHARM, V202, P1, DOI 10.1016/S0378-5173(99)00447-0; Grayson SM, 2008, J DRUG TARGET, V16, P329, DOI [10.1080/10611860801969616, 10.1080/10611860801969616 ]; Hait W. N., 2009, CANCER RES, V69, P1267; Hait WN, 2009, CANCER RES, V69, P1263, DOI 10.1158/0008-5472.CAN-08-3836; Hamad I, 2008, EXPERT OPIN DRUG DEL, V5, P205, DOI 10.1517/17425247.5.2.205; Holmstrom P, 2006, LIVER INT, V26, P976, DOI 10.1111/j.1478-3231.2006.01316.x; Hsieh MF, 2008, J NANOSCI NANOTECHNO, V8, P2362, DOI 10.1166/jnn.2008.322; Iankov ID, 2007, MOL THER, V15, P114, DOI 10.1038/sj.mt.6300020; Jain RK, 1999, ANNU REV BIOMED ENG, V1, P241, DOI 10.1146/annurev.bioeng.1.1.241; Kircheis R, 2001, GENE THER, V8, P28, DOI 10.1038/sj.gt.3301351; KONDAPI AK, 2007, Patent No. 14433; Kondapi AK, 2006, ARCH BIOCHEM BIOPHYS, V450, P123, DOI 10.1016/j.abb.2006.04.003; Kono K, 2008, BIOMATERIALS, V29, P1664, DOI 10.1016/j.biomaterials.2007.12.017; Li HY, 2002, TRENDS PHARMACOL SCI, V23, P206, DOI 10.1016/S0165-6147(02)01989-2; Lochmann D, 2005, EUR J PHARM BIOPHARM, V59, P419, DOI 10.1016/j.ejpb.2004.04.001; Lopez-Tarruella S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2226; Mier W, 2005, BIOCONJUGATE CHEM, V16, P237, DOI 10.1021/bc034216c; Minguez B, 2009, CURR OPIN GASTROEN, V25, P186, DOI 10.1097/MOG.0b013e32832962a1; Misra S, 2009, J BIOL CHEM, V284, P12432, DOI 10.1074/jbc.M806772200; Munnier E, 2008, INT J PHARMACEUT, V363, P170, DOI 10.1016/j.ijpharm.2008.07.006; PANDE G, 1986, CANCER RES, V46, P1673; Papagiannaros A, 2005, INT J PHARMACEUT, V302, P29, DOI 10.1016/j.ijpharm.2005.05.039; PLOSKER GL, 1993, DRUGS, V45, P788, DOI 10.2165/00003495-199345050-00011; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; Reddy Lakkireddy Harivardhan, 2005, Acta Pharmaceutica (Zagreb), V55, P81; Romberg B, 2008, PHARM RES, V25, P55, DOI 10.1007/s11095-007-9348-7; Singh M, 1999, CURR PHARM DESIGN, V5, P443; STEIN BS, 1984, J BIOL CHEM, V259, P4762; STORM G, 1995, ADV DRUG DELIVER REV, V17, P31, DOI 10.1016/0169-409X(95)00039-A; THORSTENSEN K, 1993, SCAND J CLIN LAB INV, V53, P113, DOI 10.3109/00365519309090703; Tian Z, 2008, BIOMED MATER, V3, DOI 10.1088/1748-6041/3/4/044116; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSENG HH, 2009, J CANC RES CLIN 0423; Udhrain A, 2007, INT J NANOMED, V2, P345; VINCENT A, 2009, ACS NANO; Wei JS, 2005, FRONT BIOSCI-LANDMRK, V10, P3058; Wong HL, 2006, J CONTROL RELEASE, V116, P275, DOI 10.1016/j.jconrel.2006.09.007; Xu JP, 2005, J CONTROL RELEASE, V107, P502, DOI 10.1016/j.jconrel.2005.06.013; Xu PS, 2009, MOL PHARMACEUT, V6, P190, DOI 10.1021/mp800137z; Yadav AK, 2008, J DRUG TARGET, V16, P464, DOI 10.1080/10611860802095494 ; Yadav AK, 2007, NANOMED-NANOTECHNOL, V3, P246, DOI 10.1016/j.nano.2007.09.004; Ying XY, 2008, PHARMAZIE, V63, P878, DOI 10.1691/ph.2008.8162; Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x; Zamboni WC, 2008, ONCOLOGIST, V13, P248, DOI 10.1634/theoncologist.2007-0180	61	55	56	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 2	2009	4	10							e7240	10.1371/journal.pone.0007240	http://dx.doi.org/10.1371/journal.pone.0007240			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	504DD	19806207	Green Published, gold, Green Submitted			2023-01-03	WOS:000270593300005
J	Ziegler, TR				Ziegler, Thomas R.			Parenteral Nutrition in the Critically Ill Patient	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE-CARE-UNIT; ENTERAL NUTRITION; GLUTAMINE DIPEPTIDE; INFECTIOUS COMPLICATIONS; ENERGY-EXPENDITURE; REFEEDING SYNDROME; CLINICAL-PRACTICE; CRITICAL ILLNESS; SEPTIC PATIENTS; CALORIC-INTAKE	A 67-year-old woman with type 2 diabetes mellitus undergoes extensive resection of the small bowel and right colon with a jejunostomy and colostomy because of mesenteric ischemia. In the surgical intensive care unit, severe systemic inflammatory response syndrome with possible sepsis develops. The patient is treated with volume resuscitation, vasopressor support, mechanical ventilation, broad-spectrum antibiotics, and intravenous insulin infusion. Low-dose tube feedings are initiated postoperatively through a nasogastric tube. However, these feedings are discontinued after the development of escalating vasopressor requirements, worsening abdominal distention, and increased gastric residual volume, along with an episode of emesis. The hospital nutritional-support service is consulted for feeding recommendations. A discussion with the patient's family reveals that during the previous 6 months, she lost approximately 15% of her usual body weight and decreased her food intake because of abdominal pain associated with eating. Her preoperative body weight was 51 kg (112 lb), or 90% of her ideal body weight. The physical examination reveals mild wasting of skeletal muscle and fat. Blood tests show hypomagnesemia, hypophosphatemia, and normal hepatic and renal function. Central venous parenteral nutrition is recommended.	[Ziegler, Thomas R.] Emory Univ, Atlanta Clin & Translat Sci Inst, Nutr & Metab Support Serv, Sch Med,Emory Univ Hosp, Atlanta, GA 30322 USA; [Ziegler, Thomas R.] Emory Univ, Dept Med, Div Endocrinol Metab & Lipids, Sch Med, Atlanta, GA 30322 USA	Emory University; Emory University	Ziegler, TR (corresponding author), Emory Univ, Atlanta Clin & Translat Sci Inst, Nutr & Metab Support Serv, Sch Med,Emory Univ Hosp, Room GG-23,1364 Clifton Rd, Atlanta, GA 30322 USA.	tzieg01@emory.edu			National Institutes of Health [U01-DK069322, K24-RR023356, UL1-RR025008]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K24RR023356, UL1RR025008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK069322] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the National Institutes of Health (U01-DK069322, K24-RR023356, and UL1-RR025008).	Anderegg BA, 2009, JPEN-PARENTER ENTER, V33, P168, DOI 10.1177/0148607108327192; *ASPEN BOARD DIR C, 2002, JPEN J PARENTER ENTE, V26, P144; ASPEN Board of Directors and the Clinical Guidelines Task Force, 2002, JPEN J Parenter Enteral Nutr, V26, p1SA; Battistella FD, 1997, J TRAUMA, V43, P52, DOI 10.1097/00005373-199707000-00013; Berger MM, 2007, CURR OPIN CRIT CARE, V13, P180, DOI 10.1097/MCC.0b013e3280895d47; Berger MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6981; Bistrian BR, 2006, CRIT CARE MED, V34, P1525, DOI 10.1097/01.CCM.0000216704.54446.FD; Bongers T, 2007, CRIT CARE MED, V35, pS545, DOI 10.1097/01.CCM.0000279193.23737.06; Braunschweig CL, 2001, AM J CLIN NUTR, V74, P534; Burnham EL, 2005, J NUTR, V135, p1818S, DOI 10.1093/jn/135.7.1818S; Cree MG, 2008, AM J PHYSIOL-ENDOC M, V294, pE1, DOI 10.1152/ajpendo.00562.2007; De Jonghe B, 2001, CRIT CARE MED, V29, P8, DOI 10.1097/00003246-200101000-00002; Dechelotte P, 2006, CRIT CARE MED, V34, P598, DOI 10.1097/01.CCM.0000201004.30750.D1; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Doig GS, 2005, ANESTH ANALG, V100, P527, DOI 10.1213/01.ANE.0000141676.12552.D0; Elke G, 2008, CRIT CARE MED, V36, P1762, DOI 10.1097/CCM.0b013e318174dcf0; Estivariz CF, 2008, JPEN-PARENTER ENTER, V32, P389, DOI 10.1177/0148607108317880; Ferrando AA, 2006, CURR OPIN CLIN NUTR, V9, P410, DOI 10.1097/01.mco.0000232901.59168.e9; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Giner M, 1996, NUTRITION, V12, P23, DOI 10.1016/0899-9007(95)00015-1; Gramlich L, 2004, NUTRITION, V20, P843, DOI 10.1016/j.nut.2004.06.003; Grau T, 2007, CRIT CARE, V11, DOI 10.1186/cc5670; Griffiths RD, 2004, CURR OPIN CLIN NUTR, V7, P175, DOI 10.1097/00075197-200403000-00012; Heidegger CP, 2007, INTENS CARE MED, V33, P963, DOI 10.1007/s00134-007-0654-7; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Heyland DK, 1998, JAMA-J AM MED ASSOC, V280, P2013, DOI 10.1001/jama.280.23.2013; Jones NE, 2008, CURR OPIN GASTROEN, V24, P215, DOI 10.1097/MOG.0b013e3282f4cdd8; Kennedy JF, 2005, NUTRITION, V21, P1127, DOI 10.1016/j.nut.2005.08.002; Koletzko Berthold, 2005, J Pediatr Gastroenterol Nutr, V41 Suppl 2, pS1, DOI 10.1097/01.mpg.0000181841.07090.f4; Koretz RL, 2001, GASTROENTEROLOGY, V121, P970, DOI [10.1053/gast.2001.28031, 10.1016/S0016-5085(01)92000-1]; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Krishnan JA, 2003, CHEST, V124, P297, DOI 10.1378/chest.124.1.297; Luo MH, 2008, NUTRITION, V24, P37, DOI 10.1016/j.nut.2007.10.004; Marik PE, 2008, CRIT CARE MED, V36, P1964, DOI 10.1097/CCM.0b013e31817612d6; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; Mayer Konstantin, 2008, Curr Opin Clin Nutr Metab Care, V11, P121, DOI 10.1097/MCO.0b013e3282f4cdc6; McClave SA, 1998, JPEN-PARENTER ENTER, V22, P375, DOI 10.1177/0148607198022006375; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; Mehta NM, 2009, JPEN-PARENTER ENTER, V33, P260, DOI 10.1177/0148607109333114; Mirtallo J, 2006, JPEN-PARENTER ENTER, V30, P177; MOORE FA, 1992, ANN SURG, V216, P172, DOI 10.1097/00000658-199208000-00008; Nardo P, 2008, CLIN NUTR, V27, P858, DOI 10.1016/j.clnu.2008.08.001; O'Brien JM, 2006, CRIT CARE MED, V34, P738, DOI 10.1097/01.CCM.0000202207.87891.FC; Pacelli F, 2001, ARCH SURG-CHICAGO, V136, P933, DOI 10.1001/archsurg.136.8.933; Peter JV, 2005, CRIT CARE MED, V33, P213, DOI 10.1097/01.CCM.0000150960.36228.C0; Plauth M, 2009, CLIN NUTR, V28, P436, DOI 10.1016/j.clnu.2009.04.019; QuinonesGalvan A, 1997, J NEPHROL, V10, P188; Reid CL, 2007, CLIN NUTR, V26, P649, DOI 10.1016/j.clnu.2007.02.003; Rhee P, 2007, J TRAUMA, V63, P1215, DOI 10.1097/TA.0b013e31815b83e9; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Sala-Vila A, 2007, CURR OPIN CLIN NUTR, V10, P165, DOI 10.1097/MCO.0b013e32802bf787; SANDSTROM R, 1993, ANN SURG, V217, P185, DOI 10.1097/00000658-199302000-00013; Schneider SM, 2004, BRIT J NUTR, V92, P105, DOI 10.1079/BJN20041152; Sena MJ, 2008, J AM COLL SURGEONS, V207, P459, DOI 10.1016/j.jamcollsurg.2008.04.028; SHAW JHF, 1987, ANN SURG, V205, P288, DOI 10.1097/00000658-198703000-00012; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; SOLOMON SM, 1990, JPEN-PARENTER ENTER, V14, P90, DOI 10.1177/014860719001400190; Stanga Z, 2008, EUR J CLIN NUTR, V62, P687, DOI 10.1038/sj.ejcn.1602854; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; Trujillo EB, 1999, JPEN-PARENTER ENTER, V23, P109, DOI 10.1177/0148607199023002109; VANDENBERGHE G, 2009, J CLIN ENDOCRIN 0616; Villet S, 2005, CLIN NUTR, V24, P502, DOI 10.1016/j.clnu.2005.03.006; Vincent JL, 2008, CURR OPIN ANESTHESIO, V21, P148, DOI 10.1097/ACO.0b013e3282f49afe; Waitzberg DL, 2006, JPEN-PARENTER ENTER, V30, P351, DOI 10.1177/0148607106030004351; Wanten GJA, 2007, AM J CLIN NUTR, V85, P1171; Wernerman J, 2008, CURR OPIN CLIN NUTR, V11, P160, DOI 10.1097/MCO.0b013e3282f53370; WILMORE DW, 1991, NEW ENGL J MED, V325, P695, DOI 10.1056/NEJM199109053251005; Wischmeyer PE, 2008, CURR OPIN GASTROEN, V24, P190, DOI 10.1097/MOG.0b013e3282f4db94; Woodcock NP, 2001, NUTRITION, V17, P1, DOI 10.1016/S0899-9007(00)00576-1; Zaloga GP, 2006, LANCET, V367, P1101, DOI 10.1016/S0140-6736(06)68307-4; Ziegler TR, 2003, ANNU REV NUTR, V23, P229, DOI 10.1146/annurev.nutr.23.011702.073036	73	150	156	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 10	2009	361	11					1088	1097		10.1056/NEJMct0806956	http://dx.doi.org/10.1056/NEJMct0806956			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	492LP	19741230	Green Accepted			2023-01-03	WOS:000269659400012
J	Farrar, S; Yi, D; Sutton, M; Chalkley, M; Sussex, J; Scott, A				Farrar, Shelley; Yi, Deokhee; Sutton, Matt; Chalkley, Martin; Sussex, Jon; Scott, Anthony			Has payment by results affected the way that English hospitals provide care? Difference-in-differences analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FINANCIAL FLOWS; QUALITY; NHS; SYSTEM	Objective To examine whether the introduction of payment by results (a fixed tariff case mix based payment system) was associated with changes in key outcome variables measuring volume, cost, and quality of care between 2003/4 and 2005/6. Setting Acute care hospitals in England. Design Difference-in-differences analysis (using a control group created from trusts in England and providers in Scotland not implementing payment by results in the relevant years); retrospective analysis of patient level secondary data with fixed effects models. Data sources English hospital episode statistics and Scottish morbidity records for 2002/3 to 2005/6. Main outcome measures Changes in length of stay and proportion of day case admissions as a proxy for unit cost; growth in number of spells to measure increases in output; and changes in in-hospital mortality, 30 day post-surgical mortality, and emergency readmission after treatment for hip fracture as measures of impact on quality of care. Results Length of stay fell more quickly and the proportion of day cases increased more quickly where payment by results was implemented, suggesting a reduction in the unit costs of care associated with payment by results. Some evidence of an association between the introduction of payment by results and growth in acute hospital activity was found. Little measurable change occurred in the quality of care indicators used in this study that can be attributed to the introduction of payment by results. Conclusion Reductions in unit costs may have been achieved without detrimental impact on the quality of care, at least in as far as these are measured by the proxy variables used in this study.	[Sutton, Matt] Univ Manchester, Hlth Methodol Res Grp, Manchester M13 9PL, Lancs, England; [Chalkley, Martin] Univ Dundee, Dept Econ Studies, Dundee DD1 4HN, Scotland; [Sussex, Jon] Off Hlth Econ, London SW1A 2DY, England	University of Manchester; University of Dundee		s.farrar@abdn.ac.uk	Yi, Deokhee/F-5913-2015; Sussex, Jon/J-5049-2014; Scott, Anthony/E-6636-2010	Yi, Deokhee/0000-0003-4894-1689; Sussex, Jon/0000-0001-8970-4546; Scott, Anthony/0000-0002-2851-5378; Chalkley, Martin/0000-0002-1091-8259; Sutton, Matt/0000-0002-6635-2127	Department of Health through the Policy Research Programme; Chief Scientist Office [HERU1] Funding Source: researchfish	Department of Health through the Policy Research Programme; Chief Scientist Office	This research was funded by the Department of Health through the Policy Research Programme. The researchers are independent of the funders. The views expressed in this paper are those of the authors and not the funding body.	APPLEBY J, 2004, NEW EC, V11, P195; *AUD COMM, 2005, EARL LESS PAYM RES; *AUD COMM, 2008, RIGHT RES PAYM RES 2; Blundell R., 2000, FISC STUD, V21, P427, DOI [10.1111/j.1475-5890.2000.tb00031.x, DOI 10.1111/J.1475-5890.2000.TB00031.X]; Chalkley M, 2000, HANDB ECON, V17, P847; *DEP HLTH, 2005, IMPL PAYM RES TECHN; *DEP HLTH, 2004, IMPL PAYM RES TECHN; *DEP HLTH, 2004, NHS REF COSTS 2003 N; Department of Health, 2002, REF NHS FIN FLOWS IN; Dismuke CE, 2002, APPL ECON, V34, P1301, DOI 10.1080/00036840110095418; Dixon J, 2004, BMJ-BRIT MED J, V328, P969, DOI 10.1136/bmj.328.7446.969; France FHR, 2003, INT J MED INFORM, V70, P215, DOI 10.1016/S1386-5056(03)00044-3; Kjerstad Egil, 2003, Int J Health Care Finance Econ, V3, P231, DOI 10.1023/A:1026084304382; Ljunggren B, 2001, SCAND J CARING SCI, V15, P283, DOI 10.1046/j.1471-6712.2001.00046.x; Manning WG, 2005, J HEALTH ECON, V24, P465, DOI 10.1016/j.jhealeco.2004.09.011; MANNION R, 2006, 14 U YORK CTR HLTH E; Marini G, 2008, HEALTH ECON, V17, P751, DOI 10.1002/hec.1292; Marini G, 2007, HEALTH POLICY, V83, P17, DOI 10.1016/j.healthpol.2006.11.007; Mikkola H, 2002, HEALTH POLICY, V59, P37, DOI 10.1016/S0168-8510(01)00169-5; NEWHOUSE JP, 1988, J HEALTH ECON, V7, P413, DOI 10.1016/0167-6296(88)90023-9; Pitches DW, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-91; PROPPER C, 2007, CTR MARKET PUBLIC OR; Qin J, 2008, J ROY STAT SOC B, V70, P329, DOI 10.1111/j.1467-9868.2007.00638.x; Raftery J, 1996, HEALTH ECON, V5, P353, DOI 10.1002/(SICI)1099-1050(199607)5:4<353::AID-HEC215>3.3.CO;2-#; Rogers R, 2005, BMJ-BRIT MED J, V330, P563, DOI 10.1136/bmj.330.7491.563; Siciliani L, 2005, HEALTH POLICY, V72, P201, DOI 10.1016/j.healthpol.2004.07.003; Street A, 2004, PUBLIC MONEY MANAGE, V24, P301, DOI 10.1111/j.1467-9302.2004.00438.x; SUSSEX J, 2005, ACTIVITY BASED FINAN; Sussex J, 2009, EUR J HEALTH ECON, V10, P197, DOI 10.1007/s10198-008-0119-0	29	105	105	2	31	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 27	2009	339								b3047	10.1136/bmj.b3047	http://dx.doi.org/10.1136/bmj.b3047			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	489AY	19713233	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000269393100001
J	Nanda, A; Chen, MH; Braccioforte, MH; Moran, BJ; D'Amico, AV				Nanda, Akash; Chen, Ming-Hui; Braccioforte, Michelle H.; Moran, Brian J.; D'Amico, Anthony V.			Hormonal Therapy Use for Prostate Cancer and Mortality in Men With Coronary Artery Disease-Induced Congestive Heart Failure or Myocardial Infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANDROGEN-DEPRIVATION THERAPY; EXTERNAL-BEAM RADIOTHERAPY; RADIATION-THERAPY; DEFINITIVE RADIOTHERAPY; CARDIOVASCULAR-DISEASE; BODY-COMPOSITION; SUPPRESSION; SURVIVAL; BRACHYTHERAPY; MANAGEMENT	Context Hormonal therapy (HT) when added to radiation therapy (RT) for treating unfavorable-risk prostate cancer leads to an increase in survival except possibly in men with moderate to severe comorbidity. However, it is unknown which comorbid conditions eliminate this survival benefit. Objective To assess whether neoadjuvant HT use affects the risk of all-cause mortality in men with prostate cancer and coronary artery disease (CAD)-induced congestive heart failure (CHF) or myocardial infarction (MI), CAD risk factors, or no comorbidity. Design, Setting, and Patients A total of 5077 men (median age, 69.5 years) with localized or locally advanced prostate cancer were consecutively treated with or without a median of 4 months of neoadjuvant HT followed by RT at a suburban cancer center between 1997 and 2006 and were followed up until July 1, 2008. Cox regression multivariable analyses were performed assessing whether neoadjuvant HT use affected the risk of all-cause mortality, adjusting for age, year and type of RT, treatment propensity score, and known prostate cancer prognostic factors in each comorbidity group. Main Outcome Measure Risk of all-cause mortality. Results Neoadjuvant HT use was not associated with an increased risk of all-cause mortality in men with no comorbidity (9.6% vs 6.7%, adjusted hazard ratio [HR], 0.97; 95% confidence interval [CI], 0.72-1.32; P=.86) or a single CAD risk factor (10.7% vs 7.0%, adjusted HR, 1.04; 95% CI, 0.75-1.43; P=.82) after median follow-ups of 5.0 and 4.4 years, respectively. However, for men with CAD-induced CHF or MI, after a median follow-up of 5.1 years, neoadjuvant HT use was significantly associated with an increased risk of all-cause mortality (26.3% vs 11.2%, adjusted HR, 1.96; 95% CI, 1.04-3.71; P=.04). Conclusion Neoadjuvant HT use is significantly associated with an increased risk of all-cause mortality among men with a history of CAD-induced CHF or MI but not among men with no comorbidity or a single CAD risk factor. JAMA. 2009; 302(8): 866-873	[Nanda, Akash] Brigham & Womens Hosp, Harvard Radiat Oncol Program, Dana Farber Canc Inst, Boston, MA 02115 USA; [D'Amico, Anthony V.] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; [Chen, Ming-Hui] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA; [Braccioforte, Michelle H.; Moran, Brian J.] Prostate Canc Fdn Chicago, Westmont, IL USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; University of Connecticut	Nanda, A (corresponding author), Brigham & Womens Hosp, Harvard Radiat Oncol Program, Dana Farber Canc Inst, 75 Francis St,ASB1 L2, Boston, MA 02115 USA.	ananda@partners.org						Agresti A., 2002, CATEGORICAL DATA ANA, V2nd; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; [Anonymous], 1979, Circulation, V59, P607; Ansell BJ, 1999, JAMA-J AM MED ASSOC, V282, P2051, DOI 10.1001/jama.282.21.2051; Beyer DC, 2005, INT J RADIAT ONCOL, V61, P1299, DOI 10.1016/j.ijrobp.2004.08.024; Bolla M, 2002, LANCET, V360, P103, DOI 10.1016/S0140-6736(02)09408-4; Braga-Basaria M, 2006, J CLIN ONCOL, V24, P3979, DOI 10.1200/JCO.2006.05.9741; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; CUPPLES LA, 1995, STAT MED, V14, P1731, DOI 10.1002/sim.4780141603; D'Amico AV, 2008, JAMA-J AM MED ASSOC, V299, P289, DOI 10.1001/jama.299.3.289; D'Amico AV, 2007, J CLIN ONCOL, V25, P2420, DOI 10.1200/JCO.2006.09.3369; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; D'Amico AV, 2004, JAMA-J AM MED ASSOC, V292, P821, DOI 10.1001/jama.292.7.821; Denham JW, 2005, LANCET ONCOL, V6, P841, DOI 10.1016/S1470-2045(05)70348-X; Gavin JR, 1997, DIABETES CARE, V20, P1183; Genuth S, 2003, DIABETES CARE, V26, P3160; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143; Hollander M., 1999, NONPARAMETRIC STAT M; Hsieh FY, 2000, CONTROL CLIN TRIALS, V21, P552, DOI 10.1016/S0197-2456(00)00104-5; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keating NL, 2006, J CLIN ONCOL, V24, P4448, DOI 10.1200/JCO.2006.06.2497; Klein JP, 2003, SURVIVAL ANAL; Lee H, 2005, CANCER-AM CANCER SOC, V104, P1633, DOI 10.1002/cncr.21381; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Merrick GS, 2006, INT J RADIAT ONCOL, V65, P669, DOI 10.1016/j.ijrobp.2006.01.030; Nag S, 1999, INT J RADIAT ONCOL, V44, P789, DOI 10.1016/S0360-3016(99)00069-3; Newgard CD, 2004, ACAD EMERG MED, V11, P953, DOI 10.1197/j.aem.2004.02.530; Piccirillo JF, 2004, JAMA-J AM MED ASSOC, V291, P2441, DOI 10.1001/jama.291.20.2441; Pilepich MV, 2001, INT J RADIAT ONCOL, V50, P1243, DOI 10.1016/S0360-3016(01)01579-6; Pilepich MV, 2005, INT J RADIAT ONCOL, V61, P1285, DOI 10.1016/j.ijrobp.2004.08.047; Potters L, 2000, J CLIN ONCOL, V18, P1187, DOI 10.1200/JCO.2000.18.6.1187; Sesso HD, 2001, CIRCULATION, V104, P393, DOI 10.1161/hc2901.093115; SHAFFER JP, 1995, ANNU REV PSYCHOL, V46, P561, DOI 10.1146/annurev.ps.46.020195.003021; Smith MR, 2008, UROLOGY, V71, P318, DOI 10.1016/j.urology.2007.08.035; Smith MR, 2002, J CLIN ENDOCR METAB, V87, P599, DOI 10.1210/jc.87.2.599; Stock RG, 2006, INT J RADIAT ONCOL, V64, P810, DOI 10.1016/j.ijrobp.2005.09.005; Sylvester JE, 2007, INT J RADIAT ONCOL, V67, P57, DOI 10.1016/j.ijrobp.2006.07.1382; Tsai HK, 2007, J NATL CANCER I, V99, P1516, DOI 10.1093/jnci/djm168; Walsh PC, 2007, NEW ENGL J MED, V357, P2696, DOI 10.1056/NEJMcp0706784; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zelefsky MJ, 2008, BRACHYTHERAPY, V7, P1, DOI 10.1016/j.brachy.2007.12.002; Zelefsky MJ, 2007, INT J RADIAT ONCOL, V67, P65, DOI 10.1016/j.ijrobp.2006.08.030; 1997, ARCH INTERN MED, V157, P2413	46	219	227	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	2009	302	8					866	873		10.1001/jama.2009.1137	http://dx.doi.org/10.1001/jama.2009.1137			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	487GN	19706860	Bronze			2023-01-03	WOS:000269260100020
J	Moreno, RP; Rhodes, A				Moreno, Rui Paulo; Rhodes, Andrew			Intensive care medicine: a specialty coming to LIFE	LANCET			English	Editorial Material									[Moreno, Rui Paulo] EPE, Ctr Hosp Lisboa Cent, Hosp Santo Antonio dos Capuchos, Unidade Cuidados Intens Polivalente, P-1169050 Lisbon, Portugal; [Rhodes, Andrew] St Georges Healthcare NHS Trust, London, England	Centro Hospitalar de Lisboa Central, EPE; Universidade de Lisboa; St Georges University London	Moreno, RP (corresponding author), EPE, Ctr Hosp Lisboa Cent, Hosp Santo Antonio dos Capuchos, Unidade Cuidados Intens Polivalente, P-1169050 Lisbon, Portugal.	r.moreno@mail.telepac.pt	Rhodes, Andrew/G-4265-2011	Rhodes, Andrew/0000-0002-8737-574X				Adhikari NKJ, 2010, LANCET, V376, P1339, DOI 10.1016/S0140-6736(10)60446-1; CHICHE JD, 2009, PATIENT SAFETY QUALI, P127; Curtis JR, 2010, LANCET, V376, P1347, DOI 10.1016/S0140-6736(10)60143-2; Halpern NA, 2010, CRIT CARE MED, V38, P65, DOI 10.1097/CCM.0b013e3181b090d0; IBSEN B, 1954, P ROY SOC MED, V47, P72, DOI 10.1177/003591575404700120; Kraemer HC, 2010, JAMA-J AM MED ASSOC, V304, P683, DOI 10.1001/jama.2010.1133; LASSEN HCA, 1953, LANCET, V264, P37; Moreno RP, 2009, INTENS CARE MED, V35, P1667, DOI 10.1007/s00134-009-1621-2; NEGOVSKY VA, 1961, CIRCULATION, V23, P452, DOI 10.1161/01.CIR.23.3.452; NEGOVSKY VA, 1986, ESSAYS REANIMATOLOGY; Vincent JL, 2010, LANCET, V376, P1354, DOI 10.1016/S0140-6736(10)60575-2; 2005, OFFICIAL J EURO 0930	12	12	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1275	1276		10.1016/S0140-6736(10)61502-4	http://dx.doi.org/10.1016/S0140-6736(10)61502-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	671RX	20934210	Green Submitted			2023-01-03	WOS:000283528600004
J	Avorn, J				Avorn, Jerry			Medication Use in Older Patients Better Policy Could Encourage Better Practice	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE		[Avorn, Jerry] Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; [Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA USA; [Avorn, Jerry] Brigham & Womens Hosp, Dept Med, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Avorn, J (corresponding author), Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Ste 3030,1620 Tremont St, Boston, MA 02120 USA.	javorn@medsoc.harvard.edu						Avorn J, 2005, POWERFUL MED BENEFIT; Avorn J, 2003, GERIATRIC MED EVIDEN, P65; Boult C, 2010, HEALTH AFFAIR, V29, P811, DOI 10.1377/hlthaff.2010.0095; Boult C, 2009, J AM GERIATR SOC, V57, P2328, DOI 10.1111/j.1532-5415.2009.02571.x; *FUT HLTH CAR WORK, 2008, RET AG AM BUILD HLTH; *IND DRUG INF SERV, BAL DAT MED; Peterson JF, 2005, ARCH INTERN MED, V165, P802, DOI 10.1001/archinte.165.7.802; Platt R, 2009, NEW ENGL J MED, V361, P645, DOI 10.1056/NEJMp0905338; SCHONDELMEYER SW, 2010, RX PRICE WATCH REPOR; Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233	10	30	31	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2010	304	14					1606	1607		10.1001/jama.2010.1495	http://dx.doi.org/10.1001/jama.2010.1495			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662OE	20940388				2023-01-03	WOS:000282816500027
J	Gill, R				Gill, Ravi			Commentary: practicalities of seeking consent and gaining understanding	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Gill, Ravi] Southampton Univ Hosp NHS Trust, Shackleton Dept Anaesthesia, Southampton SO16 6YD, Hants, England	University of Southampton; University Hospital Southampton NHS Foundation Trust	Gill, R (corresponding author), Southampton Univ Hosp NHS Trust, Shackleton Dept Anaesthesia, Southampton SO16 6YD, Hants, England.	ravi.gill@suht.swest.nhs.uk						FARRELL AM, 2010, BRIT MED J, V310, pC4336; *SER HAZ TRANSF, ANN REP 2008 SUMM	2	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 24	2010	341								c4000	10.1136/bmj.c4000	http://dx.doi.org/10.1136/bmj.c4000			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IG	20736270				2023-01-03	WOS:000281445900004
J	Unroe, M; Kahn, JM; Carson, SS; Govert, JA; Martinu, T; Sathy, SJ; Clay, AS; Chia, J; Gray, A; Tulsky, JA; Cox, CE				Unroe, Mark; Kahn, Jeremy M.; Carson, Shannon S.; Govert, Joseph A.; Martinu, Tereza; Sathy, Shailaja J.; Clay, Alison S.; Chia, Jessica; Gray, Alice; Tulsky, James A.; Cox, Christopher E.			One-Year Trajectories of Care and Resource Utilization for Recipients of Prolonged Mechanical Ventilation A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							LENGTH-OF-STAY; INTENSIVE-CARE; ECONOMIC-EVALUATION; TRACHEOSTOMY; OUTCOMES; ILLNESS; SURVIVORS; BURDEN; COST; ICU	Background: Growing numbers of critically ill patients receive prolonged mechanical ventilation. Little is known about the patterns of care as patients transition from acute care hospitals to postacute care facilities or about the associated resource utilization. Objective: To describe 1-year trajectories of care and resource utilization for patients receiving prolonged mechanical ventilation. Design: 1-year prospective cohort study. Setting: 5 intensive care units at Duke University Medical Center, Durham, North Carolina. Participants: 126 patients receiving prolonged mechanical ventilation (defined as ventilation for >= 4 days with tracheostomy placement or ventilation for >= 21 days without tracheostomy), as well as their 126 surrogates and 54 intensive care unit physicians, enrolled consecutively over 1 year. Measurements: Patients and surrogates were interviewed in the hospital, as well as 3 and 12 months after discharge, to determine patient survival, functional status, and facility type and duration of postdischarge care. Physicians were interviewed in the hospital to elicit prognoses. Institutional billing records were used to assign costs for acute care, outpatient care, and interfacility transportation. Medicare claims data were used to assign costs for postacute care. Results: 103 (82%) hospital survivors had 457 separate transitions in postdischarge care location (median, 4 transitions [interquartile range, 3 to 5 transitions]), including 68 patients (67%) who were readmitted at least once. Patients spent an average of 74% (95% CI, 68% to 80%) of all days alive in a hospital or postacute care facility or receiving home health care. At 1 year, 11 patients (9%) had a good outcome (alive with no functional dependency), 33 (26%) had a fair outcome (alive with moderate dependency), and 82 (65%) had a poor outcome (either alive with complete functional dependency [4 patients; 21%] or dead [56 patients; 44%]). Patients with poor outcomes were older, had more comorbid conditions, and were more frequently discharged to a postacute care facility than patients with either fair or good outcomes (P < 0.05 for all). The mean cost per patient was $306 135 (SD, $285 467), and total cohort cost was $38.1 million, for an estimated $3.5 million per independently functioning survivor at 1 year. Limitation: The results of this single-center study may not be applicable to other centers. Conclusion: Patients receiving prolonged mechanical ventilation have multiple transitions of care, resulting in substantial health care costs and persistent, profound disability. The optimism of surrogate decision makers should be balanced by discussions of these outcomes when considering a course of prolonged life support.	[Cox, Christopher E.] Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Durham, NC 27710 USA; Univ N Carolina, Chapel Hill, NC USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of Pennsylvania	Cox, CE (corresponding author), Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Box 102043, Durham, NC 27710 USA.	christopher.cox@duke.edu	Cox, Christopher/ABH-7957-2020	Cox, Christopher/0000-0002-4486-0681; Kahn, Jeremy/0000-0001-9688-5576	National Institutes of Health [K23 HL081048, K23 HL082650, K23 HL067068]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL067068, K23HL081048, K23HL082650] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	By the National Institutes of Health (grants K23 HL081048, K23 HL082650, and K23 HL067068).	Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; Angus DC, 2003, INTENS CARE MED, V29, P368, DOI 10.1007/s00134-002-1624-8; Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Carson SS, 2008, CRIT CARE MED, V36, P2061, DOI 10.1097/CCM.0b013e31817b8925; Carson SS, 2002, CRIT CARE CLIN, V18, P461, DOI 10.1016/S0749-0704(02)00015-5; Carson SS, 2001, CHEST, V120, P928, DOI 10.1378/chest.120.3.928; Centers for Medicare & Medicaid Services, OV PROSP PAYM SYST; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Chudgar SM, 2009, CRIT CARE MED, V37, P49, DOI 10.1097/CCM.0b013e31819265c8; Cooper LM, 2004, CRIT CARE MED, V32, P2247, DOI 10.1097/01.CCM.0000146301.47334.BD; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Cox CE, 2004, CRIT CARE MED, V32, P2219, DOI 10.1097/01.CCM.0000145232.46143.40; Cox CE, 2007, CRIT CARE MED, V35, P1918, DOI 10.1097/01.CCM.0000275391.35834.10; Cox CE, 2007, CRIT CARE, V11, DOI 10.1186/cc5667; Cox CE, 2009, CRIT CARE MED, V37, P2888, DOI 10.1097/CCM.0b013e3181ab86ed; Davis K, 2007, NEW ENGL J MED, V356, P1166, DOI 10.1056/NEJMe078007; Dewar DM, 1999, CRIT CARE MED, V27, P2640, DOI 10.1097/00003246-199912000-00006; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; El-Jawahri A, 2010, J CLIN ONCOL, V28, P305, DOI 10.1200/JCO.2009.24.7502; ELLIS SG, 1995, CIRCULATION, V92, P741, DOI 10.1161/01.CIR.92.4.741; Engoren M, 2004, CHEST, V125, P220, DOI 10.1378/chest.125.1.220; Evans LR, 2009, AM J RESP CRIT CARE, V179, P48, DOI 10.1164/rccm.200806-969OC; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Griffiths J, 2005, BMJ-BRIT MED J, V330, P1243, DOI 10.1136/bmj.38467.485671.E0; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Heyland DK, 1998, CHEST, V114, P192, DOI 10.1378/chest.114.1.192; Kahn JM, 2008, MED CARE, V46, P1226, DOI 10.1097/MLR.0b013e31817d9342; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kind P., 1999, 172 U YORK YORK HLTH; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Luo N, 2005, MED CARE, V43, P1078, DOI 10.1097/01.mlr.0000182493.57090.c1; MacIntyre NR, 2005, CHEST, V128, P3937, DOI 10.1378/chest.128.6.3937; Nasraway SA, 2000, CRIT CARE MED, V28, P19, DOI 10.1097/00003246-200001000-00004; Nathens AB, 2006, CRIT CARE MED, V34, P2919, DOI 10.1097/01.CCM.0000243800.28251.AE; Nelson JE, 2004, CRIT CARE MED, V32, P1527, DOI 10.1097/01.CCM.0000129485.08835.5A; Nelson JE, 2007, ARCH INTERN MED, V167, P2509, DOI 10.1001/archinte.167.22.2509; Nelson JE, 2006, ARCH INTERN MED, V166, P1993, DOI 10.1001/archinte.166.18.1993; Rapoport J, 2003, MED CARE, V41, P386, DOI 10.1097/00005650-200303000-00007; *RTI INT, POST CAR PAYM REF DE; Taira DA, 2003, AM HEART J, V145, P452, DOI 10.1067/mhj.2003.3; Terragni PP, 2010, JAMA-J AM MED ASSOC, V303, P1483, DOI 10.1001/jama.2010.447; Van Pelt DC, 2007, AM J RESP CRIT CARE, V175, P167, DOI 10.1164/rccm.200604-493OC; White DB, 2007, ARCH INTERN MED, V167, P461, DOI 10.1001/archinte.167.5.461; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216; Zilberberg MD, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-242	46	309	317	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	2010	153	3					167	U62		10.7326/0003-4819-153-3-201008030-00007	http://dx.doi.org/10.7326/0003-4819-153-3-201008030-00007			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634CR	20679561	Green Accepted			2023-01-03	WOS:000280557600005
J	Ligresti, A; De Petrocellis, L; de la Ossa, DHP; Aberturas, R; Cristino, L; Moriello, AS; Finizio, A; Gil, ME; Torres, AI; Molpeceres, J; Di Marzo, V				Ligresti, Alessia; De Petrocellis, Luciano; Hernan Perez de la Ossa, Dolores; Aberturas, Rosario; Cristino, Luigia; Moriello, Aniello Schiano; Finizio, Andrea; Esther Gil, Ma; Torres, Ana-Isabel; Molpeceres, Jesus; Di Marzo, Vincenzo			Exploiting Nanotechnologies and TRPV1 Channels to Investigate the Putative Anandamide Membrane Transporter	PLOS ONE			English	Article							TYPE-1 CANNABINOID RECEPTORS; PHASE-CONTRAST MICROSCOPY; CELLULAR UPTAKE; INHIBITORS; NANOPARTICLES; TEMPERATURE; HYDROLYSIS; CELLS; PALMITOYLETHANOLAMIDE; INACTIVATION	Background: Considerable efforts have been made to characterize the pathways regulating the extracellular levels of the endocannabinoid anandamide. However, none of such pathways has been so argued as the existence of a carrier-mediated transport of anandamide across the membrane. Apart from the lack of molecular evidence for such a carrier, the main reasons of this controversy lie in the methodologies currently used to study anandamide cellular uptake. Furthermore, the main evidence in favor of the existence of an "anandamide transporter" relies on synthetic inhibitors of this process, the selectivity of which has been questioned. Methodology/Principal Findings: We used the cytosolic binding site for anandamide on TRPV1 channels as a biosensor to detect anandamide entry into cells, and exploited nanotechnologies to study anandamide membrane transport into intact TRPV1-overexpressing HEK-293 cells. Both fluorescence and digital holographic (DH) quantitative phase microscopy were used to study TRPV1 activation. Poly-epsilon-caprolactone nanoparticles (PCL-NPs) were used to incorporate anandamide, which could thus enter the cell and activate TRPV1 channels bypassing any possible specific protein(s) involved in the uptake process. We reasoned that in the absence of such protein(s), pharmacological tools previously shown to inhibit the "anandamide transporter" would affect in the same way the uptake of anandamide and PCL-NP-anandamide, and hence the activation of TRPV1. However, when masked into PCL-NPs, anandamide cellular uptake became much less sensitive to these agents, although it maintained the same pharmacokinetics and pharmacodynamics as that of "free" anandamide. Conclusions: We found here that several agents previously reported to inhibit anandamide cellular uptake lose their efficacy when anandamide is prevented from interacting directly with plasma membrane proteins, thus arguing in favor of the specificity of such agents for the putative "anandamide transporter", and of the existence of such mechanism.	[Ligresti, Alessia; Di Marzo, Vincenzo] CNR, Inst Biomol Chem, Pozzuoli, Italy; [Ligresti, Alessia; De Petrocellis, Luciano; Cristino, Luigia; Moriello, Aniello Schiano; Di Marzo, Vincenzo] Endocannabinoid Res Grp, Pozzuoli, Italy; [Ligresti, Alessia; De Petrocellis, Luciano; Cristino, Luigia; Moriello, Aniello Schiano; Di Marzo, Vincenzo] Endocannabinoid Res Grp, Naples, Italy; [De Petrocellis, Luciano; Cristino, Luigia; Moriello, Aniello Schiano; Finizio, Andrea] CNR, Inst Cybernet, Pozzuoli, Italy; [Hernan Perez de la Ossa, Dolores; Esther Gil, Ma; Torres, Ana-Isabel] Univ Complutense, Dept Pharm & Pharmaceut Technol, Sch Pharm, E-28040 Madrid, Spain; [Aberturas, Rosario; Molpeceres, Jesus] Alcala Univ, Dept Pharm & Pharmaceut Technol, Sch Pharm, Madrid, Spain	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Complutense University of Madrid; Universidad de Alcala	Ligresti, A (corresponding author), CNR, Inst Biomol Chem, Pozzuoli, Italy.	vdimarzo@icmib.na.cnr.it	Torres-Suárez, Ana/N-4666-2013; Torres-SuÃrez, Ana Isabel/AAR-9320-2020; del Rosario Aberturas, María/AAA-9014-2019; Cristino, Luigia/AAE-3934-2020; Di Marzo, Vincenzo/AAD-7742-2019; Ligresti, Alessia/B-7564-2015; /Y-9512-2019	Torres-Suárez, Ana/0000-0003-2468-6177; Torres-SuÃrez, Ana Isabel/0000-0003-2468-6177; del Rosario Aberturas, María/0000-0001-7875-6009; Cristino, Luigia/0000-0002-0182-4699; Di Marzo, Vincenzo/0000-0002-1490-3070; Ligresti, Alessia/0000-0003-1787-3900; /0000-0003-4201-0795; GIL-ALEGRE, MARIA ESTHER/0000-0002-8313-8261	Consiglio Nazionale delle Ricerche	Consiglio Nazionale delle Ricerche(Consiglio Nazionale delle Ricerche (CNR))	This study was partly funded by the Consiglio Nazionale delle Ricerche. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bari M, 2005, J BIOL CHEM, V280, P12212, DOI 10.1074/jbc.M411642200; Bari M, 2008, NEUROPHARMACOLOGY, V54, P45, DOI 10.1016/j.neuropharm.2007.06.030; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 1997, J BIOL CHEM, V272, P3315, DOI 10.1074/jbc.272.6.3315; Bojesen IN, 2005, J LIPID RES, V46, P1652, DOI 10.1194/jlr.M400498-JLR200; Bojesen IN, 2006, J LIPID RES, V47, P561, DOI 10.1194/jlr.M500411-JLR200; Chawla JS, 2002, INT J PHARM, V249, P127, DOI 10.1016/S0378-5173(02)00483-0; Cuche E, 1999, OPT LETT, V24, P291, DOI 10.1364/OL.24.000291; Dausend J, 2008, MACROMOL BIOSCI, V8, P1135, DOI 10.1002/mabi.200800123; Davda J, 2002, INT J PHARM, V233, P51, DOI 10.1016/S0378-5173(01)00923-1; de Lago E, 2004, EUR J PHARMACOL, V484, P249, DOI 10.1016/j.ejphar.2003.11.027; De Petrocellis L, 2001, FEBS LETT, V506, P253, DOI 10.1016/S0014-5793(01)02934-9; De Petrocellis L, 2001, J BIOL CHEM, V276, P12856, DOI 10.1074/jbc.M008555200; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; Di Pasquale E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004989; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Fegley D, 2004, P NATL ACAD SCI USA, V101, P8756, DOI 10.1073/pnas.0400997101; Ferraro P, 2006, OPT LETT, V31, P1405, DOI 10.1364/OL.31.001405; Fowler CJ, 2004, EUR J PHARMACOL, V492, P1, DOI 10.1016/j.ejphar.2004.03.048; GARRETT ER, 1974, J PHARM SCI-US, V63, P1056, DOI 10.1002/jps.2600630705; Hajos N, 2004, EUR J NEUROSCI, V19, P2991, DOI 10.1111/j.0953-816X.2004.03433.x; Hillard CJ, 2007, J MOL NEUROSCI, V33, P18, DOI 10.1007/s12031-007-0045-0; Hillard CJ, 2003, BRIT J PHARMACOL, V140, P802, DOI 10.1038/sj.bjp.0705468; Jeong K, 2007, OPT EXPRESS, V15, P14057, DOI 10.1364/OE.15.014057; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kaczocha M, 2006, J BIOL CHEM, V281, P9066, DOI 10.1074/jbc.M509721200; Kaczocha M, 2009, P NATL ACAD SCI USA, V106, P6375, DOI 10.1073/pnas.0901515106; Karlsson M, 2004, EUR J PHARM SCI, V22, P181, DOI 10.1016/j.ejps.2004.03.009; Ligresti A, 2004, BIOCHEM J, V380, P265, DOI 10.1042/BJ20031812; Lopez-Rodriguez ML, 2003, EUR J MED CHEM, V38, P403, DOI 10.1016/S0223-5234(03)00045-X; Maccarrone M, 2000, J BIOL CHEM, V275, P13484, DOI 10.1074/jbc.275.18.13484; Mailander V, 2009, BIOMACROMOLECULES, V10, P2379, DOI 10.1021/bm900266r; Maione S, 2008, BRIT J PHARMACOL, V155, P775, DOI 10.1038/bjp.2008.308; Mann CJ, 2006, BIOMED ENG ONLINE, V5, DOI 10.1186/1475-925X-5-21; Mann CJ, 2005, OPT EXPRESS, V13, P8693, DOI 10.1364/OPEX.13.008693; MICCIO L, 2007, SPIE P, V6631; Oddi S, 2009, CHEM BIOL, V16, P624, DOI 10.1016/j.chembiol.2009.05.004; Ortar G, 2003, BIOCHEM PHARMACOL, V65, P1473, DOI 10.1016/S0006-2952(03)00109-6; Ortega-Gutierrez S, 2004, BIOCHEMISTRY-US, V43, P8184, DOI 10.1021/bi049395f; Rappaz B, 2009, BLOOD CELL MOL DIS, V42, P228, DOI 10.1016/j.bcmd.2009.01.018; Thors L, 2006, BRIT J PHARMACOL, V149, P73, DOI 10.1038/sj.bjp.0706831; Thors L, 2007, BRIT J PHARMACOL, V152, P744, DOI 10.1038/sj.bjp.0707401; Vasir JK, 2007, ADV DRUG DELIVER REV, V59, P718, DOI 10.1016/j.addr.2007.06.003	45	30	32	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 22	2010	5	4							e10239	10.1371/journal.pone.0010239	http://dx.doi.org/10.1371/journal.pone.0010239			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	586YT	20422025	gold, Green Published, Green Submitted			2023-01-03	WOS:000276952600002
J	Kitamura, T; Iwami, T; Kawamura, T; Nagao, K; Tanaka, H; Nadkarni, VM; Berg, RA; Hiraide, A				Kitamura, Tetsuhisa; Iwami, Taku; Kawamura, Takashi; Nagao, Ken; Tanaka, Hideharu; Nadkarni, Vinay M.; Berg, Robert A.; Hiraide, Atsushi		Fire & Disaster Management Agcy	Conventional and chest-compression-only cardiopulmonary resuscitation by bystanders for children who have out-of-hospital cardiac arrests: a prospective, nationwide, population-based cohort study	LANCET			English	Article							AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; ASSISTED VENTILATION; TASK-FORCE; RECOMMENDED GUIDELINES; STROKE-FOUNDATION; UTSTEIN STYLE; EPIDEMIOLOGY; CPR; STATEMENT	Background The American Heart Association recommends cardiopulmonary resuscitation (CPR) by bystanders with chest compression only for adults who have cardiac arrests, but not for children. We assessed the effect of CPR (conventional with rescue breathing or chest compression only) by bystanders on outcomes after out-of-hospital cardiac arrests in children. Methods In a nationwide, prospective, population-based, observational study, we enrolled 5170 children aged 17 years and younger who had an out-of-hospital cardiac arrest from Jan 1,2005, to Dec 31,2007. Data collected included age, cause, and presence and type of CPR by bystander. The primary endpoint was favourable neurological outcome 1 month after an out-of-hospital cardiac arrest, defined as Glasgow-Pittsburgh cerebral performance category 1 or 2. Findings 3675 (71%) children had arrests of non-cardiac causes and 1495 (29%) cardiac causes. 1551 (30%) received conventional CPR and 888 (17%) compression-only CPR. Data for type of CPR by bystander were not available for 12 children. Children who were given CPR by a bystander had a significantly higher rate of favourable neurological outcome than did those not given CPR (4.5% [110/2439] vs 1.9% [53/2719]; adjusted odds ratio [OR] 2.59,95% CI 1.81-3.71). In children aged 1-17 years who had arrests of non-cardiac causes, favourable neurological outcome was more common after bystander CPR than no CPR (5.1% [51/1004] vs 1-5% [20/1293]; OR 4.17, 2.37-7.32). However, conventional CPR produced more favourable neurological outcome than did compression-only CPR (7.2% [45/624] vs 1.6% [six of 380]; OR 5.54, 2.52-16.99). In children aged 1-17 years who had arrests of cardiac causes, favourable neurological outcome was more common after bystander CPR than no CPR (9.5% [42/440] vs 4.1% [14/339]; OR 2.21, 1.08-4.54), and did not differ between conventional and compression-only CPR (9.9% [28/282] vs 8.9% [14/158]; OR 1.20, 0.55-2.66). In infants (aged <1 year), outcomes were uniformly poor (1.7% [36/2082] with favourable neurological outcome). Interpretation For children who have out-of-hospital cardiac arrests from non-cardiac causes, conventional CPR (with rescue breathing) by bystander is the preferable approach to resuscitation. For arrests of cardiac causes, either conventional or compression-only CPR is similarly effective.	[Iwami, Taku] Kyoto Univ, Hlth Serv, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan; [Nagao, Ken] Nihon Univ Hosp, Dept Cardiol, Tokyo, Japan; [Tanaka, Hideharu] Kokushikan Univ, Grad Sch Sport Syst, Tokyo, Japan; [Nadkarni, Vinay M.; Berg, Robert A.] Univ Penn, Sch Med, Dept Anesthesia & Crit Care Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Hiraide, Atsushi] Kyoto Univ, Grad Sch Med, Ctr Med Educ, Kyoto 6068501, Japan	Kyoto University; Nihon University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Kyoto University	Iwami, T (corresponding author), Kyoto Univ, Hlth Serv, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.	iwamit@e-mail.jp	IWAMI, Taku/HCH-0599-2022; Kitamura, Tetsuhisa/AAA-2555-2020	IWAMI, Taku/0000-0002-4150-7065; Kitamura, Tetsuhisa/0000-0003-0107-0580	Fire and Disaster Management Agency; Ministry of Education, Culture, Sports, Science and Technology (Japan); Fire and Disaster Management Agency [19390458]	Fire and Disaster Management Agency; Ministry of Education, Culture, Sports, Science and Technology (Japan)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Fire and Disaster Management Agency	Fire and Disaster Management Agency and the Ministry of Education, Culture, Sports, Science and Technology (Japan).r We thank all the emergency medical service personnel and participating physicians in Japan, and the Fire and Disaster Management Agency and Institute for Fire Safety and Disaster Preparedness of Japan for their generous cooperation in establishing and following the Utstein database. This study was supported by a grant for Emergency Management Scientific Research from the Fire and Disaster Management Agency (study concerning strategy for applying the results of Utstein report for improvement of emergency service), and partially by a Grant-in-Aid for Scientific Research (19390458)	*AMB SERV PLANN OF, 2009, EFF 1 CARD ARR; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; [Anonymous], 2007, JAP GUID EM CAR CARD; Atkins DL, 2009, CIRCULATION, V119, P1484, DOI 10.1161/CIRCULATIONAHA.108.802678; Berg RA, 1997, CIRCULATION, V95, P1635; Berg RA, 1997, CIRCULATION, V96, P4364; Berg RA, 1999, CRIT CARE MED, V27, P1893, DOI 10.1097/00003246-199909000-00030; Berg RA, 2000, CIRCULATION, V101, P1743; Bohm K, 2007, CIRCULATION, V116, P2908, DOI 10.1161/CIRCULATIONAHA.107.710194; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Donoghue AJ, 2005, ANN EMERG MED, V46, P512, DOI 10.1016/j.annemergmed.2005.05.028; *EUR RES COUNC, 2005, RESUSCITATION, V67, pS1, DOI DOI 10.1016/J.RESUSCITATION.2005.10.001; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Handley AJ, 2009, RESUSCITATION, V80, P752, DOI 10.1016/j.resuscitation.2009.03.031; Herlitz J, 2005, RESUSCITATION, V64, P37, DOI 10.1016/j.resuscitation.2004.06.019; HICKEY RW, 1995, ANN EMERG MED, V25, P495, DOI 10.1016/S0196-0644(95)70265-2; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; *JAP STAT ASS, 2006, 2005 POP CENS JAP; Kinney HC, 2009, NEW ENGL J MED, V361, P795, DOI 10.1056/NEJMra0803836; KOSTER RW, 2009, BEHALF BOARD EUROPEA; KUISMA M, 1995, RESUSCITATION, V30, P141, DOI 10.1016/0300-9572(95)00888-Z; Lopez-Herce J, 2005, PEDIATR EMERG CARE, V21, P807; Nagao K, 2007, LANCET, V369, P920; Nishiyama C, 2008, RESUSCITATION, V79, P90, DOI 10.1016/j.resuscitation.2008.05.009; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; Sirbaugh PE, 1999, ANN EMERG MED, V33, P174, DOI 10.1016/S0196-0644(99)70391-4; Suominen P, 1997, ACTA ANAESTH SCAND, V41, P260, DOI 10.1111/j.1399-6576.1997.tb04677.x; The Japan Circulation Society, CALL PUSH; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; Waalewijn RA, 2001, RESUSCITATION, V50, P273, DOI 10.1016/S0300-9572(01)00354-9; Young KD, 1999, ANN EMERG MED, V33, P195, DOI 10.1016/S0196-0644(99)70394-X; Young KD, 2004, PEDIATRICS, V114, P157, DOI 10.1542/peds.114.1.157; ZARITSKY A, 1995, CIRCULATION, V92, P2006, DOI 10.1161/01.CIR.92.7.2006	35	294	306	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	2010	375	9723					1347	1354		10.1016/S0140-6736(10)60064-5	http://dx.doi.org/10.1016/S0140-6736(10)60064-5			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	588GW	20202679	Green Submitted			2023-01-03	WOS:000277057800025
J	Katsnelson, A				Katsnelson, Alla			Substandard drugs overshadowed by focus on fakes	NATURE MEDICINE			English	News Item																			0	2	2	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					364	364		10.1038/nm0410-364b	http://dx.doi.org/10.1038/nm0410-364b			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376033	Bronze			2023-01-03	WOS:000276446800026
J	Stinchcombe, TE; West, HL				Stinchcombe, Thomas E.; West, Howard L.			Maintenance therapy in non-small-cell lung cancer	LANCET			English	Editorial Material							PHASE-III TRIAL; DOCETAXEL; CHEMOTHERAPY		[Stinchcombe, Thomas E.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [West, Howard L.] Swedish Canc Inst, Seattle, WA USA	University of North Carolina; University of North Carolina Chapel Hill; Swedish Cancer Institute; Swedish Medical Center	Stinchcombe, TE (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	Thomas_Stinchcombe@med.unc.edu						[Anonymous], 2008, CHMPEWP185042006 EMA; Cappuzzo F, 2009, 13 WORLD C LUNG CANC; Ciuleanu T, 2009, LANCET, V374, P1432, DOI 10.1016/S0140-6736(09)61497-5; D'Addario G, 2009, ANN ONCOL, V20, P68, DOI 10.1093/annonc/mdp132; European Medicines Agency, 2009, COMM MED PROD HUM US; Fidias PM, 2009, J CLIN ONCOL, V27, P591, DOI 10.1200/JCO.2008.17.1405; Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Scagliotti G, 2009, ONCOLOGIST, V14, P253, DOI 10.1634/theoncologist.2008-0232; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; *US FDA, 2008, AL INJ; *US FDA, 2009, FDA APPR 1 MAINT DRU	14	12	12	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 24	2009	374	9699					1398	1400		10.1016/S0140-6736(09)61598-1	http://dx.doi.org/10.1016/S0140-6736(09)61598-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	512MZ	19767096				2023-01-03	WOS:000271255000006
J	Ranjith-Kumar, CT; Lai, Y; Sarisky, RT; Kao, CC				Ranjith-Kumar, C. T.; Lai, Yvonne; Sarisky, Robert T.; Kao, C. Cheng			Green Tea Catechin, Epigallocatechin Gallate, Suppresses Signaling by the dsRNA Innate Immune Receptor RIG-I	PLOS ONE			English	Article							PATTERN-RECOGNITION RECEPTORS; B KINASE-ACTIVITY; T-CELL-RECEPTOR; KAPPA-B; ANTIVIRAL RESPONSES; STRANDED-RNA; POLYPHENOL; (-)-EPIGALLOCATECHIN-3-GALLATE; LIPOPOLYSACCHARIDE; ACTIVATION	Background: The Innate immune system constitutes the first line of defense against pathogen infections. The Retinoic acid-inducible gene I (RIG-I) receptor recognizes triphosphorylated ssRNAs and dsRNA to initiate downstream signaling of interferon response. However, unregulated activity of these receptors could lead to autoimmune diseases. We seek to identify small molecules that can specifically regulate RIG-I signaling. Methodology/Principal Findings: Epigallocatechin gallate (EGCG), a polyphenolic catechin present in green tea, was identified in a small molecule screen. It was found to bind RIG-I and inhibits its signaling at low micromolar concentrations in HEK293T cells. Furthermore, EGCG dose-dependently inhibited the ATPase activity of recombinant RIG-I but did not compete with RIG-I interaction with RNA or with ATP. EGCG did not inhibit signaling by Toll-like receptors 3, 4, 9 or constitutive signaling by the adapter protein IPS-1. Structure activity relationship analysis showed that EGCG, its epimer GCG and a digallate-containing compound, theaflavin 3,3' digallate (TFDG) were potent RIG-I inhibitors. EGCG also inhibited IL6 secretion and IFN- beta mRNA synthesis in BEAS-2B cells, which harbors intact endogenous RIG-I signaling pathway. Conclusions/Significance: EGCG and its derivatives could have potential therapeutic use as a modulator of RIG-I mediated immune responses.	[Ranjith-Kumar, C. T.; Lai, Yvonne; Kao, C. Cheng] Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN 47405 USA; [Sarisky, Robert T.] Johnson & Johnson, Pharmaceut Res & Dev, Raritan, NJ USA	Indiana University System; Indiana University Bloomington; Johnson & Johnson; Johnson & Johnson USA	Ranjith-Kumar, CT (corresponding author), Indiana Univ, Dept Mol & Cellular Biochem, Bloomington, IN 47405 USA.	ctrkumar@indiana.edu	Kumar CT, Ranjith/J-5701-2016; Mackie, Ken/E-3384-2013		NIH [RAI075015A]; Johnson and Johnson Pharmaceuticals; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI075015] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Johnson and Johnson Pharmaceuticals(Johnson & JohnsonJohnson & Johnson USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	CK acknowledges NIH grant RAI075015A that partially supported members of the laboratory and a gift from Johnson & Johnson Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This work was funded in part by an unrestricted research grant from Johnson and Johnson Pharmaceuticals, where J&J does not have any restriction for the research direction, the use of reagents, the interpretation of the results, or any claim for intellectual property.	Chyu KY, 2004, CIRCULATION, V109, P2448, DOI 10.1161/01.CIR.0000128034.70732.C2; Crespy V, 2004, J NUTR, V134, p3431S, DOI 10.1093/jn/134.12.3431S; Cui S, 2008, MOL CELL, V29, P169, DOI 10.1016/j.molcel.2007.10.032; Dixit E, 2010, CELL, V141, P668, DOI 10.1016/j.cell.2010.04.018; Ermakova S, 2005, J BIOL CHEM, V280, P16882, DOI 10.1074/jbc.M414185200; Ermakova SP, 2006, CANCER RES, V66, P9260, DOI 10.1158/0008-5472.CAN-06-1586; Hayakawa S, 2001, BIOCHEM BIOPH RES CO, V285, P1102, DOI 10.1006/bbrc.2001.5293; Hirao K, 2010, LIFE SCI, V86, P654, DOI 10.1016/j.lfs.2010.02.017; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Le Goffic R, 2007, J IMMUNOL, V178, P3368, DOI 10.4049/jimmunol.178.6.3368; Lee KM, 2004, HELICOBACTER, V9, P632, DOI 10.1111/j.1083-4389.2004.00281.x; Li XJ, 2009, J BIOL CHEM, V284, P13881, DOI 10.1074/jbc.M900818200; Lu C, 2010, STRUCTURE, V18, P1032, DOI 10.1016/j.str.2010.05.007; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Pan MH, 2000, BIOCHEM PHARMACOL, V59, P357, DOI 10.1016/S0006-2952(99)00335-4; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Ranjith-Kumar CT, 2008, MOL CELL BIOL, V28, P4507, DOI 10.1128/MCB.00308-08; Ranjith-Kumar CT, 2009, J BIOL CHEM, V284, P1155, DOI 10.1074/jbc.M806219200; Ronnblom L, 2008, LUPUS, V17, P394, DOI 10.1177/0961203308090020; Saito T, 2008, NATURE, V454, P523, DOI 10.1038/nature07106; Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104; Samanta M, 2006, EMBO J, V25, P4207, DOI 10.1038/sj.emboj.7601314; Schlee M, 2009, IMMUNOL REV, V227, P66, DOI 10.1111/j.1600-065X.2008.00724.x; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shim JH, 2008, J BIOL CHEM, V283, P28370, DOI 10.1074/jbc.M802200200; Suzuki Y, 2001, CANCER LETT, V173, P15, DOI 10.1016/S0304-3835(01)00685-1; Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743; Takahasi K, 2008, MOL CELL, V29, P428, DOI 10.1016/j.molcel.2007.11.028; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Uzri D, 2009, J VIROL, V83, P4174, DOI 10.1128/JVI.02449-08; Veranth JM, 2004, TOXICOL SCI, V82, P88, DOI 10.1093/toxsci/kfh248; Williamson MP, 2006, J ALLERGY CLIN IMMUN, V118, P1369, DOI 10.1016/j.jaci.2006.08.016; Yang CS, 2002, ANNU REV PHARMACOL, V42, P25, DOI 10.1146/annurev.pharmtox.42.082101.154309; Yang FJ, 2001, MOL PHARMACOL, V60, P528; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200; Youn HS, 2006, BIOCHEM PHARMACOL, V72, P850, DOI 10.1016/j.bcp.2006.06.021	39	25	26	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2010	5	9							e12878	10.1371/journal.pone.0012878	http://dx.doi.org/10.1371/journal.pone.0012878			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	653AC	20877565	Green Published, Green Submitted, gold			2023-01-03	WOS:000282053100026
J	Winther, AML; Liu, HZ; Sonntag, Y; Olesen, C; le Maire, M; Soehoel, H; Olsen, CE; Christensen, SB; Nissen, P; Moller, JV				Winther, Anne-Marie L.; Liu, Huizhen; Sonntag, Yonathan; Olesen, Claus; le Maire, Marc; Soehoel, Helmer; Olsen, Carl-Erik; Christensen, S. Brogger; Nissen, Poul; Moller, Jesper V.			Critical Roles of Hydrophobicity and Orientation of Side Chains for Inactivation of Sarcoplasmic Reticulum Ca2+-ATPase with Thapsigargin and Thapsigargin Analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ TRANSPORT ATPASE; CRYSTAL-STRUCTURE; CALCIUM-PUMP; KINETIC CHARACTERIZATION; CYCLOPIAZONIC ACID; INHIBITION; BINDING; CRYSTALLOGRAPHY; PERTURBATION; TOOL	Thapsigargin (Tg), a specific inhibitor of sarco/endoplasmic Ca2+-ATPases (SERCA), binds with high affinity to the E2 conformation of these ATPases. SERCA inhibition leads to elevated calcium levels in the cytoplasm, which in turn induces apoptosis. We present x-ray crystallographic and intrinsic fluorescence data to show how Tg and chemical analogs of the compound with modified or removed side chains bind to isolated SERCA 1a membranes. This occurs by uptake via the membrane lipid followed by insertion into a resident intramembranous binding site with few adaptative changes. Our binding data indicate that a balanced hydrophobicity and accurate positioning of the side chains, provided by the central guaianolide ring structure, defines a pharmacophore of Tg that governs both high affinity and access to the protein-binding site. Tg analogs substituted with long linkers at O-8 extend from the binding site between transmembrane segments to the putative N-terminal Ca2+ entry pathway. The long chain analogs provide a rational basis for the localization of the linker, the presence of which is necessary for enabling prostate-specific antigen to cleave peptide-conjugated prodrugs targeting SERCA of cancer cells (Denmeade, S. R., Jakobsen, C. M., Janssen, S., Khan, S. R., Garrett, E. S., Lilja, H., Christensen, S. B., and Isaacs, J. T. (2003) J. Natl. Cancer Inst. 95, 990-1000). Our study demonstrates the usefulness of a simple in vitro system to test and direct development toward the formulation of new Tg derivatives with improved properties for SERCA targeting. Finally, we propose that the Tg binding pocket may be a regulatory site that, for example, is sensitive to cholesterol.	[Winther, Anne-Marie L.; Sonntag, Yonathan; Olesen, Claus; Nissen, Poul; Moller, Jesper V.] Aarhus Univ, Danish Natl Res Fdn, Ctr Membrane Pumps Cells & Dis PUMPKIN, DK-8000 Aarhus C, Denmark; [Winther, Anne-Marie L.; Sonntag, Yonathan; Nissen, Poul] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus C, Denmark; [Liu, Huizhen; Soehoel, Helmer; Christensen, S. Brogger] Univ Copenhagen, Fac Pharmaceut Sci, Dept Med Chem, DK-2100 Copenhagen O, Denmark; [Olesen, Claus; Moller, Jesper V.] Aarhus Univ, Inst Physiol & Biophys, DK-8000 Aarhus C, Denmark; [le Maire, Marc] Univ Paris Sud, SB2SM, Inst Biol & Technol Saclay, Commissariat Energie Atom, F-91191 Gif Sur Yvette, France; [le Maire, Marc] Univ Paris Sud, Lab Rech Associe 17V, F-91191 Gif Sur Yvette, France; [le Maire, Marc] CNRS, URA 2096, F-91191 Gif Sur Yvette, France; [Olsen, Carl-Erik] Univ Copenhagen, Fac Life Sci, Dept Nat Sci, DK-1780 Frederiksberg C, Denmark	Aarhus University; Danmarks Grundforskningsfond; Aarhus University; University of Copenhagen; Aarhus University; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); University of Copenhagen	Moller, JV (corresponding author), Aarhus Univ, Danish Natl Res Fdn, Ctr Membrane Pumps Cells & Dis PUMPKIN, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	jvm@biophys.au.dk	Sonntag, Yonathan/GRF-4277-2022; Nissen, Poul/D-5774-2014; Olsen, Carl E/H-3031-2014; Christensen, Søren Brøgger/H-4526-2019	Sonntag, Yonathan/0000-0002-8063-0285; Olsen, Carl E/0000-0002-2275-0596; Christensen, Søren Brøgger/0000-0002-5773-6874; Nissen, Poul/0000-0003-0948-6628; Olesen, Claus/0000-0002-0462-1686; Lund Winther, Anne-Marie/0000-0002-5776-0989	Danish Medical Research Foundation; Danish Natural Science Foundation; Danish Cancer Society; Lundbeck Foundation; Aarhus University Research Foundation; Novo Nordisk Foundation; Carlsberg Foundation; Danish Research Council for Technical Sciences and Production; Faculty of Health Science, Aarhus University; Danish Research Council for Health Sciences; Commissariat a l'Energie Atomique; CNRS; ANR France	Danish Medical Research Foundation; Danish Natural Science Foundation(Danish Natural Science Research Council); Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden); Aarhus University Research Foundation; Novo Nordisk Foundation(Novo Nordisk FoundationNovocure Limited); Carlsberg Foundation(Carlsberg Foundation); Danish Research Council for Technical Sciences and Production; Faculty of Health Science, Aarhus University; Danish Research Council for Health Sciences; Commissariat a l'Energie Atomique(French Atomic Energy Commission); CNRS(Centre National de la Recherche Scientifique (CNRS)); ANR France(French National Research Agency (ANR))	This work was supported in part by the Danish Medical Research Foundation, the Danish Natural Science Foundation (through the Dansync Program), the Danish Cancer Society, the Lundbeck Foundation, the Aarhus University Research Foundation, the Novo Nordisk Foundation, and the Carlsberg Foundation.; Recipient of a Ph.D. stipend through the Lundbeck Foundation and a postdoctoral fellowship from the Danish Research Council for Technical Sciences and Production.; Recipient of a Ph.D. stipend from the Faculty of Health Science, Aarhus University, and a postdoctoral fellowship from the Danish Research Council for Health Sciences.; Supported by Commissariat a l'Energie Atomique, CNRS, and ANR France.; Supported by a Hallas-Moller stipend from the Novo Nordisk Foundation.	ANDERSEN A, 1994, ACTA CHEM SCAND, V48, P340, DOI 10.3891/acta.chem.scand.48-0340; ANDERSEN JP, 1983, EUR J BIOCHEM, V134, P205, DOI 10.1111/j.1432-1033.1983.tb07552.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 2005, ANNU REV PHYSIOL, V67, P1, DOI 10.1146/annurev.physiol.67.040103.152647; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; CHAMPEIL P, 1986, J BIOL CHEM, V261, P6372; Christensen SB, 2009, ANTI-CANCER AGENT ME, V9, P276, DOI 10.2174/1871520610909030276; CHRISTENSEN SB, 1985, J LABELLED COMPD RAD, V22, P71; Ciulli A, 2007, CURR OPIN BIOTECH, V18, P489, DOI 10.1016/j.copbio.2007.09.003; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DEFORESTA B, 1992, EUR J BIOCHEM, V209, P1023, DOI 10.1111/j.1432-1033.1992.tb17378.x; Deng XX, 2009, J BIOL CHEM, V284, P22501, DOI 10.1074/jbc.R109.018655; Denmeade SR, 1997, CANCER RES, V57, P4924; Denmeade SR, 2005, CANCER BIOL THER, V4, P14; Denmeade SR, 2003, J NATL CANCER I, V95, P990, DOI 10.1093/jnci/95.13.990; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Jakobsen CM, 2001, J MED CHEM, V44, P4696, DOI 10.1021/jm010985a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Laursen M, 2009, J BIOL CHEM, V284, P13513, DOI 10.1074/jbc.C900031200; Lee AG, 2003, BBA-BIOMEMBRANES, V1612, P1, DOI 10.1016/S0005-2736(03)00056-7; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; Moncoq K, 2007, J BIOL CHEM, V282, P9748, DOI 10.1074/jbc.M611653200; Morth JP, 2007, NATURE, V450, P1043, DOI 10.1038/nature06419; Obara K, 2005, P NATL ACAD SCI USA, V102, P14489, DOI 10.1073/pnas.0506222102; Olesen C, 2004, SCIENCE, V306, P2251, DOI 10.1126/science.1106289; Paula S, 2004, PROTEINS, V56, P595, DOI 10.1002/prot.20105; Pedersen BP, 2007, NATURE, V450, P1111, DOI 10.1038/nature06417; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P12606; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Seekoe T, 2001, J BIOL CHEM, V276, P46737, DOI 10.1074/jbc.M106320200; Shinoda T, 2009, NATURE, V459, P446, DOI 10.1038/nature07939; SILVIUS Jr, 1984, BIOCHEMISTRY-US, V23, P538, DOI 10.1021/bi00298a022; SIMMONDS AC, 1982, BIOCHIM BIOPHYS ACTA, V693, P398, DOI 10.1016/0005-2736(82)90447-3; Sohoel H, 2006, BIOORGAN MED CHEM, V14, P2810, DOI 10.1016/j.bmc.2005.12.001; Sohoel H, 2005, J MED CHEM, V48, P7005, DOI 10.1021/jm058036v; Takahashi M, 2007, P NATL ACAD SCI USA, V104, P5800, DOI 10.1073/pnas.0700979104; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; WICTOME M, 1992, FEBS LETT, V304, P109, DOI 10.1016/0014-5793(92)80599-C; WICTOME M, 1994, BIOCHEM BIOPH RES CO, V199, P916, DOI 10.1006/bbrc.1994.1316; Xu C, 2004, J BIOL CHEM, V279, P17973, DOI 10.1074/jbc.M313263200; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542	47	77	79	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 10	2010	285	37					28883	28892		10.1074/jbc.M110.136242	http://dx.doi.org/10.1074/jbc.M110.136242			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	647CR	20551329	Green Published, hybrid			2023-01-03	WOS:000281594000053
J	Lopez-Herce, J; Alvarez, AC				Lopez-Herce, Jesus; Carrillo Alvarez, Angel			Bystander CPR for paediatric out-of-hospital cardiac arrest	LANCET			English	Editorial Material							CARDIOPULMONARY-RESUSCITATION; EPIDEMIOLOGY; OUTCOMES; MODEL		[Lopez-Herce, Jesus; Carrillo Alvarez, Angel] Hosp Gen Univ Gregorio Maranon, Pediat Intens Care Serv, Madrid 28009, Spain	General University Gregorio Maranon Hospital	Lopez-Herce, J (corresponding author), Hosp Gen Univ Gregorio Maranon, Pediat Intens Care Serv, Madrid 28009, Spain.	pielvi@ya.com	Lopez-Herce, Jesus/A-1602-2019	Lopez-Herce, Jesus/0000-0001-6105-9178				Atkins DL, 2009, CIRCULATION, V119, P1484, DOI 10.1161/CIRCULATIONAHA.108.802678; Connolly M, 2007, RESUSCITATION, V72, P270, DOI 10.1016/j.resuscitation.2006.06.031; Ewy GA, 2007, CIRCULATION, V116, P2525, DOI 10.1161/CIRCULATIONAHA.107.711820; International Liaison Committee on Resuscitation, 2005, Resuscitation, V67, P271; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Kellum MJ, 2008, ANN EMERG MED, V52, P244, DOI 10.1016/j.annemergmed.2008.02.006; Kitamura T, 2010, LANCET, V375, P1347, DOI 10.1016/S0140-6736(10)60064-5; Lopez-Herce J, 2005, PEDIATR EMERG CARE, V21, P807; Nagao K, 2007, LANCET, V369, P920; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; Sirbaugh PE, 1999, ANN EMERG MED, V33, P174, DOI 10.1016/S0196-0644(99)70391-4; Taniguchi T, 2007, RESUSCITATION, V75, P82, DOI 10.1016/j.resuscitation.2007.02.019; Yannopoulos D, 2010, CRIT CARE MED, V38, P254, DOI 10.1097/CCM.0b013e3181b42f6c; Young KD, 2004, PEDIATRICS, V114, P157, DOI 10.1542/peds.114.1.157	14	8	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 17	2010	375	9723					1321	1322		10.1016/S0140-6736(10)60316-9	http://dx.doi.org/10.1016/S0140-6736(10)60316-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	588GW	20202678				2023-01-03	WOS:000277057800004
J	Niewoehner, DE				Niewoehner, Dennis E.			Outpatient Management of Severe COPD.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; ELDERLY PERSONS; OXYGEN-THERAPY; HEALTH; BRONCHODILATOR; EXACERBATIONS; MORTALITY; SURVIVAL; TRIAL		[Niewoehner, Dennis E.] Vet Adm Med Ctr, Pulm Sect, Minneapolis, MN 55417 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Niewoehner, DE (corresponding author), Vet Adm Med Ctr, Pulm Sect 111N, 1 Vet Dr, Minneapolis, MN 55417 USA.	niewo001@umn.edu			Boehringer Ingelheim; Adams Respiratory Therapeutics; GlaxoSmithKline; AstraZeneca; Nycomed; Forest Research Institute; Pfizer; Sepracor	Boehringer Ingelheim(Boehringer Ingelheim); Adams Respiratory Therapeutics; GlaxoSmithKline(GlaxoSmithKline); AstraZeneca(AstraZeneca); Nycomed; Forest Research Institute; Pfizer(Pfizer); Sepracor	Dr. Niewoehner reports receiving consulting fees from Boehringer Ingelheim, Adams Respiratory Therapeutics, GlaxoSmithKline, AstraZeneca, Nycomed, and Forest Research Institute and speaking fees from Boehringer Ingelheim, Pfizer, Sepracor, and Nycomed. No other potential conflicts of interest relevant to this article were reported.	Aaron SD, 2003, NEW ENGL J MED, V348, P2618, DOI 10.1056/NEJMoa023161; Adams SG, 2007, ARCH INTERN MED, V167, P551, DOI 10.1001/archinte.167.6.551; Advisory Committee on Immunization Practices, 2009, Ann Intern Med, V150, P40; Agusti AGN, 2003, EUR RESPIR J, V21, P347, DOI 10.1183/09031936.03.00405703; [Anonymous], 1980, Ann Intern Med, V93, P391; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Anthonisen NR, 2005, ANN INTERN MED, V142, P233, DOI 10.7326/0003-4819-142-4-200502150-00005; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Bradley JM, 2005, COCHRANE DB SYST REV, V4; Brooks D, 2007, CAN RESPIR J, V14, P87, DOI 10.1155/2007/951498; Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Chaouat A, 1999, EUR RESPIR J, V14, P1002, DOI 10.1183/09031936.99.14510029; Dirksen A, 1999, AM J RESP CRIT CARE, V160, P1468, DOI 10.1164/ajrccm.160.5.9901055; Drummond MB, 2009, JAMA-J AM MED ASSOC, V301, P1024; Drummond MB, 2008, JAMA-J AM MED ASSOC, V300, P2407, DOI 10.1001/jama.2008.717; Ezzati M, 2005, LANCET, V366, P104, DOI 10.1016/S0140-6736(05)66845-6; Ferguson GT, 2000, CHEST, V117, P1146, DOI 10.1378/chest.117.4.1146; Fiore MC, 2009, TREATING TOBACCO USE; Fishman A, 2003, NEW ENGL J MED, V348, P2059; FLENLEY DC, 1981, LANCET, V1, P681; Gorecka D, 1997, THORAX, V52, P674, DOI 10.1136/thx.52.8.674; GRANGER R, 2006, COCHRANE DB SYST REV, V4; Griffiths TL, 2000, LANCET, V355, P362, DOI 10.1016/S0140-6736(99)07042-7; GUYATT GH, 1988, ARCH INTERN MED, V148, P1949, DOI 10.1001/archinte.148.9.1949; Hendeles L, 2007, NEW ENGL J MED, V356, P1344, DOI 10.1056/NEJMra050380; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; Jackson LA, 2003, NEW ENGL J MED, V348, P1747, DOI 10.1056/NEJMoa022678; Jemal A, 2005, JAMA-J AM MED ASSOC, V294, P1255, DOI 10.1001/jama.294.10.1255; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358, DOI 10.1164/ajrccm.164.3.2010017; Kotz D, 2009, EUR RESPIR J, V33, P754, DOI 10.1183/09031936.00116308; Lacasse Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub2; MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580; Mannino David M, 2002, Respir Care, V47, P1184; McCrory D C, 2002, Cochrane Database Syst Rev, pCD003900; Nichol KL, 1999, ARCH INTERN MED, V159, P2437, DOI 10.1001/archinte.159.20.2437; Nichol KL, 1999, ANN INTERN MED, V130, P397, DOI 10.7326/0003-4819-130-5-199903020-00003; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Niewoehner DE, 2007, CHEST, V131, P20, DOI 10.1378/chest.06-1316; Nonoyama ML, 2007, AM J RESP CRIT CARE, V176, P343, DOI 10.1164/rccm.200702-308OC; Parkes G, 2008, BMJ-BRIT MED J, V336, P598, DOI 10.1136/bmj.39503.582396.25; Poole PJ, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002733.PUB2; Qaseem A, 2007, ANN INTERN MED, V147, P633, DOI 10.7326/0003-4819-147-9-200711060-00008; RAM FS, 2006, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD004403.PUB2; Salpeter SR, 2006, J GEN INTERN MED, V21, P1011, DOI 10.1111/j.1525-1497.2006.00507.x; Schane RE, 2008, J GEN INTERN MED, V23, P1757, DOI 10.1007/s11606-008-0749-z; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Sin DD, 2003, JAMA-J AM MED ASSOC, V290, P2301, DOI 10.1001/jama.290.17.2301; Singh S, 2009, JAMA-J AM MED ASSOC, V301, P1227; Singh S, 2008, JAMA-J AM MED ASSOC, V300, P1439, DOI 10.1001/jama.300.12.1439; Stavem K, 2006, J HEART LUNG TRANSPL, V25, P75, DOI 10.1016/j.healun.2005.06.025; Strassels SA, 2001, CHEST, V119, P344, DOI 10.1378/chest.119.2.344; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Wilt T, 2005, USE SPIROMETRY CASE; Wilt TJ, 2007, NICOTINE TOB RES, V9, P21, DOI 10.1080/14622200601078509	57	40	44	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	2010	362	15					1407	1416		10.1056/NEJMcp0912556	http://dx.doi.org/10.1056/NEJMcp0912556			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	582XY	20393177				2023-01-03	WOS:000276635300009
J	Gore, ME; Griffin, CL; Hancock, B; Patel, PM; Pyle, L; Aitchison, M; James, N; Oliver, RTD; Mardiak, J; Hussain, T; Sylvester, R; Parmar, MKB; Royston, P; Mulders, PFA				Gore, Martin E.; Griffin, Clare L.; Hancock, Barry; Patel, Poulam M.; Pyle, Lynda; Aitchison, Michael; James, Nicholas; Oliver, Roderick T. D.; Mardiak, Jozef; Hussain, Tahera; Sylvester, Richard; Parmar, Mahesh K. B.; Royston, Patrick; Mulders, Peter F. A.			Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial	LANCET			English	Article							DOSE RECOMBINANT INTERLEUKIN-2; CLINICAL-TRIALS; SURVIVAL; MEDROXYPROGESTERONE; VINBLASTINE; SUNITINIB; CANCER	Background In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a. Methods RE04/30012 was an open-label randomised trial undertaken in 50 centres across eight countries. 1006 treatment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated (1 to 1) by minimisation to receive interferon alfa-2a alone or combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil. Treatment was not masked. The primary endpoint was overall survival. Treatment groups were compared with a non-stratified log-rank test. Analysis was by intention to treat. This study is registered, number ISRCTN 46518965. Findings 502 patients were randomly assigned to receive interferon alfa-2a and 504 to receive combined treatment. Median follow-up was 37.2 months (24.8-52.3). Median overall survival was 18.8 months (17.0-23.2) for patients receiving interferon alfa-2a versus 18.6 months (16.5-20.6) for those receiving combination therapy. overall survival did not differ between the two groups (hazard ratio 1.05 [95% Cl 0.90-1.21], p=0.55; absolute difference 0.3% (-5.1. to 5.6) at 1 year and 2.7% (-8.2 to 2.9) at 3 years). Serious adverse events were reported in 113 (23%) patients receiving interferon alfa-2a and 131 (26%) of those receiving combined treatment. Interpretation Although combination therapy does not improve overall or progression-free survival compared with interferon alfa-2a alone, immunotherapy might still have a role because it can produce remissions that are of clinically relevant length in some patients. identification of patients who will benefit from immunotherapy is crucial.	[Gore, Martin E.] Royal Marsden Hosp NHS Trust, Dept Med, London SW3 6JJ, England; [Griffin, Clare L.; Hussain, Tahera; Parmar, Mahesh K. B.; Royston, Patrick] MRC, Clin Trials Unit, London, England; [Hancock, Barry] Weston Pk Hosp, Sheffield, S Yorkshire, England; [Patel, Poulam M.] Univ Nottingham, Nottingham NG7 2RD, England; [Aitchison, Michael] Western Infirm & Associated Hosp, Beatson Oncol Ctr, Glasgow G11 6NT, Lanark, Scotland; [James, Nicholas] Univ Birmingham, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; [Oliver, Roderick T. D.] QMUL, Barts & London Med Sch, Inst Canc, London, England; [Mardiak, Jozef] Natl Canc Inst, Bratislava, Slovakia; [Sylvester, Richard] European Org Res & Treatment Canc Headquarters, Brussels, Belgium; [Mulders, Peter F. A.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands	Royal Marsden NHS Foundation Trust; Medical Research Council Clinical Trials Unit; Weston Park Hospital; University of Nottingham; Beatson Oncology Centre; Cancer Research UK; University of Birmingham; University of London; Queen Mary University London; National Institute of Oncology (NOU); European Organisation for Research & Treatment of Cancer; Radboud University Nijmegen	Gore, ME (corresponding author), Royal Marsden Hosp NHS Trust, Dept Med, Fulham Rd, London SW3 6JJ, England.	Martin.Gore@rmh.nhs.uk	James, Nick/AAL-6802-2020; Mulders, Peter F.A./H-8076-2014	James, Nicholas/0000-0002-7314-8204	National Cancer Institute (Bethesda, MD, USA) [5U10 CA11488-32, 5U10 CA011488-38]; EORTC Charitable Trust; UK National Health Service; MRC [E164/52] Funding Source: UKRI; Medical Research Council [E164/52] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER	National Cancer Institute (Bethesda, MD, USA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); EORTC Charitable Trust; UK National Health Service; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank all patients who participated in this trial and the research staff at the clinical centres, who helped to recruit participants and provide data. This report was supported by grants numbers 5U10 CA11488-32 to 5U10 CA011488-38 from the National Cancer Institute (Bethesda, MD, USA) and the EORTC Charitable Trust. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute, Schering-Plough provided free interferon and Chiron provided interleukin-2 at a discounted rate to M RC centres. Roche AG and Chiron provided support to the EORTC. MG acknowledges UK National Health Service funding to the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital.	Atkins MB, 2004, CLIN CANCER RES, V10, p6342S, DOI 10.1158/1078-0432.CCR-040029; Atzpodien J, 2001, BRIT J CANCER, V85, P1130, DOI 10.1054/bjoc.2001.2076; Atzpodien J, 2004, J CLIN ONCOL, V22, P1188, DOI 10.1200/JCO.2004.06.155; Coppin C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001425.pub2; De Mulder PHM, 2004, ANN ONCOL, V15, P319, DOI 10.1093/annonc/mdh946; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2009, J CLIN ONCOL, V27, P1280, DOI 10.1200/JCO.2008.19.3342; Ferlay J, 2004, GLOBOCAN 2002 CANC I; Figlin R, 1997, CANCER J SCI AM, V3, pS92; Fisher RI, 2000, CANCER J SCI AM, V6, pS55; FOSSA S, 1995, BRIT J UROL, V76, P286, DOI 10.1111/j.1464-410X.1995.tb07702.x; FYFE G, 1995, J CLIN ONCOL, V13, P688, DOI 10.1200/JCO.1995.13.3.688; HARKINS D, NATL CANC I SEER CAN; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; JONES M, 1993, CANCER BIOTHERAPY, V8, P275, DOI 10.1089/cbr.1993.8.275; KRIEGMAIR M, 1995, UROLOGY, V45, P758, DOI 10.1016/S0090-4295(99)80079-X; McDermott DF, 2005, J CLIN ONCOL, V23, P133, DOI 10.1200/JCO.2005.03.206; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Negrier S, 2007, CANCER-AM CANCER SOC, V110, P2468, DOI 10.1002/cncr.23056; Pyrhonen S, 1999, J CLIN ONCOL, V17, P2859, DOI 10.1200/JCO.1999.17.9.2859; Ritchie A, 1999, LANCET, V353, P14; Rosenberg SA, 1998, ANN SURG, V228, P307, DOI 10.1097/00000658-199809000-00004; Royston P, 2004, STAT MED, V23, P2509, DOI 10.1002/sim.1815; Royston P, 2002, STAT MED, V21, P2175, DOI 10.1002/sim.1203; Royston P, 2001, STATA J, V1, P1, DOI 10.1177/1536867X0100100101; STEINECK G, 1990, ACTA ONCOL, V29, P155, DOI 10.3109/02841869009126537; Yang JC, 2003, J CLIN ONCOL, V21, P3127, DOI 10.1200/JCO.2003.02.122	30	75	77	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	2010	375	9715					641	648		10.1016/S0140-6736(09)61921-8	http://dx.doi.org/10.1016/S0140-6736(09)61921-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	564JT	20153039	Bronze, Green Published			2023-01-03	WOS:000275210900032
J	Holbrook, TL; Galarneau, MR; Dye, JL; Quinn, K; Dougherty, AL				Holbrook, Troy Lisa; Galarneau, Michael R.; Dye, Judy L.; Quinn, Kimberly; Dougherty, Amber L.			Morphine Use after Combat Injury in Iraq and Post-Traumatic Stress Disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MENTAL-HEALTH PROBLEMS; MAJOR TRAUMA; RISK-FACTORS; PTSD; AFGHANISTAN; CARE; PHARMACOTHERAPY; INTERVENTION; PREVENTION; SYMPTOMS	BACKGROUND Post-traumatic stress disorder (PTSD) is a common adverse mental health outcome among seriously injured civilians and military personnel who are survivors of trauma. Pharmacotherapy in the aftermath of serious physical injury or exposure to traumatic events may be effective for the secondary prevention of PTSD. METHODS We identified 696 injured U. S. military personnel without serious traumatic brain injury from the Navy-Marine Corps Combat Trauma Registry Expeditionary Medical Encounter Database. Complete data on medications administered were available for all personnel selected. The diagnosis of PTSD was obtained from the Career History Archival Medical and Personnel System and verified in a review of medical records. RESULTS Among the 696 patients studied, 243 received a diagnosis of PTSD and 453 did not. The use of morphine during early resuscitation and trauma care was significantly associated with a lower risk of PTSD after injury. Among the patients in whom PTSD developed, 61% received morphine; among those in whom PTSD did not develop, 76% received morphine (odds ratio, 0.47; P<0.001). This association remained significant after adjustment for injury severity, age, mechanism of injury, status with respect to amputation, and selected injury-related clinical factors. CONCLUSIONS Our findings suggest that the use of morphine during trauma care may reduce the risk of subsequent development of PTSD after serious injury.	[Holbrook, Troy Lisa; Galarneau, Michael R.; Dye, Judy L.; Quinn, Kimberly; Dougherty, Amber L.] Naval Hlth Res Ctr, San Diego, CA 92106 USA; [Holbrook, Troy Lisa] EPI SOAR Consulting, San Diego, CA USA	United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC)	Holbrook, TL (corresponding author), Naval Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	troy@epi-soar.com			U.S. Navy Bureau of Medicine and Surgery [60808]	U.S. Navy Bureau of Medicine and Surgery	Supported by U.S. Navy Bureau of Medicine and Surgery under the Wounded, Ill, and Injured-Psychological Health-Traumatic Brain Injury Program (work unit 60808).	[Anonymous], 2000, DIAGNOSTIC STAT MANU, V4th; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BAKER WA, 1976, INORG CHIM ACTA, V16, P5, DOI 10.1016/S0020-1693(00)91684-0; BRAUN P, 1990, J CLIN PSYCHIAT, V51, P236; Bryant RA, 2009, BIOL PSYCHIAT, V65, P438, DOI 10.1016/j.biopsych.2008.10.032; Davidson JRT, 2006, J CLIN PSYCHIAT, V67, P34; Davidson JRT, 2004, J CLIN PSYCHIAT, V65, P44; Ducrocq F, 2005, ENCEPHALE, V31, P212; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gelpin E, 1996, J CLIN PSYCHIAT, V57, P390; Gennarelli T., 2005, ABBREVIATED INJURY S; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Gunderson EKE, 2005, MIL MED, V170, P172; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holbrook TL, 2001, J TRAUMA, V51, P287, DOI 10.1097/00005373-200108000-00010; Holbrook TL, 2005, J TRAUMA, V58, P764, DOI 10.1097/01.TA.0000159247.48547.7D; Holbrook TL, 2001, J TRAUMA, V50, P270, DOI 10.1097/00005373-200102000-00012; Koren D, 2005, AM J PSYCHIAT, V162, P276, DOI 10.1176/appi.ajp.162.2.276; Marmar CR, 2002, PSYCHIAT QUART, V73, P259, DOI 10.1023/A:1020459916113; MCGAUGH JL, 1988, BRAIN RES, V446, P37, DOI 10.1016/0006-8993(88)91294-2; Michaels AJ, 1998, J TRAUMA, V44, P644, DOI 10.1097/00005373-199804000-00013; Michaels AJ, 1999, J TRAUMA, V47, P867, DOI 10.1097/00005373-199911000-00009; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Morgan CA, 2003, BIOL PSYCHIAT, V53, P834, DOI 10.1016/S0006-3223(03)00116-1; *NAT CTR POSTTR ST, EP FACTS PTSD; Norman SB, 2008, PSYCHOL MED, V38, P533, DOI 10.1017/S0033291707001389; Pitman RK, 2005, CNS SPECTRUMS, V10, P99, DOI 10.1017/S109285290001943X; Saxe G, 2001, J AM ACAD CHILD PSY, V40, P915, DOI 10.1097/00004583-200108000-00013; Schlesselman JJ, 1982, CASE CONTROL STUDIES; Stein MB, 2007, J TRAUMA STRESS, V20, P923, DOI 10.1002/jts.20270; Vaiva G, 2003, BIOL PSYCHIAT, V54, P947, DOI 10.1016/S0006-3223(03)00412-8; Zatzick D, 2006, PSYCHIAT SERV, V57, P1726, DOI 10.1176/appi.ps.57.12.1726; Zatzick Douglas, 2003, Semin Clin Neuropsychiatry, V8, P158, DOI 10.1016/S1084-3612(03)00016-9; Zatzick Douglas, 2003, Semin Clin Neuropsychiatry, V8, P168, DOI 10.1016/S1084-3612(03)00015-7; Zatzick DF, 2007, J TRAUMA STRESS, V20, P401, DOI 10.1002/jts.20256; Zhang W, 2007, EXPERT OPIN PHARMACO, V8, P1861, DOI 10.1517/14656566.8.12.1861	39	288	297	1	35	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	2010	362	2					110	117		10.1056/NEJMoa0903326	http://dx.doi.org/10.1056/NEJMoa0903326			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	543FU	20071700				2023-01-03	WOS:000273558500008
J	Jeffry, JA; Yu, SQ; Sikand, P; Parihar, A; Evans, MS; Premkumar, LS				Jeffry, Joseph A.; Yu, Shuang-Quan; Sikand, Parul; Parihar, Arti; Evans, M. Steven; Premkumar, Louis S.			Selective Targeting of TRPV1 Expressing Sensory Nerve Terminals in the Spinal Cord for Long Lasting Analgesia	PLOS ONE			English	Article								Chronic pain is a major clinical problem and opiates are often the only treatment, but they cause significant problems ranging from sedation to deadly respiratory depression. Resiniferatoxin (RTX), a potent agonist of Transient Receptor Potential Vanilloid 1 (TRPV1), causes a slow, sustained and irreversible activation of TRPV1 and increases the frequency of spontaneous excitatory postsynaptic currents, but causes significant depression of evoked EPSCs due to nerve terminal depolarization block. Intrathecal administration of RTX to rats in the short-term inhibits nociceptive synaptic transmission, and in the long-term causes a localized, selective ablation of TRPV1-expressing central sensory nerve terminals leading to long lasting analgesia in behavioral models. Since RTX actions are selective for central sensory nerve terminals, other efferent functions of dorsal root ganglion neurons can be preserved. Preventing nociceptive transmission at the level of the spinal cord can be a useful strategy to treat chronic, debilitating and intractable pain.			Jeffry, JA (corresponding author), So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA.	lpremkumar@siumed.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK065742, R01DK065742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042296] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK065742, R56 DK065742, DK065742] Funding Source: Medline; NINDS NIH HHS [NS042296, R01 NS042296] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akerman S, 2004, BRIT J PHARMACOL, V142, P1354, DOI 10.1038/sj.bjp.0705896; Apostolidis A, 2005, UROLOGY, V65, P400, DOI 10.1016/j.urology.2004.10.007; Appendino G, 1997, LIFE SCI, V60, P681, DOI 10.1016/S0024-3205(96)00567-X; Baccei ML, 2003, J PHYSIOL-LONDON, V549, P231, DOI 10.1113/jphysiol.2003.040451; Brown DC, 2005, ANESTHESIOLOGY, V103, P1052, DOI 10.1097/00000542-200511000-00020; Cao DS, 2009, MOL PAIN, V5, DOI 10.1186/1744-8069-5-5; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Constantin CE, 2008, J NEUROSCI, V28, P5072, DOI 10.1523/JNEUROSCI.4476-07.2008; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; Dinis P, 2004, BJU INT, V94, P153, DOI 10.1111/j.1464-4096.2004.04855.x; Gavva NR, 2008, PAIN, V136, P202, DOI 10.1016/j.pain.2008.01.024; Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815-04.2005; Giannantoni A, 2004, J UROLOGY, V172, P240, DOI 10.1097/01.ju.0000132152.53532.5d; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; GOSO C, 1993, NEUROSCI LETT, V162, P197, DOI 10.1016/0304-3940(93)90594-B; Gram DX, 2007, EUR J NEUROSCI, V25, P213, DOI 10.1111/j.1460-9568.2006.05261.x; Gram DX, 2005, EUR J PHARMACOL, V509, P211, DOI 10.1016/j.ejphar.2004.12.039; GRUDT TJ, 1994, J NEUROSCI, V14, P1646, DOI 10.1523/JNEUROSCI.14-03-01646.1994; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Immke DC, 2006, SEMIN CELL DEV BIOL, V17, P582, DOI 10.1016/j.semcdb.2006.09.004; JANCSOGABOR A, 1970, J PHYSIOL-LONDON, V208, P449, DOI 10.1113/jphysiol.1970.sp009130; Jones RCW, 2005, J NEUROSCI, V25, P10981, DOI 10.1523/JNEUROSCI.0703-05.2005; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Karai L, 2004, J CLIN INVEST, V113, P1344, DOI 10.1172/JCI200420449; Kim JH, 2003, J SPINAL CORD MED, V26, P358, DOI 10.1080/10790268.2003.11753706; Kissin EY, 2005, ANESTH ANALG, V101, P1433, DOI 10.1213/01.ANE.0000180998.29890.B0; Lauria G, 2006, J PERIPHER NERV SYST, V11, P262, DOI 10.1111/j.1529-8027.2006.0097.x; Lazzeri M, 2004, EUR UROL, V45, P98, DOI 10.1016/S0302-2838(03)00418-4; Lehto SG, 2008, J PHARMACOL EXP THER, V326, P218, DOI 10.1124/jpet.107.132233; Medhurst SJ, 2002, PAIN, V96, P129, DOI 10.1016/S0304-3959(01)00437-7; NAGY JI, 1981, BRAIN RES, V211, P497, DOI 10.1016/0006-8993(81)90980-X; Nakatsuka T, 2002, J NEUROSCI, V22, P1228, DOI 10.1523/JNEUROSCI.22-04-01228.2002; Petersen KL, 2002, PAIN, V98, P119, DOI 10.1016/S0304-3959(02)00029-5; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Raisinghani M, 2005, J PHYSIOL-LONDON, V567, P771, DOI 10.1113/jphysiol.2005.087874; Razavi R, 2006, CELL, V127, P1123, DOI 10.1016/j.cell.2006.10.038; RUSSELL LC, 1984, BRAIN RES REV, V8, P165, DOI 10.1016/0165-0173(84)90005-5; RUSSELL LC, 1986, PAIN, V25, P109, DOI 10.1016/0304-3959(86)90013-8; Scherrer G, 2009, CELL, V137, P1148, DOI 10.1016/j.cell.2009.04.019; Sikand P, 2007, J PHYSIOL-LONDON, V581, P631, DOI 10.1113/jphysiol.2006.118620; Strecker T, 2005, CARDIOVASC RES, V65, P405, DOI 10.1016/j.cardiores.2004.10.013; Szabo T, 1999, BRAIN RES, V840, P92, DOI 10.1016/S0006-8993(99)01763-1; SZALLASI A, 1990, LIFE SCI, V47, P1399, DOI 10.1016/0024-3205(90)90518-V; Szallasi A, 2007, NAT REV DRUG DISCOV, V6, P357, DOI 10.1038/nrd2280; Varga A, 2005, NEUROSCI LETT, V385, P137, DOI 10.1016/j.neulet.2005.05.015; WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544; YAKSH TL, 1979, SCIENCE, V206, P481, DOI 10.1126/science.228392; Yang K, 1998, NEUROSCI LETT, V255, P135, DOI 10.1016/S0304-3940(98)00730-7; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	56	76	78	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e7021	10.1371/journal.pone.0007021	http://dx.doi.org/10.1371/journal.pone.0007021			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753113	Green Submitted, Green Published, gold			2023-01-03	WOS:000269796500011
J	Sackley, CM; van den Berg, ME; Lett, K; Patel, S; Hollands, K; Wright, CC; Hoppitt, TJ				Sackley, Catherine M.; van den Berg, Maayken E.; Lett, Karen; Patel, Smitaa; Hollands, Kristen; Wright, Christine C.; Hoppitt, Thomas J.			Effects of a physiotherapy and occupational therapy intervention on mobility and activity in care home residents: a cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL THERAPY; HEALTH-CARE; STROKE; REHABILITATION; EXERCISE; PERFORMANCE; CONTINENCE; DEPRESSION; RISK	Objective To compare the clinical effectiveness of a programme of physiotherapy and occupational therapy with standard care in care home residents who have mobility limitations and are dependent in performing activities of daily living. Design Cluster randomised controlled trial, with random allocation at the level of care home. Setting Care homes within the NHS South Birmingham primary care trust and the NHS Birmingham East and North primary care trust that had more than five beds and provided for people in the care categories "physical disability" and "older people." Participants Care home residents with mobility limitations, limitations in activities of daily living (as screened by the Barthel index), and not receiving end of life care were eligible to take part in the study. Intervention A targeted three month occupational therapy and physiotherapy programme. Main outcome measures Scores on the Barthel index and the Rivermead mobility index. Results 24 of 77 nursing and residential homes that catered for residents with mobility limitations and dependency for activities of daily living were selected for study: 12 were randomly allocated to the intervention arm (128 residents, mean age 86 years) and 12 to the control arm (121 residents, mean age 84 years). Participants were evaluated by independent assessors blind to study arm allocation before randomisation (0 months), three months after randomisation (at the end of the treatment period for patients who received the intervention), and again at six months after randomisation. After adjusting for home effect and baseline characteristics, no significant differences were found in mean Barthel index scores at six months post-randomisation between treatment arms (mean effect 0.08, 95% confidence interval -1.14 to 1.30; P=0.90), across assessments (-0.01, -0.63 to 0.60; P=0.96), or in the interaction between assessment and intervention (0.42, -0.48 to 1.32; P=0.36). Similarly, no significant differences were found in the mean Rivermead mobility index scores between treatment arms (0.62, -0.51 to 1.76; P=0.28), across assessments (-0.15, -0.65 to 0.35; P=0.55), or interaction (0.71, -0.02 to 1.44; P=0.06). Conclusions The three month occupational therapy and physiotherapy programme had no significant effect on mobility and independence. On the other hand, the variation in residents' functional ability, the prevalence of cognitive impairment, and the prevalence of depression were considerably higher in this sample than expected on the basis of previous work. Further research to clarify the efficacy of occupational therapy and physiotherapy is required if access to therapy services is to be recommended in this population.	[Sackley, Catherine M.; van den Berg, Maayken E.; Lett, Karen; Patel, Smitaa; Hollands, Kristen; Wright, Christine C.] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England	University of Birmingham		t.j.hoppitt@bham.ac.uk	van den Berg, Maayken/D-1670-2011	van den Berg, Maayken/0000-0002-5878-7649; sackley, catherine/0000-0002-8580-6622	Health Foundation; NHS National Institute for Health Research	Health Foundation; NHS National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the Health Foundation and the NHS National Institute for Health Research. The University of Birmingham acted as sponsors. The funders and sponsor had no involvement in the study design, data collection, analysis and interpretation, the writing of the report, or the decision to submit the paper for publication.	Adams G, 2004, J CLIN EPIDEMIOL, V57, P785, DOI 10.1016/j.jclinepi.2003.12.013; Barodawala S, 2001, CLIN REHABIL, V15, P607, DOI 10.1191/0269215501cr454oa; Berg K, 1997, AGE AGEING, V26, P37, DOI 10.1093/ageing/26.suppl_2.37; BRILL PA, 1995, GERONTOLOGIST, V35, P263; Buchanan RJ, 2006, NEUROREHABILITATION, V21, P223; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; CHIODO LK, 1992, PHYS THER, V72, P168, DOI 10.1093/ptj/72.3.168; Collen F M, 1991, Int Disabil Stud, V13, P50; Collin C, 1988, Int Disabil Stud, V10, P61; De Boer ME, 2007, DISABIL REHABIL, V29, P665, DOI 10.1080/09638280600926561; Edwards Helen, 2003, Aust Health Rev, V26, P107; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Green J, 2001, DISABIL REHABIL, V23, P670, DOI 10.1080/09638280110045382; Helbostad Jorunn L, 2005, Tidsskr Nor Laegeforen, V125, P1195; Heyn P, 2004, ARCH PHYS MED REHAB, V85, P1694, DOI 10.1016/j.apmr.2004.03.019; Kerse N, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1445; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Laird N M, 1992, Stat Methods Med Res, V1, P225, DOI 10.1177/096228029200100302; Leemrijse Chantal J, 2007, BMC Geriatr, V7, P7, DOI 10.1186/1471-2318-7-7; Legg L, 2007, BMJ-BRIT MED J, V335, P922, DOI 10.1136/bmj.39343.466863.55; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Mozley CG, 2007, AGING MENT HEALTH, V11, P99, DOI 10.1080/13607860600637810; MULROW CD, 1994, JAMA-J AM MED ASSOC, V271, P519, DOI 10.1001/jama.271.7.519; Murray PK, 2005, ARCH PHYS MED REHAB, V86, P876, DOI 10.1016/j.apmr.2004.10.045; ONEIL MB, 1992, PHYS THER, V72, P596, DOI 10.1093/ptj/72.8.596; Ouslander Joseph G, 2005, J Am Med Dir Assoc, V6, P121, DOI 10.1016/j.jamda.2005.01.004; Paterson M., 2005, BRIT J OCCUP THER, V68, P409, DOI [10.1177/030802260506800905, DOI 10.1177/030802260506800905]; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Power, 2001, NURSING STANDARD, V16, P33, DOI [10.7748/ns.16.15.33.s53, DOI 10.7748/NS.16.15.33.S53]; Przybylski BR, 1996, ARCH PHYS MED REHAB, V77, P554, DOI 10.1016/S0003-9993(96)90294-4; Puffer S, 2003, BMJ-BRIT MED J, V327, P785, DOI 10.1136/bmj.327.7418.785; Rockwood K, 2007, AGE AGEING, V36, P225, DOI 10.1093/ageing/afl160; Rydwik E, 2004, AGE AGEING, V33, P13, DOI 10.1093/ageing/afh001; Sackley C, 2006, STROKE, V37, P2336, DOI 10.1161/01.STR.0000237124.20596.92; Sackley CM, 2008, CLIN REHABIL, V22, P714, DOI 10.1177/0269215508089058; Sackley CM, 2004, BRIT J OCCUPATIONAL, V67, P104, DOI DOI 10.1177/030802260406700302; Schnelle JF, 2003, J AM GERIATR SOC, V51, P161, DOI 10.1046/j.1532-5415.2003.51053.x; Schnelle JF, 2002, J AM GERIATR SOC, V50, P1476, DOI 10.1046/j.1532-5415.2002.50401.x; Schnelle JF, 1998, J AM GERIATR SOC, V46, P771, DOI 10.1111/j.1532-5415.1998.tb03815.x; Shaw C, 2000, J CLIN NURS, V9, P574, DOI 10.1046/j.1365-2702.2000.00414.x; Sutcliffe LM, 1998, CLIN REHABIL, V12, P506, DOI 10.1191/026921598672167702; van den Berg Maayken, 2006, Nurs Times, V102, P32; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	43	35	35	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 1	2009	339								b3123	10.1136/bmj.b3123	http://dx.doi.org/10.1136/bmj.b3123			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	491CG	19723707	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000269553900004
J	Hillmen, P				Hillmen, Peter			Chronic lymphocytic leukaemia-moving towards cure?	LANCET			English	Editorial Material							FLUDARABINE PLUS CYCLOPHOSPHAMIDE; ALEMTUZUMAB; THERAPY; TRIAL		St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Hillmen, P (corresponding author), St James Univ Hosp, Leeds Teaching Hosp NHS Trust, Leeds LS9 7TF, W Yorkshire, England.	peter.hillmen@nhs.net						Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Hallek M, 2010, LANCET, V376, P1164, DOI 10.1016/S0140-6736(10)61381-5; Lozanski G, 2004, BLOOD, V103, P3278, DOI 10.1182/blood-2003-10-3729; Michos IC, 2010, DISCRETE MATH THEOR, V12, P1; Pettitt AR, 2006, LEUKEMIA, V20, P1441, DOI 10.1038/sj.leu.2404265; Zenz T, 2008, CELL CYCLE, V7, P3810, DOI 10.4161/cc.7.24.7245	9	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1122	1124		10.1016/S0140-6736(10)61512-7	http://dx.doi.org/10.1016/S0140-6736(10)61512-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888976				2023-01-03	WOS:000282915700006
J	Delamothe, T; Knapton, M; Richardson, E				Delamothe, Tony; Knapton, Mike; Richardson, Eve			We're all going to die. Deal with it	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Delamothe, Tony] BMJ, London WC1H 9JR, England; [Knapton, Mike] British Heart Fdn, London NW1 7AW, England; [Richardson, Eve] Natl Council Palliat Care, London N7 9AS, England	University of London; University College London	Delamothe, T (corresponding author), BMJ, London WC1H 9JR, England.	tdelamothe@bmj.com			British Heart Foundation	British Heart Foundation(British Heart Foundation)	We are pleased to acknowledge the financial support of the British Heart Foundation in producing this Spotlight. The articles were commissioned and peer reviewed according to the BMJ's usual process. We benefited from discussions with Jane Maher, Scott Murray, Ruth Sack, and Teresa Tate.	Barclay S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4862; Bell D, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c3231; Boyd K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4863; Ellershaw J, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4861; General Medical Council, 2010, TREATM CAR END LIF G; Grant L, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4859; Seymour JE, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4860	7	6	6	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c5028	10.1136/bmj.c5028	http://dx.doi.org/10.1136/bmj.c5028			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847024				2023-01-03	WOS:000282095800015
J	Lerman, J				Lerman, Jerrold			Perioperative respiratory complications in children	LANCET			English	Editorial Material							TRACT INFECTION; CARDIAC-ARREST; SLEEP-APNEA; MANAGEMENT; ANESTHESIA; COUGH		Womens & Childrens Hosp, Dept Anesthesia, Buffalo, NY 14222 USA	Women & Children's Hospital of Buffalo	Lerman, J (corresponding author), Womens & Childrens Hosp, Dept Anesthesia, Buffalo, NY 14222 USA.	jerrold.lerman@gmail.com		Lerman, Jerrold/0000-0003-4408-9847				Bhananker SM, 2007, ANESTH ANALG, V105, P344, DOI 10.1213/01.ane.0000268712.00756.dd; Bharti N, 2009, EUR J ANAESTH, V26, P490, DOI 10.1097/EJA.0b013e328323dac0; Brown KA, 2004, ANESTHESIOLOGY, V100, P806, DOI 10.1097/00000542-200404000-00009; de Jongste JC, 2003, THORAX, V58, P998, DOI 10.1136/thorax.58.11.998; Flick RP, 2007, ANESTHESIOLOGY, V106, P226, DOI 10.1097/00000542-200702000-00009; LERMAN J, 2010, MANUAL PEDIAT ANESTH, P171; Mvula M, 2005, J ASTHMA, V42, P9, DOI 10.1081/JAS-200044746; Oberer C, 2005, ANESTHESIOLOGY, V103, P1142, DOI 10.1097/00000542-200512000-00007; Raghavendran S, 2010, ANESTH ANALG, V110, P1093, DOI 10.1213/ANE.0b013e3181cfc435; Shields MD, 2008, THORAX, V63, P1, DOI 10.1136/thx.2007.077370; Tait AR, 2005, ANESTH ANALG, V100, P59, DOI 10.1213/01.ANE.0000139653.53618.91; von Ungern-Sternberg BS, 2010, LANCET, V376, P773, DOI 10.1016/S0140-6736(10)61193-2; von Ungern-Sternberg BS, 2009, PEDIATR ANESTH, V19, P1064, DOI 10.1111/j.1460-9592.2009.03130.x	13	12	15	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					745	746		10.1016/S0140-6736(10)61199-3	http://dx.doi.org/10.1016/S0140-6736(10)61199-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816527				2023-01-03	WOS:000281831000004
J	Tyssen, D; Henderson, SA; Johnson, A; Sterjovski, J; Moore, K; La, J; Zanin, M; Sonza, S; Karellas, P; Giannis, MP; Krippner, G; Wesselingh, S; McCarthy, T; Gorry, PR; Ramsland, PA; Cone, R; Paull, JRA; Lewis, GR; Tachedjian, G				Tyssen, David; Henderson, Scott A.; Johnson, Adam; Sterjovski, Jasminka; Moore, Katie; La, Jennifer; Zanin, Mark; Sonza, Secondo; Karellas, Peter; Giannis, Michael P.; Krippner, Guy; Wesselingh, Steve; McCarthy, Tom; Gorry, Paul R.; Ramsland, Paul A.; Cone, Richard; Paull, Jeremy R. A.; Lewis, Gareth R.; Tachedjian, Gilda			Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HERPES-SIMPLEX-VIRUS; CANDIDATE TOPICAL MICROBICIDES; RANDOMIZED CONTROLLED-TRIAL; HIV-INFECTION; SPL7013 GEL; VAGINAL MICROBICIDES; MACROPHAGE TROPISM; TYPE-1 REPLICATION; IN-VITRO	Background: Topical microbicides, used by women to prevent the transmission of HIV and other sexually transmitted infections are urgently required. Dendrimers are highly branched nanoparticles being developed as microbicides. However, the anti-HIV and HSV structure-activity relationship of dendrimers comprising benzyhydryl amide cores and lysine branches, and a comprehensive analysis of their broad-spectrum anti-HIV activity and mechanism of action have not been published. Methods and Findings: Dendrimers with optimized activity against HIV-1 and HSV-2 were identified with respect to the number of lysine branches (generations) and surface groups. Antiviral activity was determined in cell culture assays. Time-of-addition assays were performed to determine dendrimer mechanism of action. In vivo toxicity and HSV-2 inhibitory activity were evaluated in the mouse HSV-2 susceptibility model. Surface groups imparting the most potent inhibitory activity against HIV-1 and HSV-2 were naphthalene disulfonic acid (DNAA) and 3,5-disulfobenzoic acid exhibiting the greatest anionic charge and hydrophobicity of the seven surface groups tested. Their anti-HIV-1 activity did not appreciably increase beyond a second-generation dendrimer while dendrimers larger than two generations were required for potent anti-HSV-2 activity. Second (SPL7115) and fourth generation (SPL7013) DNAA dendrimers demonstrated broad-spectrum anti-HIV activity. However, SPL7013 was more active against HSV and blocking HIV-1 envelope mediated cell-to-cell fusion. SPL7013 and SPL7115 inhibited viral entry with similar potency against CXCR4-(X4) and CCR5-using (R5) HIV-1 strains. SPL7013 was not toxic and provided at least 12 h protection against HSV-2 in the mouse vagina. Conclusions: Dendrimers can be engineered with optimized potency against HIV and HSV representing a unique platform for the controlled synthesis of chemically defined multivalent agents as viral entry inhibitors. SPL7013 is formulated as VivaGel (R) and is currently in clinical development to provide protection against HIV and HSV. SPL7013 could also be combined with other microbicides.	[Tyssen, David; Johnson, Adam; Sterjovski, Jasminka; Moore, Katie; La, Jennifer; Zanin, Mark; Sonza, Secondo; Wesselingh, Steve; Gorry, Paul R.; Ramsland, Paul A.; Tachedjian, Gilda] Burnet Inst, Ctr Virol, Melbourne, Vic, Australia; [Tyssen, David; Johnson, Adam; Sterjovski, Jasminka; Moore, Katie; La, Jennifer; Zanin, Mark; Sonza, Secondo; Wesselingh, Steve; Gorry, Paul R.; Ramsland, Paul A.; Tachedjian, Gilda] Burnet Inst, Ctr Immunol, Melbourne, Vic, Australia; [Henderson, Scott A.; Karellas, Peter; Giannis, Michael P.; Krippner, Guy; McCarthy, Tom; Paull, Jeremy R. A.; Lewis, Gareth R.] Starpharma Pty Ltd, Melbourne, Vic, Australia; [Wesselingh, Steve] Monash Univ, Fac Nursing & Hlth Sci, Clayton, Vic, Australia; [La, Jennifer] Monash Univ, Fac Pharm & Pharmaceut Sci, Parkville, Vic, Australia; [Sonza, Secondo; Tachedjian, Gilda] Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; [Gorry, Paul R.] Univ Melbourne, Dept Microbiol & Immunol, Parkville, Vic 3052, Australia; [Gorry, Paul R.; Tachedjian, Gilda] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Ramsland, Paul A.] Univ Melbourne, Dept Surg Austin Hlth, Heidelberg, Vic, Australia; [Ramsland, Paul A.] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia; [Cone, Richard] Johns Hopkins Univ, Dept Biophys, Baltimore, MD USA	Burnet Institute; Burnet Institute; Monash University; Monash University; Monash University; University of Melbourne; Monash University; Austin Research Institute; University of Melbourne; Monash University; Johns Hopkins University	Tyssen, D (corresponding author), Burnet Inst, Ctr Virol, Melbourne, Vic, Australia.	gildat@burnet.edu.au	Tachedjian, Gilda/AAF-1327-2020	Tachedjian, Gilda/0000-0002-7733-7037; Paull, Jeremy/0000-0002-9981-421X; Ramsland, Paul/0000-0002-2107-2738; Sterjovski, Jasminka/0000-0002-2471-3000; Zanin, Mark/0000-0003-3158-1744	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN266200500042C, U19 AI060598]; NIAD, NIH [N01-AI-05420, N01-AI-25478]; National Health and Medical Research Council of Australia (NHMRC) [543105, 365209]; Australian Centre for HIV and Hepatitis Virology Research [ACH2]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005420, U19AI060598] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAD, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian Centre for HIV and Hepatitis Virology Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by US Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under Contract No. HHSN266200500042C and Grant No. U19 AI060598 awarded to Starpharma Pty Ltd. Southern Research Institute evaluation of dendrimer activity was supported by US funds NIAD, NIH contracts N01-AI-05420 (Principal Investigator: Dr Luke Pallansch) and N01-AI-25478 (Principal Investigator: Mr Roger Ptak), under the direction of Dr Steven Turk, Project Officer, NIAID, Division of AIDS. G. T. was supported by the National Health and Medical Research Council of Australia (NHMRC) Senior Research Fellowship 543105 and funding from the Australian Centre for HIV and Hepatitis Virology Research (ACH2). P. A. R. was supported by the NHMRC R. Douglas Wright Career Development Award 365209. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program received by the Burnet Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The results and conclusions of this report are those of the authors and do not necessarily represent the views of NIH.	Abner SR, 2005, J INFECT DIS, V192, P1545, DOI 10.1086/462424; ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; [Anonymous], 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003255, DOI 10.1002/14651858.CD003255]; Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5; Bernstein DI, 2003, ANTIMICROB AGENTS CH, V47, P3784, DOI 10.1128/AAC.47.12.3784-3788.2003; BINDER D, 1987, J MED CHEM, V30, P678, DOI 10.1021/jm00387a017; BIRCH CJ, 1992, J INFECT DIS, V166, P108, DOI 10.1093/infdis/166.1.108; Bourne N, 2000, ANTIMICROB AGENTS CH, V44, P2471, DOI 10.1128/AAC.44.9.2471-2474.2000; Boyd BJ, 2006, MOL PHARMACEUT, V3, P614, DOI 10.1021/mp060032e; Brown JM, 2007, AIDS, V21, P1515, DOI 10.1097/QAD.0b013e3282004929; Butler DM, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000447; Chen MY, 2009, JAIDS-J ACQ IMM DEF, V50, P375, DOI 10.1097/QAI.0b013e318198a7e6; CHISEMBELE M, 2010, 17 C RET OPP INF SAN; Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90; Cummins JE, 2007, ANTIMICROB AGENTS CH, V51, P1770, DOI 10.1128/AAC.01129-06; Dezzutti CS, 2004, ANTIMICROB AGENTS CH, V48, P3834, DOI 10.1128/AAC.48.10.3834-3844.2004; Etemad-Moghadam B, 2000, J VIROL, V74, P4433, DOI 10.1128/JVI.74.9.4433-4440.2000; Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474; Fletcher PS, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-46; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Gajbhiye V, 2009, J PHARM PHARMACOL, V61, P989, DOI 10.1211/jpp/61.08.0002; Galen BT, 2007, J INFECT DIS, V195, P1332, DOI 10.1086/513279; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; Gong E, 2005, ANTIVIR RES, V68, P139, DOI 10.1016/j.antiviral.2005.08.004; Gorry PR, 2001, J VIROL, V75, P10073, DOI 10.1128/JVI.75.21.10073-10089.2001; Gray L, 2005, VIROLOGY, V337, P384, DOI 10.1016/j.virol.2005.04.034; Hantson Anke, 2005, Antiviral Chemistry & Chemotherapy, V16, P253; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398; Huskens D, 2009, ANTIVIR RES, V84, P38, DOI 10.1016/j.antiviral.2009.07.013; Jiang YH, 2005, AIDS RES HUM RETROV, V21, P207, DOI 10.1089/aid.2005.21.207; *JOINT UN PROGR HI, 2003, STIGMA DISCRIMINATIO; Kaminskas LM, 2007, MOL PHARMACEUT, V4, P949, DOI 10.1021/mp070047s; KARIM QA, 2010, SCIENCE         0719; Karim SA, 2009, 16 C RETR OPP INF MO; Ketas TJ, 2007, VIROLOGY, V364, P281, DOI 10.1016/j.virol.2007.02.022; Lacey CJN, 2006, AIDS, V20, P1027, DOI 10.1097/01.aids.0000222075.83490.ca; Lackman-Smith C, 2008, ANTIMICROB AGENTS CH, V52, P1768, DOI 10.1128/AAC.01328-07; LEVY JA, 1988, JAMA-J AM MED ASSOC, V259, P3037, DOI 10.1001/jama.259.20.3037; Liu J, 2008, NATURE, V455, P109, DOI 10.1038/nature07159; MATTHEWS BR, 2002, Patent No. 02079299; McCarthy TD, 2005, MOL PHARMACEUT, V2, P312, DOI 10.1021/mp050023q; McElrath MJ, 2010, ANTIMICROB AGENTS CH, V54, P763, DOI 10.1128/AAC.00891-09; Mesquita PMM, 2009, J INFECT DIS, V200, P599, DOI 10.1086/600867; Moore JP, 2003, P NATL ACAD SCI USA, V100, P10598, DOI 10.1073/pnas.1932511100; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Nanjwade BK, 2009, EUR J PHARM SCI, V38, P185, DOI 10.1016/j.ejps.2009.07.008; O'Loughlin J, 2010, SEX TRANSM DIS, V37, P100, DOI 10.1097/OLQ.0b013e3181bc0aac; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PRICE CF, 2010, SPL7013 GEL VIVAGEL; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Roberts BP, 2009, MACROMOLECULES, V42, P2775, DOI 10.1021/ma802154e; Rusconi S, 1996, ANTIMICROB AGENTS CH, V40, P234, DOI 10.1128/AAC.40.1.234; Salazar-Gonzalez JF, 2009, J EXP MED, V206, P1273, DOI 10.1084/jem.20090378; Scordi-Bello IA, 2005, ANTIMICROB AGENTS CH, V49, P3607, DOI 10.1128/AAC.49.9.3607-3615.2005; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Skoler-Karpoff S, 2008, LANCET, V372, P1977, DOI 10.1016/S0140-6736(08)61842-5; Sonza S, 1996, J VIROL, V70, P3863, DOI 10.1128/JVI.70.6.3863-3869.1996; Sonza S, 2009, ANTIMICROB AGENTS CH, V53, P3565, DOI 10.1128/AAC.00102-09; Spear PG, 2004, CELL MICROBIOL, V6, P401, DOI 10.1111/j.1462-5822.2004.00389.x; Springer CJ, 1995, J MED CHEM, V38, P5051, DOI 10.1021/jm00026a013; Sterjovski J, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-89; Tao W, 2008, AIDS RES HUM RETROV, V24, P925, DOI 10.1089/aid.2008.0043; Van Damme L, 2008, NEW ENGL J MED, V359, P463, DOI 10.1056/NEJMoa0707957; Wawer MJ, 2009, LANCET, V374, P229, DOI 10.1016/S0140-6736(09)60998-3; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Witvrouw M, 2000, MOL PHARMACOL, V58, P1100, DOI 10.1124/mol.58.5.1100; WYATT R, 1995, J VIROL, V69, P5723, DOI 10.1128/JVI.69.9.5723-5733.1995; Yap SH, 2007, PLOS MED, V4, P1887, DOI 10.1371/journal.pmed.0040335; Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002	70	134	137	1	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 23	2010	5	8							e12309	10.1371/journal.pone.0012309	http://dx.doi.org/10.1371/journal.pone.0012309			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	641TV	20808791	Green Published, gold			2023-01-03	WOS:000281153500004
J	Lazarus, SC				Lazarus, Stephen C.			Emergency Treatment of Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE ADULT ASTHMA; CORTICOSTEROID-THERAPY; MAGNESIUM-SULFATE; RACEMIC ALBUTEROL; CONTROLLED TRIAL; SEVERITY SCORE; DOUBLE-BLIND; METHYLPREDNISOLONE; LEVALBUTEROL; MONTELUKAST	A 46-year-old woman who has had two admissions to the intensive care unit (ICU) for asthma during the past year presents with a 4-day history of upper respiratory illness and a 6-hour history of shortness of breath and wheezing. An inhaled corticosteroid has been prescribed, but she takes it only when she has symptoms, which is rarely. She generally uses albuterol twice per day but has increased its use to six to eight times per day for the past 3 days. How should this case be managed in the emergency department?	[Lazarus, Stephen C.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Lazarus, Stephen C.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lazarus, SC (corresponding author), Univ Calif San Francisco, Div Pulm & Crit Care Med, 505 Parnassus Ave, San Francisco, CA 94143 USA.	lazma@ucsf.edu						Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Blais L, 1998, AM J RESP CRIT CARE, V158, P126, DOI 10.1164/ajrccm.158.1.9707107; BOWLER SD, 1992, THORAX, V47, P584, DOI 10.1136/thx.47.8.584; Camargo CA, 2010, J ALLERGY CLIN IMMUN, V125, P374, DOI 10.1016/j.jaci.2009.11.015; Carl JC, 2003, J PEDIATR-US, V143, P731, DOI 10.1067/S0022-3476(03)00493-1; Cates CJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000052.pub2; Chey T, 1999, J CLIN EPIDEMIOL, V52, P1157, DOI 10.1016/S0895-4356(99)00111-0; DARIOLI R, 1984, AM REV RESPIR DIS, V129, P385; DHUPER S, 2008, J EMERG MED     1210; Dockhorn RJ, 2000, THORAX, V55, P260, DOI 10.1136/thorax.55.4.260; EDMONDS ML, 2003, COCHRANE DB SYST REV, V3; EMERMAN CL, 1995, CHEST, V107, P1559, DOI 10.1378/chest.107.6.1559; ENGEL T, 1990, ALLERGY, V45, P224, DOI 10.1111/j.1398-9995.1990.tb00487.x; FANTA CH, 1983, AM J MED, V74, P845, DOI 10.1016/0002-9343(83)91076-8; Gelb AF, 2008, PULM PHARMACOL THER, V21, P630, DOI 10.1016/j.pupt.2008.02.005; Gorelick MH, 2004, ACAD EMERG MED, V11, P10, DOI 10.1197/S106-6563(03)00579-7; HARRISON BDW, 1986, LANCET, V1, P181; Jones LA, 2009, EMERG MED J, V26, P783, DOI 10.1136/emj.2008.065938; JONSSON S, 1988, CHEST, V94, P723, DOI 10.1378/chest.94.4.723; Karpel JP, 1997, CHEST, V112, P348, DOI 10.1378/chest.112.2.348; Karras DJ, 2000, ACAD EMERG MED, V7, P327, DOI 10.1111/j.1553-2712.2000.tb02231.x; Kelly AM, 2004, RESP MED, V98, P777, DOI 10.1016/j.rmed.2004.01.008; Krishnan JA, 2009, AM J MED, V122, P977, DOI 10.1016/j.amjmed.2009.02.013; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; MARQUETTE CH, 1995, EUR RESPIR J, V8, P22, DOI 10.1183/09031936.95.08010022; McCarren M, 2000, ACAD EMERG MED, V7, P28, DOI 10.1111/j.1553-2712.2000.tb01887.x; Mohammed S, 2007, EMERG MED J, V24, P823, DOI 10.1136/emj.2007.052050; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; National Heart Lung and Blood Institute. National Asthma Education and Prevention Program, 2007, 3 NAT HEART LUNG BLO; *NIHR HLTH TECHN A, 2010, 3MG TRIAL RAND CONTR; Parameswaran K, 2000, COCHRANE DB SYST REV; Plotnick LH, 2000, COCHRANE DB SYST REV, V4; Qureshi F, 2005, ANN EMERG MED, V46, P29, DOI 10.1016/j.annemergmed.2005.02.001; RATTO D, 1988, JAMA-J AM MED ASSOC, V260, P527, DOI 10.1001/jama.260.4.527; Rodrigo C, 1998, CHEST, V113, P593, DOI 10.1378/chest.113.3.593; Rodrigo CJ, 2000, AM J RESP CRIT CARE, V161, P1862; Rodrigo G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002884.pub2; Rodrigo G, 1999, CHEST, V116, P285, DOI 10.1378/chest.116.2.285; Rodrigo G, 1998, CHEST, V114, P1016, DOI 10.1378/chest.114.4.1016; Rodrigo GJ, 2006, THORAX, V61, P274; Rodrigo GJ, 2002, CHEST, V122, P160, DOI 10.1378/chest.122.1.160; Rowe BH, 1999, JAMA-J AM MED ASSOC, V281, P2119, DOI 10.1001/jama.281.22.2119; Rowe BH, 2004, RESP MED, V98, P275, DOI 10.1016/j.rmed.2003.11.016; Rowe BH, 2003, COCHRANE DB SYST REV, V4; Rowe BH, 2008, CURR OPIN PULM MED, V14, P70, DOI 10.1097/MCP.0b013e3282f19867; Rowe BH, 2009, CHEST, V135, P57, DOI 10.1378/chest.07-3041; Sin DD, 2002, ARCH INTERN MED, V162, P1591, DOI 10.1001/archinte.162.14.1591; Smith SR, 2002, ACAD EMERG MED, V9, P99, DOI 10.1197/aemj.9.2.99; Soroksky A, 2003, CHEST, V123, P1018, DOI 10.1378/chest.123.4.1018; Strauss L, 1997, AM J RESP CRIT CARE, V155, P454, DOI 10.1164/ajrccm.155.2.9032178; Thill Peter J, 2004, Pediatr Crit Care Med, V5, P337, DOI 10.1097/01.PCC.0000128670.36435.83	52	55	58	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					755	764		10.1056/NEJMcp1003469	http://dx.doi.org/10.1056/NEJMcp1003469			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20818877				2023-01-03	WOS:000280996600009
J	Pulford, B; Reim, N; Bell, A; Veatch, J; Forster, G; Bender, H; Meyerett, C; Hafeman, S; Michel, B; Johnson, T; Wyckoff, AC; Miele, G; Julius, C; Kranich, J; Schenkel, A; Dow, S; Zabel, MD				Pulford, Bruce; Reim, Natalia; Bell, Aimee; Veatch, Jessica; Forster, Genevieve; Bender, Heather; Meyerett, Crystal; Hafeman, Scott; Michel, Brady; Johnson, Theodore; Wyckoff, A. Christy; Miele, Gino; Julius, Christian; Kranich, Jan; Schenkel, Alan; Dow, Steven; Zabel, Mark D.			Liposome-siRNA-Peptide Complexes Cross the Blood-Brain Barrier and Significantly Decrease PrPC on Neuronal Cells and PrPRES in Infected Cell Cultures	PLOS ONE			English	Article							PRION STRAIN DISCRIMINATION; SMALL INTERFERING RNA; CANINE KIDNEY-CELLS; HEPATITIS-B-VIRUS; LENTIVIRAL VECTORS; GENE-EXPRESSION; DNA COMPLEXES; NEUROLOGICAL DISORDERS; CYCLIC AMPLIFICATION; PROLONGS SURVIVAL	Background: Recent advances toward an effective therapy for prion diseases employ RNA interference to suppress PrPC expression and subsequent prion neuropathology, exploiting the phenomenon that disease severity and progression correlate with host PrPC expression levels. However, delivery of lentivirus encoding PrP shRNA has demonstrated only modest efficacy in vivo. Methodology/Principal Findings: Here we describe a new siRNA delivery system incorporating a small peptide that binds siRNA and acetylcholine receptors (AchRs), acting as a molecular messenger for delivery to neurons, and cationic liposomes that protect siRNA-peptide complexes from serum degradation. Conclusions/Significance: Liposome-siRNA-peptide complexes (LSPCs) delivered PrP siRNA specifically to AchR-expressing cells, suppressed PrPC expression and eliminated PrPRES formation in vitro. LSPCs injected intravenously into mice resisted serum degradation and delivered PrP siRNA throughout the brain to AchR and PrPC-expressing neurons. These data promote LSPCs as effective vehicles for delivery of PrP and other siRNAs specifically to neurons to treat prion and other neuropathological diseases.	[Pulford, Bruce; Reim, Natalia; Bell, Aimee; Veatch, Jessica; Forster, Genevieve; Bender, Heather; Meyerett, Crystal; Hafeman, Scott; Michel, Brady; Johnson, Theodore; Wyckoff, A. Christy; Julius, Christian; Schenkel, Alan; Dow, Steven; Zabel, Mark D.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA; [Miele, Gino] Pfizer Global Res & Dev, Translat Med Res Collaborat, Dundee, Scotland; [Kranich, Jan] St Vincents Hosp, Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	Colorado State University; Pfizer; University of Dundee; Garvan Institute of Medical Research; St Vincents Hospital Sydney	Pulford, B (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA.	mark.zabel@colostate.edu		Kranich, Jan/0000-0002-9928-4132	Colorado State University Infectious Disease Initiative	Colorado State University Infectious Disease Initiative	This work was funded by the Colorado State University Infectious Disease Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BARICHELLO JM, METHODS MOL BIOL, V605, P461; BECK E, 1969, BRAIN, V92, P699, DOI 10.1093/brain/92.4.699; BECK E, 1964, BRAIN, V87, P153, DOI 10.1093/brain/87.1.153; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; Campochiaro PA, 2006, GENE THER, V13, P559, DOI 10.1038/sj.gt.3302653; D'Costa J, 2009, CURR OPIN MOL THER, V11, P554; Dissen GA, 2009, METHODS, V49, P70, DOI 10.1016/j.ymeth.2009.06.004; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Dow SW, 1999, J IMMUNOL, V163, P1552; Dutertre M., CANC RES, V70, P896; Eckhardt BL, 2005, MOL CANCER RES, V3, P1; Erin N, 2009, INT J CANCER, V124, P1503, DOI 10.1002/ijc.24131; Fairman J, 2009, HUM VACCINES, V5, P141, DOI 10.4161/hv.5.3.6589; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Gallozzi M, 2008, TRANSGENIC RES, V17, P783, DOI 10.1007/s11248-008-9179-2; GIESE A, 1995, BRAIN PATHOL, V5, P213, DOI 10.1111/j.1750-3639.1995.tb00597.x; Giese A, 1998, BRAIN PATHOL, V8, P449; Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2; Gotti C, 2004, PROG NEUROBIOL, V74, P363, DOI 10.1016/j.pneurobio.2004.09.006; Gowen BB, 2009, ANTIVIR RES, V81, P37, DOI 10.1016/j.antiviral.2008.09.001; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Karapetyan YE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005730; Kim Y, 2009, ANTIVIR RES, V84, P185, DOI 10.1016/j.antiviral.2009.09.002; Klohn PC, 2003, P NATL ACAD SCI USA, V100, P11666, DOI 10.1073/pnas.1834432100; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Kutscher HL, 2010, J CONTROL RELEASE, V143, P31, DOI 10.1016/j.jconrel.2009.12.019; Lafon M, 2005, J NEUROVIROL, V11, P82, DOI 10.1080/13550280590900427; Lauren J, 2009, NATURE, V457, P1128, DOI 10.1038/nature07761; Leng Q, 2008, CANCER GENE THER, V15, P485, DOI 10.1038/cgt.2008.29; Leng Q, 2009, DRUG FUTURE, V34, P721, DOI 10.1358/dof.2009.034.09.1413267; LENTZ TL, 1982, SCIENCE, V215, P182, DOI 10.1126/science.7053569; Lin KD, 1999, BIOTECHNIQUES, V26, P318, DOI 10.2144/99262rr02; Lundberg C, 2008, CURR GENE THER, V8, P461, DOI 10.2174/156652308786847996; Mahal SP, 2007, P NATL ACAD SCI USA, V104, P20908, DOI 10.1073/pnas.0710054104; Mallucci G, 2003, SCIENCE, V302, P871, DOI 10.1126/science.1090187; Mallucci GR, 2007, NEURON, V53, P325, DOI 10.1016/j.neuron.2007.01.005; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Matveeva O, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm088; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; Meyerett C, 2008, VIROLOGY, V382, P267, DOI 10.1016/j.virol.2008.09.023; MOHUCZYDOMINIAK D, 1992, J AM SOC NEPHROL, V3, P170; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; Nadler LS, 1999, AM J PHYSIOL-CELL PH, V277, pC1220, DOI 10.1152/ajpcell.1999.277.6.C1220; NANOU A, 2009, PROG BRAIN RES, V200, P175; Nichols TA, 2009, PRION, V3, P171, DOI 10.4161/pri.3.3.9819; Paddison PJ, 2002, CANCER CELL, V2, P17, DOI 10.1016/S1535-6108(02)00092-2; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Pai SI, 2006, GENE THER, V13, P464, DOI 10.1038/sj.gt.3302694; Pfeifer A, 2006, J CLIN INVEST, V116, P3204, DOI 10.1172/JCI29236; Polymenidou M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003872; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; ROTHDIENER M, J CONTROL RELEASE; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; SAILER A, 1994, CELL, V77, P967, DOI 10.1016/0092-8674(94)90436-7; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Steele AD, 2007, P NATL ACAD SCI USA, V104, P1983, DOI 10.1073/pnas.0610779104; Tilly G, 2003, BIOCHEM BIOPH RES CO, V305, P548, DOI 10.1016/S0006-291X(03)00805-2; Valori CF, 2008, CURR GENE THER, V8, P406, DOI 10.2174/156652308786848030; White MD, 2008, P NATL ACAD SCI USA, V105, P10238, DOI 10.1073/pnas.0802759105; Zabel MD, 2007, J IMMUNOL, V179, P6144, DOI 10.4049/jimmunol.179.9.6144; Zaks K, 2006, J IMMUNOL, V176, P7335, DOI 10.4049/jimmunol.176.12.7335; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	71	72	111	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2010	5	6							e11085	10.1371/journal.pone.0011085	http://dx.doi.org/10.1371/journal.pone.0011085			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	610NX	20559428	Green Published, Green Submitted, gold			2023-01-03	WOS:000278741100004
J	Swain, SM; Jeong, JH; Geyer, CE; Costantino, JP; Pajon, ER; Fehrenbacher, L; Atkins, JN; Polikoff, J; Vogel, VG; Erban, JK; Rastogi, P; Livingston, RB; Perez, EA; Mamounas, EP; Land, SR; Ganz, PA; Wolmark, N				Swain, Sandra M.; Jeong, Jong-Hyeon; Geyer, Charles E., Jr.; Costantino, Joseph P.; Pajon, Eduardo R.; Fehrenbacher, Louis; Atkins, James N.; Polikoff, Jonathan; Vogel, Victor G.; Erban, John K.; Rastogi, Priya; Livingston, Robert B.; Perez, Edith A.; Mamounas, Eleftherios P.; Land, Stephanie R.; Ganz, Patricia A.; Wolmark, Norman			Longer Therapy, Iatrogenic Amenorrhea, and Survival in Early Breast Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT CHEMOTHERAPY; PREMENOPAUSAL WOMEN; DOXORUBICIN; DOCETAXEL; CYCLOPHOSPHAMIDE; OUTCOMES	BACKGROUND Chemotherapy regimens that combine anthracyclines and taxanes result in improved disease-free and overall survival among women with operable lymph-node-positive breast cancer. The effectiveness of concurrent versus sequential regimens is not known. METHODS We randomly assigned 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (sequential ACT); four cycles of doxorubicin and docetaxel (doxorubicin-docetaxel); or four cycles of doxorubicin, cyclophosphamide, and docetaxel (con-current ACT). The primary aims were to examine whether concurrent ACT was more effective than sequential ACT and whether the doxorubicin-docetaxel regimen would be as effective as the concurrent-ACT regimen. The secondary aims were to assess toxic effects and to correlate amenorrhea with outcomes in premenopausal women. RESULTS At a median follow-up of 73 months, overall survival was improved in the sequential-ACT group (8-year overall survival, 83%) as compared with the doxorubicin-docetaxel group (overall survival, 79%; hazard ratio for death, 0.83; P=0.03) and the concurrent-ACT group (overall survival, 79%; hazard ratio, 0.86; P=0.09). Disease-free survival was improved in the sequential-ACT group (8-year disease-free survival, 74%) as compared with the doxorubicin-docetaxel group (disease-free survival, 69%; hazard ratio for recurrence, a second malignant condition, or death, 0.80; P=0.001) and the concurrent-ACT group (disease-free survival, 69%; hazard ratio, 0.83; P=0.01). The doxorubicin-docetaxel regimen showed noninferiority to the concurrent-ACT regimen for overall survival (hazard ratio, 0.96; 95% confidence interval, 0.82 to 1.14). Overall survival was improved in patients with amenorrhea for 6 months or more across all treatment groups, independently of estrogen-receptor status. CONCLUSIONS Sequential ACT improved disease-free survival as compared with doxorubicin-docetaxel or concurrent ACT, and it improved overall survival as compared with doxorubicin-docetaxel. Amenorrhea was associated with improved survival regardless of the treatment and estrogen-receptor status. (ClinicalTrials.gov number, NCT00003782.)	[Swain, Sandra M.] Washington Hosp Ctr, Washington Canc Inst, Washington, DC 20010 USA; [Jeong, Jong-Hyeon; Costantino, Joseph P.; Land, Stephanie R.] Univ Pittsburgh, NSABP Biostat Ctr, Pittsburgh, PA USA; [Jeong, Jong-Hyeon; Costantino, Joseph P.; Land, Stephanie R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Geyer, Charles E., Jr.; Wolmark, Norman] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA; [Vogel, Victor G.; Rastogi, Priya] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; [Pajon, Eduardo R.] Colorado Canc Res Program, Denver, CO USA; [Fehrenbacher, Louis] Kaiser Permanente No Calif, Vallejo, CA USA; [Atkins, James N.] SE Canc Control Consortium, Clin Canc Oncol Program, Goldsboro, NC USA; [Polikoff, Jonathan] So Calif Kaiser Permanente, San Diego, CA USA; [Vogel, Victor G.] Amer Canc Soc, Atlanta, GA 30329 USA; [Erban, John K.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA; [Erban, John K.] Harvard Univ, Sch Med, Boston, MA USA; [Erban, John K.] Eastern Cooperat Oncol Grp, Philadelphia, PA USA; [Livingston, Robert B.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA; [Livingston, Robert B.] SW Oncol Grp, Ann Arbor, MI USA; [Perez, Edith A.] Mayo Clin, Jacksonville, FL USA; [Perez, Edith A.] N Cent Canc Treatment Grp, Rochester, MN USA; [Mamounas, Eleftherios P.] Aultman Hlth Fdn, Canton, OH USA; [Ganz, Patricia A.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Sch Med & Publ Hlth, Los Angeles, CA 90024 USA	MedStar Washington Hospital Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Surgical Adjuvant Breast & Bowel Project; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Allegheny General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kaiser Permanente; Kaiser Permanente; American Cancer Society; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Arizona Center Cancer Care; University of Arizona; Southwest Oncology Group; Mayo Clinic; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Swain, SM (corresponding author), Washington Hosp Ctr, Washington Canc Inst, 110 Irving St NW, Washington, DC 20010 USA.	sandra.m.swain@medstar.net	Geyer, Charles/AGY-0119-2022	Geyer, Charles/0000-0002-2379-5702; Swain, Sandra/0000-0002-1320-3830; Jeong, Jong/0000-0003-0596-2201	National Cancer Institute, National Institutes of Health, Department of Health and Human Services [U10-CA-37377, U10-CA-69974, U10-CA-12027, U10-CA-69651, CA07190, CA2115, CA-25224, CA-32102, CA-13612, CA-58348, CA-45808]; Sanofi-Aventis; Rhone-Poulenc-Rhorer; Genentech; Bristol-Myers Squibb; Susan G. Komen for the Cure Foundation, Living in Pink, and Safeway; Eisai; GlaxoSmithKline; Pfizer; Onyx; Novartis; Roche; Abraxis; BiPar; Wyeth; NSABP; Kaiser Permanente; Eastern Cooperative Oncology Group; Lance Armstrong Foundation; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE [U10CA069974, U10CA058348, U10CA032102, U10CA012027, U10CA007190, U10CA045808, U10CA013612, U10CA025224, U10CA069651, U10CA037377] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Sanofi-Aventis(Sanofi-Aventis); Rhone-Poulenc-Rhorer; Genentech(Roche HoldingGenentech); Bristol-Myers Squibb(Bristol-Myers Squibb); Susan G. Komen for the Cure Foundation, Living in Pink, and Safeway(Susan G. Komen Breast Cancer Foundation); Eisai(Eisai Co Ltd); GlaxoSmithKline(GlaxoSmithKline); Pfizer(Pfizer); Onyx; Novartis(Novartis); Roche(Roche Holding); Abraxis; BiPar; Wyeth(Wyeth); NSABP; Kaiser Permanente; Eastern Cooperative Oncology Group; Lance Armstrong Foundation; Breast Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Public Health Service grants (U10-CA-37377, U10-CA-69974, U10-CA-12027, and U10-CA-69651 to the National Surgical Adjuvant Breast and Bowel Project; CA07190 to Dr. Erban; CA2115 to the Eastern Cooperative Oncology Group; CA-25224 to the North Central Cancer Treatment Group; and CA-32102, CA-13612, CA-58348, and CA-45808 to the Southwest Oncology Group) from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services; and by Sanofi-Aventis.; Dr. Swain reports receiving consulting fees from Rhone-Poulenc-Rhorer, grant support from Genentech, Sanofi-Aventis, Bristol-Myers Squibb, the Susan G. Komen for the Cure Foundation, Living in Pink, and Safeway, donations to the Washington Hospital Center Foundation from Genentech, Sanofi-Aventis, and Eisai, in-kind travel fees from Sanofi-Aventis, and grants to her institution (Medstar Research Institute) from Genentech, GlaxoSmithKline, Pfizer, Onyx, Novartis, Roche, Abraxis, BiPar, and Wyeth. Dr. Pajon reports receiving travel fees from the NSABP, which also provided fees to cover the clinical research associates and data managers; and owning stocks with his spouse in Gilead, Abbott, and Bristol-Myers Squibb. Dr. Fehrenbacher reports receiving grants and travel fees from Kaiser Permanente. Dr. Vogel reports receiving grants to the University of Pittsburgh from Sanofi-Aventis. Dr. Erban reports receiving grants from the Eastern Cooperative Oncology Group. Dr. Mamounas reports receiving consulting and lecture fees and serving on an advisory board for Sanofi-Aventis. Dr. Ganz reports receiving research support from the Lance Armstrong Foundation and the Breast Cancer Research Foundation. Drs. Geyer and Wolmark report receiving funding from Sanofi-Aventis for work performed by the NSABP to cover costs for non-standard of care procedures required by the study. No other potential conflict of interest relevant to this article was reported.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; *AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN; [Anonymous], SEER CANC STAT REV 1; Brewster AM, 2008, JNCI-J NATL CANCER I, V100, P1179, DOI 10.1093/jnci/djn233; Budman DR, 1998, J NATL CANCER I, V90, P1205, DOI 10.1093/jnci/90.16.1205; Castiglione-Gertsch M, 2003, JNCI-J NATL CANCER I, V95, P1833, DOI 10.1093/jnci/djg119; COX DR, 1972, J R STAT SOC B, V34, P187; Cuzick J, 2007, LANCET, V369, P1711; Davidson NE, 2005, J CLIN ONCOL, V23, P5973, DOI 10.1200/JCO.2005.05.551; EIERMANN W, 2009, 32 ANN SAN ANT BREAS; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; Ganz P, 2008, 31 ANN SAN ANT BREAS; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Harvey V, 2006, J CLIN ONCOL, V24, P4963, DOI 10.1200/JCO.2005.05.0294; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Knobf MT, 2006, ONCOLOGIST, V11, P96, DOI 10.1634/theoncologist.11-2-96; Nabholtz JM, 2003, J CLIN ONCOL, V21, P968, DOI 10.1200/JCO.2003.04.040; Paterson A, 2002, P AN M AM SOC CLIN, V21, p35a; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Swain SM, 2009, BREAST CANCER RES TR, V113, P315, DOI 10.1007/s10549-008-9937-0; Walshe JM, 2006, J CLIN ONCOL, V24, P5769, DOI 10.1200/JCO.2006.07.2793; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774	23	243	249	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2010	362	22					2053	2065		10.1056/NEJMoa0909638	http://dx.doi.org/10.1056/NEJMoa0909638			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603XU	20519679	Green Accepted, Bronze			2023-01-03	WOS:000278242200005
J	Dainese, E; Angelucci, CB; Sabatucci, A; De Filippis, V; Mei, G; Maccarrone, M				Dainese, Enrico; Angelucci, Clotilde B.; Sabatucci, Annalaura; De Filippis, Vincenzo; Mei, Giampiero; Maccarrone, Mauro			A novel role for iron in modulating the activity and membrane-binding ability of a trimmed soybean lipoxygenase-1	FASEB JOURNAL			English	Article						limited proteolysis; metal substitution; enzyme activity; enzyme structure; pathogen infection	X-RAY-SCATTERING; CRYSTAL-STRUCTURE; TYROSINE-HYDROXYLASE; MANGANESE LIPOXYGENASE; ORGANELLE DEGRADATION; ANGSTROM RESOLUTION; HUMAN CERULOPLASMIN; NONHEME IRON; METAL-IONS; CALCIUM	Lipoxygenases (LOXs) are iron-containing enzymes that play critical roles in plants and animals. As yet, metal atom extraction, reconstitution, and substitution have not been successfully applied to soybean LOX-1 [Glycine max (L.) Merrill], a prototype member of the LOX family that is widely used in structural and kinetic studies. Here, tryptic digestion of native LOX-1, used as a control, allowed us to isolate the 60-kDa C-terminal region (termed miniLOX), that retains the catalytically active iron in a more accessible position. Then, iron was removed to obtain an unprecedented apo-miniLOX, which was reconstituted and substituted with different metal ions. These forms of miniLOX were characterized vs. native LOX-1 by kinetic analysis, near UV circular dichroism, steady-state fluorescence, and fluorescence resonance energy transfer. MiniLOX showed a 2-fold increase in the membrane-binding affinity compared with native LOX-1 and a remarkable 4-fold increase compared with apo-miniLOX (K(d) = 9.2 +/- 1.0, 17.9 +/- 2.0, and 45.4 +/- 4.3 mu M, respectively). Furthermore, miniLOX reconstituted with Fe(II) or Fe(III) partially recovered its membrane-binding ability (K(d) = 21.4 +/- 2.4 and 18.9 +/- 5.5 mu M, respectively), overall supporting a novel noncatalytic role for iron in the LOX family.-Dainese, E., Angelucci, C. B., Sabatucci, A., De Filippis, V., Mei, M., Maccarrone, M. A novel role for iron in modulating the activity and membrane-binding ability of a trimmed soybean lipoxygenase-1. FASEB J. 24, 1725-1736 (2010). www.fasebj.org	[Dainese, Enrico; Angelucci, Clotilde B.; Sabatucci, Annalaura; Maccarrone, Mauro] Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; [De Filippis, Vincenzo] Univ Padua, Dept Pharmacol Sci, Padua, Italy; [Mei, Giampiero] Univ Roma Tor Vergata, Dept Expt Med & Biochem Sci, I-00173 Rome, Italy; [Maccarrone, Mauro] European Ctr Brain Res Santa Lucia Fdn, Rome, Italy	University of Teramo; University of Padua; University of Rome Tor Vergata	Dainese, E (corresponding author), Univ Teramo, Dept Biomed Sci, Piazzo Aldo Moro N 45, I-64100 Teramo, Italy.	edainese@unite.it; mmaccarrone@unite.it	Maccarrone, Mauro/K-5398-2012; SABATUCCI, Annalaura/E-9996-2013	Maccarrone, Mauro/0000-0002-3990-2963; Dainese, Enrico/0000-0001-7163-9344; SABATUCCI, Annalaura/0000-0002-8004-2547	University of Rome Tor Vergata, Rome, Italy; Ministero dell'Universita e della Ricerca [PRIN 2005]; Ministero della Salute (Progetto Ricerca Corrente) [IZS LT 08/07 RC]; Italian Space Agency (ASI); Fondazione TERCAS	University of Rome Tor Vergata, Rome, Italy; Ministero dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); Ministero della Salute (Progetto Ricerca Corrente)(Ministry of Health, Italy); Italian Space Agency (ASI)(Agenzia Spaziale Italiana (ASI)); Fondazione TERCAS(Fondazione CarifeFondazione Caritro)	The authors thank Professor Alessandro Finazzi-Agro (University of Rome Tor Vergata, Rome, Italy) for his continuing support. The kind assistance of Dr. Maria Luisa Salucci (University of L'Aquila, L'Aquila, Italy) in the preliminary experiments on apo-miniLOX isolation and that of Dr. Annamaria Draghi, Dr. Daniela Galla, and Dr. Paolo Di Muro (University of Padua, Padua, Italy) in CD and atomic absorption measurements, respectively, are gratefully acknowledged. This work was supported by Ministero dell'Universita e della Ricerca (PRIN 2005) and by Ministero della Salute (Progetto Ricerca Corrente, IZS LT 08/07 RC to E. D.), by the Italian Space Agency (ASI) (MoMa contract 2006), and by Fondazione TERCAS (project 2005-2008 to M. M.).	AULD DS, 1988, METHOD ENZYMOL, V158, P71, DOI 10.1016/0076-6879(88)58048-5; BABA A, 1989, J BIOL CHEM, V264, P15790; BLECHERT S, 1995, P NATL ACAD SCI USA, V92, P4099, DOI 10.1073/pnas.92.10.4099; BOYINGTON JC, 1993, SCIENCE, V260, P1482, DOI 10.1126/science.8502991; BOYINGTON JC, 1994, ANN NY ACAD SCI, V744, P310; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; BUBACCO L, 1992, BIOCHEMISTRY-US, V31, P9294, DOI 10.1021/bi00153a024; Carlile AJ, 2000, MOL PLANT MICROBE IN, V13, P538, DOI 10.1094/MPMI.2000.13.5.538; Challis GL, 2003, P NATL ACAD SCI USA, V100, P14555, DOI 10.1073/pnas.1934677100; Cristea M, 2005, ARCH BIOCHEM BIOPHYS, V434, P201, DOI 10.1016/j.abb.2004.10.026; Dainese E, 2005, J MOL BIOL, V349, P143, DOI 10.1016/j.jmb.2005.03.027; Decker H, 1998, J BIOL CHEM, V273, P25889, DOI 10.1074/jbc.273.40.25889; Di Venere A, 2003, J BIOL CHEM, V278, P18281, DOI 10.1074/jbc.M212122200; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; FINAZZIAGRO A, 1973, BIOCHIM BIOPHYS ACTA, V326, P462, DOI 10.1016/0005-2760(73)90146-X; Forneris F, 2008, SCIENCE, V321, P213, DOI 10.1126/science.1151118; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Grullich C, 2001, FEBS LETT, V489, P51, DOI 10.1016/S0014-5793(01)02080-4; HAAVIK J, 1992, EUR J BIOCHEM, V210, P23, DOI 10.1111/j.1432-1033.1992.tb17386.x; HAAVIK J, 1991, EUR J BIOCHEM, V199, P371, DOI 10.1111/j.1432-1033.1991.tb16133.x; Hammel M, 2004, J MOL BIOL, V343, P917, DOI 10.1016/j.jmb.2004.08.076; Hornsten L, 2002, EUR J BIOCHEM, V269, P2690, DOI 10.1046/j.1432-1033.2002.02936.x; Kariapper MST, 2001, BIOCHEM BIOPH RES CO, V284, P563, DOI 10.1006/bbrc.2001.5011; Kim ES, 2003, PLANT MOL BIOL, V52, P1203, DOI 10.1023/B:PLAN.0000004331.94803.b0; Knapp MJ, 2003, BIOCHEMISTRY-US, V42, P11466, DOI 10.1021/bi0300884; Knapp MJ, 2002, J AM CHEM SOC, V124, P3865, DOI 10.1021/ja012205t; Komoda T, 2004, BIOSCI BIOTECH BIOCH, V68, P903, DOI 10.1271/bbb.68.903; Kuhn H, 1999, ADV EXP MED BIOL, V447, P5; Kuhn H, 2005, BIOCHEM BIOPH RES CO, V338, P93, DOI 10.1016/j.bbrc.2005.08.238; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Maccarrone M, 2001, CELL DEATH DIFFER, V8, P776, DOI 10.1038/sj.cdd.4400908; Maccarrone M, 2001, BIOCHEMISTRY-US, V40, P6819, DOI 10.1021/bi010187m; MARTINEZ A, 1993, BIOCHEMISTRY-US, V32, P6381, DOI 10.1021/bi00076a011; MATSUDA S, 1991, BIOCHIM BIOPHYS ACTA, V1084, P202; Mei G, 2008, BIOCHEMISTRY-US, V47, P9234, DOI 10.1021/bi800638v; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Minor W, 1996, BIOCHEMISTRY-US, V35, P10687, DOI 10.1021/bi960576u; MYERS JS, 1975, J BIOL CHEM, V250, P3785; Nillius D, 2008, FEBS LETT, V582, P749, DOI 10.1016/j.febslet.2008.01.056; Oldham ML, 2005, J BIOL CHEM, V280, P39545, DOI 10.1074/jbc.M506675200; Pande AH, 2005, BIOPHYS J, V88, P4084, DOI 10.1529/biophysj.104.056788; Qin S, 2004, J MOL BIOL, V344, P71, DOI 10.1016/j.jmb.2004.09.034; Radmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002; SALVATO B, 1989, BIOCHIM BIOPHYS ACTA, V998, P14, DOI 10.1016/0167-4838(89)90112-X; SCHILSTRA MJ, 1994, BIOCHEMISTRY-US, V33, P3974, DOI 10.1021/bi00179a025; SkrzypczakJankun E, 1996, ACTA CRYSTALLOGR D, V52, P959, DOI 10.1107/S0907444996005239; Solomon EI, 2000, CHEM REV, V100, P235, DOI 10.1021/cr9900275; Solomon EI, 1997, CHEM BIOL, V4, P795, DOI 10.1016/S1074-5521(97)90113-7; Sreerama N, 2001, ANAL BIOCHEM, V299, P271, DOI 10.1006/abio.2001.5420; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; Taccone-Gallucci M, 2008, NEW ENGL J MED, V358, P746, DOI 10.1056/NEJMc073333; Tatulian SA, 1998, BIOCHEMISTRY-US, V37, P15481, DOI 10.1021/bi981062t; Timasheff S.N., 1989, PROTEIN STRUCTURE PR, P331; Titus GP, 2000, NAT STRUCT BIOL, V7, P542; Vachette P, 2002, J BIOL CHEM, V277, P40823, DOI 10.1074/jbc.M207188200; van der Donk WA, 2002, BIOCHEMISTRY-US, V41, P15451, DOI 10.1021/bi026938h; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; VANDERHEIJDT LM, 1995, EUR J BIOCHEM, V231, P186, DOI 10.1111/j.1432-1033.1995.tb20685.x; Vassiliev VB, 1997, J INORG BIOCHEM, V65, P167, DOI 10.1016/S0162-0134(96)00119-5; Walther M, 2004, J BIOL CHEM, V279, P3717, DOI 10.1074/jbc.M309564200; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377; Welch KD, 2002, ARCH BIOCHEM BIOPHYS, V397, P360, DOI 10.1006/abbi.2001.2694; Xiao K, 2002, BIOL CONTROL, V23, P285, DOI 10.1006/bcon.2001.1015; Yamanaka K, 2005, MICROBIOL-SGM, V151, P2899, DOI 10.1099/mic.0.28139-0	68	21	22	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2010	24	6					1725	1736		10.1096/fj.09-141390	http://dx.doi.org/10.1096/fj.09-141390			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20081094	Green Submitted			2023-01-03	WOS:000278200000010
J	Mihardja, SS; Gao, DW; Sievers, RE; Fang, QZ; Feng, JJ; Wang, JM; Vanbrocklin, HF; Larrick, JW; Huang, M; Dae, M; Lee, RJ				Mihardja, Shirley S.; Gao, Dongwei; Sievers, Richard E.; Fang, Qizhi; Feng, Jinjin; Wang, Jianming; Vanbrocklin, Henry F.; Larrick, James W.; Huang, Manley; Dae, Michael; Lee, Randall J.			Targeted In Vivo Extracellular Matrix Formation Promotes Neovascularization in a Rodent Model of Myocardial Infarction	PLOS ONE			English	Article							ENDOTHELIAL-CELL PROLIFERATION; LEFT-VENTRICULAR GEOMETRY; IV-COLLAGEN; SYNTHETIC PEPTIDE; ALPHA(V)BETA(3) INTEGRIN; GROWTH-FACTOR; ANGIOGENESIS; ADHESION; MIGRATION; FIBRONECTIN	Background: The extracellular matrix plays an important role in tissue regeneration. We investigated whether extracellular matrix protein fragments could be targeted with antibodies to ischemically injured myocardium to promote angiogenesis and myocardial repair. Methodology/Principal Findings: Four peptides, 2 derived from fibronectin and 2 derived from Type IV Collagen, were assessed for in vitro and in vivo tendencies for angiogenesis. Three of the four peptides-Hep I, Hep III, RGD-were identified and shown to increase endothelial cell attachment, proliferation, migration and cell activation in vitro. By chemically conjugating these peptides to an anti-myosin heavy chain antibody, the peptides could be administered intravenously and specifically targeted to the site of the myocardial infarction. When administered into Sprague-Dawley rats that underwent ischemia-reperfusion myocardial infarction, these peptides produced statistically significantly higher levels of angiogenesis and arteriogenesis 6 weeks post treatment. Conclusions/Significance: We demonstrated that antibody-targeted ECM-derived peptides alone can be used to sufficiently alter the extracellular matrix microenvironment to induce a dramatic angiogenic response in the myocardial infarct area. Our results indicate a potentially new non-invasive strategy for repairing damaged tissue, as well as a novel tool for investigating in vivo cell biology.	[Mihardja, Shirley S.; Gao, Dongwei; Fang, Qizhi; Dae, Michael; Lee, Randall J.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Sievers, Richard E.; Lee, Randall J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Lee, Randall J.] Univ Calif San Francisco, Inst Regenerat Med, San Francisco, CA 94143 USA; [Gao, Dongwei; Feng, Jinjin; Vanbrocklin, Henry F.; Dae, Michael] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA; [Lee, Randall J.] Univ Calif Berkeley, UCSF, Joint Bioengn Grad Grp, Berkeley, CA 94720 USA; [Wang, Jianming; Larrick, James W.; Huang, Manley] Panorama Res Inst, Sunnyvale, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; University of California San Francisco	Mihardja, SS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA.	lee@medicine.ucsf.edu			NIH [R21 HL084121]; California Institute of Regenerative Medicine [RC1-00124-1]; American Heart Association; Margoes Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL084121] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute of Regenerative Medicine(California Institute for Regenerative Medicine); American Heart Association(American Heart Association); Margoes Foundation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by NIH R21 HL084121 and by the California Institute of Regenerative Medicine (RC1-00124-1). SSM was supported by the American Heart Association Postdoctoral Fellowship and by the Margoes Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Azarnoush K, 2005, J THORAC CARDIOV SUR, V130, P173, DOI 10.1016/j.jtcvs.2004.11.044; Bishop E T, 1999, Angiogenesis, V3, P335, DOI 10.1023/A:1026546219962; Bonanno E, 2000, IN VITRO CELL DEV-AN, V36, P336; Bouchentouf M, 2008, GENE THER, V15, P404, DOI 10.1038/sj.gt.3303059; CAMERON JD, 1991, INVEST OPHTH VIS SCI, V32, P2766; Christman KL, 2004, J AM COLL CARDIOL, V44, P654, DOI 10.1016/j.jacc.2004.04.040; Corda S, 2000, Heart Fail Rev, V5, P119, DOI 10.1023/A:1009806403194; Davis GE, 2005, CIRC RES, V97, P1093, DOI 10.1161/01.RES.0000191547.64391.e3; FORM DM, 1986, LAB INVEST, V55, P521; Gorbet MB, 2005, BIOMATERIALS, V26, P6811, DOI 10.1016/j.biomaterials.2005.04.063; Heiss C, 2008, J CELL PHYSIOL, V215, P366, DOI 10.1002/jcp.21313; Huang NF, 2006, NAT PROTOC, V1, P1596, DOI 10.1038/nprot.2006.188; Kellar RS, 2001, CIRCULATION, V104, P2063, DOI 10.1161/hc4201.097192; LITWIN SE, 1994, CIRCULATION, V89, P345, DOI 10.1161/01.CIR.89.1.345; Liu YQ, 2004, FASEB J, V18, P457, DOI 10.1096/fj.03-0948com; MALDONADO BA, 1995, INVEST OPHTH VIS SCI, V36, P364; Manohar A, 2004, J CELL SCI, V117, P4043, DOI 10.1242/jcs.01277; MOORADIAN DL, 1993, INVEST OPHTH VIS SCI, V34, P153; Nam JO, 2003, J BIOL CHEM, V278, P25902, DOI 10.1074/jbc.M300358200; NICOSIA RF, 1987, AM J PATHOL, V128, P78; Nisato Riccardo E., 2003, Angiogenesis, V6, P105, DOI 10.1023/B:AGEN.0000011801.98187.f2; Passier R, 2008, NATURE, V453, P322, DOI 10.1038/nature07040; Patel S, 2007, J BIOMED MATER RES A, V83A, P423, DOI 10.1002/jbm.a.31320; PIERSCHBACHER M, 1983, P NATL ACAD SCI-BIOL, V80, P1224, DOI 10.1073/pnas.80.5.1224; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Senger DR, 1996, AM J PATHOL, V149, P293; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Setty S, 1998, J BIOL CHEM, V273, P12244, DOI 10.1074/jbc.273.20.12244; Simons M, 2004, MOL CELL BIOCHEM, V264, P99, DOI 10.1023/B:MCBI.0000044379.25823.03; Springer ML, 2000, MOL THER, V1, P82, DOI 10.1006/mthe.1999.0006; Springer ML, 2003, MOL THER, V7, P441, DOI 10.1016/S1525-0016(03)00010-8; Strauer BE, 2003, CIRCULATION, V107, P929, DOI 10.1161/01.CIR.0000057525.13182.24; SUDA T, 1981, CURRENT EYE RES, V1; Thiagarajan P, 1996, BIOCHEMISTRY-US, V35, P4169, DOI 10.1021/bi952532b; TSILIBARY EC, 1990, J CELL BIOL, V111, P1583, DOI 10.1083/jcb.111.4.1583; Vailhe B, 2001, LAB INVEST, V81, P439, DOI 10.1038/labinvest.3780252; Vinals F, 1999, MOL CELL BIOL, V19, P2763; Virag JI, 2003, AM J PATHOL, V163, P2433, DOI 10.1016/S0002-9440(10)63598-5; Vogel V, 2003, ANNU REV BIOMED ENG, V5, P441, DOI 10.1146/annurev.bioeng.5.040202.121615; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Yu JS, 2009, J THORAC CARDIOV SUR, V137, P180, DOI 10.1016/j.jtcvs.2008.08.036	44	19	22	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2010	5	4							e10384	10.1371/journal.pone.0010384	http://dx.doi.org/10.1371/journal.pone.0010384			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	589MV	20442783	Green Submitted, Green Published, gold			2023-01-03	WOS:000277154200020
J	Detering, KM; Hancock, AD; Reade, MC; Silvester, W				Detering, Karen M.; Hancock, Andrew D.; Reade, Michael C.; Silvester, William			The impact of advance care planning on end of life care in elderly patients: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DECISION-MAKING; FAMILY-MEMBERS; MEDICAL-CARE; EVENT SCALE; DISCUSSIONS; DIRECTIVES; DEATH; DEPRESSION; SYMPTOMS; AUTONOMY	Objective To investigate the impact of advance care planning on end of life care in elderly patients. Design Prospective randomised controlled trial. Setting Single centre study in a university hospital in Melbourne, Australia. Participants 309 legally competent medical inpatients aged 80 or more and followed for six months or until death. Interventions Participants were randomised to receive usual care or usual care plus facilitated advance care planning. Advance care planning aimed to assist patients to reflect on their goals, values, and beliefs; to consider future medical treatment preferences; to appoint a surrogate; and to document their wishes. Main outcome measures The primary outcome was whether a patient's end of life wishes were known and respected. Other outcomes included patient and family satisfaction with hospital stay and levels of stress, anxiety, and depression in relatives of patients who died. Results 154 of the 309 patients were randomised to advance care planning, 125 (81%) received advance care planning, and 108 (84%) expressed wishes or appointed a surrogate, or both. Of the 56 patients who died by six months, end of life wishes were much more likely to be known and followed in the intervention group (25/29, 86%) compared with the control group (8/27, 30%; P<0.001). In the intervention group, family members of patients who died had significantly less stress (intervention 5, control 15; P<0.001), anxiety (intervention 0, control 3; P=0.02), and depression (intervention 0, control 5; P=0.002) than those of the control patients. Patient and family satisfaction was higher in the intervention group. Conclusions Advance care planning improves end of life care and patient and family satisfaction and reduces stress, anxiety, and depression in surviving relatives. Trial registration Australian New Zealand clinical trials registry ACTRN12608000539336.	[Detering, Karen M.; Hancock, Andrew D.; Silvester, William] Austin Hlth, Respecting Patient Choices Program, Heidelberg, Vic 3084, Australia; [Reade, Michael C.] Austin Hlth, Intens Care Unit, Heidelberg, Vic 3084, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Detering, KM (corresponding author), Austin Hlth, Respecting Patient Choices Program, POB 555, Heidelberg, Vic 3084, Australia.	Karen.detering@austin.org.au	Reade, Michael/G-7035-2012	Reade, Michael/0000-0003-1570-0707	Australian Commonwealth; Victorian state governments	Australian Commonwealth; Victorian state governments	Funding: This study was carried out using staff employed in the Respecting Patient Choices programme, which receives public funding from the Australian Commonwealth and the Victorian state governments. No external funding was utilised.	Adams DH, 2006, J AM OSTEOPATH ASSOC, V106, P402; *AUSTR MED ASS, 1998, OP 2 225 OPT US ORD; *AUSTR MED ASS, 2006, AMA BACKS ADV CAR PL; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Briggs LA, 2004, J PROF NURS, V20, P47, DOI 10.1016/j.profnurs.2003.12.001; Briggs Linda, 2004, J Palliat Med, V7, P341, DOI 10.1089/109662104773709503; *BRIT MED ASS, 2007, END OF LIF DEC; Cartwright Colleen M, 2004, Aust Fam Physician, V33, P815; Drazen JM, 2009, NEW ENGL J MED, V360, P444, DOI 10.1056/NEJMp0809496; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gillick MR, 2004, NEW ENGL J MED, V350, P7, DOI 10.1056/NEJMp038202; Grimaldo DA, 2001, ANESTHESIOLOGY, V95, P43, DOI 10.1097/00000542-200107000-00012; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; HAMMES BJ, 1999, LESSONS RESPECTING Y; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Keay Timothy J, 2003, J Palliat Med, V6, P205, DOI 10.1089/109662103764978452; Lautrette A, 2007, NEW ENGL J MED, V356, P469, DOI 10.1056/NEJMoa063446; Levinsky NG, 1996, NEW ENGL J MED, V335, P741, DOI 10.1056/NEJM199609053351012; Medical Research Council, 2008, DEV EV COMPL INT NEW; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; Pearlman RA, 2005, ARCH INTERN MED, V165, P667, DOI 10.1001/archinte.165.6.667; Perkins HS, 2007, ANN INTERN MED, V147, P51, DOI 10.7326/0003-4819-147-1-200707030-00008; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Prendergast TJ, 2001, CRIT CARE MED, V29, pN34, DOI 10.1097/00003246-200102001-00007; Ramsaroop SD, 2007, J AM GERIATR SOC, V55, P277, DOI 10.1111/j.1532-5415.2007.01065.x; Romer Anna L, 2004, J Palliat Med, V7, P335, DOI 10.1089/109662104773709495; Schwartz Carolyn, 2003, J Palliat Med, V6, P593, DOI 10.1089/109662103768253704; Schwartz CE, 2002, ARCH INTERN MED, V162, P1611, DOI 10.1001/archinte.162.14.1611; Singer PA, 1998, ARCH INTERN MED, V158, P879, DOI 10.1001/archinte.158.8.879; Singer PA, 1996, CAN MED ASSOC J, V155, P1689; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Skene L., 2008, LAW MED PRACTICE RIG, V3rd, P346; Song MK, 2005, MED CARE, V43, P1049, DOI 10.1097/01.mlr.0000178192.10283.b4; Song MK, 2004, NURS OUTLOOK, V52, P118, DOI 10.1016/j.outlook.2003.10.014; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Sundin EC, 2003, PSYCHOSOM MED, V65, P870, DOI 10.1097/01.PSY.0000084835.46074.F0; Tierney WM, 2001, J GEN INTERN MED, V16, P32, DOI 10.1111/j.1525-1497.2001.00215.x; Tilden VP, 2001, NURS RES, V50, P105, DOI 10.1097/00006199-200103000-00006; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Tulsky JA, 2005, JAMA-J AM MED ASSOC, V294, P359, DOI 10.1001/jama.294.3.359; Volandes AE, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2159; Winzelberg GS, 2005, J AM GERIATR SOC, V53, P1046, DOI 10.1111/j.1532-5415.2005.53317.x; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI DOI 10.1001/JAMA.1995.03530200027032	46	1410	1429	3	62	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	2010	340								c1345	10.1136/bmj.c1345	http://dx.doi.org/10.1136/bmj.c1345			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	576PO	20332506	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000276157600005
J	Kitamura, T; Iwami, T; Kawamura, T; Nagao, K; Tanaka, H; Hiraide, A				Kitamura, Tetsuhisa; Iwami, Taku; Kawamura, Takashi; Nagao, Ken; Tanaka, Hideharu; Hiraide, Atsushi		All-Japan Utstein Registry Fire	Nationwide Public-Access Defibrillation in Japan.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; HOSPITAL CARDIAC-ARREST; AUTOMATED EXTERNAL DEFIBRILLATOR; EUROPEAN-RESUSCITATION-COUNCIL; CARDIOPULMONARY-RESUSCITATION; STROKE-FOUNDATION; TASK-FORCE; STATEMENT; SURVIVAL; CARE	Background: It is unclear whether dissemination of automated external defibrillators (AEDs) in public places can improve the rate of survival among patients who have had an out-of-hospital cardiac arrest. Methods: From January 1, 2005, through December 31, 2007, we conducted a prospective, population-based, observational study involving consecutive patients across Japan who had an out-of-hospital cardiac arrest and in whom resuscitation was attempted by emergency responders. We evaluated the effect of nationwide dissemination of public-access AEDs on the rate of survival after an out-of-hospital cardiac arrest. The primary outcome measure was the 1-month rate of survival with minimal neurologic impairment. A multivariate logistic-regression analysis was performed to assess factors associated with a good neurologic outcome. Results: A total of 312,319 adults who had an out-of-hospital cardiac arrest were included in the study; 12,631 of these patients had ventricular fibrillation and had an arrest that was of cardiac origin and that was witnessed by bystanders. In 462 of these patients (3.7%), shocks were administered by laypersons with the use of public-access AEDs, and the proportion increased, from 1.2% to 6.2%, as the number of public-access AEDs increased (P<0.001 for trend). Among all patients who had a bystander-witnessed arrest of cardiac origin and who had ventricular fibrillation, 14.4% were alive at 1 month with minimal neurologic impairment; among patients who received shocks from public-access AEDs, 31.6% were alive at 1 month with minimal neurologic impairment. Early defibrillation, regardless of the type of provider (bystander or emergency-medical-services personnel), was associated with a good neurologic outcome after a cardiac arrest with ventricular fibrillation (adjusted odds ratio per 1-minute increase in the time to administration of shock, 0.91; 95% confidence interval, 0.89 to 0.92; P<0.001). The mean time to shock was reduced from 3.7 to 2.2 minutes, and the annual number of patients per 10 million population who survived with minimal neurologic impairment increased from 2.4 to 8.9 as the number of public-access AEDs increased from fewer than 1 per square kilometer of inhabited area to 4 or more. Conclusions: Nationwide dissemination of public-access AEDs in Japan resulted in earlier administration of shocks by laypersons and in an increase in the 1-month rate of survival with minimal neurologic impairment after an out-of-hospital cardiac arrest. N Engl J Med 2010;362:994-1004.	[Iwami, Taku] Kyoto Univ, Hlth Serv, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan; [Hiraide, Atsushi] Kyoto Univ, Grad Sch Med, Ctr Med Educ, Kyoto 6068501, Japan; [Nagao, Ken] Surugadai Nihon Univ Hosp, Dept Cardiol Cardiopulm Resuscitat & Emergency Ca, Tokyo, Japan; [Tanaka, Hideharu] Kokushikan Univ, Grad Sch Sport Syst, Tokyo, Japan	Kyoto University; Kyoto University; Nihon University	Iwami, T (corresponding author), Kyoto Univ, Hlth Serv, Sakyo Ku, Yoshida Honmachi, Kyoto 6068501, Japan.	iwamit@e-mail.jp	Kitamura, Tetsuhisa/AAA-2555-2020; IWAMI, Taku/HCH-0599-2022	Kitamura, Tetsuhisa/0000-0003-0107-0580; IWAMI, Taku/0000-0002-4150-7065	Fire and Disaster Management Agency; Ministry of Education, Culture, Sports, Science and Technology [19390458]	Fire and Disaster Management Agency; Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	Supported by grants from the Fire and Disaster Management Agency (to Dr. Hiraide, on behalf of the study group concerning strategy for applying the results of Utstein report for improvement of emergency service) and the Ministry of Education, Culture, Sports, Science and Technology (19390458).	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; [Anonymous], 2007, JAP GUID EM CAR CARD; Bardy GH, 2008, NEW ENGL J MED, V358, P1793, DOI 10.1056/NEJMoa0801651; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Caffrey SL, 2002, NEW ENGL J MED, V347, P1242, DOI 10.1056/NEJMoa020932; Capucci A, 2002, CIRCULATION, V106, P1065, DOI 10.1161/01.CIR.0000028148.62305.69; Cobb LA, 1999, JAMA-J AM MED ASSOC, V281, P1182, DOI 10.1001/jama.281.13.1182; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; Hallstrom AP, 2004, NEW ENGL J MED, V351, P637; Hazinski MF, 2005, CIRCULATION, V111, P3336, DOI 10.1161/CIRCULATIONAHA.105.165674; *HLTH WELF STAT AS, 2007, VIT STAT JAP 2005; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iwami T, 2009, CIRCULATION, V119, P728, DOI 10.1161/CIRCULATIONAHA.108.802058; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; *JAP STAT ASS, 2005, SOC IND PREF 2005; *JAP STAT ASS, 2006, 2005 POP CENS JAP; Kuramoto N, 2008, RESUSCITATION, V79, P475, DOI 10.1016/j.resuscitation.2008.07.005; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; MacDonald RD, 2001, ANN EMERG MED, V38, P262, DOI 10.1067/mem.2001.117953; *MIN INT AFF COMM, AMB SERV PLANN OFF F; Mitamura H, 2008, NAT CLIN PRACT CARD, V5, P690, DOI 10.1038/ncpcardio1330; Nichol G, 2009, ANN EMERG MED, V54, P226, DOI 10.1016/j.annemergmed.2009.01.021; Nishiyama C, 2008, RESUSCITATION, V79, P90, DOI 10.1016/j.resuscitation.2008.05.009; Page RL, 2000, NEW ENGL J MED, V343, P1210, DOI 10.1056/NEJM200010263431702; Rea TD, 2003, CIRCULATION, V107, P2780, DOI 10.1161/01.CIR.0000070950.17208.2A; Rea TD, 2006, CIRCULATION, V114, P2760, DOI 10.1161/CIRCULATIONAHA.106.654715; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; Valenzuela TD, 2000, NEW ENGL J MED, V343, P1206, DOI 10.1056/NEJM200010263431701; van Alem AP, 2003, BMJ-BRIT MED J, V327, P1312, DOI 10.1136/bmj.327.7427.1312; White RD, 2005, RESUSCITATION, V65, P279, DOI 10.1016/j.resuscitation.2004.10.018; REPORT STUDY SOCIAL; JAPAN FDN EMERGENCY	32	403	408	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2010	362	11					994	1004		10.1056/NEJMoa0906644	http://dx.doi.org/10.1056/NEJMoa0906644			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570CY	20237345	Bronze, Green Published			2023-01-03	WOS:000275650400010
J	Green, MJ; Myers, KR				Green, Michael J.; Myers, Kimberly R.			Graphic medicine: use of comics in medical education and patient care	BRITISH MEDICAL JOURNAL			English	Editorial Material							BOOKS; ART		[Green, Michael J.; Myers, Kimberly R.] Penn State Coll Med, Dept Humanities & Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Green, MJ (corresponding author), Penn State Coll Med, Dept Humanities & Med, 500 Univ Dr, Hershey, PA 17033 USA.	mjg15@psu.edu	Green, Martin A/H-7567-2012	Green, Martin A/0000-0002-8860-396X; Green, Michael/0000-0002-4828-4749				Bitz M, 2004, J ADOLESC ADULT LIT, V47, P574; Carney RN, 2002, EDUC PSYCHOL REV, V14, P5, DOI 10.1023/A:1013176309260; CARTER JB, 2008, TEACHING VISUAL LITE; Dolev JC, 2001, JAMA-J AM MED ASSOC, V286, P1020, DOI 10.1001/jama.286.9.1020; Doxiadis A., 2009, LOGICOMIX EPIC SEARC; FIES B, 2006, MOMS CANC ABRAMS IMA; Fisher Douglas., 2004, ENGL J, V93, P19, DOI [10.2307/4128804, DOI 10.2307/4128804]; Gerde VW, 2008, J BUS ETHICS, V77, P245, DOI 10.1007/s10551-006-9347-3; GILLIES P A, 1990, Health Education Research, V5, P27, DOI 10.1093/her/5.1.27; GREEN MJ, 2009, INT J HEALTHCARE HUM, V3, P1; Hansen B, 2004, B HIST MED, V78, P148, DOI 10.1353/bhm.2004.0018; HARVEY J, 1997, HIV J BIOCOMMUN, V24, P16; Houts PS, 2001, PATIENT EDUC COUNS, V43, P231, DOI 10.1016/S0738-3991(00)00171-3; Johnstone M., 2006, LIVING BLACK DOG HIS; Kakalios J, 2005, PHYS SUPERHEROES; Marchetto MA, 2006, CANC VIXEN TRUE STOR; MAYER RE, 1994, J EDUC PSYCHOL, V86, P389, DOI 10.1037/0022-0663.86.3.389; MCALLISTER MP, 1992, J POP CULT, V26, P1, DOI 10.1111/j.0022-3840.1992.26021.x; McCloud S, 1994, UNDERSTANDING COMICS; Medikidz, MED INF KIDS; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; Naghshineh S, 2008, J GEN INTERN MED, V23, P991, DOI 10.1007/s11606-008-0667-0; Pieper C, 2000, DIABETES RES CLIN PR, V50, P31, DOI DOI 10.1016/S0168-8227(00)81563-6; Sabin Roger, 1996, COMICS COMIX GRAPHIC; Satrapi Marjane, 2003, PERSEPOLIS; Squier SM, 2008, J MED HUMANIT, V29, P71, DOI 10.1007/s10912-008-9057-1; Versaci R., 2001, ENGL J, V91, P61, DOI DOI 10.2307/822347; VERSACI R, 2008, TEACHING VISUAL LITE; COMIC PROBLEMS	29	159	162	6	40	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 3	2010	340								c863	10.1136/bmj.c863	http://dx.doi.org/10.1136/bmj.c863			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	565FJ	20200064				2023-01-03	WOS:000275274400013
J	Margeli, M; Cirauqui, B; Castella, E; Tapia, G; Costa, C; Gimenez-Capitan, A; Barnadas, A; Ronco, MS; Benlloch, S; Taron, M; Rosell, R				Margeli, Mireia; Cirauqui, Beatriz; Castella, Eva; Tapia, Gustavo; Costa, Carlota; Gimenez-Capitan, Ana; Barnadas, Agusti; Sanchez Ronco, Maria; Benlloch, Susana; Taron, Miquel; Rosell, Rafael			The Prognostic Value of BRCA1 mRNA Expression Levels Following Neoadjuvant Chemotherapy in Breast Cancer	PLOS ONE			English	Article							LUNG-CANCER; INCREASED SENSITIVITY; SPORADIC BREAST; CHEMORESISTANCE; PROMOTER; SURVIVAL; SUBTYPES; MARKERS; PREDICT; AGENTS	Background: A fraction of sporadic breast cancers has low BRCA1 expression. BRCA1 mutation carriers are more likely to achieve a pathological complete response with DNA-damage-based chemotherapy compared to non-mutation carriers. Furthermore, sporadic ovarian cancer patients with low levels of BRCA1 mRNA have longer survival following platinum-based chemotherapy than patients with high levels of BRCA1 mRNA. Methodology/Principal Findings: Tumor biopsies were obtained from 86 breast cancer patients who were candidates for neoadjuvant chemotherapy, treated with four cycles of neoadjuvant fluorouracil, epirubicin and cyclophosphamide. Estrogen receptor (ER), progesterone receptor (PR), HER2, cytokeratin 5/6 and vimentin were examined by tissue microarray. HER2 were also assessed by chromogenic in situ hybridization, and BRCA1 mRNA was analyzed in a subset of 41 patients for whom sufficient tumor tissue was available by real-time quantitative PCR. Median time to progression was 42 months and overall survival was 55 months. In the multivariate analysis for time to progression and overall survival for 41 patients in whom BRCA1 could be assessed, low levels of BRCA1 mRNA, positive PR and negative lymph node involvement predicted a significantly lower risk of relapse, low levels of BRCA1 mRNA and positive PR were the only variables associated with significantly longer survival. Conclusions/Significance: We provide evidence for a major role for BRCA1 mRNA expression as a marker of time to progression and overall survival in sporadic breast cancers treated with anthracycline-based chemotherapy. These findings can be useful for customizing chemotherapy.	[Margeli, Mireia; Cirauqui, Beatriz; Taron, Miquel; Rosell, Rafael] Hosp Badalona Germans Trias & Pujol, Dept Med, Catalan Inst Oncol, Med Oncol Serv, Badalona, Spain; [Margeli, Mireia; Cirauqui, Beatriz; Taron, Miquel; Rosell, Rafael] Autonomous Univ Barcelona, Badalona, Spain; [Castella, Eva; Tapia, Gustavo] Hosp Badalona Germans Trias & Pujol, Pathol Serv, Badalona, Spain; [Costa, Carlota; Gimenez-Capitan, Ana; Benlloch, Susana; Taron, Miquel; Rosell, Rafael] USP Dexeus Univ Inst, Pangaea Biotech SA, Barcelona, Spain; [Sanchez Ronco, Maria] Univ Alcala de Henares, Madrid, Spain; [Barnadas, Agusti] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain	Catalan Institute of Oncology; Hospital Germans Trias i Pujol; Autonomous University of Barcelona; Hospital Germans Trias i Pujol; Universidad de Alcala; Hospital of Santa Creu i Sant Pau	Margeli, M (corresponding author), Hosp Badalona Germans Trias & Pujol, Dept Med, Catalan Inst Oncol, Med Oncol Serv, Badalona, Spain.	33198mmv@comb.es; rrosell@ico.scs.es	Giménez-Capitán, Ana/AAX-1433-2021; Tapia, Gustavo/M-9938-2017; Castellà, Eva/K-4140-2017	Tapia Melendo, Gustavo/0000-0003-1882-0368	Redes de Cancer [RD06/0056/0020]	Redes de Cancer	This study was partially supported by a grant from Redes de Cancer (RD06/0056/0020). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Boukovinas I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003695; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; BYRSKI T, 2007, BREAST CANC RES TREA; Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453; Chapppuis PO, 2002, J MED GENET, V39, P608, DOI 10.1136/jmg.39.8.608; Einspahr JG, 2003, CANCER RES, V63, P3891; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fedier A, 2003, INT J ONCOL, V22, P1169; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Font A, 2008, J CLIN ONCOL, V26; Grushko TA, 2004, CLIN CANCER RES, V10, P499, DOI 10.1158/1078-0432.CCR-0976-03; Husain A, 1998, CANCER RES, V58, P1120; Kirova YM, 2005, EUR J CANCER, V41, P2304, DOI 10.1016/j.ejca.2005.02.037; Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; LIEDTKE C, 2006, AACR M; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Maione P, 2005, J CLIN ONCOL, V23, P6865, DOI 10.1200/JCO.2005.02.527; Masters SC, 2001, MOL PHARMACOL, V60, P1325, DOI 10.1124/mol.60.6.1325; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Oehme F, 2002, BIOCHEM BIOPH RES CO, V296, P343, DOI 10.1016/S0006-291X(02)00862-8; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Quinn JE, 2003, CANCER RES, V63, P6221; Quinn JE, 2007, CLIN CANCER RES, V13, P7413, DOI 10.1158/1078-0432.CCR-07-1083; Rakha EA, 2008, HUM PATHOL, V39, P857, DOI 10.1016/j.humpath.2007.10.011; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Rosell R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001129; Rosell R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005133; Rosell Rafael, 2008, P231, DOI 10.1007/978-1-60327-088-5_13; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; SALEH EM, 2009, CELL BIOCH BIOPHYS; Scholl SM, 1995, EUR J CANCER, V31A, P1969, DOI 10.1016/0959-8049(95)00454-8; Sgagias MK, 2004, CELL CYCLE, V3, P1451, DOI 10.4161/cc.3.11.1211; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Tanner M, 2000, AM J PATHOL, V157, P1467, DOI 10.1016/S0002-9440(10)64785-2; Taron M, 2004, HUM MOL GENET, V13, P2443, DOI 10.1093/hmg/ddh260; Wang LF, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-97; Weberpals J, 2009, INT J CANCER, V124, P806, DOI 10.1002/ijc.23987	40	29	31	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2010	5	3							e9499	10.1371/journal.pone.0009499	http://dx.doi.org/10.1371/journal.pone.0009499			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	562OZ	20209131	gold, Green Submitted, Green Published			2023-01-03	WOS:000275063400009
J	Holmes, MV; Shah, T; Vickery, C; Smeeth, L; Hingorani, AD; Casas, JP				Holmes, Michael V.; Shah, Tina; Vickery, Christine; Smeeth, Liam; Hingorani, Aroon D.; Casas, Juan P.			Fulfilling the Promise of Personalized Medicine? Systematic Review and Field Synopsis of Pharmacogenetic Studies	PLOS ONE			English	Article							GENETIC ASSOCIATIONS; DISEASE; GENOME; COMMON; VARIANTS; RISK; POLYMORPHISMS; DESIGN; VKORC1; CYP2C9	Background: Studies of the genetic basis of drug response could help clarify mechanisms of drug action/metabolism, and facilitate development of genotype-based predictive tests of efficacy or toxicity (pharmacogenetics). Objectives: We conducted a systematic review and field synopsis of pharmacogenetic studies to quantify the scope and quality of available evidence in this field in order to inform future research. Data Sources: Original research articles were identified in Medline, reference lists from 24 meta-analyses/systematic reviews/review articles and U.S. Food and Drug Administration website of approved pharmacogenetic tests. Study Eligibility Criteria, Participants, and Intervention Criteria: We included any study in which either intended or adverse response to drug therapy was examined in relation to genetic variation in the germline or cancer cells in humans. Study Appraisal and Synthesis Methods: Study characteristics and data reported in abstracts were recorded. We further analysed full text from a random 10% subset of articles spanning the different subclasses of study. Results: From 102,264 Medline hits and 1,641 articles from other sources, we identified 1,668 primary research articles (1987 to 2007, inclusive). A high proportion of remaining articles were reviews/commentaries ( ratio of reviews to primary research approximately 25: 1). The majority of studies (81.8%) were set in Europe and North America focussing on cancer, cardiovascular disease and neurology/psychiatry. There was predominantly a candidate gene approach using common alleles, which despite small sample sizes (median 93 [IQR 40-222]) with no trend to an increase over time, generated a high proportion (74.5%) of nominally significant (p<0.05) reported associations suggesting the possibility of significance-chasing bias. Despite 136 examples of gene/drug interventions being the subject of >= 4 studies, only 31 meta-analyses were identified. The majority (69.4%) of end-points were continuous and likely surrogate rather than hard (binary) clinical end-points. Conclusions and Implications of Key Findings: The high expectation but limited translation of pharmacogenetic research thus far may be explained by the preponderance of reviews over primary research, small sample sizes, a mainly candidate gene approach, surrogate markers, an excess of nominally positive to truly positive associations and paucity of meta-analyses. Recommendations based on these findings should inform future study design to help realise the goal of personalised medicines. Systematic Review Registration Number: Not Registered	[Holmes, Michael V.; Shah, Tina; Vickery, Christine; Hingorani, Aroon D.] UCL, Ctr Clin Pharmacol, London, England; [Smeeth, Liam; Casas, Juan P.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England; [Hingorani, Aroon D.] UCL, Dept Epidemiol, London, England	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London	Holmes, MV (corresponding author), UCL, Ctr Clin Pharmacol, London, England.	a.hingorani@ucl.ac.uk; Juan.Pablo-Casas@lshtm.ac.uk	Holmes, Michael/AAA-2208-2021; Smeeth, Liam/X-5862-2018	Hingorani, Aroon/0000-0001-8365-0081; Smeeth, Liam/0000-0002-9168-6022; Shah, Tina/0000-0001-7724-7210	British Heart Foundation [FS05/125]; Wellcome Trust Senior Research Fellowship in Clinical Science [082178]; Academic Clinical Fellowship from the National Institute for Health Research; Medical Research Council [G0802432]; MRC [G0802432] Funding Source: UKRI	British Heart Foundation(British Heart Foundation); Wellcome Trust Senior Research Fellowship in Clinical Science(Wellcome Trust); Academic Clinical Fellowship from the National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The work reported was not the subject of a specific research grant. Aroon D. Hingorani is funded by a Senior Research Fellowship from the British Heart Foundation (FS05/125). Liam Smeeth is funded by a Wellcome Trust Senior Research Fellowship in Clinical Science (082178). Michael V. Holmes is funded by an Academic Clinical Fellowship from the National Institute for Health Research and a Population Health Scientist Fellowship from the Medical Research Council (G0802432). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Bertram L, 2007, NAT GENET, V39, P17, DOI 10.1038/ng1934; Bodmer W, 2008, NAT GENET, V40, P695, DOI 10.1038/ng.f.136; Bromley CM, 2009, PHARMACOGENOMICS J, V9, P14, DOI 10.1038/tpj.2008.11; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Colombo S, 2008, J INFECT DIS, V198, P864, DOI 10.1086/591184; CONNOR S, 2003, INDEPENDENT; *FDA, 2006, TABL VAL GEN BIOM CO; *FDA, 2009, TABL VAL GEN BIOM CO; Frank B, 2008, J NATL CANCER I, V100, P437, DOI 10.1093/jnci/djn037; Frodsham AJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-31; Goldstein DB, 2009, NEW ENGL J MED, V360, P1696, DOI 10.1056/NEJMp0806284; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Higgins JPT, 2007, AM J EPIDEMIOL, V166, P863, DOI 10.1093/aje/kwm248; Hindorff LA, 2009, CATALOG PUBLISHED GE; Hunter DJ, 2008, NEW ENGL J MED, V358, P2760, DOI 10.1056/NEJMp0804318; Hynicka LM, 2008, ANN PHARMACOTHER, V42, P1298, DOI 10.1345/aph.1L127; Ioannidis JPA, 2008, AM J EPIDEMIOL, V168, P374, DOI 10.1093/aje/kwn156; Ioannidis JPA, 2008, INT J EPIDEMIOL, V37, P120, DOI 10.1093/ije/dym159; Ioannidis JPA, 2006, AM J EPIDEMIOL, V164, P609, DOI 10.1093/aje/kwj259; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474; Ioannidis JPA, 2006, NAT GENET, V38, P3, DOI 10.1038/ng0106-3; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337; Janssens ACJW, 2006, GENET MED, V8, P395, DOI 10.1097/01.gim.0000229689.18263.f4; Khoury MJ, 2007, INT J EPIDEMIOL, V36, P439, DOI 10.1093/ije/dyl253; Klein TE, 2009, NEW ENGL J MED, V360, P753, DOI 10.1056/NEJMoa0809329; KRAFT P, 2009, NAT REV GENET; Lemonick M, 2001, TIME, P28; Limdi NA, 2008, PHARMACOGENOMICS, V9, P511, DOI 10.2217/14622416.9.5.511; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; MARR K, 2008, WASHINGTON POST; McClain MR, 2008, GENET MED, V10, P89, DOI 10.1097/GIM.0b013e31815bf924; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; *NIH, PHARM RES NETW; Pennisi E, 2007, SCIENCE, V318, P1842, DOI 10.1126/science.318.5858.1842; Pirmohamed M, 2004, BMJ-BRIT MED J, V329, P15, DOI 10.1136/bmj.329.7456.15; POLLACK A, 2005, NY TIMES        1108; Roses AD, 2000, NATURE, V405, P857, DOI 10.1038/35015728; Sagoo GS, 2008, AM J EPIDEMIOL, V168, P1233, DOI 10.1093/aje/kwn235; *SCHIZ RES FOR, SCHIZ SZGENE; Shurin SB, 2008, NEW ENGL J MED, V358, P1061, DOI 10.1056/NEJMe0800801; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Tang SS, 2009, NUCLEIC ACIDS RES, V37, pD858, DOI 10.1093/nar/gkn770; Woodcock J, 2009, NEW ENGL J MED, V360, P811, DOI 10.1056/NEJMe0810630	48	78	84	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 2	2009	4	12							e7960	10.1371/journal.pone.0007960	http://dx.doi.org/10.1371/journal.pone.0007960			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	533MU	19956635	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000272828800002
J	Terasawa, T; Dvorak, T; Ip, S; Raman, G; Lau, J; Trikalinos, TA				Terasawa, Teruhiko; Dvorak, Tomas; Ip, Stanley; Raman, Gowri; Lau, Joseph; Trikalinos, Thomas A.			Systematic Review: Charged-Particle Radiation Therapy for Cancer	ANNALS OF INTERNAL MEDICINE			English	Review							PROTON-BEAM THERAPY; RANDOMIZED CONTROLLED-TRIAL; HIGH-DOSE IRRADIATION; UVEAL MELANOMA; COST-EFFECTIVENESS; CHOROIDAL MELANOMA; LOCAL RECURRENCE; PROPENSITY SCORE; CLINICAL-TRIALS; SURVIVAL RATES	Background: Radiation therapy with charged particles can potentially deliver maximum doses while minimizing irradiation of surrounding tissues, and it may be more effective or less harmful than other forms of radiation therapy. Purpose: To review evidence about the benefits and harms of charged-particle radiation therapy for patients with cancer. Data Sources: MEDLINE (inception to 11 July 2009) was searched for publications in English, German, French, Italian, and Japanese. Web sites of manufacturers, treatment centers, and professional organizations were searched for relevant information. Study Selection: Four reviewers identified studies of any design that described clinical outcomes or adverse events in 10 or more patients with cancer treated with charged-particle radiation therapy. Data Extraction: The 4 reviewers extracted study, patient, and treatment characteristics; clinical outcomes; and adverse events for nonoverlapping sets of articles. A fifth reviewer verified data on comparative studies. Data Synthesis: Currently, 7 centers in the United States have facilities for particle (proton)-beam irradiation, and at least 4 are under construction, each costing between $100 and $225 million. In 243 eligible articles, charged- particle radiation therapy was used alone or in combination with other interventions for common (for example, lung, prostate, or breast) or uncommon (for example, skull-base tumors or uveal melanomas) types of cancer. Of 243 articles, 185 were single-group retrospective studies. Eight randomized and 9 nonrandomized clinical trials compared treatments with or without charged particles. No comparative study reported statistically significant or important differences in overall or cancer-specific survival or in total serious adverse events. Limitation: Few studies directly compared treatments with or without particle irradiation. Conclusion: Evidence on the comparative effectiveness and safety of charged-particle radiation therapy in cancer is needed to assess the benefits, risks, and costs of treatment alternatives.	[Terasawa, Teruhiko; Dvorak, Tomas; Ip, Stanley; Raman, Gowri; Lau, Joseph; Trikalinos, Thomas A.] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA	Tufts Medical Center	Terasawa, T (corresponding author), Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Box 63,800 Washington St, Boston, MA 02111 USA.	tterasawa@tuftsmedicalcenter.org			Agency for Healthcare Research and Quality [HHSA-290-2007-10055-1-EPC3]; U.S. Department of Health and Human Services	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); U.S. Department of Health and Human Services	By contract HHSA-290-2007-10055-1-EPC3 from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.	[Anonymous], 2009, COMMON TERMINOLOGY C; Behera Madhusmita, 2007, Cancer Control, V14, P160; BENK VA, 1993, INT J RADIAT ONCOL, V26, P551, DOI 10.1016/0360-3016(93)90978-5; Brada M, 2007, J CLIN ONCOL, V25, P965, DOI 10.1200/JCO.2006.10.0131; *CANC, 2004, RAD THER CANC QUEST; Castro JR, 1997, INT J RADIAT ONCOL, V38, P257, DOI 10.1016/S0360-3016(97)00039-4; Char DH, 2003, AM J OPHTHALMOL, V136, P180, DOI 10.1016/S0002-9394(02)02292-4; CHAR DH, 1993, OPHTHALMOLOGY, V100, P1547; CHAR DH, 1989, OPHTHALMOLOGY, V96, P1708; Char DH, 1996, BRIT J OPHTHALMOL, V80, P117, DOI 10.1136/bjo.80.2.117; CHUI G, 2008, SYMMETRY, V5, P24; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Desjardins L, 2006, OPHTHAL RES, V38, P255, DOI 10.1159/000094834; Desjardins L, 2003, J FR OPHTALMOL, V26, P269; DUTTENHAVER JR, 1983, CANCER, V51, P1599, DOI 10.1002/1097-0142(19830501)51:9<1599::AID-CNCR2820510908>3.0.CO;2-O; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; Galbraith M E, 2001, Oncol Nurs Forum, V28, P551; Geenen MM, 2007, JAMA-J AM MED ASSOC, V297, P2705, DOI 10.1001/jama.297.24.2705; GERWECK L, 2007, PROTON CHARGED PARTI, P8; Glasziou P, 2007, BMJ-BRIT MED J, V334, P349, DOI 10.1136/bmj.39070.527986.68; Glatstein E, 2008, J CLIN ONCOL, V26, P2438, DOI 10.1200/JCO.2008.17.1843; Glimelius B, 2005, ACTA ONCOL, V44, P836, DOI 10.1080/02841860500361049; Goitein M, 2003, CLIN ONCOL-UK, V15, pS37, DOI 10.1053/clon.2002.0174; Goitein M, 2008, J CLIN ONCOL, V26, P175, DOI 10.1200/JCO.2007.14.4329; Gragoudas ES, 2000, ARCH OPHTHALMOL-CHIC, V118, P773, DOI 10.1001/archopht.118.6.773; Halperin EC, 2006, LANCET ONCOL, V7, P676, DOI 10.1016/S1470-2045(06)70795-1; Harbour JW, 1997, OPHTHALMOLOGY, V104, P1785, DOI 10.1016/S0161-6420(97)30025-6; HERRMANN T, 1987, Radiobiologia Radiotherapia, V28, P519; HUYBRECHTS M, 2007, KCE REPORTS, V67; JANJAN NA, 1994, ANN SURG ONCOL, V1, P415, DOI 10.1007/BF02303815; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; JERMANN M, 2008, HADRON THERAPY PATIE; Johannesen TB, 2002, RADIOTHER ONCOL, V62, P227, DOI 10.1016/S0167-8140(01)00495-9; Konski A, 2007, J CLIN ONCOL, V25, P3603, DOI 10.1200/JCO.2006.09.0811; Levin WP, 2005, BRIT J CANCER, V93, P849, DOI 10.1038/sj.bjc.6602754; LINSTADT D, 1988, RADIOLOGY, V168, P261, DOI 10.1148/radiology.168.1.3132732; Lodge M, 2007, RADIOTHER ONCOL, V83, P110, DOI 10.1016/j.radonc.2007.04.007; Lomax AJ, 2001, MED PHYS, V28, P317, DOI 10.1118/1.1350587; Lundkvist J, 2005, ACTA ONCOL, V44, P850, DOI 10.1080/02841860500341157; Mell LK, 2005, CANCER-AM CANCER SOC, V104, P1296, DOI 10.1002/cncr.21284; Nakano T, 2006, CLIN CANCER RES, V12, P2185, DOI 10.1158/1078-0432.CCR-05-1907; *NAT ASS PROT THER, 2009, VOIC PROT COMM; *NAT CANC I PDQ AD, 2002, LEV EV HUM STUD CANC; Olsen DR, 2007, RADIOTHER ONCOL, V83, P123, DOI 10.1016/j.radonc.2007.03.001; *PART THER COOP GR, 2009, PART THER FAC OP; Patel RR, 2006, HEMATOL ONCOL CLIN N, V20, P97, DOI 10.1016/j.hoc.2006.01.008; Pijls-Johannesma M, 2008, RADIOTHER ONCOL, V89, P127, DOI 10.1016/j.radonc.2008.07.015; RUBIN P, 1995, RADIOTHER ONCOL, V35, P11; Santoni R, 1998, INT J RADIAT ONCOL, V41, P59, DOI 10.1016/S0360-3016(98)00031-5; SCHOENTHALER R, 1994, ANN SURG, V219, P267, DOI 10.1097/00000658-199403000-00006; SCHOENTHALER R, 1993, INT J RADIAT ONCOL, V27, P75, DOI 10.1016/0360-3016(93)90423-S; Schulz-Ertner D, 2005, CANCER-AM CANCER SOC, V104, P338, DOI 10.1002/cncr.21158; Schulz-Ertner D, 2004, INT J RADIAT ONCOL, V58, P631, DOI 10.1016/j.ijrobp.2003.09.041; Schulz-Ertner D, 2007, J CLIN ONCOL, V25, P953, DOI 10.1200/JCO.2006.09.7816; SEDDON JM, 1990, OPHTHALMOLOGY, V97, P769; SEDDON JM, 1985, AM J OPHTHALMOL, V99, P282, DOI 10.1016/0002-9394(85)90357-5; SHIPLEY WU, 1995, INT J RADIAT ONCOL, V32, P3, DOI 10.1016/0360-3016(95)00063-5; Skandarajah AR, 2009, ANN SURG ONCOL, V16, P735, DOI 10.1245/s10434-008-0287-2; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; SUIT H, 2008, NO RADIOTHER ONCOL, V86, P148; Timmerman RD, 2007, J CLIN ONCOL, V25, P947, DOI 10.1200/JCO.2006.09.7469; TRIKALINOS TA, 2008, PARTICLE BEAM RAD TH; Veldeman L, 2008, LANCET ONCOL, V9, P367, DOI 10.1016/S1470-2045(08)70098-6; Willett CG, 2007, J CLIN ONCOL, V25, P971, DOI 10.1200/JCO.2006.10.0255; Wilson MW, 1999, OPHTHALMOLOGY, V106, P1579, DOI 10.1016/S0161-6420(99)90456-6; Zietman AL, 2005, JAMA-J AM MED ASSOC, V294, P1233, DOI 10.1001/jama.294.10.1233	66	77	77	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2009	151	8					556	U75		10.7326/0003-4819-151-8-200910200-00145	http://dx.doi.org/10.7326/0003-4819-151-8-200910200-00145			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	514HY	19755348				2023-01-03	WOS:000271386200005
J	Katsumata, N; Yasuda, M; Takahashi, F; Isonishi, S; Jobo, T; Aoki, D; Tsuda, H; Sugiyama, T; Kodama, S; Kimura, E; Ochiai, K; Noda, K				Katsumata, Noriyuki; Yasuda, Makoto; Takahashi, Fumiaki; Isonishi, Seiji; Jobo, Toshiko; Aoki, Doisuke; Tsuda, Hiroshi; Sugiyama, Toru; Kodama, Shoji; Kimura, Eizo; Ochiai, Kazunori; Noda, Kiichiro		Japanese Gynecologic Oncology Grp	Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial	LANCET			English	Article							BREAST-CANCER; III TRIAL; 1ST-LINE TREATMENT; INTERGROUP TRIAL; TAXOL; ANGIOGENESIS; CARCINOMA	Background Paclitaxel and carboplatin given every 3 weeks is standard treatment for advanced ovarian carcinoma. Attempts to improve patient survival by including other drugs have yielded disappointing results. We compared a conventional regimen of paclitaxel and carboplatin with a dose-dense weekly regimen in women with advanced ovarian cancer. Methods Patients with stage II to IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer were eligible for enrolment in this phase 3, open-label, randomised controlled trial at 85 centres in Japan. Patients were randomly assigned by computer-generated randomisation sequence to receive six cycles of either paclitaxel (180 mg/m(2); 3-h intravenous infusion) plus carboplatin (area under the curve [AUC] 6 mg/mL per min), given on day 1 of a 21-day cycle (conventional regimen; n=320), or dose-dense paclitaxel (80 mg/m(2); 1-h intravenous infusion) given on days 1, 8, and 15 plus carboplatin given on day 1 of a 21-day cycle (dose-dense regimen; n=317). The primary endpoint was progression-free survival. Analysis was by intention to treat (ITT). This trial is registered with ClinicalTrials.gov, number NCT00226915. Findings 631 of the 637 enrolled patients were eligible for treatment and were included in the ITT population ((dose-dense regimen, n=312; conventional regimen, n=319). Median progression-free survival was longer in the dose-dense treatment group (28.0 months, 95% CI 22.3-35.4) than in the conventional treatment group (17.2 months, 15.7-21.1; hazard ratio [HR] 0.71; 95% CI 0.58-0.88; p=0.0015). Overall survival at 3 years was higher in the dose-dense regimen group (72.1%) than in the conventional treatment group (65.1%; HR 0.75, 0.57-0.98; p=0.03). 165 patients assigned to the dose-dense regimen and 117 assigned to the conventional regimen discontinued treatment early. Reasons for participant dropout were balanced between the groups, apart from withdrawal because of toxicity, which was higher in the dose-dense regimen group than in the conventional regimen group (n=113 vs n=69). The most common adverse event was neutropenia (dose-dense regimen, 286 [92%] of 312; conventional regimen, 276 [88%] of 314). The frequency of grade 3 and 4 anaemia was higher in the dose-dense treatment group (214 [69%]) than in the conventional treatment group (137 [44%]; p<0.0001). The frequencies of other toxic effects were similar between groups. Interpretation Dose-dense weekly paclitaxel plus carboplatin improved survival compared with the conventional regimen and represents a new treatment option in women with advanced epithelial ovarian cancer.	[Katsumata, Noriyuki] Natl Canc Ctr, Dept Med Oncol, Chuo Ku, Tokyo 1040045, Japan; [Yasuda, Makoto; Isonishi, Seiji; Ochiai, Kazunori] Jikei Univ, Dept Gynecol Oncol, Sch Med, Tokyo, Japan; [Takahashi, Fumiaki] Kitasato Univ, Dept Biostat, Tokyo, Japan; [Jobo, Toshiko] Kitasato Univ, Sch Med, Dept Gynecol, Sagamihara, Kanagawa 228, Japan; [Tsuda, Hiroshi] Keio Univ, Sch Med, Dept Obstet & Gynecol, Tokyo 160, Japan; [Sugiyama, Toru] Iwate Med Univ, Dept Gynecol Oncol, Morioka, Iwate 020, Japan; [Kodama, Shoji] Niigata Canc Ctr Hosp, Dept Gynecol Oncol, Niigata, Japan; [Kimura, Eizo] Kousei Gen Hosp, Dept Gynecol Oncol, Tokyo, Japan; [Noda, Kiichiro] Kinki Univ, Dept Gynecol, Osakasayama, Japan	National Cancer Center - Japan; Jikei University; Kitasato University; Kitasato University; Keio University; Iwate Medical University; Kindai University (Kinki University)	Katsumata, N (corresponding author), Natl Canc Ctr, Dept Med Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	nkatsuma@ncc.go.jp	Aoki, Daisuke/E-6650-2014		Bristol-Myers Squibb	Bristol-Myers Squibb(Bristol-Myers Squibb)	This study was funded by an unrestricted grant from Bristol-Myers Squibb. We thank the women who participated in this trial and Akihiro Yanagisawa, Kei Matsubara for assisting protocol design and review, Keiichi Fujiwara for internal auditing, and Robert F Ozols for protocol design and manuscript review.	Bolis G, 2004, J CLIN ONCOL, V22, P686, DOI 10.1200/JCO.2004.03.017; Bookman MA, 2009, J CLIN ONCOL, V27, P1419, DOI 10.1200/JCO.2008.19.1684; CALVERT AH, 1989, J CLIN ONCOL, V7, P1748, DOI 10.1200/JCO.1989.7.11.1748; du Bois A, 2006, J CLIN ONCOL, V24, P1127, DOI 10.1200/JCO.2005.03.2938; du Bois A, 2005, ANN ONCOL, V16, P7, DOI 10.1093/annonc/mdi961; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Hess V, 2004, J CLIN ONCOL, V22, P1040, DOI 10.1200/JCO.2004.08.078; HOSKINS PJ, 2008, 2008 ASCO ANN M CHIC; JELLIFFE RW, 1973, ANN INTERN MED, V79, P604, DOI 10.7326/0003-4819-79-4-604; Jordan MA, 1996, CANCER RES, V56, P816; KATSUMATA N, 2001, 2001 ASCO ANN M SAN; Klauber N, 1997, CANCER RES, V57, P81; LOPES NM, 1993, CANCER CHEMOTH PHARM, V32, P235, DOI 10.1007/BF00685842; National Cancer Institute, 1998, CANC THER EV PROGR C; Norton L, 2001, ONCOLOGIST, V6, P30; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Omura GA, 2003, J CLIN ONCOL, V21, P2843, DOI 10.1200/JCO.2003.10.082; Pignata S, 2008, CRIT REV ONCOL HEMAT, V66, P229, DOI 10.1016/j.critrevonc.2007.12.005; Rose PG, 2005, GYNECOL ONCOL, V96, P296, DOI 10.1016/j.ygyno.2004.03.046; Rustin GJS, 2006, J CLIN ONCOL, V24, P45, DOI 10.1200/JCO.2005.01.2757; Sehouli J, 2008, CANCER CHEMOTH PHARM, V61, P243, DOI 10.1007/s00280-007-0466-z; Seidman AD, 2008, J CLIN ONCOL, V26, P1642, DOI 10.1200/JCO.2007.11.6699; SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5; YEDEMA CA, 1992, TUMOR BIOL, V13, P18, DOI 10.1159/000217748	26	543	569	0	36	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	2009	374	9698					1331	1338		10.1016/S0140-6736(09)61157-0	http://dx.doi.org/10.1016/S0140-6736(09)61157-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	512MW	19767092				2023-01-03	WOS:000271254600029
J	Haber, PS; Demirkol, A; Lange, K; Murnion, B				Haber, Paul S.; Demirkol, Abdullah; Lange, Kezia; Murnion, Bridin			Management of injecting drug users admitted to hospital	LANCET			English	Review							ADDICTION MOLECULAR-GENETICS; ACUTE PAIN MANAGEMENT; METHADONE-MAINTENANCE; SUBSTANCE-ABUSE; HEROIN-ADDICTS; BENZODIAZEPINE USE; COST-EFFECTIVENESS; OPIOID DEPENDENCE; BUPRENORPHINE; ALCOHOL	General hospital clinicians frequently deal with injecting drug users because substance use has diverse medical and psychiatric complications. Non-specialist clinicians often initiate management when specialist consultation is not available or accepted by the patient. Here, we summarise evidence for the management of hospitalised injecting drug users. The first challenge is to engage a drug user into medical care. A non-judgmental approach towards patients and acceptance of their lifestyle choices facilitates engagement. Pragmatic clinical goals can be negotiated and achieved. We also describe common conditions of injecting drug users. Accurate diagnosis and appropriate management focus on common issues such as intoxication, withdrawal, pain management, drug seeking, psychological comorbidity, behavioural difficulties, and pregnancy. Effective management can reduce the medical and social effect of these conditions and is not difficult.	[Haber, Paul S.; Demirkol, Abdullah; Murnion, Bridin] Royal Prince Alfred Hosp, Drug Hlth Serv, Camperdown, NSW 2050, Australia; [Haber, Paul S.; Demirkol, Abdullah; Murnion, Bridin] Univ Sydney, Discipline Addict Med, Sydney, NSW 2006, Australia; [Lange, Kezia] Oxleas NHS Fdn Trust, London, England	University of Sydney; University of Sydney	Haber, PS (corresponding author), Royal Prince Alfred Hosp, Drug Hlth Serv, Missenden Rd, Camperdown, NSW 2050, Australia.	phaber@mail.usyd.edu.au	Demirkol, Apo/AAC-4329-2020; murnion, Bridin/AAK-3057-2020; Demirkol, Apo/AAI-9933-2020	Demirkol, Apo/0000-0002-7937-7948; murnion, Bridin/0000-0001-7791-3025; 	National Health and Medical Research Council	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	We thank the National Health and Medical Research Council (practitioner fellowship to PSH) for its support.	Abdala N, 2001, J ACQ IMMUN DEF SYND, V28, P487; Alford DP, 2006, ANN INTERN MED, V144, P127, DOI 10.7326/0003-4819-144-2-200601170-00010; [Anonymous], 2007, WORLD DRUG REP; Apfelbaum JL, 2003, ANESTH ANALG, V97, P534, DOI 10.1213/01.ANE.0000068822.10113.9E; *AUSTR NZ COLL AN, AC PAIN MAN SCI EV; Baewert A, 2007, EUR ADDICT RES, V13, P127, DOI 10.1159/000101548; BAKER A, 2005, NATL DRUG STRATEGY M, V51; Baumann BM, 2000, J TOXICOL-CLIN TOXIC, V38, P283, DOI 10.1081/CLT-100100933; Bell J, 2007, ADDICTION, V102, P1899, DOI 10.1111/j.1360-0443.2007.01979.x; BERNARDI E, 1989, BRIT J PSYCHIAT, V154, P677, DOI 10.1192/bjp.154.5.677; Binswanger IA, 2000, CLIN INFECT DIS, V30, P579, DOI 10.1086/313703; Brady Kathleen T, 2007, Curr Psychiatry Rep, V9, P374, DOI 10.1007/s11920-007-0048-0; Broekmans S, 2004, INT J NURS STUD, V41, P183, DOI 10.1016/S0020-7489(03)00129-9; Brown HL, 1998, AM J OBSTET GYNECOL, V179, P459, DOI 10.1016/S0002-9378(98)70379-5; Buckley PF, 2006, J CLIN PSYCHIAT, V67, P5, DOI 10.4088/JCP.0706e01; Caplehorn JRM, 1999, MED J AUSTRALIA, V170, P104, DOI 10.5694/j.1326-5377.1999.tb127675.x; Cayol V, 2000, ANN MED INTERNE, V151, pB20; Collins ED, 2005, JAMA-J AM MED ASSOC, V294, P903, DOI 10.1001/jama.294.8.903; Comer SD, 2006, ARCH GEN PSYCHIAT, V63, P210, DOI 10.1001/archpsyc.63.2.210; Connock M, 2007, HEALTH TECHNOL ASSES, V11, P1; Crome IB, 2007, SEMIN FETAL NEONAT M, V12, P98, DOI 10.1016/j.siny.2006.12.002; Crowe AV, 2000, QJM-INT J MED, V93, P147, DOI 10.1093/qjmed/93.3.147; Darke S, 1997, DRUG ALCOHOL DEPEN, V48, P135, DOI 10.1016/S0376-8716(97)00117-8; Darke S, 1994, Drug Alcohol Rev, V13, P63, DOI 10.1080/09595239400185741; Davis L, 2008, CURR OPIN PSYCHIATR, V21, P14, DOI 10.1097/YCO.0b013e3282f32408; Devlin RJ, 2008, CRIT CARE, V12, DOI 10.1186/cc6166; Dinwiddie SH, 1996, DRUG ALCOHOL DEPEN, V43, P1, DOI 10.1016/S0376-8716(96)01290-2; Dix P, 2004, BRIT J ANAESTH, V92, P235, DOI 10.1093/bja/aeh052; Dodge R, 2005, J SUBST ABUSE TREAT, V28, P189, DOI 10.1016/j.jsat.2004.12.005; Dolan K, 1999, DRUG ALCOHOL REV, V18, P139; Douaihy Antoine B, 2003, AIDS Read, V13, P375; Fagin L., 2004, ADV PSYCHIAT TREATME, V10, P93, DOI [DOI 10.1192/APT.10.2.93, 10.1192/apt.10.2.93]; Farber NJ, 2000, J GEN INTERN MED, V15, P770, DOI 10.1046/j.1525-1497.2000.90734.x; FARRELL M, 1994, BMJ-BRIT MED J, V309, P997, DOI 10.1136/bmj.309.6960.997; French MT, 2000, SOC SCI MED, V50, P1703, DOI 10.1016/S0277-9536(99)00411-6; French MT, 1996, MED CARE, V34, P890, DOI 10.1097/00005650-199609000-00003; FUNKHOUSER AW, 1993, DRUG ALCOHOL DEPEN, V33, P1, DOI 10.1016/0376-8716(93)90027-N; Galea S, 2002, PUBLIC HEALTH REP, V117, pS135; Garcia-Altes A, 2002, ADDICTION, V97, P1145, DOI 10.1046/j.1360-0443.2002.00170.x; GARFENEFSKI N, 1996, J ADOLESCENCE, V19, P503; Gibson AE, 2007, MED J AUSTRALIA, V186, P152, DOI 10.5694/j.1326-5377.2007.tb00840.x; Godfrey C, 2004, ADDICTION, V99, P697, DOI 10.1111/j.1360-0443.2004.00752.x; Gossop M, 2002, ADDICTION, V97, P1259, DOI 10.1046/j.1360-0443.2002.00227.x; GOWING L, 2004, COCHRANE DB SYST REV, V4; GOWING L, 2004, COCHRANE DB SYST REV, V4; Green AI, 2005, J CLIN PSYCHIAT, V66, P21; Haas LJ, 2005, AM FAM PHYSICIAN, V72, P2063; Havens JR, 2006, SUBST USE MISUSE, V41, P245, DOI 10.1080/10826080500391811; Healey A, 1998, BRIT J PSYCHIAT, V173, P160, DOI 10.1192/bjp.173.2.160; Healey Andrew, 2003, J Health Serv Res Policy, V8, P134, DOI 10.1258/135581903322029476; Hickie IB, 2001, MED J AUSTRALIA, V175, pS31; Jansson LM, 2004, J HUM LACT, V20, P62, DOI 10.1177/0890334403261027; Jarvis MAE, 1999, J ADDICT DIS, V18, P51, DOI 10.1300/J069v18n04_05; JENNER L, 2006, MANAGEMENT PATIENTS; Johnson SD, 2004, ARCH SEX BEHAV, V33, P55, DOI 10.1023/B:ASEB.0000007462.97961.5a; Jones HE, 2008, J SUBST ABUSE TREAT, V35, P245, DOI 10.1016/j.jsat.2007.10.007; JUDSON BA, 1980, DRUG ALCOHOL DEPEN, V6, P295, DOI 10.1016/0376-8716(80)90197-0; Kao LW, 2003, ANN EMERG MED, V41, P546, DOI 10.1067/mem.2003.110; Kapadia F, 2002, EPIDEMIOLOGY, V13, P738, DOI 10.1097/00001648-200211000-00023; Kashiwagi M, 2005, ACTA OBSTET GYN SCAN, V84, P140, DOI 10.1111/j.0001-6349.2005.00497.x; Kerr T, 2005, J PUBLIC HEALTH-UK, V27, P62, DOI 10.1093/pubmed/fdh189; Latta Kenneth S, 2002, Am J Ther, V9, P53, DOI 10.1097/00045391-200201000-00010; Leonardi C, 2008, DRUG ALCOHOL DEPEN, V94, P125, DOI 10.1016/j.drugalcdep.2007.10.017; Lingford-Hughes AR, 2004, J PSYCHOPHARMACOL, V18, P293, DOI 10.1177/026988110401800321; Lintzeris N, 2008, MED J AUSTRALIA, V188, P441, DOI 10.5694/j.1326-5377.2008.tb01712.x; Liu QR, 2006, AM J MED GENET B, V141B, P918, DOI 10.1002/ajmg.b.30436; Luty J, 2003, J SUBST ABUSE TREAT, V24, P363, DOI 10.1016/S0740-5472(03)00035-7; Lynskey MT, 2007, PSYCHOL MED, V37, P1345, DOI 10.1017/S0033291707000396; Macleod J, 2004, LANCET, V363, P1579, DOI 10.1016/S0140-6736(04)16200-4; MADDUX JF, 1984, AM J DRUG ALCOHOL AB, V10, P237, DOI 10.3109/00952998409002783; March JC, 2006, EUR ADDICT RES, V12, P33, DOI 10.1159/000088581; Mathers BM, 2008, LANCET, V372, P1733, DOI 10.1016/S0140-6736(08)61311-2; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; McCaffery M, 2007, AM J NURS, V107, P35, DOI 10.1097/01.NAJ.0000301016.18877.19; McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689; Mehta V, 2006, ANAESTHESIA, V61, P269, DOI 10.1111/j.1365-2044.2005.04503.x; Miller NS, 2001, ACAD MED, V76, P410, DOI 10.1097/00001888-200105000-00007; Minozzi S, 2008, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD006318.PUB2; Mo W, 1999, PHARMACOL RES, V40, P139, DOI 10.1006/phrs.1999.0503; *NICE, 2007, NICE CLIN GUID, V52; NOYES R, 1988, J CLIN PSYCHIAT, V49, P382; *NSW DEP HLTH, NAT CLIN GUID MAN DR; *NSW DEP HLTH, CLIN GUID METH BUPR; Nunes EV, 2004, JAMA-J AM MED ASSOC, V291, P1887, DOI 10.1001/jama.291.15.1887; Palepu A, 2001, CAN MED ASSOC J, V165, P415; Parthasarathy S, 2005, DRUG ALCOHOL DEPEN, V80, P231, DOI 10.1016/j.drugalcdep.2005.04.004; Reece AS, 2007, AUST DENT J, V52, P144, DOI 10.1111/j.1834-7819.2007.tb00480.x; RENO RR, 1993, INT J ADDICT, V28, P211, DOI 10.3109/10826089309039624; Rhodes T, 1996, ADDICTION, V91, P753, DOI 10.1111/j.1360-0443.1996.tb03565.x; RIPPETH J, 2008, J CLIN EXP NEUROPSYC, V30, P494; Ross J, 1996, DRUG ALCOHOL REV, V15, P237, DOI 10.1080/09595239600185971; Roxburgh Amanda, 2005, Harm Reduct J, V2, P7, DOI 10.1186/1477-7517-2-7; SAMET JH, 1990, AM J MED, V89, P53, DOI 10.1016/0002-9343(90)90098-X; Schindler SD, 2003, ADDICTION, V98, P103, DOI 10.1046/j.1360-0443.2003.00245.x; SCHUTZ CG, 1994, DRUG ALCOHOL DEPEN, V36, P129, DOI 10.1016/0376-8716(94)90095-7; Shearer J, 2003, ADDICTION, V98, P1137, DOI 10.1046/j.1360-0443.2003.00447.x; Simpson DD, 1997, DRUG ALCOHOL DEPEN, V47, P227; Sporer KA, 2003, BMJ-BRIT MED J, V326, P442, DOI 10.1136/bmj.326.7386.442; SRISURAPANONT M, 2001, COCHRANE DB SYST REV, V4; Stein M D, 1993, J Subst Abuse, V5, P187, DOI 10.1016/0899-3289(93)90062-G; Stein MD, 2001, DRUG ALCOHOL DEPEN, V64, P117, DOI 10.1016/S0376-8716(00)00235-0; *SUBST AB MENT HLT, 2006, NSDUH SER H, V30; Substance Abuse and Mental Health Services Administration, 2006, DHHS PUBL, VSMA 06-4194; Swift R M, 1989, J Subst Abuse, V1, P453; Thomas G., 2005, HARM REDUCTION POLIC; Uhl GR, 2008, BIOCHEM PHARMACOL, V75, P98, DOI 10.1016/j.bcp.2007.06.042; Voshaar RCO, 2006, BRIT J PSYCHIAT, V189, P213, DOI 10.1192/bjp.189.3.213; W.H. Organization, 1993, WHO APPL ICD 10 DEAT, V2; WARNER LA, 1995, ARCH GEN PSYCHIAT, V52, P219; WASHTON AM, 1983, J CLIN PSYCHIAT, V44, P335; WHEELER SF, 1993, PRIMARY CARE, V20, P191; White MK, 1998, J CLIN OUTCOMES MANA, V5, P32; WHO, ESS MED; Wisniewski Amy B, 2005, J Neurovirol, V11, P138, DOI 10.1080/13550280590922748; Wodak A, 2008, AIDS, V22, pS81, DOI 10.1097/01.aids.0000327439.20914.33; Wolff K, 2005, EUR J CLIN PHARMACOL, V61, P763, DOI 10.1007/s00228-005-0035-5; Zimmerman JL, 2003, CRIT CARE MED, V31, P2794, DOI 10.1097/01.CCM.0000100123.50896.F0	117	82	82	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	2009	374	9697					1284	1293		10.1016/S0140-6736(09)61036-9	http://dx.doi.org/10.1016/S0140-6736(09)61036-9			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	507KQ	19819393				2023-01-03	WOS:000270852500034
J	Sessler, DI				Sessler, Daniel I.			New surgical thermal management guidelines	LANCET			English	Editorial Material							WOUND-INFECTION; NORMOTHERMIA; HYPOTHERMIA		Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Sessler, DI (corresponding author), Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44195 USA.	DS@OR.org	Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077				Centers for Medicare and Medicaid Services, 2009, PHYS QUAL REP IN; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Lenhardt R, 1997, ANESTHESIOLOGY, V87, P1318, DOI 10.1097/00000542-199712000-00009; Melling AC, 2001, LANCET, V358, P876, DOI 10.1016/S0140-6736(01)06071-8; *QUAL NET, 2009, SURG CAR IMPR PROJ D; Rajagopalan S, 2008, ANESTHESIOLOGY, V108, P71, DOI 10.1097/01.anes.0000296719.73450.52; Sessler DI, 2008, ANESTHESIOLOGY, V109, P318, DOI 10.1097/ALN.0b013e31817f6d76; Sessler DI, 2000, ANESTHESIOLOGY, V92, P578, DOI 10.1097/00000542-200002000-00042	9	21	21	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP-OCT	2009	374	9695					1049	1050		10.1016/S0140-6736(09)61686-X	http://dx.doi.org/10.1016/S0140-6736(09)61686-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	501HA	19782858				2023-01-03	WOS:000270370900010
J	Steinman, MA; Hanlon, JT				Steinman, Michael A.; Hanlon, Joseph T.			Managing Medications in Clinically Complex Elders "There's Got to Be a Happy Medium"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; EMERGENCY-DEPARTMENT VISITS; OLDER-ADULTS; RISK-FACTORS; DISCONTINUING MEDICATIONS; PHARMACIST INTERVENTION; GENERAL-PRACTITIONERS; QUALITY INDICATORS; ADVANCED DEMENTIA; CONTROLLED-TRIAL	Multiple medication use is common in older adults and may ameliorate symptoms, improve and extend quality of life, and occasionally cure disease. Unfortunately, multiple medication use is also a major risk factor for prescribing and adherence problems, adverse drug events, and other adverse health outcomes. Using the case of an older patient taking multiple medications, this article summarizes the evidence-based literature about improving medication use and withdrawing specific drugs and drug classes. It also describes a systematic approach for how health professionals can assess and improve medication regimens to benefit patients and their caregivers and families. JAMA. 2010;304(14):1592-1601 www.jama.com	[Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA; [Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA; [Hanlon, Joseph T.] Univ Pittsburgh, Dept Epidemiol, Dept Med, Div Geriatr Med, Pittsburgh, PA 15261 USA; [Hanlon, Joseph T.] Univ Pittsburgh, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA; [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System	Steinman, MA (corresponding author), San Francisco VA Med Ctr, 4150 Clement St,Box 181G, San Francisco, CA 94121 USA.	mike.steinman@ucsf.edu			National Institute on Aging and the American Federation for Aging Research [K23 AG030999]; Department of Veterans Affairs [IIR 06-080]; National Institute of Aging [R01AG027017, P30AG024827, T32 AG021885, K07AG033174, R01AG034056]; National Institute of Mental Health [R34 MH082682]; National Institute of Nursing Research [R01 NR010135]; Agency for Healthcare Research and Quality [HS017695, HS018721]; Veterans Administration Health Services [IIR06-062]; SCAN Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS017695, R01HS018721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R34MH082682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR010135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG021885, K23AG030999, R01AG027017, K07AG033174, P30AG024827, R01AG034056] Funding Source: NIH RePORTER	National Institute on Aging and the American Federation for Aging Research; Department of Veterans Affairs(US Department of Veterans Affairs); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Veterans Administration Health Services; SCAN Foundation; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Steinman was supported by the National Institute on Aging and the American Federation for Aging Research (K23 AG030999) and by the Department of Veterans Affairs (IIR 06-080). Dr Hanlon was supported by grants from the National Institute of Aging (R01AG027017, P30AG024827, T32 AG021885, K07AG033174, and R01AG034056), the National Institute of Mental Health (R34 MH082682), the National Institute of Nursing Research (R01 NR010135), the Agency for Healthcare Research and Quality (HS017695 and HS018721), and a Veterans Administration Health Services research grant (IIR06-062). The Care of the Aging Patient series is made possible by funding from The SCAN Foundation.	Agostini JV, 2004, J AM GERIATR SOC, V52, P1719, DOI 10.1111/j.1532-5415.2004.52467.x; Bain KT, 2008, J AM GERIATR SOC, V56, P1946, DOI 10.1111/j.1532-5415.2008.01916.x; Bayoumi I, 2009, ANN PHARMACOTHER, V43, P1667, DOI 10.1345/aph.1M059; Bedell SE, 2000, ARCH INTERN MED, V160, P2129, DOI 10.1001/archinte.160.14.2129; Bischoff-Ferrari HA, 2004, JAMA-J AM MED ASSOC, V291, P1999, DOI 10.1001/jama.291.16.1999; Bischoff-Ferrari HA, 2009, ARCH INTERN MED, V169, P551, DOI 10.1001/archinternmed.2008.600; Boockvar KS, 2009, QUAL SAF HEALTH CARE, V18, P32, DOI 10.1136/qshc.2007.025957; *BOST U SLON EP CT, 2006, PATT MED US US; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Budnitz DS, 2006, JAMA-J AM MED ASSOC, V296, P1858, DOI 10.1001/jama.296.15.1858; Budnitz DS, 2007, ANN INTERN MED, V147, P755, DOI 10.7326/0003-4819-147-11-200712040-00006; Charpentier G, 2000, DIABETES METAB, V26, P73; CHRISCHILLES EA, 1992, ANN INTERN MED, V117, P634, DOI 10.7326/0003-4819-117-8-634; Chrischilles E, 2007, J AM GERIATR SOC, V55, P29, DOI 10.1111/j.1532-5415.2006.01034.x; Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0; Conn VS, 2009, GERONTOLOGIST, V49, P447, DOI 10.1093/geront/gnp037; Cowper PA, 1998, PHARMACOTHERAPY, V18, P327; Cutler DM, 2010, NEW ENGL J MED, V362, P1553, DOI 10.1056/NEJMp1002305; Doucette WR, 2005, CLIN THER, V27, P1104, DOI 10.1016/S0149-2918(05)00146-3; Drenth-van Maanen AC, 2009, DRUG AGING, V26, P687, DOI 10.2165/11316400-000000000-00000; Farlow M, 2003, ARCH NEUROL-CHICAGO, V60, P843, DOI 10.1001/archneur.60.6.843; Feldstein AC, 2006, ARCH INTERN MED, V166, P1848, DOI 10.1001/archinte.166.17.1848; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gangji AS, 2007, DIABETES CARE, V30, P389, DOI 10.2337/dc06-1789; Garfinkel D, 2007, ISR MED ASSOC J, V9, P430; GERETY MB, 1993, J AM GERIATR SOC, V41, P1326; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Goulding MR, 2004, ARCH INTERN MED, V164, P305, DOI 10.1001/archinte.164.3.305; Grant K, 2006, PHARM WORLD SCI, V28, P189, DOI 10.1007/s11096-006-9028-4; Graves T, 1997, ARCH INTERN MED, V157, P2205, DOI 10.1001/archinte.157.19.2205; Gray SL, 2001, ANN PHARMACOTHER, V35, P539, DOI 10.1345/aph.10295; Green Jacqueline L, 2007, Am J Geriatr Pharmacother, V5, P31, DOI 10.1016/j.amjopharm.2007.03.004; Greenfield S, 2009, ANN INTERN MED, V151, P854, DOI 10.7326/0003-4819-151-12-200912150-00005; Gurwitz JH, 2004, ARCH INTERN MED, V164, P1957, DOI 10.1001/archinte.164.18.1957; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hajjar Emily R, 2003, Am J Geriatr Pharmacother, V1, P82; Hajjar ER, 2005, J AM GERIATR SOC, V53, P1518, DOI 10.1111/j.1532-5415.2005.53523.x; Hanlon JT, 2006, J GERONTOL A-BIOL, V61, P511, DOI 10.1093/gerona/61.5.511; Hanlon JT, 2001, J AM GERIATR SOC, V49, P200, DOI 10.1046/j.1532-5415.2001.49042.x; Hanlon JT, 1996, AM J MED, V100, P428, DOI 10.1016/S0002-9343(97)89519-8; Hanlon JT, 1997, J AM GERIATR SOC, V45, P945, DOI 10.1111/j.1532-5415.1997.tb02964.x; Hebel, 1989, J AGING HEALTH, V1, P470, DOI [10.1177/089826438900100404, DOI 10.1177/089826438900100404]; Higashi T, 2004, ANN INTERN MED, V140, P714, DOI 10.7326/0003-4819-140-9-200405040-00011; Holmes C, 2004, NEUROLOGY, V63, P214, DOI 10.1212/01.WNL.0000129990.32253.7B; Holmes HM, 2006, ARCH INTERN MED, V166, P605, DOI 10.1001/archinte.166.6.605; Holmes HM, 2008, J AM GERIATR SOC, V56, P1306, DOI 10.1111/j.1532-5415.2008.01741.x; Hsu J, 2008, JAMA-J AM MED ASSOC, V299, P1929, DOI 10.1001/jama.299.16.1929; Hurley JS, 2005, J GEN INTERN MED, V20, P331, DOI 10.1111/j.1525-1497.2005.40182.x; Ickowicz E, 2003, J AM GERIATR SOC, V51, pS265; Iyer S, 2008, DRUG AGING, V25, P1021, DOI 10.2165/0002512-200825120-00004; Kaboli PJ, 2004, AM J MANAG CARE, V10, P872; Kongkaew C, 2008, ANN PHARMACOTHER, V42, P1017, DOI 10.1345/aph.1L037; Kripalani S, 2007, ARCH INTERN MED, V167, P540, DOI 10.1001/archinte.167.6.540; Krska J, 2001, AGE AGEING, V30, P205, DOI 10.1093/ageing/30.3.205; Krska J, 2006, MED EDUC, V40, P1217, DOI 10.1111/j.1365-2929.2006.02633.x; LARSON EB, 1987, ANN INTERN MED, V107, P169, DOI 10.7326/0003-4819-107-2-169; Lenaghan E, 2007, AGE AGEING, V36, P292, DOI 10.1093/ageing/afm036; LIPTON HL, 1992, MED CARE, V30, P646, DOI 10.1097/00005650-199207000-00006; Madden JM, 2008, JAMA-J AM MED ASSOC, V299, P1922, DOI 10.1001/jama.299.16.1922; Mant J, 2007, LANCET, V370, P493, DOI 10.1016/S0140-6736(07)61233-1; Minett TSC, 2003, INT J GERIATR PSYCH, V18, P988, DOI 10.1002/gps.995; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; *NAT COMM QUAL ASS, HEDIS 2010; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Parsons C, 2010, DRUG AGING, V27, P435, DOI 10.2165/11536760-000000000-00000; Pit SW, 2007, J AM GERIATR SOC, V55, P927, DOI 10.1111/j.1532-5415.2007.01181.x; Pugh MJV, 2006, J MANAGE CARE PHARM, V12, P537, DOI 10.18553/jmcp.2006.12.7.537; Raebel MA, 2007, PHARMACOEPIDEM DR S, V16, P55, DOI 10.1002/pds.1217; Raebel MA, 2010, J GEN INTERN MED, V25, P326, DOI 10.1007/s11606-009-1228-x; Reuben DB, 2009, JAMA-J AM MED ASSOC, V302, P2686, DOI 10.1001/jama.2009.1871; Richard C, 2006, PATIENT EDUC COUNS, V64, P207, DOI 10.1016/j.pec.2006.02.003; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Russell CL, 2006, AM J HEALTH BEHAV, V30, P636, DOI 10.5993/AJHB.30.6.10; Ryan C, 2009, BRIT J CLIN PHARMACO, V68, P936, DOI 10.1111/j.1365-2125.2009.03531.x; Schmader KE, 2004, AM J MED, V116, P394, DOI 10.1016/j.amjmed.2003.10.031; Schneider LS, 2005, JAMA-J AM MED ASSOC, V294, P1934, DOI 10.1001/jama.294.15.1934; Scott IA, 2010, ARCH INTERN MED, V170, P387; Scuffham PA, 2010, J GEN INTERN MED, V25, P906, DOI 10.1007/s11606-010-1352-7; Shorr RI, 1997, ARCH INTERN MED, V157, P1681, DOI 10.1001/archinte.157.15.1681; Shrank WH, 2007, J AM GERIATR SOC, V55, pS373, DOI 10.1111/j.1532-5415.2007.01345.x; Simon SR, 2005, J AM GERIATR SOC, V53, P227, DOI 10.1111/j.1532-5415.2005.53107.x; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Steinman MA, 2009, ARCH INTERN MED, V169, P1326, DOI 10.1001/archinternmed.2009.206; Steinman Michael A, 2007, Am J Geriatr Pharmacother, V5, P314, DOI 10.1016/j.amjopharm.2007.12.009; Thomas L, 2010, J MANAGE CARE PHARM, V16, P122, DOI 10.18553/jmcp.2010.16.2.122; THOMPSON CA, 2010, AM J HLTH SYST PHARM, V67, P690; Vik SA, 2004, ANN PHARMACOTHER, V38, P303, DOI 10.1345/aph.1D252; WALLSTEN SM, 1995, ANN PHARMACOTHER, V29, P359, DOI 10.1177/106002809502900403; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2750, DOI 10.1001/jama.285.21.2750; Weber V, 2008, J GEN INTERN MED, V23, P399, DOI 10.1007/s11606-007-0482-z; Weingart SN, 2005, ARCH INTERN MED, V165, P234, DOI 10.1001/archinte.165.2.234; Wenger NS, 2007, J AM GERIATR SOC, V55, pS457, DOI 10.1111/j.1532-5415.2007.01375.x; Williams ME, 2004, J AM GERIATR SOC, V52, P93, DOI 10.1111/j.1532-5415.2004.52016.x; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; Zhan Chunliu, 2001, JAMA (Journal of the American Medical Association), V286, P2823	97	217	223	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2010	304	14					1592	1601		10.1001/jama.2010.1482	http://dx.doi.org/10.1001/jama.2010.1482			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	662OE	20940385	Green Accepted			2023-01-03	WOS:000282816500024
J	Mackay, D; Haw, S; Ayres, JG; Fischbacher, C; Pell, JP				Mackay, Daniel; Haw, Sally; Ayres, Jon G.; Fischbacher, Colin; Pell, Jill P.			Smoke-free Legislation and Hospitalizations for Childhood Asthma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; CROSS-SECTIONAL SURVEY; SECONDHAND SMOKE; 2ND-HAND SMOKE; EXPOSURE; SCOTLAND; IMPLEMENTATION; CHILDREN; HEALTH	Background: Previous studies have shown that after the adoption of comprehensive smoke-free legislation, there is a reduction in respiratory symptoms among workers in bars. However, it is not known whether respiratory disease is also reduced among people who do not have occupational exposure to environmental tobacco smoke. The aim of our study was to determine whether the ban on smoking in public places in Scotland, which was initiated in March 2006, influenced the rate of hospital admissions for childhood asthma. Methods: Routine hospital administrative data were used to identify all hospital admissions for asthma in Scotland from January 2000 through October 2009 among children younger than 15 years of age. A negative binomial regression model was fitted, with adjustment for age group, sex, quintile of socioeconomic status, urban or rural residence, month, and year. Tests for interactions were also performed. Results: Before the legislation was implemented, admissions for asthma were increasing at a mean rate of 5.2% per year (95% confidence interval [CI], 3.9 to 6.6). After implementation of the legislation, there was a mean reduction in the rate of admissions of 18.2% per year relative to the rate on March 26, 2006 (95% CI, 14.7 to 21.8; P<0.001). The reduction was apparent among both preschool and school-age children. There were no significant interactions between hospital admissions for asthma and age group, sex, urban or rural residence, region, or quintile of socioeconomic status. Conclusions: In Scotland, passage of smoke-free legislation in 2006 was associated with a subsequent reduction in the rate of respiratory disease in populations other than those with occupational exposure to environmental tobacco smoke. (Funded by NHS Health Scotland.) N Engl J Med 2010;363:1139-45.	[Mackay, Daniel; Pell, Jill P.] Univ Glasgow, Sect Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; [Haw, Sally] Scottish Collaborat Publ Hlth Res Policy, Edinburgh, Midlothian, Scotland; [Ayres, Jon G.] Univ Birmingham, Inst Occupat & Environm Med, Birmingham, W Midlands, England; [Fischbacher, Colin] NHS Natl Serv, Informat Serv Div, Edinburgh, Midlothian, Scotland	University of Glasgow; University of Birmingham; NHS National Services Scotland	Pell, JP (corresponding author), Univ Glasgow, Sect Publ Hlth, Rm 305,1 Lilybank Gardens, Glasgow G12 8RZ, Lanark, Scotland.	j.pell@clinmed.gla.ac.uk		Pell, Jill/0000-0002-8898-7035; Fischbacher, Colin/0000-0003-3090-1857	NHS Health Scotland	NHS Health Scotland	Supported by a project grant from NHS Health Scotland.	Akhtar PC, 2009, TOB CONTROL, V18, P409, DOI 10.1136/tc.2009.030627; Akhtar PC, 2007, BMJ-BRIT MED J, V335, P545, DOI 10.1136/bmj.39311.550197.AE; Akhtar PC, 2010, J EPIDEMIOL COMMUN H, V64, P341, DOI 10.1136/jech.2008.084178; Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407; Ashley MJ, 1998, TOB CONTROL, V7, P61, DOI 10.1136/tc.7.1.61; Ayres JG, 2009, OCCUP ENVIRON MED, V66, P339, DOI 10.1136/oem.2008.040311; Baena-Cagnani CE, 2009, CURR OPIN ALLERGY CL, V9, P136, DOI 10.1097/ACI.0b013e3283294038; Black C, 2009, SCOTTISH SCH ADOLESC; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Haw SJ, 2007, BRIT MED J, V335, P549, DOI 10.1136/bmj.39315.670208.47; HERMAN PM, 2010, AM J PUBLIC HLT 0513; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1902, DOI 10.1016/j.jacc.2009.10.004; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1249, DOI 10.1016/j.jacc.2009.07.022; Naiman A, 2010, CAN MED ASSOC J, V182, P761, DOI 10.1503/cmaj.091130; *OFF ENV HLTH HAZ, 2005, HLTH EFF EXP ENV TOB; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; Scottish Government, 2009, SCOTL PEOPL ANN REP; Semple S, 2007, ANN OCCUP HYG, V51, P571, DOI 10.1093/annhyg/mem044; Semple S, 2007, TOB CONTROL, V16, P127, DOI 10.1136/tc.2006.018119; Vork KL, 2007, ENVIRON HEALTH PERSP, V115, P1394, DOI 10.1289/ehp.10155	20	207	215	1	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1139	1145		10.1056/NEJMoa1002861	http://dx.doi.org/10.1056/NEJMoa1002861			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843248	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000281795800008
J	Schreiber, SL; Shamji, AF; Clemons, PA; Hon, C; Koehler, AN; Munoz, B; Palmer, M; Stern, AM; Wagner, BK; Powers, S; Lowe, SW; Guo, XC; Krasnitz, A; Sawey, ET; Sordella, R; Stein, L; Trotman, LC; Califano, A; Dalla-Favera, R; Ferrando, A; Iavarone, A; Pasqualucci, L; Silva, J; Stockwell, BR; Hahn, WC; Chin, L; DePinho, RA; Boehm, JS; Gopal, S; Huang, A; Root, DE; Weir, BA; Gerhard, DS; Zenklusen, JC; Roth, MG; White, MA; Minna, JD; MacMillan, JB; Posner, BA				Schreiber, Stuart L.; Shamji, Alykhan F.; Clemons, Paul A.; Hon, Cindy; Koehler, Angela N.; Munoz, Benito; Palmer, Michelle; Stern, Andrew M.; Wagner, Bridget K.; Powers, Scott; Lowe, Scott W.; Guo, Xuecui; Krasnitz, Alex; Sawey, Eric T.; Sordella, Raffaella; Stein, Lincoln; Trotman, Lloyd C.; Califano, Andrea; Dalla-Favera, Riccardo; Ferrando, Adolfo; Iavarone, Antonio; Pasqualucci, Laura; Silva, Jose; Stockwell, Brent R.; Hahn, William C.; Chin, Lynda; DePinho, Ronald A.; Boehm, Jesse S.; Gopal, Shuba; Huang, Alan; Root, David E.; Weir, Barbara A.; Gerhard, Daniela S.; Zenklusen, Jean Claude; Roth, Michael G.; White, Michael A.; Minna, John D.; MacMillan, John B.; Posner, Bruce A.		Canc Target Discovery Dev Network	Towards patient-based cancer therapeutics	NATURE BIOTECHNOLOGY			English	Article							ONCOGENE ADDICTION; LIVER-CANCER; CELL-LINES; STEM-CELLS; IDENTIFICATION; GENOTYPE; THERAPY; MODELS; TUMORS		[Schreiber, Stuart L.; Shamji, Alykhan F.; Clemons, Paul A.; Hon, Cindy; Koehler, Angela N.; Munoz, Benito; Palmer, Michelle; Stern, Andrew M.; Wagner, Bridget K.; Canc Target Discovery Dev Network] Harvard & MIT, Broad Inst, Cambridge, MA USA; [Powers, Scott; Lowe, Scott W.; Guo, Xuecui; Krasnitz, Alex; Sawey, Eric T.; Sordella, Raffaella; Stein, Lincoln; Trotman, Lloyd C.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Califano, Andrea; Dalla-Favera, Riccardo; Ferrando, Adolfo; Iavarone, Antonio; Pasqualucci, Laura; Silva, Jose; Stockwell, Brent R.] Columbia Univ, New York, NY USA; [Hahn, William C.; Chin, Lynda; DePinho, Ronald A.; Boehm, Jesse S.; Gopal, Shuba; Huang, Alan; Root, David E.; Weir, Barbara A.] Dana Farber Canc Inst, Cambridge, MA USA; [Gerhard, Daniela S.; Zenklusen, Jean Claude] US Natl Canc Inst, Bethesda, MD USA; [Roth, Michael G.; White, Michael A.; Minna, John D.; MacMillan, John B.; Posner, Bruce A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Cold Spring Harbor Laboratory; Columbia University; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Southwestern Medical Center Dallas	Schreiber, SL (corresponding author), Harvard & MIT, Broad Inst, Cambridge, MA USA.	stuart_schreiber@harvard.edu	Stockwell, Brent R/AAE-7200-2019	Stockwell, Brent R/0000-0002-3532-3868; Stern, Andrew/0000-0002-8437-2957; Boehm, Jesse/0000-0002-6795-6336; Califano, Andrea/0000-0003-4742-3679; Roth, Michael/0000-0002-9056-332X; Powers, Scott/0000-0003-2769-1932; Sawey, Eric/0000-0003-4045-4499; MacMillan, John/0000-0003-1430-1077; Iavarone, Antonio/0000-0002-0683-4634; DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [RC2 CA148225, R01 CA071443-15, R01 CA071443-14, RC2 CA148399-01, R01 CA137050, R01 CA071443-16, R01 CA071443, RC2 CA148399] Funding Source: Medline; NATIONAL CANCER INSTITUTE [RC2CA148225, R01CA071443, RC2CA148399, R01CA137050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal S, 2010, NAT REV DRUG DISCOV, V9, P427, DOI 10.1038/nrd3186; Bach PB, 2009, NEW ENGL J MED, V360, P626, DOI 10.1056/NEJMhpr0807774; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Frye SV, 2010, NAT CHEM BIOL, V6, P159, DOI 10.1038/nchembio.296; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127; Thompson CB, 2009, CELL, V138, P1051, DOI 10.1016/j.cell.2009.09.002; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; van Staveren WCG, 2009, BBA-REV CANCER, V1795, P92, DOI 10.1016/j.bbcan.2008.12.004; Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558; Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697; Workman P, 2010, CHEM BIOL, V17, P561, DOI 10.1016/j.chembiol.2010.05.013; Zender L, 2006, CELL, V125, P1253, DOI 10.1016/j.cell.2006.05.030; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zheng HW, 2008, NATURE, V455, P1129, DOI 10.1038/nature07443; Zuber J, 2009, GENE DEV, V23, P877, DOI 10.1101/gad.1771409	22	52	53	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	SEP	2010	28	9					904	906		10.1038/nbt0910-904	http://dx.doi.org/10.1038/nbt0910-904			3	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	648UF	20829823	Green Accepted			2023-01-03	WOS:000281719100011
J	Ng, AK; Abramson, JS; Digumarthy, SR; Reingold, JS; Stone, JR				Ng, Andrea K.; Abramson, Jeremy S.; Digumarthy, Subba R.; Reingold, Jason S.; Stone, James R.			A Woman with a History of Hodgkin's Lymphoma and Sudden Onset of Dyspnea and Shock	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Lymphoma Conference	APR 30, 2010	Massachusetts Gen Hosp, Boston, MA		Massachusetts Gen Hosp		INVOLVED-FIELD RADIOTHERAPY; 2ND MALIGNANT NEOPLASMS; RADIATION-THERAPY; HEART-DISEASE; STAGE-II; ABVD CHEMOTHERAPY; LUNG-CANCER; SURVIVORS; MOPP; MORTALITY		[Ng, Andrea K.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA; [Ng, Andrea K.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Abramson, Jeremy S.] Massachusetts Gen Hosp, Dept Med, Div Med Oncol, Boston, MA 02114 USA; [Reingold, Jason S.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; [Digumarthy, Subba R.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Stone, James R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Ng, Andrea K.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA; [Abramson, Jeremy S.; Reingold, Jason S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Digumarthy, Subba R.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA USA; [Stone, James R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ng, AK (corresponding author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.		Abramson, Jeremy/N-5178-2019; Ng, Andrea/AGZ-9678-2022					Aleman BMP, 2007, BLOOD, V109, P1878, DOI 10.1182/blood-2006-07-034405; Aleman BMP, 2003, NEW ENGL J MED, V348, P2396, DOI 10.1056/NEJMoa022628; Aleman BMP, 2003, J CLIN ONCOL, V21, P3431, DOI 10.1200/JCO.2003.07.131; Bradshaw SR, 2009, CARDIOVASC PATHOL, V18, P127, DOI 10.1016/j.carpath.2009.01.001; BROSIUS FC, 1981, AM J MED, V70, P519, DOI 10.1016/0002-9343(81)90574-X; Canellos GP, 2010, J CLIN ONCOL, V28, P1611, DOI 10.1200/JCO.2009.25.3260; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; CARLSON RW, 1981, CHEST, V79, P43, DOI 10.1378/chest.79.1.43; Darby SC, 2010, INT J RADIAT ONCOL, V76, P656, DOI 10.1016/j.ijrobp.2009.09.064; Das P, 2006, ANN ONCOL, V17, P785, DOI 10.1093/annonc/mdl023; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; Dominguez AR, 2004, ANN ONCOL, V15, P1798, DOI 10.1093/annonc/mdh465; Dores GM, 2002, J CLIN ONCOL, V20, P3484, DOI 10.1200/JCO.2002.09.038; Engert A, 2010, NEW ENGL J MED, V363, P640, DOI 10.1056/NEJMoa1000067; FAJARDO LF, 1968, ARCH PATHOL, V86, P512; Furby A, 2010, J NEUROL NEUROSUR PS, V81, P101, DOI 10.1136/jnnp.2008.167577; Heidenreich PA, 2003, J AM COLL CARDIOL, V42, P743, DOI 10.1016/S0735-1097(03)00759-9; Hodgson DC, 2007, J CLIN ONCOL, V25, P1489, DOI 10.1200/JCO.2006.09.0936; Hutchinson RJ, 1998, J CLIN ONCOL, V16, P897, DOI 10.1200/JCO.1998.16.3.897; Jacobs Charlotte DeCroes, 2010, H KAPLAN STORY HODGK; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; National Comprehensive Cancer Network, 2010, CLIN PRACT GUID ONC; Ng AK, 2002, J CLIN ONCOL, V20, P2101, DOI 10.1200/JCO.2002.08.021; Noordijk EM, 2006, J CLIN ONCOL, V24, P3128, DOI 10.1200/JCO.2005.05.2746; O'Brien MM, 2010, J CLIN ONCOL, V28, P1232, DOI 10.1200/JCO.2009.24.8062; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Rosoff PM, 2006, NEW ENGL J MED, V355, P1522, DOI 10.1056/NEJMp068168; Saslow D, 2007, CA-CANCER J CLIN, V57, P185; Saslow D, 2007, CA-CANCER J CLIN, V57, P75, DOI 10.3322/canjclin.57.2.75; Specht L, 1998, J CLIN ONCOL, V16, P830, DOI 10.1200/JCO.1998.16.3.830; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; Travis LB, 2005, JNCI-J NATL CANCER I, V97, P1428, DOI 10.1093/jnci/dji290; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; Veinot JP, 1996, HUM PATHOL, V27, P766, DOI 10.1016/S0046-8177(96)90447-5; Weiner MA, 1997, J CLIN ONCOL, V15, P2769, DOI 10.1200/JCO.1997.15.8.2769; Yeh JM, 2010, ANN INTERN MED, V152, P409, DOI 10.7326/0003-4819-152-7-201004060-00005	37	6	6	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					664	675		10.1056/NEJMcpc1004087	http://dx.doi.org/10.1056/NEJMcpc1004087			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	636TN	20818858				2023-01-03	WOS:000280764600011
J	Kroenke, K; Theobald, D; Wu, JW; Norton, K; Morrison, G; Carpenter, J; Tu, WZ				Kroenke, Kurt; Theobald, Dale; Wu, Jingwei; Norton, Kelli; Morrison, Gwendolyn; Carpenter, Janet; Tu, Wanzhu			Effect of Telecare Management on Pain and Depression in Patients With Cancer A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRIMARY-CARE PATIENTS; COGNITIVE-BEHAVIORAL INTERVENTION; LONGER-TERM OUTCOMES; FORM HEALTH SURVEY; STAR-ASTERISK-D; COLLABORATIVE CARE; MENTAL-HEALTH; MUSCULOSKELETAL PAIN; SYMPTOM MANAGEMENT; ANXIETY DISORDERS	Context Pain and depression are 2 of the most prevalent and treatable cancer-related symptoms, yet they frequently go unrecognized, undertreated, or both. Objective To determine whether centralized telephone-based care management coupled with automated symptom monitoring can improve depression and pain in patients with cancer. Design, Setting, and Patients Randomized controlled trial conducted in 16 community-based urban and rural oncology practices involved in the Indiana Cancer Pain and Depression (INCPAD) trial. Recruitment occurred from March 2006 through August 2008 and follow-up concluded in August 2009. The participating patients had depression (Patient Health Questionnaire-9 score >= 10), cancer-related pain (Brief Pain Inventory [BPI] worst pain score >= 6), or both. Intervention The 202 patients randomly assigned to receive the intervention and 203 to receive usual care were stratified by symptom type. Patients in the intervention group received centralized telecare management by a nurse-physician specialist team coupled with automated home-based symptom monitoring by interactive voice recording or Internet. Main Outcome Measures Blinded assessment at baseline and at months 1, 3, 6, and 12 for depression (20-item Hopkins Symptom Checklist [HSCL-20]) and pain (BPI) severity. Results Of the 405 participants enrolled in the study, 131 had depression only, 96 had pain only, and 178 had both depression and pain. Of the 274 patients with pain, 137 patients in the intervention group had greater improvements in BPI pain severity over the 12 months of the trial whether measured as a continuous severity score or as a categorical pain responder (>= 30% decrease in BPI) than the 137 patients in the usual-care group (P<.001 for both). Similarly, of the 309 patients with depression, the 154 patients in the intervention group had greater improvements in HSCL-20 depression severity over the 12 months of the trial whether measured as a continuous severity score or as a categorical depression responder (>= 50% decrease in HSCL) than the 155 patients in the usual care group (P<.001 for both). The standardized effect size for between-group differences at 3 and 12 months was 0.67 (95% confidence interval [CI], 0.33-1.02) and 0.39 (95% CI, 0.01-0.77) for pain, and 0.42 (95% CI, 0.16-0.69) and 0.41 (95% CI, 0.08-0.72) for depression. Conclusion Centralized telecare management coupled with automated symptom monitoring resulted in improved pain and depression outcomes in cancer patients receiving care in geographically dispersed urban and rural oncology practices.	[Kroenke, Kurt; Norton, Kelli; Morrison, Gwendolyn; Tu, Wanzhu] Regenstrief Inst Inc, Indianapolis, IN 46202 USA; [Theobald, Dale] Community Canc Care, Indianapolis, IN USA; [Theobald, Dale] Community Hlth Network, Indianapolis, IN USA; [Kroenke, Kurt] Richard Roudebush VA Med Ctr, Ctr Implementing Evidence Based Practice, Indianapolis, IN USA; [Kroenke, Kurt; Wu, Jingwei; Tu, Wanzhu] Indiana Univ, Dept Med, Indianapolis, IN USA; [Carpenter, Janet] Indiana Univ, Sch Nursing, Indianapolis, IN 46204 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Kroenke, K (corresponding author), Regenstrief Inst Inc, 6th Floor,1050 Wishard Blvd, Indianapolis, IN 46202 USA.	kkroenke@regenstrief.org	Wu, Jing/GZK-5063-2022	Kroenke, Kurt/0000-0002-0114-4669	Eli Lilly; Pfizer; National Cancer Institute [R01 CA-115369]; NATIONAL CANCER INSTITUTE [R01CA115369] Funding Source: NIH RePORTER	Eli Lilly(Eli Lilly); Pfizer(Pfizer); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Dr Kroenke reported receiving research funding from Eli Lilly and Pfizer, and honoraria as a speaker, consultant, or advisory board member from Eli Lilly, Pfizer, and Forest Laboratories. No other authors reported disclosures.; This study was supported by grant R01 CA-115369 from the National Cancer Institute (Dr Kroenke).	*AM MED ASS, 2004, PAIN MAN 4; [Anonymous], 1991, EFFECT CANC QUALITY; Bookbinder M, 1996, J PAIN SYMPTOM MANAG, V12, P334, DOI 10.1016/S0885-3924(96)00204-7; Bottomley A, 1998, Eur J Cancer Care (Engl), V7, P181; Callahan CM, 2002, MED CARE, V40, P771, DOI 10.1097/00005650-200209000-00007; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; CARR D, 2002, AHRQ PUBLICATION; Cintron A, 2006, J PALLIAT MED, V9, P1454, DOI 10.1089/jpm.2006.9.1454; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Cleeland CS, 1998, JAMA-J AM MED ASSOC, V279, P1914, DOI 10.1001/jama.279.23.1914; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; Coleman K, 2009, ANNU REV PUBL HEALTH, V30, P385, DOI 10.1146/annurev.publhealth.031308.100249; Cuijpers P, 2009, PSYCHIAT RES, V168, P250, DOI 10.1016/j.psychres.2008.05.012; Dobscha SK, 2009, JAMA-J AM MED ASSOC, V301, P1242, DOI 10.1001/jama.2009.377; Dworkin RH, 2008, J PAIN, V9, P105, DOI 10.1016/j.jpain.2007.09.005; Ell K, 2008, J CLIN ONCOL, V26, P4488, DOI 10.1200/JCO.2008.16.6371; Fallowfield L, 2001, BRIT J CANCER, V84, P1011, DOI 10.1054/bjoc.2001.1724; Fann JR, 2009, J GEN INTERN MED, V24, P417, DOI 10.1007/s11606-009-0999-4; Gilbody S, 2006, ARCH INTERN MED, V166, P2314, DOI 10.1001/archinte.166.21.2314; Given C, 2004, J CLIN ONCOL, V22, P507, DOI 10.1200/JCO.2004.01.241; Given CW, 2001, J PAIN SYMPTOM MANAG, V21, P456, DOI 10.1016/S0885-3924(01)00284-6; GIVEN CW, 1994, CANCER, V74, P2128, DOI 10.1002/1097-0142(19941001)74:7+<2128::AID-CNCR2820741721>3.0.CO;2-J; Katon W, 1999, ARCH GEN PSYCHIAT, V56, P1109, DOI 10.1001/archpsyc.56.12.1109; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Keller MB, 2003, JAMA-J AM MED ASSOC, V289, P3152, DOI 10.1001/jama.289.23.3152; KELLER MB, 1996, WHO TECHNICAL REPORT, V804; Kroenke K, 2001, JAMA-J AM MED ASSOC, V286, P2947, DOI 10.1001/jama.286.23.2947; Kroenke K, 2002, PSYCHIAT ANN, V32, P509, DOI 10.3928/0048-5713-20020901-06; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroenke K, 2007, GEN HOSP PSYCHIAT, V29, P506, DOI 10.1016/j.genhosppsych.2007.08.005; Kroenke K, 2007, ANN INTERN MED, V146, P317, DOI 10.7326/0003-4819-146-5-200703060-00004; Kroenke K, 2009, GEN HOSP PSYCHIAT, V31, P240, DOI 10.1016/j.genhosppsych.2009.01.007; Kroenke K, 2009, JAMA-J AM MED ASSOC, V301, P2099, DOI 10.1001/jama.2009.723; Kurtz ME, 2001, CANCER PRACT, V9, P11, DOI 10.1046/j.1523-5394.2001.91004.x; Kurtz ME, 2002, SUPPORT CARE CANCER, V10, P494, DOI 10.1007/s00520-001-0338-8; Kurtz ME, 1999, WOMEN HEALTH, V29, P1, DOI 10.1300/J013v29n03_01; Lesser IM, 2007, MED CARE, V45, P1043, DOI 10.1097/MLR.0b013e3181271462; Mallinckrodt CH, 2001, DRUG INF J, V35, P1215, DOI 10.1177/009286150103500418; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Passik SD, 1998, J CLIN ONCOL, V16, P1594, DOI 10.1200/JCO.1998.16.4.1594; Portenoy RK, 1999, LANCET, V353, P1695, DOI 10.1016/S0140-6736(99)01310-0; Rollman BL, 2009, JAMA-J AM MED ASSOC, V302, P2095, DOI 10.1001/jama.2009.1670; Rost K, 2001, J GEN INTERN MED, V16, P143, DOI 10.1111/j.1525-1497.2001.00537.x; Rush AJ, 2006, AM J PSYCHIAT, V163, P1905, DOI 10.1176/appi.ajp.163.11.1905; Sharpe M, 2004, BRIT J CANCER, V90, P314, DOI 10.1038/sj.bjc.6601578; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Sherwood P, 2005, ONCOL NURS FORUM, V32, P1190, DOI 10.1188/05.ONF.1190-1198; Sikorskii A, 2007, J PAIN SYMPTOM MANAG, V34, P253, DOI 10.1016/j.jpainsymman.2006.11.018; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; Spitzer RL, 2006, ARCH INTERN MED, V166, P1092, DOI 10.1001/archinte.166.10.1092; Stommel M, 2002, CANCER-AM CANCER SOC, V94, P2719, DOI 10.1002/cncr.10533; Strong V, 2008, LANCET, V372, P40, DOI 10.1016/S0140-6736(08)60991-5; Unutzer J, 2001, MED CARE, V39, P785, DOI 10.1097/00005650-200108000-00005; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; WAGNER EH, 1993, J AM GERIATR SOC, V41, P241, DOI 10.1111/j.1532-5415.1993.tb06700.x; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Williams JW, 2007, GEN HOSP PSYCHIAT, V29, P91, DOI 10.1016/j.genhosppsych.2006.12.003; Williams LS, 2007, STROKE, V38, P998, DOI 10.1161/01.STR.0000257319.14023.61; Williams LS, 2004, NEUROLOGY, V63, P674, DOI 10.1212/01.WNL.0000134669.05005.95; 2004, CANC PAIN VERSION 1	60	218	222	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2010	304	2					163	171		10.1001/jama.2010.944	http://dx.doi.org/10.1001/jama.2010.944			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	624IN	20628129	Green Accepted			2023-01-03	WOS:000279811000022
J	Hotchkiss, RS; Opal, S				Hotchkiss, Richard S.; Opal, Steven			Immunotherapy for Sepsis - A New Approach against an Ancient Foe	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63130 USA; [Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63130 USA; [Hotchkiss, Richard S.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63130 USA; [Opal, Steven] Mem Hosp Rhode Isl, Div Infect Dis, Providence, RI USA; [Opal, Steven] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Brown University	Hotchkiss, RS (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63130 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044118] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM044118] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Huang X, 2009, P NATL ACAD SCI USA, V106, P6303, DOI 10.1073/pnas.0809422106; Meisel C, 2009, AM J RESP CRIT CARE, V180, P640, DOI 10.1164/rccm.200903-0363OC; Opal SM, 2009, JAMA-J AM MED ASSOC, V302, P2367, DOI 10.1001/jama.2009.1774; Said EA, 2010, NAT MED, V16, P452, DOI 10.1038/nm.2106	5	269	304	0	23	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2010	363	1					87	89		10.1056/NEJMcibr1004371	http://dx.doi.org/10.1056/NEJMcibr1004371			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	618HR	20592301	Green Accepted, Green Published			2023-01-03	WOS:000279343000016
J	Kerr, T; Montaner, JSG; Wood, E				Kerr, Thomas; Montaner, Julio S. G.; Wood, Evan			Science and politics of heroin prescription	LANCET			English	Editorial Material							ASSISTED TREATMENT; METHADONE		[Kerr, Thomas; Wood, Evan] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Urban Hlth Res Initiat, Vancouver, BC V6Z 1Y6, Canada; [Kerr, Thomas; Montaner, Julio S. G.; Wood, Evan] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia	Kerr, T (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Urban Hlth Res Initiat, Vancouver, BC V6Z 1Y6, Canada.	uhri@cfenet.ubc.ca	Montaner, Julio/K-7621-2012		NATIONAL INSTITUTE ON DRUG ABUSE [DP1DA026182] Funding Source: NIH RePORTER; NIDA NIH HHS [DP1 DA026182] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Berridge V, 2009, NEW ENGL J MED, V361, P820, DOI 10.1056/NEJMe0904243; FERRI M, 2003, COCHRANE DB SYST REV, V3; Fischer B, 2002, EUR J PUBLIC HEALTH, V12, P228, DOI 10.1093/eurpub/12.3.228; Fischer B, 2007, J URBAN HEALTH, V84, P552, DOI 10.1007/s11524-007-9198-y; Gartry CC, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-2; Haasen C, 2007, BRIT J PSYCHIAT, V191, P55, DOI 10.1192/bjp.bp.106.026112; KAHAN M, 2008, NAOMI TRIAL CRITICAL; March JC, 2006, J SUBST ABUSE TREAT, V31, P203, DOI 10.1016/j.jsat.2006.04.007; Mattick RP, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD002209; Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P2195; Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635; SCHECHTER M, 2008, PROVINCE VANCOU 0526; Sneader W, 1998, LANCET, V352, P1697, DOI 10.1016/S0140-6736(98)07115-3; Strang J, 2010, LANCET, V375, P1885, DOI 10.1016/S0140-6736(10)60349-2; Wodak AD, 2002, MED J AUSTRALIA, V176, P449, DOI 10.5694/j.1326-5377.2002.tb04510.x	15	9	9	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2010	375	9729					1849	1850		10.1016/S0140-6736(10)60544-2	http://dx.doi.org/10.1016/S0140-6736(10)60544-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	609BC	20511000				2023-01-03	WOS:000278628800005
J	Bandyopadhyay, A; Wang, L; Agyin, J; Tang, YP; Lin, S; Yeh, IT; De, K; Sun, LZ				Bandyopadhyay, Abhik; Wang, Long; Agyin, Joseph; Tang, Yuping; Lin, Shu; Yeh, I-Tien; De, Keya; Sun, Lu-Zhe			Doxorubicin in Combination with a Small TGF beta Inhibitor: A Potential Novel Therapy for Metastatic Breast Cancer in Mouse Models	PLOS ONE			English	Article							GROWTH-FACTOR-BETA; EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR KINASE INHIBITOR; IN-VIVO; STEM-CELLS; MAMMARY-CARCINOMA; TRANSFORMING GROWTH-FACTOR-BETA-1; DISEASE PROGRESSION; MDA-MB-231 CELLS; DRUG-RESISTANCE	Background: Recent studies suggested that induction of epithelial-mesenchymal transition (EMT) might confer both metastatic and self-renewal properties to breast tumor cells resulting in drug resistance and tumor recurrence. TGF beta is a potent inducer of EMT and has been shown to promote tumor progression in various breast cancer cell and animal models. Principal Findings: We report that chemotherapeutic drug doxorubicin activates TGF beta signaling in human and murine breast cancer cells. Doxorubicin induced EMT, promoted invasion and enhanced generation of cells with stem cell phenotype in murine 4T1 breast cancer cells in vitro, which were significantly inhibited by a TGF beta type I receptor kinase inhibitor (T beta RI-KI). We investigated the potential synergistic anti-tumor activity of T beta R1-KI in combination with doxorubicin in animal models of metastatic breast cancer. Combination of Doxorubicin and T beta RI-KI enhanced the efficacy of doxorubicin in reducing tumor growth and lung metastasis in the 4T1 orthotopic xenograft model in comparison to single treatments. Doxorubicin treatment alone enhanced metastasis to lung in the human breast cancer MDA-MB-231 orthotopic xenograft model and metastasis to bone in the 4T1 orthotopic xenograft model, which was significantly blocked when T beta R1-KI was administered in combination with doxorubicin. Conclusions: These observations suggest that the adverse activation of TGF beta pathway by chemotherapeutics in the cancer cells together with elevated TGF beta levels in tumor microenvironment may lead to EMT and generation of cancer stem cells resulting in the resistance to the chemotherapy. Our results indicate that the combination treatment of doxorubicin with a TGF beta inhibitor has the potential to reduce the dose and consequently the toxic side-effects of doxorubicin, and improve its efficacy in the inhibition of breast cancer growth and metastasis.	[Bandyopadhyay, Abhik; Wang, Long; Tang, Yuping; Lin, Shu; De, Keya; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Agyin, Joseph] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA; [Yeh, I-Tien] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Bandyopadhyay, A (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.	sunl@uthscsa.edu	Lin, Shu/C-3790-2013; , LuZhe/AAW-4095-2021		NIH [R01CA079683, R01CA075253, P01CA040035, P30CA054174]; Shelby Rae Tang Foundation; NATIONAL CANCER INSTITUTE [P01CA040035, R01CA075253, P30CA054174, R01CA079683] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Shelby Rae Tang Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH Grants R01CA079683, R01CA075253, P01CA040035, and P30CA054174, and by Shelby Rae Tang Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arteaga CL, 2006, CURR OPIN GENET DEV, V16, P30, DOI 10.1016/j.gde.2005.12.009; Bandyopadhyay A, 2002, CANCER RES, V62, P4690; Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565; Bandyopadhyay Abhik, 2008, V2, P723, DOI 10.1007/978-1-59745-293-9_44; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Braun S, 2005, NEW ENGL J MED, V353, P793, DOI 10.1056/NEJMoa050434; Charafe-Jauffret E, 2008, PATHOBIOLOGY, V75, P75, DOI 10.1159/000123845; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chen JH, 2005, ENDOCR-RELAT CANCER, V12, P93, DOI 10.1677/erc.1.00871; DALAL BI, 1993, AM J PATHOL, V143, P381; Davies JA, 1996, ACTA ANAT, V156, P187; Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9; Dontu G, 2005, J MAMMARY GLAND BIOL, V10, P75, DOI 10.1007/s10911-005-2542-5; Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522; Ehata S, 2007, CANCER SCI, V98, P127, DOI 10.1111/j.1349-7006.2006.00357.x; ELLIS MJ, 2004, TREATMENT METASTATIC, P749; Gamucci T, 2007, BRIT J CANCER, V97, P1040, DOI 10.1038/sj.bjc.6603982; Ge RR, 2006, CLIN CANCER RES, V12, P4315, DOI 10.1158/1078-0432.CCR-06-0162; GORSCH SM, 1992, CANCER RES, V52, P6949; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Ivanovic V, 2003, EUR J CANCER, V39, P454, DOI 10.1016/S0959-8049(02)00502-6; Kakonen SM, 2003, CANCER-AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132; Kolodziejski L, 1999, Pneumonol Alergol Pol, V67, P228; Lei XF, 2002, ONCOGENE, V21, P7514, DOI 10.1038/sj.onc.1205966; Lei XF, 2007, EXP CELL RES, V313, P1687, DOI 10.1016/j.yexcr.2007.02.016; Liu PC, 2000, INT J ONCOL, V16, P599; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin TJ, 2000, ENDOCR-RELAT CANCER, V7, P271, DOI 10.1677/erc.0.0070271; Medici D, 2006, MOL BIOL CELL, V17, P1871, DOI 10.1091/mbc.E05-08-0767; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Muraoka-Cook RS, 2006, ONCOGENE, V25, P3408, DOI 10.1038/sj.onc.1208964; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Nikolic-Vukosavljevic D, 2004, CLIN EXP METASTAS, V21, P581; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Planchard D, 2004, CANCER-AM CANCER SOC, V100, P28, DOI 10.1002/cncr.11881; Sawyer JS, 2003, J MED CHEM, V46, P3953, DOI 10.1021/jm0205705; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh J, 2003, BIOORG MED CHEM LETT, V13, P4355, DOI 10.1016/j.bmcl.2003.09.028; Sledge GW, 2003, J CLIN ONCOL, V21, P588, DOI 10.1200/JCO.2003.08.013; SOSROSENO W, 1995, BRIT J BIOMED SCI, V52, P142; Sun LZ, 2004, FRONT BIOSCI, V9, P1925, DOI 10.2741/1382; Sun LZ, 1997, J BIOL CHEM, V272, P25367, DOI 10.1074/jbc.272.40.25367; Suzuki E, 2007, CANCER RES, V67, P2351, DOI 10.1158/0008-5472.CAN-06-2389; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Teicher BA, 1997, IN VIVO, V11, P453; Teicher BA, 1997, IN VIVO, V11, P463; Tsushima H, 2001, CLIN CANCER RES, V7, P1258; Verona EV, 2007, CANCER RES, V67, P5737, DOI 10.1158/0008-5472.CAN-07-0444; WALKER RA, 1995, J PATHOL, V177, P123, DOI 10.1002/path.1711770204; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; Wu Y, 2008, ACTA BIOCH BIOPH SIN, V40, P643, DOI 10.1111/j.1745-7270.2008.00443.x; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580; Yoneda Toshiyuki, 2000, Cancer, V88, P2979, DOI 10.1002/1097-0142(20000615)88:12+<2979::AID-CNCR13>3.0.CO;2-U	56	140	150	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 28	2010	5	4							e10365	10.1371/journal.pone.0010365	http://dx.doi.org/10.1371/journal.pone.0010365			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	589MV	20442777	Green Submitted, gold, Green Published			2023-01-03	WOS:000277154200007
J	Klass, P				Klass, Perri			Disconnected.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NYU, New York, NY 10016 USA	New York University	Klass, P (corresponding author), NYU, New York, NY 10016 USA.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	2010	362	15					1358	1361		10.1056/NEJMp0911193	http://dx.doi.org/10.1056/NEJMp0911193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	582XY	20393174				2023-01-03	WOS:000276635300003
J	Moore, M; Walsh, M; Bailey, J; Brunson, D; Gulland, F; Landry, S; Mattila, D; Mayo, C; Slay, C; Smith, J; Rowles, T				Moore, Michael; Walsh, Michael; Bailey, James; Brunson, David; Gulland, Frances; Landry, Scott; Mattila, David; Mayo, Charles; Slay, Christopher; Smith, Jamison; Rowles, Teresa			Sedation at Sea of Entangled North Atlantic Right Whales (Eubalaena glacialis) to Enhance Disentanglement	PLOS ONE			English	Article								Background: The objective of this study was to enhance removal of fishing gear from right whales (Eubalaena glacialis) at sea that evade disentanglement boat approaches. Titrated intra muscular injections to achieve sedation were undertaken on two free swimming right whales. Methodology/Principal Findings: Following initial trials with beached whales, a sedation protocol was developed for right whales. Mass was estimated from sighting and necropsy data from comparable right whales. Midazolam (0.01 to 0.025 mg/ kg) was first given alone or with meperidine (0.17 to 0.25 mg/kg) either once or four times over two hours to whale # 1102 by cantilevered pole syringe. In the last attempt on whale # 1102 there appeared to be a mild effect in 20-30 minutes, with duration of less than 2 hours that included exhalation before the blowhole fully cleared the water. Boat avoidance, used as a measure of sedation depth, was not reduced. A second severely entangled animal in 2009, whale # 3311, received midazolam (0.03 mg/kg) followed by butorphanol (0.03 mg/kg) an hour later, delivered ballistically. Two months later it was then given midazolam (0.07 mg/kg) and butorphanol (0.07 mg/kg) simultaneously. The next day both drugs at 0.1 mg/kg were given as a mixture in two darts 10 minutes apart. The first attempt on whale # 3311 showed increased swimming speed and boat avoidance was observed after a further 20 minutes. The second attempt on whale # 3311 showed respiration increasing mildly in frequency and decreasing in strength. The third attempt on whale # 3311 gave a statistically significant increase in respiratory frequency an hour after injection, with increased swimming speed and marked reduction of boat evasion that enabled decisive cuts to entangling gear. Conclusions/Significance: We conclude that butorphanol and midazolam delivered ballistically in appropriate dosages and combinations may have merit in future refractory free swimming entangled right whale cases until other entanglement solutions are developed.	[Moore, Michael] Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA; [Walsh, Michael; Bailey, James] Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, Gainesville, FL 32610 USA; [Brunson, David] Pfizer Inc, Vet Specialty Team Sedat Pain Management & Anesth, Madison, WI USA; [Gulland, Frances] Marine Mammal Ctr, Sausalito, CA USA; [Landry, Scott; Mayo, Charles] Provincetown Ctr Coastal Studies, Provincetown, MA USA; [Mattila, David] Natl Oceanog Atmospher Adm, Hawaiian Islands Humpback Whale Natl Marine Sanct, Natl Ocean Serv, Kihei, HI USA; [Slay, Christopher] Coastwise Consulting Inc, Athens, GA USA; [Smith, Jamison] Natl Oceanog Atmospher Adm, Protected Resources Div, Natl Marine Fisheries Serv, Gloucester, MA USA; [Rowles, Teresa] Natl Oceanog Atmospher Adm, Marine Mammal Conservat Div, Natl Marine Fisheries Serv, Silver Spring, MD USA	Woods Hole Oceanographic Institution; State University System of Florida; University of Florida; Pfizer; National Oceanic Atmospheric Admin (NOAA) - USA; National Ocean Service, NOAA; National Aeronautics & Space Administration (NASA); National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA	Moore, M (corresponding author), Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA.	mmoore@whoi.edu	Moore, Michael/E-1707-2015	Moore, Michael/0000-0003-3074-6631	Cecil H; Ida M. Green Technology Innovation Program (WHOI); North Pond Foundation; Sloan and Wick Simmonds; Northeast Consortium; National Oceanic Atmospheric Administration (NOAA); Georgia Department of Natural Resources; Florida Fish and Wildlife Conservation Commission; Provincetown Center for Coastal Studies; Coastwise Consulting; Atlantic Large Whale Disentanglement Network; Aquatic Animal Health Program; University of Florida	Cecil H; Ida M. Green Technology Innovation Program (WHOI); North Pond Foundation; Sloan and Wick Simmonds; Northeast Consortium; National Oceanic Atmospheric Administration (NOAA)(National Oceanic Atmospheric Admin (NOAA) - USA); Georgia Department of Natural Resources; Florida Fish and Wildlife Conservation Commission; Provincetown Center for Coastal Studies; Coastwise Consulting; Atlantic Large Whale Disentanglement Network; Aquatic Animal Health Program; University of Florida(University of Florida)	This work was funded by Cecil H. and Ida M. Green Technology Innovation Program (WHOI), North Pond Foundation, Sloan and Wick Simmonds, Northeast Consortium, National Oceanic Atmospheric Administration (NOAA), Georgia Department of Natural Resources, Florida Fish and Wildlife Conservation Commission, Provincetown Center for Coastal Studies, Coastwise Consulting, the Atlantic Large Whale Disentanglement Network, and Aquatic Animal Health Program, University of Florida. NOAA was centrally involved in the permitting and undertaking of the work. The Marine Mammal Protection Act of 1972 demands that this be so. The paper was drafted by all of the authors with no influence from NOAA as an agency in terms of how it was written. Coastwise Consulting provided logistic support for the 2009 field work. Provincetown Center for Coastal Studies provided support for ballistic technology development. Woods Hole Oceanographic Institution funded initial concept development. University of Florida funded drug acquisition. Despite some of the authors being employees of the above sources of funds, the administrators of the funds so granted had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Pfizer Inc. had no financial involvement in the project.	BRUNSON D, 2002, P AM ASS ZOO VET, P320; CHITTICK E, 2006, P INT ASS AQ AN MED, P144; Geraci J.R., 2005, MARINE MAMMALS ASHOR, Vsecond; Gulland Frances M. D., 2008, Aquatic Mammals, V34, P182, DOI 10.1578/AM.34.2.2008.182; Haulena M, 2001, CRC HANDBOOK OF MARINE MAMMAL MEDICINE, SECOND EDITION, P655; JOSEPH BE, 1988, J WILDLIFE DIS, V24, P691, DOI 10.7589/0090-3558-24.4.691; Kraus SD, 2005, SCIENCE, V309, P561, DOI 10.1126/science.1111200; Lien J., 1986, Whalewatcher, V20, P3; Moore M.J., 2001, Journal of Cetacean Research and Management Special Issue, V2, P301; Moore Michael J., 2004, Journal of Cetacean Research and Management, V6, P199; Reidarson TH, 1998, J ZOO WILDLIFE MED, V29, P451; SCHEVILL WE, 1967, SCIENCE, V157, P630, DOI 10.1126/science.157.3789.630; WALSH M, 2006, P AM ASS ZOO VET	13	24	27	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2010	5	3							e9597	10.1371/journal.pone.0009597	http://dx.doi.org/10.1371/journal.pone.0009597			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565XA	20231895	Green Submitted, Green Published, gold			2023-01-03	WOS:000275328300014
J	Toh, S; Hernandez-Diaz, S; Logan, R; Rossouw, JE; Hernan, MA				Toh, Sengwee; Hernandez-Diaz, Sonia; Logan, Roger; Rossouw, Jacques E.; Hernan, Miguel A.			Coronary Heart Disease in Postmenopausal Recipients of Estrogen Plus Progestin Therapy: Does the Increased Risk Ever Disappear? A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							MARGINAL STRUCTURAL MODELS; HORMONE-THERAPY; CARDIOVASCULAR-DISEASE; WOMEN; BENEFITS; HEALTHY; HRT	Background: Estrogen plus progestin therapy increases the risk for coronary heart disease (CHD) in postmenopausal women. However, this increased risk might be limited to the first years of use and to women who start therapy late in menopause. Objective: To estimate the effect of continuous estrogen plus progestin therapy on CHD risk over time and stratified by years since menopause. Design: Women's Health Initiative randomized, double-blinded, placebo-controlled trial. (ClinicalTrials.gov registration number: NCT00000611) Setting: 40 U. S. clinical centers. Patients: 16 608 postmenopausal women with an intact uterus at baseline from 1993 to 1998. Intervention: Conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo. Measurements: Adherence-adjusted hazard ratios and CHD-free survival curves estimated through inverse probability weighting. Results: Compared with no use of hormone therapy, the hazard ratio for continuous use of estrogen plus progestin therapy was 2.36 (95% CI, 1.55 to 3.62) for the first 2 years and 1.69 (CI, 0.98 to 2.89) for the first 8 years. For women within 10 years after menopause, the hazard ratios were 1.29 (CI, 0.52 to 3.18) for the first 2 years and 0.64 (CI, 0.21 to 1.99) for the first 8 years, and the CHD-free survival curves for continuous use and no use of estrogen plus progestin crossed at about 6 years (CI, 2 years to 10 years). Limitation: The analysis may not have fully adjusted for joint determinants of adherence and CHD risk. Sample sizes for some subgroup analyses were small. Conclusion: No suggestion of a decreased risk for CHD was found within the first 2 years of estrogen plus progestin use, including in women who initiated therapy within 10 years after menopause. A possible cardioprotective effect in these women who initiated therapy closer to menopause became apparent only after 6 years of use.	Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA; MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; NHLBI, Bethesda, MD 20892 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Massachusetts Institute of Technology (MIT); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Toh, S (corresponding author), Harvard Univ, Sch Med, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, 133 Brookline Ave,6th Floor, Boston, MA 02215 USA.	darrentoh@post.harvard.edu	Toh, Sengwee/D-7567-2017	Toh, Sengwee/0000-0002-5160-0810; Hernan, Miguel/0000-0003-1619-8456	National Heart, Lung, and Blood Institute; National Institutes of Health [R01 HL080644-01]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL080644] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	National Heart, Lung, and Blood Institute.; By the National Institutes of Health (grant R01 HL080644-01).	*AM COLL OBST GYN, 2004, OBSTET GYNECOL S, V104, pS1; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Barnabei VM, 2005, OBSTET GYNECOL, V105, P1063, DOI 10.1097/01.AOG.0000158120.47542.18; Barrett-Connor E, 2007, AM J EPIDEMIOL, V166, P506, DOI 10.1093/aje/kwm214; Connelly MT, 2000, J GEN INTERN MED, V15, P542, DOI 10.1046/j.1525-1497.2000.03499.x; Cotter D, 2008, KIDNEY INT, V73, P347, DOI 10.1038/sj.ki.5002688; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hernan MA, 2005, BIOMETRICS, V61, P922, DOI 10.1111/j.0006-341X.2005.454_7.x; Hernan MA, 2008, EPIDEMIOLOGY, V19, P766, DOI 10.1097/EDE.0b013e3181875e61; Hernan MA, 2008, EPIDEMIOLOGY, V19, P789, DOI 10.1097/EDE.0b013e318188e85f; Hsia J, 2006, ARCH INTERN MED, V166, P357, DOI 10.1001/archinte.166.3.357; Johnson MS, 2005, ANN INTERN MED, V142, P855, DOI 10.7326/0003-4819-142-10-200505170-00011; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lobo RA, 2004, ARCH INTERN MED, V164, P482, DOI 10.1001/archinte.164.5.482; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Manson JE, 2007, AM J EPIDEMIOL, V166, P511, DOI 10.1093/aje/kwm213; Manson JE, 2007, NEW ENGL J MED, V356, P2591, DOI 10.1056/NEJMoa071513; Mendelsohn ME, 2007, NEW ENGL J MED, V356, P2639, DOI 10.1056/NEJMe078072; Pines A, 2008, CLIMACTERIC, V11, P267, DOI 10.1080/13697130802226866; Prentice RL, 2005, AM J EPIDEMIOL, V162, P404, DOI 10.1093/aje/kwi223; Prentice RL, 2009, AM J EPIDEMIOL, V170, P12, DOI 10.1093/aje/kwp115; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; THOMPSON WA, 1977, BIOMETRICS, V33, P463; Toh S., 2008, INT J BIOSTAT, DOI [10.2202/1557-4679.1117, DOI 10.2202/1557-4679.1117]; Utian WH, 2007, MENOPAUSE, V14, P168, DOI 10.1097/gme.0b013e31803167ab	27	74	78	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	2010	152	4					211	U30		10.7326/0003-4819-152-4-201002160-00005	http://dx.doi.org/10.7326/0003-4819-152-4-201002160-00005			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	560AF	20157135	Green Accepted			2023-01-03	WOS:000274873300002
J	Steinbrook, R				Steinbrook, Robert			Drug Shortages and Public Health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material												rsteinbrook@attglobal.net						Fazel R, 2009, NEW ENGL J MED, V361, P849, DOI 10.1056/NEJMoa0901249; Lauer MS, 2009, NEW ENGL J MED, V361, P841, DOI 10.1056/NEJMp0904735; National Research Council Committee on Medical Isotope Production Without Highly Enriched Uranium, 2009, MED IS PROD HIGHL EN	3	25	26	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	2009	361	16					1525	1527		10.1056/NEJMp0906922	http://dx.doi.org/10.1056/NEJMp0906922			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506LT	19828529				2023-01-03	WOS:000270777000003
J	Hung, DZ; Tsan, YT; Yu, YJ; Hsu, CL				Hung, Dong-Zong; Tsan, Yu-Tse; Yu, Yi-Jung; Hsu, Chia-Lung			Cyanide poisoning in Taiwan	LANCET			English	Editorial Material									[Hung, Dong-Zong] China Med Univ Hosp, Div Toxicol, Trauma & Emergency Ctr, Taichung 404, Taiwan; [Tsan, Yu-Tse; Yu, Yi-Jung; Hsu, Chia-Lung] Taichung Vet Gen Hosp, Div Toxicol, Emergency Dept, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; Taichung Veterans General Hospital	Hung, DZ (corresponding author), China Med Univ Hosp, Div Toxicol, Trauma & Emergency Ctr, 2 Yu Der Rd, Taichung 404, Taiwan.	hung02241956@yahoo.com.tw						BALLANTYNE B, 1987, CLIN EXPT TOXICOLOGY, P41; Baud FJ, 2002, CRIT CARE MED, V30, P2044, DOI 10.1097/00003246-200209000-00015; Laffey JG, 2002, NEW ENGL J MED, V347, P43, DOI 10.1056/NEJMra012457; Mycyk Mark B, 2006, Am J Ther, V13, P485, DOI 10.1097/01.mjt.0000208878.53856.a5; RTI International, 2006, Clin Toxicol (Phila), V44 Suppl 1, P47	5	9	9	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	2009	374	9696					1212	1212		10.1016/S0140-6736(09)61033-3	http://dx.doi.org/10.1016/S0140-6736(09)61033-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505IZ	19801099				2023-01-03	WOS:000270688200038
J	Zhang, FJ; Dou, ZH; Ma, Y; Zhao, Y; Liu, ZF; Bulterys, M; Chen, RY				Zhang, Fujie; Dou, Zhihui; Ma, Ye; Zhao, Yan; Liu, Zhongfu; Bulterys, Marc; Chen, Ray Y.			Five-Year Outcomes of the China National Free Antiretroviral Treatment Program	ANNALS OF INTERNAL MEDICINE			English	Article							HIV-INFECTED PATIENTS; CD4 CELL COUNT; RESOURCE-LIMITED SETTINGS; SUB-SAHARAN AFRICA; VIRAL LOAD; SCALE-UP; TREATMENT FAILURE; EARLY MORTALITY; 1ST YEAR; THERAPY	Background: China's National Free Antiretroviral Treatment Program began in 2002 and, by August 2008, included more than 52 000 patients. Objective: To report 5-year outcomes on adult mortality and immunologic treatment failure rates and risk factors. Design: Open cohort analysis of a prospectively collected, observational database. Setting: China. Patients: All patients in the national treatment database from June 2002 to August 2008. Patients were excluded if they had not started triple therapy or had missing treatment regimen information. Intervention: Antiretroviral therapy according to Chinese national treatment guidelines. Measurements: Mortality rate and immunologic treatment failure rate, according to World Health Organization criteria. Results: Of 52 191 patients, 48 785 were included. Median age was 38 years, 58% were men, 53% were infected through plasma or blood, and the median baseline CD4 cell count was 0.118 x 10(9) cells/L. Mortality was greatest during the first 3 months of treatment (22.6 deaths per 100 person-years) but decreased to a steady rate of 4 to 5 deaths per 100 person-years after 6 months and maintained this rate over the subsequent 4.5 years. The strongest mortality risk factors were a baseline CD4 cell count less than 0.050 x 10(9) cells/L (adjusted hazard ratio [HR] compared with a count >= 0.200 x 10(9) cells/L, 3.3 [95% CI, 2.9 to 3.8]) and having 4 to 5 baseline symptom categories (adjusted HR compared with no baseline symptom categories, 3.4 [CI, 2.9 to 4.0]). Treatment failure was determined among 31 070 patients with 1 or more follow-up CD4 cell counts. Overall, treatment failed for 25% of patients (12.0 treatment failures per 100 person-years), with the cumulative treatment failure rate increasing to 50% at 5 years. Limitation: Immunologic treatment failure does not necessarily correlate well with virologic treatment failure. Conclusion: The National Free Antiretroviral Treatment Program reduced mortality among adult patients in China with AIDS to rates similar to those of other low-or middle-income countries. A cumulative immunologic treatment failure rate of 50% after 5 years, due to the limited availability of second-line regimens, is of great concern.	[Zhang, Fujie] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing 100050, Peoples R China	Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention	Zhang, FJ (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, 27 Nanwei Rd, Beijing 100050, Peoples R China.	treatment@chinaaids.cn	Chen, Ray/T-5102-2019; Chen, Ray/GRJ-6736-2022	Chen, Ray/0000-0001-6344-1442	AIDS preventionand treatment of the China Ministry of Health [WA-2006-03]; U. S. National Institutes of Health [U2R TW006918, R03 TW008203]; U. S. Centers for Disease Control and Prevention Global AIDS Program to the Chinese Center for Disease Control and Prevention [1U2GPS001188-01]; FOGARTY INTERNATIONAL CENTER [R03TW008203, U2RTW006918] Funding Source: NIH RePORTER	AIDS preventionand treatment of the China Ministry of Health; U. S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U. S. Centers for Disease Control and Prevention Global AIDS Program to the Chinese Center for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	By the applied research program on AIDS preventionand treatment of the China Ministry of Health ( grant WA-2006-03), the U. S. National Institutes of Health ( grants U2R TW006918 and R03 TW008203), and a cooperative agreement from the U. S. Centers for Disease Control and Prevention Global AIDS Program to the Chinese Center for Disease Control and Prevention ( grant 1U2GPS001188-01).	Barth RE, 2008, EUR J CLIN MICROBIOL, V27, P977, DOI 10.1007/s10096-008-0534-2; Bartlett JG, 2008, J INFECT DIS, V197, pS250, DOI 10.1086/533417; BASENERO A, 2007, 4 INT AIDS SOC C HIV; Bisson GP, 2006, AIDS, V20, P1613, DOI 10.1097/01.aids.0000238407.00874.dc; Bisson GP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001725; Bisson GP, 2008, PLOS MED, V5, P777, DOI 10.1371/journal.pmed.0050109; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Bussmann H, 2008, AIDS, V22, P2303, DOI 10.1097/QAD.0b013e3283129db0; *CHIN CTR DIS CONT, 2005, CHIN FREE ART MAN; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Corey DM, 2007, JAIDS-J ACQ IMM DEF, V44, P451, DOI 10.1097/QAI.0b013e31802f8512; Fairall LR, 2008, ARCH INTERN MED, V168, P86, DOI 10.1001/archinternmed.2007.10; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Ferradini L, 2007, AIDS, V21, P2293, DOI 10.1097/QAD.0b013e32828cc8b7; Grinszten B, 2007, JAIDS-J ACQ IMM DEF, V45, P515, DOI 10.1097/QAI.0b013e3180decb6a; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; HOSSEINIPOUR M, 2007, 4 INT AIDS SOC C HIV; Ivers LC, 2005, CLIN INFECT DIS, V41, P217, DOI 10.1086/431199; Jahn A, 2008, LANCET, V371, P1603, DOI 10.1016/S0140-6736(08)60693-5; Johannessen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-52; Kamya MR, 2007, JAIDS-J ACQ IMM DEF, V46, P187, DOI 10.1097/QAI.0b013e31814278c0; Keiser O, 2008, TROP MED INT HEALTH, V13, P870, DOI 10.1111/j.1365-3156.2008.02078.x; Laurent C, 2005, JAIDS-J ACQ IMM DEF, V38, P14, DOI 10.1097/00126334-200501010-00003; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lima VD, 2009, JAIDS-J ACQ IMM DEF, V50, P529, DOI 10.1097/QAI.0b013e31819675e9; MA Y, 2009, INT J EPIDEMIOL 0625; Madec Y, 2007, AIDS, V21, P351, DOI 10.1097/QAD.0b013e328012c54f; Marazzi MC, 2008, AIDS RES HUM RETROV, V24, P555, DOI 10.1089/aid.2007.0217; Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8; Mermin J, 2008, LANCET, V371, P752, DOI 10.1016/S0140-6736(08)60345-1; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Moore DM, 2008, LANCET, V371, P1396, DOI 10.1016/S0140-6736(08)60607-8; Moore DM, 2006, JAIDS-J ACQ IMM DEF, V43, P436, DOI 10.1097/01.qai.0000243105.80393.42; Phillips AN, 2008, LANCET, V371, P1443, DOI 10.1016/S0140-6736(08)60624-8; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Severe P, 2005, NEW ENGL J MED, V353, P2325, DOI 10.1056/NEJMoa051908; Sherer R, 2008, HEALTH AFFAIR, V27, P1140, DOI 10.1377/hlthaff.27.4.1140; State Council AIDS Working Committee Office and UN Theme Group on AIDS in China, 2007, JOINT ASS HIV AIDS P; Sterne JAC, 2007, JAIDS-J ACQ IMM DEF, V46, P607, DOI 10.1097/QAI.0b013e31815b7dba; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; Toure S, 2008, AIDS, V22, P873, DOI 10.1097/QAD.0b013e3282f768f8; Van der Borght SF, 2009, ANTIVIR THER, V14, P63; Wang L, 2009, JAIDS-J ACQ IMM DEF, V50, P414, DOI 10.1097/QAI.0b013e3181958530; World Health Organization, 2006, ANT THER HIV INF AD; Zhang F., 2005, CHINA FREE ART MANUA; Zhang FJ, 2008, CLIN INFECT DIS, V47, P825, DOI 10.1086/590945; Zhang FJ, 2007, AIDS, V21, pS143, DOI 10.1097/01.aids.0000304710.10036.2b; Zhou J, 2007, HIV MED, V8, P8, DOI 10.1111/j.1468-1293.2007.00417.x	48	205	293	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 18	2009	151	4					241	W52		10.7326/0003-4819-151-4-200908180-00006	http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00006			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	484IW	19687491				2023-01-03	WOS:000269038900003
J	Kantoff, PW; Higano, CS; Shore, ND; Berger, ER; Small, EJ; Penson, DF; Redfern, CH; Ferrari, AC; Dreicer, R; Sims, RB; Xu, Y; Frohlich, MW; Schellhammer, PF; Ahmed, T; Amin, A; Arseneau, J; Barth, N; Bernstein, G; Bracken, B; Burch, P; Caggiano, V; Chin, J; Chodak, G; Chu, F; Corman, J; Curti, B; Dawson, N; Deeken, JF; Dubernet, T; Fishman, M; Flanigan, R; Gailani, F; Garbo, L; Gardner, T; Gelmann, E; George, D; Godfrey, T; Gomella, L; Guerra, M; Hall, S; Hanson, J; Israeli, R; Jancis, E; Jewett, MAS; Kassabian, V; Katz, J; Klotz, L; Koeneman, K; Koh, H; Kratzke, R; Lance, R; Lech, J; Leichman, L; Lemon, R; Liang, J; Libertino, J; Lilly, M; Malik, I; Martin, SE; McCaffrey, J; McLeod, D; McNeel, D; Miles, B; Murdock, M; Nabhan, C; Nemunaitis, J; Notter, D; Pantuck, A; Perrotte, P; Pessis, D; Petrylak, D; Polikoff, J; Pommerville, P; Ramanathan, S; Rarick, M; Richards, J; Rifkin, R; Rohatgi, N; Rosenbluth, R; Santucci, R; Sayegh, A; Seigne, J; Shapira, I; Shedhadeh, N; Shepherd, D; Sridhar, S; Stephenson, R; Teigland, C; Thaker, N; Vacirca, J; Villa, L; Vogelzang, N; Wertheim, M; Wolff, JH; Wurzel, R; Yang, C; Young, J				Kantoff, Philip W.; Higano, Celestia S.; Shore, Neal D.; Berger, E. Roy; Small, Eric J.; Penson, David F.; Redfern, Charles H.; Ferrari, Anna C.; Dreicer, Robert; Sims, Robert B.; Xu, Yi; Frohlich, Mark W.; Schellhammer, Paul F.; Ahmed, T.; Amin, A.; Arseneau, J.; Barth, N.; Bernstein, G.; Bracken, B.; Burch, P.; Caggiano, V.; Chin, J.; Chodak, G.; Chu, F.; Corman, J.; Curti, B.; Dawson, N.; Deeken, J. F.; Dubernet, T.; Fishman, M.; Flanigan, R.; Gailani, F.; Garbo, L.; Gardner, T.; Gelmann, E.; George, D.; Godfrey, T.; Gomella, L.; Guerra, M.; Hall, S.; Hanson, J.; Israeli, R.; Jancis, E.; Jewett, M. A. S.; Kassabian, V.; Katz, J.; Klotz, L.; Koeneman, K.; Koh, H.; Kratzke, R.; Lance, R.; Lech, J.; Leichman, L.; Lemon, R.; Liang, J.; Libertino, J.; Lilly, M.; Malik, I.; Martin, S. E.; McCaffrey, J.; McLeod, D.; McNeel, D.; Miles, B.; Murdock, M.; Nabhan, C.; Nemunaitis, J.; Notter, D.; Pantuck, A.; Perrotte, P.; Pessis, D.; Petrylak, D.; Polikoff, J.; Pommerville, P.; Ramanathan, S.; Rarick, M.; Richards, J.; Rifkin, R.; Rohatgi, N.; Rosenbluth, R.; Santucci, R.; Sayegh, A.; Seigne, J.; Shapira, I.; Shedhadeh, N.; Shepherd, D.; Sridhar, S.; Stephenson, R.; Teigland, C.; Thaker, N.; Vacirca, J.; Villa, L., Jr.; Vogelzang, N.; Wertheim, M.; Wolff, J. H.; Wurzel, R.; Yang, C.; Young, J.		IMPACT Study Investigators	Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MITOXANTRONE PLUS PREDNISONE; RANDOMIZED CONTROLLED-TRIAL; SURROGATE MARKER; DENDRITIC CELLS; CLINICAL-TRIALS; PHASE-III; SURVIVAL; MEN; DOCETAXEL; LEUKEMIA	Background: Sipuleucel-T, an autologous active cellular immunotherapy, has shown evidence of efficacy in reducing the risk of death among men with metastatic castration-resistant prostate cancer. Methods: In this double-blind, placebo-controlled, multicenter phase 3 trial, we randomly assigned 512 patients in a 2:1 ratio to receive either sipuleucel-T (341 patients) or placebo (171 patients) administered intravenously every 2 weeks, for a total of three infusions. The primary end point was overall survival, analyzed by means of a stratified Cox regression model adjusted for baseline levels of serum prostate-specific antigen (PSA) and lactate dehydrogenase. Results: In the sipuleucel-T group, there was a relative reduction of 22% in the risk of death as compared with the placebo group (hazard ratio, 0.78; 95% confidence interval [CI], 0.61 to 0.98; P=0.03). This reduction represented a 4.1-month improvement in median survival (25.8 months in the sipuleucel-T group vs. 21.7 months in the placebo group). The 36-month survival probability was 31.7% in the sipuleucel-T group versus 23.0% in the placebo group. The treatment effect was also observed with the use of an unadjusted Cox model and a log-rank test (hazard ratio, 0.77; 95% CI, 0.61 to 0.97; P=0.02) and after adjustment for use of docetaxel after the study therapy (hazard ratio, 0.78; 95% CI, 0.62 to 0.98; P=0.03). The time to objective disease progression was similar in the two study groups. Immune responses to the immunizing antigen were observed in patients who received sipuleucel-T. Adverse events that were more frequently reported in the sipuleucel-T group than in the placebo group included chills, fever, and headache. Conclusions: The use of sipuleucel-T prolonged overall survival among men with metastatic castration-resistant prostate cancer. No effect on the time to disease progression was observed. (Funded by Dendreon; ClinicalTrials.gov number, NCT00065442.) N Engl J Med 2010;363:411-22.	[Kantoff, Philip W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA; [Higano, Celestia S.] Univ Washington, Sch Med, Seattle, WA USA; [Shore, Neal D.] Carolina Urol Res Ctr, Myrtle Beach, SC USA; [Berger, E. Roy] SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA; [Small, Eric J.] Univ Calif San Francisco, Urol Oncol Program, San Francisco, CA 94143 USA; [Penson, David F.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Redfern, Charles H.] Sharp Healthcare, San Diego, CA USA; [Ferrari, Anna C.] NYU, Ctr Clin Canc, Langone Med Ctr, New York, NY USA; [Dreicer, Robert] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA; [Sims, Robert B.; Xu, Yi; Frohlich, Mark W.] Dendreon Corp, Seattle, WA USA; [Schellhammer, Paul F.] Eastern Virginia Med Sch, Norfolk, VA 23501 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Washington; University of Washington Seattle; Carolina Urologic Research Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California San Francisco; Vanderbilt University; New York University; NYU Langone Medical Center; Cleveland Clinic Foundation; Dendreon; Eastern Virginia Medical School	Kantoff, PW (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, 44 Binney St,Dana 1230, Boston, MA 02115 USA.	philip_kantoff@dfci.harvard.edu	Fishman, Mayer/AAG-6640-2021	McNeel, Douglas/0000-0003-1471-6723; Kantoff, Philip/0000-0001-7275-0597; Penson, David/0000-0002-2580-2697	Dendreon	Dendreon	Supported by Dendreon.	ANDERSON JR, 1983, J CLIN ONCOL, V1, P710, DOI 10.1200/JCO.1983.1.11.710; Armstrong AJ, 2007, CLIN CANCER RES, V13, P6396, DOI 10.1158/1078-0432.CCR-07-1036; Berry W, 2002, J UROLOGY, V168, P2439, DOI 10.1016/S0022-5347(05)64163-8; Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008; Burch PA, 2000, CLIN CANCER RES, V6, P2175; Carducci MA, 2007, CANCER-AM CANCER SOC, V110, P1959, DOI 10.1002/cncr.22996; CROWTHER JR, 2000, ELISA GUIDEBOOK METH; *DEP HLTH HUM SERV, 2009, GUID IND CLIN UNPUB; Goldman B, 2009, NAT BIOTECHNOL, V27, P129, DOI 10.1038/nbt0209-129; Halabi S, 2003, J CLIN ONCOL, V21, P1232, DOI 10.1200/JCO.2003.06.100; Higano C, 2009, 2009 GEN CANC S ORL; Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429; James ND, 2009, EUR UROL, V55, P1112, DOI 10.1016/j.eururo.2008.11.002; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597; Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506; Kantoff PW, 2002, PROSTATE CANC PRINCI; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lin DY, 1997, STAT MED, V16, P1515, DOI 10.1002/(SICI)1097-0258(19970715)16:13<1515::AID-SIM572>3.0.CO;2-1; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Saad F, 2002, JNCI-J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458; Sheikh NA, 2008, CANCER IMMUNOL IMMUN, V57, P1381, DOI 10.1007/s00262-008-0474-9; Small E, 2009, 2009 GEN CANC S ORL; Small EJ, 2000, J CLIN ONCOL, V18, P3894, DOI 10.1200/JCO.2000.18.23.3894; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Sternberg CN, 2009, J CLIN ONCOL, V27, P5431, DOI 10.1200/JCO.2008.20.1228; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224	32	3795	3942	9	419	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					411	422		10.1056/NEJMoa1001294	http://dx.doi.org/10.1056/NEJMoa1001294			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818862				2023-01-03	WOS:000280411300005
J	Whitney, M; Crisp, JL; Olson, ES; Aguilera, TA; Gross, LA; Ellies, LG; Tsien, RY				Whitney, Mike; Crisp, Jessica L.; Olson, Emilia S.; Aguilera, Todd A.; Gross, Larry A.; Ellies, Lesley G.; Tsien, Roger Y.			Parallel in Vivo and in Vitro Selection Using Phage Display Identifies Protease-dependent Tumor-targeting Peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-PENETRATING PEPTIDES; TYPE-1 MATRIX-METALLOPROTEINASE; POLYMORPHONUCLEAR LEUKOCYTE ELASTASE; ENDOGENOUS SERUM-ALBUMIN; PANCREATIC CYSTIC TUMORS; PRIMARY BREAST-CANCER; DRUG-DELIVERY; MOUSE MODEL; EXPRESSION; ACTIVATION	We recently developed activatable cell-penetrating peptides (ACPPs) that target contrast agents to in vivo sites of matrix metalloproteinase activity, such as tumors. Here we use parallel in vivo and in vitro selection with phage display to identify novel tumor-homing ACPPs with no bias for primary sequence or target protease. Specifically, phage displaying a library of ACPPs were either injected into tumor-bearing mice, followed by isolation of cleaved phage from dissected tumor, or isolated based on selective cleavage by extracts of tumor versus normal tissue. Selected sequences were synthesized as fluorescently labeled peptides, and tumor-specific cleavage was confirmed by digestion with tissue extracts. The most efficiently cleaved peptide contained the substrate sequence RLQLKL and labeled tumors and metastases from several cancer models with up to 5-fold contrast. This uniquely identified ACPP was not cleaved by matrix metalloproteinases or various coagulation factors but was efficiently cleaved by plasmin and elastases, both of which have been shown to be aberrantly overexpressed in tumors. The identification of an ACPP that targets tumor expressed proteases without rational design highlights the value of unbiased selection schemes for the development of potential therapeutic agents.	[Whitney, Mike; Olson, Emilia S.; Aguilera, Todd A.; Gross, Larry A.; Tsien, Roger Y.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Crisp, Jessica L.; Tsien, Roger Y.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Ellies, Lesley G.] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA; [Gross, Larry A.; Tsien, Roger Y.] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; [Olson, Emilia S.; Aguilera, Todd A.] Univ Calif San Diego, Med Scientist Training Program, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Tsien, RY (corresponding author), 9500 Gilman Dr, La Jolla, CA 92093 USA.	rtsien@ucsd.edu		Aguilera, Todd/0000-0002-3734-3758	National Institutes of Health, NCI [CA118182]; DOD [W81XWH-05-1-0183]; NATIONAL CANCER INSTITUTE [K22CA118182] Funding Source: NIH RePORTER	National Institutes of Health, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health, NCI, Grant CA118182 (to L. E.) and DOD grant W81XWH-05-1-0183 (to R. Y. T)	Aguilera TA, 2009, INTEGR BIOL, V1, P371, DOI 10.1039/b904878b; ALLES AJ, 1994, ANN SURG, V219, P131, DOI 10.1097/00000658-199402000-00004; Atwell S, 1999, P NATL ACAD SCI USA, V96, P9497, DOI 10.1073/pnas.96.17.9497; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; Bremer C, 2001, NAT MED, V7, P743, DOI 10.1038/89126; Bremer C, 2001, RADIOLOGY, V221, P523, DOI 10.1148/radiol.2212010368; Brown S, 2000, J AM CHEM SOC, V122, P6799, DOI 10.1021/ja001461n; Cuevas BD, 2006, ONCOGENE, V25, P4998, DOI 10.1038/sj.onc.1209507; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; Desmedt C, 2006, INT J CANCER, V119, P2539, DOI 10.1002/ijc.22149; Foekens JA, 2003, CANCER RES, V63, P337; Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291; Goun EA, 2006, BIOCONJUGATE CHEM, V17, P787, DOI 10.1021/bc0503216; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Jessani N, 2002, P NATL ACAD SCI USA, V99, P10335, DOI 10.1073/pnas.162187599; Jiang T, 2004, P NATL ACAD SCI USA, V101, P17867, DOI 10.1073/pnas.0408191101; KOIVUNEN E, 1991, INT J CANCER, V47, P592, DOI 10.1002/ijc.2910470419; Koshikawa N, 1998, AM J PATHOL, V153, P937, DOI 10.1016/S0002-9440(10)65635-0; Kratz F, 2002, J MED CHEM, V45, P5523, DOI 10.1021/jm020276c; Kratz F, 2000, J MED CHEM, V43, P1253, DOI 10.1021/jm9905864; Kridel SJ, 2002, J BIOL CHEM, V277, P23788, DOI 10.1074/jbc.M111574200; La Rocca G, 2004, BRIT J CANCER, V90, P1414, DOI 10.1038/sj.bjc.6601725; Laakkonen P, 2004, P NATL ACAD SCI USA, V101, P9381, DOI 10.1073/pnas.0403317101; Lacroix M, 2008, INT J CANCER, V122, P1, DOI 10.1002/ijc.23233; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Maglione JE, 2001, CANCER RES, V61, P8298; Mi ZB, 2003, MOL THER, V8, P295, DOI 10.1016/S1525-0016(03)00181-3; Miyata S, 1999, J BIOCHEM, V125, P1067, DOI 10.1093/oxfordjournals.jbchem.a022388; Olson ES, 2010, P NATL ACAD SCI USA, V107, P4311, DOI 10.1073/pnas.0910283107; Olson ES, 2009, INTEGR BIOL-UK, V1, P382, DOI 10.1039/b904890a; Paju A, 2004, CLIN CANCER RES, V10, P4761, DOI 10.1158/1078-0432.CCR-0204-03; Ratnikov BI, 2002, LAB INVEST, V82, P1583, DOI 10.1097/01.LAB.0000038555.67772.DB; Rothbard JB, 2002, J MED CHEM, V45, P3612, DOI 10.1021/jm0105676; Sabapathy KT, 1997, J CELL BIOL, V137, P953, DOI 10.1083/jcb.137.4.953; Sidhu SS, 2001, BIOMOL ENG, V18, P57, DOI 10.1016/S1389-0344(01)00087-9; Sounni NE, 2003, MATRIX BIOL, V22, P55, DOI 10.1016/S0945-053X(03)00003-9; Sperti C, 1996, CANCER, V78, P237, DOI 10.1002/(SICI)1097-0142(19960715)78:2<237::AID-CNCR8>3.0.CO;2-I; Talvensaari-Mattila A, 2003, BRIT J CANCER, V89, P1270, DOI 10.1038/sj.bjc.6601238; Thie JA, 2004, J NUCL MED, V45, P1431; Wright LR, 2003, CURR PROTEIN PEPT SC, V4, P105, DOI 10.2174/1389203033487252; YAMASHITA JI, 1994, BRIT J CANCER, V69, P72, DOI 10.1038/bjc.1994.11; Zhang Y, 2006, NANO LETT, V6, P1988, DOI 10.1021/nl0611586; Zou J, 2004, MOL BIOL REP, V31, P121, DOI 10.1023/B:MOLE.0000031459.14448.af	43	57	65	2	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 16	2010	285	29					22532	22541		10.1074/jbc.M110.138297	http://dx.doi.org/10.1074/jbc.M110.138297			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622YF	20460372	Green Published, hybrid			2023-01-03	WOS:000279702200065
J	Sinclair, AJ; Burdon, MA; Nightingale, PG; Ball, AK; Good, P; Matthews, TD; Jacks, A; Lawden, M; Clarke, CE; Stewart, PM; Walker, EA; Tomlinson, JW; Rauz, S				Sinclair, Alexandra J.; Burdon, Michael A.; Nightingale, Peter G.; Ball, Alexandra K.; Good, Peter; Matthews, Timothy D.; Jacks, Andrew; Lawden, Mark; Clarke, Carl E.; Stewart, Paul M.; Walker, Elizabeth A.; Tomlinson, Jeremy W.; Rauz, Saaeha			Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							WEIGHT-LOSS; HEADACHE IMPACT; FOLLOW-UP; ACETAZOLAMIDE; TOPIRAMATE; CEREBRI	Objective To observe intracranial pressure in women with idiopathic intracranial hypertension who follow a low energy diet. Design Prospective cohort study. Setting Outpatient department and the clinical research facility based at two separate hospitals within the United Kingdom. Participants 25 women with body mass index (BMI) > 25, with active (papilloedema and intracranial pressure > 25 cm H2O), chronic (over three months) idiopathic intracranial hypertension. Women who had undergone surgery to treat idiopathic intracranial hypertension were excluded. Intervention Stage 1: no new intervention; stage 2: nutritionally complete low energy (calorie) diet (1777 kJ/day (425 kcal/day)); stage 3: follow-up period after the diet. Each stage lasted three months. Main outcome measure The primary outcome was reduction in intracranial pressure after the diet. Secondary measures included score on headache impact test-6, papilloedema (as measured by ultrasonography of the elevation of the optic disc and diameter of the nerve sheath, together with thickness of the peripapillary retina measured by optical coherence tomography), mean deviation of Humphrey visual field, LogMAR visual acuity, and symptoms. Outcome measures were assessed at baseline and three, six, and nine months. Lumbar puncture, to quantify intracranial pressure, was measured at baseline and three and six months. Results All variables remained stable over stage 1. During stage 2, there were significant reductions in weight (mean 15.7 (SD 8.0) kg, P<0.001), intracranial pressure (mean 8.0 (SD 4.2) cm H2O, P<0.001), score on headache impact test (7.6 (SD 10.1), P=0.004), and papilloedema (optic disc elevation (mean 0.15 (SD 0.23) mm, P=0.002), diameter of the nerve sheath (mean 0.7 (SD 0.8) mm, P=0.004), and thickness of the peripapillary retina (mean 25.7 (SD 36.1) mu, P=0.001)). Mean deviation of the Humphrey visual field remained stable, and in only five patients, the LogMAR visual acuity improved by one line. Fewer women reported symptoms including tinnitus, diplopia, and obscurations (10 v 4, P=0.004; 7 v 0, P=0.008; and 4 v 0, P=0.025, respectively). Re-evaluation at three months after the diet showed no significant change in weight (0.21 (SD 6.8) kg), and all outcome measures were maintained. Conclusion Women with idiopathic intracranial hypertension who followed a low energy diet for three months had significantly reduced intracranial pressure compared with pressure measured in the three months before the diet, as well as improved symptoms and reduced papilloedema. These reductions persisted for three months after they stopped the diet.	[Sinclair, Alexandra J.; Rauz, Saaeha] Univ Birmingham, Acad Unit Ophthalmol, Sch Immun & Infect, Coll Med & Dent Sci,MRC, Birmingham B15 2TT, W Midlands, England; [Sinclair, Alexandra J.] Univ Birmingham, Ctr Endocrinol Diabet & Metab, Sch Clin & Expt Med, Coll Med & Dent Sci,MRC, Birmingham B15 2TT, W Midlands, England; [Nightingale, Peter G.] Univ Birmingham, Wellcome Trust Clin Res Facil, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Good, Peter; Matthews, Timothy D.; Jacks, Andrew] Univ Hosp Birmingham NHS Fdn Trust, Birmingham Neuroophthalmol Unit, Birmingham B15 2TH, W Midlands, England; [Lawden, Mark] Leicester Gen Hosp, Dept Neurol, Leicester LE5 4PW, Leics, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham; University Hospitals of Leicester NHS Trust; Leicester General Hospital	Rauz, S (corresponding author), Univ Birmingham, Acad Unit Ophthalmol, Sch Immun & Infect, Coll Med & Dent Sci,MRC, Birmingham B15 2TT, W Midlands, England.	s.rauz@bham.ac.uk	Rauz, Saaeha/ABF-2202-2021	Rauz, Saaeha/0000-0003-4627-3496; Clarke, Carl/0000-0003-2478-3436; Tomlinson, Jeremy/0000-0002-3170-8533; Sinclair, Alexandra/0000-0003-2777-5132	British Medical Association; Sandwell and West Birmingham Hospitals NHS Trust; West Midlands Neuroscience Teaching and Research Fund; Birmingham Eye Foundation (Registered (UK) [257549]; MRC [G0601430] Funding Source: UKRI; Medical Research Council [G0601430] Funding Source: researchfish; National Institute for Health Research [NF-SI-0508-10356] Funding Source: researchfish	British Medical Association; Sandwell and West Birmingham Hospitals NHS Trust; West Midlands Neuroscience Teaching and Research Fund; Birmingham Eye Foundation (Registered (UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the Vera Down (Neurological Diseases) 2005 and Clark and McMaster (Blinding Diseases) 2005 Awards funded by the British Medical Association, a research and development award 2005 from Sandwell and West Birmingham Hospitals NHS Trust, and by the West Midlands Neuroscience Teaching and Research Fund. AJS is a Brain Trust entry/exit scholar, Ipsen Research Fellow and MRC clinical training fellow (G0601430). The Academic Unit of Ophthalmology is supported by the Birmingham Eye Foundation (Registered (UK) Charity 257549). JWT is a MRC senior clinical fellow.	Bynke G, 2004, NEUROLOGY, V63, P1314, DOI 10.1212/01.WNL.0000140699.43019.48; Celebisoy N, 2007, ACTA NEUROL SCAND, V116, P322, DOI 10.1111/j.1600-0404.2007.00905.x; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; CORBETT JJ, 1982, ARCH NEUROL-CHICAGO, V39, P461, DOI 10.1001/archneur.1982.00510200003001; Castro DPE, 2008, ARQ BRAS OFTALMOL, V71, P523, DOI 10.1590/S0004-27492008000400011; Evers S, 2004, SCHMERZ, V18, P351; *FDA, 2009, ORL MARK ALL XEN EAR; Flum DR, 2009, NEW ENGL J MED, V361, P445, DOI 10.1056/NEJMoa0901836; Friedman DI, 2002, NEUROLOGY, V59, P1492, DOI 10.1212/01.WNL.0000029570.69134.1B; FRISEN L, 1982, J NEUROL NEUROSUR PS, V45, P13, DOI 10.1136/jnnp.45.1.13; Glueck CJ, 2005, J LAB CLIN MED, V145, P72, DOI 10.1016/j.lab.2004.09.011; Johnson LN, 1998, OPHTHALMOLOGY, V105, P2313, DOI 10.1016/S0161-6420(98)91234-9; Kosinski M, 2003, QUAL LIFE RES, V12, P963, DOI 10.1023/A:1026119331193; Kupersmith MJ, 1998, NEUROLOGY, V50, P1094, DOI 10.1212/WNL.50.4.1094; Li ZP, 2005, ANN INTERN MED, V142, P532, DOI 10.7326/0003-4819-142-7-200504050-00012; LUECK C, 2005, COCHRANE DB SYST REV, V3; NEWBORG B, 1974, ARCH INTERN MED, V133, P802, DOI 10.1001/archinte.133.5.802; Rebolleda G, 2009, INVEST OPHTH VIS SCI, V50, P5197, DOI 10.1167/iovs.08-2528; Rosenfeld WE, 1997, CLIN THER, V19, P1294, DOI 10.1016/S0149-2918(97)80006-9; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Shin HE, 2008, J CLIN NEUROL, V4, P158, DOI 10.3988/jcn.2008.4.4.158; Sinclair AJ, 2008, J NEUROIMMUNOL, V201, P212, DOI 10.1016/j.jneuroim.2008.06.029; SUGERMAN HJ, 1995, NEUROLOGY, V45, P1655, DOI 10.1212/WNL.45.9.1655; Tamburrelli C, 2000, INVEST OPHTH VIS SCI, V41, P2960; Tomlinson JW, 2004, J CLIN ENDOCR METAB, V89, P2711, DOI 10.1210/jc.2003-031376; Whiteley W, 2006, NEUROLOGY, V67, P1690, DOI 10.1212/01.wnl.0000242704.60275.e9; Who,, 2010, BMI CLASSIFICATION; Williams G, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c824; Wong R, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-15	29	172	174	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2010	341								c2701	10.1136/bmj.c2701	http://dx.doi.org/10.1136/bmj.c2701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	625DL	20610512	Green Published, hybrid			2023-01-03	WOS:000279874300001
J	Hettiarachchi, G; Nguyen, D; Wu, J; Lucas, D; Ma, D; Isaacs, L; Briken, V				Hettiarachchi, Gaya; Nguyen, Duc; Wu, Jing; Lucas, Derick; Ma, Da; Isaacs, Lyle; Briken, Volker			Toxicology and Drug Delivery by Cucurbit[n]uril Type Molecular Containers	PLOS ONE			English	Article							NANOPARTICLES; CUCURBITURIL; TUBERCULOSIS; ENCAPSULATION; CYTOTOXICITY; RESISTANCE; DENDRIMERS; COMPLEXES; TOXICITY	Background: Many drug delivery systems are based on the ability of certain macrocyclic compounds - such as cyclodextrins (CDs) - to act as molecular containers for pharmaceutical agents in water. Indeed beta-CD and its derivatives have been widely used in the formulation of hydrophobic pharmaceuticals despite their poor abilities to act as a molecular container (e. g., weak binding (K-a < 10(4) M-1) and their challenges toward chemical functionalization. Cucurbit[n]urils (CB[n]) are a class of molecular containers that bind to a variety of cationic and neutral species with high affinity (K-a < 10(4) M-1) and therefore show great promise as a drug delivery system. Methodology: In this study we investigated the toxicology, uptake, and bioactivity of two cucurbit[n]urils (CB[5] and CB[7]) and three CB[n]-type containers (Pentamer 1, methyl hexamer 2, and phenyl hexamer 3). All five containers demonstrated high cell tolerance at concentrations of up to 1 mM in cell lines originating from kidney, liver or blood tissue using assays for metabolic activity and cytotoxicity. Furthermore, the CB[7] molecular container was efficiently internalized by macrophages indicating their potential for the intracellular delivery of drugs. Bioactivity assays showed that the first-line tuberculosis drug, ethambutol, was as efficient in treating mycobacteria infected macrophages when loaded into CB[7] as when given in the unbound form. This result suggests that CB[7]-bound drug molecules can be released from the container to find their intracellular target. Conclusion: Our study reveals very low toxicity of five members of the cucurbit[n]uril family of nanocontainers. It demonstrates the uptake of containers by cells and intracellular release of container-loaded drugs. These results provide initial proof-of-concept towards the use of CB[n] molecular containers as an advanced drug delivery system.	[Hettiarachchi, Gaya; Nguyen, Duc; Briken, Volker] Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA; [Wu, Jing; Lucas, Derick; Ma, Da; Isaacs, Lyle] Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park	Hettiarachchi, G (corresponding author), Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA.	LIsaacs@umd.edu; vbriken@umd.edu	Isaacs, Lyle D/B-4472-2009	Isaacs, Lyle D/0000-0002-4079-332X; Briken, Volker/0000-0001-5830-6107	Maryland Department of Business and Economic Development (Nano-Bio Initiative); Maryland Technology Development Corporation	Maryland Department of Business and Economic Development (Nano-Bio Initiative); Maryland Technology Development Corporation	The authors thank the Maryland Department of Business and Economic Development (Nano-Bio Initiative) and the Maryland Technology Development Corporation for funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlin G, 2009, DRUG METAB DISPOS, V37, P2275, DOI 10.1124/dmd.109.028654; BARANELLO L, 2009, NUCL ACIDS RES; Biagini CP, 2006, TOXICOL IN VITRO, V20, P1051, DOI 10.1016/j.tiv.2006.01.013; Cavagnaro JA, 2002, NAT REV DRUG DISCOV, V1, P469, DOI 10.1038/nrd822; Challa R, 2005, AAPS PHARMSCITECH, V6, DOI 10.1208/pt060243; Chaoui I, 2009, J INFECT DEV COUNTR, V3, P278; Cho KJ, 2008, CLIN CANCER RES, V14, P1310, DOI 10.1158/1078-0432.CCR-07-1441; Day A, 2001, J ORG CHEM, V66, P8094, DOI 10.1021/jo015897c; Delie F, 2005, MOLECULES, V10, P65, DOI 10.3390/10010065; Delogu G, 2009, J INFECT DEV COUNTR, V3, P5, DOI 10.3855/jidc.99; Dexheimer TS, 2009, J MED CHEM, V52, P7122, DOI 10.1021/jm901061s; Ge Z, 2008, ACTA PHARMACOL SIN, V29, P990, DOI 10.1111/j.1745-7254.2008.00825.x; Gelperina S, 2005, AM J RESP CRIT CARE, V172, P1487, DOI 10.1164/rccm.200504-613PP; He H, 2008, OPT LETT, V33, P2961, DOI 10.1364/OL.33.002961; HERRLING P, 2005, IMAGING DRUG DISCOVE; Huang WH, 2008, J AM CHEM SOC, V130, P8446, DOI 10.1021/ja8013693; Jeon YJ, 2005, ORG BIOMOL CHEM, V3, P2122, DOI 10.1039/b504487a; Jeon YM, 1996, J AM CHEM SOC, V118, P9790, DOI 10.1021/ja962071x; Jia J, 2005, BRIT J PHARMACOL, V144, P80, DOI 10.1038/sj.bjp.0705984; Kemp S, 2007, SUPRAMOL CHEM, V19, P475, DOI 10.1080/10610270601124019; Kim J, 2007, ANGEW CHEM INT EDIT, V46, P7393, DOI 10.1002/anie.200702540; Kim K, 2007, CHEM SOC REV, V36, P267, DOI 10.1039/b603088m; Kramer JA, 2007, NAT REV DRUG DISCOV, V6, P636, DOI 10.1038/nrd2378; Kuo JHS, 2005, J PHARM PHARMACOL, V57, P489, DOI 10.1211/0022357055803; Kuo JHS, 2005, COLLOID SURFACE B, V41, P189, DOI 10.1016/j.colsurfb.2004.12.008; Lagona J, 2005, ANGEW CHEM INT EDIT, V44, P4844, DOI 10.1002/anie.200460675; Liu SM, 2005, J AM CHEM SOC, V127, P15959, DOI 10.1021/ja055013x; MA D, 2010, J ORG CHEM UNPUB; MOCK WL, 1986, J ORG CHEM, V51, P4440, DOI 10.1021/jo00373a018; Montes-Navajas P, 2009, PHOTOCH PHOTOBIO SCI, V8, P1743, DOI 10.1039/b9pp00041k; Pandey R, 2003, J ANTIMICROB CHEMOTH, V52, P981, DOI 10.1093/jac/dkg477; Park KM, 2009, CHEM COMMUN, P71, DOI 10.1039/b815009e; Peck RW, 2007, DRUG DISCOV TODAY, V12, P289, DOI 10.1016/j.drudis.2007.02.004; Pritchard JF, 2003, NAT REV DRUG DISCOV, V2, P542, DOI 10.1038/nrd1131; Ralph AP, 2009, CLIN INFECT DIS, V49, P574, DOI 10.1086/600889; Sakagami H, 2009, ANTICANCER RES, V29, P343; Samad A, 2009, CURR PHARM DESIGN, V15, P2958, DOI 10.2174/138161209789058200; SCHOLFIELD C, 2009, LONZA RESOURCE NOTES, P6; Shenoi S, 2009, ANNU REV MED, V60, P307, DOI 10.1146/annurev.med.60.053107.103955; SPATARO G, 2009, EUR J MED CHEM; Stella VJ, 2008, TOXICOL PATHOL, V36, P30, DOI 10.1177/0192623307310945; Thomas Philip, 2005, Journal of Pharmacological and Toxicological Methods, V51, P187, DOI 10.1016/j.vascn.2004.08.014; VANDEWATERBEEMD HL, 2003, METHODS PRINCIPLES M; Velmurugan K, 2007, PLOS PATHOG, V3, P972, DOI 10.1371/journal.ppat.0030110; Verma RK, 2002, J CONTROL RELEASE, V79, P7, DOI 10.1016/S0168-3659(01)00550-8; Wang RB, 2009, DALTON T, P3584, DOI 10.1039/b904028e; Wheate NJ, 2008, J INORG BIOCHEM, V102, P2060, DOI 10.1016/j.jinorgbio.2008.06.005; Wheate NJ, 2004, CHEM COMMUN, P1424, DOI 10.1039/b404358h; Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k; Zhang Y, 2009, INT J TUBERC LUNG D, V13, P1320; Zhao LB, 2009, J PHYS CHEM B, V113, P14172, DOI 10.1021/jp907437e; Zhao YJ, 2009, DALTON T, P5190, DOI 10.1039/b905112k; Zhao YJ, 2008, ORG BIOMOL CHEM, V6, P4509, DOI 10.1039/b813759e	53	201	203	2	88	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2010	5	5							e10514	10.1371/journal.pone.0010514	http://dx.doi.org/10.1371/journal.pone.0010514			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	592LG	20463906	Green Published, gold, Green Submitted			2023-01-03	WOS:000277379800009
J	Jo, H; Loison, F; Hattori, H; Silberstein, LE; Yu, HT; Luo, HR				Jo, Hakryul; Loison, Fabien; Hattori, Hidenori; Silberstein, Leslie E.; Yu, Hongtao; Luo, Hongbo R.			Natural Product Celastrol Destabilizes Tubulin Heterodimer and Facilitates Mitotic Cell Death Triggered by Microtubule-Targeting Anti-Cancer Drugs	PLOS ONE			English	Article							INDUCED APOPTOSIS; PROTEIN; BINDING; ARREST; PARTHENOLIDE; TRITERPENE; INHIBITOR; DISCOVERY; CLEAVAGE; PATHWAY	Background: Microtubule drugs are effective anti-cancer agents, primarily due to their ability to induce mitotic arrest and subsequent cell death. However, some cancer cells are intrinsically resistant or acquire a resistance. Lack of apoptosis following mitotic arrest is thought to contribute to drug resistance that limits the efficacy of the microtubule-targeting anticancer drugs. Genetic or pharmacological agents that selectively facilitate the apoptosis of mitotic arrested cells present opportunities to strengthen the therapeutic efficacy. Methodology and Principal Findings: We report a natural product Celastrol targets tubulin and facilitates mitotic cell death caused by microtubule drugs. First, in a small molecule screening effort, we identify Celastrol as an inhibitor of neutrophil chemotaxis. Subsequent time-lapse imaging analyses reveal that inhibition of microtubule-mediated cellular processes, including cell migration and mitotic chromosome alignment, is the earliest events affected by Celastrol. Disorganization, not depolymerization, of mitotic spindles appears responsible for mitotic defects. Celastrol directly affects the biochemical properties of tubulin heterodimer in vitro and reduces its protein level in vivo. At the cellular level, Celastrol induces a synergistic apoptosis when combined with conventional microtubule-targeting drugs and manifests an efficacy toward Taxol-resistant cancer cells. Finally, by time-lapse imaging and tracking of microtubule drug-treated cells, we show that Celastrol preferentially induces apoptosis of mitotic arrested cells in a caspase-dependent manner. This selective effect is not due to inhibition of general cell survival pathways or mitotic kinases that have been shown to enhance microtubule drug-induced cell death. Conclusions and Significance: We provide evidence for new cellular pathways that, when perturbed, selectively induce the apoptosis of mitotic arrested cancer cells, identifying a potential new strategy to enhance the therapeutic efficacy of conventional microtubule-targeting anti-cancer drugs.	[Jo, Hakryul; Loison, Fabien; Hattori, Hidenori; Silberstein, Leslie E.; Luo, Hongbo R.] Harvard Univ, Sch Med, Dept Pathol, Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA; [Yu, Hongtao] Univ Texas SW Med Ctr Dallas, Howard Hughes Med Inst, Dept Pharmacol, Dallas, TX 75390 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Howard Hughes Medical Institute; University of Texas System; University of Texas Southwestern Medical Center Dallas	Jo, H (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA.	Hongbo.Luo@childrens.harvard.edu	loison, fabien/G-3385-2014	loison, fabien/0000-0002-6678-1730; Yu, Hongtao/0000-0002-8861-049X	National Institutes of Health (NIH) [HL066987, HL085100, AI076471, HL092020, GM076084]; American Cancer Society; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092020, R01HL085100, T32HL066987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI076471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM076084] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	H. Jo is supported by National Institutes of Health (NIH) Training Grant HL066987. H. Luo is supported by NIH grants HL085100, AI076471, HL092020, and GM076084 and a Research Scholar Grant from American Cancer Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banerjee M, 2005, J MED CHEM, V48, P547, DOI 10.1021/jm0494974; BARTON JS, 1982, BIOCHIM BIOPHYS ACTA, V705, P8, DOI 10.1016/0167-4838(82)90328-4; Burris HA, 2008, SEMIN ONCOL, V35, pS15, DOI 10.1053/j.seminoncol.2008.02.002; CARLIER MF, 1984, BIOCHEMISTRY-US, V23, P1582, DOI 10.1021/bi00302a037; CORREIA JJ, 1994, ARCH BIOCHEM BIOPHYS, V309, P94, DOI 10.1006/abbi.1994.1090; CORREIA JJ, 1993, ARCH BIOCHEM BIOPHYS, V300, P105, DOI 10.1006/abbi.1993.1015; Corson TW, 2007, CELL, V130, P769, DOI 10.1016/j.cell.2007.08.021; de Carcer G, 2004, CANCER RES, V64, P5106, DOI 10.1158/0008-5472.CAN-03-2214; de Carcer G, 2001, EMBO J, V20, P2878, DOI 10.1093/emboj/20.11.2878; Fonrose X, 2007, CANCER RES, V67, P3371, DOI 10.1158/0008-5472.CAN-06-3732; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Gaertig J, 2008, CURR TOP DEV BIOL, V85, P83, DOI 10.1016/S0070-2153(08)00804-1; Hammond JW, 2008, CURR OPIN CELL BIOL, V20, P71, DOI 10.1016/j.ceb.2007.11.010; Hassane DC, 2008, BLOOD, V111, P5654, DOI 10.1182/blood-2007-11-126003; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hunt JT, 2009, MOL CANCER THER, V8, P275, DOI 10.1158/1535-7163.MCT-08-0999; Janke C, 2005, SCIENCE, V308, P1758, DOI 10.1126/science.1113010; Jin HZ, 2002, J NAT PROD, V65, P89, DOI 10.1021/np010428r; Jo H, 2008, MOL CELL BIOL, V28, P4285, DOI 10.1128/MCB.01240-07; Lewis SA, 1997, TRENDS CELL BIOL, V7, P479, DOI 10.1016/S0962-8924(97)01168-9; Lin YF, 2009, CANCER RES, V69, P6879, DOI 10.1158/0008-5472.CAN-08-4700; Luders J, 2007, NAT REV MOL CELL BIO, V8, P161, DOI 10.1038/nrm2100; MARTIN SR, 1982, BIOCHEM J, V203, P643, DOI 10.1042/bj2030643; MI L, 2009, J BIOL CHEM; Mi LX, 2008, J BIOL CHEM, V283, P22136, DOI 10.1074/jbc.M802330200; Milross CG, 1996, JNCI-J NATL CANCER I, V88, P1308, DOI 10.1093/jnci/88.18.1308; Miyata N, 2008, INT IMMUNOPHARMACOL, V8, P874, DOI 10.1016/j.intimp.2008.02.002; Mooberry Susan L, 2007, Methods Mol Med, V137, P289, DOI 10.1007/978-1-59745-442-1_20; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nagle A, 2006, CURR DRUG TARGETS, V7, P305, DOI 10.2174/138945006776054933; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Peris L, 2006, J CELL BIOL, V174, P839, DOI 10.1083/jcb.200512058; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Ross-Macdonald P, 2008, MOL CANCER THER, V7, P3490, DOI 10.1158/1535-7163.MCT-08-0826; Sethi G, 2007, BLOOD, V109, P2727, DOI 10.1182/blood-2006-10-050807; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Steinmetz MO, 2008, TRENDS BIOCHEM SCI, V33, P535, DOI 10.1016/j.tibs.2008.08.006; Symmans WF, 2000, CLIN CANCER RES, V6, P4610; Toyoshima F, 2007, DEV CELL, V13, P796, DOI 10.1016/j.devcel.2007.10.014; Weisbrich A, 2007, NAT STRUCT MOL BIOL, V14, P959, DOI 10.1038/nsmb1291; Whitfield ML, 2000, MOL CELL BIOL, V20, P4188, DOI 10.1128/MCB.20.12.4188-4198.2000; Yang HJ, 2006, CANCER RES, V66, P4758, DOI 10.1158/0008-5472.CAN-05-4529; Zhang T, 2008, MOL CANCER THER, V7, P162, DOI 10.1158/1535-7163.MCT-07-0484; Zhu D, 2006, P NATL ACAD SCI USA, V103, P14836, DOI 10.1073/pnas.0605722103	44	36	38	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 23	2010	5	4							e10318	10.1371/journal.pone.0010318	http://dx.doi.org/10.1371/journal.pone.0010318			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	588NU	20428237	gold, Green Published, Green Submitted			2023-01-03	WOS:000277079300010
J	Anglaret, X; Eholie, S				Anglaret, Xavier; Eholie, Serge			Co-trimoxazole, cART, and non-AIDS infectious diseases	LANCET			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; COTE-DIVOIRE; TRIMETHOPRIM-SULFAMETHOXAZOLE; HIV-1-INFECTED ADULTS; RURAL UGANDA; PROPHYLAXIS; MORTALITY; MORBIDITY; ABIDJAN		[Anglaret, Xavier] Univ Bordeaux 2, INSERM, U897, F-33076 Bordeaux, France; [Eholie, Serge] CHU Treichville, Serv Malad Infect & Trop, Abidjan, Cote Ivoire	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Anglaret, X (corresponding author), Univ Bordeaux 2, INSERM, U897, F-33076 Bordeaux, France.	Xavier.Anglaret@isped.u-bordeaux2.fr	Anglaret, Xavier/T-2757-2019; Eholie, Serge/T-6008-2019; Franzeck, Fabian C/B-5055-2011; Anglaret, Xavier/F-7333-2013	Anglaret, Xavier/0000-0003-3319-8423	NIAID NIH HHS [R01 AI058736] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058736] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; Anglaret X, 2003, AIDS, V17, P575, DOI 10.1097/00002030-200303070-00013; Corbett EL, 2002, CLIN INFECT DIS, V34, P1251, DOI 10.1086/339540; Gilks CF, 1996, LANCET, V347, P718, DOI 10.1016/S0140-6736(96)90076-8; HIRSCHTICK RE, 1995, NEW ENGL J MED, V333, P845, DOI 10.1056/NEJM199509283331305; Losina E, 2007, ANTIVIR THER, V12, P543; Mermin J, 2004, LANCET, V364, P1428, DOI 10.1016/S0140-6736(04)17225-5; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Walker AS, 2010, LANCET, V375, P1278, DOI 10.1016/S0140-6736(10)60057-8; Weverling GJ, 1999, LANCET, V353, P1293, DOI 10.1016/S0140-6736(99)03287-0; Whitworth J, 2000, LANCET, V356, P1051, DOI 10.1016/S0140-6736(00)02727-6; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; World Health Organization, GUID COTR PROPH HIV	13	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 10	2010	375	9722					1231	1233		10.1016/S0140-6736(10)60200-0	http://dx.doi.org/10.1016/S0140-6736(10)60200-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	585VN	20347482				2023-01-03	WOS:000276858400007
J	Jayaraman, K				Jayaraman, Killugudi			Failure of Indian whistleblower scheme points to deeper woes	NATURE MEDICINE			English	News Item																			0	1	1	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					364	364		10.1038/nm0410-364a	http://dx.doi.org/10.1038/nm0410-364a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376034	Bronze			2023-01-03	WOS:000276446800025
J	Davenport, A; Farrington, K				Davenport, Andrew; Farrington, Ken			Dialysis dose in acute kidney injury and chronic dialysis	LANCET			English	Editorial Material							NATIONAL COOPERATIVE DIALYSIS; CRITICALLY-ILL PATIENTS; HEMODIALYSIS-PATIENTS; MORTALITY; INTENSITY; MORBIDITY; SURVIVAL		[Davenport, Andrew] UCL, Sch Med, Ctr Nephrol, London NW3 2PF, England; [Farrington, Ken] Lister Hosp, Renal Unit, Stevenage, Herts, England	University of London; University College London; UCL Medical School; Lister Hospital	Davenport, A (corresponding author), UCL, Sch Med, Ctr Nephrol, Royal Free Campus, London NW3 2PF, England.	andrew.davenport@royalfree.nhs.uk	Farrington, Ken/V-1531-2019					Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Cheung AK, 2006, J AM SOC NEPHROL, V17, P546, DOI 10.1681/ASN.2005020132; DAVENPORT A, 1993, LANCET, V341, P1614, DOI 10.1016/0140-6736(93)90757-8; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; Locatelli F, 2009, J AM SOC NEPHROL, V20, P645, DOI 10.1681/ASN.2008060590; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; PARKER TF, 1994, AM J KIDNEY DIS, V23, P670, DOI 10.1016/S0272-6386(12)70277-9; Spalding EM, 2008, KIDNEY INT, V74, P348, DOI 10.1038/ki.2008.185; TISHER CC, 1994, ANN INTERN MED, V121, P62	12	27	28	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 27	2010	375	9716					705	706		10.1016/S0140-6736(09)62062-6	http://dx.doi.org/10.1016/S0140-6736(09)62062-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	564JW	20167358				2023-01-03	WOS:000275211200008
J	Ramakrishnan, V; Timm, M; Haug, JL; Kimlinger, TK; Wellik, LE; Witzig, TE; Rajkumar, SV; Adjei, AA; Kumar, S				Ramakrishnan, V.; Timm, M.; Haug, J. L.; Kimlinger, T. K.; Wellik, L. E.; Witzig, T. E.; Rajkumar, S. V.; Adjei, A. A.; Kumar, S.			Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs	ONCOGENE			English	Article						vascular endothelial growth factor; myeloma; angiogenesis; proliferation; apoptosis; microenvironment	BONE-MARROW ANGIOGENESIS; MULTIPLE-MYELOMA; K-RAS; ACTIVATING MUTATIONS; DISEASE PROGRESSION; DOWN-REGULATION; PLASMA-CELLS; TUMOR-CELLS; N-RAS; KINASE	Multiple myeloma is characterized by increased bone marrow neovascularization driven in part by vascular endothelial growth factor (VEGF). In addition, the Ras/Raf/MEK/ERK pathway is critical for the proliferation of myeloma cells and is often upregulated. Sorafenib (Nexavar) is a novel multi-kinase inhibitor that acts predominantly through inhibition of Raf-kinase and VEGF receptor 2, offering the potential for targeting two important aspects of disease biology. In in vitro studies, sorafenib-induced cytotoxicity in MM cell lines as well as freshly isolated patient myeloma cells. It retained its activity against MM cells in co-culture with stromal cells or with interleukin-6, VEGF or IGF; conditions mimicking tumor microenvironment. Examination of cellular signaling pathways showed downregulation of Mcl1 as well as decreased phosphorylation of the STAT3 and MEK/ERK, as potential mechanisms of its anti-tumor effect. Sorafenib induces reciprocal upregulation of Akt phosphorylation; and simultaneous inhibition of downstream mTOR with rapamycin leads to synergistic effects. Sorafenib also synergizes with drugs such as proteasome inhibitors and steroids. In a human in vitro angiogenesis assay, sorafenib showed potent anti-angiogenic activity. Sorafenib, through multiple mechanisms exerts potent anti-myeloma activity and these results favor further clinical evaluation and development of novel sorafenib combinations. Oncogene (2010) 29, 1190-1202; doi: 10.1038/onc.2009.403; published online 23 November 2009	[Ramakrishnan, V.; Timm, M.; Haug, J. L.; Kimlinger, T. K.; Wellik, L. E.; Witzig, T. E.; Rajkumar, S. V.; Kumar, S.] Mayo Clin, Div Hematol, Rochester, MN USA; [Adjei, A. A.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA	Mayo Clinic; Roswell Park Cancer Institute	Kumar, S (corresponding author), Mayo Clin & Mayo Fdn, Div Hematol, 200 1st St SW, Rochester, MN 55905 USA.	kumar.shaji@mayo.edu	Kumar, Shaji K/A-9853-2008; Rajkumar, S. Vincent/AAV-1834-2021	Kumar, Shaji K/0000-0001-5392-9284; Rajkumar, S. Vincent/0000-0002-5862-1833	Mayo Foundation; Lymphoma SPORE; Bayer Pharmaceuticals; NATIONAL CANCER INSTITUTE [R01CA127433, P50CA097274] Funding Source: NIH RePORTER	Mayo Foundation; Lymphoma SPORE; Bayer Pharmaceuticals(Bayer AG); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge Roberta DeGoey and Christy Finke for their assistance with processing of tumor cells and all of the patients who provided us with the tumor samples. This work was supported by Mayo Clinic Hematologic Malignancies Program, CR20 Award from Mayo Foundation and Career Development Award from Lymphoma SPORE. Sorafenib was provided through CTEP drug evaluation program by Bayer Pharmaceuticals.	Bezieau S, 2001, HUM MUTAT, V18, P212, DOI 10.1002/humu.1177; BROWN RD, 1994, LEUKEMIA LYMPHOMA, V16, P147, DOI 10.3109/10428199409114152; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Chatterjee M, 2004, BLOOD, V104, P3712, DOI 10.1182/blood-2004-04-1670; Chatterjee M, 2002, BLOOD, V100, P3311, DOI 10.1182/blood-2002-01-0102; CORRADINI P, 1993, BRIT J HAEMATOL, V83, P672, DOI 10.1111/j.1365-2141.1993.tb04711.x; Dai Y, 2002, BLOOD, V100, P3333, DOI 10.1182/blood-2002-03-0940; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; Frassanito MA, 2002, BRIT J HAEMATOL, V118, P157, DOI 10.1046/j.1365-2141.2002.03559.x; Giuliani N, 2004, LEUKEMIA, V18, P628, DOI 10.1038/sj.leu.2403269; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood-2005-08-3434; Hsu JH, 2004, ONCOGENE, V23, P3368, DOI 10.1038/sj.onc.1207459; Kimlinger T, 2006, HAEMATOLOGICA, V91, P1033; Kumar S, 2005, LEUKEMIA, V19, P1466, DOI 10.1038/sj.leu.2403823; Kumar S, 2005, LEUKEMIA, V19, P1253, DOI 10.1038/sj.leu.2403776; Kumar S, 2004, BLOOD, V104, P1159, DOI 10.1182/blood-2003-11-3811; Kumar S, 2004, BONE MARROW TRANSPL, V34, P235, DOI 10.1038/sj.bmt.1704555; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood-2002-08-2383; Liu M, 2006, J BIOL CHEM, V281, P18090, DOI 10.1074/jbc.M601324200; Liu PC, 1996, BLOOD, V88, P2699, DOI 10.1182/blood.V88.7.2699.bloodjournal8872699; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; PAQUETTE RL, 1990, ONCOGENE, V5, P1659; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Pope B, 1997, LEUKEMIA LYMPHOMA, V25, P545, DOI 10.3109/10428199709039043; PORTIER M, 1992, ONCOGENE, V7, P2539; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Raje N, 2004, BLOOD, V104, P4188, DOI 10.1182/blood-2004-06-2281; Rajkumar SV, 2002, CLIN CANCER RES, V8, P2210; Rowley M, 2002, ONCOGENE, V21, P8769, DOI 10.1038/sj.onc.1205387; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Strumberg D, 2005, ONKOLOGIE, V28, P101, DOI 10.1159/000083373; Strumberg D, 2005, DRUGS TODAY, V41, P773, DOI 10.1358/dot.2005.41.12.937959; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; UCHIYAMA H, 1993, BLOOD, V82, P3712; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zhang B, 2002, J CELL PHYSIOL, V193, P42, DOI 10.1002/jcp.10148	43	74	77	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1190	1202		10.1038/onc.2009.403	http://dx.doi.org/10.1038/onc.2009.403			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19935717	Green Accepted			2023-01-03	WOS:000274912100010
J	Patel, BP; Safdar, A; Raha, S; Tarnopolsky, MA; Hamadeh, MJ				Patel, Barkha P.; Safdar, Adeel; Raha, Sandeep; Tarnopolsky, Mark A.; Hamadeh, Mazen J.			Caloric Restriction Shortens Lifespan through an Increase in Lipid Peroxidation, Inflammation and Apoptosis in the G93A Mouse, an Animal Model of ALS	PLOS ONE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU/ZN-SUPEROXIDE-DISMUTASE; HEAT-SHOCK PROTEINS; SKELETAL-MUSCLE; OXIDATIVE STRESS; GENE-EXPRESSION; DIETARY RESTRICTION; MITOCHONDRIAL-DNA; UP-REGULATION; RADICAL GENERATION	Caloric restriction (CR) extends lifespan through a reduction in oxidative stress, delays the onset of morbidity and prolongs lifespan. We previously reported that long-term CR hastened clinical onset, disease progression and shortened lifespan, while transiently improving motor performance in G93A mice, a model of amyotrophic lateral sclerosis (ALS) that shows increased free radical production. To investigate the long-term CR-induced pathology in G93A mice, we assessed the mitochondrial bioenergetic efficiency and oxidative capacity (CS - citrate synthase content and activity, cytochrome c oxidase - COX activity and protein content of COX subunit-I and IV and UCP3- uncoupling protein 3), oxidative damage (MDA - malondialdehyde and PC - protein carbonyls), antioxidant enzyme capacity (Mn-SOD, Cu/Zn-SOD and catalase), inflammation (TNF-alpha), stress response (Hsp70) and markers of apoptosis (Bax, Bcl-2, caspase 9, cleaved caspase 9) in their skeletal muscle. At age 40 days, G93A mice were divided into two groups: Ad libitum (AL; n = 14; 7 females) or CR (n = 13; 6 females), with a diet equal to 60% of AL. COX/CS enzyme activity was lower in CR vs. AL male quadriceps (35%), despite a 2.3-fold higher COX-IV/CS protein content. UCP3 was higher in CR vs. AL females only. MnSOD and Cu/Zn-SOD were higher in CR vs. AL mice and CR vs. AL females. MDA was higher (83%) in CR vs. AL red gastrocnemius. Conversely, PC was lower in CR vs. AL red (62%) and white (30%) gastrocnemius. TNF-alpha was higher (52%) in CR vs. AL mice and Hsp70 was lower (62%) in CR vs. AL quadriceps. Bax was higher in CR vs. AL mice (41%) and CR vs. AL females (52%). Catalase, Bcl-2 and caspases did not differ. We conclude that CR increases lipid peroxidation, inflammation and apoptosis, while decreasing mitochondrial bioenergetic efficiency, protein oxidation and stress response in G93A mice.	[Patel, Barkha P.; Hamadeh, Mazen J.] York Univ, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada; [Patel, Barkha P.; Hamadeh, Mazen J.] York Univ, Muscle Hlth Res Ctr, Toronto, ON M3J 2R7, Canada; [Safdar, Adeel; Raha, Sandeep; Tarnopolsky, Mark A.; Hamadeh, Mazen J.] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Safdar, Adeel; Tarnopolsky, Mark A.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Safdar, Adeel] McMaster Univ, Dept Kinesiol, Hamilton, ON, Canada	York University - Canada; York University - Canada; McMaster University; McMaster University; McMaster University	Patel, BP (corresponding author), York Univ, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada.	hamadeh@yorku.ca	Patel, Barkha/AAJ-2355-2020; Raha, Sandeep/AAF-3655-2020	Raha, Sandeep/0000-0001-7307-3292; Safdar, Adeel/0000-0003-2469-0467; Hamadeh, Mazen/0000-0002-3511-4345; Safdar, Adeel/0000-0002-7453-7770	Hamilton Health Sciences; Hamilton Health Sciences Foundation New Investigator Fund; National Sciences and Engineering Research Council of Canada; York University-Faculty of Health; Hamilton Health Sciences Foundation William E. Noonan Research Career Award; Canadian Institute of Health Research - Institute of Aging Doctoral Research Award	Hamilton Health Sciences; Hamilton Health Sciences Foundation New Investigator Fund; National Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); York University-Faculty of Health; Hamilton Health Sciences Foundation William E. Noonan Research Career Award; Canadian Institute of Health Research - Institute of Aging Doctoral Research Award(Canadian Institutes of Health Research (CIHR))	This research was funded by Hamilton Health Sciences, Hamilton Health Sciences Foundation New Investigator Fund, the National Sciences and Engineering Research Council of Canada (http://www.nserc-crsng.gc.ca/) and York University-Faculty of Health. M. J. Hamadeh was recipient of the Hamilton Health Sciences Foundation William E. Noonan Research Career Award. A. Safdar was recipient of the Canadian Institute of Health Research - Institute of Aging Doctoral Research Award (http://www.cihr.ca). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AEBI H, 1984, METHOD ENZYMOL, V105, P121; Alexianu ME, 2001, NEUROLOGY, V57, P1282, DOI 10.1212/WNL.57.7.1282; Ando K, 2002, MICROSC RES TECHNIQ, V59, P293, DOI 10.1002/jemt.10207; Andrews ZB, 2005, NAT REV NEUROSCI, V6, P829, DOI 10.1038/nrn1767; Andrus PK, 1998, J NEUROCHEM, V71, P2041; Barber SC, 2006, BBA-MOL BASIS DIS, V1762, P1051, DOI 10.1016/j.bbadis.2006.03.008; BARJA G, 1994, COMP BIOCHEM PHYS B, V108, P501, DOI 10.1016/0305-0491(94)90103-1; Bartlett JB, 2004, NAT REV CANCER, V4, P314, DOI 10.1038/nrc1323; Batulan Z, 2003, J NEUROSCI, V23, P5789; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; BEHRENS WA, 1977, J BIOENERG BIOMEMBR, V9, P41, DOI 10.1007/BF00745042; Bevilacqua L, 2005, AM J PHYSIOL-ENDOC M, V289, pE429, DOI 10.1152/ajpendo.00435.2004; Bogdanov MB, 1998, J NEUROCHEM, V71, P1321; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Chen S, 2007, CELL STRESS CHAPERON, V12, P51, DOI 10.1379/CSC-236R.1; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; Corral LG, 1999, ANN RHEUM DIS, V58, P107, DOI 10.1136/ard.58.2008.i107; DAVIS LJ, 1993, MECH AGEING DEV, V72, P155, DOI 10.1016/0047-6374(93)90097-B; Desport JC, 1999, NEUROLOGY, V53, P1059, DOI 10.1212/WNL.53.5.1059; Dirks AJ, 2004, FREE RADICAL BIO MED, V36, P27, DOI 10.1016/j.freeradbiomed.2003.10.003; Dirks AJ, 2006, J NUTR BIOCHEM, V17, P501, DOI 10.1016/j.jnutbio.2005.11.002; Dupuis L, 2003, FASEB J, V17, P2091, DOI 10.1096/fj.02-1182fje; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Fergani A, 2007, J LIPID RES, V48, P1571, DOI 10.1194/jlr.M700017-JLR200; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gianni P, 2004, EXP GERONTOL, V39, P1391, DOI 10.1016/j.exger.2004.06.002; Gifondorwa DJ, 2007, J NEUROSCI, V27, P13173, DOI 10.1523/JNEUROSCI.4057-07.2007; Goodall Emily F., 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406010854; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; Gredilla R, 2001, J BIOENERG BIOMEMBR, V33, P279, DOI 10.1023/A:1010603206190; Gruber J, 2008, FRONT BIOSCI-LANDMRK, V13, P6554, DOI 10.2741/3174; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Gursoy E, 2001, EXP BIOL MED, V226, P97, DOI 10.1177/153537020122600206; Hall ED, 1998, GLIA, V23, P249, DOI 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#; Hamadeh MJ, 2006, MUSCLE NERVE, V34, P709, DOI 10.1002/mus.20630; Hamadeh MJ, 2005, MUSCLE NERVE, V31, P214, DOI 10.1002/mus.20255; HAMADEH MJ, 2005, ANN NUTR METAB S1, V49, P164; HAVERKAMP LJ, 1995, BRAIN, V118, P707, DOI 10.1093/brain/118.3.707; Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968; Hensley K, 2003, NEUROBIOL DIS, V14, P74, DOI 10.1016/S0969-9961(03)00087-1; Higami Y, 2003, FASEB J, V17, P415, DOI 10.1096/fj.03-0678fje; HILL JO, 1986, J NUTR, V116, P2000, DOI 10.1093/jn/116.10.2000; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Joseph AM, 2004, AM J PHYSIOL-CELL PH, V286, pC867, DOI 10.1152/ajpcell.00191.2003; Judge S, 2004, AM J PHYSIOL-REG I, V286, pR254, DOI 10.1152/ajpregu.00502.2003; Kalain R, 2006, J GERONTOL A-BIOL, V61, P211, DOI 10.1093/gerona/61.3.211; Kasarskis EJ, 1996, AM J CLIN NUTR, V63, P130, DOI 10.1093/ajcn/63.1.130; Kiaei M, 2006, J NEUROSCI, V26, P2467, DOI 10.1523/JNEUROSCI.5253-05.2006; Kim JD, 1996, FREE RADICAL BIO MED, V20, P83, DOI 10.1016/0891-5849(95)02023-3; KOIZUMI A, 1987, J NUTR, V117, P361, DOI 10.1093/jn/117.2.361; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Lee CK, 2004, FREE RADICAL BIO MED, V36, P1043, DOI 10.1016/j.freeradbiomed.2004.01.015; Lee JH, 2004, EXP GERONTOL, V39, P1361, DOI 10.1016/j.exger.2004.06.015; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Mahoney DJ, 2006, MUSCLE NERVE, V33, P809, DOI 10.1002/mus.20542; Mair W, 2003, SCIENCE, V301, P1731, DOI 10.1126/science.1086016; Mattson MP, 2007, NEUROMOL MED, V9, P17, DOI 10.1385/NMM:9:1:17; Mhatre M, 2004, J ALZHEIMERS DIS, V6, P147; Minamiyama Y, 2007, J PHARMACOL EXP THER, V320, P535, DOI 10.1124/jpet.106.110460; Mittendorfer B, 2001, AM J PHYSIOL-ENDOC M, V281, pE1333, DOI 10.1152/ajpendo.2001.281.6.E1333; Moien-Afshari F, 2008, DIABETOLOGIA, V51, P1327, DOI 10.1007/s00125-008-0996-x; Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; Phillips T, 2005, FASEB J, V19, P668, DOI 10.1096/fj.04-2870fje; Pollack M, 2002, ANN NY ACAD SCI, V959, P93, DOI 10.1111/j.1749-6632.2002.tb02086.x; Ramsey JJ, 2000, FREE RADICAL BIO MED, V29, P946, DOI 10.1016/S0891-5849(00)00417-2; Roy J, 1998, J NEUROSCI, V18, P9673; Sango K, 1996, NAT GENET, V14, P348, DOI 10.1038/ng1196-348; Sato A, 1998, BIOL PHARM BULL, V21, P1271, DOI 10.1248/bpb.21.1271; Selman C, 2003, EXP GERONTOL, V38, P897, DOI 10.1016/S0531-5565(03)00091-3; Selsby JT, 2005, EXP GERONTOL, V40, P37, DOI 10.1016/j.exger.2004.08.012; Sen CK, 1997, J APPL PHYSIOL, V83, P189, DOI 10.1152/jappl.1997.83.1.189; Seng JE, 2003, TOXICOL APPL PHARM, V193, P281, DOI 10.1016/j.taap.2003.07.008; Shelke RRJ, 2003, FASEB J, V17, P494, DOI 10.1096/fj.02-0803fje; Simpson EP, 2003, CURR OPIN RHEUMATOL, V15, P730, DOI 10.1097/00002281-200311000-00008; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Siu PM, 2004, FASEB J, V18, P1150, DOI 10.1096/fj.03-1291fje; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; SLOWIE LA, 1983, J AM DIET ASSOC, V83, P44; Stein O, 2003, BIOCHEM BIOPH RES CO, V308, P29, DOI 10.1016/S0006-291X(03)01313-5; Valle A, 2007, AM J PHYSIOL-CELL PH, V293, pC1302, DOI 10.1152/ajpcell.00203.2007; Vina J, 2003, ANTIOXID REDOX SIGN, V5, P549, DOI 10.1089/152308603770310194; Vukosavic S, 1999, J NEUROCHEM, V73, P2460, DOI 10.1046/j.1471-4159.1999.0732460.x; Weydt P, 2003, NEUROREPORT, V14, P1051, DOI 10.1097/01.wnr.0000073685.00308.89; Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025; Wu AG, 2003, NEUROSCI LETT, V339, P166, DOI 10.1016/S0304-3940(03)00008-9; Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007	95	54	55	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 24	2010	5	2							e9386	10.1371/journal.pone.0009386	http://dx.doi.org/10.1371/journal.pone.0009386			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	560SX	20195368	Green Submitted, gold, Green Published			2023-01-03	WOS:000274924200013
J	Foy, R; Hempel, S; Rubenstein, L; Suttorp, M; Seelig, M; Shanman, R; Shekelle, PG				Foy, Robbie; Hempel, Susanne; Rubenstein, Lisa; Suttorp, Marika; Seelig, Michelle; Shanman, Roberta; Shekelle, Paul G.			Meta-analysis: Effect of Interactive Communication Between Collaborating Primary Care Physicians and Specialists	ANNALS OF INTERNAL MEDICINE			English	Review							DISEASE MANAGEMENT PROGRAM; MENTAL-HEALTH-SERVICES; RANDOMIZED-TRIAL; PSYCHIATRIC-CONSULTATION; GENERAL-PRACTITIONERS; QUALITY IMPROVEMENT; LIAISON PSYCHIATRY; DIABETES CARE; SHARED CARE; DEPRESSION	Background: Whether collaborative care models that enable interactive communication (timely, 2-way exchange of pertinent clinical information directly between primary care and specialist physicians) improve patient outcomes is uncertain. Purpose: To assess the effects of interactive communication between collaborating primary care physicians and key specialists on outcomes for patients receiving ambulatory care. Data Sources: PubMed, PsycInfo, EMBASE, CINAHL, Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, and Web of Science through June 2008 and secondary references, with no language restriction. Study Selection: Studies that evaluated the effects of interactive communication between collaborating primary care physicians and specialists on outcomes for patients with diabetes, psychiatric conditions, or cancer. Data Extraction: Contextual, intervention, and outcome data from 23 studies were extracted by one reviewer and checked by another. Study quality was assessed with a 13-item checklist. Disagreement was resolved by consensus. Main outcomes for analysis were selected by reviewers who were blinded to study results. Data Synthesis: Meta-analysis indicated consistent effects across 11 randomized mental health studies (pooled effect size, -0.41 [95% CI, -0.73 to -0.10]), 7 nonrandomized mental health studies (pooled effect size, -0.47 [CI, -0.84 to -0.09]), and 5 nonrandomized diabetes studies (pooled effect size, -0.64 [CI, -0.93 to -0.34]). These findings remained robust to sensitivity analyses. Meta-regression indicated studies that included interventions to enhance the quality of information exchange had larger effects on patient outcomes than those that did not (-0.84 vs. -0.27; P = 0.002). Limitations: Because collaborative interventions were inherently multifaceted, the efficacy of interactive communication by itself cannot be established. Inclusion of study designs with lower internal validity increased risk for bias. No studies involved oncologists. Conclusion: Consistent and clinically important effects suggest a potential role of interactive communication for improving the effectiveness of primary care-specialist collaboration.	[Foy, Robbie] Univ Leeds, Leeds Inst Hlth Sci, Leeds LS2 9LJ, W Yorkshire, England; RAND Hlth Div, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Grp Hlth Cooperat Puget Sound, Seattle, WA USA	University of Leeds; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Group Health Cooperative	Foy, R (corresponding author), Univ Leeds, Leeds Inst Hlth Sci, Charles Thackrah Bldg,101 Clarendon Rd, Leeds LS2 9LJ, W Yorkshire, England.	r.foy@leeds.ac.uk		Foy, Robbie/0000-0003-0605-7713; Hempel, Susanne/0000-0003-1597-5110	RAND Health's Comprehensive Assessment of Reform Options Initiative; Veterans Affairs Center for the Study of Provider Behavior; Commonwealth Fund; Health Foundation	RAND Health's Comprehensive Assessment of Reform Options Initiative; Veterans Affairs Center for the Study of Provider Behavior; Commonwealth Fund; Health Foundation	RAND Health's Comprehensive Assessment of Reform Options Initiative, the Veterans Affairs Center for the Study of Provider Behavior, The Commonwealth Fund, and the Health Foundation.	Abrahamian H, 2002, J TELEMED TELECARE, V8, P350, DOI 10.1258/135763302320939248; Atlas SJ, 2009, ANN INTERN MED, V150, P325, DOI 10.7326/0003-4819-150-5-200903030-00008; BARR M, 2006, ADV MED HOME PATIENT; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Berendsen AJ, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-4; BERKEY CS, 1995, STAT MED, V14, P395, DOI 10.1002/sim.4780140406; Bodlund O, 1999, SCAND J PRIM HEALTH, V17, P153; Boon H, 2004, BMC HEALTH SERV RES, V4, DOI 10.1186/1472-6963-4-15; Bower P, 2005, BRIT J PSYCHIAT, V186, P11, DOI 10.1192/bjp.186.1.11; Bower P, 2005, BRIT MED J, V330, P839, DOI 10.1136/bmj.330.7495.839; Bower P, 2006, BRIT J PSYCHIAT, V189, P484, DOI 10.1192/bjp.bp.106.023655; Campbell MK, 2001, STAT MED, V20, P391, DOI 10.1002/1097-0258(20010215)20:3<391::AID-SIM800>3.0.CO;2-Z; Carr VJ, 1997, AUST NZ J PSYCHIAT, V31, P714; Chan AW, 2008, PLOS MED, V5, P1533, DOI 10.1371/journal.pmed.0050230; Chelminski PR, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-3; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Christensen H, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-25; Cochrane Effective Practice and Organisation of Care Review Group, 2002, DAT COLL CHECKL; Cohen J., 2013, STAT POWER ANAL BEHA; Craven MA, 2006, CAN J PSYCHIAT, V51, p7S; Datto CJ, 2003, GEN HOSP PSYCHIAT, V25, P169, DOI 10.1016/S0163-8343(03)00019-7; DATTO CJ, 2003, J CLIN OUTCOMES MANA, V10, P79; Davidoff F, 2005, QUAL SAF HEALTH CARE, V14, P319, DOI 10.1136/qshc.2005.014787; Davidson KW, 2003, ANN BEHAV MED, V26, P161, DOI 10.1207/S15324796ABM2603_01; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dietrich AJ, 2004, BMJ-BRIT MED J, V329, P602, DOI 10.1136/bmj.38219.481250.55; Dietrich AJ, 2003, J AM BOARD FAM PRACT, V16, P107, DOI 10.3122/jabfm.16.2.107; Donner A, 2002, STAT MED, V21, P2971, DOI 10.1002/sim.1301; Doze S, 1999, J TELEMED TELECARE, V5, P38, DOI 10.1258/1357633991932379; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FELKER B, 1998, MED PSYCHIAT, V1, P36; Felker BL, 2004, PSYCHIAT SERV, V55, P442, DOI 10.1176/appi.ps.55.4.442; FERGUSON B, 1992, BRIT J PSYCHIAT, V160, P493, DOI 10.1192/bjp.160.4.493; Fisher ES, 2008, NEW ENGL J MED, V359, P1202, DOI 10.1056/NEJMp0806233; Forrest CB, 2003, BRIT MED J, V326, P692, DOI 10.1136/bmj.326.7391.692; Fraser Cynthia, 2006, BMC Med Res Methodol, V6, P41, DOI 10.1186/1471-2288-6-41; Furukawa TA, 2006, J CLIN EPIDEMIOL, V59, P7, DOI 10.1016/j.jclinepi.2005.06.006; Gilbody S, 2003, JAMA-J AM MED ASSOC, V289, P3145, DOI 10.1001/jama.289.23.3145; Gittell JH, 2000, MED CARE, V38, P807, DOI 10.1097/00005650-200008000-00005; Goodman DC, 2008, JAMA-J AM MED ASSOC, V299, P335, DOI 10.1001/jama.299.3.335; Green LW, 2006, EVAL HEALTH PROF, V29, P126, DOI 10.1177/0163278705284445; Grimshaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8060; Gunn J, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-88; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Harris S, 2008, CAN FAM PHYSICIAN, V54, P550; Hedrick SC, 2003, J GEN INTERN MED, V18, P9, DOI 10.1046/j.1525-1497.2003.11109.x; HICKMAN M, 1994, J PUBLIC HEALTH MED, V16, P447, DOI 10.1093/oxfordjournals.pubmed.a043026; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hilty Donald M, 2007, Psychiatry (Edgmont), V4, P58; Hulscher MEJL, 2003, QUAL SAF HEALTH CARE, V12, P40, DOI 10.1136/qhc.12.1.40; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Ioannidis JPA, 2008, BMJ-BRIT MED J, V336, P1413, DOI 10.1136/bmj.a117; JACKSON G, 1993, BRIT J PSYCHIAT, V162, P375, DOI 10.1192/bjp.162.3.375; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kates N, 1997, GEN HOSP PSYCHIAT, V19, P324, DOI 10.1016/S0163-8343(97)00051-0; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P86, DOI 10.1016/0163-8343(92)90033-7; Katon W, 2002, J GEN INTERN MED, V17, P741, DOI 10.1046/j.1525-1497.2002.11051.x; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Katon WJ, 2004, ARCH GEN PSYCHIAT, V61, P1042, DOI 10.1001/archpsyc.61.10.1042; Katzelnick DJ, 2000, ARCH FAM MED, V9, P345, DOI 10.1001/archfami.9.4.345; Kennedy C, 2003, J TELEMED TELECARE, V9, P12, DOI 10.1258/135763303321159639; Kerry SM, 1998, BRIT MED J, V316, P1455, DOI 10.1136/bmj.316.7142.1455; King EB, 2006, DIABETES EDUCATOR, V32, P723, DOI 10.1177/0145721706292599; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; KISKER CT, 1980, PEDIATRICS, V66, P900; LONGEST BB, 1999, HLTH CARE MANAGEMENT, P210; Macinko J, 2007, INT J HEALTH SERV, V37, P111, DOI 10.2190/3431-G6T7-37M8-P224; Maislos M, 2002, ACTA DIABETOL, V39, P49, DOI 10.1007/s005920200012; McCulloch D K, 1998, Eff Clin Pract, V1, P12; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; McKechnie A A, 1981, J R Coll Gen Pract, V31, P611; MOODY G, 2008, STATES ACTION BIMONT, P13; Pham HH, 2009, ANN INTERN MED, V150, P236, DOI 10.7326/0003-4819-150-4-200902170-00004; Pincus HA, 2001, GEN HOSP PSYCHIAT, V23, P311, DOI 10.1016/S0163-8343(01)00165-7; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; SHADISH WRJ, 2002, STAT CONCLUSION VALI, P33; Sharma VK, 2001, INT J SOC PSYCHIATR, V47, P16, DOI 10.1177/002076400104700402; Shekelle P.G., 2006, EVID REP TECHNOL ASS, V132, P1, DOI DOI 10.23970/ahrqepcerta132; Simmons D, 2003, INTERN MED J, V33, P581, DOI 10.1111/j.1445-5994.2003.00491.x; Smit A, 2005, PRIMARY CARE COMMUN, V10, P39, DOI 10.1185/135525705X40382; Smith SM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004910.pub2; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Sutor Bruce, 2007, Minn Med, V90, P39; Sutton A.J., 2000, METHODS METAANALYSIS; THORN PA, 1973, BRIT MED J, V2, P534, DOI 10.1136/bmj.2.5865.534; Turner Erick H, 2008, N Engl J Med, V358, P252, DOI 10.1056/NEJMsa065779; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; TYRER P, 1990, ACTA PSYCHIAT SCAND, V81, P359, DOI 10.1111/j.1600-0447.1990.tb05464.x; Unutzer J, 2002, JAMA-J AM MED ASSOC, V288, P2836, DOI 10.1001/jama.288.22.2836; van der Feltz-Cornelis CM, 2006, PSYCHOTHER PSYCHOSOM, V75, P282, DOI 10.1159/000093949; Wagner E H, 1998, Eff Clin Pract, V1, P2; WELCH WP, 1993, NEW ENGL J MED, V328, P621, DOI 10.1056/NEJM199303043280906; WOOD K, 1995, AUST NZ J PSYCHIAT, V29, P223, DOI 10.3109/00048679509075914; Worrall G, 1999, CAN MED ASSOC J, V161, P37; YANO EM, 1995, ARCH INTERN MED, V155, P1146, DOI 10.1001/archinte.155.11.1146; Younes N, 2008, SOC PSYCH PSYCH EPID, V43, P113, DOI 10.1007/s00127-007-0285-x	97	109	114	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 16	2010	152	4					247	U95		10.7326/0003-4819-152-4-201002160-00010	http://dx.doi.org/10.7326/0003-4819-152-4-201002160-00010			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	560AF	20157139				2023-01-03	WOS:000274873300007
J	Janes, MR; Limon, JJ; So, LM; Chen, J; Lim, RJ; Chavez, MA; Vu, C; Lilly, MB; Mallya, S; Ong, ST; Konopleva, M; Martin, MB; Ren, PD; Liu, Y; Rommel, C; Fruman, DA				Janes, Matthew R.; Limon, Jose J.; So, Lomon; Chen, Jing; Lim, Raymond J.; Chavez, Melissa A.; Vu, Collin; Lilly, Michael B.; Mallya, Sharmila; Ong, S. Tiong; Konopleva, Marina; Martin, Michael B.; Ren, Pingda; Liu, Yi; Rommel, Christian; Fruman, David A.			Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor	NATURE MEDICINE			English	Article							MAMMALIAN TARGET; PHILADELPHIA-CHROMOSOME; RAPAMYCIN; MTOR; ACTIVATION; TYROSINE; 3-KINASE; PATHWAY; COMPLEX; PI3K	Targeting the mammalian target of rapamycin (mTOR) protein is a promising strategy for cancer therapy. The mTOR kinase functions in two complexes, TORC1 (target of rapamycin complex-1) and TORC2 (target of rapamycin complex-2); however, neither of these complexes is fully inhibited by the allosteric inhibitor rapamycin or its analogs. We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation. We demonstrate that PP242, but not rapamycin, causes death of mouse and human leukemia cells. In vivo, PP242 delays leukemia onset and augments the effects of the current front-line tyrosine kinase inhibitors more effectively than does rapamycin. Unexpectedly, PP242 has much weaker effects than rapamycin on the proliferation and function of normal lymphocytes. PI-103, a less selective TORC1/2 inhibitor that also targets phosphoinositide 3-kinase (PI3K), is more immunosuppressive than PP242. These findings establish that Ph+ transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.	[Janes, Matthew R.; Limon, Jose J.; So, Lomon; Chen, Jing; Lim, Raymond J.; Chavez, Melissa A.; Fruman, David A.] Univ Calif Irvine, Inst Immunol, Irvine, CA 92717 USA; [Janes, Matthew R.; Limon, Jose J.; So, Lomon; Chen, Jing; Lim, Raymond J.; Chavez, Melissa A.; Fruman, David A.] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA; [Vu, Collin; Lilly, Michael B.; Mallya, Sharmila] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92717 USA; [Ong, S. Tiong] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore; [Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Stem Cell Transplantat, Houston, TX 77030 USA; [Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Dept Cellular Therapy, Houston, TX 77030 USA; [Martin, Michael B.; Ren, Pingda; Liu, Yi; Rommel, Christian] Intellikine Inc, La Jolla, CA USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; National University of Singapore; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fruman, DA (corresponding author), Univ Calif Irvine, Inst Immunol, Irvine, CA 92717 USA.	dfruman@uci.edu		Ong, S. Tiong/0000-0001-9460-3483	University of California Irvine [CA-62203, GM-076516]; US National Institutes of Health [T32-CA009054, T34GM069337]; University of California Industry-University Cooperative Research Program; Chao Family Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [T32CA009054, P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM076516, R25GM055246, T34GM069337] Funding Source: NIH RePORTER	University of California Irvine(University of California System); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of California Industry-University Cooperative Research Program(University of California System); Chao Family Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank K. Shokat, T. Wilson, and M. Kharas for support and helpful discussions and R. Nguyen for constructing BCR-ABL mutants. For access to the LSM710 Zeiss confocal microscope we thank E. Gratton's laboratory in the Department of Biomedical Engineering, University of California-Irvine. The SUP-B15 cells stably expressing firefly luciferase (SUP-B15<SUP>ffLuc</SUP>) were a kind gift from M. Jensen ( City of Hope). Technical assistance was provided through the Optical Biology Core facility of the Developmental Biology Center, a shared resource supported in part by the Cancer Center Support Grant (CA-62203) and the Center for Complex Biological Systems Support Grant (GM-076516) at the University of California Irvine. The Lumina IVIS bioluminescent imager was supported by a grant to the University of California-Irvine from the California Institute of Regenerative Medicine. This work was supported by US National Institutes of Health training grant T32-CA009054 ( to M.R.J.), National Institutes of Health Minority Access to Research Careers grant T34GM069337 ( to M. A. C.), a Research Scholar Grant from the American Cancer Society ( to D. A. F.), a Discovery Grant from the University of California Industry-University Cooperative Research Program ( to D. A. F.), a sponsored research agreement from Intellikine, Inc. ( to D. A. F.) and a Bridge award from the Chao Family Comprehensive Cancer Center. M.R.J. is an awardee of the Jackie Murphy and Carol Malouf Scholar Achievement Rewards for College Scientists.	Abraham RT, 2008, EXPERT OPIN THER TAR, V12, P209, DOI [10.1517/14728222.12.2.209, 10.1517/14728222.12.2.209 ]; Abraham Robert T, 2009, F1000 Biol Rep, V1, P8, DOI 10.3410/B1-8; Apsel B, 2008, NAT CHEM BIOL, V4, P691, DOI 10.1038/nchembio.117; Burgess MR, 2006, THESCIENTIFICWORLDJO, V6, P918, DOI 10.1100/tsw.2006.184; Chiarini F, 2009, CANCER RES, V69, P3520, DOI 10.1158/0008-5472.CAN-08-4884; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Durand CA, 2009, J IMMUNOL, V183, P5673, DOI 10.4049/jimmunol.0900432; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Foa R, 2008, BLOOD, V112, P119; Fruman DA, 2009, IMMUNOL REV, V228, P253, DOI 10.1111/j.1600-065X.2008.00750.x; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gruber F, 2009, BRIT J HAEMATOL, V145, P581, DOI 10.1111/j.1365-2141.2009.07666.x; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Guertin DA, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe24; Hedrick SM, 2009, NAT IMMUNOL, V10, P1057, DOI 10.1038/ni.1784; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Janes MR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe25; Kennedy JA, 2008, LEUKEMIA, V22, P2029, DOI 10.1038/leu.2008.206; Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337; Kojima K, 2008, LEUKEMIA, V22, P1728, DOI 10.1038/leu.2008.158; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; LOPEZFAUQUED M, INT J CANCER, DOI DOI 10.1002/IJC.24926; Luo FR, 2006, CLIN CANCER RES, V12, P7180, DOI 10.1158/1078-0432.CCR-06-1112; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Martelli AM, 2005, HISTOL HISTOPATHOL, V20, P239, DOI 10.14670/HH-20.239; McCubrey JA, 2008, LEUKEMIA, V22, P708, DOI 10.1038/leu.2008.27; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Park S, 2008, LEUKEMIA, V22, P1698, DOI 10.1038/leu.2008.144; Prabhu S, 2007, ONCOGENE, V26, P1188, DOI 10.1038/sj.onc.1209901; Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615; Samuels Y, 2006, CURR OPIN ONCOL, V18, P77, DOI 10.1097/01.cco.0000198021.99347.b9; Sankhala K, 2009, TARGET ONCOL, V4, P135, DOI 10.1007/s11523-009-0107-z; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; Shor B, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-28; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Thomson AW, 2009, NAT REV IMMUNOL, V9, P324, DOI 10.1038/nri2546; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Zhang M, 2008, MOL CELL BIOL, V28, P6496, DOI 10.1128/MCB.00477-08	49	289	344	0	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	FEB	2010	16	2					205	U115		10.1038/nm.2091	http://dx.doi.org/10.1038/nm.2091			10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	552MZ	20072130	Green Accepted			2023-01-03	WOS:000274297000042
J	Jha, AK; Orav, EJ; Epstein, AM				Jha, Ashish K.; Orav, E. John; Epstein, Arnold M.			Public Reporting of Discharge Planning and Rates of Readmissions	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGESTIVE-HEART-FAILURE; QUALITY-OF-CARE; MEDICARE BENEFICIARIES; RANDOMIZED-TRIALS; MORTALITY-RATES; UNITED-STATES; PERFORMANCE; SYSTEM	BACKGROUND A reduction in hospital readmissions may improve quality and reduce costs. The Centers for Medicare and Medicaid Services has initiated a national effort to measure and publicly report on the conduct of discharge planning. We know little about how U. S. hospitals perform on the current discharge metrics, the factors that underlie better performance, and whether better performance is related to lower readmission rates. METHODS We examined hospital performance on the basis of two measures of discharge planning: the adequacy of documentation in the chart that discharge instructions were provided to patients with congestive heart failure, and patient-reported experiences with discharge planning. We examined the association between performance on these measures and rates of readmission for congestive heart failure and pneumonia. RESULTS We found a weak correlation in performance between the two discharge measures (r = 0.05, P<0.001). Although larger hospitals performed better on the chart-based measure, smaller hospitals and those with higher nurse-staffing levels performed better on the patient-reported measure. We found no association between performance on the chart-based measure and readmission rates among patients with congestive heart failure ( readmission rates among hospitals performing in the highest quartile vs. the lowest quartile, 23.7% vs. 23.5%; P = 0.54) and only a very modest association between performance on the patient-reported measure and readmission rates for congestive heart failure ( readmission rates among hospitals performing in the highest quartile vs. the lowest quartile, 22.4% vs. 24.7%; P<0.001) and pneumonia (17.5% vs. 19.5%, P<0.001). CONCLUSIONS Our findings suggest that current efforts to collect and publicly report data on discharge planning are unlikely to yield large reductions in unnecessary readmissions.	[Jha, Ashish K.; Orav, E. John; Epstein, Arnold M.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Jha, Ashish K.; Orav, E. John; Epstein, Arnold M.] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Jha, Ashish K.] Vet Affairs Boston Healthcare Syst, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Jha, AK (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	ajha@hsph.harvard.edu			Commonwealth Fund	Commonwealth Fund	Supported by the Commonwealth Fund.	[Anonymous], 2007, MPA COMMITTEE REPORT; Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Epstein AM, 2009, NEW ENGL J MED, V360, P1457, DOI 10.1056/NEJMe0901006; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jha AK, 2008, NEW ENGL J MED, V359, P1921, DOI 10.1056/NEJMsa0804116; Jha AK, 2007, HEALTH AFFAIR, V26, P1104, DOI 10.1377/hlthaff.26.4.1104; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; McAlister FA, 2001, AM J MED, V110, P378, DOI 10.1016/S0002-9343(00)00743-9; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; *QUALITYNET, 2009, SPEC MAN NAT HOSP IN; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; Schoen C, 2006, HEALTH AFFAIR, V25, pW457, DOI 10.1377/hlthaff.25.w457; Wennberg JE, 1998, DARTMOUTH ATLAS HLTH	19	185	186	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	2009	361	27					2637	2645		10.1056/NEJMsa0904859	http://dx.doi.org/10.1056/NEJMsa0904859			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538JV	20042755	Bronze			2023-01-03	WOS:000273181300011
J	Rawlins, L; Woollard, M; Williams, J; Hallam, P				Rawlins, L.; Woollard, M.; Williams, J.; Hallam, P.			CHRISTMAS 2009: MUSIC Effect of listening to Nellie the Elephant during CPR training on performance of chest compressions by lay people: randomised crossover trial	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HOSPITAL CARDIAC-ARREST; CARDIOPULMONARY-RESUSCITATION; SKILLS; RETENTION; RATES	Objectives To determine whether listening to music during cardiopulmonary resuscitation (CPR) training increases the proportion of lay people delivering chest compressions of 100 per minute. Design Prospective randomised crossover trial. Setting Large UK university. Participants 130 volunteers (81 men) recruited on an opportunistic basis. Exclusion criteria included age under 18, trained health professionals, and cardiopulmonary resuscitation (CPR) training within the past three months. Interventions Volunteers performed three sequences of one minute of continuous chest compressions on a skill meter resuscitation manikin accompanied by no music, repeated choruses of Nellie the Elephant (Nellie), and That's the Way (I like it) (TTW) according to a pre-randomised order. Main outcome measures Rate of chest compressions delivered (primary outcome), depth of compressions, proportion of incorrect compressions, and type of error. Results Median (interquartile range) compression rates were 110 (93-119) with no music, 105 (98-107) with Nellie, and 109 (103-110) with TTW. There were significant differences within groups between Nellie v no music and Nellie v TTW (P<0.001) but not no music v TTW (P=0.055). A compression rate of between 95 and 105 was achieved with no music, Nellie, and TTW for 15/130 (12%), 42/130 (32%), and 12/130 (9%) attempts, respectively. Differences in proportions were significant for Nellie v no music and Nellie v TTW (P<0.001) but not for no music v TTW (P=0.55). Relative risk for a compression rate between 95 and 105 was 2.8 (95% confidence interval 1.66 to 4.80) for Nellie v no music, 0.8 (0.40 to 1.62) for TTW v no music, and 3.5 (1.97 to 6.33) for Nellie v TTW. The number needed to treat for listening to Nellie v no music was 5 (4 to 10)-that is, the number of cardiac arrests required during which lay responders listen to Nellie to facilitate one patient receiving compressions at the correct rate (v no music) would be between four and 10. A greater proportion of compressions were too shallow when participants listened to Nellie v no music (56% v 47%, P=0.022). Conclusions Listening to Nellie the Elephant significantly increased the proportion of lay people delivering compression rates at close to 100 per minute. Unfortunately it also increased the proportion of compressions delivered at an inadequate depth. As current resuscitation guidelines give equal emphasis to correct rate and depth, listening to Nellie the Elephant as a learning aid during CPR training should be discontinued. Further research is required to identify music that, when played during CPR training, increases the proportion of lay responders providing chest compressions at both the correct rate and depth.	[Woollard, M.] Coventry Univ, Prehosp Emergency & Cardiovasc Care Appl Res Grp, Coventry CV1 5FB, W Midlands, England; [Rawlins, L.] Univ Birmingham, Sch Med, Birmingham B15 2TT, W Midlands, England; [Williams, J.] Univ Hertfordshire, Sch Hlth & Emergency Profess, Hatfield AL10 9AB, Herts, England; [Hallam, P.] W Midlands Ambulance Serv NHS Trust, Brierley Hill DY5 1LX, W Midlands, England	Coventry University; University of Birmingham; University of Hertfordshire	Woollard, M (corresponding author), Coventry Univ, Prehosp Emergency & Cardiovasc Care Appl Res Grp, Coventry CV1 5FB, W Midlands, England.	Malcolm.woollard@coventry.ac.uk	Williams, Julia/AAQ-8655-2021	Williams, Julia/0000-0003-0796-5465				BERDEN HJJM, 1994, ANN EMERG MED, V23, P1003, DOI 10.1016/S0196-0644(94)70094-X; Christenson J, 2007, RESUSCITATION, V74, P52, DOI 10.1016/j.resuscitation.2006.11.005; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; Eftestol T, 2002, CIRCULATION, V105, P2270, DOI 10.1161/01.CIR.0000016362.42586.FE; Handley JA, 1998, RESUSCITATION, V36, P3, DOI 10.1016/S0300-9572(97)00095-6; Int Liaison Comm Resuscitation, 2005, RESUSCITATION, V67, P181, DOI 10.1016/j.resuscitation.2005.09.010; LARSEN MP, 1993, ANN EMERG MED, V22, P1652, DOI 10.1016/S0196-0644(05)81302-2; Matlock D, 2008, ANN EMERG MED, V52, pS67, DOI 10.1016/j.annemergmed.2008.06.149; Mellor Ric, 2010, Int Emerg Nurs, V18, P61, DOI 10.1016/j.ienj.2009.08.003; MOSER DK, 1992, HEART LUNG, V21, P372; Norris RM, 2005, HEART, V91, P1537, DOI 10.1136/hrt.2004.057018; Resuscitation Council (UK), 2005, AD BAS LIF SUPP GUID; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737; Vaillancourt C, 2008, CAN J EMERG MED, V10, P51, DOI 10.1017/S1481803500010010; WILSON E, 1983, ANN EMERG MED, V12, P482, DOI 10.1016/S0196-0644(83)80643-X; Woollard M, 2004, RESUSCITATION, V60, P17, DOI 10.1016/j.resuscitation.2003.09.006; Woollard M, 2003, RESUSCITATION, V59, P123, DOI 10.1016/S0300-9572(03)00174-6; Woollard M, 2003, AMBULANCE UK, V18, P263	19	31	33	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 13	2009	339								b4707	10.1136/bmj.b4707	http://dx.doi.org/10.1136/bmj.b4707			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531VJ	20008376	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000272697900001
J	Jain, S; Kamimoto, L; Bramley, AM; Schmitz, AM; Benoit, SR; Louie, J; Sugerman, DE; Druckenmiller, JK; Ritger, KA; Chugh, R; Jasuja, S; Deutscher, M; Chen, S; Walker, JD; Duchin, JS; Lett, S; Soliva, S; Wells, EV; Swerdlow, D; Uyeki, TM; Fiore, AE; Olsen, SJ; Fry, AM; Bridges, CB; Finelli, L				Jain, Seema; Kamimoto, Laurie; Bramley, Anna M.; Schmitz, Ann M.; Benoit, Stephen R.; Louie, Janice; Sugerman, David E.; Druckenmiller, Jean K.; Ritger, Kathleen A.; Chugh, Rashmi; Jasuja, Supriya; Deutscher, Meredith; Chen, Sanny; Walker, John D.; Duchin, Jeffrey S.; Lett, Susan; Soliva, Susan; Wells, Eden V.; Swerdlow, David; Uyeki, Timothy M.; Fiore, Anthony E.; Olsen, Sonja J.; Fry, Alicia M.; Bridges, Carolyn B.; Finelli, Lyn		2009 Pandemic Influenza H1N1 Virus	Hospitalized Patients with 2009 H1N1 Influenza in the United States, April-June 2009.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANT-WOMEN; VIRUS-INFECTION; CHILDREN; COMPLICATIONS; SURVEILLANCE; ADMISSIONS; CALIFORNIA; MORTALITY; VACCINES; HUMANS	Background: During the spring of 2009, a pandemic influenza A (H1N1) virus emerged and spread globally. We describe the clinical characteristics of patients who were hospitalized with 2009 H1N1 influenza in the United States from April 2009 to mid-June 2009. Methods: Using medical charts, we collected data on 272 patients who were hospitalized for at least 24 hours for influenza-like illness and who tested positive for the 2009 H1N1 virus with the use of a real-time reverse-transcriptase-polymerase-chain-reaction assay. Results: Of the 272 patients we studied, 25% were admitted to an intensive care unit and 7% died. Forty-five percent of the patients were children under the age of 18 years, and 5% were 65 years of age or older. Seventy-three percent of the patients had at least one underlying medical condition; these conditions included asthma; diabetes; heart, lung, and neurologic diseases; and pregnancy. Of the 249 patients who underwent chest radiography on admission, 100 (40%) had findings consistent with pneumonia. Of the 268 patients for whom data were available regarding the use of antiviral drugs, such therapy was initiated in 200 patients (75%) at a median of 3 days after the onset of illness. Data suggest that the use of antiviral drugs was beneficial in hospitalized patients, especially when such therapy was initiated early. Conclusions: During the evaluation period, 2009 H1N1 influenza caused severe illness requiring hospitalization, including pneumonia and death. Nearly three quarters of the patients had one or more underlying medical conditions. Few severe illnesses were reported among persons 65 years of age or older. Patients seemed to benefit from antiviral therapy. N Engl J Med 2009;361:1935-44.	[Jain, Seema; Kamimoto, Laurie; Bramley, Anna M.; Sugerman, David E.; Uyeki, Timothy M.; Fiore, Anthony E.; Olsen, Sonja J.; Fry, Alicia M.; Bridges, Carolyn B.; Finelli, Lyn] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA; [Schmitz, Ann M.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Natl Ctr Zoonot Vector Borne & Enter Dis, Atlanta, GA 30333 USA; [Benoit, Stephen R.] Ctr Dis Control & Prevent, Div Emergency Preparedness & Response, Natl Ctr Publ Hlth Informat, Atlanta, GA 30333 USA; [Deutscher, Meredith; Chen, Sanny; Swerdlow, David] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30333 USA; [Deutscher, Meredith] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA; [Louie, Janice] Calif Dept Publ Hlth, Richmond, CA USA; [Swerdlow, David] San Diego Cty Hlth & Human Serv, San Diego, CA USA; [Druckenmiller, Jean K.] Wisconsin Div Publ Hlth, Madison, WI USA; [Ritger, Kathleen A.] Chicago Dept Publ Hlth, Chicago, IL USA; [Chugh, Rashmi] DuPage Cty Hlth Dept, Wheaton, IL USA; [Jasuja, Supriya] Cook Cty Dept Publ Hlth, Oak Pk, IL USA; [Chen, Sanny] Arizona Dept Publ Hlth, Phoenix, AZ USA; [Walker, John D.] Texas Dept State Hlth Serv, Austin, TX USA; [Duchin, Jeffrey S.] Publ Health Seattle & King Cty, Seattle, WA USA; [Lett, Susan; Soliva, Susan] Massachusetts Dept Hlth, Jamaica Plain, MA USA; [Wells, Eden V.] Michigan Dept Community Hlth, Lansing, MI USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; California Department of Public Health; Chicago Department of Public Health; Texas Department of State Health Services; MDHHS - Michigan Department of Health & Human Services	Jain, S (corresponding author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA.	bwc8@cdc.gov	Fiore, Anthony/AAO-8956-2020; Finelli, Lyn/AAK-2360-2020	Kainer, Marion/0000-0001-7678-8744; Cocoros, Noelle/0000-0001-7090-2761; Meites, Elissa/0000-0002-0077-2591; Read, Robert/0000-0002-4297-6728; Biggerstaff, Matthew/0000-0001-5108-8311	Influenza Division; Office of Workforce and Career Development	Influenza Division; Office of Workforce and Career Development(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Supported by the Influenza Division and Office of Workforce and Career Development at the CDC.	Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475; [Anonymous], UPD INT REC US ANT M; [Anonymous], MMWR MORB MORTAL WKL; [Anonymous], 2009, MMWR MORB MORTAL WKL, V58, P536; [Anonymous], 2009, HARRIET LANE HDB; CATE TR, 1977, J INFECT DIS, V136, pS518, DOI 10.1093/infdis/136.Supplement_3.S518; Centers for Disease Control and Prevention, FLUVIEW WEEKL INFL S; Cox NJ, 1999, LANCET, V354, P1277, DOI 10.1016/S0140-6736(99)01241-6; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; Dodds L, 2007, CAN MED ASSOC J, V176, P463, DOI 10.1503/cmaj.061435; DOLIN R, 1977, J INFECT DIS, V136, pS435, DOI 10.1093/infdis/136.Supplement_3.S435; Finelli L, 2008, PEDIATRICS, V122, P805, DOI 10.1542/peds.2008-1336; FREEMAN DW, 1959, AM J OBSTET GYNECOL, V78, P1172, DOI 10.1016/0002-9378(59)90570-8; Garten RJ, 2009, SCIENCE, V325, P197, DOI 10.1126/science.1176225; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Hanshaoworakul W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006051; Harper SA, 2009, CLIN INFECT DIS, V48, P1003, DOI 10.1086/598513; Harris JW, 1919, J AMER MED ASSOC, V72, P978, DOI 10.1001/jama.1919.02610140008002; Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0; Keren R, 2005, JAMA-J AM MED ASSOC, V294, P2188, DOI 10.1001/jama.294.17.2188; LOURIA DB, 1959, J CLIN INVEST, V38, P213, DOI 10.1172/JCI103789; McGeer A, 2007, CLIN INFECT DIS, V45, P1568, DOI 10.1086/523584; Moore DL, 2006, PEDIATRICS, V118, pE610, DOI 10.1542/peds.2005-2744; Neuzil KM, 2003, CLIN INFECT DIS, V37, P201, DOI 10.1086/375604; Neuzil KM, 1998, AM J EPIDEMIOL, V148, P1094, DOI 10.1093/oxfordjournals.aje.a009587; Nicholson K G, 1992, Semin Respir Infect, V7, P26; *NOV SWIN OR INFL, 2009, NEW ENGL J MED, V361, P102; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Schrag SJ, 2006, PEDIATR INFECT DIS J, V25, P395, DOI 10.1097/01.inf.0000214988.81379.71; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Walsh EE, 2002, J AM GERIATR SOC, V50, P1498, DOI 10.1046/j.1532-5415.2002.50404.x; World Health Organization, PAND H1N1 2009 UPD 6 PAND H1N1 2009 UPD 6; 2008, MMWR RECOMM REP, V57, P1	34	1279	1376	3	157	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	2009	361	20					1935	1944		10.1056/NEJMoa0906695	http://dx.doi.org/10.1056/NEJMoa0906695			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	518AI	19815859				2023-01-03	WOS:000271660500007
J	Olivier, V; Queen, J; Satchell, KJF				Olivier, Verena; Queen, Jessica; Satchell, Karla J. F.			Successful Small Intestine Colonization of Adult Mice by Vibrio cholerae Requires Ketamine Anesthesia and Accessory Toxins	PLOS ONE			English	Article								Vibrio cholerae colonizes the small intestine of adult C57BL/6 mice. In this study, the physical and genetic parameters that facilitate this colonization were investigated. Successful colonization was found to depend upon anesthesia with ketamine-xylazine and neutralization of stomach acid with sodium bicarbonate, but not streptomycin treatment. A variety of common mouse strains were colonized by O1, O139, and non-O1/non-O139 strains. All combinations of mutants in the genes for hemolysin, the multifunctional, autoprocessing RTX toxin (MARTX), and hemagglutinin/protease were assessed, and it was found that hemolysin and MARTX are each sufficient for colonization after a low dose infection. Overall, this study suggests that, after intragastric inoculation, V. cholerae encounters barriers to infection including an acidic environment and an immediate immune response that is circumvented by sodium bicarbonate and the anti-inflammatory effects of ketamine-xylazine. After initial adherence in the small intestine, the bacteria are subjected to additional clearance mechanisms that are evaded by the independent toxic action of hemolysin or MARTX. Once colonization is established, it is suggested that, in humans, these now persisting bacteria initiate synthesis of the major virulence factors to cause cholera disease. This adult mouse model of intestinal V. cholerae infection, now well-characterized and fully optimized, should serve as a valuable tool for studies of pathogenesis and testing vaccine efficacy.			Olivier, V (corresponding author), Intercell AG, Vienna, Austria.	k-satchell@northwestern.edu	Satchell, Karla/GSN-3100-2022; Sears, Cynthia L/AAJ-6704-2020	Sears, Cynthia L/0000-0003-4059-1661; Queen, Jessica/0000-0002-4924-6621	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI072461, R01AI051490] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI072461-01A2, AI072461, R21 AI072461, R01 AI051490, AI051490] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALM RA, 1988, MOL MICROBIOL, V2, P481; Bina J, 2003, P NATL ACAD SCI USA, V100, P2801, DOI 10.1073/pnas.2628026100; CASH RA, 1974, J INFECT DIS, V129, P45, DOI 10.1093/infdis/129.1.45; Chiang SL, 1999, INFECT IMMUN, V67, P976, DOI 10.1128/IAI.67.2.976-980.1999; Cordero CL, 2007, J CLIN MICROBIOL, V45, P2289, DOI 10.1128/JCM.00349-07; FREYE E, 1994, ANAESTHESIST, V43, P87, DOI 10.1007/s001010050036; Fullner KJ, 2000, EMBO J, V19, P5315, DOI 10.1093/emboj/19.20.5315; Fullner KJ, 2002, J EXP MED, V195, P1455, DOI 10.1084/jem.20020318; Fullner KJ, 1999, INFECT IMMUN, V67, P1393, DOI 10.1128/IAI.67.3.1393-1404.1999; Ghosh A, 2006, INFECT IMMUN, V74, P2937, DOI 10.1128/IAI.74.5.2937-2946.2006; GOLDBERG I, 1986, J BACTERIOL, V165, P715, DOI 10.1128/jb.165.3.715-722.1986; HANNE LF, 1982, INFECT IMMUN, V36, P209, DOI 10.1128/IAI.36.1.209-214.1982; Helmer KS, 2003, J SURG RES, V112, P70, DOI 10.1016/S0022-4804(03)00138-0; Helmer KS, 2003, SHOCK, V20, P63, DOI 10.1097/01.shk.0000065766.72937.cf; Herbert J, 1998, EXP GERONTOL, V33, P713, DOI 10.1016/S0531-5565(98)00039-4; Hsiao A, 2006, P NATL ACAD SCI USA, V103, P14542, DOI 10.1073/pnas.0604650103; Kirn TJ, 2000, MOL MICROBIOL, V35, P896, DOI 10.1046/j.1365-2958.2000.01764.x; KNOP J, 1975, AUST J EXP BIOL MED, V53, P137, DOI 10.1038/icb.1975.14; Li MR, 2002, INFECT IMMUN, V70, P2441, DOI 10.1128/IAI.70.5.2441-2453.2002; MEKALANOS JJ, 1983, CELL, V35, P253, DOI 10.1016/0092-8674(83)90228-3; NIYOGI SG, 1979, INDIAN J MED RES, V70, P892; NYGREN E, 2009, INFECT IMMUN; Olivier V, 2007, INFECT IMMUN, V75, P5043, DOI 10.1128/IAI.00508-07; Olivier V, 2007, INFECT IMMUN, V75, P5035, DOI 10.1128/IAI.00506-07; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Suliburk JW, 2005, J SURG RES, V127, P203, DOI 10.1016/j.jss.2005.03.021; Valeva A, 2008, MED MICROBIOL IMMUN, V197, P285, DOI 10.1007/s00430-007-0061-2; WALDOR MK, 1994, INFECT IMMUN, V62, P72, DOI 10.1128/IAI.62.1.72-78.1994	28	64	68	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 8	2009	4	10							e7352	10.1371/journal.pone.0007352	http://dx.doi.org/10.1371/journal.pone.0007352			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	504DL	19812690	Green Submitted, Green Published, gold			2023-01-03	WOS:000270594200004
J	Cooley, K; Szczurko, O; Perri, D; Mills, EJ; Bernhardt, B; Zhou, Q; Seely, D				Cooley, Kieran; Szczurko, Orest; Perri, Dan; Mills, Edward J.; Bernhardt, Bob; Zhou, Qi; Seely, Dugald			Naturopathic Care for Anxiety: A Randomized Controlled Trial ISRCTN78958974	PLOS ONE			English	Article							WHOLE SYSTEMS RESEARCH; WITHANIA-SOMNIFERA; ADAPTOGENIC ACTIVITY; DISORDERS; COMPLEMENTARY; EPIDEMIOLOGY; MEDICINE; HEALTH; PREVALENCE; VALIDATION	Background: Anxiety is a serious personal health condition and represents a substantial burden to overall quality of life. Additionally anxiety disorders represent a significant cost to the health care system as well as employers through benefits coverage and days missed due to incapacity. This study sought to explore the effectiveness of naturopathic care on anxiety symptoms using a randomized trial. Methods: Employees with moderate to severe anxiety of longer than 6 weeks duration were randomized based on age and gender to receive naturopathic care (NC) (n = 41) or standardized psychotherapy intervention (PT) (n = 40) over a period of 12 weeks. Blinding of investigators and participants during randomization and allocation was maintained. Participants in the NC group received dietary counseling, deep breathing relaxation techniques, a standard multi-vitamin, and the herbal medicine, ashwagandha (Withania somnifera) (300 mg b.i.d. standardized to 1.5% withanolides, prepared from root). The PT intervention received psychotherapy, and matched deep breathing relaxation techniques, and placebo. The primary outcome measure was the Beck Anxiety Inventory (BAI) and secondary outcome measures included the Short Form 36 (SF-36), Fatigue Symptom Inventory (FSI), and Measure Yourself Medical Outcomes Profile (MY-MOP) to measure anxiety, mental health, and quality of life respectively. Participants were blinded to the placebo-controlled intervention. Results: Seventy-five participants (93%) were followed for 8 or more weeks on the trial. Final BAI scores decreased by 56.5% (p < 0.0001) in the NC group and 30.5% (p < 0.0001) in the PT group. BAI group scores were significantly decreased in the NC group compared to PT group (p = 0.003). Significant differences between groups were also observed in mental health, concentration, fatigue, social functioning, vitality, and overall quality of life with the NC group exhibiting greater clinical benefit. No serious adverse reactions were observed in either group. Relevance: Many patients seek alternatives and/or complementary care to conventional anxiety treatments. To date, no study has evaluated the potential of a naturopathic treatment protocol to effectively treat anxiety. Knowledge of the efficacy, safety or risk of natural health products, and naturopathic treatments is important for physicians and the public in order to make informed decisions. Interpretation: Both NC and PT led to significant improvements in patients' anxiety. Group comparison demonstrated a significant decrease in anxiety levels in the NC group over the PT group. Significant improvements in secondary quality of life measures were also observed in the NC group as compared to PT. The whole system of naturopathic care for anxiety needs to be investigated further including a closer examination of the individual components within the context of their additive effect. Trial Registration: Controlled-Trials.com ISRCTN78958974			Cooley, K (corresponding author), Canadian Coll Naturopath Med, Dept Res & Clin Epidemiol, Toronto, ON, Canada.	kcooley@ccnm.edu	Cooley, Kieran/L-3080-2019; Zhou, Qi/GSM-9583-2022	Cooley, Kieran/0000-0001-7960-6504; 				Alonso J, 2007, J CLIN PSYCHIAT, V68, P3; [Anonymous], 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003383; Archana R, 1999, J ETHNOPHARMACOL, V64, P91, DOI 10.1016/S0378-8741(98)00107-X; Bhattacharya SK, 2003, PHARMACOL BIOCHEM BE, V75, P547, DOI 10.1016/S0091-3057(03)00110-2; Bhattacharya SK, 2000, PHYTOMEDICINE, V7, P463, DOI 10.1016/S0944-7113(00)80030-6; Borgerson K, 2005, PERSPECT BIOL MED, V48, P502, DOI 10.1353/pbm.2005.0084; Bower P, 2003, PSYCHOL MED, V33, P203, DOI 10.1017/S0033291702006979; Brawman-Mintzer O, 2004, CNS SPECTRUMS, V9, P19, DOI 10.1017/S1092852900002339; Brown R P, 2001, J Psychiatr Pract, V7, P75, DOI 10.1097/00131746-200103000-00002; *CAN H, 2009, NAT HLTH PROD REG; Dhuley JN, 1998, J ETHNOPHARMACOL, V60, P173, DOI 10.1016/S0378-8741(97)00151-7; Elder C, 2006, J ALTERN COMPLEM MED, V12, P843, DOI 10.1089/acm.2006.12.843; Erickson DH, 2007, PSYCHIAT SERV, V58, P1205, DOI 10.1176/appi.ps.58.9.1205; Faragher EB, 2005, OCCUP ENVIRON MED, V62, P105, DOI 10.1136/oem.2002.006734; Furukawa TA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004364.pub2; Godwin Marshall, 2003, BMC Med Res Methodol, V3, P28, DOI 10.1186/1471-2288-3-28; Grunze H, 2000, NEUROPSYCHOBIOLOGY, V42, P28, DOI 10.1159/000054849; Hann DM, 1998, QUAL LIFE RES, V7, P301, DOI 10.1023/A:1024929829627; Herman PM, 2008, ALTERN THER HEALTH M, V14, P32; Hotopf M, 1999, BRIT J PSYCHIAT, V175, P217, DOI 10.1192/bjp.175.3.217; Howell HB, 2001, PSYCHIAT CLIN N AM, V24, P165, DOI 10.1016/S0193-953X(05)70212-4; JONAS WB, 2002, CLIN RES METHODS COM, P3; KICK SD, 1994, PSYCHOSOM MED, V56, P570, DOI 10.1097/00006842-199411000-00014; KIRSANAPRAKOMKI.T, 2006, COCHRANE DB SYST REV; LE CP, 2001, HLTH NUMBERS PROBLEM; Leahy, 2017, COGNITIVE THERAPY TE; Lepine JP, 2002, J CLIN PSYCHIAT, V63, P4; Marciniak M, 2004, DEPRESS ANXIETY, V19, P112, DOI 10.1002/da.10131; Mishra L C, 2000, Altern Med Rev, V5, P334; MONTEIRO MG, 1990, J CLIN PSYCHIAT, V51, P12; Nutt DJ, 2007, J CLIN PSYCHIAT, V68, P42; Osman A, 2004, PSYCHOL ASSESSMENT, V16, P120, DOI 10.1037/1040-3590.16.2.120; Paterson C, 2000, QUAL LIFE RES, V9, P521, DOI 10.1023/A:1008930521566; Paterson C, 1996, BRIT MED J, V312, P1016; Paterson C, 2000, J Health Serv Res Policy, V5, P27; Pilkington K, 2006, HOMEOPATHY, V95, P151, DOI 10.1016/j.homp.2006.05.005; Rafferty AP, 2002, AM J PUBLIC HEALTH, V92, P1598, DOI 10.2105/AJPH.92.10.1598; RAINEY JM, 1984, PSYCHOPHARMACOL BULL, V20, P45; Ritenbaugh C, 2003, ALTERN THER HEALTH M, V9, P32; ROSNER B, 2001, FUNDAMENTALS BIOSTAT; Roy-Byrne PP, 2005, PSYCHOSOMATICS, V46, P117, DOI 10.1176/appi.psy.46.2.117; Sarris J, 2007, PHYTOTHER RES, V21, P703, DOI 10.1002/ptr.2187; SEELY D, 2007, ECAM, V4, P75; Singh B, 2003, PHYTOTHER RES, V17, P531, DOI 10.1002/ptr.1189; Smith MJ, 2002, MED CLIN N AM, V86, P173, DOI 10.1016/S0025-7125(03)00079-8; Somer E, 2005, BEHAV RES THER, V43, P669, DOI 10.1016/j.brat.2004.05.006; STRAZNICKY NE, 1993, J HYPERTENS, V11, P427, DOI 10.1097/00004872-199304000-00014; SZCZURKO O, 2007, PUBLIC LIB IN PRESS; Timmermans S., 2003, GOLD STANDARD CHALLE; USTUN TB, 1995, MENTAL ILLNESS GEN H; Van der Windt DAWM, 2000, BRIT J GEN PRACT, V50, P371; Verhoef MJ, 2005, COMPLEMENT THER MED, V13, P206, DOI 10.1016/j.ctim.2005.05.001; Ware DL, 1996, QUALITY LIFE PHARMAC, P337; ALTERN MED REV, V9, P211	54	62	62	1	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6628	10.1371/journal.pone.0006628	http://dx.doi.org/10.1371/journal.pone.0006628			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	489JH	19718255	Green Published, gold			2023-01-03	WOS:000269415900001
J	Goldbach-Mansky, R; Wilson, M; Fleischmann, R; Olsen, N; Silverfield, J; Kempf, P; Kivitz, A; Sherrer, Y; Pucino, F; Csako, G; Costello, R; Pham, TH; Snyder, C; van der Heijde, D; Tao, XL; Wesley, R; Lipsky, PE				Goldbach-Mansky, Raphaela; Wilson, Mildred; Fleischmann, Roy; Olsen, Nancy; Silverfield, Joel; Kempf, Phillip; Kivitz, Alan; Sherrer, Yvonne; Pucino, Frank; Csako, Gyorgy; Costello, Rene; Pham, Tuyet Hang; Snyder, Christopher; van der Heijde, Desiree; Tao, Xuelian; Wesley, Robert; Lipsky, Peter E.			Comparison of Tripterygium wilfordii Hook F Versus Sulfasalazine in the Treatment of Rheumatoid Arthritis A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							MODIFYING ANTIRHEUMATIC DRUGS; NF-KAPPA-B; DOUBLE-BLIND; TRIPTOLIDE; DISEASE; METHOTREXATE; LEFLUNOMIDE; INHIBITOR; EFFICACY; EXTRACT	Background: Extracts of the medicinal plant Tripterygium wilfordii Hook F (TwHF) have been used in China for centuries to treat a spectrum of inflammatory diseases. Objective: To compare the benefits and side effects of TwHF extract with those of sulfasalazine for the treatment of active rheumatoid arthritis. Design: Randomized, controlled trial. A computer-generated code with random, permuted blocks was used to assign treatment. Setting: 2 U. S. academic centers (National Institutes of Health, Bethesda, Maryland, and University of Texas, Dallas, Texas) and 9 rheumatology subspecialty clinics (in Dallas and Austin, Texas; Tampa and Fort Lauderdale, Florida; Arlington, Virginia; Duncanville, Pennsylvania; Wheaton and Greenbelt, Maryland; and Lansing, Michigan). Patients: 121 patients with active rheumatoid arthritis and 6 or more painful and swollen joints. Intervention: TwHF extract, 60 mg 3 times daily, or sulfasalazine, 1 g twice daily. Patients could continue stable doses of oral prednisone or nonsteroidal anti-inflammatory drugs but had to stop taking disease-modifying antirheumatic drugs at least 28 days before randomization. Measurements: The primary outcome was the rate of achievement of 20% improvement in the American College of Rheumatology criteria (ACR 20) at 24 weeks. Secondary end points were safety; radiographic scores of joint damage; and serum levels of interleukin-6, cholesterol, cortisol, and adrenocorticotropic hormone. Results: Outcome data were available for only 62 patients at 24 weeks. In a mixed-model analysis that imputed data for patients who dropped out, 65.0% (95% CI, 51.6% to 76.9%) of the TwHF group and 32.8% (CI, 21.3% to 46.0%) of the sulfasalazine group met the ACR 20 response criteria (P = 0.001). Patients receiving TwHF also had significantly higher response rates for ACR 50 and ACR 70 in mixed-model analyses. Analyses of only completers showed similar significant differences between the treatment groups. Significant improvement was demonstrated in all individual components of the ACR response, including the Health Assessment Questionnaire disability score. Interleukin-6 levels rapidly and significantly decreased in the TwHF group. Although not statistically significant, radiographic progression was lower in the TwHF group. The frequency of adverse events was similar in both groups. Limitations: Only 62% and 41% of patients continued receiving TwHF extract and sulfasalazine, respectively, during the 24 weeks of the study. Long-term outcome data were not collected on participants who discontinued treatment. Conclusion: In patients who continued treatment for 24 weeks and could also use stable oral prednisone and nonsteroidal anti-inflammatory drugs, attainment of the ACR 20 response criteria was significantly greater with TwHF extract than with sulfasalazine.	[Goldbach-Mansky, Raphaela] NIAMSD, NIH, US Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; Metroplex Clin Res Ctr, Dallas, TX USA; Tampa Med Grp, Tampa, FL USA; Arthrit Ctr, Ft Lauderdale, FL USA; Arthrit Clin No Virginia, Arlington, VA USA; Altoona Ctr Clin Res, Duncanville, PA USA; Leiden Univ, Med Ctr, Leiden, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Texas System; University of Texas Southwestern Medical Center Dallas; Metroplex Clinical Research Center; Altoona Center for Clinical Research; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Goldbach-Mansky, R (corresponding author), NIAMSD, NIH, US Dept Hlth & Human Serv, Bldg 10,Room 6D-47B,10 Ctr Dr, Bethesda, MD 20892 USA.	goldbacr@mail.nih.gov	Wilson, Jennifer/Q-3623-2019; van der Heijde, Désirée/I-6774-2019	van der Heijde, Désirée/0000-0002-5781-158X	National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and Phytomedics	National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and Phytomedics(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	By the Intramural Research Program of the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, and Phytomedics.	*AR CTR ED RES THE, QT DRUG LISTS; Bai JP, 2002, CONTRACEPTION, V65, P441, DOI 10.1016/S0010-7824(02)00312-8; Brinker AM, 2007, PHYTOCHEMISTRY, V68, P732, DOI 10.1016/j.phytochem.2006.11.029; Chen L, 2005, AM J CHINESE MED, V33, P945, DOI 10.1142/S0192415X05003521; Cohen S, 2001, ARTHRITIS RHEUM-US, V44, P1984, DOI 10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B; Cohen SB, 2006, ARTHRITIS RHEUM-US, V54, P2793, DOI 10.1002/art.22025; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Donahue KE, 2008, ANN INTERN MED, V148, P124, DOI 10.7326/0003-4819-148-2-200801150-00192; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; GU C-X, 1989, Zhonghua Xinxueguanbing Zazhi, V17, P236; Gu J, 2001, J Tradit Chin Med, V21, P50; Ji SM, 2006, TRANSPL P, V38, P1274, DOI 10.1016/j.transproceed.2006.03.017; Kremer JM, 2006, ANN INTERN MED, V144, P865, DOI 10.7326/0003-4819-144-12-200606200-00003; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Leuenroth SJ, 2007, P NATL ACAD SCI USA, V104, P4389, DOI 10.1073/pnas.0700499104; Li K, 1998, Se Pu, V16, P356; Liu H, 2000, ACTA PHARMACOL SIN, V21, P782; Lu H, 1999, TRANSPLANT P, V31, P2056, DOI 10.1016/S0041-1345(99)00262-6; Maetzel A, 2000, RHEUMATOLOGY, V39, P975, DOI 10.1093/rheumatology/39.9.975; Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064; O'Dell JR, 2004, NEW ENGL J MED, V350, P2591, DOI 10.1056/NEJMra040226; Proudman SM, 2000, ARTHRITIS RHEUM, V43, P1809, DOI 10.1002/1529-0131(200008)43:8<1809::AID-ANR17>3.0.CO;2-D; QIU D, 2003, HOOK F DRUG R D BACK, V4, P1; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; REDELMEIER DA, 1993, ARCH INTERN MED, V153, P1337, DOI 10.1001/archinte.153.11.1337; Ren J, 2007, DIGEST DIS SCI, V52, P1790, DOI 10.1007/s10620-007-9747-y; SCOTT DL, 1987, LANCET, V1, P1108; Seriolo B, 2006, ANN NY ACAD SCI, V1069, P414, DOI 10.1196/annals.1351.039; Sharp JT, 2000, ARTHRITIS RHEUM-US, V43, P495, DOI 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U; Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140-6736(07)60784-3; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; Suarez-Almazor ME, 2000, COCHRANE DB SYST REV; Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411; Tao XL, 1998, ARTHRITIS RHEUM-US, V41, P130, DOI 10.1002/1529-0131(199801)41:1<130::AID-ART16>3.3.CO;2-W; Tao XL, 2000, RHEUM DIS CLIN N AM, V26, P29, DOI 10.1016/S0889-857X(05)70118-6; Tao XL, 2001, J RHEUMATOL, V28, P2160; van der Heijde D, 2006, ARTHRITIS RHEUM-US, V54, P1063, DOI 10.1002/art.21655; van der Heijde D, 2000, J RHEUMATOL, V27, P261; Wang B, 2004, ARTHRITIS RHEUM-US, V50, P2995, DOI 10.1002/art.20459; Yen JH, 2006, BIOMED PHARMACOTHER, V60, P688, DOI 10.1016/j.biopha.2006.09.008; Zheng J R, 1987, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V9, P317	43	171	193	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 18	2009	151	4					229	W51		10.7326/0003-4819-151-4-200908180-00005	http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00005			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	484IW	19687490	Green Accepted			2023-01-03	WOS:000269038900002
J	Chlebowski, RT; Anderson, GL; Gass, M; Lane, DS; Aragaki, AK; Kuller, LH; Manson, JE; Stefanick, ML; Ockene, J; Sarto, GE; Johnson, KC; Wactawski-Wende, J; Ravdin, PM; Schenken, R; Hendrix, SL; Rajkovic, A; Rohan, TE; Yasmeen, S; Prentice, RL				Chlebowski, Rowan T.; Anderson, Garnet L.; Gass, Margery; Lane, Dorothy S.; Aragaki, Aaron K.; Kuller, Lewis H.; Manson, JoAnn E.; Stefanick, Marcia L.; Ockene, Judith; Sarto, Gloria E.; Johnson, Karen C.; Wactawski-Wende, Jean; Ravdin, Peter M.; Schenken, Robert; Hendrix, Susan L.; Rajkovic, Aleksandar; Rohan, Thomas E.; Yasmeen, Shagufta; Prentice, Ross L.		WHI Investigators	Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; ANGIOGENESIS; MAMMOGRAPHY; RISK; SURVIVAL; BENEFITS; DISEASE; GROWTH; USERS	Context In the Women's Health Initiative randomized, placebo-controlled trial of estrogen plus progestin, after a mean intervention time of 5.6 (SD, 1.3) years (range, 3.7-8.6 years) and a mean follow-up of 7.9 (SD, 1.4) years, breast cancer incidence was increased among women who received combined hormone therapy. Breast cancer mortality among participants in the trial has not been previously reported. Objective To determine the effects of therapy with estrogen plus progestin on cumulative breast cancer incidence and mortality after a total mean follow-up of 11.0 (SD, 2.7) years, through August 14, 2009. Design, Setting, and Participants A total of 16 608 postmenopausal women aged 50 to 79 years with no prior hysterectomy from 40 US clinical centers were randomly assigned to receive combined conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, or placebo pill. After the original trial completion date (March 31, 2005), reconsent was required for continued follow-up for breast cancer incidence and was obtained from 12 788 (83%) of the surviving participants. Main Outcome Measures Invasive breast cancer incidence and breast cancer mortality. Results In intention-to-treat analyses including all randomized participants and censoring those not consenting to additional follow-up on March 31, 2005, estrogen plus progestin was associated with more invasive breast cancers compared with placebo (385 cases [0.42% per year] vs 293 cases [0.34% per year]; hazard ratio [HR], 1.25; 95% confidence interval [CI], 1.07-1.46; P=.004). Breast cancers in the estrogen-plus-progestin group were similar in histology and grade to breast cancers in the placebo group but were more likely to be node-positive (81 [23.7%] vs43 [16.2%], respectively; HR, 1.78; 95% CI, 1.23-2.58; P=.03). There were more deaths directly attributed to breast cancer (25 deaths [0.03% per year] vs 12 deaths [0.01% per year]; HR, 1.96; 95% CI, 1.00-4.04; P=.049) as well as more deaths from all causes occurring after a breast cancer diagnosis (51 deaths [0.05% per year] vs 31 deaths [0.03% per year]; HR, 1.57; 95% CI, 1.01-2.48; P=.045) among women who received estrogen plus progestin compared with women in the placebo group. Conclusions Estrogen plus progestin was associated with greater breast cancer incidence, and the cancers are more commonly node-positive. Breast cancer mortality also appears to be increased with combined use of estrogen plus progestin.	[Chlebowski, Rowan T.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA; [Anderson, Garnet L.; Aragaki, Aaron K.; Prentice, Ross L.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Gass, Margery] Univ Cincinnati, Cincinnati, OH USA; [Lane, Dorothy S.] SUNY Stony Brook, Stony Brook, NY 11794 USA; [Kuller, Lewis H.] Univ Pittsburgh, Pittsburgh, PA USA; [Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Stefanick, Marcia L.] Stanford Prevent Res Ctr, Stanford, CA USA; [Ockene, Judith] Univ Massachusetts, Fallon Clin, Worcester, MA 01605 USA; [Sarto, Gloria E.] Univ Wisconsin, Madison, WI 53706 USA; [Johnson, Karen C.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA; [Wactawski-Wende, Jean] SUNY Buffalo, Buffalo, NY 14260 USA; [Ravdin, Peter M.] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA; [Schenken, Robert] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Hendrix, Susan L.] Wayne State Sch Med, Detroit, MI USA; [Hendrix, Susan L.] Hurtzel Hosp, Detroit, MI USA; [Rajkovic, Aleksandar] Baylor Coll Med, Houston, TX 77030 USA; [Rohan, Thomas E.] Albert Einstein Coll Med, New York, NY USA; [Yasmeen, Shagufta] Univ Calif Davis, Sacramento, CA 95817 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; Fred Hutchinson Cancer Center; University System of Ohio; University of Cincinnati; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Stanford University; University of Massachusetts System; University of Massachusetts Worcester; University of Wisconsin System; University of Wisconsin Madison; University of Tennessee System; University of Tennessee Health Science Center; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Wayne State University; Baylor College of Medicine; Yeshiva University; University of California System; University of California Davis	Chlebowski, RT (corresponding author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St, Torrance, CA 90502 USA.	rchlebowski@gmail.com	Wactawski-Wende, Jean/AGH-5457-2022; Stafford, Randall/F-3974-2017	Wactawski-Wende, Jean/0000-0003-3096-9595; Stafford, Randall/0000-0003-1805-1271; Caan, Bette/0000-0002-5803-310X; Anderson, Garnet/0000-0001-5087-7837	AstraZeneca; Novartis; Pfizer; Amgen; Procter Gamble; Wyeth Laboratories; Upsher-Smith Laboratories; Wyeth Pharmaceuticals; Meditrina Pharmaceuticals Inc; Merck; Boehringer Ingelheim; Organon; National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, 44221]; WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH [N01WH042117, N01WH042121, N01WH042129, N01WH032109, N01WH032118, N01WH042111, N01WH042124, N01WH042107, N01WH032112, N01WH022110, N01WH032101, N01WH042114, N01WH032106, N01WH042131, N01WH042125, N01WH042116, N01WH032108, N01WH042126, N01WH042113, N01WH042110, N01WH042120, N01WH042109, N01WH042108, N01WH032119, N01WH032113, N01WH042115, N01WH042122, N01WH032115, N01WH032122, N01WH032100, N01WH032105, N01WH042112, N01WH042119, N01WH042118, N01WH042132, N01WH032111, N01WH042123, N01WH032102, N01WH042130] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); Novartis(Novartis); Pfizer(Pfizer); Amgen(Amgen); Procter Gamble(Procter & Gamble); Wyeth Laboratories(Wyeth); Upsher-Smith Laboratories(Randox Laboratories); Wyeth Pharmaceuticals(Wyeth); Meditrina Pharmaceuticals Inc; Merck(Merck & Company); Boehringer Ingelheim(Boehringer Ingelheim); Organon; National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Dr Chlebowski reports that he has received consulting fees from AstraZeneca, Novartis, and Pfizer, lecture fees from AstraZeneca and Novartis, and grant funding from Amgen. Dr Gass reports that she has received funding for multisite clinical trials from Procter & Gamble and Wyeth Laboratories and consulting fees from Upsher-Smith Laboratories, Wyeth Pharmaceuticals, and Procter & Gamble. Dr Hendrix reports that she has received consulting fees from Meditrina Pharmaceuticals Inc, lecture fees from Merck, and grant funding from Boehringer Ingelheim and Organon. Dr Rohan reports that he has received consulting fees from legal firms regarding hormone therapy issues. No other financial disclosures were reported.; The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services, through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.	Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2006, MATURITAS, V55, P103, DOI 10.1016/j.maturitas.2006.05.004; Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Calvo A, 2008, ONCOGENE, V27, P5373, DOI 10.1038/onc.2008.155; Chen WY, 2004, CANCER, V101, P1490, DOI 10.1002/cncr.20499; Chlebowski RT, 2008, ARCH INTERN MED, V168, P370, DOI 10.1001/archinternmed.2007.123; Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Chlebowski RT, 2009, NEW ENGL J MED, V360, P573, DOI 10.1056/NEJMoa0807684; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; Christante D, 2008, AM J SURG, V196, P505, DOI 10.1016/j.amjsurg.2008.06.023; Curb JD, 2003, ANN EPIDEMIOL, V13, pS122, DOI 10.1016/S1047-2797(03)00048-6; Dobrzycka B, 2009, ENDOKRYNOL POL, V60, P210; Dong WL, 2008, CANCER EPIDEM BIOMAR, V17, P1096, DOI 10.1158/1055-9965.EPI-08-0201; Fournier A, 2009, J CLIN ONCOL, V27, P5138, DOI 10.1200/JCO.2008.21.6432; Haller DG, 2006, J CLIN ONCOL, V24, p149S; Hays J, 2003, ANN EPIDEMIOL, V13, pS18, DOI 10.1016/S1047-2797(03)00042-5; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Hersh AL, 2004, JAMA-J AM MED ASSOC, V291, P47, DOI 10.1001/jama.291.1.47; Holli K, 1998, J CLIN ONCOL, V16, P3115, DOI 10.1200/JCO.1998.16.9.3115; Hyder SM, 1998, CANCER RES, V58, P392; Joffe MM, 2001, EPIDEMIOLOGY, V12, P429, DOI 10.1097/00001648-200107000-00013; Kerlikowske K, 2003, J CLIN ONCOL, V21, P4314, DOI 10.1200/JCO.2003.05.151; Liang Y, 2007, CANCER RES, V67, P9929, DOI 10.1158/0008-5472.CAN-07-1103; Losordo DW, 2001, ARTERIOSCL THROM VAS, V21, P6, DOI 10.1161/01.ATV.21.1.6; National Cancer Institute, SURV EP END RES PROG; Newcomb PA, 2008, CANCER EPIDEM BIOMAR, V17, P864, DOI 10.1158/1055-9965.EPI-07-0610; Pinder MC, 2007, J CLIN ONCOL, V25, P3808, DOI 10.1200/JCO.2006.10.4976; Power ML, 2009, MENOPAUSE, V16, P500, DOI 10.1097/gme.0b013e31818fc36e; Prentice RL, 2008, AM J EPIDEMIOL, V167, P1207, DOI 10.1093/aje/kwn044; Ravdin PM, 2007, NEW ENGL J MED, V356, P1670, DOI 10.1056/NEJMsr070105; Rosenberg LU, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2145; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sener SF, 2009, AM J SURG, V197, P403, DOI 10.1016/j.amjsurg.2008.11.014; Shen Y, 2005, JNCI-J NATL CANCER I, V97, P1195, DOI 10.1093/jnci/dji239; Sihto H, 2008, CLIN CANCER RES, V14, P4103, DOI 10.1158/1078-0432.CCR-07-5003; Stevenson JC, 2009, ATHEROSCLEROSIS, V207, P336, DOI 10.1016/j.atherosclerosis.2009.05.033; Toh S, 2010, ANN INTERN MED, V152, P211, DOI 10.7326/0003-4819-152-4-201002160-00005; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	40	377	402	1	34	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 20	2010	304	15					1684	1692		10.1001/jama.2010.1500	http://dx.doi.org/10.1001/jama.2010.1500			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	666PZ	20959578	Green Accepted, Bronze			2023-01-03	WOS:000283129700022
J	Frankel, A; Vecchio, P				Frankel, Adam; Vecchio, Phillip			Personal View Commonly used, easily confused: let's eliminate hyper and hypo	BRITISH MEDICAL JOURNAL			English	Editorial Material							DOCTOR-PATIENT COMMUNICATION		[Frankel, Adam; Vecchio, Phillip] Princess Alexandra Hosp, Medicat Safety Team, Woolloongabba, Qld 4102, Australia		Frankel, A (corresponding author), Princess Alexandra Hosp, Medicat Safety Team, Woolloongabba, Qld 4102, Australia.	a.frankel@uq.edu.au; phillip_vecchio@health.qld.gov.au	Frankel, Adam J/A-5001-2013	Frankel, Adam J/0000-0002-5198-7664				Kountz DS, 2009, POSTGRAD MED, V121, P171, DOI 10.3810/pgm.2009.09.2065; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; Reason J., 1990, HUMAN ERROR; Roughead Elizabeth E, 2009, Aust New Zealand Health Policy, V6, P18, DOI 10.1186/1743-8462-6-18; Schroeder R E, 1999, J Health Adm Educ, V17, P175; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; Valentin A, 2006, INTENS CARE MED, V32, P1591, DOI 10.1007/s00134-006-0290-7	7	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 20	2010	341								c5867	10.1136/bmj.c5867	http://dx.doi.org/10.1136/bmj.c5867			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	671ZL	20961983				2023-01-03	WOS:000283552700002
J	Bulger, EM; May, S; Brasel, KJ; Schreiber, M; Kerby, JD; Tisherman, SA; Newgard, C; Slutsky, A; Coimbra, R; Emerson, S; Minei, JP; Bardarson, B; Kudenchuk, P; Baker, A; Christenson, J; Idris, A; Davis, D; Fabian, TC; Aufderheide, TP; Callaway, C; Williams, C; Banek, J; Vaillancourt, C; van Heest, R; Sopko, G; Hata, JS; Hoyt, DB				Bulger, Eileen M.; May, Susanne; Brasel, Karen J.; Schreiber, Martin; Kerby, Jeffrey D.; Tisherman, Samuel A.; Newgard, Craig; Slutsky, Arthur; Coimbra, Raul; Emerson, Scott; Minei, Joseph P.; Bardarson, Berit; Kudenchuk, Peter; Baker, Andrew; Christenson, Jim; Idris, Ahamed; Davis, Daniel; Fabian, Timothy C.; Aufderheide, Tom P.; Callaway, Clifton; Williams, Carolyn; Banek, Jane; Vaillancourt, Christian; van Heest, Rardi; Sopko, George; Hata, J. Steven; Hoyt, David B.		ROC Investigators	Out-of-Hospital Hypertonic Resuscitation Following Severe Traumatic Brain Injury A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GLASGOW OUTCOME SCALE; RAPID-SEQUENCE INTUBATION; DISABILITY RATING-SCALE; SEVERE HEAD-INJURY; INTRACRANIAL-PRESSURE; SALINE RESUSCITATION; CONSENSUS CONFERENCE; PROSTAGLANDIN E(2); SEPSIS; SCORE	Context Hypertonic fluids restore cerebral perfusion with reduced cerebral edema and modulate inflammatory response to reduce subsequent neuronal injury and thus have potential benefit in resuscitation of patients with traumatic brain injury (TBI). Objective To determine whether out-of-hospital administration of hypertonic fluids improves neurologic outcome following severe TBI. Design, Setting, and Participants Multicenter, double-blind, randomized, placebo-controlled clinical trial involving 114 North American emergency medical services agencies within the Resuscitation Outcomes Consortium, conducted between May 2006 and May 2009 among patients 15 years or older with blunt trauma and a prehospital Glasgow Coma Scale score of 8 or less who did not meet criteria for hypovolemic shock. Planned enrollment was 2122 patients. Intervention A single 250-mL bolus of 7.5% saline/6% dextran 70 (hypertonic saline/dextran), 7.5% saline (hypertonic saline), or 0.9% saline (normal saline) initiated in the out-of-hospital setting. Main Outcome Measure Six-month neurologic outcome based on the Extended Glasgow Outcome Scale (GOSE) (dichotomized as >4 or <= 4). Results The study was terminated by the data and safety monitoring board after randomization of 1331 patients, having met prespecified futility criteria. Among the 1282 patients enrolled, 6-month outcomes data were available for 1087 (85%). Baseline characteristics of the groups were equivalent. There was no difference in 6-month neurologic outcome among groups with regard to proportions of patients with severe TBI (GOSE <= 4) (hypertonic saline/dextran vs normal saline: 53.7% vs 51.5%; difference, 2.2% [95% CI, -4.5% to 9.0%]; hypertonic saline vs normal saline: 54.3% vs 51.5%; difference, 2.9% [95% CI, -4.0% to 9.7%]; P=.67). There were no statistically significant differences in distribution of GOSE category or Disability Rating Score by treatment group. Survival at 28 days was 74.3% with hypertonic saline/dextran, 75.7% with hypertonic saline, and 75.1% with normal saline (P=.88). Conclusion Among patients with severe TBI not in hypovolemic shock, initial resuscitation with either hypertonic saline or hypertonic saline/dextran, compared with normal saline, did not result in superior 6-month neurologic outcome or survival.	[Bulger, Eileen M.] Univ Washington, Harborview Med Ctr, Dept Surg, Seattle, WA 98104 USA; [May, Susanne; Emerson, Scott] Univ Washington, Dept Biostat, Seattle, WA 98104 USA; [Kudenchuk, Peter] Univ Washington, Dept Med, Seattle, WA 98104 USA; [Bardarson, Berit] Univ Washington, Clin Trials Ctr, Seattle, WA 98104 USA; [Brasel, Karen J.] Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; [Aufderheide, Tom P.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Schreiber, Martin] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA; [Newgard, Craig] Oregon Hlth & Sci Univ, Dept Emergency Med, Portland, OR 97201 USA; [Newgard, Craig] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Kerby, Jeffrey D.; Williams, Carolyn] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA; [Tisherman, Samuel A.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA; [Callaway, Clifton] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [Slutsky, Arthur] Univ Toronto, Dept Med, Toronto, ON, Canada; [Baker, Andrew] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Baker, Andrew] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Coimbra, Raul] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Davis, Daniel] Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; [Minei, Joseph P.; Idris, Ahamed] Univ Texas SW Med Ctr Dallas, Dept Surg, Dallas, TX 75390 USA; [Christenson, Jim] Emergency & Hlth Serv Commiss, Vancouver, BC, Canada; [Fabian, Timothy C.] Univ Tennessee, Dept Surg, Memphis, TN USA; [Banek, Jane; Vaillancourt, Christian] Ottawa Res Inst, Dept Emergency Med, Ottawa, ON, Canada; [van Heest, Rardi] Royal Columbia Hosp, Trauma Serv, New Westminster, BC, Canada; [Sopko, George] NHLBI, NIH, Bethesda, MD 20892 USA; [Hata, J. Steven] Univ Iowa, Div Crit Care, Iowa City, IA USA; [Hoyt, David B.] Amer Coll Surg, Chicago, IL USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Medical College of Wisconsin; Medical College of Wisconsin; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; University of Alabama System; University of Alabama Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Toronto; University of Toronto; University of Toronto; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Tennessee System; University of Tennessee Health Science Center; University of Ottawa; Ottawa Hospital Research Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Iowa; American College of Surgeons	Bulger, EM (corresponding author), Univ Washington, Harborview Med Ctr, Dept Surg, 325 9th Ave,POB 359796, Seattle, WA 98104 USA.	ebulger@u.washington.edu	Hata, J./ABI-1484-2020; Coimbra, Raul/AAP-3019-2020; Cheskes, Sheldon/I-4456-2015; Slutsky, Arthur/M-3325-2019; Tisherman, Samuel A./AAK-9377-2020; Welsford, Michelle/H-5535-2017	Coimbra, Raul/0000-0002-3759-6851; Cheskes, Sheldon/0000-0001-7835-3074; Tisherman, Samuel A./0000-0003-3810-3729; Callaway, Clifton/0000-0002-3309-1573; Idris, Ahamed/0000-0001-7113-6499; Hostler, David/0000-0002-7711-4001; Gabriel, Erin/0000-0002-0504-8404; Welsford, Michelle/0000-0003-2682-641X	National Heart, Lung, and Blood Institute [5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077887, HL077873, HL077865]; National Institute of Neurological Disorders and Stroke; US Army Medical Research and Materiel Command; Canadian Institutes of Health Research (CIHR) Institute of Circulatory and Respiratory Health; Defence Research and Development Canada; Heart and Stroke Foundation of Canada; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL077863, U01HL077872, U01HL077866, U01HL077885, U01HL077865, U01HL077887, U01HL077867, U01HL077871, U01HL077881, U01HL077873, U01HL077908] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); US Army Medical Research and Materiel Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Canadian Institutes of Health Research (CIHR) Institute of Circulatory and Respiratory Health(Canadian Institutes of Health Research (CIHR)); Defence Research and Development Canada; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Resuscitation Outcome Consortium is supported by a series of cooperative agreements with 10 regional clinical centers and 1 data coordinating center (5U01 HL077863, HL077881, HL077871, HL077872, HL077866, HL077908, HL077867, HL077885, HL077887, HL077873, HL077865) from the National Heart, Lung, and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical Research and Materiel Command, the Canadian Institutes of Health Research (CIHR) Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, and the Heart and Stroke Foundation of Canada.	BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Bulger EM, 2009, ANN EMERG MED, V53, P341, DOI 10.1016/j.annemergmed.2008.07.021; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; Coimbra R, 1996, J SURG RES, V64, P203, DOI 10.1006/jsre.1996.0329; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; COIMBRA R, 1995, SHOCK, V4, P45, DOI 10.1097/00024382-199507000-00007; COOKE RS, 1995, INJURY, V26, P399, DOI 10.1016/0020-1383(95)00064-G; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Davis DP, 2007, PREHOSP EMERG CARE, V11, P369, DOI 10.1080/10903120701537147; Davis DP, 2005, J EMERG MED, V29, P391, DOI 10.1016/j.jemermed.2005.04.012; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; *GLUE GRANT, 2009, INFL HOST RESP INJ C; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Horn P, 1999, NEUROL RES, V21, P758, DOI 10.1080/01616412.1999.11741010; Inoue Y, 2008, CRIT CARE MED, V36, P2569, DOI 10.1097/CCM.0b013e3181841a91; JUNGER WG, 1994, CIRC SHOCK, V42, P190; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kittelson JM, 1999, BIOMETRICS, V55, P874, DOI 10.1111/j.0006-341X.1999.00874.x; Loomis WH, 2003, J BIOL CHEM, V278, P4590, DOI 10.1074/jbc.M207868200; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Sheffe H., 1959, ANAL VARIANCE; Tisherman SA, 2008, CIRCULATION, V118, P1585, DOI 10.1161/CIRCULATIONAHA.107.764084; Tyagi R, 2007, NEUROSURG REV, V30, P277, DOI 10.1007/s10143-007-0091-7; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wakai A, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001049.pub2; WALDER AD, 1995, INTENS CARE MED, V21, P606, DOI 10.1007/BF01700170; WANG SK, 1987, BIOMETRICS, V43, P193, DOI 10.2307/2531959; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	41	160	171	1	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2010	304	13					1455	1464		10.1001/jama.2010.1405	http://dx.doi.org/10.1001/jama.2010.1405			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658SO	20924011	Bronze, Green Accepted			2023-01-03	WOS:000282509900021
J	Abernethy, AP; McDonald, CF; Frith, PA; Clark, K; Herndon, JE; Marcello, J; Young, IH; Bull, J; Wilcock, A; Booth, S; Wheeler, JL; Tulsky, JA; Crockett, AJ; Currow, DC				Abernethy, Amy P.; McDonald, Christine F.; Frith, Peter A.; Clark, Katherine; Herndon, James E., II; Marcello, Jennifer; Young, Iven H.; Bull, Janet; Wilcock, Andrew; Booth, Sara; Wheeler, Jane L.; Tulsky, James A.; Crockett, Alan J.; Currow, David C.			Effect of palliative oxygen versus room air in relief of breathlessness in patients with refractory dyspnoea: a double-blind, randomised controlled trial	LANCET			English	Article							QUALITY-OF-LIFE; OBSTRUCTIVE PULMONARY-DISEASE; CANCER-PATIENTS; MANAGEMENT; THERAPY; QUESTIONNAIRE; BENEFIT	Background Palliative oxygen therapy is widely used for treatment of dyspnoea in individuals with life-limiting illness who are ineligible for long-term oxygen therapy. We assessed the effectiveness of oxygen compared with room air delivered by nasal cannula for relief of breathlessness in this population of patients. Methods Adults from outpatient clinics at nine sites in Australia, the USA, and the UK were eligible for enrolment in this double-blind, randomised controlled trial if they had life-limiting illness, refractory dyspnoea, and partial pressure of oxygen in arterial blood (PaO2) more than 7.3 kPa. Participants were randomly assigned in a 1:1 ratio by a central computer-generated system to receive oxygen or room air via a concentrator through a nasal cannula at 2 L per min for 7 days. Participants were instructed to use the concentrator for at least 15 h per day. The randomisation sequence was stratified by baseline PaO2 with balanced blocks of four patients. The primary outcome measure was breathlessness (0-10 numerical rating scale [NRS]), measured twice a day (morning and evening). All randomised patients who completed an assessment were included in the primary analysis for that data point (no data were imputed). This study is registered, numbers NCT00327873 and ISRCTN67448752. Findings 239 participants were randomly assigned to treatment (oxygen, n=120; room air, n=119). 112 (93%) patients assigned to receive oxygen and 99 (83%) assigned to receive room air completed all 7 days of assessments. From baseline to day 6, mean morning breathlessness changed by -0.9 points (95% CI -1.3 to -0.5) in patients assigned to receive oxygen and by -0.7 points (-1.2 to 0.2) in patients assigned to receive room air (p=0.504). Mean evening breathlessness changed by 0.3 points (-0.7 to 0.1) in the oxygen group and by -0.5 (-0.9 to 0.1) in the room air group (p=0.554). The frequency of side-effects did not differ between groups. Extreme drowsiness was reported by 12 (10%) of 116 patients assigned to receive oxygen compared with 14 (13%) of 108 patients assigned to receive room air. Two (2%) patients in the oxygen group reported extreme symptoms of nasal irritation compared with seven (6%) in the room air group. One patient reported an extremely troublesome nose bleed (oxygen group). Interpretation Since oxygen delivered by a nasal cannula provides no additional symptomatic benefit for relief of refractory dyspnoea in patients with fife-limiting illness compared with room air, less burdensome strategies should be considered after brief assessment of the effect of oxygen therapy on the individual patient.	[Abernethy, Amy P.; Wheeler, Jane L.] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA; [Herndon, James E., II] Duke Univ, Med Ctr, Dept Biostat & Bioinformat, Durham, NC 27710 USA; [Herndon, James E., II; Marcello, Jennifer] Duke Univ, Med Ctr, Canc Ctr Biostat, Durham, NC 27710 USA; [Tulsky, James A.] Duke Univ, Med Ctr, Dept Med, Div Gen Internal Med, Durham, NC 27710 USA; [Abernethy, Amy P.; Currow, David C.] Flinders Univ S Australia, Div Med, Dept Palliat & Support Serv, Bedford Pk, SA 5042, Australia; [Abernethy, Amy P.; Currow, David C.] Repatriat Gen Hosp, So Adelaide Palliat Serv, Daw Pk, SA, Australia; [Frith, Peter A.] Flinders Univ S Australia, Adelaide, SA 5001, Australia; [Frith, Peter A.] Repatriat Gen Hosp, Adelaide, SA, Australia; [Clark, Katherine] Univ Notre Dame, Cunningham Ctr Palliat Care, Sydney, NSW, Australia; [Young, Iven H.] Univ Sydney, Cent Clin Sch Med, Sydney, NSW 2006, Australia; [Bull, Janet] Four Seasons, Flat Rock, NC USA; [Wilcock, Andrew] Nottingham Univ Hosp NHS Trust, Nottingham, England; [Booth, Sara] Univ Cambridge, Cambridge, England; [Tulsky, James A.] Vet Adm Med Ctr, Ctr Hlth Serv Res, Durham, NC USA; [Crockett, Alan J.] Univ Adelaide, Discipline Gen Practice, Adelaide, SA, Australia	Duke University; Duke University; Duke University; Duke University; Flinders University South Australia; Flinders University South Australia; Flinders University South Australia; University of Notre Dame Australia; University of Sydney; Nottingham University Hospital NHS Trust; University of Cambridge; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Adelaide	Abernethy, AP (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Box 3436, Durham, NC 27710 USA.	amy.abernethy@duke.edu	McDonald, Christine Faye/AAU-9083-2021; Crockett, Alan Joseph/K-3859-2019; Crockett, Alan J/F-4553-2013; Wilcock, Andrew/A-9396-2012	Abernethy, Amy/0000-0001-6930-8722; Booth, Sara/0000-0003-2996-4578; Wilcock, Andrew/0000-0002-3214-1188; Frith, Peter Anthony/0000-0003-3265-0131; Currow, David/0000-0003-1988-1250	AstraZeneca; GlaxoSmithKline; Boehringer Ingelheim; US National Institutes of Health (NIH) [R01 AG026469]; Australian National Health and Medical Research Council [324770, 375127]; Duke Institute for Care at the End of Life; Doris Duke Charitable Foundation; NATIONAL INSTITUTE ON AGING [R01AG026469] Funding Source: NIH RePORTER	AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); Boehringer Ingelheim(Boehringer Ingelheim); US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Duke Institute for Care at the End of Life; Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	CFM has received honoraria for presenting at scientific meetings sponsored by AstraZeneca, GlaxoSmithKline, and Boehringer Ingelheim and has served as an advisory board member for these same corporations. JB is on the speaker's bureau for Wyeth Pharmaceuticals, Pfizer, and Meda Pharmaceuticals. All other authors declare that they have no conflicts of interest.; This study was funded through grants from the US National Institutes of Health (NIH; R01 AG026469), Australian National Health and Medical Research Council (324770 and 375127), Duke Institute for Care at the End of Life, and Doris Duke Charitable Foundation. None of the study sponsors had a role in the conduct of this study or its reporting, except through the input of the Data Safety Monitoring Board as mandated by the NIH. We thank the many patients with advanced life-limiting illness who generously participated in this study, and their carers. We also thank Bernadette Kenny and Belinda Fazekas (Southern Adelaide Palliative Services, Adelaide, Australia) for their important contributions in study and data management, and David Woods (Tasmania Statewide Palliative Care Service, Australia) for his assistance with participant recruitment in Tasmania, Australia.	Abernethy AP, 2008, PROG PALLIAT CARE, V16, P15, DOI 10.1179/096992608X291243; Abernethy AP, 2005, PALLIATIVE MED, V19, P168, DOI 10.1177/026921630501900219; Abernethy AP, 2003, BRIT MED J, V327, P523, DOI 10.1136/bmj.327.7414.523; Bausewein C, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005623.pub2; Booth S, 1996, AM J RESP CRIT CARE, V153, P1515, DOI 10.1164/ajrccm.153.5.8630595; Booth S, 2004, RESP MED, V98, P66, DOI 10.1016/j.rmed.2003.08.008; Bruera E, 2003, PALLIATIVE MED, V17, P659, DOI 10.1191/0269216303pm826oa; BURGESS KR, 1988, J APPL PHYSIOL, V64, P371, DOI 10.1152/jappl.1988.64.1.371; Cohen SR, 1997, PALLIATIVE MED, V11, P3; Cranston JM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004769.pub2; Currow DC, 2007, J PAIN SYMPTOM MANAG, V34, P113, DOI 10.1016/j.jpainsymman.2007.03.004; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; Fierro-Carrion G, 2004, CHEST, V125, P77, DOI 10.1378/chest.125.1.77; Fisher R.A., 1963, STAT TABLES BIOL AGR, V6th; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALBRAITH S, 2008, DOES HANDHELD FAN IM; Guyatt GH, 2000, CHEST, V118, P1303, DOI 10.1378/chest.118.5.1303; Gysels M, 2008, J PAIN SYMPTOM MANAG, V36, P451, DOI 10.1016/j.jpainsymman.2007.11.008; HEYSEMOORE LH, 1993, DYSPNOEA ADV CANC; Jennings AL, 2002, THORAX, V57, P939, DOI 10.1136/thorax.57.11.939; Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Mercadante S, 2000, J PAIN SYMPTOM MANAG, V20, P104, DOI 10.1016/S0885-3924(00)00160-3; Nonoyama ML, 2007, AM J RESP CRIT CARE, V176, P343, DOI 10.1164/rccm.200702-308OC; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; ODONOHUE WJ, 1995, CHEST, V107, P301, DOI 10.1378/chest.107.2.301; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Robb BW, 2003, J BURN CARE REHABIL, V24, P403, DOI 10.1097/01.BCR.0000096275.27946.68; SCHWARTZSTEIN RM, 1987, AM REV RESPIR DIS, V136, P58, DOI 10.1164/ajrccm/136.1.58; Tanaka K, 2002, J PAIN SYMPTOM MANAG, V23, P484, DOI 10.1016/S0885-3924(02)00394-9; Tierney RM, 1998, PALLIATIVE MED, V12, P333, DOI 10.1191/026921698670933919; Uronis HE, 2008, BRIT J CANCER, V98, P294, DOI 10.1038/sj.bjc.6604161; URONIS HE, 2007, COCHRANE DB SYST REV, V2; Uronis Hope E, 2006, Int J Chron Obstruct Pulmon Dis, V1, P289, DOI 10.2147/copd.2006.1.3.289; Uronis Hope E, 2008, Curr Opin Support Palliat Care, V2, P89, DOI 10.1097/SPC.0b013e3282ff0f5d; Young IH, 1998, MED J AUSTRALIA, V168, P21, DOI 10.5694/j.1326-5377.1998.tb123340.x	38	274	279	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					784	793		10.1016/S0140-6736(10)61115-4	http://dx.doi.org/10.1016/S0140-6736(10)61115-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816546	Green Accepted			2023-01-03	WOS:000281831000029
J	Cooper, BA; Branley, P; Bulfone, L; Collins, JF; Craig, JC; Fraenkel, MB; Harris, A; Johnson, DW; Kesselhut, J; Li, JJ; Luxton, G; Pilmore, A; Tiller, DJ; Harris, DC; Pollock, CA				Cooper, Bruce A.; Branley, Pauline; Bulfone, Liliana; Collins, John F.; Craig, Jonathan C.; Fraenkel, Margaret B.; Harris, Anthony; Johnson, David W.; Kesselhut, Joan; Li, Jing Jing; Luxton, Grant; Pilmore, Andrew; Tiller, David J.; Harris, David C.; Pollock, Carol A.		IDEAL Study	A Randomized, Controlled Trial of Early versus Late Initiation of Dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RESIDUAL RENAL-FUNCTION; START; COMORBIDITY; PREDICTION; CREATININE	BACKGROUND In clinical practice, there is considerable variation in the timing of the initiation of maintenance dialysis for patients with stage V chronic kidney disease, with a worldwide trend toward early initiation. In this study, conducted at 32 centers in Australia and New Zealand, we examined whether the timing of the initiation of maintenance dialysis influenced survival among patients with chronic kidney disease. METHODS We randomly assigned patients 18 years of age or older with progressive chronic kidney disease and an estimated glomerular filtration rate (GFR) between 10.0 and 15.0 ml per minute per 1.73 m(2) of body-surface area (calculated with the use of the Cockcroft-Gault equation) to planned initiation of dialysis when the estimated GFR was 10.0 to 14.0 ml per minute (early start) or when the estimated GFR was 5.0 to 7.0 ml per minute (late start). The primary outcome was death from any cause. RESULTS Between July 2000 and November 2008, a total of 828 adults (mean age, 60.4 years; 542 men and 286 women; 355 with diabetes) underwent randomization, with a median time to the initiation of dialysis of 1.80 months (95% confidence interval [CI], 1.60 to 2.23) in the early-start group and 7.40 months (95% CI, 6.23 to 8.27) in the late-start group. A total of 75.9% of the patients in the late-start group initiated dialysis when the estimated GFR was above the target of 7.0 ml per minute, owing to the development of symptoms. During a median follow-up period of 3.59 years, 152 of 404 patients in the early-start group (37.6%) and 155 of 424 in the late-start group (36.6%) died (hazard ratio with early initiation, 1.04; 95% CI, 0.83 to 1.30; P = 0.75). There was no significant difference between the groups in the frequency of adverse events (cardiovascular events, infections, or complications of dialysis). CONCLUSIONS In this study, planned early initiation of dialysis in patients with stage V chronic kidney disease was not associated with an improvement in survival or clinical outcomes. (Funded by the National Health and Medical Research Council of Australia and others; Australian New Zealand Clinical Trials Registry number, 12609000266268.)	[Cooper, Bruce A.; Kesselhut, Joan; Pollock, Carol A.] Royal N Shore Hosp, Sydney Med Sch, Dept Renal Med, Sydney, NSW, Australia; [Craig, Jonathan C.] Childrens Hosp Westmead, Sydney Sch Publ Hlth, Dept Nephrol, Sydney, NSW, Australia; [Tiller, David J.] Sydney Med Sch, Sch Rural Hlth, Sydney, NSW, Australia; [Harris, David C.] Univ Sydney, Westmead Millennium Inst, Ctr Transplantat & Renal Res, Sydney, NSW 2006, Australia; [Luxton, Grant] Univ New S Wales, Prince Wales Hosp, Dept Nephrol, Sydney, NSW, Australia; [Branley, Pauline] Monash Med Ctr, Melbourne, Vic, Australia; [Branley, Pauline] Eastern Hlth Renal Units, Melbourne, Vic, Australia; [Bulfone, Liliana] Deakin Univ, Sch Hlth & Social Dev, Burwood, Australia; [Fraenkel, Margaret B.] Austin Hosp, Dept Renal Med, Heidelberg, Vic 3084, Australia; [Harris, Anthony; Li, Jing Jing] Monash Univ, Ctr Hlth Econ, Clayton, Vic, Australia; [Johnson, David W.] Univ Queensland, Princess Alexandra Hosp, Ctr Kidney Dis Res, Brisbane, Qld, Australia; [Collins, John F.; Pilmore, Andrew] Auckland City Hosp, Dept Renal Med, Auckland, New Zealand	Royal North Shore Hospital; University of Sydney; University of Sydney; University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of New South Wales Sydney; Monash University; Deakin University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Monash University; University of Queensland; Auckland City Hospital	Cooper, BA (corresponding author), Royal N Shore Hosp, Dept Renal Med, St Leonards, NSW 2065, Australia.	bcooper@med.usyd.edu.au	Gray, Nicholas Andrew/D-8340-2011; Craig, Jonathan/E-2813-2013; Johnson, David/F-2897-2011; Hug, Balthasar L./G-1568-2010; Gray, Nicholas/O-4300-2019; Healy, Helen/G-2686-2010; Mantha, Murty/W-2825-2019; Harris, David/W-4786-2019; Fassett, Robert G/F-1752-2010	Gray, Nicholas Andrew/0000-0001-9112-0304; Craig, Jonathan/0000-0002-2548-4035; Johnson, David/0000-0001-5491-3460; Gray, Nicholas/0000-0001-9112-0304; Healy, Helen/0000-0003-4342-5300; Fassett, Robert G/0000-0002-5318-6940; Bulfone, Liliana/0000-0001-6406-5231; Harris, Anthony/0000-0003-1641-3320	National Health and Medical Research Council of Australia [211146, 465095]; Australian Health Ministers Advisory Council [PDR 2001/10]; Royal Australasian College of Physicians/Australian and New Zealand Society of Nephrology; National Heart Foundation (Australia); National Heart Foundation (New Zealand); Baxter Healthcare; Health Funding Authority New Zealand; International Society for Peritoneal Dialysis; Amgen Australia; Janssen-Cilag; Amgen; Roche; AstraZeneca; Fresenius Medical Care; Shire	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Australian Health Ministers Advisory Council; Royal Australasian College of Physicians/Australian and New Zealand Society of Nephrology; National Heart Foundation (Australia)(National Heart Foundation of Australia); National Heart Foundation (New Zealand); Baxter Healthcare; Health Funding Authority New Zealand; International Society for Peritoneal Dialysis; Amgen Australia(Amgen); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Amgen(Amgen); Roche(Roche Holding); AstraZeneca(AstraZeneca); Fresenius Medical Care; Shire	Supported by grants from the National Health and Medical Research Council of Australia (211146 and 465095), the Australian Health Ministers Advisory Council (PDR 2001/10), the Royal Australasian College of Physicians/Australian and New Zealand Society of Nephrology (Don and Lorraine Jacquot Fellowship), the National Heart Foundation (Australia), and the National Heart Foundation (New Zealand), and by unrestricted grants from Baxter Healthcare, Health Funding Authority New Zealand (Te Mana Putea Hauora O Aotearoa), the International Society for Peritoneal Dialysis, Amgen Australia, and Janssen-Cilag.; Dr. Johnson reports receiving consulting fees from Baxter Healthcare, Amgen, Roche, and AstraZeneca, grant support from Baxter Healthcare, lecture fees from Baxter Healthcare, Fresenius Medical Care, Amgen, Shire, Roche, and Janssen-Cilag, payment for development of educational presentations from Shire and Janssen-Cilag, and travel support from Amgen, Baxter Healthcare, and Roche; Dr. D. C. Harris, receiving consulting fees and travel support from Amgen Australia; and Dr. Pollock, receiving consulting fees from Amgen, lecture fees from Amgen and Baxter Healthcare, payment for development of educational presentations from Amgen and Baxter Healthcare, and travel support from Amgen. The University of Queensland Princess Alexandra Hospital has received grant support from Baxter Healthcare for services provided by Dr. Johnson. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2001, Am J Kidney Dis, V37, pS65; [Anonymous], 1997, Am J Kidney Dis, V30, pS67; [Anonymous], 2006, AM J KIDNEY DIS, DOI [10.1053/j.ajkd.2006.03.051, DOI 10.1053/J.AJKD.2006.03.051.MEDLINE]; ANSELL D, 2009, CLIN PRACT S1, V111, pC113; *AUSTR NZ DIAL TRA, 2009, REG REP 2008; Beddhu S, 2003, J AM SOC NEPHROL, V14, P2305, DOI 10.1097/01.ASN.0000080184.67406.11; BONOMINI V, 1986, NEPHRON, V44, P267, DOI 10.1159/000184004; BONOMINI V, 1978, KIDNEY INT, pS112; Churchill DN, 1999, J AM SOC NEPHROL, V10, pS289; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Cooper BA, 2004, PERITON DIALYSIS INT, V24, P176; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Grassmann A, 2005, NEPHROL DIAL TRANSPL, V20, P2587, DOI 10.1093/ndt/gfi159; Grassmann A, 2006, ARTIF ORGANS, V30, P895, DOI 10.1111/j.1525-1594.2006.00321.x; HAKIM RM, 1995, J AM SOC NEPHROL, V6, P1319; Hawthorne G, 1999, QUAL LIFE RES, V8, P209, DOI 10.1023/A:1008815005736; Kazmi WH, 2005, AM J KIDNEY DIS, V46, P887, DOI 10.1053/j.ajkd.2005.08.005; Kelly J, 2005, NEPHROLOGY, V10, pS46, DOI 10.1111/j.1440-1797.2005.00486_1.x; Kim Seoung Gu, 2009, Korean Journal of Internal Medicine, V24, P55, DOI 10.3904/kjim.2009.24.1.55; Lassalle M, 2010, KIDNEY INT, V77, P700, DOI 10.1038/ki.2010.14; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Liu H, 2008, RENAL FAILURE, V30, P685, DOI 10.1080/08860220802212619; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Pollack MH, 2005, CNS SPECTRUMS, V10, P4, DOI 10.1017/S1092852900026481; Pollock C, 2005, NEPHROLOGY, V10, pS177, DOI 10.1111/j.1440-1797.2005.00506.x; Rosansky SJ, 2009, KIDNEY INT, V76, P257, DOI 10.1038/ki.2009.161; Stel VS, 2009, NEPHROL DIAL TRANSPL, V24, P3175, DOI 10.1093/ndt/gfp264; TATTERSALL J, 1995, AM J NEPHROL, V15, P283, DOI 10.1159/000168850; Traynor JP, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000025294.40179.E8; 2006, AM J KIDNEY DIS S1, V48, pS98	31	566	595	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					609	619		10.1056/NEJMoa1000552	http://dx.doi.org/10.1056/NEJMoa1000552			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20581422	Bronze			2023-01-03	WOS:000280764600004
J	Berman, BM; Langevin, HH; Witt, CM; Dubner, R				Berman, Brian M.; Langevin, Helene H.; Witt, Claudia M.; Dubner, Ronald			Acupuncture for Chronic Low Back Pain.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONNECTIVE-TISSUE; PSYCHOLOGICAL DISTRESS; PRIMARY-CARE; GRAY-MATTER; TRIAL; BRAIN; INDIVIDUALS; EXPECTANCY; DISABILITY; MANAGEMENT		[Berman, Brian M.] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21207 USA; [Dubner, Ronald] Univ Maryland, Sch Dent, Baltimore, MD 21207 USA; [Langevin, Helene H.] Univ Vermont, Coll Med, Dept Neurol, Burlington, VT 05405 USA; [Langevin, Helene H.] Univ Vermont, Coll Med, Program Integrat Hlth, Burlington, VT 05405 USA; [Witt, Claudia M.] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Vermont; University of Vermont; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Berman, BM (corresponding author), Univ Maryland, Sch Med, Ctr Integrat Med, 2200 Kernan Dr, Baltimore, MD 21207 USA.	bberman@compmed.umm.edu	Witt, Claudia M./AAX-2370-2021	Witt, Claudia M./0000-0002-5440-7805				Ammendolia C, 2008, SPINE J, V8, P160, DOI 10.1016/j.spinee.2007.10.014; Andersson GBJ, 1999, LANCET, V354, P581, DOI 10.1016/S0140-6736(99)01312-4; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Apkarian AV, 2004, J NEUROSCI, V24, P10410, DOI 10.1523/JNEUROSCI.2541-04.2004; Baliki MN, 2006, J NEUROSCI, V26, P12165, DOI 10.1523/JNEUROSCI.3576-06.2006; Borsook D, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-25; Brinkhaus B, 2006, ARCH INTERN MED, V166, P450; Buckalew N, 2008, PAIN MED, V9, P240, DOI 10.1111/j.1526-4637.2008.00412.x; Carragee Eugene J, 2005, Spine J, V5, P24, DOI 10.1016/j.spinee.2004.05.250; Cheng X., 1987, CHINESE ACUPUNCTURE, P322; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P378; Cherkin DC, 2009, ARCH INTERN MED, V169, P858, DOI 10.1001/archinternmed.2009.65; Chou Roger, 2008, Ann Intern Med, V148, P247; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Chung A, 2003, CAN FAM PHYSICIAN, V49, P985; Dagenais S, 2010, SPINE J, V10, P514, DOI 10.1016/j.spinee.2010.03.032; Demoulin C, 2007, JOINT BONE SPINE, V74, P9, DOI 10.1016/j.jbspin.2006.02.013; Derbyshire, 1999, Curr Rev Pain, V3, P265, DOI 10.1007/s11916-999-0044-7; Deyo RA, 2001, NEW ENGL J MED, V344, P363, DOI 10.1056/NEJM200102013440508; Deyo RA, 2006, SPINE, V31, P2724, DOI 10.1097/01.brs.0000244618.06877.cd; Dhond RP, 2007, J ALTERN COMPLEM MED, V13, P603, DOI 10.1089/acm.2007.7040; Dionne CE, 2005, J CLIN EPIDEMIOL, V58, P714, DOI 10.1016/j.jclinepi.2004.12.005; Ee CC, 2008, AM J OBSTET GYNECOL, V198, P254, DOI 10.1016/j.ajog.2007.11.008; Giesecke T, 2004, ARTHRITIS RHEUM-US, V50, P613, DOI 10.1002/art.20063; GOLDMAN N, 2010, NAT NEUROSCI    0530; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Han JS, 2003, TRENDS NEUROSCI, V26, P17, DOI 10.1016/S0166-2236(02)00006-1; Harris RE, 2009, NEUROIMAGE, V47, P1077, DOI 10.1016/j.neuroimage.2009.05.083; HART LG, 1995, SPINE, V20, P11, DOI 10.1097/00007632-199501000-00003; HELMS J, 2007, GETTING KNOW YOU PHY; Hurwitz EL, 2003, J CLIN EPIDEMIOL, V56, P463, DOI 10.1016/S0895-4356(03)00010-6; Jarvik JG, 2005, SPINE, V30, P1541, DOI 10.1097/01.brs.0000167536.60002.87; Jarvik JG, 2002, ANN INTERN MED, V137, P586, DOI 10.7326/0003-4819-137-7-200210010-00010; Jarvik JJ, 2001, SPINE, V26, P1158, DOI 10.1097/00007632-200105150-00014; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; *KAIS FAM FDN HLTH, 2004, EMPL HLTH BEN 2004 A; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kobayashi Yoshitaka, 2009, Spine (Phila Pa 1976), V34, P2431, DOI 10.1097/BRS.0b013e3181b1fb76; Kong J, 2009, NEUROIMAGE, V45, P940, DOI 10.1016/j.neuroimage.2008.12.025; Langevin HM, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-151; Langevin HM, 2002, FASEB J, V16, P872, DOI 10.1096/fj.01-0925fje; Langevin HM, 2001, FASEB J, V15, P2275, DOI 10.1096/fj.01-0015hyp; Lewis K, 2010, CLIN J PAIN, V26, P60, DOI 10.1097/AJP.0b013e3181bad71e; Li AH, 2008, BMC COMPLEM ALTERN M, V8, DOI 10.1186/1472-6882-8-20; Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006; Liu T, 2009, EVID-BASED COMPL ALT, V6, P185, DOI 10.1093/ecam/nen002; Luo XM, 2004, SPINE, V29, P79, DOI 10.1097/01.BRS.0000105527.13866.0F; MacPherson H, 2001, BMJ-BRIT MED J, V323, P486, DOI 10.1136/bmj.323.7311.486; McNeil JM, 2001, JAMA-J AM MED ASSOC, V285, P1571; Melchart D, 2004, ARCH INTERN MED, V164, P104, DOI 10.1001/archinte.164.1.104; Napadow V, 2007, HUM BRAIN MAPP, V28, P159, DOI 10.1002/hbm.20261; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Pincus Tamar, 2002, Spine (Phila Pa 1976), V27, pE109, DOI 10.1097/00007632-200203010-00017; Pomeranz B, 1996, J Altern Complement Med, V2, P53, DOI 10.1089/acm.1996.2.53; RUBINSTEIN SM, 2010, EUR SPINE J     0314; Sandberg M, 2003, EUR J APPL PHYSIOL, V90, P114, DOI 10.1007/s00421-003-0825-3; Schmidt-Wilcke T, 2006, PAIN, V125, P89, DOI 10.1016/j.pain.2006.05.004; Sherman KJ, 2003, ALTERN THER HEALTH M, V9, P54; Speed C, 2004, BRIT MED J, V328, P1119, DOI 10.1136/bmj.328.7448.1119; Stanton TR, 2008, SPINE, V33, P2923, DOI 10.1097/BRS.0b013e31818a3167; Thomas KJ, 2006, BMJ-BRIT MED J, V333, P623, DOI 10.1136/bmj.38878.907361.7C; Tsao H, 2008, BRAIN, V131, P2161, DOI 10.1093/brain/awn154; Wang SM, 2008, ANESTH ANALG, V106, P602, DOI 10.1213/01.ane.0000277493.42335.7b; White A, 2004, RHEUMATOLOGY, V43, P662, DOI 10.1093/rheumatology/keg005; White A, 2001, BRIT MED J, V323, P485, DOI 10.1136/bmj.323.7311.485; Witt CM, 2006, AM J EPIDEMIOL, V164, P487, DOI 10.1093/aje/kwj224; Witt CM, 2009, FORSCH KOMPLEMENTMED, V16, P91, DOI 10.1159/000209315; Woby SR, 2004, BEHAV RES THER, V42, P761, DOI 10.1016/S0005-7967(03)00195-5; Yuan J, 2008, SPINE, V33, pE887, DOI 10.1097/BRS.0b013e318186b276; 2009, 88 NAT I HLTH CLIN E	71	145	162	7	64	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					454	461		10.1056/NEJMct0806114	http://dx.doi.org/10.1056/NEJMct0806114			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818865				2023-01-03	WOS:000280411300009
J	Svensson, L; Bohm, K; Castren, M; Pettersson, H; Engerstrom, L; Herlitz, J; Rosenqvist, M				Svensson, Leif; Bohm, Katarina; Castren, Maaret; Pettersson, Hans; Engerstrom, Lars; Herlitz, Johan; Rosenqvist, Marten			Compression-Only CPR or Standard CPR in Out-of-Hospital Cardiac Arrest.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTINUOUS CHEST COMPRESSIONS; BASIC LIFE-SUPPORT; MOUTH-TO-MOUTH; CARDIOPULMONARY-RESUSCITATION; VENTILATION; SURVIVAL	Background: Emergency medical dispatchers give instructions on how to perform cardiopulmonary resuscitation (CPR) over the telephone to callers requesting help for a patient with suspected cardiac arrest, before the arrival of emergency medical services (EMS) personnel. A previous study indicated that instructions to perform CPR consisting of only chest compression result in a treatment efficacy that is similar or even superior to that associated with instructions given to perform standard CPR, which consists of both compression and ventilation. That study, however, was not powered to assess a possible difference in survival. The aim of this prospective, randomized study was to evaluate the possible superiority of compression-only CPR over standard CPR with respect to survival. Methods: Patients with suspected, witnessed, out-of-hospital cardiac arrest were randomly assigned to undergo either compression-only CPR or standard CPR. The primary end point was 30-day survival. Results: Data for the primary analysis were collected from February 2005 through January 2009 for a total of 1276 patients. Of these, 620 patients had been assigned to receive compression-only CPR and 656 patients had been assigned to receive standard CPR. The rate of 30-day survival was similar in the two groups: 8.7% (54 of 620 patients) in the group receiving compression-only CPR and 7.0% (46 of 656 patients) in the group receiving standard CPR (absolute difference for compression-only vs. standard CPR, 1.7 percentage points; 95% confidence interval, -1.2 to 4.6; P=0.29). Conclusions: This prospective, randomized study showed no significant difference with respect to survival at 30 days between instructions given by an emergency medical dispatcher, before the arrival of EMS personnel, for compression-only CPR and instructions for standard CPR in patients with suspected, witnessed, out-of-hospital cardiac arrest. (Funded by the Swedish Heart-Lung Foundation and others; Karolinska Clinical Trial Registration number, CT20080012.) N Engl J Med 2010;363:434-42.	[Svensson, Leif] Soder Sjukhuset, Stockholm Prehosp Ctr, Karolinska Inst, Dept Clin Sci & Educ, S-11883 Stockholm, Sweden; [Svensson, Leif] Soder Sjukhuset, Karolinska Inst, Sect Prehosp Med, S-11883 Stockholm, Sweden; [Bohm, Katarina; Rosenqvist, Marten] Soder Sjukhuset, Karolinska Inst, Cardiol Sect, S-11883 Stockholm, Sweden; [Castren, Maaret] Soder Sjukhuset, Karolinska Inst, Sect Emergency Med, S-11883 Stockholm, Sweden; [Engerstrom, Lars] Swedish Emergency Med Commun Ctr, SOS Alarm, Stockholm, Sweden; [Herlitz, Johan] Univ Gothenburg, Serv Cardiol, Sahlgrenska Hosp, Gothenburg, Sweden	Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Karolinska Institutet; Sodersjukhuset Hospital; Sahlgrenska University Hospital; University of Gothenburg	Svensson, L (corresponding author), Soder Sjukhuset, Stockholm Prehosp Ctr, Karolinska Inst, Dept Clin Sci & Educ, S-11883 Stockholm, Sweden.	leif.svensson@sodersjukhuset.se			Stockholm County Council, SOS Alarm; Swedish Heart-Lung Foundation	Stockholm County Council, SOS Alarm(Stockholm County Council); Swedish Heart-Lung Foundation(Swedish Heart-Lung Foundation)	Supported by grants from the Stockholm County Council, SOS Alarm, and the Swedish Heart-Lung Foundation.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Assar D, 2000, RESUSCITATION, V45, P7, DOI 10.1016/S0300-9572(00)00152-0; Berg RA, 1997, CIRCULATION, V96, P4364; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Bohm K, 2009, RESUSCITATION, V80, P1025, DOI 10.1016/j.resuscitation.2009.06.004; Bohm K, 2007, CIRCULATION, V116, P2908, DOI 10.1161/CIRCULATIONAHA.107.710194; Chamberlain D, 2005, RESUSCITATION, V67, P157, DOI 10.1016/j.resuscitation.2005.05.011; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Hollenberg J, 2007, RESUSCITATION, V74, P242, DOI 10.1016/j.resuscitation.2006.12.014; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Jelinek GA, 2001, RESUSCITATION, V51, P239, DOI 10.1016/S0300-9572(01)00411-7; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Kern KB, 1998, RESUSCITATION, V39, P179, DOI 10.1016/S0300-9572(98)00141-5; Nagao K, 2007, LANCET, V369, P920; Odegaard S, 2006, RESUSCITATION, V71, P335, DOI 10.1016/j.resuscitation.2006.05.012; Paal P, 2006, RESUSCITATION, V70, P117, DOI 10.1016/j.resuscitation.2005.03.024; Rea TD, 2001, CIRCULATION, V104, P2513, DOI 10.1161/hc4601.099468; Shibata K, 2000, RESUSCITATION, V44, P187, DOI 10.1016/S0300-9572(00)00143-X; Willerson JT, 2000, CIRCULATION, V102, P1	21	178	197	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					434	442		10.1056/NEJMoa0908991	http://dx.doi.org/10.1056/NEJMoa0908991			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818864	Green Published			2023-01-03	WOS:000280411300007
J	Loxterkamp, DA				Loxterkamp, David A.			Old Men and the Sea	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												dr.loxterkamp@myfairpoint.net							0	1	1	5	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2010	304	1					18	19		10.1001/jama.2010.902	http://dx.doi.org/10.1001/jama.2010.902			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	620SJ	20606138				2023-01-03	WOS:000279519600001
J	Konstantinidou, V; Covas, MI; Munoz-Aguayo, D; Khymenets, O; de la Torre, R; Saez, G; Tormos, MD; Toledo, E; Marti, A; Ruiz-Gutierrez, V; Mendez, MVR; Fito, M				Konstantinidou, Valentini; Covas, Maria-Isabel; Munoz-Aguayo, Daniel; Khymenets, Olha; de la Torre, Rafael; Saez, Guillermo; del Carmen Tormos, Maria; Toledo, Estefania; Marti, Amelia; Ruiz-Gutierrez, Valentina; Ruiz Mendez, Maria Victoria; Fito, Montserrat			In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial	FASEB JOURNAL			English	Article						inflammation; oxidative stress; DNA damage; gene expression; IFN gamma	PHYSICAL-ACTIVITY QUESTIONNAIRE; RISK-FACTORS; HYPERCHOLESTEROLEMIC PATIENTS; INTERLEUKIN-7 RECEPTOR; GENE-EXPRESSION; DISEASE; INFLAMMATION; VALIDATION; ADHERENCE; TIME	The aim of the study was to assess whether benefits associated with the traditional Mediterranean diet (TMD) and virgin olive oil (VOO) consumption could be mediated through changes in the expression of atherosclerosis-related genes. A randomized, parallel, controlled clinical trial in healthy volunteers (n=90) aged 20 to 50 yr was performed. Three-month intervention groups were as follows: 1) TMD with VOO ( TMD+VOO), 2) TMD with washed virgin olive oil (TMD+WOO), and 3) control with participants' habitual diet. WOO was similar to VOO, but with a lower polyphenol content (55 vs. 328 mg/kg, respectively). TMD consumption decreased plasma oxidative and inflammatory status and the gene expression related with both inflammation [INF-gamma (INF gamma), Rho GTPase-activating protein15 (ARHGAP15), and interleukin-7 receptor (IL7R)] and oxidative stress [adrenergic beta(2)-receptor (ADRB2) and polymerase (DNA-directed) kappa (POLK)] in peripheral blood mononuclear cells. All effects, with the exception of the decrease in POLK expression, were particularly observed when VOO, rich in polyphenols, was present in the TMD dietary pattern. Our results indicate a significant role of olive oil polyphenols in the down-regulation of proatherogenic genes in the context of a TMD. In addition, the benefits associated with a TMD and olive oil polyphenol consumption on cardiovascular risk can be mediated through nutrigenomic effects.-Konstantinidou, V., Covas, M.-I., Munoz-Aguayo, D., Khymenets, O., de la Torre, R., Saez, G., del Carmen Tormos, M., Toledo, E., Marti, A., Ruiz-Gutierrez, V., Ruiz Mendez, M. V., Fito, M. In vivo nutrigenomic effects of virgin olive oil polyphenols within the frame of the Mediterranean diet: a randomized controlled trial. FASEB J. 24, 2546-2557 (2010). www.fasebj.org	[Konstantinidou, Valentini; Covas, Maria-Isabel; Munoz-Aguayo, Daniel; Fito, Montserrat] Hosp del Mar, IMIM, Cardiovasc Risk & Nutr Res Grp, Ctr Invest Biomed Eu Red Fisiopatol Obesidad & Nu, Barcelona, Spain; [Khymenets, Olha; de la Torre, Rafael] Hosp del Mar, IMIM, Human Pharmacol & Clin Neurosci Res Grp, Ctr Invest Biomed Eu Red Fisiopatol Obesidad & Nu, Barcelona, Spain; [Konstantinidou, Valentini] Pompeu Fabra Univ, Dept Ciencies Expt & Salut, PhD Program Biomed, Barcelona, Spain; [Saez, Guillermo; del Carmen Tormos, Maria] Univ Valencia, Dept Biochem & Mol Biol, Valencia, Spain; [Toledo, Estefania] Univ Navarra, Dept Prevent Med & Publ Hlth, Navarra, Spain; [Marti, Amelia] Univ Navarra, Dept Nutr Food Sci Physiol & Toxicol, Navarra, Spain; [Ruiz-Gutierrez, Valentina; Ruiz Mendez, Maria Victoria] Inst Grasa, Inst Nutr & Lipid Metab, Seville, Spain	Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Pompeu Fabra University; University of Valencia; University of Navarra; University of Navarra; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG)	Covas, MI (corresponding author), Hosp del Mar, IMIM, Cardiovasc Risk & Nutr Res Grp, Ctr Invest Biomed Eu Red Fisiopatol Obesidad & Nu, PRBB,Carrer Dr Aiguader 88-08003, Barcelona, Spain.	mcovas@imim.es	Fito, Montserrat/C-1822-2012; Toledo, Estefania/H-6211-2014; Marti, Amelia/M-2709-2019; Martí, Amelia/H-1192-2017; de la Torre, Rafael/D-3561-2018; Khymenets, Olha/I-9752-2014; Ruiz-Méndez, M. Victoria/P-1627-2014	Fito, Montserrat/0000-0002-1817-483X; Toledo, Estefania/0000-0002-6263-4434; Marti, Amelia/0000-0001-9832-7981; Martí, Amelia/0000-0001-9832-7981; de la Torre, Rafael/0000-0002-6765-1866; Khymenets, Olha/0000-0002-8668-580X; Ruiz-Méndez, M. Victoria/0000-0003-0750-7915; Saez, Guillermo/0000-0002-8164-4048	Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (FIS-FEDER) [PI041308]; Sistema National de Salud (SNS) [CP06/00100]; Instituto de Salud Carlos III; Greek State Scholarship Foundation (Athens, Greece); Generalitat of Catalunya [2005 SGR 00577]	Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (FIS-FEDER); Sistema National de Salud (SNS); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Greek State Scholarship Foundation (Athens, Greece); Generalitat of Catalunya(Generalitat de Catalunya)	The CIBER de Fisiopatolog a de la Obesidad y Nutricion is an initiative of the Instituto de Salud Carlos III, Madrid, Spain. This work was supported by Fondo de Investigacion Sanitaria-Fondo Europeo de Desarrollo Regional (FIS-FEDER; PI041308), by Sistema National de Salud (SNS) contract Miguel Servet (CP06/00100) Instituto de Salud Carlos III, and by the Greek State Scholarship Foundation (Athens, Greece), and partially supported by the Generalitat of Catalunya (2005 SGR 00577). The authors declare no conflicting financial interests.	Acin S, 2006, J BIOCHEM, V140, P383, DOI 10.1093/jb/mvj166; Beauchamp GK, 2005, NATURE, V437, P45, DOI 10.1038/437045a; Benetou V, 2008, BRIT J CANCER, V99, P191, DOI 10.1038/sj.bjc.6604418; Bogani P, 2007, ATHEROSCLEROSIS, V190, P181, DOI 10.1016/j.atherosclerosis.2006.01.011; Choi HK, 2005, CURR OPIN RHEUMATOL, V17, P141, DOI 10.1097/01.cco.0000152664.87204.3c; Chrysohoou C, 2004, J AM COLL CARDIOL, V44, P152, DOI 10.1016/j.jacc.2004.03.039; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110; Covas MI, 2007, PHARMACOL RES, V55, P175, DOI 10.1016/j.phrs.2007.01.010; Covas MI, 2006, NUTR REV, V64, pS20, DOI 10.1111/j.1753-4887.2006.tb00260.x; Covas MI, 2006, ANN INTERN MED, V145, P333, DOI 10.7326/0003-4819-145-5-200609050-00006; Damas JK, 2003, CIRCULATION, V107, P2670, DOI 10.1161/01.CIR.0000070542.18001.87; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; ELOSUA R, 1994, AM J EPIDEMIOL, V139, P1197, DOI 10.1093/oxfordjournals.aje.a116966; Elosua R, 2000, MED SCI SPORT EXER, V32, P1431, DOI 10.1097/00005768-200008000-00011; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Estruch R, 2006, ANN INTERN MED, V145, P1, DOI 10.7326/0003-4819-145-1-200607040-00004; Feldman I, 2008, P NATL ACAD SCI USA, V105, P4323, DOI 10.1073/pnas.0701722105; Fito M, 2008, EUR J CLIN NUTR, V62, P570, DOI 10.1038/sj.ejcn.1602724; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Ghittoni R, 2005, FASEB J, V19, P605, DOI 10.1096/fj.04-2702fje; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Gregory SG, 2007, NAT GENET, V39, P1083, DOI 10.1038/ng2103; Hao JJ, 2010, J NUTR BIOCHEM, V21, P634, DOI 10.1016/j.jnutbio.2009.03.012; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Imadome K, 2008, CANCER BIOL THER, V7, P208, DOI 10.4161/cbt.7.2.5255; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; Khymenets O, 2005, ANAL BIOCHEM, V347, P156, DOI 10.1016/j.ab.2005.07.007; Khymenets O, 2008, CLIN BIOCHEM, V41, P1348, DOI 10.1016/j.clinbiochem.2008.08.064; Khymenets O, 2009, OMICS, V13, P7, DOI 10.1089/omi.2008.0079; Konstantinidou V, 2009, FOLIA BIOL-PRAGUE, V55, P85; Konstantinidou V, 2009, OMICS, V13, P431, DOI 10.1089/omi.2008.0085; Kunkel TA, 2003, DNA REPAIR, V2, P135, DOI 10.1016/S1568-7864(02)00224-0; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Llorente-Cortes V, 2010, ATHEROSCLEROSIS, V208, P442, DOI 10.1016/j.atherosclerosis.2009.08.004; Machowetz A, 2007, FASEB J, V21, P45, DOI 10.1096/fj.06-6328com; Martinez-Dominguez E, 2001, INFLAMM RES, V50, P102, DOI 10.1007/s000110050731; MARTINMORENO JM, 1993, INT J EPIDEMIOL, V22, P512, DOI 10.1093/ije/22.3.512; Menendez JA, 2006, EUR J CANCER, V42, P2425, DOI 10.1016/j.ejca.2005.10.016; Miro-Casas E, 2001, ANAL BIOCHEM, V294, P63, DOI 10.1006/abio.2001.5160; Mobini R, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-19; Pacheco YM, 2007, BRIT J NUTR, V98, P260, DOI 10.1017/S0007114507701666; Paniagua JA, 2007, DIABETES CARE, V30, P1717, DOI 10.2337/dc06-2220; Parikh P, 2005, J AM COLL CARDIOL, V45, P1379, DOI 10.1016/j.jacc.2004.11.068; Perez-Jimenez F, 2005, EUR J CLIN INVEST, V35, P421, DOI 10.1111/j.1365-2362.2005.01516.x; Philipson L. H., 2002, Journal of Allergy and Clinical Immunology, V110, pS313, DOI 10.1067/mai.2002.129702; Rough J, 2009, SURGERY, V145, P235, DOI 10.1016/j.surg.2008.09.013; Ruano J, 2005, J AM COLL CARDIOL, V46, P1864, DOI 10.1016/j.jacc.2005.06.078; Ruano J, 2007, AM J CLIN NUTR, V86, P341, DOI 10.1093/ajcn/86.2.341; Salas-Salvado J, 2008, ARCH INTERN MED, V168, P2449, DOI 10.1001/archinte.168.22.2449; Seoh ML, 2003, FEBS LETT, V539, P131, DOI 10.1016/S0014-5793(03)00213-8; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; Takahata Y, 2009, J CELL PHYSIOL, V218, P268, DOI 10.1002/jcp.21594; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Trichopoulou A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2337; Visioli F, 2005, EUR J NUTR, V44, P121, DOI 10.1007/s00394-004-0504-0; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X	60	200	205	1	69	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2546	2557		10.1096/fj.09-148452	http://dx.doi.org/10.1096/fj.09-148452			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20179144				2023-01-03	WOS:000279343600041
J	Andreu, JM; Schaffner-Barbero, C; Huecas, S; Alonso, D; Lopez-Rodriguez, ML; Ruiz-Avila, LB; Nunez-Ramirez, R; Llorca, O; Martin-Galiano, AJ				Andreu, Jose M.; Schaffner-Barbero, Claudia; Huecas, Sonia; Alonso, Dulce; Lopez-Rodriguez, Maria L.; Ruiz-Avila, Laura B.; Nunez-Ramirez, Rafael; Llorca, Oscar; Martin-Galiano, Antonio J.			The Antibacterial Cell Division Inhibitor PC190723 Is an FtsZ Polymer-stabilizing Agent That Induces Filament Assembly and Condensation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-BETA-TUBULIN; ESCHERICHIA-COLI; PROTEIN FTSZ; STRUCTURAL INSIGHTS; IN-VITRO; Z-RING; MICROTUBULE; PROTOFILAMENTS; GTP; DYNAMICS	Cell division protein FtsZ can form single-stranded filaments with a cooperative behavior by self-switching assembly. Subsequent condensation and bending of FtsZ filaments are important for the formation and constriction of the cytokinetic ring. PC190723 is an effective bactericidal cell division inhibitor that targets FtsZ in the pathogen Staphylococcus aureus and Bacillus subtilis and does not affect Escherichia coli cells, which apparently binds to a zone equivalent to the binding site of the antitumor drug taxol in tubulin (Haydon, D. J., Stokes, N. R., Ure, R., Galbraith, G., Bennett, J. M., Brown, D. R., Baker, P. J., Barynin, V. V., Rice, D. W., Sedelnikova, S. E., Heal, J. R., Sheridan, J. M., Aiwale, S. T., Chauhan, P. K., Srivastava, A., Taneja, A., Collins, I., Errington, J., and Czaplewski, L. G. (2008) Science 312, 16731675). We have found that the benzamide derivative PC190723 is an FtsZ polymer-stabilizing agent. PC190723 induced nucleated assembly of Bs-FtsZ into single-stranded coiled protofilaments and polymorphic condensates, including bundles, coils, and toroids, whose formation could be modulated with different solution conditions. Under conditions for reversible assembly of Bs-FtsZ, PC190723 binding reduced the GTPase activity and induced the formation of straight bundles and ribbons, which was also observed with Sa-FtsZ but not with nonsusceptible Ec-FtsZ. The fragment 2,6-difluoro-3-methoxybenzamide also induced Bs-FtsZ bundling. We propose that polymer stabilization by PC190723 suppresses in vivo FtsZ polymer dynamics and bacterial division. The biochemical action of PC190723 on FtsZ parallels that of the microtubule-stabilizing agent taxol on the eukaryotic structural homologue tubulin. Both taxol and PC190723 stabilize polymers against disassembly by preferential binding to each assembled protein. It is yet to be investigated whether both ligands target structurally related assembly switches.	[Andreu, Jose M.; Schaffner-Barbero, Claudia; Huecas, Sonia; Ruiz-Avila, Laura B.; Nunez-Ramirez, Rafael; Llorca, Oscar; Martin-Galiano, Antonio J.] CSIC, Ctr Invest Biol, Madrid 28040, Spain; [Alonso, Dulce; Lopez-Rodriguez, Maria L.] Univ Complutense Madrid, Fac Ciencias Quim, Dept Quim Organ, E-28040 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Complutense University of Madrid	Andreu, JM (corresponding author), CSIC, Ctr Invest Biol, Ramiro de Maeztu 9, Madrid 28040, Spain.	j.m.andreu@cib.csic.es	Huecas, Sonia/P-2542-2019; Llorca, Oscar/K-1144-2014; Lopez-Rodriguez, Maria L/S-6342-2016; Llorca, Oscar/P-2784-2019; Physics, Biophym IEM-CSIC Macromolecular/C-7939-2011; Huecas, Sonia/K-1754-2014	Huecas, Sonia/0000-0002-6419-441X; Llorca, Oscar/0000-0001-5705-0699; Lopez-Rodriguez, Maria L/0000-0001-8607-1085; Llorca, Oscar/0000-0001-5705-0699; Huecas, Sonia/0000-0002-6419-441X; Nunez, Rafael/0000-0002-2949-8709; Martin-Galiano, Antonio Javier/0000-0002-6662-329X; Andreu, Jose M/0000-0001-8064-6933	Ministerio de Ciencia (MCINN) [BFU2008-00013, SAF2007-67008, S-SAL-249-2006, SAF2008-00451]; Comunidad Autonoma de Madrid [S-BIO-0214-2006]; Red Tematica de Investigacion Cooperativa en Cancer [RD06-0020-1001]; Human Frontiers Science Program [RGP39-2008]; Formacion de Personal Investigation; Consejo Superior de Investigaciones Cientificas i3p; Juan de la Cierva	Ministerio de Ciencia (MCINN); Comunidad Autonoma de Madrid(Comunidad de Madrid); Red Tematica de Investigacion Cooperativa en Cancer; Human Frontiers Science Program(Human Frontier Science Program); Formacion de Personal Investigation; Consejo Superior de Investigaciones Cientificas i3p; Juan de la Cierva(Instituto de Salud Carlos III)	This work was supported by Grants Ministerio de Ciencia (MCINN) BFU2008-00013 (to J. M. A.), Comunidad Autonoma de Madrid S-BIO-0214-2006 (to J. M. A. and O. L.), MCINN SAF2007-67008 (to M. L. L.-R.), S-SAL-249-2006 (to M. L. L.-R.), SAF2008-00451 (to O. L.), Red Tematica de Investigacion Cooperativa en Cancer RD06-0020-1001 (to O. L.), Human Frontiers Science Program RGP39-2008 (to O. L.) and contracts Formacion de Personal Investigation (to C. S.-B.), Consejo Superior de Investigaciones Cientificas i3p (to S. H.), and Juan de la Cierva (to A. J. M.-G.).	Abal M, 2001, CELL MOTIL CYTOSKEL, V49, P1, DOI 10.1002/cm.1016; Adams DW, 2009, NAT REV MICROBIOL, V7, P642, DOI 10.1038/nrmicro2198; ANDREU JM, 1982, BIOCHEMISTRY-US, V21, P534, DOI 10.1021/bi00532a019; Bennett MJ, 2009, BIOCHEMISTRY-US, V48, P4858, DOI 10.1021/bi900200q; Beuria TK, 2009, BIOCHEM J, V423, P61, DOI 10.1042/BJ20090817; BI E, 1991, NATURE, V354, P161, DOI 10.1038/354161a0; Buey RM, 2006, BIOCHEMISTRY-US, V45, P5933, DOI 10.1021/bi060334m; CASPAR DLD, 1980, BIOPHYS J, V32, P103, DOI 10.1016/S0006-3495(80)84929-0; Chen YD, 2009, BIOCHEMISTRY-US, V48, P6664, DOI 10.1021/bi8022653; Czaplewski LG, 2009, BIOORG MED CHEM LETT, V19, P524, DOI 10.1016/j.bmcl.2008.11.021; Dajkovic A, 2006, J MOL MICROB BIOTECH, V11, P140, DOI 10.1159/000094050; Diaz JF, 2009, TOP CURR CHEM, V286, P121, DOI 10.1007/128_2008_12; DIAZ JF, 1993, BIOCHEMISTRY-US, V32, P10067, DOI 10.1021/bi00089a023; Elie-Caille C, 2007, CURR BIOL, V17, P1765, DOI 10.1016/j.cub.2007.08.063; Erickson HP, 2009, P NATL ACAD SCI USA, V106, P9238, DOI 10.1073/pnas.0902258106; Gebremichael Y, 2008, BIOPHYS J, V95, P2487, DOI 10.1529/biophysj.108.129072; Goh S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006061; Gonzalez JM, 2003, J BIOL CHEM, V278, P37664, DOI 10.1074/jbc.M305230200; Haydon DJ, 2008, SCIENCE, V321, P1673, DOI 10.1126/science.1159961; Huecas S, 2008, BIOPHYS J, V94, P1796, DOI 10.1529/biophysj.107.115493; Huecas S, 2007, J BIOL CHEM, V282, P37515, DOI 10.1074/jbc.M706399200; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Lan GH, 2008, BIOPHYS J, V95, P4045, DOI 10.1529/biophysj.108.132837; Lappchen T, 2008, CHEM BIOL, V15, P189, DOI 10.1016/j.chembiol.2007.12.013; Larsen RA, 2007, GENE DEV, V21, P1340, DOI 10.1101/gad.1546107; Li Z, 2007, EMBO J, V26, P4694, DOI 10.1038/sj.emboj.7601895; Lowe J, 1999, EMBO J, V18, P2364, DOI 10.1093/emboj/18.9.2364; Margalit DN, 2004, P NATL ACAD SCI USA, V101, P11821, DOI 10.1073/pnas.0404439101; Margolin W, 2005, NAT REV MOL CELL BIO, V6, P862, DOI 10.1038/nrm1745; Marrington R, 2004, J BIOL CHEM, V279, P48821, DOI 10.1074/jbc.M404944200; Michie KA, 2006, ANNU REV BIOCHEM, V75, P467, DOI 10.1146/annurev.biochem.75.103004.142452; Miraldi ER, 2008, BIOPHYS J, V95, P2470, DOI 10.1529/biophysj.107.126219; Monahan LG, 2009, MOL MICROBIOL, V74, P1004, DOI 10.1111/j.1365-2958.2009.06914.x; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NAT STRUCT BIOL, V5, P451, DOI 10.1038/nsb0698-451; Nova E, 2007, ARCH BIOCHEM BIOPHYS, V465, P315, DOI 10.1016/j.abb.2007.06.032; Oliva MA, 2004, NAT STRUCT MOL BIOL, V11, P1243, DOI 10.1038/nsmb855; Oliva MA, 2003, J BIOL CHEM, V278, P33562, DOI 10.1074/jbc.M303798200; Oliva MA, 2007, J MOL BIOL, V373, P1229, DOI 10.1016/j.jmb.2007.08.056; Osawa M, 2008, SCIENCE, V320, P792, DOI 10.1126/science.1154520; Osawa M, 2009, EMBO J, V28, P3476, DOI 10.1038/emboj.2009.277; Popp D, 2009, BIOPOLYMERS, V91, P340, DOI 10.1002/bip.21136; Rice LM, 2008, P NATL ACAD SCI USA, V105, P5378, DOI 10.1073/pnas.0801155105; Rivas G, 2000, J BIOL CHEM, V275, P11740, DOI 10.1074/jbc.275.16.11740; Santra MK, 2004, J BIOL CHEM, V279, P25959, DOI 10.1074/jbc.M312473200; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; Stricker J, 2002, P NATL ACAD SCI USA, V99, P3171, DOI 10.1073/pnas.052595099; Vollmer W, 2006, APPL MICROBIOL BIOT, V73, P37, DOI 10.1007/s00253-006-0586-0; Xiao H, 2006, P NATL ACAD SCI USA, V103, P10166, DOI 10.1073/pnas.0603704103; Yu XC, 1997, EMBO J, V16, P5455, DOI 10.1093/emboj/16.17.5455	51	128	131	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 7	2010	285	19					14239	14246		10.1074/jbc.M109.094722	http://dx.doi.org/10.1074/jbc.M109.094722			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	591KQ	20212044	Green Published, hybrid			2023-01-03	WOS:000277299700020
J	Gill, TM; Gahbauer, EA; Han, L; Allore, HG				Gill, Thomas M.; Gahbauer, Evelyne A.; Han, Ling; Allore, Heather G.			Trajectories of Disability in the Last Year of Life.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OLDER PERSONS; FUNCTIONAL DECLINE; SAS PROCEDURE; HEALTH; MORBIDITY; FRAILTY; STATES	Background: Despite the importance of functional status to older persons and their families, little is known about the course of disability at the end of life. Methods: We evaluated data on 383 decedents from a longitudinal study involving 754 community-dwelling older persons. None of the subjects had disability in essential activities of daily living at the beginning of the study, and the level of disability was ascertained during monthly interviews for more than 10 years. Information on the conditions leading to death was obtained from death certificates and comprehensive assessments that were completed at 18-month intervals after the baseline assessment. Results: In the last year of life, five distinct trajectories were identified, from no disability to the most severe disability: 65 subjects had no disability (17.0%), 76 had catastrophic disability (19.8%), 67 had accelerated disability (17.5%), 91 had progressive disability (23.8%), and 84 had persistently severe disability (21.9%). The most common condition leading to death was frailty (in 107 subjects [27.9%]), followed by organ failure (in 82 subjects [21.4%]), cancer (in 74 subjects [19.3%]), other causes (in 57 subjects [14.9%]), advanced dementia (in 53 subjects [13.8%]), and sudden death (in 10 subjects [2.6%]). When the distribution of the disability trajectories was evaluated according to the conditions leading to death, a predominant trajectory was observed only for subjects who died from advanced dementia (67.9% of these subjects had a trajectory of persistently severe disability) and sudden death (50.0% of these subjects had no disability). For the four other conditions leading to death, no more than 34% of the subjects had any of the disability trajectories. The distribution of disability trajectories was particularly heterogeneous among the subjects with organ failure (from 12.2 to 32.9% of the subjects followed a specific trajectory) and frailty (from 14.0 to 27.1% of the subjects followed a specific trajectory). Conclusions: In most of the decedents, the course of disability in the last year of life did not follow a predictable pattern based on the condition leading to death. N Engl J Med 2010;362:1173-80.	[Gill, Thomas M.] Yale Univ, Sch Med, Adler Geriatr Ctr, Dept Internal Med, New Haven, CT 06510 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Adler Geriatr Ctr, Dept Internal Med, 874 Howard Ave, New Haven, CT 06510 USA.	thomas.gill@yale.edu	Maier, Andrea B./Q-5548-2019; Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	National Institute on Aging [R37AG17560, R01AG022993, K24AG021507]; Yale Claude D. Pepper Older Americans Independence Center [P30AG21342]; NATIONAL INSTITUTE ON AGING [R01AG022993, P30AG021342, K24AG021507, R37AG017560] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Yale Claude D. Pepper Older Americans Independence Center; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants from the National Institute on Aging (R37AG17560 and R01AG022993) and the Yale Claude D. Pepper Older Americans Independence Center (P30AG21342) and by a Midcareer Investigator Award in Patient-Oriented Research from the National Institute on Aging (K24AG021507, to Dr. Gill).	Bandeen-Roche K, 2006, J GERONTOL A-BIOL, V61, P262, DOI 10.1093/gerona/61.3.262; Chen JH, 2007, J GERONTOL A-BIOL, V62, P531, DOI 10.1093/gerona/62.5.531; Efron B., 1993, INTRO BOOTSTRAP, DOI [10.1007/978-1-4899-4541-9, DOI 10.1111/1467-9639.00050]; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; Gazelle G, 2007, NEW ENGL J MED, V357, P321, DOI 10.1056/NEJMp078067; Gill TM, 2008, J AM GERIATR SOC, V56, P436, DOI 10.1111/j.1532-5415.2007.01603.x; Gill TM, 2006, ARCH INTERN MED, V166, P418, DOI 10.1001/.418; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; Hardy SE, 2005, AM J EPIDEMIOL, V161, P575, DOI 10.1093/aje/kwi083; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; Ives DG, 2009, J AM GERIATR SOC, V57, P133, DOI 10.1111/j.1532-5415.2008.02056.x; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Jones BL, 2007, SOCIOL METHOD RES, V35, P542, DOI 10.1177/0049124106292364; Liao YL, 1999, AM J EPIDEMIOL, V149, P1097; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Lunney JR, 2002, J AM GERIATR SOC, V50, P1108, DOI 10.1046/j.1532-5415.2002.50268.x; Manton KG, 2006, P NATL ACAD SCI USA, V103, P18374, DOI 10.1073/pnas.0608483103; Nagin D.S., 2005, GROUP BASED MODELING; Weiss CO, 2007, JAMA-J AM MED ASSOC, V298, P1160, DOI 10.1001/jama.298.10.1160-a	24	556	568	0	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 1	2010	362	13					1173	1180		10.1056/NEJMoa0909087	http://dx.doi.org/10.1056/NEJMoa0909087			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	577QQ	20357280	Bronze, Green Accepted			2023-01-03	WOS:000276239500007
J	Niederhuber, JE				Niederhuber, John E.			Translating Discovery to Patient Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TUMOR MICROENVIRONMENT; CANCER		NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Niederhuber, JE (corresponding author), NCI, 31 Ctr Dr,Room 11A48, Bethesda, MD 20892 USA.	niederj@mail.nih.gov						Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Caussinus Emmanuel, 2007, Prog Mol Subcell Biol, V45, P205; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Danish M, 2008, CANCER BIOL THER, V7, P331, DOI 10.4161/cbt.7.3.5761; Ischehko I, 2009, SURGERY, V146, P430, DOI 10.1016/j.surg.2009.05.003; Khalil I, 2010, GYNECOL ONCOL, V116, P282, DOI 10.1016/j.ygyno.2009.10.085; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Ross JS, 2004, AM J CLIN PATHOL, V122, P598, DOI 10.1309/5CWPU41AFR1VYM3F; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271	9	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2010	303	11					1088	1089		10.1001/jama.2010.281	http://dx.doi.org/10.1001/jama.2010.281			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569KC	20233829				2023-01-03	WOS:000275594100024
J	Yang, L; Chen, J; Shi, LM; Hudock, MP; Wang, KJ; He, L				Yang, Lun; Chen, Jian; Shi, Leming; Hudock, Michael P.; Wang, Kejian; He, Lin			Identifying Unexpected Therapeutic Targets via Chemical-Protein Interactome	PLOS ONE			English	Article							HISTONE DEACETYLASE INHIBITORS; HUMAN ACETYLCHOLINESTERASE; DOCKING; LIGAND; IDENTIFICATION; SYSTEM; VISUALIZATION; PHARMACOLOGY; STRATEGIES; RESIDUES	Drug medications inevitably affect not only their intended protein targets but also other proteins as well. In this study we examined the hypothesis that drugs that share the same therapeutic effect also share a common therapeutic mechanism by targeting not only known drug targets, but also by interacting unexpectedly on the same cryptic targets. By constructing and mining an Alzheimer's disease (AD) drug-oriented chemical-protein interactome (CPI) using a matrix of 10 drug molecules known to treat AD towards 401 human protein pockets, we found that such cryptic targets exist. We recovered from CPI the only validated therapeutic target of AD, acetylcholinesterase (ACHE), and highlighted several other putative targets. For example, we discovered that estrogen receptor (ER) and histone deacetylase (HDAC), which have recently been identified as two new therapeutic targets of AD, might already have been targeted by the marketed AD drugs. We further established that the CPI profile of a drug can reflect its interacting character towards multi-protein sets, and that drugs with the same therapeutic attribute will share a similar interacting profile. These findings indicate that the CPI could represent the landscape of chemical-protein interactions and uncover "behind-the-scenes" aspects of the therapeutic mechanisms of existing drugs, providing testable hypotheses of the key nodes for network pharmacology or brand new drug targets for one-target pharmacology paradigm.	[Yang, Lun; Chen, Jian; Hudock, Michael P.; Wang, Kejian; He, Lin] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio Ctr X, Shanghai 200030, Peoples R China; [Yang, Lun; Chen, Jian; He, Lin] Fudan Univ, Inst Biomed Sci, Shanghai 200433, Peoples R China; [Shi, Leming] US FDA, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA; [He, Lin] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Shanghai, Peoples R China	Shanghai Jiao Tong University; Fudan University; US Food & Drug Administration (FDA); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Yang, L (corresponding author), Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Bio Ctr X, Shanghai 200030, Peoples R China.	lunyang@gmail.com; helinhelin@gmail.com	Shi, Leming/B-3150-2010; Yang, Lun/B-4859-2012	Shi, Leming/0000-0002-7143-2033; 	National Natural Science Foundation of China [30900841]; Postdoctoral Science Foundation of China [200902243]; China Postdoctoral Science Foundation [20070420660]; Shanghai Postdoctoral Science Foundation [61444]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Shanghai Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by National Natural Science Foundation of China [ 30900841], Special Reward Funding from Postdoctoral Science Foundation of China (200902243), China Postdoctoral Science Foundation (20070420660) and Shanghai Postdoctoral Science Foundation (No. 61444). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140; Carageorgiou H, 2005, BASIC CLIN PHARMACOL, V97, P320, DOI 10.1111/j.1742-7843.2005.pto_174.x; Carswell HVO, 2004, AM J PHYSIOL-HEART C, V287, pH1501, DOI 10.1152/ajpheart.00227.2004; Chang CI, 1998, AM J PHYSIOL-HEART C, V274, pH342, DOI 10.1152/ajpheart.1998.274.1.H342; Chen X, 2002, NUCLEIC ACIDS RES, V30, P412, DOI 10.1093/nar/30.1.412; Chen YZ, 2001, PROTEINS, V43, P217, DOI 10.1002/1097-0134(20010501)43:2<217::AID-PROT1032>3.0.CO;2-G; Ewing TJA, 2001, J COMPUT AID MOL DES, V15, P411, DOI 10.1023/A:1011115820450; Fang H, 2008, CURR DRUG METAB, V9, P1038, DOI 10.2174/138920008786927802; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fischer A, 2007, NATURE, V447, P178, DOI 10.1038/nature05772; Gao ZT, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-104; Gordus A, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.72; Hahnen E, 2008, EXPERT OPIN INV DRUG, V17, P169, DOI 10.1517/13543784.17.2.169; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Ji ZL, 2003, DRUG SAFETY, V26, P685, DOI 10.2165/00002018-200326100-00002; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Li CY, 2007, CELL RES, V17, P357, DOI 10.1038/cr.2007.27; Li HL, 2006, NUCLEIC ACIDS RES, V34, pW219, DOI 10.1093/nar/gkl114; Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106; Morales LBJ, 2006, J NEUROSCI, V26, P6823, DOI 10.1523/JNEUROSCI.0453-06.2006; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nacasch N, 1998, CLIN NEUROPHARMACOL, V21, P132; Nicholson JK, 2003, NAT REV DRUG DISCOV, V2, P668, DOI 10.1038/nrd1157; Ong SE, 2009, P NATL ACAD SCI USA, V106, P4617, DOI 10.1073/pnas.0900191106; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Rich RL, 2001, ANAL BIOCHEM, V296, P197, DOI 10.1006/abio.2001.5314; Saldanha AJ, 2004, BIOINFORMATICS, V20, P3246, DOI 10.1093/bioinformatics/bth349; Schatz RA, 2003, ANN PHARMACOTHER, V37, P1321, DOI 10.1345/aph.1D050; Schmitt S, 2002, J MOL BIOL, V323, P387, DOI 10.1016/S0022-2836(02)00811-2; Shafferman A, 1996, BIOCHEM J, V318, P833, DOI 10.1042/bj3180833; SHAFFERMAN A, 1992, J BIOL CHEM, V267, P17640; Shimohama S, 1998, NEUROSCI LETT, V245, P159, DOI 10.1016/S0304-3940(98)00209-2; Strimmer K, 2008, BIOINFORMATICS, V24, P1461, DOI 10.1093/bioinformatics/btn209; Tiwari-Woodruff S, 2007, P NATL ACAD SCI USA, V104, P14813, DOI 10.1073/pnas.0703783104; Vecsey CG, 2007, J NEUROSCI, V27, P6128, DOI 10.1523/JNEUROSCI.0296-07.2007; Vigers GPA, 2004, J MED CHEM, V47, P80, DOI 10.1021/jm030161o; von Rechenberg M, 2005, PROTEOMICS, V5, P1764, DOI 10.1002/pmic.200301088; VURAL H, 2008, BIOL TRACE ELEM RES; Warren GL, 2006, J MED CHEM, V49, P5912, DOI 10.1021/jm050362n; Xie L, 2007, PLOS COMPUT BIOL, V3, P2324, DOI 10.1371/journal.pcbi.0030217; Yamanishi Y, 2008, BIOINFORMATICS, V24, pI232, DOI 10.1093/bioinformatics/btn162; YANG L, 2009, PLOS COMPUT IN PRESS; Yang L, 2009, NUCLEIC ACIDS RES, V37, pW406, DOI 10.1093/nar/gkp312; Zhang JX, 2007, BIOINFORMATICS, V23, P1710, DOI 10.1093/bioinformatics/btm139	48	40	44	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2010	5	3					A71	A81	e9568	10.1371/journal.pone.0009568	http://dx.doi.org/10.1371/journal.pone.0009568			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565WZ	20221449	gold, Green Submitted, Green Published			2023-01-03	WOS:000275328200007
J	Dames, SA				Dames, Sonja A.			Structural Basis for the Association of the Redox-sensitive Target of Rapamycin FATC Domain with Membrane-mimetic Micelles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN TARGET; FKBP12-RAPAMYCIN-ASSOCIATED PROTEIN; SUBCELLULAR-LOCALIZATION; 3-DIMENSIONAL STRUCTURE; NMR-SPECTROSCOPY; MTOR PATHWAY; COMPLEX; KINASE; TOR; ACTIVATION	The target of rapamycin (TOR) is a conserved eukaryotic Ser/Thr kinase that regulates cellular growth in response to the nutrient and energy state. TOR signaling plays an important role in the development of diseases such as cancer, obesity, and diabetes and in different redox-sensitive processes (hypoxia, apoptosis, and aging). Because TOR has been detected at different cellular membranes and in the nucleus, its localization may influence the specific signaling readout. To better understand how TOR can associate with different membranes, the lipid-binding properties of the redox-sensitive yeast TOR1 FATC domain (y1fatc) have been characterized by solution NMR spectroscopy. Binding studies with different lipids indicate that y1fatc interacts specifically with a membrane-mimetic environment but appears not to recognize a specific lipid headgroup. In both, the structures of oxidized and reduced micelle-bound y1fatc, residues Ile-2456 to Trp-2470 of the lipid-binding motif form a hydrophobic bulb that has a rim of charged residues. The diffusion constants for both micelle-bound states are consistent with the rotational correlation times from the analysis of the N-15 relaxation data. Based on the K-d values, the oxidized form (K-d similar to 0.31 mM) binds dodecyl phosphocholine micelles slightly tighter than the reduced form (K-d similar to 1.86 mM). Binding studies with y1fatc in which one or both tryptophans (Trp-2466 and Trp-2470) were replaced by alanine suggest that these residues are important for the exact positioning in the membrane and that the other aromatic (His-2462, Tyr-2463, and Phe-2469) and aliphatic residues (Ile-2456, Leu-2459, Ile-2464, and Pro-2468) in the lipid-binding motif contribute significantly to the affinity.	[Dames, Sonja A.] Univ Basel, Dept Biol Struct, Biozentrum, CH-4056 Basel, Switzerland	University of Basel	Dames, SA (corresponding author), Tech Univ Munich, Dept Chem, Biomol NMR Spect, Lichtenbergstr 4, D-85747 Garching, Germany.	sonja.dames@tum.de		Dames, Sonja/0000-0001-7495-6943	Swiss National Science Foundation [31-109712]; German Research Foundation (Deutsche Forschungsgemeinschaft) [1195/3-1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG))	This work was supported in part by the Swiss National Science Foundation through a grant (SNF Grant 31-109712) to Stephan Grzesiek and by the German Research Foundation (Deutsche Forschungsgemeinschaft Grant DA 1195/3-1 to S.A.D.).	Adami A, 2007, MOL CELL, V27, P509, DOI 10.1016/j.molcel.2007.05.040; Ahn HC, 2006, J AM CHEM SOC, V128, P4398, DOI 10.1021/ja057773d; Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572; Asnaghi L, 2004, PHARMACOL RES, V50, P545, DOI 10.1016/j.phrs.2004.03.007; Begotka BA, 2006, MAGN RESON CHEM, V44, P586, DOI 10.1002/mrc.1793; Berchtold D, 2009, MOL BIOL CELL, V20, P1565, DOI 10.1091/mbc.E08-10-1001; Blagosklonny MV, 2008, CELL CYCLE, V7, P3344, DOI 10.4161/cc.7.21.6965; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Buerger C, 2006, BIOCHEM BIOPH RES CO, V344, P869, DOI 10.1016/j.bbrc.2006.03.220; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dosset P, 2000, J BIOMOL NMR, V16, P23, DOI 10.1023/A:1008305808620; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Dunlop EA, 2009, CELL SIGNAL, V21, P827, DOI 10.1016/j.cellsig.2009.01.012; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gouet P, 2003, NUCLEIC ACIDS RES, V31, P3320, DOI 10.1093/nar/gkg556; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; Ha SH, 2006, CELL SIGNAL, V18, P2283, DOI 10.1016/j.cellsig.2006.05.021; Hall M N, 2008, Transplant Proc, V40, pS5, DOI 10.1016/j.transproceed.2008.10.009; Hansen IA, 2005, J BIOL CHEM, V280, P20565, DOI 10.1074/jbc.M500712200; Jaworski J, 2006, MOL NEUROBIOL, V34, P205, DOI 10.1385/MN:34:3:205; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Kutateladze TG, 2004, J BIOL CHEM, V279, P3050, DOI 10.1074/jbc.M309007200; Lane HA, 2009, CURR OPIN CELL BIOL, V21, P219, DOI 10.1016/j.ceb.2009.01.016; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LAUTERWEIN J, 1979, BIOCHIM BIOPHYS ACTA, V556, P244, DOI 10.1016/0005-2736(79)90046-4; Lazaridis T, 2005, J PHYS CHEM B, V109, P15098, DOI 10.1021/jp0516801; Liu W, 2006, BIOCHEMISTRY-US, V45, P11713, DOI 10.1021/bi0608414; Lucas LH, 2004, CONCEPT MAGN RESON A, V20A, P24, DOI 10.1002/cmr.a.10094; Nanga RPR, 2009, J AM CHEM SOC, V131, P8252, DOI 10.1021/ja9010095; Orfi L, 1998, ANAL CHEM, V70, P1339, DOI 10.1021/ac971011m; Partovian C, 2008, MOL CELL, V32, P140, DOI 10.1016/j.molcel.2008.09.010; Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416; Polak P, 2009, CURR OPIN CELL BIOL, V21, P209, DOI 10.1016/j.ceb.2009.01.024; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Seewald MJ, 2000, PROTEIN SCI, V9, P1177, DOI 10.1110/ps.9.6.1177; Shao C, 2008, J BIOL CHEM, V283, P7230, DOI 10.1074/jbc.M705195200; Sun H, 2008, J BIOL CHEM, V283, P22233, DOI 10.1074/jbc.M802074200; Takahashi T, 2000, GENES CELLS, V5, P765, DOI 10.1046/j.1365-2443.2000.00365.x; Thevenot C, 2005, COLLOID SURFACE A, V252, P105, DOI 10.1016/j.colsurfa.2004.10.062; Tieleman DP, 2000, J PHYS CHEM B, V104, P6380, DOI 10.1021/jp001268f; Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Withers DJ, 1997, BIOCHEM BIOPH RES CO, V241, P704, DOI 10.1006/bbrc.1997.7878; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200	58	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	2010	285	10					7766	7775		10.1074/jbc.M109.058404	http://dx.doi.org/10.1074/jbc.M109.058404			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567AV	20042596	Green Published, hybrid			2023-01-03	WOS:000275415600084
J	Cohen, SP; Brown, C; Kurihara, C; Plunkett, A; Nguyen, C; Strassels, SA				Cohen, Steven P.; Brown, Charlie; Kurihara, Connie; Plunkett, Anthony; Nguyen, Conner; Strassels, Scott A.			Diagnoses and factors associated with medical evacuation and return to duty for service members participating in Operation Iraqi Freedom or Operation Enduring Freedom: a prospective cohort study	LANCET			English	Article							LOW-BACK-PAIN; NECK PAIN; GULF-WAR; MILITARY; MANAGEMENT; CASUALTIES; DISORDERS; INJURY	Background Anticipation of the types of injuries that occur in modem warfare is essential to plan operations and maintain a healthy military. We aimed to identify the diagnoses that result in most medical evacuations, and ascertain which demographic and clinical variables were associated with return to duty. Methods Demographic and clinical data were prospectively obtained for US military personnel who had been medically evacuated from Operation Iraqi Freedom or Operation Enduring Freedom (January, 2004-December, 2007). Diagnoses were categorised post hoc according to the International Classification of Diseases codes that were recorded at the time of transfer. The primary outcome measure was return to duty within 2 weeks. Findings 34006 personnel were medically evacuated, of whom 89% were men, 91% were enlisted, 82% were in the army, and 86% sustained an injury in Iraq. The most common reasons for medical evacuation were: musculoskeletal and connective tissue disorders (n=8104 service members, 24%), combat injuries (n=4713, 14%), neurological disorders (n=3502, 10%), psychiatric diagnoses (n=3108, 9%), and spinal pain (n=2445, 7%). The factors most strongly associated with return to duty were being a senior officer (adjusted OR 2.01, 95% Cl 1.71-2.35, p<0.0001), having a non-battle-related injury or disease (3.18, 2.77-3.67, p<0.0001), and presenting with chest or abdominal pain (2.48, 1.61-3.81, p<0.0001), a gastrointestinal disorder (non-surgical 2.32, 1.51-3.56, p=0.0001; surgical 2.62, 1.69-4.06, p<0.0001), or a genitourinary disorder (2.19, 1.43-3.36, p=0.0003). Covariates associated with a decreased probability of return to duty were serving in the navy or coast guard (0.59, 0.45-0.78, p=0.0002), or marines (0.86,0.77-0.96, p=0.0083); and presenting with a combat injury (0.27, 0.17-0.44, p<0.0001), a psychiatric disorder (0.28, 0.18-0.43, p<0.0001), musculoskeletal or connective tissue disorder (0.46, 0.30-0.71, p=0.0004), spinal pain (0.41, 0.26-0.63, p=0.0001), or other wound (0.54, 0.34-0.84, p=0.0069). Interpretation Implementation of preventive measures for service members who are at highest risk of evacuation, forward-deployed treatment, and therapeutic interventions could reduce the effect of non-battle-related injuries and disease on military readiness.	[Cohen, Steven P.] Johns Hopkins Sch Med, Pain Management Div, Baltimore, MD USA; [Brown, Charlie] Johns Hopkins Sch Med, Dept Anesthesiol, Baltimore, MD USA; [Cohen, Steven P.; Kurihara, Connie; Plunkett, Anthony] Walter Reed Army Med Ctr, Pain Management Div, Anesthesia Serv, Dept Surg, Washington, DC 20307 USA; [Nguyen, Conner] Landstuhl Reg Med Ctr, Dept Surg, Landstuhl, Germany; [Strassels, Scott A.] Univ Texas Austin, Div Pharm Practice, Austin, TX 78712 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Landstuhl Regional Medical Center; University of Texas System; University of Texas Austin	Cohen, SP (corresponding author), 550 North Broadway,Suite 301, Baltimore, MD 21029 USA.	scohen40@jhmi.edu			John P Murtha Neuroscience and Pain Institute, Johnstown, PA, USA; US Army Regional Anesthesia and Pain Management Initiative, Washington, DC, USA	John P Murtha Neuroscience and Pain Institute, Johnstown, PA, USA; US Army Regional Anesthesia and Pain Management Initiative, Washington, DC, USA	Funded by a Congressional grant from the John P Murtha Neuroscience and Pain Institute, Johnstown, PA, USA; and the US Army Regional Anesthesia and Pain Management Initiative, Washington, DC, USA. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.	[Anonymous], 2014, INT CLASS DIS 9 REV; Ariens GAM, 2001, AM J IND MED, V39, P180, DOI 10.1002/1097-0274(200102)39:2<180::AID-AJIM1005>3.0.CO;2-#; Barrett DH, 2002, PSYCHOSOMATICS, V43, P195, DOI 10.1176/appi.psy.43.3.195; Bellamy RF, 1996, ANESTHESIA PERIOPERA; Carroll LJ, 2008, SPINE, V33, pS93, DOI 10.1097/BRS.0b013e31816445d4; Cohen SP, 2005, ANESTH ANALG, V101, P1098, DOI 10.1213/01.ane.0000169332.45209.cf; COHEN SP, SPINE IN PRESS; Cohen SP, 2009, ARCH INTERN MED, V169, P1916, DOI 10.1001/archinternmed.2009.380; Cohen SP, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2718; Croft AM, 1999, MIL MED, V164, P460, DOI 10.1093/milmed/164.7.460; HOEFFLER DF, 1981, MIL MED, V146, P776; Holcomb JB, 2006, J TRAUMA, V60, P397, DOI 10.1097/01.ta.0000203581.75241.f1; Leclerc A, 1999, SPINE, V24, P1455, DOI 10.1097/00007632-199907150-00011; Peake JB, 2000, AM J PREV MED, V18, P4, DOI 10.1016/S0749-3797(00)00104-5; Pincus Tamar, 2002, Spine (Phila Pa 1976), V27, pE109, DOI 10.1097/00007632-200203010-00017; Pransky G, 2002, SPINE, V27, P864, DOI 10.1097/00007632-200204150-00017; SHANE L, 2005, STARS STRIPES W 1209; SONGTAG D, 2008, NY TIMES NEW YO 0113; TYSON AS, 2006, WASHINGTON POST 1220; *US DEP VET AFF, HOM VET OV HOM; White RL, 2007, ANESTHESIOLOGY, V107, P1003, DOI 10.1097/01.anes.0000290605.55736.e1; Writer JV, 2000, AM J PREV MED, V18, P64, DOI 10.1016/S0749-3797(00)00115-X; Young Richard S K, 2008, Conn Med, V72, P13; ZOROYA G, 2008, US TODAY WASHIN 1020	24	131	141	0	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 23	2010	375	9711					301	309		10.1016/S0140-6736(09)61797-9	http://dx.doi.org/10.1016/S0140-6736(09)61797-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549QS	20109957				2023-01-03	WOS:000274069300031
J	Banerjee, A; Hollis, A; Pogge, T				Banerjee, Amitava; Hollis, Aidan; Pogge, Thomas			The Health Impact Fund: incentives for improving access to medicines	LANCET			English	Editorial Material							PATENTS		[Banerjee, Amitava] Univ Oxford, Stroke Prevent Res Unit, Oxford OX3 9DU, England; [Pogge, Thomas] Yale Univ, Dept Philosophy, New Haven, CT USA; [Hollis, Aidan] Univ Calgary, Dept Econ, Calgary, AB T2N 1N4, Canada	University of Oxford; Yale University; University of Calgary	Banerjee, A (corresponding author), Univ Oxford, John Radcliffe Hosp, Stroke Prevent Res Unit, Level 6,West Wing, Oxford OX3 9DU, England.	amitava.banerjee@clneuro.ox.ac.uk	Banerjee, Amitava/D-4381-2014	Banerjee, Amitava/0000-0001-8741-3411; Hollis, Aidan/0000-0001-5125-2193				[Anonymous], 2009, LANCET, V373, P693, DOI 10.1016/S0140-6736(09)60410-4; Attaran A, 2004, HEALTH AFFAIR, V23, P155, DOI 10.1377/hlthaff.23.3.155; Attaran A, 2001, JAMA-J AM MED ASSOC, V286, P1886, DOI 10.1001/jama.286.15.1886; BACIU A, 2007, FUTURE DRUG SAFETY P; CHEN S, 2008, 4703 WPS WORLD BANK; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3; Garber AM, 2009, NEW ENGL J MED, V360, P1169, DOI 10.1056/NEJMp0808414; Gemmill MC, 2007, HEALTH ECON, V16, P627, DOI 10.1002/hec.1190; HOLLIS A, 2007, WHO PUBL HEAR UNPUB; HOLLIS A, HLTH IMPACT FUND MAK; Horton R, 2002, LANCET, V359, P1605, DOI 10.1016/S0140-6736(02)08523-9; OLIVEIRA MA, 2004, B WORLD HEALTH ORGAN, V82, P8150; PEDERSEN TR, 1994, LANCET, V344, P1383; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; *UN MILL DEV GOALS, GAT UN SYST WORK MDG; von Schirnding Y, 2005, GLOBALIZATION HEALTH, V1, DOI 10.1186/1744-8603-1-8; *WHO, 2005, CHRON DIS REP 2005, pCH2; WHO (World Health Organization), 1988, WORLD DRUG SIT; WITTY A, 2009, BIG PHARMA CATALYST; World Trade Organization, TRAD REL ASP INT PRO; 2000, GLOBAL POVERTY REPOR	21	49	50	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 9	2010	375	9709					166	169		10.1016/S0140-6736(09)61296-4	http://dx.doi.org/10.1016/S0140-6736(09)61296-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	544NM	20109894				2023-01-03	WOS:000273664500034
J	Kilby, JM				Kilby, J. Michael			Switching HIV therapies: competing host and viral factors	LANCET			English	Editorial Material							IMMUNODEFICIENCY-VIRUS-INFECTION; INTEGRASE INHIBITOR RALTEGRAVIR; RANDOMIZED CONTROLLED-TRIAL; TREATMENT-NAIVE PATIENTS; SOCIETY-USA PANEL; 2008 RECOMMENDATIONS; COMBINATION THERAPY; EFFICACY; SAFETY		Med Univ S Carolina, Charleston, SC 29425 USA	Medical University of South Carolina	Kilby, JM (corresponding author), Med Univ S Carolina, Charleston, SC 29425 USA.	mkilby@musc.edu		Kilby, J. Michael/0000-0003-3222-1003				ELMERDEWITT P, 1996, TIME            1230, P54; Eron JJ, 2010, LANCET, V375, P396, DOI 10.1016/S0140-6736(09)62041-9; Grinsztejn B, 2007, LANCET, V369, P1261, DOI 10.1016/S0140-6736(07)60597-2; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; Hirsch MS, 2008, CLIN INFECT DIS, V47, P266, DOI 10.1086/589297; Lennox JL, 2009, LANCET, V374, P796, DOI 10.1016/S0140-6736(09)60918-1; Markowitz M, 2007, JAIDS-J ACQ IMM DEF, V46, P125, DOI 10.1097/QAI.0b013e318157131c; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Riddler SA, 2008, NEW ENGL J MED, V358, P2095, DOI 10.1056/NEJMoa074609; Shlay JC, 2007, JAIDS-J ACQ IMM DEF, V44, P506, DOI 10.1097/QAI.0b013e31804216cf	11	3	3	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN-FEB	2010	375	9712					352	354		10.1016/S0140-6736(10)60067-0	http://dx.doi.org/10.1016/S0140-6736(10)60067-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	552PK	20074790				2023-01-03	WOS:000274305500006
J	Guzman, J				Guzman, Jaime			Neck pain and low-level laser: does it work and how?	LANCET			English	Editorial Material									Univ British Columbia, Vancouver, BC V6H 3X5, Canada	University of British Columbia	Guzman, J (corresponding author), Univ British Columbia, Vancouver, BC V6H 3X5, Canada.	jaime@ohsah.bc.ca	Guzman, Jaime/P-1836-2014	Guzman, Jaime/0000-0001-8977-2581				Carragee EJ, 2008, SPINE, V33, pS153, DOI 10.1097/BRS.0b013e31816445ea; Chow RT, 2009, LANCET, V374, P1897, DOI 10.1016/S0140-6736(09)61522-1; Gross AR, 2007, J RHEUMATOL, V34, P1083; Guzman J, 2008, SPINE, V33, pS199, DOI 10.1097/BRS.0b013e3181644641; Hawkins D, 2005, ANN NY ACAD SCI, V1056, P486, DOI 10.1196/annals.1352.040; Hurwitz EL, 2008, SPINE, V33, pS123, DOI 10.1097/BRS.0b013e3181644b1d; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]	7	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 5	2009	374	9705					1875	1876		10.1016/S0140-6736(09)61837-7	http://dx.doi.org/10.1016/S0140-6736(09)61837-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531EQ	19913901				2023-01-03	WOS:000272646900008
J	Katz, DA; Kiarie, JN; John-Stewart, GC; Richardson, BA; John, FN; Farquhar, C				Katz, David A.; Kiarie, James N.; John-Stewart, Grace C.; Richardson, Barbra A.; John, Francis N.; Farquhar, Carey			Male Perspectives on Incorporating Men into Antenatal HIV Counseling and Testing	PLOS ONE			English	Article							TO-CHILD TRANSMISSION; RESOURCE-POOR SETTINGS; PREGNANT-WOMEN; BURKINA-FASO; RURAL MALAWI; COTE-DIVOIRE; SCALING-UP; ACCEPTABILITY; PREVENTION; NEVIRAPINE	Background: Male partner involvement in antenatal voluntary HIV counseling and testing (VCT) has been shown to increase uptake of interventions to reduce the risk of HIV transmission in resource-limited settings. We aimed to identify methods for increasing male involvement in antenatal VCT and determine male correlates of accepting couple counseling in these settings. Methodology/Principal Findings: We invited women presenting to a Nairobi antenatal clinic to return with their male partners for individual or couples VCT. Male attitudes towards VCT and correlates of accompanying female partners to antenatal clinic and receiving couple counseling were determined. Of 1,993 women who invited their partner, 313 (16%) returned with their partners to ANC. Men attending antenatal clinic were married (>99%), employed (98%), and unlikely to report prior HIV testing (14%). Wanting an HIV test (87%) or health information (11%) were the most commonly cited reasons for attending. Most (95%) men who came to antenatal clinic accepted HIV testing and 39% elected to receive counseling as a couple. Men who received counseling with partners were younger, had fewer children, and were less knowledgeable about prevention of mother-to-child HIV transmission (PMTCT) than those who received counseling individually (p<0.05). Only 27% of men stated they would prefer HIV testing at a site other than the ANC. There was agreement between male and female reports for sociodemographic characteristics; however, men were more likely to report HIV preventive behaviors and health communication within the partnership than their partners (p<0.05). Conclusions/Significance: Offering VCT services to men at antenatal clinic with options for couple and individual counseling is an important opportunity and acceptable strategy for increasing male involvement in PMTCT and promoting male HIV testing.			Katz, DA (corresponding author), Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.	dkatz7@u.washington.edu	John-Stewart, Grace/L-3650-2019; John-Stewart, Grace/U-3351-2019	kiarie, james/0000-0003-4180-7858	FIC NIH HHS [D43 TW000007] Funding Source: Medline; NICHD NIH HHS [K23 HD041879, K24 HD054314] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K24HD054314] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K23HD041879] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [D43TW000007] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		[Anonymous], 2001, THE J, V35, P206, DOI [10.1023/A:1010484013306, DOI 10.1023/A:1010484013306, DOI 10.1023/A:1009584623712]; Baiden F, 2005, AIDS CARE, V17, P648, DOI 10.1080/09540120412331319688; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; deGraft-Johnson J, 2005, AIDS BEHAV, V9, P475, DOI 10.1007/s10461-005-9018-x; Desgrees-du-Lou A, 2002, INT J STD AIDS, V13, P462, DOI 10.1258/09564620260079617; Farquhar C, 2004, JAIDS-J ACQ IMM DEF, V37, P1620, DOI 10.1097/00126334-200412150-00016; Farquhar C, 2001, AIDS, V15, P815, DOI 10.1097/00002030-200104130-00027; Gage AJ, 2005, AIDS CARE, V17, P153, DOI 10.1080/09540120512331325635; Homsy J, 2006, JAIDS-J ACQ IMM DEF, V42, P149, DOI 10.1097/01.qai.0000225032.52766.c2; Johnson SK, 2008, LEADERSHIP QUART, V19, P1, DOI 10.1016/j.leaqua.2007.12.001; Kiarie J, 2000, AIDS, V14, P1468, DOI 10.1097/00002030-200007070-00030; Kiarie JN, 2003, AIDS, V17, P65, DOI 10.1097/00002030-200301030-00009; MACHEKANO R, 2000, AIDS BEHAV, V4, P63; Manzi M, 2005, TROP MED INT HEALTH, V10, P1242, DOI 10.1111/j.1365-3156.2005.01526.x; Meda N, 2002, AIDS, V16, P2323, DOI 10.1097/00002030-200211220-00013; Msuya SE, 2006, JAIDS-J ACQ IMM DEF, V43, P85, DOI 10.1097/01.qai.0000225016.50890.7e; Nebie Y, 2001, J ACQ IMMUN DEF SYND, V28, P367, DOI 10.1097/00126334-200112010-00010; Painter TM, 2005, INT J STD AIDS, V16, P237, DOI 10.1258/0956462053420158; Semrau K, 2005, AIDS, V19, P603, DOI 10.1097/01.aids.0000163937.07026.a0; Stringer EM, 2003, AIDS, V17, P1377, DOI 10.1097/00002030-200306130-00012; Stringer JSA, 2003, JAIDS-J ACQ IMM DEF, V32, P506, DOI 10.1097/00126334-200304150-00007; Temmerman M, 2003, AIDS, V17, P1239, DOI 10.1097/00002030-200305230-00016; Urassa P, 2005, AIDS CARE, V17, P842, DOI 10.1080/09540120500038231	24	90	90	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 2	2009	4	11							e7602	10.1371/journal.pone.0007602	http://dx.doi.org/10.1371/journal.pone.0007602			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	514RX	19881884	gold, Green Submitted, Green Published			2023-01-03	WOS:000271414400001
J	Wiebe, C; Reslerova, M; Komenda, P; Bueti, J; Rigatto, C; Sood, MM				Wiebe, Chris; Reslerova, Martina; Komenda, Paul; Bueti, Joe; Rigatto, Claudio; Sood, Manish M.			Atypical clinical presentation of H1N1 influenza in a dialysis patient	LANCET			English	Editorial Material									[Sood, Manish M.] St Boniface Gen Hosp, Manitoba Renal Program, Dept Med, Winnipeg, MB, Canada; [Wiebe, Chris] Univ Manitoba, Dept Med, Winnipeg, MB, Canada; [Bueti, Joe] Hlth Sci Ctr, Deparment Med, Winnipeg, MB, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Sood, MM (corresponding author), St Boniface Gen Hosp, Manitoba Renal Program, Dept Med, Bg007,409 Tache Ave, Winnipeg, MB, Canada.	msood99@gmail.com	Sood, Manish M/H-3134-2019	Sood, Manish M/0000-0002-9146-2344; Wiebe, Chris/0000-0002-1006-3545; Komenda, Paul/0000-0001-7016-7146				Hauser AB, 2008, PERITON DIALYSIS INT, V28, pS183; Robson R, 2006, NEPHROL DIAL TRANSPL, V21, P2556, DOI 10.1093/ndt/gfl267; *US CDC, UPD INT REC US ANT M; *US CDC, INT GUID CLIN ID CAR; World Health Organization, PAND H1N1 2009 UPD 6 PAND H1N1 2009 UPD 6	5	9	10	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	2009	374	9697					1300	1300		10.1016/S0140-6736(09)61596-8	http://dx.doi.org/10.1016/S0140-6736(09)61596-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507KQ	19819394				2023-01-03	WOS:000270852500036
J	Dunn, EF; Iida, M; Myers, RA; Campbell, DA; Hintz, KA; Armstrong, EA; Li, C; Wheeler, DL				Dunn, E. F.; Iida, M.; Myers, R. A.; Campbell, D. A.; Hintz, K. A.; Armstrong, E. A.; Li, C.; Wheeler, D. L.			Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab	ONCOGENE			English	Article						colorectal cancer; KRAS mutation; cetuximab resistance; Src family kinases; dasatinib	GROWTH-FACTOR RECEPTOR; SRC-FAMILY KINASES; COLON-CANCER CELLS; CARCINOMA-ASSOCIATED ANTIGEN; PP60C-SRC PROTEIN-KINASE; FOCAL-ADHESION KINASE; C-SRC; ACQUIRED-RESISTANCE; TYROSINE KINASES; SIGNAL-TRANSDUCTION	KRAS mutation is a predictive biomarker for resistance to cetuximab (Erbitux) in metastatic colorectal cancer (mCRC). This study sought to determine if KRAS mutant CRC lines could be sensitized to cetuximab using dasatinib (BMS-354825, Sprycel), a potent, orally bioavailable inhibitor of several tyrosine kinases, including the Src family kinases (SFKs). We analyzed 16 CRC lines for: (1) KRAS mutation status, (2) dependence on mutant KRAS signaling and (3) expression level of epidermal growth factor receptor (EGFR) and SFKs. From these analyses, we selected three KRAS mutant (LS180, LoVo and HCT116) cell lines and two KRAS wild-type cell lines (SW48 and CaCo2). In vitro, using poly-D-lysine/laminin plates, KRAS mutant cell lines were resistant to cetuximab, whereas KRAS wild-type lines showed sensitivity to cetuximab. Treatment with cetuximab and dasatinib showed a greater antiproliferative effect on KRAS mutant lines when compared with either agent alone in vitro and in vivo. To investigate potential mechanisms for this antiproliferative response in the combinatorial therapy, we performed Human Phospho-Kinase Antibody Array analysis, measuring the relative phosphorylation levels of 39 intracellular proteins in untreated, cetuximab, dasatinib or the combinatorial treatment in the KRAS mutant lines LS180, LoVo and HCT116 cells. The results of this experiment showed a decrease in a broad spectrum of kinases centered on the beta-catenin pathway, the mitogen-activated protein kinase (MAPK) pathway, AKT/mammalian target of rapamycin (mTOR) pathway and the family of signal transducers and activators of transcription (STATs) when compared with the untreated control or monotherapy treatments. Next, we analyzed tumor growth with cetuximab, dasatinib or their combination in vivo. KRAS mutant xenografts showed resistance to cetuximab therapy, whereas KRAS wild type demonstrated an antitumor response when treated with cetuximab. KRAS mutant tumors exhibited minimal response to dasatinib monotherapy. However, as in vitro, KRAS mutant lines exhibited a response to the combination of cetuximab and dasatinib. Combinatorial treatment of KRAS mutant xenografts resulted in decreased cell proliferation, as measured by Ki67, and higher rates of apoptosis, as measured by TUNEL terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling). The data presented in this study indicate that dasatinib can sensitize KRAS mutant CRC tumors to cetuximab and may do so by altering the activity of several key signaling pathways. Furthermore, these results suggest that signaling via EGFR and SFKs may be necessary for cell proliferation and survival of KRAS mutant CRC tumors. These data strengthen the rationale for clinical trials combining cetuximab and dasatinib in the KRAS mutant CRC genetic setting. Oncogene (2011) 30, 561-574; doi: 10.1038/onc.2010.430; published online 18 October 2010	[Wheeler, D. L.] Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Wheeler, DL (corresponding author), Univ Wisconsin, Dept Human Oncol, Ctr Comprehens Canc, Sch Med & Publ Hlth, 1111 Highland Ave,WIMR 3159, Madison, WI 53705 USA.	dlwheeler@wisc.edu	Li, Chunrong/F-6955-2011; Wheeler, Deric/B-7175-2013	Wheeler, Deric/0000-0001-5915-3675	Bristol-Myers Squibb; National Cancer Institute [P30CA014520]; National Center for Research Resources, National Institutes of Health [1UL1RR025011]; American Cancer Society [RSG-10-193-01TBG]; National Institutes of Health [CA009614-17]; NATIONAL CANCER INSTITUTE [P30CA014520, T32CA009614] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025011] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Research Resources, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	DLW has held a sponsored research agreement with Bristol-Myers Squibb.; This project was supported, in part, by grant P30CA014520 from the National Cancer Institute, grant 1UL1RR025011 from the Clinical and Translational Science Award program of the National Center for Research Resources, National Institutes of Health (to DLW), by grant RSG-10-193-01TBG from the American Cancer Society (to DLW) and T32 grant CA009614-17 Physician Scientist Training in Cancer Medicine from the National Institutes of Health (to EFD).	Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116; Belsches A P, 1997, Front Biosci, V2, pd501; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bivona TG, 2003, NATURE, V424, P694, DOI 10.1038/nature01806; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Cappuzzo F, 2008, ANN ONCOL, V19, P717, DOI 10.1093/annonc/mdm492; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496; DeMali KA, 1999, EXP CELL RES, V253, P271, DOI 10.1006/excr.1999.4669; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685; Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fu YN, 2008, ONCOGENE, V27, P957, DOI 10.1038/sj.onc.1210684; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Hantschel O, 2008, LEUKEMIA LYMPHOMA, V49, P615, DOI 10.1080/10428190801896103; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Irby R, 1997, CELL GROWTH DIFFER, V8, P1287; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kantarjian H, 2006, NAT REV DRUG DISCOV, V5, P717, DOI 10.1038/nrd2135; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kijima T, 2002, CELL GROWTH DIFFER, V13, P355; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001; Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Rini BI, 2008, CLIN CANCER RES, V14, P1286, DOI 10.1158/1078-0432.CCR-07-4719; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Viloria-Petit A, 2001, CANCER RES, V61, P5090; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang J, 2007, AM J PATHOL, V170, P366, DOI 10.2353/ajpath.2007.060706	78	102	107	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					561	574		10.1038/onc.2010.430	http://dx.doi.org/10.1038/onc.2010.430			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	20956938	Green Accepted			2023-01-03	WOS:000286922300005
J	Lamont, T; Cousins, D; Hillson, R; Bischler, A; Terblanche, M				Lamont, Tara; Cousins, David; Hillson, Rowan; Bischler, Anna; Terblanche, Martinette			Safety Alerts Safer administration of insulin: summary of a safety report from the National Patient Safety Agency	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Lamont, Tara; Cousins, David; Bischler, Anna; Terblanche, Martinette] Natl Patient Safety Agcy, Natl Reporting & Learning Serv, London W1T 5HD, England; [Hillson, Rowan] Hillingdon Hosp, London UB8 3NN, England	Brunel University; Imperial College London	Lamont, T (corresponding author), Natl Patient Safety Agcy, Natl Reporting & Learning Serv, London W1T 5HD, England.	tara.lamont@npsa.nhs.uk						Belknap S., 2001, INT J QUAL HEALTH C, V13, P339; Cox AR., 2009, BR J DIABETES VASC D, V9, P84, DOI 10.1177/1474651409103902; Derr RL, 2007, DIABETES SPECTR, V20, P177, DOI DOI 10.2337/diaspect.20.3.177; Fowler D., 2010, SAFE EFFECTIVE USE I; *NHS DIAB, 2010, FIND 2009 NAT DIAB I; PAGE MD, 1992, DIABETIC MED, V9, P938, DOI 10.1111/j.1464-5491.1992.tb01735.x; Rushmer R, 2008, DIABETIC MED, V25, P960, DOI 10.1111/j.1464-5491.2008.02470.x; United States Pharmacopeia, 2010, MEDMARX 5 ANN DAT RE	8	27	27	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	OCT 13	2010	341								c5269	10.1136/bmj.c5269	http://dx.doi.org/10.1136/bmj.c5269			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	668FB	20943723				2023-01-03	WOS:000283252900017
J	Bodenheimer, T; West, D				Bodenheimer, Thomas; West, David			Low-Cost Lessons from Grand Junction, Colorado	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bodenheimer, Thomas] Univ Calif San Francisco, Sch Med, Dept Family & Community Med, Ctr Excellence Primary Care, San Francisco, CA 94143 USA; [West, David] St Marys Hosp, Grand Junction, CO USA	University of California System; University of California San Francisco	Bodenheimer, T (corresponding author), Univ Calif San Francisco, Sch Med, Dept Family & Community Med, Ctr Excellence Primary Care, San Francisco, CA 94143 USA.							Berenson RA, 2010, NEW ENGL J MED, V363, P101, DOI 10.1056/NEJMp1005588; Gawande A., 2009, NEW YORKER; Medicare Payment Advisory Committee, 2009, REP C MEAS REG VAR S; Nichols L., 2009, GRAND JUNCTION COLOR; WEST D, 2009, MESA COUNTY COLORADO	5	8	8	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	2010	363	15					1391	1393		10.1056/NEJMp1008450	http://dx.doi.org/10.1056/NEJMp1008450			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	659NV	20925540				2023-01-03	WOS:000282575100002
J	Litvak, E; Pronovost, PJ				Litvak, Eugene; Pronovost, Peter J.			Rethinking Rapid Response Teams	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Litvak, Eugene] Inst Healthcare Optimizat, Newton, MA 02459 USA; [Litvak, Eugene] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Pronovost, Peter J.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA; [Pronovost, Peter J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Harvard University; Harvard T.H. Chan School of Public Health; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Litvak, E (corresponding author), Inst Healthcare Optimizat, 7 Wells Ave, Newton, MA 02459 USA.	elitvak@ihoptimize.org						Baker DR, 2009, CRIT CARE MED, V37, P2882, DOI 10.1097/CCM.0b013e3181b01caf; Berwick DM, 2006, JAMA-J AM MED ASSOC, V295, P324, DOI 10.1001/jama.295.3.324; BUTTERFIELD S, 2007, ACP HOSP         DEC; DeVita MA, 2006, CRIT CARE MED, V34, P2463, DOI 10.1097/01.CCM.0000235743.38172.6E; Gross D., 2008, FUNDAMENTALS QUEUING; Litvak E., 2009, MANAGING PATIENT FLO; Litvak E, 2005, JT COMM J QUAL PATIE, V31, P330, DOI 10.1016/S1553-7250(05)31044-0; Organisation for Economic Co-operation and Development, OECD HLTH DAT 2010 S; Ranji SR, 2007, J HOSP MED, V2, P422, DOI 10.1002/jhm.238; Sakai T, 2009, J ANESTH, V23, P403, DOI 10.1007/s00540-009-0778-8	10	58	73	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1375	1376		10.1001/jama.2010.1385	http://dx.doi.org/10.1001/jama.2010.1385			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652LK	20858881				2023-01-03	WOS:000282007900021
J	de Bono, JS; Ashworth, A				de Bono, J. S.; Ashworth, Alan			Translating cancer research into targeted therapeutics	NATURE			English	Article							CIRCULATING TUMOR-CELLS; RESISTANT PROSTATE-CANCER; PROGRESSION-FREE SURVIVAL; CLINICAL-TRIAL; ABIRATERONE ACETATE; PHASE-I; DRUG; GENE; IMATINIB; INHIBITION	The emphasis in cancer drug development has shifted from cytotoxic, non-specific chemotherapies to molecularly targeted, rationally designed drugs promising greater efficacy and less side effects. Nevertheless, despite some successes drug development remains painfully slow. Here, we highlight the issues involved and suggest ways in which this process can be improved and expedited. We envision an increasing shift to integrated cancer research and biomarker-driven adaptive and hypothesis testing clinical trials. The goal is the development of specific cancer medicines to treat the individual patient, with treatment selection being driven by a detailed understanding of the genetics and biology of the patient and their cancer.	[de Bono, J. S.] Inst Canc Res, Sutton SM2 5NG, Surrey, England; [de Bono, J. S.] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England; [Ashworth, Alan] Inst Canc Res, Breakthrough Breast Canc Ctr, London SW3 6JB, England	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	de Bono, JS (corresponding author), Inst Canc Res, Cotswold Rd, Sutton SM2 5NG, Surrey, England.	johann.de-bono@icr.ac.uk; alan.ashworth@icr.ac.uk		de Bono, Johann S/0000-0002-2034-595X	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812; Attard G, 2008, J CLIN PATHOL, V61, P891, DOI 10.1136/jcp.2008.056341; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Attard G, 2009, CANCER CELL, V16, P458, DOI 10.1016/j.ccr.2009.11.006; Attard G, 2009, NAT REV UROL, V6, P473, DOI 10.1038/nrurol.2009.130; Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Becher OJ, 2006, CANCER RES, V66, P3355, DOI 10.1158/0008-5472.CAN-05-3827; Betensky RA, 2002, J CLIN ONCOL, V20, P2495, DOI 10.1200/JCO.2002.06.140; BOLLAG G, 2010, NATURE          0907, DOI DOI 10.1038/NATURE09454; Budd GT, 2006, CLIN CANCER RES, V12, P6403, DOI 10.1158/1078-0432.CCR-05-1769; Buyse M, 2000, BIOSTATISTICS, V1, P49, DOI DOI 10.1093/BIOSTATISTICS/1.1.49; Buyse M, 2007, J CLIN ONCOL, V25, P5218, DOI 10.1200/JCO.2007.11.8836; Carden CP, 2009, CLIN PHARMACOL THER, V85, P131, DOI 10.1038/clpt.2008.223; Carden CP, 2010, DRUG DISCOV TODAY, V15, P88, DOI 10.1016/j.drudis.2009.11.006; Collins I, 2006, NAT CHEM BIOL, V2, P689, DOI 10.1038/nchembio840; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; de Bono JS, 2007, CLIN CANCER RES, V13, P3611, DOI 10.1158/1078-0432.CCR-07-0268; de Bono JS, 2003, BREAST CANCER RES, V5, P154, DOI 10.1186/bcr597; De Giorgi U, 2009, J CLIN ONCOL, V27, P3303, DOI 10.1200/JCO.2008.19.4423; DiMasi JA, 2007, J CLIN ONCOL, V25, P209, DOI 10.1200/JCO.2006.09.0803; Dowsett M, 2007, JNCI-J NATL CANCER I, V99, P167, DOI 10.1093/jnci/djk020; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Goodsaid F, 2007, AAPS J, V9, pE105, DOI 10.1208/aapsj0901010; Grantab R, 2006, CANCER RES, V66, P1033, DOI 10.1158/0008-5472.CAN-05-3077; Greystoke A, 2008, ANN ONCOL, V19, P990, DOI 10.1093/annonc/mdn014; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hennessy BT, 2009, CLIN CANCER RES, V15, P417, DOI 10.1158/1078-0432.CCR-08-2620; INGLE JN, 1981, NEW ENGL J MED, V304, P16, DOI 10.1056/NEJM198101013040104; Iorns E, 2007, NAT REV DRUG DISCOV, V6, P556, DOI 10.1038/nrd2355; Jordan VC, 2003, J NATL CANCER I, V95, P338, DOI 10.1093/jnci/95.5.338; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kantarjian H, 2006, NEW ENGL J MED, V354, P2542, DOI 10.1056/NEJMoa055104; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kreeger PK, 2010, CARCINOGENESIS, V31, P2, DOI 10.1093/carcin/bgp261; Kwak EL, 2009, J CLIN ONCOL, V27; Lord CJ, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-38; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Mandrekar SJ, 2009, J CLIN ONCOL, V27, P4027, DOI 10.1200/JCO.2009.22.3701; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Olmos D, 2009, ANN ONCOL, V20, P27, DOI 10.1093/annonc/mdn544; Propper DJ, 2003, J CLIN ONCOL, V21, P203, DOI 10.1200/JCO.2003.02.008; Reid AHM, 2010, BRIT J CANCER, V102, P678, DOI 10.1038/sj.bjc.6605554; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200/JCO.2009.24.6819; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Sarker D, 2009, CLIN CANCER RES, V15, P4799, DOI 10.1158/1078-0432.CCR-08-0125; Sausville EA, 2006, CANCER RES, V66, P3351, DOI 10.1158/0008-5472.CAN-05-3627; Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sobrero A, 2009, J CLIN ONCOL, V27, P5868, DOI 10.1200/JCO.2009.22.4162; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229; Taube SE, 2009, JNCI-J NATL CANCER I, V101, P1453, DOI 10.1093/jnci/djp334; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NATURE, V448, P595, DOI 10.1038/nature06024; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Von Hoff DD, 2009, NEW ENGL J MED, V361, P1164, DOI 10.1056/NEJMoa0905360; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Workman P, 2008, CURR OPIN PHARMACOL, V8, P359, DOI 10.1016/j.coph.2008.07.007; Workman P, 2006, JNCI-J NATL CANCER I, V98, P580, DOI 10.1093/jnci/djj162; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P393, DOI 10.1016/j.coph.2008.08.004	70	242	246	2	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP	2010	467	7315					543	549		10.1038/nature09339	http://dx.doi.org/10.1038/nature09339			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	655TT	20882008				2023-01-03	WOS:000282273100029
J	Stephan, MT; Moon, JJ; Um, SH; Bershteyn, A; Irvine, DJ				Stephan, Matthias T.; Moon, James J.; Um, Soong Ho; Bershteyn, Anna; Irvine, Darrell J.			Therapeutic cell engineering with surface-conjugated synthetic nanoparticles	NATURE MEDICINE			English	Article							T-LYMPHOCYTES; STEM-CELLS; TRANSPLANTATION; ANTIGEN; IMPACT; CANCER; EXPANSION; TARGET; IL-15; TRIAL	A major limitation of cell therapies is the rapid decline in viability and function of the transplanted cells. Here we describe a strategy to enhance cell therapy via the conjugation of adjuvant drug-loaded nanoparticles to the surfaces of therapeutic cells. With this method of providing sustained pseudoautocrine stimulation to donor cells, we elicited marked enhancements in tumor elimination in a model of adoptive T cell therapy for cancer. We also increased the in vivo repopulation rate of hematopoietic stem cell grafts with very low doses of adjuvant drugs that were ineffective when given systemically. This approach is a simple and generalizable strategy to augment cytoreagents while minimizing the systemic side effects of adjuvant drugs. In addition, these results suggest therapeutic cells are promising vectors for actively targeted drug delivery.	[Stephan, Matthias T.; Moon, James J.; Um, Soong Ho; Bershteyn, Anna; Irvine, Darrell J.] MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; [Stephan, Matthias T.; Moon, James J.; Um, Soong Ho; Bershteyn, Anna; Irvine, Darrell J.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA; [Um, Soong Ho; Irvine, Darrell J.] MIT, Dept Biol Engn, Cambridge, MA 02139 USA; [Irvine, Darrell J.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA; [Irvine, Darrell J.] Harvard Univ, Boston, MA 02115 USA; [Irvine, Darrell J.] Howard Hughes Med Inst, Chevy Chase, MD USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Howard Hughes Medical Institute	Irvine, DJ (corresponding author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.	djirvine@mit.edu	Moon, James J/ABE-4429-2021	Moon, James J/0000-0003-2238-2372; Stephan, Matthias/0000-0001-8310-0100	US National Institutes of Health [CA140476]; US National Science Foundation [DMR-02-13282]; US National Cancer Institute [P30-CA14051]; NATIONAL CANCER INSTITUTE [R01CA140476, P30CA014051] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Science Foundation(National Science Foundation (NSF)); US National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the US National Institutes of Health (CA140476), the US National Science Foundation (Materials Research Science and Engineering Center award DMR-02-13282), Cancer Center Support (core) grant P30-CA14051 from the US National Cancer Institute and a gift to the Koch Institute by Curtis and Cathy Marble. D.J.I. is an investigator of the Howard Hughes Medical Institute. We thank M. Sadelain (Memorial Sloan-Kettering Cancer Center) for extG-luc and M. van den Brink (Memorial Sloan-Kettering Cancer Center) for F-luc-transgenic mice.	Alison MR, 2009, CURR OPIN MOL THER, V11, P364; Alper J, 2009, NAT BIOTECHNOL, V27, P213, DOI 10.1038/nbt0309-213a; Bartlett DW, 2007, P NATL ACAD SCI USA, V104, P15549, DOI 10.1073/pnas.0707461104; Berger C, 2009, BLOOD, V114, P2417, DOI 10.1182/blood-2008-12-189266; BERNSTEIN I, 2008, BIOL BLOOD MARROW TR, V14, P94; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; Dhar S, 2008, P NATL ACAD SCI USA, V105, P17356, DOI 10.1073/pnas.0809154105; Dimos JT, 2008, SCIENCE, V321, P1218, DOI 10.1126/science.1158799; Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038; Fiorina P, 2008, AM J TRANSPLANT, V8, P1990, DOI 10.1111/j.1600-6143.2008.02353.x; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Jain RK, 2009, NEW ENGL J MED, V360, P2669, DOI 10.1056/NEJMcibr0902054; Kirpotin DB, 2006, CANCER RES, V66, P6732, DOI 10.1158/0008-5472.CAN-05-4199; Lu J, 2002, CLIN CANCER RES, V8, P3877; Mackinnon S, 2008, BLOOD CELL MOL DIS, V40, P63, DOI 10.1016/j.bcmd.2007.07.003; Morgan RA, 2006, SCIENCE, V314, P126, DOI 10.1126/science.1129003; Na HB, 2009, ADV MATER, V21, P2133, DOI 10.1002/adma.200802366; Overwijk WW, 1998, J EXP MED, V188, P277, DOI 10.1084/jem.188.2.277; Prescher JA, 2004, NATURE, V430, P873, DOI 10.1038/nature02791; Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]; Reichardt W, 2008, J IMMUNOL, V181, P4770, DOI 10.4049/jimmunol.181.7.4770; Rubinstein MP, 2006, P NATL ACAD SCI USA, V103, P9166, DOI 10.1073/pnas.0600240103; Sahaf B, 2003, P NATL ACAD SCI USA, V100, P4001, DOI 10.1073/pnas.2628032100; THOMPSON JA, 1987, CANCER RES, V47, P4202; Tong R, 2009, MRS BULL, V34, P422, DOI 10.1557/mrs2009.118; TREISMAN J, 1995, BLOOD, V85, P139, DOI 10.1182/blood.V85.1.139.bloodjournal851139; Trowbridge JJ, 2006, NAT MED, V12, P89, DOI 10.1038/nm1339; Wallace A, 2008, CLIN CANCER RES, V14, P3966, DOI 10.1158/1078-0432.CCR-08-0356; Weissleder R, 2005, NAT BIOTECHNOL, V23, P1418, DOI 10.1038/nbt1159; Woodrow KA, 2009, NAT MATER, V8, P526, DOI [10.1038/NMAT2444, 10.1038/nmat2444]; Zeng R, 2005, J EXP MED, V201, P139, DOI 10.1084/jem.20041057	32	491	508	15	324	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	SEP	2010	16	9					1035	U135		10.1038/nm.2198	http://dx.doi.org/10.1038/nm.2198			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	647MP	20711198	Green Accepted			2023-01-03	WOS:000281622900034
J	Goldman, N; Chen, M; Fujita, T; Xu, QW; Peng, WG; Liu, W; Jensen, TK; Pei, Y; Wang, FS; Han, XN; Chen, JF; Schnermann, J; Takano, T; Bekar, L; Tieu, K; Nedergaard, M				Goldman, Nanna; Chen, Michael; Fujita, Takumi; Xu, Qiwu; Peng, Weiguo; Liu, Wei; Jensen, Tina K.; Pei, Yong; Wang, Fushun; Han, Xiaoning; Chen, Jiang-Fan; Schnermann, Jurgen; Takano, Takahiro; Bekar, Lane; Tieu, Kim; Nedergaard, Maiken			Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture	NATURE NEUROSCIENCE			English	Article							PROSTATIC ACID-PHOSPHATASE; ADENOSINE A(1) RECEPTOR; TUBULOGLOMERULAR FEEDBACK; INFLAMMATORY PAIN; CINGULATE CORTEX; DORSAL-HORN; SPINAL-CORD; MICE; RAT; ELECTROACUPUNCTURE	Acupuncture is an invasive procedure commonly used to relieve pain. Acupuncture is practiced worldwide, despite difficulties in reconciling its principles with evidence-based medicine. We found that adenosine, a neuromodulator with anti-nociceptive properties, was released during acupuncture in mice and that its anti-nociceptive actions required adenosine A1 receptor expression. Direct injection of an adenosine A1 receptor agonist replicated the analgesic effect of acupuncture. Inhibition of enzymes involved in adenosine degradation potentiated the acupuncture-elicited increase in adenosine, as well as its anti-nociceptive effect. These observations indicate that adenosine mediates the effects of acupuncture and that interfering with adenosine metabolism may prolong the clinical benefit of acupuncture.	[Goldman, Nanna; Chen, Michael; Fujita, Takumi; Xu, Qiwu; Peng, Weiguo; Liu, Wei; Jensen, Tina K.; Pei, Yong; Wang, Fushun; Han, Xiaoning; Takano, Takahiro; Bekar, Lane; Tieu, Kim; Nedergaard, Maiken] Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Chen, Jiang-Fan] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Schnermann, Jurgen] NIDDKD, US Natl Inst Hlth, Bethesda, MD USA	University of Rochester; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Nedergaard, M (corresponding author), Univ Rochester, Med Ctr, Ctr Translat Neuromed, Rochester, NY 14642 USA.	nedergaard@urmc.rochester.edu	Tieu, Kim/AAG-7336-2019; Bekar, Lane K./AAI-2645-2021; Tieu, Kim/F-5426-2012	Tieu, Kim/0000-0001-6606-4371; Tieu, Kim/0000-0001-6606-4371; Chen, Jiang-Fan/0000-0002-0446-3956; Bekar, Lane/0000-0001-5083-0967; Takano, Takahiro/0000-0002-6235-6673	US National Institutes of Health; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014899, R21ES017470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS075177] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by a grant from the US National Institutes of Health to M.N. and K.T.	Abbracchio MP, 2009, TRENDS NEUROSCI, V32, P19, DOI 10.1016/j.tins.2008.10.001; Bekar L, 2008, NAT MED, V14, P75, DOI 10.1038/nm1693; Bonafede M, 2008, MED CARE, V46, P41, DOI 10.1097/MLR.0b013e3181589b7d; Burnstock G, 2007, PHYSIOL REV, V87, P659, DOI 10.1152/physrev.00043.2006; Burnstock G, 2009, MED HYPOTHESES, V73, P470, DOI 10.1016/j.mehy.2009.05.031; Castrop H, 2004, J CLIN INVEST, V114, P634, DOI 10.1172/JCI200421851; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cui M, 2010, J BIOL CHEM, V285, P11740, DOI 10.1074/jbc.M109.066662; CULLITON BJ, 1972, SCIENCE, V177, P592, DOI 10.1126/science.177.4049.592; CUNHA RA, 1991, EUR J PHARMACOL, V197, P83, DOI 10.1016/0014-2999(91)90368-Z; Davis KD, 1997, J NEUROPHYSIOL, V77, P3370, DOI 10.1152/jn.1997.77.6.3370; Eisenach JC, 2004, J PAIN, V5, P64, DOI 10.1016/j.jpain.2003.10.001; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Fredholm BB, 2001, PHARMACOL REV, V53, P527; GOLEMBIOWSKA K, 1995, BRAIN RES, V699, P315, DOI 10.1016/0006-8993(95)00926-H; Han JS, 2004, NEUROSCI LETT, V361, P258, DOI 10.1016/j.neulet.2003.12.019; Huang C, 2002, BRAIN RES, V945, P20, DOI 10.1016/S0006-8993(02)02503-9; KARLSTEN R, 1992, Pharmacology and Toxicology, V70, P434; Kelly RB, 2009, AM FAM PHYSICIAN, V80, P481; Lamanna Nicole, 2009, Clin Adv Hematol Oncol, V7, P386; Lao LX, 2004, BRAIN RES, V1020, P18, DOI 10.1016/j.brainres.2004.01.092; Li JH, 2005, CIRCULATION, V111, P2748, DOI 10.1161/CIRCULATIONAHA.104.510669; Li JH, 2003, J APPL PHYSIOL, V95, P577, DOI 10.1152/japplphysiol.00185.2003; Li WM, 2005, JPN J PHYSIOL, V55, P339, DOI 10.2170/jjphysiol.RP001505; LOHSE MJ, 1988, N-S ARCH PHARMACOL, V337, P687; Maione S, 2007, PAIN, V131, P281, DOI 10.1016/j.pain.2007.01.013; Martucci C, 2008, PAIN, V137, P81, DOI 10.1016/j.pain.2007.08.017; POORTMANS JR, 2003, PRINCIPLES EXERCISE; Quintero IB, 2007, CANCER RES, V67, P6549, DOI 10.1158/0008-5472.CAN-07-1651; Raghavendra V, 2004, EUR J NEUROSCI, V20, P467, DOI 10.1111/j.1460-9568.2004.03514.x; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; REEVE AJ, 1995, NEUROSCI LETT, V194, P81, DOI 10.1016/0304-3940(95)11732-C; SALTER MW, 1987, NEUROSCIENCE, V22, P631, DOI 10.1016/0306-4522(87)90359-9; Sawynok J, 1998, EUR J PHARMACOL, V347, P1, DOI 10.1016/S0014-2999(97)01605-1; Sawynok J, 1998, PAIN, V74, P75, DOI 10.1016/S0304-3959(97)00153-X; Sichardt K, 2007, PURINERG SIGNAL, V3, P285, DOI 10.1007/s11302-007-9065-z; Sjolund KF, 1999, ANESTH ANALG, V88, P605, DOI 10.1097/00000539-199903000-00027; Sun DQ, 2001, P NATL ACAD SCI USA, V98, P9983, DOI 10.1073/pnas.171317998; Takakura Nobuari, 2009, Open Med, V3, pe54; Volonte MG, 2004, J PHARMACEUT BIOMED, V35, P647, DOI 10.1016/j.jpba.2004.02.002; Wei F, 2001, J PHYSIOL-LONDON, V532, P823, DOI 10.1111/j.1469-7793.2001.0823e.x; Weidenhammer W, 2007, CLIN J PAIN, V23, P128, DOI 10.1097/01.ajp.0000210952.09127.df; Zhao ZQ, 2008, PROG NEUROBIOL, V85, P355, DOI 10.1016/j.pneurobio.2008.05.004; Zijlstra FJ, 2003, MEDIAT INFLAMM, V12, P59, DOI 10.1080/0962935031000114943; Zylka MJ, 2008, NEURON, V60, P111, DOI 10.1016/j.neuron.2008.08.024	45	503	578	10	193	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	JUL	2010	13	7					883	U130		10.1038/nn.2562	http://dx.doi.org/10.1038/nn.2562			7	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	615YF	20512135	Green Accepted			2023-01-03	WOS:000279173900022
J	Petruney, T; Harlan, SV; Lanham, M; Robinson, ET				Petruney, Tricia; Harlan, Sarah V.; Lanham, Michele; Robinson, Elizabeth T.			Increasing Support for Contraception as HIV Prevention: Stakeholder Mapping to Identify Influential Individuals and Their Perceptions	PLOS ONE			English	Article							TO-CHILD TRANSMISSION; WOMEN; PROGRAMS; DESIRES	Background: Voluntary contraceptive use by HIV-positive women currently prevents more HIV-positive births, at a lower cost, than anti-retroviral drug (ARV) regimens. Despite this evidence, most prevention of mother-to-child transmission (PMTCT) programs focus solely on providing ARV prophylaxis to pregnant women and rarely include the prevention of unintended pregnancies among HIV-positive women. Methodology/Principal Findings: To strengthen support for family planning as HIV prevention, we systematically identified key individuals in the field of international HIV/AIDS-those who could potentially influence the issue-and sought to determine their perceptions of barriers to and facilitators for implementing this PMTCT strategy. We used a criteria-based approach to determine which HIV/AIDS stakeholders have the most significant impact on HIV/AIDS research, programs, funding and policy and stratified purposive sampling to conduct interviews with a subset of these individuals. The interview findings pointed to obstacles to strengthening linkages between family planning and HIV/AIDS, including the need for: resources to integrate family planning and HIV services, infrastructure or capacity to provide integrated services at the facility level, national leadership and coordination, and targeted advocacy to key decision-makers. Conclusions/Significance: The individuals we identified as having regional or international influence in the field of HIV/AIDS have the ability to leverage an increasingly conducive funding environment and a growing evidence base to address the policy, programmatic and operational challenges to integrating family planning with HIV/AIDS. Fostering greater support for implementing contraception for HIV prevention will require the dedication, collaboration and coordination of many such actors. Our findings can inform a targeted advocacy campaign.	[Petruney, Tricia] Family Hlth Int, Res Utilizat, Res Triangle Pk, NC 27709 USA; [Harlan, Sarah V.; Robinson, Elizabeth T.] Family Hlth Int, Informat Programs, Res Triangle Pk, NC 27709 USA; [Lanham, Michele] Family Hlth Int, Behav & Biomed Res, Res Triangle Pk, NC 27709 USA		Petruney, T (corresponding author), Family Hlth Int, Res Utilizat, POB 13950, Res Triangle Pk, NC 27709 USA.	tpetruney@fhi.org		Lanham, Michele/0000-0003-3012-5683	Family Health International (FHI), United States Agency for International Development (USAID) [GPO-A-00-05-00022-00]	Family Health International (FHI), United States Agency for International Development (USAID)(United States Agency for International Development (USAID))	Funding: Support for this study was provided by Family Health International (FHI) with funds from the United States Agency for International Development (USAID), Cooperative Agreement Number GPO-A-00-05-00022-00, although the views expressed in this publication do not necessarily reflect those of FHI or USAID (www.usaid.gov). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Berwick DM, 2003, JAMA-J AM MED ASSOC, V289, P1969, DOI 10.1001/jama.289.15.1969; Biesma RG, 2009, HEALTH POLICY PLANN, V24, P239, DOI 10.1093/heapol/czp025; Dearing JW, 2004, J HEALTH COMMUN, V9, P21, DOI 10.1080/10810730490271502; Desgrees-du-Lou A, 2002, INT J STD AIDS, V13, P462, DOI 10.1258/09564620260079617; Elul B, 2009, AIDS, V23, pS19, DOI 10.1097/01.aids.0000363774.91376.dc; Gladwell M., 2000, TIPPING POINT LITTLE; Guest G., 2008, HDB TEAM BASED QUALI; Halperin DT, 2009, AIDS, V23, pS123, DOI 10.1097/01.aids.0000363785.73450.5a; Heys J, 2009, AIDS, V23, pS37, DOI 10.1097/01.aids.0000363776.76129.fd; Homsy J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004149; Johnson KB, 2009, AIDS, V23, pS7, DOI 10.1097/01.aids.0000363773.83753.27; Kates J., 2009, FINANCING RESPONSE A; Nutt P.C., 1992, STRATEG MANAG; Patton M. Q, 2015, QUALITATIVE RES EVAL, V4th; *PEPFAR, 2009, PEPFAR OV US COMM GL; Reynolds HW, 2008, SEX TRANSM INFECT, V84, pII49, DOI 10.1136/sti.2008.030049; Reynolds HW, 2006, SEX TRANSM DIS, V33, P350, DOI 10.1097/01.olq.0000194602.01058.e1; Reynolds HW, 2005, SEX TRANSM INFECT, V81, P184, DOI 10.1136/sti.2004.012013; Rochat TJ, 2006, JAMA-J AM MED ASSOC, V295, P1376, DOI 10.1001/jama.295.12.1376; Rogers EM, 2010, DIFFUSION INNOVATION; Rutenberg N, 2005, STUD FAMILY PLANN, V36, P235, DOI 10.1111/j.1728-4465.2005.00064.x; Schmeer K., 1999, GUIDELINES CONDUCTIN; Singh S, 2009, ADDING IT COSTS BENE; Spaulding AB, 2009, AIDS, V23, pS79, DOI 10.1097/01.aids.0000363780.42956.ff; Sweat MD, 2004, AIDS, V18, P1661, DOI 10.1097/01.aids.0000131353.06784.8f; Ulin PR, 2005, QUALITATIVE RES METH; Valente TW, 1999, ANN AM ACAD POLIT SS, V566, P55, DOI 10.1177/0002716299566001005; [WHO UNAIDS UNICEF], 2009, UN ACC SCAL PRIOR HI; *WHO, 2002, WHO M PRES MORG SWIT; Wilcher R, 2008, SEX TRANSM INFECT, V84, pII54, DOI 10.1136/sti.2008.030098; World Health Organization, 2002, STRAT APPR PREV HIV; World Health Organization (WHO), 2009, STRAT CONS STRENGTH	32	12	12	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 24	2010	5	5							e10781	10.1371/journal.pone.0010781	http://dx.doi.org/10.1371/journal.pone.0010781			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	601CC	20520728	Green Submitted, gold, Green Published			2023-01-03	WOS:000278034600004
J	Percec, V; Wilson, DA; Leowanawat, P; Wilson, CJ; Hughes, AD; Kaucher, MS; Hammer, DA; Levine, DH; Kim, AJ; Bates, FS; Davis, KP; Lodge, TP; Klein, ML; DeVane, RH; Aqad, E; Rosen, BM; Argintaru, AO; Sienkowska, MJ; Rissanen, K; Nummelin, S; Ropponen, J				Percec, Virgil; Wilson, Daniela A.; Leowanawat, Pawaret; Wilson, Christopher J.; Hughes, Andrew D.; Kaucher, Mark S.; Hammer, Daniel A.; Levine, Dalia H.; Kim, Anthony J.; Bates, Frank S.; Davis, Kevin P.; Lodge, Timothy P.; Klein, Michael L.; DeVane, Russell H.; Aqad, Emad; Rosen, Brad M.; Argintaru, Andreea O.; Sienkowska, Monika J.; Rissanen, Kari; Nummelin, Sami; Ropponen, Jarmo			Self-Assembly of Janus Dendrimers into Uniform Dendrimersomes and Other Complex Architectures	SCIENCE			English	Article							BLOCK-COPOLYMER VESICLES; DRUG-DELIVERY; LIPOSOMES; TRANSITION; MEMBRANES; DYNAMICS; ORIGINS; SYSTEMS; MODELS; PORES	Self-assembled nanostructures obtained from natural and synthetic amphiphiles serve as mimics of biological membranes and enable the delivery of drugs, proteins, genes, and imaging agents. Yet the precise molecular arrangements demanded by these functions are difficult to achieve. Libraries of amphiphilic Janus dendrimers, prepared by facile coupling of tailored hydrophilic and hydrophobic branched segments, have been screened by cryogenic transmission electron microscopy, revealing a rich palette of morphologies in water, including vesicles, denoted dendrimersomes, cubosomes, disks, tubular vesicles, and helical ribbons. Dendrimersomes marry the stability and mechanical strength obtainable from polymersomes with the biological function of stabilized phospholipid liposomes, plus superior uniformity of size, ease of formation, and chemical functionalization. This modular synthesis strategy provides access to systematic tuning of molecular structure and of self-assembled architecture.	[Percec, Virgil; Wilson, Daniela A.; Leowanawat, Pawaret; Wilson, Christopher J.; Hughes, Andrew D.; Kaucher, Mark S.; Aqad, Emad; Rosen, Brad M.; Argintaru, Andreea O.; Sienkowska, Monika J.] Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA; [Hammer, Daniel A.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Hammer, Daniel A.] Univ Penn, Inst Med & Engn, Philadelphia, PA 19104 USA; [Hammer, Daniel A.; Levine, Dalia H.; Kim, Anthony J.] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA; [Bates, Frank S.; Davis, Kevin P.; Lodge, Timothy P.] Univ Minnesota, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; [Lodge, Timothy P.] Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; [Klein, Michael L.; DeVane, Russell H.] Temple Univ, Inst Computat Mol Sci, Philadelphia, PA 19122 USA; [Rissanen, Kari; Nummelin, Sami; Ropponen, Jarmo] Univ Jyvaskyla, Dept Chem, Nanosci Ctr, Jyu 40014, Finland; [Nummelin, Sami] Aalto Univ, Dept Appl Phys, Sch Sci & Technol, FI-02150 Espoo, Finland	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Jyvaskyla; Aalto University	Percec, V (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA.	percec@sas.upenn.edu	Kim, Anthony/A-1681-2012; Rosen, Brad/A-5174-2008; Wilson, Christopher J/C-9390-2009; Percec, Virgil/H-6316-2014; Wilson, Christopher/T-5925-2019; Wilson, Christopher/ABC-5819-2020; Nummelin, Sami/P-4185-2019; Nummelin, Sami J/O-5741-2015; Sienkowska, Monika/GLR-1518-2022; Wilson, Daniela A./A-8119-2010; Rissanen, Kari T/B-5688-2008	Wilson, Christopher J/0000-0003-0760-3421; Percec, Virgil/0000-0001-5926-0489; Wilson, Christopher/0000-0003-0760-3421; Wilson, Christopher/0000-0003-0760-3421; Nummelin, Sami/0000-0003-2195-4818; Nummelin, Sami J/0000-0003-2195-4818; Wilson, Daniela A./0000-0002-8796-2274; Rissanen, Kari T/0000-0002-7282-8419; Aqad, Emad/0000-0002-8907-7391; Bates, Frank/0000-0003-3977-1278; Lodge, Timothy/0000-0001-5916-8834	NSF [DMR-0548559]; Academy of Finland; P. Roy Vagelos Chair at the University of Pennsylvania; Finnish Cultural Foundation	NSF(National Science Foundation (NSF)); Academy of Finland(Academy of Finland); P. Roy Vagelos Chair at the University of Pennsylvania; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science)	We thank the NSF (grant DMR-0548559), NSF-funded Materials Research Science and Engineering Centers at the University of Pennsylvania and at the University of Minnesota, the Academy of Finland, and the P. Roy Vagelos Chair at the University of Pennsylvania for financial support. We also thank T. Tuttila, N. Kuuloja, and M. Lahtinen from the University of Jyvaskyla for contributions on the synthesis and analysis of some Janus dendrimers from library 1. Additional funding was provided by the Finnish Cultural Foundation.	Almgren M, 2000, COLLOID SURFACE A, V174, P3, DOI 10.1016/S0927-7757(00)00516-1; [Anonymous], 1992, INTERMOLECULAR SURFA; BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6; Barenholz Y, 2001, CURR OPIN COLLOID IN, V6, P66, DOI 10.1016/S1359-0294(00)00090-X; Bridson RH, 2006, J PHARM PHARMACOL, V58, P775, DOI 10.1211/jpp.58.6.0008; CHIRUVOLU S, 1994, SCIENCE, V266, P1222, DOI 10.1126/science.7973704; Discher BM, 1999, SCIENCE, V284, P1143, DOI 10.1126/science.284.5417.1143; Discher DE, 2002, SCIENCE, V297, P967, DOI 10.1126/science.1074972; Dobereiner HG, 2000, CURR OPIN COLLOID IN, V5, P256, DOI 10.1016/S1359-0294(00)00064-9; Dubois M, 2001, NATURE, V411, P672, DOI 10.1038/35079541; Esfand R, 2001, DRUG DISCOV TODAY, V6, P427, DOI 10.1016/S1359-6446(01)01757-3; Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m; GHADIRI MR, 1994, NATURE, V369, P301, DOI 10.1038/369301a0; Guo X, 2003, ACCOUNTS CHEM RES, V36, P335, DOI 10.1021/ar9703241; Haluska CK, 2006, P NATL ACAD SCI USA, V103, P15841, DOI 10.1073/pnas.0602766103; Hanczyc MM, 2004, CURR OPIN CHEM BIOL, V8, P660, DOI 10.1016/j.cbpa.2004.10.002; Jung HT, 2001, P NATL ACAD SCI USA, V98, P1353, DOI 10.1073/pnas.041420998; Kita-Tokarczyk K, 2008, CHIMIA, V62, P820, DOI 10.2533/chimia.2008.820; Klein ML, 2008, SCIENCE, V321, P798, DOI 10.1126/science.1157834; Krafft MP, 2001, ADV DRUG DELIVER REV, V47, P209, DOI 10.1016/S0169-409X(01)00107-7; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; Lee CC, 2005, NAT BIOTECHNOL, V23, P1517, DOI 10.1038/nbt1171; Matsen MW, 1996, MACROMOLECULES, V29, P7641, DOI 10.1021/ma960744q; Percec V, 2004, NATURE, V430, P764, DOI 10.1038/nature02770; Rank A, 2009, LANGMUIR, V25, P1337, DOI 10.1021/la802709v; RINGSDORF H, 1988, ANGEW CHEM INT EDIT, V27, P113, DOI 10.1002/anie.198801131; Rosen BM, 2009, J AM CHEM SOC, V131, P17500, DOI 10.1021/ja907882n; Rosen BM, 2009, CHEM REV, V109, P6275, DOI 10.1021/cr900157q; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; Thiele J, 2010, LANGMUIR, V26, P6860, DOI 10.1021/la904163v; THOMAS JL, 1992, ACCOUNTS CHEM RES, V25, P336, DOI 10.1021/ar00020a003; van Dongen SFM, 2009, CHEM REV, V109, P6212, DOI 10.1021/cr900072y; WALTER A, 1991, BIOPHYS J, V60, P1315, DOI 10.1016/S0006-3495(91)82169-5; Yang L, 2001, BIOPHYS J, V81, P1475, DOI 10.1016/S0006-3495(01)75802-X; Zhu TF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005009	35	556	565	16	853	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	2010	328	5981					1009	1014		10.1126/science.1185547	http://dx.doi.org/10.1126/science.1185547			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	598YW	20489021				2023-01-03	WOS:000277877100036
J	Xavier, JB; Sander, C				Xavier, Joao B.; Sander, Chris			Principle of System Balance for Drug Interactions.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Xavier, Joao B.; Sander, Chris] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Xavier, JB (corresponding author), Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, 1275 York Ave, New York, NY 10021 USA.		Xavier, Joao/H-5471-2011	Xavier, Joao/0000-0003-3592-1689				Bollenbach T, 2009, CELL, V139, P707, DOI 10.1016/j.cell.2009.10.025; Chait R, 2007, NATURE, V446, P668, DOI 10.1038/nature05685; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890	3	7	7	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	2010	362	14					1339	1340		10.1056/NEJMcibr1001270	http://dx.doi.org/10.1056/NEJMcibr1001270			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	579SN	20375413				2023-01-03	WOS:000276393700016
J	Ghosn, Z				Ghosn, Zeinab			Crackdown on pharmacies in Lebanon spurs blame game	NATURE MEDICINE			English	News Item																			0	3	3	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					359	359		10.1038/nm0410-359a	http://dx.doi.org/10.1038/nm0410-359a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376022				2023-01-03	WOS:000276446800014
J	Walker, EP				Walker, Eric P.			HIV Clinic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												epwalker@uabmc.edu							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2010	303	9					819	819		10.1001/jama.2010.209	http://dx.doi.org/10.1001/jama.2010.209			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562NU	20197520				2023-01-03	WOS:000275059500001
J	Ehlenbach, WJ; Hough, CL; Crane, PK; Haneuse, SJPA; Carson, SS; Curtis, JR; Larson, EB				Ehlenbach, William J.; Hough, Catherine L.; Crane, Paul K.; Haneuse, Sebastien J. P. A.; Carson, Shannon S.; Curtis, J. Randall; Larson, Eric B.			Association Between Acute Care and Critical Illness Hospitalization and Cognitive Function in Older Adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; PEOPLE AGED 65; SURVIVORS; DEMENTIA; OUTCOMES; EPIDEMIOLOGY; DYSFUNCTION; DISEASE; DELIRIUM; MEMORY	Context Studies suggest that many survivors of critical illness experience long-term cognitive impairment but have not included premorbid measures of cognitive functioning and have not evaluated risk for dementia associated with critical illness. Objectives To determine whether decline in cognitive function was greater among older individuals who experienced acute care or critical illness hospitalizations relative to those not hospitalized and to determine whether the risk for incident dementia differed by these exposures. Design, Setting, and Participants Analysis of data from a prospective cohort study from 1994 through 2007 comprising 2929 individuals 65 years old and older without dementia at baseline residing in the community in the Seattle area and belonging to the Group Health Cooperative. Participants with 2 or more study visits were included, and those who had a hospitalization for a diagnosis of primary brain injury were censored at the time of hospitalization. Individuals were screened with the Cognitive Abilities Screening Instrument (CASI) (score range, 0-100) every 2 years at follow-up visits, and those with a score less than 86 underwent a clinical examination for dementia. Main Outcome Measures Score on the CASI at follow-up study visits and incident dementia diagnosed in study participants, adjusted for baseline cognitive scores, age, and other risk factors. Results During a mean (SD) follow-up of 6.1 (3.2) years, 1601 participants had no hospitalization, 1287 had 1 or more noncritical illness hospitalizations, and 41 had 1 or more critical illness hospitalizations. The CASI score was assessed more than 45 days after discharge for 94.3% of participants. Adjusted CASI scores averaged 1.01 points lower for visits following acute care illness hospitalization compared with follow-up visits not following any hospitalization (95% confidence interval [CI], -1.33 to -0.70; P<.001) and 2.14 points lower on average for visits following critical illness hospitalization (95% CI, -4.24 to -0.03; P=.047). There were 146 cases of dementia among those not hospitalized, 228 cases of dementia among those with 1 or more noncritical illness hospitalizations, and 5 cases of dementia among those with 1 or more critical illness hospitalizations. The adjusted hazard ratio for incident dementia was 1.4 following a noncritical illness hospitalization (95% CI, 1.1 to 1.7; P=.001) and 2.3 following a critical illness hospitalization (95% CI, 0.9 to 5.7; P=.09). Conclusions Among a cohort of older adults without dementia at baseline, those who experienced acute care hospitalization and critical illness hospitalization had a greater likelihood of cognitive decline compared with those who had no hospitalization. Noncritical illness hospitalization was significantly associated with the development of dementia. JAMA. 2010; 303(8): 763-770	[Ehlenbach, William J.] Dept Vet Affairs, Hlth Serv Res & Dev, Seattle, WA 98101 USA; [Ehlenbach, William J.; Hough, Catherine L.; Crane, Paul K.; Curtis, J. Randall; Larson, Eric B.] Univ Washington, Dept Med, Seattle, WA USA; [Haneuse, Sebastien J. P. A.; Larson, Eric B.] Grp Hlth Res Inst, Seattle, WA USA; [Carson, Shannon S.] Univ N Carolina, Div Pulm & Crit Care Med, Chapel Hill, NC USA	University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill	Ehlenbach, WJ (corresponding author), Dept Vet Affairs, Hlth Serv Res & Dev, 1100 Olive Way,Ste 1400, Seattle, WA 98101 USA.	wje1@u.washington.edu	Ehlenbach, William J./R-5784-2019	Ehlenbach, William J./0000-0002-2864-5543; Crane, Paul/0000-0003-4278-7465	National Institutes of Health (NIH) National Institute on Aging [UO1 AG06781]; John A. Hartford Foundation; National Heart, Lung, and Blood Institute [1 K24 HL068593]; National Institute on Aging [R01 AG029672]; NIH [5T32HL007287-30]; Department of Veterans Affairs; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL068593, R01HL096504, T32HL007287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG006781, R01AG029672] Funding Source: NIH RePORTER	National Institutes of Health (NIH) National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); John A. Hartford Foundation; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Funding/Support: The Adult Changes in Thought study is funded by a National Institutes of Health (NIH) National Institute on Aging Cooperative Grant (UO1 AG06781; principal investigator [PI]: Dr Larson). Additional funding for this study was provided by the John A. Hartford Foundation (PI: Dr Hough), a K24 Award from the National Heart, Lung, and Blood Institute (1 K24 HL068593; PI: Dr Curtis), and an R01 from the National Institute on Aging (R01 AG029672; PI: Dr Crane). Dr Ehlenbach was supported by an NIH Respiratory Research Training Grant (5T32HL007287-30; PI: Leonard Hudson, MD, University of Washington) and a Department of Veterans Affairs Health Services Research and Development Postdoctoral Fellowship.	Al-Saidi F, 2003, AM J RESP CRIT CARE, V167, pA737; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Carson Shannon S, 2006, J Intensive Care Med, V21, P173, DOI 10.1177/0885066605282784; Carson SS, 2003, CRIT CARE CLIN, V19, P605, DOI 10.1016/S0749-0704(03)00051-4; Clark TG, 2002, LANCET, V359, P1309, DOI 10.1016/S0140-6736(02)08272-7; Crane PK, 2008, J CLIN EPIDEMIOL, V61, P1018, DOI 10.1016/j.jclinepi.2007.11.011; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Diggle PJ, 1994, ANAL LONGITUDINAL DA, V1st; Elenkov IJ, 2005, NEUROIMMUNOMODULAT, V12, P255, DOI 10.1159/000087104; Girard TD, 2009, AM J RESP CRIT CARE, V179, pA5477; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hopkins R O, 1995, J Int Neuropsychol Soc, V1, P501; Hopkins RO, 2006, CLIN CHEST MED, V27, P679, DOI 10.1016/j.ccm.2006.06.003; Hopkins RO, 2006, CHEST, V130, P869, DOI 10.1378/chest.130.3.869; HOPKINS RO, 1995, BRAIN COGNITION, V27, P180, DOI 10.1006/brcg.1995.1016; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; HOPKINS RO, 2005, INT NEUR SOC 33 ANN; Huber P. J., 1967, P 5 BERK S MATH STAT; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jackson JC, 2003, ARCH CLIN NEUROPSYCH, V18, P688; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Kukull WA, 2002, ARCH NEUROL-CHICAGO, V59, P1737, DOI 10.1001/archneur.59.11.1737; Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004; MARQUIS K, 2000, AM J RESP CRIT CARE, V161, pA383; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976; Rudolph JL, 2008, ANAESTHESIA, V63, P941, DOI 10.1111/j.1365-2044.2008.05523.x; SAMEJIMA F, 1969, PSYCHOMETRIKA, V34, P1; SAMEJIMA F, 1997, GRADED RESPONSE MODE; *SCI SOFTW INT, 2003, PARSC WIND COMP PROG; STARR JM, 1994, DRUG SAFETY, V11, P310, DOI 10.2165/00002018-199411050-00003; SUCHYTA MR, 2004, AM J RESP CRIT CARE, V169, pA18; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; Wang L, 2002, J AM GERIATR SOC, V50, P1525, DOI 10.1046/j.1532-5415.2002.50408.x; Wang L, 2004, J AM GERIATR SOC, V52, P2045, DOI 10.1111/j.1532-5415.2004.52568.x; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; Zsembik BA, 2001, J GERONTOL B-PSYCHOL, V56, pS266, DOI 10.1093/geronb/56.5.S266	46	355	365	1	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	2010	303	8					763	770		10.1001/jama.2010.167	http://dx.doi.org/10.1001/jama.2010.167			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	559DD	20179286	Green Accepted, Green Submitted, Bronze			2023-01-03	WOS:000274800000028
J	Brochard, L				Brochard, Laurent			Less sedation in intensive care: the pendulum swings back	LANCET			English	Editorial Material							CRITICALLY-ILL PATIENTS		[Brochard, Laurent] Ctr Hosp Albert Chenevier Henri Mondor, AP HP, Med Intens Care Unit, F-94000 Creteil, France; [Brochard, Laurent] Hop Henri Mondor, INSERM, U955, F-94010 Creteil, France; [Brochard, Laurent] Univ Paris Est, Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Brochard, L (corresponding author), Ctr Hosp Albert Chenevier Henri Mondor, AP HP, Med Intens Care Unit, F-94000 Creteil, France.	laurent.brochard@hmn.aphp.fr						Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Payen JF, 2007, ANESTHESIOLOGY, V106, P687, DOI 10.1097/01.anes.0000264747.09017.da; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9	5	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 6	2010	375	9713					436	438		10.1016/S0140-6736(10)60103-1	http://dx.doi.org/10.1016/S0140-6736(10)60103-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PV	20116840				2023-01-03	WOS:000274757900005
J	Khanim, FL; Hayden, RE; Birtwistle, J; Lodi, A; Tiziani, S; Davies, NJ; Ride, JP; Viant, MR; Gunther, UL; Mountford, JC; Schrewe, H; Green, RM; Murray, JA; Drayson, MT; Bunce, CM				Khanim, Farhat L.; Hayden, Rachel E.; Birtwistle, Jane; Lodi, Alessia; Tiziani, Stefano; Davies, Nicholas J.; Ride, Jon P.; Viant, Mark R.; Gunther, Ulrich L.; Mountford, Joanne C.; Schrewe, Heinrich; Green, Richard M.; Murray, Jim A.; Drayson, Mark T.; Bunce, Chris M.			Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia	PLOS ONE			English	Article							ACTIVATED-RECEPTOR-GAMMA; INHIBITS CELL-GROWTH; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); CYCLOPENTENONE PROSTAGLANDIN; OLDER PATIENTS; MYELODYSPLASTIC-SYNDROME; PROMYELOCYTIC LEUKEMIA; OXIDATIVE STRESS; INDUCE APOPTOSIS; DOWN-REGULATION	Background: The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are urgently required. In particular, therapies that have anti-leukaemic activity but that, unlike conventional chemotherapy, do not impair normal haemopoiesis. Principal Findings: Here we demonstrate the potent anti-leukaemic activity of the combination of the lipid-regulating drug bezafibrate (BEZ) and the sex hormone medroxyprogesterone acetate (MPA) against AML cell lines and primary AML cells. The combined activity of BEZ and MPA (B/M) converged upon the increased synthesis and reduced metabolism of prostaglandin D-2 (PGD(2)) resulting in elevated levels of the downstream highly bioactive, anti-neoplastic prostaglandin 15-deoxy Delta(12,14) PGJ(2) (15d-PGJ(2)). BEZ increased PGD(2) synthesis via the generation of reactive oxygen species (ROS) and activation of the lipid peroxidation pathway. MPA directed prostaglandin synthesis towards 15d-PGJ(2) by inhibiting the PGD(2) 11 beta-ketoreductase activity of the aldo-keto reductase AKR1C3, which metabolises PGD(2) to 9 alpha 11 beta-PGF(2 alpha). B/M treatment resulted in growth arrest, apoptosis and cell differentiation in both AML cell lines and primary AML cells and these actions were recapitulated by treatment with 15d-PGJ(2). Importantly, the actions of B/M had little effect on the survival of normal adult myeloid progenitors. Significance: Collectively our data demonstrate that B/M treatment of AML cells elevated ROS and delivered the antineoplastic actions of 15d-PGJ(2). These observations provide the mechanistic rationale for the redeployment of B/M in elderly and relapsed AML.	[Khanim, Farhat L.; Hayden, Rachel E.; Birtwistle, Jane; Davies, Nicholas J.; Ride, Jon P.; Viant, Mark R.; Green, Richard M.; Bunce, Chris M.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England; [Lodi, Alessia; Tiziani, Stefano; Gunther, Ulrich L.] Univ Birmingham, Henry Wellcome Bldg Biomol NMR Spect, CRUK Inst Canc Studies, Birmingham, W Midlands, England; [Mountford, Joanne C.] Univ Glasgow, Div Canc Sci & Mol Pathol, Glasgow, Lanark, Scotland; [Schrewe, Heinrich] Max Planck Inst Mol Genet, Dept Dev Genet, Berlin, Germany; [Schrewe, Heinrich] Charite, Inst Med Genet, D-13353 Berlin, Germany; [Murray, Jim A.] Queen Elizabeth Hosp, Ctr Clin Haematol, Birmingham B15 2TH, W Midlands, England; [Drayson, Mark T.] Univ Birmingham, Div Immun & Infect, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Glasgow; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Birmingham; University of Birmingham	Khanim, FL (corresponding author), Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England.	C.M.Bunce@bham.ac.uk	Viant, Mark R/B-6339-2009; mountford, joanne c/H-1010-2012	Viant, Mark R/0000-0001-5898-4119; mountford, joanne c/0000-0003-2142-6572; Drayson, Mark/0000-0002-1528-7564; Bunce, Chris/0000-0003-4084-8973	Leukaemia Research UK; Marie Curie Transfer of Knowledge (ToK) (MOTET)	Leukaemia Research UK; Marie Curie Transfer of Knowledge (ToK) (MOTET)(European Commission)	Funding was recieved from Leukaemia Research UK and Marie Curie Transfer of Knowledge (ToK) (MOTET). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aldini G, 2007, BIOCHEMISTRY-US, V46, P2707, DOI 10.1021/bi0618565; Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468; Birtwistle L, 2009, MUTAT RES-FUND MOL M, V662, P67, DOI 10.1016/j.mrfmmm.2008.12.010; Breitkreutz I, 2008, EXPERT OPIN DRUG MET, V4, P973, DOI [10.1517/17425255.4.7.973, 10.1517/17425255.4.7.973 ]; Brunoldi EA, 2007, CHEM RES TOXICOL, V20, P1528, DOI 10.1021/tx700231a; Bunce CM, 1996, BBA-MOL CELL RES, V1311, P189, DOI 10.1016/0167-4889(96)00005-5; Burnett AK, 2006, SEMIN HEMATOL, V43, P96, DOI 10.1053/j.seminhematol.2006.01.003; Burnett AK, 2009, BRIT J HAEMATOL, V145, P318, DOI 10.1111/j.1365-2141.2009.07604.x; Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a; Cox B, 2002, BBA-MOL CELL BIOL L, V1584, P37, DOI 10.1016/S1388-1981(02)00267-6; Craig CM, 2008, BLOOD REV, V22, P221, DOI 10.1016/j.blre.2008.03.002; Date M, 2003, LIVER INT, V23, P460, DOI 10.1111/j.1478-3231.2003.00877.x; Deschler B, 2006, HAEMATOLOGICA, V91, P1513; Desmond JC, 2003, CANCER RES, V63, P505; Druker BJ, 2008, BLOOD, V112, P4808, DOI 10.1182/blood-2008-07-077958; Estey E, 2007, J CLIN ONCOL, V25, P1908, DOI 10.1200/JCO.2006.10.2731; Fedotcheva NI, 2006, FREE RADICAL BIO MED, V41, P56, DOI 10.1016/j.freeradbiomed.2006.02.012; Fenton SL, 1999, BRIT J HAEMATOL, V105, P448, DOI 10.1111/j.1365-2141.1999.01355.x; Fenton SL, 2003, LEUKEMIA, V17, P568, DOI 10.1038/sj.leu.2402843; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gao L, 2003, J BIOL CHEM, V278, P28479, DOI 10.1074/jbc.M303984200; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Goldstone AH, 2001, BLOOD, V98, P1302, DOI 10.1182/blood.V98.5.1302; Grant S, 2008, BEST PRACT RES CL HA, V21, P629, DOI 10.1016/j.beha.2008.08.003; Hasegawa H, 2007, BLOOD, V110, P1664, DOI 10.1182/blood-2007-01-068981; Hayashi N, 2004, INT J ONCOL, V24, P89; Hayden RE, 2009, LEUKEMIA, V23, P292, DOI 10.1038/leu.2008.283; Hodges NJ, 2007, MUTAGENESIS, V22, P189, DOI 10.1093/mutage/gem001; KALANTARI P, 2009, FASEB J; Kantarjian H, 2008, CANCER-AM CANCER SOC, V113, P1933, DOI 10.1002/cncr.23655; Kim HS, 1996, PROSTAGLANDINS, V51, P413, DOI 10.1016/0090-6980(96)00047-0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Kohrt Holbrook E, 2008, J Natl Compr Canc Netw, V6, P1003; Kondo M, 2002, P NATL ACAD SCI USA, V99, P7367, DOI 10.1073/pnas.112212599; Kuendgen A, 2007, CANCER-AM CANCER SOC, V110, P943, DOI 10.1002/cncr.22891; Landar A, 2006, BIOCHEM J, V394, P185, DOI 10.1042/BJ20051259; Lin MS, 2007, J DIGEST DIS, V8, P82, DOI 10.1111/j.1443-9573.2007.00290.x; Lin SX, 2006, MOL CELL ENDOCRINOL, V248, P38, DOI 10.1016/j.mce.2005.11.035; Lovering AL, 2004, CANCER RES, V64, P1802, DOI 10.1158/0008-5472.CAN-03-2847; Mailloux RJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000690; Mills KI, 1998, FEBS LETT, V440, P158, DOI 10.1016/S0014-5793(98)01435-5; Milne GL, 2005, ANTIOXID REDOX SIGN, V7, P210, DOI 10.1089/ars.2005.7.210; Montuschi P, 2007, CURR MED CHEM, V14, P703, DOI 10.2174/092986707780059607; Moriai M, 2009, INT J ONCOL, V34, P1363, DOI 10.3892/ijo_00000263; Morosetti R, 2004, INT J ONCOL, V25, P493; Nagase T, 1995, DNA Res, V2, P37, DOI 10.1093/dnares/2.1.37; Nikitakis NG, 2002, BRIT J CANCER, V87, P1396, DOI 10.1038/sj.bjc.6600618; NILSSON A, 1995, EUR J CELL BIOL, V67, P379; Oh JY, 2008, BIOCHEM J, V411, P297, DOI [10.1042/BJ20071189, 10.1042/bj20071189]; Paumi CM, 2003, BIOCHEMISTRY-US, V42, P5429, DOI 10.1021/bi027347u; PENNING TM, 1985, J BIOL CHEM, V260, P5266; Perez-Sala D, 2003, J BIOL CHEM, V278, P51251, DOI 10.1074/jbc.M309409200; Ray DM, 2006, J IMMUNOL, V177, P5068, DOI 10.4049/jimmunol.177.8.5068; Renedo M, 2007, BIOCHEMISTRY-US, V46, P6607, DOI 10.1021/bi602389p; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sanchez-Gomez FJ, 2007, ARCH BIOCHEM BIOPHYS, V457, P150, DOI 10.1016/j.abb.2006.10.032; Scatena R, 2004, BIOCHEM BIOPH RES CO, V319, P967, DOI 10.1016/j.bbrc.2004.05.072; Scatena R, 2003, CHEM RES TOXICOL, V16, P1440, DOI 10.1021/tx0341052; Scatena R, 1999, CELL DEATH DIFFER, V6, P781, DOI 10.1038/sj.cdd.4400551; Scher JU, 2005, CLIN IMMUNOL, V114, P100, DOI 10.1016/j.clim.2004.09.008; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Shibata T, 2002, J BIOL CHEM, V277, P10459, DOI 10.1074/jbc.M110314200; Stamatakis K, 2006, ANN NY ACAD SCI, V1091, P548, DOI 10.1196/annals.1378.096; Stamatakis K, 2006, J AM SOC NEPHROL, V17, P89, DOI 10.1681/ASN.2005030329; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Tallman MS, 2008, SEMIN HEMATOL, V45, pS25, DOI 10.1053/j.seminhematol.2008.07.008; Tallman MS, 2005, BLOOD, V106, P1154, DOI 10.1182/blood-2005-01-0178; Tallman MS, 2004, SEMIN HEMATOL, V41, P27, DOI 10.1053/j.seminhematol.2004.02.004; Tiziani S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004251	69	53	57	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 7	2009	4	12							e8147	10.1371/journal.pone.0008147	http://dx.doi.org/10.1371/journal.pone.0008147			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	533NB	19997560	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000272829500009
J	Hutchings, A; Durand, MA; Grieve, R; Harrison, D; Rowan, K; Green, J; Cairns, J; Black, N				Hutchings, Andrew; Durand, Mary Alison; Grieve, Richard; Harrison, David; Rowan, Kathy; Green, Judith; Cairns, John; Black, Nick			Evaluation of modernisation of adult critical care services in England: time series and cost effectiveness analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTENSIVE-CARE; OUTREACH SERVICES; NATIONAL-AUDIT; IMPACT; MORTALITY; UNIT; ICU	Objective To evaluate the impact and cost effectiveness of a programme to transform adult critical care throughout England initiated in late 2000. Design Evaluation of trends in inputs, processes, and outcomes during 1998-2000 compared with last quarter of 2000-6. Setting 96 critical care units in England. Participants 349 817 admissions to critical care units. Interventions Adoption of key elements of modernisation and increases in capacity. Units were categorised according to when they adopted key elements of modernisation and increases in capacity. Main outcome measures Trends in inputs (beds, costs), processes (transfers between units, discharge practices, length of stay, readmissions), and outcomes (unit and hospital mortality), with adjustment for case mix. Differences in annual costs and quality adjusted life years (QALYs) adjusted for case mix were used to calculate net monetary benefits (valuing a QALY gain at 20 pound 000 ($33 170, (sic)22 100)). The incremental net monetary benefits were reported as the difference in net monetary benefits after versus before 2000. Results In the six years after 2000, the risk of unit mortality adjusted for case mix fell by 11.3% and hospital mortality by 13.4% compared with the steady state in the three preceding years. This was accompanied by substantial reductions both in transfers between units and in unplanned night discharges. The mean annual net monetary benefit increased significantly after 2000 (from 402 pound ($667, (sic)445) to 1096 pound ($1810, (sic)1210)), indicating that the changes were relatively cost effective. The relative contribution of the different initiatives to these improvements is unclear. Conclusion Substantial improvements in NHS critical care have occurred in England since 2000. While it is unclear which factors were responsible, collectively the interventions represented a highly cost effective use of NHS resources.	[Hutchings, Andrew; Grieve, Richard; Green, Judith; Cairns, John; Black, Nick] Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England; [Harrison, David; Rowan, Kathy] Intens Care Natl Audit & Res Ctr, London WC1H 9HR, England	University of London; London School of Hygiene & Tropical Medicine; Intensive Care National Audit & Research Centre	Hutchings, A (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.	andrew.hutchings@lshtm.ac.uk	Cairns, John/AAD-1168-2020; Harrison, David A/O-4355-2018	Harrison, David A/0000-0002-9002-9098; Grieve, Richard/0000-0001-8899-1301; Durand, Mary Alison/0000-0003-2205-4002; Rowan, Kathryn/0000-0001-8217-5602; Hutchings, Andrew/0000-0003-0215-9923; Green, Judith/0000-0002-2315-5326	NIHR SDO research and development programme [SDO/133/2006]; MRC [G106/1240] Funding Source: UKRI; Medical Research Council [G106/1240] Funding Source: researchfish	NIHR SDO research and development programme; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The study was funded by the NIHR SDO research and development programme (grant SDO/133/2006). AH was supported by a MRC special training fellowship in health services research. The study funders had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. The researchers were independent from the funders	Calhoun AW, 2008, MED CARE, V46, P635, DOI 10.1097/MLR.0b013e3181649412; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; Cocanour CS, 2006, J TRAUMA, V61, P122, DOI 10.1097/01.ta.0000223971.25845.b3; Crunden Eddie, 2005, Nurs Crit Care, V10, P242; DAWSON D, 2006, CRIT CARE NURSE, V22, P4; *DEP HLTH, 2004, AG CHANG FIN AGR; *DEP HLTH, 2000, COMPR CRIT CAR REV A; *DEP HLTH, 2000, HOSP ACT STAT; *DEP HLTH, 2000, NHS PLAN; Department of Health, 2009, NHS REF COSTS 2007 0; Department of Health, 2005, IMPL IMP HOSP NIGHT; Esmonde L, 2006, INTENS CARE MED, V32, P1713, DOI 10.1007/s00134-006-0380-6; Gao F, 2005, CRIT CARE, V9, pR764, DOI 10.1186/cc3909; Gao H, 2007, CRIT CARE, V11, DOI 10.1186/cc6163; Hampton Debra C, 2005, Rehabil Nurs, V30, P160; Harrison DA, 2004, CRIT CARE, V8, pR99, DOI 10.1186/cc2834; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Hoch JS, 2002, HEALTH ECON, V11, P415, DOI 10.1002/hec.678; Jain M, 2006, QUAL SAF HEALTH CARE, V15, P235, DOI 10.1136/qshc.2005.016576; Keenan SP, 2002, CRIT CARE MED, V30, P501, DOI 10.1097/00003246-200203000-00002; McDonnell A, 2007, J CRIT CARE, V22, P212, DOI 10.1016/j.jcrc.2007.02.002; NHS England, 2004, 10 HIGH IMP CHANG SE; *NHS EX, 2007, HOSP COMM HLTH SERV; *OFF NAT STAT, 2008, INT LIF TABL 2000 20; Resar R, 2005, JT COMM J QUAL PATIE, V31, P243, DOI 10.1016/S1553-7250(05)31031-2; Robson W, 2006, Intensive Crit Care Nurs, V22, P1, DOI 10.1016/j.iccn.2005.09.006; Stevens K, 2005, APPL HEALTH ECON HEA, V4, P257, DOI 10.2165/00148365-200504040-00008; Williams TA, 2008, CRIT CARE MED, V36, P1523, DOI 10.1097/CCM.0b013e318170a405; Wordsworth Sarah, 2005, Eur J Health Econ, V6, P38, DOI 10.1007/s10198-004-0259-9; Youngquist P, 2007, JT COMM J QUAL PATIE, V33, P219, DOI 10.1016/S1553-7250(07)33026-2	30	72	73	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	2009	339								b4353	10.1136/bmj.b4353	http://dx.doi.org/10.1136/bmj.b4353			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	520HM	19906740	hybrid, Green Published, Green Accepted			2023-01-03	WOS:000271833900001
J	Cuthbertson, BH; Rattray, J; Campbell, MK; Gager, M; Roughton, S; Smith, A; Hull, A; Breeman, S; Norrie, J; Jenkinson, D; Hernandez, R; Johnston, M; Wilson, E; Waldmann, C				Cuthbertson, B. H.; Rattray, J.; Campbell, M. K.; Gager, M.; Roughton, S.; Smith, A.; Hull, A.; Breeman, S.; Norrie, J.; Jenkinson, D.; Hernandez, R.; Johnston, M.; Wilson, E.; Waldmann, C.		PRaCTICaL Study Grp	The PRaCTICaL study of nurse led, intensive care follow-up programmes for improving long term outcomes from critical illness: a pragmatic randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; ILL PATIENTS; SURVIVORS	Objectives To test the hypothesis that nurse led follow-up programmes are effective and cost effective in improving quality of life after discharge from intensive care. Design A pragmatic, non-blinded, multicentre, randomised controlled trial. Setting Three UK hospitals (two teaching hospitals and one district general hospital). Participants 286 patients aged >= 18 years were recruited after discharge from intensive care between September 2006 and October 2007. Intervention Nurse led intensive care follow-up programmes versus standard care. Main outcome measure(s) Health related quality of life (measured with the SF-36 questionnaire) at 12 months after randomisation. A cost effectiveness analysis was also performed. Results 286 patients were recruited and 192 completed one year follow-up. At 12 months, there was no evidence of a difference in the SF-36 physical component score (mean 42.0 (SD 10.6) v 40.8 (SD 11.9), effect size 1.1 (95% CI -1.9 to 4.2), P=0.46) or the SF-36 mental component score (effect size 0.4 (-3.0 to 3.7), P=0.83). There were no statistically significant differences in secondary outcomes or subgroup analyses. Follow-up programmes were significantly more costly than standard care and are unlikely to be considered cost effective. Conclusions A nurse led intensive care follow-up programme showed no evidence of being effective or cost effective in improving patients' quality of life in the year after discharge from intensive care. Further work should focus on the roles of early physical rehabilitation, delirium, cognitive dysfunction, and relatives in recovery from critical illness. Intensive care units should review their follow-up programmes in light of these results.	[Cuthbertson, B. H.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Rattray, J.; Smith, A.] Univ Dundee, Sch Nursing & Midwifery, Dundee, Scotland; [Campbell, M. K.; Roughton, S.; Breeman, S.; Jenkinson, D.; Hernandez, R.] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB32, Scotland; [Gager, M.; Waldmann, C.] Royal Berkshire & Battle Hosp, Intens Care Unit, Reading, Berks, England; [Roughton, S.] Aberdeen Royal Infirm, Intens Care Unit, Aberdeen, Scotland; [Hull, A.] Murray Royal Hosp, Dept Mental Hlth, Perth, WA, Australia; [Norrie, J.] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Hernandez, R.] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB9 1FX, Scotland; [Johnston, M.] Univ Aberdeen, Hlth Psychol Unit, Aberdeen AB9 1FX, Scotland; [Wilson, E.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Anaesthesia & Intens Care Med, Dundee DD1 9SY, Scotland	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Dundee; University of Aberdeen; University of Aberdeen; University of Glasgow; University of Aberdeen; University of Aberdeen; University of Dundee	Cuthbertson, BH (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada.	brian.cuthbertson@sunnybrook.ca	Campbell, Marion/ABB-7063-2020; Ramsay, Craig/AAD-8249-2021	Ramsay, Craig/0000-0003-4043-7349; Hernandez, Rodolfo/0000-0003-2619-8230; Campbell, Marion/0000-0001-5386-4097	Chief Scientist Office of the Scottish Government Health Directorates; University of Aberdeen; Chief Scientist Office [HERU2, CZG/2/202, HERU1, HSRU2] Funding Source: researchfish	Chief Scientist Office of the Scottish Government Health Directorates; University of Aberdeen; Chief Scientist Office	The study is supported by a research grant from the Chief Scientist Office of the Scottish Government Health Directorates. The Health Services Research Unit is also funded by the Chief Scientist Office of the Scottish Government Health Directorates. The researchers are completely independent of the funders, and the views expressed are those of the authors alone. The study sponsor was the University of Aberdeen, which had no role in the study design; collection, analysis, and interpretation of data; writing of the article; or the decision to submit it for publication. The researchers are completely independent of the sponsors in their research activities.	Brooks N, 1996, NURS CRIT CARE, V1, P90; Broomhead LR, 2002, CRIT CARE, V6, P411, DOI 10.1186/cc1532; Cameron JI, 2006, CRIT CARE MED, V34, P81, DOI 10.1097/01.CCM.0000190428.71765.31; Crocker Cheryl, 2003, Br J Nurs, V12, P910; Cuthbertson BH, 2005, ANAESTHESIA, V60, P332, DOI 10.1111/j.1365-2044.2004.04109.x; Cuthbertson BH, 2004, INTENS CARE MED, V30, P450, DOI 10.1007/s00134-003-2004-8; Cuthbertson BH, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-116; Davidson JRT, 1997, PSYCHOL MED, V27, P153, DOI 10.1017/S0033291796004229; Denehy L, 2008, OPEN CRIT CARE MED J, V1, P39; *DEP HLTH, 2000, COMPR CRIT CAR REV A; Department of Health, 2003, CRIT CAR OUTR PROGR; Dowdy DW, 2006, INTENS CARE MED, V32, P1115, DOI 10.1007/s00134-006-0217-3; Eddleston JM, 2000, CRIT CARE MED, V28, P2293, DOI 10.1097/00003246-200007000-00018; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Gordon SM, 2004, INTENS CARE MED, V30, P1997, DOI 10.1007/s00134-004-2418-y; GRANT L, 1999, J RES DEV EDUC, V33, P15; Green A, 1996, Intensive Crit Care Nurs, V12, P131, DOI 10.1016/S0964-3397(96)80435-6; Griffiths JA, 2006, ANAESTHESIA, V61, P950, DOI 10.1111/j.1365-2044.2006.04792.x; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Jones C, 2003, CRIT CARE MED, V31, P2456, DOI 10.1097/01.CCM.0000089938.56725.33; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Kapfhammer HP, 2004, AM J PSYCHIAT, V161, P45, DOI 10.1176/appi.ajp.161.1.45; Lipsett PA, 2000, J TRAUMA, V49, P737, DOI 10.1097/00005373-200010000-00024; Niskanen M, 1999, CRIT CARE MED, V27, P1132, DOI 10.1097/00003246-199906000-00035; Rattray J, 2004, J ADV NURS, V47, P64, DOI 10.1111/j.1365-2648.2004.03066.x; Ridley SA, 1997, ANAESTHESIA, V52, P195, DOI 10.1111/j.1365-2044.1997.073-az0068.x; *ROYAL PHARM SOC G, 2007, BRIT NAT FORM; Rundshagen I, 2002, INTENS CARE MED, V28, P38, DOI 10.1007/s00134-001-1168-3; Schelling G, 1998, CRIT CARE MED, V26, P651, DOI 10.1097/00003246-199804000-00011; Scottish Intensive Care Society, 2007, ANN AUD; Scragg P, 2001, ANAESTHESIA, V56, P9, DOI 10.1046/j.1365-2044.2001.01714.x; Ware JE, 2001, SCORE VERSION 2 SF 3; Williams, 1995, 138 CTR HLTH EC; Williams TA, 2008, CRIT CARE MED, V36, P1523, DOI 10.1097/CCM.0b013e318170a405; Wright JC, 2003, ANAESTHESIA, V58, P637, DOI 10.1046/j.1365-2044.2003.03205.x; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	36	214	218	1	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 16	2009	339								b3723	10.1136/bmj.b3723	http://dx.doi.org/10.1136/bmj.b3723			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	508DS	19837741	Green Accepted, Green Published, hybrid			2023-01-03	WOS:000270908500002
J	Adamsen, L; Quist, M; Andersen, C; Moller, T; Herrstedt, J; Kronborg, D; Baadsgaard, MT; Vistisen, K; Midtgaard, J; Christiansen, B; Stage, M; Kronborg, MT; Rorth, M				Adamsen, Lis; Quist, Morten; Andersen, Christina; Moller, Tom; Herrstedt, Jorn; Kronborg, Dorte; Baadsgaard, Marie T.; Vistisen, Kirsten; Midtgaard, Julie; Christiansen, Birgitte; Stage, Maria; Kronborg, Morten T.; Rorth, Mikael			Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; BREAST-CANCER; RESISTANCE EXERCISE; PHYSICAL CAPACITY; FATIGUE; SURVIVORS; HEALTH; INSTRUMENT; SYMPTOMS; PROGRAM	Objective To assess the effect of a multimodal group exercise intervention, as an adjunct to conventional care, on fatigue, physical capacity, general wellbeing, physical activity, and quality of life in patients with cancer who were undergoing adjuvant chemotherapy or treatment for advanced disease. Design Randomised controlled trial. Setting Two university hospitals in Copenhagen, Denmark. Participants 269 patients with cancer; 73 men, 196 women, mean age 47 years (range 20-65) representing 21 diagnoses. Main exclusion criteria were brain or bone metastases. 235 patients completed follow-up. Intervention Supervised exercise comprising high intensity cardiovascular and resistance training, relaxation and body awareness training, massage, nine hours weekly for six weeks in addition to conventional care, compared with conventional care. Main outcome measures European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), Medical Outcomes Study Short Form (MOS SF-36), Leisure Time Physical Activity Questionnaire, muscular strength (one repetition maximum), maximum oxygen consumption (Vo(2)max). Statistical methods The general linear model was used for continuous outcome while analysis of associates between categorical outcomes was performed as analysis of marginal homogeneity in contingency tables. Results Adjusted for baseline score, disease, and demographic covariates, the intervention group showed an estimated improvement at six weeks for the primary outcome, fatigue, of -6.6 points (95% confidence interval -12.3 to -0.9, P=0.02; effect size=0.33, 0.04 to 0.61). Significant effects were seen on vitality (effect size 0.55, 95% CI 0.27 to 0.82), physical functioning (0.37, 0.09 to 0.65), role physical (0.37, 0.10 to 0.64), role emotional (0.32, 0.05 to 0.59), and mental health (0.28, 0.02 to 0.56) scores. Improvement was noted in physical capacity: estimated mean difference between groups for maximum oxygen consumption was 0.16 l/min (95% CI 0.1 to 0.2, P<0.0001) and for muscular strength (leg press) was 29.7 kg (23.4 to 34.9, P<0.0001). No significant effect was seen on global health status/quality of life. Conclusion A supervised multimodal exercise intervention including high and low intensity components was feasible and could safely be used in patients with various cancers who were receiving adjuvant chemotherapy or treatment for advanced disease. The intervention reduced fatigue and improved vitality, aerobic capacity, muscular strength, and physical and functional activity, and emotional wellbeing, but not quality of life.	[Adamsen, Lis; Quist, Morten; Andersen, Christina; Moller, Tom; Baadsgaard, Marie T.; Midtgaard, Julie; Stage, Maria] Copenhagen Univ Hosp, Univ Hosp, Ctr Nursing & Care Res, DK-2100 Copenhagen, Denmark; [Adamsen, Lis] Univ Copenhagen, Inst Publ Hlth, Copenhagen, Denmark; [Herrstedt, Jorn] Odense Univ Hosp, Dept Oncol, DK-5000 Odense, Denmark; [Kronborg, Dorte] Copenhagen Business Sch, Ctr Stat, Frederiksberg, Denmark; [Vistisen, Kirsten; Christiansen, Birgitte] Herlev Univ Hosp, Dept Oncol, DK-2730 Herlev, Denmark; [Kronborg, Morten T.] Univ Copenhagen, Dept Math Sci, Copenhagen, Denmark; [Rorth, Mikael] Copenhagen Univ Hosp, Dept Oncol, DK-2100 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Southern Denmark; Odense University Hospital; Copenhagen Business School; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; University of Copenhagen	Adamsen, L (corresponding author), Copenhagen Univ Hosp, Univ Hosp, Ctr Nursing & Care Res, DK-2100 Copenhagen, Denmark.	la@ucsf.dk	Midtgaard, Julie/P-9211-2019; Herrstedt, Jørn/AAB-7400-2022	Midtgaard, Julie/0000-0003-2381-2127; Quist, Morten/0000-0002-0983-957X; Kronborg, Dorte/0000-0001-6511-4138; Moller, Tom/0000-0003-1908-258X	Lundbeck Foundation; Novo Nordic Foundation; Egmont Foundation; Danish Cancer Society; Svend Andersen Foundation; Aase and Ejnar Danielsen Foundation; Beckett Foundation; WedellWedellsborg Foundation; Hede Nielsen Family Foundation; Gangsted Foundation; Copenhagen University Hospital	Lundbeck Foundation(Lundbeckfonden); Novo Nordic Foundation(Novo Nordisk Foundation); Egmont Foundation; Danish Cancer Society(Danish Cancer Society); Svend Andersen Foundation; Aase and Ejnar Danielsen Foundation; Beckett Foundation; WedellWedellsborg Foundation; Hede Nielsen Family Foundation; Gangsted Foundation; Copenhagen University Hospital	This research was supported by grants from The Lundbeck Foundation, The Novo Nordic Foundation, The Egmont Foundation, The Danish Cancer Society, The Svend Andersen Foundation, The Aase and Ejnar Danielsen Foundation, The Beckett Foundation, The WedellWedellsborg Foundation, The Hede Nielsen Family Foundation, The Gangsted Foundation, Copenhagen University Hospital. The authors' work was independent from the funders.	Aadahl M, 2003, MED SCI SPORT EXER, V35, P1196, DOI 10.1249/01.MSS.0000074446.02192.14; AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Adamsen L, 2006, SUPPORT CARE CANCER, V14, P116, DOI 10.1007/s00520-005-0864-x; Adamsen L, 2004, EUR J CANCER CARE, V13, P362, DOI 10.1111/j.1365-2354.2004.00502.x; Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; Anderson BD, 2000, ORTHOP PHYS THER CLI, V9, P395; Andersen L. B., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P318; Baum A, 2001, PSYCHOSOC INTERV, P3; Bjorner JB., 1997, DANSK MANUAL SF 36 S; Bower Julienne E, 2005, Cancer Control, V12, P165; Brzycki M., 1993, J PHYS EDUC RECREAT, V64, P88, DOI [DOI 10.1080/07303084.1993.10606684, 10.1080/07303084.1993.10606684]; Canadian Cancer Society/National Cancer Institute of Canada, 2008, CAN CANC STAT 2008; *CANC RES UK, 2005, UK CANC INC STAT COU; CLEMMENSEN IH, 2006, KRAEFT DANMARK OPSLA; Cohen J., 2013, STAT POWER ANAL BEHA; Courneya KS, 2007, J CLIN ONCOL, V25, P4396, DOI 10.1200/JCO.2006.08.2024; da Costa BR, 2008, J REHABIL MED, V40, P321, DOI 10.2340/16501977-0204; De Bruin A., 1996, HLTH INTERVIEW SURVE; Dimeo F, 2003, SUPPORT CARE CANCER, V11, P623, DOI 10.1007/s00520-003-0512-2; Espey DK, 2007, CANCER-AM CANCER SOC, V110, P2119, DOI 10.1002/cncr.23044; FENTEM P, 1994, BRIT MED J, V308, P1291, DOI 10.1136/bmj.308.6939.1291; FERRELLTORRY AT, 1993, CANCER NURS, V16, P93; Galvao DA, 2005, J CLIN ONCOL, V23, P899, DOI 10.1200/JCO.2005.06.085; Gayda M, 2009, J ELECTROMYOGR KINES, V19, pE32, DOI 10.1016/j.jelekin.2007.08.009; Henry DH, 2008, SUPPORT CARE CANCER, V16, P791, DOI 10.1007/s00520-007-0380-2; Jarden M, 2007, BONE MARROW TRANSPL, V40, P793, DOI 10.1038/sj.bmt.1705807; Kangas M, 2008, PSYCHOL BULL, V134, P700, DOI 10.1037/a0012825; King MT, 1996, QUAL LIFE RES, V5, P555, DOI 10.1007/BF00439229; Klee M, 1997, QUAL LIFE RES, V6, P27; Kraemer WJ, 2002, MED SCI SPORT EXER, V34, P364, DOI 10.1097/00005768-200202000-00027; Kwekkeboom Kristine L, 2008, Complement Ther Clin Pract, V14, P185, DOI 10.1016/j.ctcp.2008.04.002; Lucia A, 2003, LANCET ONCOL, V4, P616, DOI 10.1016/S1470-2045(03)01221-X; Luebbert K, 2001, PSYCHO-ONCOLOGY, V10, P490, DOI 10.1002/pon.537; Markes M, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005001; McCaffery M., 2008, PAIN CLIN MANUAL NUR; McNeely ML, 2006, CAN MED ASSOC J, V175, P34, DOI 10.1503/cmaj.051073; Milne HM, 2008, BREAST CANCER RES TR, V108, P279, DOI 10.1007/s10549-007-9602-z; Moinuddin I, 2008, ADV CHRONIC KIDNEY D, V15, P83, DOI 10.1053/j.ackd.2007.10.004; Mutrie N, 2007, BMJ-BRIT MED J, V334, P517, DOI 10.1136/bmj.39094.648553.AE; Nader GA, 2006, MED SCI SPORT EXER, V38, P1965, DOI 10.1249/01.mss.0000233795.39282.33; Nakagawa S, 2007, BIOL REV, V82, P591, DOI 10.1111/j.1469-185X.2007.00027.x; O'Connor PJ, 2005, MED SCI SPORT EXER, V37, P299, DOI 10.1249/01.MSS.0000152802.89770.CF; Pinto BM, 2000, ANN BEHAV MED, V22, P38, DOI 10.1007/BF02895166; Quist M, 2006, SCAND J MED SCI SPOR, V16, P349, DOI 10.1111/j.1600-0838.2005.00503.x; Roila F, 2006, ANN ONCOL, V17, P20, DOI 10.1093/annonc/mdj078; SALTIN B, 1968, CIRCULATION, V38, P1104, DOI 10.1161/01.CIR.38.6.1104; SALTIN B, 1983, HDB PHYSL, V10, P555; Schmitz KH, 2005, CANCER EPIDEM BIOMAR, V14, P1588, DOI 10.1158/1055-9965.EPI-04-0703; Segal R, 2001, J CLIN ONCOL, V19, P657, DOI 10.1200/JCO.2001.19.3.657; SMETS EMA, 1993, BRIT J CANCER, V68, P220, DOI 10.1038/bjc.1993.319; Thomas DR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002968.pub2; Uitterhoeve RJ, 2004, BRIT J CANCER, V91, P1050, DOI 10.1038/sj.bjc.6602103; van Emmerik AAP, 2002, LANCET, V360, P766, DOI 10.1016/S0140-6736(02)09897-5; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	54	300	304	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 13	2009	339								b3410	10.1136/bmj.b3410	http://dx.doi.org/10.1136/bmj.b3410			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	508DO	19826172	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000270908100001
J	Chlebowski, RT; Schwartz, AG; Wakelee, H; Anderson, GL; Stefanick, ML; Manson, JE; Rodabough, RJ; Chien, JW; Wactawski-Wende, J; Gass, M; Kotchen, JM; Johnson, KC; O'Sullivan, MJ; Ockene, JK; Chen, C; Hubbell, FA				Chlebowski, Rowan T.; Schwartz, Ann G.; Wakelee, Heather; Anderson, Garnet L.; Stefanick, Marcia L.; Manson, JoAnn E.; Rodabough, Rebecca J.; Chien, Jason W.; Wactawski-Wende, Jean; Gass, Margery; Kotchen, Jane Morley; Johnson, Karen C.; O'Sullivan, Mary Jo; Ockene, Judith K.; Chen, Chu; Hubbell, F. Allan		Women's Hlth Initiative Investigat	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial	LANCET			English	Article							HORMONE REPLACEMENT THERAPY; BREAST-CANCER; REPRODUCTIVE FACTORS; RISK; ANGIOGENESIS; SURVIVAL; BEVACIZUMAB; MAMMOGRAPHY; PACLITAXEL; BENEFITS	Background In the post-intervention period of the Women's Health Initiative (WHI) trial, women assigned to treatment with oestrogen plus progestin had a higher risk of cancer than did those assigned to placebo. Results also suggested that the combined hormone therapy might increase mortality from lung cancer. To assess whether such an association exists, we undertook a post-hoc analysis of lung cancers diagnosed in the trial over the entire follow-up period. Methods The WHI study was a randomised, double-blind, placebo-controlled trial undertaken in 40 centres in the USA. 16608 postmenopausal women aged 50-79 years with an intact uterus were randomly assigned by a computerised, stratified, permuted block algorithm to receive a once-daily tablet of 0.625 mg conjugated equine oestrogen plus 2.5 mg medroxyprogesterone acetate (n=8506) or matching placebo (n=8102). We assessed incidence and mortality rates for all lung cancer, small-cell lung cancer, and non-small-cell lung cancer by use of data from treatment and post-intervention follow-up periods. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00000611. Findings After a mean of 5.6 years (SD 1.3) of treatment and 2.4 years (0.4) of additional follow-up, 109 women in the combined hormone therapy group had been diagnosed with lung cancer compared with 85 in the placebo group (incidence per year 0.16% vs 0.13%; hazard ratio [HR] 1.23, 95% CI 0.92-1.63, p=0.16). 96 women assigned to combined therapy had non-small-cell lung cancer compared with 72 assigned to placebo (0.14% vs 0.11%; HR 1.28, 0.94-1.73, p=0.12). More women died from lung cancer in the combined hormone therapy group than in the placebo group (73 vs 40 deaths; 0.11% vs 0.06%; HR 1.71, 1.16-2.52, p=0.01), mainly as a result of a higher number of deaths from non-small-cell lung cancer in the combined therapy group (62 vs 31 deaths; 0.09% vs 0.05%; HR 1.87, 1.22-2.88, p=0.004). incidence and mortality rates of small-cell lung cancer were similar between groups. Interpretation Although treatment with oestrogen plus progestin in postmenopausal women did not increase incidence of lung cancer, it increased the number of deaths from lung cancer, in particular deaths from non-small-cell lung cancer. These findings should be incorporated into risk-benefit discussions with women considering combined hormone therapy, especially those with a high risk of lung cancer. Funding National Heart, Lung and Blood Institute, National Institutes of Health.	[Chlebowski, Rowan T.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90502 USA; [Schwartz, Ann G.] Karmanos Canc Inst, Dept Internal Med, Detroit, MI USA; [Wakelee, Heather; Stefanick, Marcia L.] Stanford Univ, Dept Med, Palo Alto, CA 94304 USA; [Anderson, Garnet L.; Rodabough, Rebecca J.; Chien, Jason W.; Chen, Chu] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Manson, JoAnn E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; [Wactawski-Wende, Jean] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; [Gass, Margery] Univ Cincinnati, Cincinnati, OH USA; [Kotchen, Jane Morley] Med Coll Wisconsin, Dept Populat Hlth, Milwaukee, WI 53226 USA; [Johnson, Karen C.] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA; [O'Sullivan, Mary Jo] Univ Miami, Dept Obstet & Gynecol, Miami, FL USA; [Ockene, Judith K.] Univ Massachusetts, Fallon Clin, Dept Med, Worcester, MA 01605 USA; [Hubbell, F. Allan] Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; Lundquist Institute; Barbara Ann Karmanos Cancer Institute; Stanford University; Fred Hutchinson Cancer Center; Harvard University; Brigham & Women's Hospital; Harvard Medical School; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University System of Ohio; University of Cincinnati; Medical College of Wisconsin; University of Tennessee System; University of Tennessee Health Science Center; University of Miami; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California Irvine	Chlebowski, RT (corresponding author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, 1124 W Carson St, Torrance, CA 90502 USA.	rchlebowski@gmail.com	Cauley, Jane A/N-4836-2015; Wakelee, Heather/P-2623-2019; Wactawski-Wende, Jean/AGH-5457-2022; Stafford, Randall/F-3974-2017	Cauley, Jane A/0000-0003-0752-4408; Wactawski-Wende, Jean/0000-0003-3096-9595; Caan, Bette/0000-0002-5803-310X; Anderson, Garnet/0000-0001-5087-7837; Stafford, Randall/0000-0003-1805-1271	National Heart, Lung and Blood Institute; National Institutes of Health; Department of Health and Human Services [N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, 44221]; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH [N01WH042129, N01WH042123, N01WH042108, N01WH042107, N01WH032106, N01WH042132, N01WH032105, N01WH032108, N01WH032112, N01WH032109, N01WH042112, N01WH032118, N01WH042131, N01WH042117, N01WH032122, N01WH042110, N01WH042115, N01WH042114, N01WH042130, N01WH042111, N01WH042116, N01WH032101, N01WH032119, N01WH032102, N01WH032111, N01WH032115, N01WH042109, N01WH042113, N01WH042118, N01WH042124, N01WH042122, N01WH042119, N01WH032113, N01WH042125, N01WH042126, N01WH032100, N01WH042121, N01WH042120, N01WH022110] Funding Source: NIH RePORTER	National Heart, Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); WOMEN&apos;S HEALTH INITIATIVE - OFFICE OF THE DIRECTOR NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We acknowledge the dedicated efforts of investigators and staffat the Women's Health Initiative (WHI) clinical centres, the WHI Clinical Coordinating Center, and the National Heart, Lung and Blood program office (listing available at http://www.whi.org). We also recognise the WH I participants for their extraordinary commitment to the WH I programme. The WHI programme is funded by the National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services through contracts N01WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221.	ALBAIN KS, 2007, 2007 ASCO ANN M CHIC; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; Anderson GL, 2003, ANN EPIDEMIOL, V13, pS5, DOI 10.1016/S1047-2797(03)00043-7; Baik CS, 2009, J CLIN ONCOL, V27; Bremnes RM, 2003, LUNG CANCER, V39, P303, DOI 10.1016/S0169-5002(02)00508-1; CAGLE PT, 1990, CANCER RES, V50, P6632; Calvo A, 2008, ONCOGENE, V27, P5373, DOI 10.1038/onc.2008.155; Cauley JA, 2003, JAMA-J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729; Chlebowski RT, 2008, ARCH INTERN MED, V168, P370, DOI 10.1001/archinternmed.2007.123; Chlebowski RT, 2009, NEW ENGL J MED, V360, P573, DOI 10.1056/NEJMoa0807684; Chlebowski RT, 1996, NUTRITION, V12, pS43; Chlebowski RT, 2004, NEW ENGL J MED, V350, P991, DOI 10.1056/NEJMoa032071; Chlebowski RT, 2003, JAMA-J AM MED ASSOC, V289, P3243, DOI 10.1001/jama.289.24.3243; COX DR, 1972, J R STAT SOC B, V187, P220; Cushman M, 2004, JAMA-J AM MED ASSOC, V292, P1573, DOI 10.1001/jama.292.13.1573; Dobrzycka B, 2009, ENDOKRYNOL POL, V60, P210; Elkin M, 2004, JNCI-J NATL CANCER I, V96, P875, DOI 10.1093/jnci/djh140; Ganti AK, 2006, J CLIN ONCOL, V24, P59, DOI 10.1200/JCO.2005.02.9827; Hammoud Z, 2008, ENDOCR-RELAT CANCER, V15, P475, DOI 10.1677/ERC-08-0002; Heiss G, 2008, JAMA-J AM MED ASSOC, V299, P1036, DOI 10.1001/jama.299.9.1036; Henschke CI, 2006, JAMA-J AM MED ASSOC, V296, P180; Huang B, 2009, CANCER, V115, P4167, DOI 10.1002/cncr.24475; Hulley S, 2002, JAMA-J AM MED ASSOC, V288, P58, DOI 10.1001/jama.288.1.58; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kreuzer M, 2003, INT J EPIDEMIOL, V32, P263, DOI 10.1093/ije/dyg064; Liu Y, 2005, INT J CANCER, V117, P662, DOI 10.1002/ijc.21229; Losordo DW, 2001, ARTERIOSCL THROM VAS, V21, P6, DOI 10.1161/01.ATV.21.1.6; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Marquez-Garban DC, 2009, ANN NY ACAD SCI, V1155, P194, DOI 10.1111/j.1749-6632.2009.04116.x; Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113; Rodriguez C, 2008, CANCER EPIDEM BIOMAR, V17, P655, DOI 10.1158/1055-9965.EPI-07-2683; ROSS H, 2007, 2007 ASCO ANN M CHIC; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schabath MB, 2004, CLIN CANCER RES, V10, P113, DOI 10.1158/1078-0432.CCR-0911-3; Schwartz AG, 2007, J CLIN ONCOL, V25, P5785, DOI 10.1200/JCO.2007.13.3975; Stabile LP, 2002, CANCER RES, V62, P2141; Stabile LP, 2005, CANCER RES, V65, P1459, DOI 10.1158/0008-5472.CAN-04-1872; Stefanick ML, 2006, JAMA-J AM MED ASSOC, V295, P1647, DOI 10.1001/jama.295.14.1647; TAIOLI E, 1994, J NATL CANCER I, V86, P869, DOI 10.1093/jnci/86.11.869; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652, DOI DOI 10.1001/JAMA.1973.03230060030009; Wakelee HA, 2006, J THORAC ONCOL, V1, P441, DOI 10.1097/01243894-200606000-00011; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101	45	217	223	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	2009	374	9697					1243	1251		10.1016/S0140-6736(09)61526-9	http://dx.doi.org/10.1016/S0140-6736(09)61526-9			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507KQ	19767090	Green Accepted			2023-01-03	WOS:000270852500030
J	Lowenberg, B; Ossenkoppele, GJ; van Putten, W; Schouten, HC; Graux, C; Ferrant, A; Sonneveld, P; Maertens, J; Jongen-Lavrencic, M; von Lilienfeld-Toal, M; Biemond, BJ; Vellenga, E; Kooy, MV; Verdonck, LF; Beck, J; Dohner, H; Gratwohl, A; Pabst, T; Verhoef, G				Lowenberg, Bob; Ossenkoppele, Gert J.; van Putten, Wim; Schouten, Harry C.; Graux, Carlos; Ferrant, Augustin; Sonneveld, Pieter; Maertens, Johan; Jongen-Lavrencic, Mojca; von Lilienfeld-Toal, Marie; Biemond, Bart J.; Vellenga, Edo; Kooy, Marinus van Marwijk; Verdonck, Leo F.; Beck, Joachim; Doehner, Hartmut; Gratwohl, Alois; Pabst, Thomas; Verhoef, Gregor		Dutch-Belgian Cooperative Trial Gr; German AML Study Grp AMLSG; Swiss Grp Clinical Canc Res SAKK C	High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REMISSION-INDUCTION CHEMOTHERAPY; RISK MYELODYSPLASTIC SYNDROME; COLONY-STIMULATING FACTOR; RANDOMIZED PHASE-III; ELDERLY-PATIENTS; EUROPEAN ORGANIZATION; CYTARABINE; TRIAL; AML; AGE	Background A complete remission is essential for prolonging survival in patients with acute myeloid leukemia (AML). Daunorubicin is a cornerstone of the induction regimen, but the optimal dose is unknown. In older patients, it is usual to give daunorubicin at a dose of 45 to 50 mg per square meter of body-surface area. Methods Patients in whom AML or high-risk refractory anemia had been newly diagnosed and who were 60 to 83 years of age ( median, 67) were randomly assigned to receive cytarabine, at a dose of 200 mg per square meter by continuous infusion for 7 days, plus daunorubicin for 3 days, either at the conventional dose of 45 mg per square meter ( 411 patients) or at an escalated dose of 90 mg per square meter ( 402 patients); this treatment was followed by a second cycle of cytarabine at a dose of 1000 mg per square meter for 6 days. The primary end point was event-free survival. Results The complete remission rates were 64% in the group that received the escalated dose of daunorubicin and 54% in the group that received the conventional dose (P = 0.002); the rates of remission after the first cycle of induction treatment were 52% and 35%, respectively (P<0.001). There was no significant difference between the two groups in the incidence of hematologic toxic effects, 30-day mortality (11% and 12% in the two groups, respectively), or the incidence of moderate, severe, or life-threatening adverse events (P=0.08). Survival end points in the two groups did not differ significantly overall, but patients in the escalated-treatment group who were 60 to 65 years of age, as compared with the patients in the same age group who received the conventional dose, had higher rates of complete remission (73% vs. 51%), event-free survival (29% vs. 14%), and overall survival (38% vs. 23%). Conclusions In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. ( Current Controlled Trials number, ISRCTN77039377; and Netherlands National Trial Register number, NTR212.)	[Lowenberg, Bob] Erasmus Univ, Med Ctr, Dept Hematol L413, NL-3000 CA Rotterdam, Netherlands; [Ossenkoppele, Gert J.] Free Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands; [van Putten, Wim] Erasmus Univ, Med Ctr, HOVON Data Ctr, NL-3000 CA Rotterdam, Netherlands; [van Putten, Wim] Erasmus Univ, Med Ctr, Dept Trials & Stat, NL-3000 CA Rotterdam, Netherlands; [Schouten, Harry C.] Univ Med Ctr, Maastricht, Netherlands; [Biemond, Bart J.] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Vellenga, Edo] Univ Groningen, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands; [Kooy, Marinus van Marwijk] Isala Hosp, Zwolle, Netherlands; [Verdonck, Leo F.] Univ Med Ctr, Utrecht, Netherlands; [Graux, Carlos] Hop Mont Godinne, Yvoir, Belgium; [Ferrant, Augustin] Hop St Luc, Brussels, Belgium; [Maertens, Johan; Verhoef, Gregor] Univ Hosp Gasthuisberg, B-3000 Leuven, Belgium; [von Lilienfeld-Toal, Marie] Univ Hosp, Bonn, Germany; [Beck, Joachim] Univ Hosp, Dept Internal Med 3, Mainz, Germany; [Doehner, Hartmut] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany; [Gratwohl, Alois] Univ Basel Hosp, CH-4031 Basel, Switzerland; [Pabst, Thomas] Univ Bern, Inselspital, CH-3010 Bern, Switzerland	Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Maastricht University; Maastricht University Medical Centre (MUMC); University of Amsterdam; University of Groningen; Utrecht University; Utrecht University Medical Center; Universite Catholique Louvain; Universite Catholique Louvain Hospital; KU Leuven; University Hospital Leuven; University of Bonn; University Hospital Mainz; Ulm University; University of Basel; University of Bern	Lowenberg, B (corresponding author), Erasmus Univ, Med Ctr, Dept Hematol L413, POB 2040, NL-3000 CA Rotterdam, Netherlands.	b.lowenberg@erasmusmc.nl	Döhner, Hartmut/C-8933-2016; Biesma, Douwe H./AAV-6343-2020; Zachee, Pierre/B-5391-2018	Döhner, Hartmut/0000-0003-2116-5536; Biesma, Douwe H./0000-0001-8334-3057; Zachee, Pierre/0000-0002-2275-5143	Dutch Cancer Society Queen Wilhelmina Foundation	Dutch Cancer Society Queen Wilhelmina Foundation	Supported by the Dutch Cancer Society Queen Wilhelmina Foundation.	Anderson JE, 2002, BLOOD, V100, P3869, DOI 10.1182/blood-2001-12-0354; Appelbaum FR, 2006, BLOOD, V107, P3481, DOI 10.1182/blood-2005-09-3724; Baer MR, 2002, BLOOD, V100, P1224, DOI 10.1182/blood.V100.4.1224.h81602001224_1224_1232; Baz R, 2007, CANCER, V110, P1752, DOI 10.1002/cncr.22976; Breems DA, 2008, J CLIN ONCOL, V26, P4791, DOI 10.1200/JCO.2008.16.0259; Buchner T, 2003, J CLIN ONCOL, V21, P4496, DOI 10.1200/JCO.2003.02.133; Buchner T, 2009, J CLIN ONCOL, V27, P61, DOI 10.1200/JCO.2007.15.4245; Burnett AK, 2009, BRIT J HAEMATOL, V145, P318, DOI 10.1111/j.1365-2141.2009.07604.x; DOMBRET H, 1995, NEW ENGL J MED, V332, P1678, DOI 10.1056/NEJM199506223322504; Erba Harry P, 2007, Hematology Am Soc Hematol Educ Program, P420; Estey E, 2007, J CLIN ONCOL, V25, P1908, DOI 10.1200/JCO.2006.10.2731; Frohling S, 2006, BLOOD, V108, P3280, DOI 10.1182/blood-2006-04-014324; Godwin JE, 1998, BLOOD, V91, P3607, DOI 10.1182/blood.V91.10.3607.3607_3607_3615; Goldstone AH, 2001, BLOOD, V98, P1302, DOI 10.1182/blood.V98.5.1302; Greenberg, 1998, BLOOD, V91, P1100; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; KAHN SB, 1984, J CLIN ONCOL, V2, P865, DOI 10.1200/JCO.1984.2.8.865; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1090, DOI 10.1002/cncr.21723; Lopez A, 2001, LEUKEMIA RES, V25, P685, DOI 10.1016/S0145-2126(01)00006-6; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; LOWENBERG B, 1989, J CLIN ONCOL, V7, P1268; Lowenberg B, 1998, J CLIN ONCOL, V16, P872; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; Rowe JM, 2004, BLOOD, V103, P479, DOI 10.1182/blood-2003-05-1686; Stone RM, 2001, BLOOD, V98, P548, DOI 10.1182/blood.V98.3.548; van der Holt B, 2005, BLOOD, V106, P2646, DOI 10.1182/blood-2005-04-1395; van der Holt B, 2007, BRIT J HAEMATOL, V136, P96, DOI 10.1111/j.1365-2141.2006.06403.x; Wheatley K, 2009, BRIT J HAEMATOL, V145, P598, DOI 10.1111/j.1365-2141.2009.07663.x	28	615	648	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	2009	361	13					1235	1248		10.1056/NEJMoa0901409	http://dx.doi.org/10.1056/NEJMoa0901409			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497RN	19776405				2023-01-03	WOS:000270078700005
J	Christensen, MS; Lundbye-Jensen, J; Grey, MJ; Vejlby, AD; Belhage, B; Nielsen, JB				Christensen, Mark Schram; Lundbye-Jensen, Jesper; Grey, Michael James; Vejlby, Alexandra Damgaard; Belhage, Bo; Nielsen, Jens Bo			Illusory Sensation of Movement Induced by Repetitive Transcranial Magnetic Stimulation	PLOS ONE			English	Article							ELECTRICAL-STIMULATION; SOMATOSENSORY CORTEX; MOTOR CORTEX; SENSE; CONSEQUENCES; CEREBELLUM; READINESS; INTENTION; VARIANCE; FEEDBACK	Human movement sense relies on both somatosensory feedback and on knowledge of the motor commands used to produce the movement. We have induced a movement illusion using repetitive transcranial magnetic stimulation over primary motor cortex and dorsal premotor cortex in the absence of limb movement and its associated somatosensory feedback. Afferent and efferent neural signalling was abolished in the arm with ischemic nerve block, and in the leg with spinal nerve block. Movement sensation was assessed following trains of high-frequency repetitive transcranial magnetic stimulation applied over primary motor cortex, dorsal premotor cortex, and a control area (posterior parietal cortex). Magnetic stimulation over primary motor cortex and dorsal premotor cortex produced a movement sensation that was significantly greater than stimulation over the control region. Movement sensation after dorsal premotor cortex stimulation was less affected by sensory and motor deprivation than was primary motor cortex stimulation. We propose that repetitive transcranial magnetic stimulation over dorsal premotor cortex produces a corollary discharge that is perceived as movement.	[Christensen, Mark Schram; Lundbye-Jensen, Jesper; Grey, Michael James; Nielsen, Jens Bo] Univ Copenhagen, Dept Exercise & Sport Sci, Copenhagen, Denmark; [Christensen, Mark Schram] Univ Copenhagen, Hvidovre Hosp, Danish Res Ctr Magnet Resonance, DK-2650 Hvidovre, Denmark; [Christensen, Mark Schram; Lundbye-Jensen, Jesper; Grey, Michael James; Nielsen, Jens Bo] Univ Copenhagen, Dept Neurosci & Pharmacol, Copenhagen, Denmark; [Vejlby, Alexandra Damgaard] Herlev Hosp, Dept Anaesthesiol, DK-2730 Herlev, Denmark; [Belhage, Bo] Bispebjerg Hosp, Dept Anaesthesiol, DK-2400 Copenhagen, Denmark	University of Copenhagen; University of Copenhagen; University of Copenhagen; University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg Hospital	Christensen, MS (corresponding author), Univ Copenhagen, Dept Exercise & Sport Sci, Copenhagen, Denmark.	markc@drcmr.dk	Grey, Michael J/B-4029-2011; Lundbye-Jensen, Jesper/ABH-4025-2020; Nielsen, Jens Bo/C-7632-2015	Lundbye-Jensen, Jesper/0000-0003-3144-861X; Nielsen, Jens Bo/0000-0001-5568-2916	Danish Medical Research Council [09-062846/FSS]	Danish Medical Research Council(Danish Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The study was funded by the Danish Medical Research Council (09-062846/FSS) (http://www.fi.dk/). The Simon Spies Foundation donated the MR-scanner. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AMASSIAN VE, 1989, BRAIN RES, V479, P355, DOI 10.1016/0006-8993(89)91640-5; Blakemore SJ, 1998, NAT NEUROSCI, V1, P635, DOI 10.1038/2870; BRASILNETO JP, 1992, NEUROLOGY, V42, P1302, DOI 10.1212/WNL.42.7.1302; BROMAGE PR, 1964, BRIT J ANAESTH, V36, P342, DOI 10.1093/bja/36.6.342; Christensen MS, 2007, NAT NEUROSCI, V10, P417, DOI 10.1038/nn1873; Christensen MS, 2007, CEREB CORTEX, V17, P1906, DOI 10.1093/cercor/bhl101; Cotterill RMJ, 2001, PROG NEUROBIOL, V64, P1, DOI 10.1016/S0301-0082(00)00058-7; Crapse TB, 2008, NAT REV NEUROSCI, V9, P587, DOI 10.1038/nrn2457; Cunnington R, 2003, NEUROIMAGE, V20, P404, DOI 10.1016/S1053-8119(03)00291-X; Desmurget M, 2009, SCIENCE, V324, P811, DOI 10.1126/science.1169896; Ellaway PH, 2004, J PHYSIOL-LONDON, V556, P651, DOI 10.1113/jphysiol.2003.060483; FRIED I, 1991, J NEUROSCI, V11, P3656; Gandevia SC, 2006, J PHYSIOL-LONDON, V571, P703, DOI 10.1113/jphysiol.2005.103093; Gandevia SC, 2002, ADV EXP MED BIOL, V508, P61; GLASS GV, 1972, REV EDUC RES, V42, P237, DOI 10.3102/00346543042003237; Haggard P, 2004, COGNITIVE BRAIN RES, V19, P52, DOI 10.1016/j.cogbrainres.2003.10.018; Holmes G, 1917, BRAIN, V40, P461, DOI 10.1093/brain/40.4.461; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; LIBET B, 1964, J NEUROPHYSIOL, V27, P546, DOI 10.1152/jn.1964.27.4.546; LIBET B, 1983, BRAIN, V106, P623, DOI 10.1093/brain/106.3.623; Lix LM, 1996, REV EDUC RES, V66, P579, DOI 10.2307/1170654; MIALL RC, 1993, J MOTOR BEHAV, V25, P203, DOI 10.1080/00222895.1993.9942050; Miall RC, 2003, NEUROREPORT, V14, P2135, DOI 10.1097/00001756-200312020-00001; SADATO N, 1995, ANN NEUROL, V37, P74, DOI 10.1002/ana.410370114; Scarff JE, 1940, ARCH NEURO PSYCHIATR, V44, P243, DOI 10.1001/archneurpsyc.1940.02280080003001; Schwartz AB, 2004, SCIENCE, V303, P380, DOI 10.1126/science.1087788; Shibasaki H, 2006, CLIN NEUROPHYSIOL, V117, P2341, DOI 10.1016/j.clinph.2006.04.025; SPERRY RW, 1950, J COMP PHYSIOL PSYCH, V43, P482, DOI 10.1037/h0055479; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503	29	16	16	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2010	5	10							e13301	10.1371/journal.pone.0013301	http://dx.doi.org/10.1371/journal.pone.0013301			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	661SK	20948962	Green Published, gold, Green Submitted, Green Accepted			2023-01-03	WOS:000282748100027
J	Nygaard, I				Nygaard, Ingrid			Idiopathic Urgency Urinary Incontinence.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OVERACTIVE BLADDER; OLDER WOMEN; STRESS; SYMPTOMS	At least weekly, a 62-year-old kindergarten teacher has a strong sense of urgency to urinate that is followed by urinary leakage while she rushes to the bathroom during her lunch break. She also infrequently leaks drops of urine while exercising. Her medical history is notable for mild hypertension, for which she takes hydrochlorothiazide. On physical examination, she is found to be obese and not to have abdominal masses or clinically significant pelvic-organ prolapse. How should her case be evaluated and treated?	Univ Utah, Sch Med, Dept Obstet & Gynecol, Div Urogynecol & Reconstruct Pelv Surg, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Nygaard, I (corresponding author), Univ Utah, Sch Med, Dept Obstet & Gynecol, Div Urogynecol & Reconstruct Pelv Surg, Salt Lake City, UT 84132 USA.							Albo ME, 2007, NEW ENGL J MED, V356, P2143, DOI 10.1056/NEJMoa070416; *AM COLL OBST GYN, 2005, UR INC WOM; Arya LA, 2000, OBSTET GYNECOL, V96, P85, DOI 10.1016/S0029-7844(00)00808-5; Bradley CS, 2005, AM J OBSTET GYNECOL, V192, P66, DOI 10.1016/j.ajog.2004.07.037; Brown JS, 2006, ANN INTERN MED, V144, P715, DOI 10.7326/0003-4819-144-10-200605160-00005; Brubaker L, 2008, J UROLOGY, V180, P217, DOI 10.1016/j.juro.2008.03.028; Brubaker L, 2009, NEUROUROL URODYNAM, V28, P268, DOI 10.1002/nau.20698; Bryant Charmaine M, 2002, Br J Nurs, V11, P560; Burgio KL, 2008, ANN INTERN MED, V149, P161, DOI 10.7326/0003-4819-149-3-200808050-00005; Burgio KL, 2002, JAMA-J AM MED ASSOC, V288, P2293, DOI 10.1001/jama.288.18.2293; Burgio KL, 1998, JAMA-J AM MED ASSOC, V280, P1995, DOI 10.1001/jama.280.23.1995; Cody JD, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001405.pub2; Dumoulin C, 2010, COCHRANE DB SYST REV, V1; Duthie J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005493; Emmons SL, 2005, OBSTET GYNECOL, V106, P138, DOI 10.1097/01.AOG.0000163258.57895.ec; Fitzgerald MP, 2006, J UROLOGY, V175, P989, DOI 10.1016/S0022-5347(05)00416-7; FitzGerald MP, 2002, AM J OBSTET GYNECOL, V187, P1384, DOI 10.1067/mob.2002.126865; Gameiro MO, 2010, INT UROGYNECOL J, V21, P395, DOI 10.1007/s00192-009-1059-7; Hartmann Katherine E, 2009, Evid Rep Technol Assess (Full Rep), P1; Hay-Smith EJ, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD005654; Haylen BT, 2010, NEUROUROL URODYNAM, V29, P4, DOI 10.1002/nau.20798; Hendrix SL, 2005, JAMA-J AM MED ASSOC, V293, P935, DOI 10.1001/jama.293.8.935; Herbison GP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004202.pub2; HERBISON P, 2002, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002114; Hu TW, 2003, UROLOGY, V61, P1123, DOI 10.1016/S0090-4295(03)00009-8; KEGEL AH, 1951, JAMA-J AM MED ASSOC, V146, P915, DOI 10.1001/jama.1951.03670100035008; *NAT I HLTH CLIN E, 2006, CG40 UR INC QUICK RE; Peters KM, 2010, J UROLOGY, V183, P1438, DOI 10.1016/j.juro.2009.12.036; Rosier PFWM, 2010, NEUROUROL URODYNAM, V29, P140, DOI 10.1002/nau.20764; Shamliyan Tatyana, 2007, Evid Rep Technol Assess (Full Rep), P1; Stewart WF, 2002, WORLD J UROL, V20, P327, DOI 10.1007/s00345-002-0301-4; Subak LL, 2009, NEW ENGL J MED, V360, P481, DOI 10.1056/NEJMoa0806375; Wallace SA, 2004, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001308.pub2, DOI 10.1002/14651858.CD001308.PUB2]; Williams KS, 2006, BJU INT, V98, P1043, DOI 10.1111/j.1464-410X.2006.06484.x; [No title captured], DOI DOI 10.1111/J.1471-0528.2008.01751.X	35	45	45	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1156	1162		10.1056/NEJMcp1003849	http://dx.doi.org/10.1056/NEJMcp1003849			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843250				2023-01-03	WOS:000281795800010
J	Dvorak-Ewell, M; Wendt, D; Hague, C; Christianson, T; Koppaka, V; Crippen, D; Kakkis, E; Vellard, M				Dvorak-Ewell, Melita; Wendt, Dan; Hague, Chuck; Christianson, Terri; Koppaka, Vish; Crippen, Danielle; Kakkis, Emil; Vellard, Michel			Enzyme Replacement in a Human Model of Mucopolysaccharidosis IVA In Vitro and Its Biodistribution in the Cartilage of Wild Type Mice	PLOS ONE			English	Article							N-ACETYLGALACTOSAMINE-6-SULFATE SULFATASE; MORQUIO-SYNDROME; KERATAN SULFATE; MATRIX COMPONENTS; MURINE MODEL; MPS IVA; DISEASE; DEFICIENCY; GENE; PURIFICATION	Mucopolysaccharidosis IVA (MPS IVA; Morquio A syndrome) is a lysosomal storage disorder caused by deficiency of N-acetylgalactosamine-6-sulfatase (GALNS), an enzyme that degrades keratan sulfate (KS). Currently no therapy for MPS IVA is available. We produced recombinant human (rh) GALNS as a potential enzyme replacement therapy for MPS IVA. Chinese hamster ovary cells stably overexpressing GALNS and sulfatase modifying factor-1 were used to produce active (similar to 2 U/mg) and pure (>= 97%) rhGALNS. The recombinant enzyme was phosphorylated and was dose-dependently taken up by mannose-6-phosphate receptor (K-uptake = 2.5 nM), thereby restoring enzyme activity in MPS IVA fibroblasts. In the absence of an animal model with a skeletal phenotype, we established chondrocytes isolated from two MPS IVA patients as a disease model in vitro. MPS IVA chondrocyte GALNS activity was not detectable and the cells exhibited KS storage up to 11-fold higher than unaffected chondrocytes. MPS IVA chondrocytes internalized rhGALNS into lysosomes, resulting in normalization of enzyme activity and decrease in KS storage. rhGALNS treatment also modulated gene expression, increasing expression of chondrogenic genes Collagen II, Collagen X, Aggrecan and Sox9 and decreasing abnormal expression of Collagen I. Intravenous administration of rhGALNS resulted in biodistribution throughout all layers of the heart valve and the entire thickness of the growth plate in wild-type mice. We show that enzyme replacement therapy with recombinant human GALNS results in clearance of keratan sulfate accumulation, and that such treatment ameliorates aberrant gene expression in human chondrocytes in vitro. Penetration of the therapeutic enzyme throughout poorly vascularized, but clinically relevant tissues, including growth plate cartilage and heart valve, as well as macrophages and hepatocytes in wild-type mouse, further supports development of rhGALNS as enzyme replacement therapy for MPS IVA.	[Dvorak-Ewell, Melita; Wendt, Dan; Hague, Chuck; Christianson, Terri; Koppaka, Vish; Kakkis, Emil; Vellard, Michel] BioMarin Pharmaceut Inc, Novato, CA USA; [Crippen, Danielle] Buck Inst, Novato, CA USA	BioMarin Pharmaceutical Inc.; Buck Institute for Research on Aging	Dvorak-Ewell, M (corresponding author), BioMarin Pharmaceut Inc, Novato, CA USA.	mvellard@bmrn.com			BioMarin Pharmaceutical Inc.	BioMarin Pharmaceutical Inc.	This study was funded by BioMarin Pharmaceutical Inc. the employer of all the authors except DC. The described study was a part of the drug development program at BioMarin. The internal publication review committee approved the manuscript for publication.	ANDERSON CE, 1962, J BONE JOINT SURG AM, V44, P295, DOI 10.2106/00004623-196244020-00006; Bank RA, 2009, MOL GENET METAB, V97, P196, DOI 10.1016/j.ymgme.2009.03.008; Beck M, 2001, J INHERIT METAB DIS, V24, P47, DOI 10.1023/A:1012463605992; BIELICKI J, 1995, BIOCHEM J, V311, P333, DOI 10.1042/bj3110333; Castaneda JA, 2008, ACTA NEUROPATHOL, V115, P159, DOI 10.1007/s00401-007-0296-4; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; Dangel JH, 1998, EUR J PEDIATR, V157, P534, DOI 10.1007/s004310050872; De Franceschi L, 2007, OSTEOARTHR CARTILAGE, V15, P1311, DOI 10.1016/j.joca.2007.04.008; ELIMA K, 1989, FEBS LETT, V258, P195, DOI 10.1016/0014-5793(89)81651-5; ENGFELDT B, 1982, ACTA PAEDIATR SCAND, V71, P353, DOI 10.1111/j.1651-2227.1982.tb09434.x; FACTOR SM, 1978, VIRCHOWS ARCH A, V379, P1, DOI 10.1007/BF00432778; Fraldi A, 2007, BIOCHEM J, V403, P305, DOI 10.1042/BJ20061783; Funderburgh ML, 2008, MOL VIS, V14, P308; Gagne TA, 2000, J ORTHOPAED RES, V18, P882, DOI 10.1002/jor.1100180606; Goldring MB, 2006, BEST PRACT RES CL RH, V20, P1003, DOI 10.1016/j.berh.2006.06.003; Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95; Grande-Allen KJ, 2004, GLYCOBIOLOGY, V14, P621, DOI 10.1093/glycob/cwh076; HAMMON JW, 1974, J THORAC CARDIOV SUR, V68, P352; HOLLISTER DW, 1975, JOHNS HOPKINS MED J, V137, P176; JOHN RM, 1990, ARCH DIS CHILD, V65, P746, DOI 10.1136/adc.65.7.746; Kakkis ED, 2002, EXPERT OPIN INV DRUG, V11, P675, DOI 10.1517/13543784.11.5.675; Landgrebe J, 2003, GENE, V316, P47, DOI 10.1016/S0378-1119(03)00746-7; MARODI L, 1995, BLOOD, V86, P4645, DOI 10.1182/blood.V86.12.4645.bloodjournal86124645; MASUE M, 1991, J BIOCHEM-TOKYO, V110, P965, DOI 10.1093/oxfordjournals.jbchem.a123697; MCCLURE J, 1986, PATHOLOGY, V18, P217, DOI 10.3109/00313028609059462; Melching LI, 1999, MATRIX BIOL, V18, P381, DOI 10.1016/S0945-053X(99)00033-5; MINAMI R, 1979, CLIN CHIM ACTA, V93, P207; MINAMI R, 1983, TOHOKU J EXP MED, V139, P321, DOI 10.1620/tjem.139.321; Montano AM, 2007, J INHERIT METAB DIS, V30, P165, DOI 10.1007/s10545-007-0529-7; MONTANO AM, 2008, IMPLICATIONS ABSENCE; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; NEUFELD EF, 1995, METABOLIC MOL BASIS; Northover H, 1996, J INHERIT METAB DIS, V19, P357, DOI 10.1007/BF01799267; Peters C, 2003, BONE MARROW TRANSPL, V31, P229, DOI 10.1038/sj.bmt.1703839; SHIM SS, 1986, CLIN ORTHOP RELAT R, P119; STEVENS JM, 1991, J BONE JOINT SURG BR, V73, P851, DOI 10.1302/0301-620X.73B5.1910048; Tomatsu S, 2005, HUM MOL GENET, V14, P3321, DOI 10.1093/hmg/ddi364; Tomatsu S, 2003, HUM MOL GENET, V12, P3349, DOI 10.1093/hmg/ddg366; TOMATSU S, MOL THER; Tomatsu S, 2008, HUM MOL GENET, V17, P815, DOI 10.1093/hmg/ddm353; Tomatsu S, 2007, MOL GENET METAB, V91, P251, DOI 10.1016/j.ymgme.2007.02.009; Tomatsu S, 2007, MOL GENET METAB, V91, P69, DOI 10.1016/j.ymgme.2007.01.004; VANDIGGELEN OP, 1990, CLIN CHIM ACTA, V187, P131, DOI 10.1016/0009-8981(90)90339-T; Vogler C, 1987, Am J Med Genet Suppl, V3, P243	46	47	51	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2010	5	8							e12194	10.1371/journal.pone.0012194	http://dx.doi.org/10.1371/journal.pone.0012194			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	639IH	20808938	gold, Green Published, Green Submitted			2023-01-03	WOS:000280968000019
J	Bate, R; Hess, K				Bate, Roger; Hess, Kimberly			Assessing Website Pharmacy Drug Quality: Safer Than You Think?	PLOS ONE			English	Article							RAMAN-SPECTROSCOPY	Background: Internet-sourced drugs are often considered suspect. The World Health Organization reports that drugs from websites that conceal their physical address are counterfeit in over 50 percent of cases; the U. S. Food and Drug Administration (FDA) works with the National Association of Boards of Pharmacy (NABP) to regularly update a list of websites likely to sell drugs that are illegal or of questionable quality. Methods and Findings: This study examines drug purchasing over the Internet, by comparing the sales of five popular drugs from a selection of websites stratified by NABP or other ratings. The drugs were assessed for price, conditions of purchase, and basic quality. Prices and conditions of purchase varied widely. Some websites advertised single pills while others only permitted the purchase of large quantities. Not all websites delivered the exact drugs ordered, some delivered no drugs at all; many websites shipped from multiple international locations, and from locations that were different from those advertised on the websites. All drug samples were tested against approved U. S. brand formulations using Raman spectrometry. Many (17) websites substituted drugs, often in different formulations from the brands requested. These drugs, some of which were probably generics or perhaps non-bioequivalent copy versions, could not be assessed accurately. Of those drugs that could be assessed, none failed from "approved", "legally compliant" or "not recommended" websites (0 out of 86), whereas 8.6% (3 out of 35) failed from "highly not recommended" and unidentifiable websites. Conclusions: Of those drugs that could be assessed, all except Viagra (R) passed spectrometry testing. Of those that failed, few could be identified either by a country of manufacture listed on the packaging, or by the physical location of the website pharmacy. If confirmed by future studies on other drug samples, then U. S. consumers should be able to reduce their risk by relying on credentialing agencies recommended lists and by using common sense when examining packaging and pills.	[Bate, Roger] Amer Enterprise Inst Publ Policy Res, Washington, DC 20036 USA; [Bate, Roger; Hess, Kimberly] Africa Fighting Malaria, Washington, DC USA	American Enterprise Institute for Public Policy Research	Bate, R (corresponding author), Amer Enterprise Inst Publ Policy Res, Washington, DC 20036 USA.	RBate@aei.org			Searle Freedom Trust; Legatum Institute; Legatum Foundation	Searle Freedom Trust; Legatum Institute; Legatum Foundation	The Searle Freedom Trust provided the initial grant and bulk of funding for this project. Subsequent funding was provided by the Legatum Institute and Legatum Foundation. The authors thank their funders for this support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bugay DE, 2010, APPL SPECTROSC, V64, P467, DOI 10.1366/000370210791211745; de Veij M, 2007, J RAMAN SPECTROSC, V38, P181, DOI 10.1002/jrs.1621; Deloitte Center for Health Solutions, 2009, 2009 SURV HLTH CAR C; *EUR COMM TAX CUST, 2005, REP COMM CUST ACT CO; Gryniewicz C.M., 2007, AM PHARM REV, V10, P24; *IMH HLTH, 2008, CHANN DISTR US SAL; *KAIS FAM FDN, 2008, PRESCR DRUG TRENDS; LIVINGSTON G, 2009, DAILY REFLECTOR 0603; *MARK MON, 2008, BRANDJ IND; *STAE FOOD DRUG AD, 2009, SDFA ISS 2009 1 SAF; *US FDA, 2007, FDA SAYS CONS CONT; US Government Accountability Office, 2004, INT PHARM SOM POS SA; WITKOWSKI M, 2005, USE RAMAN SPECTROSCO; 2004, WALL STREET J ONLINE, V3	14	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2010	5	8							e12199	10.1371/journal.pone.0012199	http://dx.doi.org/10.1371/journal.pone.0012199			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	638AP	20730049	Green Published, gold			2023-01-03	WOS:000280862200030
J	Rea, TD; Fahrenbruch, C; Culley, L; Donohoe, RT; Hambly, C; Innes, J; Bloomingdale, M; Subido, C; Romines, S; Eisenberg, MS				Rea, Thomas D.; Fahrenbruch, Carol; Culley, Linda; Donohoe, Rachael T.; Hambly, Cindy; Innes, Jennifer; Bloomingdale, Megan; Subido, Cleo; Romines, Steven; Eisenberg, Mickey S.			CPR with Chest Compression Alone or with Rescue Breathing.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOSPITAL CARDIAC-ARREST; BYSTANDER CARDIOPULMONARY-RESUSCITATION; AMERICAN-HEART-ASSOCIATION; CLINICAL-TRIALS; SURVIVAL; MODEL; CARE; VENTILATION; COMMITTEE	Background: The role of rescue breathing in cardiopulmonary resuscitation (CPR) performed by a layperson is uncertain. We hypothesized that the dispatcher instructions to bystanders to provide chest compression alone would result in improved survival as compared with instructions to provide chest compression plus rescue breathing. Methods: We conducted a multicenter, randomized trial of dispatcher instructions to bystanders for performing CPR. The patients were persons 18 years of age or older with out-of-hospital cardiac arrest for whom dispatchers initiated CPR instruction to bystanders. Patients were randomly assigned to receive chest compression alone or chest compression plus rescue breathing. The primary outcome was survival to hospital discharge. Secondary outcomes included a favorable neurologic outcome at discharge. Results: Of the 1941 patients who met the inclusion criteria, 981 were randomly assigned to receive chest compression alone and 960 to receive chest compression plus rescue breathing. We observed no significant difference between the two groups in the proportion of patients who survived to hospital discharge (12.5% with chest compression alone and 11.0% with chest compression plus rescue breathing, P=0.31) or in the proportion who survived with a favorable neurologic outcome in the two sites that assessed this secondary outcome (14.4% and 11.5%, respectively; P=0.13). Prespecified subgroup analyses showed a trend toward a higher proportion of patients surviving to hospital discharge with chest compression alone as compared with chest compression plus rescue breathing for patients with a cardiac cause of arrest (15.5% vs. 12.3%, P=0.09) and for those with shockable rhythms (31.9% vs. 25.7%, P=0.09). Conclusions: Dispatcher instruction consisting of chest compression alone did not increase the survival rate overall, although there was a trend toward better outcomes in key clinical subgroups. The results support a strategy for CPR performed by laypersons that emphasizes chest compression and minimizes the role of rescue breathing. (Funded in part by the Laerdal Foundation for Acute Medicine and the Medic One Foundation; ClinicalTrials.gov number, NCT00219687.) N Engl J Med 2010;363:423-33.	[Rea, Thomas D.; Fahrenbruch, Carol; Culley, Linda; Bloomingdale, Megan; Subido, Cleo; Eisenberg, Mickey S.] Emergency Med Serv, Div Publ Hlth Seattle & King Cty, Seattle, WA USA; [Rea, Thomas D.; Eisenberg, Mickey S.] Univ Washington, Seattle, WA 98195 USA; [Donohoe, Rachael T.; Innes, Jennifer] London Ambulance Serv, London, England; [Hambly, Cindy; Romines, Steven] Thurston Cty Med One, Olympia, WA USA	University of Washington; University of Washington Seattle	Rea, TD (corresponding author), 401 5th Ave,Suite 1200, Seattle, WA 98104 USA.	rea123@u.washington.edu		Fothergill, Rachael/0000-0003-1341-6200	Laerdal Foundation for Acute Medicine; Medic One Foundation; Philips Medical Systems and Physio-Control; Medtronic Foundation	Laerdal Foundation for Acute Medicine; Medic One Foundation; Philips Medical Systems and Physio-Control; Medtronic Foundation	Supported in part by grants from the Laerdal Foundation for Acute Medicine and the Medic One Foundation.; Drs. Rea and Eisenberg report receiving defibrillators and funding from Philips Medical Systems and Physio-Control to evaluate research questions related to automated external defibrillator training and use, and report that their institutions, the University of Washington and Public Health for Seattle and King County, have received funding from the Medtronic Foundation involving community-based translation of resuscitation science. Dr. Rea reports being a member of the American Heart Association Basic Life Support Committee. No other potential conflict of interest relevant to this article was reported.	Atwood C, 2005, RESUSCITATION, V67, P75, DOI 10.1016/j.resuscitation.2005.03.021; Berg RA, 2000, CRIT CARE MED, V28, pN193, DOI 10.1097/00003246-200011001-00005; Bohm K, 2007, CIRCULATION, V116, P2908, DOI 10.1161/CIRCULATIONAHA.107.710194; Ewy GA, 2007, CIRCULATION, V116, P2525, DOI 10.1161/CIRCULATIONAHA.107.711820; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Hauff SR, 2003, ANN EMERG MED, V42, P731, DOI 10.1016/S0196-0644(03)00423-2; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Kouwenhoven WB, 1960, JAMA-J AM MED ASSOC, V173, P94; LOCKE CJ, 1995, ARCH INTERN MED, V155, P938, DOI 10.1001/archinte.155.9.938; Mercer SL, 2007, AM J PREV MED, V33, P139, DOI 10.1016/j.amepre.2007.04.005; Nagao K, 2007, LANCET, V369, P920; NICHOL G, 2008, JAMA-J AM MED ASSOC, V300, P1763; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Paredes VL, 2004, ACAD EMERG MED, V11, P71, DOI 10.1197/S1069-6563(03)00587-6; Ramaraj R, 2009, HEART, V95, P1978, DOI 10.1136/hrt.2009.174268; Rea TD, 2001, CIRCULATION, V104, P2513, DOI 10.1161/hc4601.099468; Rea TD, 2008, RESUSCITATION, V77, P6, DOI 10.1016/j.resuscitation.2007.10.010; Rea TD, 2010, RESUSCITATION, V81, P293, DOI 10.1016/j.resuscitation.2009.12.002; Rea TD, 2010, CIRCULATION, V121, P1134, DOI 10.1161/CIRCULATIONAHA.109.899799; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; STEEN PA, 2008, CIRCULATION, V117, pE20; Steen PA, 2007, CIRCULATION, V116, P2514, DOI 10.1161/CIRCULATIONAHA.107.739086; Stiell I, 2003, CIRCULATION, V108, P1939, DOI 10.1161/01.CIR.0000095028.95929.B0; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; White L, 2010, CIRCULATION, V121, P91, DOI 10.1161/CIRCULATIONAHA.109.872366; Williams JG, 2006, PREHOSP EMERG CARE, V10, P247, DOI 10.1080/10903120500541027; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466	31	188	199	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	2010	363	5					423	433		10.1056/NEJMoa0908993	http://dx.doi.org/10.1056/NEJMoa0908993			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	632GS	20818863				2023-01-03	WOS:000280411300006
J	Deere, JD; Higgins, J; Cannavo, E; Villalobos, A; Adamson, L; Fromentin, E; Schinazi, RF; Luciw, PA; North, TW				Deere, Jesse D.; Higgins, Joanne; Cannavo, Elda; Villalobos, Andradi; Adamson, Lourdes; Fromentin, Emilie; Schinazi, Raymond F.; Luciw, Paul A.; North, Thomas W.			Viral Decay Kinetics in the Highly Active Antiretroviral Therapy-Treated Rhesus Macaque Model of AIDS	PLOS ONE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; REVERSE-TRANSCRIPTASE GENE; CD4(+) T-CELLS; INFECTED INDIVIDUALS; HIV-1; VIREMIA; REPLICATION; SUPPRESSION; PERSISTENCE; LYMPHOCYTES	To prevent progression to AIDS, persons infected with human immunodeficiency virus type 1 (HIV-1) must remain on highly active antiretroviral therapy (HAART) indefinitely since this modality does not eradicate the virus. The mechanisms involved in viral persistence during HAART are poorly understood, but an animal model of HAART could help elucidate these mechanisms and enable studies of HIV-1 eradication strategies. Due to the specificity of non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs) for HIV-1, we have used RT-SHIV, a chimeric virus of simian immunodeficiency virus with RT from HIV-1. This virus is susceptible to NNRTIs and causes an AIDS-like disease in rhesus macaques. In this study, two groups of HAART-treated, RT-SHIV-infected macaques were analyzed to determine viral decay kinetics. In the first group, viral loads were monitored with a standard TaqMan RT-PCR assay with a limit of detection of 50 viral RNA copies per mL. Upon initiation of HAART, viremia decayed in a bi-phasic manner with half-lives of 1.7 and 8.5 days, respectively. A third phase was observed with little further decay. In the second group, the macaques were followed longitudinally with a more sensitive assay utilizing ultracentrifugation to concentrate virus from plasma. Bi-phasic decay of viral RNA was also observed in these animals with half-lives of 1.8 and 5.8 days. Viral loads in these animals during a third phase ranged from 2-58 RNA copies/mL, with little decay over time. The viral decay kinetics observed in these macaques are similar to those reported for HIV-1 infected humans. These results demonstrate that low-level viremia persists in RT-SHIV-infected macaques despite a HAART regimen commonly used in humans.	[Deere, Jesse D.; Higgins, Joanne; Cannavo, Elda; Villalobos, Andradi; Adamson, Lourdes; Luciw, Paul A.; North, Thomas W.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Luciw, Paul A.] Univ Calif Davis, Dept Pathol, Sch Med, Davis, CA 95616 USA; [North, Thomas W.] Univ Calif Davis, Dept Vet Mol Biosci, Davis, CA 95616 USA; [Fromentin, Emilie; Schinazi, Raymond F.] Emory Univ, Sch Med, Biochem Pharmacol Lab, Ctr AIDS Res,Dept Pediat,Vet Affairs Med Ctr, Decatur, GA 30033 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Deere, JD (corresponding author), Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA.	twnorth@ucdavis.edu	Deere, Jesse Dee/ABH-7940-2020; Schinazi, Raymond F/B-6777-2017	Deere, Jesse/0000-0002-2539-0338	NIH [P01-AI058708, T32-AI60555, 1R01-RR025996]; Department of Veterans Affairs; NIH CFAR [2P30-AI-050409]; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR025996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI060555, P30AI050409, P01AI058708] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); NIH CFAR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported in part by NIH program project grant P01-AI058708. J. D. Deere was supported by NIH training grant T32-AI60555 as well as NIH grant 1R01-RR025996 (TWN and RFS). RFS is also supported by NIH CFAR grant 2P30-AI-050409 and the Department of Veterans Affairs. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ambrose Z, 2007, J VIROL, V81, P12145, DOI 10.1128/JVI.01301-07; BALZARINI J, 1995, BIOCHEM BIOPH RES CO, V211, P850, DOI 10.1006/bbrc.1995.1890; Balzarini J, 1997, J ACQ IMMUN DEF SYND, V15, P1, DOI 10.1097/00042560-199705010-00001; Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324; Chun TW, 2005, J CLIN INVEST, V115, P3250, DOI 10.1172/JCI26197; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1999, P NATL ACAD SCI USA, V96, P10958, DOI 10.1073/pnas.96.20.10958; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Cline AN, 2005, J MED PRIMATOL, V34, P303; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106; Dinoso JB, 2009, J VIROL, V83, P9247, DOI 10.1128/JVI.00840-09; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; GARDNER MB, 1989, FASEB J, V3, P2593, DOI 10.1096/fasebj.3.14.2556312; GARDNER MB, 2004, AIDS OTHER MANIFESTA, P195; Gavegnano Christina, 2009, Antiviral Chemistry & Chemotherapy, V20, P63, DOI 10.3851/IMP1374; Geeraert L, 2008, ANNU REV MED, V59, P487, DOI 10.1146/annurev.med.59.062806.123001; Giuffre AC, 2003, ANTIMICROB AGENTS CH, V47, P1756, DOI 10.1128/AAC.47.5.1756-1759.2003; GRANT CK, 1977, J IMMUNOL, V119, P401; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; Hatziioannou T, 2009, P NATL ACAD SCI USA, V106, P4425, DOI 10.1073/pnas.0812587106; Havlir DV, 2003, J VIROL, V77, P11212, DOI 10.1128/JVI.77.20.11212-11219.2003; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Hofman MJ, 2004, ANTIMICROB AGENTS CH, V48, P3483, DOI 10.1128/AAC.48.9.3483-3490.2004; Joos B, 2008, P NATL ACAD SCI USA, V105, P16725, DOI 10.1073/pnas.0804192105; Lassen K, 2004, TRENDS MOL MED, V10, P525, DOI 10.1016/j.molmed.2004.09.006; Leutenegger CM, 2001, AIDS RES HUM RETROV, V17, P243, DOI 10.1089/088922201750063160; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; LUCIW PA, 1995, P NATL ACAD SCI USA, V92, P7490, DOI 10.1073/pnas.92.16.7490; Lundgren JD, 2008, J INFECT DIS, V197, P1145, DOI 10.1086/529523; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; North TW, 2010, J VIROL, V84, P2913, DOI 10.1128/JVI.02356-09; North TW, 2005, J VIROL, V79, P7349, DOI 10.1128/JVI.79.12.7349-7354.2005; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Perelson AS, 1997, AIDS, V11, pS17; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Shen AD, 2003, J VIROL, V77, P4938, DOI 10.1128/JVI.77.8.4938-4949.2003; Soderberg K, 2002, J VIROL, V76, P5803, DOI 10.1128/JVI.76.11.5803-5806.2002; Tandon R, 2005, J VIROL METHODS, V130, P124, DOI 10.1016/j.jviromet.2005.06.017; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; UBERLA K, 1995, P NATL ACAD SCI USA, V92, P8210, DOI 10.1073/pnas.92.18.8210; Van Rompay KKA, 2004, ANTIMICROB AGENTS CH, V48, P1469, DOI 10.1128/AAC.48.5.1469-1487.2004; Van Rompay KKA, 2002, J VIROL, V76, P6083, DOI 10.1128/JVI.76.12.6083-6092.2002; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565	53	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2010	5	7							e11640	10.1371/journal.pone.0011640	http://dx.doi.org/10.1371/journal.pone.0011640			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	630AQ	20668516	gold, Green Published, Green Submitted			2023-01-03	WOS:000280243800003
J	Edelman, D; Fredrickson, SK; Melnyk, SD; Coffman, CJ; Jeffreys, AS; Datta, S; Jackson, GL; Harris, AC; Hamilton, NS; Stewart, H; Stein, J; Weinberger, M				Edelman, David; Fredrickson, Sonja K.; Melnyk, Stephanie D.; Coffman, Cynthia J.; Jeffreys, Amy S.; Datta, Santanu; Jackson, George L.; Harris, Amy C.; Hamilton, Natia S.; Stewart, Helen; Stein, Jeannette; Weinberger, Morris			Medical Clinics Versus Usual Care for Patients With Both Diabetes and Hypertension A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							SELF-MANAGEMENT PROGRAM; BLOOD-PRESSURE; GROUP VISITS; HEALTH-STATUS; ASSOCIATION; OUTCOMES; AGREE	Background: Group medical clinics (GMCs) are widely used in the management of diabetes and hypertension, but data on their effectiveness are limited. Objective: To test the effectiveness of GMCs in the management of comorbid diabetes and hypertension. Design: Randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00286741) Setting: 2 Veterans Affairs Medical Centers in North Carolina and Virginia. Patients: 239 patients with poorly controlled diabetes (hemoglobin A(1c) [HbA(1c)] level >= 7.5%) and hypertension (systolic blood pressure >140 mm Hg or diastolic blood pressure >90 mm Hg). Intervention: Patients were randomly assigned within each center to either attend a GMC or receive usual care. Clinics comprised 7 to 8 patients and a care team that consisted of a primary care general internist, a pharmacist, and a nurse or other certified diabetes educator. Each session included structured group interactions moderated by the educator. The pharmacist and physician adjusted medication to manage each patient's HbA(1c) level and blood pressure. Measurements: Hemoglobin A(1c) level and systolic blood pressure, measured by blinded research personnel at baseline, study midpoint (median, 6.8 months), and study completion (median follow-up, 12.8 months). Linear mixed models, adjusted for clustering within GMCs, were used to compare HbA(1c) levels and systolic blood pressure between the intervention and control groups. Results: Mean baseline systolic blood pressure and HbA(1c) level were 152.9 mm Hg (SD, 14.2) and 9.2% (SD, 1.4), respectively. At the end of the study, mean systolic blood pressure improved by 13.7 mm Hg in the GMC group and 6.4 mm Hg in the usual care group (P = 0.011 by linear mixed model), whereas mean HbA(1c) level improved by 0.8% in the GMC group and 0.5% in the usual care group (P = 0.159). Limitation: Measurements of effectiveness may have been limited by concomitant improvements in the usual care group that were due to co-intervention. Conclusion: Group medical clinics are a potent strategy for improving blood pressure but not HbA(1c) level in diabetic patients.	[Edelman, David] Durham Vet Affairs Med Ctr, Durham, NC 27705 USA; Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; Hunter Holmes McGuire Veterinary Affairs Medical Center	Edelman, D (corresponding author), Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA.	dedelman@duke.edu		Edelman, David/0000-0001-7112-6151	Department of Veterans Affairs Health Services Research and Development Service [IIR 03-084]	Department of Veterans Affairs Health Services Research and Development Service(US Department of Veterans Affairs)	Grant Support: By the Department of Veterans Affairs Health Services Research and Development Service (grant IIR 03-084).	ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, 2002, JAMA-J AM MED ASSOC, V288, P2981; Amer Diabet Assoc, 2009, DIABETES CARE, V32, pS85, DOI 10.2337/dc09-S085; [Anonymous], 2000, LANCET, V355, P253, DOI DOI 10.1016/S0140-6736(99)12323-7; Beck A, 1997, J AM GERIATR SOC, V45, P543, DOI 10.1111/j.1532-5415.1997.tb03085.x; Bent S, 2006, ANN INTERN MED, V144, P257, DOI 10.7326/0003-4819-144-4-200602210-00007; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; *CDCP, 2005, NAT DIAB FACT SHEET; Clancy DE, 2007, J GEN INTERN MED, V22, P620, DOI 10.1007/s11606-007-0150-3; Coleman EA, 1999, J AM GERIATR SOC, V47, P775, DOI 10.1111/j.1532-5415.1999.tb03832.x; Diggle P., 2002, J R STAT SOC, DOI DOI 10.2307/2983303; Fitzmaurice GM, 2004, APPL LONGITUDINAL AN; Heisler M, 2003, J GEN INTERN MED, V18, P893, DOI 10.1046/j.1525-1497.2003.21132.x; Hoerger TJ, 2002, JAMA-J AM MED ASSOC, V287, P2542; Jaber R, 2006, J AM BOARD FAM MED, V19, P276, DOI 10.3122/jabfm.19.3.276; Kim JW, 2005, J GEN INTERN MED, V20, P647, DOI 10.1007/s11606-005-0112-6; LITTLE RJA, 2002, STAT ANAL MISSING DA, P112; Lloyd-Jones DM, 2000, HYPERTENSION, V36, P594, DOI 10.1161/01.HYP.36.4.594; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lorig KR, 2004, MED CARE, V42, P346, DOI 10.1097/01.mlr.0000118709.74348.65; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Mancia G, 2005, ACTA DIABETOL, V42, pS17, DOI 10.1007/s00592-005-0177-z; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; OSSIPKLEIN DJ, 1984, ADDICT BEHAV, V9, P85, DOI 10.1016/0306-4603(84)90010-8; Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8; Petersen M, 2008, DIABETES CARE, V31, P1271, DOI 10.2337/dc08-9017; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; Pogach LM, 2006, DIABETES CARE, V29, P241, DOI 10.2337/diacare.29.02.06.dc05-1468; Sadur CN, 1999, DIABETES CARE, V22, P2011, DOI 10.2337/diacare.22.12.2011; SCHMUCKER D, 2006, GROUP MED APPOINTMEN; Sega R, 2005, CIRCULATION, V111, P1777, DOI 10.1161/01.CIR.0000160923.04524.5B; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; Trento M, 2001, DIABETES CARE, V24, P995, DOI 10.2337/diacare.24.6.995; Verbeke G, 2000, LINEAR MIXED MODELS; Villano CL, 2002, AM J DRUG ALCOHOL AB, V28, P213, DOI 10.1081/ADA-120002971; Wagner EH, 2001, DIABETES CARE, V24, P695, DOI 10.2337/diacare.24.4.695	36	116	118	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 1	2010	152	11					689	W287		10.7326/0003-4819-152-11-201006010-00001	http://dx.doi.org/10.7326/0003-4819-152-11-201006010-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	608CT	20513826				2023-01-03	WOS:000278560000001
J	Sellier, P; Mannioui, A; Bourry, O; Dereuddre-Bosquet, N; Delache, B; Brochard, P; Calvo, J; Prevot, S; Roques, P				Sellier, Pierre; Mannioui, Abdelkrim; Bourry, Olivier; Dereuddre-Bosquet, Nathalie; Delache, Benoit; Brochard, Patricia; Calvo, Julien; Prevot, Sophie; Roques, Pierre			Antiretroviral Treatment Start-Time during Primary SIVmac Infection in Macaques Exerts a Different Impact on Early Viral Replication and Dissemination	PLOS ONE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; T-CELL DEPLETION; POSTEXPOSURE PROPHYLAXIS; HIV-INFECTION; GASTROINTESTINAL-TRACT; ANTIVIRAL THERAPY; TYPE-1 INFECTION; RHESUS MACAQUES; LYMPHOID-TISSUE; RESTORATION	Background: The time therapy (ART) on the peripheral viral load and the establishment of viral reservoirs are poorly understood. Methodology/Principal Findings: Six groups of macaques, infected intravenously with SIVmac251, were given placebo or antiretroviral therapy to explore reservoir establishment; macaques were treated for 2 weeks, with treatment starting 4 hours, 7 or 14 days after infection. Viral replication and dissemination were measured in the gut (rectum), in the lung and in blood and lymphoid tissues (peripheral lymph nodes), by quantifying viral RNA, DNA and 2LTR circles. We used immunohistochemistry (CD4 and CD68) to assess the impact of these treatments on the relative amount of virus target cells in tissue. Treatment that was started 4 hours post-infection (pi) decreased viral replication and dissemination in blood and tissue samples, which were assessed on day 14 (RNA/DNA/2LTR circles). The virus remained detectable and lymphoid tissues were activated in LN and the gut in both placebo- and ART-treated animals. Viral RNA in plasma continued to be lower in macaques treated seven days after infection; however, this was not the case for viral DNA in peripheral blood mononuclear cells. There was a small but significant difference in RNA and DNA levels in tissues between placebo- and ART-treated animals on day 21. When started 14 days after infection, treatment resulted in a limited decrease in the plasma viral load. Conclusions: Treatment that was started 4 hours after infection significantly reduced viral replication and dissemination. When started 7 days after infection, it was of slight virological benefit in peripheral blood and in tissues, and treatment was even less effective if started 14 days pi. These data favor starting ART no longer than one week after intravenous SIVmac251 exposure.	[Sellier, Pierre; Mannioui, Abdelkrim; Bourry, Olivier; Dereuddre-Bosquet, Nathalie; Delache, Benoit; Brochard, Patricia; Calvo, Julien; Roques, Pierre] CEA, Inst Emerging Dis & Innovat Therapies IMETI, Div ImmunoVirol SIV, Fontenay Aux Roses, France; [Sellier, Pierre; Mannioui, Abdelkrim; Bourry, Olivier; Dereuddre-Bosquet, Nathalie; Delache, Benoit; Brochard, Patricia; Calvo, Julien; Roques, Pierre] Univ Paris 11, UMR E1, Orsay, France; [Sellier, Pierre] Hop Lariboisiere, AP HP, F-75475 Paris, France; [Prevot, Sophie] Hop Antoine Beclere, AP HP, Serv Anat & Cytol Pathol, Clamart, France	CEA; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Sellier, P (corresponding author), CEA, Inst Emerging Dis & Innovat Therapies IMETI, Div ImmunoVirol SIV, Fontenay Aux Roses, France.	pierre.roques@cea.fr	Roques, Pierre/M-2212-2013; Calvo, Julien/HCI-0693-2022	Roques, Pierre/0000-0003-1825-1054; 	APHP-CEA PhD; EMPRO [LSH-2002-2.3.0-2]; Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS, Paris France); Commissariat a l'Energie Atomique (CEA, France)	APHP-CEA PhD; EMPRO; Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS, Paris France)(ANRSFrench National Research Agency (ANR)); Commissariat a l'Energie Atomique (CEA, France)(French Atomic Energy Commission)	PS was awarded an APHP-CEA PhD fellowship. AM is financed by the "European Microbicide project'' EMPRO (LSH-2002-2.3.0-2). This work was supported by Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS, Paris France), and the Commissariat a l'Energie Atomique (CEA, France). AZT and 3TC were provided by GSK GlaxoSmithKline. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Benlhassan-Chahour K, 2003, J VIROL, V77, P12479, DOI 10.1128/JVI.77.23.12479-12493.2003; Bourry O, 2009, AIDS, V23, P447, DOI 10.1097/QAD.0b013e328321302d; Cara A, 2004, VIROLOGY, V324, P531, DOI 10.1016/j.virol.2004.04.006; Clayton F, 1997, CLIN EXP IMMUNOL, V107, P288, DOI 10.1111/j.1365-2249.1997.236-ce1111.x; George MD, 2005, J VIROL, V79, P2709, DOI 10.1128/JVI.79.5.2709-2719.2005; Guadalupe M, 2003, J VIROL, V77, P11708, DOI 10.1128/JVI.77.21.11708-11717.2003; Hodge S, 1999, J VIROL, V73, P8630, DOI 10.1128/JVI.73.10.8630-8639.1999; Hu LH, 2004, WORLD J GASTROENTERO, V10, P3514; Hu YL, 2004, PRENATAL DIAG, V24, P704, DOI 10.1002/pd.968; Karlsson I, 2007, J VIROL, V81, P13456, DOI 10.1128/JVI.01619-07; Le Grand R, 2000, AIDS, V14, P1864; LEGRAND R, 1994, AIDS RES HUM RETROV, V10, P1279, DOI 10.1089/aid.1994.10.1279; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; LIM SG, 1993, CLIN EXP IMMUNOL, V92, P448, DOI 10.1111/j.1365-2249.1993.tb03419.x; Mallik RC, 2008, MET MATER INT, V14, P223, DOI 10.3365/met.mat.2008.04.223; Mannioui A, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-106; Mattapallil JJ, 1999, J VIROL, V73, P6661, DOI 10.1128/JVI.73.8.6661-6669.1999; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2004, J EXP MED, V200, P761, DOI 10.1084/jem.20041196; Mehandru S, 2007, J VIROL, V81, P599, DOI 10.1128/JVI.01739-06; Merchant RC, 2004, EMERG MED J, V21, P449, DOI 10.1136/emj.2002.002824; Mowat AM, 1997, IMMUNOL REV, V156, P145, DOI 10.1111/j.1600-065X.1997.tb00966.x; Otten RA, 2000, J VIROL, V74, P9771, DOI 10.1128/JVI.74.20.9771-9775.2000; Peruchon S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005966; Puaux AL, 2004, VACCINE, V22, P3535, DOI 10.1016/j.vaccine.2004.03.044; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Schacker TW, 2002, J CLIN INVEST, V110, P1133, DOI 10.1172/JCI0216413; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; SCHNEIDER T, 1995, GUT, V37, P524, DOI 10.1136/gut.37.4.524; Smith Dawn K., 2005, Morbidity and Mortality Weekly Report, V54, P1; Smith MS, 2000, VIROLOGY, V277, P306, DOI 10.1006/viro.2000.0609; Tincati C, 2009, ANTIVIR THER, V14, P321; Tsai CC, 1998, J VIROL, V72, P4265, DOI 10.1128/JVI.72.5.4265-4273.1998; Veazey RS, 1998, SCIENCE, V280, P427, DOI 10.1126/science.280.5362.427; Verhoeven D, 2007, J MED PRIMATOL, V36, P219, DOI 10.1111/j.1600-0684.2007.00239.x; Verhoeven D, 2008, J VIROL, V82, P4016, DOI 10.1128/JVI.02164-07; YENI P, 2008, PRISE CHARGE MED PER, P412	37	18	18	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2010	5	5							e10570	10.1371/journal.pone.0010570	http://dx.doi.org/10.1371/journal.pone.0010570			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594UB	20485497	Green Published, gold, Green Submitted			2023-01-03	WOS:000277563200006
J	Frank, RT; Edmiston, M; Kendall, SE; Najbauer, J; Cheung, CW; Kassa, T; Metz, MZ; Kim, SU; Glackin, CA; Wu, AM; Yazaki, PJ; Aboody, KS				Frank, Richard T.; Edmiston, Marissa; Kendall, Stephen E.; Najbauer, Joseph; Cheung, Chia-Wei; Kassa, Thewodros; Metz, Marianne Z.; Kim, Seung U.; Glackin, Carlotta A.; Wu, Anna M.; Yazaki, Paul J.; Aboody, Karen S.			Neural Stem Cells as a Novel Platform for Tumor-Specific Delivery of Therapeutic Antibodies	PLOS ONE			English	Article							BREAST-CANCER CELLS; BRAIN METASTASES; RESISTANCE; HERCEPTIN; TROPISM; TARGET; GROWTH	Background: Recombinant monoclonal antibodies have emerged as important tools for cancer therapy. Despite the promise shown by antibody-based therapies, the large molecular size of antibodies limits their ability to efficiently penetrate solid tumors and precludes efficient crossing of the blood-brain-barrier into the central nervous system (CNS). Consequently, poorly vascularized solid tumors and CNS metastases cannot be effectively treated by intravenously-injected antibodies. The inherent tumor-tropic properties of human neural stem cells (NSCs) can potentially be harnessed to overcome these obstacles and significantly improve cancer immunotherapy. Intravenously-delivered NSCs preferentially migrate to primary and metastatic tumor sites within and outside the CNS. Therefore, we hypothesized that NSCs could serve as an ideal cellular delivery platform for targeting antibodies to malignant tumors. Methods and Findings: As proof-of-concept, we selected Herceptin(TM) (trastuzumab), a monoclonal antibody widely used to treat HER2-overexpressing breast cancer. HER2 overexpression in breast cancer is highly correlated with CNS metastases, which are inaccessible to trastuzumab therapy. Therefore, NSC-mediated delivery of trastuzumab may improve its therapeutic efficacy. Here we report, for the first time, that human NSCs can be genetically modified to secrete anti-HER2 immunoglobulin molecules. These NSC-secreted antibodies assemble properly, possess tumor cell-binding affinity and specificity, and can effectively inhibit the proliferation of HER2-overexpressing breast cancer cells in vitro. We also demonstrate that immunoglobulin-secreting NSCs exhibit preferential tropism to tumor cells in vivo, and can deliver antibodies to human breast cancer xenografts in mice. Conclusions: Taken together, these results suggest that NSCs modified to secrete HER2-targeting antibodies constitute a promising novel platform for targeted cancer immunotherapy. Specifically, this NSC-mediated antibody delivery system has the potential to significantly improve clinical outcome for patients with HER2-overexpressing breast cancer.	[Frank, Richard T.; Edmiston, Marissa; Najbauer, Joseph; Metz, Marianne Z.; Aboody, Karen S.] City Hope Natl Med Ctr, Div Hematol, Duarte, CA 91010 USA; [Frank, Richard T.; Edmiston, Marissa; Najbauer, Joseph; Metz, Marianne Z.; Aboody, Karen S.] City Hope Natl Med Ctr, Div Hematopoiet Cell Transplantat, Duarte, CA 91010 USA; [Frank, Richard T.; Edmiston, Marissa; Kendall, Stephen E.; Najbauer, Joseph; Cheung, Chia-Wei; Kassa, Thewodros; Metz, Marianne Z.; Glackin, Carlotta A.; Yazaki, Paul J.; Aboody, Karen S.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA; [Kendall, Stephen E.; Glackin, Carlotta A.] City Hope Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA; [Cheung, Chia-Wei; Kassa, Thewodros; Yazaki, Paul J.] City Hope Natl Med Ctr, Dept Canc Immunotherapy & Tumor Immunol, Duarte, CA 91010 USA; [Aboody, Karen S.] City Hope Natl Med Ctr, Dept Neurosci, Duarte, CA 91010 USA; [Wu, Anna M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Kim, Seung U.] Univ British Columbia, Dept Med, Div Neurol, UBC Hosp, Vancouver, BC V6T 1W5, Canada; [Kim, Seung U.] Gachon Univ, Gil Hosp, Inst Regenerat Med, Inchon, South Korea	City of Hope; City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; City of Hope; City of Hope; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of British Columbia; Gachon University	Frank, RT (corresponding author), City Hope Natl Med Ctr, Div Hematol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	rikfrank@gmail.com; kaboody@coh.org		Wu, Anna/0000-0001-8487-823X	Rosalinde and Arthur Gilbert Foundation; STOP CANCER; Jewish Federation's Jeanne Schnitzer Reynolds Fund for Women's Health; Ziman Family Foundation; Helen and Morgan Chu Graduate Student Fellowship; Irell and Manella Graduate School of Biological Sciences; Beckman Research Institute at City of Hope	Rosalinde and Arthur Gilbert Foundation; STOP CANCER; Jewish Federation's Jeanne Schnitzer Reynolds Fund for Women's Health; Ziman Family Foundation; Helen and Morgan Chu Graduate Student Fellowship; Irell and Manella Graduate School of Biological Sciences; Beckman Research Institute at City of Hope	This work was supported by the Rosalinde and Arthur Gilbert Foundation, STOP CANCER, The Jewish Federation's Jeanne Schnitzer Reynolds Fund for Women's Health, Ziman Family Foundation, the Helen and Morgan Chu Graduate Student Fellowship, the Irell and Manella Graduate School of Biological Sciences and the Beckman Research Institute at City of Hope. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Aboody KS, 2008, GENE THER, V15, P739, DOI 10.1038/gt.2008.41; Aboody KS, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000023; Aboody KS, 2006, NEURO-ONCOLOGY, V8, P119, DOI 10.1215/15228517-2005-012; Adams GP, 2001, CANCER RES, V61, P4750; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Brown AB, 2003, HUM GENE THER, V14, P1777, DOI 10.1089/104303403322611782; Danks MK, 2007, CANCER RES, V67, P22, DOI 10.1158/0008-5472.CAN-06-3607; Dimopoulou I, 2006, ANN ONCOL, V17, P372, DOI 10.1093/annonc/mdj057; Gutova M, 2008, STEM CELLS, V26, P1406, DOI 10.1634/stemcells.2008-0141; Joo KM, 2009, MOL THER, V17, P570, DOI 10.1038/mt.2008.290; Kim Seung U, 2002, Methods Mol Biol, V198, P55; Kute T, 2004, CYTOM PART A, V57A, P86, DOI 10.1002/cyto.a.10095; Melisko ME, 2009, NAT CLIN PRACT ONCOL, V6, P25, DOI 10.1038/ncponc1243; Molina MA, 2001, CANCER RES, V61, P4744; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Negro A, 2004, RECENT PROG HORM RES, V59, P1, DOI 10.1210/rp.59.1.1; Nielsen DL, 2009, CANCER TREAT REV, V35, P121, DOI 10.1016/j.ctrv.2008.09.003; Palmieri D, 2007, CANCER RES, V67, P4190, DOI 10.1158/0008-5472.CAN-06-3316; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; SPECTOR NL, 2009, J CLIN ONCOL; Yazaki PJ, 2004, PROTEIN ENG DES SEL, V17, P481, DOI 10.1093/protein/gzh056; Zhao DH, 2008, MOL CANCER RES, V6, P1819, DOI 10.1158/1541-7786.MCR-08-0146	22	59	61	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2009	4	12							e8314	10.1371/journal.pone.0008314	http://dx.doi.org/10.1371/journal.pone.0008314			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	533ON	20016813	Green Published, gold, Green Submitted			2023-01-03	WOS:000272833800010
J	Brown, RE				Brown, Raeford E., Jr.			Don't Touch Me	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												rbrow1@email.uky.edu		Brown, Raeford/0000-0002-2295-2657					0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	2009	302	22					2409	2410		10.1001/jama.2009.1675	http://dx.doi.org/10.1001/jama.2009.1675			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529MD	19996391				2023-01-03	WOS:000272520500001
J	Chow, RT; Johnson, MI; Lopes-Martins, RAB; Bjordal, JM				Chow, Roberta T.; Johnson, Mark I.; Lopes-Martins, Rodrigo A. B.; Bjordal, Jan M.			Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials	LANCET			English	Review							LOW-POWER LASER; CERVICAL MYOFASCIAL PAIN; SKELETAL-MUSCLE FATIGUE; FORM HEALTH SURVEY; 830 NM LASER; DOUBLE-BLIND; DIODE-LASER; NEUROMUSCULAR-JUNCTIONS; ACUPUNCTURE POINTS; TRIGGER POINTS	Background Neck pain is a common and costly condition for which pharmacological management has limited evidence of efficacy and side-effects. Low-level laser therapy (LLLT) is a relatively uncommon, non-invasive treatment for neck pain, in which non-thermal laser irradiation is applied to sites of pain. We did a systematic review and meta-analysis of randomised controlled trials to assess the efficacy of LLLT in neck pain. Methods We searched computerised databases comparing efficacy of LLLT using any wavelength with placebo or with active control in acute or chronic neck pain. Effect size for the primary outcome, pain intensity, was defined as a pooled estimate of mean difference in change in mm on 100 mm visual analogue scale. Findings We identified 16 randomised controlled trials including a total of 820 patients. In acute neck pain, results of two trials showed a relative risk (RR) of 1.69 (95% Cl 1.22-2.33) for pain improvement of LLLT versus placebo. Five trials of chronic neck pain reporting categorical data showed an RR for pain improvement of 4.05 (2.74-5.98) of LLLT. Patients in 11 trials reporting changes in visual analogue scale had pain intensity reduced by 19.86 mm (10.04-29.68). Seven trials provided follow-up data for 1-22 weeks after completion of treatment, with short-term pain relief persisting in the medium term with a reduction of 22.07 mm (17.42-26.72). Side-effects from LLLT were mild and not different from those of placebo. Interpretation We show that LLLT reduces pain immediately after treatment in acute neck pain and up to 22 weeks after completion of treatment in patients with chronic neck pain.	[Chow, Roberta T.] Univ Sydney, Nerve Res Fdn, Brain & Mind Res Inst, Sydney, NSW 2050, Australia; [Johnson, Mark I.] Leeds Metropolitan Univ, Fac Hlth, Leeds LS1 3HE, W Yorkshire, England; [Lopes-Martins, Rodrigo A. B.] Univ Sao Paulo, Dept Pharmacol, Inst Biomed Sci, Sao Paulo, Brazil; [Bjordal, Jan M.] Bergen Univ Coll, Inst Physiotherapy, Fac Hlth & Social Sci, Bergen, Norway; [Bjordal, Jan M.] Univ Bergen, Inst Publ Hlth & Primary Hlth Care, Sect Physiotherapy Sci, Bergen, Norway	University of Sydney; Leeds Beckett University; Universidade de Sao Paulo; Western Norway University of Applied Sciences; University of Bergen	Chow, RT (corresponding author), Univ Sydney, Nerve Res Fdn, Brain & Mind Res Inst, 100 Mallett St, Sydney, NSW 2050, Australia.	robertachow@iinet.net.au	Lopes-Martins, Rodrigo Alvaro/G-6972-2012; Bjordal, Jan Magnus/T-7122-2019; Lopes-Martins, Rodrigo A B/E-2013-2013	Lopes-Martins, Rodrigo Alvaro/0000-0003-4942-988X; Lopes-Martins, Rodrigo A B/0000-0002-4533-1335	Fundacao de Amparo do Estado de Sgo Paulo (FAPESP, Brazil); WALT; Norwegian Manual Therapy Association; Norwegian Neck and Back Congress; Norwegian Research Council; Norwegian Fund for Postgraduate Training in Physiotherapy; Grieg Foundation	Fundacao de Amparo do Estado de Sgo Paulo (FAPESP, Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); WALT; Norwegian Manual Therapy Association; Norwegian Neck and Back Congress; Norwegian Research Council(Research Council of NorwayEuropean Commission); Norwegian Fund for Postgraduate Training in Physiotherapy; Grieg Foundation	RTC is a member of the World Association for Laser Therapy (WALT), the Australian Medical Acupuncture College, the British Medical Acupuncture Society, the Australian Pain Society, the Australian Medical Association, and the Royal Australian College of General Practitioners. MIJ is a member of the International Association of the Study of Pain. RABL-M is funded by Fundacao de Amparo do Estado de Sgo Paulo (FAPESP, Brazil) and is scientific secretary of WALT, from which he has never received funding, grants, or fees. J M B is a member of the Norwegian Physiotherapy Association, Norwegian Sports Physiotherapy Society, Norwegian Society for Rheumatological and Orthopedic Physiotherapy, and has received research awards and grants from the Norwegian Manual Therapy Association, the Norwegian Neck and Back Congress, the Norwegian Research Council, the Norwegian Fund for Postgraduate Training in Physiotherapy, and the Grieg Foundation. He is also president of WALT, a position for which he has never received funding, grants, or fees.	Aigner N, 2006, WIEN KLIN WOCHENSCHR, V118, P95, DOI 10.1007/s00508-006-0530-4; Aimbire F, 2007, PHOTOMED LASER SURG, V25, P112, DOI 10.1089/pho.2006.1041; Aimbire F, 2006, PHOTOMED LASER SURG, V24, P33, DOI 10.1089/pho.2006.24.33; Albertini R, 2004, J PHOTOCH PHOTOBIO B, V74, P101, DOI 10.1016/j.jphotobiol.2004.03.002; Altan L, 2005, RHEUMATOL INT, V25, P23, DOI 10.1007/s00296-003-0396-y; BARNSLEY L, 2003, RHEUMATOLOGY, P567; BASFORD JR, 1995, LASER SURG MED, V16, P331, DOI 10.1002/lsm.1900160404; BAXTER GD, 1994, EXP PHYSIOL, V79, P227, DOI 10.1113/expphysiol.1994.sp003755; BEGG CB, 1988, J ROY STAT SOC A STA, V151, P419, DOI 10.2307/2982993; Binder AI, 2007, BMJ-BRIT MED J, V334, P527, DOI 10.1136/bmj.39127.608299.80; Bjordal JM, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-51; Bjordal JM, 2006, PHOTOMED LASER SURG, V24, P533; Bjordal JM, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-75; Bjordal JM, 2006, PHOTOMED LASER SURG, V24, P158, DOI 10.1089/pho.2006.24.158; Bjordal JM, 2006, BRIT J SPORT MED, V40, P76, DOI 10.1136/bjsm.2005.020842; Bjordal JM, 2003, AUST J PHYSIOTHER, V49, P107, DOI 10.1016/S0004-9514(14)60127-6; Bjordal JM, 2003, EUR J PAIN, V7, P181, DOI 10.1016/S1090-3801(02)00098-8; Bjordal JM., 2001, PHYS THER REV, V6, P91, DOI [10.1179/ptr.2001.6.2.91, DOI 10.1179/PTR.2001.6.2.91]; Bogduk Nikolai, 1998, Current Opinion in Rheumatology, V10, P110, DOI 10.1097/00002281-199803000-00004; Bogduk Nikolai, 2003, Phys Med Rehabil Clin N Am, V14, P455, DOI 10.1016/S1047-9651(03)00041-X; Borghouts JAJ, 1999, PAIN, V80, P629, DOI 10.1016/S0304-3959(98)00268-1; Brosseau L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002049.pub2; Campana Vilma R., 1999, Laser Therapy, V11, P36; CECCHERELLI F, 1989, CLIN J PAIN, V5, P301, DOI 10.1097/00002508-198912000-00005; Chow RT, 2007, J PERIPHER NERV SYST, V12, P28, DOI 10.1111/j.1529-8027.2007.00114.x; Chow RT, 2006, PAIN, V124, P201, DOI 10.1016/j.pain.2006.05.018; Chow RT, 2005, LASER SURG MED, V37, P46, DOI 10.1002/lsm.20193; Chow RT, 2004, J MUSCULOSKELET PAIN, V12, P71, DOI 10.1300/J094v12n02_09; Christie A, 2007, PHYS THER, V87, P1697, DOI 10.2522/ptj.20070039; Cousins MJ, 1999, ANESTHESIOLOGY, V91, P538, DOI 10.1097/00000542-199908000-00029; Djavid GE, 2007, AUST J PHYSIOTHER, V53, P155, DOI 10.1016/S0004-9514(07)70022-3; Dorsher PT, 2008, J ALTERN COMPLEM MED, V14, P353, DOI 10.1089/acm.2007.0810; Dundar U, 2007, CLIN RHEUMATOL, V26, P930, DOI 10.1007/s10067-006-0438-4; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Enwemeka CS, 2004, PHOTOMED LASER SURG, V22, P323, DOI 10.1089/1549541041797841; Enwemeka CS, 2001, LASER THER, V13, P95; EssinkBot ML, 1997, MED CARE, V35, P522, DOI 10.1097/00005650-199705000-00008; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; Fejer R, 2006, EUR SPINE J, V15, P834, DOI 10.1007/s00586-004-0864-4; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FLOTER T, 1990, TOP MED, V4, P52; Gagliese L, 1997, PAIN, V70, P3, DOI 10.1016/0304-3959(77)90032-X; GROSS A, 1996, ONLINE J CURR CLIN T, V5, P1; GROSS AR, 2007, J RHEUMATOL, V34, P1; Gur A, 2004, LASER SURG MED, V35, P229, DOI 10.1002/lsm.20082; Gur A, 2003, LASER SURG MED, V33, P330, DOI 10.1002/lsm.10236; GURSOY B, 1996, LASER THER, V8, P18; Hakguder A, 2003, LASER SURG MED, V33, P339, DOI 10.1002/lsm.10241; Ilbuldu E, 2004, PHOTOMED LASER SURG, V22, P306; JADAD A, 1998, RANDOMISED CONTROLLE, P97; Jensen I, 2007, BEST PRACT RES CL RH, V21, P93, DOI 10.1016/j.berh.2006.10.003; KUDOH C, 1989, LASER THER, V1, P63; Laakso E. Liisa, 1997, Laser Therapy, V9, P67; Larsson R, 1999, PAIN, V79, P45, DOI 10.1016/S0304-3959(98)00144-4; LEAK AM, 1994, BRIT J RHEUMATOL, V33, P469; Li LC, 2005, J RHEUMATOL, V32, P21; LONGO L, 1991, J EUR MED LASER ASS, V3, P16; Lopes-Martins RAB, 2006, J APPL PHYSIOL, V101, P283, DOI 10.1152/japplphysiol.01318.2005; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MESTER E, 1972, ACTA CHIR HUNG, V13, P315; Nicolau RA, 2004, LASER SURG MED, V35, P236, DOI 10.1002/lsm.20087; Nicolau RA, 2004, LASER SURG MED, V34, P277, DOI 10.1002/lsm.20006; NUSSBAUM EL, 2007, PHYSIOTHER CAN, V59, P194; Ohshiro Toshio, 1996, Laser Therapy, V8, P185; OLAVI A, 1989, ACUPUNCTURE ELECTRO, V14, P9, DOI 10.3727/036012989816358560; Oron U, 2006, PHOTOMED LASER SURG, V24, P111, DOI 10.1089/pho.2006.24.111; Ozdemir F, 2001, CLIN RHEUMATOL, V20, P181, DOI 10.1007/s100670170061; Peloso P, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000319.pub4; Picavet HSJ, 2003, PAIN, V102, P167, DOI 10.1016/S0304-3959(02)00372-X; Leal ECP, 2008, PHOTOMED LASER SURG, V26, P419, DOI 10.1089/pho.2007.2160; Leal ECP, 2009, LASER MED SCI, V24, P425, DOI 10.1007/s10103-008-0592-9; Sakurai Y, 2000, EUR J ORAL SCI, V108, P29, DOI 10.1034/j.1600-0722.2000.00783.x; Sattayut S., 1999, Laser Therapy, V11, P88; SEIDEL U, 2002, DTSCH Z AKUPUNKTUR, V45, P258; SIENDENTOPF C, 2002, NEUROSCI LETT, V327, P3; Soriano Fernando, 1998, Laser Therapy, V10, P175; Soriano Fernando A., 1996, Laser Therapy, V8, P149; Stergioulas A, 2008, PHOTOMED LASER SURG, V26, P99, DOI 10.1089/pho.2007.2138; TAVERNA E, 1990, MINERVA ORTOP TRAUMA, V41, P631; Toya Shigeo, 1994, Laser Therapy, V6, P143; Trinh KV, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004870.pub3; TSUCHIYA K, 1993, NEUROSCI LETT, V161, P65, DOI 10.1016/0304-3940(93)90141-7; TSUCHIYA K, 1994, BRAIN RES BULL, V34, P369, DOI 10.1016/0361-9230(94)90031-0; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; TUNER J, 1999, LOW LEVEL LASER THER, P101; van Tulder M, 2003, SPINE, V28, P1290, DOI 10.1097/01.BRS.0000065484.95996.AF; VASSELJEN O, 1992, SCAND J REHABIL MED, V24, P37; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; WALKER J, 1983, NEUROSCI LETT, V43, P339, DOI 10.1016/0304-3940(83)90211-2; WALT, 2006, PHOTOMED LASER SURG, V24, P761, DOI 10.1089/PHO.2006.24.6W2; Webb R, 2003, SPINE, V28, P1195, DOI 10.1097/00007632-200306010-00021; Wheeler AH, 1999, SPINE, V24, P1290, DOI 10.1097/00007632-199907010-00004; Woodruff LD, 2004, PHOTOMED LASER SURG, V22, P241, DOI 10.1089/1549541041438623; *WORLD ASS LAS THE, 2005, REC ANT DOS LOW LEV; Yousefi-Nooraie R, 2007, COCHRANE DB SYST REV, V2; Zhang WY, 1996, J CLIN PHARM THER, V21, P261, DOI 10.1111/j.1365-2710.1996.tb01148.x	96	352	365	2	73	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 5	2009	374	9705					1897	1908		10.1016/S0140-6736(09)61522-1	http://dx.doi.org/10.1016/S0140-6736(09)61522-1			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	531EQ	19913903				2023-01-03	WOS:000272646900023
J	Ford, N; Nachega, JB; Engel, ME; Mills, EJ				Ford, Nathan; Nachega, Jean B.; Engel, Mark E.; Mills, Edward J.			Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials	LANCET			English	Article							SELF-ADMINISTERED THERAPY; INFECTED DRUG-USERS; ADHERENCE; HAART; RESISTANCE; TUBERCULOSIS; EFFICACY; FAILURE; DOT	Background Directly observed therapy has been recommended to improve adherence for patients with HIV infection who are on highly active antiretroviral therapy, but the benefit and cost-effectiveness of this approach has not been established conclusively. We did a systematic review and meta-analysis of randomised trials of directly observed versus self-administered antiretroviral treatment. Methods We did duplicate searches of databases (from inception to July 27, 2009), searchable websites of major HIV conferences (up to July, 2009), and lay publications and websites (March-July, 2009) to identify randomised trials assessing directly observed therapy to promote adherence to antiretroviral therapy in adults. Our primary outcome was virological suppression at study completion. We calculated relative risks (95% CIs), and pooled estimates using a random-effects method. Findings 12 studies met our inclusion criteria; four of these were done in groups that were judged to be at high risk of poor adherence (drug users and homeless people). Ten studies reported on the primary outcome (n=1862 participants); we calculated a pooled relative risk of 1.04 (95% CI 0.91-1.20, p=0.55), and noted moderate heterogeneity between the studies (I-2= 53.8%, 95% CI 0-75.7, p=0.0247) for directly observed versus self-administered treatment. Interpretation Directly observed antiretroviral therapy seems to offer no benefit over self-administered treatment, which calls into question the use of such an approach to support adherence in the general patient population.	[Ford, Nathan] Med Sans Frontieres, Cape Town, Western Cape, South Africa; [Nachega, Jean B.] Univ Stellenbosch, Dept Med, Cape Town, Western Cape, South Africa; [Nachega, Jean B.] Univ Stellenbosch, Ctr Infect Dis, Fac Hlth Sci, Cape Town, Western Cape, South Africa; [Nachega, Jean B.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Nachega, Jean B.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Nachega, Jean B.; Engel, Mark E.] Univ Cape Town, Dept Med, ZA-7925 Cape Town, Western Cape, South Africa; [Mills, Edward J.] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada	Stellenbosch University; Stellenbosch University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Cape Town; University of Ottawa	Ford, N (corresponding author), Med Sans Frontieres, POB 27401,Rhine Rd, Cape Town, Western Cape, South Africa.	Nathan.ford@joburg.msf.org	Engel, Mark/AAP-6570-2020	Engel, Mark/0000-0002-1334-8829; Nachega, Jean/0000-0002-2862-4443	US National Institute of Allergy and Infections Diseases (NIAID); US National Institutes of Health [AI 553590]; NIAID/NIH [K23 AI068582-01]; Canadian Institutes of Health Research Canada; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI068582] Funding Source: NIH RePORTER	US National Institute of Allergy and Infections Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Canadian Institutes of Health Research Canada(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	JBN acknowledges research support from the US National Institute of Allergy and Infections Diseases (NIAID) and US National Institutes of Health (NIH; grant number AI 553590), and is the recipient of an NIAID/NIH Mentored Patient-Oriented Research Career Award (K23 AI068582-01). EJM is supported by a Canadian Institutes of Health Research Canada Research Chair. We thank Joanna Downer and Aline Raymond for administrative support.	Altice FL, 2007, CLIN INFECT DIS, V45, P770, DOI 10.1086/521166; ARNSTEN J, 2009, 4 INT C HIV TREATM A; BANGSBERG D, 2009, 4 INT C HIV TREATM A; BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; BUSSMANN H, 2007, 14 C RETR OPP INF LO; Bussmann H, 2009, JAIDS-J ACQ IMM DEF, V51, P37, DOI 10.1097/QAI.0b013e31819ff102; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; ELLIOT D, 2008, 17 INT AIDS C MEX CI; Farmer P, 2001, B WORLD HEALTH ORGAN, V79, P1145; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GRODENSKY C, 2009, 4 INT C HIV TREATM A; Gross R, 2006, J INFECT DIS, V194, P1108, DOI 10.1086/507680; Gross R, 2009, ARCH INTERN MED, V169, P1224, DOI 10.1001/archinternmed.2009.172; Harrigan PR, 2005, J INFECT DIS, V191, P339, DOI 10.1086/427192; Hedges L.V., 2014, STAT METHODS META AN; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Hozo S.P., 2005, BMC MED RES METHODOL, V5, P13, DOI [10.1186/1471-2288-5-13, DOI 10.1186/1471-2288-5-13]; Liechty CA, 2003, AIDS, V17, P1383, DOI 10.1097/00002030-200306130-00013; Lucas GM, 2002, AIDS PATIENT CARE ST, V16, P527, DOI 10.1089/108729102761041083; Macalino GE, 2007, AIDS, V21, P1473, DOI 10.1097/QAD.0b013e32811ebf68; Maher D, 2003, BRIT MED J, V327, P822, DOI 10.1136/bmj.327.7419.822; Maru DSR, 2007, JAIDS-J ACQ IMM DEF, V46, P555, DOI 10.1097/QAI.0b013e318158c0bd; Maru DSR, 2009, JAIDS-J ACQ IMM DEF, V50, P176, DOI 10.1097/QAI.0b013e3181938e7e; Maskew M, 2007, SAMJ S AFR MED J, V97, P853; Meade MO, 2001, AM J RESP CRIT CARE, V163, P490, DOI 10.1164/ajrccm.163.2.2006067; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; NAIDOO A, 2009, 5 IAS C HIV PATH TRE; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Page-Shipp LS, 2007, SEX TRANSM INFECT, V83, P383, DOI 10.1136/sti.2007.025585; Pearson CR, 2007, JAIDS-J ACQ IMM DEF, V46, P238, DOI 10.1097/QAI.0b013e318153f7ba; Pearson CR, 2006, JAIDS-J ACQ IMM DEF, V43, pS134, DOI 10.1097/01.qai.0000248339.82567.17; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; Ram M., 2009, 16 C RETR OPP INF MO; Rigsby MO, 2000, J GEN INTERN MED, V15, P841, DOI 10.1046/j.1525-1497.2000.00127.x; Robert C.P., 2004, TECHNOMETRICS, DOI DOI 10.2307/1270959; ROSENBLUM M, 2009, 16 C RETR OPP INF MO; Sackett DL, 2001, CAN MED ASSOC J, V165, P1226; Sarna A, 2008, JAIDS-J ACQ IMM DEF, V48, P611, DOI 10.1097/QAI.0b013e3181806bf1; Sherer R, 1998, JAMA-J AM MED ASSOC, V280, P567, DOI 10.1001/jama.280.6.567; Simoni JM, 2006, JAIDS-J ACQ IMM DEF, V43, pS23, DOI 10.1097/01.qai.0000248342.05438.52; TAIWO BO, 2008, 3 INT C HIV TREATM A; Tam LWY, 2008, JAIDS-J ACQ IMM DEF, V49, P266, DOI 10.1097/QAI.0b013e318189a753; Verma Geetika, 2004, BMC Med Ethics, V5, pE2, DOI 10.1186/1472-6939-5-2; Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2; Wohl AR, 2006, CLIN INFECT DIS, V42, P1619, DOI 10.1086/503906; World Health Organization, 1997, WHOTB97220	49	78	79	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC-JAN	2009	374	9707					2064	2071		10.1016/S0140-6736(09)61671-8	http://dx.doi.org/10.1016/S0140-6736(09)61671-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	537OO	19954833				2023-01-03	WOS:000273122900029
J	King, FW; Fong, S; Griffin, C; Shoemaker, M; Staub, R; Zhang, YL; Cohen, I; Shtivelman, E				King, Frank W.; Fong, Sylvia; Griffin, Chandi; Shoemaker, Mark; Staub, Rick; Zhang, Yan-Ling; Cohen, Isaac; Shtivelman, Emma			Timosaponin AIII Is Preferentially Cytotoxic to Tumor Cells through Inhibition of mTOR and Induction of ER Stress	PLOS ONE			English	Article								The aqueous extract of Anemarrhena asphodeloides (BN108) induces apoptosis in various cancer cell lines but is significantly less cytotoxic in non-transformed cells. Chemical fractionation of BN108 showed that its cytotoxicity is associated with timosaponins, steroidal saponins of coprostane type. Timosaponin BII (TBII) is a major saponin in BN108, but it shows little cytotoxicity. A much less abundant TAIII induces cell death in tumor cells but not in normal cells, reproducing the selectivity of the total extract BN108. Glycosidase treatment, by removing the extra sugar moiety in TBII, converts it to TAIII and confers cytotoxic activity. Analysis of the mechanisms of death induced by TAIII revealed activation of two distinct pro-apoptotic pathways: first, inhibition of mTORC1 manifested in much reduced phosphorylation of mTORC1 targets; second, induction of endoplasmic reticulum stress culminating in phosphorylation of eIF2 alpha and activation of caspase 4. These pro-apoptotic pathways are activated by TAIII selectively in tumor cells but not in normal cells. Both pathways play a causative role in TAIII cytotoxicity, as restoration of either mTOR activity or relief of ER stress alone offer only partial protection from TAIII. Inhibition of mTORC1 and induction of ER stress apparently contribute to the induction of the previously reported autophagic response in TAIII-treated cells. TAIII induced autophagy plays a protective role in TAIII induced death signaling, and failure to mount autophagic response is associated with heightened sensitivity to TAIII induced apoptosis. The multiple death-promoting and apparently tumor-selective responses to TAIII, its ability to inhibit mTORC1, and the possibility of further enhancing its cytotoxicity by pharmacological inhibition of autophagy, make TAIII an attractive candidate for development as a cancer therapeutic agent.	[King, Frank W.; Fong, Sylvia; Griffin, Chandi; Shoemaker, Mark; Staub, Rick; Zhang, Yan-Ling; Cohen, Isaac; Shtivelman, Emma] BioNovo Inc, Emeryville, CA USA		King, FW (corresponding author), BioNovo Inc, Emeryville, CA USA.	emmas@bionovo.com		Fong, Sylvia/0000-0002-3818-4146				Audas TE, 2008, MOL CELL BIOL, V28, P3952, DOI 10.1128/MCB.01439-07; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Carra S, 2009, J BIOL CHEM, V284, P5523, DOI 10.1074/jbc.M807440200; Colgan SM, 2007, INT J BIOCHEM CELL B, V39, P1843, DOI 10.1016/j.biocel.2007.05.002; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Diaz-Troya S, 2008, AUTOPHAGY, V4, P851, DOI 10.4161/auto.6555; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Harding HP, 2005, CELL METAB, V2, P361, DOI 10.1016/j.cmet.2005.11.005; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Horton JD, 2002, COLD SPRING HARB SYM, V67, P491, DOI 10.1101/sqb.2002.67.491; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; KAWASAKI T, 1963, Chem Pharm Bull (Tokyo), V11, P1221; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; KOVACS WJ, 2008, J BIOL CHEM; Lee JN, 2004, J BIOL CHEM, V279, P45257, DOI 10.1074/jbc.M408235200; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Li J, 2008, CELL DEATH DIFFER, V15, P1460, DOI 10.1038/cdd.2008.81; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Proud CG, 2009, BIOCHEM SOC T, V37, P227, DOI 10.1042/BST0370227; Radhakrishnan A, 2008, CELL METAB, V8, P512, DOI 10.1016/j.cmet.2008.10.008; Rao RV, 2002, FEBS LETT, V514, P122, DOI 10.1016/S0014-5793(02)02289-5; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; SAITO S, 1994, CHEM PHARM BULL, V42, P2342, DOI 10.1248/cpb.42.2342; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Shoemaker M, 2005, PHYTOTHER RES, V19, P649, DOI 10.1002/ptr.1702; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Skeen JE, 2006, CANCER CELL, V10, P269, DOI 10.1016/j.ccr.2006.08.022; Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Yorimitsu T, 2007, AUTOPHAGY, V3, P160, DOI 10.4161/auto.3653; Zhang JY, 1999, CLIN CHIM ACTA, V289, P79, DOI 10.1016/S0009-8981(99)00160-6	43	64	71	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7283	10.1371/journal.pone.0007283	http://dx.doi.org/10.1371/journal.pone.0007283			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789631	Green Submitted, Green Published, gold			2023-01-03	WOS:000270354100029
J	Krasner, MS; Epstein, RM; Beckman, H; Suchman, AL; Chapman, B; Mooney, CJ; Quill, TE				Krasner, Michael S.; Epstein, Ronald M.; Beckman, Howard; Suchman, Anthony L.; Chapman, Benjamin; Mooney, Christopher J.; Quill, Timothy E.			Association of an Educational Program in Mindful Communication With Burnout, Empathy, and Attitudes Among Primary Care Physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRESS REDUCTION; JEFFERSON SCALE; LIFE-STYLE; SATISFACTION; MEDICINE; SPECIALTY; VALIDITY; BELIEFS; GENDER; HEALTH	Context Primary care physicians report high levels of distress, which is linked to burnout, attrition, and poorer quality of care. Programs to reduce burnout before it results in impairment are rare; data on these programs are scarce. Objective To determine whether an intensive educational program in mindfulness, communication, and self-awareness is associated with improvement in primary care physicians' well-being, psychological distress, burnout, and capacity for relating to patients. Design, Setting, and Participants Before-and-after study of 70 primary care physicians in Rochester, New York, in a continuing medical education (CME) course in 2007-2008. The course included mindfulness meditation, self-awareness exercises, narratives about meaningful clinical experiences, appreciative interviews, didactic material, and discussion. An 8-week intensive phase (2.5 h/wk, 7-hour retreat) was followed by a 10-month maintenance phase (2.5 h/mo). Main Outcome Measures Mindfulness (2 subscales), burnout (3 subscales), empathy (3 subscales), psychosocial orientation, personality (5 factors), and mood (6 subscales) measured at baseline and at 2, 12, and 15 months. Results Over the course of the program and follow-up, participants demonstrated improvements in mindfulness (raw score, 45.2 to 54.1; raw score change [Delta], 8.9; 95% confidence interval [CI], 7.0 to 10.8); burnout (emotional exhaustion, 26.8 to 20.0; Delta = -6.8; 95% CI, -4.8 to -8.8; depersonalization, 8.4 to 5.9; Delta = -2.5; 95% CI, -1.4 to -3.6; and personal accomplishment, 40.2 to 42.6; Delta = 2.4; 95% CI, 1.2 to 3.6); empathy (116.6 to 121.2; Delta = 4.6; 95% CI, 2.2 to 7.0); physician belief scale (76.7 to 72.6; Delta = -4.1; 95% CI, -1.8 to -6.4); total mood disturbance (33.2 to 16.1; Delta = -17.1; 95% CI, -11 to -23.2), and personality (conscientiousness, 6.5 to 6.8; Delta = 0.3; 95% CI, 0.1 to 5 and emotional stability, 6.1 to 6.6; Delta = 0.5; 95% CI, 0.3 to 0.7). Improvements in mindfulness were correlated with improvements in total mood disturbance (r = -0.39, P < .001), perspective taking subscale of physician empathy (r = 0.31, P < .001), burnout (emotional exhaustion and personal accomplishment subscales, r = -0.32 and 0.33, respectively; P < .001), and personality factors (conscientiousness and emotional stability, r = 0.29 and 0.25, respectively; P < .001). Conclusions Participation in a mindful communication program was associated with short-term and sustained improvements in well-being and attitudes associated with patient-center care. Because before-and-after designs limit inferences about intervention effects, these findings warrant randomized trials involving a variety of practicing physicians. JAMA. 2009;302(12):1284-1293	[Krasner, Michael S.; Beckman, Howard; Suchman, Anthony L.; Quill, Timothy E.] Univ Rochester, Med Ctr, Dept Internal Med, Rochester, NY 14618 USA; [Epstein, Ronald M.; Beckman, Howard] Univ Rochester, Med Ctr, Dept Family Med, Rochester, NY 14618 USA; [Epstein, Ronald M.; Chapman, Benjamin; Quill, Timothy E.] Univ Rochester, Med Ctr, Dept Psychiat, Rochester, NY 14618 USA; [Epstein, Ronald M.; Quill, Timothy E.] Univ Rochester, Med Ctr, Dept Oncol, Rochester, NY 14618 USA; [Mooney, Christopher J.] Univ Rochester, Med Ctr, Off Med Educ, Rochester, NY 14618 USA; [Epstein, Ronald M.; Quill, Timothy E.] Univ Rochester, Med Ctr, Ctr Improve Commun Hlth Care, Rochester, NY 14618 USA; [Epstein, Ronald M.; Quill, Timothy E.] Univ Rochester, Med Ctr, Ctr Eth Humanities & Palliat Care, Rochester, NY 14618 USA; [Beckman, Howard] Rochester Individual Practice Assoc, Rochester, NY USA; [Suchman, Anthony L.] Relationship Ctr Hlth Care, Rochester, NY USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester; University of Rochester	Krasner, MS (corresponding author), Univ Rochester, Sch Med & Dent, Dept Med, Olsan Med Grp, 2400 5 Clinton Ave,Bldg H,230, Rochester, NY 14618 USA.	michael_krasner@urmc.rochester.edu	Girault, Johann/B-2430-2012	Chapman, Benjamin/0000-0002-5170-3131	Physicians' Foundation for Health Systems Excellence; New York Chapter of the American College of Physicians; National Institutes of Health [K08AG31328]; NATIONAL INSTITUTE ON AGING [K08AG031328] Funding Source: NIH RePORTER	Physicians' Foundation for Health Systems Excellence; New York Chapter of the American College of Physicians; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The study was funded by the Physicians' Foundation for Health Systems Excellence and sponsored by the New York Chapter of the American College of Physicians. Work done on this project by Dr Chapman was facilitated by grant K08AG31328 from the National Institutes of Health.	ASHWORTH CD, 1984, SOC SCI MED, V19, P1235, DOI 10.1016/0277-9536(84)90376-9; Baer RA, 2006, ASSESSMENT, V13, P27, DOI 10.1177/1073191105283504; Baer RA, 2008, ASSESSMENT, V15, P329, DOI 10.1177/1073191107313003; Beddoe AE, 2004, J NURS EDUC, V43, P305; Bellini LM, 2002, JAMA-J AM MED ASSOC, V287, P3143, DOI 10.1001/jama.287.23.3143; Benjamini Y, 2001, ANN STAT, V29, P1165; Berwick DM, 2008, JAMA-J AM MED ASSOC, V299, P1182, DOI 10.1001/jama.299.10.1182; Bodenheimer T, 2006, NEW ENGL J MED, V355, P861, DOI 10.1056/NEJMp068155; Buchbinder SB, 1999, AM J MANAG CARE, V5, P1431; Burton P, 1998, STAT MED, V17, P1261, DOI 10.1002/(SICI)1097-0258(19980615)17:11<1261::AID-SIM846>3.0.CO;2-Z; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; CHARON R, 1994, SOC SCI MED, V39, P955, DOI 10.1016/0277-9536(94)90207-0; Cohen J., 2013, STAT POWER ANAL BEHA; Connelly JE, 2005, PERSPECT BIOL MED, V48, P84, DOI 10.1353/pbm.2005.0006; Cooperrider D. L., 2005, APPRECIATIVE INQUIRY; Crane M, 1998, Med Econ, V75, P210; CRANE M, 1998, MED ECON, V75, P215; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; DOHERTY WJ, 1989, JAMA-J AM MED ASSOC, V261, P2374, DOI 10.1001/jama.261.16.2374; Dorsey ER, 2003, JAMA-J AM MED ASSOC, V290, P1173, DOI 10.1001/jama.290.9.1173; Dunn PM, 2007, J GEN INTERN MED, V22, P1544, DOI 10.1007/s11606-007-0363-5; Dyrbye LN, 2008, ANN INTERN MED, V149, P334, DOI 10.7326/0003-4819-149-5-200809020-00008; Dyrbye LN, 2006, MAYO CLIN PROC, V81, P1435, DOI 10.4065/81.11.1435; Epstein RM, 1999, JAMA-J AM MED ASSOC, V282, P833, DOI 10.1001/jama.282.9.833; Epstein RM, 2005, ANN FAM MED, V3, P415, DOI 10.1370/afm.348; Epstein RM, 2008, J CONTIN EDUC HEALTH, V28, P5, DOI 10.1002/chp.149; Epstein RM, 2007, ANN FAM MED, V5, P21, DOI 10.1370/afm.621; Everitt B. S., 2004, STAT ASPECTS DESIGN; Field CA, 2007, J R STAT SOC B, V69, P369, DOI 10.1111/j.1467-9868.2007.00593.x; Fiscella K, 2004, MED CARE, V42, P1049, DOI 10.1097/00005650-200411000-00003; Grepmair L, 2007, PSYCHOTHER PSYCHOSOM, V76, P332, DOI 10.1159/000107560; Haas JS, 2000, J GEN INTERN MED, V15, P122, DOI 10.1046/j.1525-1497.2000.02219.x; Hassed C, 2009, ADV HEALTH SCI EDUC, V14, P387, DOI 10.1007/s10459-008-9125-3; Hojat M, 2002, AM J PSYCHIAT, V159, P1563, DOI 10.1176/appi.ajp.159.9.1563; Hojat M, 2002, ACAD MED, V77, pS58, DOI 10.1097/00001888-200210001-00019; Hojat M, 2001, EDUC PSYCHOL MEAS, V61, P349, DOI 10.1177/00131640121971158; HOROWITZ CR, 1995, ANN INTERN MED, V138, P772; Kabat-Zinn J., 1994, WHEREVER YOU GO THER; Kabat-Zinn J., 1990, FULL CATASTROPHE LIV; Kalauokalani D, 2007, PAIN MED, V8, P17, DOI 10.1111/j.1526-4637.2007.00170.x; KRASNER M, 2007, BEST BUDDHIST WRITIN, P200; Krupat E, 2001, J FAM PRACTICE, V50, P1057; Landon BE, 2006, MED CARE, V44, P234, DOI 10.1097/01.mlr.0000199848.17133.9b; Lovas JG, 2008, J DENT EDUC, V72, P998; Ludwig DS, 2008, JAMA-J AM MED ASSOC, V300, P1350, DOI 10.1001/jama.300.11.1350; MASLACH C, 1998, EVALUATING STRESS BO, P191; McNair D. M., 1971, MANUAL PROFILE MOOD; Mercer SL, 2007, AM J PREV MED, V33, P139, DOI 10.1016/j.amepre.2007.04.005; Michels PJ, 2003, ACAD MED, V78, P69, DOI 10.1097/00001888-200301000-00013; Musick DW, 2006, ACAD MED, V81, P759, DOI 10.1097/00001888-200608000-00015; Nyenhuis DL, 1999, J CLIN PSYCHOL, V55, P79, DOI 10.1002/(SICI)1097-4679(199901)55:1<79::AID-JCLP8>3.0.CO;2-7; OConnor PG, 1997, MED CLIN N AM, V81, P1037, DOI 10.1016/S0025-7125(05)70562-9; Ospina-Kammerer Veronika, 2003, Int J Emerg Ment Health, V5, P29; RAFFERTY JP, 1986, J CLIN PSYCHOL, V42, P488, DOI 10.1002/1097-4679(198605)42:3<488::AID-JCLP2270420315>3.0.CO;2-S; Reuben DB, 2007, AM J MED, V120, P99, DOI 10.1016/j.amjmed.2006.10.019; Rosenzweig S, 2003, TEACH LEARN MED, V15, P88, DOI 10.1207/S15328015TLM1502_03; Santorelli S., 1999, HEAL THY SELF LESSON; SAUCIER G, 1994, J PERS ASSESS, V63, P506, DOI 10.1207/s15327752jpa6303_8; Segal Z. V., 2013, MINDFULNESS BASED CO, V2nd; Shadish William R., 2002, EXPT QUASIEXPERIMENT; Shanafelt TD, 2005, J GEN INTERN MED, V20, P559, DOI 10.1007/s11606-005-0102-8; Shanafelt TD, 2005, ONCOLOGY-BASEL, V68, P23, DOI 10.1159/000084519; Shanafelt TD, 2003, AM J MED, V114, P513, DOI 10.1016/S0002-9343(03)00117-7; Shanafelt TD, 2002, ANN INTERN MED, V136, P358, DOI 10.7326/0003-4819-136-5-200203050-00008; Shapiro S L, 2000, Adv Mind Body Med, V16, P128; Shapiro S. L., 2005, INT J STRESS MANAGE, V12, P164, DOI [10.1037/1072-5245.12.2.164, DOI 10.1037/1072-5245.12.2.164]; Shapiro SL, 1998, J BEHAV MED, V21, P581, DOI 10.1023/A:1018700829825; SHAPIRO SL, 1998, INTEGRATIVE MED, V1, P93, DOI DOI 10.1016/S1096-2190(98)00034-1; Singh NN, 2006, BEHAV MODIF, V30, P423, DOI 10.1177/0145445504272971; Spickard A, 2002, JAMA-J AM MED ASSOC, V288, P1447, DOI 10.1001/jama.288.12.1447; Street RL, 2007, MED DECIS MAKING, V27, P550, DOI 10.1177/0272989x07307581; Suchman AL, 2001, WESTERN J MED, V174, P43, DOI 10.1136/ewjm.174.1.43; Thomas NK, 2004, JAMA-J AM MED ASSOC, V292, P2880, DOI 10.1001/jama.292.23.2880; Treadway K, 2008, NEW ENGL J MED, V359, P2086, DOI 10.1056/NEJMp0805762; *U MA MED SCH, STRESS RED PROGR TUI; Williams ES, 2001, HEALTH CARE MANAGE R, V26, P7, DOI 10.1097/00004010-200101000-00002; 2003, APPRECIATIVE INQUIRY	77	917	936	9	239	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	2009	302	12					1284	1293		10.1001/jama.2009.1384	http://dx.doi.org/10.1001/jama.2009.1384			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	497AR	19773563	Bronze			2023-01-03	WOS:000270026000010
J	Fortuna, RJ; Robbins, BW; Halterman, JS				Fortuna, Robert J.; Robbins, Brett W.; Halterman, Jill S.			Ambulatory Care Among Young Adults in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED-TRIAL; MEDICAL-CARE; HEALTH; ADOLESCENTS; SERVICES; UNINSURANCE; DELIVERY; BEHAVIOR; VISITS; RISK	Background: Young adults are the most likely age group to be uninsured and have the highest prevalence of substance abuse, motor vehicle accidents, and sexually transmitted diseases, yet little is known about their use of ambulatory care. Objective: To characterize ambulatory care of young adults. Design: Cross-sectional data from the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey. Setting: Community and hospital-based clinics. Patients: Nonpregnant young adults age 20 to 29 years. Measurements: Ambulatory care utilization, types of visits, and preventive care. Results: Insured young adults had more visits (2.16 [95% CI, 2.14 to 2.19] annual visits per capita) than those without insurance (0.59 [CI, 0.54 to 0.67] annual visits per capita). Young men utilized ambulatory medical care less than adolescents age 15 to 19 years or older adults age 30 to 39 years (1.10, 1.65, and 1.73 annual visits per capita, respectively) and had lower rates of utilization than young women (1.10 vs. 2.31 annual visits per capita). Young black and Hispanic men had considerably fewer annual visits per capita (0.75 and 0.65, respectively) than did young white men (1.21). Young men had nearly one half the preventive care visits compared with male adolescents or older men (0.11, 0.24, and 0.19 annual visits per capita, respectively) and less than one quarter the visits compared with young women (0.11 vs. 0.48 annual visits per capita). Only 30.6% of visits by young adults included any preventive counseling, and few encounters included counseling directed toward injury prevention (2.4%), mental health (4.1%), or sexually transmitted diseases (2.7%). Limitation: School-based clinics were not included, and counseling may be underreported. Conclusion: Young adults use less ambulatory medical care relative to other groups and infrequently receive preventive care directed at the greatest threats to their health. Efforts to ensure appropriate preventive care are needed.	[Fortuna, Robert J.] Univ Rochester, Sch Med & Dent, Ctr Primary Care, Rochester, NY 14609 USA; Univ Rochester, Sch Med & Dent, Strong Childrens Res Ctr, Rochester, NY 14609 USA	University of Rochester; University of Rochester	Fortuna, RJ (corresponding author), Univ Rochester, Sch Med & Dent, Ctr Primary Care, 913 Culver Rd, Rochester, NY 14609 USA.	Robert_Fortuna@urmc.rochester.edu			Center for Primary Care	Center for Primary Care	The authors thank the Center for Primary Care at the University of Rochester School of Medicine and Dentistry for support of this project.	American Academy of Pediatrics, 2008, BRIGHT FUT GUID HLTH; Arnett JJ, 2000, AM PSYCHOL, V55, P469, DOI 10.1037/0003-066X.55.5.469; BIEN TH, 1993, ADDICTION, V88, P315, DOI 10.1111/j.1360-0443.1993.tb00820.x; Callahan ST, 2005, PEDIATRICS, V116, P88, DOI 10.1542/peds.2004-1449; Callahan ST, 2004, PEDIATRICS, V113, P291, DOI 10.1542/peds.113.2.291; *CDCP, 2008, SEX TRANSM DIS SURV; ELSTER A, 2004, GUIDELINES ADOLESCEN; Gilchrist VJ, 2004, MED CARE, V42, P276, DOI 10.1097/01.mlr.0000114916.95639.af; HIBBARD JH, 1986, WOMEN HEALTH, V11, P21, DOI 10.1300/J013v11n02_03; *I CLIN SYST IMPR, PREV SERV CHILDR AD; Johnston BD, 2002, PEDIATRICS, V110, P267, DOI 10.1542/peds.110.2.267; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Klein JD, 2001, ARCH PEDIAT ADOL MED, V155, P597, DOI 10.1001/archpedi.155.5.597; Kriss Jennifer L, 2008, Issue Brief (Commonw Fund), V38, P1; Ma J, 2005, J ADOLESCENT HEALTH, V37, P434, DOI 10.1016/j.jadohealth.2005.07.012; Marcell AV, 2002, J ADOLESCENT HEALTH, V30, P35, DOI 10.1016/S1054-139X(01)00319-6; *NAT CTR HLTH STAT, US ULT CLUST MOD NAM; *NAT CTR HLTH STAT, PROT 2003 05 NAT AMB; National Center for Health Statistics, NCHS PUBL US DAT FIL; Ortega-Sanchez R, 2004, PREV MED, V38, P219, DOI 10.1016/j.ypmed.2003.09.042; Ozer E, 2003, J ADOLESCENT HEALTH, V32, P132, DOI 10.1016/S1054-139X(02)00638-9; Park MJ, 2008, J ADOLESCENT HEALTH, V42, P329, DOI 10.1016/j.jadohealth.2008.01.008; Park MJ, 2006, J ADOLESCENT HEALTH, V39, P305, DOI 10.1016/j.jadohealth.2006.04.017; Rand CM, 2005, J ADOLESCENT HEALTH, V37, P87, DOI 10.1016/j.jadohealth.2005.02.008; Rand CM, 2007, ARCH PEDIAT ADOL MED, V161, P252, DOI 10.1001/archpedi.161.3.252; *ROCH COMM WID CLI, 2007, PREV CAR AD AG 19 YE; Stein RJ, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.5.e66; *SUBST AB MENT HLT, 2008, NSDUH REP TREATM YEA; Substance Abuse and Mental Health Services Administration Office of Applied Studies, 2008, NSDUH SERIES H; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; *US BUR CENS POP D, MONTHL POP EST US; *US BUR CENS POP D, CENS 2000 BRIEFS SPE; VERBRUGGE LM, 1982, PUBLIC HEALTH REP, V97, P417; Ziv A, 1999, PEDIATRICS, V104, P35, DOI 10.1542/peds.104.1.35	34	89	89	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	2009	151	6					379	W119		10.7326/0003-4819-151-6-200909150-00002	http://dx.doi.org/10.7326/0003-4819-151-6-200909150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	501OB	19755363				2023-01-03	WOS:000270390100002
J	Vincent, JL; Singer, M				Vincent, Jean-Louis; Singer, Mervyn			Critical Care 3 Critical care: advances and future perspectives	LANCET			English	Article							ACTIVATED PROTEIN-C; INTENSIVE INSULIN THERAPY; SURVIVING SEPSIS CAMPAIGN; QUALITY-OF-LIFE; ILL PATIENTS; INTRAVENOUS IMMUNOGLOBULIN; HEMODYNAMIC OPTIMIZATION; ECONOMIC OUTCOMES; DIGESTIVE-TRACT; SEPTIC SHOCK	Intensive care offers a standard of monitoring, intervention, and organ support that cannot be readily delivered in a general ward. Its expansion in the past few decades, including the creation of emergency and outreach teams, emphasises that intensive care has an increasingly prominent role within the hospital. Although outcomes are clearly improving, intensive care remains a nascent specialty in which we are still learning how to harness a powerful ability to manipulate physiology, biochemistry, and immunology to achieve best outcomes for the patient. The results of many multicentre studies have not lent support to, or have even confounded, expectations, drawing attention to several issues related to patient heterogeneity, trial design, and elucidation of underlying pathophysiological processes. However, these results have generated constructive introspection and reappraisal of treatments and management strategies that have benefited the patient. In addition to the medical, financial, and logistical challenges in the future, exciting opportunities will arise as new developments in diagnostic tests, therapeutic interventions, and technology are used to exploit an increasing awareness of how critical illness should be managed.	[Vincent, Jean-Louis] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium; [Singer, Mervyn] UCL, Dept Med, Bloomsbury Inst Intens Care Med, London, England	Universite Libre de Bruxelles; University of London; University College London	Vincent, JL (corresponding author), Erasme Univ Hosp, Dept Intens Care, Route Lennik 808, B-1070 Brussels, Belgium.	jlvincen@ulb.ac.be	Singer, Mervyn/Q-6142-2019; Singer, Mervyn/J-4425-2012	Singer, Mervyn/0000-0002-1042-6350; Singer, Mervyn/0000-0002-1042-6350; Vincent, Jean-Louis/0000-0001-6011-6951	Eisai; Eli Lilly; Artisan; Astellas; UK Department of Health's National Institute for Health Research Comprehensive Biomedical Research Centre	Eisai(Eisai Co Ltd); Eli Lilly(Eli Lilly); Artisan; Astellas(Astellas Pharmaceuticals); UK Department of Health's National Institute for Health Research Comprehensive Biomedical Research Centre	J-LV has served as a paid consultant for Eli Lilly, Eisai, and GlaxoSmithKline; participated in clinical trials sponsored by Eisai, Eli Lilly, Artisan, and Astellas; and been an invited speaker at conferences supported by Eli Lilly, Esai, and GlaxoSmithKline. MS has served as a consultant to, and has been an invited speaker at conferences supported by, Eli Lilly and Deltas Medical. Additionally, Deltex Medical provides a yearly unrestricted donation to MS's research fund at University College London.; University College London Hospital/University College London receives support from the UK Department of Health's National Institute for Health Research Comprehensive Biomedical Research Centre funding scheme.	Abraham E, 2005, NEW ENGL J MED, V353, P1332, DOI 10.1056/NEJMoa050935; *AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Angus DC, 2004, CRIT CARE MED, V32, P2199, DOI 10.1097/01.CCM.0000145228.62451.F6; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Armstrong L, 1999, AM J RESP CRIT CARE, V160, P1910, DOI 10.1164/ajrccm.160.6.9811084; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Breslow MJ, 2004, CRIT CARE MED, V32, P31, DOI 10.1097/01.CCM.0000104204.61296.41; Brienza N, 2009, CRIT CARE MED, V37, P2079, DOI 10.1097/CCM.0b013e3181a00a43; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Cuthbertson BH, 2010, CRIT CARE, V14, DOI 10.1186/cc8848; de Backer D, 2006, CRIT CARE MED, V34, P1918, DOI 10.1097/01.CCM.0000220498.48773.3C; de Jonge E, 2003, LANCET, V362, P1011, DOI 10.1016/S0140-6736(03)14409-1; de Smet AMGA, 2009, NEW ENGL J MED, V360, P20, DOI 10.1056/NEJMoa0800394; Dellinger RP, 2008, INTENS CARE MED, V34, P17, DOI 10.1007/s00134-007-0934-2; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Dhainaut JF, 2004, J THROMB HAEMOST, V2, P1924, DOI 10.1111/j.1538-7836.2004.00955.x; Eichacker PQ, 2007, INTENS CARE MED, V33, P396, DOI 10.1007/s00134-007-0556-8; Eichacker PQ, 2006, NEW ENGL J MED, V355, P1640, DOI 10.1056/NEJMp068197; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; Esteban A, 2004, NEW ENGL J MED, V350, P2452, DOI 10.1056/NEJMoa032736; Ferrer R, 2008, JAMA-J AM MED ASSOC, V299, P2294, DOI 10.1001/jama.299.19.2294; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Flabouris Arthas, 2008, Crit Care Resusc, V10, P97; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Gomersall CD, 2000, CRIT CARE MED, V28, P607, DOI 10.1097/00003246-200003000-00001; Griffiths RD, 2007, CURR OPIN CRIT CARE, V13, P508, DOI 10.1097/MCC.0b013e3282efae05; Gupta A, 2009, J AM SOC NEPHROL, V20, P267, DOI 10.1681/ASN.2008030294; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Herzig SJ, 2009, JAMA-J AM MED ASSOC, V301, P2120, DOI 10.1001/jama.2009.722; Hillman Ken, 2002, Curr Opin Crit Care, V8, P594, DOI 10.1097/00075198-200212000-00019; Jackson JC, 2009, CRIT CARE CLIN, V25, P615, DOI 10.1016/j.ccc.2009.04.005; Joyce DE, 2004, CRIT CARE MED, V32, pS280, DOI 10.1097/01.CCM.0000128037.72072.22; Joyce DE, 2001, J BIOL CHEM, V276, P11199, DOI 10.1074/jbc.C100017200; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kreyrnann KG, 2007, CRIT CARE MED, V35, P2677, DOI 10.1097/01.CCM.0000295263.12774.97; Laupland KB, 2007, CRIT CARE MED, V35, P2686, DOI 10.1097/01.CCM.0000295312.13466.1C; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Mackenzie AF, 2005, INTENS CARE MED, V31, P1624, DOI 10.1007/s00134-005-2829-4; MacLaren R, 2008, CRIT CARE MED, V36, P3184, DOI 10.1097/CCM.0b013e31818f2269; Marshall JC, 2008, J LEUKOCYTE BIOL, V83, P471, DOI 10.1189/jlb.0607380; Marshall JC, 2009, CRIT CARE MED, V37, P2290, DOI 10.1097/CCM.0b013e3181a02afc; Martin G, 2009, CRIT CARE, V13, DOI 10.1186/cc7936; Matzo M, 2009, BIOSECUR BIOTERROR, V7, P199, DOI 10.1089/bsp.2009.0017; Moran JL, 2008, CRIT CARE MED, V36, P46, DOI 10.1097/01.CCM.0000295313.08084.58; Nadel S, 2007, LANCET, V369, P836, DOI 10.1016/S0140-6736(07)60411-5; Nobre V, 2008, AM J RESP CRIT CARE, V177, P498, DOI 10.1164/rccm.200708-1238OC; Ospina-Tascon GA, 2008, CRIT CARE MED, V36, P1311, DOI 10.1097/CCM.0b013e318168ea3e; Papadimos Thomas J, 2008, Patient Saf Surg, V2, P3, DOI 10.1186/1754-9493-2-3; Poeze M, 2005, CRIT CARE, V9, pR771, DOI 10.1186/cc3902; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Pontes-Arruda A, 2008, JPEN-PARENTER ENTER, V32, P596, DOI 10.1177/0148607108324203; Pronovost P, 2006, CRIT CARE MED, V34, P1988, DOI 10.1097/01.CCM.0000226412.12612.B6; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Protti A, 2006, CRIT CARE, V10, DOI 10.1186/cc5014; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rubinson L, 2008, CHEST, V133, p18S, DOI 10.1378/chest.07-2690; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Shulman R, 2005, CRIT CARE, V9, pR516, DOI 10.1186/cc3793; Singer M, 2004, LANCET, V364, P545, DOI 10.1016/S0140-6736(04)16815-3; Singer M, 2007, LANCET, V370, P636, DOI 10.1016/S0140-6736(07)61317-8; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; Tan T, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b822; Turgeon AF, 2007, ANN INTERN MED, V146, P193, DOI 10.7326/0003-4819-146-3-200702060-00009; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; *VET AFF TOT PAR N, 1991, NEW ENGL J MED, V325, P525, DOI DOI 10.1056/NEJM199108223250801; Vincent JL, 2006, PLOS MED, V3, P1488, DOI 10.1371/journal.pmed.0030346; Vincent JL, 2010, CRIT CARE MED, V38, P283, DOI 10.1097/CCM.0b013e3181b785a2; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Vincent JL, 2005, CRIT CARE MED, V33, P2266, DOI 10.1097/01.CCM.0000181729.46010.83; Vincent JL, 2005, CRIT CARE MED, V33, P1225, DOI 10.1097/01.CCM.0000165962.16682.46; Wagner F, 2009, CRIT CARE, V13, DOI 10.1186/cc7700; Zambon M, 2008, CHEST, V133, P1120, DOI 10.1378/chest.07-2134	79	50	54	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1354	1361		10.1016/S0140-6736(10)60575-2	http://dx.doi.org/10.1016/S0140-6736(10)60575-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20934211				2023-01-03	WOS:000283528600039
J	Ryan, MA; Nattamai, KJ; Xing, E; Schleimer, D; Daria, D; Sengupta, A; Kohler, A; Liu, W; Gunzer, M; Jansen, M; Ratner, N; Le Cras, TD; Waterstrat, A; Van Zant, G; Cancelas, JA; Zheng, Y; Geiger, H				Ryan, Marnie A.; Nattamai, Kalpana J.; Xing, Ellen; Schleimer, David; Daria, Deidre; Sengupta, Amitava; Koehler, Anja; Liu, Wei; Gunzer, Matthias; Jansen, Michael; Ratner, Nancy; Le Cras, Timothy D.; Waterstrat, Amanda; Van Zant, Gary; Cancelas, Jose A.; Zheng, Yi; Geiger, Hartmut			Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem cell mobilization	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; PROGENITOR CELLS; CDC42; RECEPTOR; ADHESION; GTPASES; ACTIVATION; EXPRESSION; MIGRATION; MURINE	Mobilization of hematopoietic stem and progenitor cells (HSPCs) from bone marrow into peripheral blood by the cytokine granulocyte colony-stimulating factor (G-CSF) has become the preferred source of HSPCs for stem cell transplants(1-9). However, G-CSF fails to mobilize sufficient numbers of stem cells in up to 10% of donors, precluding autologous transplantation in those donors or substantially delaying transplant recovery time(2). Consequently, new regimens are needed to increase the number of stem cells in peripheral blood upon mobilization. Using a forward genetic approach in mice, we mapped the gene encoding the epidermal growth factor receptor (Egfr) to a genetic region modifying G-CSF-mediated HSPC mobilization. Amounts of EGFR in HSPCs inversely correlated with the cells' ability to be mobilized by G-CSF, implying a negative role for EGFR signaling in mobilization. In combination with G-CSF treatment, genetic reduction of EGFR activity in HSPCs (in waved-2 mutant mice) or treatment with the EGFR inhibitor erlotinib increased mobilization. Increased mobilization due to suppression of EGFR activity correlated with reduced activity of cell division control protein-42 (Cdc42), and genetic Cdc42 deficiency in vivo also enhanced G-CSF-induced mobilization. Our findings reveal a previously unknown signaling pathway regulating stem cell mobilization and provide a new pharmacological approach for improving HSPC mobilization and thereby transplantation outcomes.	[Ryan, Marnie A.; Nattamai, Kalpana J.; Xing, Ellen; Schleimer, David; Daria, Deidre; Sengupta, Amitava; Liu, Wei; Jansen, Michael; Ratner, Nancy; Cancelas, Jose A.; Zheng, Yi; Geiger, Hartmut] CCHMC, Div Expt Hematol & Canc Biol, Cincinnati, OH USA; [Daria, Deidre; Geiger, Hartmut] Univ Ulm, Dept Dermatol & Allerg Dis, Ulm, Germany; [Koehler, Anja; Gunzer, Matthias] Otto VonGuericke Univ Magdegurg, Inst Mol & Clin Immunol, D-39016 Magdeburg, Germany; [Le Cras, Timothy D.] CCHMC, Div Pulm Biol, Cincinnati, OH USA; [Waterstrat, Amanda] Eastern Kentucky Univ, Dept Biol Sci, Richmond, KY 40475 USA; [Van Zant, Gary] Univ Kentucky, Dept Internal Med, Markey Canc Ctr, Div Hematol Oncol, Lexington, KY USA; [Cancelas, Jose A.] Univ Cincinnati, Coll Med, Hoxworth Blood Ctr, Cincinnati, OH USA	Ulm University; Otto von Guericke University; University of Kentucky; University System of Ohio; University of Cincinnati	Geiger, H (corresponding author), CCHMC, Div Expt Hematol & Canc Biol, Cincinnati, OH USA.	hartmut.geiger@cchmc.org	Gunzer, Matthias/AAW-7026-2021; Zheng, Yi/J-7235-2015; Cancelas, Jose/AAR-9324-2020	Gunzer, Matthias/0000-0002-5534-6055; Zheng, Yi/0000-0001-7089-6074; RATNER, NANCY/0000-0001-5030-9354; Le Cras, Timothy/0000-0001-8538-2703	US National Institutes of Health [HL076604, DK077762, AG024950, HD060915]; American Heart Association [0740069N]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD060915] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076604] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK077762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024950] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by a Cincinnati Children's Hospital Medical Center Translational Research Initiative Award to H. G. and M. A. R., grants from the US National Institutes of Health, HL076604 and DK077762 to H. G., AG024950 and HD060915 to G.V.Z. and an American Heart Association established investigator award to T. D. L. C. (0740069N). H. G. is a New Investigator in Aging, and G.V.Z. is a Senior Scholar in Aging of The Ellison Medical Foundation. A. S. is a recipient of the Lady Tata Memorial Trust Fellowship Award. We would like to thank T. Weaver and M.-D. Filippi for discussions and critical comments on the manuscript. We would like to thank B. Hardie for advice on the erlotinib experiments and the Comprehensive Mouse and Cancer Core as well as the Flow Cytometry Core at CCHMC for help with the experiments and OSI Pharmaceuticals for providing erlotinib.	Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281; Bonig H, 2008, BLOOD, V111, P3439, DOI 10.1182/blood-2007-09-112052; Breems DA, 1996, BLOOD, V87, P5370, DOI 10.1182/blood.V87.12.5370.bloodjournal87125370; Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385; Buerger H, 2000, CANCER RES, V60, P854; Cancelas JA, 2005, NAT MED, V11, P886, DOI 10.1038/nm1274; Carlo-Stella C, 2004, BLOOD, V103, P3287, DOI 10.1182/blood-2003-07-2428; Christopher MJ, 2009, BLOOD, V114, P1331, DOI 10.1182/blood-2008-10-184754; Christopherson KW, 2003, BLOOD, V101, P4680, DOI 10.1182/blood-2002-12-3893; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Flomenberg N, 2005, BLOOD, V106, P1867, DOI 10.1182/blood-2005-02-0468; Geiger H, 2004, EXP HEMATOL, V32, P60, DOI 10.1016/j.exphem.2003.09.015; Giet O, 2002, BLOOD, V99, P2023, DOI 10.1182/blood.V99.6.2023; Glimm H, 2000, BLOOD, V96, P4185, DOI 10.1182/blood.V96.13.4185.h8004185_4185_4193; GRIGG AP, 1995, BLOOD, V86, P4437, DOI 10.1182/blood.V86.12.4437.bloodjournal86124437; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Hasegawa M, 2000, BLOOD, V95, P1872, DOI 10.1182/blood.V95.5.1872.005k26_1872_1874; Huygen S, 2002, BLOOD, V100, P2744, DOI 10.1182/blood.V100.8.2744; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; LEVESQUE JP, 1995, J EXP MED, V181, P1805, DOI 10.1084/jem.181.5.1805; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Natarajan A, 2007, P NATL ACAD SCI USA, V104, P17081, DOI 10.1073/pnas.0704126104; Papayannopoulou T, 2008, BLOOD, V111, P3923, DOI 10.1182/blood-2007-08-078147; Purton LE, 2007, CELL STEM CELL, V1, P263, DOI 10.1016/j.stem.2007.08.016; Roberts AW, 1997, BLOOD, V89, P2736, DOI 10.1182/blood.V89.8.2736; Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood-2004-01-0272; Seo MR, 2004, J BIOL CHEM, V279, P17366, DOI 10.1074/jbc.M312442200; Tu S, 2003, J BIOL CHEM, V278, P49293, DOI 10.1074/jbc.M307021200; Wang L, 2006, BLOOD, V107, P98, DOI 10.1182/blood-2005-05-2171; Wang L, 2007, P NATL ACAD SCI USA, V104, P1248, DOI 10.1073/pnas.0609149104; Waterstrat A, 2010, BLOOD, V115, P408, DOI 10.1182/blood-2008-03-143370; Xing ZL, 2006, BLOOD, V108, P2190, DOI 10.1182/blood-2005-12-010272; Yamaguchi M, 1998, BLOOD, V92, P842; Yang FC, 2001, P NATL ACAD SCI USA, V98, P5614, DOI 10.1073/pnas.101546898; Yang L, 2007, P NATL ACAD SCI USA, V104, P5091, DOI 10.1073/pnas.0610819104; Yang L, 2006, MOL BIOL CELL, V17, P4675, DOI 10.1091/mbc.E06-05-0466; Yuan R, 2005, EXP HEMATOL, V33, P243, DOI 10.1016/j.exphem.2004.10.014	40	47	49	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	OCT	2010	16	10					1141	U121		10.1038/nm.2217	http://dx.doi.org/10.1038/nm.2217			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	660LR	20871610	Green Accepted			2023-01-03	WOS:000282644800045
J	Waage, J; Banerji, R; Campbell, O; Chirwa, E; Collender, G; Dieltiens, V; Dorward, A; Godfrey-Faussett, P; Hanvoravongchai, P; Kingdon, G; Little, A; Mills, A; Mulholland, K; Mwinga, A; North, A; Patcharanarumol, W; Poulton, C; Tangcharoensathien, V; Unterhalter, E				Waage, Jeff; Banerji, Rukmini; Campbell, Oona; Chirwa, Ephraim; Collender, Guy; Dieltiens, Veerle; Dorward, Andrew; Godfrey-Faussett, Peter; Hanvoravongchai, Piya; Kingdon, Geeta; Little, Angela; Mills, Anne; Mulholland, Kim; Mwinga, Alwyn; North, Amy; Patcharanarumol, Walaiporn; Poulton, Colin; Tangcharoensathien, Viroj; Unterhalter, Elaine			The Millennium Development Goals: a cross-sectoral analysis and principles for goal setting after 2015	LANCET			English	Review							HEALTH-CARE; CHILD-MORTALITY; POVERTY; GENDER; EQUITY; INEQUALITIES; PROGRESS; AFRICA; POLICY		[Waage, Jeff; Collender, Guy] London Int Dev Ctr, London WC1H 0PD, England; [Banerji, Rukmini] Pratham ASER Ctr, New Delhi, India; [Campbell, Oona; Godfrey-Faussett, Peter; Hanvoravongchai, Piya; Mills, Anne; Mulholland, Kim] London Sch Hyg & Trop Med, London WC1, England; [Hanvoravongchai, Piya] London Sch Hyg & Trop Med, Bangkok, Thailand; [Chirwa, Ephraim] Univ Malawi, Zomba, Malawi; [Dieltiens, Veerle] Univ Witwatersrand, Johannesburg, South Africa; [Dorward, Andrew; Poulton, Colin] Univ London, Sch Oriental & African Studies, London, England; [Kingdon, Geeta; Little, Angela; North, Amy; Unterhalter, Elaine] Univ London, Inst Educ, London WC1N 1AZ, England; [Mwinga, Alwyn] Ctr Dis Control & Prevent, Global AIDS Program, Lusaka, Zambia; [Patcharanarumol, Walaiporn; Tangcharoensathien, Viroj] Int Hlth Policy Program, Nonthaburi, Thailand	University of London; London School of Hygiene & Tropical Medicine; University of Malawi; University of Witwatersrand; University of London; University of London School Oriental & African Studies (SOAS); University of London; University College London; UCL Institute of Education	Waage, J (corresponding author), London Int Dev Ctr, 36 Gordon Sq, London WC1H 0PD, England.	jeff.waage@lidc.bloomsbury.ac.uk	Hanvoravongchai, Piya/A-1569-2012; North, Amy/AAS-7619-2021; Kingdon, Geeta/AAQ-2321-2021	Hanvoravongchai, Piya/0000-0003-4256-1271; North, Amy/0000-0003-0546-2397; Mills, Anne/0000-0001-9863-9950; Unterhalter, Elaine/0000-0002-2302-6583; Kingdon, Geeta/0000-0002-1583-5540; Campbell, Oona/0000-0002-9311-0115	Economic and Social Research Council [RES-167-25-0260]; ESRC [ES/E021859/1] Funding Source: UKRI; Economic and Social Research Council [ES/E021859/1] Funding Source: researchfish	Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	EU has received a grant from the Economic and Social Research Council (award number RES-167-25-0260).	ADDISON T, 2008, CHRONIC POVERTY REPO; Anand S, 2000, WORLD DEV, V28, P2029, DOI 10.1016/S0305-750X(00)00071-1; [Anonymous], MILL DEV GOALS REP 2; [Anonymous], 2010, GLOBAL INEQUALITIES; Barton Carol., 2005, GENDER DEV, V13, P25, DOI DOI 10.1080/13552070512331332274; Bhana D, 2009, EDUC REV, V61, P49, DOI 10.1080/00131910802684771; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bose C., 2009, GLOBAL GENDER RES TR; BOURGUIGNON F, 2009, 2015 BRUSS JUN; Brundtland G.H., 1987, OUR COMMON FUTURE RE; CABRERA L, 2005, POLITICAL THEORY GLO; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Castello LD, 2010, ENVIRON SCI POLICY, V13, P154, DOI 10.1016/j.envsci.2009.12.001; *CENTR STAT OFF MA, 2009, ZAMB DEM HLTH SURV 2; CHEN S, 2007, ABSOLUTE POVERTY MEA; *COMM MACR HLTH, 2002, INV HLTH EC DEV; *COMM MACR HLTH, 2002, 5 WHO COMM MACR HLTH; CONWAY GR, 1985, AGR ADMIN EXT, V20, P31, DOI 10.1016/0309-586X(85)90064-0; Corbett EL, 2009, INT J TUBERC LUNG D, V13, P1231; *CSO CENTR BOARD H, 2003, ZAMB DEM HLTH SURV 2; *DAW, 2009, EXP GROUP M IMP IMPL; *DFID, 2006, CHIN COUNTR ASS PLAN; DFID, 2009, EL WORLD POV BUILD O; *DHS, 2003, ER 2002 FIN REP; Diaz S., 2005, EC HUM WELL BEING SY, V5, DOI 10.1196/annals.1439.003; Dieltiens V, 2009, PERSPECT EDUC, V27, P365; Dorward A, 2009, DEV POLICY REV, V27, P131, DOI 10.1111/j.1467-7679.2009.00439.x; Easterly W, 2009, WORLD DEV, V37, P26, DOI 10.1016/j.worlddev.2008.02.009; FISCHER AM, 2009, 2015 PROM PROP POL M; FLEISCH B, 2007, PRIMARY ED CRISIS S; FLEURBAEY M, 2008, GDP IS THERE PROGR M; Fraser Nancy, 1997, JUSTICE INTERRUPTUS; FUKUDAPARR S, 2008, 48 UN DEV PROGR INT; Glewwe P, 2002, J ECON LIT, V40, P436, DOI 10.1257/002205102320161258; GORE C, 2009, 2015 PROM PROP POL M; Gore C, 2010, IDS BULL-I DEV STUD, V41, P70, DOI 10.1111/j.1759-5436.2010.00106.x; *GOV MAL, 2008, MAL MILL DEV GOALS R; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Grubb M, 2010, CLIM POLICY, V10, P127, DOI 10.3763/cpol.2010.ED83; *GRZ, 2008, ZAMB MILL DEV GOALS; GWATICIN DR, 2000, CURRENT STATE KNOWLE; Gwatkin D. R., 2005, REACHING POOR HLTH N; Habermas J, 1984, THEORY COMMUNICATIVE; Held D., 2005, POLITICAL PHILOS COS, P10; HILLS J, 2010, ANATOMY EC INEQUALIT; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; Houweling TAJ, 2007, B WORLD HEALTH ORGAN, V85, P745, DOI 10.2471/BLT.06.038588; Hulme D., 2007, MAKING MILLENNIUM DE; HULME D, 2009, 2015 PROM PROP POL M; Jahan R., 1995, ELUSIVE AGENDA MAINS; Jewkes R, 2002, SOC SCI MED, V55, P1603, DOI 10.1016/S0277-9536(01)00294-5; Joint United Nations Programme on HIV/AIDS (UNAIDS) Zambia National HIV/AIDS/STI/TB Council, 2009, ZAMB HIV PREV RESP M; Jones N, 2010, IDS BULL-I DEV STUD, V41, P113, DOI 10.1111/j.1759-5436.2010.00112.x; KABEER N, 2008, POVERTY FOCUS, V13, P3; Kai M., 2006, 11 5 YEAR PLAN TARGE; KAKURU DM, 2008, GENDER EQUALITY HIV; KINGDON G, 2010, WPS201014 CSAE U OXF; Kingdon GG, 2006, J DEV STUD, V42, P1199, DOI 10.1080/00220380600884167; Knights F, 2010, EARLY MUSIC, V38, P1, DOI 10.1093/em/caq003; Langford M, 2010, IDS BULL-I DEV STUD, V41, P83, DOI 10.1111/j.1759-5436.2010.00108.x; Limwattananon S, 2007, B WORLD HEALTH ORGAN, V85, P600, DOI 10.2471/BLT.06.033720; Limwattananon S, 2010, B WORLD HEALTH ORGAN, V88, P420, DOI 10.2471/BLT.09.068791; Macdonald M., 2003, GENDER EQUALITY MAIN; Malawi Government, 2011, MAL GROWTH DEV STRAT; Manning, 2009, USING INDICATORS ENC; McCowan, 2009, RETHINKING CITIZENSH; *MHRD, 2006, ANN REP 2005 2006; *MIN HLTH ZAMB, 2005, NAT HLTH STRAT PLAN; *MIN HLTH ZAMB, 2000, NAT HLTH STRAT PLAN; MINUJIN A, 2004, SOCIOECONOMIC INEQUA; MOLETSANE R, 2010, ENG EMP ED EQ E4 C D; MOOROSI P, 2006, THESIS U KWAZULUNATA; Morrell R., 2009, GENDER EQUALITY S AF; Moser C., 2005, GENDER DEV, V13, P11, DOI DOI 10.1080/13552070512331332283; Mulholland EK, 2008, B WORLD HEALTH ORGAN, V86, P399, DOI 10.2471/BLT.07.044545; *NAC, 2008, COMPR HIV AIDS PREV; *OECD, 2008, EFF AID BETT HLTH; OECD, 1996, SHAP 21 CENT CONTR D; Office of the National Economic and Social Development Board, 2004, THAIL MILL DEV GOALS; Phillips Anne, 2007, MULTICULTURALISM CUL; Pogge Thomas, 2008, GLOBAL JUSTICE SEMIN; Prakongsai P, 2009, J INT DEV, V21, P291, DOI 10.1002/jid.1553; PRIDMORE P, 2007, CREATE PATHWAYS ACCE, V2; Prins G, 2010, HARTWELL PAPER NEW D; Reetika Khera, 2006, Economic and Political Weekly, V41, P4742; Rohde J, 2008, LANCET, V372, P950, DOI 10.1016/S0140-6736(08)61405-1; ROLLESTON C, 2009, HUMAN CAPITAL POVERT; Ruger JP, 2008, GEORGETOWN LAW J, V96, P423; Rutherford ME, 2009, B WORLD HEALTH ORGAN, V87, P216, DOI 10.2471/BLT.08.052175; Sachs J., 2005, END POVERTY WE CAN M; Samb B, 2009, LANCET, V373, P2137, DOI 10.1016/S0140-6736(09)60919-3; Schaefer I., 2013, WORLD BANK; Schech S, 2010, SOC POLIT, V17, P111, DOI 10.1093/sp/jxp025; Sen A., 2003, READINGS HUMAN DEV C; Sen A., 2009, IDEA JUSTICE; Sen Amartya, 1999, DEV FREEDOM; SETS A, 1992, INEQUALITY REEXAMINE; SHETTY S, 2009, 2015 BRUSS JUN; Skard T, 2009, FORUM DEV STUD, V36, P155, DOI 10.1080/08039410.2009.9666429; Snow RW, 2010, LANCET, V376, P137, DOI 10.1016/S0140-6736(10)60577-6; Stiglitz J, MEASUREMENT EC PERFO; Sumner A., 2009, BROKER, V14, P8; Sumner A, 2010, IDS BULL-I DEV STUD, V41, P1, DOI 10.1111/j.1759-5436.2010.00097.x; TANGCHAROENSATH.V, 2009, BUILDING DECENT SOC; Tangcharoensathien V, 2005, SOC POLICY DEV CONTE, P257; *TASKF INN INT FIN, 2009, 1 WHO TASKF INN INT; Tiwari M., 2009, 2015 INT DEV POLICY; Tottrup C, 2009, TROP MED INT HEALTH, V14, P653, DOI 10.1111/j.1365-3156.2009.02275.x; *UN MDG GAP TASK F, 2009, STRENGTH GLOB PARTN; *UN STAT DIV, OFF LIST MDG IND 200; *UNDG, 2005, MAK MDGS MATT COUNTR; UNDP, 2003, HUM DEV REP 2003 MIL; *UNDP, MDG PLUS CAS STUD TH; UNESCO, 2010, ED ALL GLOB MON REP; *UNESCO, 2008, ED ALL GLOB MON REP; United Nation, 2001, ROAD MAP IMPL UN MIL; United Nations, 2010, MILL DEV GOALS REP 2; United Nations Development Programme (UNDP), 2007, HUMAN DEV REPORT 200; United Nations General Assembly Resolution, 2000, A55L2 UN; UNTERHALTER E, 2000, CHALLENGING DEMOCRAC; UNTERHALTER E, 2009, 1 GEND ED GLOB POV R; Unterhalter E, 2009, STUD PHILOS EDUC, V28, P415, DOI 10.1007/s11217-009-9125-7; *USAID DEL PROJ, 2009, ZAMB NAT LONG TERM F; Vandemoortele J, 2009, DEV POLICY REV, V27, P355, DOI 10.1111/j.1467-7679.2009.00451.x; Vapattanawong P, 2007, LANCET, V369, P850, DOI 10.1016/S0140-6736(07)60413-9; Victora CG, 2006, B WORLD HEALTH ORGAN, V84, P792, DOI 10.2471/BLT.06.030502; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Wilkinson R., 2009, SPIRIT LEVEL WHY MOR; World Bank, 1993, INV HLTH WORLD DEV R; World Health Organization, 2007, EVERYBODYS BUSINESS; 2009, ASER ANN STATUS ED R; COUNTDOWN 2015 TRACK	132	197	203	0	50	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 18	2010	376	9745					991	1023		10.1016/S0140-6736(10)61196-8	http://dx.doi.org/10.1016/S0140-6736(10)61196-8			33	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	655JZ	20833426	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000282247600031
J	Udwadia, ZF; Pinto, LM; Uplekar, MW				Udwadia, Zarir F.; Pinto, Lancelot M.; Uplekar, Mukund W.			Tuberculosis Management by Private Practitioners in Mumbai, India: Has Anything Changed in Two Decades?	PLOS ONE			English	Article							MULTIDRUG-RESISTANT TUBERCULOSIS; CONTROL PROGRAM; CARE	Setting: Mumbai, India. A study conducted in Mumbai two decades ago revealed the extent of inappropriate tuberculosis (TB) management practices of private practitioners. Over the years, India's national TB programme has made significant progress in TB control. Efforts to engage private practitioners have also been made with several successful documented public-private mix initiatives in place. Objective: To study prescribing practices of private practitioners in the treatment of tuberculosis, two decades after a similar study conducted in the same geographical area revealed dismal results. Methods: Survey questionnaire administered to practicing general practitioners attending a continuing medical education programme. Results: The participating practitioners had never been approached or oriented by the local TB programme. Only 6 of the 106 respondents wrote a prescription with a correct drug regimen. 106 doctors prescribed 63 different drug regimens. There was tendency to over treat with more drugs for longer durations. Only 3 of the 106 respondents could write an appropriate prescription for treatment of multidrug-resistant TB. Conclusions: With a vast majority of private practitioners unable to provide a correct prescription for treating TB and not approached by the national TB programme, little seems to have changed over the years. Strategies to control TB through public sector health services will have little impact if inappropriate management of TB patients in private clinics continues unabated. Large scale implementation of public-private mix approaches should be a top priority for the programme. Ignoring the private sector could worsen the epidemic of multidrug-resistant and extensively drug-resistant forms of TB.	[Udwadia, Zarir F.; Pinto, Lancelot M.] PD Hinduja Natl Hosp & Med Res Ctr, Dept Resp Dis, Mumbai, Maharashtra, India; [Uplekar, Mukund W.] WHO, Stop TB Dept, CH-1211 Geneva, Switzerland	World Health Organization	Udwadia, ZF (corresponding author), PD Hinduja Natl Hosp & Med Res Ctr, Dept Resp Dis, Mumbai, Maharashtra, India.	lance.pinto@gmail.com		Pinto, Lancelot/0000-0002-5418-5448				Agrawal D, 2009, INT J TUBERC LUNG D, V13, P79; Almeida D, 2003, CLIN INFECT DIS, V36, pE152, DOI 10.1086/374931; [Anonymous], WHOHTMTB2008394; Chugh Satish, 2008, J Indian Med Assoc, V106, P596; D'souza DTB, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-211; Dewan PK, 2006, BMJ-BRIT MED J, V332, P574, DOI 10.1136/bmj.38738.473252.7C; Global Alliance for TB drug development, 2007, PATHW PAT CHART DYN; Hopewell PC, 2006, LANCET INFECT DIS, V6, P710, DOI 10.1016/S1473-3099(06)70628-4; *IPPS, 2005, NAT FAM HLTH SURV NF, V1; JAIN S, 2007, AM THOR SOC 2007 INT; Kelkar-Khambete A, 2008, INT J TUBERC LUNG D, V12, P87; *MIN HLTH FAM WELF, 2009, TB IND 2009 RNTCP ST; Pantoja A, 2009, INT J TUBERC LUNG D, V13, P705; Pinto LM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-357; Rodrigues C, 2006, INT J TUBERC LUNG D, V10, P1421; Uplekar M, 2001, LANCET, V358, P912, DOI 10.1016/S0140-6736(01)06076-7; Uplekar M, 1998, INT J TUBERC LUNG D, V2, P324; UPLEKAR MW, 1991, TUBERCLE, V72, P284, DOI 10.1016/0041-3879(91)90055-W; *WHO, 2009, GLOB TUB CONTR SUV P; *WHO, 2006, ENG ALL CAR PROV TUB; World Health Organization, WHOCDSTB2003313, V313	21	137	137	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2010	5	8							e12023	10.1371/journal.pone.0012023	http://dx.doi.org/10.1371/journal.pone.0012023			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	636XC	20711502	Green Published, Green Submitted, gold			2023-01-03	WOS:000280776800013
J	Maemondo, M; Inoue, A; Kobayashi, K; Sugawara, S; Oizumi, S; Isobe, H; Gemma, A; Harada, M; Yoshizawa, H; Kinoshita, I; Fujita, Y; Okinaga, S; Hirano, H; Yoshimori, K; Harada, T; Ogura, T; Ando, M; Miyazawa, H; Tanaka, T; Saijo, Y; Hagiwara, K; Morita, S; Nukiwa, T				Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro		NE Japan Study Grp	Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR-RECEPTOR; PREVIOUSLY TREATED PATIENTS; RANDOMIZED PHASE-III; JAPANESE PATIENTS; MUTATIONS; SURVIVAL; PACLITAXEL; DOCETAXEL; DISEASE; TRIAL	Background: Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of standard chemotherapy. Methods: We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel. The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects. Results: In the planned interim analysis of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the standard-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study. The gefitinib group had a significantly longer median progression-free survival (10.8 months, vs. 5.4 months in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001). The median overall survival was 30.5 months in the gefitinib group and 23.6 months in the chemotherapy group (P=0.31). The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%). One patient receiving gefitinib died from interstitial lung disease. Conclusions: First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy. (UMIN-CTR number, C000000376.) N Engl J Med 2010;362:2380-8.	[Inoue, Akira] Tohoku Univ Hosp, Dept Resp Med, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Maemondo, Makoto] Miyagi Canc Ctr, Sendai, Miyagi, Japan; [Sugawara, Shunichi] Sendai Kousei Hosp, Sendai, Miyagi, Japan; [Nukiwa, Toshihiro] Tohoku Univ, Grad Sch Med, Sendai, Miyagi 980, Japan; [Kobayashi, Kunihiko] Saitama Med Univ, Int Med Ctr, Saitama, Japan; [Oizumi, Satoshi] Hokkaido Univ, Sch Med, Sapporo, Hokkaido 060, Japan; [Isobe, Hiroshi] Kokka Komuin Kyosai Kumiai Rengokai Sapporo Med C, Sapporo, Hokkaido, Japan; [Harada, Masao] Natl Hosp Org, Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan; [Kinoshita, Ichiro] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan; [Harada, Toshiyuki] Hokkaido Social Insurance Hosp, Sapporo, Hokkaido, Japan; [Gemma, Akihiko] Nippon Med Sch, Tokyo 113, Japan; [Yoshimori, Kozo] Fukujuji Hosp, AntiTB Assoc, Tokyo, Japan; [Yoshizawa, Hirohisa] Niigata Univ, Med & Dent Hosp, Niigata, Japan; [Fujita, Yuka] Dohoku Natl Hosp, Natl Hosp Org, Asahikawa, Hokkaido, Japan; [Hirano, Haruto] Iwate Cent Prefectural Hosp, Morioka, Iwate, Japan; [Ogura, Takashi] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan; [Morita, Satoshi] Yokohama City Univ, Med Ctr, Yokohama, Kanagawa 232, Japan; [Ando, Masahiro] Tsuboi Canc Ctr Hosp, Koriyama, Fukushima, Japan; [Saijo, Yasuo] Hirosaki Univ, Grad Sch Med, Hirosaki, Aomori, Japan	Tohoku University; Miyagi Cancer Center; Sendai Kousei Hospital; Tohoku University; Saitama Medical University; Hokkaido University; Hokkaido University; Nippon Medical School; Fukujuji Hospital; Niigata University; Iwate Prefectural Central Hospital; Kanagawa Cardiovascular & Respiratory Center; Yokohama City University; Hirosaki University	Inoue, A (corresponding author), Tohoku Univ Hosp, Dept Resp Med, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.	akinoue@idac.tohoku.ac.jp	Oizumi, Satoshi/G-6717-2012	Usui, Kazuhiro/0000-0002-4492-9327	Japan Society for Promotion of Science; Japanese Foundation for the Multidisciplinary Treatment of Cancer; Tokyo Cooperative Oncology Group; Grants-in-Aid for Scientific Research [21591006] Funding Source: KAKEN	Japan Society for Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Japanese Foundation for the Multidisciplinary Treatment of Cancer; Tokyo Cooperative Oncology Group; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	Supported by grants-in-aid from the Japan Society for Promotion of Science and the Japanese Foundation for the Multidisciplinary Treatment of Cancer and a grant from the Tokyo Cooperative Oncology Group.	Ando M, 2006, J CLIN ONCOL, V24, P2549, DOI 10.1200/JCO.2005.04.9866; Asahina H, 2006, BRIT J CANCER, V95, P998, DOI 10.1038/sj.bjc.6603393; Bell DW, 2005, J CLIN ONCOL, V23, P8081, DOI 10.1200/JCO.2005.02.7078; Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Inoue, 2009, J CLIN ONCOL, V27, P3071, DOI 10.1200/JCO.2009.23.6935; Inoue A, 2003, LANCET, V361, P137, DOI 10.1016/S0140-6736(03)12190-3; Inoue A, 2006, J CLIN ONCOL, V24, P3340, DOI 10.1200/JCO.2005.05.4692; Inoue A, 2009, J CLIN ONCOL, V27, P1394, DOI 10.1200/JCO.2008.18.7658; Isomura M, 2004, J CLIN ONCOL, V22, p200S; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; KOBAYASHI K, 2009, J CLIN ONCOL S, V27, pS411, DOI DOI 10.1056/NEJMOA0904554; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Kudoh S, 2008, AM J RESP CRIT CARE, V177, P1348, DOI 10.1164/rccm.200710-1501OC; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maruyama R, 2008, J CLIN ONCOL, V26, P4244, DOI 10.1200/JCO.2007.15.0185; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Morita S, 2009, CLIN CANCER RES, V15, P4493, DOI 10.1158/1078-0432.CCR-09-0391; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Ohe Y, 2007, ANN ONCOL, V18, P317, DOI 10.1093/annonc/mdl377; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Sutani A, 2006, BRIT J CANCER, V95, P1483, DOI 10.1038/sj.bjc.6603466; Tanaka T, 2010, INT J CANCER, V126, P651, DOI 10.1002/ijc.24746; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Toyooka S, 2008, CANCER SCI, V99, P303, DOI 10.1111/j.1349-7006.2007.00688.x	32	4165	4406	9	360	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 24	2010	362	25					2380	2388		10.1056/NEJMoa0909530	http://dx.doi.org/10.1056/NEJMoa0909530			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614GO	20573926	Bronze			2023-01-03	WOS:000279043800007
J	Marozin, S; De Toni, EN; Rizzani, A; Altomonte, J; Junger, A; Schneider, G; Thasler, WE; Kato, N; Schmid, RM; Ebert, O				Marozin, Sabrina; De Toni, Enrico N.; Rizzani, Antonia; Altomonte, Jennifer; Junger, Alexandra; Schneider, Guenter; Thasler, Wolfgang E.; Kato, Nobuyuki; Schmid, Roland M.; Ebert, Oliver			Cell Cycle Progression or Translation Control Is Not Essential for Vesicular Stomatitis Virus Oncolysis of Hepatocellular Carcinoma	PLOS ONE			English	Article							HEPATITIS-C-VIRUS; HERPES-SIMPLEX-VIRUS; PROTEIN-SYNTHESIS; CANCER-CELLS; HUMAN HEPATOCYTES; STEM-CELLS; INITIATION; REPLICATION; INTERFERON; THERAPY	The intrinsic oncolytic specificity of vesicular stomatitis virus (VSV) is currently being exploited to develop alternative therapeutic strategies for hepatocellular carcinoma (HCC). Identifying key regulators in diverse transduction pathways that define VSV oncolysis in cancer cells represents a fundamental prerequisite to engineering more effective oncolytic viral vectors and adjusting combination therapies. After having identified defects in the signalling cascade of type I interferon induction, responsible for attenuated antiviral responses in human HCC cell lines, we have now investigated the role of cell proliferation and translation initiation. Cell cycle progression and translation initiation factors eIF4E and eIF2B epsilon have been recently identified as key regulators of VSV permissiveness in T-lymphocytes and immortalized mouse embryonic fibroblasts, respectively. Here, we show that in HCC, decrease of cell proliferation by cell cycle inhibitors or siRNA-mediated reduction of G(1) cyclin-dependent kinase activities (CDK4) or cyclin D1 protein expression, do not significantly alter viral growth. Additionally, we demonstrate that translation initiation factors eIF4E and eIF2B epsilon are negligible in sustaining VSV replication in HCC. Taken together, these results indicate that cellular proliferation and the initiation phase of cellular protein synthesis are not essential for successful VSV oncolysis of HCC. Moreover, our observations indicate the importance of cell-type specificity for VSV oncolysis, an important aspect to be considered in virotherapy applications in the future.	[Marozin, Sabrina; Altomonte, Jennifer; Junger, Alexandra; Schneider, Guenter; Schmid, Roland M.; Ebert, Oliver] Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin 2, D-8000 Munich, Germany; [De Toni, Enrico N.; Rizzani, Antonia] Univ Munich, Klinikum Grosshadern, Med Klin & Poliklin 2, D-8000 Munich, Germany; [Thasler, Wolfgang E.] Univ Munich, Klinikum Grosshadern, Chirurg Klin & Poliklin, D-8000 Munich, Germany; [Kato, Nobuyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol, Okayama, Japan	Technical University of Munich; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munich; University of Munich; Okayama University	Marozin, S (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin & Poliklin 2, D-8000 Munich, Germany.	oliver.ebert@lrz.tum.de	Marozin, Sabrina/N-7033-2014; De Toni, Enrico N/C-6496-2008	Marozin, Sabrina/0000-0003-1650-9488; Altomonte, Jennifer/0000-0003-1079-3633	German Research Aid; Federal Ministry of Education and Research [01GU0505]; German Research Foundation, Bonn, Germany (DFG) [SFB 824 (Sonderforschungsbereich 824)]	German Research Aid; Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); German Research Foundation, Bonn, Germany (DFG)(German Research Foundation (DFG))	This work was supported in part by the German Research Aid (Max-Eder Research Program), the Federal Ministry of Education and Research (Grant 01GU0505) and the SFB 824 (DFG Sonderforschungsbereich 824), German Research Foundation, Bonn, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed M, 2003, J VIROL, V77, P4646, DOI 10.1128/JVI.77.8.4646-4657.2003; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Balachandran S, 2004, CANCER CELL, V5, P51, DOI 10.1016/S1535-6108(03)00330-1; Bianchini A, 2008, CARCINOGENESIS, V29, P2279, DOI 10.1093/carcin/bgn221; Cascone T, 2008, J CELL PHYSIOL, V216, P698, DOI 10.1002/jcp.21444; Chakraborty P, 2009, EMBO REP, V10, P1154, DOI 10.1038/embor.2009.179; CHIANG PC, 2009, BIOCH PHARM; Connor JH, 2002, J VIROL, V76, P10177, DOI 10.1128/JVI.76.20.10177-10187.2002; Cripe TP, 2009, MOL THER, V17, P1677, DOI 10.1038/mt.2009.193; Dancey JE, 2006, CANCER BIOL THER, V5, P1065, DOI 10.4161/cbt.5.9.3175; Dansako H, 2003, VIRUS RES, V97, P17, DOI 10.1016/S0168-1702(03)00218-1; Dansako H, 2007, FEBS J, V274, P4161, DOI 10.1111/j.1742-4658.2007.05942.x; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; DUNN EF, 2009, J VIROL; Ebert O, 2003, CANCER RES, V63, P3605; Ebert O, 2004, CANCER GENE THER, V26, P26; Fabregat I, 2009, WORLD J GASTROENTERO, V15, P513, DOI 10.3748/wjg.15.513; Gallagher JW, 2008, CANCER RES, V68, P8752, DOI 10.1158/0008-5472.CAN-08-1042; Hallenbeck PL, 1999, HUM GENE THER, V10, P1721, DOI 10.1089/10430349950017725; Hamid NA, 2009, CELL MOL LIFE SCI, V66, P1700, DOI 10.1007/s00018-009-8631-7; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Ikeda M, 1998, VIRUS RES, V56, P157, DOI 10.1016/S0168-1702(98)00063-X; Joshi S, 2009, P NATL ACAD SCI USA, V106, P12097, DOI 10.1073/pnas.0900562106; Kato N, 1996, JPN J CANCER RES, V87, P787, DOI 10.1111/j.1349-7006.1996.tb02101.x; Kemeny N, 2006, HUM GENE THER, V17, P1214, DOI 10.1089/hum.2006.17.1214; Kjellerup RB, 2008, EXP DERMATOL, V17, P498, DOI 10.1111/j.1600-0625.2007.00672.x; Larsson O, 2007, CANCER RES, V67, P6814, DOI 10.1158/0008-5472.CAN-07-0752; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lun XQ, 2009, CLIN CANCER RES, V15, P2777, DOI 10.1158/1078-0432.CCR-08-2342; Marozin S, 2008, MOL THER, V16, P1789, DOI 10.1038/mt.2008.201; Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004; Mishra L, 2009, HEPATOLOGY, V49, P318, DOI 10.1002/hep.22704; Newell P, 2009, J HEPATOL, V51, P725, DOI 10.1016/j.jhep.2009.03.028; Nguyen TLA, 2009, CELL MICROBIOL, V11, P889, DOI 10.1111/j.1462-5822.2009.01317.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oliere S, 2008, J VIROL, V82, P5735, DOI 10.1128/JVI.02601-07; Orlando JS, 2006, J VIROL, V80, P4005, DOI 10.1128/JVI.80.8.4005-4016.2006; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Schang Luis M, 2003, Prog Cell Cycle Res, V5, P103; Sei S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-47; Sell S, 2008, J CLIN ONCOL, V26, P2800, DOI 10.1200/JCO.2007.15.5945; Shinozaki K, 2005, HEPATOLOGY, V41, P196, DOI 10.1002/hep.20536; Shinozaki K, 2004, MOL THER, V9, P368, DOI 10.1016/j.ymthe.2003.12.004; Silva RLA, 2008, CELL CYCLE, V7, P553, DOI 10.4161/cc.7.5.5486; Sun M, 2008, J VIROL, V82, P105, DOI 10.1128/JVI.01520-07; Thasler Wolfgang E., 2003, Cell and Tissue Banking, V4, P49, DOI 10.1023/A:1026392429112; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Villanueva A, 2008, GASTROENTEROLOGY, V135, P1972, DOI 10.1053/j.gastro.2008.08.008; Wang F, 2009, J VIROL, V83, P5928, DOI 10.1128/JVI.02587-08; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Yang SX, 2007, ONCOL REP, V17, P281	51	8	8	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2010	5	6							e10988	10.1371/journal.pone.0010988	http://dx.doi.org/10.1371/journal.pone.0010988			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	606YU	20539760	Green Published, Green Submitted, gold			2023-01-03	WOS:000278465900008
J	Halfon, P; Giorgetti, C; Khiri, H; Penaranda, G; Terriou, P; Porcu-Buisson, G; Chabert-Orsini, V				Halfon, Philippe; Giorgetti, Claude; Khiri, Hacene; Penaranda, Guillaume; Terriou, Philippe; Porcu-Buisson, Geraldine; Chabert-Orsini, Veronique			Semen May Harbor HIV Despite Effective HAART: Another Piece in the Puzzle	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS; HIV-1-DISCORDANT COUPLES; SEXUAL TRANSMISSION; RNA; SPERM; BLOOD; COMPARTMENTALIZATION; INFECTION; EFFICIENT	Background: The risk of male-to-female intravaginal HIV-1 transmission is estimated at about 1 event per 200-2000 coital acts. The aim of this study was to assess the residual risk of HIV presence in semen in patients under HAART therapy. Methods and Findings: The study took place in France from October 2001 to March 2009. 394 paired blood and semen samples were provided from 332 HIV-1 infected men. The Roche Cobas AMPLICOR Monitor HIV assay was used to quantify HIV-1 RNA in blood and in seminal plasma. Three percent of 394 HIV-1 infected men enrolled in an assisted reproductive technology program harbored detectable HIV-1 RNA in semen, although they had no other sexually transmitted disease and their blood viral load was undetectable for at least 6 months under antiretroviral treatment. Conclusion: These data suggest that undetectable plasma HIV RNA means a lower risk of viral transmission through seminal fluid on a population level, but not necessarily at the level of the individual.	[Halfon, Philippe] Lab Alphabio, Dept Virol, Marseille, France; [Giorgetti, Claude; Terriou, Philippe; Porcu-Buisson, Geraldine; Chabert-Orsini, Veronique] Inst Reprod Med, Marseille, France; [Khiri, Hacene] Lab Alphabio, Dept Mol Biol, Marseille, France; [Penaranda, Guillaume] Lab Alphabio, Dept Biostat, Marseille, France		Halfon, P (corresponding author), Lab Alphabio, Dept Virol, Marseille, France.	philippe.halfon@alphabio.fr; g.penaranda@alphabio.fr		PENARANDA, Guillaume/0000-0002-7461-4254				BEATEN J, 2009, GENITAL HIV 1 RNA CO; Bujan L, 2004, AIDS, V18, P757, DOI 10.1097/00002030-200403260-00006; Coombs RW, 1998, J INFECT DIS, V177, P320, DOI 10.1086/514213; Gray RH, 2001, LANCET, V357, P1149, DOI 10.1016/S0140-6736(00)04331-2; Gupta P, 2000, J INFECT DIS, V182, P79, DOI 10.1086/315644; Haase AT, 2005, NAT REV IMMUNOL, V5, P783, DOI 10.1038/nri1706; Halfon P, 2006, AIDS, V20, P241, DOI 10.1097/01.aids.0000200532.56490.fe; Kashima K, 2009, JPN J INFECT DIS, V62, P173; Leruez-Ville M, 2002, AIDS, V16, P486, DOI 10.1097/00002030-200202150-00023; Marcelin AG, 2008, AIDS, V22, P1677, DOI 10.1097/QAD.0b013e32830abdc8; Miller CJ, 2003, MICROBES INFECT, V5, P59, DOI 10.1016/S1286-4579(02)00056-4; Munch J, 2005, J VIROL, V79, P10547, DOI 10.1128/JVI.79.16.10547-10560.2005; Pasquier C, 2009, J CLIN MICROBIOL, V47, P2883, DOI 10.1128/JCM.02131-08; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Sheth PM, 2009, AIDS, V23, P2050, DOI 10.1097/QAD.0b013e3283303e04; Taylor S, 2001, J ANTIMICROB CHEMOTH, V48, P351, DOI 10.1093/jac/48.3.351; TAYLOR S, 2010, DARUNAVIR DRV CONCEN; Vernazza P, 2008, B MED SUISSES, V89, P165, DOI DOI 10.4414/BMS.2008.13252; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006	20	41	41	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 13	2010	5	5							e10569	10.1371/journal.pone.0010569	http://dx.doi.org/10.1371/journal.pone.0010569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	595SN	20485526	gold, Green Published			2023-01-03	WOS:000277633500005
J	Hermans, SM; Kiragga, AN; Schaefer, P; Kambugu, A; Hoepelman, AIM; Manabe, YC				Hermans, Sabine M.; Kiragga, Agnes N.; Schaefer, Petra; Kambugu, Andrew; Hoepelman, Andy I. M.; Manabe, Yukari C.			Incident Tuberculosis during Antiretroviral Therapy Contributes to Suboptimal Immune Reconstitution in a Large Urban HIV Clinic in Sub-Saharan Africa	PLOS ONE			English	Article							LOW-INCOME COUNTRIES; CD4 CELL COUNT; TERM IMMUNOLOGICAL RESPONSE; RESOURCE-LIMITED SETTINGS; INFECTED PATIENTS; SOUTH-AFRICA; TREATMENT FAILURE; PULMONARY TUBERCULOSIS; VIROLOGICAL RESPONSES; DISCORDANT RESPONSES	Background: Antiretroviral therapy (ART) effectively decreases tuberculosis (TB) incidence long-term, but is associated with high TB incidence rates in the first 6 months. We sought to determine the incidence and the long-term effects of TB during ART on HIV treatment outcome, and the risk factors for incident TB during ART in a large urban HIV clinic in Uganda. Methodology/Principal Findings: Routinely collected longitudinal clinical data from all patients initiated on first-line ART was retrospectively analysed. 5,982 patients were included with a median baseline CD4+ T cell count (CD4 count) of 117 cells/mm(3) (interquartile range [IQR]; 42, 182). In the first 2 years, there were 336 (5.6%) incident TB events in 10,710 person-years (py) of follow-up (3.14 cases/100pyar [95% CI 2.82-3.49]); incidence rates at 0-3, 3-6, 6-12 and 12-24 months were 11.25 (9.58-13.21), 6.27 (4.99-7.87), 2.47 (1.87-3.36) and 1.02 (0.80-1.31), respectively. Incident TB during ART was independently associated with baseline CD4 count of < 50 cells/mm(3) (hazard ratio [HR] 1.84 [1.25-2.70], P=0.002) and male gender (HR 1.68 [1.34-2.11], P < 0.001). After two years on ART, the patients who had developed TB in the first 12 months had a significantly lower median CD4 count increase (184 cells/mm(3) [IQR; 107, 258, n=118] vs 209 cells/mm(3) [124, 309, n=2166], P=0.01), a larger proportion of suboptimal immune reconstitution according to two definitions (increase in CD4 count < 200 cells/mm(3): 57.4% vs 46.9%, P=0.03, and absolute CD4 count < 200 cells/mm(3): 30.4 vs 19.9%, P=0.006), and a higher percentage of immunological failure according to the WHO criteria (13.6% vs 6.5%, P=0.003). Incident TB during ART was independently associated with poor CD4 count recovery and fulfilling WHO immunogical failure definitions. Conclusions/Significance: Incident TB during ART occurs most often within 3 months and in patients with CD4 counts less than 50 cells/mm(3). Incident TB during ART is associated with long-term impairment in immune recovery.	[Hermans, Sabine M.; Hoepelman, Andy I. M.] Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands; [Hermans, Sabine M.; Kiragga, Agnes N.; Schaefer, Petra; Kambugu, Andrew; Manabe, Yukari C.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda; [Manabe, Yukari C.] Johns Hopkins Univ, Sch Med, Dept Med, Div Infect Dis, Baltimore, MD 21205 USA	Utrecht University; Utrecht University Medical Center; Makerere University; Johns Hopkins University	Hermans, SM (corresponding author), Univ Med Ctr Utrecht, Dept Internal Med & Infect Dis, Utrecht, Netherlands.	shermans@idi.co.ug		Hermans, Sabine/0000-0001-5146-2932	Infectious Diseases Institute research department; Gilead IDSA Exchange Fellowship; University Medical Center Utrecht; Accordia Global Health Foundation; Wellcome Trust	Infectious Diseases Institute research department; Gilead IDSA Exchange Fellowship(Gilead Sciences); University Medical Center Utrecht; Accordia Global Health Foundation; Wellcome Trust(Wellcome TrustEuropean Commission)	This study was funded by the Infectious Diseases Institute research department core funding. S. H. was supported by a Gilead IDSA Exchange Fellowship as well as by the University Medical Center Utrecht. Y.M. receives salary support from Accordia Global Health Foundation. A. K. is supported by a Wellcome Trust Uganda PhD Fellowship in Infection and Immunity. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Austin JF, 2004, INT J TUBERC LUNG D, V8, P435; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; Battegay M, 2006, LANCET INFECT DIS, V6, P280, DOI 10.1016/S1473-3099(06)70463-7; Bonnet MMB, 2006, AIDS, V20, P1275, DOI 10.1097/01.aids.0000232235.26630.ee; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Breen RAM, 2006, J INFECT DIS, V193, P1437, DOI 10.1086/503437; Cassol E, 2005, J INFECT DIS, V191, P324, DOI 10.1086/427337; Castelnuovo B, 2009, CLIN INFECT DIS, V49, P965, DOI 10.1086/605500; Castelnuovo B, 2009, AIDS, V23, P1295, DOI 10.1097/QAD.0b013e32832cbd43; Chi BH, 2009, JAIDS-J ACQ IMM DEF, V52, P125, DOI 10.1097/QAI.0b013e3181ab6d8b; Costagliola D, 2005, CLIN INFECT DIS, V41, P1772, DOI 10.1086/498315; Eggena MP, 2005, J INFECT DIS, V191, P694, DOI 10.1086/427516; Egger S, 2009, JAIDS-J ACQ IMM DEF, V50, P513, DOI 10.1097/QAI.0b013e31819906d3; Garcia F, 2004, JAIDS-J ACQ IMM DEF, V36, P702, DOI 10.1097/00126334-200406010-00007; Gazzola L, 2009, CLIN INFECT DIS, V48, P328, DOI 10.1086/595851; Gutierrez F, 2008, CURR HIV RES, V6, P100, DOI 10.2174/157016208783885038; Hansjee N, 2004, JAIDS-J ACQ IMM DEF, V36, P671, DOI 10.1097/00126334-200406010-00003; Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114; Hirsch CS, 1999, J INFECT DIS, V179, P945, DOI 10.1086/314667; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Huttner AC, 2007, AIDS, V21, P939, DOI 10.1097/QAD.0b013e3280f00fd6; Ivers LC, 2005, CLIN INFECT DIS, V41, P217, DOI 10.1086/431199; Kantor R, 2009, CLIN INFECT DIS, V49, P454, DOI 10.1086/600396; Kassu A, 2001, CLIN DIAGN LAB IMMUN, V8, P1171, DOI 10.1128/CDLI.8.6.1171-1176.2001; Kaufmann GR, 2003, ARCH INTERN MED, V163, P2187, DOI 10.1001/archinte.163.18.2187; Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484; Keiser O, 2008, TROP MED INT HEALTH, V13, P870, DOI 10.1111/j.1365-3156.2008.02078.x; Keiser O, 2009, TROP MED INT HEALTH, V14, P1220, DOI 10.1111/j.1365-3156.2009.02338.x; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Kigozi Brian K, 2009, AIDS Res Ther, V6, P17, DOI 10.1186/1742-6405-6-17; Lawn SD, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-59; Lawn SD, 2005, CLIN INFECT DIS, V41, P1783, DOI 10.1086/498308; Lawn SD, 2005, AIDS, V19, P2109, DOI 10.1097/01.aids.0000194808.20035.c1; Lawn SD, 2004, J INFECTION, V48, P1, DOI 10.1016/j.jinf.2003.09.001; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Lawn SD, 2006, AIDS, V20, P1605, DOI 10.1097/01.aids.0000238406.93249.cd; Lawn SD, 2009, AIDS, V23, P1717, DOI 10.1097/QAD.0b013e32832d3b6d; Lawn SD, 2009, AIDS, V23, P335, DOI 10.1097/QAD.0b013e328321823f; Manabe YC, 2009, J INFECT DIS, V199, P437, DOI 10.1086/595985; Marchetti G, 2006, AIDS, V20, P1727, DOI 10.1097/01.aids.0000242819.72839.db; Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Miller MF, 2005, CLIN INFECT DIS, V41, P713, DOI 10.1086/432618; Ministry of Health Uganda, 2008, NAT ANT TREATM CAR G; Miranda A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000826; Moore D, 2007, AIDS, V21, P713, DOI 10.1097/QAD.0b013e328013f632; Moore DM, 2009, JAIDS-J ACQ IMM DEF, V52, P357, DOI 10.1097/QAI.0b013e3181b62933; Moore DM, 2008, JAIDS-J ACQ IMM DEF, V49, P477, DOI 10.1097/QAI.0b013e318186eb18; Moore DM, 2005, JAIDS-J ACQ IMM DEF, V40, P288, DOI 10.1097/01.qai.0000182847.38098.d1; Mussini C, 2008, AIDS, V22, P2461, DOI 10.1097/QAD.0b013e328314b5f1; MUWANGA A, 2008, C RETR OPP INF; Nakamura H, 2008, PHYS STATUS SOLIDI C, V5, P23, DOI 10.1002/pssc.200776546; Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9; Patel A, 2004, JAIDS-J ACQ IMM DEF, V37, P1166, DOI 10.1097/01.qai.0000135956.96166.f0; Reynolds SJ, 2009, AIDS, V23, P697, DOI 10.1097/QAD.0b013e3283262a78; Santoro-Lopes G, 2002, CLIN INFECT DIS, V34, P543, DOI 10.1086/338641; Tuboi SH, 2007, JAIDS-J ACQ IMM DEF, V45, P52, DOI 10.1097/QAI.0b013e318042e1c3; Tuboi SH, 2010, JAIDS-J ACQ IMM DEF, V53, P70, DOI 10.1097/QAI.0b013e3181c22d19; van Oosterhout JJG, 2009, TROP MED INT HEALTH, V14, P856, DOI 10.1111/j.1365-3156.2009.02309.x; *WHO, 2009, REP GLOB TUB CONTR; World Health Organization, 2006, ANT THER HIV INF AD	61	60	60	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 7	2010	5	5							e10527	10.1371/journal.pone.0010527	http://dx.doi.org/10.1371/journal.pone.0010527			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	593OI	20479873	Green Published, gold, Green Submitted			2023-01-03	WOS:000277467800011
J	Hawkins, JL				Hawkins, Joy L.			Epidural Analgesia for Labor and Delivery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED-TRIAL; INTERVILLOUS BLOOD-FLOW; CESAREAN DELIVERY; PAIN RELIEF; INTRAVENOUS ANALGESIA; NEURAXIAL ANALGESIA; RISK; BUPIVACAINE; MANAGEMENT; WOMEN	A 30-year-old nulliparous woman at 39 weeks' gestation is undergoing induction of labor because of premature rupture of membranes. She is currently receiving an oxytocin infusion, and her cervical dilatation is 1 cm. Her obstetrician has ordered intermittent intravenous administration of fentanyl for pain relief, but she feels nauseated, has been unable to rest, and describes her pain as 9 on a scale of 10. The patient strongly prefers a vaginal delivery to cesarean delivery and is concerned that epidural analgesia may alter the progress of labor. The anesthesiologist is consulted to discuss the use of epidural analgesia during labor and delivery.	Univ Colorado, Denver Sch Med, Dept Anesthesiol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus	Hawkins, JL (corresponding author), Univ Colorado, Denver Sch Med, Dept Anesthesiol, 12631 E 17th Ave,Mail Stop 8203, Aurora, CO 80045 USA.	joy.hawkins@ucdenver.edu						ABBOUD TK, 1983, ANESTHESIOLOGY, V59, P1, DOI 10.1097/00000542-198307000-00001; Abrao KC, 2009, OBSTET GYNECOL, V113, P41, DOI 10.1097/AOG.0b013e31818f5eb6; American College of Obstetricians and Gynecologists Committee on Obstetric Practice, 2006, Obstet Gynecol, V107, P1487; Anim-Somuah M, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000331.pub2; [Anonymous], 2004, Obstet Gynecol, V104, P213; [Anonymous], 2007, ANESTHESIOLOGY, V106, P843; Arzola C, 2007, ANESTH ANALG, V104, P1188, DOI 10.1213/01.ane.0000250912.66057.41; Ayad S, 2003, REGION ANESTH PAIN M, V28, P512, DOI 10.1016/S1098-7339(03)00393-6; Beilin Y, 2005, ANESTHESIOLOGY, V103, P1211, DOI 10.1097/00000542-200512010-00016; Capogna G, 2007, INT J OBSTET ANESTH, V16, P110, DOI 10.1016/j.ijoa.2006.08.009; Catterall W. A., 2006, GOODMAN GILMANS PHAR, P369; Cluett ER, 2004, BMJ-BRIT MED J, V328, P314, DOI 10.1136/bmj.37963.606412.EE; Dickinson JE, 2003, AUST NZ J OBSTET GYN, V43, P463, DOI 10.1046/j.0004-8666.2003.00152.x; EIDELMAN AI, 1993, OBSTET GYNECOL, V81, P764; Fanning RA, 2008, ANESTH ANALG, V107, P1303, DOI 10.1213/ane.0b013e3181804245; Goetzl L, 2007, OBSTET GYNECOL, V109, P687, DOI 10.1097/01.AOG.0000255976.14297.f6; Grondin LS, 2009, ANESTHESIOLOGY, V111, P165, DOI 10.1097/ALN.0b013e3181a4c6f2; Halpern SH, 2004, ANESTH ANALG, V99, P1532, DOI 10.1213/01.ANE.0000136850.08972.07; Halpern SH, 1999, BIRTH-ISS PERINAT C, V26, P83, DOI 10.1046/j.1523-536x.1999.00083.x; Harvey M, 2009, ANESTHESIOLOGY, V111, P467, DOI 10.1097/ALN.0b013e3181afe083; Hebl JR, 2006, REGION ANESTH PAIN M, V31, P311, DOI 10.1016/j.rapm.2006.04.004; Hiltunen P, 2004, ACTA OBSTET GYN SCAN, V83, P257, DOI 10.1111/j.0001-6349.2004.0302.x; HOLLMEN AI, 1982, BRIT J ANAESTH, V54, P837, DOI 10.1093/bja/54.8.837; Horlocker TT, 2010, ANESTHESIOLOGY, V112, P530, DOI 10.1097/ALN.0b013e3181c4c7d8; Horlocker TT, 2010, REGION ANESTH PAIN M, V35, P64, DOI 10.1097/AAP.0b013e3181c15c70; Horlocker TT, 2009, ANESTHESIOLOGY, V110, P218, DOI 10.1097/ALN.0b013e31818ec946; Howell CJ, 2002, BMJ-BRIT MED J, V325, P580; Howell CJ, 2002, BMJ-BRIT MED J, V325, P357, DOI 10.1136/bmj.325.7360.357; Huang C, 2002, PHARMACOECONOMICS, V20, P305, DOI 10.2165/00019053-200220050-00002; Huntley AL, 2004, AM J OBSTET GYNECOL, V191, P36, DOI 10.1016/j.ajog.2003.12.008; Impey LWM, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.06.011; JOUPPILA P, 1982, OBSTET GYNECOL, V59, P158; Lee H, 2004, AM J OBSTET GYNECOL, V191, P1573, DOI 10.1016/j.ajog.2004.05.027; Lieberman E, 1997, PEDIATRICS, V99, P415, DOI 10.1542/peds.99.3.415; Lim Y, 2008, ANESTH ANALG, V107, P1968, DOI 10.1213/ane.0b013e3181887ffb; Liu EHC, 2004, BMJ-BRIT MED J, V328, P1410, DOI 10.1136/bmj.38097.590810.7C; Mazoit JX, 2009, ANESTHESIOLOGY, V110, P380, DOI 10.1097/ALN.0b013e318194b252; MELZACK R, 1984, PAIN, V19, P321, DOI 10.1016/0304-3959(84)90079-4; Miro M, 2008, INT J OBSTET ANESTH, V17, P15, DOI 10.1016/j.ijoa.2007.07.003; Nielsen PE, 1996, ANESTH ANALG, V83, P742, DOI 10.1097/00000539-199610000-00014; Ohel G, 2006, AM J OBSTET GYNECOL, V194, P600, DOI 10.1016/j.ajog.2005.10.821; RAMIN SM, 1995, OBSTET GYNECOL, V86, P783, DOI 10.1016/0029-7844(95)00269-W; Ruppen W, 2006, ANESTHESIOLOGY, V105, P394, DOI 10.1097/00000542-200608000-00023; Scott KD, 1999, AM J OBSTET GYNECOL, V180, P1054, DOI 10.1016/S0002-9378(99)70594-6; Seyb ST, 1999, OBSTET GYNECOL, V94, P600, DOI 10.1016/S0029-7844(99)00377-4; Sharma SK, 2004, ANESTHESIOLOGY, V100, P142, DOI 10.1097/00000542-200401000-00023; SHNIDER SM, 1979, ANESTHESIOLOGY, V50, P524; Soet JE, 2003, BIRTH-ISS PERINAT C, V30, P36, DOI 10.1046/j.1523-536X.2003.00215.x; van der Vyver M, 2002, BRIT J ANAESTH, V89, P459, DOI 10.1093/bja/aef217; Wiklund I, 2009, MIDWIFERY, V25, pE31, DOI 10.1016/j.midw.2007.07.005; Wilson MJA, 2009, BRIT J ANAESTH, V102, P97, DOI 10.1093/bja/aen313; Wong CA, 2005, NEW ENGL J MED, V352, P655, DOI 10.1056/NEJMoa042573; Wong CA, 2009, OBSTET GYNECOL, V113, P1066, DOI 10.1097/AOG.0b013e3181a1a9a8; 2002, OBSTET GYNECOL, V100, P177	54	135	162	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 22	2010	362	16					1503	1510		10.1056/NEJMct0909254	http://dx.doi.org/10.1056/NEJMct0909254			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586GP	20410515				2023-01-03	WOS:000276894700009
J	Fontana, L; Partridge, L; Longo, VD				Fontana, Luigi; Partridge, Linda; Longo, Valter D.			Extending Healthy Life Span-From Yeast to Humans	SCIENCE			English	Review							DIETARY RESTRICTION; CALORIE RESTRICTION; DROSOPHILA-MELANOGASTER; STRESS RESISTANCE; I RECEPTOR; EXTENSION; LONGEVITY; TOR; DISRUPTION; MECHANISM	When the food intake of organisms such as yeast and rodents is reduced (dietary restriction), they live longer than organisms fed a normal diet. A similar effect is seen when the activity of nutrient-sensing pathways is reduced by mutations or chemical inhibitors. In rodents, both dietary restriction and decreased nutrient-sensing pathway activity can lower the incidence of age-related loss of function and disease, including tumors and neurodegeneration. Dietary restriction also increases life span and protects against diabetes, cancer, and cardiovascular disease in rhesus monkeys, and in humans it causes changes that protect against these age-related pathologies. Tumors and diabetes are also uncommon in humans with mutations in the growth hormone receptor, and natural genetic variants in nutrient-sensing pathways are associated with increased human life span. Dietary restriction and reduced activity of nutrient-sensing pathways may thus slow aging by similar mechanisms, which have been conserved during evolution. We discuss these findings and their potential application to prevention of age-related disease and promotion of healthy aging in humans, and the challenge of possible negative side effects.	[Fontana, Luigi] Washington Univ, Sch Med, Div Geriatr & Nutr Sci, St Louis, MO 63110 USA; [Fontana, Luigi] Ist Super Sanita, Div Nutr & Aging, I-00161 Rome, Italy; [Partridge, Linda] UCL, Inst Healthy Aging & GEE, London WC1E 6BT, England; [Longo, Valter D.] Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; [Longo, Valter D.] Univ So Calif, Andrus Gerontol Ctr, Los Angeles, CA 90089 USA	Washington University (WUSTL); Istituto Superiore di Sanita (ISS); University of London; University College London; University of Southern California; University of Southern California	Fontana, L (corresponding author), Washington Univ, Sch Med, Div Geriatr & Nutr Sci, St Louis, MO 63110 USA.	lfontana@dom.wustl.edu; l.partridge@ucl.ac.uk; vlongo@usc.edu	Fontana, Luigi/A-8371-2013; Partridge, Linda/E-7342-2015; Fontana, Luigi/K-4773-2013; Partridge, Linda/A-5501-2010	Fontana, Luigi/0000-0001-8500-5537; Partridge, Linda/0000-0001-9615-0094	American Federation for Aging Research, Bakewell Foundation; NIH [AG20642, AG025135, GM075308]; National Center for Research Resources [UL1 RR024992]; National Institute of Diabetes and Digestive and Kidney Diseases [P30DK056341]; Istituto Superiore di Sanita/National Institutes of Health Collaboration Program, Ministero della Salute; Longer Life Foundation; Bakewell Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025135, R01AG020642] Funding Source: NIH RePORTER	American Federation for Aging Research, Bakewell Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Istituto Superiore di Sanita/National Institutes of Health Collaboration Program, Ministero della Salute(Ministry of Health, Italy); Longer Life Foundation; Bakewell Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank M. Wei for careful reading of the manuscript. This work was supported in part by a grant from the American Federation for Aging Research, Bakewell Foundation, and by NIH grants AG20642, AG025135, and GM075308 (to V. D. L.). Support was also provided by the National Center for Research Resources (grant UL1 RR024992) and the National Institute of Diabetes and Digestive and Kidney Diseases (grant P30DK056341); by grants from Istituto Superiore di Sanita/National Institutes of Health Collaboration Program, Ministero della Salute, the Longer Life Foundation (an RGA/Washington University Partnership), and the Bakewell Foundation; and by a donation from the Scott and Annie Appleby Charitable Trust (to L. F.).	Amador-Noguez D, 2007, AGING CELL, V6, P453, DOI 10.1111/j.1474-9726.2007.00300.x; Anderson RM, 2009, TOXICOL PATHOL, V37, P47, DOI 10.1177/0192623308329476; Bartke A, 2005, ENDOCRINOLOGY, V146, P3718, DOI 10.1210/en.2005-0411; Bass TM, 2007, J GERONTOL A-BIOL, V62, P1071, DOI 10.1093/gerona/62.10.1071; Bass TM, 2007, MECH AGEING DEV, V128, P546, DOI 10.1016/j.mad.2007.07.007; Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010; Bonafe M, 2003, J CLIN ENDOCR METAB, V88, P3299, DOI 10.1210/jc.2002-021810; Bonkowski MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004567; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Brown-Borg HM, 2007, AGEING RES REV, V6, P28, DOI 10.1016/j.arr.2007.02.005; Burtner CR, 2009, CELL CYCLE, V8, P1256, DOI 10.4161/cc.8.8.8287; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; Chen D, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000486; Cohen E, 2009, CELL, V139, P1157, DOI 10.1016/j.cell.2009.11.014; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Doonan R, 2008, GENE DEV, V22, P3236, DOI 10.1101/gad.504808; Enns LC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005963; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Fontana L, 2008, AGING CELL, V7, P681, DOI 10.1111/j.1474-9726.2008.00417.x; Fontana L, 2007, JAMA-J AM MED ASSOC, V297, P986, DOI 10.1001/jama.297.9.986; Garcia AM, 2008, MECH AGEING DEV, V129, P528, DOI 10.1016/j.mad.2008.04.013; Giannakou ME, 2008, AGING CELL, V7, P187, DOI 10.1111/j.1474-9726.2007.00362.x; GOURMELEN M, 1991, ACTA PAEDIATR SCAND, P115; Grandison RC, 2009, NATURE, V462, P1061, DOI 10.1038/nature08619; Greer EL, 2009, AGING CELL, V8, P113, DOI 10.1111/j.1474-9726.2009.00459.x; Gronke S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000857; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Ikeno Y, 2009, J GERONTOL A-BIOL, V64, P522, DOI 10.1093/gerona/glp017; Johnson TE, 2008, EXP GERONTOL, V43, P1, DOI 10.1016/j.exger.2007.09.008; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kaeberlein M, 2007, PLOS GENET, V3, P655, DOI 10.1371/journal.pgen.0030084; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kristan DM, 2008, AGE, V30, P147, DOI 10.1007/s11357-008-9056-1; Kuningas M, 2007, EUR J HUM GENET, V15, P294, DOI 10.1038/sj.ejhg.5201766; Libert S, 2007, SCIENCE, V315, P1133, DOI 10.1126/science.1136610; Libina N, 2003, CELL, V115, P489, DOI 10.1016/S0092-8674(03)00889-4; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; McElwee JJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r132; Medvedik O, 2007, PLOS BIOL, V5, P2330, DOI 10.1371/journal.pbio.0050261; Mehta R, 2009, SCIENCE, V324, P1196, DOI 10.1126/science.1173507; Min KJ, 2008, AGING CELL, V7, P199, DOI 10.1111/j.1474-9726.2008.00373.x; Oliveira JLM, 2007, J CLIN ENDOCR METAB, V92, P4664, DOI 10.1210/jc.2007-1636; Pan Y, 2009, AGING-US, V1, P131, DOI 10.18632/aging.100016; Patel NV, 2005, NEUROBIOL AGING, V26, P995, DOI 10.1016/j.neurobiolaging.2004.09.014; Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011; Pearson KJ, 2008, P NATL ACAD SCI USA, V105, P2325, DOI 10.1073/pnas.0712162105; Piper MDW, 2008, J INTERN MED, V263, P179, DOI 10.1111/j.1365-2796.2007.01906.x; Piper MDW, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030057; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105; Reed MJ, 1996, MECH AGEING DEV, V89, P21, DOI 10.1016/0047-6374(96)01737-X; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; Shevah O, 2007, GROWTH HORM IGF RES, V17, P54, DOI 10.1016/j.ghir.2006.10.007; SHIMOKAWA I, 1993, J GERONTOL, V48, pB27, DOI 10.1093/geronj/48.1.B27; Smith DL, 2007, AGING CELL, V6, P649, DOI 10.1111/j.1474-9726.2007.00326.x; Smith ED, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-49; Steffen KK, 2008, CELL, V133, P292, DOI 10.1016/j.cell.2008.02.037; Steinkraus KA, 2008, AGING CELL, V7, P394, DOI 10.1111/j.1474-9726.2008.00385.x; Suh Y, 2008, P NATL ACAD SCI USA, V105, P3438, DOI 10.1073/pnas.0705467105; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Wei M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040013; Wei M, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000467; Wong R, 2008, NAT METHODS, V5, P214, DOI 10.1038/nmeth0308-214; Yan L, 2007, CELL, V130, P247, DOI 10.1016/j.cell.2007.05.038	69	1907	1975	14	587	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 16	2010	328	5976					321	326		10.1126/science.1172539	http://dx.doi.org/10.1126/science.1172539			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	583NR	20395504	Green Accepted			2023-01-03	WOS:000276685000028
J	Gurley, ES; Rahman, M; Hossain, MJ; Nahar, N; Faiz, MA; Islam, N; Sultana, R; Khatun, S; Uddin, MZ; Haider, MS; Islam, MS; Ahmed, BN; Rahman, MW; Mondal, UK; Luby, SP				Gurley, Emily S.; Rahman, Mahmudur; Hossain, M. Jahangir; Nahar, Nazmun; Faiz, M. Abul; Islam, Nazrul; Sultana, Rebeca; Khatun, Selina; Uddin, Mohammad Zashim; Haider, M. Sabbir; Islam, M. Saiful; Ahmed, Be-Nazir; Rahman, Muhammad Waliur; Mondal, Utpal Kumar; Luby, Stephen P.			Fatal Outbreak from Consuming Xanthium strumarium Seedlings during Time of Food Scarcity in Northeastern Bangladesh	PLOS ONE			English	Article							WESTERN UTTAR-PRADESH; COCKLEBUR; CHILDREN; REDEFINITION; INTOXICATION; PRINCIPLE	Background: An outbreak characterized by vomiting and rapid progression to unconsciousness and death was reported in Sylhet Distrct in northeastern Bangladesh following destructive monsoon floods in November 2007. Methods and Findings: We identified cases presenting to local hospitals and described their clinical signs and symptoms. We interviewed patients and their families to collect illness histories and generate hypotheses about exposures associated with disease. An epidemiological study was conducted in two outbreak villages to investigate risk factors for developing illness. 76 patients were identified from 9 villages; 25% (19/76) died. Common presenting symptoms included vomiting, elevated liver enzymes, and altered mental status. In-depth interviews with 33 cases revealed that 31 (94%) had consumed ghagra shak, an uncultivated plant, in the hours before illness onset. Ghagra shak was consumed as a main meal by villagers due to inaccessibility of other foods following destructive monsoon flooding and rises in global food prices. Persons who ate this plant were 34.2 times more likely (95% CI 10.2 to 115.8, p-value<0.000) than others to develop vomiting and unconsciousness during the outbreak in our multivariate model. Ghagra shak is the local name for Xanthium strumarium, or common cocklebur. Conclusions: The consumption of Xanthium strumarium seedlings in large quantities, due to inaccessibility of other foods, caused this outbreak. The toxic chemical in the plant, carboxyatratyloside, has been previously described and eating X. strumarium seeds and seedlings has been associated with fatalities in humans and livestock. Unless people are able to meet their nutritional requirements with safe foods, they will continue to be at risk for poor health outcomes beyond undernutrition.	[Gurley, Emily S.; Hossain, M. Jahangir; Nahar, Nazmun; Sultana, Rebeca; Islam, M. Saiful; Rahman, Muhammad Waliur; Mondal, Utpal Kumar; Luby, Stephen P.] Int Ctr Diarrhoeal Dis Res, Programme Infect Dis & Vaccine Sci, Dhaka 1000, Bangladesh; [Rahman, Mahmudur; Khatun, Selina; Haider, M. Sabbir; Ahmed, Be-Nazir] Govt Bangladesh, Minist Hlth & Family Welf, IEDCR, Dhaka, Bangladesh; [Faiz, M. Abul] Govt Bangladesh, Minist Hlth & Family Welf, Directorate Gen Hlth Serv, Dhaka, Bangladesh; [Islam, Nazrul] Bangabandhu Sheikh Mujib Med Univ, Dept Virol, Dhaka, Bangladesh; [Uddin, Mohammad Zashim] Univ Dhaka, Dept Bot, Dhaka 1000, Bangladesh; [Luby, Stephen P.] Ctr Dis Control & Prevent, Atlanta, GA USA	International Centre for Diarrhoeal Disease Research (ICDDR); Bangabandhu Sheikh Mujib Medical University (BSMMU); University of Dhaka; Centers for Disease Control & Prevention - USA	Gurley, ES (corresponding author), Int Ctr Diarrhoeal Dis Res, Programme Infect Dis & Vaccine Sci, GPO Box 128, Dhaka 1000, Bangladesh.	egurley@icddrb.org		Nahar, Nazmun/0000-0002-4530-6009; Sultana, Rebeca/0000-0002-4180-5679	Centers for Disease Control and Prevention, USA (CDC) [U01 CI000298]; Government of the People's Republic of Bangladesh (GoB); NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID) [U01CI000298] Funding Source: NIH RePORTER	Centers for Disease Control and Prevention, USA (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Government of the People's Republic of Bangladesh (GoB); NATIONAL CENTER FOR INFECTIOUS DISEASES (NCID)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	This research was funded by the Centers for Disease Control and Prevention, USA (CDC), cooperative agreement U01 CI000298, and by the Government of the People's Republic of Bangladesh (GoB). ICDDR, B acknowledges with gratitude the commitment of CDC and the GoB to the authors' research efforts. Co-authors on this paper include representatives from both the Centers for Disease Control and Prevention and the GoB, the two organizations who provided financial support for this work. These co-authors, and therefore CDC and the Government of Bangladesh, were both involved in hypothesis generation, study design, data interpretation, and review of the manuscript for publication.	Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; COLE RJ, 1980, J AGR FOOD CHEM, V28, P1330, DOI 10.1021/jf60232a043; FAO, 2008, SPEC REP FAO WFP CRO; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; HATCH RC, 1982, AM J VET RES, V43, P111; Loewenberg S, 2008, LANCET, V372, P1209, DOI 10.1016/S0140-6736(08)61502-0; Mendez MD, 1998, VET HUM TOXICOL, V40, P144; Rosegrant MW, 2003, SCIENCE, V302, P1917, DOI 10.1126/science.1092958; STUART BP, 1981, VET PATHOL, V18, P368, DOI 10.1177/030098588101800310; Turgut M, 2005, ANN TROP PAEDIATR, V25, P125, DOI 10.1179/146532805X45728; Vashishtha VM, 2007, INDIAN J MED RES, V125, P756; Vashishtha VM, 2007, INDIAN J MED RES, V125, P523; Vashishtha VM, 2007, INDIAN PEDIATR, V44, P522; Witte S T, 1990, J Vet Diagn Invest, V2, P263	14	20	26	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 18	2010	5	3							e9756	10.1371/journal.pone.0009756	http://dx.doi.org/10.1371/journal.pone.0009756			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	580NO	20305785	gold, Green Submitted, Green Published			2023-01-03	WOS:000276456300007
J	Van den Bruel, A; Haj-Hassan, T; Thompson, M; Buntinx, F; Mant, D				Van den Bruel, Ann; Haj-Hassan, Tanya; Thompson, Matthew; Buntinx, Frank; Mant, David		European Res Network Recognising S	Diagnostic value of clinical features at presentation to identify serious infection in children in developed countries: a systematic review	LANCET			English	Review							C-REACTIVE PROTEIN; BACTERIAL-INFECTIONS; FEBRILE CHILDREN; OUTPATIENT MANAGEMENT; MENINGOCOCCAL DISEASE; OBSERVATION SCALES; PREDICTIVE MODEL; FEVER; EMERGENCY; BACTEREMIA	Background Our aim was to identify which clinical features have value in confirming or excluding the possibility of serious infection in children presenting to ambulatory care settings in developed countries. Methods In this systematic review, we searched electronic databases (Medline, Embase, DARE, CINAHL), reference lists of relevant studies, and contacted experts to identify articles assessing clinical features of serious infection in children. 1939 potentially relevant studies were identified. Studies were selected on the basis of six criteria: design (studies of diagnostic accuracy or prediction rules), participants (otherwise healthy children aged 1 month to 18 years), setting (ambulatory care), outcome (serious infection), features assessed (assessable in ambulatory care setting), and sufficient data reported. Quality assessment was based on the Quality Assessment of Diagnostic Accuracy Studies criteria. We calculated likelihood ratios for the presence (positive likelihood ratio) or absence (negative likelihood ratio) of each clinical feature and pre-test and post-test probabilities of the outcome. Clinical features with a positive likelihood ratio of more than 5.0 were deemed red flags (ie, warning signs for serious infection); features with a negative likelihood ratio of less than 0.2 were deemed rule-out signs. Findings 30 studies were included in the analysis. Cyanosis (positive likelihood ratio range 2.66-52.20), rapid breathing (1.26-9.78), poor peripheral perfusion (2.39-38.80), and petechial rash (6.18-83.70) were identified as red flags in several studies. Parental concern (positive likelihood ratio 14.40, 95% CI 9.30-22.10) and clinician instinct (positive likelihood ratio 23.50, 95% CI 16.80-32.70) were identified as strong red flags in one primary care study. Temperature of 40 C or more has value as a red flag in settings with a low prevalence of serious infection. No single clinical feature has rule-out value but some combinations can be used to exclude the possibility of serious infection for example, pneumonia is very unlikely (negative likelihood ratio 0.07, 95% CI 0.01-0.46) if the child is not short of breath and there is no parental concern. The Yale Observation Scale had little value in confirming (positive likelihood ratio range 1.10-6.70) or excluding (negative likelihood ratio range 0.16-0.97) the possibility of serious infection. Interpretation The red flags for serious infection that we identified should be used routinely, but serious illness will still be missed without effective use of precautionary measures. We now need to identify the level of risk at which clinical action should be taken.	[Van den Bruel, Ann; Buntinx, Frank] Katholieke Univ Leuven, Dept Gen Practice, B-3000 Louvain, Belgium; [Haj-Hassan, Tanya; Thompson, Matthew; Mant, David] Univ Oxford, Dept Primary Hlth Care, Oxford, England	KU Leuven; University of Oxford	Van den Bruel, A (corresponding author), Katholieke Univ Leuven, Dept Gen Practice, Kapucijnenvoer 33 Blok J, B-3000 Louvain, Belgium.	ann.vandenbruel@med.kuleuven.be	Van den Bruel, Ann/AAC-2442-2020; Buntinx, Frank/E-4950-2011	Van den Bruel, Ann/0000-0001-9012-2009; Aertgeerts, Bert/0000-0003-1142-5402	Health Technology Assessment [07/37/05]; National Institute for Health Research National School for Primary Care Research; Fonds Wetenschappelijk Onderzoek Vlaanderen; National Institute for Health Research [07/37/05, CL-2009-13-007] Funding Source: researchfish	Health Technology Assessment; National Institute for Health Research National School for Primary Care Research; Fonds Wetenschappelijk Onderzoek Vlaanderen(FWO); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the Health Technology Assessment Project 07/37/05 (Systematic review and validation of clinical prediction rules for identifying children with serious infections in emergency departments and urgent-access primary care) and the National Institute for Health Research National School for Primary Care Research. We would like to thank Paul Glasziou (Centre for Evidence Based Medicine, Oxford, UK) for advising us on the tables and figures. The Fonds Wetenschappelijk Onderzoek Vlaanderen (Research Foundation-Flanders) initially funded the study by Van den Bruel and colleagues' and granted extension to pay for some of the work presented in this report.	Almond S, 2009, BRIT J GEN PRACT, V59, P872, DOI 10.3399/bjgp09X472971; Andreola B, 2007, PEDIATR INFECT DIS J, V26, P672, DOI 10.1097/INF.0b013e31806215e3; Armon K, 2001, ARCH DIS CHILD, V84, P390, DOI 10.1136/adc.84.5.390; Bachur RG, 2001, PEDIATRICS, V108, P311, DOI 10.1542/peds.108.2.311; BAKER MD, 1990, PEDIATRICS, V85, P1040; Baker MD, 1999, PEDIATRICS, V103, P627, DOI 10.1542/peds.103.3.627; BAKER MD, 1993, NEW ENGL J MED, V329, P1437, DOI 10.1056/NEJM199311113292001; Berger RMF, 1996, EUR J PEDIATR, V155, P468, DOI 10.1007/BF01955183; Bleeker SE, 2007, ACTA PAEDIATR, V96, P100, DOI 10.1111/j.1651-2227.2006.00033.x; BONADIO WA, 1993, CLIN PEDIATR, V32, P401, DOI 10.1177/000992289303200703; Bruijnzeels MA, 1998, BRIT J GEN PRACT, V48, P880; Carlin JB, 2008, LANCET, V371, P135, DOI 10.1016/S0140-6736(08)60106-3; Confidential Enquiry into Maternal and Child Health (CEMACH), 2008, WHY CHILDR DIE PIL S; CROCKER PJ, 1985, ANN EMERG MED, V14, P1172, DOI 10.1016/S0196-0644(85)81024-6; Duke T, 2005, ARCH DIS CHILD, V90, P200, DOI 10.1136/adc.2003.047951; Fleming D M, 2002, Commun Dis Public Health, V5, P7; Galetto-Lacour A, 2003, PEDIATRICS, V112, P1054, DOI 10.1542/peds.112.5.1054; Garra G, 2005, ACAD EMERG MED, V12, P921, DOI 10.1197/j.aem.2005.06.006; Gorelick MH, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.5.e6; GOVE S, 1977, B WHO S1, V75, P7; Grupo de Trabajo sobre el Nino Febril de la Sociedad Espanola de Urgencias de Pediatria, 2001, An Esp Pediatr, V55, P5; Haddon RA, 1999, MED J AUSTRALIA, V170, P475, DOI 10.5694/j.1326-5377.1999.tb127847.x; Hsiao AL, 2006, PEDIATRICS, V117, P1695, DOI 10.1542/peds.2005-1673; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JAFFE DM, 1991, PEDIATRICS, V87, P670; JOFFE A, 1983, AM J DIS CHILD, V137, P1153, DOI 10.1001/archpedi.1983.02140380013005; Kai J, 1996, BRIT MED J, V313, P983; Lacour AG, 2001, EUR J PEDIATR, V160, P95, DOI 10.1007/s004310000681; Lacour AG, 2008, PEDIATR INFECT DIS J, V27, P654, DOI 10.1097/INF.0b013e318168d2b4; MACKENZIE A, 1989, LANCET, V2, P605; Mahabee-Gittens EM, 2005, CLIN PEDIATR, V44, P427, DOI 10.1177/000992280504400508; MCCARTHY PL, 1982, PEDIATRICS, V70, P802; MCCARTHY PL, 1987, J PEDIATR-US, V110, P26, DOI 10.1016/S0022-3476(87)80282-2; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P111, DOI 10.1136/adc.66.1.111; Nademi Z, 2001, J INFECTION, V43, P221, DOI 10.1053/jinf.2001.0920; National Institute for Health and Clinical Excellence (NICE), 2007, UR TRACT INF CHILDR; NICE, 2007, FEV ILLN CHILDR ASS; Nielsen HE, 2001, ARCH DIS CHILD, V85, P160, DOI 10.1136/adc.85.2.160; OFFRINGA M, 1992, CLIN PEDIATR, V31, P514, DOI 10.1177/000992289203100901; Oostenbrink R, 2001, ACTA PAEDIATR, V90, P611, DOI 10.1080/080352501750258649; Osman O, 2002, Health Bull (Edinb), V60, P33; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; Shavit I, 2006, PEDIATRICS, V118, P2402, DOI 10.1542/peds.2006-1108; TAYLOR JA, 1995, ARCH PEDIAT ADOL MED, V149, P283, DOI 10.1001/archpedi.1995.02170150063011; TEELE DW, 1975, J PEDIATR-US, V87, P227, DOI 10.1016/S0022-3476(75)80584-1; Thayyil S, 2005, ACTA PAEDIATR, V94, P155, DOI 10.1080/08035250410025140; Thompson M, 2009, ARCH DIS CHILD, V94, P888, DOI 10.1136/adc.2009.159095; Thompson MJ, 2006, LANCET, V367, P397, DOI 10.1016/S0140-6736(06)67932-4; Trautner BW, 2006, PEDIATRICS, V118, P34, DOI 10.1542/peds.2005-2823; Van den Bruel A, 2007, BRIT J GEN PRACT, V57, P538; WASKERWITZ S, 1981, J PEDIATR-US, V99, P231, DOI 10.1016/S0022-3476(81)80458-1; Wells LC, 2001, ARCH DIS CHILD, V85, P218, DOI 10.1136/adc.85.3.218; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25	53	209	213	2	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	2010	375	9717					834	845		10.1016/S0140-6736(09)62000-6	http://dx.doi.org/10.1016/S0140-6736(09)62000-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570MO	20132979				2023-01-03	WOS:000275682600033
J	Sutton, GM; Begriche, K; Kumar, KG; Gimble, JM; Perez-Tilve, D; Nogueiras, R; McMillan, RP; Hulver, MW; Tschop, MH; Butler, AA				Sutton, Gregory M.; Begriche, Karima; Kumar, K. Ganesh; Gimble, Jeffrey M.; Perez-Tilve, Diego; Nogueiras, Ruben; McMillan, Ryan P.; Hulver, Matthew W.; Tschoep, Matthias H.; Butler, Andrew A.			Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle	FASEB JOURNAL			English	Article						hypothalamus; circadian biology; liver metabolism; glucose; ketones	AGOUTI-RELATED PROTEIN; NEURONAL ACTIVATION; BRAIN; OBESITY; CLOCK; FOOD; HYPOTHALAMUS; PATHOGENESIS; MECHANISMS; RHYTHMS	Melanocortin-3 receptors (Mc3rs) in the central nervous system are involved in expression of anticipatory rhythms and synchronizing clocks maintaining circadian rhythms during restricted feeding (RF) [mice housed under a 12-h light-dark cycle with lights on between zeitgeber time (ZT) 0 to ZT12 fed 60% of normal calories between ZT7 and ZT11]. Because the systems governing circadian rhythms are important for adaptation to RF, we investigated whether Mc3rs are required for metabolic adaption to RF. Mc3r(-/-) mice subjected to RF exhibited normal weight loss; however, they developed hyper-insulinemia, glucose intolerance, increased expression of lipogenic genes, and increased ketogenesis relative to controls. Rhythmic expression of transcription factors regulating liver clock activity and energy metabolism (Bmal1, Rev-erb alpha, Pgc1, Foxo1, Hnf4 alpha, and Pck1) was severely compromised in Mc3r(-/-) mice during RF. Inhibition of neural melanocortin receptors by agouti-related peptide also attenuated rhythmicity in the hepatic expression of these genes during RF. Collectively, these data suggest that neural Mc3rs are important for adapting metabolism and maintaining rhythms of liver metabolism during periods when feeding is restricted to the light cycle.-Sutton, G. M., Begriche, K., Kumar, K. G., Gimble, J. M., Perez-Tilve, D., Nogueiras, R., McMillan, R. P., Hulver, M. W., Tschop, M. H., Butler, A. A. Central nervous system melanocortin-3 receptors are required for synchronizing metabolism during entrainment to restricted feeding during the light cycle. FASEB J. 24, 862-872 (2010). www.fasebj.org	[Begriche, Karima; Kumar, K. Ganesh; Butler, Andrew A.] Scripps Res Inst, Dept Metab & Aging, Jupiter, FL 33458 USA; [Sutton, Gregory M.; Begriche, Karima; Kumar, K. Ganesh; Butler, Andrew A.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Neuropeptides Lab, Baton Rouge, LA USA; [Gimble, Jeffrey M.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Stem Cell Biol Lab, Baton Rouge, LA USA; [Gimble, Jeffrey M.; Butler, Andrew A.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Clin Nutr Res Unit, Baton Rouge, LA USA; [Perez-Tilve, Diego; Nogueiras, Ruben; Tschoep, Matthias H.] German Inst Human Nutr Potsdam Rehbrucke, Dept Pharmacol, Nuthetal, Germany; [Nogueiras, Ruben; Tschoep, Matthias H.] Univ Cincinnati, Obes Res Ctr, Dept Psychiat, Cincinnati, OH USA; [McMillan, Ryan P.; Hulver, Matthew W.] Virginia Polytech & State Univ, Dept Human Nutr Food & Exercise, Blacksburg, VA USA	Scripps Research Institute; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); University System of Ohio; University of Cincinnati; Virginia Polytechnic Institute & State University	Butler, AA (corresponding author), Scripps Res Inst, Dept Metab & Aging, 130 Scripps Way, Jupiter, FL 33458 USA.	abutler@scripps.edu	Tschoep, Matthias H/I-5443-2014; Nogueiras, Ruben/AAS-9427-2021; Begriche, Karima/Y-9444-2019	Nogueiras, Ruben/0000-0002-9976-9930; Tschoep, Matthias/0000-0002-4744-371X; Begriche, Karima/0000-0002-6378-3861; Butler, Andrew/0000-0001-7196-0170; Perez-Tilve, Diego/0000-0002-0351-4133	National Institutes of Health [DK073189]; Pennington Biomedical Research Foundation; National Institute of Diabetes and Digestive and Kidney Diseases [1P30 DK072476]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK073189, P30DK072476] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennington Biomedical Research Foundation; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr. Jennifer Rood, Dr. Robert Koza, Dr. Jose Galgani, Brian Goh, Emily Meyer, Armand Centanni, and Xiying Wu for technical assistance. We thank Dr. H. Henry Dong (Rangos Research Center, Children's Hospital of Pittsburgh, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA) for providing the Foxo1 antibody. Funding for this work was provided by the National Institutes of Health (DK073189 to A. A. B.). A. A. B. and J.M.G. acknowledge the support of the Pennington Biomedical Research Foundation and Clinical Nutrition Research Unit Center grant, "Nutritional Programming: Environmental and Molecular Interactions" (1P30 DK072476), sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases. The authors declare that they have no competing interests.	Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Butler AA, 2006, PEPTIDES, V27, P281, DOI 10.1016/j.peptides.2005.02.029; Caspi L, 2007, CELL METAB, V6, P99, DOI 10.1016/j.cmet.2007.07.005; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Cone RD, 2006, ENDOCR REV, V27, P736, DOI 10.1210/er.2006-0034; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Davidson AJ, 2006, AM J PHYSIOL-REG I, V290, pR1524, DOI 10.1152/ajpregu.00073.2006; Dudley CA, 2003, SCIENCE, V301, P379, DOI 10.1126/science.1082795; Duez H, 2008, FEBS LETT, V582, P19, DOI 10.1016/j.febslet.2007.08.032; Garfield AS, 2009, TRENDS ENDOCRIN MET, V20, P203, DOI 10.1016/j.tem.2009.02.002; Gavrilova O, 2003, J BIOL CHEM, V278, P34268, DOI 10.1074/jbc.M300043200; Green CB, 2008, CELL, V134, P728, DOI 10.1016/j.cell.2008.08.022; Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25; Guo HN, 2005, P NATL ACAD SCI USA, V102, P3111, DOI 10.1073/pnas.0409734102; Gupta RK, 2004, TRENDS MOL MED, V10, P521, DOI 10.1016/j.molmed.2004.09.004; Gutierrez-Juarez R, 2004, J BIOL CHEM, V279, P49704, DOI 10.1074/jbc.M408665200; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Johnstone LE, 2006, CELL METAB, V4, P313, DOI 10.1016/j.cmet.2006.08.003; Konner AC, 2007, CELL METAB, V5, P438, DOI 10.1016/j.cmet.2007.05.004; Kornmann B, 2007, COLD SPRING HARB SYM, V72, P319, DOI 10.1101/sqb.2007.72.041; Lam TKT, 2007, NAT MED, V13, P171, DOI 10.1038/nm1540; Lamia KA, 2008, P NATL ACAD SCI USA, V105, P15172, DOI 10.1073/pnas.0806717105; Levin BE, 2007, CELL METAB, V6, P252, DOI 10.1016/j.cmet.2007.09.005; Liu C, 2007, NATURE, V447, P477, DOI 10.1038/nature05767; MacNeil DJ, 2002, EUR J PHARMACOL, V450, P91, DOI 10.1016/S0014-2999(02)01989-1; Mistlberger Ralph E, 2009, J Circadian Rhythms, V7, P3, DOI 10.1186/1740-3391-7-3; Myers MG, 2008, ANNU REV PHYSIOL, V70, P537, DOI 10.1146/annurev.physiol.70.113006.100707; Nogueiras R, 2007, J CLIN INVEST, V117, P3475, DOI 10.1172/JCI31743; Obici S, 2001, J CLIN INVEST, V108, P1079, DOI 10.1172/JCI200112954; Obici S, 2009, ENDOCRINOLOGY, V150, P2512, DOI 10.1210/en.2009-0409; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Parton LE, 2007, NATURE, V449, P228, DOI 10.1038/nature06098; Pendergast JS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004860; Perlemuter G, 2007, NAT CLIN PRACT ENDOC, V3, P458, DOI 10.1038/ncpendmet0505; Peschke E, 2008, J PINEAL RES, V44, P26, DOI 10.1111/j.1600-079X.2007.00519.x; Petersen KF, 2007, P NATL ACAD SCI USA, V104, P12587, DOI 10.1073/pnas.0705408104; Pocai A, 2005, CELL METAB, V1, P53, DOI 10.1016/j.cmet.2004.11.001; Pocai A, 2005, NATURE, V434, P1026, DOI 10.1038/nature03439; Qu S, 2006, ENDOCRINOLOGY, V147, P5641, DOI 10.1210/en.2006-0541; Ramsey KM, 2009, P NATL ACAD SCI USA, V106, P4069, DOI 10.1073/pnas.0901304106; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; Rossi M, 1998, ENDOCRINOLOGY, V139, P4428, DOI 10.1210/en.139.10.4428; Singru PS, 2007, ENDOCRINOLOGY, V148, P638, DOI 10.1210/en.2006-1233; Small CJ, 2001, DIABETES, V50, P248, DOI 10.2337/diabetes.50.2.248; Staels B, 2006, NAT MED, V12, P54, DOI 10.1038/nm0106-54; Stephan FK, 2002, J BIOL RHYTHM, V17, P284, DOI 10.1177/074873002129002591; Storch KF, 2009, P NATL ACAD SCI USA, V106, P6808, DOI 10.1073/pnas.0902063106; Sutton GM, 2006, ENDOCRINOLOGY, V147, P2183, DOI 10.1210/en.2005-1209; Sutton GM, 2008, J NEUROSCI, V28, P12946, DOI 10.1523/JNEUROSCI.3615-08.2008; Wijnen H, 2009, SCIENCE, V324, P598, DOI 10.1126/science.1174132; Zhou L, 2007, CELL METAB, V6, P398, DOI 10.1016/j.cmet.2007.10.008	53	39	39	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2010	24	3					862	872		10.1096/fj.09-142000	http://dx.doi.org/10.1096/fj.09-142000			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	561KE	19837866	Bronze, Green Published			2023-01-03	WOS:000274974600022
J	Mayack, SR; Shadrach, JL; Kim, FS; Wagers, AJ				Mayack, Shane R.; Shadrach, Jennifer L.; Kim, Francis S.; Wagers, Amy J.			RETRACTED: Systemic signals regulate ageing and rejuvenation of blood stem cell niches (Retracted article. See vol. 467, pg. 872, 2010)	NATURE			English	Article; Retracted Publication							HEMATOPOIETIC-STEM; IGF-I; PROGENITOR CELLS; SKELETAL-MUSCLE; GROWTH; OSTEOBLASTS; PATHWAYS; BONE; IDENTIFICATION; REGENERATION	Ageing in multicellular organisms typically involves a progressive decline in cell replacement and repair processes, resulting in several physiological deficiencies, including inefficient muscle repair, reduced bone mass, and dysregulation of blood formation (haematopoiesis). Although defects in tissue-resident stem cells clearly contribute to these phenotypes, it is unclear to what extent they reflect stem cell intrinsic alterations or age-related changes in the stem cell supportive microenvironment, or niche. Here, using complementary in vivo and in vitro heterochronic models, we show that age-associated changes in stem cell supportive niche cells deregulate normal haematopoiesis by causing haematopoietic stem cell dysfunction. Furthermore, we find that age-dependent defects in niche cells are systemically regulated and can be reversed by exposure to a young circulation or by neutralization of the conserved longevity regulator, insulin-like growth factor-1, in the marrow microenvironment. Together, these results show a new and critical role for local and systemic factors in signalling age-related haematopoietic decline, and highlight a new model in which blood-borne factors in aged animals act through local niche cells to induce age-dependent disruption of stem cell function.	[Mayack, Shane R.; Shadrach, Jennifer L.; Kim, Francis S.; Wagers, Amy J.] Harvard Univ, Howard Hughes Med Inst, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst,Joslin Diabet Ctr, Boston, MA 02115 USA	Harvard University; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute	Wagers, AJ (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Stem Cell & Regenerat Biol, Harvard Stem Cell Inst,Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02115 USA.	amy.wagers@joslin.harvard.edu			Burroughs-Welcome Fund; WM Keck Foundation; Glenn Foundation; National Institutes of Health (NIH) [1 DP2 OD004345-01, T32DK07260-29]; Iacocca Foundation; Joslin Diabetes Center DERC [P30DK036836]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007260, P30DK036836] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP2OD004345] Funding Source: NIH RePORTER	Burroughs-Welcome Fund(Burroughs Wellcome Fund); WM Keck Foundation(W.M. Keck Foundation); Glenn Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Iacocca Foundation; Joslin Diabetes Center DERC; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part by funding from the Burroughs-Welcome Fund, WM Keck Foundation, Glenn Foundation, and National Institutes of Health (NIH) 1 DP2 OD004345-01 (to A. J. W.), by fellowships from the NIH (T32DK07260-29) and the Iacocca Foundation (to S. R. M.), and by the Joslin Diabetes Center DERC (P30DK036836). We thank J. LaVecchio and G. Buruzula for expert cell sorting, C. J. Luckey for anti-IGF-1 antibody, and L. Zon, R. Lee, D. Rossi, L. P. Kane, S. Lowe and C. Dall'Osso for helpful advice and critical reading of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	Arai F, 2005, TRENDS CARDIOVAS MED, V15, P75, DOI 10.1016/j.tcm.2005.03.002; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Caspari R, 2004, P NATL ACAD SCI USA, V101, P10895, DOI 10.1073/pnas.0402857101; Cornish J, 2004, BIOCHEM BIOPH RES CO, V318, P240, DOI 10.1016/j.bbrc.2004.04.020; DiGirolamo DJ, 2007, J BIOL CHEM, V282, P31666, DOI 10.1074/jbc.M705219200; Eggan K, 2006, NATURE, V441, P1109, DOI 10.1038/nature04929; Ema H, 2006, NAT PROTOC, V1, P2979, DOI 10.1038/nprot.2006.447; Fisher MC, 2005, BONE, V37, P741, DOI 10.1016/j.bone.2005.07.024; Fulzele K, 2007, J BIOL CHEM, V282, P25649, DOI 10.1074/jbc.M700651200; GIBSON LF, 1993, BLOOD, V82, P3005; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Jones DL, 2008, NAT REV MOL CELL BIO, V9, P11, DOI 10.1038/nrm2319; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kuro-O M, 2008, BIOL CHEM, V389, P233, DOI 10.1515/BC.2008.028; Liang Y, 2005, BLOOD, V106, P1479, DOI 10.1182/blood-2004-11-4282; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Mayack SR, 2008, BLOOD, V112, P519, DOI 10.1182/blood-2008-01-133710; Morrison SJ, 1997, DEVELOPMENT, V124, P1929; Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Nakasaki M, 2008, BONE, V43, P869, DOI 10.1016/j.bone.2008.07.241; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rossi DJ, 2007, NATURE, V447, P725, DOI 10.1038/nature05862; Rossi DJ, 2005, P NATL ACAD SCI USA, V102, P9194, DOI 10.1073/pnas.0503280102; Sherwood RI, 2004, CELL, V119, P543, DOI 10.1016/j.cell.2004.10.021; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; Wagers AJ, 2005, CELL, V122, P659, DOI 10.1016/j.cell.2005.08.021; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang YM, 2007, J BONE MINER RES, V22, P1329, DOI 10.1359/JBMR.070517; Welniak LA, 2004, BIOL BLOOD MARROW TR, V10, P32, DOI 10.1016/j.bbmt.2003.09.008; Wilson A, 2006, NAT REV IMMUNOL, V6, P93, DOI 10.1038/nri1779; Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	37	104	112	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 28	2010	463	7280					495	U109		10.1038/nature08749	http://dx.doi.org/10.1038/nature08749			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	548QK	20110993				2023-01-03	WOS:000273981100041
J	Cohen, AS; Burns, B; Goadsby, PJ				Cohen, Anna S.; Burns, Brian; Goadsby, Peter J.			High-Flow Oxygen for Treatment of Cluster Headache A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DOUBLE-BLIND; ZOLMITRIPTAN; SUMATRIPTAN	Context Cluster headache is an excruciatingly painful primary headache syndrome, with attacks of unilateral pain and cranial autonomic symptoms. The current licensed treatment for acute attacks is subcutaneous sumatriptan. Objective To ascertain whether high-flow inhaled oxygen was superior to placebo in the acute treatment of cluster headache. Design, Setting, and Patients A double-blind, randomized, placebo-controlled crossover trial of 109 adults (aged 18-70 years) with cluster headache as defined by the International Headache Society. Patients treated 4 headache episodes with high-flow inhaled oxygen or placebo, alternately. Patients were randomized to the order in which they received the active treatment or placebo. Patients were recruited and followed up between 2002 and 2007 at the National Hospital for Neurology and Neurosurgery, London, England. Intervention Inhaled oxygen at 100%, 12 L/min, delivered by face mask, for 15 minutes at the start of an attack of cluster headache or high-flow air placebo delivered alternately for 4 attacks. Main Outcome Measures The primary end point was to render the patient pain free, or in the absence of a diary to have adequate relief, at 15 minutes. Secondary end points included rendering the patient pain free at 30 minutes, reduction in pain up to 60 minutes, need for rescue medication 15 minutes after treatment, overall response to the treatment and overall functional disability, and effect on associated symptoms. Results Fifty-seven patients with episodic cluster headache and 19 with chronic cluster headache were available for the analysis. For the primary end point the difference between oxygen, 78% (95% confidence interval, 71%-85% for 150 attacks) and air, 20% (95% confidence interval, 14%-26%; for 148 attacks) was significant (Wald test, chi(2)(5)=66.7, P<.001). There were no important adverse events. Conclusion Treatment of patients with cluster headache at symptom onset using inhaled high-flow oxygen compared with placebo was more likely to result in being pain-free at 15 minutes. Trial Registration isrctn.org Identifier: ISRCTN94092997 JAMA. 2009; 302(22): 2451-2457	[Goadsby, Peter J.] Univ Calif San Francisco, Dept Neurol, Headache Grp, San Francisco, CA 94115 USA; [Cohen, Anna S.; Burns, Brian; Goadsby, Peter J.] Natl Hosp Neurol & Neurosurg, Inst Neurol, Headache Grp, Queen Sq London, England	University of California System; University of California San Francisco; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Goadsby, PJ (corresponding author), Univ Calif San Francisco, Dept Neurol, Headache Grp, 1701 Div St, San Francisco, CA 94115 USA.	pgoadsby@headache.ucsf.edu	Goadsby, Peter J/Z-1970-2019	Goadsby, Peter J/0000-0003-3260-5904	University College London	University College London(General Electric)	The trial was jointly sponsored by University College London and BOC Limited (now Linde Gases, Priestley Road, Guildford, Surrey, UK), who supplied the cylinders and the masks.	Akerman S, 2009, HEADACHE, V49, P1131, DOI 10.1111/j.1526-4610.2009.01501.x; Bahra A, 2002, NEUROLOGY, V58, P354, DOI 10.1212/WNL.58.3.354; Bahra A, 2000, NEUROLOGY, V54, P1832, DOI 10.1212/WNL.54.9.1832; Cittadini E, 2006, ARCH NEUROL-CHICAGO, V63, P1537, DOI 10.1001/archneur.63.11.nct60002; Cohen AS, 2007, CEPHALALGIA, V27, P1188; DEXTER JD, 1970, NEUROLOGY, V20, P513, DOI 10.1212/WNL.20.5.513; Dodick D, 2004, HEADACHE, V44, P414, DOI 10.1111/j.1526-4610.2004.04078.x; EKBOM K, 1992, CEPHALALGIA, V12, P254, DOI 10.1046/j.1468-2982.1992.1204254.x; EKBOM K, 1993, ACTA NEUROL SCAND, V88, P63; EKBOM K, 1991, NEW ENGL J MED, V325, P322, DOI 10.1056/nejm199108013250505; FOGAN L, 1985, ARCH NEUROL-CHICAGO, V42, P362, DOI 10.1001/archneur.1985.04060040072015; Goadsby PJ, 2007, CURR NEUROL NEUROSCI, V7, P117, DOI 10.1007/s11910-007-0006-6; KUDROW L, 1981, HEADACHE, V21, P1, DOI 10.1111/j.1526-4610.1981.hed2101001.x; Matharu MS, 2004, ANN NEUROL, V56, P488, DOI 10.1002/ana.20210; May A, 2006, EUR J NEUROL, V13, P1066, DOI 10.1111/j.1468-1331.2006.01566.x; OLESEN J, 1999, FRONTIERS HEADACHE R, V9; Paemeleire K, 2006, NEUROLOGY, V67, P109, DOI 10.1212/01.wnl.0000223332.35936.6e; Rapoport AM, 2007, NEUROLOGY, V69, P821, DOI 10.1212/01.wnl.0000267886.85210.37; Silberstein SD, 2004, CEPHALALGIA, V24, P2, DOI 10.1111/j.1468-2982.2004.00892.x; Sjaastad O, 2003, CEPHALALGIA, V23, P528, DOI 10.1046/j.1468-2982.2003.00585.x; Snijders T. A., 2012, MULTILEVEL ANAL INTR; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; van Vliet JA, 2003, NEUROLOGY, V60, P630, DOI 10.1212/01.WNL.0000046589.45855.30; Yang M, 2000, J ROY STAT SOC A STA, V163, P49, DOI 10.1111/1467-985X.00156	24	195	199	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 9	2009	302	22					2451	2457		10.1001/jama.2009.1855	http://dx.doi.org/10.1001/jama.2009.1855			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	529MD	19996400				2023-01-03	WOS:000272520500024
J	Korenromp, EL; Viisainen, KM				Korenromp, Eline L.; Viisainen, Kirsi M.			ART in rural Uganda-efficient scale-up with home-based care?	LANCET			English	Editorial Material							MORTALITY; PROGRAM; SERVICE		[Korenromp, Eline L.; Viisainen, Kirsi M.] Global Fund Fight AIDS TB & Malaria, CH-1214 Geneva, Switzerland; [Korenromp, Eline L.] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Korenromp, EL (corresponding author), Global Fund Fight AIDS TB & Malaria, CH-1214 Geneva, Switzerland.	eline.korenromp@theglobalfund.org						Amuron B, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-290; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Cleary Susan M, 2006, Cost Eff Resour Alloc, V4, P20, DOI 10.1186/1478-7547-4-20; *GLOB FUND FIGHT A, 2009, VAL MON GLOB FUND SU; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; Koenig SP, 2008, COST EFF RESOUR ALLO, V6, P3; Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095; *UK DEP INT DEV, 2009, ACH UN ACC UKS STRAT; UNAIDS, 2009, WHAT COUNTR NEED INV; *UNAIDS WORLD BANK, 2009, GLOB EC CRIS HIV PRE; *US PEPFAR, 2009, ACT AUTH APPR FISC Y; Vitoria M, 2006, ANTIRETROVIRAL THERA; [WHO UNAIDS UNICEF], 2009, UN ACC SCAL PRIOR HI	13	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC-JAN	2009	374	9707					2034	2035		10.1016/S0140-6736(09)62027-4	http://dx.doi.org/10.1016/S0140-6736(09)62027-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	537OO	19939444				2023-01-03	WOS:000273122900007
J	Moss, AJ; Hall, WJ; Cannom, DS; Klein, H; Brown, MW; Daubert, JP; Estes, NAM; Foster, E; Greenberg, H; Higgins, SL; Pfeffer, MA; Solomon, SD; Wilber, D; Zareba, W				Moss, Arthur J.; Hall, W. Jackson; Cannom, David S.; Klein, Helmut; Brown, Mary W.; Daubert, James P.; Estes, N. A. Mark, III; Foster, Elyse; Greenberg, Henry; Higgins, Steven L.; Pfeffer, Marc A.; Solomon, Scott D.; Wilber, David; Zareba, Wojciech		MADIT-CRT Trial Investigators	Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROPHYLACTIC IMPLANTATION; DEFIBRILLATOR; TRIAL; GUIDELINES; COMMITTEE; CHAMBER	Background: This trial was designed to determine whether cardiac-resynchronization therapy (CRT) with biventricular pacing would reduce the risk of death or heart-failure events in patients with mild cardiac symptoms, a reduced ejection fraction, and a wide QRS complex. Methods: During a 4.5-year period, we enrolled and followed 1820 patients with ischemic or nonischemic cardiomyopathy, an ejection fraction of 30% or less, a QRS duration of 130 msec or more, and New York Heart Association class I or II symptoms. Patients were randomly assigned in a 3:2 ratio to receive CRT plus an implantable cardioverter-defibrillator (ICD) (1089 patients) or an ICD alone (731 patients). The primary end point was death from any cause or a nonfatal heart-failure event (whichever came first). Heart-failure events were diagnosed by physicians who were aware of the treatment assignments, but they were adjudicated by a committee that was unaware of assignments. Results: During an average follow-up of 2.4 years, the primary end point occurred in 187 of 1089 patients in the CRT-ICD group (17.2%) and 185 of 731 patients in the ICD-only group (25.3%) (hazard ratio in the CRT-ICD group, 0.66; 95% confidence interval [CI], 0.52 to 0.84; P=0.001). The benefit did not differ significantly between patients with ischemic cardiomyopathy and those with nonischemic cardiomyopathy. The superiority of CRT was driven by a 41% reduction in the risk of heart-failure events, a finding that was evident primarily in a prespecified subgroup of patients with a QRS duration of 150 msec or more. CRT was associated with a significant reduction in left ventricular volumes and improvement in the ejection fraction. There was no significant difference between the two groups in the overall risk of death, with a 3% annual mortality rate in each treatment group. Serious adverse events were infrequent in the two groups. Conclusions: CRT combined with ICD decreased the risk of heart-failure events in relatively asymptomatic patients with a low ejection fraction and wide QRS complex. (ClinicalTrials.gov number, NCT00180271.) N Engl J Med 2009;361:1329-38.	[Moss, Arthur J.] Univ Rochester, Med Ctr, Heart Res Follow Up Program, Dept Med, Rochester, NY 14642 USA; [Hall, W. Jackson] Univ Rochester, Med Ctr, Dept Biostat & Computat Biol, Rochester, NY 14642 USA; [Cannom, David S.] Hosp Good Samaritan, Div Cardiol, Los Angeles, CA 90017 USA; [Daubert, James P.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; [Estes, N. A. Mark, III] Tufts Univ New England Med Ctr, New England Cardiac Arrhythmia Ctr, Boston, MA USA; [Foster, Elyse] Univ Calif San Francisco, Cardiol Unit, San Francisco, CA 94143 USA; [Greenberg, Henry] St Lukes Roosevelt Hosp, Cardiol Unit, New York, NY 10025 USA; [Higgins, Steven L.] Scripps Mem Hosp, Dept Cardiol, La Jolla, CA USA; [Pfeffer, Marc A.; Solomon, Scott D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; [Wilber, David] Loyola Univ, Med Ctr, Cardiovasc Inst, Chicago, IL 60611 USA	University of Rochester; University of Rochester; Duke University; Tufts Medical Center; University of California System; University of California San Francisco; Mount Sinai St. Luke's; Mount Sinai West; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Loyola University Chicago	Moss, AJ (corresponding author), Univ Rochester, Med Ctr, Heart Res Follow Up Program, Dept Med, Box 653, Rochester, NY 14642 USA.	heartajm@heart.rochester.edu	Solomon, Scott/I-5789-2013; Zhang, Hui/E-8112-2010; Daubert, James P./ABC-1476-2021	Sharma, Arjun/0000-0002-6484-1250; Zhang, Hui/0000-0001-6825-5649; Duru, Firat/0000-0002-4748-0158; Katz, Amos/0000-0003-0422-934X	Boston Scientific to the University of Rochester	Boston Scientific to the University of Rochester	Supported by a research grant from Boston Scientific to the University of Rochester, with funds distributed to the coordination and data center, enrolling centers, core laboratories, committees, and boards under subcontracts from the University of Rochester.	Bardy GH, 2005, NEW ENGL J MED, V352, P2146; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; COX DR, 1972, J R STAT SOC B, V187, P220; Curtis AB, 2009, CIRCULATION, V120, P921, DOI 10.1161/CIRCULATIONAHA.109.890335; Epstein AE, 2008, CIRCULATION, V117, P2820, DOI 10.1161/CIRCUALTIONAHA.108.189741; Goldenberg I, 2006, CIRCULATION, V113, P2810, DOI 10.1161/CIRCULATIONAHA.105.577262; Hall WJ, 2002, BIOMETRIKA, V89, P699, DOI 10.1093/biomet/89.3.699; HEALY B, 1989, NEW ENGL J MED, V320, P949, DOI 10.1056/NEJM198904063201432; Kalbfleisch J.D., 2002, STAT ANAL FAILURE TI; Lang RM, 2005, J AM SOC ECHOCARDIOG, V18, P1440, DOI 10.1016/j.echo.2005.10.005; Linde C, 2008, J AM COLL CARDIOL, V52, P1834, DOI 10.1016/j.jacc.2008.08.027; Moss AJ, 2005, ANN NONINVAS ELECTRO, V10, P34, DOI 10.1111/j.1542-474X.2005.00073.x; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474; Sharma AD, 2005, HEART RHYTHM, V2, P830, DOI 10.1016/j.hrthm.2005.05.015; Skali H, 2006, CIRCULATION, V114, P2298, DOI 10.1161/CIRCULATIONAHA.106.620039; WANG SK, 1987, BIOMETRICS, V43, P193, DOI 10.2307/2531959; Wilkoff BL, 2002, JAMA-J AM MED ASSOC, V288, P3115	19	1993	2067	2	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 1	2009	361	14					1329	1338		10.1056/NEJMoa0906431	http://dx.doi.org/10.1056/NEJMoa0906431			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500KZ	19723701	Bronze			2023-01-03	WOS:000270300000007
J	Cho, SS; Strafella, AP				Cho, Sang Soo; Strafella, Antonio P.			rTMS of the Left Dorsolateral Prefrontal Cortex Modulates Dopamine Release in the Ipsilateral Anterior Cingulate Cortex and Orbitofrontal Cortex	PLOS ONE			English	Article								Background: Brain dopamine is implicated in the regulation of movement, attention, reward and learning and plays an important role in Parkinson's disease, schizophrenia and drug addiction. Animal experiments have demonstrated that brain stimulation is able to induce significant dopaminergic changes in extrastriatal areas. Given the up-growing interest of non-invasive brain stimulation as potential tool for treatment of neurological and psychiatric disorders, it would be critical to investigate dopaminergic functional interactions in the prefrontal cortex and more in particular the effect of dorsolateral prefrontal cortex (DLPFC) (areas 9/46) stimulation on prefrontal dopamine (DA). Methodology/Principal Findings: Healthy volunteers were studied with a high-affinity DA D2-receptor radioligand, [C-11] FLB 457-PET following 10 Hz repetitive transcranial magnetic stimulation (rTMS) of the left and right DLPFC. rTMS on the left DLPFC induced a significant reduction in [C-11] FLB 457 binding potential (BP) in the ipsilateral subgenual anterior cingulate cortex (ACC) (BA 25/12), pregenual ACC (BA 32) and medial orbitofrontal cortex (BA 11). There were no significant changes in [C-11] FLB 457 BP following right DLPFC rTMS. Conclusions/Significance: To our knowledge, this is the first study to provide evidence of extrastriatal DA modulation following acute rTMS of DLPFC with its effect limited to the specific areas of medial prefrontal cortex. [C-11] FLB 457-PET combined with rTMS may allow to explore the neurochemical functions of specific cortical neural networks and help to identify the neurobiological effects of TMS for the treatment of different neurological and psychiatric diseases.			Cho, SS (corresponding author), Univ Toronto, UHN, Toronto Western Res Inst & Hosp, Toronto, ON, Canada.	antonio.strafella@uhnres.utoronto.ca	cho, sang soo/J-2990-2015	cho, sang soo/0000-0002-4280-5099				Aalto S, 2005, J NEUROSCI, V25, P2471, DOI 10.1523/JNEUROSCI.2097-04.2005; Aalto S, 2005, PSYCHOPHARMACOLOGY, V182, P375, DOI 10.1007/s00213-005-0092-6; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; BEAN AJ, 1991, J NEUROSCI, V11, P2694; BEAN AJ, 1989, J NEUROCHEM, V53, P655, DOI 10.1111/j.1471-4159.1989.tb07384.x; BenShachar D, 1997, J NEURAL TRANSM, V104, P191, DOI 10.1007/BF01273180; Bigliani V, 2000, PSYCHOPHARMACOLOGY, V150, P132, DOI 10.1007/s002130000435; Brooks DJ, 2001, J NEURAL TRANSM, V108, P1283, DOI 10.1007/s007020100005; Brunelin J, 2007, ENCEPHALE, V33, P126; Carlson JN, 1996, BRAIN RES, V711, P1, DOI 10.1016/0006-8993(95)01290-7; CARLSSON M, 1990, TRENDS NEUROSCI, V13, P272, DOI 10.1016/0166-2236(90)90108-M; Carr DB, 2000, J NEUROSCI, V20, P3864, DOI 10.1523/JNEUROSCI.20-10-03864.2000; Chou YH, 2000, SYNAPSE, V38, P138, DOI 10.1002/1098-2396(200011)38:2<138::AID-SYN4>3.0.CO;2-7; Christian BT, 2006, NEUROIMAGE, V31, P139, DOI 10.1016/j.neuroimage.2005.11.052; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; Farde L, 1997, PSYCHOPHARMACOLOGY, V133, P396, DOI 10.1007/s002130050420; Friston KJ, 1996, NEUROIMAGE, V4, P223, DOI 10.1006/nimg.1996.0074; GRACE AA, 1991, NEUROSCIENCE, V41, P1, DOI 10.1016/0306-4522(91)90196-U; Grace AA, 2000, ADDICTION, V95, pS119; Gunn RN, 1997, NEUROIMAGE, V6, P279, DOI 10.1006/nimg.1997.0303; Gusnard DA, 2001, P NATL ACAD SCI USA, V98, P4259, DOI 10.1073/pnas.071043098; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagelberg N, 2004, PAIN, V109, P86, DOI 10.1016/j.pain.2004.01.013; Isenberg Keith, 2005, Ann Clin Psychiatry, V17, P153, DOI 10.1080/10401230591002110; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P2015, DOI 10.1016/S1388-2457(01)00673-3; Kanno M, 2004, J NEUROL SCI, V217, P73, DOI 10.1016/j.jns.2003.08.013; Karreman M, 1996, J NEUROCHEM, V66, P589; Keck ME, 2002, NEUROPHARMACOLOGY, V43, P101, DOI 10.1016/S0028-3908(02)00069-2; Keck ME, 2000, EUR J NEUROSCI, V12, P3713, DOI 10.1046/j.1460-9568.2000.00243.x; KESSLER RM, 1993, BRAIN RES, V609, P237, DOI 10.1016/0006-8993(93)90878-Q; Khedr EM, 2003, EUR J NEUROL, V10, P567, DOI 10.1046/j.1468-1331.2003.00649.x; Knoch D, 2006, NEUROIMAGE, V31, P641, DOI 10.1016/j.neuroimage.2005.12.025; Knoch D, 2006, J NEUROSCI, V26, P6469, DOI 10.1523/JNEUROSCI.0804-06.2006; Ko JH, 2008, EUR J NEUROSCI, V28, P2147, DOI 10.1111/j.1460-9568.2008.06501.x; Koch G, 2003, NEUROLOGY, V60, P1844, DOI 10.1212/WNL.60.11.1844; Koski L, 2000, EXP BRAIN RES, V133, P55, DOI 10.1007/s002210000400; Lammertsma AA, 1996, NEUROIMAGE, V4, P153, DOI 10.1006/nimg.1996.0066; Lumme V, 2007, PSYCHIAT RES-NEUROIM, V156, P69, DOI 10.1016/j.pscychresns.2006.12.012; Margulies DS, 2007, NEUROIMAGE, V37, P579, DOI 10.1016/j.neuroimage.2007.05.019; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Middleton FA, 2001, J NEUROSCI, V21, P700, DOI 10.1523/JNEUROSCI.21-02-00700.2001; Montgomery AJ, 2007, J CEREBR BLOOD F MET, V27, P369, DOI 10.1038/sj.jcbfm.9600339; MURASE S, 1993, NEUROSCI LETT, V157, P53, DOI 10.1016/0304-3940(93)90641-W; Nieoullon A, 2002, PROG NEUROBIOL, V67, P53, DOI 10.1016/S0301-0082(02)00011-4; O'Reardon JP, 2007, BIOL PSYCHIAT, V62, P1208, DOI 10.1016/j.biopsych.2007.01.018; Olsson H, 2004, NEUROIMAGE, V22, P794, DOI 10.1016/j.neuroimage.2004.02.002; Olsson H, 1999, J CEREBR BLOOD F MET, V19, P1164, DOI 10.1097/00004647-199910000-00013; Padberg F, 2002, NEUROPSYCHOPHARMACOL, V27, P638; Pascual-Leone A, 1998, J CLIN NEUROPHYSIOL, V15, P333, DOI 10.1097/00004691-199807000-00005; Paus T, 2001, NAT REV NEUROSCI, V2, P417, DOI 10.1038/35077500; Paus T, 2001, EUR J NEUROSCI, V14, P1405, DOI 10.1046/j.0953-816x.2001.01757.x; Petrides M, 1999, EUR J NEUROSCI, V11, P1011, DOI 10.1046/j.1460-9568.1999.00518.x; Pogarell O, 2007, PSYCHIAT RES-NEUROIM, V156, P251, DOI 10.1016/j.pscychresns.2007.05.002; Pogarell O, 2006, J PSYCHIATR RES, V40, P307, DOI 10.1016/j.jpsychires.2005.09.001; Sandrini M, 2008, NEUROPSYCHOLOGIA, V46, P2056, DOI 10.1016/j.neuropsychologia.2008.02.003; Schmahmann JD, 1997, J NEUROSCI, V17, P438, DOI 10.1523/JNEUROSCI.17-01-00438.1997; Schultz W, 2001, NEUROSCIENTIST, V7, P293, DOI 10.1177/107385840100700406; Slifstein M, 2004, SYNAPSE, V54, P46, DOI 10.1002/syn.20062; Stern WM, 2007, J NEUROPSYCH CLIN N, V19, P179, DOI 10.1176/appi.neuropsych.19.2.179; Strafella AP, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0003.2001; Strafella AP, 2005, EUR J NEUROSCI, V22, P2946, DOI 10.1111/j.1460-9568.2005.04476.x; Strafella AP, 2003, BRAIN, V126, P2609, DOI 10.1093/brain/awg268; TABER MT, 1995, J NEUROCHEM, V65, P1407; TABER MT, 1993, NEUROPSYCHOPHARMACOL, V9, P271, DOI 10.1038/npp.1993.63; Toga AW, 2003, NAT REV NEUROSCI, V4, P37, DOI 10.1038/nrn1009; VOGT BA, 1992, CEREB CORTEX, V2, P435, DOI 10.1093/cercor/2.6.435-a; VOGT BA, 1987, J COMP NEUROL, V262, P271, DOI 10.1002/cne.902620208; Volkow ND, 2004, NEUROPHARMACOLOGY, V47, P3, DOI 10.1016/j.neuropharm.2004.07.019; Wassermann EM, 2001, CLIN NEUROPHYSIOL, V112, P1367, DOI 10.1016/S1388-2457(01)00585-5; Westerink BHC, 1998, J PHARMACOL EXP THER, V285, P143; Williams SM, 1998, CEREB CORTEX, V8, P321, DOI 10.1093/cercor/8.4.321	71	268	279	0	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2009	4	8							e6725	10.1371/journal.pone.0006725	http://dx.doi.org/10.1371/journal.pone.0006725			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	487JB	19696930	Green Submitted, gold, Green Published			2023-01-03	WOS:000269267600013
J	Murakami, E; Tolstykh, T; Bao, HY; Niu, CR; Steuer, HMM; Bao, DH; Chang, W; Espiritu, C; Bansal, S; Lam, AM; Otto, MJ; Sofia, MJ; Furman, PA				Murakami, Eisuke; Tolstykh, Tatiana; Bao, Haiying; Niu, Congrong; Steuer, Holly M. Micolochick; Bao, Donghui; Chang, Wonsuk; Espiritu, Christine; Bansal, Shalini; Lam, Angela M.; Otto, Michael J.; Sofia, Michael J.; Furman, Phillip A.			Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE ANALOG INHIBITORS; C VIRUS-REPLICATION; HEPATITIS-C; PHOSPHORAMIDATE DERIVATIVES; CARBOXYLESTERASE ISOZYMES; SUBSTRATE-SPECIFICITY; RNA-POLYMERASE; HUMAN-LIVER; HYDROLYSIS; HIV	A phosphoramidate prodrug of 2'-deoxy-2'-alpha-fluoro-beta-C-methyluridine-5'-monophosphate, PSI-7851, demonstrates potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. PSI-7851 is a mixture of two diastereoisomers, PSI-7976 and PSI-7977, with PSI-7977 being the more active inhibitor of HCV RNA replication in the HCV replicon assay. To inhibit the HCV NS5B RNA-dependent RNA polymerase, PSI-7851 must be metabolized to the active triphosphate form. The first step, hydrolysis of the carboxyl ester by human cathepsin A (CatA) and/or carboxylesterase 1 (CES1), is a stereospecific reaction. Western blot analysis showed that CatA and CES1 are both expressed in primary human hepatocytes. However, expression of CES1 is undetectable in clone A replicon cells. Studies with inhibitors of CatA and/or CES1 indicated that CatA is primarily responsible for hydrolysis of the carboxyl ester in clone A cells, although in primary human hepatocytes, both CatA and CES1 contribute to the hydrolysis. Hydrolysis of the ester is followed by a putative nucleophilic attack on the phosphorus by the carboxyl group resulting in the spontaneous elimination of phenol and the production of an alaninyl phosphate metabolite, PSI-352707, which is common to both isomers. The removal of the amino acid moiety of PSI-352707 is catalyzed by histidine triad nucleotide-binding protein 1 (Hint1) to give the 5'-monophosphate form, PSI-7411. siRNA-mediated Hint1 knockdown studies further indicate that Hint1 is, at least in part, responsible for converting PSI-352707 to PSI-7411. PSI-7411 is then consecutively phosphorylated to the diphosphate, PSI-7410, and to the active triphosphate metabolite, PSI-7409, by UMP-CMP kinase and nucleoside diphosphate kinase, respectively.	[Murakami, Eisuke; Tolstykh, Tatiana; Bao, Haiying; Niu, Congrong; Steuer, Holly M. Micolochick; Bao, Donghui; Chang, Wonsuk; Espiritu, Christine; Bansal, Shalini; Lam, Angela M.; Otto, Michael J.; Sofia, Michael J.; Furman, Phillip A.] Pharmasset Inc, Princeton, NJ 08540 USA		Murakami, E (corresponding author), 303 A Coll Rd E, Princeton, NJ 08540 USA.	emurakami@pharmasset.com; pfurman@pharmasset.com		Chang, Wonsuk/0000-0003-4697-4663				Birkus G, 2007, ANTIMICROB AGENTS CH, V51, P543, DOI 10.1128/AAC.00968-06; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; BLOCK W, 1978, BIOCHIM BIOPHYS ACTA, V524, P85, DOI 10.1016/0005-2744(78)90106-7; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Carroll S. S., 2006, Infectious Disorders - Drug Targets, V6, P17, DOI 10.2174/187152606776056698; Chou TF, 2005, J BIOL CHEM, V280, P15356, DOI 10.1074/jbc.M500434200; Chou TF, 2007, J BIOL CHEM, V282, P15137, DOI 10.1074/jbc.M606972200; Chou TF, 2007, J MOL BIOL, V373, P978, DOI 10.1016/j.jmb.2007.08.023; Chou TF, 2007, MOL PHARMACEUT, V4, P208, DOI 10.1021/mp060070y; Crow JA, 2007, TOXICOL APPL PHARM, V221, P1, DOI 10.1016/j.taap.2007.03.002; De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424; Derudas M, 2009, J MED CHEM, V52, P5520, DOI 10.1021/jm9007856; DUARTE MIS, 1989, J SUBMICR CYTOL PATH, V21, P275; FE RIRG, 2008, REV MED VIROL */* E, V18, P19; Forestier N, 2007, HEPATOLOGY, V46, P640, DOI 10.1002/hep.21774; Furman PA, 2009, FUTURE MED CHEM, V1, P1429, DOI 10.4155/FMC.09.88; Hewlett G, 2004, CURR OPIN PHARMACOL, V4, P453, DOI 10.1016/j.coph.2004.06.004; Hiraiwa M, 1999, CELL MOL LIFE SCI, V56, P894, DOI 10.1007/s000180050482; Huang HZ, 2005, CHEM RES TOXICOL, V18, P1371, DOI 10.1021/tx050072+; Imai T, 2006, DRUG METAB PHARMACOK, V21, P173, DOI 10.2133/dmpk.21.173; Imai T, 2006, DRUG METAB DISPOS, V34, P1734, DOI 10.1124/dmd.106.009381; Kwong AD, 2008, CURR OPIN PHARMACOL, V8, P522, DOI 10.1016/j.coph.2008.09.007; Liverton NJ, 2010, ANTIMICROB AGENTS CH, V54, P305, DOI 10.1128/AAC.00677-09; Ma H, 2007, J BIOL CHEM, V282, P29812, DOI 10.1074/jbc.M705274200; McGuigan C, 1998, ANTIVIR CHEM CHEMOTH, V9, P473, DOI 10.1177/095632029800900603; McGuigan C, 1998, ANTIVIR CHEM CHEMOTH, V9, P109, DOI 10.1177/095632029800900202; Murakami E, 2008, ANTIMICROB AGENTS CH, V52, P458, DOI 10.1128/AAC.01184-07; Murakami E, 2007, ANTIMICROB AGENTS CH, V51, P503, DOI 10.1128/AAC.00400-06; NAESENS L, 2001, E Herpes, V8, P12; Stuyver Lieven J., 2006, Antiviral Chemistry & Chemotherapy, V17, P79; Stuyver LJ, 2003, J VIROL, V77, P10689, DOI 10.1128/JVI.77.19.10689-10694.2003; Sun ZJ, 2004, J PHARMACOL EXP THER, V310, P469, DOI 10.1124/jpet.104.067116; Valette G, 1996, J MED CHEM, V39, P1981, DOI 10.1021/jm9507338; Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x; Yang DF, 2009, BIOCHEM PHARMACOL, V77, P238, DOI 10.1016/j.bcp.2008.10.005; Yang J, 2007, MOL PHARMACOL, V72, P686, DOI 10.1124/mol.107.036889	36	211	258	3	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 5	2010	285	45					34337	34347		10.1074/jbc.M110.161802	http://dx.doi.org/10.1074/jbc.M110.161802			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	673KL	20801890	Green Published, hybrid			2023-01-03	WOS:000283659100007
J	Curtis, JR; Vincent, JL				Curtis, J. Randall; Vincent, Jean-Louis			Critical Care 2 Ethics and end-of-life care for adults in the intensive care unit	LANCET			English	Article							RANDOMIZED CONTROLLED-TRIAL; SURROGATE DECISION-MAKING; ICU FAMILY CONFERENCES; MECHANICAL VENTILATION; ILL PATIENTS; SUSTAINING TREATMENTS; ADVANCE DIRECTIVES; PALLIATIVE CARE; NURSING STAFF; NORTH-AMERICA	The intensive care unit (ICU) is where patients are given some of the most technologically advanced life-sustaining treatments, and where difficult decisions are made about the usefulness of such treatments. The substantial regional variability in these ethical decisions is a result of many factors, including religious and cultural beliefs. Because most critically ill patients lack the capacity to make decisions, family and other individuals often act as the surrogate decision makers, and in many regions communication between the clinician and family is central to decision making in the ICU. Elsewhere, involvement of the family is reduced and that of the physicians is increased. End-of-life care is associated with increased burnout and distress among clinicians working in the ICU. Since many deaths in the ICU are preceded by a decision to withhold or withdraw life support, high-quality decision making and end-of-life care are essential in all regions, and can improve patient and family outcomes, and also retention of clinicians working in the ICU. To make such a decision requires adequate training, good communication between the clinician and family, and the collaboration of a well functioning interdisciplinary team.	[Curtis, J. Randall] Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Seattle, WA 98104 USA; [Vincent, Jean-Louis] Univ Libre Bruxelles, Erasme Hosp, Dept Intens Care, Brussels, Belgium	Harborview Medical Center; University of Washington; University of Washington Seattle; Universite Libre de Bruxelles	Curtis, JR (corresponding author), Univ Washington, Harborview Med Ctr, Div Pulm & Crit Care Med, Box 359762,325 9Th Ave, Seattle, WA 98104 USA.	jrc@u.washington.edu		Vincent, Jean-Louis/0000-0001-6011-6951	National Institute of Nursing Research [R01NR-05226]; NATIONAL INSTITUTE OF NURSING RESEARCH [R01NR005226] Funding Source: NIH RePORTER	National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Funding was provided by a grant from the National Institute of Nursing Research (R01NR-05226 to JRC). The sponsor was not involved in developing, drafting, or reviewing the report, or in the decision to publish.	American Thoracic Society, 1991, Ann Intern Med, V115, P478; Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Azoulay E, 2005, AM J RESP CRIT CARE, V171, P987, DOI 10.1164/rccm.200409-1295OC; Azoulay E, 2000, CRIT CARE MED, V28, P3044, DOI 10.1097/00003246-200008000-00061; Azoulay E, 2004, CRIT CARE MED, V32, P1832, DOI 10.1097/01.CCM.0000139693.88931.59; Azoulay E, 2009, AM J RESP CRIT CARE, V180, P853, DOI 10.1164/rccm.200810-1614OC; Azoulay E, 2009, INTENS CARE MED, V35, P623, DOI 10.1007/s00134-008-1310-6; Bakker J, 2008, AM J HOSP PALLIAT ME, V25, P152, DOI 10.1177/1049909108315511; Benbenishty J, 2006, INTENS CARE MED, V32, P129, DOI 10.1007/s00134-005-2864-1; Buckley TA, 2004, CRIT CARE MED, V32, P415, DOI 10.1097/01.CCM.0000110675.34569.A9; Bulow HH, 2008, INTENS CARE MED, V34, P423, DOI 10.1007/s00134-007-0973-8; Campbell ML, 1999, CRIT CARE MED, V27, P73, DOI 10.1097/00003246-199901000-00029; Carlet J, 2004, INTENS CARE MED, V30, P770, DOI 10.1007/s00134-004-2241-5; Carline JD, 2003, J PAIN SYMPTOM MANAG, V25, P19, DOI 10.1016/S0885-3924(02)00537-7; Chan JD, 2004, CHEST, V126, P286, DOI 10.1378/chest.126.1.286; Cohen S, 2005, INTENS CARE MED, V31, P1215, DOI 10.1007/s00134-005-2742-x; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; COOK DJ, 1995, JAMA-J AM MED ASSOC, V273, P703, DOI 10.1001/jama.273.9.703; Curtis JR, 2008, CHEST, V134, P835, DOI 10.1378/chest.08-0235; Curtis JR, 2005, AM J RESP CRIT CARE, V171, P844, DOI 10.1164/rccm.200409-1267OC; *DEP HLTH NAT EX, 1996, GUID ADM DISCH INT C; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Egol A, 1999, CRIT CARE MED, V27, P633; Ehlenbach WJ, 2009, NEW ENGL J MED, V361, P22, DOI 10.1056/NEJMoa0810245; Embriaco N, 2007, AM J RESP CRIT CARE, V175, P686, DOI 10.1164/rccm.200608-1184OC; Esteban A, 2001, INTENS CARE MED, V27, P1744, DOI 10.1007/s00134-001-1111-7; Evans LR, 2009, AM J RESP CRIT CARE, V179, P48, DOI 10.1164/rccm.200806-969OC; Ferrand E, 2003, AM J RESP CRIT CARE, V167, P1310, DOI 10.1164/rccm.200207-752OC; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Gajewska K, 2004, INTENS CARE MED, V30, P1224, DOI 10.1007/s00134-004-2308-3; Garland A, 2007, J PALLIAT MED, V10, P1298, DOI 10.1089/jpm.2007.0061; Gerstel E, 2008, AM J RESP CRIT CARE, V178, P798, DOI 10.1164/rccm.200711-1617OC; Giannini A, 2003, INTENS CARE MED, V29, P1902, DOI 10.1007/s00134-003-1919-4; Gries CJ, 2008, CHEST, V133, P704, DOI 10.1378/chest.07-1773; Heyland DK, 2003, CHEST, V124, P392, DOI 10.1378/chest.124.1.392; Heyland DK, 2003, J CRIT CARE, V18, P3, DOI 10.1053/jcrc.2003.YJCRC2; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Keenan SP, 1998, CRIT CARE MED, V26, P245, DOI 10.1097/00003246-199802000-00018; Kollef MH, 1999, CRIT CARE MED, V27, P2125, DOI 10.1097/00003246-199910000-00008; Kompanje EJO, 2008, INTENS CARE MED, V34, P1593, DOI 10.1007/s00134-008-1172-y; Lanken PN, 2008, AM J RESP CRIT CARE, V177, P912, DOI 10.1164/rccm.200605-587ST; Lanken PN, 1997, AM J RESP CRIT CARE, V156, P1282; Levin PD, 2005, CRIT CARE, V9, P230, DOI 10.1186/cc3487; Luce JM, 2000, AM J RESP CRIT CARE, V162, P2029, DOI 10.1164/ajrccm.162.6.1-00; Luce JM, 2007, AM J RESP CRIT CARE, V175, P1104, DOI 10.1164/rccm.200609-1397CP; Mani RK, 2009, INTENS CARE MED, V35, P1713, DOI 10.1007/s00134-009-1561-x; McDonagh JR, 2004, CRIT CARE MED, V32, P1484, DOI 10.1097/01.CCM.0000127262.16690.65; Mealer ML, 2007, AM J RESP CRIT CARE, V175, P693, DOI 10.1164/rccm.200606-735OC; Melltorp G, 1997, INTENS CARE MED, V23, P1264, DOI 10.1007/s001340050496; Moselli NM, 2006, ACTA ANAESTH SCAND, V50, P1177, DOI 10.1111/j.1399-6576.2006.01150.x; Nolin T, 2003, ACTA ANAESTH SCAND, V47, P501, DOI 10.1034/j.1399-6576.2003.00128.x; Norris K, 2007, J PALLIAT MED, V10, P1101, DOI 10.1089/jpm.2006.2546; Norris Wendi M, 2005, J Palliat Med, V8, P1016, DOI 10.1089/jpm.2005.8.1016; Pham K, 2008, CHEST, V134, P109, DOI 10.1378/chest.07-2852; Pochard F, 2001, CRIT CARE MED, V29, P1893, DOI 10.1097/00003246-200110000-00007; Poncet MC, 2007, AM J RESP CRIT CARE, V175, P698, DOI 10.1164/rccm.200606-806OC; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Ravitsky V, 2005, BRIT MED J, V330, P415, DOI 10.1136/bmj.330.7488.415; Schneiderman LJ, 2003, JAMA-J AM MED ASSOC, V290, P1166, DOI 10.1001/jama.290.9.1166; Selph RB, 2008, J GEN INTERN MED, V23, P1311, DOI 10.1007/s11606-008-0643-8; Silveira MJ, 2010, NEW ENGL J MED, V362, P1211, DOI 10.1056/NEJMsa0907901; Sprung CL, 2007, INTENS CARE MED, V33, P1732, DOI 10.1007/s00134-007-0693-0; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Stapleton RD, 2006, CRIT CARE MED, V34, P1679, DOI 10.1097/01.CCM.0000218409.58256.AA; Steinberg A, 2006, INTENS CARE MED, V32, P1234, DOI 10.1007/s00134-006-0186-6; Studdert DM, 2003, INTENS CARE MED, V29, P1489, DOI 10.1007/s00134-003-1853-5; Teno JM, 2007, J AM GERIATR SOC, V55, P189, DOI 10.1111/j.1532-5415.2007.01045.x; Thornton JD, 2009, CRIT CARE MED, V37, P89, DOI 10.1097/CCM.0b013e3181926430; Treece PD, 2004, CRIT CARE MED, V32, P1141, DOI 10.1097/01.CCM.0000125509.34805.0C; Truog RD, 2008, CRIT CARE MED, V36, P953, DOI 10.1097/CCM.0B013E3181659096; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; Vincent JL, 1997, INTENS CARE MED, V23, P1181, DOI 10.1007/s001340050479; Vincent JL, 1999, CRIT CARE MED, V27, P1626, DOI 10.1097/00003246-199908000-00042; Wall RJ, 2007, CHEST, V132, P1425, DOI 10.1378/chest.07-0419; Wall RJ, 2007, CRIT CARE MED, V35, P1084, DOI 10.1097/01.CCM.0000259382.36414.06; West Heather F, 2005, J Palliat Med, V8, P797, DOI 10.1089/jpm.2005.8.797; White DB, 2010, CRIT CARE MED, V38, P743, DOI 10.1097/CCM.0b013e3181c58842; White DB, 2009, AM J RESP CRIT CARE, V180, P320, DOI 10.1164/rccm.200811-1776OC; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Wunsch H, 2005, INTENS CARE MED, V31, P823, DOI 10.1007/s00134-005-2644-y; Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8; Yaguchi A, 2005, ARCH INTERN MED, V165, P1970, DOI 10.1001/archinte.165.17.1970; Yazigi A, 2005, INTENS CARE MED, V31, P562, DOI 10.1007/s00134-005-2578-4; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	85	204	211	4	44	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1347	1353		10.1016/S0140-6736(10)60143-2	http://dx.doi.org/10.1016/S0140-6736(10)60143-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20934213				2023-01-03	WOS:000283528600038
J	Lachman, ME; Agrigoroaei, S				Lachman, Margie E.; Agrigoroaei, Stefan			Promoting Functional Health in Midlife and Old Age: Long-Term Protective Effects of Control Beliefs, Social Support, and Physical Exercise	PLOS ONE			English	Article							QUALITY-OF-LIFE; ELDERLY POPULATION; PERCEIVED CONTROL; ACTIVITY PROGRAMS; ALLOSTATIC LOAD; UNITED-STATES; RISK-FACTORS; DISABILITY; PREDICTORS; MACARTHUR	Background: Previous studies have examined physical risk factors in relation to functional health, but less work has focused on the protective role of psychological and social factors. We examined the individual and joint protective contribution of control beliefs, social support and physical exercise to changes in functional health, beyond the influence of health status and physical risk factors in middle-aged and older adults. Given that functional health typically declines throughout adulthood, it is important to identify modifiable factors that can be implemented to maintain functioning, improve quality of life, and reduce disability. Methodology/Principal Findings: We conducted a national longitudinal study, Midlife in the United States (MIDUS), with assessments in 1995-1996 and 2004-2006, and 3,626 community-residing adults, aged 32 to 84, were included in the analyses. Functional health (Physical Functioning subscale of the SF-36) and protective factors were measured at both occasions. While controlling for socio-demographic, health status, and physical risk factors (large waist circumference, smoking, and alcohol or drug problems), a composite of the three protective variables (control beliefs, social support, and physical exercise) at Time 1 was significantly related to functional health change. The more of these factors at Time 1, the better the health maintenance over 10 years. Among middle-aged and older adults, declines in health were significantly reduced with an increased number of protective factors. Conclusion/Significance: Age-related declines in health were reduced among those with more protective factors up to a decade earlier in life. Modifiable psychological, social, and physical protective factors, individually and in the aggregate, are associated with maintenance of functional health, beyond the damaging effects of physical risk factors. The results are encouraging for the prospect of developing interventions to promote functional health and for reducing public health expenditures for physical disability in later life.	[Lachman, Margie E.; Agrigoroaei, Stefan] Brandeis Univ, Dept Psychol, Waltham, MA 02254 USA	Brandeis University	Lachman, ME (corresponding author), Brandeis Univ, Dept Psychol, Waltham, MA 02254 USA.	Lachman@brandeis.edu		Lachman, Margie/0000-0003-3027-8735	National Institute on Aging [PO1 AG20166, RO1 AG17920, RO1 AG032271]; NATIONAL INSTITUTE ON AGING [R01AG017920, P01AG020166, R01AG032271] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by grants (PO1 AG20166, RO1 AG17920, RO1 AG032271) from the National Institute on Aging (http://www.nia.nih.gov/). The first wave of the study was supported by the John D. and Catherine T. MacArthur Foundation Research Network on Successful Midlife Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert MS, 1995, PSYCHOL AGING, V10, P578, DOI 10.1037/0882-7974.10.4.578; Alley DE, 2007, JAMA-J AM MED ASSOC, V298, P2020, DOI 10.1001/jama.298.17.2020; Anderson RT, 1998, J GERONTOL B-PSYCHOL, V53, pS17, DOI 10.1093/geronb/53B.1.S17; Andrew MK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002232; Antonucci T.C., 2001, HDB PSYCHOL AGING, P427, DOI DOI 10.1016/B0-08-043076-7/01699-5; Antonucci T.C., 2009, HDB THEORIES AGING, V2nd ed., P247; Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; Berkman LF, 2000, SOC SCI MED, V51, P843, DOI 10.1016/S0277-9536(00)00065-4; Berkman LE, 2009, ANNU REV PUBL HEALTH, V30, P27, DOI 10.1146/annurev.publhealth.031308.100310; Boyle PA, 2007, J AM GERIATR SOC, V55, P195, DOI 10.1111/j.1532-5415.2007.01038.x; Brim O.G., 2004, HLTH ARE WE NATL STU; Britton A, 2008, J AM GERIATR SOC, V56, P1098, DOI 10.1111/j.1532-5415.2008.01740.x; Busetto L, 2009, J AM GERIATR SOC, V57, P1015, DOI 10.1111/j.1532-5415.2009.02273.x; Centers for Disease Control and Prevention National Center for Health Statistics, HLTH DAT INT; Chen HL, 2008, J AM GERIATR SOC, V56, P689, DOI 10.1111/j.1532-5415.2007.01624.x; Chipperfield JG, 2004, J AGING HEALTH, V16, P116, DOI 10.1177/0898264303260447; Cohen J., 2003, APPL MULTIPLE REGRES, V3rd; Cooney MT, 2009, J AM COLL CARDIOL, V54, P1209, DOI 10.1016/j.jacc.2009.07.020; Cotter KA, 2010, PSYCHOL HEALTH, V25, P805, DOI 10.1080/08870440902883212; Ferrer E, 2010, CURR DIR PSYCHOL SCI, V19, P149, DOI 10.1177/0963721410370300; Ferrucci L, 1999, J AM GERIATR SOC, V47, P639, DOI 10.1111/j.1532-5415.1999.tb01583.x; Fiatarone MA, 1996, RES Q EXERCISE SPORT, V67, pS70; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; Freedman VA, 2002, JAMA-J AM MED ASSOC, V288, P3137, DOI 10.1001/jama.288.24.3137; Freedman VA, 1998, AM J PUBLIC HEALTH, V88, P1457, DOI 10.2105/AJPH.88.10.1457; Fries JF, 2002, JAMA-J AM MED ASSOC, V288, P3164, DOI 10.1001/jama.288.24.3164; Gruenewald TL, 2009, J AM GERIATR SOC, V57, P1525, DOI 10.1111/j.1532-5415.2009.02389.x; GURALNIK JM, 1989, AM J PUBLIC HEALTH, V79, P703, DOI 10.2105/AJPH.79.6.703; Hanson GR, 2003, JAMA-J AM MED ASSOC, V289, P1031, DOI 10.1001/jama.289.8.1031; He XXZ, 2004, AM J PUBLIC HEALTH, V94, P1567, DOI 10.2105/AJPH.94.9.1567; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; Hubbard RE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006174; Jette AM, 1999, AM J PUBLIC HEALTH, V89, P66, DOI 10.2105/AJPH.89.1.66; Jette AM, 1998, GERONTOLOGIST, V38, P412, DOI 10.1093/geront/38.4.412; Johnstone B, 2009, REHABIL PSYCHOL, V54, P422, DOI 10.1037/a0017758; Khaw KT, 2008, PLOS MED, V5, P39, DOI 10.1371/journal.pmed.0050012; Kim JY, 2007, SOC SCI MED, V65, P2489, DOI 10.1016/j.socscimed.2007.07.022; King AC, 2000, J GERONTOL A-BIOL, V55, pM74; Krause N, 2003, RES AGING, V25, P559, DOI 10.1177/0164027503256695; Kvaavik E, 2010, ARCH INTERN MED, V170, P711, DOI 10.1001/archinternmed.2010.76; Lachman ME, 1986, PSYCHOL AGING, V1, P34, DOI 10.1037/0882-7974.1.1.34; Lachman ME, 2008, PSYCHOL SCI, V19, P889, DOI 10.1111/j.1467-9280.2008.02173.x; Lachman ME, 2006, CURR DIR PSYCHOL SCI, V15, P282, DOI 10.1111/j.1467-8721.2006.00453.x; Lachman ME, 2004, ANNU REV PSYCHOL, V55, P305, DOI 10.1146/annurev.psych.55.090902.141521; Lachman ME, 1998, J PERS SOC PSYCHOL, V74, P763, DOI 10.1037/0022-3514.74.3.763; LACHMAN ME, 2004, HLTH ARE WE NATL STU; LACHMAN ME, HDB PSYCHOL IN PRESS; Levy BR, 2002, J GERONTOL B-PSYCHOL, V57, pP409, DOI 10.1093/geronb/57.5.P409; Manandhar MC, 1995, P NUTR SOC, V54, P677, DOI 10.1079/PNS19950067; MARMOT MG, 2004, STATUS SYNDROME SOCI, P319; Mavandadi S, 2007, J GERONTOL B-PSYCHOL, V62, pS361, DOI 10.1093/geronb/62.6.S361; McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071; Miller RR, 2004, J AM GERIATR SOC, V52, P217, DOI 10.1046/j.0002-8614.2004.52057.x; MIROWSKY J, 1995, SOC PSYCHOL QUART, V58, P31, DOI 10.2307/2787141; MOR V, 1994, AM J PUBLIC HEALTH, V84, P1274, DOI 10.2105/AJPH.84.8.1274; Murabito JM, 2008, AM J PUBLIC HEALTH, V98, P1256, DOI 10.2105/AJPH.2007.128132; *NAT CTR HLTH STAT, 2008, HLTH US 2008 CHARTB; Newson RS, 2006, EXP AGING RES, V32, P341, DOI 10.1080/03610730600699134; Poortinga W, 2007, PREV MED, V44, P124, DOI 10.1016/j.ypmed.2006.10.006; POPE AM, 1991, DISABILITY AM NATL A; Radler BT, 2010, J AGING HEALTH, V22, P307, DOI 10.1177/0898264309358617; Rains SA, 2009, HUM COMMUN RES, V35, P309, DOI 10.1111/j.1468-2958.2009.01353.x; Rodin J, 1985, Annu Rev Gerontol Geriatr, V5, P3; RODIN J, 1986, SCIENCE, V233, P1271, DOI 10.1126/science.3749877; Rothman AJ, 2006, J COMMUN, V56, pS202, DOI 10.1111/j.1460-2466.2006.00290.x; Rowe J. W., 1998, SUCCESSFUL AGING; Ruger JP, 2010, AM J PUBLIC HEALTH, V100, P41, DOI 10.2105/AJPH.2008.143651; Sapolsky R.M., 1998, WHY ZEBRAS DONT GET; Sarna L, 2008, QUAL LIFE RES, V17, P1217, DOI 10.1007/s11136-008-9404-8; Seeman TE, 1997, ARCH INTERN MED, V157, P2259; SEEMAN TE, 1995, J GERONTOL A-BIOL, V50, pM177, DOI 10.1093/gerona/50A.4.M177; Seeman TE, 2004, SOC SCI MED, V58, P1985, DOI 10.1016/S0277-9536(03)00402-7; Seeman TE, 2010, AM J PUBLIC HEALTH, V100, P100, DOI 10.2105/AJPH.2008.157388; SINGER BH, 2001, NEW HORIZONS HLTH IN; Spencer SM, 2008, J AM GERIATR SOC, V56, P553, DOI 10.1111/j.1532-5415.2007.01595.x; StataCorp, 2009, STAT STAT SOFTW; Stewart AL, 1992, MEASURING FUNCTIONIN, P67; Sturman MT, 2005, ARCH NEUROL-CHICAGO, V62, P1750, DOI 10.1001/archneur.62.11.1750; Syddall HE, 2009, J NUTR HEALTH AGING, V13, P57, DOI 10.1007/s12603-009-0010-4; van Dam RM, 2008, BRIT MED J, V337, pa1440, DOI [DOI 10.1136/BMJ.A1440, 10.1136/bmj.a1440]; Walen HR, 2000, J SOC PERS RELAT, V17, P5, DOI 10.1177/0265407500171001; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; White AM, 2009, AM J PUBLIC HEALTH, V99, P1872, DOI 10.2105/AJPH.2008.146894; Willcox BJ, 2006, JAMA-J AM MED ASSOC, V296, P2343, DOI 10.1001/jama.296.19.2343; Wrosch C, 2009, PSYCHOSOM MED, V71, P996, DOI 10.1097/PSY.0b013e3181ba6cd1; Yan TJ, 2009, GERONTOLOGIST, V49, P847, DOI 10.1093/geront/gnp113	86	100	103	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 11	2010	5	10							e13297	10.1371/journal.pone.0013297	http://dx.doi.org/10.1371/journal.pone.0013297			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	661SK	20949016	Green Published, gold, Green Submitted			2023-01-03	WOS:000282748100023
J	Maggiolo, F; Leone, S				Maggiolo, Franco; Leone, Sebastiano			Is HAART modifying the HIV epidemic?	LANCET			English	Editorial Material							COMBINATION ANTIRETROVIRAL THERAPY; SEXUAL TRANSMISSION; PREVENTION; COHORT		[Maggiolo, Franco; Leone, Sebastiano] Osped Riuniti Bergamo, Div Infect Dis, I-24128 Bergamo, Italy	Ospedali Riuniti di Bergamo	Maggiolo, F (corresponding author), Osped Riuniti Bergamo, Div Infect Dis, I-24128 Bergamo, Italy.	franco31556@hotmail.com						Attia S, 2009, AIDS, V23, P1397, DOI 10.1097/QAD.0b013e32832b7dca; Bertozzi SM, 2008, LANCET, V372, P831, DOI 10.1016/S0140-6736(08)60889-2; Castel A, 2010, 17 C RETR OPP INF CR; Cohen MS, 2005, J INFECT DIS, V191, P1391, DOI 10.1086/429414; Cohen MS, 2007, ANN INTERN MED, V146, P591, DOI 10.7326/0003-4819-146-8-200704170-00010; Cohen MS, 2010, CLIN INFECT DIS, V50, pS85, DOI 10.1086/651478; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) 2009, 2009, AIDS EP UPD DEC 2009; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; Piot P, 2008, LANCET, V372, P845, DOI 10.1016/S0140-6736(08)60888-0; Velasco-Hernandez JX, 2002, LANCET INFECT DIS, V2, P487, DOI 10.1016/S1473-3099(02)00346-8	12	11	11	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 14	2010	376	9740					492	493		10.1016/S0140-6736(10)61057-4	http://dx.doi.org/10.1016/S0140-6736(10)61057-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	643BE	20638714				2023-01-03	WOS:000281266800006
J	Pan, H; Myerson, JW; Ivashyna, O; Soman, NR; Marsh, JN; Hood, JL; Lanza, GM; Schlesinger, PH; Wickline, SA				Pan, Hua; Myerson, Jacob W.; Ivashyna, Olena; Soman, Neelesh R.; Marsh, Jon N.; Hood, Joshua L.; Lanza, Gregory M.; Schlesinger, Paul H.; Wickline, Samuel A.			Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures	FASEB JOURNAL			English	Article						molecular imaging; targeted drug delivery; biomarker; nanoparticles; liposome	ADHESION MOLECULES; MELITTIN; ANGIOGENESIS; BINDING; MICROPARTICLES; KINETICS; DELIVERY	Current strategies for deploying synthetic nanocarriers involve the creation of agents that incorporate targeting ligands, imaging agents, and/or therapeutic drugs into particles as an integral part of the formulation process. Here we report the development of an amphipathic peptide linker that enables postformulation editing of payloads without the need for reformulation to achieve multiplexing capability for lipidic nanocarriers. To exemplify the flexibility of this peptide linker strategy, 3 applications were demonstrated: converting nontargeted nanoparticles into targeting vehicles; adding cargo to preformulated targeted nanoparticles for in vivo site-specific delivery; and labeling living cells for in vivo tracking. This strategy is expected to enhance the clinical application of molecular imaging and/or targeted therapeutic agents by offering extended flexibility for multiplexing targeting ligands and/or drug payloads that can be selected after base nanocarrier formulation.-Pan, H., Myerson, J. W., Ivashyna, O., Soman, N. R., Marsh, J. N., Hood, J. L., Lanza, G. M., Schlesinger, P. H., Wickline, S. A.. Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures. FASEB J. 24, 2928-2937 (2010). www.fasebj.org	[Wickline, Samuel A.] Washington Univ, Sch Med, C TRAIN, Dept Med, St Louis, MO 63108 USA; [Myerson, Jacob W.; Soman, Neelesh R.; Lanza, Gregory M.; Wickline, Samuel A.] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO 63108 USA; [Ivashyna, Olena; Schlesinger, Paul H.; Wickline, Samuel A.] Washington Univ, Sch Med, Dept Mol & Cell Biol, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Wickline, SA (corresponding author), Washington Univ, Sch Med, C TRAIN, Dept Med, 4320 Forest Pk Ave,Suite 101,Campus Box 8215, St Louis, MO 63108 USA.	wicklines@aol.com	Hood, Joshua L./I-9797-2019; Pan, Hua/C-7662-2011; Schlesinger, Paul H/C-6049-2012	Hood, Joshua L./0000-0003-3998-4118; 	National Institutes of Health [HL073646, CA119342]; NATIONAL CANCER INSTITUTE [U54CA119342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056223] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors thank Stacy J. Allen, Michael J. Scott, and Xiaoxia Yang for critical support with the animal study, Eric T. Christenson for helpful discussions, Ralph Fuhrhop for the PFC nanoparticle formulation, and Huiying Zhang for assisting with the histological analysis. This work was supported by National Institutes of Health grants HL073646 and CA119342 to S.A.W.	ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303, DOI 10.1039/dc9868100303; BAZZO R, 1988, EUR J BIOCHEM, V173, P139, DOI 10.1111/j.1432-1033.1988.tb13977.x; Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2; BLONDELLE SE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P331, DOI 10.1016/0167-4838(93)90024-L; Cai WB, 2008, J NUCL MED, V49, p113S, DOI 10.2967/jnumed.107.045922; DAWSON CR, 1978, BIOCHIM BIOPHYS ACTA, V510, P75, DOI 10.1016/0005-2736(78)90131-1; DEGRADO WF, 1982, BIOPHYS J, V37, P329, DOI 10.1016/S0006-3495(82)84681-X; DEMPSEY CE, 1991, FEBS LETT, V281, P240, DOI 10.1016/0014-5793(91)80402-O; DEMPSEY CE, 1990, BIOCHIM BIOPHYS ACTA, V1031, P143, DOI 10.1016/0304-4157(90)90006-X; DUFOURCQ J, 1977, BIOCHIM BIOPHYS ACTA, V467, P1, DOI 10.1016/0005-2736(77)90236-X; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; GEVOD VS, 1984, BIOPHYS J, V45, P1079, DOI 10.1016/S0006-3495(84)84255-1; Hartge Martin M, 2007, Diab Vasc Dis Res, V4, P84; Kelly KA, 2006, MOL IMAGING BIOL, V8, P201, DOI 10.1007/s11307-006-0043-6; Klocek G, 2009, BIOCHEMISTRY-US, V48, P2586, DOI 10.1021/bi802127h; Lanza GM, 2005, CURR TOP DEV BIOL, V70, P57, DOI 10.1016/S0070-2153(05)70003-X; Li D, 2007, J BIOMAT SCI-POLYM E, V18, P545, DOI 10.1163/156856207780852532; McAteer MA, 2008, ARTERIOSCL THROM VAS, V28, P77, DOI 10.1161/ATVBAHA.107.145466; McAteer MA, 2007, NAT MED, V13, P1253, DOI 10.1038/nm1631; MOLLAY C, 1973, BIOCHIM BIOPHYS ACTA, V316, P196, DOI 10.1016/0005-2760(73)90009-X; Morawski AM, 2004, MAGN RESON MED, V52, P1255, DOI 10.1002/mrm.20287; Namiki Y, 2009, NAT NANOTECHNOL, V4, P598, DOI [10.1038/NNANO.2009.202, 10.1038/nnano.2009.202]; Rapoport M, 2009, EXPERT OPIN DRUG DEL, V6, P453, DOI [10.1517/17425240902887029, 10.1517/17425240902887029 ]; Rex S, 2000, BIOPHYS CHEM, V85, P209, DOI 10.1016/S0301-4622(00)00121-6; Rivett DE, 1996, BIOCHEM J, V316, P525, DOI 10.1042/bj3160525; Schmieder AH, 2005, MAGN RESON MED, V53, P621, DOI 10.1002/mrm.20391; SESSA G, 1969, J BIOL CHEM, V244, P3575; Soman NR, 2008, NANO LETT, V8, P1131, DOI 10.1021/nl073290r; Soman NR, 2009, J CLIN INVEST, V119, P2830, DOI 10.1172/JCI38842; STROM R, 1978, FEBS LETT, V96, P45, DOI 10.1016/0014-5793(78)81059-X; Toraya S, 2004, BIOPHYS J, V87, P3323, DOI 10.1529/biophysj.104.046102; TOSTESON MT, 1981, BIOPHYS J, V36, P109, DOI 10.1016/S0006-3495(81)84719-4; Waters EA, 2008, MAGN RESON MED, V60, P1232, DOI 10.1002/mrm.21794; WEISSMANN G, 1969, BIOCHEM PHARMACOL, V18, P1771, DOI 10.1016/0006-2952(69)90167-1; WERKMEISTER JA, 1993, BIOCHIM BIOPHYS ACTA, V1157, P50, DOI 10.1016/0304-4165(93)90077-L; Willmann JK, 2008, RADIOLOGY, V248, P936, DOI 10.1148/radiol.2483072231; Winter PM, 2006, ARTERIOSCL THROM VAS, V26, P2103, DOI 10.1161/01.ATV.0000235724.11299.76; Wu TC, 2007, CANCER RES, V67, P6003, DOI 10.1158/0008-5472.CAN-07-1543	38	28	35	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2010	24	8					2928	2937		10.1096/fj.09-153130	http://dx.doi.org/10.1096/fj.09-153130			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	690LD	20335225	Green Published			2023-01-03	WOS:000285005400032
J	Juul, T; Malolepszy, A; Dybkaer, K; Kidmose, R; Rasmussen, JT; Andersen, GR; Johnsen, HE; Jorgensen, JE; Andersen, SU				Juul, Trine; Malolepszy, Anna; Dybkaer, Karen; Kidmose, Rune; Rasmussen, Jan Trige; Andersen, Gregers Rom; Johnsen, Hans Erik; Jorgensen, Jan-Elo; Andersen, Stig Uggerhoj			The in Vivo Toxicity of Hydroxyurea Depends on Its Direct Target Catalase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE-ACTIVITY; RESISTANT HAMSTER-CELLS; ARABIDOPSIS-THALIANA; OXIDATIVE STRESS; GENE-EXPRESSION; DRUG; MOUSE; OVERPRODUCTION; DISEASE; STATE	Hydroxyurea (HU) is a well tolerated ribonucleotide reductase inhibitor effective in HIV, sickle cell disease, and blood cancer therapy. Despite a positive initial response, however, most treated cancers eventually progress due to development of HU resistance. Although RNR properties influence HU resistance in cell lines, the mechanisms underlying cancer HU resistance in vivo remain unclear. To address this issue, we screened for HU resistance in the plant Arabidopsis thaliana and identified seventeen unique catalase mutants, thereby establishing that HU toxicity depends on catalase in vivo. We further demonstrated that catalase is a direct HU target by showing that HU acts as a competitive inhibitor of catalase-mediated hydrogen peroxide decomposition. Considering also that catalase can accelerate HU decomposition in vitro and that co-treatment with another catalase inhibitor alleviates HU effects in vivo, our findings suggests that HU could act as a catalase-activated pro-drug. Clinically, we found high catalase activity in circulating cells from untreated chronic myeloid leukemia, offering a possible explanation for the efficacy of HU against this malignancy.	[Jorgensen, Jan-Elo; Andersen, Stig Uggerhoj] Aarhus Univ, Dept Mol Biol, DK-8000 Aarhus, Denmark; [Dybkaer, Karen; Johnsen, Hans Erik] Aarhus Univ Hosp, Aalborg Hosp Sci & Innovat Ctr, Dept Hematol, DK-9000 Aalborg, Denmark	Aarhus University; Aalborg University; Aalborg University Hospital; Aarhus University	Andersen, SU (corresponding author), Aarhus Univ, Dept Mol Biol, Gustav Wieds Vej 10, DK-8000 Aarhus, Denmark.	sua@mb.au.dk		Andersen, Gregers Rom/0000-0001-6292-3319; Andersen, Stig U./0000-0002-1096-1468; Rasmussen, Jan Trige/0000-0002-2809-7225; Johnsen, Hans Erik/0000-0001-8253-2913; Dybkaer, Karen/0000-0003-2488-435X; Malolepszy, Anna/0000-0001-8862-9054	Danish Research Council for Technology and Production [274-06-0096]; K.E. Jensen Foundation; Proof-of-Concept grant	Danish Research Council for Technology and Production; K.E. Jensen Foundation; Proof-of-Concept grant(Luxembourg National Research Fund)	This work was supported by The Danish Research Council for Technology and Production (Grant 274-06-0096 to J.-E.J.), the K.E. Jensen Foundation (to H.E.J. and K. D.), and a Proof-of-Concept grant (to T.J., J.-E.J., and S. U. A.).	AKERBLOM L, 1981, P NATL ACAD SCI-BIOL, V78, P2159, DOI 10.1073/pnas.78.4.2159; Bachir D, 2007, HEMOGLOBIN, V31, P417, DOI 10.1080/03630260701587745; BEERS RF, 1952, J BIOL CHEM, V195, P133; Bueso E, 2007, PLANT J, V52, P1052, DOI 10.1111/j.1365-313X.2007.03305.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHOY BK, 1988, CANCER RES, V48, P2029; Cokic VP, 2003, J CLIN INVEST, V111, P231, DOI 10.1172/JCI200316672; Dalziel K, 2004, HEALTH TECHNOL ASSES, V8, P1; ELFORD HL, 1968, BIOCHEM BIOPH RES CO, V33, P129, DOI 10.1016/0006-291X(68)90266-0; Elleingand E, 1998, EUR J BIOCHEM, V258, P485, DOI 10.1046/j.1432-1327.1998.2580485.x; GAO WY, 1994, MOL PHARMACOL, V46, P767; Gigon A, 2004, ANN BOT-LONDON, V94, P345, DOI 10.1093/aob/mch150; Hankins J, 2009, BRIT J HAEMATOL, V145, P296, DOI 10.1111/j.1365-2141.2009.07602.x; Ho YS, 2004, J BIOL CHEM, V279, P32804, DOI 10.1074/jbc.M404800200; Huang JM, 2004, J MED CHEM, V47, P3495, DOI 10.1021/jm030547z; HURTA RAR, 1990, BIOCHIM BIOPHYS ACTA, V1087, P165, DOI 10.1016/0167-4781(90)90201-C; Jong AY, 1998, J BIOMED SCI, V5, P62, DOI 10.1007/BF02253357; LEWIS WH, 1978, J CELL PHYSIOL, V97, P83; LEWIS WH, 1983, MOL CELL BIOL, V3, P1053, DOI 10.1128/MCB.3.6.1053; Lori F, 2007, CURR MED CHEM, V14, P233, DOI 10.2174/092986707779313336; MCCLARTY GA, 1986, SOMAT CELL MOLEC GEN, V12, P121, DOI 10.1007/BF01560659; Navarra P, 1999, CRIT REV ONCOL HEMAT, V29, P249, DOI 10.1016/S1040-8428(98)00032-8; Paton NI, 2002, LANCET, V359, P1667, DOI 10.1016/S0140-6736(02)08557-4; Queval G, 2007, PLANT J, V52, P640, DOI 10.1111/j.1365-313X.2007.03263.x; Rodriguez GI, 1998, BLOOD, V91, P1533, DOI 10.1182/blood.V91.5.1533.1533_1533_1541; Stamatoyannopoulos G, 2005, EXP HEMATOL, V33, P259, DOI 10.1016/j.exphem.2004.11.007; TAGGER AY, 1988, INT J CANCER, V42, P760, DOI 10.1002/ijc.2910420522; TAKAHARA S, 1952, LANCET, V263, P1101; TONIN PN, 1987, CYTOGENET CELL GENET, V45, P102, DOI 10.1159/000132438; WRIGHT JA, 1983, BIOSCIENCE REP, V3, P741, DOI 10.1007/BF01120985	30	39	39	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 9	2010	285	28					21411	21415		10.1074/jbc.M110.103564	http://dx.doi.org/10.1074/jbc.M110.103564			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620RD	20452979	Green Published, hybrid			2023-01-03	WOS:000279516100027
J	Mulherin, TC				Mulherin, Timothy C.			Personal View Don't forget the family	BRITISH MEDICAL JOURNAL			English	Editorial Material									Deakin Univ, Melbourne, Vic, Australia	Deakin University	Mulherin, TC (corresponding author), Deakin Univ, Melbourne, Vic, Australia.	tmulherin1@hotmail.com							0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2010	341								c3486	10.1136/bmj.c3486	http://dx.doi.org/10.1136/bmj.c3486			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	625DL	20610495				2023-01-03	WOS:000279874300007
J	Zuluaga, AF; Agudelo, M; Cardeno, JJ; Rodriguez, CA; Vesga, O				Zuluaga, Andres F.; Agudelo, Maria; Cardeno, John J.; Rodriguez, Carlos A.; Vesga, Omar			Determination of Therapeutic Equivalence of Generic Products of Gentamicin in the Neutropenic Mouse Thigh Infection Model	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA; DRUG SUBSTITUTION; BIOEQUIVALENCE; ISSUES; MICE; CEFUROXIME; EXCIPIENTS; MEDICINES; CALCIUM; HEPARIN	Background: Drug regulatory agencies (DRA) support prescription of generic products of intravenous antibiotics assuming therapeutic equivalence from pharmaceutical equivalence. Recent reports of deaths associated with generic heparin and metoprolol have raised concerns about the efficacy and safety of DRA-approved drugs. Methodology/Principal Findings: To challenge the assumption that pharmaceutical equivalence predicts therapeutic equivalence, we determined in vitro and in vivo the efficacy of the innovator product and 20 pharmaceutically equivalent generics of gentamicin. The data showed that, while only 1 generic product failed in vitro (MIC = 45.3 vs. 0.7 mg/L, P < 0.05), 10 products (including gentamicin reference powder) failed in vivo against E. coli due to significantly inferior efficacy (E-max = 4.81 to 5.32 vs. 5.99 log(10) CFU/g, P <= 0.043). Although the design lacked power to detect differences in survival after thigh infection with P. aeruginosa, dissemination to vital organs was significantly higher in animals treated with generic gentamicin despite 4 days of maximally effective treatment. Conclusion: Pharmaceutical equivalence does not predict therapeutic equivalence of generic gentamicin. Stricter criteria based on solid experimental evidence should be required before approval for human use.	[Zuluaga, Andres F.; Rodriguez, Carlos A.; Vesga, Omar] Univ Antioquia, Sch Med, Dept Pharmacol & Toxicol, Medellin, Colombia; [Zuluaga, Andres F.; Agudelo, Maria; Cardeno, John J.; Rodriguez, Carlos A.; Vesga, Omar] Univ Antioquia, Sch Med, Grp Investigador Problemas Enfermedades Infeccios, Medellin, Colombia; [Vesga, Omar] Hosp Univ San Vicente de Paul, Dept Med, Infect Dis Sect, Medellin, Colombia	Universidad de Antioquia; Universidad de Antioquia	Zuluaga, AF (corresponding author), Univ Antioquia, Sch Med, Dept Pharmacol & Toxicol, Medellin, Colombia.	omar.vesga@siu.udea.edu.co	Rodriguez, Carlos A./P-8324-2019; Zuluaga, Andres F./K-7366-2016	Rodriguez, Carlos A./0000-0002-4042-4313; Zuluaga, Andres F./0000-0001-5656-4153; Cardeno, John/0000-0003-3145-3945	University of Antioquia, and Colciencias [1115-04-731-98]	University of Antioquia, and Colciencias	This work was financed by the University of Antioquia, and Colciencias (grant number 1115-04-731-98). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akers MJ, 2002, J PHARM SCI-US, V91, P2283, DOI 10.1002/jps.10154; Allen LV, 2008, CLIN THER, V30, P2102, DOI 10.1016/j.clinthera.2008.11.015; Ammerlaan H, 2009, CLIN INFECT DIS, V49, P997, DOI 10.1086/605555; APTE SP, 2003, PHARM TECHNOL EUROPE, V15, P45; Blossom DB, 2008, NEW ENGL J MED, V359, P2674, DOI 10.1056/NEJMoa0806450; Brashier MK, 1998, AM J VET RES, V59, P1055; *CLIN LAB STAND I, 2003, M7A6 CLSI; Craig WA, 1998, CLIN INFECT DIS, V26, P1, DOI 10.1086/516284; Crowley PJ, 1999, PHARM SCI TECHNOL TO, V2, P237, DOI 10.1016/S1461-5347(99)00158-3; DETTELBACH HR, 1986, J CLIN PHARMACOL, V26, P307, DOI 10.1002/j.1552-4604.1986.tb03530.x; Dodd S, 2009, CURR DRUG SAF, V4, P1, DOI 10.2174/157488609787354431; Duenas-Laita A, 2009, NEW ENGL J MED, V361, P1317, DOI 10.1056/NEJMc0904562; Dupont WD, 1997, CONTROL CLIN TRIALS, V18, P274, DOI 10.1016/S0197-2456(97)00074-3; Feldschreiber P, 2009, CLIN MED, V9, P63, DOI 10.7861/clinmedicine.9-1-63; *FOOD DRUG ADM, 2001, GUID IND BIOAN METH, V22; *GEN DRUGS, 2002, MED LETT DRUGS THER, V44, P89; GERBER AU, 1983, J INFECT DIS, V147, P910, DOI 10.1093/infdis/147.5.910; Glantz SA, 2006, PRIMER BIOSTATISTICS; Gonzalez LS, 1998, AM FAM PHYSICIAN, V58, P1811; Henderson JD, 2001, SOUTHERN MED J, V94, P16; Henry D, 2002, LANCET, V360, P1590, DOI 10.1016/S0140-6736(02)11527-3; Jia H, 2008, NAT BIOTECHNOL, V26, P477, DOI 10.1038/nbt0508-477; Jones RN, 2008, DIAGN MICR INFEC DIS, V61, P76, DOI 10.1016/j.diagmicrobio.2007.12.010; Katzung BG, 2007, BASIC CLIN PHARM; Kirking D M, 2001, J Am Pharm Assoc (Wash), V41, P578; Lees P, 2004, J VET PHARMACOL THER, V27, P397, DOI 10.1111/j.1365-2885.2004.00620.x; Mastoraki E, 2008, J INFECTION, V56, P35, DOI 10.1016/j.jinf.2007.09.011; Mattew A, 2006, M2A9 CLSI; Meredith P, 2003, CLIN THER, V25, P2875, DOI 10.1016/S0149-2918(03)80340-5; Moellering RC, 2009, CLIN INFECT DIS, V49, P1006, DOI 10.1086/605556; NAPKE E, 1984, CAN MED ASSOC J, V131, P1449; NATION RL, 1994, PHARMACOL THERAPEUT, V62, P41, DOI 10.1016/0163-7258(94)90004-3; POLLACK M, 1984, REV INFECT DIS, V6, pS617; Recht MI, 1999, EMBO J, V18, P3133, DOI 10.1093/emboj/18.11.3133; RHEINSTEIN PH, 1990, DRUG SAFETY, V5, P114, DOI 10.2165/00002018-199000051-00018; Rodriguez CA, 2009, J INFECTION, V59, P277, DOI 10.1016/j.jinf.2009.08.005; Roy Jiben, 2002, AAPS PharmSciTech, V3, pE6; SINGH YN, 1978, ANESTHESIOLOGY, V48, P418, DOI 10.1097/00000542-197806000-00008; STROM BL, 1987, NEW ENGL J MED, V316, P1456, DOI 10.1056/NEJM198706043162306; Toutain PL, 2004, J VET PHARMACOL THER, V27, P467, DOI 10.1111/j.1365-2885.2004.00613.x; Tracy M, 2001, ANTIMICROB AGENTS CH, V45, P1511, DOI 10.1128/AAC.45.5.1511-1514.2001; *US FDA, 2001, GUID IND STAT APPR; *US PHARM CONV, 2002, PHARM US AM; WANG D, 1994, J PHARM SCI, V83, P577, DOI 10.1002/jps.2600830427; WEINSTEIN MJ, 1963, J MED CHEM, V6, P463, DOI 10.1021/jm00340a034; Welage L S, 2001, J Am Pharm Assoc (Wash), V41, P856; Zuluaga AF, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-55; Zuluaga Andres F, 2009, BMC Clin Pharmacol, V9, P1, DOI 10.1186/1472-6904-9-1	48	41	44	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2010	5	5							e10744	10.1371/journal.pone.0010744	http://dx.doi.org/10.1371/journal.pone.0010744			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	600VP	20505762	Green Published, Green Submitted, gold			2023-01-03	WOS:000278017300016
J	[Anonymous]				[Anonymous]			Frustrations With Hospitalist Care: Need to Improve Transitions and Communication	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																		Ault MJ, 2010, ANN INTERN MED, V152, P475, DOI 10.7326/0003-4819-152-7-201004060-00018; Beckman Howard, 2009, Ann Intern Med, V151, P890, DOI 10.7326/0003-4819-151-12-200912150-00011; Coffman J, 2005, MED CARE RES REV, V62, P379, DOI 10.1177/1077558705277379; Harrison Jeffrey P, 2009, J Health Care Finance, V35, P22; Kumar PD, 2010, ANN INTERN MED, V152, P476, DOI 10.7326/0003-4819-152-7-201004060-00020; Lo B, 2001, AM J MED, V111, P48, DOI 10.1016/S0002-9343(01)00972-X; Meltzer D, 2002, ANN INTERN MED, V137, P866, DOI 10.7326/0003-4819-137-11-200212030-00007; Reynolds CH, 2010, ANN INTERN MED, V152, P474, DOI 10.7326/0003-4819-152-7-201004060-00017; Stillman MD, 2010, ANN INTERN MED, V152, P475, DOI 10.7326/0003-4819-152-7-201004060-00019; Wachter RM, 2010, ANN INTERN MED, V152, P474, DOI 10.7326/0003-4819-152-7-201004060-00016	10	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 6	2010	152	7					469	469		10.7326/0003-4819-152-7-201004060-00013	http://dx.doi.org/10.7326/0003-4819-152-7-201004060-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	579QI	20368654				2023-01-03	WOS:000276386900009
J	Dunn, KM; Saunders, KW; Rutter, CM; Banta-Green, CJ; Merrill, JO; Sullivan, MD; Weisner, CM; Silverberg, MJ; Campbell, CI; Psaty, BM; Von Korff, M				Dunn, Kate M.; Saunders, Kathleen W.; Rutter, Carolyn M.; Banta-Green, Caleb J.; Merrill, Joseph O.; Sullivan, Mark D.; Weisner, Constance M.; Silverberg, Michael J.; Campbell, Cynthia I.; Psaty, Bruce M.; Von Korff, Michael			Opioid Prescriptions for Chronic Pain and Overdose A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC NONCANCER PAIN; MUSCULOSKELETAL PAIN; ANALGESICS; THERAPY; DEATHS; TRENDS; PHYSICIANS; MORTALITY; EFFICACY; ABUSE	Background: Long-term opioid therapy for chronic noncancer pain is becoming increasingly common in community practice. Concomitant with this change in practice, rates of fatal opioid overdose have increased. The extent to which overdose risks are elevated among patients receiving medically prescribed long-term opioid therapy is unknown. Objective: To estimate rates of opioid overdose and their association with an average prescribed daily opioid dose among patients receiving medically prescribed, long-term opioid therapy. Design: Cox proportional hazards models were used to estimate overdose risk as a function of average daily opioid dose (morphine equivalents) received at the time of overdose. Setting: HMO. Patients: 9940 persons who received 3 or more opioid prescriptions within 90 days for chronic noncancer pain between 1997 and 2005. Measurements: Average daily opioid dose over the previous 90 days from automated pharmacy data. Primary outcomes-nonfatal and fatal overdoses-were identified through diagnostic codes from inpatient and outpatient care and death certificates and were confirmed by medical record review. Results: 51 opioid-related overdoses were identified, including 6 deaths. Compared with patients receiving 1 to 20 mg/d of opioids (0.2% annual overdose rate), patients receiving 50 to 99 mg/d had a 3.7-fold increase in overdose risk (95% CI, 1.5 to 9.5) and a 0.7% annual overdose rate. Patients receiving 100 mg/d or more had an 8.9-fold increase in overdose risk (CI, 4.0 to 19.7) and a 1.8% annual overdose rate. Limitations: Increased overdose risk among patients receiving higher dose regimens may be due to confounding by patient differences and by use of opioids in ways not intended by prescribing physicians. The small number of overdoses in the study cohort is also a limitation. Conclusion: Patients receiving higher doses of prescribed opioids are at increased risk for overdose, which underscores the need for close supervision of these patients.	[Von Korff, Michael] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98101 USA; Univ Washington, Seattle, WA 98195 USA; Keele Univ, Arthrit Res Campaign Natl Primary Care Ctr, Keele, Staffs, England; No Calif Kaiser Permanente, Oakland, CA USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Group Health Cooperative; University of Washington; University of Washington Seattle; Keele University; Kaiser Permanente; University of California System; University of California San Francisco	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.	vonkorff.m@ghc.org	Rutter, Carolyn/AAZ-3677-2021	VonKorff, Michael/0000-0001-5386-8477; Banta-Green, Caleb/0000-0003-4084-6943	National Institute of Drug Abuse [DA022557]; Wellcome Trust [083572]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA022557] Funding Source: NIH RePORTER	National Institute of Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Grant Support: This research was supported by a grant to Dr. Von Korff from the National Institute of Drug Abuse (DA022557). Dr. Dunn participated in this work with Dr. Von Korff at the Group Health Research Institute through a grant from the Wellcome Trust (083572).	Ballantyne JC, 2008, CLIN J PAIN, V24, P469, DOI 10.1097/AJP.0b013e31816b2f26; Ballantyne Jane C, 2007, Pain Physician, V10, P479; Ballantyne JC, 2003, NEW ENGL J MED, V349, P1943, DOI 10.1056/NEJMra025411; BOUDREAU D, 2009, PHARMACOEPIDEMIOL DR; Breivik H, 2005, EUR J PAIN, V9, P127, DOI 10.1016/j.ejpain.2004.05.013; Caudill-Slosberg MA, 2004, PAIN, V109, P514, DOI 10.1016/j.pain.2004.03.006; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Eriksen J, 2006, PAIN, V125, P172, DOI 10.1016/j.pain.2006.06.009; Fernandez W, 2006, J SUBST ABUSE TREAT, V31, P151, DOI 10.1016/j.jsat.2006.04.008; Fishman PA, 2003, MED CARE, V41, P84, DOI 10.1097/00005650-200301000-00011; Fishman SM, 2006, PHARMACOEPIDEM DR S, V15, P628, DOI 10.1002/pds.1292; Franklin GM, 2005, AM J IND MED, V48, P91, DOI 10.1002/ajim.20191; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Hartung DM, 2007, ANN PHARMACOTHER, V41, P921, DOI 10.1345/aph.1K066; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1213, DOI 10.1001/jama.2009.367; Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006; McLellan AT, 2008, JAMA-J AM MED ASSOC, V300, P2672, DOI 10.1001/jama.2008.793; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI 10.1016/j.amepre.2006.08.017; Reidenberg MM, 2007, CLIN PHARMACOL THER, V81, P903, DOI 10.1038/sj.clpt.6100127; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1085, DOI 10.1016/0895-4356(93)90106-B; SAS/STAT, 2008, SAS STAT 9 2 US GUID; Saunders KW, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P223; Shah NG, 2008, ADDICTION, V103, P126, DOI 10.1111/j.1360-0443.2007.02054.x; Therneau T.M., 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8; Trescot AM, 2008, PAIN PHYSICIAN, V11, pS5; Von Korff M, 2004, PAIN, V109, P207, DOI 10.1016/j.pain.2004.02.019; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Washington State Department of Health, 2007, HLTH WASH STAT 2007; Won A, 2006, J GERONTOL A-BIOL, V61, P165, DOI 10.1093/gerona/61.2.165; Wysowski DK, 2007, DRUG SAFETY, V30, P533, DOI 10.2165/00002018-200730060-00007	33	935	944	1	74	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	2010	152	2					85	+		10.7326/0003-4819-152-2-201001190-00006	http://dx.doi.org/10.7326/0003-4819-152-2-201001190-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548IE	20083827	Green Accepted			2023-01-03	WOS:000273953000003
J	Mavigner, M; Delobel, P; Cazabat, M; Dubois, M; L'Faqihi-Olive, FE; Raymond, S; Pasquier, C; Marchou, B; Massip, P; Izopet, J				Mavigner, Maud; Delobel, Pierre; Cazabat, Michelle; Dubois, Martine; L'Faqihi-Olive, Fatima-Ezzahra; Raymond, Stephanie; Pasquier, Christophe; Marchou, Bruno; Massip, Patrice; Izopet, Jacques			HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HUMAN PERIPHERAL-BLOOD; IN-VIVO; VIRAL LOAD; REPLICATION-COMPETENT; INFECTED PATIENTS; LATENT RESERVOIR; PROGENITOR CELLS; DRUG-RESISTANCE; PLASMA VIREMIA	Background: The clinical significance and cellular sources of residual human immunodeficiency virus type 1 (HIV-1) production despite suppressive combination antiretroviral therapy (cART) remain unclear and the effect of low-level viremia on T-cell homeostasis is still debated. Methodology/Principal Findings: We characterized the recently produced residual viruses in the plasma and short-lived blood monocytes of 23 patients with various immunological responses to sustained suppressive cART. We quantified the residual HIV-1 in the plasma below 50 copies/ml, and in the CD14(high) CD16(-) and CD16(+) monocyte subsets sorted by flow cytometry, and predicted coreceptor usage by genotyping V3 env sequences. We detected residual viremia in the plasma of 8 of 10 patients with poor CD4(+) T-cell reconstitution in response to cART and in only 5 of 13 patients with good CD4(+) T-cell reconstitution. CXCR4-using viruses were frequent among the recently produced viruses in the plasma and in the main CD14(high) CD16(-) monocyte subset. Finally, the residual viremia was correlated with persistent CD4(+) and CD8(+) T-cell activation in patients with poor immune reconstitution. Conclusions: Low-level viremia could result from the release of archived viruses from cellular reservoirs and/or from ongoing virus replication in some patients. The compartmentalization of the viruses between the plasma and the blood monocytes suggests at least two origins of residual virus production during effective cART. CXCR4-using viruses might be produced preferentially in patients on cART. Our results also suggest that low-level HIV-1 production in some patients may contribute to persistent immune dysfunction despite cART.			Mavigner, M (corresponding author), Fac Med Toulouse, INSERM, U563, U317, F-31073 Toulouse, France.	izopet.j@chu-toulouse.fr	Raymond, Stephanie/K-4507-2014; IZOPET, Jacques/L-5756-2014; Delobel, Pierre/K-3166-2014; Delobel, Pierre/Q-6028-2019; Raymond, Stephanie/L-8401-2019	Delobel, Pierre/0000-0002-2874-3581; Delobel, Pierre/0000-0002-2874-3581; Raymond, Stephanie/0000-0002-3780-5844; PASQUIER, Christophe/0000-0001-9223-0150				Alexaki A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000215; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; Benito JM, 2004, AIDS RES HUM RETROV, V20, P227, DOI 10.1089/088922204773004950; Blaak H, 2000, P NATL ACAD SCI USA, V97, P1269, DOI 10.1073/pnas.97.3.1269; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Brenchley JM, 2004, J VIROL, V78, P1160, DOI 10.1128/JVI.78.3.1160-1168.2004; Brooks DG, 2001, NAT MED, V7, P459, DOI 10.1038/86531; BUZON M, 2009, TRANSIENT INCREASE E; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Chun TW, 1998, P NATL ACAD SCI USA, V95, P8869, DOI 10.1073/pnas.95.15.8869; Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204; DAVIS BR, 1991, J VIROL, V65, P1985, DOI 10.1128/JVI.65.4.1985-1990.1991; Delobel P, 2005, JAIDS-J ACQ IMM DEF, V38, P382, DOI 10.1097/01.qai.0000152835.17747.47; Delobel P, 2007, J CLIN MICROBIOL, V45, P1572, DOI 10.1128/JCM.02090-06; Delobel P, 2006, J VIROL, V80, P10229, DOI 10.1128/JVI.00965-06; Diaz M, 2003, AIDS, V17, P1145, DOI 10.1097/00002030-200305230-00005; Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106; Dion ML, 2004, IMMUNITY, V21, P757, DOI 10.1016/j.immuni.2004.10.013; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Ellery PJ, 2007, J IMMUNOL, V178, P6581, DOI 10.4049/jimmunol.178.10.6581; EVERING T, 2009, SINGLE GENOME ANAL H; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fulcher JA, 2004, J VIROL, V78, P7883, DOI 10.1128/JVI.78.15.7883-7893.2004; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; GANDHI R, 2009, RALTEGRAVIR INTENSIF; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Grage-Griebenow E, 2001, J LEUKOCYTE BIOL, V69, P11; Gunthard HF, 1999, VIROLOGY, V259, P154, DOI 10.1006/viro.1999.9774; Havlir DV, 2003, J VIROL, V77, P11212, DOI 10.1128/JVI.77.20.11212-11219.2003; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Johnston ER, 2003, J VIROL, V77, P7682, DOI 10.1128/JVI.77.13.7682-7688.2003; JONES J, 2009, DECREASE RESIDUAL VI; Kieffer TL, 2004, J INFECT DIS, V189, P1452, DOI 10.1086/382488; Kolluri SK, 1999, GENE DEV, V13, P1742, DOI 10.1101/gad.13.13.1742; Llewellyn N, 2006, J LEUKOCYTE BIOL, V80, P1118, DOI 10.1189/jlb.0306144; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; Martinez MA, 1999, VIROLOGY, V256, P180, DOI 10.1006/viro.1999.9601; Melby T, 2006, J INFECT DIS, V194, P238, DOI 10.1086/504693; MEURET G, 1974, BLOOD, V44, P801, DOI 10.1182/blood.V44.6.801.801; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; NEAL TF, 1995, BLOOD, V86, P1749, DOI 10.1182/blood.V86.5.1749.bloodjournal8651749; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; Nokta MA, 2002, AIDS, V16, P2119, DOI 10.1097/00002030-200211080-00003; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; Ostrowski MA, 1999, J VIROL, V73, P6430, DOI 10.1128/JVI.73.8.6430-6435.1999; Ostrowski SR, 2008, SCAND J IMMUNOL, V68, P652, DOI 10.1111/j.1365-3083.2008.02184.x; Owen A, 2004, J VIROL, V78, P12022, DOI 10.1128/JVI.78.21.12022-12029.2004; Palmer S, 2003, J CLIN MICROBIOL, V41, P4531, DOI 10.1128/JCM.41.10.4531-4536.2003; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Palmisano L, 2005, AIDS, V19, P1843, DOI 10.1097/01.aids.0000188426.87538.ed; Parera M, 2004, J INFECT DIS, V189, P1444, DOI 10.1086/382485; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Raymond S, 2008, AIDS, V22, pF11, DOI 10.1097/QAD.0b013e32830ebcd4; Sahu GK, 2009, J MED VIROL, V81, P9, DOI 10.1002/jmv.21366; Schmitt N, 2003, J VIROL, V77, P5784, DOI 10.1128/JVI.77.10.5784-5793.2003; Sharkey M, 2005, J VIROL, V79, P5203, DOI 10.1128/JVI.79.8.5203-5210.2005; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Sonza S, 2001, AIDS, V15, P17, DOI 10.1097/00002030-200101050-00005; Steel A, 2007, ANTIVIR THER, V12, P971; Taylor JR, 2001, J VIROL, V75, P8752, DOI 10.1128/JVI.75.18.8752-8760.2001; Tilling R, 2002, AIDS, V16, P589, DOI 10.1097/00002030-200203080-00010; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; VONLAER D, 1990, BLOOD, V76, P1281; Weber C, 2000, J LEUKOCYTE BIOL, V67, P699, DOI 10.1002/jlb.67.5.699; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WHITELAW DM, 1972, CELL TISSUE KINET, V5, P311, DOI 10.1111/j.1365-2184.1972.tb00369.x; Wilkin TJ, 2007, CLIN INFECT DIS, V44, P591, DOI 10.1086/511035; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Xu YN, 2008, J INFECT DIS, V197, P309, DOI 10.1086/524847; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhu TF, 2002, J VIROL, V76, P707, DOI 10.1128/JVI.76.2.707-716.2002; ZieglerHeitbrock HWL, 1996, IMMUNOL TODAY, V17, P424, DOI 10.1016/0167-5699(96)10029-3	79	108	109	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7658	10.1371/journal.pone.0007658	http://dx.doi.org/10.1371/journal.pone.0007658			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19876401	Green Submitted, Green Published, gold			2023-01-03	WOS:000271414300012
J	Putensen, C; Theuerkauf, N; Zinserling, J; Wrigge, H; Pelosi, P				Putensen, Christian; Theuerkauf, Nils; Zinserling, Joerg; Wrigge, Hermann; Pelosi, Paolo			Meta-analysis: Ventilation Strategies and Outcomes of the Acute Respiratory Distress Syndrome and Acute Lung Injury	ANNALS OF INTERNAL MEDICINE			English	Review							END-EXPIRATORY PRESSURE; TIDAL VOLUME VENTILATION; MECHANICAL VENTILATION; RECRUITMENT; TRIALS; REDUCTION; COLLAPSE; BENCH	Background: Trials have provided conflicting results regarding the effect of different ventilatory strategies on the outcomes of patients with the acute respiratory distress syndrome (ARDS) and acute lung injury. Purpose: To determine whether ventilation with low tidal volume (VT) and limited airway pressure or higher positive end-expiratory pressure (PEEP) improves outcomes for patients with ARDS or acute lung injury. Data Sources: Multiple computerized databases (through March 2009), reference lists of identified articles, and queries of principal investigators. No language restrictions were applied. Study Selection: Randomized, controlled trials (RCTs) reporting mortality and comparing lower versus higher VT ventilation, lower versus higher PEEP, or a combination of both in adults with ARDS or acute lung injury. Data Extraction: Using a standard protocol, 2 reviewer teams assessed trial eligibility and abstracted data on quality of study design and conduct, population characteristics, intervention, co-interventions, and confounding variables. Data Synthesis: 4 RCTs tested lower versus higher VT ventilation at similar PEEP in 1149 patients, 3 RCTs compared lower versus higher PEEP at low VT ventilation in 2299 patients, and 2 RCTs compared a combination of higher VT and lower PEEP ventilation versus lower VT and higher PEEP ventilation in 148 patients. Lower VT ventilation reduced hospital mortality (odds ratio, 0.75 [95% CI, 0.58 to 0.96]; P = 0.02) compared with higher VT ventilation at similar PEEP. Higher PEEP did not reduce hospital mortality ( odds ratio, 0.86 [CI, 0.72 to 1.02]; P = 0.08) compared with lower PEEP using low VT ventilation. Higher PEEP reduced the need for rescue therapy to prevent life-threatening hypoxemia (odds ratio, 0.51 [CI, 0.36 to 0.71]; P < 0.001) and death (odds ratio, 0.51 [CI, 0.36 to 0.71]; P < 0.001) in patients receiving rescue therapies. Limitations: Pooling according to similar ventilatory strategies resulted in few RCTs analyzed in each group. The benefit of low VT is derived from only 1 study. Conclusion: Available evidence from a limited number of RCTs shows better outcomes with routine use of low VT but not high PEEP ventilation in unselected patients with ARDS or acute lung injury. High PEEP may help to prevent life-threatening hypoxemia in selected patients.	Univ Hosp Bonn, Bonn, Germany; Univ Insubria, Varese, Italy	University of Bonn; University of Insubria	Putensen, C (corresponding author), Univ Bonn, Dept Anaesthesiol & Intens Care Med, Sigmund Freud Str 25, D-53105 Bonn, Germany.	putensen@buni-bonn.de; joerg.zinserling@ukb.uni-bonn.de	Wrigge, Hermann/AAJ-8985-2021; Rocco, Patricia/I-7460-2012	Wrigge, Hermann/0000-0002-9035-6822; Rocco, Patricia/0000-0003-1412-7136; Pelosi, Paolo/0000-0001-5055-3023				Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Borges JB, 2006, AM J RESP CRIT CARE, V174, P268, DOI 10.1164/rccm.200506-976OC; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chiumello D, 2008, AM J RESP CRIT CARE, V178, P346, DOI 10.1164/rccm.200710-1589OC; Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157; DENZIN NK, 1995, J COMMUN, V45, P177, DOI 10.1111/j.1460-2466.1995.tb00735.x; Dixon-Woods M, 2004, QUAL SAF HEALTH CARE, V13, P223, DOI 10.1136/qshc.2003.008714; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1510, DOI 10.1164/rccm.200208-956OC; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; GATTINONI L, 1995, AM J RESP CRIT CARE, V151, P1807, DOI 10.1164/ajrccm.151.6.7767524; Gattinoni L, 2008, JAMA-J AM MED ASSOC, V299, P691, DOI 10.1001/jama.299.6.691; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Halter JM, 2003, AM J RESP CRIT CARE, V167, P1620, DOI 10.1164/rccm.200205-435OC; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; LENNON M, 2005, CRIT CARE RESUSC, V7, P60; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; Marini JJ, 2003, CRIT CARE, V7, P435, DOI 10.1186/cc2392; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Moran JL, 2005, INTENS CARE MED, V31, P227, DOI 10.1007/s00134-004-2506-z; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; Pelosi P, 2001, AM J RESP CRIT CARE, V164, P122, DOI 10.1164/ajrccm.164.1.2007010; Petrucci N, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003844.pub3; Petrucci N, 2004, ANESTH ANALG, V99, P193, DOI 10.1213/01.ANE.0000118102.93688.97; Pinhu L, 2003, LANCET, V361, P332, DOI 10.1016/S0140-6736(03)12329-X; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Routly JJ, 2003, CRIT CARE MED, V31, pS285, DOI 10.1097/01.CCM.0000057905.74813.BC; Sakr Y, 2005, CHEST, V128, P3098, DOI 10.1378/chest.128.5.3098; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Terragni PP, 2007, AM J RESP CRIT CARE, V175, P160, DOI 10.1164/rccm.200607-915OC; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Tremblay LN, 2005, AM J PHYSIOL-LUNG C, V288, pL596, DOI 10.1152/ajplung.00438.2004; Vieira SRR, 1998, AM J RESP CRIT CARE, V158, P1571, DOI 10.1164/ajrccm.158.5.9802101; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01; Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564	44	255	270	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2009	151	8					566	U96		10.7326/0003-4819-151-8-200910200-00011	http://dx.doi.org/10.7326/0003-4819-151-8-200910200-00011			20	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	514HY	19841457	Green Submitted			2023-01-03	WOS:000271386200006
J	Wald, HS				Wald, Hedy S.			Separation Anxiety	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												hedy_wald@brown.edu							0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	2009	302	13					1403	1404		10.1001/jama.2009.1339	http://dx.doi.org/10.1001/jama.2009.1339			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	503CL	19809014				2023-01-03	WOS:000270509600001
J	Rousseau, P				Rousseau, Paul			The Other Person	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												palliativedoctor@aol.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	2009	302	8					832	832		10.1001/jama.2009.1263	http://dx.doi.org/10.1001/jama.2009.1263			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	487GN	19706850				2023-01-03	WOS:000269260100001
J	Boysen, G; Krarup, LH; Zeng, XR; Oskedra, A; Korv, J; Andersen, G; Gluud, C; Pedersen, A; Lindahl, M; Hansen, L; Winkel, P; Truelsen, T				Boysen, Gudrun; Krarup, Lars-Henrik; Zeng, Xianrong; Oskedra, Adam; Korv, Janika; Andersen, Grethe; Gluud, Christian; Pedersen, Anders; Lindahl, Marianne; Hansen, Lotte; Winkel, Per; Truelsen, Thomas		ExStroke Pilot Trial Grp	ExStroke Pilot Trial of the effect of repeated instructions to improve physical activity after ischaemic stroke: a multinational randomised controlled clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACTIVITY SCALE; ELDERLY PASE; GENERAL-PRACTICE; FOLLOW-UP; RISK; EXERCISE; ASSOCIATION; VALIDITY; PROMOTE; ADVICE	Objectives To investigate if repeated verbal instructions about physical activity to patients with ischaemic stroke could increase long term physical activity. Design Multicentre, multinational, randomised clinical trial with masked outcome assessment. Setting Stroke units in Denmark, China, Poland, and Estonia. Participants 314 patients with ischaemic stroke aged >= 40 years who were able to walk-157 ( mean age 69. 7 years) randomised to the intervention, 157 (mean age 69.4 years) in the control group. Interventions Patients randomised to the intervention were instructed in a detailed training programme before discharge and at five follow-up visits during 24 months. Control patients had follow-up visits with the same frequency but without instructions in physical activity. Main outcome measures Physical activity assessed with the Physical Activity Scale for the Elderly (PASE) at each visit. Secondary outcomes were clinical events. Results The estimated mean PASE scores were 69.1 in the intervention group and 64.0 in the control group (difference 5.0 (95% confidence interval -5.8 to 15.9), P=0.36. The intervention had no significant effect on mortality, recurrent stroke, myocardial infarction, or falls and fractures. Conclusion Repeated encouragement and verbal instruction in being physically active did not lead to a significant increase in physical activity measured by the PASE score. More intensive strategies seem to be needed to promote physical activity after ischaemic stroke.	[Boysen, Gudrun; Krarup, Lars-Henrik; Pedersen, Anders; Lindahl, Marianne; Hansen, Lotte; Truelsen, Thomas] Univ Copenhagen Hosp, Bispebjerg Hosp, Dept Neurol, DK-2400 Copenhagen NV, Denmark; [Zeng, Xianrong] Sichuan Prov Peoples Hosp, Dept Neurol, Chengdu, Peoples R China; [Oskedra, Adam] Inst Psychiat & Neurol, Dept Neurol, Warsaw, Poland; [Korv, Janika] Univ Tartu, Dept Neurol & Neurosurg, Tartu, Estonia; [Andersen, Grethe] Aarhus Univ Hosp, Dept Neurol, Aarhus, Denmark; [Krarup, Lars-Henrik; Gluud, Christian; Winkel, Per] Univ Copenhagen Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, DK-2400 Copenhagen NV, Denmark	University of Copenhagen; Bispebjerg Hospital; Sichuan Provincial People's Hospital; Institute of Psychiatry & Neurology; University of Tartu; Aarhus University; Rigshospitalet; University of Copenhagen	Boysen, G (corresponding author), Univ Copenhagen Hosp, Bispebjerg Hosp, Dept Neurol, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.	gb01@bbh.regionh.dk	krarup, lh/K-8404-2019; Krarup, Lars-Henrik/K-7199-2019; Gluud, Christian/AAY-1027-2021; Kõrv, Janika/I-4395-2015; Truelsen, Thomas/AAY-1549-2020; Lindahl, Marianne/AAF-9142-2020; Gluud, Christian/HGB-3191-2022	Gluud, Christian/0000-0002-8861-0799; Kõrv, Janika/0000-0002-6074-0727; Iversen, Helle Klingenberg/0000-0002-5880-6352; Andersen, Grethe/0000-0001-6807-2500	Ludvig and Sara Elsass' Foundation; Hede Nielsen Foundation; Eva and Henry Fraenkel's Foundation; Soren and Helene Hempel's Foundation; King Christian X Foundation	Ludvig and Sara Elsass' Foundation; Hede Nielsen Foundation; Eva and Henry Fraenkel's Foundation; Soren and Helene Hempel's Foundation; King Christian X Foundation	The ExStroke Pilot Trial was funded by the Ludvig and Sara Elsass' Foundation, Hede Nielsen Foundation, Eva and Henry Fraenkel's Foundation, Soren and Helene Hempel's Foundation, and King Christian X Foundation. The funding sources had no involvement in the design of the trial; data collection, management, analysis, interpretation, and reporting; writing of the paper; or submission of the article for publication.	ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; Calfas KJ, 1996, PREV MED, V25, P225, DOI 10.1006/pmed.1996.0050; Dinger MK, 2004, J SPORT MED PHYS FIT, V44, P186; Duncan P, 1998, STROKE, V29, P2055, DOI 10.1161/01.STR.29.10.2055; Eden KB, 2002, ANN INTERN MED, V137, P208, DOI 10.7326/0003-4819-137-3-200208060-00015; Ellekjaer H, 2000, STROKE, V31, P14, DOI 10.1161/01.STR.31.1.14; Foster C., 2005, COCHRANE DB SYST REV, V1, P1, DOI 10.1002/14651858.cd003180.pub2; Gillum RF, 1996, AM J EPIDEMIOL, V143, P860, DOI 10.1093/oxfordjournals.aje.a008829; Gluud LL, 2006, AM J EPIDEMIOL, V163, P493, DOI 10.1093/aje/kwj069; Gordon NF, 2004, CIRCULATION, V109, P2031, DOI 10.1161/01.CIR.0000126280.65777.A4; Hu FB, 2000, JAMA-J AM MED ASSOC, V283, P2961, DOI 10.1001/jama.283.22.2961; Hudon C, 2008, CAN FAM PHYSICIAN, V54, P1130; Krarup LH, 2008, CONTEMP CLIN TRIALS, V29, P410, DOI 10.1016/j.cct.2007.09.008; Krarup LH, 2007, CEREBROVASC DIS, V24, P296, DOI 10.1159/000105683; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Lawlor DA, 2001, J PUBLIC HEALTH MED, V23, P219, DOI 10.1093/pubmed/23.3.219; Lee CD, 2003, STROKE, V34, P2475, DOI 10.1161/01.STR.0000091843.02517.9D; Lee IM, 1998, STROKE, V29, P2049, DOI 10.1161/01.STR.29.10.2049; Lee IM, 1999, STROKE, V30, P1, DOI 10.1161/01.STR.30.1.1; Lindahl M, 2008, EUR J PHYSIOTHER, V10, P188, DOI 10.1080/14038190802490025; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; Martin KA, 1999, MED SCI SPORT EXER, V31, P627, DOI 10.1097/00005768-199905000-00001; Mead GE, 2007, J AM GERIATR SOC, V55, P892, DOI 10.1111/j.1532-5415.2007.01185.x; Molenberghs G, 2007, STAT PRACTICE; POTEMPA K, 1995, STROKE, V26, P101, DOI 10.1161/01.STR.26.1.101; RANKIN J, 1957, Scott Med J, V2, P200; RIKLI R, 2001, SENIOR FITNESS TEST, P13; Saunders DH, 2008, ARCH PHYS MED REHAB, V89, P677, DOI 10.1016/j.apmr.2007.09.034; Saunders DH, 2009, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003316.PUB2; Schuit AJ, 1997, J CLIN EPIDEMIOL, V50, P541, DOI 10.1016/S0895-4356(97)00010-3; Smith BJ, 2000, BRIT J SPORT MED, V34, P262, DOI 10.1136/bjsm.34.4.262; Steptoe A, 1999, BRIT MED J, V319, P943, DOI 10.1136/bmj.319.7215.943; Teixeira-Salmela LF, 2001, J REHABIL MED, V33, P53; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4; Washburn RA, 1999, J CLIN EPIDEMIOL, V52, P643, DOI 10.1016/S0895-4356(99)00049-9	36	83	83	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 22	2009	339								b2810	10.1136/bmj.b2810	http://dx.doi.org/10.1136/bmj.b2810			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	475IL	19900934	Green Published, hybrid			2023-01-03	WOS:000268351700008
J	Volpp, KG; Friedman, W; Romano, PS; Rosen, A; Silber, JH				Volpp, Kevin G.; Friedman, William; Romano, Patrick S.; Rosen, Amy; Silber, Jeffrey H.			Residency Training at a Crossroads: Duty-Hour Standards 2010	ANNALS OF INTERNAL MEDICINE			English	Article							MORTALITY; RISK; SLEEP; TIME	In 2003, the Accreditation Council for Graduate Medical Education (ACGME) implemented a single duty-hour standard nationwide. The evidence to date suggests that this neither improved nor worsened patient outcomes. In June 2010, the ACGME proposed a new set of duty-hour standards for implementation in July 2011. The main disadvantage of this approach is that there is no ability to determine whether different standards would have worked better to reduce resident fatigue while improving patient safety. Many unanswered questions remain about how to design duty-hour standards, but relatively little evidence exists. In addition, the same approach may not work in all specialties and all hospitals. A more flexible, dynamic policy that emphasizes ongoing testing and evaluation would be more likely to achieve improvements in clinical and educational outcomes.	[Silber, Jeffrey H.] Childrens Hosp Philadelphia, Ctr Outcomes Res, Philadelphia, PA 19104 USA; Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA; Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA; Univ Florida, Gainesville, FL 32610 USA; Univ Calif Davis, Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA; Vet Affairs Boston Healthcare Syst, Ctr Org Leadership & Management Res, Boston, MA USA; Boston Univ, Sch Publ Hlth, Boston, MA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Pennsylvania Medicine; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; State University System of Florida; University of Florida; University of California System; University of California Davis; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System; Boston University	Silber, JH (corresponding author), Childrens Hosp Philadelphia, Ctr Outcomes Res, 3535 Market St,Suite 1029, Philadelphia, PA 19104 USA.	silber@email.chop.edu	Romano, Patrick S/N-4225-2014; Friedman, William/GLR-1220-2022	Romano, Patrick S/0000-0001-6749-3979; Volpp, Kevin/0000-0003-1423-4599	National Heart, Lung, and Blood Institute [R01 HL082637]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082637] Funding Source: NIH RePORTER	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	By grant R01 HL082637 from the National Heart, Lung, and Blood Institute.	Antiel RM, 2010, NEW ENGL J MED, V363, DOI 10.1056/NEJMp1008305; Arora VM, 2008, QUAL SAF HEALTH CARE, V17, P11, DOI 10.1136/qshc.2006.018952; Arora V, 2006, ANN INTERN MED, V144, P792, DOI 10.7326/0003-4819-144-11-200606060-00005; Arora VM, 2009, J HOSP MED, V4, P433, DOI 10.1002/jhm.573; Ayas NT, 2006, JAMA-J AM MED ASSOC, V296, P1055, DOI 10.1001/jama.296.9.1055; Barger LK, 2005, NEW ENGL J MED, V352, P125, DOI 10.1056/NEJMoa041401; Ericsson KA, 2008, ACAD EMERG MED, V15, P988, DOI 10.1111/j.1553-2712.2008.00227.x; Kirch DG, 2010, COMMUNICATION   0809; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Nasca P., 2010, BASICS ZYNADDSUBFX; Nasca TJ, 2010, NEW ENGL J MED, V363, DOI 10.1056/NEJMsb1005800; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Pollack R, 2010, COMMUNICATION   0806; Richardson GS, 1996, SLEEP, V19, P718; Rosen AK, 2009, MED CARE, V47, P723, DOI 10.1097/MLR.0b013e31819a588f; Shetty KD, 2007, ANN INTERN MED, V147, P73, DOI 10.7326/0003-4819-147-2-200707170-00161; Silber JH, 2009, MED CARE, V47, P1191, DOI 10.1097/MLR.0b013e3181adcbff; Ulmer C, 2009, RESIDENT DUTY HOURS: ENHANCING SLEEP, SUPERVISION, AND SAFETY, P1; Volpp KG, 2008, JAMA-J AM MED ASSOC, V300, P1197, DOI 10.1001/jama.300.10.1197; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P984, DOI 10.1001/jama.298.9.984; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P975, DOI 10.1001/jama.298.9.975; Volpp KG, 2009, J GEN INTERN MED, V24, P1149, DOI 10.1007/s11606-009-1011-z	22	15	15	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	2010	153	12					826	+		10.7326/0003-4819-153-12-201012210-00287	http://dx.doi.org/10.7326/0003-4819-153-12-201012210-00287			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PL	20956679	Green Accepted			2023-01-03	WOS:000285453700006
J	Seymour, JE; French, J; Richardson, E				Seymour, Jane E.; French, Jeff; Richardson, Eve			Spotlight: Palliative Care Beyond Cancer Dying matters: let's talk about it	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN-ASSISTED SUICIDE; HOSPICE CARE; ATTITUDES; DEATH; LIFE; END		[Seymour, Jane E.] Univ Nottingham, Sch Nursing Midwif & Physiother, Nottingham NG7 2HA, England; [French, Jeff] Strateg Soc Marketing, Liphook, Guildford GU30 7QW, England; [Richardson, Eve] Natl Council Palliat Care, London N7 9AS, England	University of Nottingham	Seymour, JE (corresponding author), Univ Nottingham, Sch Nursing Midwif & Physiother, Nottingham NG7 2HA, England.	jane.seymour@nottingham.ac.uk	Seymour, Jane E/C-1610-2009	Seymour, Jane E/0000-0002-9384-2551	National Council for Palliative Care	National Council for Palliative Care	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: JS had support from the National Council for Palliative Care and the National End of Life Care Programme for the submitted work; JF is a consultant to the Dying Matters coalition; no other relationships or activities that could appear to have influenced the submitted work.	Arber S, 2008, J AGING STUD, V22, P366, DOI 10.1016/j.jaging.2008.05.009; Bauman Zygmunt, 1992, MORTALITY IMMORTALIT; Berger Peter Ludwig, 1973, SOCIAL REALITY RELIG; Born Wendi, 2004, J Palliat Med, V7, P247, DOI 10.1089/109662104773709369; Burdette AM, 2005, J SCI STUD RELIG, V44, P79, DOI 10.1111/j.1468-5906.2005.00266.x; Catt S, 2005, PALLIATIVE MED, V19, P402, DOI 10.1191/0269216305pm1037oa; CLARK DA, 2007, EUR J PALLIAT CARE S; Clery E, 2007, BRIT SOCIAL ATTITUDE; Department of Health, 2008, END LIF CAR STRAT PR; *DYING MATT COAL, 2009, NATCEN SURV ATT DYIN; Emanuel EJ, 2002, ARCH INTERN MED, V162, P142, DOI 10.1001/archinte.162.2.142; French J., 2017, SOCIAL MARKETING PUB, VSecond, DOI 10.1093/med/9780198717690.001.0001; *HLTH CAR COMM, 2009, SPOTL COMPL REP 2 ST, V9; *ICM RES END UK, 2006, HAV GOOD HLTH GEN PU; Johnson KS, 2008, J AM GERIATR SOC, V56, P1953, DOI 10.1111/j.1532-5415.2008.01919.x; Kellehear A., 2008, Critical Public Health, V18, P111, DOI 10.1080/09581590701848960; Lloyd-Williams M, 2007, J PAIN SYMPTOM MANAG, V34, P60, DOI 10.1016/j.jpainsymman.2006.09.028; *M CUR CANC CAR, 2004, VIEWS DYING HOM SURV; *NAT COUNC PALL CA, 2010, DYING MATT LETS TALK; O'Neill C, 2003, SOC SCI MED, V57, P721, DOI 10.1016/S0277-9536(02)00421-5; Rietjens JAC, 2006, PALLIATIVE MED, V20, P685, DOI 10.1177/0269216306070241; Scottish Government, 2008, LIV DYING WELL NAT A; Seymour J., 2009, PUBLIC ATTITUDES DEA; WILLIAMS R, 1990, PROTESTANT LEGACY AT	24	22	23	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c4860	10.1136/bmj.c4860	http://dx.doi.org/10.1136/bmj.c4860			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653MO	20847020				2023-01-03	WOS:000282095800003
J	Liberman, J; O'Brien, M; Hall, W; Hill, D				Liberman, Jonathan; O'Brien, Megan; Hall, Wayne; Hill, David			Ending inequities in access to effective pain relief?	LANCET			English	Editorial Material									[Liberman, Jonathan; O'Brien, Megan; Hill, David] Int Union Canc, Geneva, Switzerland; [Liberman, Jonathan] Canc Council Victoria, Canton S, Vic 3053, Australia; [O'Brien, Megan] Amer Canc Soc, Washington, DC USA; [Hall, Wayne] Univ Queensland, Clin Res Ctr, Brisbane, Qld, Australia	Cancer Council Victoria; American Cancer Society; University of Queensland	Liberman, J (corresponding author), Int Union Canc, Geneva, Switzerland.	jonathan.liberman@cancervic.org.au	Hall, Wayne D/A-3283-2008	Hall, Wayne D/0000-0003-1984-0096				Amon J, 2009, LANCET, V374, P1676, DOI 10.1016/S0140-6736(09)61990-5; [Anonymous], 1961, SINGL CONV NARC DRUG; [Anonymous], 2008, REP INT NARC CONTR B; Barrett D, 2009, UN DRUG POLICY HUMAN; Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581; Taylor AL, 2007, J LAW MED ETHICS, V35, P556, DOI 10.1111/j.1748-720X.2007.00180.x; *UN EC SOC COUNC C, 2010, UN EC SOC COUNC COMM; United Nations, 2010, REP INT NARC CONTR B; United Nations, 1971, CONV PSYCH SUBST; WHO Commission on Social Determinants of Health World Health Organization, 2008, CLOS GAP GEN HLTH EQ; World Health Organization, 2009, ACC CONTR MED PROGR	11	10	10	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 11	2010	376	9744					856	857		10.1016/S0140-6736(10)60880-X	http://dx.doi.org/10.1016/S0140-6736(10)60880-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	653DW	20833289				2023-01-03	WOS:000282069100010
J	Follett, KA; Weaver, FM; Stern, M; Hur, K; Harris, CL; Luo, P; Marks, WJ; Rothlind, J; Sagher, O; Moy, C; Pahwa, R; Burchiel, K; Hogarth, P; Lai, EC; Duda, JE; Holloway, K; Samii, A; Horn, S; Bronstein, JM; Stoner, G; Starr, PA; Simpson, R; Baltuch, G; De Salles, A; Huang, GD; Reda, DJ				Follett, Kenneth A.; Weaver, Frances M.; Stern, Matthew; Hur, Kwan; Harris, Crystal L.; Luo, Ping; Marks, William J., Jr.; Rothlind, Johannes; Sagher, Oren; Moy, Claudia; Pahwa, Rajesh; Burchiel, Kim; Hogarth, Penelope; Lai, Eugene C.; Duda, John E.; Holloway, Kathryn; Samii, Ali; Horn, Stacy; Bronstein, Jeff M.; Stoner, Gatana; Starr, Philip A.; Simpson, Richard; Baltuch, Gordon; De Salles, Antonio; Huang, Grant D.; Reda, Domenic J.		CSP 468 Study Grp	Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; GLOBUS-PALLIDUS; FOLLOW-UP; MOTOR FLUCTUATIONS; NUCLEUS; TRIAL; VALIDATION; EFFICACY	BACKGROUND Deep-brain stimulation is the surgical procedure of choice for patients with advanced Parkinson's disease. The globus pallidus interna and the subthalamic nucleus are accepted targets for this procedure. We compared 24-month outcomes for patients who had undergone bilateral stimulation of the globus pallidus interna (pallidal stimulation) or subthalamic nucleus (subthalamic stimulation). METHODS At seven Veterans Affairs and six university hospitals, we randomly assigned 299 patients with idiopathic Parkinson's disease to undergo either pallidal stimulation (152 patients) or subthalamic stimulation (147 patients). The primary outcome was the change in motor function, as blindly assessed on the Unified Parkinson's Disease Rating Scale, part III (UPDRS-III), while patients were receiving stimulation but not receiving antiparkinsonian medication. Secondary outcomes included self-reported function, quality of life, neurocognitive function, and adverse events. RESULTS Mean changes in the primary outcome did not differ significantly between the two study groups (P=0.50). There was also no significant difference in self-reported function. Patients undergoing subthalamic stimulation required a lower dose of dopaminergic agents than did those undergoing pallidal stimulation (P=0.02). One component of processing speed (visuomotor) declined more after subthalamic stimulation than after pallidal stimulation (P=0.03). The level of depression worsened after subthalamic stimulation and improved after pallidal stimulation (P=0.02). Serious adverse events occurred in 51% of patients undergoing pallidal stimulation and in 56% of those undergoing subthalamic stimulation, with no significant between-group differences at 24 months. CONCLUSIONS Patients with Parkinson's disease had similar improvement in motor function after either pallidal or subthalamic stimulation. Nonmotor factors may reasonably be included in the selection of surgical target for deep-brain stimulation. (ClinicalTrials.gov numbers, NCT00056563 and NCT01076452.)	[Weaver, Frances M.] Hines Vet Affairs Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA; [Follett, Kenneth A.] Iowa City Vet Affairs Med Ctr, Iowa City, IA USA; [Stoner, Gatana] Univ Iowa Hlth Care, Iowa City, IA USA; [Follett, Kenneth A.] Univ Nebraska Med Ctr, Omaha, NE USA; [Hur, Kwan; Luo, Ping; Reda, Domenic J.] Hines Vet Affairs Hosp, Cooperat Studies Coordinating Ctr, Hines, IL 60141 USA; [Weaver, Frances M.] Loyola Univ, Stritch Sch Med, Maywood, IL 60153 USA; [Stern, Matthew; Horn, Stacy; Baltuch, Gordon] Univ Penn Hlth Syst, Philadelphia, PA USA; [Stern, Matthew; Duda, John E.; Baltuch, Gordon] Philadelphia VA Med Ctr, Philadelphia, PA USA; [Harris, Crystal L.] VA Cooperat Studies Program, Clin Res Pharm, Albuquerque, NM USA; [Marks, William J., Jr.; Rothlind, Johannes; Starr, Philip A.] San Francisco VA Med Ctr, San Francisco, CA USA; [Marks, William J., Jr.; Rothlind, Johannes; Starr, Philip A.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Sagher, Oren] Univ Michigan, Med Ctr, Ann Arbor, MI USA; [Moy, Claudia] NINDS, Rockville, MD USA; [Pahwa, Rajesh] Univ Kansas, Med Ctr, Kansas City, MO USA; [Burchiel, Kim] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Burchiel, Kim; Hogarth, Penelope] Portland VA Med Ctr, Portland, OR USA; [Lai, Eugene C.; Simpson, Richard] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Lai, Eugene C.; Simpson, Richard] Baylor Coll Med, Houston, TX 77030 USA; [Hur, Kwan] Richmond VA Med Ctr, Richmond, VA USA; [Samii, Ali] VA Puget Sound Hlth Care Syst, Seattle, WA USA; [Bronstein, Jeff M.; De Salles, Antonio] Univ Calif Los Angeles, W Los Angeles VA Med Ctr, Los Angeles, CA USA; [Bronstein, Jeff M.; De Salles, Antonio] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Huang, Grant D.] US Dept Vet Affairs, Cooperat Studies Program, Cent Off, Washington, DC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Kansas; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; Baylor College of Medicine; Baylor College of Medicine; Hunter Holmes McGuire Veterinary Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs	Weaver, FM (corresponding author), Hines Vet Affairs Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave,151H, Hines, IL 60141 USA.	frances.weaver@va.gov	Weaver, Frances/S-1540-2019; Larson, Paul/AAT-9415-2020	, Domenic/0000-0003-1831-4270; Holloway, Kathryn/0000-0003-3777-0060	Department of Veterans Affairs Office of Research and Development; National Institute of Neurological Disorders and Stroke; Medtronic; Novartis; Teva; Schering-Plough; Boehringer Ingelheim; Vernalis; Ipsen; Ceregene; Sofamor Danek; Schering-Plough Research Institute; Samueli Institute; Ipsen Pharmaceuticals; Teva Pharmaceuticals; Boston Scientific; SurgiVision	Department of Veterans Affairs Office of Research and Development(US Department of Veterans Affairs); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Medtronic(Medtronic); Novartis(Novartis); Teva(Teva Pharmaceutical Industries); Schering-Plough(Merck & CompanySchering Plough Corporation); Boehringer Ingelheim(Boehringer Ingelheim); Vernalis; Ipsen(Ipsen); Ceregene; Sofamor Danek; Schering-Plough Research Institute(Merck & Company); Samueli Institute; Ipsen Pharmaceuticals(Ipsen); Teva Pharmaceuticals(Teva Pharmaceutical Industries); Boston Scientific(Boston Scientific); SurgiVision	Supported by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development, the National Institute of Neurological Disorders and Stroke, and Medtronic.; Dr. Stern reports receiving consulting fees from Novartis, Teva, Schering-Plough, Boehringer Ingelheim, Vernalis, and Ipsen and lecture fees from Novartis and having an equity interest in Adamis; Dr. Harris, having an equity interest in Johnson & Johnson; Dr. Marks, receiving consulting and lecture fees from Medtronic and grant support from Boehringer Ingelheim and Ceregene; Dr. Pahwa, receiving consulting and lecture fees from Medtronic; Dr. Burchiel, having an equity interest in Medtronic and receiving grant support from Medtronic and Sofamor Danek; Dr. Hogarth, receiving grant support from Schering-Plough Research Institute; Dr. Lai, receiving grant support from Medtronic; Dr. Duda, receiving consulting fees from Boehringer Ingelheim and grant support from the Samueli Institute; Dr. Holloway, receiving consulting fees and grant support from Medtronic; Dr. Samii, receiving lecture fees from Ipsen Pharmaceuticals, Boehringer Ingelheim, and Teva Pharmaceuticals; Dr. Starr, receiving consulting fees from Medtronic and Boston Scientific and grant support from SurgiVision; Dr. Simpson, receiving consulting and lecture fees from Medtronic; and Dr. De Salles, receiving fellowship support from Medtronic. No other potential conflict of interest relevant to this article was reported.	Anderson VC, 2005, ARCH NEUROL-CHICAGO, V62, P554, DOI 10.1001/archneur.62.4.554; Barcio-Salorio JL, 1999, STEREOT FUNCT NEUROS, V72, P202, DOI 10.1159/000029727; Deuschl G, 2006, NEW ENGL J MED, V355, P896, DOI 10.1056/NEJMoa060281; Durif F, 2002, MOVEMENT DISORD, V17, P803, DOI 10.1002/mds.10128; Fahn S, 1987, RECENT DEV PARKINSON, V2, P153; Ghika J, 1998, J NEUROSURG, V89, P713, DOI 10.3171/jns.1998.89.5.0713; Goetz CG, 1997, MOVEMENT DISORD, V12, P1039, DOI 10.1002/mds.870120631; Gross C, 1997, J NEUROSURG, V87, P491, DOI 10.3171/jns.1997.87.4.0491; Hauser RA, 2004, MOVEMENT DISORD, V19, P1409, DOI 10.1002/mds.20248; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; Houeto JL, 2000, NEUROLOGY, V55, P728, DOI 10.1212/WNL.55.5.728; Krack P, 2003, NEW ENGL J MED, V349, P1925, DOI 10.1056/NEJMoa035275; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Lyons KE, 2002, STEREOT FUNCT NEUROS, V79, P214, DOI 10.1159/000070834; Okun MS, 2009, ANN NEUROL, V65, P586, DOI 10.1002/ana.21596; Peto V, 1998, J NEUROL, V245, pS10, DOI 10.1007/PL00007730; Rodriguez-Oroz MC, 2005, BRAIN, V128, P2240, DOI 10.1093/brain/awh571; Schrag A, 2000, J NEUROL NEUROSUR PS, V69, P308, DOI 10.1136/jnnp.69.3.308; Schrag A, 2006, MOVEMENT DISORD, V21, P1200, DOI 10.1002/mds.20914; Schwab J., 1968, 3 S PARK DIS, P152; Volkmann J, 2004, ANN NEUROL, V55, P871, DOI 10.1002/ana.20091; Volkmann J, 2004, J CLIN NEUROPHYSIOL, V21, P6, DOI 10.1097/00004691-200401000-00003; Weaver F, 2005, J NEUROSURG, V103, P956, DOI 10.3171/jns.2005.103.6.0956; Weaver FM, 2009, JAMA-J AM MED ASSOC, V301, P63, DOI 10.1001/jama.2008.929; Zahodne LB, 2009, J NEUROL, V256, P1321, DOI 10.1007/s00415-009-5121-7	25	853	880	2	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2010	362	22					2077	2091		10.1056/NEJMoa0907083	http://dx.doi.org/10.1056/NEJMoa0907083			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603XU	20519680				2023-01-03	WOS:000278242200007
J	Filippi, M; Riccitelli, G; Falini, A; Di Salle, F; Vuilleumier, P; Comi, G; Rocca, MA				Filippi, Massimo; Riccitelli, Gianna; Falini, Andrea; Di Salle, Francesco; Vuilleumier, Patrik; Comi, Giancarlo; Rocca, Maria A.			The Brain Functional Networks Associated to Human and Animal Suffering Differ among Omnivores, Vegetarians and Vegans	PLOS ONE			English	Article							AMYGDALA RESPONSE; EMPATHY QUOTIENT; EMOTION; FMRI; STIMULI; CORTEX; METAANALYSIS; NEUROSCIENCE; MODULATION; SYSTEMS	Empathy and affective appraisals for conspecifics are among the hallmarks of social interaction. Using functional MRI, we hypothesized that vegetarians and vegans, who made their feeding choice for ethical reasons, might show brain responses to conditions of suffering involving humans or animals different from omnivores. We recruited 20 omnivore subjects, 19 vegetarians, and 21 vegans. The groups were matched for sex and age. Brain activation was investigated using fMRI and an event-related design during observation of negative affective pictures of human beings and animals (showing mutilations, murdered people, human/animal threat, tortures, wounds, etc.). Participants saw negative-valence scenes related to humans and animals, alternating with natural landscapes. During human negative valence scenes, compared with omnivores, vegetarians and vegans had an increased recruitment of the anterior cingulate cortex (ACC) and inferior frontal gyrus (IFG). More critically, during animal negative valence scenes, they had decreased amygdala activation and increased activation of the lingual gyri, the left cuneus, the posterior cingulate cortex and several areas mainly located in the frontal lobes, including the ACC, the IFG and the middle frontal gyrus. Nonetheless, also substantial differences between vegetarians and vegans have been found responding to negative scenes. Vegetarians showed a selective recruitment of the right inferior parietal lobule during human negative scenes, and a prevailing activation of the ACC during animal negative scenes. Conversely, during animal negative scenes an increased activation of the inferior prefrontal cortex was observed in vegans. These results suggest that empathy toward non conspecifics has different neural representation among individuals with different feeding habits, perhaps reflecting different motivational factors and beliefs.	[Filippi, Massimo; Riccitelli, Gianna; Rocca, Maria A.] Inst Sci, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, Milan, Italy; [Filippi, Massimo; Riccitelli, Gianna; Falini, Andrea; Rocca, Maria A.] Univ Hosp San Raffaele, Milan, Italy; [Filippi, Massimo; Rocca, Maria A.] Inst Sci, Dept Neurol, Milan, Italy; [Falini, Andrea] Inst Sci, Dept Neuroradiol, Milan, Italy; [Di Salle, Francesco] Univ Maastricht, Dept Cognit Neurosci, Maastricht Brain Imaging Ctr, Maastricht, Netherlands; [Vuilleumier, Patrik] Univ Geneva, Ctr Med Univ Geneva, Geneva, Switzerland	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Maastricht University; University of Geneva	Filippi, M (corresponding author), Inst Sci, Neuroimaging Res Unit, Inst Expt Neurol, Div Neurosci, Milan, Italy.	filippi.massimo@hsr.it	Filippi, Massimo/K-1755-2018; Vuilleumier, Patrik/AAJ-1839-2021; Rocca, Maria Assunta/K-1619-2018; Riccitelli, Gianna Carla/AAD-9415-2020	Filippi, Massimo/0000-0002-5485-0479; Vuilleumier, Patrik/0000-0002-8198-9214; Rocca, Maria Assunta/0000-0003-2358-4320; Riccitelli, Gianna Carla/0000-0002-1202-5534; falini, andrea/0000-0002-1461-8755				Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; Botvinick MM, 2007, COGN AFFECT BEHAV NE, V7, P356, DOI 10.3758/CABN.7.4.356; Chakrabarti B, 2006, SOC NEUROSCI-UK, V1, P364, DOI 10.1080/17470910601041317; Cheng YW, 2007, CURR BIOL, V17, P1708, DOI 10.1016/j.cub.2007.09.020; DARGEMBEAU A, 2009, J COGN NEUROSCI; Decety J, 2003, CONSCIOUS COGN, V12, P577, DOI 10.1016/S1053-8100(03)00076-X; Decety Jean, 2004, Behav Cogn Neurosci Rev, V3, P71, DOI 10.1177/1534582304267187; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Duvernoy H.M., 1999, HUMAN BRAIN SURFACE; Friston KJ, 2005, NEUROIMAGE, V25, P661, DOI 10.1016/j.neuroimage.2005.01.013; Friston KJ, 1999, NEUROIMAGE, V10, P385, DOI 10.1006/nimg.1999.0484; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Harenski CL, 2006, NEUROIMAGE, V30, P313, DOI 10.1016/j.neuroimage.2005.09.034; Hariri AR, 2003, BIOL PSYCHIAT, V53, P494, DOI 10.1016/S0006-3223(02)01786-9; Hariri AR, 2002, NEUROIMAGE, V17, P317, DOI 10.1006/nimg.2002.1179; Hein G, 2008, CURR OPIN NEUROBIOL, V18, P153, DOI 10.1016/j.conb.2008.07.012; Iacoboni M, 2009, ANNU REV PSYCHOL, V60, P653, DOI 10.1146/annurev.psych.60.110707.163604; Kapogiannis D, 2009, P NATL ACAD SCI USA, V106, P4876, DOI 10.1073/pnas.0811717106; Lang P. J., 2008, INT AFFECTIVE PICTUR, DOI DOI 10.1007/978-3-319-28099-8_42-1; Lawrence EJ, 2004, PSYCHOL MED, V34, P911, DOI 10.1017/S0033291703001624; Maddock RJ, 1999, TRENDS NEUROSCI, V22, P310, DOI 10.1016/S0166-2236(98)01374-5; Mottaghy FM, 2006, NEUROIMAGE, V29, P225, DOI 10.1016/j.neuroimage.2005.07.034; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Phillips ML, 1997, NATURE, V389, P495, DOI 10.1038/39051; Regan T., 1985, CASE ANIMAL RIGHTS; Rubia K, 2003, NEUROIMAGE, V20, P351, DOI 10.1016/S1053-8119(03)00275-1; Schienle A, 2006, NEUROSCI LETT, V393, P174, DOI 10.1016/j.neulet.2005.09.072; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2006, NATURE, V439, P466, DOI 10.1038/nature04271; Singer T, 2004, NEURON, V41, P653, DOI 10.1016/S0896-6273(04)00014-5; Singer T, 2006, NEUROSCI BIOBEHAV R, V30, P855, DOI 10.1016/j.neubiorev.2006.06.011; Singer T, 2009, ANN NY ACAD SCI, V1156, P81, DOI 10.1111/j.1749-6632.2009.04418.x; Teasdale JD, 1999, AM J PSYCHIAT, V156, P209; Van Overwalle F, 2009, HUM BRAIN MAPP, V30, P829, DOI 10.1002/hbm.20547; Vuilleumier P, 2001, NEURON, V30, P829, DOI 10.1016/S0896-6273(01)00328-2; Westbury HR, 2008, BIOL PSYCHOL, V78, P66, DOI 10.1016/j.biopsycho.2007.12.009	39	50	52	5	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2010	5	5							e10847	10.1371/journal.pone.0010847	http://dx.doi.org/10.1371/journal.pone.0010847			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	603PW	20520767	gold, Green Submitted, Green Published			2023-01-03	WOS:000278221500032
J	Ford, N; Darder, M; Spelman, T; Maclean, E; Mills, E; Boulle, A				Ford, Nathan; Darder, Marta; Spelman, Tim; Maclean, Emi; Mills, Edward; Boulle, Andrew			Early Adherence to Antiretroviral Medication as a Predictor of Long-Term HIV Virological Auppression: Five-Year Follow Up of an Observational Cohort	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; CLINICAL-TRIALS; SOUTH-AFRICA; VIRAL LOAD; THERAPY; METAANALYSIS; KHAYELITSHA; SURVIVAL; OUTCOMES; FAILURE	Background: The majority of antiretroviral treatment programmes in sub-Saharan Africa are scaling up antiretroviral treatment using a fixed dose first-line antiretroviral regimen containing stavudine, lamivudine, and nevirapine. One of the primary concerns with the use of this regimen is nevirapine-associated hepatotoxicity. Methodology: Study participants were 1809 HIV-infected, antiretroviral naive adults initiating nevirapine-based antiretroviral therapy between November 2002 and December 2006. The primary outcome was early hepatotoxicity. Secondary outcomes were associations with hepatotoxicity and mortality at six months. The cumulative proportion of early hepatotoxicity ranged from 1.0-2.0% giving an incidence-rate at 102 days of 3.6-7.6 per 100 person-years. Median time to hepatotoxicity was 32 (IQR 28-58) days. At 12 weeks, only 8% of patients had alanine aminotransferase monitoring at all the time-points recommended by national guidelines. No association was found between age, gender, baseline CD4 count, concurrent tuberculosis infection, prior participation in a prevention of mother-to-child-transmission program, or baseline weight and early hepatotoxicity. There was no association between early hepatotoxicity and mortality. Conclusions: The cumulative proportion of early hepatotoxicity in nevirapine based antiretroviral therapy was low in this resource-constrained setting. Hepatotoxicity was not associated with mortality. Frequent routine monitoring of alanine aminotransferase proved difficult to implement in this public sector primary care programme. Focused monitoring in the first month may be a more cost-effective and pragmatic option in settings with limited resources. Correlation with clinical signs and symptoms may allow future alanine aminotransferase testing to be dictated by clinical criteria.	[Ford, Nathan; Darder, Marta; Maclean, Emi] Med Sans Frontieres, Cape Town, South Africa; [Spelman, Tim] Burnet Inst, Melbourne, Vic, Australia; [Mills, Edward] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada; [Boulle, Andrew] Univ Cape Town, Ctr Infect Dis & Epidemiol Res, ZA-7925 Cape Town, South Africa	Burnet Institute; University of Ottawa; University of Cape Town	Ford, N (corresponding author), Med Sans Frontieres, Cape Town, South Africa.	nathan.ford@joburg.msf.org	Boulle, Andrew/C-1413-2008	Boulle, Andrew/0000-0002-7713-8062	M�decins Sans Fronti�res [09_NAT_ERB_014] Funding Source: researchfish	M�decins Sans Fronti�res		Ahoua L, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-81; Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201; Boulle A, 2009, 5 IAS C HIV PATH TRE; Boulle A, 2007, ANTIVIR THER, V12, P753; Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Byakika-Tusiime J, 2009, AIDS BEHAV, V13, pS82, DOI 10.1007/s10461-009-9546-x; Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073; Chesney MA, 2000, AIDS CARE, V12, P255, DOI 10.1080/09540120050042891; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Colosimo EA, 2002, J STAT COMPUT SIM, V72, P299, DOI 10.1080/00949650212847; Ford N, 2009, LANCET, V374, P2064, DOI 10.1016/S0140-6736(09)61671-8; Friedland GH, 2006, JAIDS-J ACQ IMM DEF, V43, pS3, DOI 10.1097/01.qai.0000248333.44449.ea; Garcia R, 2006, AIDS RES HUM RETROV, V22, P1248, DOI 10.1089/aid.2006.22.1248; Gill VS, 2010, CLIN INFECT DIS, V50, P98, DOI 10.1086/648729; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Keiser O, 2008, TROP MED INT HEALTH, V13, P870, DOI 10.1111/j.1365-3156.2008.02078.x; Martin M, 2008, AIDS RES HUM RETROV, V24, P1263, DOI 10.1089/aid.2008.0141; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; Orrell C, 2009, ANTIVIR THER, V14, P523; Oyugi JH, 2004, JAIDS-J ACQ IMM DEF, V36, P1100, DOI 10.1097/00126334-200408150-00014; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008	23	59	60	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 5	2010	5	5							e10460	10.1371/journal.pone.0010460	http://dx.doi.org/10.1371/journal.pone.0010460			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	592LC	20485480	Green Published, gold			2023-01-03	WOS:000277379400012
J	Strom, T; Martinussen, T; Toft, P				Strom, Thomas; Martinussen, Torben; Toft, Palle			A protocol of no sedation for critically ill patients receiving mechanical ventilation: a randomised trial	LANCET			English	Article							INTENSIVE-CARE-UNIT; CONFUSION ASSESSMENT METHOD; DAILY INTERRUPTION; PROPOFOL; ANALGESICS; INFUSIONS; EFFICACY; DELIRIUM	Background Standard treatment of critically ill patients undergoing mechanical ventilation is continuous sedation. Daily interruption of sedation has a beneficial effect, and in the general intesive care unit of Odense University Hospital, Denmark, standard practice is a protocol of no sedation. We aimed to establish whether duration of mechanical ventilation could be reduced with a protocol of no sedation versus daily interruption of sedation. Methods Of 428 patients assessed for eligibility, we enrolled 140 critically ill adult patients who were undergoing mechanical ventilation and were expected to need ventilation for more than 24 h. Patients were randomly assigned in a 1:1 ratio (unblinded) to receive: no sedation (n=70 patients); or sedation (20 mg/mL propofal for 48 h, 1 mg/mL midazolam thereafter) with daily interruption until awake (n=70, control group). Both groups were treated with bolus doses of morphine (2.5 or 5 mg). The primary outcome was the number of days without mechanical ventilation in a 28-day period, and we also recorded the length of stay in the intensive care unit (from admission to 28 days) and in hospital (from admission to 90 days). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00466492. Findings 27 patients died or were successfully extubated within 48 h, and, as per our study design, were excluded from the study and statistical analysis. Patients receiving no sedation had significantly more days without ventilation (n=55; mean 13.8 days, SD 11.0) than did those receiving interrupted sedation (n=58; mean 9.6 days, SD 10.0; mean difference 4.2 days, 95% CI 0.3-8.1; p=0.0191). No sedation was also associated with a shorter stay in the intensive care unit (H R 1.86, 95% Cl 1.05-3.23; p=0.0316), and, for the first 30 days studied, in hospital (3.57, 1.52-9.09; p=0.0039), than was interrupted sedation. No difference was recorded in the occurrences of accidental extubations, the need for CT or MRI brain scans, or ventilator-associated pneumonia. Agitated delirium was more frequent in the intervention group than in the control group (n=11, 20% vs n=4, 7%; p=0.0400). Interpretation No sedation of critically ill patients receiving mechanical ventilation is associated with an increase in days without ventilation. A multicentre study is needed to establish whether this effect can be reproduced in other facilities.	[Strom, Thomas; Toft, Palle] Univ So Denmark, Odense Univ Hosp, Dept Anesthesia & Intens Care Med, DK-5000 Odense C, Denmark; [Martinussen, Torben] Univ So Denmark, Fac Hlth Sci, Dept Biostat, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark	Strom, T (corresponding author), Univ So Denmark, Odense Univ Hosp, Dept Anesthesia & Intens Care Med, DK-5000 Odense C, Denmark.	t.s@dadlnet.dk		Toft, Palle/0000-0002-3188-449X; Strom, Thomas/0000-0002-1868-0978	Fund of Danielsen; Danish Society of Anesthesiology and Intensive Care Medicine; Fund of Kirsten Jensa la Cour; Fund of Holger og Ruth Hess	Fund of Danielsen; Danish Society of Anesthesiology and Intensive Care Medicine; Fund of Kirsten Jensa la Cour; Fund of Holger og Ruth Hess	PT and TS received research grants from the Fund of Danielsen; and TS received research grants from the Danish Society of Anesthesiology and Intensive Care Medicine, the Fund of Kirsten Jensa la Cour, and the Fund of Holger og Ruth Hess. None of these funding organisations affected the trial or publication. We thank the nurses and our colleagues in the Department of Anesthesia and intensive Care Medicine at Odense University Hospital for their participation and support in the study.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arroliga A, 2005, CHEST, V128, P496, DOI 10.1378/chest.128.2.496; Brook AD, 1999, CRIT CARE MED, V27, P2609, DOI 10.1097/00003246-199912000-00001; Egerod I, 2006, INTENS CARE MED, V32, P60, DOI 10.1007/s00134-005-2856-1; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2001, CRIT CARE MED, V29, P1370, DOI 10.1097/00003246-200107000-00012; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Girard TD, 2009, CRIT CARE MED, V37, P2654, DOI 10.1097/CCM.0b013e3181ad76f4; Hall Jesse B, 2009, Crit Care Med, V37, pS416, DOI 10.1097/CCM.0b013e3181b6f95b; Jacobi J, 2002, CRIT CARE MED, V30, P119, DOI 10.1097/00003246-200201000-00020; Jones C, 2001, CRIT CARE MED, V29, P573, DOI 10.1097/00003246-200103000-00019; Kam PCA, 2007, ANAESTHESIA, V62, P690, DOI 10.1111/j.1365-2044.2007.05055.x; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 2003, AM J RESP CRIT CARE, V168, P1457, DOI 10.1164/rccm.200303-455OC; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; MARTINUSSEN T, 2006, STAT BIOL HEALTH, P1; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Peeters MMM, 2008, CLIN PHARMACOL THER, V83, P443, DOI 10.1038/sj.clpt.6100309; Petty TL, 1998, CHEST, V114, P360, DOI 10.1378/chest.114.2.360; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Schweickert WD, 2004, CRIT CARE MED, V32, P1272, DOI 10.1097/01.CCM.0000127263.54807.79; Vasile B, 2003, INTENS CARE MED, V29, P1417, DOI 10.1007/s00134-003-1905-x; Vincent Jean-Louis, 2009, Crit Care Med, V37, pS296, DOI 10.1097/CCM.0b013e3181b6f1e1	25	557	601	0	42	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 6	2010	375	9713					475	480		10.1016/S0140-6736(09)62072-9	http://dx.doi.org/10.1016/S0140-6736(09)62072-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	558PV	20116842				2023-01-03	WOS:000274757900030
J	Snyderman, R; Dinan, MA				Snyderman, Ralph; Dinan, Michaela A.			Improving Health by Taking It Personally	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PRIMARY-CARE; MEDICINE; TRANSFORMATION; SUPPORT		[Snyderman, Ralph; Dinan, Michaela A.] Duke Univ, Med Ctr, Ctr Res Prospect Hlth Care, Durham, NC 27710 USA	Duke University	Snyderman, R (corresponding author), Duke Univ, Med Ctr, Ctr Res Prospect Hlth Care, DUMC 3059, Durham, NC 27710 USA.	ralph.snyderman@duke.edu						*DUK PROSP HLTH, DUK PROSP HLTH PROGR; Goroll AH, 2007, J GEN INTERN MED, V22, P410, DOI 10.1007/s11606-006-0083-2; Plomin R, 2009, NAT REV GENET, V10, P872, DOI 10.1038/nrg2670; Rosenthal TC, 2008, J AM BOARD FAM MED, V21, P427, DOI 10.3122/jabfm.2008.05.070287; Schoen C, 2007, HEALTH AFFAIR, V26, pW717, DOI 10.1377/hlthaff.26.6.w717; Snyderman R, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-104; Snyderman R, 2003, ACAD MED, V78, P1079, DOI 10.1097/00001888-200311000-00002; Whellan DJ, 2001, ARCH INTERN MED, V161, P2223, DOI 10.1001/archinte.161.18.2223; Williams RS, 2003, SCIENCE, V300, P549, DOI 10.1126/science.300.5619.549; Yoediono Z, 2008, PERS MED, V5, P47, DOI 10.2217/17410541.5.1.47	10	19	20	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	2010	303	4					363	364		10.1001/jama.2010.34	http://dx.doi.org/10.1001/jama.2010.34			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548IC	20103762				2023-01-03	WOS:000273952800027
J	Wang, Q; Mynar, JL; Yoshida, M; Lee, E; Lee, M; Okuro, K; Kinbara, K; Aida, T				Wang, Qigang; Mynar, Justin L.; Yoshida, Masaru; Lee, Eunji; Lee, Myongsoo; Okuro, Kou; Kinbara, Kazushi; Aida, Takuzo			High-water-content mouldable hydrogels by mixing clay and a dendritic molecular binder	NATURE			English	Article							NANOCOMPOSITE HYDROGELS; MEDICINE; POLYMER	With the world's focus on reducing our dependency on fossil-fuel energy, the scientific community can investigate new plastic materials that are much less dependent on petroleum than are conventional plastics. Given increasing environmental issues, the idea of replacing plastics with water-based gels, so-called hydrogels, seems reasonable. Here we report that water and clay (2-3 per cent by mass), when mixed with a very small proportion (<0.4 per cent by mass) of organic components, quickly form a transparent hydrogel. This material can be moulded into shape-persistent, free-standing objects owing to its exceptionally great mechanical strength, and rapidly and completely self-heals when damaged. Furthermore, it preserves biologically active proteins for catalysis. So far(1) no other hydrogels, including conventional ones formed by mixing polymeric cations and anions(2,3) or polysaccharides and borax(4), have been reported to possess all these features. Notably, this material is formed only by non-covalent forces resulting from the specific design of a telechelic dendritic macromolecule with multiple adhesive termini for binding to clay.	[Wang, Qigang; Mynar, Justin L.; Okuro, Kou; Kinbara, Kazushi; Aida, Takuzo] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, Tokyo 1138656, Japan; [Mynar, Justin L.; Aida, Takuzo] Natl Museum Emerging Sci & Innovat, Japan Sci & Technol Agcy, ERATO SORST Nanospace Project, Koto Ku, Tokyo 1350064, Japan; [Yoshida, Masaru] Natl Inst Adv Ind Sci & Technol, Nanotechnol Res Inst, Tsukuba, Ibaraki 3058565, Japan; [Lee, Eunji; Lee, Myongsoo] Seoul Natl Univ, Dept Chem, Seoul 151747, South Korea; [Lee, Eunji; Lee, Myongsoo] Seoul Natl Univ, Ctr Supramol Nanoassembly, Seoul 151747, South Korea	University of Tokyo; Japan Science & Technology Agency (JST); National Institute of Advanced Industrial Science & Technology (AIST); Seoul National University (SNU); Seoul National University (SNU)	Aida, T (corresponding author), Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138656, Japan.	jmynar@berkeley.edu; aida@macro.t.u-tokyo.ac.jp	Lee, Eunji/H-1301-2011; Wang, Qigang/G-1124-2010; Aida, Takuzo/I-9117-2012; Kinbara, Kazushi/E-6347-2017; Lee, Myongsoo/A-8106-2011; Yoshida, Masaru/B-7380-2018	Lee, Eunji/0000-0001-7494-1776; Wang, Qigang/0000-0002-4026-3337; Kinbara, Kazushi/0000-0002-5945-9612; Okuro, Kou/0000-0003-0445-6358; Yoshida, Masaru/0000-0002-9220-4312	Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	Q. W. thanks the Japan Society for the Promotion of Science postdoctoral fellowship for foreign researchers. We thank Y. Arakawa for his support for the synthesis of PEG-G3-dendron.	Carnahan MA, 2002, J AM CHEM SOC, V124, P5291, DOI 10.1021/ja025576y; Crompton KE, 2007, BIOMATERIALS, V28, P441, DOI 10.1016/j.biomaterials.2006.08.044; Das AK, 2008, SMALL, V4, P279, DOI 10.1002/smll.200700889; Dong L, 2006, NATURE, V442, P551, DOI 10.1038/nature05024; Gong JP, 2003, ADV MATER, V15, P1155, DOI 10.1002/adma.200304907; Haraguchi K, 2002, ADV MATER, V14, P1120, DOI 10.1002/1521-4095(20020816)14:16<1120::AID-ADMA1120>3.0.CO;2-9; Hirst AR, 2008, ANGEW CHEM INT EDIT, V47, P8002, DOI 10.1002/anie.200800022; Ihre H, 2001, J AM CHEM SOC, V123, P5908, DOI 10.1021/ja010524e; Jayawarna V, 2006, ADV MATER, V18, P611, DOI 10.1002/adma.200501522; Kiyonaka S, 2004, NAT MATER, V3, P58, DOI 10.1038/nmat1034; Ladet S, 2008, NATURE, V452, P76, DOI 10.1038/nature06619; Li P, 2009, J APPL POLYM SCI, V111, P1786, DOI 10.1002/app.29061; Liu Y, 2006, POLYMER, V47, P1, DOI 10.1016/j.polymer.2005.11.030; Marsich E, 2008, J BIOMED MATER RES A, V84A, P364, DOI 10.1002/jbm.a.31307; Nowak AP, 2002, NATURE, V417, P424, DOI 10.1038/417424a; Okada A, 2006, MACROMOL MATER ENG, V291, P1449, DOI 10.1002/mame.200600260; Okay O, 2007, MACROMOLECULES, V40, P3378, DOI 10.1021/ma062929v; Okuro K, 2009, J AM CHEM SOC, V131, P1626, DOI 10.1021/ja800491v; Peppas NA, 2000, ANNU REV BIOMED ENG, V2, P9, DOI 10.1146/annurev.bioeng.2.1.9; PEZRON E, 1988, MACROMOLECULES, V21, P1121, DOI 10.1021/ma00182a045; *ROCKW ADD LTD, 1990, L21101G ROCKW ADD LT; Rokita B, 2009, MACROMOLECULES, V42, P3269, DOI 10.1021/ma802565p; Schnepp ZAC, 2006, ADV MATER, V18, P1869, DOI 10.1002/adma.200502545; Sijbesma RP, 1997, SCIENCE, V278, P1601, DOI 10.1126/science.278.5343.1601; Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783; Sreenivasachary N, 2005, P NATL ACAD SCI USA, V102, P5938, DOI 10.1073/pnas.0501663102; Wang QG, 2007, CHEM COMMUN, P1032, DOI 10.1039/b615223f; Wathier M, 2004, J AM CHEM SOC, V126, P12744, DOI 10.1021/ja045870l; Xing BG, 2002, J AM CHEM SOC, V124, P14846, DOI 10.1021/ja028539f; Yoshida M, 2007, J AM CHEM SOC, V129, P11039, DOI 10.1021/ja0738677	30	1277	1328	54	1947	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 21	2010	463	7279					339	343		10.1038/nature08693	http://dx.doi.org/10.1038/nature08693			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	545PM	20090750				2023-01-03	WOS:000273748100040
J	Johansson, K; Neovius, M; Lagerros, YT; Harlid, R; Rossner, S; Granath, F; Hemmingsson, E				Johansson, Kari; Neovius, Martin; Lagerros, Ylva Trolle; Harlid, Richard; Roessner, Stephan; Granath, Fredrik; Hemmingsson, Erik			Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-CALORIE DIET; WEIGHT-REDUCTION PROGRAM; LONG-TERM MAINTENANCE; RISK-FACTORS; BARIATRIC SURGERY; MEDICAL THERAPY; LIFE-STYLE; EPIDEMIOLOGY; POPULATION; MORTALITY	Objective To assess the effect of weight loss induced by a very low energy diet on moderate and severe obstructive sleep apnoea in obese men. Design Single centre, two arm, parallel, randomised, controlled, open label trial. Blocked randomisation procedure used for treatment allocation. Setting Outpatient obesity clinic in a university hospital in Stockholm, Sweden. Participants 63 obese men (body mass index 30-40, age 30-65 years) with moderate to severe obstructive sleep apnoea (apnoea-hypopnoea index (AHI) >= 15), treated with continuous positive airway pressure. Interventions The intervention group received a liquid very low energy diet (2.3 MJ/day) for seven weeks to promote weight loss, followed by two weeks of gradual introduction of normal food, reaching 6.3 MJ/day at week 9. The control group adhered to their usual diet during the nine weeks of follow-up. Main outcome measure AHI, the major disease severity index for obstructive sleep apnoea. Data from all randomised patients were included in an intention to treat analysis ( baseline carried forward for missing data). Results Of the 63 eligible patients, 30 were randomised to intervention and 33 to control. Two patients in the control group were dissatisfied with allocation and immediately discontinued. All other patients completed the trial. Both groups had a mean AHI of 37 events/h (SD 15) at baseline. At week 9, the intervention group's mean body weight was 20 kg (95% confidence interval 18 to 21) lower than that of the control group, while its mean AHI was 23 events/h ( 15 to 30) lower. In the intervention group, five of 30 ( 17%) were disease free after the energy restricted diet ( AHI < 5), with 15 of 30 (50%) having mild disease (AHI 5-14.9), whereas the AHI of all patients in the control group except one remained at 15 or higher. In a subgroup analysis of the intervention group, baseline AHI significantly modified the effectiveness of treatment, with a greater improvement in AHI in patients with severe obstructive sleep apnoea (AHI > 30) at baseline compared with those with moderate (AHI 15-30) sleep apnoea (AHI -38 v -12, P<0.001), despite similar weight loss (-19.2 v -18.2 kg, P=0.55). Conclusion Treatment with a low energy diet improved obstructive sleep apnoea in obese men, with the greatest effect in patients with severe disease. Long term treatment studies are needed to validate weight loss as a primary treatment strategy for obstructive sleep apnoea. Trial registration Current Controlled Trials ISRCTN70090382.	[Johansson, Kari; Roessner, Stephan] Karolinska Inst, Dept Med, Obes Unit, SE-14186 Stockholm, Sweden; [Lagerros, Ylva Trolle; Granath, Fredrik] Karolinska Inst, Dept Med, Clin Epidemiol Unit, SE-14186 Stockholm, Sweden; [Harlid, Richard] Aleris Fysiologlab, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Johansson, K (corresponding author), Karolinska Inst, Dept Med, Obes Unit, M73, SE-14186 Stockholm, Sweden.	kari.johansson@ki.se	Johanson, Kari/AAZ-4397-2020; Lagerros, Ylva Trolle/AAH-7683-2020	Lagerros, Ylva Trolle/0000-0001-6816-7577; Hemmingsson, Erik/0000-0001-7335-3796; Neovius, Martin/0000-0003-2300-3055	Cambridge Manufacturing Company Limited; Novo Nordisk Scandinavia AB	Cambridge Manufacturing Company Limited; Novo Nordisk Scandinavia AB(Novo Nordisk)	This study was partly supported by a grant from Cambridge Manufacturing Company Limited and Novo Nordisk Scandinavia AB. The funders played no part in the analysis or write up of this paper.	Apfelbaum M, 1999, AM J MED, V106, P179, DOI 10.1016/S0002-9343(98)00411-2; Banno K, 2007, SLEEP MED, V8, P400, DOI 10.1016/j.sleep.2007.03.003; Bar A, 2003, CHEST, V123, P695, DOI 10.1378/chest.123.3.695; de Sousa AGP, 2008, OBES REV, V9, P340, DOI 10.1111/j.1467-789X.2008.00478.x; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Foster GD, 2009, DIABETES CARE, V32, P1017, DOI 10.2337/dc08-1776; Franz MJ, 2007, J AM DIET ASSOC, V107, P1755, DOI 10.1016/j.jada.2007.07.017; Fritscher LG, 2007, RESPIRATION, V74, P647, DOI 10.1159/000107736; Hakala K, 2000, CLIN PHYSIOL, V20, P50; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kajaste S, 2004, SLEEP MED, V5, P125, DOI 10.1016/j.sleep.2003.07.007; Kansanen M, 1998, CLIN PHYSIOL, V18, P377, DOI 10.1046/j.1365-2281.1998.00114.x; Kemppainen T, 2008, AM J RHINOL, V22, P410, DOI 10.2500/ajr.2008.22.3203; Lettieri CJ, 2008, J CLIN SLEEP MED, V4, P333; Lojander J, 1998, J INTERN MED, V244, P251; Marshall NS, 2008, SLEEP, V31, P1079; Mathus-Vliegen EMH, 2005, EUR J CLIN NUTR, V59, pS31, DOI 10.1038/sj.ejcn.1602172; Morgenthaler TI, 2006, SLEEP, V29, P1031; Neovius M, 2007, MED SCI SPORT EXER, V39, P2199, DOI 10.1249/mss.0b013e3181579.38a; Newman AB, 2005, ARCH INTERN MED, V165, P2408, DOI 10.1001/archinte.165.20.2408; Peppard PE, 2000, JAMA-J AM MED ASSOC, V284, P3015, DOI 10.1001/jama.284.23.3015; PILLAR G, 1994, CHEST, V106, P1702, DOI 10.1378/chest.106.6.1702; Punjabi Naresh M, 2008, Proc Am Thorac Soc, V5, P136, DOI 10.1513/pats.200709-155MG; Richelsen B, 2007, DIABETES CARE, V30, P27, DOI 10.2337/dc06-0210; *SCI COOP QUEST RE, SCOOP VLCD TASK 7 3; Shaw JE, 2008, DIABETES RES CLIN PR, V81, P2, DOI 10.1016/j.diabres.2008.04.025; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; SURATT PM, 1992, AM J CLIN NUTR, V56, P182; Tishler PV, 2003, JAMA-J AM MED ASSOC, V289, P2230, DOI 10.1001/jama.289.17.2230; Tuomilehto HPI, 2009, AM J RESP CRIT CARE, V179, P320, DOI 10.1164/rccm.200805-669OC; Valencia-Flores M, 2004, OBES SURG, V14, P755, DOI 10.1381/0960892041590773; Veasey SC, 2006, SLEEP, V29, P1036, DOI 10.1093/sleep/29.8.1036; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Young T, 2008, SLEEP, V31, P1071; Zou D, 2006, SLEEP, V29, P367, DOI 10.1093/sleep/29.3.367	36	147	150	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	2009	339								b4609	10.1136/bmj.b4609	http://dx.doi.org/10.1136/bmj.b4609			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	528NT	19959590	Green Published, hybrid			2023-01-03	WOS:000272453400005
J	Smets, T; Bilsen, J; Cohen, J; Rurup, ML; Mortier, F; Deliens, L				Smets, Tinne; Bilsen, Johan; Cohen, Joachim; Rurup, Mette L.; Mortier, Freddy; Deliens, Luc			Reporting of euthanasia in medical practice in Flanders, Belgium: cross sectional analysis of reported and unreported cases	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OF-LIFE DECISIONS; PHYSICIAN-ASSISTED SUICIDE; NETHERLANDS; DEATH; LAW; NOTIFICATION	Objectives To estimate the rate of reporting of euthanasia cases to the Federal Control and Evaluation Committee and to compare the characteristics of reported and unreported cases of euthanasia. Design Cross sectional analysis. Setting Flanders, Belgium. Participants A stratified at random sample was drawn of people who died between 1 June 2007 and 30 November 2007. The certifying physician of each death was sent a questionnaire on end of life decision making in the death concerned. Main outcome measures The rate of euthanasia cases reported to the Federal Control and Evaluation Committee; physicians' reasons for not reporting cases of euthanasia; the relation between reporting and non-reporting and the characteristics of the physician and patient; the time by which life was shortened according to the physician; the labelling of the end of life decision by the physician involved; and differences in characteristics of due care between reported and unreported euthanasia cases. Results The survey response rate was 58.4% (3623/6202 eligible cases). The estimated total number of cases of euthanasia in Flanders in 2007 was 1040 (95% CI 970 to 1109), thus the incidence of euthanasia was estimated as 1.9% of all deaths (95% CI 1.6% to 2.3%). Approximately half (549/1040 (52.8%, 95% CI 43.9% to 60.5%)) of all estimated cases of euthanasia were reported to the Federal Control and Evaluation Committee. Physicians who perceived their case as euthanasia reported it in 93.1% (67/72) of cases. Cases of euthanasia were reported less often when the time by which life was shortened was less than one week compared with when the perceived life shortening was greater (37.3% v 74.1%; P<0.001). Unreported cases were generally dealt with less carefully than reported cases: a written request for euthanasia was more often absent (87.7% v 17.6% verbal request only; P<0.001), other physicians and caregivers specialised in palliative care were consulted less often (54.6% v 97.5%; 33.0% v 63.9%; P<0.001 for both), the life ending act was more often performed with opioids or sedatives (92.1% v 4.4%; P<0.001), and the drugs were more often administered by a nurse (41.3% v 0.0%; P<0.001). Conclusions One out of two euthanasia cases is reported to the Federal Control and Evaluation Committee. Most non-reporting physicians do not perceive their act as euthanasia. Countries debating legalisation of euthanasia should simultaneously consider developing a policy facilitating the due care and reporting obligations of physicians.	[Smets, Tinne; Bilsen, Johan; Cohen, Joachim; Deliens, Luc] Vrije Univ Brussel, Fac Med & Pharm, End Life Care Res Grp, B-1090 Brussels, Belgium; [Rurup, Mette L.; Deliens, Luc] Vrije Univ Amsterdam Med Ctr, Expertise Ctr Palliat Care, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Mortier, Freddy] Univ Ghent, Bioeth Inst Ghent, B-9000 Ghent, Belgium	Vrije Universiteit Brussel; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Ghent University	Smets, T (corresponding author), Vrije Univ Brussel, Fac Med & Pharm, End Life Care Res Grp, Laarbeeklaan 103, B-1090 Brussels, Belgium.	tinne.smets@vub.ac.be	Smets, Tinne/G-3988-2012; Cohen, Joachim/B-6803-2008	Cohen, Joachim/0000-0002-7224-9476; Mortier, Freddy/0000-0002-5390-3508; Smets, Tinne/0000-0003-1439-316X; Deliens, Luc/0000-0002-8158-2422	Institute for the Promotion of Innovation by Science and Technology in Flanders (Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen) [050158]	Institute for the Promotion of Innovation by Science and Technology in Flanders (Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT))	This study is part of the Monitoring Quality of End of Life Care (MELC) study, a collaboration between the Vrije Universiteit Brussel, Ghent University, Antwerp University, the Scientific Institute of Public Health, all in Belgium, and VU University Medical Center Amsterdam, The Netherlands. This study is supported by a grant from the Institute for the Promotion of Innovation by Science and Technology in Flanders (Instituut voor de aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen; SBO IWT nr. 050158). The funders had no role in study design; in the collection, analysis and interpretation of the data; in the writing of the manuscript; or in the decision to submit for publication.	ADAMS M, 2001, REGULATING PHYS NEGO, P29; Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Chambaere Kenneth, 2010, J Pain Symptom Manage, V39, pe5, DOI 10.1016/j.jpainsymman.2009.10.001; Chambaere K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-299; Deliens L, 2003, LANCET, V362, P1239, DOI 10.1016/S0140-6736(03)14520-5; Deliens L, 2000, LANCET, V356, P1806, DOI 10.1016/S0140-6736(00)03233-5; DILLMAN T, 1978, MAIL TELEPHONE SURVE; Distelmans W, 2006, PSYCHO-ONCOLOGY, V15, pS226; Distelmans W, 2008, PSYCHO-ONCOL, V17, pS222; Douglas C, 2008, BIOETHICS, V22, P388, DOI 10.1111/j.1467-8519.2008.00661.x; George RJD, 2005, BMJ-BRIT MED J, V331, P684, DOI 10.1136/bmj.331.7518.684; Keown J, 2006, J MED ETHICS, V32, P29, DOI 10.1136/jme.2004.011148; Magnusson RS, 2004, J MED ETHICS, V30, P441, DOI 10.1136/jme.2003.005090; Materstvedt LJ, 2003, PALLIATIVE MED, V17, P97, DOI 10.1191/0269216303pm673oa; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; Mortier F, 2000, BIOETHICS, V14, P254, DOI 10.1111/1467-8519.00195; New York State Task Force on Life and the Law, 1994, DEATH IS SOUGHT ASS; Onwuteaka-Philipsen BD, 2000, SOC SCI MED, V51, P429, DOI 10.1016/S0277-9536(99)00476-1; Pollard BJ, 2001, PALLIATIVE MED, V15, P61, DOI 10.1191/026921601668201749; Rurup ML, 2008, MED CARE, V46, P1198, DOI 10.1097/MLR.0b013e31817d69e8; Smets T, 2010, MED CARE, V48, P187, DOI 10.1097/MLR.0b013e3181bd4dde; Smets T, 2009, HEALTH POLICY, V90, P181, DOI 10.1016/j.healthpol.2008.10.003; Sprung CL, 2008, CRIT CARE MED, V36, P8, DOI 10.1097/01.CCM.0000295304.99946.58; Teno Joan M, 2005, J Palliat Med, V8 Suppl 1, pS42; Van den Block L, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-79; van der Heide A, 2004, LANCET, V364, P24, DOI 10.1016/S0140-6736(04)17628-9; van der Heide A, 2003, LANCET, V362, P345, DOI 10.1016/S0140-6736(03)14019-6; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; Van Wesemael Y, 2009, HEALTH SERV RES, V44, P2180, DOI 10.1111/j.1475-6773.2009.01042.x; vanderWal G, 1996, NEW ENGL J MED, V335, P1706; Weide MCJV, 2005, ARCH INTERN MED, V165, P1698, DOI 10.1001/archinte.165.15.1698; Weide MCJVD, 2004, HEALTH POLICY, V69, P365, DOI 10.1016/j.healthpol.2004.04.010; Weyers H, 2006, SOCIOL HEALTH ILL, V28, P802, DOI 10.1111/j.1467-9566.2006.00543.x	33	46	46	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 5	2010	341								c5174	10.1136/bmj.c5174	http://dx.doi.org/10.1136/bmj.c5174			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	663JB	20923842	Green Published, hybrid			2023-01-03	WOS:000282879000004
J	Schillaci, MA; Waitzkin, H; Carson, EA; Romain, SJ				Schillaci, Michael A.; Waitzkin, Howard; Carson, E. Ann; Romain, Sandra J.			Prenatal Care Utilization for Mothers from Low-Income Areas of New Mexico, 1989-1999	PLOS ONE			English	Article							MEDICAID MANAGED CARE; LOW-BIRTH-WEIGHT; HEALTH; PRETERM; MORBIDITY; INSURANCE; ADEQUACY; WOMEN; COST	Background: Prenatal care is considered to be an important component of primary health care. Our study compared prenatal care utilization and rates of adverse birth outcomes for mothers from low-and higher-income areas of New Mexico between 1989 and 1999. Methodology/Principal Findings: Prenatal care indicators included the number of prenatal care visits and the first month of prenatal care. Birth outcome indicators included low birth weight, premature birth, and births linked with death certificates. The results of our study indicated that mothers from low-income areas started their prenatal care significantly later in their pregnancies between 1989 and 1999, and had significantly fewer prenatal visits between 1989 and 1997. For the most part, there were not significant differences in birth outcome indicators between income groupings. Conclusions/Significance: These findings suggest that while mothers from low-income areas received lower levels of prenatal care, they did not experience a higher level of adverse birth outcomes.	[Schillaci, Michael A.] Univ Toronto, Dept Social Sci, Scarborough, ON M1C 1A4, Canada; [Waitzkin, Howard] Univ New Mexico, Dept Sociol, Albuquerque, NM 87131 USA; [Waitzkin, Howard] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA; [Waitzkin, Howard] Univ New Mexico, Dept Family & Community Med, Albuquerque, NM 87131 USA; [Carson, E. Ann] Intellica Corp, San Antonio, TX USA; [Romain, Sandra J.] Univ Toronto, Dept Anthropol, Toronto, ON M5S 1A1, Canada	University of Toronto; University Toronto Scarborough; University of New Mexico; University of New Mexico; University of New Mexico; University of Toronto	Schillaci, MA (corresponding author), Univ Toronto, Dept Social Sci, Scarborough, ON M1C 1A4, Canada.	schillaci@utsc.utoronto.ca			Agency for Healthcare Research and Quality [R01 HS09703]; New Mexico Department of Health [98.665.42.194]; Hospital of the University of New Mexico; University of New Mexico School of Medicine; University of Toronto; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS009703] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); New Mexico Department of Health; Hospital of the University of New Mexico; University of New Mexico School of Medicine; University of Toronto(University of Toronto); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Partial funding for this research was provided by the Agency for Healthcare Research and Quality (R01 HS09703), the New Mexico Department of Health (98.665.42.194), the Hospital of the University of New Mexico, the Dedicated Health Research Funds of the University of New Mexico School of Medicine, and the University of Toronto. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alessandrini EA, 2001, PEDIATRICS, V107, P1335, DOI 10.1542/peds.107.6.1335; ALEXANDER GR, 1995, FUTURE CHILD, V5, P103, DOI 10.2307/1602510; Alexander GR, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e61; Alexander GR, 2001, PUBLIC HEALTH REP, V116, P306; Braveman P, 2000, OBSTET GYNECOL, V95, P874, DOI 10.1016/S0029-7844(00)00780-8; Conway KS, 2006, HEALTH ECON, V15, P461, DOI 10.1002/hec.1097; Dubay L, 2007, HEALTH AFFAIR, V26, pW22, DOI 10.1377/hlthaff.26.1.w22; Fanaroff Avroy A, 2007, Am J Obstet Gynecol, V196, DOI 10.1016/j.ajog.2006.09.014; Goffinet F, 2005, BJOG-INT J OBSTET GY, V112, P38, DOI 10.1111/j.1471-0528.2005.00583.x; Herbst MA, 2003, AM J OBSTET GYNECOL, V189, P930, DOI 10.1067/S0002-9378(03)01055-X; Hueston WJ, 2003, J COMMUN HEALTH, V28, P199, DOI 10.1023/A:1022908307844; Kogan MD, 1998, PEDIATRICS, V102, P25, DOI 10.1542/peds.102.1.25; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; Markestad T, 2005, PEDIATRICS, V115, P1289, DOI 10.1542/peds.2004-1482; Moos MK, 2006, JOGNN-J OBST GYN NEO, V35, P278, DOI 10.1111/J.1552-6909.2006.00039.x; Nothnagle M, 2000, Matern Child Health J, V4, P251; Petrou S, 2005, BJOG-INT J OBSTET GY, V112, P10, DOI 10.1111/j.1471-0528.2005.00577.x; PIANTADOSI S, 1988, AM J EPIDEMIOL, V127, P893, DOI 10.1093/oxfordjournals.aje.a114892; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; Russell RB, 2007, PEDIATRICS, V120, pE1, DOI 10.1542/peds.2006-2386; SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019; Schillaci MA, 2004, ANN FAM MED, V2, P13, DOI 10.1370/afm.100; Schillaci MA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003953; Schmitt SK, 2006, PEDIATRICS, V117, P154, DOI 10.1542/peds.2005-0484; Shi L, 2004, J EPIDEMIOL COMMUN H, V58, P374, DOI 10.1136/jech.2003.013078; Stringer M, 2005, JOGNN-J OBST GYN NEO, V34, P551, DOI 10.1177/0884217505280276; Waitzkin H, 2002, AM J PUBLIC HEALTH, V92, P598, DOI 10.2105/AJPH.92.4.598; Waitzkin H, 2008, HEALTH SERV RES, V43, P1325, DOI 10.1111/j.1475-6773.2008.00842.x; *WHO, 2008, INT STAT DIS REL HLT; Willging CE, 2005, MED ANTHROPOL Q, V19, P84, DOI 10.1525/maq.2005.19.1.084	30	11	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2010	5	9							e12809	10.1371/journal.pone.0012809	http://dx.doi.org/10.1371/journal.pone.0012809			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	651XL	20862298	Green Submitted, gold, Green Published			2023-01-03	WOS:000281960800015
J	Ofek, P; Fischer, W; Calderon, M; Haag, R; Satchi-Fainaro, R				Ofek, Paula; Fischer, Wiebke; Calderon, Marcelo; Haag, Rainer; Satchi-Fainaro, Ronit			In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers	FASEB JOURNAL			English	Article						angiogenesis; polymer therapeutics; dendrimers; luciferase; glioblastoma; noninvasive intravital imaging	MACROMOLECULAR THERAPEUTICS; DIVALENT PEPTIDE; CATIONIC LIPIDS; GENE; CONJUGATE; ACCUMULATION; EXPRESSION; LIPOSOMES; CHLORIDE; CELLS	New targets for RNA interference (RNAi)based cancer therapy are constantly emerging from the increasing knowledge on key molecular pathways that are paramount for carcinogenesis. Nevertheless, in vivo delivery of small interfering RNA (siRNA) remains a crucial challenge for therapeutic success. siRNAs on their own are not taken up by most mammalian cells in a way that preserves their activity. Moreover, when applied in vivo, siRNA-based approaches are all limited by poor penetration into the target tissue and low silencing efficiency. To circumvent these limitations, we have developed novel polymerized polyglycerol-based dendrimer core shell structures to deliver siRNA to tumors in vivo. These cationic dendrimers can strongly improve the stability of the siRNA, its intracellular trafficking, its silencing efficacy, and its accumulation in the tumor environment owing to the enhanced permeability and retention effect. Here, we show that our dendritic nanocarriers exhibited low cytotoxicity and high efficacy in delivering active siRNA into cells. With use of human glioblastoma and murine mammary adenocarcinoma cell lines as model systems, these siRNA-dendrimer polyplexes silenced the luciferase gene, ectopically overexpressed in these cells. Importantly, significant gene silencing was accomplished in vivo within 24 h of treatment with our luciferase siRNA-nanocarrier polyplexes, as measured by noninvasive intravital bioluminescence imaging. Moreover, our siRNA-nanocarriers show very low levels of toxicity as no significant weight loss was observed after intravenous administration of the polyplexes. We show a proof of concept for siRNA delivery in vivo using a luciferase-based model. We predict that in vivo silencing of important cell growth and angiogenesis regulator genes in a selective manner will justify this approach as a successful anticancer therapy.-Ofek, P., Fischer, W., Calderon, M., Haag, R., Satchi-Fainaro, R. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J. 24, 3122-3134 (2010). www.fasebj.org	[Ofek, Paula; Satchi-Fainaro, Ronit] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; [Fischer, Wiebke; Calderon, Marcelo; Haag, Rainer] Free Univ Berlin, Inst Chem & Biochem, D-1000 Berlin, Germany	Tel Aviv University; Sackler Faculty of Medicine; Free University of Berlin	Satchi-Fainaro, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	ronitsf@post.tau.ac.il	Satchi-Fainaro, Ronit/F-9137-2011; Calderon, Marcelo/A-3594-2013	Satchi-Fainaro, Ronit/0000-0002-7360-7837; Calderon, Marcelo/0000-0002-2734-9742; Ofek, Paula/0000-0002-8516-1107; Calderon, Marcelo/0000-0002-3108-3852	Israel Science Foundation [1300/06]; Marguerite Stolz Research Fellowship; Adams Super Center for Brain Studies; German Ministry of Science	Israel Science Foundation(Israel Science Foundation); Marguerite Stolz Research Fellowship; Adams Super Center for Brain Studies; German Ministry of Science	The authors thank Leonid Mitelman (Interdepartmental Core Facility at the Sackler School of Medicine) for his excellent assistance with the confocal laser scanning microscope. The authors thank Professor Ronit Sagi-Eisenberg for insightful discussion on endocytosis and Andrea Schulz for AFM measurements. The authors also thank Merkel Technologies Ltd. and David Merkel Golan for his kind assistance using the ImageStream multispectral imaging flow cytometer. This research was supported by the Israel Science Foundation (grant 1300/06), the Marguerite Stolz Research Fellowship Fund for Outstanding Junior Faculty, and the Adams Super Center for Brain Studies. R. H. is grateful to the German Ministry of Science for a NanoFuture award.	Behlke MA, 2006, MOL THER, V13, P644, DOI 10.1016/j.ymthe.2006.01.001; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839; CAIN BF, 1978, J MED CHEM, V21, P658, DOI 10.1021/jm00205a013; Calderon M, 2010, ADV MATER, V22, P190, DOI 10.1002/adma.200902144; CARRASCO L, 1994, FEBS LETT, V350, P151, DOI 10.1016/0014-5793(94)00780-2; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, P2705, DOI 10.1093/nar/gkg393; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9; DIJKSTRA J, 1984, BIOCHIM BIOPHYS ACTA, V804, P58, DOI 10.1016/0167-4889(84)90099-5; DUNCAN R, 1994, J DRUG TARGET, V2, P341, DOI 10.3109/10611869409015915; FELGNER PL, 1989, NATURE, V337, P387, DOI 10.1038/337387a0; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Firon M, 2000, ONCOGENE, V19, P2386, DOI 10.1038/sj.onc.1203557; FU YX, 1990, CANCER RES, V50, P227; Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021; Geall AJ, 2000, J PHARMACEUT BIOMED, V22, P849, DOI 10.1016/S0731-7085(00)00250-8; Grimm D, 2007, J CLIN INVEST, V117, P3633, DOI 10.1172/JCI34129; Guillot-Nieckowski M, 2007, LANGMUIR, V23, P737, DOI 10.1021/la0624891; Haag R, 2006, ANGEW CHEM INT EDIT, V45, P1198, DOI 10.1002/anie.200502113; HAAG R, 2004, Patent No. 10211664; HARD T, 1988, EUR BIOPHYS J BIOPHY, V16, P231, DOI 10.1007/BF00261265; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Karmali PP, 2007, MED RES REV, V27, P696, DOI 10.1002/med.20090; Kramer M, 2005, MACROMOLECULES, V38, P8308, DOI 10.1021/ma0510791; Kramer M, 2004, CHEMBIOCHEM, V5, P1081, DOI 10.1002/cbic.200300905; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Layzer JM, 2004, RNA, V10, P766, DOI 10.1261/rna.5239604; Lv HT, 2006, J CONTROL RELEASE, V114, P100, DOI 10.1016/j.jconrel.2006.04.014; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Martin B, 2005, CURR PHARM DESIGN, V11, P375, DOI 10.2174/1381612053382133; MATSUMURA Y, 1986, CANCER RES, V46, P6387; Melnikov S, 2009, CELL SIGNAL, V21, P1607, DOI 10.1016/j.cellsig.2009.06.007; Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133; Misinzo G, 2008, J VIROL, V82, P1128, DOI 10.1128/JVI.01229-07; Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018; Persengiev SP, 2004, RNA, V10, P12, DOI 10.1261/rna5160904; Roller S, 2005, MOL DIVERS, V9, P305, DOI 10.1007/s11030-005-8117-y; Ryppa C, 2008, BIOCONJUGATE CHEM, V19, P1414, DOI 10.1021/bc800117r; Ryppa C, 2009, INT J PHARMACEUT, V368, P89, DOI 10.1016/j.ijpharm.2008.09.055; Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140; Segal E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005233; Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200; Sunder A, 1999, MACROMOLECULES, V32, P4240, DOI 10.1021/ma990090w; Sunder A, 2000, MACROMOLECULES, V33, P253, DOI 10.1021/ma9915881; Takakura Y, 2002, J DRUG TARGET, V10, P99, DOI 10.1080/10611860290016694; Welsh DJ, 2009, ANGEW CHEM INT EDIT, V48, P4047, DOI 10.1002/anie.200900401	48	103	108	1	29	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2010	24	9					3122	3134		10.1096/fj.09-149641	http://dx.doi.org/10.1096/fj.09-149641			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20385622				2023-01-03	WOS:000281446400003
J	Wang, CC; Schmid, CH; Rones, R; Kalish, R; Yinh, J; Goldenberg, DL; Lee, Y; McAlindon, T				Wang, Chenchen; Schmid, Christopher H.; Rones, Ramel; Kalish, Robert; Yinh, Janeth; Goldenberg, Don L.; Lee, Yoojin; McAlindon, Timothy			A Randomized Trial of Tai Chi for Fibromyalgia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TREATING KNEE OSTEOARTHRITIS; MINDFULNESS MEDITATION; IMPACT QUESTIONNAIRE; HEALTH OUTCOMES; EXERCISE; MANAGEMENT; PAIN; INTERVENTION; EDUCATION; EFFICACY	BACKGROUND Previous research has suggested that tai chi offers a therapeutic benefit in patients with fibromyalgia. METHODS We conducted a single-blind, randomized trial of classic Yang-style tai chi as compared with a control intervention consisting of wellness education and stretching for the treatment of fibromyalgia (defined by American College of Rheumatology 1990 criteria). Sessions lasted 60 minutes each and took place twice a week for 12 weeks for each of the study groups. The primary end point was a change in the Fibromyalgia Impact Questionnaire (FIQ) score (ranging from 0 to 100, with higher scores indicating more severe symptoms) at the end of 12 weeks. Secondary end points included summary scores on the physical and mental components of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). All assessments were repeated at 24 weeks to test the durability of the response. RESULTS Of the 66 randomly assigned patients, the 33 in the tai chi group had clinically important improvements in the FIQ total score and quality of life. Mean (+/- SD) baseline and 12-week FIQ scores for the tai chi group were 62.9 +/- 15.5 and 35.1 +/- 18.8, respectively, versus 68.0 +/- 11 and 58.6 +/- 17.6, respectively, for the control group (change from baseline in the tai chi group vs. change from baseline in the control group, -18.4 points; P<0.001). The corresponding SF-36 physical-component scores were 28.5 +/- 8.4 and 37.0 +/- 10.5 for the tai chi group versus 28.0 +/- 7.8 and 29.4 +/- 7.4 for the control group (between-group difference, 7.1 points; P = 0.001), and the mental-component scores were 42.6 +/- 12.2 and 50.3 +/- 10.2 for the tai chi group versus 37.8 +/- 10.5 and 39.4 +/- 11.9 for the control group (between-group difference, 6.1 points; P = 0.03). Improvements were maintained at 24 weeks (between-group difference in the FIQ score, -18.3 points; P<0.001). No adverse events were observed. CONCLUSIONS Tai chi may be a useful treatment for fibromyalgia and merits long-term study in larger study populations.	[Wang, Chenchen; Kalish, Robert; Yinh, Janeth; McAlindon, Timothy] Tufts Univ, Sch Med, Div Rheumatol, Tufts Med Ctr, Boston, MA 02111 USA; [Schmid, Christopher H.; Lee, Yoojin] Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Tufts Med Ctr, Boston, MA 02111 USA; [Rones, Ramel] Mind Body Therapies, Boston, MA USA; [Goldenberg, Don L.] Newton Wellesley Hosp, Newton, MA USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Newton Wellesley Hospital	Wang, CC (corresponding author), Tufts Univ, Sch Med, Div Rheumatol, Tufts Med Ctr, 800 Washington St,Box 406, Boston, MA 02111 USA.	cwang2@tuftsmedicalcenter.org	Schmid, Christopher H./J-2398-2014	Schmid, Christopher H./0000-0002-0855-5313	National Center for Complementary and Alternative Medicine of the National Institutes of Health [R21AT003621]; American College of Rheumatology Research and Education Foundation; Boston Claude D. Pepper Older Americans Independence Center; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT003621] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); American College of Rheumatology Research and Education Foundation; Boston Claude D. Pepper Older Americans Independence Center; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Supported by a grant (R21AT003621) from the National Center for Complementary and Alternative Medicine of the National Institutes of Health, the American College of Rheumatology Research and Education Foundation Health Professional Investigator Award, and the Boston Claude D. Pepper Older Americans Independence Center Research Career Development Award.	Astin JA, 2003, J RHEUMATOL, V30, P2257; Barnes Patricia M., 2008, NATL HLTH STAT REPOR, V12, P1, DOI DOI 10.1037/E623942009-001; Bennett RM, 2009, J RHEUMATOL, V36, P1304, DOI 10.3899/jrheum.081090; Birdee GS, 2009, J ALTERN COMPLEM MED, V15, P969, DOI 10.1089/acm.2009.0174; Burckhardt C., 2005, APS CLIN PRACTICE GU; BURCKHARDT CS, 1991, J RHEUMATOL, V18, P728; Burckhardt CS, 2006, CURR PHARM DESIGN, V12, P59, DOI 10.2174/138161206775193217; Busch AJ, 2008, J RHEUMATOL, V35, P1130; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Carville SF, 2008, ANN RHEUM DIS, V67, P536, DOI 10.1136/ard.2007.071522; CHINA SPORTS, 1983, SIMPL TAIJ, P1; Creamer P, 2000, ARTHRIT CARE RES, V13, P198, DOI 10.1002/1529-0131(200008)13:4<198::AID-ANR4>3.0.CO;2-P; Davidson RJ, 2003, PSYCHOSOM MED, V65, P564, DOI 10.1097/01.PSY.0000077505.67574.E3; Farrar JT, 2001, PAIN, V94, P149, DOI 10.1016/S0304-3959(01)00349-9; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Goldenberg DL, 2004, JAMA-J AM MED ASSOC, V292, P2388, DOI 10.1001/jama.292.19.2388; Hauser W, 2009, ARTHRIT RHEUM-ARTHR, V61, P216, DOI 10.1002/art.24276; Irwin MR, 2007, J AM GERIATR SOC, V55, P511, DOI 10.1111/j.1532-5415.2007.01109.x; Jones KD, 2009, RHEUM DIS CLIN N AM, V35, P373, DOI 10.1016/j.rdc.2009.05.004; KAPLAN KH, 1993, GEN HOSP PSYCHIAT, V15, P284, DOI 10.1016/0163-8343(93)90020-O; King S, 1999, J RHEUMATOL, V26, P2233; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; Lush E, 2009, J CLIN PSYCHOL MED S, V16, P200, DOI 10.1007/s10880-009-9153-z; Mannerkorpi K, 2000, J RHEUMATOL, V27, P2473; National Food and Agriculture Organization. Ministry of Agriculture and Cooperatives, 2004, QUEST ANSW FIBR, P1; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ramel J, 2009, CURR RHEUMATOL REV, V5, P188, DOI 10.2174/157339709790192459; Rooks DS, 2007, ARCH INTERN MED, V167, P2192, DOI 10.1001/archinte.167.20.2192; Schulz R, 2002, GERONTOLOGIST, V42, P589, DOI 10.1093/geront/42.5.589; Sephton SE, 2007, ARTHRIT RHEUM-ARTHR, V57, P77, DOI 10.1002/art.22478; Shapiro SL, 2006, J CLIN PSYCHOL, V62, P373, DOI 10.1002/jclp.20237; Sinclair D, 2005, MANUAL TENDER POINT; STEINHARDT MA, 1989, J OCCUP ENVIRON MED, V31, P536, DOI 10.1097/00043764-198906000-00011; Taggart Helen M, 2003, Orthop Nurs, V22, P353, DOI 10.1097/00006416-200309000-00013; Valkeinen H, 2006, ARTHRITIS RHEUM, V54, P1334, DOI 10.1002/art.21751; Wang CC, 2004, ARCH INTERN MED, V164, P493, DOI 10.1001/archinte.164.5.493; Wang CC, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-23; Wang CC, 2009, ARTHRIT RHEUM-ARTHR, V61, P1545, DOI 10.1002/art.24832; Wang CC, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471-2474-9-108; Wang Chenchen, 2008, V52, P218, DOI 10.1159/000134302; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; Ware JE., 1994, SF 36 PHYS MENTAL HL; Wayne PM, 2008, J ALTERN COMPLEM MED, V14, P95, DOI 10.1089/acm.2007.7170A; WOLFE F, 1995, ARTHRITIS RHEUM-US, V38, P19, DOI 10.1002/art.1780380104; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 1997, ARTHRITIS RHEUM, V40, P1560, DOI 10.1002/art.1780400904; Yocum DE, 2000, RHEUM DIS CLIN N AM, V26, P145, DOI 10.1016/S0889-857X(05)70128-9	47	258	276	3	128	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					743	754		10.1056/NEJMoa0912611	http://dx.doi.org/10.1056/NEJMoa0912611			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	639TE	20818876	Green Accepted, Bronze			2023-01-03	WOS:000280996600008
J	Poon, EG; Keohane, CA; Yoon, CS; Ditmore, M; Bane, A; Levtzion-Korach, O; Moniz, T; Rothschild, JM; Kachalia, AB; Hayes, J; Churchill, WW; Lipsitz, S; Whittemore, AD; Bates, DW; Gandhi, TK				Poon, Eric G.; Keohane, Carol A.; Yoon, Catherine S.; Ditmore, Matthew; Bane, Anne; Levtzion-Korach, Osnat; Moniz, Thomas; Rothschild, Jeffrey M.; Kachalia, Allen B.; Hayes, Judy; Churchill, William W.; Lipsitz, Stuart; Whittemore, Anthony D.; Bates, David W.; Gandhi, Tejal K.			Effect of Bar-Code Technology on the Safety of Medication Administration.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADVERSE DRUG EVENTS; PHYSICIAN ORDER ENTRY; PATIENT SAFETY; INFORMATION-TECHNOLOGY; ERRORS; PREVENTION; SYSTEMS; CARE; HOSPITALS; IMPACT	Background: Serious medication errors are common in hospitals and often occur during order transcription or administration of medication. To help prevent such errors, technology has been developed to verify medications by incorporating bar-code verification technology within an electronic medication-administration system (bar-code eMAR). Methods: We conducted a before-and-after, quasi-experimental study in an academic medical center that was implementing the bar-code eMAR. We assessed rates of errors in order transcription and medication administration on units before and after implementation of the bar-code eMAR. Errors that involved early or late administration of medications were classified as timing errors and all others as nontiming errors. Two clinicians reviewed the errors to determine their potential to harm patients and classified those that could be harmful as potential adverse drug events. Results: We observed 14,041 medication administrations and reviewed 3082 order transcriptions. Observers noted 776 nontiming errors in medication administration on units that did not use the bar-code eMAR (an 11.5% error rate) versus 495 such errors on units that did use it (a 6.8% error rate) -- a 41.4% relative reduction in errors (P<0.001). The rate of potential adverse drug events (other than those associated with timing errors) fell from 3.1% without the use of the bar-code eMAR to 1.6% with its use, representing a 50.8% relative reduction (P<0.001). The rate of timing errors in medication administration fell by 27.3% (P<0.001), but the rate of potential adverse drug events associated with timing errors did not change significantly. Transcription errors occurred at a rate of 6.1% on units that did not use the bar-code eMAR but were completely eliminated on units that did use it. Conclusions: Use of the bar-code eMAR substantially reduced the rate of errors in order transcription and in medication administration as well as potential adverse drug events, although it did not eliminate such errors. Our data show that the bar-code eMAR is an important intervention to improve medication safety. (ClinicalTrials.gov number, NCT00243373.) N Engl J Med 2010;362:1698-707.	[Poon, Eric G.] Brigham & Womens Hosp, Div Gen Med Primary Care, Boston, MA 02120 USA; [Poon, Eric G.; Rothschild, Jeffrey M.; Kachalia, Allen B.; Whittemore, Anthony D.; Bates, David W.; Gandhi, Tejal K.] Harvard Univ, Sch Med, Boston, MA USA; [Poon, Eric G.; Bates, David W.] Partners Informat Syst, Boston, MA USA; [Hayes, Judy] Faulkner Hosp, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Poon, EG (corresponding author), Brigham & Womens Hosp, Div Gen Med Primary Care, 3-F,1620 Tremont St, Boston, MA 02120 USA.	epoon@partners.org	Bates, David/AAE-7283-2019	Poon, Eric/0000-0002-7251-5842	Healthcare Research and Quality [HS14053-02]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS014053] Funding Source: NIH RePORTER	Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Supported by a grant (HS14053-02) from the Agency for Healthcare Research and Quality.	Barker KN, 2002, ARCH INTERN MED, V162, P1897, DOI 10.1001/archinte.162.16.1897; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Cochran GL, 2007, JT COMM J QUAL PATIE, V33, P293, DOI 10.1016/S1553-7250(07)33034-1; DiConsiglio John, 2008, Mater Manag Health Care, V17, P26; FLYNN EA, 1999, MED ERRORS CAUSES PR; FOLLI HL, 1987, PEDIATRICS, V79, P718; Franklin BD, 2007, QUAL SAF HEALTH CARE, V16, P279, DOI 10.1136/qshc.2006.019497; Greenberg CC, 2008, ANN SURG, V247, P612, DOI 10.1097/SLA.0b013e3181656cd5; *HLTH IT POL COMM, 2009, FIN MEAN US OBJ MEAS; JOHNSON CL, 2003, J HEALTHC INF MANAG, V16, P46; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Koppel R, 2008, J AM MED INFORM ASSN, V15, P408, DOI 10.1197/jamia.M2616; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Mahoney CD, 2007, AM J HEALTH-SYST PH, V64, P1969, DOI 10.2146/ajhp060617; McDonald CJ, 2006, ANN INTERN MED, V145, P235, DOI 10.7326/0003-4819-145-3-200608010-00022; Neuenschwander M, 2003, AM J HEALTH-SYST PH, V60, P1219; Paoletti RD, 2007, AM J HEALTH-SYST PH, V64, P536, DOI 10.2146/ajhp060140; Patterson ES, 2002, J AM MED INFORM ASSN, V9, P540, DOI 10.1197/jamia.M1061; Poon EG, 2006, ANN INTERN MED, V145, P426, DOI 10.7326/0003-4819-145-6-200609190-00006; Poon EG, 2008, J NURS ADMIN, V38, P541, DOI 10.1097/NNA.0b013e31818ebf1c; PUCKETT F, 1995, AM J HEALTH-SYST PH, V52, P1305, DOI 10.1093/ajhp/52.12.1305; RAO JNK, 1987, ANN STAT, V15, P385, DOI 10.1214/aos/1176350273; Woods D. D., 2007, HDB HUMAN FACTORS ER, P459; Wright AA, 2005, NEW ENGL J MED, V353, P329, DOI 10.1056/NEJMp058101; Yang M, 2002, IMPACT INFORM TECHNO, P37; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	31	326	343	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 6	2010	362	18					1698	1707		10.1056/NEJMsa0907115	http://dx.doi.org/10.1056/NEJMsa0907115			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	591OQ	20445181				2023-01-03	WOS:000277311200007
J	Strang, J; Metrebian, N; Lintzeris, N; Potts, L; Carnwath, T; Mayet, S; Williams, H; Zador, D; Evers, R; Groshkova, T; Charles, V; Martin, A; Forzisi, L				Strang, John; Metrebian, Nicola; Lintzeris, Nicholas; Potts, Laura; Carnwath, Tom; Mayet, Soraya; Williams, Hugh; Zador, Deborah; Evers, Richard; Groshkova, Teodora; Charles, Vikki; Martin, Anthea; Forzisi, Luciana			Supervised injectable heroin or injectable methadone versus optimised oral methadone as treatment for chronic heroin addicts in England after persistent failure in orthodox treatment (RIOTT): a randomised trial	LANCET			English	Article							DEPENDENT DRUG-USERS; ASSISTED TREATMENT; OPIOID DEPENDENCE; ILLICIT HEROIN; MAINTENANCE; PRESCRIPTION; FEASIBILITY; MANAGEMENT; DOCTORS	Background Some heroin addicts persistently fail to benefit from conventional treatments. We aimed to compare the effectiveness of supervised injectable treatment with medicinal heroin (diamorphine or diacetylmorphine) or supervised injectable methadone versus optimised oral methadone for chronic heroin addiction. Methods In this multisite, open-label, randomised controlled trial, we enrolled chronic heroin addicts who were receiving conventional oral treatment (>= 6 months), but continued to inject street heroin regularly (>= 50% of days in preceding 3 months). Randomisation by minimisation was used to assign patients to receive supervised injectable methadone, supervised injectable heroin, or optimised oral methadone. Treatment was provided for 26 weeks in three supervised injecting clinics in England. Primary outcome was 50% or more of negative specimens for street heroin on weekly urinalysis during weeks 14-26. Primary analysis was by intention to treat; data were adjusted for centre, regular crack use at baseline, and treatment with optimised oral methadone at baseline. Percentages were calculated with Rubin's rules and were then used to estimate numbers of patients in the multiple imputed samples. This study is registered, ISRCTN01338071. Findings Of 301 patients screened, 127 were enrolled and randomly allocated to receive injectable methadone (n=42 patients), injectable heroin (n=43), or oral methadone (n=42); all patients were included in the primary analysis. At 26 weeks, 80% (n=101) patients remained in assigned treatment: 81% (n=34) on injectable methadone, 88% (n=38) on injectable heroin, and 69% (n=29) on oral methadone. Patients on injectable heroin were significantly more likely to have achieved the primary outcome (72% [n=31]) than were those on oral methadone (27% [n=11], OR 7.42,95% CI 2.69-20.46, p<0.0001; adjusted: 66% [n=28] vs 19% [n=8], 8.17, 2.88-23.16, p<0.0001), with number needed to treat of 2.17 (95% CI 1.60-3.97). For injectable methadone (39% [n=16]; adjusted: 30% [n=14]) versus oral methadone, the difference was not significant (OR 1.74,95% CI 0.66-4.60, p=0.264; adjusted: 1.79, 0.67-4.82, p=0.249). For injectable heroin versus injectable methadone, a significant difference was recorded (4 26, 1.63-11.14, p=0.003; adjusted: 4.57, 1.71-12.19, p=0.002), but the study was not powered for this comparison. Differences were evident within the first 6 weeks of treatment. Interpretation Treatment with supervised injectable heroin leads to significantly lower use of street heroin than does supervised injectable methadone or optimised oral methadone. UK Government proposals should be rolled out to support the positive response that can be achieved with heroin maintenance treatment for previously unresponsive chronic heroin addicts.	[Strang, John] Kings Coll London, Natl Addict Ctr, Addict Dept, London SE5 8BB, England; [Strang, John; Lintzeris, Nicholas; Mayet, Soraya; Zador, Deborah] S London & Maudsley NHS Fdn Trust, London, England; [Lintzeris, Nicholas] Univ Sydney, Langton Ctr, Sydney, NSW 2006, Australia; [Evers, Richard] Kings Coll Hosp London, London, England	University of London; King's College London; South London & Maudsley NHS Trust; University of Sydney; King's College Hospital NHS Foundation Trust; King's College Hospital	Strang, J (corresponding author), Kings Coll London, Natl Addict Ctr, Addict Dept, 4 Windsor Walk, London SE5 8BB, England.	john.strang@kcl.ac.uk	Strang, John/H-5460-2011; Evers, Richard/I-4787-2019	Strang, John/0000-0002-5413-2725; Evers, Richard/0000-0002-2983-3642	Department of Health (England); National Treatment Agency (England); Reckitt Benckiser; Schering-Plough; Community Fund (Big Lottery) Research section; Hedley Foundation; UK National Health Service Research and Development; National Health Medical Research Council, Australia; Tees, Esk and Wear Valleys Foundation NHS NIHR Flexibility and Sustainability Funding	Department of Health (England); National Treatment Agency (England); Reckitt Benckiser; Schering-Plough(Merck & CompanySchering Plough Corporation); Community Fund (Big Lottery) Research section; Hedley Foundation; UK National Health Service Research and Development; National Health Medical Research Council, Australia(National Health and Medical Research Council (NHMRC) of Australia); Tees, Esk and Wear Valleys Foundation NHS NIHR Flexibility and Sustainability Funding	JS and NL have contributed to UK National Treatment Agency for Substance Misuse and Department of Health guidelines on the role of injectable prescribing in the management of opiate addiction (2003; chaired by (S), and JS also chaired the broader-scope pan-UK working group preparing the 2007 Orange Guidelines for the UK Departments of Health, providing guidance on management and treatment of drug dependence and misuse. JS has provided consultancy advice to Britannia/Genus, Auralis, and Martindale Pharmaceuticals; JS and JS's institution have received support and funding from the Department of Health (England) and National Treatment Agency (England); and JS has close associations with the charity Action on Addiction. NL has received honoraria, travel and conference support, and consultancy fees from Reckitt Benckiser and Schering-Plough. NL has an untied educational grant for research related to buprenorphine in the management of opioid dependence. JS, NM, NL, and TC have previously undertaken research study of British heroin policy and have given varied commentaries and contributed to professional and public debate. LP, SM, HW, DZ, RE, TG, VC, AM, and LF declare that they have no conflicts of interest.; We thank all participants of this trial; the staff and colleagues without whom the trial would not have been possible; research and treatment funders; Ed Day, chairman of the trial steering committee; members of the data monitoring committee (Sheila Bird, Senior Statistician, Medical Research Council Biostatistics Unit, Cambridge, UK; Louise Sell, Consultant Addiction Psychiatrist and Service Director, Greater Manchester West Mental Health NHS Foundation Trust, Manchester, UK; and Philip Robson, Consultant Addiction Psychiatrist, GW Pharmaceuticals, Wiltshire, UK); Jenny Hellier (Clinical Trials Unit, Institute of Psychiatry, King's College London, London, UK) for additional statistical analysis; David Taylor, Glynis Ivin, and Godwin Achunine (South London and Maudsley NHS Foundation Trust, London, UK) for pharmacy advice, coordination, and support; and Rob van der Waal (South London and Maudsley NHS Foundation Trust, London, UK) for help with development of the clinical protocol and for training nursing staff. Diamorphine ampoules were supplied by DiaMo (Switzerland) and Auralis (UK). Research funding was provided by the Community Fund (Big Lottery) Research section, through Action on Addiction; Hedley Foundation; and UK National Health Service Research and Development support. Organisational support was provided by the Clinical Trials Unit at the Institute of Psychiatry, and by the UK Mental Health Research Network. Funding for treatment was provided through the UK National Treatment Agency for Substance Misuse for the Department of Health and the Home Office, and local commissioners. NL was partly funded by the National Health Medical Research Council, Australia. Tees, Esk and Wear Valleys Foundation NHS NIHR Flexibility and Sustainability Funding provided supplementary funding for TG. King's College London and South London and Maudsley NHS Foundation Trust are now within the Academic Health Sciences Centre, King's Health Partners.	Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; [Anonymous], 2008, DRUGS PROT FAM COMM; Ferri M, 2006, J SUBST ABUSE TREAT, V30, P63, DOI 10.1016/j.jsat.2005.09.003; Haasen C, 2007, BRIT J PSYCHIAT, V191, P55, DOI 10.1192/bjp.bp.106.026112; *HOM OFF, 2002, UPD DRUG STRAT 2002, P56; Lintzeris Nicholas, 2006, Harm Reduct J, V3, P28, DOI 10.1186/1477-7517-3-28; Lintzeris N, 2009, CNS DRUGS, V23, P463, DOI 10.2165/00023210-200923060-00002; March JC, 2006, J SUBST ABUSE TREAT, V31, P203, DOI 10.1016/j.jsat.2006.04.007; Metrebian N, 2002, ADDICTION, V97, P1155, DOI 10.1046/j.1360-0443.2002.00193.x; Metrebian N, 2001, DRUG ALCOHOL REV, V20, P267; MITCHESON M, 2005, HEROIN ADDICTION BRI, V2, P41; Oviedo-Joekes E, 2009, NEW ENGL J MED, V361, P777, DOI 10.1056/NEJMoa0810635; Paterson S, 2006, J ANAL TOXICOL, V30, P267, DOI 10.1093/jat/30.4.267; Paterson S, 2005, ADDICTION, V100, P1832, DOI 10.1111/j.1360-0443.2005.01225.x; Perneger TV, 1998, BMJ-BRIT MED J, V317, P13, DOI 10.1136/bmj.317.7150.13; Rehm J, 2001, LANCET, V358, P1417, DOI 10.1016/S0140-6736(01)06529-1; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Sell L, 2004, ADDICTION, V99, P442, DOI 10.1111/j.1360-0443.2003.00668.x; Strang J, 1996, BMJ-BRIT MED J, V313, P270, DOI 10.1136/bmj.313.7052.270; Strang J, 2000, ADDICTION, V95, P1631, DOI 10.1046/j.1360-0443.2000.951116314.x; STRANG J, 1990, AIDS DRUG MISUSE CHA, P142; Strang J, 2005, HEROIN ADDICTION BRI, V2, P1; TOBER G, 2003, METHADONE MATTERS EV, P131; UCHTENHAGEN A, 1999, PRESCRIPTION NARCOTI; van den Brink W, 2003, BRIT MED J, V327, P310, DOI 10.1136/bmj.327.7410.310; Verthein U, 2008, ADDICTION, V103, P960, DOI 10.1111/j.1360-0443.2008.02185.x; Witton J, 2005, J DRUG ISSUES, V35, P779, DOI 10.1177/002204260503500406; Zador D, 2001, ADDICTION, V96, P547, DOI 10.1046/j.1360-0443.2001.9645473.x; ZADOR D, 2005, HEROIN ADDICTION BRI, V2, P121	29	127	128	0	26	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2010	375	9729					1885	1895		10.1016/S0140-6736(10)60349-2	http://dx.doi.org/10.1016/S0140-6736(10)60349-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	609BC	20511018				2023-01-03	WOS:000278628800030
J	Wong, A				Wong, Albert			Modified Epidermal Growth Factor Receptor (EGFR)-Bearing Liposomes (MRBLs) Are Sensitive to EGF in Solution	PLOS ONE			English	Article							HUMAN PANCREATIC-CARCINOMA; DRUG-DELIVERY; RECONSTITUTION; CHEMOTHERAPY; RADIOTHERAPY; INHIBITORS; H-1-NMR	Cancers often overexpress EGF and other growth factors to promote cell replication and migration. Previous work has not produced targeted drug carriers sensitive to abnormal amounts of growth factors. This work demonstrates that liposomes bearing EGF receptors covalently crosslinked to p-toluic acid or methyl-PEO4-NHS ester (or, in short, MRBLs) exhibit an increased rate of release of encapsulated drug compounds when EGF is present in solution. Furthermore, the modified EGF receptors retain the abilities to form dimers in the presence of EGF and bind specifically to EGF. These results demonstrate that MRBLs are sensitive to EGF in solution and indicate that MRBL-reconstituted modified EGF receptors, in the presence of EGF in solution, form dimers which increase MRBL permeability to encapsulated compounds.			Wong, A (corresponding author), Yale Univ, Program Biol & Biomed Sci, New Haven, CT 06520 USA.	albert.wong@yale.edu						Agero ALC, 2006, J AM ACAD DERMATOL, V55, P657, DOI 10.1016/j.jaad.2005.10.010; ARNUM PV, 2006, PHARM TECH EPT; DeAngelis LM, 2002, J CLIN ONCOL, V20, P4643, DOI 10.1200/JCO.2002.11.013; DeSilva NS, 2003, AM J RESP CELL MOL, V29, P757, DOI 10.1165/rcmb.2003-0186OC; Dromi S, 2007, CLIN CANCER RES, V13, P2722, DOI 10.1158/1078-0432.CCR-06-2443; FEIGENSON GW, 1974, NUCL MAGNETIC RELAXA; Forastiere AA, 2003, NEW ENGL J MED, V349, P2091, DOI 10.1056/NEJMoa031317; Galimont-Collen AFS, 2007, EUR J CANCER, V43, P845, DOI 10.1016/j.ejca.2006.11.016; Gansauge F, 1998, LANGENBECK ARCH SURG, V383, P152, DOI 10.1007/PL00008076; Ge GX, 2001, BIOCHEM BIOPH RES CO, V282, P511, DOI 10.1006/bbrc.2001.4600; Gerasimov OV, 1999, ADV DRUG DELIVER REV, V38, P317, DOI 10.1016/S0169-409X(99)00035-6; GRABAREK Z, 1990, ANAL BIOCHEM, V185, P131, DOI 10.1016/0003-2697(90)90267-D; JURETSCHKE HP, 1984, EUR J BIOCHEM, V143, P651, DOI 10.1111/j.1432-1033.1984.tb08418.x; Kumar V., 2004, ROBBINS COTRAN PATHO; LAX I, 1991, J BIOL CHEM, V266, P13828; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Maurer N, 1998, BBA-BIOMEMBRANES, V1374, P9, DOI 10.1016/S0005-2736(98)00125-4; MIMMS LT, 1981, BIOCHEMISTRY-US, V20, P833, DOI 10.1021/bi00507a028; Mouritsen OG, 2005, FRONT COLLECT, P1, DOI 10.1007/b138577; PANAYOTOU GN, 1985, FEBS LETT, V183, P321, DOI 10.1016/0014-5793(85)80802-4; PATEL TB, 2006, EPIDERMAL GROWTH FAC; Poch B, 2001, PANCREAS, V23, P280, DOI 10.1097/00006676-200110000-00009; Robert C, 2006, TARGET ONCOL, V1, P100, DOI 10.1007/s11523-006-0013-6; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; SCHNEIDER WJ, 1983, J CELL BIOCHEM, V23, P95, DOI 10.1002/jcb.240230110; Tuthill TJ, 2006, J VIROL, V80, P172, DOI 10.1128/JVI.80.1.172-180.2006	26	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 9	2009	4	10							e7391	10.1371/journal.pone.0007391	http://dx.doi.org/10.1371/journal.pone.0007391			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	504DM	19816581	gold, Green Published, Green Submitted			2023-01-03	WOS:000270594300011
J	Zid, BM; Rogers, AN; Katewa, SD; Vargas, MA; Kolipinski, MC; Lu, TA; Benzer, S; Kapahi, P				Zid, Brian M.; Rogers, Aric N.; Katewa, Subhash D.; Vargas, Misha A.; Kolipinski, Marysia C.; Lu, Tony Au; Benzer, Seymour; Kapahi, Pankaj			4E-BP Extends Lifespan upon Dietary Restriction by Enhancing Mitochondrial Activity in Drosophila	CELL			English	Article							CAENORHABDITIS-ELEGANS; MESSENGER-RNAS; SIGNALING PATHWAY; GENE-EXPRESSION; FACTOR EIF-4E; CELL-GROWTH; TRANSLATION; EXTENSION; CANCER; TOR	Dietary restriction (DR) extends lifespan in multiple species. To examine the mechanisms of lifespan extension upon DR, we assayed genome-wide translational changes in Drosophila. A number of nuclear encoded mitochondrial genes, including those in Complex I and IV of the electron transport chain, showed increased ribosomal loading and enhanced overall activity upon DR. We found that various mitochondrial genes possessed shorter and less structured 5'UTRs, which were important for their enhanced mRNA translation. The translational repressor 4E-BP, the eukaryotic translation initiation factor 4E binding protein, was upregulated upon DR and mediated DR dependent changes in mitochondrial activity and lifespan extension. Inhibition of individual mitochondrial subunits from Complex I and IV diminished the lifespan extension obtained upon DR, reflecting the importance of enhanced mitochondrial function during DR. Our results imply that translational regulation of nuclear-encoded mitochondrial gene expression by 4E-BP plays an important role in lifespan extension upon DR. For a video summary of this article, see the PaperFlick file with the Supplemental Data available online.	[Rogers, Aric N.; Katewa, Subhash D.; Vargas, Misha A.; Kolipinski, Marysia C.; Kapahi, Pankaj] Buck Inst Age Res, Novato, CA 94945 USA; [Zid, Brian M.; Lu, Tony Au; Benzer, Seymour] CALTECH, Pasadena, CA 91125 USA	Buck Institute for Research on Aging; California Institute of Technology	Zid, BM (corresponding author), Harvard Univ, Cambridge, MA 02138 USA.	zid@fas.harvard.edu; pkapahi@buckinstitute.org	Rogers, Aric/AAH-2748-2019	Rogers, Aric/0000-0002-6149-6842; Zid, Brian/0000-0003-1876-2479	National Institutes of Health [RL1AAG032113, 1R21AG028241-01]; Ellison Medical Foundation; American Foundation; Hillblom foundation; Nathan Shock Startup; Reta Haynes Family Foundation; Millard and Muriel Jacobs Genetics and Genomics Laboratory at California Institute of Technology; NATIONAL INSTITUTE ON AGING [RL1AG032113, P30AG025708, R21AG028241, T32AG000266] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison Medical Foundation(Lawrence Ellison Foundation); American Foundation; Hillblom foundation; Nathan Shock Startup; Reta Haynes Family Foundation; Millard and Muriel Jacobs Genetics and Genomics Laboratory at California Institute of Technology; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This manuscript is dedicated to the memory of Seymour Benzer, who passed away in the interim between research and publication of the manuscript. We thank David Nicholls, Martin Brand, Judith Campisi, Gordon Lithgow, Nagendra Yadav, Paul Sternberg, Eric Schwarz, Eimear Kenny, and members of the Kapahi and Benzer Labs, for helpful discussions. We would also like to thank the Kimbrell, Lasko, Sonenberg, Tijan, Tower, and Hafen labs for donation of strains and antibodies. This work was funded by grants from the National Institutes of Health (S. B.), a T32 NIH training grant fellowship (A. R.), grants from the Ellison Medical Foundation, American Foundation for aging research, Hillblom foundation, a Nathan Shock Startup award, a gift from the Harold J. and Reta Haynes Family Foundation, and the NIH (RL1AAG032113, 1R21AG028241-01) ( P. K.). The microarray work was supported by the Millard and Muriel Jacobs Genetics and Genomics Laboratory at California Institute of Technology.	Arava Y, 2003, P NATL ACAD SCI USA, V100, P3889, DOI 10.1073/pnas.0635171100; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Bernal A, 2000, P NATL ACAD SCI USA, V97, P6019, DOI 10.1073/pnas.100391597; Bonawitz ND, 2007, CELL METAB, V5, P265, DOI 10.1016/j.cmet.2007.02.009; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen D, 2007, AGING CELL, V6, P525, DOI 10.1111/j.1474-9726.2007.00305.x; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Curran SP, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030056; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Ford D, 2007, EXP GERONTOL, V42, P483, DOI 10.1016/j.exger.2007.01.004; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Giannakou ME, 2008, AGING CELL, V7, P187, DOI 10.1111/j.1474-9726.2007.00362.x; Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x; Harris Thurl E, 2003, Sci STKE, V2003, pre15; Henderson ST, 2006, J GERONTOL A-BIOL, V61, P444, DOI 10.1093/gerona/61.5.444; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; JOSHIBARVE S, 1992, J BIOL CHEM, V267, P21038; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kaeberlein M, 2007, PLOS GENET, V3, P655, DOI 10.1371/journal.pgen.0030084; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; KAPAHI P, 2004, SCI AGING KNOWLEDGE, pPE34; Katewa SD, 2007, INSECT BIOCHEM MOLEC, V37, P213, DOI 10.1016/j.ibmb.2006.11.002; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Lachance PED, 2002, MOL CELL BIOL, V22, P1656, DOI 10.1128/MCB.22.6.1656-1663.2002; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Lewis E.B., 1960, DROS INFORM SERV, V34, P117, DOI DOI 10.1101/PDB.REC081414; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Magwere T, 2006, J GERONTOL A-BIOL, V61, P36, DOI 10.1093/gerona/61.1.36; Mair W, 2005, PLOS BIOL, V3, P1305, DOI 10.1371/journal.pbio.0030223; Mair W, 2004, EXP GERONTOL, V39, P1011, DOI 10.1016/j.exger.2004.03.018; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; McCarroll SA, 2004, NAT GENET, V36, P197, DOI 10.1038/ng1291; Min KJ, 2008, AGING CELL, V7, P199, DOI 10.1111/j.1474-9726.2008.00373.x; Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Nusbaum TJ, 1999, J GERONTOL A-BIOL, V54, pB192, DOI 10.1093/gerona/54.5.B192; Pan KZ, 2007, AGING CELL, V6, P111, DOI 10.1111/j.1474-9726.2006.00266.x; Partridge L, 2005, CELL, V120, P461, DOI 10.1016/j.cell.2005.01.026; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Shantz LM, 1996, CANCER RES, V56, P3265; Sonenberg N, 2000, TRANSLATIONAL CONTRO; Steffen KK, 2008, CELL, V133, P292, DOI 10.1016/j.cell.2008.02.037; Syntichaki P, 2007, NATURE, V445, P922, DOI 10.1038/nature05603; Teleman AA, 2005, GENE DEV, V19, P1844, DOI 10.1101/gad.341505; Teleman AA, 2008, CELL METAB, V7, P21, DOI 10.1016/j.cmet.2007.11.010; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; WARBURG O, 1956, SCIENCE, V124, P269; Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371; Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	59	386	403	1	37	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	2009	139	1					149	160		10.1016/j.cell.2009.07.034	http://dx.doi.org/10.1016/j.cell.2009.07.034			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	501NM	19804760	Bronze, Green Accepted			2023-01-03	WOS:000270388600023
J	Minas, H				Minas, Harry			Mentally ill patients dying in social shelters in Indonesia	LANCET			English	Editorial Material							HUMAN-RIGHTS; ILLNESS		Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Int Mental Hlth, Parkville, Vic 3010, Australia	University of Melbourne	Minas, H (corresponding author), Univ Melbourne, Melbourne Sch Populat Hlth, Ctr Int Mental Hlth, Parkville, Vic 3010, Australia.	h.minas@unimelb.edu.au	Minas, Harry/O-8276-2019; Minas, Harry/F-7718-2010	Minas, Harry/0000-0003-1719-7367; 				*AS HUM RIGHTS COM, 2006, IND RAT KEY HUM RIGH; BEECH H, 2003, TIME ASIA       1103; Gostin LO, 2008, PUBLIC HEALTH, V122, P906, DOI 10.1016/j.puhe.2007.11.003; IRMANSYAH PY, 2009, INT J MENT HLTH SYST, V3, P14; *MENT HLTH COUNC A, 2005, NOT SERV EXP INJ DES; Minas Harry, 2007, Int J Ment Health Syst, V1, P1, DOI 10.1186/1752-4458-1-1; Minas Harry, 2008, Int J Ment Health Syst, V2, P8, DOI 10.1186/1752-4458-2-8; NADIRSYAH H, 2007, MUSLIM WORLD, V97, P200; PRIMANITA A, 2009, JAKARTA GLOBE   0523; Silove D, 2001, LANCET, V357, P1436, DOI 10.1016/S0140-6736(00)04575-X; STANMEYER J, 2006, TIME ASIA; Tobin John, 2007, Irish Journal of Psychological Medicine, V24, P31, DOI 10.1017/S0790966700010144	12	14	14	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 22	2009	374	9690					592	593		10.1016/S0140-6736(09)61206-X	http://dx.doi.org/10.1016/S0140-6736(09)61206-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	486TU	19699994				2023-01-03	WOS:000269222600006
J	Hallek, M; Fischer, K; Fingerle-Rowson, G; Fink, AM; Busch, R; Mayer, J; Hensel, M; Hopfinger, G; Hess, G; von Grunhagen, U; Bergmann, M; Catalano, J; Zinzani, PL; Caligaris-Cappio, F; Seymour, JF; Berrebi, A; Jager, U; Cazin, B; Trneny, M; Westermann, A; Wendtner, CM; Eichhorst, BF; Staib, P; Buhler, A; Winkler, D; Zenz, T; Bottcher, S; Ritgen, M; Mendila, M; Kneba, M; Dohner, H; Stilgenbauer, S				Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Busch, R.; Mayer, J.; Hensel, M.; Hopfinger, G.; Hess, G.; von Gruenhagen, U.; Bergmann, M.; Catalano, J.; Zinzani, P. L.; Caligaris-Cappio, F.; Seymour, J. F.; Berrebi, A.; Jaeger, U.; Cazin, B.; Trneny, M.; Westermann, A.; Wendtner, C. M.; Eichhorst, B. F.; Staib, P.; Buehler, A.; Winkler, D.; Zenz, T.; Boettcher, S.; Ritgen, M.; Mendila, M.; Kneba, M.; Doehner, H.; Stilgenbauer, S.		Int Grp Investigators; German Chronic Lymphocytic Leukaem	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial	LANCET			English	Article							STEM-CELL TRANSPLANTATION; PROGRESSION-FREE SURVIVAL; PLUS CYCLOPHOSPHAMIDE; CYTOKINE-RELEASE; INITIAL THERAPY; III TRIAL; CHEMOIMMUNOTHERAPY; EXPRESSION; LYMPHOMA; DELETION	Background On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia. Methods Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on day 1 of second to sixth courses) in 190 centres in 11 countries. Investigators and patients were not masked to the computer-generated treatment assignment. The primary endpoint was progression-free survival (PFS). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00281918. Findings 408 patients were assigned to fludarabine, cyclophosphamide, and rituximab (chemoimmunotherapy group) and 409 to fludarabine and cyclophosphamide (chemotherapy group); all patients were analysed. At 3 years after randomisation, 65% of patients in the chemoimmunotherapy group were free of progression compared with 45% in the chemotherapy group (hazard ratio 0.56 [95% CI 0.46-0.69], p<0.0001); 87% were alive versus 83%, respectively (0.67 [0.48-0.92]; p=0.01). Chemoimmunotherapy was more frequently associated with grade 3 and 4 neutropenia (136 [34%] of 404 vs 83 [21%] of 396; p<0.0001) and leucocytopenia (97 [24%] vs 48 [12%]; p<0.0001). Other side-effects, including severe infections, were not increased. There were eight (2%) treatment-related deaths in the chemoimmunotherapy group compared with ten (3%) in the chemotherapy group. Interpretation Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia. Moreover, the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytic leukaemia.	[Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Westermann, A.; Wendtner, C. M.; Eichhorst, B. F.] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany; [Hallek, M.; Fischer, K.; Fingerle-Rowson, G.; Fink, A. M.; Westermann, A.; Wendtner, C. M.; Eichhorst, B. F.] Univ Cologne, Ctr Integrated Oncol, D-50924 Cologne, Germany; [Busch, R.] Tech Univ, Inst Med Stat & Epidemiol, Munich, Germany; [Mayer, J.] Univ Hosp Brno, Dept Internal Med Haematol & Oncol, Brno, Czech Republic; [Hensel, M.] Univ Heidelberg, Heidelberg, Germany; [Hopfinger, G.] Hanusch Hosp, Dept Med 3, Vienna, Austria; [Hess, G.] Johannes Gutenberg Univ Mainz, Dept Haematol & Oncol, Mainz, Germany; [von Gruenhagen, U.] Praxis Hamatol & Onkol, Cottbus, Germany; [Bergmann, M.] Univ Munich, Dept Internal Med 3, Munich, Germany; [Catalano, J.] Frankston Hosp, Haematol Dept & Dorevitch Pathol, Frankston, Vic, Australia; [Zinzani, P. L.] Univ Bologna, Dept Haematol & Oncol, Bologna, Italy; [Caligaris-Cappio, F.] Univ Sci Res Inst San Raffaele, Milan, Italy; [Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia; [Seymour, J. F.] Univ Melbourne, Melbourne, Vic, Australia; [Berrebi, A.] Kaplan Med Ctr, Haematol Inst, Rehovot, Israel; [Jaeger, U.] Med Univ Vienna, Div Haematol & Haemostaseol, Dept Internal Med 1, Vienna, Austria; [Cazin, B.] Hop Claude Huriez, Serv Malad Sang, Lille, France; [Trneny, M.] Charles Univ Prague, Gen Hosp, Dept Med 1, Prague, Czech Republic; [Staib, P.] St Antonius Hosp, Klin Hamatol & Onkol, Eschweiler, Germany; [Buehler, A.; Winkler, D.; Zenz, T.; Doehner, H.; Stilgenbauer, S.] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany; [Boettcher, S.; Ritgen, M.; Kneba, M.] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Kiel, Germany; [Mendila, M.] Hoffmann La Roche AG, Div Pharmaceut, Basel, Switzerland	University of Cologne; University of Cologne; Technical University of Munich; University Hospital Brno; Ruprecht Karls University Heidelberg; WGKK - Hanusch Hospital; Johannes Gutenberg University of Mainz; University of Munich; Frankston Hospital; University of Bologna; Peter Maccallum Cancer Center; University of Melbourne; Hebrew University of Jerusalem; Kaplan Medical Center; Medical University of Vienna; Universite de Lille - ISITE; CHU Lille; Charles University Prague; General University Hospital Prague; Saint Antonius Hospital; Ulm University; University of Kiel; Schleswig Holstein University Hospital; Roche Holding	Hallek, M (corresponding author), Univ Cologne, Dept Internal Med 1, Kerpener Str 62, D-50924 Cologne, Germany.	michael.hallek@uni-koeln.de	Seymour, John/K-7326-2019; Mayer, Jiri/I-2377-2014; Zinzani, Pier Luigi/J-9182-2016; Hallek, Michael/Y-3191-2019; Pigeot, Iris/A-2722-2012; Döhner, Hartmut/C-8933-2016; Stilgenbauer, Stephan/ABE-6609-2020	Seymour, John/0000-0003-2188-6835; Zinzani, Pier Luigi/0000-0002-2112-2651; Hallek, Michael/0000-0002-7425-4455; Pigeot, Iris/0000-0001-7483-0726; Döhner, Hartmut/0000-0003-2116-5536; Trneny, Marek/0000-0002-6952-6073; Fink, Anna Maria/0000-0002-7669-7890	F Hoffmann-La Roche	F Hoffmann-La Roche(Hoffmann-La Roche)	The trial was funded by F Hoffmann-La Roche. We thank all patients and physicians for their participation in the study; and Stephan Zurfluh and Jamie Wingate for their excellent support and cooperation during the conduct of this trial. Preliminary results were presented in part at the annual meetings of the American Society of Hematology, San Francisco, CA, USA, Dec 6-9, 2008, and New Orleans, LA, USA, Dec 5-8, 2009.	ALMASRI NM, 1992, AM J HEMATOL, V40, P259, DOI 10.1002/ajh.2830400404; Binet JL, 2006, BLOOD, V107, P859, DOI 10.1182/blood-2005-04-1677; BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V; Byrd JC, 2005, BLOOD, V105, P49, DOI 10.1182/blood-2004-03-0796; Catovsky D, 2007, LANCET, V370, P230, DOI 10.1016/S0140-6736(07)61125-8; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Dohner H, 1997, BLOOD, V89, P2516, DOI 10.1182/blood.V89.7.2516; Dores GAM, 2007, BRIT J HAEMATOL, V139, P809, DOI 10.1111/j.1365-2141.2007.06856.x; Eichhorst BF, 2006, BLOOD, V107, P885, DOI 10.1182/blood-2005-06-2395; Extermann M, 1998, J CLIN ONCOL, V16, P1582, DOI 10.1200/JCO.1998.16.4.1582; Flinn IW, 2007, J CLIN ONCOL, V25, P793, DOI 10.1200/JCO.2006.08.0762; Geisler C, 1999, JNCI-J NATL CANCER I, V91, P861; Golay J, 2001, BLOOD, V98, P3383, DOI 10.1182/blood.V98.12.3383; Grever MR, 2007, J CLIN ONCOL, V25, P799, DOI 10.1200/JCO.2006.08.3089; GREVER MR, 1988, NOUV REV FR HEMATOL, V30, P457; Hallek M, 1996, LEUKEMIA LYMPHOMA, V22, P439, DOI 10.3109/10428199609054782; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; HAN T, 1973, CANCER-AM CANCER SOC, V31, P502, DOI 10.1002/1097-0142(197303)31:3<502::AID-CNCR2820310303>3.0.CO;2-7; Huhn D, 2001, BLOOD, V98, P1326, DOI 10.1182/blood.V98.5.1326; Keating MJ, 2005, J CLIN ONCOL, V23, P4079, DOI 10.1200/JCO.2005.12.051; KEATING MJ, 1989, BLOOD, V74, P19; KNOSPE WH, 1974, CANCER, V33, P555, DOI 10.1002/1097-0142(197402)33:2<555::AID-CNCR2820330234>3.0.CO;2-I; Kunzmann V, 2001, BLOOD, V98, P1991, DOI 10.1182/blood.V98.6.1991; Maloney DG, 2002, SEMIN ONCOL, V29, P2, DOI 10.1053/sonc.2002.30156; Michallet AS, 2009, BLOOD REV, V23, P11, DOI 10.1016/j.blre.2008.05.002; Moreno C, 2005, J CLIN ONCOL, V23, P3433, DOI 10.1200/JCO.2005.04.531; Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508; O'Brien SM, 2001, J CLIN ONCOL, V19, P2165, DOI 10.1200/JCO.2001.19.8.2165; RAI KR, 1975, BLOOD, V46, P219, DOI 10.1182/blood.V46.2.219.219; Schetelig J, 2008, J CLIN ONCOL, V26, P5094, DOI 10.1200/JCO.2008.16.2982; Schlette EJ, 2009, LEUKEMIA LYMPHOMA, V50, P1597, DOI 10.1080/10428190903165241; Schulz H, 2002, BLOOD, V100, P3115, DOI 10.1182/blood-2002-03-0972; Schulz H, 2007, JNCI-J NATL CANCER I, V99, P706, DOI 10.1093/jnci/djk152; Tam CS, 2008, BLOOD, V112, P975, DOI 10.1182/blood-2008-02-140582; Tsimberidou AM, 2009, CANCER-AM CANCER SOC, V115, P373, DOI 10.1002/cncr.23993; Wierda W, 2005, J CLIN ONCOL, V23, P4070, DOI 10.1200/JCO.2005.12.516; Winkler U, 1999, BLOOD, V94, P2217, DOI 10.1182/blood.V94.7.2217.419k02_2217_2224	41	1452	1505	0	98	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1164	1174		10.1016/S0140-6736(10)61381-5	http://dx.doi.org/10.1016/S0140-6736(10)61381-5			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888994				2023-01-03	WOS:000282915700033
J	Fuss, J; Ben Abdallah, NMB; Hensley, FW; Weber, KJ; Hellweg, R; Gass, P				Fuss, Johannes; Ben Abdallah, Nada M. B.; Hensley, Frank W.; Weber, Klaus-Josef; Hellweg, Rainer; Gass, Peter			Deletion of Running-Induced Hippocampal Neurogenesis by Irradiation Prevents Development of an Anxious Phenotype in Mice	PLOS ONE			English	Article							DENTATE GYRUS; ADULT NEUROGENESIS; CELL-PROLIFERATION; FOS EXPRESSION; C-FOS; ANXIETY; BEHAVIOR; MEMORY; NEURONS; INTEGRATION	Recent evidence postulates a role of hippocampal neurogenesis in anxiety behavior. Here we report that elevated levels of neurogenesis elicit increased anxiety in rodents. Mice performing voluntary wheel running displayed both highly elevated levels of neurogenesis and increased anxiety in three different anxiety-like paradigms: the open field, elevated O-maze, and dark-light box. Reducing neurogenesis by focalized irradiation of the hippocampus abolished this exercise-induced increase of anxiety, suggesting a direct implication of hippocampal neurogenesis in this phenotype. On the other hand, irradiated mice explored less frequently the lit compartment of the dark-light box test irrespective of wheel running, suggesting that irradiation per se induced anxiety as well. Thus, our data suggest that intermediate levels of neurogenesis are related to the lowest levels of anxiety. Moreover, using c-Fos immunocytochemistry as cellular activity marker, we observed significantly different induction patterns between runners and sedentary controls when exposed to a strong anxiogenic stimulus. Again, this effect was altered by irradiation. In contrast, the well-known induction of brain-derived neurotrophic factor ( BDNF) by voluntary exercise was not disrupted by focal irradiation, indicating that hippocampal BDNF levels were not correlated with anxiety under our experimental conditions. In summary, our data demonstrate to our knowledge for the first time that increased neurogenesis has a causative implication in the induction of anxiety.	[Fuss, Johannes; Ben Abdallah, Nada M. B.; Gass, Peter] Heidelberg Univ, Dept Psychiat & Psychotherapy, Cent Inst Mental Hlth Mannheim ZI, D-6800 Mannheim, Germany; [Hensley, Frank W.; Weber, Klaus-Josef] Heidelberg Univ, Dept Radiooncol, Heidelberg, Germany; [Hellweg, Rainer] Univ Med Berlin, Dept Psychiat, Berlin, Germany	Central Institute of Mental Health; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Fuss, J (corresponding author), Heidelberg Univ, Dept Psychiat & Psychotherapy, Cent Inst Mental Hlth Mannheim ZI, D-6800 Mannheim, Germany.	johannes.fuss@zi-mannheim.de	Fuss, Johannes/AAI-6580-2021; Weber, Klaus/P-8241-2019	Weber, Klaus/0000-0002-2421-6178; Hellweg, Rainer/0000-0001-8033-389X	Deutsche Forschungsgemeinschaft [GA427/9-1, HE 1392/3-1, SFB636-B3]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was funded by grant sponsor Deutsche Forschungsgemeinschaft (http://www.dfg.de/en/index.jsp), under grant numbers: GA427/9-1, HE 1392/3-1, SFB636-B3. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acsady L, 1998, J NEUROSCI, V18, P3386; Amrein I, 2004, EUR J NEUROSCI, V20, P3342, DOI 10.1111/j.1460-9568.2004.03795.x; Augustsson H, 2004, PHYSIOL BEHAV, V81, P685, DOI 10.1016/j.physbeh.2004.03.014; Bannerman DM, 2004, NEUROSCI BIOBEHAV R, V28, P273, DOI 10.1016/j.neubiorev.2004.03.004; BELZUNG C, 2007, NEURAL PLAST; Ben Abdallah NMB, 2007, HIPPOCAMPUS, V17, P1230, DOI 10.1002/hipo.20358; Bergami M, 2008, P NATL ACAD SCI USA, V105, P15570, DOI 10.1073/pnas.0803702105; BLANCHARD RJ, 1993, BEHAV BRAIN RES, V58, P155, DOI 10.1016/0166-4328(93)90100-5; BRAGIN A, 1995, J NEUROSCI, V15, P47; Castro JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008618; Cazorla M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009777; Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663; CLARK PJ, 2010, BEHAV BRAIN RES; DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Earnheart JC, 2007, J NEUROSCI, V27, P3845, DOI 10.1523/JNEUROSCI.3609-06.2007; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Freud S, 1926, HEMMUNG SYMPTOM ANGS; Fuss J, 2010, HIPPOCAMPUS, V20, P364, DOI 10.1002/hipo.20634; Ge SY, 2006, NATURE, V439, P589, DOI 10.1038/nature04404; Govindarajan A, 2006, P NATL ACAD SCI USA, V103, P13208, DOI 10.1073/pnas.0605180103; Grace L, 2009, METAB BRAIN DIS, V24, P643, DOI 10.1007/s11011-009-9162-5; Gray JA, 2000, NEUROPSYCHOLOGY ANXI, pxvi; Hale MW, 2008, NEUROSCIENCE, V155, P659, DOI 10.1016/j.neuroscience.2008.05.054; Heidegger M., 1949, SEIN ZEIT; Hellweg R, 2003, EXP NEUROL, V183, P346, DOI 10.1016/S0014-4886(03)00127-4; Holmes MM, 2004, J NEUROSCI RES, V76, P216, DOI 10.1002/jnr.20039; Kornack DR, 1999, P NATL ACAD SCI USA, V96, P5768, DOI 10.1073/pnas.96.10.5768; Lee E, 2009, BMB REP, V42, P239, DOI 10.5483/BMBRep.2009.42.5.239; Menard J, 2001, BRAIN RES, V888, P163, DOI 10.1016/S0006-8993(00)03046-8; Mizumatsu S, 2003, CANCER RES, V63, P4021; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Petrovich GD, 2001, BRAIN RES REV, V38, P247, DOI 10.1016/S0165-0173(01)00080-7; Revest JM, 2009, MOL PSYCHIATR, V14, P959, DOI 10.1038/mp.2009.15; Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969; Salome N, 2004, BIOL PSYCHIAT, V55, P715, DOI 10.1016/j.biopsych.2003.10.021; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Saxe MD, 2007, P NATL ACAD SCI USA, V104, P4642, DOI 10.1073/pnas.0611718104; Saxe MD, 2006, P NATL ACAD SCI USA, V103, P17501, DOI 10.1073/pnas.0607207103; Scobie KN, 2009, J NEUROSCI, V29, P9875, DOI 10.1523/JNEUROSCI.2260-09.2009; Shimazu K, 2006, LEARN MEMORY, V13, P307, DOI 10.1101/lm.76006; Toni N, 2008, NAT NEUROSCI, V11, P901, DOI 10.1038/nn.2156; Troakes C, 2009, STRESS, V12, P362, DOI 10.1080/10253890802506391; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhao XY, 2003, P NATL ACAD SCI USA, V100, P6777, DOI 10.1073/pnas.1131928100	50	87	87	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2010	5	9							e12769	10.1371/journal.pone.0012769	http://dx.doi.org/10.1371/journal.pone.0012769			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	650QH	20862278	Green Published, gold, Green Submitted			2023-01-03	WOS:000281864100014
J	Papazian, L; Forel, JM; Gacouin, A; Penot-Ragon, C; Perrin, G; Loundou, A; Jaber, S; Arnal, JM; Perez, D; Seghboyan, JM; Constantin, JM; Courant, P; Lefrant, JY; Guerin, C; Prat, G; Morange, S; Roch, A				Papazian, Laurent; Forel, Jean-Marie; Gacouin, Arnaud; Penot-Ragon, Christine; Perrin, Gilles; Loundou, Anderson; Jaber, Samir; Arnal, Jean-Michel; Perez, Didier; Seghboyan, Jean-Marie; Constantin, Jean-Michel; Courant, Pierre; Lefrant, Jean-Yves; Guerin, Claude; Prat, Gwenael; Morange, Sophie; Roch, Antoine		ACURASYS Study Investigators	Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LUNG INJURY; MECHANICAL VENTILATION; BLOCKING-AGENTS; WEAKNESS; OUTCOMES	Background: In patients undergoing mechanical ventilation for the acute respiratory distress syndrome (ARDS), neuromuscular blocking agents may improve oxygenation and decrease ventilator-induced lung injury but may also cause muscle weakness. We evaluated clinical outcomes after 2 days of therapy with neuromuscular blocking agents in patients with early, severe ARDS. Methods: In this multicenter, double-blind trial, 340 patients presenting to the intensive care unit (ICU) with an onset of severe ARDS within the previous 48 hours were randomly assigned to receive, for 48 hours, either cisatracurium besylate (178 patients) or placebo (162 patients). Severe ARDS was defined as a ratio of the partial pressure of arterial oxygen (PaO(sub 2)) to the fraction of inspired oxygen (FIO(sub 2)) of less than 150, with a positive end-expiratory pressure of 5 cm or more of water and a tidal volume of 6 to 8 ml per kilogram of predicted body weight. The primary outcome was the proportion of patients who died either before hospital discharge or within 90 days after study enrollment (i.e., the 90-day in-hospital mortality rate), adjusted for predefined covariates and baseline differences between groups with the use of a Cox model. Results: The hazard ratio for death at 90 days in the cisatracurium group, as compared with the placebo group, was 0.68 (95% confidence interval [CI], 0.48 to 0.98; P=0.04), after adjustment for both the baseline PaO(sub 2):FIO(sub 2) and plateau pressure and the Simplified Acute Physiology II score. The crude 90-day mortality was 31.6% (95% CI, 25.2 to 38.8) in the cisatracurium group and 40.7% (95% CI, 33.5 to 48.4) in the placebo group (P=0.08). Mortality at 28 days was 23.7% (95% CI, 18.1 to 30.5) with cisatracurium and 33.3% (95% CI, 26.5 to 40.9) with placebo (P=0.05). The rate of ICU-acquired paresis did not differ significantly between the two groups. Conclusions: In patients with severe ARDS, early administration of a neuromuscular blocking agent improved the adjusted 90-day survival and increased the time off the ventilator without increasing muscle weakness. (Funded by Assistance Publique-Hopitaux de Marseille and the Programme Hospitalier de Recherche Clinique Regional 2004-26 of the French Ministry of Health; ClinicalTrials.gov number, NCT00299650.) N Engl J Med 2010;363:1107-16.	[Papazian, Laurent] Hop Nord Marseille, Serv Reanimat Med, Assistance Publ Hop Marseille, CNRS,URMITE,UMR 6236, F-13009 Marseille, France; [Loundou, Anderson] Univ Aix Marseille 2, Fac Med, F-13284 Marseille 07, France; [Penot-Ragon, Christine] Hop St Marguerite, Marseille, France; [Morange, Sophie] Assistance Publ Hop Marseille, INSERM 9502, Ctr Invest Clin, Marseille, France; [Seghboyan, Jean-Marie] Hop Ambroise Pare, Marseille, France; [Gacouin, Arnaud] Hop Pontchaillou, Rennes, France; [Jaber, Samir] Hop St Eloi, Montpellier, France; [Perez, Didier] Hop Jean Minjoz, F-25030 Besancon, France; [Arnal, Jean-Michel] Hop Font Pre, Toulon, France; [Constantin, Jean-Michel] Hop Hotel Dieu, Clermont Ferrand, France; [Courant, Pierre] Ctr Hosp, Avignon, France; [Lefrant, Jean-Yves] Hop Caremeau, Nimes, France; [Guerin, Claude] Hop Croix Rousse, F-69317 Lyon, France; [Prat, Gwenael] Hop Cavale Blanche, Brest, France	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; CHU Rennes; Universite de Montpellier; CHU de Montpellier; Universite de Franche-Comte; CHU Besancon; CHU Clermont Ferrand; Universite de Montpellier; CHU de Nimes; CHU Lyon; CHU Brest; Universite de Bretagne Occidentale	Papazian, L (corresponding author), Hop Nord Marseille, Serv Reanimat Med, Assistance Publ Hop Marseille, CNRS,URMITE,UMR 6236, Chemin Bourrely, F-13009 Marseille, France.	laurent.papazian@ap-hm.fr	Leone, Marc/P-4835-2016; guerin, claude/H-5692-2014	Leone, Marc/0000-0002-3097-758X; guerin, claude/0000-0003-4700-6672; Guervilly, Christophe/0000-0001-9066-6591; ALLARDET-SERVENT, Jerome/0000-0002-6464-2382	Assistance Publique-Hopitaux de Marseille; Ministere de la Sante	Assistance Publique-Hopitaux de Marseille; Ministere de la Sante	Supported by the Assistance Publique-Hopitaux de Marseille and a grant from the Ministere de la Sante (Programme Hospitalier de Recherche Clinique Regional 2004-26). GlaxoSmithKline France provided the study drugs.	*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Bernard GR, 2005, AM J RESP CRIT CARE, V172, P798, DOI 10.1164/rccm.200504-663OE; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Davis NA, 1998, CRIT CARE MED, V26, P1290, DOI 10.1097/00003246-199807000-00038; DE JONGHE B, 2002, JAMA-J AM MED ASSOC, V288, P2859; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2008, AM J RESP CRIT CARE, V177, P170, DOI 10.1164/rccm.200706-893OC; Forel JM, 2006, CRIT CARE MED, V34, P2749, DOI 10.1097/01.CCM.0000239435.87433.0D; Gainnier M, 2004, CRIT CARE MED, V32, P113, DOI 10.1097/01.CCM.0000104114.72614.BC; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; HANSENFLASCHEN JH, 1991, JAMA-J AM MED ASSOC, V266, P2870, DOI 10.1001/jama.266.20.2870; Leatherman JW, 1996, AM J RESP CRIT CARE, V153, P1686, DOI 10.1164/ajrccm.153.5.8630621; Malhotra A, 2007, NEW ENGL J MED, V357, P1113, DOI 10.1056/NEJMct074213; Mehta S, 2006, CRIT CARE MED, V34, P374, DOI 10.1097/01.CCM.0000196830.61965.F1; Murray MJ, 2002, CRIT CARE MED, V30, P142, DOI 10.1097/00003246-200201000-00021; MURRAY MJ, 1995, CRIT CARE MED, V23, P450, DOI 10.1097/00003246-199503000-00007; Reisine T, 1996, GOODMAN GILMANS PHAR, P521; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Samuelson Karin A, 2003, Intensive Crit Care Nurs, V19, P350; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; SEGREDO V, 1992, NEW ENGL J MED, V327, P524, DOI 10.1056/NEJM199208203270804; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Testelmans D, 2006, CRIT CARE MED, V34, P3018, DOI 10.1097/01.CCM.0000245783.28478.AD; Vender Jeffery S, 2004, Crit Care Med, V32, pS554, DOI 10.1097/01.CCM.0000145907.86298.12; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806	25	1449	1548	1	66	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1107	1116		10.1056/NEJMoa1005372	http://dx.doi.org/10.1056/NEJMoa1005372			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	649TD	20843245				2023-01-03	WOS:000281795800005
J	Rhein, V; Giese, M; Baysang, G; Meier, F; Rao, S; Schulz, KL; Hamburger, M; Eckert, A				Rhein, Virginie; Giese, Maria; Baysang, Ginette; Meier, Fides; Rao, Stefania; Schulz, Kathrin L.; Hamburger, Matthias; Eckert, Anne			Ginkgo Biloba Extract Ameliorates Oxidative Phosphorylation Performance and Rescues A beta-Induced Failure	PLOS ONE			English	Article							AMYLOID PRECURSOR PROTEIN; TRANSGENIC MOUSE MODEL; CYTOCHROME-C-OXIDASE; ALZHEIMERS-DISEASE; MITOCHONDRIAL-FUNCTION; DOUBLE-BLIND; EGB 761; NEUROPSYCHIATRIC FEATURES; HIPPOCAMPAL-NEURONS; RESPIRATORY-CHAIN	Background: Energy deficiency and mitochondrial failure have been recognized as a prominent, early event in Alzheimer's disease (AD). Recently, we demonstrated that chronic exposure to amyloid-beta (A beta) in human neuroblastoma cells over-expressing human wild-type amyloid precursor protein (APP) resulted in (i) activity changes of complexes III and IV of the oxidative phosphorylation system (OXPHOS) and in (ii) a drop of ATP levels which may finally instigate loss of synapses and neuronal cell death in AD. Therefore, the aim of the present study was to investigate whether standardized Ginkgo biloba extract LI 1370 (GBE) is able to rescue A beta-induced defects in energy metabolism. Methodology/Principal Findings: We used a high-resolution respiratory protocol to evaluate OXPHOS respiratory capacity under physiological condition in control (stably transfected with the empty vector) and APP cells after treatment with GBE. In addition, oxygen consumption of isolated mitochondria, activities of mitochondrial respiratory enzymes, ATP and reactive oxygen species (ROS) levels as well as mitochondrial membrane mass and mitochondrial DNA content were determined. We observed a general antioxidant effect of GBE leading to an increase of the coupling state of mitochondria as well as energy homeostasis and a reduction of ROS levels in control cells and in APP cells. GBE effect on OXPHOS was even preserved in mitochondria after isolation from treated cells. Moreover, these functional data were paralleled by an up-regulation of mitochondrial DNA. Improvement of the OXPHOS efficiency was stronger in APP cells than in control cells. In APP cells, the GBE-induced amelioration of oxygen consumption most likely arose from the modulation and respective normalization of the A beta-induced disturbance in the activity of mitochondrial complexes III and IV restoring impaired ATP levels possibly through decreasing A beta and oxidative stress level. Conclusions/Significance: Although the underlying molecular mechanisms of the mode of action of GBE remain to be determined, our study clearly highlights the beneficial effect of GBE on the cellular OXPHOS performance and restoration of A beta-induced mitochondrial dysfunction.	[Rhein, Virginie; Giese, Maria; Baysang, Ginette; Meier, Fides; Rao, Stefania; Schulz, Kathrin L.; Eckert, Anne] Univ Basel, Neurobiol Lab Brain Aging & Mental Hlth, Psychiat Univ Clin, Basel, Switzerland; [Hamburger, Matthias] Univ Basel, Inst Pharmaceut Biol, Basel, Switzerland	University of Basel; University of Basel	Rhein, V (corresponding author), Univ Basel, Neurobiol Lab Brain Aging & Mental Hlth, Psychiat Univ Clin, Basel, Switzerland.	anne.eckert@upkbs.ch		Eckert, Anne/0000-0002-9341-3669	SNSF (Swiss National Science Foundation) [310000-108223]; Vifor SA, Switzerland	SNSF (Swiss National Science Foundation)(Swiss National Science Foundation (SNSF)); Vifor SA, Switzerland	This research was supported by a grant from the SNSF (Swiss National Science Foundation) #310000-108223 to A. E. and an unrestricted research grant from Vifor SA, Switzerland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Kader R, 2007, PHARMACOL RES, V56, P493, DOI 10.1016/j.phrs.2007.09.011; Augustin S, 2009, ARCH BIOCHEM BIOPHYS, V481, P177, DOI 10.1016/j.abb.2008.10.032; Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8; Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; Blass JP, 2003, NEUROL RES, V25, P556, DOI 10.1179/016164103101201995; Cardoso SM, 2004, J NEUROCHEM, V89, P1417, DOI 10.1111/j.1471-4159.2004.02438.x; Cardoso SM, 2004, NEUROBIOL AGING, V25, P105, DOI 10.1016/S0197-4580(03)00033-2; Carvalho C, 2009, J BIOENERG BIOMEMBR, V41, P433, DOI 10.1007/s10863-009-9247-1; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Colciaghi F, 2004, NEUROBIOL DIS, V16, P454, DOI 10.1016/j.nbd.2004.03.011; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; D'Aurelio M, 2006, HUM MOL GENET, V15, P2157, DOI 10.1093/hmg/ddl141; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; David DC, 2005, J BIOL CHEM, V280, P23802, DOI 10.1074/jbc.M500356200; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; Devore EE, 2010, ARCH NEUROL-CHICAGO, V67, P819, DOI 10.1001/archneurol.2010.144; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; DOUSSIERE J, 1984, BIOCHIM BIOPHYS ACTA, V766, P492, DOI 10.1016/0005-2728(84)90265-2; Eckert A, 2005, ANN NY ACAD SCI, V1056, P474, DOI 10.1196/annals.1352.023; Eckert A, 2003, PHARMACOPSYCHIATRY, V36, pS15; Eckert A, 2008, J MOL MED, V86, P1255, DOI 10.1007/s00109-008-0391-6; Eckert A, 2010, MOL NEUROBIOL, V41, P107, DOI 10.1007/s12035-010-8109-5; Fernandez-Vizarra P, 2004, HISTOL HISTOPATHOL, V19, P823, DOI 10.14670/HH-19.823; Gibson GE, 1998, J NEURAL TRANSM, V105, P855, DOI 10.1007/s007020050099; Gnaiger E, 2009, INT J BIOCHEM CELL B, V41, P1837, DOI 10.1016/j.biocel.2009.03.013; Hauptmann S, 2009, NEUROBIOL AGING, V30, P1574, DOI 10.1016/j.neurobiolaging.2007.12.005; Hou Y, 2010, NEUROPHARMACOLOGY, V58, P911, DOI 10.1016/j.neuropharm.2009.11.002; Iijima-Ando K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008310; Janssens D, 1999, BIOCHEM PHARMACOL, V58, P109, DOI 10.1016/S0006-2952(99)00061-1; JANSSENS D, 1995, BIOCHEM PHARMACOL, V50, P991, DOI 10.1016/0006-2952(95)00227-Q; Kanowski S, 1996, PHARMACOPSYCHIATRY, V29, P47, DOI 10.1055/s-2007-979544; Keil U, 2004, J BIOL CHEM, V279, P50310, DOI 10.1074/jbc.M405600200; KISH SJ, 1992, J NEUROCHEM, V59, P776, DOI 10.1111/j.1471-4159.1992.tb09439.x; KUROIWA T, 1994, MICROSC RES TECHNIQ, V27, P220, DOI 10.1002/jemt.1070270304; Laurin D, 2004, AM J EPIDEMIOL, V159, P959, DOI 10.1093/aje/kwh124; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Leuner K, 2007, ANTIOXID REDOX SIGN, V9, P1659, DOI 10.1089/ars.2007.1763; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230; McCarney R, 2008, INT J GERIATR PSYCH, V23, P1222, DOI 10.1002/gps.2055; Mix JA, 2002, HUM PSYCHOPHARM CLIN, V17, P267, DOI 10.1002/hup.412; Moreira PI, 2010, BBA-MOL BASIS DIS, V1802, P212, DOI 10.1016/j.bbadis.2009.10.007; Moreira PI, 2010, BBA-MOL BASIS DIS, V1802, P2, DOI 10.1016/j.bbadis.2009.10.006; Napryeyenko O, 2007, ARZNEIMITTELFORSCH, V57, P4; Navarro A, 2005, AM J PHYSIOL-REG I, V289, pR1392, DOI 10.1152/ajpregu.00834.2004; Plecita-Hlavata L, 2009, INT J BIOCHEM CELL B, V41, P1697, DOI 10.1016/j.biocel.2009.02.015; Rhein V, 2009, CELL MOL NEUROBIOL, V29, P1063, DOI 10.1007/s10571-009-9398-y; Rhein Virginie, 2007, Archives of Physiology and Biochemistry, V113, P131, DOI 10.1080/13813450701572288; Rhein V, 2009, P NATL ACAD SCI USA, V106, P20057, DOI 10.1073/pnas.0905529106; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Schindowski K, 2001, J NEURAL TRANSM, V108, P969, DOI 10.1007/s007020170016; Shi QL, 2007, ALZ DIS ASSOC DIS, V21, P276, DOI 10.1097/WAD.0b013e31815721c3; Smith JV, 2002, CELL MOL BIOL, V48, P699; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Tchantchou F, 2009, J ALZHEIMERS DIS, V18, P787, DOI 10.3233/JAD-2009-1189; Tendi EA, 2002, NEUROCHEM RES, V27, P319, DOI 10.1023/A:1014963313559; Trumbeckaite S, 2007, J ETHNOPHARMACOL, V111, P512, DOI 10.1016/j.jep.2006.12.028; Valla J, 2001, J NEUROSCI, V21, P4923, DOI 10.1523/JNEUROSCI.21-13-04923.2001; Wang XL, 2009, J NEUROSCI, V29, P9090, DOI 10.1523/JNEUROSCI.1357-09.2009; Yancheva S, 2009, AGING MENT HEALTH, V13, P183, DOI 10.1080/13607860902749057; Yao ZX, 2001, BRAIN RES, V889, P181, DOI 10.1016/S0006-8993(00)03131-0	63	52	54	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2010	5	8							e12359	10.1371/journal.pone.0012359	http://dx.doi.org/10.1371/journal.pone.0012359			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	641UD	20808761	Green Submitted, gold, Green Published			2023-01-03	WOS:000281154300003
J	Sims, M; Maxwell, R; Bauld, L; Gilmore, A				Sims, Michelle; Maxwell, Roy; Bauld, Linda; Gilmore, Anna			Short term impact of smoke-free legislation in England: retrospective analysis of hospital admissions for myocardial infarction	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY-HEART-DISEASE; PARTICULATE AIR-POLLUTION; PASSIVE SMOKING; SECONDHAND SMOKE; YOUNG-ADULTS; SEASONAL-VARIATION; EUROPEAN-SOCIETY; WORKING GROUP; BAN; MORTALITY	Objective To measure the short term impact on hospital admissions for myocardial infarction of the introduction of smoke-free legislation in England on 1 July 2007. Design An interrupted time series design with routinely collected hospital episode statistics data. Analysis of admissions from July 2002 to September 2008 (providing five years' data from before the legislation and 15 months' data from after) using segmented Poisson regression. Setting England. Population All patients aged 18 or older living in England with an emergency admission coded with a primary diagnosis of myocardial infarction. Main outcome measures Weekly number of completed hospital admissions. Results After adjustment for secular and seasonal trends and variation in population size, there was a small but significant reduction in the number of emergency admissions for myocardial infarction after the implementation of smoke-free legislation (-2.4%, 95% confidence interval -4.06% to -0.66%, P=0.007). This equates to 1200 fewer emergency admissions for myocardial infarction (1600 including readmissions) in the first year after legislation. The reduction in admissions was significant in men (3.1%, P=0.001) and women (3.8%, P=0.007) aged 60 and over, and men (3.5%, P<0.01) but not women (2.5% P=0.38) aged under 60. Conclusion This study adds to a growing body of evidence that smoke-free legislation leads to reductions in myocardial infarctions. It builds on previous work by showing that such declines are observed even when underlying reductions in admissions and potential confounders are controlled for. The considerably smaller decline in admissions observed in England compared with many other jurisdictions probably reflects aspects of the study design and the relatively low levels of exposure to secondhand smoke in England before the legislation.	[Sims, Michelle; Gilmore, Anna] Univ Bath, Sch Hlth, Bath BA2 7AY, Avon, England; [Sims, Michelle; Bauld, Linda; Gilmore, Anna] Univ Bath, UK Ctr Tobacco Control Studies, Bath BA2 7AY, Avon, England; [Maxwell, Roy] SW Publ Hlth Observ, Bristol BS8 2RA, Avon, England; [Bauld, Linda] Univ Bath, Dept Social & Policy Sci, Bath BA2 7AY, Avon, England; [Gilmore, Anna] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of Bath; University of Bath; University of Bath; University of London; London School of Hygiene & Tropical Medicine	Gilmore, A (corresponding author), Univ Bath, Sch Hlth, Bath BA2 7AY, Avon, England.	a.gilmore@bath.ac.uk	gilmore, anna B/I-7130-2012	gilmore, anna B/0000-0003-0281-1248	Department of Health; Health Foundation; British Heart Foundation; Cancer Research UK; Economic and Social Research Council; Medical Research Council; Economic and Social Research Council [ES/G007489/1] Funding Source: researchfish	Department of Health; Health Foundation; British Heart Foundation(British Heart Foundation); Cancer Research UK(Cancer Research UK); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Economic and Social Research Council(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	This work was undertaken by the University of Bath, which received funding from the Department of Health's Policy Research Programme. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health. AG is supported by a Health Foundation Clinician Scientist Fellowship. MS, LB, and AG are members of the UK Centre for Tobacco Control, a UKCRC Public Health Research: Centre of Excellence. Funding from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council and the Department of Health, under the auspices of the UK Clinical Research Collaboration is gratefully acknowledged. The funders played no role in the study design, analysis, and interpretation of data nor in the writing of the report or the decision to submit the article for publication.	Akaike H., 1973, INFORM THEORY EXTENS, P267; Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Barnoya J, 2005, CIRCULATION, V111, P2684, DOI 10.1161/CIRCULATIONAHA.104.492215; Barone-Adesi F, 2006, EUR HEART J, V27, P2468, DOI 10.1093/eurheartj/ehl201; Bartecchi C, 2006, CIRCULATION, V114, P1490, DOI 10.1161/CIRCULATIONAHA.106.615245; Cesaroni G, 2008, CIRCULATION, V117, P1183, DOI 10.1161/CIRCULATIONAHA.107.729889; Crawford VLS, 2003, QJM-INT J MED, V96, P45, DOI 10.1093/qjmed/hcg005; Croxton PJ, 2006, INT J CLIMATOL, V26, P2287, DOI 10.1002/joc.1378; *DEP HLTH, 2009, SMOK ENGL ON YEAR; Dinno A, 2007, PREV MED, V45, P9, DOI 10.1016/j.ypmed.2007.03.013; Douglas AS, 1995, J EPIDEMIOL COMMUN H, V49, P575, DOI 10.1136/jech.49.6.575; Edwards E, 2006, SMOKE HAS CLEARED EV; Ford ES, 2007, J AM COLL CARDIOL, V50, P2128, DOI 10.1016/j.jacc.2007.05.056; Fox KAA, 2004, HEART, V90, P603, DOI 10.1136/hrt.2004.038679; Gemmell I, 2000, INT J EPIDEMIOL, V29, P274, DOI 10.1093/ije/29.2.274; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; Haw SJ, 2007, BRIT MED J, V335, P549, DOI 10.1136/bmj.39315.670208.47; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; *IARC, 2009, IARC HDB CANC PREV T; Institute of Medicine, 2009, SEC SMOK EXP CARD EF; Juster HR, 2007, AM J PUBLIC HEALTH, V97, P2035, DOI 10.2105/AJPH.2006.099994; Khuder SA, 2007, PREV MED, V45, P3, DOI 10.1016/j.ypmed.2007.03.011; Kloner RA, 2004, CIRCULATION, V110, P3744, DOI 10.1161/01.CIR.0000151786.03797.18; Koek HL, 2006, HEART, V92, P162, DOI 10.1136/hrt.2004.054486; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; Lemstra M, 2008, CAN J PUBLIC HEALTH, V99, P62, DOI 10.1007/BF03403743; Lightwood JM, 2009, CIRCULATION, V120, P1373, DOI 10.1161/CIRCULATIONAHA.109.870691; Luepker RV, 2003, CIRCULATION, V108, P2543, DOI 10.1161/01.CIR.0000100560.46946.EA; MacIntyre K, 2006, HEART, V92, P691, DOI 10.1136/hrt.2005.068742; Marques-Vidal P, 2000, HEART, V84, P171, DOI 10.1136/heart.84.2.171; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1249, DOI 10.1016/j.jacc.2009.07.022; Murphy NF, 2004, BMJ-BRIT MED J, V328, P1413, DOI 10.1136/bmj.38111.650741.F7; *NHS INF CTR HLTH, 2010, HOSP EP STAT ONL; O'Flaherty M, 2008, HEART, V94, P178, DOI 10.1136/hrt.2007.118323; O'Flaherty M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2613; OFARRELL AM, 2004, HOSP DISCHARGE RATES; Otsuka R, 2001, JAMA-J AM MED ASSOC, V286, P436, DOI 10.1001/jama.286.4.436; PARKER DE, 1992, INT J CLIMATOL, V12, P317, DOI 10.1002/joc.3370120402; Pechacek TF, 2004, BRIT MED J, V328, P980, DOI 10.1136/bmj.328.7446.980; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; Pell JP, 1999, QJM-INT J MED, V92, P689, DOI 10.1093/qjmed/92.12.689; Peters A, 2001, CIRCULATION, V103, P2810; Pope CA, 2009, CIRCULATION, V120, P941, DOI 10.1161/CIRCULATIONAHA.109.857888; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Raupach T, 2006, EUR HEART J, V27, P386, DOI 10.1093/eurheartj/ehi601; Richiardi L, 2009, PREV MED, V48, P167, DOI 10.1016/j.ypmed.2008.11.013; Royal College of Physicians, 2005, GOING SMOK FREE MED; Sargent RP, 2004, BMJ-BRIT MED J, V328, P977, DOI 10.1136/bmj.38055.715683.55; SEMPLE S, 2010, ANN OCCUP HYG   0219; Seo DC, 2007, J DRUG EDUC, V37, P217, DOI 10.2190/DE.37.3.a; Sims M, 2010, ADDICTION, V105, P543, DOI 10.1111/j.1360-0443.2009.02805.x; Thun M, 1999, ENVIRON HEALTH PERSP, V107, P841, DOI 10.2307/3434563; Tu JV, 2009, CAN MED ASSOC J, V180, pE118, DOI 10.1503/cmaj.081197; *UK MET OFF, 2009, HIST CENTR ENGL TEMP; Vasselli S, 2008, Minerva Cardioangiol, V56, P197; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; WARDIE H, 2008, HLTH SURVEY ENGLAND, V1; WARDLE H, 2009, IMPACT SMOKEFREE LEG; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8; Whincup PH, 2004, BRIT MED J, V329, P200, DOI 10.1136/bmj.38146.427188.55; Wood S.N, 2017, GEN ADDITIVE MODELS; World Health Organization, 2004, ICD 10 INT STAT CLAS	63	110	114	1	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2010	340								c2161	10.1136/bmj.c2161	http://dx.doi.org/10.1136/bmj.c2161			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	611MB	20530563	hybrid, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000278818300002
J	Lima, VD; Hogg, RS; Montaner, JSG				Lima, Viviane D.; Hogg, Robert S.; Montaner, Julio S. G.			Expanding HAART Treatment to All Currently Eligible Individuals under the 2008 IAS-USA Guidelines in British Columbia, Canada	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HIV PREVENTION; SCALING-UP; TRANSMISSION; ACCESS; IMPACT; INFECTION; GROWTH; CURB	Background: In 2008, the IAS-USA published the revised guidelines for the use of HAART in adults substantially increasing the number of individuals eligible for HAART. The epidemic in British Columbia (BC) is mainly among men who have sex with men and those with injection drug use. Here, we explored the potential impact of different HAART coverage scenarios, based on the new guidelines, on the HIV-related incidence, morbidity and mortality in BC, Canada. Methodology: We built a mathematical transmission model to investigate different HAART coverage scenarios (50%, 60%, 75% and 100%) of those medically eligible to receive HAART under the 2008 IAS guidelines. All new scenarios were compared to the current coverage in BC under the 2006 IAS guidelines (i.e. baseline scenario). In BC, it is estimated that 25-30% of individuals are unaware of their status. Costs were drug-related and reported in Canadian dollars. HIV-related morbidity and mortality were estimated based on the disability-adjusted life years (DALY) methodology. Principal Findings: Currently, there are 4379 individuals on HAART under the IAS 2006 guidelines and 6781 individuals who qualify for treatment based on the new guidelines. Within 5 years, increasing HAART coverage decreased yearly new infections by at least 44.8%. In the 50% scenario, in 5 years, DALY decreased by 53% corresponding to 4155 averted DALYs, and in 25 years it decreased by 66% corresponding to 5837 averted DALYs. The effect was even stronger if the 75% scenario was chosen instead. Compared to the 100% expansion scenario, we observed an excess in annual direct treatment expenditures at the end of 5 years of approximately 1 million dollars in the 75% scenario, and of approximately 2 million dollars in the 50% scenario. Conclusions/Significance: The individual and public health benefits of these new guidelines are immense. The results show that by increasing the number of individuals on HAART save lives, it is cost averting, and it positively impacts society by decreasing the number of new HIV infections. Thus, public health community should consider incremental gains when considering guidelines and policy.	[Lima, Viviane D.; Hogg, Robert S.; Montaner, Julio S. G.] St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; [Lima, Viviane D.; Montaner, Julio S. G.] Univ British Columbia, Fac Med, Dept Med, Div Aids, Vancouver, BC, Canada; [Hogg, Robert S.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; Simon Fraser University	Lima, VD (corresponding author), St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada.	vlima@cfenet.ubc.ca	Hogg, Robert S/B-2783-2012; Montaner, Julio/K-7621-2012	Hogg, Robert S/0000-0003-3463-5488; 	Canadian Institutes of Health Research; Michael Smith Foundation for Health Research; National Institute on Drug Abuse at the US National Institutes of Health; NATIONAL INSTITUTE ON DRUG ABUSE [DP1DA026182] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research(Michael Smith Foundation for Health Research); National Institute on Drug Abuse at the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This work was supported by the Canadian Institutes of Health Research and Michael Smith Foundation for Health Research through fellowship awards to Dr. Lima. Dr. Montaner is a recipient of an Avant-Garde Award from the National Institute on Drug Abuse at the US National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas UL, 2006, JAIDS-J ACQ IMM DEF, V41, P632, DOI 10.1097/01.qai.0000194234.31078.bf; [Anonymous], 14 C RETR OPP INF FE; [Anonymous], GLOB BURD DIS 2004 U; *BRIT COL CTR DIS, 2008, STI HIV ANN REP 2008; *BRIT COL CTR DIS, 2007, HIV AIDS ANN REP 200; *BRIT COL CTR EXC, 2010, HIV PREV BRIT COL; Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45; De Cock KM, 2009, LANCET, V373, P7, DOI 10.1016/S0140-6736(08)61732-8; DeCruttola V, 2008, AIDS, V22, P2554, DOI 10.1097/QAD.0b013e32831940d3; Dube S, 2008, JAIDS-J ACQ IMM DEF, V48, P72, DOI 10.1097/QAI.0b013e31816bcdbb; Egger M, 2008, LANCET, V371, P1558, DOI 10.1016/S0140-6736(08)60669-8; Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601; Ferradini L, 2006, LANCET, V367, P1335, DOI 10.1016/S0140-6736(06)68580-2; Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x; Gill VS, 2010, CLIN INFECT DIS, V50, P98, DOI 10.1086/648729; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Hogg Robert S, 2005, Harm Reduct J, V2, P26, DOI 10.1186/1477-7517-2-26; Joy R, 2008, JAIDS-J ACQ IMM DEF, V47, P500, DOI 10.1097/QAI.0b013e3181648dfd; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Lagakos SW, 2008, NEW ENGL J MED, V358, P1543, DOI 10.1056/NEJMp0802028; LIMA V, 2009, 5 IAS C HIV PATH TRE; Lima VD, 2008, J INFECT DIS, V198, P59, DOI 10.1086/588673; Lima VD, 2007, AIDS, V21, P685, DOI 10.1097/QAD.0b013e32802ef30c; Markel H, 2005, NEW ENGL J MED, V353, P753, DOI 10.1056/NEJMp058146; Marshall BDL, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-7; Martinez V, 2008, CURR OPIN INFECT DIS, V21, P42, DOI 10.1097/QCO.0b013e3282f3d9d3; McInnes CW, 2009, HARM REDUCT J, V6, DOI 10.1186/1477-7517-6-5; Montaner J, 2009, AIDS, V23, P1031, DOI 10.1097/QAD.0b013e32832a128b; Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9; *PAN ANT GUID AD A, 2008, GUID US ANT AG HIV 1; Public Health Agency of Canada, 2007, HIV AIDS EP UPD NOV; Rotheram-Borus MJ, 2009, ANNU REV CLIN PSYCHO, V5, P143, DOI 10.1146/annurev.clinpsy.032408.153530; Smith RJ, 2010, SCIENCE, V327, P697, DOI 10.1126/science.1180556; SPAAR A, 2009, 5 IAS C HIV PATH TRE; *STAT CAN, 2010, CANSIM; Steinbrook R, 2008, NEW ENGL J MED, V359, P885, DOI 10.1056/NEJMp0805761; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; TOVANABUTRA S, 2002, J ACQ IMMUN DEF SYND, V3, P275; UNAIDS, 2008, REP GLOB AIDS EP; VERMUND SH, 2009, HIV AIDS, V4, P266; Wood E, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1649; 2009, AIDS READ, V19, P229; 2010, SEEK TREAT OPTIMAL P	45	41	42	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 7	2010	5	6							e10991	10.1371/journal.pone.0010991	http://dx.doi.org/10.1371/journal.pone.0010991			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	606YU	20539817	Green Submitted, Green Published, gold			2023-01-03	WOS:000278465900009
J	Hu, JW; Ljubimova, JY; Inoue, S; Konda, B; Patil, R; Ding, H; Espinoza, A; Wawrowsky, KA; Patil, C; Ljubimov, AV; Black, KL				Hu, Jinwei; Ljubimova, Julia Y.; Inoue, Satoshi; Konda, Bindu; Patil, Rameshwar; Ding, Hui; Espinoza, Andres; Wawrowsky, Kolja A.; Patil, Chirag; Ljubimov, Alexander V.; Black, Keith L.			Phosphodiesterase Type 5 Inhibitors Increase Herceptin Transport and Treatment Efficacy in Mouse Metastatic Brain Tumor Models	PLOS ONE			English	Article							ACTIVATED POTASSIUM CHANNELS; BREAST-CANCER; BLOOD-BRAIN; BARRIER PERMEABILITY; INTRACAROTID INFUSION; BRADYKININ ANALOG; NITRIC-OXIDE; LUNG-CANCER; IN-VIVO; CHEMOTHERAPY	Background: Chemotherapeutic drugs and newly developed therapeutic monoclonal antibodies are adequately delivered to most solid and systemic tumors. However, drug delivery into primary brain tumors and metastases is impeded by the blood-brain tumor barrier (BTB), significantly limiting drug use in brain cancer treatment. Methodology/Principal Findings: We examined the effect of phosphodiesterase 5 (PDE5) inhibitors in nude mice on drug delivery to intracranially implanted human lung and breast tumors as the most common primary tumors forming brain metastases, and studied underlying mechanisms of drug transport. In vitro assays demonstrated that PDE5 inhibitors enhanced the uptake of [C-14] dextran and trastuzumab (Herceptin (R), a humanized monoclonal antibody against HER2/neu) by cultured mouse brain endothelial cells (MBEC). The mechanism of drug delivery was examined using inhibitors for caveolae-mediated endocytosis, macropinocytosis and coated pit/clathrin endocytosis. Inhibitor analysis strongly implicated caveolae and macropinocytosis endocytic pathways involvement in the PDE5 inhibitor-enhanced Herceptin uptake by MBEC. Oral administration of PDE5 inhibitor, vardenafil, to mice with HER2-positive intracranial lung tumors led to an increased tumor permeability to high molecular weight [C-14] dextran (2.6-fold increase) and to Herceptin (2-fold increase). Survival time of intracranial lung cancer-bearing mice treated with Herceptin in combination with vardenafil was significantly increased as compared to the untreated, vardenafil- or Herceptin-treated mice (p<0.01). Log-rank survival analysis of mice bearing HER2-positive intracranial breast tumor also showed a significant survival increase (p<0.02) in the group treated with Herceptin plus vardenafil as compared to other groups. However, vardenafil did not exert any beneficial effect on survival of mice bearing intracranial breast tumor with low HER2 expression and co-treated with Herceptin (p>0.05). Conclusions/Significance: These findings suggest that PDE5 inhibitors may effectively modulate BTB permeability, and enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary tumors that had metastasized to the brain.	[Hu, Jinwei; Ljubimova, Julia Y.; Inoue, Satoshi; Konda, Bindu; Patil, Rameshwar; Ding, Hui; Espinoza, Andres; Patil, Chirag; Black, Keith L.] Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Dept Neurosurg, Los Angeles, CA 90048 USA; [Wawrowsky, Kolja A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Ljubimov, Alexander V.] Cedars Sinai Med Ctr, Dept Surg, Los Angeles, CA 90048 USA; [Ljubimov, Alexander V.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hu, JW (corresponding author), Cedars Sinai Med Ctr, Maxine Dunitz Neurosurg Inst, Dept Neurosurg, Los Angeles, CA 90048 USA.	ljubimovaj@cshs.org	Ljubimov, Alexander/CAE-9130-2022; Ljubimov, Alexander V/E-5883-2013	Patil, Chirag/0000-0001-9068-1898; Ljubimov, Alexander/0000-0003-2398-5319; Black, Keith/0000-0002-0546-4934	NATIONAL CANCER INSTITUTE [R01CA123495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013431] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA123495] Funding Source: Medline; NCRR NIH HHS [M01 RR000425, M01 RR00425] Funding Source: Medline; NEI NIH HHS [R01 EY13431, R01 EY013431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arpino G, 2007, JNCI-J NATL CANCER I, V99, P694, DOI 10.1093/jnci/djk151; Asotra Kamlesh, 2003, Methods Mol Med, V89, P177; Black KL, 2008, BRAIN RES, V1230, P290, DOI 10.1016/j.brainres.2008.06.122; Black KL, 1997, J NEUROSURG, V86, P603, DOI 10.3171/jns.1997.86.4.0603; Boolell M, 1996, Int J Impot Res, V8, P47; Contessa JN, 2008, MOL PHARMACOL, V73, P271, DOI 10.1124/mol.107.042986; Cornford Eain M, 2005, NeuroRx, V2, P27, DOI 10.1007/BF03206640; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Doolittle ND, 2007, J NEURO-ONCOL, V81, P81, DOI 10.1007/s11060-006-9209-y; Fine RL, 2006, CLIN CANCER RES, V12, P5770, DOI 10.1158/1078-0432.CCR-05-2356; Fujita Manabu, 2006, Angiogenesis, V9, P183, DOI 10.1007/s10456-006-9046-9; Hashizume K, 2002, J NEUROPATH EXP NEUR, V61, P725, DOI 10.1093/jnen/61.8.725; Hau P, 2004, CANCER, V100, P1199, DOI 10.1002/cncr.20073; Hu JW, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-22; INAMURA T, 1994, J CEREBR BLOOD F MET, V14, P862, DOI 10.1038/jcbfm.1994.108; Juilfs D M, 1999, Rev Physiol Biochem Pharmacol, V135, P67, DOI 10.1007/BFb0033670; Laquintana V, 2009, EXPERT OPIN DRUG DEL, V6, P1017, DOI 10.1517/17425240903167942; Lin NU, 2004, J CLIN ONCOL, V22, P3608, DOI 10.1200/JCO.2004.01.175; Linder AE, 2005, J PHARMACOL EXP THER, V314, P9, DOI 10.1124/jpet.105.083634; Lu Jing, 2009, Cancer Res, V69, P4951, DOI 10.1158/0008-5472.CAN-09-0099; Matsukado K, 1996, NEUROSURGERY, V39, P125, DOI 10.1097/00006123-199607000-00025; Meijering BDM, 2009, CIRC RES, V104, P679, DOI 10.1161/CIRCRESAHA.108.183806; Menendez JA, 2005, ANN ONCOL, V16, P359, DOI 10.1093/annonc/mdi090; Mercer J, 2009, NAT CELL BIOL, V11, P510, DOI 10.1038/ncb0509-510; Michel CC, 1998, J MOL CELL CARDIOL, V30, P2541, DOI 10.1006/jmcc.1998.0825; Nakano S, 1996, CANCER RES, V56, P4027; Nam HY, 2009, J CONTROL RELEASE, V135, P259, DOI 10.1016/j.jconrel.2009.01.018; Ningaraj NS, 2009, EUR J PHARMACOL, V602, P188, DOI 10.1016/j.ejphar.2008.10.056; Ningaraj NS, 2003, CANCER RES, V63, P8899; Ningaraj NS, 2003, DRUG NEWS PERSPECT, V16, P291, DOI 10.1358/dnp.2003.16.5.878815; Ningaraj NS, 2002, J PHARMACOL EXP THER, V301, P838, DOI 10.1124/jpet.301.3.838; Ono M, 2009, INT J CLIN ONCOL, V14, P48, DOI 10.1007/s10147-008-0797-8; Pestalozzi BC, 2000, J CLIN ONCOL, V18, P2350, DOI 10.1200/JCO.2000.18.11.2349; RIZZI A, 1990, TUMORI, V76, P579, DOI 10.1177/030089169007600614; Sagita M, 1998, CANCER RES, V58, P914; SCHNITZER JE, 1994, J BIOL CHEM, V269, P6072; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stark S, 2001, EUR UROL, V40, P181, DOI 10.1159/000049770; STEWART PA, 1994, MICROSC RES TECHNIQ, V27, P516, DOI 10.1002/jemt.1070270606; Sun MH, 2009, CLIN CANCER RES, V15, P4829, DOI 10.1158/1078-0432.CCR-08-2921; Tan M, 2006, CANCER RES, V66, P3764, DOI 10.1158/0008-5472.CAN-05-2747; Yau T, 2006, ACTA ONCOL, V45, P196, DOI 10.1080/02841860500486630; Yumoto R, 2006, AM J PHYSIOL-LUNG C, V290, pL946, DOI 10.1152/ajplung.00173.2005	43	35	37	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 19	2010	5	4							e10108	10.1371/journal.pone.0010108	http://dx.doi.org/10.1371/journal.pone.0010108			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	585UC	20419092	gold, Green Submitted, Green Published			2023-01-03	WOS:000276853800005
J	Kahn, KL; Adams, JL; Weeks, JC; Chrischilles, EA; Schrag, D; Ayanian, JZ; Kiefe, CI; Ganz, PA; Bhoopalam, N; Potosky, AL; Harrington, DP; Fletcher, RH				Kahn, Katherine L.; Adams, John L.; Weeks, Jane C.; Chrischilles, Elizabeth A.; Schrag, Deborah; Ayanian, John Z.; Kiefe, Catarina I.; Ganz, Patricia A.; Bhoopalam, Nirmala; Potosky, Arnold L.; Harrington, David P.; Fletcher, Robert H.			Adjuvant Chemotherapy Use and Adverse Events Among Older Patients With Stage III Colon Cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARGINAL STRUCTURAL MODELS; CARE OUTCOMES RESEARCH; COLORECTAL-CANCER; ELDERLY-PATIENTS; CLINICAL-TRIALS; RANDOMIZED-TRIAL; POOLED ANALYSIS; OF-LIFE; FLUOROURACIL; LEUCOVORIN	Context Randomized trials suggest adjuvant chemotherapy is effective for older patients with stage III colon cancer. However, older patients are less likely to receive this therapy than younger patients, perhaps because of concern about adverse effects. Objective To evaluate adjuvant chemotherapy use and outcomes for older patients with stage III colon cancer from well-defined population-based settings and health care systems. Design Observational study of adjuvant chemotherapy use and outcomes by age using Poisson regression to estimate the number of adverse events adjusted for demographic and clinical factors, including comorbid illness and specific elements of chemotherapy regimens documented with clinically detailed medical record reviews and patient and surrogate surveys. Setting Five geographically defined regions (Alabama, Iowa, Los Angeles County, northern California, and North Carolina), 5 integrated health care delivery systems, and 15 Veterans Affairs hospitals. Patients Six hundred seventy-five patients diagnosed with stage III colon cancer from 2003 through 2005 who underwent surgical resection and were followed up for as long as 15 months postdiagnosis. Main Outcome Measures Chemotherapy regimen, dose, duration, and annualized mean number of adverse events stratified by age. Results Of 202 patients aged 75 years and older, 101 (50%) received adjuvant chemotherapy compared with 87% of 473 younger patients (difference, 37%; 95% confidence interval [CI], 30%-45%). Among patients who received adjuvant chemotherapy, 14 patients (14%) aged 75 years and older and 178 younger patients (44%) received a regimen containing oxaliplatin (difference, 30%; 95% CI, 21%-38%). Older patients were less likely to continue treatment, such that by 150 days, 99 patients (40%) aged 65 years and older and 68 younger patients (25%) had discontinued chemotherapy (difference, 15%; 95% CI, 7%-23%). Overall, 162 patients (24%) had at least 1 adverse clinical event, with more events among patients treated with vs without adjuvant chemotherapy (mean, 0.39 vs 0.16; difference, 0.23; 95% CI, 0.11-0.36; P<.001). Among patients receiving adjuvant chemotherapy, adjusted rates of late clinical adverse events were lower for patients 75 years and older (mean, 0.28) vs for younger patients (0.35 for ages 18-54 years, 0.52 for ages 55-64 years, and 0.45 for ages 65-74 years; P=.008 for any age effect). Conclusion Among patients with stage III colon cancer who underwent surgical resection and received adjuvant chemotherapy, older patients in the community received less-toxic and shorter chemotherapy regimens, and those treated had fewer adverse events than younger patients. JAMA. 2010; 303(11): 1037-1045	[Kahn, Katherine L.; Adams, John L.] RAND Corp, Santa Monica, CA 90401 USA; [Kahn, Katherine L.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA; [Ganz, Patricia A.] Univ Calif Los Angeles, Div Hematol & Med Oncol, Los Angeles, CA USA; [Kahn, Katherine L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Ganz, Patricia A.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA; [Weeks, Jane C.] Div Populat Sci, Boston, MA USA; [Harrington, David P.] Dept Biostat & Computat Biol, Boston, MA USA; [Schrag, Deborah] Dana Farber Canc Inst, Boston, MA 02115 USA; [Chrischilles, Elizabeth A.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA; [Ayanian, John Z.] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Ayanian, John Z.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Fletcher, Robert H.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02115 USA; [Kiefe, Catarina I.] Univ Massachusetts, Sch Med, Worcester, MA USA; [Bhoopalam, Nirmala] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA; [Potosky, Arnold L.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Canc Control Program, Washington, DC 20007 USA; [Fletcher, Robert H.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Fletcher, Robert H.] Univ N Carolina, Dept Social Med, Chapel Hill, NC USA	RAND Corporation; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Harvard University; Dana-Farber Cancer Institute; University of Iowa; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Georgetown University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Kahn, KL (corresponding author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.	kahn@rand.org	Kahn, Katherine/AAE-2857-2020; Adams, John/ABE-6170-2021	Kahn, Katherine/0000-0002-6605-1455; 	National Cancer Institute (NCI) [U01 CA093344, U01 CA093348]; Harvard Medical School and Northern California Cancer Center [U01 CA093324]; Dana-Farber Cancer Institute and Cancer Research Network [U01 CA093332]; University of Alabama at Birmingham [U01 CA093329]; University of Iowa [U01 CA01013]; University of North Carolina [U01 CA093326]; Department of Veterans Affairs [U01 CDA093344 [MOU], HARQ 03-438MO-03]; NATIONAL CANCER INSTITUTE [U01CA093324, U01CA093348, U01CA093344, U01CA093332, U01CA093326, U01CA093329] Funding Source: NIH RePORTER	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Harvard Medical School and Northern California Cancer Center; Dana-Farber Cancer Institute and Cancer Research Network; University of Alabama at Birmingham; University of Iowa; University of North Carolina; Department of Veterans Affairs(US Department of Veterans Affairs); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding/Support: The Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium was supported by grants from the National Cancer Institute (NCI) to the statistical coordinating center at the Dana-Farber Cancer Institute (U01 CA093344) and the primary data collection and research centers at RAND Corporation and University of California, Los Angeles (U01 CA093348); Harvard Medical School and Northern California Cancer Center (U01 CA093324); Dana-Farber Cancer Institute and Cancer Research Network (U01 CA093332); University of Alabama at Birmingham (U01 CA093329); University of Iowa (U01 CA01013); and University of North Carolina (U01 CA093326) and by a Department of Veterans Affairs grant to the Durham VA Medical Center (U01 CDA093344 [MOU] and HARQ 03-438MO-03).	American Joint Committee on Cancer, 2006, AJCC CANC STAG ATL; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771; [Anonymous], DEC MAK TOOLS HLTH C; Arias Elizabeth, 2007, Natl Vital Stat Rep, V56, P1; Ayanian JZ, 2004, J CLIN ONCOL, V22, P2992, DOI 10.1200/JCO.2004.06.020; Ayanian JZ, 2003, J CLIN ONCOL, V21, P1293, DOI 10.1200/JCO.2003.06.178; Dencausse Y, 2002, ONKOLOGIE, V25, P426, DOI 10.1159/000067436; Folprecht G, 2004, ANN ONCOL, V15, P1330, DOI 10.1093/annonc/mdh344; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; Haller DG, 2005, J CLIN ONCOL, V23, P8671, DOI 10.1200/JCO.2004.00.5686; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Jessup JM, 2005, JAMA-J AM MED ASSOC, V294, P2703, DOI 10.1001/jama.294.21.2703; Kahn KL, 2008, J CLIN ONCOL, V26, P523, DOI 10.1200/JCO.2007.13.1870; Keating NL, 2008, J CLIN ONCOL, V26, P2532, DOI 10.1200/JCO.2007.15.9434; Keating NL, 2010, CANCER-AM CANCER SOC, V116, P998, DOI 10.1002/cncr.24761; Kohne CH, 2008, ONCOLOGIST, V13, P390, DOI 10.1634/theoncologist.2007-0043; Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; Malin JL, 2006, SUPPORT CARE CANCER, V14, P837, DOI 10.1007/s00520-005-0902-8; Minino AM, 2007, NATL VITAL STAT REP, V55, P1; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; National Cancer Institute, CANC THER EV PROGR C; Neugut AI, 2006, J CLIN ONCOL, V24, P2368, DOI 10.1200/JCO.2005.04.5005; O'Connell MJ, 1998, J CLIN ONCOL, V16, P295, DOI 10.1200/JCO.1998.16.1.295; Piccirillo AF, 2003, J REGISTRY MANAG, V30, P117; Piccirillo JF, 2004, ORL J OTO-RHINO-LARY, V66, P180, DOI 10.1159/000079875; Potosky AL, 2002, J CLIN ONCOL, V20, P1192, DOI 10.1200/JCO.20.5.1192; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sargent D, 2009, J CLIN ONCOL, V27, P872, DOI 10.1200/JCO.2008.19.5362; Sargent DJ, 2001, NEW ENGL J MED, V345, P1091, DOI 10.1056/NEJMoa010957; Schrag D, 2001, J NATL CANCER I, V93, P850, DOI 10.1093/jnci/93.11.850; StataCorp, 2005, STAT STAT SOFTW REL; Sundararajan V, 2002, ANN INTERN MED, V136, P349, DOI 10.7326/0003-4819-136-5-200203050-00007; Townsley CA, 2005, J CLIN ONCOL, V23, P3112, DOI 10.1200/JCO.2005.00.141; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Zaniboni A, 1998, CANCER, V82, P2135, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2135::AID-CNCR7>3.0.CO;2-U	38	114	119	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	2010	303	11					1037	1045		10.1001/jama.2010.272	http://dx.doi.org/10.1001/jama.2010.272			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	569KC	20233821	Bronze, Green Accepted, Green Submitted			2023-01-03	WOS:000275594100016
J	Kalthoff, S; Ehmer, U; Freiberg, N; Manns, MP; Strassburg, CP				Kalthoff, Sandra; Ehmer, Ursula; Freiberg, Nicole; Manns, Michael P.; Strassburg, Christian P.			Interaction between Oxidative Stress Sensor Nrf2 and Xenobiotic-activated Aryl Hydrocarbon Receptor in the Regulation of the Human Phase II Detoxifying UDP-glucuronosyltransferase 1A10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTIONAL ACTIVATION; SUPEROXIDE-DISMUTASE; MEDIATED EXPRESSION; GENE-EXPRESSION; DEFICIENT MICE; AH RECEPTOR; HUMAN COLON; GLUCURONIDATION; PROTEINS	The defense against oxidative stress is a critical feature that prevents cellular and DNA damage. UDP-glucuronosyltransferases (UGTs) catalyze the glucuronidation of xenobiotics, mutagens, and reactive metabolites and thus act as indirect antioxidants. Aim of this study was to elucidate the regulation of UGTs expressed in the mucosa of the gastrointestinal tract by xenobiotics and the main mediator of antioxidant defense, Nrf2 (nuclear factor erythroid 2-related factor 2). Xenobiotic (XRE) and antioxidant (ARE) response elements were detected in the promoters of UGT1A8, UGT1A9, and UGT1A10. Reporter gene experiments demonstrated XRE-mediated induction by dioxin in addition to tert-butylhydroquinone (ARE)-mediated induction of UGT1A8 and UGT1A10, which are expressed in extrahepatic tissue in humans in vivo. The responsible XRE and ARE motifs were identified by mutagenesis. Small interfering RNA knockdown, electrophoretic mobility shifts, and supershifts identified a functional interaction of Nrf2 and the aryl hydrocarbon receptor (AhR). Induction of UGT1A8 and UGT1A10 requires Nrf2 and AhR. It proceeds by utilizing XRE- as well as ARE-binding motifs. In summary, we demonstrate the coordinated AhR- and Nrf2-dependent transcriptional regulation of human UGT1As. Cellular protection by glucuronidation is thus inducible by xenobiotics via AhR and by oxidative metabolites via Nrf2 linking glucuronidation to cellular protection and defense against oxidative stress.	[Kalthoff, Sandra; Ehmer, Ursula; Freiberg, Nicole; Manns, Michael P.; Strassburg, Christian P.] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, D-30625 Hannover, Germany	Hannover Medical School	Strassburg, CP (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	strassburg.christian@mh-hannover.de			Deutsche Forschungsgemeinschaft [SFB621 C3]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by Deutsche Forschungsgemeinschaft Grant SFB621 C3.	Auten RL, 2006, AM J PHYSIOL-LUNG C, V290, pL32, DOI 10.1152/ajplung.00133.2005; BREIMER LH, 1990, MOL CARCINOGEN, V3, P188, DOI 10.1002/mc.2940030405; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cheng ZQ, 1998, ARCH BIOCHEM BIOPHYS, V356, P301, DOI 10.1006/abbi.1998.0781; Dellinger RW, 2007, CARCINOGENESIS, V28, P2412, DOI 10.1093/carcin/bgm164; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Erichsen TJ, 2008, TOXICOL APPL PHARM, V230, P252, DOI 10.1016/j.taap.2008.02.020; Goetz ME, 2008, CANCER LETT, V266, P73, DOI 10.1016/j.canlet.2008.02.035; Gregory PA, 2004, MOL PHARMACOL, V65, P953, DOI 10.1124/mol.65.4.953; Ho YS, 2004, J BIOL CHEM, V279, P32804, DOI 10.1074/jbc.M404800200; Holtzclaw WD, 2004, ADV ENZYME REGUL, V44, P335, DOI 10.1016/j.advenzreg.2003.11.013; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Iyer LV, 2003, TOXICOL SCI, V73, P36, DOI 10.1093/toxsci/kfg066; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Koo HC, 2005, AM J PHYSIOL-LUNG C, V288, pL718, DOI 10.1152/ajplung.00456.2003; Lankisch TO, 2008, ARCH TOXICOL, V82, P573, DOI 10.1007/s00204-008-0347-1; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; Miao WM, 2005, J BIOL CHEM, V280, P20340, DOI 10.1074/jbc.M412081200; Mojarrabi B, 1998, BIOCHEM BIOPH RES CO, V247, P704, DOI 10.1006/bbrc.1998.8843; Munzel PA, 2003, BIOCHEM PHARMACOL, V66, P841, DOI 10.1016/S0006-2952(03)00389-7; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen T, 2003, ANNU REV PHARMACOL, V43, P233, DOI 10.1146/annurev.pharmtox.43.100901.140229; Nishiyama T, 2008, ARCH BIOCHEM BIOPHYS, V478, P75, DOI 10.1016/j.abb.2008.06.013; Petrulis JR, 2002, CHEM-BIOL INTERACT, V141, P25, DOI 10.1016/S0009-2797(02)00064-9; QUATTROCHI LC, 1993, MOL PHARMACOL, V43, P504; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Reddy VP, 2009, J ALZHEIMERS DIS, V16, P763, DOI 10.3233/JAD-2009-1013; Segal BH, 2007, AM J PHYSIOL-LUNG C, V292, pL760, DOI 10.1152/ajplung.00281.2006; Strassburg C, 2008, CRIT REV CL LAB SCI, V45, P485, DOI 10.1080/10408360802374624 ; Strassburg CP, 1997, CANCER RES, V57, P2979; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Vasiliou V, 1995, BIOCHEM PHARMACOL, V50, P2057, DOI 10.1016/0006-2952(95)02108-6; Venkatraman M, 2008, BIOL PHARM BULL, V31, P1639, DOI 10.1248/bpb.31.1639; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Videan EN, 2009, COMPARATIVE MED, V59, P287; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; WHITLOCK JP, 1990, ANNU REV PHARMACOL, V30, P251; Yeager RL, 2009, TOXICOL SCI, V111, P238, DOI 10.1093/toxsci/kfp115; Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017	40	87	91	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 26	2010	285	9					5993	6002		10.1074/jbc.M109.075770	http://dx.doi.org/10.1074/jbc.M109.075770			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	566JW	20053997	Green Published, hybrid			2023-01-03	WOS:000275367500002
J	Escudier, B				Escudier, Bernard			Chemo-immunotherapy in RCC: the end of a story	LANCET			English	Editorial Material							RENAL-CELL CARCINOMA; INTERFERON-ALPHA; RECOMBINANT INTERLEUKIN-2; COMBINATION; SUNITINIB; THERAPY		Inst Gustave Roussy, Dept Med Oncol, F-94805 Villejuif, France	UNICANCER; Gustave Roussy	Escudier, B (corresponding author), Inst Gustave Roussy, Dept Med Oncol, Rue Camille Desmoulins, F-94805 Villejuif, France.	bernard.escudier@igr.fr						Atzpodien J, 2001, BRIT J CANCER, V85, P1130, DOI 10.1054/bjoc.2001.2076; Atzpodien J, 2004, J CLIN ONCOL, V22, P1188, DOI 10.1200/JCO.2004.06.155; Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7; Escudier B, 2009, J CLIN ONCOL, V27, P1280, DOI 10.1200/JCO.2008.19.3342; Gore ME, 2010, LANCET, V375, P641, DOI 10.1016/S0140-6736(09)61921-8; Hanninen EL, 1996, J UROLOGY, V155, P19, DOI 10.1016/S0022-5347(01)66527-3; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Negrier S, 2000, J CLIN ONCOL, V18, P4009, DOI 10.1200/JCO.2000.18.24.4009; Negrier S, 2007, CANCER-AM CANCER SOC, V110, P2468, DOI 10.1002/cncr.23056; Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847; Ritchie A, 1999, LANCET, V353, P14; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; WEST WH, 1987, NEW ENGL J MED, V316, P898, DOI 10.1056/NEJM198704093161502; YANG JC, 1994, J CLIN ONCOL, V12, P1572, DOI 10.1200/JCO.1994.12.8.1572	16	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 20	2010	375	9715					613	614		10.1016/S0140-6736(10)60209-7	http://dx.doi.org/10.1016/S0140-6736(10)60209-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	564JT	20171385				2023-01-03	WOS:000275210900004
J	Rafikova, ER; Melikov, K; Ramos, C; Dye, L; Chernomordik, LV				Rafikova, Elvira R.; Melikov, Kamran; Ramos, Corinne; Dye, Louis; Chernomordik, Leonid V.			Transmembrane Protein-free Membranes Fuse into Xenopus Nuclear Envelope and Promote Assembly of Functional Pores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CELL-CYCLE; EGG EXTRACTS; FORMATION INVITRO; FUSION; COMPLEXES; SNARE; CHROMATIN; DYNAMICS; ROLES	Post-mitotic reassembly of nuclear envelope (NE) and the endoplasmic reticulum (ER) has been reconstituted in a cell-free system based on interphase Xenopus egg extract. To evaluate the relative contributions of cytosolic and transmembrane proteins in NE and ER assembly, we replaced a part of native membrane vesicles with ones either functionally impaired by trypsin or N-ethylmaleimide treatments or with protein-free liposomes. Although neither impaired membrane vesicles nor liposomes formed ER and nuclear membrane, they both supported assembly reactions by fusing with native membrane vesicles. At membrane concentrations insufficient to generate full-sized functional nuclei, addition of liposomes and their fusion with membrane vesicles resulted in an extensive expansion of NE, further chromatin decondensation, restoration of the functionality, and spatial distribution of the nuclear pore complexes (NPCs), and, absent newly delivered transmembrane proteins, an increase in NPC numbers. This rescue of the nuclear assembly by liposomes was inhibited by wheat germ agglutinin and thus required active nuclear transport, similarly to the assembly of full-sized functional NE with membrane vesicles. Mechanism of fusion between liposomes and between liposomes and membrane vesicles was investigated using lipid mixing assay. This fusion required interphase cytosol and, like fusion between native membrane vesicles, was inhibited by guanosine 5'-3-O-(thio) triphosphate, soluble N-ethylmaleimide-sensitive factor attachment protein, and N-ethylmaleimide. Our findings suggest that interphase cytosol contains proteins that mediate the fusion stage of ER and NE reassembly, emphasize an unexpected tolerance of nucleus assembly to changes in concentrations of transmembrane proteins, and reveal the existence of a feedback mechanism that couples NE expansion with NPC assembly.	[Rafikova, Elvira R.; Melikov, Kamran; Chernomordik, Leonid V.] Eunice Kennedy Shriver NICHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, NIH, Bethesda, MD 20892 USA; [Ramos, Corinne] Univ Calif San Diego, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of California System; University of California San Diego	Chernomordik, LV (corresponding author), Bldg 10,Rm 10D04A,10 Ctr Dr, Bethesda, MD 20892 USA.	chernoml@mail.nih.gov			National Institutes of Health Intramural Research Program of the Eunice Kennedy Shriver NICHD; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001501] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001501] Funding Source: NIH RePORTER	National Institutes of Health Intramural Research Program of the Eunice Kennedy Shriver NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was supported, in whole or in part, by National Institutes of Health Intramural Research Program of the Eunice Kennedy Shriver NICHD (to L. V. C.).	Anderson DJ, 2008, CURR OPIN CELL BIOL, V20, P386, DOI 10.1016/j.ceb.2008.03.016; Anderson DJ, 2008, J CELL SCI, V121, P137, DOI 10.1242/jcs.005777; Anderson DJ, 2007, NAT CELL BIOL, V9, P1160, DOI 10.1038/ncb1636; Antonin W, 2005, MOL CELL, V17, P83, DOI 10.1016/j.molcel.2004.12.010; Antonin W, 2008, FEBS LETT, V582, P2004, DOI 10.1016/j.febslet.2008.02.067; Barszczewski M, 2008, MOL BIOL CELL, V19, P776, DOI 10.1091/mbc.E07-05-0498; Baur T, 2007, J CELL SCI, V120, P2895, DOI 10.1242/jcs.010181; Bostrom P, 2007, NAT CELL BIOL, V9, P1286, DOI 10.1038/ncb1648; Brandhorst D, 2006, P NATL ACAD SCI USA, V103, P2701, DOI 10.1073/pnas.0511138103; Brugger B, 2000, EMBO J, V19, P1272, DOI 10.1093/emboj/19.6.1272; Burger KNJ, 2000, TRAFFIC, V1, P605, DOI 10.1034/j.1600-0854.2000.010804.x; Burke B, 2006, ANNU REV GENOM HUM G, V7, P369, DOI 10.1146/annurev.genom.7.080505.115732; Byrne RD, 2007, CELL SIGNAL, V19, P913, DOI 10.1016/j.cellsig.2006.10.011; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; D'Angelo MA, 2006, SCIENCE, V312, P440, DOI 10.1126/science.1124196; DAVIS LI, 1987, P NATL ACAD SCI USA, V84, P7552, DOI 10.1073/pnas.84.21.7552; Dreier L, 2000, J CELL BIOL, V148, P883, DOI 10.1083/jcb.148.5.883; Drummond S, 1999, J CELL BIOL, V144, P225, DOI 10.1083/jcb.144.2.225; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; FINLAY DR, 1987, J CELL BIOL, V104, P189, DOI 10.1083/jcb.104.2.189; FOLCH J, 1957, J BIOL CHEM, V226, P497; Franz C, 2005, EMBO J, V24, P3519, DOI 10.1038/sj.emboj.7600825; Fukasawa M, 2004, P NATL ACAD SCI USA, V101, P4815, DOI 10.1073/pnas.0401183101; Gant TM, 1999, J CELL BIOL, V144, P1083, DOI 10.1083/jcb.144.6.1083; GOLDBERG M, 1995, J CELL SCI, V108, P3451; Goldberg MW, 1997, J CELL SCI, V110, P409; Goldman RD, 2004, P NATL ACAD SCI USA, V101, P8963, DOI 10.1073/pnas.0402943101; Haraguchi T, 2000, J CELL SCI, V113, P779; Hawryluk-Gara LA, 2008, MOL BIOL CELL, V19, P1753, DOI 10.1091/mbc.E07-08-0820; Hetzer M, 2000, MOL CELL, V5, P1013, DOI 10.1016/S1097-2765(00)80266-X; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Hetzer MW, 2005, ANNU REV CELL DEV BI, V21, P347, DOI 10.1146/annurev.cellbio.21.090704.151152; Howe JA, 1996, P NATL ACAD SCI USA, V93, P2060, DOI 10.1073/pnas.93.5.2060; Hu JJ, 2008, SCIENCE, V319, P1247, DOI 10.1126/science.1153634; Jun Y, 2007, EMBO J, V26, P4935, DOI 10.1038/sj.emboj.7601915; Larijani B, 2001, BIOCHEM J, V356, P495, DOI 10.1042/0264-6021:3560495; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; Liu Q, 2007, J CELL BIOL, V178, P785, DOI 10.1083/jcb.200704108; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1984, J CELL BIOL, V98, P1222, DOI 10.1083/jcb.98.4.1222; LOHKA MJ, 1988, CELL BIOL INT REP, V12, P833, DOI 10.1016/0309-1651(88)90091-4; Ma Y, 2007, J CELL SCI, V120, P520, DOI 10.1242/jcs.03355; Macaulay C, 1996, J CELL BIOL, V132, P5, DOI 10.1083/jcb.132.1.5; Maeshima K, 2006, J CELL SCI, V119, P4442, DOI 10.1242/jcs.03207; Mansfeld J, 2006, MOL CELL, V22, P93, DOI 10.1016/j.molcel.2006.02.015; Martens S, 2007, SCIENCE, V316, P1205, DOI 10.1126/science.1142614; Mattaj IW, 2004, NAT REV MOL CELL BIO, V5, P65, DOI 10.1038/nrm1263; MILLER M, 1991, PHYSIOL REV, V71, P909, DOI 10.1152/physrev.1991.71.3.909; Murakami MS, 1998, DEVELOPMENT, V125, P237; Nakatogawa H, 2007, CELL, V130, P165, DOI 10.1016/j.cell.2007.05.021; NEWMEYER DD, 1986, J CELL BIOL, V103, P2091, DOI 10.1083/jcb.103.6.2091; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; POWERS M, 2001, CURR PROTOC CELL BIO, V11; Prescott GR, 2009, J NEUROCHEM, V110, P1135, DOI 10.1111/j.1471-4159.2009.06205.x; Pyrpasopoulou A, 1996, EMBO J, V15, P7108, DOI 10.1002/j.1460-2075.1996.tb01102.x; Ramos C, 2006, BIOCHEM J, V400, P393, DOI 10.1042/BJ20061218; RIZZO AM, 1994, CELL BIOL INT, V18, P1085, DOI 10.1006/cbir.1994.1032; Rothman JE, 1996, PROTEIN SCI, V5, P185; Salpingidou G, 2008, J CELL SCI, V121, P706, DOI 10.1242/jcs.019968; Sapir A, 2008, DEV CELL, V14, P11, DOI 10.1016/j.devcel.2007.12.008; Sasagawa S, 1999, EUR J CELL BIOL, V78, P593, DOI 10.1016/S0171-9335(99)80025-9; Scarcelli JJ, 2007, J CELL BIOL, V178, P799, DOI 10.1083/jcb.200702120; Segura-Totten M, 2002, J CELL BIOL, V158, P475, DOI 10.1083/jcb.200202019; SHEEHAN MA, 1988, J CELL BIOL, V106, P1, DOI 10.1083/jcb.106.1.1; Shen S, 2009, MOL BIOL CELL, V20, P2438, DOI 10.1091/mbc.E08-10-0987; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Stavru F, 2006, J CELL BIOL, V173, P509, DOI 10.1083/jcb.200601001; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; Voeltz GK, 2006, CELL, V124, P573, DOI 10.1016/j.cell.2005.11.047; Vogel K, 2000, J BIOL CHEM, V275, P2959, DOI 10.1074/jbc.275.4.2959; Whyte JRC, 2002, J CELL SCI, V115, P2627; Wiese C, 1997, J CELL SCI, V110, P1489; WILSON KL, 1988, J CELL BIOL, V107, P57, DOI 10.1083/jcb.107.1.57; Xie LX, 2009, INFLAMM RES, V58, P407, DOI 10.1007/s00011-009-0006-x; Zhang CM, 2000, SCIENCE, V288, P1429, DOI 10.1126/science.288.5470.1429; Zhang Y, 2007, P NATL ACAD SCI USA, V104, P18526, DOI 10.1073/pnas.0706441104	78	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 23	2009	284	43					29847	29859		10.1074/jbc.M109.044453	http://dx.doi.org/10.1074/jbc.M109.044453			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	507ZW	19696024	Green Published, hybrid			2023-01-03	WOS:000270896800065
J	Perilongo, G; Maibach, R; Shafford, E; Brugieres, L; Brock, P; Morland, B; de Camargo, B; Zsiros, J; Roebuck, D; Zimmermann, A; Aronson, D; Childs, M; Widing, E; Laithier, V; Plaschkes, J; Pritchard, J; Scopinaro, M; MacKinlay, G; Czauderna, P				Perilongo, Giorgio; Maibach, Rudolf; Shafford, Elisabeth; Brugieres, Laurence; Brock, Penelope; Morland, Bruce; de Camargo, Beatriz; Zsiros, Jozsef; Roebuck, Derek; Zimmermann, Arthur; Aronson, Daniel; Childs, Margaret; Widing, Eva; Laithier, Veronique; Plaschkes, Jack; Pritchard, Jon; Scopinaro, Marcello; MacKinlay, Gordon; Czauderna, Piotr			Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk Hepatoblastoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRETREATMENT PROGNOSTIC-FACTORS; PEDIATRIC-ONCOLOGY-GROUP; CHILDHOOD HEPATOBLASTOMA; INTERNATIONAL SOCIETY; LIVER-TUMOR; INFUSION DOXORUBICIN; CHILDREN; CHEMOTHERAPY; TOXICITY; SYSTEM	Background Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk hepatoblastoma (a tumor involving three or fewer sectors of the liver that is associated with an alpha-fetoprotein level of >100 ng per milliliter). Methods Children with standard-risk hepatoblastoma who were younger than 16 years of age were eligible for inclusion in the study. After they received one cycle of cisplatin (80 mg per square meter of body-surface area per 24 hours), we randomly assigned patients to receive cisplatin (every 14 days) or cisplatin plus doxorubicin administered in three preoperative cycles and two postoperative cycles. The primary outcome was the rate of complete resection, and the trial was powered to test the noninferiority of cisplatin alone (<10% difference in the rate of complete resection). Results Between June 1998 and December 2006, 126 patients were randomly assigned to receive cisplatin and 129 were randomly assigned to receive cisplatin plus doxorubicin. The rate of complete resection was 95% in the cisplatin-alone group and 93% in the cisplatin-doxorubicin group in the intention-to-treat analysis (difference, 1.4%; 95% confidence interval [CI],-4.1 to 7.0); these rates were 99% and 95%, respectively, in the per-protocol analysis. Three-year event-free survival and overall survival were, respectively, 83% (95% CI, 77 to 90) and 95% (95% CI, 91 to 99) in the cisplatin group, and 85% (95% CI, 79 to 92) and 93% (95% CI, 88 to 98) in the cisplatin-doxorubicin group (median follow-up, 46 months). Acute grade 3 or 4 adverse events were more frequent with combination therapy (74.4% vs. 20.6%). Conclusions As compared with cisplatin plus doxorubicin, cisplatin monotherapy achieved similar rates of complete resection and survival among children with standard-risk hepatoblastoma. Doxorubicin can be safely omitted from the treatment of standard-risk hepatoblastoma. (ClinicalTrials.gov number, NCT00003912.)	[Perilongo, Giorgio] Univ Hosp Padua, Dept Pediat, Div Hematol Oncol, I-35128 Padua, Italy; [Maibach, Rudolf] Int Breast Canc Study Grp, Coordinating Ctr, Bern, Switzerland; [Zimmermann, Arthur] Univ Bern, Inst Pathol, Dept Surg Pathol, Bern, Switzerland; [Plaschkes, Jack] Univ Childrens Hosp, Dept Surg, Bern, Switzerland; [Shafford, Elisabeth; Childs, Margaret] Childrens Canc & Leukaemia Grp, Ctr Data, Leicester, Leics, England; [Brock, Penelope; Roebuck, Derek] Great Ormond St Hosp Sick Children, London, England; [Morland, Bruce] Birmingham Childrens Hosp, Birmingham, W Midlands, England; [Pritchard, Jon; MacKinlay, Gordon] Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland; [Brugieres, Laurence; Laithier, Veronique] Inst Gustave Roussy, Dept Pediat, Villejuif, France; [de Camargo, Beatriz] Hosp Canc, Dept Res, Sao Paulo, Brazil; [Zsiros, Jozsef] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Pediat Oncol, NL-1105 AZ Amsterdam, Netherlands; [Aronson, Daniel] Radboud Univ Nijmegen, Nijmegen Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Widing, Eva] Ullevaal Univ Hosp, Dept Pediat, Oslo, Norway; [Scopinaro, Marcello] Prof Dr Juan P Garrahan Childrens Hosp, Serv Hematooncol, Buenos Aires, DF, Argentina; [Czauderna, Piotr] Med Univ Gdansk, Dept Surg & Urol Children & Adolescents, Gdansk, Poland	University of Padua; Azienda Ospedaliera - Universita di Padova; International Breast Cancer Study Group; University of Bern; University of Bern; University Hospital of Bern; University of Leicester; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Birmingham; UNICANCER; Gustave Roussy; A.C.Camargo Cancer Center; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Radboud University Nijmegen; University of Oslo; Hospital de Pediatria Doctor Juan Garrahan; Fahrenheit Universities; Medical University Gdansk	Perilongo, G (corresponding author), Univ Hosp Padua, Dept Pediat, Div Hematol Oncol, Via Giustiniani 3, I-35128 Padua, Italy.	giorgio.perilongo@unipd.it	de Camargo, Beatriz/I-8414-2014; Czauderna, Piotr/AAR-8455-2020; Roebuck, Derek/ABB-8690-2021	de Camargo, Beatriz/0000-0002-5794-1042; Czauderna, Piotr/0000-0002-5266-8665; Roebuck, Derek/0000-0003-1734-2536; PERILONGO, GIORGIO/0000-0002-3712-0386	Cancer Research UK; Cancer Research Switzerland/Oncosuisse	Cancer Research UK(Cancer Research UK); Cancer Research Switzerland/Oncosuisse	Supported in part by grants from Cancer Research UK and Cancer Research Switzerland/Oncosuisse.	Aronson DC, 2005, J CLIN ONCOL, V23, P1245, DOI 10.1200/JCO.2005.07.145; BROCK PR, 1991, MED PEDIATR ONCOL, V19, P295, DOI 10.1002/mpo.2950190415; Brown J, 2000, EUR J CANCER, V36, P1418, DOI 10.1016/S0959-8049(00)00074-5; De Ioris M, 2008, EUR J CANCER, V44, P545, DOI 10.1016/j.ejca.2007.11.022; DOUGLASS EC, 1993, J CLIN ONCOL, V11, P96, DOI 10.1200/JCO.1993.11.1.96; Finegold MJ, 2002, MED PEDIATR ONCOL, V39, P484, DOI 10.1002/mpo.10172; Fuchs J, 2002, CANCER-AM CANCER SOC, V95, P172, DOI 10.1002/cncr.10632; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; NINANE J, 1991, MED PEDIATR ONCOL, V19, P199, DOI 10.1002/mpo.2950190310; Ortega JA, 2000, J CLIN ONCOL, V18, P2665, DOI 10.1200/JCO.2000.18.14.2665; ORTEGA JA, 1991, J CLIN ONCOL, V9, P2167, DOI 10.1200/JCO.1991.9.12.2167; Perilongo G, 2004, EUR J CANCER, V40, P411, DOI 10.1016/j.ejca.2003.06.003; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Piaggio G, 2006, JAMA-J AM MED ASSOC, V296, P1842; Pritchard J, 2000, J CLIN ONCOL, V18, P3819, DOI 10.1200/JCO.2000.18.22.3819; Sasaki F, 2002, J PEDIATR SURG, V37, P851, DOI 10.1053/jpsu.2002.32886; Trobaugh-Lotrario AD, 2009, PEDIATR BLOOD CANCER, V52, P328, DOI 10.1002/pbc.21834; vonSchweinitz D, 1997, EUR J CANCER, V33, P1243	18	180	198	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	2009	361	17					1662	1670		10.1056/NEJMoa0810613	http://dx.doi.org/10.1056/NEJMoa0810613			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	508YW	19846851	Green Published			2023-01-03	WOS:000270977400008
J	Mori, S; Chang, JT; Andrechek, ER; Potti, A; Nevins, JR				Mori, Seiichi; Chang, Jeffrey T.; Andrechek, Eran R.; Potti, Anil; Nevins, Joseph R.			Utilization of Genomic Signatures to Identify Phenotype-Specific Drugs	PLOS ONE			English	Article							HUMAN BREAST-CANCER; EXPRESSION SIGNATURES; ESTROGEN-RECEPTOR; DISCOVERY; GROWTH; IDENTIFICATION; PREVENTION; ONCOGENES; PROFILES; THERAPY	Genetic and genomic studies highlight the substantial complexity and heterogeneity of human cancers and emphasize the general lack of therapeutics that can match this complexity. With the goal of expanding opportunities for drug discovery, we describe an approach that makes use of a phenotype-based screen combined with the use of multiple cancer cell lines. In particular, we have used the NCI-60 cancer cell line panel that includes drug sensitivity measures for over 40,000 compounds assayed on 59 independent cells lines. Targets are cancer-relevant phenotypes represented as gene expression signatures that are used to identify cells within the NCI-60 panel reflecting the signature phenotype and then connect to compounds that are selectively active against those cells. As a proof-of-concept, we show that this strategy effectively identifies compounds with selectivity to the RAS or PI3K pathways. We have then extended this strategy to identify compounds that have activity towards cells exhibiting the basal phenotype of breast cancer, a clinically-important breast cancer characterized as ER-, PR-, and Her2- that lacks viable therapeutic options. One of these compounds, Simvastatin, has previously been shown to inhibit breast cancer cell growth in vitro and importantly, has been associated with a reduction in ER-, PR-breast cancer in a clinical study. We suggest that this approach provides a novel strategy towards identification of therapeutic agents based on clinically relevant phenotypes that can augment the conventional strategies of target-based screens.			Mori, S (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Genom Oncol Programme, Singapore 117548, Singapore.	nevin001@mc.duke.edu		Andrechek, Eran/0000-0002-8680-3423	NATIONAL CANCER INSTITUTE [U54CA112952] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R00LM009837] Funding Source: NIH RePORTER; NCI NIH HHS [5U54CA-112952-05, U54 CA112952] Funding Source: Medline; NLM NIH HHS [R00 LM009837] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Balis FM, 2002, J NATL CANCER I, V94, P78, DOI 10.1093/jnci/94.2.78; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Demierre MF, 2005, NAT REV CANCER, V5, P930, DOI 10.1038/nrc1751; Dressman HK, 2007, J CLIN ONCOL, V25, P517, DOI 10.1200/JCO.2006.06.3743; Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; Hehlmann R, 2007, LANCET, V370, P342, DOI 10.1016/S0140-6736(07)61165-9; Herbst RS, 2006, J CLIN ONCOL, V24, P190, DOI 10.1200/JCO.2005.04.8678; Hieronymus H, 2006, CANCER CELL, V10, P321, DOI 10.1016/j.ccr.2006.09.005; Hsu DS, 2007, J CLIN ONCOL, V25, P4350, DOI 10.1200/JCO.2007.11.0593; Ikediobi ON, 2006, MOL CANCER THER, V5, P2606, DOI 10.1158/1535-7163.MCT-06-0433; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Kumar AS, 2008, CANCER EPIDEM BIOMAR, V17, P1028, DOI 10.1158/1055-9965.EPI-07-0726; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Mitin N, 2005, CURR BIOL, V15, pR563, DOI 10.1016/j.cub.2005.07.010; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Prochownik Edward V, 2004, Expert Rev Anticancer Ther, V4, P289, DOI 10.1586/14737140.4.2.289; RAMASWAMY S, 2003, NAT GENET, V33, P59; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; TAKAHASHI K, 1979, J ANTIBIOT, V32, P36, DOI 10.7164/antibiotics.32.36; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Tanaka H, 1999, JPN J CANCER RES, V90, P1139, DOI 10.1111/j.1349-7006.1999.tb00688.x; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; TOBERT JA, 1987, CIRCULATION, V76, P534, DOI 10.1161/01.CIR.76.3.534; Trusheim MR, 2007, NAT REV DRUG DISCOV, V6, P287, DOI 10.1038/nrd2251; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; von Tresckow B, 2007, HAEMATOL-HEMATOL J, V92, P682, DOI 10.3324/haematol.11020; Wei G, 2006, CANCER CELL, V10, P331, DOI 10.1016/j.ccr.2006.09.006; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yaziji H, 2004, JAMA-J AM MED ASSOC, V291, P1972, DOI 10.1001/jama.291.16.1972; Zanders E D, 2000, Pharmacogenomics, V1, P375, DOI 10.1517/14622416.1.4.375	48	19	21	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2009	4	8							e6772	10.1371/journal.pone.0006772	http://dx.doi.org/10.1371/journal.pone.0006772			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JG	19714244	gold, Green Submitted, Green Published			2023-01-03	WOS:000269415800002
J	Nolan, JP; Soar, J				Nolan, Jerry P.; Soar, Jasmeet			Dispatcher-assisted bystander CPR: a KISS for a kiss	LANCET			English	Editorial Material							HOSPITAL CARDIAC ARRESTS; COMPRESSION-ONLY CPR; CARDIOPULMONARY-RESUSCITATION; CHEST-COMPRESSION; SURVIVAL		[Nolan, Jerry P.] Royal United Hosp NHS Trust, Dept Anaesthesia, Bath BA1 3NG, Avon, England; [Soar, Jasmeet] N Bristol NHS Trust, Southmead Hosp, Dept Anaesthesia, Bristol, Avon, England	North Bristol NHS Trust; Southmead Hospital	Nolan, JP (corresponding author), Royal United Hosp NHS Trust, Dept Anaesthesia, Bath BA1 3NG, Avon, England.	jerry.nolan@nhs.net	Soar, Jasmeet/HGA-2279-2022; Nolan, Jerry P./ABF-2561-2020	Soar, Jasmeet/0000-0001-5970-6073; Nolan, Jerry/0000-0003-3141-3812				Bobrow BJ, 2010, JAMA-J AM MED ASSOC, V304, P1447, DOI 10.1001/jama.2010.1392; Bobrow BJ, 2008, CIRCULATION, V118, P2550, DOI 10.1161/CIRCULATIONAHA.108.799940; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Hupfl M, 2010, LANCET, V376, P1552, DOI 10.1016/S0140-6736(10)61454-7; Kitamura T, 2010, CIRCULATION, V122, P293, DOI 10.1161/CIRCULATIONAHA.109.926816; Kitamura T, 2010, LANCET, V375, P1347, DOI 10.1016/S0140-6736(10)60064-5; O'Neill JF, 2007, RESUSCITATION, V74, P63, DOI 10.1016/j.resuscitation.2006.11.007; Rea TD, 2001, CIRCULATION, V104, P2513, DOI 10.1161/hc4601.099468; Rea TD, 2010, NEW ENGL J MED, V363, P423, DOI 10.1056/NEJMoa0908993; Roppolo LP, 2005, RESUSCITATION, V65, P203, DOI 10.1016/j.resuscitation.2004.11.025; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Svensson L, 2010, NEW ENGL J MED, V363, P434, DOI 10.1056/NEJMoa0908991	13	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2010	376	9752					1522	1524		10.1016/S0140-6736(10)61857-0	http://dx.doi.org/10.1016/S0140-6736(10)61857-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QE	20951423				2023-01-03	WOS:000284248700007
J	de Bono, JS; Oudard, S; Ozguroglu, M; Hansen, S; Machiels, JP; Kocak, I; Gravis, G; Bodrogi, I; Mackenzie, MJ; Shen, L; Roessner, M; Gupta, S; Sartor, AO				de Bono, Johann Sebastian; Oudard, Stephane; Ozguroglu, Mustafa; Hansen, Steinbjorn; Machiels, Jean-Pascal; Kocak, Ivo; Gravis, Gwenaelle; Bodrogi, Istvan; Mackenzie, Mary J.; Shen, Liji; Roessner, Martin; Gupta, Sunil; Sartor, A. Oliver		TROPIC Investigators	Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial	LANCET			English	Article							EVERY 3 WEEKS; SOLID TUMORS; END-POINTS; CHEMOTHERAPY; ESTRAMUSTINE; TAXANE; PAIN	Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment. Methods We undertook an open-label randomised phase 3 trial in men with metastatic castration-resistant prostate cancer who had received previous hormone therapy, but whose disease had progressed during or after treatment with a docetaxel-containing regimen. Participants were treated with 10 mg oral prednisone daily, and were randomly assigned to receive either 12 mg/m(2) mitoxantrone intravenously over 15-30 min or 25 mg/m(2) cabazitaxel intravenously over 1 h every 3 weeks. The random allocation schedule was computer-generated; patients and treating physicians were not masked to treatment allocation, but the study team was masked to the data analysis. The primary endpoint was overall survival. Secondary endpoints included progression-free survival and safety. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, NCT00417079. Findings 755 men were allocated to treatment groups (377 mitoxantrone, 378 cabazitaxel) and were included in the intention-to-treat analysis. At the cutoff for the final analysis (Sept 25, 2009), median survival was 15.1 months (95% CI 14.1-16.3) in the cabazitaxel group and 12.7 months (11.6-13.7) in the mitoxantrone group. The hazard ratio for death of men treated with cabazitaxel compared with those taking mitoxantrone was 0.70 (95% CI 0.59-0.83, p<0.0001). Median progression-free survival was 2.8 months (95% CI 2.4-3.0) in the cabazitaxel group and 1.4 months (1.4-1.7) in the mitoxantrone group (HR 0.74, 0.64-0.86, p<0.0001). The most common clinically significant grade 3 or higher adverse events were neutropenia (cabazitaxel, 303 [82%] patients vs mitoxantrone, 215 [58%]) and diarrhoea (23 [6%] vs one [<1%]). 28 (8%) patients in the cabazitaxel group and five (1%) in the mitoxantrone group had febrile neutropenia. Interpretation Treatment with cabazitaxel plus prednisone has important clinical antitumour activity, improving overall survival in patients with metastatic castration-resistant prostate cancer whose disease has progressed during or after docetaxel-based therapy.	[de Bono, Johann Sebastian] Royal Marsden NHS Fdn Trust, Sutton SM2 5PT, Surrey, England; [de Bono, Johann Sebastian] Inst Canc Res, Sutton SM2 5PT, Surrey, England; [Sartor, A. Oliver] Tulane Univ, New Orleans, LA 70118 USA; [Oudard, Stephane] Hop Europeen Georges Pompidou, Paris, France; [Ozguroglu, Mustafa] Istanbul Univ, Istanbul, Turkey; [Hansen, Steinbjorn] Odense Univ Hosp, DK-5000 Odense, Denmark; [Machiels, Jean-Pascal] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium; [Kocak, Ivo] Masarykuv Onkol Ustav, Brno, Czech Republic; [Gravis, Gwenaelle] Inst Paoli Calmette Hop Jour, Marseille, France; [Bodrogi, Istvan] Orszagos Onkol Intezet, Budapest, Hungary; [Mackenzie, Mary J.] London Hlth Sci Ctr, London, ON, Canada; [Shen, Liji; Roessner, Martin; Gupta, Sunil] Sanofi Aventis, Malvern, PA USA	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Tulane University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Istanbul University; University of Southern Denmark; Odense University Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Masaryk Memorial Cancer Institute; UNICANCER; Institut Paoli-Calmette (IPC); London Health Sciences Centre; Sanofi-Aventis	de Bono, JS (corresponding author), Royal Marsden NHS Fdn Trust, Downs Rd, Sutton SM2 5PT, Surrey, England.	johann.de-bono@icr.ac.uk	MUSTAFA, ÖZGÜROĞLU/A-8234-2016; Gravis, Gwenaelle/CAG-3019-2022	MUSTAFA, ÖZGÜROĞLU/0000-0002-8417-8628; Gravis, Gwenaelle/0000-0002-3127-1554; OUDARD, Stephane/0000-0003-0893-285X; de Bono, Johann S/0000-0002-2034-595X; Hansen, Steinbjorn/0000-0001-5651-6493	Sanofi-Aventis	Sanofi-Aventis(Sanofi-Aventis)	Sanofi-Aventis funded this clinical trial. JSB, AOS, SO, and SH have served as paid consultants for Sanofi-Aventis. LS, MR, and SG are employees of Sanofi-Aventis.	Aller AW, 2000, P AM ASSOC CANC RES, V41, P303; American Cancer Society, GLOB CANC FACTS FIG; Attard G, 2006, PATHOL BIOL, V54, P72, DOI 10.1016/j.patbio.2005.03.003; Berry DL, 2006, J CLIN ONCOL, V24, P2828, DOI 10.1200/JCO.2005.04.8207; Bissery C, 2000, P AM ASSOC CANC RES, V41, P214; Cancer Therapy Evaluation Program, 2006, COMM TERM CRIT ADV E; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; EISENBERGER MA, 1985, J CLIN ONCOL, V3, P827, DOI 10.1200/JCO.1985.3.6.827; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kramer G, 2006, BRIT J CANCER, V94, P1592, DOI 10.1038/sj.bjc.6603129; MedDRA, MED DICT REG ACT MED; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; Mita AC, 2009, CLIN CANCER RES, V15, P723, DOI 10.1158/1078-0432.CCR-08-0596; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Pivot X, 2008, ANN ONCOL, V19, P1547, DOI 10.1093/annonc/mdn171; Rosenberg JE, 2007, CANCER-AM CANCER SOC, V110, P556, DOI 10.1002/cncr.22811; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205	20	2406	2446	2	150	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1147	1154		10.1016/S0140-6736(10)61389-X	http://dx.doi.org/10.1016/S0140-6736(10)61389-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888992				2023-01-03	WOS:000282915700031
J	Quah-Smith, I; Sachdev, PS; Wen, W; Chen, XH; Williams, MA				Quah-Smith, Im; Sachdev, Perminder S.; Wen, Wei; Chen, Xiaohua; Williams, Mark A.			The Brain Effects of Laser Acupuncture in Healthy Individuals: An fMRI Investigation	PLOS ONE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; STIMULATION; DEPRESSION; ACTIVATION; HUMANS; ELECTROACUPUNCTURE; COMPLEMENTARY; HYPOTHALAMUS; CONNECTIVITY; MODULATION	Background: As laser acupuncture is being increasingly used to treat mental disorders, we sought to determine whether it has a biologically plausible effect by using functional magnetic resonance imaging (fMRI) to investigate the cerebral activation patterns from laser stimulation of relevant acupoints. Methodology/Principal Findings: Ten healthy subjects were randomly stimulated with a fibreoptic infrared laser on 4 acupoints (LR14, CV14, LR8 and HT7) used for depression following the principles of Traditional Chinese Medicine (TCM), and 1 control non-acupoint (sham point) in a blocked design (alternating verum laser and placebo laser/rest blocks), while the blood oxygenation level-dependent (BOLD) fMRI response was recorded from the whole brain on a 3T scanner. Many of the acupoint laser stimulation conditions resulted in different patterns of neural activity. Regions with significantly increased activation included the limbic cortex (cingulate) and the frontal lobe (middle and superior frontal gyrus). Laser acupuncture tended to be associated with ipsilateral brain activation and contralateral deactivation that therefore cannot be simply attributed to somatosensory stimulation. Conclusions/Significance: We found that laser stimulation of acupoints lead to activation of frontal-limbic-striatal brain regions, with the pattern of neural activity somewhat different for each acupuncture point. This is the first study to investigate laser acupuncture on a group of acupoints useful in the management of depression. Differing activity patterns depending on the acupoint site were demonstrated, suggesting that neurological effects vary with the site of stimulation. The mechanisms of activation and deactivation and their effects on depression warrant further investigation.	[Quah-Smith, Im; Sachdev, Perminder S.; Wen, Wei; Chen, Xiaohua] Univ New S Wales, Fac Med, Sch Psychiat, Randwick, NSW, Australia; [Sachdev, Perminder S.; Wen, Wei; Chen, Xiaohua] Prince Wales Hosp, Inst Neuropsychiat, Randwick, NSW 2031, Australia; [Sachdev, Perminder S.; Wen, Wei; Chen, Xiaohua] Univ New S Wales, Brain & Ageing Res Program, Sch Psychiat, Randwick, NSW, Australia; [Williams, Mark A.] Macquarie Univ, Macquarie Ctr Cognit Sci, Sydney, NSW 2109, Australia	University of New South Wales Sydney; University of New South Wales Sydney; Macquarie University	Quah-Smith, I (corresponding author), Univ New S Wales, Fac Med, Sch Psychiat, Randwick, NSW, Australia.	p.sachdev@unsw.edu.au	Sachdev, Perminder/ABC-1137-2020	Sachdev, Perminder/0000-0002-9595-3220; Williams, Mark/0000-0002-3897-5167; Wen, Wei/0000-0003-2753-3870	Louise and Gary Dobson; James Fairfax; Thyne Reid Foundation	Louise and Gary Dobson; James Fairfax; Thyne Reid Foundation	The authors acknowledge financial support from Louise and Gary Dobson, James Fairfax and the Thyne Reid Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agelink MW, 2003, FORTSCHR NEUROL PSYC, V71, P141, DOI 10.1055/s-2003-37756; Aung SKH, 2007, CLIN INTRO MED ACUPU, P99; Campbell Anthony, 2006, Acupunct Med, V24, P118; Chang S, 2008, CHINESE J PHYSIOL, V51, P167; Dhond RP, 2008, PAIN, V136, P407, DOI 10.1016/j.pain.2008.01.011; Fang JL, 2004, NEURORADIOLOGY, V46, P359, DOI 10.1007/s00234-003-1125-7; GENG L, 2006, J MAGN RESON IMAGING, V24, P1018; George M. S., 1996, ADV BIOL PSYCHIAT, P63; Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34; Haker E, 2000, J AUTONOM NERV SYST, V79, P52, DOI 10.1016/S0165-1838(99)00090-9; Hsieh JC, 2001, NEUROSCI LETT, V307, P105, DOI 10.1016/S0304-3940(01)01952-8; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Jorm AF, 2002, MED J AUSTRALIA, V176, pS84; Kessler RC, 2001, AM J PSYCHIAT, V158, P289, DOI 10.1176/appi.ajp.158.2.289; Kong J, 2007, NEUROIMAGE, V34, P1171, DOI 10.1016/j.neuroimage.2006.10.019; Lund Irene, 2009, Chin Med, V4, P1, DOI 10.1186/1749-8546-4-1; Lundeberg T, 2009, ACUPUNCT MED, V27, P31, DOI 10.1136/aim.2008.000133; Maciocia G., 1994, PRACTICE CHINESE MED, P197; MacPherson H, 2008, NEUROSCI LETT, V434, P144, DOI 10.1016/j.neulet.2008.01.058; Napadow V, 2007, PAIN, V130, P254, DOI 10.1016/j.pain.2006.12.003; Napadow V, 2005, HUM BRAIN MAPP, V24, P193, DOI 10.1002/hbm.20081; Olausson H, 2002, NAT NEUROSCI, V5, P900, DOI 10.1038/nn896; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; Paterson C, 2008, J ALTERN COMPLEM MED, V14, P199, DOI 10.1089/acm.2007.0682; Qin W, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-55; Quah-Smith Joo Im, 2005, Acupunct Med, V23, P103; Reiman EM, 1997, J CLIN PSYCHIAT, V58, P4; RINDGE D, 2009, ACUPUNCTURE TODAY, V11, P5; Rogers BP, 2007, MAGN RESON IMAGING, V25, P1347, DOI 10.1016/j.mri.2007.03.007; Sheline YI, 2003, BIOL PSYCHIAT, V54, P338, DOI 10.1016/S0006-3223(03)00347-0; Siedentopf CM, 2005, LASER MED SCI, V20, P68, DOI 10.1007/s10103-005-0340-3; Siedentopf CM, 2002, NEUROSCI LETT, V327, P53, DOI 10.1016/S0304-3940(02)00383-X; Spielberger C.D., 1970, MANUAL STATE TRAIT A, DOI 10.2307/1831273; Tsukayama H, 2006, CLIN J PAIN, V22, P346, DOI 10.1097/01.ajp.0000176359.94644.mL; Napadow V, 2005, P ANN INT IEEE EMBS, P4496, DOI 10.1109/IEMBS.2005.1615466; Wu JH, 2009, PHOTOMED LASER SURG, V27, P273, DOI 10.1089/pho.2007.2235; Wu MT, 1999, RADIOLOGY, V212, P133, DOI 10.1148/radiology.212.1.r99jl04133; Yan B, 2005, NEUROSCI LETT, V383, P236, DOI 10.1016/j.neulet.2005.04.021; Yoo SS, 2004, NEUROIMAGE, V22, P932, DOI 10.1016/j.neuroimage.2004.02.017; Zhang WT, 2004, NEUROSCI LETT, V354, P50, DOI 10.1016/j.neulet.2003.09.080; Zhang WT, 2003, BRAIN RES, V982, P168, DOI 10.1016/S0006-8993(03)02983-4	42	37	41	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2010	5	9							e12619	10.1371/journal.pone.0012619	http://dx.doi.org/10.1371/journal.pone.0012619			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647PO	20838644	gold, Green Published			2023-01-03	WOS:000281631300039
J	Holmes, CB; Coggin, W; Jamieson, D; Mihm, H; Granich, R; Savio, P; Hope, M; Ryan, C; Moloney-Kitts, M; Goosby, EP; Dybul, M				Holmes, Charles B.; Coggin, William; Jamieson, David; Mihm, Heidi; Granich, Reuben; Savio, Phillip; Hope, Michael; Ryan, Caroline; Moloney-Kitts, Michele; Goosby, Eric P.; Dybul, Mark			Use of Generic Antiretroviral Agents and Cost Savings in PEPFAR Treatment Programs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TENOFOVIR	Context One of the biggest hurdles to the rapid scale-up of antiretroviral therapy in the developing world was the price of antiretroviral drugs (ARVs). Modification of an existing US Food and Drug Administration (FDA) process to expedite review and approval of generic ARVs quickly resulted in a large number of FDA-tentatively approved ARVs available for use by the US President's Emergency Plan for AIDS Relief (PEPFAR). Objective To evaluate the uptake of generic ARVs among PEPFAR-supported programs in Guyana, Haiti, Vietnam, and 13 countries in Africa, and changes over time in ARV use and costs. Design, Setting, and Participants An annual survey from 2005 to 2008 of ARVs purchased in 16 countries by PEPFAR implementing and procurement partners (organizations using PEPFAR funding to purchase ARVs). Main Outcome Measures Drug expenditures, ARV types and volumes (assessed per pack, a 1-month supply), proportion of generic procurement across years and countries, and cost savings from generic procurement. Results ARV expenditures increased from $116.8 million (2005) to $202.2 million (2008); and procurement increased from 6.2 million to 22.1 million monthly packs. The proportion spent on generic ARVs increased from 9.17% (95% confidence interval [CI], 9.17%-9.18%) in 2005 to 76.41% (95% CI, 76.41%-76.42%) in 2008 (P<.001), and the proportion of generic packs procured increased from 14.8% (95% CI, 14.79%-14.84%) in 2005 to 89.33% (95% CI, 89.32%-89.34%) in 2008 (P similar to. 001). In 2008, there were 8 PEPFAR programs that procured at least 90.0% of ARV packs in generic form; South Africa had the lowest generic procurement (24.7%; 95% CI, 24.6%-24.8%). Procurement of generic fixed-dose combinations increased from 33.3% (95% CI, 33.24%-33.43%) in 2005 to 42.73% (95% CI, 42.71%-42.75%) in 2008. Estimated yearly savings generated through generic ARV use were $8 108 444 in 2005, $24 940 014 in 2006, $75 645 816 in 2007, and $214 648 982 in 2008, a total estimated savings of $323 343 256. Conclusion Among PEPFAR-supported programs in 16 countries, availability of generic ARVs was associated with increased ARV procurement and substantial estimated cost savings. JAMA. 2010;304(3):313-320 www.jama.com	[Holmes, Charles B.; Coggin, William; Granich, Reuben; Ryan, Caroline; Moloney-Kitts, Michele; Goosby, Eric P.; Dybul, Mark] US Dept State, Off US Global AIDS Coordinator, Washington, DC 20522 USA; [Jamieson, David; Savio, Phillip] Supply Chain Management Syst, Arlington, VA USA; [Mihm, Heidi; Hope, Michael] US Agcy Int Dev, Washington, DC 20523 USA	United States Agency for International Development (USAID)	Holmes, CB (corresponding author), US Dept State, Off US Global AIDS Coordinator, 2100 Penn Ave, Washington, DC 20522 USA.	holmescb@state.gov			US government	US government	This study was funded by the President's Emergency Plan for AIDS Relief (PEPFAR) of the US government.	Agresti A, 1998, AM STAT, V52, P119, DOI 10.2307/2685469; Bender MA, 2010, CLIN INFECT DIS, V50, P416, DOI 10.1086/649884; Bermudez Jorge, 2010, Open AIDS J, V4, P37, DOI 10.2174/1874613601004020037; El-Khatib Z, 2009, SAMJ S AFR MED J, V99, P412; Ford N, 2008, S AFR J HIV MED, P8; Husain M, 2009, INDIAN J CHEM B, V48, P1174; Martinson N, 2009, JAIDS-J ACQ IMM DEF, V50, P327, DOI 10.1097/QAI.0b013e3181958546; *MIN HLTH ZAMB, ANT THER CHRON HIV I; MSF Campaign for Access to Essential Medicines, UNT WEB ANT PRIC RED; Rosen S, 2008, JAIDS-J ACQ IMM DEF, V48, P334, DOI 10.1097/QAI.0b013e31817ae5ef; *SUPPL CHAIN MAN S, US; US Food and Drug Administration, PRES EM PLAN AIDS RE; *US PRES PLAN AIDS, 2008, REP C US GLOB AIDS C; *US PRES PLAN AIDS, WORLD AIDS DAY 2009; *WHO, WHO HLTH SYST SERV P; World Health Organization, 2009, RAP ADV ANT THER HIV	16	66	66	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2010	304	3					313	320		10.1001/jama.2010.993	http://dx.doi.org/10.1001/jama.2010.993			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	628HV	20639565	Bronze			2023-01-03	WOS:000280107500021
J	Smith, LN; James, R; Barber, M; Ramsay, S; Gillespie, D; Chung, C				Smith, Lorraine N.; James, Roberta; Barber, Mark; Ramsay, Scott; Gillespie, David; Chung, Charlie		Guideline Dev Grp	Guidelines Rehabilitation of patients with stroke: summary of SIGN guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							RECOVERY; PAIN		[Smith, Lorraine N.] Univ Glasgow, Fac Med, Glasgow G12 8LL, Lanark, Scotland; [James, Roberta] SIGN, Edinburgh EH7 5EA, Midlothian, Scotland; [Ramsay, Scott] St Johns Hosp, Livingston EH54 6PP, Scotland; [Gillespie, David] Astley Ainslie Hosp, Dept Clin Psychol, Edinburgh EH9 2HL, Midlothian, Scotland	University of Glasgow	Smith, LN (corresponding author), Univ Glasgow, Fac Med, Glasgow G12 8LL, Lanark, Scotland.	l.n.smith@clinmed.gla.ac.uk		Barber, Mark/0000-0002-2893-1566; Todhunter-Brown, Alex/0000-0003-4941-7985				[Anonymous], 1988, USERS GUIDE GEN HLTH; Bernhardt J, 2004, STROKE, V35, P1005, DOI 10.1161/01.STR.0000120727.40792.40; De Wit L, 2007, STROKE, V38, P2101, DOI 10.1161/STROKEAHA.107.482869; Hackett ML, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003689.pub3; Jensen MP, 2003, J PAIN, V4, P2, DOI 10.1054/jpai.2003.1; Kalra L, 2007, J REHABIL MED, V39, P97, DOI 10.2340/16501977-0043; Langhorne P, 2007, J REHABIL MED, V39, P103, DOI 10.2340/16501977-0042; LEIJON G, 1989, PAIN, V36, P27, DOI 10.1016/0304-3959(89)90108-5; Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666; *NHS NAT SERV SCOT, ANN PUBL SUMM NHS NA; Saunders DH, 2009, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003316.PUB2; Scottish Intercollegiate Guidelines Network (SIGN), 2008, SIGN PUBL, V108; Scottish Intercollegiate Guidelines Network (SIGN), 2010, SIGN PUBL, V119; Scottish Intercollegiate Guidelines Network (SIGN), 2010, SIGN PUBL, V118; Sutcliffe LM, 1998, CLIN REHABIL, V12, P506, DOI 10.1191/026921598672167702; Teasell RW, 2005, STROKE, V36, P215, DOI 10.1161/01.STR.0000153061.02375.04	16	6	7	1	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 15	2010	340								c2845	10.1136/bmj.c2845	http://dx.doi.org/10.1136/bmj.c2845			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614JA	20551122	Green Accepted			2023-01-03	WOS:000279051800005
J	Pollock, S; Antrobus, R; Newton, L; Kampa, B; Rossa, J; Latham, S; Nichita, NB; Dwek, RA; Zitzmann, N				Pollock, Stephanie; Antrobus, Robin; Newton, Laura; Kampa, Bettina; Rossa, Jan; Latham, Sally; Nichita, Norica Branza; Dwek, Raymond A.; Zitzmann, Nicole			Uptake and trafficking of liposomes to the endoplasmic reticulum	FASEB JOURNAL			English	Article						drug delivery; lipid trafficking; imaging tool; purification tool	HEPATITIS-C VIRUS; N-BUTYL-DEOXYNOJIRIMYCIN; PLASMA-MEMBRANE; BUTYLDEOXYNOJIRIMYCIN; CHOLESTEROL; INFECTION; MACROPHAGES; COMBINATION; ENDOSOMES; PATHWAY	Liposomes are vesicular structures consisting of an aqueous core surrounded by a lipid bilayer. Apart from the cytosol and lysosomes, no other intracellular compartment has been successfully targeted using liposomal delivery. Here, we report the development of liposomes capable of specific targeting to the endoplasmic reticulum (ER) and associated membranes. Using competition and inhibitor assays along with confocal microscopy, we have determined that ER liposomes utilize scavenger and low-density lipoprotein receptors for endocytosis and enter cells through a caveolin- and microtubule-dependent mechanism. They traffic intact to the ER, where fusion with the ER membrane occurs after 22-25 min, which was confirmed by fluorescence-dequenching assays. Once inside the ER, tagged lipids intercalate with the ER membrane and are subsequently incorporated into ER-assembling entities, such as the ER-budding viruses hepatitis C virus (HCV) and bovine viral diarrhea virus (BVDV), lipid droplets, and secreted lipoproteins. ER liposomes are superior to cytosolic liposome formulations for the intracellular delivery of aqueous cargo, such as HIV-1 antivirals, and are especially suited for the prolonged delivery of lipids and lipophilic drugs into human cells.-Pollock, S., Antrobus, R., Newton, L., Kampa, B., Rossa, J., Latham, S., Branza Nichita, N., Dwek, R. A., Zitzmann, N. Uptake and trafficking of liposomes to the endoplasmic reticulum. FASEB J. 24, 1866-1878 (2010). www.fasebj.org	[Pollock, Stephanie; Antrobus, Robin; Newton, Laura; Kampa, Bettina; Rossa, Jan; Latham, Sally; Dwek, Raymond A.; Zitzmann, Nicole] Univ Oxford, Oxford Antiviral Drug Discovery Unit, Dept Biochem, Oxford OX1 3QU, England; [Nichita, Norica Branza] Romanian Univ, Inst Biochem, Bucharest, Romania	University of Oxford; Romanian Academy of Sciences; Institute of Biochemistry, Bucharest; University of Bucharest	Zitzmann, N (corresponding author), Univ Oxford, Oxford Antiviral Drug Discovery Unit, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	nicole.zitzmann@bioch.ox.ac.uk		Newton, Laura/0000-0002-5328-8314	Oxford Glycobiology Endowment; Canadian Institutes of Health Research; United Therapeutics Corp.; IDEI [84]	Oxford Glycobiology Endowment; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); United Therapeutics Corp.; IDEI	The authors thank Takaji Wakita (Tokyo Metropolitan Institute for Neuroscience, Tokyo, Japan), Jens Bukh (U. S. National Institutes of Health, Bethesda, MD, USA), Charles M. Rice (The Rockefeller University, New York, NY, USA) and Ralf Bartenschlager (University of Heidelberg, Heidelberg, Germany) for reagents. This work is funded by the Oxford Glycobiology Endowment, by the Canadian Institutes of Health Research (to S. P.), and by a Blue Skies research grant from United Therapeutics Corp., of which R. A. D is a director and member of the scientific board. N. Z. is a senior research fellow of Linacre College, Oxford. N. B. N. was financially supported by IDEI grant ID_84 [Consiliului National al Cercetarii Stiintifice din Invatamantul Superior (CNCSIS)].	BLOCK TM, 1994, P NATL ACAD SCI USA, V91, P2235, DOI 10.1073/pnas.91.6.2235; Campbell SM, 2002, AIDS, V16, P2253, DOI 10.1097/00002030-200211220-00004; Chapel C, 2007, J GEN VIROL, V88, P1133, DOI 10.1099/vir.0.82465-0; FISCHER P, 1995, J VIROL, V69, P5791, DOI 10.1128/JVI.69.9.5791-5797.1995; FISCHL MA, 1994, J ACQ IMMUN DEF SYND, V7, P139; Fujinaga Y, 2003, MOL BIOL CELL, V14, P4783, DOI 10.1091/mbc.E03-06-0354; Guyader M, 2002, J VIROL, V76, P10356, DOI 10.1128/JVI.76.20.10356-10364.2002; Huth US, 2006, J CONTROL RELEASE, V110, P490, DOI 10.1016/j.jconrel.2005.10.018; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; Macovei A, 2010, J VIROL, V84, P243, DOI 10.1128/JVI.01207-09; Martin S, 2006, NAT REV MOL CELL BIO, V7, P373, DOI 10.1038/nrm1912; Miller JL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040017; Molina S, 2007, J HEPATOL, V46, P411, DOI 10.1016/j.jhep.2006.09.024; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Pagler TA, 2006, J BIOL CHEM, V281, P11193, DOI 10.1074/jbc.M510261200; Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96; Schwendener RA, 2007, ADV EXP MED BIOL, V620, P117; Sharma DK, 2003, J BIOL CHEM, V278, P7564, DOI 10.1074/jbc.M210457200; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Steinmann E, 2007, HEPATOLOGY, V46, P330, DOI 10.1002/hep.21686; SWIFT LL, 1995, J LIPID RES, V36, P395; TIERNEY M, 1995, J ACQ IMMUN DEF SYND, V10, P549, DOI 10.1097/00042560-199510050-00008; Torchilin VP, 1993, J LIPOSOME RES, V3, P201, DOI DOI 10.3109/08982109309148213]; Woodhouse SD, 2008, ANTIMICROB AGENTS CH, V52, P1820, DOI 10.1128/AAC.01181-07	25	61	72	0	40	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2010	24	6					1866	1878		10.1096/fj.09-145755	http://dx.doi.org/10.1096/fj.09-145755			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	603HR	20097877				2023-01-03	WOS:000278200000022
J	Fainaru, O; Almog, N; Yung, CW; Nakai, K; Montoya-Zavala, M; Abdollahi, A; D'Amato, R; Ingber, DE				Fainaru, Ofer; Almog, Nava; Yung, Chong Wing; Nakai, Kei; Montoya-Zavala, Martin; Abdollahi, Amir; D'Amato, Robert; Ingber, Donald E.			Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells	FASEB JOURNAL			English	Article						immune cells; vasculogenesis	DIFFERENTIATION; PRECURSORS; DEPLETION	Dendritic cells (DCs)-immunomodulatory cells that initiate adaptive immune responses-have recently been shown to exert proangiogenic effects when infiltrating the tumor microenvironment. As tumors that escape immune surveillance inhibit DC maturation, we explored whether maturation status determines their ability to promote angiogenesis and whether angiogenesis depends on the presence of DCs. Using mouse xenograft models of human tumors, we show that fast-growing "angiogenic" tumors are infiltrated by a more immature DC population than respective dormant avascular tumors. Accordingly, supplementation of immature DCs, but not mature DCs, enhanced tumor growth. When DCs were mixed with Matrigel and injected subcutaneously into mice, only immature DCs promoted the ingrowth of patent blood vessels. Notably, depletion of DCs in a transgenic mouse model that allows for their conditional ablation completely abrogated basic fibroblast growth factor-induced angiogenesis in Matrigel plugs, and significantly inhibited tumor growth in these mice. Because immature DCs actively promote angiogenesis and tumor growth, whereas DC maturation or ablation suppresses this response, we conclude that angiogenesis is dependent on the presence of immature DCs. Thus, cancer immunotherapies that promote DC maturation may act by both augmenting the host immune response to the tumor and by suppressing tumor angiogenesis.-Fainaru, O., Almog, N., Yung, C. W., Nakai, K., Montoya-Zavala, M., Abollahi, A., D'Amato, R., Ingber, D. E. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J. 24, 1411-1418 (2010). www.fasebj.org	[Ingber, Donald E.] Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, Boston, MA 02115 USA; [Fainaru, Ofer; Yung, Chong Wing; Montoya-Zavala, Martin; D'Amato, Robert; Ingber, Donald E.] Childrens Hosp, Dept Surg, Boston, MA 02115 USA; [Fainaru, Ofer; Yung, Chong Wing; Montoya-Zavala, Martin] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Ingber, Donald E.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Nakai, Kei; D'Amato, Robert] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA; [Montoya-Zavala, Martin; Ingber, Donald E.] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA; [Ingber, Donald E.] Harvard Univ, Harvard Sch Engn & Appl Sci, Boston, MA 02115 USA; [Almog, Nava; Abdollahi, Amir] Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Ctr Canc Syst Biol, Boston, MA 02111 USA; [Abdollahi, Amir] Heidelberg Univ, Dept Radiat Oncol, Sch Med, Heidelberg, Germany; [Abdollahi, Amir] German Canc Res Ctr, D-6900 Heidelberg, Germany	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard University; St. Elizabeth's Medical Center; Tufts University; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Ingber, DE (corresponding author), Harvard Univ, Sch Med, Childrens Hosp Boston, Vasc Biol Program, 300 Longwood Ave, Boston, MA 02115 USA.	donald.ingber@childrens.harvard.edu	Ingber, Donald E/AAC-5894-2019		Fulbright and Rothschild Foundations; European Molecular Biology Organization (EMBO); German Research Council [DFG-SPP1190]; National Aeronautics and Space Administration Specialized Center of Research (NSCOR) [NNJ04HJ12G]; U.S. Department of Defense [W81XWH-04-1-0316]; U.S. National Institutes of Health [P01 CA045548]; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER	Fulbright and Rothschild Foundations; European Molecular Biology Organization (EMBO)(European Molecular Biology Organization (EMBO)); German Research Council(German Research Foundation (DFG)); National Aeronautics and Space Administration Specialized Center of Research (NSCOR); U.S. Department of Defense(United States Department of Defense); U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is dedicated to Dr. Judah Folkman, who helped launch and guide this effort. The authors also thank Lauren Bazinet for her expert technical assistance, and Kristin Johnson and Clare Lamont for photography and graphic art. This research was supported by the Fulbright and Rothschild Foundations and the European Molecular Biology Organization (EMBO) Fellowship (O.F.); German Research Council Priority Research Program Tumor-Vessel Interface (DFG-SPP1190) and National Aeronautics and Space Administration Specialized Center of Research (NSCOR) NNJ04HJ12G (A. A.); and U.S. Department of Defense Breast Cancer Innovator award W81XWH-04-1-0316 and U.S. National Institutes of Health award P01 CA045548 (D. I.).	Adini A, 2009, J IMMUNOL METHODS, V342, P78, DOI 10.1016/j.jim.2008.11.016; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bennett CL, 2007, TRENDS IMMUNOL, V28, P525, DOI 10.1016/j.it.2007.08.011; Carmi Y, 2009, J IMMUNOL, V183, P4705, DOI 10.4049/jimmunol.0901511; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; Coukos G, 2005, BRIT J CANCER, V92, P1182, DOI 10.1038/sj.bjc.6602476; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; De Palma M, 2006, BBA-REV CANCER, V1766, P159, DOI 10.1016/j.bbcan.2006.06.003; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Fainaru O, 2008, FASEB J, V22, P522, DOI 10.1096/fj.07-9034com; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Huarte E, 2008, CANCER RES, V68, P7684, DOI 10.1158/0008-5472.CAN-08-1167; Jinushi M, 2007, CLIN CANCER RES, V13, P3762, DOI 10.1158/1078-0432.CCR-07-0880; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Lutz MB, 2000, EUR J IMMUNOL, V30, P1813, DOI 10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8; Marigo I, 2008, IMMUNOL REV, V222, P162, DOI 10.1111/j.1600-065X.2008.00602.x; Melief CJM, 2008, IMMUNITY, V29, P372, DOI 10.1016/j.immuni.2008.08.004; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nakai K, 2008, INVEST OPHTH VIS SCI, V49, P3666, DOI 10.1167/iovs.07-1640; NAUMOV GN, J NATL CANC I, V98, P316; PASSANITI A, 1992, LAB INVEST, V67, P519; Plaks V, 2008, J CLIN INVEST, V118, P3954, DOI 10.1172/JCI36682; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040	29	77	81	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1411	1418		10.1096/fj.09-147025	http://dx.doi.org/10.1096/fj.09-147025			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20008545	Green Published			2023-01-03	WOS:000277158900014
J	McCabe, CJ; Goldie, SJ; Fisman, DN				McCabe, Caitlin J.; Goldie, Sue J.; Fisman, David N.			The Cost-Effectiveness of Directly Observed Highly-Active Antiretroviral Therapy in the Third Trimester in HIV-Infected Pregnant Women	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERSISTENT MITOCHONDRIAL DYSFUNCTION; ELECTIVE CESAREAN DELIVERY; MONTE-CARLO-SIMULATION; PERINATAL TRANSMISSION; VERTICAL TRANSMISSION; GESTATIONAL-AGE; PRETERM INFANTS; VIRAL LOAD; ADHERENCE	Background: In HIV-infected pregnant women, viral suppression prevents mother-to-child HIV transmission. Directly observed highly-active antiretroviral therapy (HAART) enhances virological suppression, and could prevent transmission. Our objective was to project the effectiveness and cost-effectiveness of directly observed administration of antiretroviral drugs in pregnancy. Methods and Findings: A mathematical model was created to simulate cohorts of one million asymptomatic HIV-infected pregnant women on HAART, with women randomly assigned self-administered or directly observed antiretroviral therapy (DOT), or no HAART, in a series of Monte Carlo simulations. Our primary outcome was the quality-adjusted life expectancy in years (QALY) of infants born to HIV-infected women, with the rates of Caesarean section and HIV-transmission after DOT use as intermediate outcomes. Both self-administered HAART and DOT were associated with decreased costs and increased life-expectancy relative to no HAART. The use of DOT was associated with a relative risk of HIV transmission of 0.39 relative to conventional HAART; was highly cost-effective in the cohort as a whole (cost-utility ratio $14,233 per QALY); and was cost-saving in women whose viral loads on self-administered HAART would have exceeded 1000 copies/ml. Results were stable in wide-ranging sensitivity analyses, with directly observed therapy cost-saving or highly cost-effective in almost all cases. Conclusions: Based on the best available data, programs that optimize adherence to HAART through direct observation in pregnancy have the potential to diminish mother-to-child HIV transmission in a highly cost-effective manner. Targeted use of DOT in pregnant women with high viral loads, who could otherwise receive self-administered HAART would be a cost-saving intervention. These projections should be tested with randomized clinical trials.	[McCabe, Caitlin J.; Fisman, David N.] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; [Goldie, Sue J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Fisman, David N.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Fisman, David N.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Harvard T.H. Chan School of Public Health; University of Toronto; University of Toronto	McCabe, CJ (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	david.fisman@gmail.com			Ontario Ministry of Research and Innovation	Ontario Ministry of Research and Innovation(Ministry of Research and Innovation, Ontario)	Dr. Fisman is supported by an Early Researcher Award of the Ontario Ministry of Research and Innovation. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abaasa AM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-241; Ades AE, 2000, PHARMACOECONOMICS, V18, P9, DOI 10.2165/00019053-200018010-00002; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; [Anonymous], 2009, CHOOS INT AR COST EF; Barret B, 2003, AIDS, V17, P1769, DOI 10.1097/00002030-200308150-00006; Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0; Bulterys M, 2000, J ACQ IMMUN DEF SYND, V25, P261, DOI 10.1097/00126334-200011010-00009; *BUR LAB STAT, 2009, PRIC LIV COND; Burdge DR, 2003, CAN MED ASSOC J, V168, P1683; Burman WJ, 1997, CHEST, V112, P63, DOI 10.1378/chest.112.1.63; CASCADE Collaboration, 2000, LANCET, V355, P1158, DOI 10.1016/S0140-6736(00)02069-9; *CDCP, 2009, VITALSTATS; *CDCP, 2009, HIV AIDS SURV REP 20; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P285; Chen KT, 2001, OBSTET GYNECOL, V97, P161, DOI 10.1016/S0029-7844(00)01107-8; Chesney MA, 1999, AIDS, V13, pS271; Clumeck N, 2003, AIDS, V17, pS3, DOI 10.1097/01.aids.0000060397.18106.12; COHEN H, 2003, 2003 DRUG TOPICS RED; Dabis F, 2004, JAIDS-J ACQ IMM DEF, V35, P167, DOI 10.1097/00126334-200402010-00011; De Jose MI, 2001, ARCH INTERN MED, V161, P2738, DOI 10.1001/archinte.161.22.2738; de Kleine MJK, 2003, ARCH DIS CHILD, V88, P870, DOI 10.1136/adc.88.10.870; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; DeHovitz JA, 2000, J INFECT DIS, V182, P1527, DOI 10.1086/315875; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Giaquinto C, 2005, CLIN INFECT DIS, V40, P458, DOI 10.1086/427287; Gilbert WM, 2003, OBSTET GYNECOL, V102, P488, DOI 10.1016/S0029-7844(03)00617-3; Granados JMS, 2003, PEDIATR INFECT DIS J, V22, P863, DOI 10.1097/01.inf.0000091282.70253.5f; Halpern EF, 2000, MED DECIS MAKING, V20, P314, DOI 10.1177/0272989X0002000308; Halpern MT, 2000, AIDS, V14, P691, DOI 10.1097/00002030-200004140-00008; Havens PL, 1997, PEDIATR INFECT DIS J, V16, P607, DOI 10.1097/00006454-199706000-00012; Holmgren PA, 2001, ACTA OBSTET GYN SCAN, V80, P525, DOI 10.1034/j.1600-0412.2001.080006525.x; Immergluck LC, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e54; Ioannidis JPA, 1999, NEW ENGL J MED, V341, P1698; Ioannidis JPA, 2001, J INFECT DIS, V183, P539, DOI 10.1086/318530; John-Stewart G, 2004, JAIDS-J ACQ IMM DEF, V35, P196, DOI 10.1097/00126334-200402010-00015; Khanlou H, 2003, JAIDS-J ACQ IMM DEF, V33, P651, DOI 10.1097/00126334-200308150-00017; Kirkland LR, 2002, CLIN INFECT DIS, V34, P511, DOI 10.1086/338400; Laine C, 2000, OBSTET GYNECOL, V95, P167, DOI 10.1016/S0029-7844(99)00523-2; Lanzafame M, 2000, J ACQ IMMUN DEF SYND, V25, P200, DOI 10.1097/00126334-200010010-00018; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lipshultz SE, 2002, LANCET, V360, P368, DOI 10.1016/S0140-6736(02)09607-1; Lucas GM, 2002, AIDS PATIENT CARE ST, V16, P527, DOI 10.1089/108729102761041083; Macalino GE, 2007, AIDS, V21, P1473, DOI 10.1097/QAD.0b013e32811ebf68; Maru DSR, 2009, JAIDS-J ACQ IMM DEF, V50, P176, DOI 10.1097/QAI.0b013e3181938e7e; Mellins CA, 2008, AIDS CARE, V20, P958, DOI 10.1080/09540120701767208; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mitty JA, 2002, CLIN INFECT DIS, V34, P984, DOI 10.1086/339447; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Mrus JM, 2000, AIDS, V14, P2543, DOI 10.1097/00002030-200011100-00017; Mrus JM, 2002, MED DECIS MAKING, V22, pS38, DOI 10.1177/027298902237710; NEWELL ML, 1994, LANCET, V343, P1464; Paltiel AD, 1998, MED DECIS MAKING, V18, pS93, DOI 10.1177/0272989X9801800211; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; *PER HIV GUID WORK, 2009, REC US ANT DRUGS PRE, P1; Pinkerton SD, 2000, PREV MED, V30, P64, DOI 10.1006/pmed.1999.0601; SANDE M, 2003, ANTIRETROVIRAL THERA, P18; Schackman BR, 2002, MED DECIS MAKING, V22, P27, DOI 10.1177/02729890222062892; Selik RM, 2003, PEDIATR INFECT DIS J, V22, P635, DOI 10.1097/00006454-200307000-00013; Sethi AK, 2003, CLIN INFECT DIS, V37, P1112, DOI 10.1086/378301; Snyder DC, 1999, AM J RESP CRIT CARE, V160, P582, DOI 10.1164/ajrccm.160.2.9901049; Stone VE, 2001, J ACQ IMMUN DEF SYND, V28, P124, DOI 10.1097/00042560-200110010-00003; Tarnow-Mordi W, 2000, ARCH DIS CHILD-FETAL, V82, pF118; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; Turner BJ, 2000, MED CARE, V38, P911, DOI 10.1097/00005650-200009000-00005; Turner BJ, 2000, AM J PUBLIC HEALTH, V90, P85, DOI 10.2105/AJPH.90.1.85; Vollmer B, 2003, PEDIATRICS, V112, P1108, DOI 10.1542/peds.112.5.1108; WAITZMAN NJ, 1994, INQUIRY-J HEALTH CAR, V31, P188; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; White BL, 2006, AIDS PATIENT CARE ST, V20, P408, DOI 10.1089/apc.2006.20.408; Wohl AR, 2006, CLIN INFECT DIS, V42, P1619, DOI 10.1086/503906; World Bank, 2009, DAT STAT COUNTR GROU; Zaric GS, 2000, J ACQ IMMUN DEF SYND, V25, P403, DOI 10.1097/00126334-200012150-00004; Zupancic JAF, 2003, PEDIATRICS, V111, P146, DOI 10.1542/peds.111.1.146	80	19	20	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2010	5	4							e10154	10.1371/journal.pone.0010154	http://dx.doi.org/10.1371/journal.pone.0010154			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	583UV	20405011	Green Submitted, Green Published, gold			2023-01-03	WOS:000276706300010
J	Ghaemmaghami, S; Ullman, J; Ahn, M; St Martin, S; Prusiner, SB				Ghaemmaghami, Sina; Ullman, Julie; Ahn, Misol; St Martin, Susan; Prusiner, Stanley B.			Chemical Induction of Misfolded Prion Protein Conformers in Cell Culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE PRION; BRANCHED POLYAMINES; POTENT INHIBITION; PRPSC; DISEASE; ACCUMULATION; ANTIBODIES; STRAINS; MUTANT; THERAPEUTICS	Prion-infected cells accumulate a heterogeneous population of aberrantly folded PrP conformers, including the disease-causing isoform (PrPSc). We found that specific chemicals can modulate the levels of various PrP conformers in cultured cells. Positively charged polyamidoamines (dendrimers) eliminated protease-resistant (r) PrPSc from prion-infected cells and induced the formation of insoluble, protease-sensitive PrP aggregates (designated PrPA). Larger, positively charged polyamidoamines more efficaciously induced the formation of PrPA and cleared rPrP(Sc), whereas negatively charged polyamidoamines neither induced PrPA nor cleared rPrP(Sc). Although the biochemical properties of PrPA were shown to be similar to protease-sensitive (s) PrPSc, bioassays of PrPA indicated that it is not infectious. Our studies argue that PrPA represents an aggregated PrP species that is off-pathway relative to the formation of rPrP(Sc). It remains to be established whether the formation of PrPA inhibits the formation of rPrP(Sc) by sequestering PrPC in the form of benign, insoluble aggregates.	[Ghaemmaghami, Sina; Ullman, Julie; Ahn, Misol; St Martin, Susan; Prusiner, Stanley B.] Univ Calif San Francisco, Inst Neurodegenerat Dis, San Francisco, CA 94143 USA; [Ghaemmaghami, Sina; Prusiner, Stanley B.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Prusiner, SB (corresponding author), 513 Parnassus Ave,HSE 774, San Francisco, CA 94143 USA.	stanley@ind.ucsf.edu		Ghaemmaghami, Sina/0000-0002-8696-2950; Ullman, Julie/0000-0003-1325-0650; Ahn, Misol/0000-0002-6088-8481	National Institutes of Health [AG02132, AG10770, AG021601]; NATIONAL INSTITUTE ON AGING [P01AG002132, P01AG010770, P01AG021601] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported, in whole or in part, by National Institutes of Health Grants AG02132, AG10770, and AG021601 as well as by gifts from the G. Harold and Leila Y. Mathers Foundation, Hillblom Foundation, Fight for Mike Homer Program, and Mr. Robert Galvin.	Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1992, J NEUROCHEM, V59, P768, DOI 10.1111/j.1471-4159.1992.tb09437.x; Colby DW, 2007, P NATL ACAD SCI USA, V104, P20914, DOI 10.1073/pnas.0710152105; Colby DW, 2009, P NATL ACAD SCI USA, V106, P20417, DOI 10.1073/pnas.0910350106; Doh-Ura K, 2000, J VIROL, V74, P4894, DOI 10.1128/JVI.74.10.4894-4897.2000; Ertmer A, 2004, J BIOL CHEM, V279, P41918, DOI 10.1074/jbc.M405652200; Gambetti P, 2003, BRIT MED BULL, V66, P213, DOI 10.1093/bmb/66.1.213; Gambetti P, 2008, ANN NEUROL, V63, P697, DOI 10.1002/ana.21420; Ghaemmaghami S, 2007, P NATL ACAD SCI USA, V104, P17971, DOI 10.1073/pnas.0708372104; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Govaerts C, 2004, P NATL ACAD SCI USA, V101, P8342, DOI 10.1073/pnas.0402254101; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kong Qingzhong, 2004, VVolume 41, P673; Korth C, 2001, P NATL ACAD SCI USA, V98, P9836, DOI 10.1073/pnas.161274798; Leclerc E, 2003, J MOL BIOL, V326, P475, DOI 10.1016/S0022-2836(02)01365-7; Lee IS, 2005, J AM CHEM SOC, V127, P13802, DOI 10.1021/ja055219y; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Legname G, 2006, P NATL ACAD SCI USA, V103, P19105, DOI 10.1073/pnas.0608970103; Ma JY, 2002, SCIENCE, V298, P1785, DOI 10.1126/science.1073619; May BCH, 2003, P NATL ACAD SCI USA, V100, P3416, DOI 10.1073/pnas.2627988100; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; PAN YT, 1983, BIOCHEMISTRY-US, V22, P3975, DOI 10.1021/bi00285a038; Pastrana MA, 2006, BIOCHEMISTRY-US, V45, P15710, DOI 10.1021/bi0615442; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Prior M, 2007, J VIROL, V81, P11195, DOI 10.1128/JVI.02559-06; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; Rambold AS, 2008, J NEUROCHEM, V107, P218, DOI 10.1111/j.1471-4159.2008.05611.x; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2005, P NATL ACAD SCI USA, V102, P3501, DOI 10.1073/pnas.0409651102; Safar JG, 2005, J GEN VIROL, V86, P2913, DOI 10.1099/vir.0.80947-0; Sonawane ND, 2003, J BIOL CHEM, V278, P44826, DOI 10.1074/jbc.M308643200; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Supattapone S, 2001, J VIROL, V75, P3453, DOI 10.1128/JVI.75.7.3453-3461.2001; Tremblay P, 2004, J VIROL, V78, P2088, DOI 10.1128/JVI.78.4.2088-2099.2004; Trevitt CR, 2006, BRAIN, V129, P2241, DOI 10.1093/brain/awl150; Tzaban S, 2002, BIOCHEMISTRY-US, V41, P12868, DOI 10.1021/bi025958g; Williamson RA, 1998, J VIROL, V72, P9413, DOI 10.1128/JVI.72.11.9413-9418.1998; Williamson TL, 1998, P NATL ACAD SCI USA, V95, P9631, DOI 10.1073/pnas.95.16.9631	45	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 2	2010	285	14					10415	10423		10.1074/jbc.M109.045112	http://dx.doi.org/10.1074/jbc.M109.045112			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	578AC	19955177	Green Published, hybrid			2023-01-03	WOS:000276264600027
J	Livesley, B				Livesley, Brian			Personal View Assisted suicide: a substitute for a caring doctor?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England	Imperial College London	Livesley, B (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.	brian.livesley@doctors.org.uk						Gale J, 1974, Age Ageing, V3, P49, DOI 10.1093/ageing/3.1.49; KAMISAR Y, 1958, MINN LAW REV, V42, P969; The Crown Prosecution Service, POL PROS RESP CAS EN	3	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2010	340								c1590	10.1136/bmj.c1590	http://dx.doi.org/10.1136/bmj.c1590			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	576PO	20332309				2023-01-03	WOS:000276157600001
J	Lamont, T; Luettel, D; Scarpello, J; O'Driscoll, BR; Connew, S				Lamont, Tara; Luettel, Dagmar; Scarpello, John; O'Driscoll, B. Ronan; Connew, Steven			Safety Alerts Improving the safety of oxygen therapy in hospitals: summary of a safety report from the National Patient Safety Agency	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Lamont, Tara; Luettel, Dagmar; Scarpello, John] Natl Patient Safety Agcy, Natl Reporting & Learning Serv, London W1T 5HD, England; [O'Driscoll, B. Ronan] Salford Royal NHS Fdn Trust, Salford M6 8HD, Lancs, England; [Connew, Steven] Colchester Hosp Univ NHS Fdn Trust, Colchester CO4 5JL, Essex, England	Salford Royal NHS Foundation Trust	Lamont, T (corresponding author), Natl Patient Safety Agcy, Natl Reporting & Learning Serv, London W1T 5HD, England.	tara.lamont@npsa.nhs.uk						*BRIT THOR SOC, NAT AUD RES EM OX US; DAVIS R M, 1989, California Agriculture, V43, P4; Leach RM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2790; *NAT I HLTH CLIN E, 2007, CLIN GUID NAT I HLTH, V50; National Patient Safety Agency, 2007, REC RESP APPR EARL S; O'Driscoll BR, 2008, THORAX, V63, DOI 10.1136/thx.2008.102947; SLUTSKY AS, 1994, INTENS CARE MED, V20, P64, DOI 10.1007/BF02425061	7	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 26	2010	340								c187	10.1136/bmj.c187	http://dx.doi.org/10.1136/bmj.c187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YA	20103511				2023-01-03	WOS:000274089200001
J	Nugus, P; Bridges, J; Braithwaite, J				Nugus, Peter; Bridges, Jackie; Braithwaite, Jeffrey			Christmas 2009: Professional Matters Selling patients	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Braithwaite, Jeffrey] Univ New S Wales, Fac Med, Australian Inst Hlth Innovat, Ctr Clin Governance Res, Sydney, NSW 2052, Australia	University of New South Wales Sydney		p.nugus@unsw.edu.au	Braithwaite, Jeffrey/AAN-1467-2020	Braithwaite, Jeffrey/0000-0003-0296-4957; Bridges, Jackie/0000-0001-6776-736X				BLOOR M, 1976, SOCIOLOGY, V10, P43, DOI 10.1177/003803857601000103; Eisenberg EM, 2005, COMMUN MONOGR, V72, P390, DOI 10.1080/03637750500322602; EMERSON RM, 1991, SOC PROBL, V38, P198, DOI 10.1525/sp.1991.38.2.03a00060; HAMMERSLEY M, 1990, SOCIOLOGY, V24, P597, DOI 10.1177/0038038590024004003; Hammersley M., 1995, ETHNOGRAPHY PRINCIPL, V2nd; Hartswood M., 2003, Computer Supported Cooperative Work: The Journal of Collaborative Computing, V12, P241, DOI 10.1023/A:1025055829026; Hewett DG, 2009, SOC SCI MED, V69, P1732, DOI 10.1016/j.socscimed.2009.09.048; Hughes Geoffrey, 2004, Emerg Med Australas, V16, P387, DOI 10.1111/j.1742-6723.2004.00641.x; Innes G, 2000, CJEM, V2, P47; Jean YA, 2004, SOCIOL HEALTH ILL, V26, P385, DOI 10.1111/j.0141-9889.2004.00396.x; Merton Robert K., 1957, STUDENT PHYS INTRO S; Nugus P, 2010, SOC SCI MED, V70, P511, DOI 10.1016/j.socscimed.2009.11.001; Ragin C., 1994, CONSTRUCTING SOCIAL; Salhan D, 2009, SOC SCI MED, V68, P1221, DOI 10.1016/j.socscimed.2009.01.041; Shem Samuel, 1978, HOUSE GOD; Strauss AL., 1985, SOCIAL ORG MED WORK; Sudnow D., 1967, PASSING SOCIAL ORG D; Tesch R., 1990, QUALITATIVE RES ANAL; WHALEN MR, 1990, LANG SOC, V19, P465, DOI 10.1017/S0047404500014779	19	14	14	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 14	2009	339								b5201	10.1136/bmj.b5201	http://dx.doi.org/10.1136/bmj.b5201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	534XF	20008442				2023-01-03	WOS:000272930100003
J	Navon, A; Ciechanover, A				Navon, Ami; Ciechanover, Aaron			The 26 S Proteasome: From Basic Mechanisms to Drug Targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NF-KAPPA-B; UNFOLDED PROTEIN RESPONSE; 20S PROTEASOME; MULTIUBIQUITIN-CHAIN; MULTIPLE-MYELOMA; UBIQUITIN CHAINS; CRYSTAL-STRUCTURE; ANTICANCER DRUGS; CANCER-THERAPY; CORE PARTICLE	The regulated degradation of proteins within eukaryotes and bacterial cells is catalyzed primarily by large multimeric proteases in ATP-dependent manner. In eukaryotes, the 26 S proteasome is essential for the rapid destruction of key regulatory proteins, such as cell cycle regulators and transcription factors, whose fast and tuned elimination is necessary for the proper control of the fundamental cell processes they regulate. In addition, the 26 S proteasome is responsible for cell quality control by eliminating defective proteins from the cytosol and endoplasmic reticulum. These defective proteins can be misfolded proteins, nascent prematurely terminated polypeptides, or proteins that fail to assemble into complexes. These diverse activities and its central role in apoptosis have made the proteasome an important target for drug development, in particular to combat malignancies.	[Navon, Ami] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Ciechanover, Aaron] Technion Israel Inst Technol, Canc & Vasc Biol Res Ctr, Rappaport Fac Med, IL-31096 Haifa, Israel; [Ciechanover, Aaron] Technion Israel Inst Technol, Res Inst, IL-31096 Haifa, Israel	Weizmann Institute of Science; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology	Navon, A (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel.	ami.navon@weizmann.ac.il	Ciechanover, Aaron J/C-9166-2017		Israel Science Foundation; Minerva Foundation (Germany); German-Israeli Foundation for Scientific Research and Development; Foundation for Promotion of Research in the Technion	Israel Science Foundation(Israel Science Foundation); Minerva Foundation (Germany); German-Israeli Foundation for Scientific Research and Development(German-Israeli Foundation for Scientific Research and Development); Foundation for Promotion of Research in the Technion	The work performed in the laboratory of A.N. was supported by the Israel Science Foundation, the Minerva Foundation (Germany), the German-Israeli Foundation for Scientific Research and Development, and a special gift from Rolando Uziel. The work performed in the laboratory of A. C. was supported by grants from the Dr. Miriam and Sheldon Adelson Foundation for Medical Research, the Israel Science Foundation, the German-Israeli Foundation for Scientific Research and Development, the European Union Networks of Excellence NeuroNE and Rubicon, a professorship from the Israel Cancer Research Fund USA, and a grant from the Foundation for Promotion of Research in the Technion. This is the eleventh article in the Thematic Minireview Series on Proteolytic Enzymes. The first article was published in the November 7, 2008 issue; the second and third articles in the May 22, 2009 issue; the fourth and fifth articles in the July 31, 2009 issue; the sixth and seventh articles in the August 14, 2009 issue; the eighth article in the August 28, 2009 issue; the ninth article in the November 6, 2009 issue; and the tenth article in the November 27, 2009 issue. This mini-review will be reprinted in	Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; AKI M, 1994, J BIOCHEM, V115, P257, DOI 10.1093/oxfordjournals.jbchem.a124327; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Corey EJ, 1999, CHEM PHARM BULL, V47, P1; Crosas B, 2006, CELL, V127, P1401, DOI 10.1016/j.cell.2006.09.051; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2005, NAT CELL BIOL, V7, P742, DOI 10.1038/ncb0805-742; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Groll M, 2006, STRUCTURE, V14, P451, DOI 10.1016/j.str.2005.11.019; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; Hartmann-Petersen R, 2001, ARCH BIOCHEM BIOPHYS, V386, P89, DOI 10.1006/abbi.2000.2178; Hendil KB, 2002, J MOL BIOL, V315, P627, DOI 10.1006/jmbi.2001.5285; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Husnjak K, 2008, NATURE, V453, P481, DOI 10.1038/nature06926; ImajohOhmi S, 1995, BIOCHEM BIOPH RES CO, V217, P1070, DOI 10.1006/bbrc.1995.2878; Jakob C, 2007, BLOOD, V109, P2100, DOI 10.1182/blood-2006-04-016360; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kisselev AF, 2001, CHEM BIOL, V8, P739, DOI 10.1016/S1074-5521(01)00056-4; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Kravtsova-Ivantsiv Y, 2009, MOL CELL, V33, P496, DOI 10.1016/j.molcel.2009.01.023; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100; Lee SJ, 2008, BRIT J HAEMATOL, V143, P511, DOI 10.1111/j.1365-2141.2008.07378.x; Li W, 2007, NATURE, V446, P333, DOI 10.1038/nature05542; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Medalia N, 2009, J BIOL CHEM, V284, P22952, DOI 10.1074/jbc.M809643200; Murata S, 2009, NAT REV MOL CELL BIO, V10, P104, DOI 10.1038/nrm2630; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Nickell S, 2007, BIOCHEM BIOPH RES CO, V353, P115, DOI 10.1016/j.bbrc.2006.11.141; Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078-0432.CCR-07-2218; Orlowski RZ, 1998, CANCER RES, V58, P4342; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Rabl J, 2008, MOL CELL, V30, P360, DOI 10.1016/j.molcel.2008.03.004; Ravid T, 2007, NAT CELL BIOL, V9, P422, DOI 10.1038/ncb1558; Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Saeki Y, 2009, EMBO J, V28, P359, DOI 10.1038/emboj.2008.305; Schreiner P, 2008, NATURE, V453, P548, DOI 10.1038/nature06924; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Vembar SS, 2008, NAT REV MOL CELL BIO, V9, P944, DOI 10.1038/nrm2546; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Voorhees PM, 2006, ANNU REV PHARMACOL, V46, P189, DOI 10.1146/annurev.pharmtox.46.120604.141300; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Wang QH, 2003, BIOCHEMISTRY-US, V42, P13529, DOI 10.1021/bi035391j; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041	70	140	143	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 4	2009	284	49					33713	33718		10.1074/jbc.R109.018481	http://dx.doi.org/10.1074/jbc.R109.018481			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	524TE	19812037	hybrid, Green Published			2023-01-03	WOS:000272165200001
J	Fernandez, HF; Sun, ZX; Yao, XP; Litzow, MR; Luger, SM; Paietta, EM; Racevskis, J; Dewald, GW; Ketterling, RP; Bennett, JM; Rowe, JM; Lazarus, HM; Tallman, MS				Fernandez, Hugo F.; Sun, Zhuoxin; Yao, Xiaopan; Litzow, Mark R.; Luger, Selina M.; Paietta, Elisabeth M.; Racevskis, Janis; Dewald, Gordon W.; Ketterling, Rhett P.; Bennett, John M.; Rowe, Jacob M.; Lazarus, Hillard M.; Tallman, Martin S.			Anthracycline Dose Intensification in Acute Myeloid Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE NONLYMPHOCYTIC LEUKEMIA; ACUTE MYELOCYTIC-LEUKEMIA; UNTREATED ADULT PATIENTS; CYTOSINE-ARABINOSIDE; INDUCTION CHEMOTHERAPY; REMISSION INDUCTION; DAUNORUBICIN; CYTARABINE; THERAPY; CONSOLIDATION	Background In young adults with acute myeloid leukemia (AML), intensification of the anthracycline dose during induction therapy has improved the rate of complete remission but not of overall survival. We evaluated the use of cytarabine plus either standard-dose or high-dose daunorubicin as induction therapy, followed by intensive consolidation therapy, in inducing complete remission to improve overall survival. Methods In this phase 3 randomized trial, we assigned 657 patients between the ages of 17 and 60 years who had untreated AML to receive three once-daily doses of daunorubicin at either the standard dose (45 mg per square meter of body-surface area) or a high dose (90 mg per square meter), combined with seven daily doses of cytarabine (100 mg per square meter) by continuous intravenous infusion. Patients who had a complete remission were offered either allogeneic hematopoietic stem-cell transplantation or high-dose cytarabine, with or without a single dose of the monoclonal antibody gemtuzumab ozogamicin, followed by autologous stem-cell transplantation. The primary end point was overall survival. Results In the intention-to-treat analysis, high-dose daunorubicin, as compared with a standard dose of the drug, resulted in a higher rate of complete remission (70.6% vs. 57.3%, P<0.001) and improved overall survival (median, 23.7 vs. 15.7 months; P = 0.003). The rates of serious adverse events were similar in the two groups. Median follow-up was 25.2 months. Conclusions In young adults with AML, intensifying induction therapy with a high daily dose of daunorubicin improved the rate of complete remission and the duration of overall survival, as compared with the standard dose. (ClinicalTrials.gov number, NCT00049517.)	[Fernandez, Hugo F.] Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA; [Sun, Zhuoxin; Yao, Xiaopan] Dana Farber Canc Inst, Boston, MA 02115 USA; [Litzow, Mark R.; Dewald, Gordon W.; Ketterling, Rhett P.] Mayo Clin, Rochester, MN USA; [Luger, Selina M.] Univ Penn, Philadelphia, PA 19104 USA; [Paietta, Elisabeth M.; Racevskis, Janis] Montefiore Med Ctr, North Div, Bronx, NY 10467 USA; [Bennett, John M.] Univ Rochester, Rochester, NY USA; [Rowe, Jacob M.] Rambam Med Ctr, Haifa, Israel; [Lazarus, Hillard M.] Univ Hosp Case Med Ctr, Cleveland, OH USA; [Tallman, Martin S.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; University of Pennsylvania; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Rochester; Rambam Health Care Campus; Technion Israel Institute of Technology; Case Western Reserve University; Case Western Reserve University Hospital; Northwestern University; Feinberg School of Medicine	Fernandez, HF (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, 12902 Magnolia Dr,Rm 3116, Tampa, FL 33612 USA.	hugo.fernandez@moffitt.org		Ketterling, Rhett/0000-0001-6479-7897	Public Health Service [CA23318, CA66636, CA21115, CA13650, CA15488, CA17145, CA14548]; National Cancer Institute and the Department of Health and Human Services; Wyeth Pharmaceuticals and Immunex; NATIONAL CANCER INSTITUTE [U10CA073590, U24CA114737, U10CA015488, U10CA021115, U10CA014958, U10CA023318, U10CA011083, U10CA013650, U10CA014548, U10CA017145, U10CA066636] Funding Source: NIH RePORTER	Public Health Service(United States Department of Health & Human ServicesUnited States Public Health Service); National Cancer Institute and the Department of Health and Human Services; Wyeth Pharmaceuticals and Immunex; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported in part by grants from the Public Health Service (CA23318, CA66636, CA21115, CA13650, CA15488, CA17145, and CA14548) and from the National Cancer Institute and the Department of Health and Human Services. Funding for laboratory correlative studies was provided by Wyeth Pharmaceuticals and Immunex through a grant to the ECOG.	APPELBAUM FR, 1984, ANN INTERN MED, V101, P581, DOI 10.7326/0003-4819-101-5-581; ARLIN Z, 1990, LEUKEMIA, V4, P177; Bennett JM, 1997, CANCER, V80, P2205; Bishop JF, 1998, LEUKEMIA LYMPHOMA, V28, P315, DOI 10.3109/10428199809092687; BUCHNER T, 1985, J CLIN ONCOL, V3, P1583; Cassileth PA, 2005, LEUKEMIA LYMPHOMA, V46, P55, DOI 10.1080/10428190412331283288; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Jaffe ES, 2001, WHO CLASSIFICATION T; Kolitz JE, 2004, J CLIN ONCOL, V22, P4290, DOI 10.1200/JCO.2004.11.106; MAYER RJ, 1994, NEW ENGL J MED, V331, P896, DOI 10.1056/NEJM199410063311402; Noguera N, 2002, LEUKEMIA, V16, P2185, DOI 10.1038/sj.leu.2402723; PREISLER H, 1987, BLOOD, V69, P1441; RAI KR, 1981, BLOOD, V58, P1203; Rowe JM, 1997, BLOOD, V90, P2121; ROWE JM, 1995, BLOOD, V86, P457, DOI 10.1182/blood.V86.2.457.bloodjournal862457; SCHILLER G, 1992, BRIT J HAEMATOL, V81, P170, DOI 10.1111/j.1365-2141.1992.tb08203.x; SCHILLER G, 1992, BLOOD, V80, P2977; Schnittger S, 2000, LEUKEMIA, V14, P796, DOI 10.1038/sj.leu.2401773; Slovak ML, 2000, BLOOD, V96, P4075, DOI 10.1182/blood.V96.13.4075; van Dongen JJM, 1999, LEUKEMIA, V13, P1901, DOI 10.1038/sj.leu.2401592; Vance GH, 2007, LEUKEMIA RES, V31, P605, DOI 10.1016/j.leukres.2006.07.026; Weick JK, 1996, BLOOD, V88, P2841, DOI 10.1182/blood.V88.8.2841.bloodjournal8882841; Wheatley D, 1998, BRIT J HAEMATOL, V103, P100; WIERNIK PH, 1992, BLOOD, V79, P313; Willman CL, 1996, LEUKEMIA, V10, pS33; YATES J, 1982, BLOOD, V60, P454	26	642	671	4	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	2009	361	13					1249	1259		10.1056/NEJMoa0904544	http://dx.doi.org/10.1056/NEJMoa0904544			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	497RN	19776406	Green Accepted			2023-01-03	WOS:000270078700006
J	Young, JQ; Wachter, RM				Young, John Q.; Wachter, Robert M.			Academic Year-End Transfers of Outpatients From Outgoing to Incoming Residents An Unaddressed Patient Safety Issue	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SIGN-OUT; CARE; COMMUNICATION; CONSEQUENCES; STRATEGIES		[Young, John Q.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; [Wachter, Robert M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Young, JQ (corresponding author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.	jqyoung@lppi.ucsf.edu	Young, John Q./L-5916-2019	Young, John Q./0000-0003-2219-5657	NATIONAL INSTITUTE OF MENTAL HEALTH [R25MH060482] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Arora V, 2005, QUAL SAF HEALTH CARE, V14, P401, DOI 10.1136/qshc.2005.015107; Arora V, 2006, JT COMM J QUAL PATIE, V32, P646, DOI 10.1016/S1553-7250(06)32084-3; Arora VM, 2008, MED CLIN N AM, V92, P315, DOI 10.1016/j.mcna.2007.11.002; Boockvar K, 2004, ARCH INTERN MED, V164, P545, DOI 10.1001/archinte.164.5.545; DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005; Horwitz LI, 2008, ARCH INTERN MED, V168, P1755, DOI 10.1001/archinte.168.16.1755; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Mischoulon D, 2000, ACAD PSYCHIATR, V24, P156, DOI 10.1176/appi.ap.24.3.156; Patterson ES, 2004, INT J QUAL HEALTH C, V16, P125, DOI 10.1093/intqhc/mzh026; Roy MJ, 2003, J GEN INTERN MED, V18, P364, DOI 10.1046/j.1525-1497.2003.20747.x; Salsberg E, 2008, JAMA-J AM MED ASSOC, V300, P1174, DOI 10.1001/jama.300.10.1174; Scalise D, 2006, HOSP HEALTH NETWORK, V80, P40; Sinha M, 2007, ACAD EMERG MED, V14, P192, DOI 10.1197/j.aem.2006.09.048; Vidyarthi AR, 2006, J HOSP MED, V1, P257, DOI 10.1002/jhm.103; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487	15	35	35	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	2009	302	12					1327	1329		10.1001/jama.2009.1399	http://dx.doi.org/10.1001/jama.2009.1399			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	497AR	19773568				2023-01-03	WOS:000270026000015
J	Dickhaut, K; Hoepner, S; Eckhard, J; Wiesmueller, KH; Schindler, L; Jung, G; Falk, K; Roetzschke, O				Dickhaut, Katharina; Hoepner, Sabine; Eckhard, Jamina; Wiesmueller, Karl-Heinz; Schindler, Luise; Jung, Guenther; Falk, Kirsten; Roetzschke, Olaf			Enhancement of Tumour-Specific Immune Responses In Vivo by 'MHC Loading-Enhancer' (MLE)	PLOS ONE			English	Article							T-CELL CLONES; PEPTIDE-RECEPTIVE STATE; PARTICLE VACCINE; LIGAND-EXCHANGE; DENDRITIC CELLS; YOUNG-WOMEN; NY-ESO-1; ANTIGEN; IDENTIFICATION; LYMPHOCYTES	Background: Class II MHC molecules (MHC II) are cell surface receptors displaying short protein fragments for the surveillance by CD4+ T cells. Antigens therefore have to be loaded onto this receptor in order to induce productive immune responses. On the cell surface, most MHC II molecules are either occupied by ligands or their binding cleft has been blocked by the acquisition of a non-receptive state. Direct loading with antigens, as required during peptide vaccinations, is therefore hindered. Principal Findings: Here we show, that the in vivo response of CD4+ T cells can be improved, when the antigens are administered together with 'MHC-loading enhancer' (MLE). MLE are small catalytic compounds able to open up the MHC binding site by triggering ligand-release and stabilizing the receptive state. Their enhancing effect on the immune response was demonstrated here with an antigen from the influenza virus and tumour associated antigens (TAA) derived from the NYESO-1 protein. The application of these antigens in combination with adamantane ethanol (AdEtOH), an MLE compound active on human HLA-DR molecules, significantly increased the frequency of antigen-specific CD4+ T cells in mice transgenic for the human MHC II molecule. Notably, the effect was evident only with the MLE-susceptible HLA-DR molecule and not with murine MHC II molecules non-susceptible for the catalytic effect of the MLE. Conclusion: MLE can specifically increase the potency of a vaccine by facilitating the efficient transfer of the antigen onto the MHC molecule. They may therefore open a new way to improve vaccination efficacy and tumour-immunotherapy.			Dickhaut, K (corresponding author), Max Delbruck Ctr Mol Med, Berlin, Germany.	falk@mdc-berlin.de						Bouneaud C, 2000, IMMUNITY, V13, P829, DOI 10.1016/S1074-7613(00)00080-7; Call MJ, 2009, J IMMUNOL, V182, P6342, DOI 10.4049/jimmunol.0803464; Chen QY, 2004, P NATL ACAD SCI USA, V101, P9363, DOI 10.1073/pnas.0403271101; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Corthay A, 2005, IMMUNITY, V22, P371, DOI 10.1016/j.immuni.2005.02.003; DERES K, 1989, NATURE, V342, P561, DOI 10.1038/342561a0; Falk K, 2002, J BIOL CHEM, V277, P2709, DOI 10.1074/jbc.M109098200; FFRENCH RA, 1989, J VIROL, V63, P3087, DOI 10.1128/JVI.63.7.3087-3094.1989; Fontenot JD, 2005, NAT IMMUNOL, V6, P331, DOI 10.1038/ni1179; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Gnjatic S, 2006, ADV CANCER RES, V95, P1, DOI 10.1016/S0065-230X(06)95001-5; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; Gupta S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001814; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Hopner S, 2006, J BIOL CHEM, V281, P38535, DOI 10.1074/jbc.M606437200; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jager E, 2000, J EXP MED, V191, P625, DOI 10.1084/jem.191.4.625; JANEWAY C, 1989, COLD SPRING HARB S Q; Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215; LAMB JR, 1982, NATURE, V300, P66, DOI 10.1038/300066a0; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Marin-Esteban V, 2004, J BIOL CHEM, V279, P50684, DOI 10.1074/jbc.M407598200; Marin-Esteban V, 2003, J AUTOIMMUN, V20, P63, DOI 10.1016/S0896-8411(02)00107-5; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Nicholson MJ, 2006, J IMMUNOL, V176, P4208, DOI 10.4049/jimmunol.176.7.4208; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; Rabinowitz JD, 1998, IMMUNITY, V9, P699, DOI 10.1016/S1074-7613(00)80667-6; Reed SG, 2009, TRENDS IMMUNOL, V30, P23, DOI 10.1016/j.it.2008.09.006; Rosloniec EF, 1997, J EXP MED, V185, P1113, DOI 10.1084/jem.185.6.1113; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Tacken PJ, 2005, BLOOD, V106, P1278, DOI 10.1182/blood-2005-01-0318; Toes REM, 1999, J EXP MED, V189, P753, DOI 10.1084/jem.189.5.753; Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7; WIESMULLER KH, 1989, VACCINE, V7, P29, DOI 10.1016/0264-410X(89)90007-8; Zarour HM, 2002, CANCER RES, V62, P213; Zarour HM, 2000, CANCER RES, V60, P4946; Zeng G, 2000, J IMMUNOL, V165, P1153, DOI 10.4049/jimmunol.165.2.1153	41	11	13	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 7	2009	4	9							e6811	10.1371/journal.pone.0006811	http://dx.doi.org/10.1371/journal.pone.0006811			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZH	19738910	Green Published, gold, Green Submitted			2023-01-03	WOS:000269622300003
J	Goodpaster, BH; DeLany, JP; Otto, AD; Kuller, L; Vockley, J; South-Paul, JE; Thomas, SB; Brown, J; McTigue, K; Hames, KC; Lang, W; Jakicic, JM				Goodpaster, Bret H.; DeLany, James P.; Otto, Amy D.; Kuller, Lewis; Vockley, Jerry; South-Paul, Jeannette E.; Thomas, Stephen B.; Brown, Jolene; McTigue, Kathleen; Hames, Kazanna C.; Lang, Wei; Jakicic, John M.			Effects of Diet and Physical Activity Interventions on Weight Loss and Cardiometabolic Risk Factors in Severely Obese Adults A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TYPE-2 DIABETES-MELLITUS; LOW-CALORIE DIET; INSULIN-RESISTANCE; OVERWEIGHT WOMEN; FAT DISTRIBUTION; CARDIOVASCULAR-DISEASE; METABOLIC SYNDROME; LOW-CARBOHYDRATE; GASTRIC BYPASS; MORBID-OBESITY	Context The prevalence of severe obesity is increasing markedly, as is prevalence of comorbid conditions such as hypertension and type 2 diabetes mellitus; however, apart from bariatric surgery and pharmacotherapy, few clinical trials have evaluated the treatment of severe obesity. Objective To determine the efficacy of a weight loss and physical activity intervention on the adverse health risks of severe obesity. Design, Setting, and Participants Single-blind randomized trial conducted from February 2007 through April 2010 at the University of Pittsburgh. Participants were 130 (37% African American) severely obese (class II or III) adult participants without diabetes recruited from the community. Interventions One-year intensive lifestyle intervention consisting of diet and physical activity. One group (initial physical activity) was randomized to diet and physical activity for the entire 12 months; the other group (delayed physical activity) had the identical dietary intervention but with physical activity delayed for 6 months. Main Outcome Measures Changes in weight. Secondary outcomes were additional components comprising cardiometabolic risk, including waist circumference, abdominal adipose tissue, and hepatic fat content. Results Of 130 participants randomized, 101 (78%) completed the 12-month follow-up assessments. Although both intervention groups lost a significant amount of weight at 6 months, the initial-activity group lost significantly more weight in the first 6 months compared with the delayed-activity group (10.9 kg [95% confidence interval {CI}, 9.1-12.7] vs 8.2 kg [95% CI, 6.4-9.9], P=.02 for group x time interaction). Weight loss at 12 months, however, was similar in the 2 groups (12.1 kg [95% CI, 10.0-14.2] vs 9.9 kg [95% CI, 8.0-11.7], P=.25 for group x time interaction). Waist circumference, visceral abdominal fat, hepatic fat content, blood pressure, and insulin resistance were all reduced in both groups. The addition of physical activity promoted greater reductions in waist circumference and hepatic fat content. Conclusion Among patients with severe obesity, a lifestyle intervention involving diet combined with initial or delayed initiation of physical activity resulted in clinically significant weight loss and favorable changes in cardiometabolic risk factors.	[Goodpaster, Bret H.; DeLany, James P.; Brown, Jolene; Hames, Kazanna C.] Univ Pittsburgh, Sch Med, Dept Med, Div Endocrinol & Metab, Pittsburgh, PA 15213 USA; [McTigue, Kathleen] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA; [Vockley, Jerry] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; [Otto, Amy D.; Hames, Kazanna C.; Jakicic, John M.] Univ Pittsburgh, Dept Hlth & Phys Act, Phys Act & Weight Management Res Ctr, Pittsburgh, PA 15213 USA; [Kuller, Lewis] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15213 USA; [Vockley, Jerry] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; [Thomas, Stephen B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Behav & Community Hlth Sci, Pittsburgh, PA 15213 USA; [South-Paul, Jeannette E.] Univ Pittsburgh, Sch Med, Dept Family Med, Pittsburgh, PA 15213 USA; [Lang, Wei] Wake Forest Univ, Sch Med, Dept Biostat Sci, Wake Forest, NC USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University	Goodpaster, BH (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Div Endocrinol & Metab, MUH N810,3459 5th Ave, Pittsburgh, PA 15213 USA.	bgood@pitt.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457; DeLany, James/0000-0003-0366-3849	Bodymedia Inc; Beverage Institute for Health Wellness; Commonwealth of Pennsylvania Department of Health; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases [T32 DK07052]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078775, T32DK007052] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG024827] Funding Source: NIH RePORTER	Bodymedia Inc; Beverage Institute for Health Wellness(General Electric); Commonwealth of Pennsylvania Department of Health; National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Jakicic reported serving on the scientific advisory board for Free and Clear, serving as a consultant to Proctor & Gamble Inc, BodyMedia Inc, and the University of Pittsburgh Medical Center Health Plan; and receiving research funding from Bodymedia Inc and the Beverage Institute for Health & Wellness. No other authors reported disclosures.; This study was funded by the Commonwealth of Pennsylvania Department of Health. Dr Brown was supported by National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases grant T32 DK07052.	ANDERSON J W, 1992, American Journal of Clinical Nutrition, V56, p244S, DOI 10.1093/ajcn/56.1.244S; Anderson JW, 2007, AM J CLIN NUTR, V86, P301, DOI 10.1093/ajcn/86.2.301; Brown CD, 2000, OBES RES, V8, P605, DOI 10.1038/oby.2000.79; Cossrow N, 2004, J CLIN ENDOCR METAB, V89, P2590, DOI 10.1210/jc.2004-0339; Dixon JB, 2008, JAMA-J AM MED ASSOC, V299, P316, DOI 10.1001/jama.299.3.316; Donnelly JE, 2009, MED SCI SPORT EXER, V41, P459, DOI 10.1249/MSS.0b013e3181949333; Espeland M, 2007, DIABETES CARE, V30, P1374; Fabbrini E, 2009, P NATL ACAD SCI USA, V106, P15430, DOI 10.1073/pnas.0904944106; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; FLICKINGER EG, 1984, ANN SURG, V199, P555, DOI 10.1097/00000658-198405000-00010; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Goodpaster BH, 1999, DIABETES, V48, P839, DOI 10.2337/diabetes.48.4.839; Goodpaster BH, 2005, ARCH INTERN MED, V165, P777, DOI 10.1001/archinte.165.7.777; Hwang JH, 2007, AM J PHYSIOL-ENDOC M, V293, pE1663, DOI 10.1152/ajpendo.00590.2006; Jacobs EJ, 2010, ARCH INTERN MED, V170, P1293, DOI 10.1001/archinternmed.2010.201; Jakicic JM, 2003, JAMA-J AM MED ASSOC, V290, P1323, DOI 10.1001/jama.290.10.1323; Jakicic JM, 1999, JAMA-J AM MED ASSOC, V282, P1554, DOI 10.1001/jama.282.16.1554; JAKICIC JM, 1995, INT J OBESITY, V19, P893; Jakicic JM, 2008, ARCH INTERN MED, V168, P1550, DOI 10.1001/archinte.168.14.1550; Jakicic JM, 2009, OBESITY, V17, pS34, DOI 10.1038/oby.2009.386; Katsuki A, 2003, DIABETES CARE, V26, P2341, DOI 10.2337/diacare.26.8.2341; Kelley DE, 2001, J CLIN ENDOCR METAB, V86, P5412, DOI 10.1210/jc.86.11.5412; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; McKimmie RL, 2008, AM J GASTROENTEROL, V103, P3029, DOI 10.1111/j.1572-0241.2008.02188.x; Miyazaki Y, 2002, AM J PHYSIOL-ENDOC M, V283, pE1135, DOI 10.1152/ajpendo.0327.2001; Monkhouse SJW, 2009, POSTGRAD MED J, V85, P678, DOI 10.1136/pgmj.2009.082271; O'Brien PE, 2006, ANN INTERN MED, V144, P625, DOI 10.7326/0003-4819-144-9-200605020-00005; Paeratakul S, 2002, INT J OBESITY, V26, P1205, DOI 10.1038/sj.ijo.0802026; Park YW, 2003, ARCH INTERN MED, V163, P427, DOI 10.1001/archinte.163.4.427; Ryan DH, 2010, ARCH INTERN MED, V170, P146, DOI 10.1001/archinternmed.2009.508; Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637; Schauer PR, 2003, ANN SURG, V238, P467, DOI 10.1097/01.sla.0000089851.41115.1b; Sjostrom L, 2004, NEW ENGL J MED, V351, P2683, DOI 10.1056/NEJMoa035622; Sturm R, 2007, PUBLIC HEALTH, V121, P492, DOI 10.1016/j.puhe.2007.01.006; Sturm R, 2003, ARCH INTERN MED, V163, P2146, DOI 10.1001/archinte.163.18.2146; WADDEN TA, 1989, INT J OBESITY, V13, P39; Wing RR, 2007, MED SCI SPORT EXER, V39, P2107, DOI 10.1249/mss.0b013e31815614cb; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586	38	367	378	0	83	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2010	304	16					1795	1802		10.1001/jama.2010.1505	http://dx.doi.org/10.1001/jama.2010.1505			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671JZ	20935337	Bronze, Green Accepted			2023-01-03	WOS:000283501300020
J	Ellershaw, J; Dewar, S; Murphy, D				Ellershaw, John; Dewar, Steve; Murphy, Deborah			Spotlight: Palliative Care Beyond Cancer Achieving a good death for all	BRITISH MEDICAL JOURNAL			English	Article									[Ellershaw, John; Murphy, Deborah] Univ Liverpool, Marie Curie Palliat Care Inst, Liverpool L69 3BX, England; [Dewar, Steve] Marie Curie Canc Care, London SE1 7TP, England; [Ellershaw, John; Murphy, Deborah] Royal Liverpool & Broadgreen Univ Hosp NHS Trust, Liverpool L7 8XP, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital	Ellershaw, J (corresponding author), Univ Liverpool, Marie Curie Palliat Care Inst, Liverpool L69 3BX, England.	j.e.ellershaw@liv.ac.uk		Ellershaw, John/0000-0001-9789-3180				Abel J, 2009, PALLIATIVE MED, V23, P616, DOI 10.1177/0269216309106460; Addicott R, 2008, IMPROVING CHOICE END; CANDY B, 2009, NONSTATUTORY PALLIAT; DAVIES E, 2004, WHO EUROPE BETTER PA; *DEP HLTH, 2008, ENGL END LIF CAR STR; Department of Health, 2009, END LIF CAR STRAT QU; Gambles M, 2006, INT J PALLIAT NURS, V12, P414, DOI 10.12968/ijpn.2006.12.9.21869; Gambles MA, 2009, INT J CARE COORD, V13, P51, DOI 10.1258/jicp.2009.009011; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Hockley J, 2005, J RES NURS, V10, P135, DOI 10.1177/174498710501000209; Jack Barbara A, 2003, Int J Palliat Nurs, V9, P375; *M CUR PALL CAR I, 2009, LCP GEN VERS 12 COR; *M CUR PALL CAR I, 2007, NAT CAR DYING AUD HO; Marie Curie Palliative Care Institute Liverpool and Clinical Standards Department of the Royal College of Physicians, 2009, NAT CAR DYING AUD HO; MAYLAND CR, 2009, EUR ASS PALL CAR 11; National Audit Office, 2008, END LIF CAR; National Institute for Health and Clinical Excellence, 2004, IMPR SUPP PALL CAR A; Office for National Statistics, MORT STAT DEATHS REG; ROBERTS A, 2007, PALLIATIVE NURSING I; Saunders C, 1989, TXB PAIN, P624; SMITH R, 2009, DAILY TELEGRAPH 1017; St John of God Health Care, 2019, OUR VIS; Veerbeek L, 2008, PALLIATIVE MED, V22, P145, DOI 10.1177/0269216307087164	23	15	16	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	SEP 16	2010	341								c4861	10.1136/bmj.c4861	http://dx.doi.org/10.1136/bmj.c4861			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847021				2023-01-03	WOS:000282095800001
J	Grant, L; Murray, SA; Sheikh, A				Grant, Liz; Murray, Scott A.; Sheikh, Aziz			Spotlight: Palliative Care Beyond Cancer Spiritual dimensions of dying in pluralist societies	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LUNG-CANCER; ILLNESS; PEOPLE; NEEDS; LIFE		Univ Edinburgh, Ctr Pop Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Scotland	University of Edinburgh	Sheikh, A (corresponding author), Univ Edinburgh, Ctr Pop Hlth Sci, Primary Palliat Care Res Grp, Edinburgh, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; Grant, Liz/0000-0001-7248-7792	COMPASS Collaborative; National Cancer Research Institute; Office of the Scottish Government	COMPASS Collaborative; National Cancer Research Institute; Office of the Scottish Government	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; AS and SM are grantholders on the COMPASS Collaborative, a programme grant for the development and evaluation of complex interventions in end of life care, which is supported by the National Cancer Research Institute; LG, SM, and AS had support from the Chief Scientist's Office of the Scottish Government, which has informed the submitted work; no other relationships or activities that could appear to have influenced the submitted work.	Breitbart William, 2009, Palliat Support Care, V7, P139, DOI 10.1017/S1478951509000182; Bryson Kenneth A, 2004, Palliat Support Care, V2, P321; CARPENITOMOYET L, 2008, HDB NURSING DIAGNOSI, P639; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; FOWLER M, 1997, J SUPERVISION TRAINI, V18, P46; Frankl V. E., 1984, MANS SEARCH MEANING; Gatrad AR, 2003, LANCET, V362, P748, DOI 10.1016/S0140-6736(03)14219-5; Gatrad AR, 2003, BRIT MED J, V327, P176, DOI 10.1136/bmj.327.7408.176; GATRAD AR, 2006, PALLIATIVE CARE S AS; *GEN MED COUNC, 2009, END LIF TREATM CAR G; Grant E, 2003, J PALLIATIVE CARE, V19, P159, DOI 10.1177/082585970301900303; Grant Elizabeth, 2004, Palliat Support Care, V2, P371; *I MED, 1997, APPR DEATH IMPR CAR; Kissane DW, 2001, J PALLIAT CARE, V17, P12, DOI 10.1177/082585970101700103; LLOYDWILLIAMS M, 2003, PSYCHOSOCIAL ISSUES; *M CUR CANC CAR, 1980, SPIR REL CAR COMP SP; McClain CS, 2003, LANCET, V361, P1603, DOI 10.1016/S0140-6736(03)13310-7; Meador Keith G, 2004, N C Med J, V65, P226; Murray SA, 2004, PALLIATIVE MED, V18, P39, DOI 10.1191/0269216304pm837oa; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murray SA, 2003, BRIT J GEN PRACT, V53, P957; Murray SA, 2007, J PAIN SYMPTOM MANAG, V34, P393, DOI 10.1016/j.jpainsymman.2006.12.009; Narayanasamy Aru, 2002, Br J Nurs, V11, P948; National Institute for Health and Clinical Excellence, 2004, IMPR SUPP PALL CAR A; Puchalski C, 2004, CRIT CARE CLIN, V20, P487, DOI 10.1016/j.ccc.2004.03.007; Sheikh A, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a273; Sloan RP, 1999, LANCET, V353, P664, DOI 10.1016/S0140-6736(98)07376-0; Sweeney K, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2862; who, WHO DEF PALL CAR; Worth A, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b183	30	17	18	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	2010	341								c4859	10.1136/bmj.c4859	http://dx.doi.org/10.1136/bmj.c4859			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847019	Green Submitted			2023-01-03	WOS:000282095800012
J	Santosham, M; Chandran, A; Fitzwater, S; Fischer-Walker, C; Baqui, AH; Black, R				Santosham, Mathuram; Chandran, Aruna; Fitzwater, Sean; Fischer-Walker, Christa; Baqui, Abdullah H.; Black, Robert			Progress and barriers for the control of diarrhoeal disease	LANCET			English	Review							ZINC SUPPLEMENTATION; ORAL REHYDRATION; MORTALITY; COUNTRIES; CHILDREN	Discovery of intestinal sodium-glucose transport was the basis for development of oral rehydration solution, and was hailed as potentially the most important medical advance of the 20th century. Before widespread use of oral rehydration solution, treatment for diarrhoea was restricted to intravenous fluid replacement, for which patients had to go to a health-care facility to access appropriate equipment. These facilities were usually neither available nor reasonable to use in the resource-poor settings most affected by diarrhoea. Use of oral rehydration solution has stagnated, despite being effective, inexpensive, and widely available. Thus, diarrhoea continues to be a leading cause of child death with consistent mortality rates during the past 5 years. New methods for prevention, management, and treatment of diarrhoea-including an improved oral rehydration formulation, zinc supplementation, and rotavirus vaccines-make now the time to revitalise efforts to reduce diarrhoea mortality worldwide.	[Santosham, Mathuram; Chandran, Aruna; Fitzwater, Sean; Fischer-Walker, Christa; Baqui, Abdullah H.; Black, Robert] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Santosham, M (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.	msantosh@jhsph.edu		Black, Robert/0000-0001-9926-7984				[Anonymous], 1978, LANCET, V2, P300; [Anonymous], 2009, Wkly Epidemiol Rec, V84, P220; Awasthi S, 2006, J PEDIATR GASTR NUTR, V42, P300; Baqui AH, 2002, BRIT MED J, V325, P1059, DOI 10.1136/bmj.325.7372.1059; Bhandari N, 2008, PEDIATRICS, V121, pE1279, DOI 10.1542/peds.2007-1939; Bhutta ZA, 1999, J PEDIATR-US, V135, P689, DOI 10.1016/S0022-3476(99)70086-7; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; CLAESON M, 1990, PEDIATR INFECT DIS J, V9, P345, DOI 10.1097/00006454-199005000-00008; ELRAFIE M, 1990, LANCET, V335, P334; Forsberg BC, 2007, B WORLD HEALTH ORGAN, V85, P42, DOI 10.2471/BLT.06.030866; Hahn S., 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002847; Howteerakul N, 2003, SOC SCI MED, V57, P1031, DOI 10.1016/S0277-9536(02)00478-1; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Lazzerini M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005436.pub2; MILLER P, 1995, SOC SCI MED, V40, pS1, DOI 10.1016/0277-9536(95)00001-N; Podewils Laura Jean, 2004, Semin Pediatr Infect Dis, V15, P155, DOI 10.1053/j.spid.2004.05.008; Ryland S, 1998, DHS COMP STUDIES; Santosham M, 1987, Pediatr Rev, V8, P273, DOI 10.1542/pir.8-9-273; Santosham M, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.5.e10; Taneja D K, 1996, Indian Pediatr, V33, P117; TAYLOR CE, 1989, ANNU REV PUBL HEALTH, V10, P221, DOI 10.1146/annurev.pu.10.050189.001253; *UNICEF OFF STAT M, CHILD MON SIT CHILDR; Victora CG, 2000, B WORLD HEALTH ORGAN, V78, P1246; Victora CG, 1996, HEALTH POLICY PLANN, V11, P132, DOI 10.1093/heapol/11.2.132; Walker CLF, 2009, B WORLD HEALTH ORGAN, V87, P780, DOI 10.2471/BLT.08.058990; WHO/UNICEF, 2009, DIARRH WHY CHILDR AR; WHO/UNICEF, 2004, CLIN MAN AC DIARRH; World Health Organization, 2003, AN REV INT MAN CHILD; World Health Organization, 2005, TREATM DIARRH MAN PH; 1988, WKLY EPIDEMIOL REC, V63, P49; 2009, ICF MACRO DEMOGRAPHI	31	154	162	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2010	376	9734					63	67		10.1016/S0140-6736(10)60356-X	http://dx.doi.org/10.1016/S0140-6736(10)60356-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	624SR	20609988				2023-01-03	WOS:000279841600025
J	Shapiro, RL; Hughes, MD; Ogwu, A; Kitch, D; Lockman, S; Moffat, C; Makhema, J; Moyo, S; Thior, I; McIntosh, K; van Widenfelt, E; Leidner, J; Powis, K; Asmelash, A; Tumbare, E; Zwerski, S; Sharma, U; Handelsman, E; Mburu, K; Jayeoba, O; Moko, E; Souda, S; Lubega, E; Akhtar, M; Wester, C; Tuomola, R; Snowden, W; Martinez-Tristani, M; Mazhani, L; Essex, M				Shapiro, R. L.; Hughes, M. D.; Ogwu, A.; Kitch, D.; Lockman, S.; Moffat, C.; Makhema, J.; Moyo, S.; Thior, I.; McIntosh, K.; van Widenfelt, E.; Leidner, J.; Powis, K.; Asmelash, A.; Tumbare, E.; Zwerski, S.; Sharma, U.; Handelsman, E.; Mburu, K.; Jayeoba, O.; Moko, E.; Souda, S.; Lubega, E.; Akhtar, M.; Wester, C.; Tuomola, R.; Snowden, W.; Martinez-Tristani, M.; Mazhani, L.; Essex, M.			Antiretroviral Regimens in Pregnancy and Breast-Feeding in Botswana	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOTHER-TO-CHILD; HIV-INFECTED WOMEN; LOW-BIRTH-WEIGHT; RANDOMIZED-TRIAL; PREMATURE DELIVERY; LOPINAVIR EXPOSURE; EQUIVALENCE TRIAL; PRETERM DELIVERY; INCREASED RISK; COTE-DIVOIRE	Background The most effective highly active antiretroviral therapy (HAART) to prevent mother-to-child transmission of human immunodeficiency virus type 1 (HIV-1) in pregnancy and its efficacy during breast-feeding are unknown. Methods We randomly assigned 560 HIV-1-infected pregnant women (CD4+ count, >= 200 cells per cubic millimeter) to receive coformulated abacavir, zidovudine, and lamivudine (the nucleoside reverse-transcriptase inhibitor [NRTI] group) or lopinavir-ritonavir plus zidovudine-lamivudine (the protease-inhibitor group) from 26 to 34 weeks' gestation through planned weaning by 6 months post partum. A total of 170 women with CD4+ counts of less than 200 cells per cubic millimeter received nevirapine plus zidovu-dine-lamivudine (the observational group). Infants received single-dose nevirapine and 4 weeks of zidovudine. Results The rate of virologic suppression to less than 400 copies per milliliter was high and did not differ significantly among the three groups at delivery (96% in the NRTI group, 93% in the protease-inhibitor group, and 94% in the observational group) or throughout the breast-feeding period (92% in the NRTI group, 93% in the protease-inhibitor group, and 95% in the observational group). By 6 months of age, 8 of 709 live-born infants (1.1%) were infected (95% confidence interval [CI], 0.5 to 2.2): 6 were infected in utero (4 in the NRTI group, 1 in the protease-inhibitor group, and 1 in the observational group), and 2 were infected during the breast-feeding period (in the NRTI group). Treatment-limiting adverse events occurred in 2% of women in the NRTI group, 2% of women in the protease-inhibitor group, and 11% of women in the observational group. Conclusions All regimens of HAART from pregnancy through 6 months post partum resulted in high rates of virologic suppression, with an overall rate of mother-to-child transmission of 1.1%. (ClinicalTrials.gov number, NCT00270296.)	[Shapiro, R. L.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; [Shapiro, R. L.; Lockman, S.; Thior, I.; McIntosh, K.; Leidner, J.; Essex, M.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; [Hughes, M. D.; Kitch, D.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Lockman, S.] Brigham & Womens Hosp, Infect Dis Unit, Boston, MA 02115 USA; [Tuomola, R.] Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; [McIntosh, K.] Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA; [Powis, K.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Powis, K.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA; [Ogwu, A.; Moffat, C.; Makhema, J.; Moyo, S.; Thior, I.; van Widenfelt, E.; Asmelash, A.; Tumbare, E.; Mburu, K.; Jayeoba, O.; Moko, E.; Souda, S.; Lubega, E.; Akhtar, M.; Wester, C.] Botswana Harvard AIDS Inst, Gaborone, Botswana; [Mazhani, L.] Botswana Minist Hlth, Gaborone, Botswana; [Zwerski, S.; Sharma, U.; Handelsman, E.] NIAID, NIH, Bethesda, MD 20892 USA; [Snowden, W.] GlaxoSmithKline Inc, Greenford, Middx, England; [Martinez-Tristani, M.] Abbott Virol, Abbott Pk, IL USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Botswana-Harvard AIDS Institute Partnership; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); GlaxoSmithKline	Shapiro, RL (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, 110 Francis St,Suite GB, Boston, MA 02215 USA.	rshapiro@hsph.harvard.edu	Powis, Kathleen/AAU-5123-2021; Moyo, Sikhulile/E-1464-2015	Moyo, Sikhulile/0000-0003-3821-4592	National Institute of Allergy and Infectious Diseases [U01-AI066454]; Fogarty International Cente [D43 TW00004]; FOGARTY INTERNATIONAL CENTER [D43TW000004] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066454] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Fogarty International Cente(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a grant (U01-AI066454) from the National Institute of Allergy and Infectious Diseases and by a grant (D43 TW00004) from the Fogarty International Center, which supported several of the trainees who were involved in this study.	Aebi C, 2000, AIDS, V14, P2913, DOI 10.1097/00002030-200012220-00013; ARENDT V, 2007, 4 INT AIDS SOC C HIV; Bouillon-Pichault M, 2009, J ANTIMICROB CHEMOTH, V63, P1223, DOI 10.1093/jac/dkp123; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x; Bussmann H, 2009, JAIDS-J ACQ IMM DEF, V51, P37, DOI 10.1097/QAI.0b013e31819ff102; Chasela C, 2009, 5 INT AIDS SOC C HIV; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Cotter AM, 2006, J INFECT DIS, V193, P1195, DOI 10.1086/503045; De Vincenzi I, 2009, 5 INT AIDS SOC C HIV; Dorenbaum A, 2002, JAMA-J AM MED ASSOC, V288, P189, DOI 10.1001/jama.288.2.189; Ekouevi DK, 2008, AIDS, V22, P1815, DOI 10.1097/QAD.0b013e32830b8ab9; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Kaleebu P, 2006, AIDS, V20, P1391, DOI 10.1097/01.aids.0000233572.59522.45; Kilewo C, 2009, JAIDS-J ACQ IMM DEF, V52, P406, DOI 10.1097/QAI.0b013e3181b323ff; Kourtis AP, 2007, AIDS, V21, P607, DOI 10.1097/QAD.0b013e32802ef2f6; Kumar Princy N, 2009, AIDS Res Ther, V6, P3, DOI 10.1186/1742-6405-6-3; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; Leroy V, 2002, AIDS, V16, P631, DOI 10.1097/00002030-200203080-00016; Leroy V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001645; Lockman S, 2009, 16 C RETR OPP INF MO; Lockman S, 2007, NEW ENGL J MED, V356, P135, DOI 10.1056/NEJMoa062876; Lyons F, 2007, AIDS, V21, P1053, DOI 10.1097/QAD.0b013e3281053a1e; Martin F, 2007, J INFECT DIS, V196, P558, DOI 10.1086/519848; Mirochnick M, 2008, JAIDS-J ACQ IMM DEF, V49, P485, DOI 10.1097/QAI.0b013e318186edd0; Palombi L, 2007, AIDS, V21, pS65, DOI 10.1097/01.aids.0000279708.09180.f5; *PUBL HLTH SERV TA, REC US ANT DRUGS PRE; Rollins NC, 2007, JAIDS-J ACQ IMM DEF, V44, P321, DOI 10.1097/QAI.0b013e31802ea4b0; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; Stek AM, 2006, AIDS, V20, P1931, DOI 10.1097/01.aids.0000247114.43714.90; Szyld EG, 2006, AIDS, V20, P2345, DOI 10.1097/01.aids.0000253362.01696.9d; TEMMERMAN M, 1990, AIDS, V4, P1087, DOI 10.1097/00002030-199011000-00006; Thior I, 2006, JAMA-J AM MED ASSOC, V296, P794, DOI 10.1001/jama.296.7.794; THOMAS T, 2008, 15 C RETR OPP INF BO; Thorne C, 2004, AIDS, V18, P2337, DOI 10.1097/00002030-200411190-00019; Townsend CL, 2007, AIDS, V21, P1019, DOI 10.1097/QAD.0b013e328133884b; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; Tuomala RK, 2005, JAIDS-J ACQ IMM DEF, V38, P449, DOI 10.1097/01.qai.0000139398.38236.4d; Vibhagool A, 2004, CURR MED RES OPIN, V20, P1103, DOI 10.1185/030079904125004006; WHO, 2006, ANT DRUGS TREAT PREG; WHO UNAIDS UNICEF, 2007, UN ACC SCAL PRIOR HI; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; 2006, MMWR MORB MORTAL WKL, V55, P592; 2002, LANCET, V359, P1178	44	362	370	0	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 17	2010	362	24					2282	2294		10.1056/NEJMoa0907736	http://dx.doi.org/10.1056/NEJMoa0907736			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611LJ	20554983	Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000278816300007
J	Cools, F; Askie, LM; Offringa, M; Asselin, JM; Calvert, SA; Courtney, SE; Dani, C; Durand, DJ; Gerstmann, DR; Henderson-Smart, DJ; Marlow, N; Peacock, JL; Pillow, JJ; Soll, RF; Thome, UH; Truffert, P; Schreiber, MD; Van Reempts, P; Vendettuoli, V; Vento, G				Cools, Filip; Askie, Lisa M.; Offringa, Martin; Asselin, Jeanette M.; Calvert, Sandra A.; Courtney, Sherry E.; Dani, Carlo; Durand, David J.; Gerstmann, Dale R.; Henderson-Smart, David J.; Marlow, Neil; Peacock, Janet L.; Pillow, J. Jane; Soll, Roger F.; Thome, Ulrich H.; Truffert, Patrick; Schreiber, Michael D.; Van Reempts, Patrick; Vendettuoli, Valentina; Vento, Giovanni		PreVILIG Collaboration	Elective high-frequency oscillatory versus conventional ventilation in preterm infants: a systematic review and meta-analysis of individual patients' data	LANCET			English	Article							RESPIRATORY-DISTRESS-SYNDROME; MECHANICAL VENTILATION; LUNG INFLAMMATION; RANDOMIZED-TRIAL; VOLUME GUARANTEE; BLOOD-FLOW; PULMONARY; PRESSURE; DISEASE; INJURY	Background Population and study design heterogeneity has confounded previous meta-analyses, leading to uncertainty about effectiveness and safety of elective high-frequency oscillatory ventilation (HFOV) in preterrn infants. We assessed effectiveness of elective HFOV versus conventional ventilation in this group. Methods We did a systematic review and meta-analysis of individual patients' data from 3229 participants in ten randomised controlled trials, with the primary outcomes of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age, death or severe adverse neurological event, or any of these outcomes. Findings For infants ventilated with HFOV, the relative risk of death or bronchopulmonary dysplasia at 36 weeks' postmenstrual age was 0.95 (95% CI 0.88-1.03), of death or severe adverse neurological event 1.00 (0.88-1.13), or any of these outcomes 0.98 (0.91-1.05). No subgroup of infants (eg, gestational age, birthweight for gestation, initial lung disease severity, or exposure to antenatal corticosteroids) benefited more or less from HFOV. Ventilator type or ventilation strategy did not change the overall treatment effect. Interpretation HFOV seems equally effective to conventional ventilation in preterm infants. Our results do not support selection of preterm infants for HFOV on the basis of gestational age, birthweight for gestation, initial lung disease severity, or exposure to antenatal corticosteroids.	[Cools, Filip] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Neonatal Intens Care Unit, B-1090 Brussels, Belgium; [Askie, Lisa M.] Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia; [Offringa, Martin] Univ Amsterdam, Acad Med Ctr, Dept Neonatol, NL-1105 AZ Amsterdam, Netherlands; [Asselin, Jeanette M.; Durand, David J.] Childrens Hosp, Div Neonatol, Oakland, CA 94609 USA; [Asselin, Jeanette M.; Durand, David J.] Res Ctr Oakland, Oakland, CA USA; [Calvert, Sandra A.] Univ London St Georges Hosp, Neonatol Unit, Dept Child Hlth, London, England; [Courtney, Sherry E.] SUNY Stony Brook, Med Ctr, Dept Neonatol, Stony Brook, NY 11794 USA; [Dani, Carlo] Univ Florence, Sect Neonatol, Dept Surg & Med Crit Care, Florence, Italy; [Gerstmann, Dale R.] Timpanogos Reg Hosp, Neonatal Intens Care Unit, Orem, UT USA; [Henderson-Smart, David J.] Univ Sydney, Ctr Perinatal Hlth Serv Res, Sydney, NSW 2006, Australia; [Marlow, Neil] UCL, Dept Acad Neonatol, Elizabeth Garrett Anderson Inst Womens Hlth, London, England; [Peacock, Janet L.] Univ Southampton, Southampton Gen Hosp, Sch Med, Southampton, Hants, England; [Pillow, J. Jane] Univ Western Australia, Sch Womens & Infants Hlth, King Edward Mem Hosp, Subiaco, WA, Australia; [Soll, Roger F.] Fletcher Allen Hlth Care, Div Neonatal Perinatal Med, Burlington, VT USA; [Thome, Ulrich H.] Univ Hosp Children & Adolescents, Womens & Childrens Hosp, Dept Neonatol, Leipzig, Germany; [Truffert, Patrick] Univ Lille, Jeanne Flanders Hosp, Reg Hosp Ctr, Lille, France; [Schreiber, Michael D.] Univ Chicago, Med Ctr, Dept Pediat, Chicago, IL 60637 USA; [Van Reempts, Patrick] Univ Antwerp Hosp, Dept Neonatol, Antwerp, Belgium; [Vendettuoli, Valentina] Univ Milan, Dept Maternal & Paediat Sci, Div Neonatol, Milan, Italy; [Vento, Giovanni] Univ Cattolica Sacro Cuore, Dept Paediat, Div Neonatol, I-00168 Rome, Italy	University Hospital Brussels; Vrije Universiteit Brussel; University of Sydney; University of Amsterdam; Academic Medical Center Amsterdam; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; St Georges University London; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Florence; University of Sydney; University of London; University College London; University of Southampton; King Edward Memorial Hospital; University of Western Australia; University of Vermont Medical Center; Leipzig University; Universite de Lille - ISITE; CHU Lille; Universite de Lille; University of Chicago; University of Chicago Medical Center; University of Antwerp; University of Milan; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Cools, F (corresponding author), Vrije Univ Brussel, Univ Ziekenhuis Brussel, Neonatal Intens Care Unit, Laarbeeklaan 101, B-1090 Brussels, Belgium.	filip.cools@uzbrussel.be	Marlow, Neil/D-2918-2009; Pillow, Jane/A-3335-2009; Plavka, Richard/K-2222-2017	Marlow, Neil/0000-0001-5890-2953; Pillow, Jane/0000-0002-6500-0138; Vento, Giovanni/0000-0003-3121-9569; Plavka, Richard/0000-0003-2579-2393; Durand, David/0000-0003-1181-0941; Cools, Filip/0000-0002-6581-7009; Offringa, Martin/0000-0002-4402-5299; Peacock, Janet/0000-0002-0310-2518	Nestle Belgium; Belgian Red Cross; Drager International	Nestle Belgium(Nestle SA); Belgian Red Cross; Drager International	Funding Nestle Belgium, Belgian Red Cross, and Drager International.	Bjorklund LJ, 1997, PEDIATR RES, V42, P348; Cambonie G, 2003, ACTA PAEDIATR, V92, P1068, DOI 10.1080/08035250310004856; CLARK RH, 1992, PEDIATRICS, V89, P5; Cools F, 2009, COCHRANE DB SYST REV, V3; Cools F, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-33; Courtney SE, 2002, NEW ENGL J MED, V347, P643, DOI 10.1056/NEJMoa012750; Courtney SE, 2003, CRIT CARE, V7, P423, DOI 10.1186/cc2178; Craft Alissa P, 2003, J Perinatol, V23, P14; Dani C, 2006, PEDIATR PULM, V41, P242, DOI 10.1002/ppul.20350; Doyle LW, 2006, PEDIATRICS, V118, P108, DOI 10.1542/peds.2005-2522; Durand D J, 2001, J Perinatol, V21, P221, DOI 10.1038/sj.jp.7210527; GARNER A, 1984, PEDIATRICS, V74, P127; Gerstmann DR, 1996, PEDIATRICS, V98, P1044; HENDERSONSMART DJ, 2007, COCHRANE DB SYST REV, V3, P104; HIFI Study Group, 1989, N Engl J Med, V320, P88; Johnson AH, 2002, NEW ENGL J MED, V347, P633, DOI 10.1056/NEJMoa020432; Katz-Salamon M, 2000, ARCH DIS CHILD-FETAL, V83, pF1, DOI 10.1136/fn.83.1.F1; Lambert PC, 2002, J CLIN EPIDEMIOL, V55, P86, DOI 10.1016/S0895-4356(01)00414-0; Lemons JA, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.1.e1; Lista G, 2008, ARCH DIS CHILD-FETAL, V93, pF252, DOI 10.1136/adc.2006.112102; MCCULLOCH PR, 1988, AM REV RESPIR DIS, V137, P1185, DOI 10.1164/ajrccm/137.5.1185; MEREDITH KS, 1989, J APPL PHYSIOL, V66, P2150, DOI 10.1152/jappl.1989.66.5.2150; Moriette G, 2001, PEDIATRICS, V107, P363, DOI 10.1542/peds.107.2.363; OGAWA Y, 1993, EARLY HUM DEV, V32, P1, DOI 10.1016/0378-3782(93)90088-C; Osborn DA, 2003, J PEDIATR-US, V143, P192, DOI 10.1067/S0022-3476(03)00359-7; PAPILE LU, 1987, J PEDIAT, V92, P529; Pillow JJ, 2001, AM J RESP CRIT CARE, V164, P1019, DOI 10.1164/ajrccm.164.6.2005008; Pillow JJ, 1999, J APPL PHYSIOL, V87, P407, DOI 10.1152/jappl.1999.87.1.407; Plavka R, 1999, INTENS CARE MED, V25, P68, DOI 10.1007/s001340050789; Polglase GR, 2008, J APPL PHYSIOL, V105, P603, DOI 10.1152/japplphysiol.00041.2008; Rettwitz-Volk W, 1998, J PEDIATR-US, V132, P249, DOI 10.1016/S0022-3476(98)70440-8; Schreiber MD, 2003, NEW ENGL J MED, V349, P2099, DOI 10.1056/NEJMoa031154; Simmonds MC, 2005, CLIN TRIALS, V2, P209, DOI 10.1191/1740774505cn087oa; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Termote J, 2000, J PEDIAT OPHTH STRAB, V37, P142; Thome U, 1999, J PEDIATR-US, V135, P39, DOI 10.1016/S0022-3476(99)70325-2; Van Reempts P, 2003, EUR J PEDIATR, V162, P219, DOI 10.1007/s00431-002-01145-z; Vento G, 2005, INTENS CARE MED, V31, P463, DOI 10.1007/s00134-005-2556-x	38	87	93	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2010	375	9731					2082	2091		10.1016/S0140-6736(10)60278-4	http://dx.doi.org/10.1016/S0140-6736(10)60278-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	614OK	20552718				2023-01-03	WOS:000279069300020
J	Hagan, CL; Kim, S; Kahne, D				Hagan, Christine L.; Kim, Seokhee; Kahne, Daniel			Reconstitution of Outer Membrane Protein Assembly from Purified Components	SCIENCE			English	Article							BETA-BARREL PROTEINS; ESCHERICHIA-COLI; YAET COMPLEX; IN-VITRO; TRANSLOCATION; SURA; PROTEOLIPOSOMES; IDENTIFICATION; BIOGENESIS; SECA	beta-barrel membrane proteins in Gram-negative bacteria, mitochondria, and chloroplasts are assembled by highly conserved multi-protein complexes. The mechanism by which these molecular machines fold and insert their substrates is poorly understood. It has not been possible to dissect the folding and insertion pathway because the process has not been reproduced in a biochemical system. We purified the components that fold and insert Escherichia coli outer membrane proteins and reconstituted beta-barrel protein assembly in proteoliposomes using the enzymatic activity of a protein substrate to report on its folding state. The assembly of this protein occurred without an energy source but required a soluble chaperone in addition to the multi-protein assembly complex.	[Hagan, Christine L.; Kim, Seokhee; Kahne, Daniel] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; [Kahne, Daniel] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Kahne, D (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.	kahne@chemistry.harvard.edu	Kim, Seokhee/C-2303-2018	Kim, Seokhee/0000-0003-0806-583X	NIH [AI081059]; NSF; Amherst College; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI081059] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Amherst College; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The Biophysics Resource of the Keck Facility at Yale University performed the size exclusion-light scattering analysis and amino acid analysis. This work is supported by NIH grant AI081059. C. L. H. is supported by a NSF Graduate Research Fellowship and a Kellogg fellowship from Amherst College.	AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Burgess NK, 2008, J BIOL CHEM, V283, P26748, DOI 10.1074/jbc.M802754200; Driessen AJM, 2008, ANNU REV BIOCHEM, V77, P643, DOI 10.1146/annurev.biochem.77.061606.160747; Eggert US, 2001, SCIENCE, V294, P361, DOI 10.1126/science.1063611; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hennecke G, 2005, J BIOL CHEM, V280, P23540, DOI 10.1074/jbc.M413742200; Ieva R, 2009, P NATL ACAD SCI USA, V106, P19120, DOI 10.1073/pnas.0907912106; Jansen C, 2000, EUR J BIOCHEM, V267, P3792, DOI 10.1046/j.1432-1327.2000.01417.x; Kim S, 2007, SCIENCE, V317, P961, DOI 10.1126/science.1143993; Kleinschmidt JH, 2006, CHEM PHYS LIPIDS, V141, P30, DOI 10.1016/j.chemphyslip.2006.02.004; Kramer RA, 2000, EUR J BIOCHEM, V267, P885, DOI 10.1046/j.1432-1327.2000.01073.x; Kutik S, 2008, CELL, V132, P1011, DOI 10.1016/j.cell.2008.01.028; Malinverni JC, 2006, MOL MICROBIOL, V61, P151, DOI 10.1111/j.1365-2958.2006.05211.x; Mogensen JE, 2005, MOL MICROBIOL, V57, P326, DOI 10.1111/j.1365-2958.2005.04674.x; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; Onufryk C, 2005, J BACTERIOL, V187, P4552, DOI 10.1128/JB.187.13.4552-4561.2005; Paschen SA, 2003, NATURE, V426, P862, DOI 10.1038/nature02208; Reumann S, 1999, P NATL ACAD SCI USA, V96, P784, DOI 10.1073/pnas.96.2.784; Rizzitello AE, 2001, J BACTERIOL, V183, P6794, DOI 10.1128/JB.183.23.6794-6800.2001; Ruiz N, 2005, CELL, V121, P307, DOI 10.1016/j.cell.2005.02.014; Sklar JG, 2007, GENE DEV, V21, P2473, DOI 10.1101/gad.1581007; Sklar JG, 2007, P NATL ACAD SCI USA, V104, P6400, DOI 10.1073/pnas.0701579104; Ureta AR, 2007, J BACTERIOL, V189, P446, DOI 10.1128/JB.01103-06; Vertommen D, 2009, PROTEOMICS, V9, P2432, DOI 10.1002/pmic.200800794; Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973; Wiedemann N, 2003, NATURE, V424, P565, DOI 10.1038/nature01753; Wimley WC, 2003, CURR OPIN STRUC BIOL, V13, P404, DOI 10.1016/S0959-440X(03)00099-X; Wu T, 2005, CELL, V121, P235, DOI 10.1016/j.cell.2005.02.015; Xu XH, 2007, J MOL BIOL, V373, P367, DOI 10.1016/j.jmb.2007.07.069; Yakushi T, 2000, NAT CELL BIOL, V2, P212, DOI 10.1038/35008635	31	195	205	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 14	2010	328	5980					890	892		10.1126/science.1188919	http://dx.doi.org/10.1126/science.1188919			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	595NT	20378773	Green Accepted			2023-01-03	WOS:000277618800048
J	Koek, MBG; Sigurdsson, V; van Weelden, H; Steegmans, PHA; Bruijnzeel-Koomen, CAFM; Buskens, E				Koek, Mayke B. G.; Sigurdsson, Vigfus; van Weelden, Huib; Steegmans, Paul H. A.; Bruijnzeel-Koomen, Carla A. F. M.; Buskens, Erik			Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EARLY MYCOSIS-FUNGOIDES; UVB PHOTOTHERAPY; HEALTH-CARE; PATIENT; PRODUCTIVITY; GUIDELINES; MANAGEMENT; ACITRETIN; SEVERITY; MODERATE	Objective To assess the costs and cost effectiveness of phototherapy with ultraviolet B light provided at home compared with outpatient ultraviolet B phototherapy for psoriasis. Design Cost utility, cost effectiveness, and cost minimisation analyses performed alongside a pragmatic randomised clinical trial (the PLUTO study) at the end of phototherapy (mean 17.6 weeks) and at one year after the end of phototherapy (mean 68.4 weeks). Setting Secondary care, provided by a dermatologist in the Netherlands. Participants 196 adults with psoriasis who were clinically eligible for narrowband (TL-01) ultraviolet B phototherapy were recruited from the dermatology departments of 14 hospitals and were followed until the end of phototherapy. From the end of phototherapy onwards, follow-up was continued for an unselected, consecutive group of 105 patients for one year after end of phototherapy. Interventions Ultraviolet B phototherapy provided at home (intervention) and conventional outpatient ultraviolet B phototherapy (control) in a setting reflecting routine practice in the Netherlands. Both treatments used narrowband ultraviolet B lamps (TL-01). Main outcome measures Total costs to society, quality adjusted life years (QALYs) as calculated using utilities measured by the EQ-5D questionnaire, and the number of days with a relevant treatment effect (>= 50% improvement of the baseline self administered psoriasis area and severity index (SAPASI)). Results Home phototherapy is at least as effective and safe as outpatient phototherapy, therefore allowing cost minimisation analyses (simply comparing costs). The average total costs by the end of phototherapy were (sic)800 for home treatment and (sic)752 for outpatient treatment, showing an incremental cost per patient of (sic)48 (95% CI (sic)-77 to (sic)174). The average total costs by one year after the end of phototherapy were (sic)1272 and (sic)1148 respectively (difference (sic)124, 95% CI (sic)-155 to (sic)403). Cost utility analyses revealed that patients experienced equal health benefits-that is, a gain of 0.296 versus 0.291 QALY (home v outpatient) by the end of phototherapy (difference 0.0052, -0.0244 to 0.0348) and 1.153 versus 1.126 QALY by one year after the end of phototherapy (difference 0.0267, -0.024 to 0.078). Incremental costs per QALY gained were (sic)9276 and (sic)4646 respectively, both amounts well below the normally accepted standard of (sic)20 000 per QALY. Cost effectiveness analyses indicated that the mean number of days with a relevant treatment effect was 42.4 versus 55.3 by the end of phototherapy (difference -12.9, -23.4 to -2.4). By one year after the end of phototherapy the number of days with a relevant treatment effect were 216.5 and 210.4 respectively (6.1, -41.1 to 53.2), yielding an incremental cost of (sic)20 per additional day with a relevant treatment effect. Conclusions Home ultraviolet B phototherapy for psoriasis is not more expensive than phototherapy in an outpatient setting and proved to be cost effective. As both treatments are at least equally effective and patients express a preference for home treatment, the authors conclude that home phototherapy should be the primary treatment option for patients who are eligible for phototherapy with ultraviolet B light.	[Koek, Mayke B. G.; Sigurdsson, Vigfus; van Weelden, Huib; Bruijnzeel-Koomen, Carla A. F. M.] Univ Med Ctr Utrecht, Dept Dermatol Allergol G02 124, NL-3584 CX Utrecht, Netherlands; [Steegmans, Paul H. A.] St Antonius Hosp, Dept Dermatol, NL-3435 CM Nieuwegein, Netherlands; [Buskens, Erik] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 GZ Groningen, Netherlands; [Buskens, Erik] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; St. Antonius Hospital Utrecht; University of Groningen; Utrecht University; Utrecht University Medical Center	Koek, MBG (corresponding author), Univ Med Ctr Utrecht, Dept Dermatol Allergol G02 124, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	author@koek.com			Netherlands Organisation for Health Research and Development (ZonMW) [945-02-017]	Netherlands Organisation for Health Research and Development (ZonMW)(Netherlands Organization for Health Research and Development)	This study was supported by grant 945-02-017 from the Netherlands Organisation for Health Research and Development (ZonMW). ZonMW had no role in the study design; collection, analysis, and interpretation of data; production of the manuscript; or the decision to submit the article for publication. The researchers are independent from the funders.	ABEL EA, 1985, CUTIS, V35, P127; Anstey A, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b607; Barbagallo J, 2001, CUTIS, V68, P345; Bilsland D, 1997, BRIT J DERMATOL, V137, P327, DOI 10.1046/j.1365-2133.1997.18441939.x; Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8; Brazier J, 2004, HEALTH ECON, V13, P873, DOI 10.1002/hec.866; Cameron H, 2002, BRIT J DERMATOL, V147, P957, DOI 10.1046/j.1365-2133.2002.04860.x; de Rie MA, 2001, DERMATOLOGY, V202, P38, DOI 10.1159/000051583; *DUTCH HLTH CAR IN, 2003, MED GUID 2003; Feldman SR, 1996, J INVEST DERMATOL, V106, P183, DOI 10.1111/1523-1747.ep12329912; Feldman SR, 2003, EXPERT OPIN PHARMACO, V4, P1525, DOI 10.1517/eoph.4.9.1525.21059; Feldman SR, 1996, CUTIS, V58, P71; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; FLEISCHER AB, 1994, J INVEST DERMATOL, V102, P967, DOI 10.1111/1523-1747.ep12384205; Fleischer Alan B. Jr., 1999, Journal of Dermatology (Tokyo), V26, P210; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Ibbotson SH, 2004, BRIT J DERMATOL, V151, P283, DOI 10.1111/j.1365-2133.2004.06128.x; Jacob-Tacken KHM, 2005, HEALTH ECON, V14, P435, DOI 10.1002/hec.948; JORDAN WP, 1981, J AM ACAD DERMATOL, V4, P584, DOI 10.1016/S0190-9622(81)70061-6; Koek Mayke B G, 2006, BMC Med Res Methodol, V6, P39, DOI 10.1186/1471-2288-6-39; Koek MBG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1542; Koek MBG, 2006, BRIT J DERMATOL, V154, P701, DOI 10.1111/j.1365-2133.2006.07136.x; LARKO O, 1979, BRIT J DERMATOL, V101, P13, DOI 10.1111/j.1365-2133.1979.tb15286.x; LOWE NJ, 1992, SEMIN DERMATOL, V11, P284; MATTO DM, 2003, MED CONTACT, V58, P950; MILSTEIN HJ, 1982, J AM ACAD DERMATOL, V6, P355, DOI 10.1016/S0190-9622(82)70029-5; Naldi L, 2005, BRIT J DERMATOL, V152, P597, DOI 10.1111/j.1365-2133.2005.06563.x; *NAT HLTH TAR AUTH, 2006, ONL PRIC LISTS; Oostenbrink JB, 2004, MANUAL COSTING METHO; RESNIK KS, 1993, J AM ACAD DERMATOL, V29, P73, DOI 10.1016/0190-9622(93)70155-M; *ROYAL DUTCH ASS A, 2006, PRIC REIMB SYST MED; Severens JL, 1998, ALIMENT PHARM THERAP, V12, P919, DOI 10.1046/j.1365-2036.1998.00376.x; Simpson GL, 2006, J DERMATOL TREAT, V17, P359, DOI 10.1080/09546630601028786; Spuls PI, 1998, ARCH DERMATOL, V134, P1591, DOI 10.1001/archderm.134.12.1591; *STAT NETH CBS, 2006, ZORGR KEMC UITG CONF; *TASK FORC PSOR NE, 2004, GUID PHOT SYST THER; van Vloten W A, 1993, Ned Tijdschr Geneeskd, V137, P2525; vanRoijen L, 1996, INT J TECHNOL ASSESS, V12, P405, DOI 10.1017/S0266462300009764; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Yelverton CB, 2008, ARCH DERMATOL, V144, P1224, DOI 10.1001/archderm.144.9.1224; Simpson Jason F, 2006, Manag Care Interface, V19, P39; Yentzer BA, 2008, J AM ACAD DERMATOL, V59, P577, DOI 10.1016/j.jaad.2008.06.007; *ZORG ZEK, 2008, ONL LIST TAR REIMB; 1991, NATL PSORIASIS FDN B, V22, P15	44	35	35	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 20	2010	340								c1490	10.1136/bmj.c1490	http://dx.doi.org/10.1136/bmj.c1490			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	589HM	20406865	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000277137700002
J	Brousseau, DC; Owens, PL; Mosso, AL; Panepinto, JA; Steiner, CA				Brousseau, David C.; Owens, Pamela L.; Mosso, Andrew L.; Panepinto, Julie A.; Steiner, Claudia A.			Acute Care Utilization and Rehospitalizations for Sickle Cell Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK-FACTORS; HOSPITAL READMISSION; VASOOCCLUSIVE CRISES; HEART-FAILURE; CHILDREN; QUALITY; LENGTH; STATE	Context Published rates of health care utilization and rehospitalization by people with sickle cell disease have had limited generalizability and are not population based. Objective To provide benchmark data for rates of acute care utilization and rehospitalizations for patients with sickle cell disease. Design Retrospective cohort of sickle cell disease-related emergency department (ED) visits and hospitalizations from select states in the 2005 and 2006 Healthcare Cost and Utilization Project (HCUP) State Inpatient Databases and State Emergency Department Databases. Setting Eight geographically dispersed states (Arizona, California, Florida, Massachusetts, Missouri, New York, South Carolina, and Tennessee) that provide encrypted identifiers and have sufficient numbers of patients with sickle cell disease; together these states have 33% of the US population with sickle cell disease. Patients A total of 21 112 patients with sickle cell-related treat-and-release ED visits or inpatient hospitalizations. Main Outcome Measures Rates of acute care utilization and rehospitalizations. Population-based utilization rates were also calculated. Results The 21 112 people with sickle cell disease had 109 344 encounters, a mean of 2.59 (95% confidence interval [CI], 2.53-2.65) encounters per patient per year, 1.52 (95% CI, 1.48-1.55) encounters for hospitalizations and 1.08 (95% CI, 1.04-1.11) for treat-and-release ED visits. Utilization was highest for 18- to 30-year-olds, 3.61 (95% CI, 3.47-3.75) encounters per patient per year, and those with public insurance, 3.22 (95% CI, 3.13-3.31) encounters per patient per year. Publicly insured 18- to 30-year-olds had 4.80 (95% CI, 4.58-5.02) encounters per patient per year. Approximately 29% of the population had no encounters while 16.9% had 3 or more encounters per year. The 30-day and 14-day rehospitalization rates were 33.4% (95% CI, 33.0%-33.8%) and 22.1% (95% CI, 21.8%-22.4%), respectively. The rehospitalization rate was highest for 18- to 30-year-olds, with 41.1% (95% CI, 40.5%-41.7%) rehospitalized within 30 days and 28.4% (95% CI, 27.8%-29.0%) within 14 days. Rehospitalizations were also highest for publicly insured patients. Conclusion Among patients with sickle cell disease, acute care encounters and rehospitalizations were frequent, particularly for 18- to 30-year-olds. JAMA. 2010; 303(13): 1288-1294	[Brousseau, David C.] Med Coll Wisconsin, Dept Pediat, Sect Emergency Med, Milwaukee, WI 53226 USA; [Panepinto, Julie A.] Med Coll Wisconsin, Sect Hematol Oncol Bone Marrow Transplant, Milwaukee, WI 53226 USA; [Owens, Pamela L.; Steiner, Claudia A.] Agcy Healthcare Res & Qual, Healthcare Cost & Utilizat Project, Rockville, MD USA; [Owens, Pamela L.; Steiner, Claudia A.] Agcy Healthcare Res & Qual, Ctr Delivery Org & Markets, Rockville, MD USA; [Owens, Pamela L.] Washington Univ, Sch Med, Dept Internal Med, Div Infect Dis, St Louis, MO 63110 USA; [Mosso, Andrew L.] Social & Sci Syst Inc, Silver Spring, MD USA; [Brousseau, David C.; Panepinto, Julie A.] Childrens Res Inst, Milwaukee, WI USA	Medical College of Wisconsin; Medical College of Wisconsin; Agency for Healthcare Research & Quality; Agency for Healthcare Research & Quality; Washington University (WUSTL); Social & Scientific Systems	Brousseau, DC (corresponding author), Med Coll Wisconsin, Dept Pediat, Sect Emergency Med, 999 N 92nd St,CCC 550, Milwaukee, WI 53226 USA.	dbrousse@mcw.edu			Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Work on this study was funded in part by a Career Development Award (D.C.B.) from the Agency for Healthcare Research and Quality.	*AG HEALTHC RES QU, CLIN CALSS SOFTW CCS; Agency for Healthcare Research and Quality, OV STAT INP DAT SID; [Anonymous], OV STAT EM DEP DAT S; Ashley-Koch A, 2000, AM J EPIDEMIOL, V151, P839; Ballas SK, 2005, AM J HEMATOL, V79, P17, DOI 10.1002/ajh.20336; Basu J, 2007, MED CARE RES REV, V64, P544, DOI 10.1177/1077558707301955; Brousseau DC, 2010, AM J HEMATOL, V85, P77, DOI 10.1002/ajh.21570; CASTRO O, 1994, BLOOD, V84, P643, DOI 10.1182/blood.V84.2.643.643; *CTR MED MED SERV, 2007, MED SCHIP QUAL IMPR; Ellison AM, 2007, J NATL MED ASSOC, V99, P192; Fosdal Marian B, 2007, J Pediatr Nurs, V22, P342; Frei-Jones MJ, 2009, PEDIATR BLOOD CANCER, V52, P481, DOI 10.1002/pbc.21854; Guice KS, 2007, J TRAUMA, V63, pS68, DOI 10.1097/TA.0b013e31815acbb6; Harjai KJ, 2001, AM J CARDIOL, V87, P234, DOI 10.1016/S0002-9149(00)01328-X; Jasti H, 2008, CLIN INFECT DIS, V46, P550, DOI 10.1086/526526; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Johnson RW, 2000, HEALTH SERV RES, V35, P911; Lorey FW, 1996, GENET EPIDEMIOL, V13, P501, DOI 10.1002/(SICI)1098-2272(1996)13:5<501::AID-GEPI6>3.0.CO;2-4; Panepinto JA, 2005, PEDIATR BLOOD CANCER, V44, P182, DOI 10.1002/pbc.20180; PLATT OS, 1991, NEW ENGL J MED, V325, P11, DOI 10.1056/NEJM199107043250103; Quinn CT, 2009, PEDIATR BLOOD CANCER, V52, P435, DOI 10.1002/pbc.21904; Reznik M, 2006, J ASTHMA, V43, P37, DOI 10.1080/02770900500446997; Robbins JM, 2006, MED CARE, V44, P292, DOI 10.1097/01.mlr.0000199639.20342.87; Ross JS, 2006, JAMA-J AM MED ASSOC, V295, P2027, DOI 10.1001/jama.295.17.2027; Scanlon DP, 2008, HEALTH SERV RES, V43, P1849, DOI 10.1111/j.1475-6773.2008.00889.x; Schwalenstocker E, 2009, PEDIATR BLOOD CANCER, V53, P1361, DOI 10.1002/pbc.22212; Shankar SM, 2005, AM J HEMATOL, V80, P262, DOI 10.1002/ajh.20485; Taylor A K, 2001, Health Serv Res, V36, P16; VanSuch M, 2006, QUAL SAF HEALTH CARE, V15, P414, DOI 10.1136/qshc.2005.017640	29	391	393	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 7	2010	303	13					1288	1294		10.1001/jama.2010.378	http://dx.doi.org/10.1001/jama.2010.378			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	579FM	20371788	Bronze			2023-01-03	WOS:000276353700029
J	Adams, JL; Mehrotra, A; Thomas, JW; McGlynn, EA				Adams, John L.; Mehrotra, Ateev; Thomas, J. William; McGlynn, Elizabeth A.			Physician Cost Profiling -- Reliability and Risk of Misclassification.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY-CARE PHYSICIANS	Background: Insurance products with incentives for patients to choose physicians classified as offering lower-cost care on the basis of cost-profiling tools are increasingly common. However, no rigorous evaluation has been undertaken to determine whether these tools can accurately distinguish higher-cost physicians from lower-cost physicians. Methods: We aggregated claims data for the years 2004 and 2005 from four health plans in Massachusetts. We used commercial software to construct clinically homogeneous episodes of care (e.g., treatment of diabetes, heart attack, or urinary tract infection), assigned each episode to a physician, and created a summary profile of resource use (i.e., cost) for each physician on the basis of all assigned episodes. We estimated the reliability (signal-to-noise ratio) of each physician's cost-profile score on a scale of 0 to 1, with 0 indicating that all differences in physicians' cost profiles are due to a lack of precision in the measure (noise) and 1 indicating that all differences are due to real variation in costs of services (signal). We used the reliability results to estimate the proportion of physicians in each specialty whose cost performance would be classified inaccurately in a two-tiered insurance product in which the physicians with cost profiles in the lowest quartile were labeled as ``lower cost.'' Results: Median reliabilities ranged from 0.05 for vascular surgery to 0.79 for gastroenterology and otolaryngology. Overall, 59% of physicians had cost-profile scores with reliabilities of less than 0.70, a commonly used marker of suboptimal reliability. Using our reliability results, we estimated that 22% of physicians would be misclassified in a two-tiered system. Conclusions: Current methods for profiling physicians with respect to costs of services may produce misleading results. N Engl J Med 2010;362:1014-21.	[Adams, John L.; Mehrotra, Ateev; McGlynn, Elizabeth A.] RAND Corp, Santa Monica, CA USA; [Adams, John L.; Mehrotra, Ateev; McGlynn, Elizabeth A.] RAND Corp, Pittsburgh, PA 15213 USA; [Mehrotra, Ateev] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; [Thomas, J. William] Univ So Maine, Portland, ME 04103 USA	RAND Corporation; RAND Corporation; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Maine System; University of Southern Maine	Mehrotra, A (corresponding author), RAND Corp, 4570 5th Ave,Suite 600, Pittsburgh, PA 15213 USA.	mehrotra@rand.org	Mehrotra, Ateev/AAO-8454-2021; Adams, John/ABE-6170-2021	Mehrotra, Ateev/0000-0003-2223-1582; 	Department of Labor [J-9-P-2-0033]; National Center for Research Resources at the National Institutes of Health [05 KL2 RR024154-04]; Robert Wood Johnson Foundation; American Medical Association; Massachusetts Medical Society; Physicians Advocacy Institute; Commonwealth Fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024154] Funding Source: NIH RePORTER	Department of Labor; National Center for Research Resources at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); American Medical Association; Massachusetts Medical Society; Physicians Advocacy Institute; Commonwealth Fund; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by a contract from the Department of Labor (J-9-P-2-0033), a career development award from the National Center for Research Resources at the National Institutes of Health (05 KL2 RR024154-04, to Dr. Mehrotra), and a grant from the Robert Wood Johnson Foundation (to Dr. Thomas).; Dr. Thomas reports receiving consulting fees from the Integrated Healthcare Association, the American Medical Association, the American Board of Medical Specialties, and the Arkansas Medical Society; Dr. McGlynn, serving as a paid member of the American Board of Internal Medicine Foundation; and Drs. Adams, Mehrotra, and McGlynn, grant support from the American Medical Association, the Massachusetts Medical Society, the Physicians Advocacy Institute, and the Commonwealth Fund. Ingenix provided a free research license for the use of its commercial programs. No other potential conflict of interest relevant to this article was reported.	Brennan TA, 2008, HEALTH AFFAIR, V27, P1160, DOI 10.1377/hlthaff.27.4.1160; *CTR MED MED SERV, MED RES US MEAS PLAN; Fleiss J.L., 2003, STAT METHODS RATES P; Friedberg MW, 2007, J GEN INTERN MED, V22, P1385, DOI 10.1007/s11606-007-0234-0; Hays RD., 2005, ASSESSING QUALITY LI, V2, P25; Hayward RA, 2001, JAMA-J AM MED ASSOC, V286, P415, DOI 10.1001/jama.286.4.415; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Hofer TP, 2000, MED CARE, V38, P152, DOI 10.1097/00005650-200002000-00005; Institute of Medicine, 2006, PERF MEAS ACC IMPR; LAKE T, 2007, HLTH PLANS USE PHYSI; *LEAPFR GROUP, 2004, BRIDG EXC MEAS PROV; McDowell I, 1996, J NUTR EDUC, DOI DOI 10.1016/S0022-3182(88)80070-0; MEHROTRA A, ANN INTERN IN PRESS; Milstein A, 2007, NEW ENGL J MED, V357, P2649, DOI 10.1056/NEJMp0706521; *NAT COMM QUAL ASS, 2008, STAND GUID CERT PHYS; National Quality Forum, 2009, MEAS FRAM EV EFF PAT; RAUDENBUCH SW, 2002, HIERARCHICAL LINEAR; Safran DG, 2006, J GEN INTERN MED, V21, P13, DOI 10.1111/j.1525-1497.2005.00311.x; Sandy LG, 2008, J GEN INTERN MED, V23, P1521, DOI 10.1007/s11606-008-0684-z; Scholle SH, 2008, AM J MANAG CARE, V14, P829; Sirovich B, 2008, HEALTH AFFAIR, V27, P813, DOI 10.1377/hlthaff.27.3.813; Sorbero M, 2006, ASSESSMENT PAY FOR P; Thomas JW, 2006, INQUIRY-J HEALTH CAR, V43, P271, DOI 10.5034/inquiryjrnl_43.3.271; TUKEY JW, 1962, ANN MATH STAT, V33, P1, DOI 10.1214/aoms/1177704711; 2008, ENHANCING PHYS QUALI	25	121	121	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 18	2010	362	11					1014	1021		10.1056/NEJMsa0906323	http://dx.doi.org/10.1056/NEJMsa0906323			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570CY	20237347	Bronze, Green Accepted			2023-01-03	WOS:000275650400012
J	Hochman, M; McCormick, D				Hochman, Michael; McCormick, Danny			Characteristics of Published Comparative Effectiveness Studies of Medications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACEBO-CONTROLLED TRIALS; RANDOMIZED-TRIALS; CLINICAL-TRIALS; SYSTEMATIC REVIEWS; NONINFERIORITY; SAFETY; EQUIVALENCE; ASSOCIATION; DRUG; CONCLUSIONS	Context Policy makers and physician organizations have recently called for more comparative effectiveness (CE) research, yet little is known about existing CE studies. Objective To describe the characteristics of recently published CE studies evaluating medications. Design, Setting, and Participants Analysis of all randomized trials, observational studies, and meta-analyses involving medications published in the 6 general medicine and internal medicine journals with the highest impact factor between June 1, 2008, and September 30, 2009. Main Outcome Measures The prevalence and characteristics of CE studies (those comparing existing, active treatments) and non-CE studies (those involving novel therapies or those using an inactive control). Results We identified 328 studies evaluating medications, 104 of which were CE studies. Among the CE studies, 45 (43%; 95% confidence interval [CI], 34%-53%) compared different medications, 11 (11%; 95% CI, 5%-18%) compared medications with nonpharmacologic interventions, 32 (31%; 95% CI, 22%-41%) compared different pharmacologic strategies, and 16 (15%; 95% CI, 9%-24%) compared different medication dosing schedules. Twenty (19%; 95% CI, 12%-28%) CE studies focused on safety and 2 (2%; 95% CI, 0%-7%) included cost-effectiveness analyses. Comparative effectiveness studies were less likely than non-CE studies to have been exclusively commercially funded: 13% (95% CI, 8%-22%) vs 45% (95% CI, 38%-52%), respectively (P < .001). In total, 90 (87%; 95% CI, 78%-92%) of the CE studies received noncommercial funding, including 66 that received government funding (63%; 95% CI, 53%-73%). Of 212 randomized trials, 97 (46%; 95% CI, 39%-63%) used an active comparator; the rest used an inactive control. Active-comparator trials were less likely than trials with inactive controls to report positive results: 44% (95% CI, 33%-55%) vs 66% (95% CI, 57%-75%), respectively (P=.002). Conclusions In these high-impact general medicine journals, approximately one-third of studies evaluating medications were CE studies. Of these studies, only a minority compared pharmacologic and nonpharmacologic therapies, few focused on safety or cost, and most were funded by noncommercial funding sources. JAMA. 2010;303(10):951-958	Cambridge Hlth Alliance, Dept Med, Cambridge, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Cambridge Health Alliance; Harvard University; Harvard Medical School	Hochman, M (corresponding author), Univ So Calif, Dept Med, Keck Sch Med, 1975 Zonal Ave,KAM 500, Los Angeles, CA 90089 USA.	mhochman@usc.edu						Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; *AM COLL PHYS, 2008, IMPR AV COMP EFF INF; BACIU A, 2006, FUTURE DRUG SAFETY P; Bekelman JE, 2003, JAMA-J AM MED ASSOC, V289, P454, DOI 10.1001/jama.289.4.454; Bhandari M, 2004, CAN MED ASSOC J, V170, P477; Chan AW, 2004, CAN MED ASSOC J, V171, P735, DOI 10.1503/cmaj.1041086; Clement FM, 2009, JAMA-J AM MED ASSOC, V302, P1437, DOI 10.1001/jama.2009.1409; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; Ernst E, 2001, BRIT MED J, V323, P546, DOI 10.1136/bmj.323.7312.546; Ernst E, 2001, ARCH INTERN MED, V161, P125, DOI 10.1001/archinte.161.1.125-a; Fontanarosa PB, 2004, JAMA-J AM MED ASSOC, V292, P2647, DOI 10.1001/jama.292.21.2647; Gomberg-Maitland M, 2003, AM HEART J, V146, P398, DOI 10.1016/S0002-8703(03)00324-7; Goodman DC, 2005, PEDIATRICS, V116, P493, DOI 10.1542/peds.2005-1231; Greene CJ, 2008, J TRAUMA STRESS, V21, P433, DOI 10.1002/jts.20367; *I MED, KNOW WHAT WORKS HEAL; *I MED ROUNDT EV B, 2007, LEARN WHAT WORKS BES; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; Ioannidis John P A, 2008, Philos Ethics Humanit Med, V3, P14, DOI 10.1186/1747-5341-3-14; JACOBSON GA, 2007, CRS REPORT C COMP CL; Katz KA, 2006, J AM ACAD DERMATOL, V55, P814, DOI 10.1016/j.jaad.2006.07.005; Kirschner N, 2008, ANN INTERN MED, V148, P956, DOI 10.7326/0003-4819-148-12-200806170-00222; Kjaergard LL, 2002, BMJ-BRIT MED J, V325, P249, DOI 10.1136/bmj.325.7358.249; LEWIS TR, 2007, CASE PUBLIC FUNDING, V4; Misbin RI, 2001, DIABETES CARE, V24, P773, DOI 10.2337/diacare.24.4.773; Papanikolaou PN, 2004, AM J PSYCHIAT, V161, P1692, DOI 10.1176/appi.ajp.161.9.1692; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; Pitrou I, 2009, ARCH INTERN MED, V169, P1756, DOI 10.1001/archinternmed.2009.306; Ridker PM, 2006, JAMA-J AM MED ASSOC, V295, P2270, DOI 10.1001/jama.295.19.2270; Sox HC, 2009, ANN INTERN MED, V151, P203, DOI 10.7326/0003-4819-151-3-200908040-00125; Stafford RS, 2009, NEW ENGL J MED, V361, P1230, DOI 10.1056/NEJMp0906490; StataCorp, 2009, STAT STAT SOFTW REL; *THOMS REUT, SCI J CIT REP ISI SU; Tuma RS, 2007, J NATL CANCER I, V99, P1746, DOI 10.1093/jnci/djm258; *US C BUDG OFF, 2007, RES COMP EFF MED TRE; *US DEP HHS, COMP EFF RES FUND FE; *US FDA, 2001, REG INF CHOIC CONTR; VANDENBROUKE JP, 2008, JAMA-J AM MED ASSOC, V3, P2417; Vitiello B, 2004, BIOL PSYCHIAT, V56, P3, DOI 10.1016/j.biopsych.2004.03.011; Vlahakes GJ, 2006, NEW ENGL J MED, V354, P413, DOI 10.1056/NEJMe058272; Vlopp KG, 2009, NEW ENGL J MED, V361, P331, DOI 10.1056/NEJMp0903496	41	62	64	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 10	2010	303	10					951	958		10.1001/jama.2010.240	http://dx.doi.org/10.1001/jama.2010.240			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	565UC	20215609	Bronze			2023-01-03	WOS:000275319300022
J	Lister, S				Lister, Sam			Social Care No quick fix for long term care	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Times, London, England		Lister, S (corresponding author), Times, London, England.	Sam.Lister@thetimes.co.uk						CUTHBERT M, 2010, PUBLIC FINANCE  0122; Department of Health, 2000, NHS PLAN GOV RESP RO; FERGUSON T, 1948, LANCET, V254, P417; LISTER S, 2009, TIMES           1120; Royal Commission on Long Term Care, 1999, RESP OLD AG LONG TER; 1954, BMJ, V1, P1425	6	1	1	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 11	2010	340								c814	10.1136/bmj.c814	http://dx.doi.org/10.1136/bmj.c814			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	554ZV	20150195				2023-01-03	WOS:000274477200006
J	Liang, BA; Mackey, T				Liang, Bryan A.; Mackey, Tim			Reforming Off-Label Promotion to Enhance Orphan Disease Treatment	SCIENCE			English	Editorial Material							DRUGS; FDA		[Liang, Bryan A.; Mackey, Tim] Calif Western Sch Law, Inst Hlth Law Studies, San Diego, CA 92101 USA; [Liang, Bryan A.] Univ Calif San Diego, San Diego Sch Med, San Diego Ctr Patient Safety, Dept Anesthesiol, San Diego, CA 92103 USA	University of California System; University of California San Diego	Liang, BA (corresponding author), Calif Western Sch Law, Inst Hlth Law Studies, San Diego, CA 92101 USA.	baliang@alum.mit.edu	Mackey, Tim/H-9156-2013	Mackey, Tim/0000-0002-2191-7833; Liang, Bryan/0000-0001-7801-5673				ABELSON R, 2009, NY TIMES        0127, pA22, DOI DOI 10.1007/S00228-005-0981-Y; Berenson Alex, 2006, N Y Times Web, pC2; Boos J, 2003, ANN ONCOL, V14, P1, DOI 10.1093/annonc/mdg035; Brewer GJ, 2009, TRANSL RES, V154, P314, DOI 10.1016/j.trsl.2009.03.008; Canadian Organization for Rare Disorders, 2005, CAN ORPH DRUG POL LE; *DHHS, 2001, OEI090000380 DHHS; FDA, 2009, GOOD REPR PRACT DIST; Hampton T, 2007, JAMA-J AM MED ASSOC, V297, P683, DOI 10.1001/jama.297.7.683; Krammer MG, 2003, NATL ORG RARE DISORD; Liang BA, 2007, HARVARD J LEGIS, V44, P363; Mello MM, 2009, NEW ENGL J MED, V360, P1557, DOI 10.1056/NEJMhle0807695; POLLACK A, 1990, NY TIMES        0116, pD1; Psaty BM, 2008, JAMA-J AM MED ASSOC, V299, P1949, DOI 10.1001/jama.299.16.1949; Radley DC, 2006, ARCH INTERN MED, V166, P1021, DOI 10.1001/archinte.166.9.1021; *RAR CANC FOR, 2009, OFF LIM INV NHS ORG; Richey EA, 2009, J CLIN ONCOL, V27, P4398, DOI 10.1200/JCO.2008.21.1961; SALBU SR, 1999, FLA L REV, V51, P181, DOI DOI 10.1377/HLTHAFF.2010.1032; Schlander M, 2009, CURR MED RES OPIN, V25, P1285, DOI [10.1185/03007990902892633, 10.1185/03007990902892633 ]; Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107; 2008, NIH NEWS; 1997, FED REG, V62, P64073; 1996, FED REG, V61, P52800	22	24	24	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 15	2010	327	5963					273	274		10.1126/science.1181567	http://dx.doi.org/10.1126/science.1181567			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	544CM	20075234				2023-01-03	WOS:000273629700021
J	Pasman, HRW; Rurup, ML; Willems, DL; Onwuteaka-Philipsen, BD				Pasman, H. R. W.; Rurup, M. L.; Willems, D. L.; Onwuteaka-Philipsen, B. D.			Concept of unbearable suffering in context of ungranted requests for euthanasia: qualitative interviews with patients and physicians	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NETHERLANDS	Objective To obtain in-depth information about the views of patients and physicians on suffering in patients who requested euthanasia in whom the request was not granted or granted but not performed. Design In-depth interviews with a topic list. Setting Patients' homes and physicians' offices. Participants 10 patients who explicitly requested euthanasia but whose request was not granted or performed and eight physicians of these patients; and eight physicians of patients who had requested euthanasia but had died before the request had been granted or performed or had died after the request was refused by the physician or after the patient had withdrawn his or her request. Results Not all patients who requested euthanasia thought their suffering was unbearable, although they had a lasting wish to die. Patients and physicians seemed to agree about this. In cases in which patients said they suffered unbearably there was less agreement about what constitutes unbearable suffering; patients put more emphasis on psychosocial suffering, such as dependence and deterioration, whereas physicians referred more often to physical suffering. In some cases the physician thought that the suffering was not unbearable because the patient's behaviour seemed incompatible with unbearable suffering-for instance, because the patient was still reading books. Conclusions Patients do not always think that their suffering is unbearable, even if they have a lasting wish to die. Physicians seem to have a narrower perspective on unbearable suffering than patients and than case law suggests. In an attempt to solve the problem of different perspectives, physicians should take into account the different aspects of suffering as described in the literature and a framework for assessing the suffering of patients who ask for euthanasia.	[Pasman, H. R. W.; Rurup, M. L.; Onwuteaka-Philipsen, B. D.] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth,Expertise Ctr Palliat Ca, NL-1081 BT Amsterdam, Netherlands; [Willems, D. L.] Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, NL-1105 AZ Amsterdam, Netherlands	Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Pasman, HRW (corresponding author), Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Dept Publ & Occupat Hlth,Expertise Ctr Palliat Ca, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	hrw.pasman@vumc.nl			Right to Die-NL (NVVE); Pieter van Foreest Foundation	Right to Die-NL (NVVE); Pieter van Foreest Foundation	This study was supported by a grant from Right to Die-NL (NVVE) and the Pieter van Foreest Foundation. The funders approved the study design and were not involved in the collection, analysis, and interpretation of data, the writing of the report, and the decision to submit the article for publication. The researchers were independent from the funders.	Baines B K, 2000, Am J Hosp Palliat Care, V17, P319, DOI 10.1177/104990910001700509; *BOARD ROYAL DUTCH, 2003, VIS EUTH; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; Haverkate I, 2000, BRIT MED J, V321, P865, DOI 10.1136/bmj.321.7265.865; KIMSMA GK, 2000, MEDISCH CONTACT, V55, P1757; Onwuteaka-Philipsen BD, 2003, LANCET, V362, P395, DOI 10.1016/S0140-6736(03)14029-9; Onwuteaka-Philipsen BD, 2007, EVALUATION LAW REV E; Strauss A., 1990, BASICS GROUNDED THEO; VANDAM H, 2005, DIFFERENT LOOK PRACT; Weide MCJV, 2005, ARCH INTERN MED, V165, P1698, DOI 10.1001/archinte.165.15.1698; 2007, REGIONAL EUTHANASIA	12	51	52	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 16	2009	339								b4362	10.1136/bmj.b4362	http://dx.doi.org/10.1136/bmj.b4362			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	523SU	19917578	Green Published, hybrid			2023-01-03	WOS:000272095600002
J	Chenu, O; Vuillerme, N; Demongeot, J; Payan, Y				Chenu, Olivier; Vuillerme, Nicolas; Demongeot, Jacques; Payan, Yohan			A Wireless Lingual Feedback Device to Reduce Overpressures in Seated Posture: A Feasibility Study	PLOS ONE			English	Article							PLACED TACTILE BIOFEEDBACK; ELECTROTACTILE STIMULUS ARRAY; JOINT POSITION SENSE; TONGUE; THRESHOLD; SYSTEM; ANKLE	Background: Pressure sores are localized injuries to the skin and underlying tissues and are mainly resulting from overpressure. Paraplegic peoples are particularly subjects to pressure sores because of long-time seated postures and sensory deprivation at the lower limbs. Methodology/Principal Findings: Here we report outcomes of a feasibility trial involving a biofeedback system aimed at reducing buttock overpressure whilst an individual is seated. The system consists of (1) pressure sensors, (2) a laptop coupling sensors and actuator (3) a wireless Tongue Display Unit (TDU) consisting of a circuit embedded in a dental retainer with electrodes put in contact with the tongue. The principle consists in (1) detecting overpressures in people who are seated over long periods of time, (2) estimating a postural change that could reduce these overpressures and (3) communicating this change through directional information transmitted by the TDU. Twenty-four healthy subjects voluntarily participated in this study. Twelve healthy subjects initially formed the experimental group (EG) and were seated on a chair with the wireless TDU inside their mouth. They were asked to follow TDU orders that were randomly spread throughout the session. They were evaluated during two experimental sessions during which 20 electro-stimulations were sent. Twelve other subjects, added retrospectively, formed the control group (CG). These subjects participated in one session of the same experiment without any biofeedback. Three dependent variables were computed: (1) the ability of subjects to reach target posture (EG versus CG), (2) high pressure reductions after a biofeedback (EG versus CG) and (3) the level of these reductions relative to their initial values (EG only). Results show (1) that EG reached target postures in 90.2% of the trials, against 5,3% in the CG, (2) a significant reduction in overpressures in the EG compared to the CG and (3), for the EG, that the higher the initial pressures were, the more they were decreased. Conclusions/Significance: The findings suggest that, in this trial, subjects were able to use a tongue tactile feedback system to reduce buttock overpressure while seated. Further evaluation of this system on paraplegic subjects remains to be done.			Chenu, O (corresponding author), TIMC IMAG, CNRS, UJF, UMR 5525, La Tronche, France.	olivier.chenu@imag.fr	Nicolas, Vuillerme/C-6692-2009; Payan, Yohan/N-3980-2019; Demongeot, Jacques/AAZ-2539-2020; Demongeot, Jacques/GQI-1558-2022; PAYAN, Yohan/E-3993-2013; VUILLERME, Nicolas/U-5767-2019	Nicolas, Vuillerme/0000-0002-5202-4173; Payan, Yohan/0000-0002-6012-4123; Demongeot, Jacques/0000-0002-8335-9240; PAYAN, Yohan/0000-0002-6012-4123; VUILLERME, Nicolas/0000-0003-3773-393X				BACH P, 1969, NATURE, V221, P963, DOI 10.1038/221963a0; Bach-y-Rita P, 1998, J REHABIL RES DEV, V35, P427; Bach-y-Rita P., 1972, BRAIN MECH SENSORY S; Cardenas DD, 2004, ARCH PHYS MED REHAB, V85, P1757, DOI 10.1016/j.apmr.2004.03.016; COLIN B, 2008, Patent No. 2008139099; CULLUM N, 2004, COCHRANE DATABASE SY; KACZMAREK KA, 1991, THESIS U WISCONSIN M; Linder-Ganz E, 2006, J BIOMECH, V39, P2725, DOI 10.1016/j.jbiomech.2005.08.010; Moreau-Gaudry A, 2006, STUD HEALTH TECHNOL, V124, P926; Reddy M, 2006, JAMA-J AM MED ASSOC, V296, P974, DOI 10.1001/jama.296.8.974; Robineau F, 2007, IEEE T BIO-MED ENG, V54, P711, DOI 10.1109/TBME.2006.889180; Sampaio E, 2001, BRAIN RES, V908, P204, DOI 10.1016/S0006-8993(01)02667-1; Trulsson M, 1997, J NEUROPHYSIOL, V77, P737, DOI 10.1152/jn.1997.77.2.737; Vuillerme N, 2008, NEUROSCI LETT, V431, P206, DOI 10.1016/j.neulet.2007.11.049; Vuillerme N, 2007, EXP BRAIN RES, V183, P235, DOI 10.1007/s00221-007-1039-4; Vuillerme N, 2007, EXP BRAIN RES, V181, P547, DOI 10.1007/s00221-007-0953-9; Vuillerme N, 2007, EXP BRAIN RES, V179, P409, DOI 10.1007/s00221-006-0800-4; Vuillerme N, 2006, NEUROSCI LETT, V405, P19, DOI 10.1016/j.neulet.2006.06.035	18	17	17	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 30	2009	4	10							e7550	10.1371/journal.pone.0007550	http://dx.doi.org/10.1371/journal.pone.0007550			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RW	19888336	Green Published, Green Submitted, gold			2023-01-03	WOS:000271414300002
J	Craig, JC; Simpson, JM; Williams, GJ; Lowe, A; Reynolds, GJ; McTaggart, SJ; Hodson, EM; Carapetis, JR; Cranswick, NE; Smith, G; Irwig, LM; Caldwell, PHY; Hamilton, S; Roy, LP				Craig, Jonathan C.; Simpson, Judy M.; Williams, Gabrielle J.; Lowe, Alison; Reynolds, Graham J.; McTaggart, Steven J.; Hodson, Elisabeth M.; Carapetis, Jonathan R.; Cranswick, Noel E.; Smith, Grahame; Irwig, Les M.; Caldwell, Patrina H. Y.; Hamilton, Sana; Roy, Leslie P.		Prevention Recurrent Urinary Tract	Antibiotic Prophylaxis and Recurrent Urinary Tract Infection in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY VESICOURETERAL REFLUX; CONTROLLED-TRIAL; RISK-FACTORS; RENAL SCARS; PREVENTION; PYELONEPHRITIS; ASSOCIATION; MULTICENTER; THERAPY; OLD	BACKGROUND Antibiotics are widely administered to children with the intention of preventing urinary tract infection, but adequately powered, placebo-controlled trials regarding efficacy are lacking. This study from four Australian centers examined whether low-dose, continuous oral antibiotic therapy prevents urinary tract infection in predisposed children. METHODS We randomly assigned children under the age of 18 years who had had one or more microbiologically proven urinary tract infections to receive either daily trimethoprim-sulfamethoxazole suspension (as 2 mg of trimethoprim plus 10 mg of sulfamethoxazole per kilogram of body weight) or placebo for 12 months. The primary outcome was microbiologically confirmed symptomatic urinary tract infection. Intention-to-treat analyses were performed with the use of time-to-event data. RESULTS From December 1998 to March 2007, a total of 576 children (of 780 planned) underwent randomization. The median age at entry was 14 months; 64% of the patients were girls, 42% had known vesicoureteral reflux (at least grade III in 53% of these patients), and 71% were enrolled after the first diagnosis of urinary tract infection. During the study, urinary tract infection developed in 36 of 288 patients (13%) in the group receiving trimethoprim-sulfamethoxazole (antibiotic group) and in 55 of 288 patients (19%) in the placebo group (hazard ratio in the antibiotic group, 0.61; 95% confidence interval, 0.40 to 0.93; P = 0.02 by the log-rank test). In the antibiotic group, the reduction in the absolute risk of urinary tract infection (6 percentage points) appeared to be consistent across all subgroups of patients (P >= 0.20 for all interactions). CONCLUSIONS Long-term, low-dose trimethoprim-sulfamethoxazole was associated with a decreased number of urinary tract infections in predisposed children. The treatment effect appeared to be consistent but modest across subgroups. (Australian New Zealand Clinical Trials Registry number, ACTRN12608000470392.)	[Craig, Jonathan C.; Williams, Gabrielle J.; Lowe, Alison; Hodson, Elisabeth M.; Caldwell, Patrina H. Y.; Hamilton, Sana; Roy, Leslie P.] Childrens Hosp Westmead, Ctr Kidney Res, Sydney, NSW 2145, Australia; [Craig, Jonathan C.; Williams, Gabrielle J.; Irwig, Les M.] Univ Sydney, Screening & Test Evaluat Program, Sydney, NSW 2006, Australia; [Craig, Jonathan C.; Simpson, Judy M.; Hodson, Elisabeth M.; Irwig, Les M.] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; [Smith, Grahame] Childrens Hosp Westmead, Dept Urol & Surg, Sydney, NSW 2145, Australia; [Reynolds, Graham J.] Australian Natl Univ, Dept Paediat & Child Hlth, Sch Med, Canberra, ACT, Australia; [McTaggart, Steven J.] Queensland Child & Adolescent Renal Serv, Brisbane, Qld, Australia; [McTaggart, Steven J.] Univ Queensland, Brisbane, Qld, Australia; [Carapetis, Jonathan R.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0909, Australia; [Cranswick, Noel E.] Univ Melbourne, Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Cranswick, Noel E.] Univ Melbourne, Royal Childrens Hosp, Melbourne, Vic, Australia	University of Sydney; University of Sydney; University of Sydney; University of Sydney; Australian National University; University of Queensland; Charles Darwin University; Menzies School of Health Research; Murdoch Children's Research Institute; University of Melbourne; Royal Children's Hospital Melbourne; University of Melbourne	Craig, JC (corresponding author), Childrens Hosp Westmead, Ctr Kidney Res, Locked Bag 4001, Sydney, NSW 2145, Australia.		Carapetis, Jonathan R/H-8933-2014; Craig, Jonathan/E-2813-2013; Caldwell, Patrina/C-4211-2013	Carapetis, Jonathan R/0000-0002-1182-9792; Craig, Jonathan/0000-0002-2548-4035; Simpson, Judy M/0000-0001-5172-3004; Smith, Grahame/0000-0002-2911-6520; Caldwell, Patrina/0000-0003-1124-6578	National Health and Medical Research Council of Australia [990735, 301999, 402764]; Financial Markets Foundation for Children of Australia [058-2003]; Manildra Group	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Financial Markets Foundation for Children of Australia; Manildra Group	Supported by grants from the National Health and Medical Research Council of Australia (990735, 301999, and 402764) and from the Financial Markets Foundation for Children of Australia (058-2003) and by a private donation by J.T. Honan of the Manildra Group.	Altman DG, 1999, BRIT MED J, V319, P1492, DOI 10.1136/bmj.319.7223.1492; *AM AC PED COMM QU, 2000, PEDIATRICS, V105, P141; American Academy of Pediatrics, 1999, PEDIATRICS, V103, P1052; [Anonymous], 1991, J R Coll Physicians Lond, V25, P36; ARANT BS, 1991, AM J KIDNEY DIS, V17, P491, DOI 10.1016/S0272-6386(12)80490-2; Bailey R R, 1973, Clin Nephrol, V1, P132; Bergman DA, 1999, PEDIATRICS, V103, P843; Bergman DA, 1999, PEDIATRICS, V104, P118; Caldwell PHY, 2004, LANCET, V364, P803, DOI 10.1016/S0140-6736(04)16942-0; Conway PH, 2007, JAMA-J AM MED ASSOC, V298, P179, DOI 10.1001/jama.298.2.179; Coulthard MG, 1997, BMJ-BRIT MED J, V315, P918; Craig JC, 2001, CURR OPIN INFECT DIS, V14, P309, DOI 10.1097/00001432-200106000-00011; Disney APS, 1991, P 2 CJ HODS S REFL N, P53; Elder JS, 1997, J UROLOGY, V157, P1846, DOI 10.1016/S0022-5347(01)64882-1; Garin EH, 2006, PEDIATRICS, V117, P626, DOI 10.1542/peds.2005-1362; GOLDRAICH NP, 1989, PEDIATR NEPHROL, V3, P1, DOI 10.1007/BF00859614; Hellerstein S, 1995, PEDIATR CLIN N AM, V42, P1433; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; Hoberman A, 1999, PEDIATR INFECT DIS J, V18, P1020, DOI 10.1097/00006454-199911000-00018; Hodson EM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001532.pub3; JONES KV, 1990, ARCH DIS CHILD, V65, P327, DOI 10.1136/adc.65.3.327; Keren R, 2007, CURR OPIN PEDIATR, V19, P705, DOI 10.1097/MOP.0b013e3282f1dcd7; LEBOWITZ RL, 1985, PEDIATR RADIOL, V15, P105, DOI 10.1007/BF02388714; LOHR JA, 1977, PEDIATRICS, V59, P562; Montini G, 2008, PEDIATRICS, V122, P1064, DOI 10.1542/peds.2007-3770; Myers MW, 1997, BRIT J CLIN PHARMACO, V43, P446, DOI 10.1046/j.1365-2125.1997.00584.x; Panaretto KS, 1999, J PAEDIATR CHILD H, V35, P454, DOI 10.1046/j.1440-1754.1999.355417.x; Pennesi M, 2008, PEDIATRICS, V121, pE1489, DOI 10.1542/peds.2007-2652; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Reddy PP, 1997, PEDIATRICS, V100, P555; Roussey-Kesler G, 2008, J UROLOGY, V179, P674, DOI 10.1016/j.juro.2007.09.090; SAVAGE DCL, 1975, LANCET, V1, P358; Singh-Grewal D, 2005, ARCH DIS CHILD, V90, P853, DOI 10.1136/adc.2004.049353; SMELLIE JM, 1978, LANCET, V2, P175; STANSFELD JM, 1975, BRIT MED J, V3, P65, DOI 10.1136/bmj.3.5975.65; *U NC, RAND INT CHILDR VES; Westwood Marie E, 2005, BMC Pediatr, V5, P2, DOI 10.1186/1471-2431-5-2; Williams G, 2009, CURR OPIN INFECT DIS, V22, P72, DOI 10.1097/QCO.0b013e328320a885; WILLIAMS GJ, 2006, COCHRANE DB SYST REV, V3	40	249	260	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	2009	361	18					1748	1759		10.1056/NEJMoa0902295	http://dx.doi.org/10.1056/NEJMoa0902295			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	511RY	19864673				2023-01-03	WOS:000271185600007
J	Hupfl, M; Selig, HF; Nagele, P				Huepfl, Michael; Selig, Harald F.; Nagele, Peter			Chest-compression-only versus standard cardiopulmonary resuscitation: a meta-analysis	LANCET			English	Article							BASIC LIFE-SUPPORT; HOSPITAL CARDIAC ARRESTS; SURVIVAL; CPR	Background In out-of-hospital cardiac arrest, dispatcher-assisted chest-compression-only bystander CPR might be superior to standard bystander CPR (chest compression plus rescue ventilation), but trial findings have not shown significantly improved outcomes. We aimed to establish the association of chest-compression-only CPR with survival in patients with out-of-hospital cardiac arrest. Methods Medline and Embase were systematically reviewed for studies published between January, 1985, and August, 2010, in which chest-compression-only bystander CPR was compared with standard bystander CPR for adult patients with out-of-hospital cardiac arrest. In the primary meta-analysis, we included trials in which patients were randomly allocated to receive one of the two CPR techniques, according to dispatcher instructions; and in the secondary meta-analysis, we included observational cohort studies of chest-compression-only CPR. All studies had to supply survival data. The primary outcome was survival to hospital discharge. A fixed-effects model was used for both meta-analyses because of an absence of heterogeneity among the studies (I-2=0%). Findings In the primary meta-analysis, pooled data from three randomised trials showed that chest-compression-only CPR was associated with improved chance of survival compared with standard CPR (14% [211/1500] vs 12% [178/1531]; risk ratio 1.22, 95% CI 1.01-1.46). The absolute increase in survival was 2.4% (95% CI 0.1-4.9), and the number needed to treat was 41 (95% CI 20-1250). In the secondary meta-analysis of seven observational cohort studies, no difference was recorded between the two CPR techniques (8% [223/2731] vs 8% [863/11 152]; risk ratio 0.96, 95% CI 0.83-1.11). Interpretation For adults with out-of-hospital cardiac arrest, instructions to bystanders from emergency medical services dispatch should focus on chest-compression-only CPR.	[Nagele, Peter] Washington Univ, Sch Med, Dept Anesthesiol, St Louis, MO 63110 USA; [Huepfl, Michael; Selig, Harald F.] Med Univ Vienna, Dept Anesthesiol Crit Care & Pain Therapy, Vienna, Austria	Washington University (WUSTL); Medical University of Vienna	Nagele, P (corresponding author), Washington Univ, Sch Med, Dept Anesthesiol, 660 S Euclid Ave,Box 8054, St Louis, MO 63110 USA.	nagelep@wustl.edu	Nagele, Peter/AAW-1651-2020; Nagele, Peter/A-2922-2008; Nagele, Peter/ABA-5189-2020	Nagele, Peter/0000-0001-8369-3858; Nagele, Peter/0000-0001-8369-3858; 	Roche Diagnostics; Gerson Lehrman Group; US National Institutes of Health; American Heart Association; St John's Ambulance Service, Vienna, Austria; Novo Nordisk; National Institute of General Medical Sciences, National Institutes of Health; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM087534] Funding Source: NIH RePORTER	Roche Diagnostics; Gerson Lehrman Group; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); St John's Ambulance Service, Vienna, Austria; Novo Nordisk(Novo Nordisk); National Institute of General Medical Sciences, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	PN's institution has received research support from Roche Diagnostics, unrelated to this study; PN has received consultancy fees from Gerson Lehrman Group; and PN and his institution have received grants from the US National Institutes of Health and American Heart Association. MH is receiving a salary and has received payment for development of educational presentations from St John's Ambulance Service, Vienna, Austria; and has received research support, lecture fees, and travel support from Novo Nordisk. HFS declares that he has no conflicts of interest.; We thank J Philipp Miller, director division of Biostatistics, Washington University School of Medicine, St Louis, MO, USA, for his statistical contributions during report preparation and revision. PN is supported by grants from the National Institute of General Medical Sciences, National Institutes of Health, and from the American Heart Association.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; BERG RA, 1993, CIRCULATION, V88, P1907, DOI 10.1161/01.CIR.88.4.1907; Bohm K, 2007, CIRCULATION, V116, P2908, DOI 10.1161/CIRCULATIONAHA.107.710194; Ewy GA, 2007, CIRCULATION, V116, P2894, DOI 10.1161/CIRCULATIONAHA.107.751065; Ewy GA, 2007, CIRCULATION, V116, P2525, DOI 10.1161/CIRCULATIONAHA.107.711820; Gold LS, 2008, PREHOSP EMERG CARE, V12, P406, DOI 10.1080/10903120802096696; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Handley AJ, 2005, RESUSCITATION, V67, pS7, DOI 10.1016/j.resuscitation.2005.10.007; Heidenreich JW, 2004, RESUSCITATION, V62, P283, DOI 10.1016/j.resuscitation.2004.05.013; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Kern KB, 2002, CIRCULATION, V105, P645, DOI 10.1161/hc0502.102963; Kitamura T, 2010, CIRCULATION, V122, P293, DOI 10.1161/CIRCULATIONAHA.109.926816; Kitamura T, 2010, LANCET, V375, P1347, DOI 10.1016/S0140-6736(10)60064-5; Koster RW, 2008, RESUSCITATION, V77, P283, DOI 10.1016/j.resuscitation.2008.04.008; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Nagao K, 2007, LANCET, V369, P920; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nolan J, 2010, ANAESTHESIA, V65, P771, DOI 10.1111/j.1365-2044.2010.06448.x; Olasveengen TM, 2008, ACTA ANAESTH SCAND, V52, P914, DOI 10.1111/j.1399-6576.2008.01723.x; Ong MEH, 2008, RESUSCITATION, V78, P119, DOI 10.1016/j.resuscitation.2008.03.012; Rea TD, 2010, NEW ENGL J MED, V363, P423, DOI 10.1056/NEJMoa0908993; Sanders AB, 2002, ANN EMERG MED, V40, P553, DOI 10.1067/mem.2002.129507; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Svensson L, 2010, NEW ENGL J MED, V363, P434, DOI 10.1056/NEJMoa0908991; VANHOEYWEGHEN RJ, 1993, RESUSCITATION, V26, P47, DOI 10.1016/0300-9572(93)90162-J; Waalewijn RA, 2001, RESUSCITATION, V50, P273, DOI 10.1016/S0300-9572(01)00354-9	26	184	194	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	2010	376	9752					1552	1557		10.1016/S0140-6736(10)61454-7	http://dx.doi.org/10.1016/S0140-6736(10)61454-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QE	20951422	Green Accepted			2023-01-03	WOS:000284248700032
J	Bol, V; Desjardins, F; Reusens, B; Balligand, JL; Remacle, C				Bol, Vanesa; Desjardins, Fanny; Reusens, Brigitte; Balligand, Jen-Luc; Remacle, Claude			Does Early Mismatched Nutrition Predispose to Hypertension and Atherosclerosis, in Male Mice?	PLOS ONE			English	Article							CATCH-UP GROWTH; DIET-INDUCED OBESITY; PROTEIN RESTRICTION; BLOOD-PRESSURE; RECEPTOR EXPRESSION; METABOLIC SYNDROME; GENE-EXPRESSION; ADIPOSE-TISSUE; DEVELOPMENTAL ORIGINS; CIRCADIAN-RHYTHMS	Background: A link between early mismatched nutritional environment and development of components of the metabolic syndrome later in life has been shown in epidemiological and animal data. The aim of this study was to investigate whether an early mismatched nutrition produced by catch-up growth after fetal protein restriction could induce the appearance of hypertension and/or atherosclerosis in adult male mice. Methodology/Principal Findings: Wild-type C57BL6/J or LDLr-/- dams were fed a low protein (LP) or a control (C) diet during gestation. Catch-up growth was induced in LP offspring by feeding dams with a control diet and by culling the litter to 4 pups against 8 in controls. At weaning, male mice were fed either standard chow or an obesogenic diet (OB), leading to 4 experimental groups. Blood pressure (BP) and heart rate (HR) were assessed in conscious unrestrained wild-type mice by telemetry. Atherosclerosis plaque area was measured in aortic root sections of LDLr-/- mice. We found that: (1) postnatal OB diet increased significantly BP (P<0.0001) and HR (P<0.008) in 3-month old OB-C and OB-LP offspring, respectively; (2) that maternal LP diet induced a significant higher BP (P<0.009) and HR (P<0.004) and (3) an altered circadian rhythm in addition to higher plasma corticosterone concentration in 9 months-old LP offspring; (4) that, although LP offspring showed higher plasma total cholesterol than control offspring, atherosclerosis assessed in aortic roots of 6-mo old mice featured increased plaque area due to OB feeding but not due to early mismatched nutrition. Conclusions/Significance: These results indicate a long-term effect of early mismatched nutrition on the appearance of hypertension independently of obesity, while no effect on atherosclerosis was noticed at this age.	[Bol, Vanesa; Reusens, Brigitte; Remacle, Claude] Catholic Univ Louvain, Inst Life Sci, Cell Biol Lab, B-1348 Louvain, Belgium; [Desjardins, Fanny; Balligand, Jen-Luc] Catholic Univ Louvain, Unit Pharmacol & Theurapeut, B-1200 Brussels, Belgium	Universite Catholique Louvain; Universite Catholique Louvain	Bol, V (corresponding author), Catholic Univ Louvain, Inst Life Sci, Cell Biol Lab, B-1348 Louvain, Belgium.	claude.remacle@uclouvain.be	Balligand, Jean-Luc J/D-7543-2012	BALLIGAND, Jean-Luc/0000-0002-0522-4156	European Commission [FOOD-CT-2005-007036]; Partenon Trust (London, UK); Belgian Fonds National de la Recherche Scientifique (FNRS); Politique Scientifique Federale [PAI-P6/30]; Belgian Fonds pour la Recherche dans l'Industrie et l'Agriculture (FRIA)	European Commission(European CommissionEuropean Commission Joint Research Centre); Partenon Trust (London, UK); Belgian Fonds National de la Recherche Scientifique (FNRS)(Fonds de la Recherche Scientifique - FNRS); Politique Scientifique Federale; Belgian Fonds pour la Recherche dans l'Industrie et l'Agriculture (FRIA)(Fonds de la Recherche Scientifique - FNRS)	This work was supported by the European Commission (FOOD-CT-2005-007036), the Partenon Trust (London, UK), the Belgian Fonds National de la Recherche Scientifique (FNRS), Politique Scientifique Federale (PAI-P6/30) and the Belgian Fonds pour la Recherche dans l'Industrie et l'Agriculture (FRIA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adair LS, 2003, HYPERTENSION, V41, P451, DOI 10.1161/01.HYP.0000054212.23528.B2; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; BARKER DJP, 1989, LANCET, V2, P577; Bieswal F, 2004, J NUTR, V134, P1493, DOI 10.1093/jn/134.6.1493; Bieswal F, 2006, OBESITY, V14, P1330, DOI 10.1038/oby.2006.151; Bol VV, 2009, AM J PHYSIOL-REG I, V297, pR291, DOI 10.1152/ajpregu.90497.2008; Boullu-Ciocca S, 2005, DIABETES, V54, P197, DOI 10.2337/diabetes.54.1.197; Breton C, 2009, AM J PHYSIOL-ENDOC M, V296, pE462, DOI 10.1152/ajpendo.90740.2008; BROUBRED F, 2009, AM J PHYSIOL-RENAL, V297, pF943; Cleal JK, 2007, P NATL ACAD SCI USA, V104, P9529, DOI 10.1073/pnas.0610373104; Cole TJ, 2007, ACTA PAEDIATR, V96, P2, DOI 10.1111/j.1651-2227.2007.00162.x; Coupe B, 2010, ENDOCRINOLOGY, V151, P702, DOI 10.1210/en.2009-0893; Coupe B, 2009, AM J PHYSIOL-REG I, V297, pR813, DOI 10.1152/ajpregu.00201.2009; Erhuma A, 2007, AM J PHYSIOL-ENDOC M, V292, pE1702, DOI 10.1152/ajpendo.00605.2006; Fantuzzi G, 2007, ARTERIOSCL THROM VAS, V27, P996, DOI 10.1161/ATVBAHA.106.131755; Fernandez-Twinn DS, 2006, AM J PHYSIOL-REG I, V291, pR429, DOI 10.1152/ajpregu.00608.2005; Gluckman PD, 2005, MATERN CHILD NUTR, V1, P130, DOI 10.1111/j.1740-8709.2005.00020.x; Goharkhay N, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.08.002; Goldberg IJ, 2008, DIABETES, V57, P1674, DOI 10.2337/db08-0083; Groot PHE, 1996, ARTERIOSCL THROM VAS, V16, P926, DOI 10.1161/01.ATV.16.8.926; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 2005, BR MED B, V60, P5; Hasty AH, 2001, J BIOL CHEM, V276, P37402, DOI 10.1074/jbc.M010176200; Hoppe CC, 2007, AM J PHYSIOL-REG I, V292, pR462, DOI 10.1152/ajpregu.00079.2006; Langley-Evans SC, 2001, P NUTR SOC, V60, P505, DOI 10.1079/PNS2001111; Langley-Evans SC, 1998, NUTRITION, V14, P39, DOI 10.1016/S0899-9007(97)00391-2; Li P, 1999, AM J PHYSIOL-REG I, V276, pR500, DOI 10.1152/ajpregu.1999.276.2.R500; Lucas A, 1996, BRIT J NUTR, V76, P605, DOI 10.1079/BJN19960066; McMillen IC, 2005, PHYSIOL REV, V85, P571, DOI 10.1152/physrev.00053.2003; McMullen S, 2005, HYPERTENSION, V46, P1374, DOI 10.1161/01.HYP.0000188702.96256.46; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; Mistlberger RE, 1999, PHYSIOL BEHAV, V66, P329, DOI 10.1016/S0031-9384(98)00311-4; Mistlberger RE, 1998, APPETITE, V30, P255, DOI 10.1006/appe.1997.0134; Napoli C, 2002, CIRCULATION, V105, P1360, DOI 10.1161/01.CIR.0000013090.96919.FA; O'Regan D, 2008, J ENDOCRINOL, V196, P343, DOI 10.1677/JOE-07-0327; Painter RC, 2005, REPROD TOXICOL, V20, P345, DOI 10.1016/j.reprotox.2005.04.005; Petry C J, 2001, Int J Exp Diabetes Res, V2, P139; Petry CJ, 2000, DIABETIC MED, V17, P848, DOI 10.1046/j.1464-5491.2000.00392.x; Phillips DIW, 2006, ANN NY ACAD SCI, V1083, P28, DOI 10.1196/annals.1367.027; Poulos SP, 2010, MOL CELL ENDOCRINOL, V323, P20, DOI 10.1016/j.mce.2009.12.011; Remacle C, 2004, INT J OBESITY, V28, pS46, DOI 10.1038/sj.ijo.0802800; Rothwell PM, 2010, LANCET, V375, P938, DOI 10.1016/S0140-6736(10)60309-1; Russell JC, 2006, CARDIOVASC PATHOL, V15, P318, DOI 10.1016/j.carpath.2006.09.001; Samuelsson AM, 2008, HYPERTENSION, V51, P383, DOI 10.1161/HYPERTENSIONAHA.107.101477; Sathishkumar K, 2009, J VASC RES, V46, P229, DOI 10.1159/000166390; Schibler U, 2003, J BIOL RHYTHM, V18, P250, DOI 10.1177/0748730403018003007; Staessen JA, 2003, LANCET, V361, P1629, DOI 10.1016/S0140-6736(03)13302-8; Stanner S A, 2001, Twin Res, V4, P287, DOI 10.1375/1369052012498; Stanner SA, 1997, BMJ-BRIT MED J, V315, P1342, DOI 10.1136/bmj.315.7119.1342; Sugden MC, 2001, EUR J ENDOCRINOL, V145, P529, DOI 10.1530/eje.0.1450529; Tonkiss J, 1998, HYPERTENSION, V32, P108, DOI 10.1161/01.HYP.32.1.108; Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213; Watkins AJ, 2008, BIOL REPROD, V78, P299, DOI 10.1095/biolreprod.107.064220; Yates Z, 2009, BRIT J NUTR, V101, P1185, DOI 10.1017/S0007114508066786; Young ME, 2006, AM J PHYSIOL-HEART C, V290, pH1, DOI 10.1152/ajpheart.00582.2005	55	24	25	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2010	5	9							e12656	10.1371/journal.pone.0012656	http://dx.doi.org/10.1371/journal.pone.0012656			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	648IW	20844591	Green Published, Green Submitted, gold			2023-01-03	WOS:000281687200017
J	Baum, M				Baum, Michael			Homoeopathy waives the rules	LANCET			English	Editorial Material									Royal Free & Univ Coll Med Sch, Ctr Clin Sci & Technol, Clin Trials Grp, London N19 5LW, England	University of London; University College London	Baum, M (corresponding author), Royal Free & Univ Coll Med Sch, Ctr Clin Sci & Technol, Clin Trials Grp, London N19 5LW, England.	michael@mbaum.freeserve.co.uk						Department of Health, 2010, GOV RESP SCI TECHN C; Kmietowicz Z, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1091; Vaidya JS, 2010, LANCET, V376, P91, DOI 10.1016/S0140-6736(10)60837-9; DISCUSSIONS DEP HLTH	4	2	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 21	2010	376	9741					577	577		10.1016/S0140-6736(10)61227-5	http://dx.doi.org/10.1016/S0140-6736(10)61227-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	643PB	20728742				2023-01-03	WOS:000281309100010
J	Armitage, JO				Armitage, James O.			CURRENT CONCEPTS Early-Stage Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INVOLVED-FIELD RADIOTHERAPY; COMBINED-MODALITY THERAPY; RADIATION-THERAPY; COMBINATION CHEMOTHERAPY; ABVD CHEMOTHERAPY; LUNG-CANCER; FOLLOW-UP; DISEASE; RISK; TRIAL		Univ Nebraska, Med Ctr, Div Hematol Oncol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Armitage, JO (corresponding author), Univ Nebraska, Med Ctr, Div Hematol Oncol, 8722 LTC,42nd & Emile, Omaha, NE 68198 USA.	joarmita@unmc.edu			Allos Therapeutics; Ziopharm Oncology; Biogen IDEC; Eisai Pharmaceuticals; Amgen; L'Oreal; Groupe d'Etude des Lymphomes de l'Adulte (French lymphoma cooperative group)	Allos Therapeutics; Ziopharm Oncology; Biogen IDEC(Biogen); Eisai Pharmaceuticals(Eisai Co Ltd); Amgen(Amgen); L'Oreal(L'Oreal Group); Groupe d'Etude des Lymphomes de l'Adulte (French lymphoma cooperative group)	Dr. Armitage reports serving on the boards of MGI Pharma and the Roche Foundation for Anemia Research; receiving consulting fees from Allos Therapeutics, Ziopharm Oncology, Biogen IDEC, Eisai Pharmaceuticals, Amgen, L'Oreal, and Groupe d'Etude des Lymphomes de l'Adulte (French lymphoma cooperative group); and receiving speaking fees from and participating in educational activities for Imedex, Clinical Care Options, PRIME Oncology, and the Institute for Medical Education and Research. No other potential conflict of interest relevant to this article was reported.	Adams MJ, 2004, J CLIN ONCOL, V22, P3139, DOI 10.1200/JCO.2004.09.109; Al-Mansour M, 2010, J CLIN ONCOL, V28, P793, DOI 10.1200/JCO.2009.24.9516; Aleman BMP, 2007, BLOOD, V109, P1878, DOI 10.1182/blood-2006-07-034405; Barnes JA, 2008, BLOOD, V112, P518; BARTLETT NL, 1995, J CLIN ONCOL, V13, P1080, DOI 10.1200/JCO.1995.13.5.1080; BLAYNEY DW, 1987, NEW ENGL J MED, V316, P710, DOI 10.1056/NEJM198703193161203; Bonadonna G, 2004, J CLIN ONCOL, V22, P2835, DOI 10.1200/JCO.2004.12.170; Borchmann P, 2009, BLOOD, V114, P299; Canellos GP, 2010, J CLIN ONCOL, V28, P1611, DOI 10.1200/JCO.2009.25.3260; CARBONE PP, 1971, CANCER RES, V31, P1860; Chen RC, 2010, J CLIN ONCOL, V28, P136, DOI 10.1200/JCO.2009.24.0945; De Bruin ML, 2009, JNCI-J NATL CANCER I, V101, P928, DOI 10.1093/jnci/djp147; DEVITA VT, 1970, ANN INTERN MED, V73, P881, DOI 10.7326/0003-4819-73-6-881; Dominguez AR, 2004, ANN ONCOL, V15, P1798, DOI 10.1093/annonc/mdh465; EASSON EC, 1963, BRIT MED J, P1704, DOI 10.1136/bmj.1.5347.1704; Engert A, 2003, J CLIN ONCOL, V21, P3601, DOI 10.1200/JCO.2003.03.023; ENGERT A, 2010, NEW ENGL J MED, V363, P32; Evens AM, 2008, ONCOLOGY-NY, V22, P1369; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Franklin J, 2006, ANN ONCOL, V17, P1749, DOI 10.1093/annonc/mdl302; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Heidenreich PA, 2005, AM HEART J, V150, P977, DOI 10.1016/j.ahj.2004.12.026; Hentrich M, 2006, ANN ONCOL, V17, P914, DOI 10.1093/annonc/mdl063; Heutte N, 2009, LANCET ONCOL, V10, P1160, DOI 10.1016/S1470-2045(09)70258-X; KAPLAN HS, 1962, RADIOLOGY, V78, P553, DOI 10.1148/78.4.553; Klimm B, 2007, ANN ONCOL, V18, P357, DOI 10.1093/annonc/mdl379; Longo DL, 2006, BLOOD, V108, p33A; MACMAHON B, 1971, CANCER RES, V31, P1854; MACMAHON B, 1966, CANCER RES, V26, P1189; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; National Comprehensive Cancer Network Inc, NCCN GUID CLIN RES; Ng AK, 2004, ANN ONCOL, V15, P261, DOI 10.1093/annonc/mdh044; Noordijk EM, 2006, J CLIN ONCOL, V24, P3128, DOI 10.1200/JCO.2005.05.2746; OLWENY CLM, 1978, CANCER-AM CANCER SOC, V42, P787, DOI 10.1002/1097-0142(197808)42:2<787::AID-CNCR2820420251>3.0.CO;2-4; Pavone V, 2008, ANN ONCOL, V19, P763, DOI 10.1093/annonc/mdm575; PETERS MV, 1958, AMER J ROENTGENOL RA, V79, P114; Rizack T, 2009, AM J HEMATOL, V84, P830, DOI 10.1002/ajh.21547; Rosenberg SA, 1999, HODGKIN'S DISEASE, P47; Sher DJ, 2009, ANN ONCOL, V20, P1848, DOI 10.1093/annonc/mdp071; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; Swerdlow AJ, 2001, J CLIN ONCOL, V19, P1610, DOI 10.1200/JCO.2001.19.6.1610; Swerdlow AJ, 2007, J NATL CANCER I, V99, P206, DOI 10.1093/jnci/djk029; Swerdlow S.H., 2008, WHO CLASSIFICATION T; Travis LB, 2005, JNCI-J NATL CANCER I, V97, P1428, DOI 10.1093/jnci/dji290; Travis LB, 2002, JNCI-J NATL CANCER I, V94, P182, DOI 10.1093/jnci/94.3.182; van Leeuwen FE, 2003, JNCI-J NATL CANCER I, V95, P971, DOI 10.1093/jnci/95.13.971; Weekes CD, 2002, J CLIN ONCOL, V20, P1087, DOI 10.1200/JCO.20.4.1087; ZIEGLER JL, 1972, LANCET, V2, P679	48	104	115	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					653	662		10.1056/NEJMra1003733	http://dx.doi.org/10.1056/NEJMra1003733			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20818856				2023-01-03	WOS:000280764600008
J	Frohman, EM; Wingerchuk, DM				Frohman, Elliot M.; Wingerchuk, Dean M.			Transverse Myelitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MULTIPLE-SCLEROSIS; NEUROMYELITIS-OPTICA; PLASMA-EXCHANGE; DOUBLE-BLIND; NEUROPATHIC PAIN; EFFICACY; FATIGUE; CORTICOSTEROIDS; MODAFINIL; DIAGNOSIS	An otherwise healthy 28-year-old woman presents to the emergency department with progressive weakness that began 3 days earlier. She reports difficulty walking, numbness in the body below her breasts, and urinary urgency, and she notes that neck flexion triggers an electrical sensation that radiates to the coccyx. Physical examination reveals moderate paraparesis with hyperreflexia, a left extensor plantar response, impairment of vibratory and proprioceptive sensation, and a sensory level at T6. Magnetic resonance imaging (MRI) reveals a lower cervical cord lesion that enhances after gadolinium administration, a finding that is consistent with transverse myelitis. How should she be further evaluated and treated?	[Frohman, Elliot M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75235 USA; [Frohman, Elliot M.] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75235 USA; [Wingerchuk, Dean M.] Mayo Clin, Dept Neurol, Scottsdale, AZ USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Mayo Clinic; Mayo Clinic Phoenix	Frohman, EM (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	elliot.frohman@utsouthwestern.edu			Biogen Idec; Teva Neuroscience; Bayer; Novartis; Abbott; Genzyme; Alexion; Genentech; Organon (now part of Merck); National Multiple Sclerosis Society; VLST; Guthy-Jackson Charitable Foundation	Biogen Idec(Biogen); Teva Neuroscience(Teva Pharmaceutical Industries); Bayer(Bayer AG); Novartis(Novartis); Abbott(Abbott Laboratories); Genzyme(Sanofi-AventisGenzyme Corporation); Alexion; Genentech(Roche HoldingGenentech); Organon (now part of Merck); National Multiple Sclerosis Society(National Multiple Sclerosis Society); VLST; Guthy-Jackson Charitable Foundation	Dr. Frohman reports receiving speaking fees from Biogen Idec, Teva Neuroscience, Bayer, and Novartis and consulting fees from Biogen Idec, Teva Neuroscience, Abbott, and Genzyme; and Dr. Wingerchuk, receiving research support from Alexion, Genzyme, Genentech, Organon (now part of Merck), and the National Multiple Sclerosis Society and consulting fees from Novartis, Teva Neuroscience, VLST, and the Guthy-Jackson Charitable Foundation. No other potential conflict of interest relevant to this article was reported.	Abrams P, 1998, BRIT J UROL, V81, P801; [Anonymous], 2007, COCHRANE DATABASE SY, DOI 10.1002/14651858.CD005454.pub2; Barnes G, 2002, NEUROLOGY, V59, P499, DOI 10.1212/wnl.59.4.499; Bennett JK, 2000, MOL UROL, V4, P415; BERMAN M, 1981, NEUROLOGY, V31, P969; Bhat A, 2010, AUTOIMMUN REV, V9, pA395, DOI 10.1016/j.autrev.2009.12.007; Bonnan M, 2009, MULT SCLER J, V15, P487, DOI 10.1177/1352458508100837; Branas P., 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4270; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Courtney AM, 2009, MED CLIN N AM, V93, P451, DOI 10.1016/j.mcna.2008.09.014; de Seze J, 2005, NEUROLOGY, V65, P1950, DOI 10.1212/01.wnl.0000188896.48308.26; de Seze J, 2001, BRAIN, V124, P1509, DOI 10.1093/brain/124.8.1509; Debette S, 2009, J NEUROL, V256, P980, DOI 10.1007/s00415-009-5058-x; Fletcher SG, 2009, NAT CLIN PRACT UROL, V6, P96, DOI 10.1038/ncpuro1298; Frohman EM, 2007, NEUROTHERAPEUTICS, V4, P618, DOI 10.1016/j.nurt.2007.07.008; Goodman AD, 2009, LANCET, V373, P732, DOI 10.1016/S0140-6736(09)60442-6; Greenberg BM, 2007, NEUROLOGY, V68, P1614, DOI 10.1212/01.wnl.0000260970.63493.c8; Groves L, 1998, ADV THER, V15, P241; Hummers LK, 2004, NEUROLOGY, V62, P147, DOI 10.1212/01.WNL.0000101715.32569.1A; Jacob A, 2008, SEMIN NEUROL, V28, P105, DOI 10.1055/s-2007-1019132; Kaplin AI, 2005, NEUROLOGIST, V11, P2, DOI 10.1097/01.nrl.0000149975.39201.0b; Kesselring J, 2005, LANCET NEUROL, V4, P643, DOI 10.1016/S1474-4422(05)70193-9; Kumar N, 2004, ARCH NEUROL-CHICAGO, V61, P586, DOI 10.1001/archneur.61.4.586; Lemack GE, 2006, UROLOGY, V67, P960, DOI 10.1016/j.urology.2005.11.061; Lennon VA, 2005, J EXP MED, V202, P473, DOI 10.1084/jem.20050304; Martinelli V, 2009, NEUROLOGY, V73, P1842, DOI 10.1212/WNL.0b013e3181c3fd5b; Misu T, 2005, NEUROLOGY, V65, P1479, DOI 10.1212/01.wnl.0000183151.19351.82; Namaka Michael, 2009, Consult Pharm, V24, P885, DOI 10.4140/TCP.n.2009.885; Pidcock FS, 2007, NEUROLOGY, V68, P1474, DOI 10.1212/01.wnl.0000260609.11357.6f; Pittock SJ, 2008, ARCH NEUROL-CHICAGO, V65, P78, DOI 10.1001/archneurol.2007.17; Pittock SJ, 2006, CURR OPIN NEUROL, V19, P362, DOI 10.1097/01.wco.0000236615.59215.d3; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; SAARTO T, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD005454; Scott TF, 2007, ACTA NEUROL SCAND, V115, P371, DOI 10.1111/j.1600-0404.2007.00835.x; Spivack S B, 1997, J Spinal Cord Med, V20, P402; Stankoff B, 2005, NEUROLOGY, V64, P1139, DOI 10.1212/01.WNL.0000158272.27070.6A; Tomassini V, 2004, J NEUROL SCI, V218, P103, DOI 10.1016/j.jns.2003.11.005; Tzellos TG, 2008, EUR J CLIN PHARMACOL, V64, P851, DOI 10.1007/s00228-008-0523-5; Watanabe S, 2007, MULT SCLER J, V13, P128, DOI 10.1177/1352458506071174; Weinshenker BG, 2006, ANN NEUROL, V59, P566, DOI 10.1002/ana.20770; Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q; Wiffen PJ, 2005, COCHRANE DB SYST REV, V3; Wingerchuk DM, 2006, NEUROLOGY, V66, P1485, DOI 10.1212/01.wnl.0000216139.44259.74; Wingerchuk DM, 2008, CURR TREAT OPTION NE, V10, P55, DOI 10.1007/s11940-008-0007-z; Wingerchuk DM, 2007, LANCET NEUROL, V6, P805, DOI 10.1016/S1474-4422(07)70216-8; Wingerchuk Dean M, 2003, Curr Neurol Neurosci Rep, V3, P256, DOI 10.1007/s11910-003-0086-x; Wingerchuk DM, 1999, NEUROLOGY, V53, P1107, DOI 10.1212/WNL.53.5.1107	47	104	110	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	2010	363	6					564	572		10.1056/NEJMcp1001112	http://dx.doi.org/10.1056/NEJMcp1001112			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	634BB	20818891				2023-01-03	WOS:000280552700010
J	Helliwell, PS; Crawshaw, DP; Hensor, EMA; Hay, EM; Aldous, SJ; Conaghan, PG				Helliwell, Philip S.; Crawshaw, Dickon P.; Hensor, Elizabeth M. A.; Hay, Elaine M.; Aldous, Simon J.; Conaghan, Philip G.			Exercise therapy after corticosteroid injection for moderate to severe shoulder pain: large pragmatic randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MANUAL PHYSICAL-THERAPY; DOUBLE-BLIND; SUPERVISED EXERCISES; GENERAL-PRACTICE; ARTHROSCOPIC SURGERY; IMPINGEMENT SYNDROME; PRIMARY-CARE; PHYSIOTHERAPY; DISORDERS; SINGLE	Objective To compare the effectiveness of subacromial corticosteroid injection combined with timely exercise and manual therapy (injection plus exercise) or exercise and manual therapy alone (exercise only) in patients with subacromial impingement syndrome. Design Pragmatic randomised clinical trial. Setting Primary care based musculoskeletal service. Patients Adults aged 40 or over with subacromial impingement syndrome with moderate or severe shoulder pain. Interventions Injection plus exercise or exercise only. Main outcome measures Primary outcome was the difference in improvement in the total shoulder pain and disability index at 12 weeks. Results 232 participants were randomised (115 to injection plus exercise, 117 to exercise only). The mean age was 56 (range 40-78), 127 were women, and all had had a median of 16 weeks of shoulder pain (interquartile range 1228). At week 12 there was no significant difference between the groups in change in total pain and disability index (mean difference between change in groups 3.26 (95% confidence interval -0.81 to 7.34), P=0.116). Improvement was significantly greater in the injection plus exercise group at week 1 (6.56, 4.30 to 8.82) and week 6 (7.37, 4.34 to 10.39) for the total pain and disability index (P<0.001), with no differences at week 24 (-2.26, -6.77 to 2.25, P=0.324). Conclusions In the treatment of patients with subacromial impingement syndrome, injection plus exercise and exercise only are similarly effective at 12 weeks.	[Crawshaw, Dickon P.] Leeds Community Healthcare, Leeds Musculoskelet & Rehab Serv, Leeds LS7 4SA, W Yorkshire, England; [Helliwell, Philip S.; Crawshaw, Dickon P.; Conaghan, Philip G.] Univ Leeds, Leeds Inst Mol Med, Leeds LS7 4SA, W Yorkshire, England; [Hensor, Elizabeth M. A.; Conaghan, Philip G.] Chapel Allerton Hosp, Leeds Musculoskelet & Rehab Serv, NIHR Leeds Musculoskelet Biomed Res Unit, Leeds LS7 4SA, W Yorkshire, England; [Hay, Elaine M.] Keele Univ, Arthrit Res UK Natl Primary Care Res Ctr, Keele ST5 5BG, Staffs, England; [Aldous, Simon J.] Leeds Teaching Hosp NHS Trust, Physiother Dept, Leeds LS9 7TF, W Yorkshire, England	University of Leeds; Chapel Allerton Hospital; Keele University; University of Leeds	Conaghan, PG (corresponding author), Leeds Community Healthcare, Leeds Musculoskelet & Rehab Serv, Leeds LS7 4SA, W Yorkshire, England.	p.conaghan@leeds.ac.uk		Conaghan, Philip/0000-0002-3478-5665; Hensor, Elizabeth/0000-0002-5245-4755	Arthritis Research UK [17236]	Arthritis Research UK(Versus Arthritis)	The study was funded by a project grant 17236 from Arthritis Research UK.	ACPOM, 1999, CLIN GUID US INJ THE; ADEBAJO AO, 1990, J RHEUMATOL, V17, P1207; Arroll B, 2005, BRIT J GEN PRACT, V55, P224; Bamji AN, 2004, ANN RHEUM DIS, V63, P607; Bang MD, 2000, J ORTHOP SPORT PHYS, V30, P126, DOI 10.2519/jospt.2000.30.3.126; Blair B, 1996, J BONE JOINT SURG AM, V78A, P1685, DOI 10.2106/00004623-199611000-00007; Brox JI, 1999, J SHOULDER ELB SURG, V8, P102, DOI 10.1016/S1058-2746(99)90001-0; BROX JI, 1993, BMJ-BRIT MED J, V307, P899, DOI 10.1136/bmj.307.6909.899; Brox JI, 1997, ARCH PHYS MED REHAB, V78, P1260, DOI 10.1016/S0003-9993(97)90341-5; Calis M, 2000, ANN RHEUM DIS, V59, P44, DOI 10.1136/ard.59.1.44; Carette S, 2003, ARTHRITIS RHEUM, V48, P829, DOI 10.1002/art.10954; CHARD MD, 1991, ARTHRITIS RHEUM-US, V34, P766, DOI 10.1002/art.1780340619; Croft P, 1996, BRIT MED J, V313, P601; Ekeberg OM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3112; Engebretsen K, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3360; Foster NE, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-3; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; Green S, 2003, Cochrane Database Syst Rev, pCD004258; Hay EM, 2003, ANN RHEUM DIS, V62, P394, DOI 10.1136/ard.62.5.394; Kuhn JE, 2009, J SHOULDER ELB SURG, V18, P138, DOI 10.1016/j.jse.2008.06.004; Kuijpers T, 2006, PAIN, V120, P276, DOI 10.1016/j.pain.2005.11.004; Linsell L, 2006, RHEUMATOLOGY, V45, P215, DOI 10.1093/rheumatology/kei139; MacDonald PB, 2000, J SHOULDER ELB SURG, V9, P299, DOI 10.1067/mse.2000.106918; McInerney JJ, 2003, EMERG MED J, V20, P218, DOI 10.1136/emj.20.3.218; Morrison DS, 1997, J BONE JOINT SURG AM, V79A, P732, DOI 10.2106/00004623-199705000-00013; Naredo E, RANDOMIZED COMP STUD; NEER CS, 1983, CLIN ORTHOP RELAT R, P70; Ostor AJK, 2005, RHEUMATOLOGY, V44, P800, DOI 10.1093/rheumatology/keh598; PETRI M, 1987, ARTHRITIS RHEUM-US, V30, P1040, DOI 10.1002/art.1780300911; Plafki C, 2000, INT ORTHOP, V24, P40, DOI 10.1007/s002640050010; Roach K E, 1991, Arthritis Care Res, V4, P143, DOI 10.1002/art.1790040403; Roland M, 1998, BRIT MED J, V316, P285, DOI 10.1136/bmj.316.7127.285; Sauers EL, 2005, J ATHL TRAINING, V40, P221; Saunders S, 1997, INJECTION TECHNIQUES; Senbursa G, 2007, KNEE SURG SPORT TR A, V15, P915, DOI 10.1007/s00167-007-0288-x; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; van der Windt DAWM, 1998, BRIT MED J, V317, P1292, DOI 10.1136/bmj.317.7168.1292; vanderWindt DAWM, 1996, BRIT J GEN PRACT, V46, P519; VANDERWINDT DAWM, 1995, ANN RHEUM DIS, V54, P959, DOI 10.1136/ard.54.12.959; VECCHIO PC, 1993, BRIT J RHEUMATOL, V32, P743; Watson J, 2008, RHEUMATOLOGY, V47, P1795, DOI 10.1093/rheumatology/ken360; WILLIAMS JW, 1995, J RHEUMATOL, V22, P727; Winters JC, 1997, BRIT MED J, V314, P1320, DOI 10.1136/bmj.314.7090.1320	43	55	58	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 28	2010	340								c3037	10.1136/bmj.c3037	http://dx.doi.org/10.1136/bmj.c3037			21	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	845JZ	20584793	Green Published, hybrid			2023-01-03	WOS:000296820300001
J	Bojang, KA; Milligan, PJM; Conway, DJ; Sisay-Joof, F; Jallow, M; Nwakanma, DC; Abubakr, I; Njie, F; Greenwood, B				Bojang, Kalifa A.; Milligan, Paul J. M.; Conway, David J.; Sisay-Joof, Fatou; Jallow, Muminatou; Nwakanma, Davis C.; Abubakr, Ismaela; Njie, Fanta; Greenwood, Brian			Prevention of the Recurrence of Anaemia in Gambian Children Following Discharge from Hospital	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM; SULFADOXINE-PYRIMETHAMINE; DIHYDROFOLATE-REDUCTASE; PRESCHOOL-CHILDREN; MALARIA; MORTALITY; TRANSMISSION; TRANSFUSION; IMPACT; IRON	Background: In malaria endemic countries, children who have experienced an episode of severe anaemia are at increased risk of a recurrence of anaemia. There is a need to find ways of protecting these at risk children from malaria and chemoprevention offers a potential way of achieving this objective. Methods: During the 2003 and 2004 malaria transmission seasons, 1200 Gambian children with moderate or severe anaemia (Hb concentration <7 g/dL) were randomised to receive either monthly sulfadoxine-pyrimethamine (SP) or placebo until the end of the malaria transmission season in which they were enrolled, in a double-blind trial. All study subjects were treated with oral iron for 28 days and morbidity was monitored through surveillance at health centres. The primary endpoint was the proportion of children with moderate or severe anaemia at the end of the transmission season. Secondary endpoints included the incidence of clinical episodes of malaria during the surveillance period, outpatient attendances, the prevalence of parasitaemia and splenomegaly, nutritional status at the end of the malaria transmission season and compliance with the treatment regimen. Results: The proportions of children with a Hb concentration of,7 g/dL at the end of the malaria transmission season were similar in the two study groups, 14/464 (3.0%) in children who received at least one dose of SP and 16/471 (3.4%) in those who received placebo, prevalence ratio 0.89 (0.44, 1.8) P = 0.742. The protective efficacy of SP against episodes of clinical malaria was 53% (95% CI 37%, 65%). Treatment with SP was safe and well tolerated; no serious adverse events related to SP administration were observed. Mortality following discharge from hospital was low among children who received SP or placebo (6 in the SP group and 9 in the placebo group respectively). Conclusions: Intermittent treatment with SP did not reduce the proportion of previously anaemic children with moderate or severe anaemia at the end of the malaria season, although it prevented malaria. The combination of appropriate antimalarial treatment plus one month of iron supplementation and good access to healthcare during follow-up proved effective in restoring haemoglobin to an acceptable level in the Gambian setting.	[Bojang, Kalifa A.; Conway, David J.; Sisay-Joof, Fatou; Jallow, Muminatou; Nwakanma, Davis C.; Abubakr, Ismaela; Njie, Fanta] MRC Labs, Banjul, Gambia; [Milligan, Paul J. M.; Greenwood, Brian] London Sch Hyg & Trop Med, London WC1, England	MRC Laboratory Molecular Biology; University of London; London School of Hygiene & Tropical Medicine	Bojang, KA (corresponding author), MRC Labs, Banjul, Gambia.	kbojang@mrc.gm	Milligan, Paul/D-8985-2017	Milligan, Paul/0000-0003-3430-3395; Bojang, Kalifa/0000-0001-7506-0938; Nwakanma, Davis/0000-0002-6706-6069; Conway, David/0000-0002-8711-3037	Gates malaria partnership	Gates malaria partnership	The study received financial support from the Gates malaria partnership. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7; Barnes KI, 2006, CLIN PHARMACOL THER, V80, P582, DOI 10.1016/j.clpt.2006.08.016; Biemba G, 2000, TROP MED INT HEALTH, V5, P9, DOI 10.1046/j.1365-3156.2000.00506.x; Bojang KA, 1997, T ROY SOC TROP MED H, V91, P557, DOI 10.1016/S0035-9203(97)90025-0; Brabin BJ, 2001, J NUTR, V131, p636S, DOI 10.1093/jn/131.2.636S; BREWSTER DR, 1993, ANN TROP PAEDIATR, V13, P133, DOI 10.1080/02724936.1993.11747637; Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2; Cisse B, 2006, LANCET, V367, P659, DOI 10.1016/S0140-6736(06)68264-0; CRAIGHEAD IB, 1993, TROP DOCT, V23, P59, DOI 10.1177/004947559302300207; Desai MR, 2003, J INFECT DIS, V187, P658, DOI 10.1086/367986; Dicko A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-123; Dunyo S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010014; Duraisingh MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/expr.1998.4274; EMERTON DGC, 1992, T ROY SOC TROP MED H, V86, P476, DOI 10.1016/0035-9203(92)90073-L; Ghattas H, 2003, LANCET, V361, P2048, DOI 10.1016/S0140-6736(03)13617-3; GREENWOOD BM, 1991, T ROY SOC TROP MED H, V85, P186, DOI 10.1016/0035-9203(91)90015-Q; Hay SI, 2000, T ROY SOC TROP MED H, V94, P113, DOI 10.1016/S0035-9203(00)90246-3; HEDBERG K, 1993, AM J TROP MED HYG, V48, P365, DOI 10.4269/ajtmh.1993.48.365; Kweku M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004000; Lackritz EM, 1997, AIDS, V11, P1487, DOI 10.1097/00002030-199712000-00013; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102; Ntab B, 2007, AM J TROP MED HYG, V77, P411, DOI 10.4269/ajtmh.2007.77.411; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Sazawal S, 2006, LANCET, V367, P133, DOI 10.1016/S0140-6736(06)67962-2; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; SLUTSKER L, 1994, T ROY SOC TROP MED H, V88, P548, DOI 10.1016/0035-9203(94)90157-0; Sokhna C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001471; Verhoef H, 2002, LANCET, V360, P908, DOI 10.1016/S0140-6736(02)11027-0; WACHOLDER S, 1986, AM J EPIDEMIOL, V123, P174, DOI 10.1093/oxfordjournals.aje.a114212; Zucker JR, 2003, AM J TROP MED HYG, V68, P386, DOI 10.4269/ajtmh.2003.68.386; Zucker JR, 1996, AM J TROP MED HYG, V55, P655, DOI 10.4269/ajtmh.1996.55.655	33	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2010	5	6							e11227	10.1371/journal.pone.0011227	http://dx.doi.org/10.1371/journal.pone.0011227			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	614KV	20574541	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000279058300016
J	Bueno, H; Ross, JS; Wang, Y; Chen, J; Vidan, MT; Normand, SLT; Curtis, JP; Drye, EE; Lichtman, JH; Keenan, PS; Kosiborod, M; Krumholz, HM				Bueno, Hector; Ross, Joseph S.; Wang, Yun; Chen, Jersey; Vidan, Maria T.; Normand, Sharon-Lise T.; Curtis, Jeptha P.; Drye, Elizabeth E.; Lichtman, Judith H.; Keenan, Patricia S.; Kosiborod, Mikhail; Krumholz, Harlan M.			Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							READMISSION RATES; TEMPORAL TRENDS; MORTALITY; SURVIVAL; CARE; PERFORMANCE	Context Whether decreases in the length of stay during the past decade for patients with heart failure (HF) may be associated with changes in outcomes is unknown. Objective To describe the temporal changes in length of stay, discharge disposition, and short-term outcomes among older patients hospitalized for HF. Design, Setting, and Participants An observational study of 6 955 461 Medicare fee-for-service hospitalizations for HF between 1993 and 2006, with a 30-day follow-up. Main Outcome Measures Length of hospital stay, in-patient and 30-day mortality, and 30-day readmission rates. Results Between 1993 and 2006, mean length of stay decreased from 8.81 days (95% confidence interval [CI], 8.79-8.83 days) to 6.33 days (95% CI, 6.32-6.34 days). In-hospital mortality decreased from 8.5% (95% CI, 8.4%-8.6%) in 1993 to 4.3% (95% CI, 4.2%-4.4%) in 2006, whereas 30-day mortality decreased from 12.8% (95% CI, 12.8%-12.9%) to 10.7% (95% CI, 10.7%-10.8%). Discharges to home or under home care service decreased from 74.0% to 66.9% and discharges to skilled nursing facilities increased from 13.0% to 19.9%. Thirty-day readmission rates increased from 17.2% (95% CI, 17.1%-17.3%) to 20.1% (95% CI, 20.0%-20.2%; all P<.001). Consistent with the unadjusted analyses, the 2005-2006 risk-adjusted 30-day mortality risk ratio was 0.92 (95% CI, 0.91-0.93) compared with 1993-1994, and the 30-day readmission risk ratio was 1.11 (95% CI, 1.10-1.11). Conclusion For patients admitted with HF during the past 14 years, reductions in length of stay and in-hospital mortality, less marked reductions in 30-day mortality, and changes in discharge disposition accompanied by increases in 30-day readmission rates were observed. JAMA. 2010; 303(21): 2141-2147	[Bueno, Hector] Hosp Gen Univ Gregorio Maranon, Dept Cardiol, Madrid, Spain; [Vidan, Maria T.] Hosp Gen Univ Gregorio Maranon, Serv Geriatr Med, Madrid, Spain; [Ross, Joseph S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA; [Ross, Joseph S.] James J Peters VA Med Ctr, HSR&D Res Enhancement Award Program, Bronx, NY USA; [Ross, Joseph S.] James J Peters VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA; [Wang, Yun; Chen, Jersey; Curtis, Jeptha P.; Drye, Elizabeth E.; Krumholz, Harlan M.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Internal Med, Sch Publ Hlth, New Haven, CT 06510 USA; [Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Robert Wood Johnson Clin Scholars Program, New Haven, CT 06510 USA; [Lichtman, Judith H.] Yale Univ, Sch Med, Sch Publ Hlth, Sect Chron Dis Epidemiol, New Haven, CT 06510 USA; [Keenan, Patricia S.; Krumholz, Harlan M.] Yale Univ, Sch Med, Sch Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA; [Normand, Sharon-Lise T.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Normand, Sharon-Lise T.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Kosiborod, Mikhail] Univ Missouri, St Lukes Hosp, Mid Amer Heart Inst, Kansas City, MO USA; [Kosiborod, Mikhail] Univ Missouri, Dept Med, Kansas City, MO USA	General University Gregorio Maranon Hospital; General University Gregorio Maranon Hospital; Icahn School of Medicine at Mount Sinai; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Yale University; Yale University; Yale University; Yale University; Yale University; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Saint Luke's Hospital - Missouri; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sch Publ Hlth, 1 Church St,Ste 200, New Haven, CT 06510 USA.	harlan.krumholz@yale.edu	Kosiborod, Mikhail/HDO-1541-2022; Bueno, Hector/I-3910-2015; , Harlan/AAI-2875-2020	Kosiborod, Mikhail/0000-0002-3750-9789; Bueno, Hector/0000-0003-0277-7596; Normand, Sharon-Lise/0000-0001-7027-4769; Ross, Joseph/0000-0002-9218-3320	Centers for Medicare & Medicaid Services, US Department of Health and Human Services [HHSM-500-2005-CO001C]; Centers for Disease Control and Prevention [K01 DP000085-05]; Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III, Spain [BA08/90010, BA08/90012]; National Institute on Aging [K08 AG032886]; American Federation for Aging Research; American Heart Association; Almirall; Bayer; Bristol-Myers Squibb; Sanofi-Aventis; Astra-Zeneca; Pfizer; Centers for Medicare & Medicaid Services; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO [K01DP000085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG032886] Funding Source: NIH RePORTER	Centers for Medicare & Medicaid Services, US Department of Health and Human Services; Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III, Spain(Instituto de Salud Carlos III); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research; American Heart Association(American Heart Association); Almirall(Almirall); Bayer(Bayer AG); Bristol-Myers Squibb(Bristol-Myers Squibb); Sanofi-Aventis(Sanofi-Aventis); Astra-Zeneca(AstraZeneca); Pfizer(Pfizer); Centers for Medicare & Medicaid Services; NATIONAL CENTER FOR CHRONIC DISEASE PREV AND HEALTH PROMO(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The analyses upon which this publication is based were performed under contract HHSM-500-2005-CO001C, entitled "Utilization and Quality Control Quality Improvement Organization for the State (commonwealth) of Colorado," which was funded by the Centers for Medicare & Medicaid Services, an agency of the US Department of Health and Human Services. This work was also funded by grant K01 DP000085-05 from the Centers for Disease Control and Prevention. Drs Bueno and Vidan were supported in part by grants BA08/90010 and BA08/90012, respectively, from the Fondo de Investigacion Sanitaria del Instituto de Salud Carlos III, Spain, while at the Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, where they participated in the development of this study. Dr Ross is supported by grant K08 AG032886 from the National Institute on Aging and by the American Federation for Aging Research through the Paul B. Beeson Career Development Award Program. Dr Kosiborod is supported by the American Heart Association Career Development Award in Implementation Research.; Dr Bueno reported having received consulting fees from Almirall, Bayer, Bristol-Myers Squibb, and Sanofi-Aventis, and research grants from Astra-Zeneca, Bristol-Myers Squibb, and Pfizer. Drs Wang, Chen, Normand, Curtis, Drye, Keenan, and Krumholz reported that they develop and maintain performance measures under contract with the Centers for Medicare & Medicaid Services. Dr Kosiborod reported serving on the advisory board of Sanofi-Aventis and receiving speaking honoraria from the Vascular Biology Working Group and DiaVed Inc. Dr Krumholz reported chairing a scientific advisory board for United Healthcare. Drs Ross, Vidan, and Lichtman did not report any disclosures.	*AM HOSP ASS, TRENDW CHARTB 2008 T; Baker DW, 2004, ARCH INTERN MED, V164, P538, DOI 10.1001/archinte.164.5.538; Baker DW, 2003, AM HEART J, V146, P258, DOI 10.1016/S0002-8703(02)94784-8; Curtis LH, 2008, ARCH INTERN MED, V168, P2481, DOI 10.1001/archinte.168.22.2481; CUZICK J, 1985, STAT MED, V4, P87, DOI 10.1002/sim.4780040112; Fang J, 2008, J AM COLL CARDIOL, V52, P428, DOI 10.1016/j.jacc.2008.03.061; Feldman DE, 2001, CAN MED ASSOC J, V165, P1033; Fonarow GC, 2007, AM HEART J, V153, P1021, DOI [10.1016/j.ahj.2007.03.012, 10.1016/j.ahj.2007.07.043]; Haldeman GA, 1999, AM HEART J, V137, P352, DOI 10.1053/hj.1999.v137.95495; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; Kosiborod M, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.11.019; Krumholz HM, 2008, CIRCULATION, V118, P1885, DOI 10.1161/CIRCULATIONAHA.108.190500; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Krumholz HM, 2006, CIRCULATION, V113, P1693, DOI 10.1161/CIRCULATIONAHA.105.611194; Lee DS, 2004, AM J MED, V116, P581, DOI 10.1016/j.amjmed.2003.11.025; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; McDermontt MM, 1997, AM HEART J, V134, P901, DOI 10.1016/S0002-8703(97)80013-0; *MEDPAC, REP C REF DEL SYST; Polanczyk CA, 2000, ARCH INTERN MED, V160, P325, DOI 10.1001/archinte.160.3.325; Roger VL, 2004, JAMA-J AM MED ASSOC, V292, P344, DOI 10.1001/jama.292.3.344; Ross JS, 2010, CIRC-HEART FAIL, V3, P97, DOI 10.1161/CIRCHEARTFAILURE.109.885210; Setoguchi S, 2008, INT J CARDIOL, V125, P172, DOI 10.1016/j.ijcard.2007.10.009; Shimada SL, 2009, MED CARE, V47, P517, DOI 10.1097/MLR.0b013e318195f86e; Smith NL, 2004, AM HEART J, V148, P710, DOI 10.1016/j.ahj.2004.04.002; Stafford RS, 2003, J AM COLL CARDIOL, V41, P56, DOI 10.1016/S0735-1097(02)02670-0	27	463	475	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2010	303	21					2141	2147		10.1001/jama.2010.748	http://dx.doi.org/10.1001/jama.2010.748			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603BE	20516414	Green Accepted, Bronze			2023-01-03	WOS:000278182100022
J	Paoletti, X; Oba, K; Burzykowski, T; Michiels, S; Ohashi, Y; Pignon, JP; Rougier, P; Sakamoto, J; Sargent, D; Sasako, M; Van Cutsem, E; Buyse, M				Paoletti, Xavier; Oba, Koji; Burzykowski, Tomasz; Michiels, Stefan; Ohashi, Yasuo; Pignon, Jean-Pierre; Rougier, Philippe; Sakamoto, Junichi; Sargent, Daniel; Sasako, Mitsuru; Van Cutsem, Eric; Buyse, Marc		GASTRIC Grp	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHASE-III TRIAL; CURATIVE RESECTION; RANDOMIZED-TRIAL; FOLLOW-UP; UPDATED METAANALYSIS; CLINICAL-TRIAL; ONCOLOGY-GROUP; PLUS TEGAFUR; NO TREATMENT; MITOMYCIN-C	Context Despite potentially curative resection of stomach cancer, 50% to 90% of patients die of disease relapse. Numerous randomized clinical trials (RCTs) have compared surgery alone with adjuvant chemotherapy, but definitive evidence is lacking. Objectives To perform an individual patient-level meta-analysis of all RCTs to quantify the potential benefit of chemotherapy after complete resection over surgery alone in terms of overall survival and disease-free survival, and to further study the role of regimens, including monochemotherapy; combined chemotherapy with fluorouracil derivatives, mitomycin C, and other therapies but no anthracyclines; combined chemotherapy with fluorouracil derivatives, mitomycin C, and anthracyclines; and other treatments. Data Sources Data from all RCTs comparing adjuvant chemotherapy with surgery alone in patients with resectable gastric cancer. We searched MEDLINE (up to 2009), the Cochrane Central Register of Controlled Trials, the National Institutes of Health trial registry, and published proceedings from major oncologic and gastrointestinal cancer meetings. Study Selection All RCTs closed to patient recruitment before 2004 were eligible. Trials testing radiotherapy; neoadjuvant, perioperative, or intraperitoneal chemotherapy; or immunotherapy were excluded. Thirty-one eligible trials (6390 patients) were identified. Data Extraction As of 2010, individual patient data were available from 17 trials (3838 patients representing 60% of the targeted data) with a median follow-up exceeding 7 years. Results There were 1000 deaths among 1924 patients assigned to chemotherapy groups and 1067 deaths among 1857 patients assigned to surgery-only groups. Adjuvant chemotherapy was associated with a statistically significant benefit in terms of overall survival (hazard ratio [HR], 0.82; 95% confidence interval [CI], 0.76-0.90; P < .001) and disease-free survival (HR, 0.82; 95% CI, 0.75-0.90; P < .001). There was no significant heterogeneity for overall survival across RCTs (P=.52) or the 4 regimen groups (P=.13). Five-year overall survival increased from 49.6% to 55.3% with chemotherapy. Conclusion Among the RCTs included, postoperative adjuvant chemotherapy based on fluorouracil regimens was associated with reduced risk of death in gastric cancer compared with surgery alone. JAMA. 2010; 303(17):1729-1737 www.jama.com	[Paoletti, Xavier] Natl Canc Inst, Direct Rech, F-92510 Boulogne, France; [Oba, Koji] Kyoto Univ, EBM Res Ctr, Kyoto, Japan; [Burzykowski, Tomasz] Hasselt Univ, Diepenbeek, Belgium; [Michiels, Stefan; Pignon, Jean-Pierre] Inst Gustave Roussy, Villejuif, France; [Ohashi, Yasuo] Univ Tokyo, Tokyo, Japan; [Rougier, Philippe] Univ Hosp Ambroise Pare, AP HP, Boulogne, France; [Sakamoto, Junichi] Nagoya Univ, Aichi, Japan; [Sargent, Daniel] Mayo Clin, Rochester, MN USA; [Sasako, Mitsuru] Hyogo Coll Med, Nishinomiya, Hyogo, Japan; [Van Cutsem, Eric] Univ Hosp Gasthuisberf, Digest Oncol Unit, Leuven, Belgium; [Buyse, Marc] Int Inst Drug Dev, Louvain, Belgium	Institut National du Cancer (INCA) France; Kyoto University; Hasselt University; UNICANCER; Gustave Roussy; University of Tokyo; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Nagoya University; Mayo Clinic; Hyogo College of Medicine; International Drug Development Institute	Paoletti, X (corresponding author), Natl Canc Inst, Direct Rech, 52 Ave Morizet, F-92510 Boulogne, France.	xpaoletti@institutcancer.fr	Oba, Koji/A-6956-2012; Michiels, Stefan/L-1516-2013; Di Bartolomeo, Maria/D-1655-2017; OBA, Koji/I-3980-2019; Burzykowski, Tomasz/T-2222-2018; Van+Cutsem, Eric/ABE-1762-2021; Buyse, Marc/J-4658-2013	Michiels, Stefan/0000-0002-6963-2968; Di Bartolomeo, Maria/0000-0002-7954-6609; OBA, Koji/0000-0001-5468-8988; Burzykowski, Tomasz/0000-0003-3378-975X; Pozzo, Carmelo/0000-0003-4004-9098; Coombes, Raoul Charles/0000-0002-4811-1100; Sargent, Daniel/0000-0002-2684-4741; Buyse, Marc/0000-0002-4559-0994; PIGNON, Jean-Pierre/0000-0003-2047-1582	Japan Clinical Research Support Unit (J-CRSU); Epidemiological and Clinical Research Information Network (ECRIN); Institut National du Cancer (INCa), France	Japan Clinical Research Support Unit (J-CRSU); Epidemiological and Clinical Research Information Network (ECRIN)(NPO Epidemiological and Clinical Research Information Network (ECRIN)); Institut National du Cancer (INCa), France(Institut National du Cancer (INCA) France)	This project was partially funded by the Japan Clinical Research Support Unit (J-CRSU), the Epidemiological and Clinical Research Information Network (ECRIN), and the Institut National du Cancer (INCa), France.	Ajani JA, 2010, J CLIN ONCOL, V28, P1547, DOI 10.1200/JCO.2009.25.4706; ALLUM WH, 1989, LANCET, V1, P571; Bajetta E, 2002, ANN ONCOL, V13, P299, DOI 10.1093/annonc/mdf040; Boige V, 2007, J CLIN ONCOL, V25; BONFANTI G, 1988, BRIT J SURG, V75, P1100; Bouche O, 2005, ANN ONCOL, V16, P1488, DOI 10.1093/annonc/mdi270; CARRATO A, 1995, P AN M AM SOC CLIN, V14, P468; Chipponi J, 2004, AM J SURG, V187, P440, DOI 10.1016/j.amjsurg.2003.12.014; CHOU FF, 1994, J SURG ONCOL, V57, P239, DOI 10.1002/jso.2930570407; Cirera L, 1999, J CLIN ONCOL, V17, P3810, DOI 10.1200/JCO.1999.17.12.3810; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; COOMBES RC, 1990, J CLIN ONCOL, V8, P1362, DOI 10.1200/JCO.1990.8.8.1362; Crew KD, 2006, WORLD J GASTROENTERO, V12, P354, DOI 10.3748/wjg.v12.i3.354; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; D'Ugo D, 2009, LANCET ONCOL, V10, P191, DOI 10.1016/S1470-2045(09)70021-X; De Vita F, 2007, ANN ONCOL, V18, P1354, DOI 10.1093/annonc/mdm128; Di Costanzo F, 2008, JNCI-J NATL CANCER I, V100, P388, DOI 10.1093/jnci/djn054; DOUGLASS HO, 1982, CANCER-AM CANCER SOC, V49, P1116; *EARL BREAST CANC, 1992, LANCET, V339, P1; ENGSTROM PF, 1985, CANCER-AM CANCER SOC, V55, P1868, DOI 10.1002/1097-0142(19850501)55:9<1868::AID-CNCR2820550904>3.0.CO;2-B; Fujii M, 1994, Gan To Kagaku Ryoho, V21, P1199; Gebski V, 2007, LANCET ONCOL, V8, P226, DOI 10.1016/S1470-2045(07)70039-6; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; GRAU JJ, 1993, EUR J CANCER, V29A, P340, DOI 10.1016/0959-8049(93)90381-O; HALLISSEY MT, 1994, LANCET, V343, P1309, DOI 10.1016/S0140-6736(94)92464-3; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HUGUIER M, 1980, AM J SURG, V139, P197, DOI 10.1016/0002-9610(80)90253-6; Jakesz R, 1988, Recent Results Cancer Res, V110, P44; Janunger KG, 2002, EUR J SURG, V168, P597, DOI 10.1080/11024150201680005; KROOK JE, 1991, CANCER, V67, P2454, DOI 10.1002/1097-0142(19910515)67:10<2454::AID-CNCR2820671010>3.0.CO;2-2; LISE M, 1995, J CLIN ONCOL, V13, P2757, DOI 10.1200/JCO.1995.13.11.2757; Liu TS, 2008, EJSO-EUR J SURG ONC, V34, P1208, DOI 10.1016/j.ejso.2008.02.002; MACDONALD JS, 1995, ANN SURG ONCOL, V2, P488, DOI 10.1007/BF02307081; Macdonald JS, 2001, NEW ENGL J MED, V345, P725, DOI 10.1056/NEJMoa010187; Mari E, 2000, ANN ONCOL, V11, P837, DOI 10.1023/A:1008377101672; Nakajima T, 2007, BRIT J SURG, V94, P1468, DOI 10.1002/bjs.5996; NAKAJIMA T, 1984, J CLIN ONCOL, V2, P1366, DOI 10.1200/JCO.1984.2.12.1366; Nakajima T, 1999, LANCET, V354, P273, DOI 10.1016/S0140-6736(99)01048-X; Nashimoto A, 2003, J CLIN ONCOL, V21, P2282, DOI 10.1200/JCO.2003.06.103; Neri B, 1996, BRIT J CANCER, V73, P549, DOI 10.1038/bjc.1996.95; Nitti D, 2006, ANN ONCOL, V17, P262, DOI 10.1093/annonc/mdj077; Oba K, 2006, J CHEMOTHERAPY, V18, P311, DOI 10.1179/joc.2006.18.3.311; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Pignon JP, 2001, LANCET ONCOL, V2, P475, DOI 10.1016/S1470-2045(01)00453-3; Popiela Tadeusz, 2004, Gastric Cancer, V7, P240, DOI 10.1007/s10120-004-0299-y; Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SCHLAG P, 1982, RECENT RES CANCER, V80, P277; Stewart B.W., 2003, WORLD CANC REPORT; STEWART LA, 1995, STAT MED, V14, P2057, DOI 10.1002/sim.4780141902; Tsavaris N, 1996, CHEMOTHERAPY, V42, P220, DOI 10.1159/000239446; Zhao SL, 2008, CANCER INVEST, V26, P317, DOI 10.1080/07357900701834686	53	603	628	2	75	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2010	303	17					1729	1737		10.1001/jama.2010.534	http://dx.doi.org/10.1001/jama.2010.534			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	591CR	20442389				2023-01-03	WOS:000277276600026
J	Spence, D				Spence, Des			From the Frontline Bad medicine: type 2 diabetes	BRITISH MEDICAL JOURNAL			English	Editorial Material							DECLINE; DISEASE; COHORT					destwo@yahoo.co.uk						Burrows NR, 2010, DIABETES CARE, V33, P73, DOI 10.2337/dc09-0343; Currie CJ, 2010, LANCET, V375, P481, DOI 10.1016/S0140-6736(09)61969-3; Dale AC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.39582.447998.BE; Fox CS, 2004, JAMA-J AM MED ASSOC, V292, P2495, DOI 10.1001/jama.292.20.2495	4	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 3	2010	340								c1216	10.1136/bmj.c1216	http://dx.doi.org/10.1136/bmj.c1216			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	565FJ	20200060				2023-01-03	WOS:000275274400006
J	Tong, EHY; Guo, JJ; Xu, SX; Mak, K; Chung, SK; Chung, SSM; Huang, AL; Ko, BCB				Tong, Edith H. Y.; Guo, Jin-Jun; Xu, Song-Xiao; Mak, Keri; Chung, Sookja K.; Chung, Stephen S. M.; Huang, Ali-Long; Ko, Ben C. B.			Inducible Nucleosome Depletion at OREBP-Binding-Sites by Hypertonic Stress	PLOS ONE			English	Article							T-CELL-ACTIVATION; TRANSCRIPTION FACTOR; SACCHAROMYCES-CEREVISIAE; HISTONE MODIFICATIONS; CHROMATIN-STRUCTURE; OSMOTIC-STRESS; NUCLEOCYTOPLASMIC TRAFFICKING; STIMULATES TRANSCRIPTION; FACTOR TONEBP/OREBP; GENE-TRANSCRIPTION	Background: Osmotic Response Element-Binding Protein (OREBP), also known as TonEBP or NFAT5, is a unique transcription factor. It is hitherto the only known mammalian transcription factor that regulates hypertonic stress-induced gene transcription. In addition, unlike other monomeric members of the NFAT family, OREBP exists as a homodimer and it is the only transcription factor known to bind naked DNA targets by complete encirclement in vitro. Nevertheless, how OREBP interacts with target DNA, also known as ORE/TonE, and how it elicits gene transcription in vivo, remains unknown. Methodology: Using hypertonic induction of the aldose reductase (AR) gene activation as a model, we showed that OREs contained dynamic nucleosomes. Hypertonic stress induced a rapid and reversible loss of nucleosome(s) around the OREs. The loss of nucleosome(s) was found to be initiated by an OREBP-independent mechanism, but was significantly potentiated in the presence of OREBP. Furthermore, hypertonic induction of AR gene was associated with an OREBP-dependent hyperacetylation of histones that spanned the 59 upstream sequences and at least some exons of the gene. Nevertheless, nucleosome loss was not regulated by the acetylation status of histone. Significance: Our findings offer novel insights into the mechanism of OREBP-dependent transcriptional regulation and provide a basis for understanding how histone eviction and transcription factor recruitment are coupled.	[Tong, Edith H. Y.; Xu, Song-Xiao; Ko, Ben C. B.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Tong, Edith H. Y.; Xu, Song-Xiao; Ko, Ben C. B.] Chinese Univ Hong Kong, State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China; [Guo, Jin-Jun; Huang, Ali-Long] Chongqing Univ Med Sci, Inst Viral Hepatitis, Minist Educ, Key Lab Mol Biol Infect Dis, Chongqing, Peoples R China; [Mak, Keri; Chung, Sookja K.] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Tong, Edith H. Y.; Chung, Stephen S. M.] Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chongqing Medical University; University of Hong Kong; University of Hong Kong	Tong, EHY (corresponding author), Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.	benko@cuhk.edu.hk	Ko, Chi-bun/ACH-7514-2022; Xu, Songxiao/L-5737-2019	Ko, Ben Chi Bun/0000-0003-2027-5899	Research Grant Council [CUHK 7327/04M, CUHK 466108]; Chinese University of Hong Kong Direct [2041317]	Research Grant Council(Hong Kong Research Grants Council); Chinese University of Hong Kong Direct(Chinese University of Hong Kong)	This work was supported by the Research Grant Council Grants CUHK 7327/04M, CUHK 466108 and by the Chinese University of Hong Kong Direct Grant for Research 2041317 ( to B. C. B. K). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott DW, 2001, J BIOL CHEM, V276, P41945, DOI 10.1074/jbc.M108217200; ADAMS CC, 1995, MOL CELL BIOL, V15, P1405; Adkins MW, 2004, MOL CELL, V14, P657, DOI 10.1016/j.molcel.2004.05.016; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Boeger H, 2004, MOL CELL, V14, P667, DOI 10.1016/j.molcel.2004.05.013; Brigotti M, 2003, BIOCHEM J, V369, P369, DOI 10.1042/BJ20021056; Bruno M, 2003, MOL CELL, V12, P1599, DOI 10.1016/S1097-2765(03)00499-4; Burg MB, 1996, KIDNEY INT, V49, P1684, DOI 10.1038/ki.1996.247; Burkhart BA, 2007, J BIOL CHEM, V282, P4400, DOI 10.1074/jbc.M609041200; Carey M, 2000, TRANSCRIPTIONAL REGU; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P16800, DOI 10.1073/pnas.222659799; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; Gevry N, 2007, GENE DEV, V21, P1869, DOI 10.1101/gad.1545707; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Ito T, 2004, BIOCHEM J, V382, P177, DOI 10.1042/BJ20031838; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Katsani KR, 2003, CURR TOP MICROBIOL, V274, P113; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Korber P, 2004, MOL CELL BIOL, V24, P10965, DOI 10.1128/MCB.24.24.10965-10974.2004; Kosuge K, 2007, MOL PHARMACOL, V72, P826, DOI 10.1124/mol.107.034504; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lam AKM, 2004, J BIOL CHEM, V279, P48048, DOI 10.1074/jbc.M407224200; Lee W, 2007, NAT GENET, V39, P1235, DOI 10.1038/ng2117; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0; Lorch Y, 2006, P NATL ACAD SCI USA, V103, P3090, DOI 10.1073/pnas.0511050103; MAK KM, 2006, 2006 NEUR M PLANN AT; Mellor J, 2006, TRENDS GENET, V22, P320, DOI 10.1016/j.tig.2006.03.008; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Na KY, 2003, J AM SOC NEPHROL, V14, P283, DOI 10.1097/01.ASN.0000045050.19544.B2; Nakatani F, 2003, J BIOL CHEM, V278, P15105, DOI 10.1074/jbc.M211470200; O'Connor RS, 2007, J CELL SCI, V120, P149, DOI 10.1242/jcs.03307; OwenHughes T, 1996, EMBO J, V15, P4702, DOI 10.1002/j.1460-2075.1996.tb00847.x; PANTAZIS P, 1984, MOL CELL BIOL, V4, P1186, DOI 10.1128/MCB.4.6.1186; Phelan ML, 2000, MOL CELL BIOL, V20, P6380, DOI 10.1128/MCB.20.17.6380-6389.2000; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Reinke H, 2004, BBA-GENE STRUCT EXPR, V1677, P24, DOI 10.1016/j.bbaexp.2003.09.014; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945; Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Stroud JC, 2002, NAT STRUCT BIOL, V9, P90, DOI 10.1038/nsb749; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tong EHY, 2006, J BIOL CHEM, V281, P23870, DOI 10.1074/jbc.M602556200; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; Tsukuda T, 2005, NATURE, V438, P379, DOI 10.1038/nature04148; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Vicent GP, 2004, MOL CELL, V16, P439, DOI 10.1016/j.molcel.2004.10.025; Waldegger S, 1998, NEPHROL DIAL TRANSPL, V13, P867, DOI 10.1093/ndt/13.4.867; Wang Y, 2005, J BIOL CHEM, V280, P19986, DOI 10.1074/jbc.M501689200; Warskulat U, 2004, J INVEST DERMATOL, V123, P516, DOI 10.1111/j.0022-202X.2004.23313.x; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; Xu SX, 2008, J BIOL CHEM, V283, P17624, DOI 10.1074/jbc.M800281200; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zhou XM, 2006, AM J PHYSIOL-RENAL, V290, pF1169, DOI 10.1152/ajprenal.00378.2005	71	33	34	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 24	2009	4	12							e8435	10.1371/journal.pone.0008435	http://dx.doi.org/10.1371/journal.pone.0008435			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	537HN	20041176	Green Published, gold, Green Submitted			2023-01-03	WOS:000273104000005
J	Snitz, BE; O'Meara, ES; Carlson, MC; Arnold, AM; Ives, DG; Rapp, SR; Saxton, J; Lopez, OL; Dunn, LO; Sink, KM; DeKosky, ST				Snitz, Beth E.; O'Meara, Ellen S.; Carlson, Michelle C.; Arnold, Alice M.; Ives, Diane G.; Rapp, Stephen R.; Saxton, Judith; Lopez, Oscar L.; Dunn, Leslie O.; Sink, Kaycee M.; DeKosky, Steven T.		GEM Study Investigators	Ginkgo biloba for Preventing Cognitive Decline in Older Adults A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXTRACT EGB-761; BASE-LINE; MEMORY; IMPAIRMENT; DEMENTIA	Context The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning. Objective To determine whether G biloba slows the rates of global or domain-specific cognitive decline in older adults. Design, Setting, and Participants The Ginkgo Evaluation of Memory ( GEM) study, a randomized, double-blind, placebo-controlled clinical trial of 3069 community-dwelling participants aged 72 to 96 years, conducted in 6 academic medical centers in the United States between 2000 and 2008, with a median follow-up of 6.1 years. Intervention Twice-daily dose of 120-mg extract of G biloba (n=1545) or identical-appearing placebo (n=1524). Main Outcome Measures Rates of change over time in the Modified Mini-Mental State Examination (3MSE), in the cognitive subscale of the Alzheimer Disease Assessment Scale (ADAS-Cog), and in neuropsychological domains of memory, attention, visual-spatial construction, language, and executive functions, based on sums of z scores of individual tests. Results Annual rates of decline in z scores did not differ between G biloba and placebo groups in any domains, including memory (0.043; 95% confidence interval [CI], 0.034-0.051 vs 0.041; 95% CI, 0.032-0.050), attention ( 0.043; 95% CI, 0.037-0.050 vs 0.048; 95% CI, 0.041-0.054), visuospatial abilities (0.107; 95% CI, 0.097-0.117 vs 0.118; 95% CI, 0.108-0.128), language (0.045; 95% CI, 0.037-0.054 vs 0.041; 95% CI, 0.033-0.048), and executive functions (0.092; 95% CI, 0.086-0.099 vs 0.089; 95% CI, 0.082-0.096). For the 3MSE and ADAS-Cog, rates of change varied by baseline cognitive status ( mild cognitive impairment), but there were no differences in rates of change between treatment groups ( for 3MSE, P=.71; for ADAS-Cog, P=.97). There was no significant effect modification of treatment on rate of decline by age, sex, race, education, APOE*E4 allele, or baseline mild cognitive impairment (P>.05). Conclusion Compared with placebo, the use of G biloba, 120 mg twice daily, did not result in less cognitive decline in older adults with normal cognition or with mild cognitive impairment. Trial Registration clinicaltrials.gov Identifier: NCT00010803 JAMA. 2009;302(24):2663-2670 www.jama.com	[DeKosky, Steven T.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; [Snitz, Beth E.; Saxton, Judith; Lopez, Oscar L.; Dunn, Leslie O.; DeKosky, Steven T.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; [Ives, Diane G.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15260 USA; [O'Meara, Ellen S.; Arnold, Alice M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Carlson, Michelle C.] Johns Hopkins Med Inst, Dept Mental Hlth, Baltimore, MD 21205 USA; [Rapp, Stephen R.] Wake Forest Univ, Dept Psychiat & Behav Med, Winston Salem, NC 27109 USA; [Sink, Kaycee M.] Wake Forest Univ, Dept Internal Med Geriatr Gerontol, Sch Med, Winston Salem, NC 27109 USA	University of Virginia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins Medicine; Wake Forest University; Wake Forest University	DeKosky, ST (corresponding author), Univ Virginia, Sch Med, POB 800793, Charlottesville, VA 22908 USA.	dekosky@virginia.edu	Sink, Kaycee/AAY-5920-2020	Nahin, Richard/0000-0002-3682-4816; DeKosky, Steven/0000-0003-3743-2758; Sink, Kaycee/0000-0001-9608-3856	NCCAM [U01 AT000162]; the National Institute on Aging; National Heart, Lung, and Blood Institute; University of Pittsburgh; Alzheimer's Disease Research Center [P50AG05133]; Roena Kulynych Center for Memory and Cognition Research; National Institute of Neurological Disorders and Stroke; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [U01AT000162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U19AG010483, P50AG005133] Funding Source: NIH RePORTER	NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); the National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); University of Pittsburgh(University of Pittsburgh); Alzheimer's Disease Research Center; Roena Kulynych Center for Memory and Cognition Research; National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was funded by grant U01 AT000162 from the NCCAM and the Office of Dietary Supplements and by support from the National Institute on Aging, National Heart, Lung, and Blood Institute, University of Pittsburgh Alzheimer's Disease Research Center (grant P50AG05133), Roena Kulynych Center for Memory and Cognition Research, and National Institute of Neurological Disorders and Stroke. We gratefully acknowledge Schwabe Pharmaceuticals, Karlsruhe, Germany, for donation of G biloba tablets and identical placebos.	ALLAIN H, 1993, CLIN THER, V15, P549; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barnes P. M., 2008, NATL HLTH STAT REPOR; BECKER JT, 1987, CORTEX, V23, P59, DOI 10.1016/S0010-9452(87)80019-9; Bernick C, 2005, NEUROLOGY, V65, P1388, DOI 10.1212/01.wnl.0000182897.18229.ec; Birks J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003120.pub3; Brandt J., 1988, NEUROPSY NEUROPSY BE, V1, P111; Chen X, 1997, CLIN EXP PHARMACOL P, V24, P958, DOI 10.1111/j.1440-1681.1997.tb02727.x; DeKosky ST, 2008, JAMA-J AM MED ASSOC, V300, P2253, DOI 10.1001/jama.2008.683; DeKosky ST, 2006, CONTEMP CLIN TRIALS, V27, P238, DOI 10.1016/j.cct.2006.02.007; Delis D.C., 1987, CALIFORNIA VERBAL LE; Dodge HH, 2008, NEUROLOGY, V70, P1809, DOI 10.1212/01.wnl.0000303814.13509.db; Fitzpatrick AL, 2006, CONTEMP CLIN TRIALS, V27, P541, DOI 10.1016/j.cct.2006.06.007; Hadjiivanova CI, 2002, PHYTOTHER RES, V16, P488, DOI 10.1002/ptr.933; HINDMARCH I, 1986, PRESSE MED, V15, P1592; Huang SY, 2004, CLIN NUTR, V23, P615, DOI 10.1016/j.clnu.2003.10.010; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; HUGUET F, 1992, J PHARM PHARMACOL, V44, P24, DOI 10.1111/j.2042-7158.1992.tb14357.x; Kaschel R, 2009, HUM PSYCHOPHARM CLIN, V24, P345, DOI 10.1002/hup.1037; Kennedy DO, 2000, PSYCHOPHARMACOLOGY, V151, P416, DOI 10.1007/s002130000501; Lopez OL, 2006, J NEUROL NEUROSUR PS, V77, P159, DOI 10.1136/jnnp.2004.045567; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Mohs R C, 1996, Int Psychogeriatr, V8, P195, DOI 10.1017/S1041610296002578; Pietri S, 1997, J MOL CELL CARDIOL, V29, P733, DOI 10.1006/jmcc.1996.0316; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Saxton J, 2000, CLIN NEUROPSYCHOL, V14, P526, DOI 10.1076/clin.14.4.526.7204; Schwartz BS, 2004, ENVIRON HEALTH PERSP, V112, P314, DOI 10.1289/ehp.6727; Snitz BE, 2009, AGING MENT HEALTH, V13, P171, DOI 10.1080/13607860802380656; Solomon PR, 2002, JAMA-J AM MED ASSOC, V288, P835, DOI 10.1001/jama.288.7.835; Spreen O., 1998, COMPENDIUM NEUROPSYC, Vsecond; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; van Dongen M, 2003, J CLIN EPIDEMIOL, V56, P367, DOI 10.1016/S0895-4356(03)00003-9; Wesnes KA, 2000, PSYCHOPHARMACOLOGY, V152, P353, DOI 10.1007/s002130000533; Winblad B, 2004, J INTERN MED, V256, P240, DOI 10.1111/j.1365-2796.2004.01380.x	36	214	224	1	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	2009	302	24					2663	2670		10.1001/jama.2009.1913	http://dx.doi.org/10.1001/jama.2009.1913			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	535JU	20040554	Green Accepted, Bronze			2023-01-03	WOS:000272965300022
J	Aronson, JK				Aronson, Jeffrey K.			Christmas 2009: Years Like This Patent medicines and secret remedies	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford	Aronson, JK (corresponding author), Univ Oxford, Dept Primary Hlth Care, Oxford OX3 7LF, England.	jeffrey.aronson@clinpharm.ox.ac.uk						Adair James Makittrick, 1790, ESSAYS FASHIONABLE D; Aronson J, 1997, BRIT MED J, V315, P165; ARONSON J, 2009, QJM             0722; ARONSON J, 2007, BRIT MED J, V334, P429; BARTRIP PWJ, 1990, MIRROR MED HIST BMJ, P181; BERRIDGE V, 1987, OPIUM PEOPLE OPIATE, P123; British Medical Association, 1912, MOR SECR REM WHAT TH; British Medical Association, 1909, SECR REM WHAT THEY C; CARSON G, 1961, ONE MAN 2 HORSE; Church Roy A., 2007, KNOWLEDGE TRUST PROF; HUNT JA, 2001, PHARM J, V266, P191; Loudon I., 1986, MED CARE GEN PRACTIT; Nahin Richard L, 2009, Natl Health Stat Report, P1; Proprietary Association, 1908, FACTS WORTH KNOW FAL; ROY P, 1989, HLTH SALE; Teschke R, 2009, J ETHNOPHARMACOL, V123, P378, DOI 10.1016/j.jep.2009.03.038; TURNER ES, 1952, SHOCKING HIST ADVERT, P142; 1906, BMJ, V2, P1645; 1906, BMJ, V2, P1223; 1904, BMJ, V2, P1585; 1906, BMJ, V2, P27	21	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 14	2009	339								b5415	10.1136/bmj.b5415	http://dx.doi.org/10.1136/bmj.b5415			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	534XF	20008435				2023-01-03	WOS:000272930100005
J	Jayaraman, S; Mabweijano, JR; Lipnick, MS; Caldwell, N; Miyamoto, J; Wangoda, R; Mijumbi, C; Hsia, R; Dicker, R; Ozgediz, D				Jayaraman, Sudha; Mabweijano, Jacqueline R.; Lipnick, Michael S.; Caldwell, Nolan; Miyamoto, Justin; Wangoda, Robert; Mijumbi, Cephas; Hsia, Renee; Dicker, Rochelle; Ozgediz, Doruk			First Things First: Effectiveness and Scalability of a Basic Prehospital Trauma Care Program for Lay First-Responders in Kampala, Uganda	PLOS ONE			English	Article							LOW-INCOME COUNTRIES; COST-EFFECTIVENESS; MEDICAL-SERVICES; NORTH IRAQ; EXPERIENCE; MORTALITY; INJURIES; CAMBODIA; SYSTEMS; HEALTH	Background: We previously showed that in the absence of a formal emergency system, lay people face a heavy burden of injuries in Kampala, Uganda, and we demonstrated the feasibility of a basic prehospital trauma course for lay people. This study tests the effectiveness of this course and estimates the costs and cost-effectiveness of scaling up this training. Methods and Findings: For six months, we prospectively followed 307 trainees (police, taxi drivers, and community leaders) who completed a one-day basic prehospital trauma care program in 2008. Cross-sectional surveys and fund of knowledge tests were used to measure their frequency of skill and supply use, reasons for not providing aid, perceived utility of the course and kit, confidence in using skills, and knowledge of first-aid. We then estimated the cost-effectiveness of scaling up the program. At six months, 188 (62%) of the trainees were followed up. Their knowledge retention remained high or increased. The mean correct score on a basic fund of knowledge test was 92%, up from 86% after initial training (n = 146 pairs, p = 0.0016). 97% of participants had used at least one skill from the course: most commonly haemorrhage control, recovery position and lifting/moving and 96% had used at least one first-aid item. Lack of knowledge was less of a barrier and trainees were significantly more confident in providing first-aid. Based on cost estimates from the World Health Organization, local injury data, and modelling from previous studies, the projected cost of scaling up this program was $0.12 per capita or $25-75 per life year saved. Key limitations of the study include small sample size, possible reporter bias, preliminary local validation of study instruments, and an indirect estimate of mortality reduction. Conclusions: Lay first-responders effectively retained knowledge on prehospital trauma care and confidently used their first-aid skills and supplies for at least six months. The costs of scaling up this intervention to cover Kampala are very modest. This may be a cost-effective first step toward developing formal emergency services in Uganda other resource-constrained settings. Further research is needed in this critical area of trauma care in low-income countries.			Jayaraman, S (corresponding author), Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA.	dozgediz@hotmail.com	Jayaraman, Sudha/AAH-3059-2019	Jayaraman, Sudha/0000-0003-1094-5836				Aboutanos MB, 2007, J TRAUMA, V62, P714, DOI 10.1097/TA.0b013e318031b56d; [Anonymous], 2000, STRAT PLAN 2000; AYYAZ M, 2008, AM COLL SURG 94 ANN; Backman G, 2008, LANCET, V372, P2047, DOI 10.1016/S0140-6736(08)61781-X; Baker R, 1999, JAMA-J AM MED ASSOC, V281, P859, DOI 10.1001/jama.281.9.859; Bishai D, 2008, INJURY PREV, V14, P223, DOI 10.1136/ip.2008.018341; Bishai D, 2007, AIDS, V21, P1333, DOI 10.1097/QAD.0b013e328137709e; GAUTHAM S, 2008, AM COLL SURG 94 ANN; Husum H, 2003, MIL MED, V168, P934, DOI 10.1093/milmed/168.11.934; Husum H, 2003, J TRAUMA, V54, P1188, DOI 10.1097/01.TA.0000073609.12530.19; Husum H, 2003, MED TEACH, V25, P142, DOI 10.1080/0142159031000092526; JAYARAMAN S, 2009, WORLD J SUR IN PRESS; Kobusingye OC, 2000, J TRAUMA, V48, P498, DOI 10.1097/00005373-200003000-00022; Kobusingye OC, 2002, INJ PREV, V8, P133, DOI 10.1136/ip.8.2.133; Kobusingye OC, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P1261; Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442; Mock C, 2004, LANCET, V363, P2172, DOI 10.1016/S0140-6736(04)16510-0; Mock C., 2004, GUIDELINES ESSENTIAL; Mock C, 2006, WORLD J SURG, V30, P946, DOI 10.1007/s00268-005-0768-4; Mock CN, 1998, J TRAUMA, V44, P804, DOI 10.1097/00005373-199805000-00011; Mock CN, 1997, J TRAUMA, V42, P504, DOI 10.1097/00005373-199703000-00019; Mock CN, 2002, J TRAUMA, V53, P90, DOI 10.1097/00005373-200207000-00018; Nantulya Vinand M, 2003, Inj Control Saf Promot, V10, P13, DOI 10.1076/icsp.10.1.13.14116; Peden M., 2004, WORLD REPORT ROAD TR; POGGETTI R, 2008, AM COLL SURG 94 ANN; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Roberts I, 2005, BRIT MED J, V331, P1094, DOI 10.1136/bmj.331.7525.1094; Sachs J., 2001, INVESTING HLTH REPOR; Tiska MA, 2004, EMERG MED J, V21, P237, DOI 10.1136/emj.2002.002097; *WHO, 2005, PREH TRAUM CAR SYST; WHO, 2008, WORLD HLTH STAT	31	98	98	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6955	10.1371/journal.pone.0006955	http://dx.doi.org/10.1371/journal.pone.0006955			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759831	gold, Green Published, Green Submitted			2023-01-03	WOS:000269696600007
J	Bryan, CS; Podolsky, SH				Bryan, Charles S.; Podolsky, Scott H.			Medical History: Dr. Holmes at 200-- The Spirit of Skepticism.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Bryan, Charles S.] Providence Hosp, Columbia, SC 29203 USA; [Bryan, Charles S.] Univ S Carolina, Columbia, SC 29208 USA; [Podolsky, Scott H.] Harvard Univ, Sch Med, Boston, MA USA; [Podolsky, Scott H.] Ctr Hist Med, Francis A Countway Lib Med, Boston, MA USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Harvard University; Harvard Medical School	Bryan, CS (corresponding author), Providence Hosp, Columbia, SC 29203 USA.							Dowling William C, 2006, OW HOLMES PARIS MED; Gibian P., 2001, OW HOLMES CULTURE CO, DOI [10.1017/CBO9780511485503, DOI 10.1017/CBO9780511485503]; Warner John Harley, 1998, SPIRIT SYSTEM FRENCH; Whorton James C., 1980, HIST ANTIBIOTICS, P125; 1879, LECT 1 YEAR CL UNPUB	5	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 27	2009	361	9					846	847		10.1056/NEJMp0905310	http://dx.doi.org/10.1056/NEJMp0905310			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	487XV	19710482				2023-01-03	WOS:000269312700003
J	Powell, LH; Calvin, JE; Richardson, D; Janssen, I; de Leon, CFM; Flynn, KJ; Grady, KL; Rucker-Whitaker, CS; Eaton, C; Avery, E				Powell, Lynda H.; Calvin, James E., Jr.; Richardson, Dejuran; Janssen, Imke; de Leon, Carlos F. Mendes; Flynn, Kristin J.; Grady, Kathleen L.; Rucker-Whitaker, Cheryl S.; Eaton, Claudia; Avery, Elizabeth		HART Investigators	Self-management Counseling in Patients With Heart Failure The Heart Failure Adherence and Retention Randomized Behavioral Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; READMISSION RATES; METAANALYSIS; STRATEGIES; PROGRAM; SUPPORT	Context Motivating patients with heart failure to adhere to medical advice has not translated into clinical benefit, but past trials have had methodological limitations. Objective To determine the value of self-management counseling plus heart failure education, compared with heart failure education alone, for the primary end point of death or heart failure hospitalization. Design, Setting, and Patients The Heart Failure Adherence and Retention Trial (HART), a single-center, multiple-hospital, partially blinded behavioral efficacy randomized controlled trial involving 902 patients with mild to moderate heart failure and reduced or preserved systolic function, randomized from the Chicago metropolitan area between October 2001 and October 2004 and undergoing follow-up for 2 to 3 subsequent years. Interventions All patients were offered 18 contacts and 18 heart failure educational tip sheets during the course of 1 year. Patients randomized to the education group received tip sheets in the mail and telephone calls to check comprehension. Patients randomized to the self-management group received tip sheets in groups and were taught self-management skills to implement the advice. Main Outcome Measure Death or heart failure hospitalization during a median of 2.56 years of follow-up. Results Patients were representative of typical clinical populations (mean age, 63.6 years; 47% women, 40% racial/ethnic minority, 52% with annual family income less than $30 000, and 23% with preserved systolic function). The rate of the primary end point in the self-management group was no different from that in the education group (163 [40.1%)] vs 171 [41.2%], respectively; odds ratio, 0.95 [95% confidence interval, 0.72-1.26]). There were no significant differences on any secondary end points, including death, heart failure hospitalization, all-cause hospitalization, or quality of life. Conclusions Compared with an enhanced educational intervention alone, the addition of self-management counseling did not reduce death or heart failure hospitalization in patients with mild to moderate heart failure.	[Powell, Lynda H.; Janssen, Imke; Eaton, Claudia; Avery, Elizabeth] Rush Univ, Med Ctr, Dept Prevent Med, Chicago, IL 60612 USA; [Calvin, James E., Jr.; de Leon, Carlos F. Mendes] Rush Univ, Med Ctr, Dept Med, Chicago, IL 60612 USA; [Richardson, Dejuran] Lake Forest Coll, Dept Math, Lake Forest, IL 60045 USA; [Flynn, Kristin J.] Univ Missouri, Dept Hlth Psychol, Columbia, MO 65211 USA; [Grady, Kathleen L.] Northwestern Univ, Bluhm Cardiovasc Inst, Div Cardiac Surg, Chicago, IL 60611 USA; [Rucker-Whitaker, Cheryl S.] Chicago Community Trust, Chicago, IL USA	Rush University; Rush University; University of Missouri System; University of Missouri Columbia; Northwestern University	Powell, LH (corresponding author), Rush Univ, Med Ctr, Dept Prevent Med, 1700 W Van Buren St, Chicago, IL 60612 USA.	lpowell@rush.edu		Janssen, Imke/0000-0003-1184-2812	Novartis; National Institutes of Health [HL065547]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065547] Funding Source: NIH RePORTER	Novartis(Novartis); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Calvin reported receiving research funding from Novartis, initiated after the conclusion of this trial. No other authors reported disclosures.; Support for The HART study was provided by National Institutes of Health grant HL065547.	ANDERSON KM, 1991, BIOMETRICS, V47, P281, DOI 10.2307/2532512; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Clark RA, 2007, BMJ-BRIT MED J, V334, P942, DOI 10.1136/bmj.39156.536968.55; Collett D, 2003, MODELING SURVIVAL DA; Debusk Robert F., 1996, Cardiology Clinics, V14, P143; DeWalt DA, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-30; FERRANS CE, 1985, ADV NURS SCI, V8, P15, DOI 10.1097/00012272-198510000-00005; Flynn Kristin J, 2005, Congest Heart Fail, V11, P297, DOI 10.1111/j.1527-5299.2005.04361.x; FRIEDMAN M, 1984, AM HEART J, V108, P237, DOI 10.1016/0002-8703(84)90606-9; Gwadry-Sridhar FH, 2004, ARCH INTERN MED, V164, P2315, DOI 10.1001/archinte.164.21.2315; Harrison MB, 2002, MED CARE, V40, P271, DOI 10.1097/00005650-200204000-00003; Hunt SA, 2009, J AM COLL CARDIOL, V53, pE1, DOI 10.1016/j.jacc.2008.11.013; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Klersy C, 2009, J AM COLL CARDIOL, V54, P1683, DOI 10.1016/j.jacc.2009.08.017; Kozak Andrea T, 2007, Congest Heart Fail, V13, P280, DOI 10.1111/j.1527-5299.2007.07236.x; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; McAlister FA, 2004, J AM COLL CARDIOL, V44, P810, DOI 10.1016/j.jacc.2004.05.055; O'Connor CM, 2009, JAMA-J AM MED ASSOC, V301, P1439, DOI 10.1001/jama.2009.454; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Powell LH, 2008, AM HEART J, V156, P452, DOI 10.1016/j.ahj.2008.05.011; Prasun Marilyn A, 2005, J Cardiovasc Nurs, V20, P62; RYFF CD, 1995, J PERS SOC PSYCHOL, V69, P719; Sethares KA, 2004, HEART LUNG, V33, P249, DOI 10.1016/j.hrtlng.2004.03.005; SHERBOURNE CD, 1991, SOC SCI MED, V32, P705, DOI 10.1016/0277-9536(91)90150-B; VAN DER WAL MHL, 2008, INT J CARDIOL, V125, P203; VON KORFF M, 1997, ANN INTERN MED, V127, P1097; Wagner EH, 2004, ANN INTERN MED, V141, P644, DOI 10.7326/0003-4819-141-8-200410190-00015; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wright SP, 2003, EUR J HEART FAIL, V5, P371, DOI 10.1016/S1388-9842(03)00039-4; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2003, LANCET, V362, P777, DOI 10.1016/S0140-6736(03)14285-7	33	140	145	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2010	304	12					1331	1338		10.1001/jama.2010.1362	http://dx.doi.org/10.1001/jama.2010.1362			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	652LK	20858878	Green Accepted			2023-01-03	WOS:000282007900016
J	Ramnarayan, P; Thiru, K; Parslow, RC; Harrison, DA; Draper, ES; Rowan, KM				Ramnarayan, Padmanabhan; Thiru, Krish; Parslow, Roger C.; Harrison, David A.; Draper, Elizabeth S.; Rowan, Kathy M.			Effect of specialist retrieval teams on outcomes in children admitted to paediatric intensive care units in England and Wales: a retrospective cohort study	LANCET			English	Article							CRITICALLY-ILL; HOSPITAL VOLUME; HEALTH-CARE; MORTALITY; REDUCTION; TRANSPORT; IMPLEMENTATION; ADMISSION; DELIVERY; SURGERY	Background Intensive care services for children have undergone substantial centralisation in the UK. Along with the establishment of regional paediatric intensive care units (PICUs), specialist retrieval teams were set up to transport critically ill children from other hospitals. We studied the outcome of children transferred from local hospitals to PICUs. Methods We analysed data that were gathered for a cohort of children (<= 16 years) admitted consecutively to 29 PICUs in England and Wales during 4 years (Jan 1, 2005, to Dec 31, 2008). We compared unplanned admissions from wards within the same hospital as the PICU and from other hospitals; interhospital transfers by non-specialist and specialist retrieval teams; and patients transferred to their nearest PICU and those who were not. Primary outcome measures were mortality rate in PICU and length of stay in P ICU. We analysed data by use of logistic regression analysis. Findings There were 57997 admissions to PICUs during the study. Nearly half of unplanned admissions (17 649 [53%] of 33 492) were from other hospitals. Although children admitted from other hospitals were younger (median 10 months [IQR 1-55] vs 18 months [3-85]), sicker at admission (median predicted risk of mortality 6% [4-10] vs 4% [2-7]), stayed longer in PICUs (75 h [33-153] vs 43 h [18-116]), and had higher crude mortality rates (1384 [8%] of 17 649 vs 996 [6%] of 15843; odds ratio 1.27, 95% CI 1.16-1.38), the risk-adjusted mortality rate in PICUs was lower than among children admitted from within the same hospital (0.65, 0.53-0.80). In a multivariable analysis, use of a specialist retrieval team for transfer was associated with improved survival (0 58, 0.39-0.87). Interpretation These findings support the policy of combining centralisation of intensive care services for children with transfer by specialist retrieval teams.	[Ramnarayan, Padmanabhan] Great Ormond St Hosp Sick Children, Childrens Acute Transport Serv, London, England; [Thiru, Krish] City Univ London, Sch Informat, Ctr Hlth Informat, London EC1V 0HB, England; [Parslow, Roger C.] Leeds Inst Genet Hlth & Therapeut, Ctr Biostat & Epidemiol, Paediat Epidemiol Grp, Leeds, W Yorkshire, England; [Harrison, David A.; Draper, Elizabeth S.] Intens Care Natl Audit & Res Ctr, London, England; [Draper, Elizabeth S.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; City University London; University of Leeds; Intensive Care National Audit & Research Centre; University of Leicester	Ramnarayan, P (corresponding author), Great Ormond St Hosp NHS Trust, Childrens Acute Transport Serv, 44-B Bedford Row, London WC1R 4LL, England.		Harrison, David A/O-4355-2018; Draper, Elizabeth/S-6874-2019; Draper, Elizabeth S/I-6304-2018; Parslow, Roger/AAV-1477-2020; Ramnarayan, Padmanabhan/AAI-6783-2020	Harrison, David A/0000-0002-9002-9098; Draper, Elizabeth/0000-0001-9340-8176; Draper, Elizabeth S/0000-0001-9340-8176; Ramnarayan, Padmanabhan/0000-0003-0784-8154; Rowan, Kathryn/0000-0001-8217-5602; Parslow, Roger/0000-0002-3945-5294	National Clinical Audit and Patient Outcomes Programme through Healthcare Quality Improvement Partnership; Health Commission Wales Specialised Services	National Clinical Audit and Patient Outcomes Programme through Healthcare Quality Improvement Partnership; Health Commission Wales Specialised Services	PICANet is funded by the National Clinical Audit and Patient Outcomes Programme through Healthcare Quality Improvement Partnership, Health Commission Wales Specialised Services. National Health Service (NHS) Lothian and National Service Division NHS Scotland. the Royal Belfast Hospital for Sick Children, and the Pan Thames PICU Commissioning Consortium We thank all the staff in participating hospitals who gathered data for PICANet A full list of participating PICUs and steering group and clinical advisory group membership is available on the latest PICANet Annual Report We thank Steve Harris for commenting on an early draft of this report and contributing to discussions about the sensitivity analyses, and Philip McShane for extracting the study data from the PICANet database	Bazzani LG, 2007, CIRCULATION, V115, P2652, DOI 10.1161/CIRCULATIONAHA.106.678904; Begg CB, 1998, JAMA-J AM MED ASSOC, V280, P1747, DOI 10.1001/jama.280.20.1747; Bellingan G, 2000, INTENS CARE MED, V26, P740; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Booy R, 2001, ARCH DIS CHILD, V85, P386, DOI 10.1136/adc.85.5.386; BRITTO J, 1995, BRIT MED J, V311, P836, DOI 10.1136/bmj.311.7009.836; Chan PS, 2008, JAMA-J AM MED ASSOC, V300, P2506, DOI 10.1001/jama.2008.715; CHAN PS, ARCH INTERN MED, V170, P18; Combes A, 2005, CRIT CARE MED, V33, P705, DOI 10.1097/01.CCM.0000158518.32730.C5; Department of Health, 1997, PAED INT CAR FRAM FU; Dudley RA, 2000, JAMA-J AM MED ASSOC, V283, P1159, DOI 10.1001/jama.283.9.1159; ESCARCE JJ, 1990, JAMA-J AM MED ASSOC, V264, P2389, DOI 10.1001/jama.264.18.2389; FIELD D, 1991, ARCH DIS CHILD-FETAL, V66, P408, DOI 10.1136/adc.66.4_Spec_No.408; Gregory CJ, 2008, PEDIATRICS, V121, pE906, DOI 10.1542/peds.2007-2089; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; Hanson CC, 2009, QUAL SAF HEALTH CARE, V18, P500, DOI 10.1136/qshc.2007.026054; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Maybloom B, 1997, LANCET, V350, P65, DOI 10.1016/S0140-6736(97)26027-7; McDonnell A, 2007, J CRIT CARE, V22, P212, DOI 10.1016/j.jcrc.2007.02.002; Odetola FO, 2008, PEDIATR CRIT CARE ME, V9, P20, DOI 10.1097/01.PCC.0000298642.11872.29; Orr RA, 2009, PEDIATRICS, V124, P40, DOI 10.1542/peds.2008-0515; Pearson G, 1997, LANCET, V349, P1213, DOI 10.1016/S0140-6736(96)12396-5; *PICA NET, 2006, NAT REP PAED INT CAR; Rosenberg AL, 2003, ANN INTERN MED, V138, P882, DOI 10.7326/0003-4819-138-11-200306030-00009; Shann F, 1997, INTENS CARE MED, V23, P201, DOI 10.1007/s001340050317; Stevenson A, 2005, EMERG MED J, V22, P795, DOI 10.1136/emj.2004.017822; Tibballs J, 2005, ARCH DIS CHILD, V90, P1148, DOI 10.1136/adc.2004.069401; *U YORK, 1996, EFF HLTH CAR HOSP VO; Vos GD, 2004, INTENS CARE MED, V30, P302, DOI 10.1007/s00134-003-2066-7	29	96	99	1	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2010	376	9742					698	704		10.1016/S0140-6736(10)61113-0	http://dx.doi.org/10.1016/S0140-6736(10)61113-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646YW	20708255				2023-01-03	WOS:000281582900029
J	Kapoor, K; Rehan, M; Lynn, AM; Prasad, R				Kapoor, Khyati; Rehan, Mohd; Lynn, Andrew M.; Prasad, Rajendra			Employing Information Theoretic Measures and Mutagenesis to Identify Residues Critical for Drug-Proton Antiport Function in Mdr1p of Candida albicans	PLOS ONE			English	Article							MAJOR FACILITATOR SUPERFAMILY; HUMAN PATHOGENIC YEAST; ANTIFUNGAL EFFLUX; PROTEIN; ALIGNMENT; IDENTIFICATION; STRATEGY; CDR1P; PUMP	By employing information theoretic measures, this study presents a structure and functional analysis of a multidrug-proton antiporter Mdr1p of Candida albicans. Since CaMdr1p belongs to drug-proton antiporter (DHA1) family of Major Facilitator Superfamily (MFS) of transporters, we contrasted DHA1 (antiporters) with Sugar Porter family (symporters). Cumulative Relative Entropy (CRE) calculated for these two sets of alignments enabled us to selectively identify conserved residues of not only CaMdr1p but for the entire DHA1 family. Based on CRE, the highest scoring thirty positions were selected and predicted to impart functional specificity to CaMdr1p as well as to other drug-proton antiporters. Nineteen positions wherein the CaMdr1p residue matched with the most frequent amino acid at a particular alignment position of DHA1 members were subjected to site-directed mutagenesis and were replaced with either alanine or leucine. All these mutant variants, except one, displayed either complete or selective sensitivity to the tested drugs. The enhanced susceptibility of these mutant variants was corroborated with the simultaneously abrogated efflux of substrates. Taken together, based on scaled CRE between two MFS sub-families, we could accurately predict the functionally relevant residues of CaMdr1p. An extrapolation of these predictions to the entire DHA1 family members as validated from previously published data shows that these residues are functionally critical in other members of the DHA1 family also.	[Kapoor, Khyati; Prasad, Rajendra] Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India; [Rehan, Mohd; Lynn, Andrew M.] Jawaharlal Nehru Univ, Sch Informat Technol, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi; Jawaharlal Nehru University, New Delhi	Kapoor, K (corresponding author), Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India.	andrew@mail.jnu.ac.in; rp47jnu@gmail.com	Rehan, Mohd/H-9835-2012	Rehan, Mohd/0000-0003-4898-6043	Department of Science and Technology, Indo-Swiss [INT/SWISS/P-31/2009]; Department of Biotechnology [BT/PR9100/Med/29/03/2007, BT/PR9563/BRB/10/567/2007, BT/PR11158/BRB/10/640/2008]; Council of Scientific and Industrial Research, India	Department of Science and Technology, Indo-Swiss(Department of Science & Technology (India)); Department of Biotechnology; Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India)	The work presented in this paper has been supported in parts by grants to one of us (RP) from Department of Science and Technology, Indo-Swiss, (INT/SWISS/P-31/2009), Department of Biotechnology (BT/PR9100/Med/29/03/2007, BT/PR9563/BRB/10/567/2007, BT/PR11158/BRB/10/640/2008). KK acknowledges Council of Scientific and Industrial Research, India, for the award of senior research fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Chakrabarti S, 2007, J MOL BIOL, V373, P801, DOI 10.1016/j.jmb.2007.08.036; Chandrasekaran A, 2006, J NEUROCHEM, V98, P1551, DOI 10.1111/J.1471-4159.2006.03975.X; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Durbin R., 1998, BIOL SEQUENCE ANAL P; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Gaur M, 2005, J MOL MICROB BIOTECH, V9, P3, DOI 10.1159/000088141; Gaur M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-579; Ginn SL, 2000, J BACTERIOL, V182, P1492, DOI 10.1128/JB.182.6.1492-1498.2000; Hannenhalli SS, 2000, J MOL BIOL, V303, P61, DOI 10.1006/jmbi.2000.4036; Ivnitski-Steele I, 2009, ANAL BIOCHEM, V394, P87, DOI 10.1016/j.ab.2009.07.001; Jeon J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000522; Kapoor K, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000624; KIMURA M, 1979, SCI AM, V241, P98, DOI 10.1038/scientificamerican1179-98; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Law CJ, 2008, ANNU REV MICROBIOL, V62, P289, DOI 10.1146/annurev.micro.61.080706.093329; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; Lo LW, 2003, P NATL ACAD SCI USA, V100, P4463, DOI 10.1073/pnas.0737647100; Nakamura K, 2001, ANTIMICROB AGENTS CH, V45, P3366, DOI 10.1128/AAC.45.12.3366-3374.2001; Ohno S., 1970, EVOLUTION GENE DUPLI; Pasrija R, 2007, EUKARYOT CELL, V6, P443, DOI 10.1128/EC.00315-06; Paulsen IT, 1996, MICROBIOL REV, V60, P575, DOI 10.1128/MMBR.60.4.575-608.1996; Pirovano W, 2008, BIOINFORMATICS, V24, P492, DOI 10.1093/bioinformatics/btm636; Prasad R, 2005, INT REV CYTOL, V242, P215; Saini P, 2005, J ANTIMICROB CHEMOTH, V56, P77, DOI 10.1093/jac/dki183; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x; SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x; Smriti, 2002, YEAST, V19, P303, DOI 10.1002/yea.818; Srivastava PK, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-104; Valdar WSJ, 2002, PROTEINS, V48, P227, DOI 10.1002/prot.10146	32	19	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2010	5	6							e11041	10.1371/journal.pone.0011041	http://dx.doi.org/10.1371/journal.pone.0011041			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	608QA	20548793	gold, Green Submitted, Green Published			2023-01-03	WOS:000278599600004
J	Heimburger, DC; Koethe, JR; Nyirenda, C; Bosire, C; Chiasera, JM; Blevins, M; Munoz, AJ; Shepherd, BE; Potter, D; Zulu, I; Chisembele-Taylor, A; Chi, BH; Stringer, JSA; Kabagambe, EK				Heimburger, Douglas C.; Koethe, John R.; Nyirenda, Christopher; Bosire, Claire; Chiasera, Janelle M.; Blevins, Meridith; Munoz, Andres Julian; Shepherd, Bryan E.; Potter, Dara; Zulu, Isaac; Chisembele-Taylor, Angela; Chi, Benjamin H.; Stringer, Jeffrey S. A.; Kabagambe, Edmond K.			Serum Phosphate Predicts Early Mortality in Adults Starting Antiretroviral Therapy in Lusaka, Zambia: A Prospective Cohort Study	PLOS ONE			English	Article							REFEEDING SYNDROME; CLINICAL-OUTCOMES; 1ST YEAR; AFRICA; ADHERENCE; DISTRICT; PROGRAM; DEATH	Background: Patients starting antiretroviral therapy (ART) for acquired immunodeficiency syndrome (AIDS) in sub-Saharan Africa have high rates of mortality in the initial weeks of treatment. We assessed the association of serum phosphate with early mortality among HIV-infected adults with severe malnutrition and/or advanced immunosuppression. Methodology/Principal Findings: An observational cohort of 142 HIV-infected adults initiating ART in Lusaka, Zambia with body mass index (BMI),16 kg/m(2) or CD4(+) lymphocyte count <50 cells/mu L, or both, was followed prospectively during the first 12 weeks of ART. Detailed health and dietary intake history, review of systems, physical examination, serum metabolic panel including phosphate, and serum ferritin and high-sensitivity C-reactive protein (hsCRP) were monitored. The primary outcome was mortality. Baseline serum phosphate was a significant predictor of mortality; participants alive at 12 weeks had a median value of 1.30 mmol/L (interquartile range [IQR]: 1.04, 1.43), compared to 1.06 mmol/L (IQR: 0.89, 1.27) among those who died (p<0.01). Each 0.1 mmol/L increase in baseline phosphate was associated with an incremental decrease in mortality (AHR 0.83; 95% CI 0.72 to 0.95). The association was independent of other metabolic parameters and known risk factors for early ART-associated mortality in sub-Saharan Africa. While participant attrition represented a limitation, it was consistent with local program experience. Conclusions/Significance: Low serum phosphate at ART initiation was an independent predictor of early mortality among HIV patients starting ART with severe malnutrition or advanced immunosuppression. This may represent a physiologic phenomenon similar to refeeding syndrome, and may lead to therapeutic interventions that could reduce mortality.	[Heimburger, Douglas C.; Koethe, John R.; Nyirenda, Christopher; Potter, Dara; Zulu, Isaac; Chisembele-Taylor, Angela; Chi, Benjamin H.; Stringer, Jeffrey S. A.] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Heimburger, Douglas C.] Vanderbilt Univ, Inst Global Hlth, Nashville, TN USA; [Heimburger, Douglas C.; Koethe, John R.] Vanderbilt Univ, Dept Med, Nashville, TN USA; [Blevins, Meridith; Shepherd, Bryan E.] Vanderbilt Univ, Dept Biostat, Nashville, TN USA; [Nyirenda, Christopher; Zulu, Isaac] Univ Teaching Hosp, Dept Internal Med, Lusaka, Zambia; [Heimburger, Douglas C.; Bosire, Claire; Munoz, Andres Julian] Univ Alabama, Dept Nutr Sci, Birmingham, AL 35294 USA; [Bosire, Claire; Kabagambe, Edmond K.] Univ Alabama, Dept Epidemiol, Birmingham, AL 35294 USA; [Chi, Benjamin H.; Stringer, Jeffrey S. A.] Univ Alabama, Dept Obstet & Gynecol, Birmingham, AL 35294 USA; [Chiasera, Janelle M.] Univ Alabama, Dept Clin Lab Sci, Birmingham, AL 35294 USA; [Munoz, Andres Julian] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Zambia; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan	Heimburger, DC (corresponding author), Ctr Infect Dis Res Zambia, Lusaka, Zambia.	douglas.heimburger@vanderbilt.edu	Stringer, Jeffrey S. A./AAU-2342-2021	Stringer, Jeffrey/0000-0002-9590-7216; Chiasera, Janelle/0000-0003-2994-485X; Blevins, Meridith/0000-0002-3861-9859; Kabagambe, Edmond/0000-0002-8993-3186	National Institute of Allergy and Infectious Diseases, US National Institutes of Health [R21 AI076430]; University of Alabama at Birmingham Center for AIDS Research; Fogarty International Clinical Research Scholars Program; United States Department of State; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI076430] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); University of Alabama at Birmingham Center for AIDS Research; Fogarty International Clinical Research Scholars Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); United States Department of State; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project was supported by Award Number R21 AI076430 from the National Institute of Allergy and Infectious Diseases, US National Institutes of Health. The study was also supported by the University of Alabama at Birmingham Center for AIDS Research; the Fogarty International Clinical Research Scholars Program; and the Fulbright Scholars Program, United States Department of State. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1987, MMWR-MORBID MORTAL W, V36, p1S; Au JT, 2006, AIDS, V20, P2116, DOI 10.1097/01.aids.0000247580.16073.1b; Boateng AA, 2010, NUTRITION, V26, P156, DOI 10.1016/j.nut.2009.11.017; Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; BROZEK J, 1948, JAMA-J AM MED ASSOC, V137, P1569, DOI 10.1001/jama.1948.02890520001001; *CENTR STAT OFF, 2002, PREL REP CENS 2000; CHI BH, 2009, J ACQ IMMUN DEF SYND, P2009; Fauci Braunwald, HARRISONS PRINCIPLES, VII, P2738; Hardon AP, 2007, AIDS CARE, V19, P658, DOI 10.1080/09540120701244943; Heimburger D.C., 2006, HDB CLIN NUTR; Jerene D, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-136; Johannessen A, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-52; KNOCHEL JP, 1977, ARCH INTERN MED, V137, P203, DOI 10.1001/archinte.137.2.203; Koethe JR, 2010, JAIDS-J ACQ IMM DEF, V53, P507, DOI 10.1097/QAI.0b013e3181b32baf; Kohn MR, 1998, J ADOLESCENT HEALTH, V22, P239, DOI 10.1016/S1054-139X(97)00163-8; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Krebs DW, 2008, AIDS CARE, V20, P311, DOI 10.1080/09540120701594776; Lawn SD, 2005, AIDS, V19, P2141, DOI 10.1097/01.aids.0000194802.89540.e1; Lawn SD, 2008, AIDS, V22, P1897, DOI 10.1097/QAD.0b013e32830007cd; Little R. J. A., 1987, STAT ANAL MISSING DA; Marazzi MC, 2008, AIDS RES HUM RETROV, V24, P555, DOI 10.1089/aid.2007.0217; Muranga F. I., 2007, African Journal of Biochemistry Research, V1, P72; Nyirenda C., 2009, BMJ CASE REPORTS; Nyirenda D. B., 2005, REVISED FOOD COMPOSI; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; SCHNITKER MA, 1951, ANN INTERN MED, V35, P69, DOI 10.7326/0003-4819-35-1-69; Stringer JSA, 2006, JAMA-J AM MED ASSOC, V296, P782, DOI 10.1001/jama.296.7.782; UNAIDS, 2008, REP GLOB AIDS EP; *US AG INT DEV, US AG INT DEV FOOD C; Zachariah R, 2006, AIDS, V20, P2355, DOI 10.1097/QAD.0b013e32801086b0	31	29	29	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2010	5	5							e10687	10.1371/journal.pone.0010687	http://dx.doi.org/10.1371/journal.pone.0010687			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597RA	20502700	Green Published, gold, Green Submitted			2023-01-03	WOS:000277776500005
J	Sud, S; Sud, M; Friedrich, JO; Meade, MO; Ferguson, ND; Wunsch, H; Adhikari, NKJ				Sud, Sachin; Sud, Maneesh; Friedrich, Jan O.; Meade, Maureen O.; Ferguson, Niall D.; Wunsch, Hannah; Adhikari, Neill K. J.			High frequency oscillation in patients with acute lung injury and acute respiratory distress syndrome (ARDS): systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							END-EXPIRATORY PRESSURE; CRITICALLY-ILL PATIENTS; CONVENTIONAL MECHANICAL VENTILATION; OPTIMAL PHYSIOLOGICAL APPROACH; 2009 INFLUENZA A(H1N1); TIDAL VOLUME; PROTECTIVE-VENTILATION; RECRUITMENT MANEUVERS; ADULTS; STRATEGY	Objective To determine clinical and physiological effects of high frequency oscillation compared with conventional ventilation in patients with acute lung injury/acute respiratory distress syndrome (ARDS). Design Systematic review and meta-analysis. Data sources Electronic databases to March 2010, conference proceedings, bibliographies, and primary investigators. Study selection Randomised controlled trials of high frequency oscillation compared with conventional ventilation in adults or children with acute lung injury/ARDS. Data selection Three authors independently extracted data on clinical, physiological, and safety outcomes according to a predefined protocol. We contacted investigators of all included studies to clarify methods and obtain additional data. Analyses used random effects models. Results Eight randomised controlled trials (n=419 patients) were included; almost all patients had ARDS. Methodological quality was good. The ratio of partial pressure of oxygen to inspired fraction of oxygen at 24, 48, and 72 hours was 16-24% higher in patients receiving high frequency oscillation. There were no significant differences in oxygenation index because mean airway pressure rose by 22-33% in patients receiving high frequency oscillation (P=0.01). In patients randomised to high frequency oscillation, mortality was significantly reduced (risk ratio 0.77, 95% confidence interval 0.61 to 0.98, P=0.03; six trials, 365 patients, 160 deaths), and treatment failure (refractory hypoxaemia, hypercapnoea, hypotension, or barotrauma) resulting in discontinuation of assigned therapy was less likely (0.67, 0.46 to 0.99, P=0.04; five trials, 337 patients, 73 events). Other risks were similar. There was substantial heterogeneity between trials for physiological (I-2=21-95%) but not clinical (I-2=0%) outcomes. Pooled results were based on few events for most clinical outcomes. Conclusion High frequency oscillation might improve survival and is unlikely to cause harm. As ongoing large multicentre trials will not be completed for several years, these data help clinicians who currently use or are considering this technique for patients with ARDS.	[Friedrich, Jan O.] Univ Toronto, Interdepartmental Div Crit Care, Toronto, ON M5B 1W8, Canada; [Sud, Sachin] Univ Toronto, Toronto Gen Hosp, Interdepartmental Div Crit Care, Crit Care Med Program, Toronto, ON M5G 2N2, Canada; [Sud, Maneesh] Univ Manitoba, Fac Med Brodie Ctr 260, Undergrad Med Off, Winnipeg, MB R3E 3P5, Canada; [Friedrich, Jan O.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Crit Care Dept, Toronto, ON M5B 1W8, Canada; [Friedrich, Jan O.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Dept Med, Toronto, ON M5B 1W8, Canada; [Friedrich, Jan O.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Meade, Maureen O.] McMaster Univ, Med Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Meade, Maureen O.] McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; [Ferguson, Niall D.] Univ Toronto, Interdepartmental Div Crit Care, Toronto, ON M5G 1X5, Canada; [Ferguson, Niall D.] Univ Hlth Network, Div Respirol, Dept Med, Toronto, ON M5G 1X5, Canada; [Ferguson, Niall D.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada; [Wunsch, Hannah] Columbia Univ, Dept Anesthesiol, New York, NY 10032 USA; [Adhikari, Neill K. J.] Univ Toronto, Interdepartmental Div Crit Care, Toronto, ON M4N 3M5, Canada; [Adhikari, Neill K. J.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Manitoba; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University; McMaster University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Columbia University; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Friedrich, JO (corresponding author), Univ Toronto, Interdepartmental Div Crit Care, 30 Bond St,4-015 Bond Wing, Toronto, ON M5B 1W8, Canada.	j.friedrich@utoronto.ca	Ferguson, Niall/D-7619-2019	Ferguson, Niall/0000-0002-6213-5264; Friedrich, Jan/0000-0001-7248-2350	Canadian Institutes of Health Research (CIHR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	The study received no specific funding. JOF is supported by a Clinician-Scientist award from the Canadian Institutes of Health Research (CIHR). NDF is supported by a CIHR New Investigator Award. CIHR had no involvement in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure. pdf ( available on request from the corresponding author) and declare that all authors had: ( 1) No financial support for the submitted work from anyone other than their employer; (2) No financial relationships with commercial entities that might have an interest in the submitted work; ( 3) No spouses, partners, or children with relationships with commercial entities that might have an interest in the submitted work; ( 4) The following non-financial interests relevant to the submitted work: MOM and NDF are primary investigators and JOF and NKJA are co-investigators for the ongoing Canadian Institutes of Health Research (CIHR) funded OSCILLATE study. CareFusion (formerly SensorMedics) is providing study oscillators to some of the hospitals involved in the OSCILLATE study for the duration of the study.	*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Adhikari NKJ, 2007, BMJ-BRIT MED J, V334, P779, DOI 10.1136/bmj.39139.716794.55; Albuali WH, 2007, PEDIATR CRIT CARE ME, V8, P324, DOI 10.1097/01.PCC.0000269390.48450.AF; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; *ANZICS H1N1 ECMO, 2009, JAMA-J AM MED ASSOC, V302, P1888; ARNOLD JH, 1994, CRIT CARE MED, V22, P1530, DOI 10.1097/00003246-199422100-00006; Artigas A, 1998, AM J RESP CRIT CARE, V157, P1332, DOI 10.1164/ajrccm.157.4.ats2-98; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bein T, 2007, ANAESTHESIST, V56, P226, DOI 10.1007/s00101-007-1134-8; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; Bernard GR, 2008, NEW ENGL J MED, V359, P2166, DOI 10.1056/NEJMe0806637; Bollen CW, 2005, CRIT CARE, V9, pR430, DOI 10.1186/cc3737; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Cartotto R, 2004, BURNS, V30, P453, DOI 10.1016/j.burns.2004.01.015; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; Chan Kenneth P W, 2005, Crit Care Med, V33, pS170, DOI 10.1097/01.CCM.0000155915.97462.80; Cheung AM, 2006, AM J RESP CRIT CARE, V174, P538, DOI 10.1164/rccm.200505-693OC; Demory D, 2007, CRIT CARE MED, V35, P106, DOI 10.1097/01.CCM.0000251128.60336.FE; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Ferguson ND, 2005, CRIT CARE MED, V33, P479, DOI 10.1097/01.CCM.0000155785.23200.9E; Ferguson ND, 2008, J APPL PHYSIOL, V104, P1230, DOI 10.1152/japplphysiol.01226.2007; Fessler HE, 2007, CRIT CARE MED, V35, P1649, DOI 10.1097/01.CCM.0000269026.40739.2E; Finkielman JD, 2006, BMC EMERG MED, V6, DOI 10.1186/1471-227X-6-2; Fort P, 1997, CRIT CARE MED, V25, P937, DOI 10.1097/00003246-199706000-00008; Friedrich JO, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-32; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gattinoni L, 2005, INTENS CARE MED, V31, P776, DOI 10.1007/s00134-005-2627-z; Hager DN, 2007, CRIT CARE MED, V35, P1522, DOI 10.1097/01.CCM.0000266586.04676.55; Hanson James H, 2006, Respir Care Clin N Am, V12, P349; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Higgins J., 2009, COCHRANE HDB SYSTEMA; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kacmarek RM, 2008, J APPL PHYSIOL, V104, P1232, DOI 10.1152/japplphysiol.01226.2007a; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Leonet S, 2002, INTENS CARE MED, V28, P576, DOI 10.1007/s00134-002-1274-x; Macaskill P, 2001, STAT MED, V20, P641, DOI 10.1002/sim.698; Meade MO, 2009, AM J RESP CRIT CARE, V179; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Meade MO, 1997, ANN INTERN MED, V127, P531, DOI 10.7326/0003-4819-127-7-199710010-00005; Mehta S, 2004, CHEST, V126, P518, DOI 10.1378/chest.126.2.518; Mehta S, 2001, CRIT CARE MED, V29, P1360, DOI 10.1097/00003246-200107000-00011; Mentzelopoulos SD, 2007, INTENS CARE MED, V33, pS142; Mentzelopoulos SD, 2007, CRIT CARE MED, V35, P1500, DOI 10.1097/01.CCM.0000265738.80832.BE; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Miller MP, 2008, CHEST, V134, P969, DOI 10.1378/chest.08-0743; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Muellenbach RM, 2007, INTENS CARE MED, V33, P1423, DOI 10.1007/s00134-007-0708-x; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Papazian L, 2005, CRIT CARE MED, V33, P2162, DOI 10.1097/01.CCM.0000181298.05474.2B; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; Rimensberger PC, 2003, CRIT CARE, V7, P342, DOI 10.1186/cc2327; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Samransamruajkit R, 2005, ASIAN PAC J ALLERGY, V23, P181; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Sedeek KA, 2003, ANESTHESIOLOGY, V99, P1102, DOI 10.1097/00000542-200311000-00016; Shah SB, 2004, INTENS CARE MED, V30, pS84; Slutsky AS, 2009, JAMA-J AM MED ASSOC, V302, P2030, DOI 10.1001/jama.2009.1653; Slutsky AS, 2002, NEW ENGL J MED, V347, P630, DOI 10.1056/NEJMp020082; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Sud S, 2008, CRIT CARE MED, V36, P2711, DOI 10.1097/CCM.0b013e3181846fc0; Sud S, 2007, CRIT CARE MED, V35, pA225; Sud S, 2010, INTENS CARE MED, V36, P585, DOI 10.1007/s00134-009-1748-1; Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01; Wunsch H, 2004, COCHRANE DB SYST REV	73	158	177	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 18	2010	340								c2327	10.1136/bmj.c2327	http://dx.doi.org/10.1136/bmj.c2327			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	601LR	20483951	hybrid			2023-01-03	WOS:000278061500006
J	Carr, BG; Addyson, DK; Kahn, JM				Carr, Brendan G.; Addyson, Daniel K.; Kahn, Jeremy M.			Variation in Critical Care Beds Per Capita in the United States: Implications for Pandemic and Disaster Planning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							2009 INFLUENZA A(H1N1); SERVICES		[Carr, Brendan G.] Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA; [Addyson, Daniel K.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Kahn, Jeremy M.] Univ Penn, Sch Med, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Carr, BG (corresponding author), Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA.	jmkahn@mail.med.upenn.edu		Kahn, Jeremy/0000-0001-9688-5576	AHRQ HHS [K08HS017960, K08 HS017960] Funding Source: Medline; NHLBI NIH HHS [K23 HL082650, K23HL082650] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS017960] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL082650] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnato AE, 2007, CRIT CARE MED, V35, P1003, DOI 10.1097/01.CCM.0000259535.06205.B4; Farmer JC, 2006, CRIT CARE MED, V34, pS56, DOI 10.1097/01.CCM.0000199989.44467.2E; Institute of Medicine, 2007, HOSP BAS EM CAR BREA; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; White DB, 2009, JAMA-J AM MED ASSOC, V302, P1905, DOI 10.1001/jama.2009.1539; Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8	6	52	53	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	2010	303	14					1371	1372		10.1001/jama.2010.394	http://dx.doi.org/10.1001/jama.2010.394			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	582KX	20388892	Green Accepted			2023-01-03	WOS:000276597300021
J	Swanson, MD; Winter, HC; Goldstein, IJ; Markovitz, DM				Swanson, Michael D.; Winter, Harry C.; Goldstein, Irwin J.; Markovitz, David M.			A Lectin Isolated from Bananas Is a Potent Inhibitor of HIV Replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN GP120; INFECTIOUS MOLECULAR CLONE; HEPATITIS-C VIRUS; CYANOVIRIN-N; PLANT-LECTINS; CARBOHYDRATE-BINDING; ANTIBODY 2G12; IN-VITRO; V3 LOOP	BanLec is a jacalin-related lectin isolated from the fruit of bananas, Musa acuminata. This lectin binds to high mannose carbohydrate structures, including those found on viruses containing glycosylated envelope proteins such as human immunodeficiency virus type-1 (HIV-1). Therefore, we hypothesized that BanLec might inhibit HIV-1 through binding of the glycosylated HIV-1 envelope protein, gp120. We determined that BanLec inhibits primary and laboratory-adapted HIV-1 isolates of different tropisms and subtypes. BanLec possesses potent anti-HIV activity, with IC50 values in the low nanomolar to picomolar range. The mechanism for BanLec-mediated antiviral activity was investigated by determining if this lectin can directly bind the HIV-1 envelope protein and block entry of the virus into the cell. Anenzyme-linked immunosorbent assay confirmed direct binding of BanLec to gp120 and indicated that BanLec can recognize the high mannose structures that are recognized by the monoclonal antibody 2G12. Furthermore, BanLec is able to block HIV-1 cellular entry as indicated by temperature-sensitive viral entry studies and by the decreased levels of the strong-stop product of early reverse transcription seen in the presence of BanLec. Thus, our data indicate that BanLec inhibits HIV-1 infection by binding to the glycosylated viral envelope and blocking cellular entry. The relative anti-HIV activity of BanLec compared favorably to other anti-HIV lectins, such as snowdrop lectin and Griffithsin, and to T-20 and mara-viroc, two anti-HIV drugs currently in clinical use. Based on these results, BanLec is a potential component for an anti-viral microbicide that could be used to prevent the sexual transmission of HIV-1.	[Markovitz, David M.] Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, Ann Arbor, MI 48109 USA; [Swanson, Michael D.; Markovitz, David M.] Univ Michigan, Med Ctr, Program Immunol, Ann Arbor, MI 48109 USA; [Markovitz, David M.] Univ Michigan, Med Ctr, Cellular & Mol Biol Program, Ann Arbor, MI 48109 USA; [Winter, Harry C.; Goldstein, Irwin J.] Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Markovitz, DM (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Infect Dis, 5220 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.	dmarkov@umich.edu			National Institutes of Health [R01 AI062248]; Burroughs Wellcome Fund Clinical Scientist Award in Translational Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI062248] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund Clinical Scientist Award in Translational Research(Burroughs Wellcome Fund); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported, in whole or in part, by National Institutes of Health Grant R01 AI062248 (of D. M. M.). This work was also supported by a Burroughs Wellcome Fund Clinical Scientist Award in Translational Research.	ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; Arhel NJ, 2007, EMBO J, V26, P3025, DOI 10.1038/sj.emboj.7601740; BACK NKT, 1994, VIROLOGY, V199, P431, DOI 10.1006/viro.1994.1141; BALZARINI J, 1991, ANTIMICROB AGENTS CH, V35, P410, DOI 10.1128/AAC.35.3.410; Balzarini J, 2004, ANTIMICROB AGENTS CH, V48, P3858, DOI 10.1128/AAC.48.10.3858-3870.2004; Balzarini J, 2007, NAT REV MICROBIOL, V5, P583, DOI 10.1038/nrmicro1707; Balzarini J, 2007, LANCET, V369, P787, DOI 10.1016/S0140-6736(07)60202-5; Balzarini O, 2005, LANCET INFECT DIS, V5, P726, DOI 10.1016/S1473-3099(05)70271-1; Barrientos LG, 2004, J INFECT DIS, V189, P1440, DOI 10.1086/382658; Barrientos LG, 2003, ANTIVIR RES, V58, P47, DOI 10.1016/S0166-3542(02)00183-3; Bertaux C, 2007, VIROLOGY, V366, P40, DOI 10.1016/j.virol.2007.04.008; Boyd MR, 1997, ANTIMICROB AGENTS CH, V41, P1521, DOI 10.1128/AAC.41.7.1521; Buffa V, 2009, J GEN VIROL, V90, P234, DOI 10.1099/vir.0.004358-0; Chackerian B, 1997, J VIROL, V71, P3932, DOI 10.1128/JVI.71.5.3932-3939.1997; CHESEBRO B, 1991, J INFECT DIS, V163, P64, DOI 10.1093/infdis/163.1.64; CHESEBRO B, 1991, J VIROL, V65, P5782, DOI 10.1128/JVI.65.11.5782-5789.1991; CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; Clevestig P, 2006, J GEN VIROL, V87, P607, DOI 10.1099/vir.0.81510-0; COLLMAN R, 1992, J VIROL, V66, P7517, DOI 10.1128/JVI.66.12.7517-7521.1992; Crosby R, 2005, J AM COLL HEALTH, V54, P143, DOI 10.3200/JACH.54.3.143-148; Derdeyn CA, 2000, J VIROL, V74, P8358, DOI 10.1128/JVI.74.18.8358-8367.2000; FREED EO, 1995, J VIROL, V69, P3949, DOI 10.1128/JVI.69.6.3949-3954.1995; GARTNER S, 1986, SCIENCE, V233, P215, DOI 10.1126/science.3014648; Gavrovic-Jankulovic M, 2008, INT J BIOCHEM CELL B, V40, P929, DOI 10.1016/j.biocel.2007.10.033; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; GEYER H, 1988, J BIOL CHEM, V263, P11760; Gray ES, 2007, J VIROL, V81, P10769, DOI 10.1128/JVI.01106-07; Gupta GR, 2002, BRIT MED J, V324, P183, DOI 10.1136/bmj.324.7331.183; Helle F, 2006, J BIOL CHEM, V281, P25177, DOI 10.1074/jbc.M602431200; Huskens D, 2008, INT J BIOCHEM CELL B, V40, P2802, DOI 10.1016/j.biocel.2008.05.023; Jeyaprakash AA, 2004, J MOL BIOL, V338, P757, DOI 10.1016/j.jmb.2004.03.040; Keyaerts E, 2007, ANTIVIR RES, V75, P179, DOI 10.1016/j.antiviral.2007.03.003; KOSHTE VL, 1990, BIOCHEM J, V272, P721, DOI 10.1042/bj2720721; Kothe DL, 2006, VIROLOGY, V352, P438, DOI 10.1016/j.virol.2006.05.011; Li BQ, 2000, BIOCHEM BIOPH RES CO, V276, P534, DOI 10.1006/bbrc.2000.3485; Li M, 2005, J VIROL, V79, P10108, DOI 10.1128/JVI.79.16.10108-10125.2005; LI Y, 1993, J VIROL, V67, P584, DOI 10.1128/JVI.67.1.584-588.1993; Lis H., 2003, LECTINS; MATTHEWS TJ, 1987, P NATL ACAD SCI USA, V84, P5424, DOI 10.1073/pnas.84.15.5424; Meagher JL, 2005, GLYCOBIOLOGY, V15, P1033, DOI 10.1093/glycob/cwi088; Mkrtchyan SR, 2005, J VIROL, V79, P11161, DOI 10.1128/JVI.79.17.11161-11169.2005; Mo HQ, 2001, EUR J BIOCHEM, V268, P2609, DOI 10.1046/j.1432-1327.2001.02148.x; Mori T, 2005, J BIOL CHEM, V280, P9345, DOI 10.1074/jbc.M411122200; Nakamura-Tsuruta S, 2008, FEBS J, V275, P1227, DOI 10.1111/j.1742-4658.2008.06282.x; O'Doherty U, 2000, J VIROL, V74, P10074, DOI 10.1128/JVI.74.21.10074-10080.2000; O'Keefe BR, 2009, P NATL ACAD SCI USA, V106, P6099, DOI 10.1073/pnas.0901506106; Peumans WJ, 2000, PLANTA, V211, P546, DOI 10.1007/s004250000307; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Randolph ME, 2007, ARCH SEX BEHAV, V36, P844, DOI 10.1007/s10508-007-9213-0; Saidi H, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-28; Sanders RW, 2002, J VIROL, V76, P7293, DOI 10.1128/JVI.76.14.7293-7305.2002; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Schmidtmayerova H, 1998, J VIROL, V72, P4633, DOI 10.1128/JVI.72.6.4633-4642.1998; Shen R, 2009, J VIROL, V83, P3258, DOI 10.1128/JVI.01796-08; Singh DD, 2005, GLYCOBIOLOGY, V15, P1025, DOI 10.1093/glycob/cwi087; Smee DF, 2008, ANTIVIR RES, V80, P266, DOI 10.1016/j.antiviral.2008.06.003; Takeuchi Y, 2008, J VIROL, V82, P12585, DOI 10.1128/JVI.01726-08; TOOHEY K, 1995, VIROLOGY, V213, P70, DOI 10.1006/viro.1995.1547; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; Tsai CC, 2003, AIDS RES HUM RETROV, V19, P535, DOI 10.1089/088922203322230897; Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459; UNAIDS, 2008, REP GLOB AIDS EP; Underhill K, 2007, BMJ-BRIT MED J, V335, P248, DOI 10.1136/bmj.39245.446586.BE; VANDAMME EJM, 1987, FEBS LETT, V215, P140, DOI 10.1016/0014-5793(87)80129-1; Warrilow D, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-77; Warrilow D, 2008, J VIROL, V82, P1425, DOI 10.1128/JVI.01808-07; WATTS C, 2002, MICROBICIDES; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; Witvrouw M, 2005, J VIROL, V79, P7777, DOI 10.1128/JVI.79.12.7777-7784.2005; Zappe H, 2008, ADV DRUG DELIVER REV, V60, P79, DOI 10.1016/j.addr.2007.05.016; Ziolkowska NE, 2006, STRUCTURE, V14, P1127, DOI 10.1016/j.str.2006.05.017	73	134	141	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 19	2010	285	12					8646	8655		10.1074/jbc.M109.034926	http://dx.doi.org/10.1074/jbc.M109.034926			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	568VZ	20080975	hybrid, Green Published			2023-01-03	WOS:000275553700017
J	Elstgeest, LE; Martens, SE; Lopriore, E; Walther, FJ; te Pas, AB				Elstgeest, Liset E.; Martens, Shirley E.; Lopriore, Enrico; Walther, Frans J.; te Pas, Arjan B.			Does Parenteral Nutrition Influence Electrolyte and Fluid Balance in Preterm Infants in the First Days after Birth?	PLOS ONE			English	Article							POSTNATAL SODIUM SUPPLEMENTATION; RANDOMIZED CONTROLLED-TRIAL; PATENT DUCTUS-ARTERIOSUS; GESTATIONAL-AGE; WEIGHT INFANTS; BODY-COMPOSITION; ASSOCIATION	Background: New national guidelines recommend more restricted fluid intake and early initiation of total parenteral nutrition (TPN) in very preterm infants. The aim was study the effect of these guidelines on serum sodium and potassium levels and fluid balance in the first three days after birth. Methods: Two cohorts of infants <28 weeks gestational age, born at the Leiden University Medical Center in the Netherlands, were compared retrospectively before (2002-2004, late-TPN) and after (2006-2007, early-TPN) introduction of the new Dutch guideline. Outcome measures were serum sodium and potassium levels, diuresis, and changes in body weight in the first three postnatal days. Results: In the first three postnatal days no differences between late-TPN (N = 70) and early-TPN cohort (N = 73) in mean (SD) serum sodium (141.1 (3.8) vs 141.0 (3.7) mmol/l) or potassium (4.3 (0.5) vs 4.3 (0.5) mmol/l) were found, but in the early-TPN cohort diuresis (4.5 (1.6) vs 3.2 (1.4) ml/kg/h) and loss of body weight were decreased (26.0% (7.7) vs 20.8% (8.0)). Conclusions: Initiation of TPN immediately after birth and restricted fluid intake in very preterm infants do not seem to influence serum sodium and potassium levels in first three postnatal days. Further research is needed to see if a decreased diuresis and loss of body weight in the first days is the result of a delayed postnatal adaptation or better energy balance.	[Elstgeest, Liset E.; Martens, Shirley E.; Lopriore, Enrico; Walther, Frans J.; te Pas, Arjan B.] Leiden Univ, Med Ctr, Dept Pediat, Div Neonatol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Elstgeest, LE (corresponding author), Leiden Univ, Med Ctr, Dept Pediat, Div Neonatol, Leiden, Netherlands.	a.b.te_pas@lumc.nl	Lopriore, Enrico/ABE-3576-2021; pas, arjan te/AAA-9019-2020	Lopriore, Enrico/0000-0002-3513-5066; pas, arjan te/0000-0001-7831-8797; Walther, Frans/0000-0003-1931-159X				Aggarwal Rajiv, 2001, Indian Journal of Pediatrics, V68, P1139, DOI 10.1007/BF02722931; Bell EF, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000503.pub2; BELL EF, 1979, LANCET, V2, P90; BELL EF, 1980, NEW ENGL J MED, V302, P598, DOI 10.1056/NEJM198003133021103; Bhatia J, 2006, J PERINATOL, V26, pS19, DOI 10.1038/sj.jp.7211466; Braake FWJT, 2007, SEMIN FETAL NEONAT M, V12, P11, DOI 10.1016/j.siny.2006.10.002; COCKBURN F, 1993, LANCET, V342, P193; COSTARINO AT, 1992, J PEDIATR-US, V120, P99, DOI 10.1016/S0022-3476(05)80611-0; DELL KM, 2006, FANAROFF MARTINS NEO, P695; Gawlowski Z, 2006, J PAEDIATR CHILD H, V42, P771, DOI 10.1111/j.1440-1754.2006.00975.x; Hartnoll G, 2000, ARCH DIS CHILD-FETAL, V82, pF19, DOI 10.1136/fn.82.1.F19; Hartnoll G, 2000, ARCH DIS CHILD-FETAL, V82, pF24, DOI 10.1136/fn.82.1.F24; Hartnoll G, 2001, ARCH DIS CHILD-FETAL, V85, pF29, DOI 10.1136/fn.85.1.F29; HEIMLER R, 1993, J PEDIATR-US, V122, P110, DOI 10.1016/S0022-3476(05)83502-4; KOOLEN AMP, 2004, WERKBOEK ENTERALE PA, P17; LORENZ JM, 1982, J PEDIATR-US, V101, P423, DOI 10.1016/S0022-3476(82)80078-4; Lorenz JM, 1997, J PEDIATR-US, V131, P81, DOI 10.1016/S0022-3476(97)70128-8; Mildenberger E, 2002, EUR J PEDIATR, V161, P415, DOI 10.1007/s00431-002-0986-9; Modi N, 2004, ARCH DIS CHILD-FETAL, V89, P108, DOI 10.1136/adc.2001.004275; MODI N, 1993, ARCH DIS CHILD-FETAL, V69, P87, DOI 10.1136/adc.69.1_Spec_No.87; Oh W, 2005, J PEDIATR-US, V147, P786, DOI 10.1016/j.jpeds.2005.06.039; Omar SA, 2000, PEDIATRICS, V106, P561, DOI 10.1542/peds.106.3.561; Poindexter BB, 2006, J PEDIATR-US, V148, P300, DOI 10.1016/j.jpeds.2005.10.038; POINDEXTER BB, 2006, FANAROFF MARTINS NEO, P679; PUTHOFF TD, 2004, NEWBORN INFANT NURS, V4, P98; SHAFFER SG, 1989, J PEDIATR-US, V115, P285, DOI 10.1016/S0022-3476(89)80087-3; STEVENSON JG, 1977, J PEDIATR-US, V90, P257, DOI 10.1016/S0022-3476(77)80645-8; Tang W, 1997, ARCH DIS CHILD-FETAL, V77, pF28, DOI 10.1136/fn.77.1.F28; Van den Akker CHP, 2006, PEDIATR RES, V59, P732, DOI 10.1203/01.pdr.0000214990.86879.26; VANMARTER LJ, 1990, J PEDIATR-US, V116, P942; Wadhawan R, 2007, J PERINATOL, V27, P359, DOI 10.1038/sj.jp.7211751	31	16	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2010	5	2							e9033	10.1371/journal.pone.0009033	http://dx.doi.org/10.1371/journal.pone.0009033			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	554ZA	20140260	gold, Green Published, Green Submitted			2023-01-03	WOS:000274474200019
J	Tsertsvadze, A; Fink, HA; Yazdi, F; MacDonald, R; Bella, AJ; Ansari, MT; Garritty, C; Soares-Weiser, K; Daniel, R; Sampson, M; Fox, S; Moher, D; Wilt, TJ				Tsertsvadze, Alexander; Fink, Howard A.; Yazdi, Fatemeh; MacDonald, Roderick; Bella, Anthony J.; Ansari, Mohammed T.; Garritty, Chantelle; Soares-Weiser, Karla; Daniel, Raymond; Sampson, Margaret; Fox, Steven; Moher, David; Wilt, Timothy J.			Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article							ISCHEMIC OPTIC NEUROPATHY; PLACEBO-CONTROLLED TRIAL; SILDENAFIL CITRATE VIAGRA((R)); RANDOMIZED DOUBLE-BLIND; ON-DEMAND TADALAFIL; SPARING RADICAL PROSTATECTOMY; INCREASES PENILE RIGIDITY; SERUM TESTOSTERONE LEVELS; FLEXIBLE-DOSE VARDENAFIL; IMPROVES SEXUAL FUNCTION	Background: Erectile dysfunction (ED) is a common male sexual disorder. The relative benefits and harms of pharmacologic therapies for ED, as well as the value of hormonal testing in men with ED, are uncertain. Purpose: To evaluate the efficacy and harms of oral phosphodiesterase-5 (PDE-5) inhibitors and hormonal treatments for ED and assess the effect of measuring serum hormone levels on treatment outcomes for ED. Data Sources: English-language studies from MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, PsycINFO, AMED, and SCOPUS through April 2009. Trial reference lists also were scanned. Study Selection: Randomized, controlled trials (RCTs) of oral PDE-5 inhibitors and hormonal treatment for ED, and observational studies reporting measurement of serum hormone levels, prevalence of hormonal abnormalities, or both in men with ED. Data Extraction: Two independent reviewers abstracted data on study, participant, and treatment characteristics; efficacy and harms outcomes; and prevalence of hormonal abnormalities. Data Synthesis: Data, primarily from short-term trials (<= 12 weeks), indicate that PDE-5 inhibitors were more effective than placebo in improving sexual intercourse success (69.0% vs. 35.0%). The proportion of men with improved erections was significantly greater among those treated with PDE-5 inhibitors (range, 67.0% to 89.0%) than with placebo (range, 27.0% to 35.0%). The PDE-5 inhibitors were associated with increased risk for any adverse events compared with placebo (for example, relative risk with sildenafil, 1.72 [95% CI, 1.53 to 1.93]). In 4 head-to-head RCTs comparing sildenafil, vardenafil, and tadalafil, improvement of ED and adverse events did not differ among treatments. Results from 15 RCTs evaluating hormonal treatment of ED were inconsistent on whether treatment improved outcomes. Evidence was insufficient regarding whether men with ED had a higher prevalence of hypogonadism than men without ED. Limitations: Many RCTs were of low methodological and reporting quality, particularly those involving hormonal treatments or directly comparing different PDE-5 inhibitors. Most RCTs provided only short-term efficacy and harms data. Conclusion: Oral PDE-5 inhibitors improved erectile functioning and had similar efficacy and safety profiles. Results on the efficacy of hormonal treatments and the value of hormone testing in men with ED were inconclusive. Primary Funding Source: Agency for Healthcare Research and Quality.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada; Minneapolis Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Geriatr Res Educ & Clin Ctr, Minneapolis, MN USA; Minneapolis Evidence Based Practice Ctr, Minneapolis, MN USA; Enhance Reviews, Kefar Sava, Israel; Agcy Healthcare Res & Qual, Rockville, MD USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Children's Hospital of Eastern Ontario; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; Agency for Healthcare Research & Quality	Fink, HA (corresponding author), Vet Affairs Med Ctr 11 G, 1 Vet Dr, Minneapolis, MN 55417 USA.	howard.fink@va.gov	Fink, Howard/F-3933-2012; Garritty, Chantelle/ABG-7790-2020; Garritty, Chantelle Marie/AAC-4136-2022	Moher, David/0000-0003-2434-4206; Sampson, Margaret/0000-0003-2550-9893; Daniel, Raymond/0000-0002-1753-6683	Agency for Healthcare Research and Quality; Pfizer, Lilly, Bayer	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Pfizer, Lilly, Bayer(Eli LillyBayer AGPfizer)	Agency for Healthcare Research and Quality.; Honoraria: A. J. Bella (Pfizer, Lilly, Bayer).	Abdel-Naser MB, 2004, INT J IMPOT RES, V16, P552, DOI 10.1038/sj.ijir.3901245; Acar D, 2004, ARCH ANDROLOGY, V50, P247, DOI 10.1080/01485010490448769; Akash R, 2005, J OCUL PHARMACOL TH, V21, P315, DOI 10.1089/jop.2005.21.315; AKPUNONU BE, 1994, J GEN INTERN MED, V9, P336, DOI 10.1007/BF02599183; ALBUQUERQUE DC, 2005, INT BRAZ J UROL, V31, P354; Albuquerque Denilson C., 2005, Int. braz j urol., V31, P342, DOI 10.1590/S1677-55382005000400008; Althof SE, 2006, J SEX MED, V3, P521, DOI 10.1111/j.1743-6109.2006.00234.x; Araujo AB, 2007, J CLIN ENDOCR METAB, V92, P4241, DOI 10.1210/jc.2007-1245; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Aversa A, 2007, INT J IMPOT RES, V19, P200, DOI 10.1038/sj.ijir.3901513; Aversa A, 2003, CLIN ENDOCRINOL, V58, P632, DOI 10.1046/j.1365-2265.2003.01764.x; Aversa A, 2000, CLIN ENDOCRINOL, V53, P517, DOI 10.1046/j.1365-2265.2000.01118.x; BANCROFT J, 1983, ARCH SEX BEHAV, V12, P59, DOI 10.1007/BF01542116; Bannowsky A, 2008, BJU INT, V101, P1279, DOI 10.1111/j.1464-410X.2008.07515.x; *BAYER AG, 2006, BAY ANN REP 2005; Becher E, 2002, INT J IMPOT RES, V14, pS33, DOI 10.1038/sj.ijir.3900896; Bocchio M, 2008, ATHEROSCLEROSIS, V196, P313, DOI 10.1016/j.atherosclerosis.2006.09.035; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Boulton AJM, 2001, DIABETOLOGIA, V44, P1296, DOI 10.1007/s001250100656; Boyanov M A, 2003, Aging Male, V6, P1; Bunch T J, 2002, Aging Male, V5, P38, DOI 10.1080/713604648; Buranakitjaroen Peera, 2007, Journal of the Medical Association of Thailand, V90, P1100; Burnett AL, 1998, NAT MED, V4, P84, DOI 10.1038/nm0198-084; Burnett AL, 2009, J UROLOGY, V181, P245, DOI 10.1016/j.juro.2008.09.005; Buvat J, 1997, J UROLOGY, V158, P1764, DOI 10.1016/S0022-5347(01)64123-5; Buvat J, 2008, BJU INT, V102, P1645, DOI 10.1111/j.1464-410X.2008.07908.x; Cappelleri JC, 2000, UROLOGY, V56, P477, DOI 10.1016/S0090-4295(00)00697-X; Carrier S, 2005, J SEX MED, V2, P685, DOI 10.1111/j.1743-6109.2005.00097.x; Carson C, 2005, UROLOGY, V65, P353, DOI 10.1016/j.urology.2004.09.056; Carson CC, 2004, BJU INT, V94, P1301, DOI 10.1111/j.1464-410X.2004.05161.x; Cavallini G, 2005, UROLOGY, V66, P1080, DOI 10.1016/j.urology.2005.05.014; Cavallini G, 2004, UROLOGY, V63, P641, DOI 10.1016/j.urology.2003.11.009; Chen KK, 2001, INT J IMPOT RES, V13, P221, DOI 10.1038/sj.ijir.3900685; Chen KK, 2004, J SEX MED, V1, P201, DOI 10.1111/j.1743-6109.2004.04029.x; Chiang HS, 2007, INT J IMPOT RES, V19, P411, DOI 10.1038/sj.ijir.3901562; Choi HK, 2003, INT J IMPOT RES, V15, P80, DOI 10.1038/sj.ijir.3900944; CHOI HK, 2006, TAEHAN PINYOGIKWA HA, V47, P852; Christiansen E, 2000, INT J IMPOT RES, V12, P177, DOI 10.1038/sj.ijir.3900527; Citron JT, 1996, J UROLOGY, V155, P529, DOI 10.1016/S0022-5347(01)66441-3; CLOPPER RR, 1993, PSYCHONEUROENDOCRINO, V18, P149, DOI 10.1016/0306-4530(93)90066-T; Corona G, 2008, J SEX MED, V5, P2454, DOI 10.1111/j.1743-6109.2008.00856.x; Cunningham AV, 2001, J NEURO-OPHTHALMOL, V21, P22, DOI 10.1097/00041327-200103000-00006; De Rose AF, 2005, INT J IMPOT RES, V17, P76, DOI 10.1038/sj.ijir.3901265; de Tejada IS, 2002, DIABETES CARE, V25, P2159; DeBusk RF, 2004, AM J CARDIOL, V93, P147, DOI 10.1016/j.amjcard.2003.09.030; Demir E, 2006, TRANSPL P, V38, P1379, DOI 10.1016/j.transproceed.2006.02.076; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dheer Somna, 2002, J Assoc Physicians India, V50, P265; Dinsmore WW, 1999, UROLOGY, V53, P800, DOI 10.1016/S0090-4295(98)00586-X; DRINKA PJ, 1993, SOUTHERN MED J, V86, P1264, DOI 10.1097/00007611-199311000-00017; Eardley I, 2002, BRIT J CLIN PHARMACO, V53, p61S, DOI 10.1046/j.0306-5251.2001.00034.x; Eardley I, 2005, BJU INT, V96, P1323, DOI 10.1111/j.1464-410X.2005.05892.x; Eardley I, 2004, BJU INT, V94, P871, DOI 10.1111/j.1464-410X.2004.05049.x; Eardley I, 2001, BRIT J PSYCHIAT, V178, P325, DOI 10.1192/bjp.178.4.325; Earle CM, 2003, UROLOGY, V62, P727, DOI 10.1016/S0090-4295(03)00508-9; Edwards D, 2006, J SEX MED, V3, P1028, DOI 10.1111/j.1743-6109.2006.00329.x; Egan R, 2000, ARCH OPHTHALMOL-CHIC, V118, P291; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; El-Sakka AI, 2007, J SEX MED, V4, P1691, DOI 10.1111/j.1743-6109.2006.00342.x; El-Sakka AI, 2006, J UROLOGY, V176, P2589, DOI 10.1016/j.juro.2006.08.005; El-Sakka AI, 2005, J SEX MED, V2, P551, DOI 10.1111/j.1743-6109.2005.00082.x; Fahmy AK, 1999, BJU INT, V84, P482; Fava M, 2006, J CLIN PSYCHIAT, V67, P240, DOI 10.4088/JCP.v67n0210; Fazio L, 2004, CAN MED ASSOC J, V170, P1429, DOI 10.1503/cmaj.1020049; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FORSBERG L, 1990, SCAND J UROL NEPHROL, V24, P83, DOI 10.3109/00365599009180368; Fowler CJ, 2005, J NEUROL NEUROSUR PS, V76, P700, DOI 10.1136/jnnp.2004.038695; Gedik S, 2007, EYE, V21, P129, DOI 10.1038/sj.eye.6702445; GLINA S, 2001, BRAZ J UROL, V27, P148; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Goldstein I, 2005, J SEX MED, V2, P819, DOI 10.1111/j.1743-6109.2005.00147.x; Goldstein I, 2003, DIABETES CARE, V26, P777, DOI 10.2337/diacare.26.3.777; GOMAA AA, 2006, J MENS HLTH GEND, V3, P47; Gomez F, 2002, INT J IMPOT RES, V14, pS42, DOI 10.1038/sj.ijir.3900897; Gopalakrishnan R, 2006, AM J PSYCHIAT, V163, P494, DOI 10.1176/appi.ajp.163.3.494; Govier F, 2003, CLIN THER, V25, P2709, DOI 10.1016/S0149-2918(03)80328-4; Gruhn N, 2005, ACTA OPHTHALMOL SCAN, V83, P131, DOI 10.1111/j.1600-0420.2005.00374.x; Guay A, 2007, J SEX MED, V4, P1046, DOI 10.1111/j.1743-6109.2007.00530.x; GUAY AT, 1991, UROLOGY, V38, P317, DOI 10.1016/0090-4295(91)80143-U; Guo YL, 2006, INT J UROL, V13, P721, DOI 10.1111/j.1442-2042.2006.01393.x; Gupta B, 2008, ACTA OPHTHALMOL, V86, P924, DOI 10.1111/j.1600-0420.2007.01115.x; Haren M, 2005, AGE AGEING, V34, P125, DOI 10.1093/ageing/afi003; Hatzichristou D, 2004, EUR UROL, V45, P634, DOI 10.1016/j.eururo.2004.01.014; Hatzichristou D, 2008, DIABETIC MED, V25, P138, DOI 10.1111/j.1464-5491.2007.02338.x; Hatzichristou D, 2002, J UROLOGY, V168, P615, DOI 10.1016/S0022-5347(05)64690-3; Heiman JR, 2007, BJOG-INT J OBSTET GY, V114, P437, DOI 10.1111/j.1471-0528.2006.01228.x; Hellstrom WJG, 2002, J ANDROL, V23, P763; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Hong SK, 2007, J UROLOGY, V178, P613, DOI 10.1016/j.juro.2007.03.132; Hundertmark J, 2007, J SEX MED, V4, P1126, DOI 10.1111/j.1743-6109.2007.00536.x; Hussain IF, 2001, J NEUROL NEUROSUR PS, V71, P371, DOI 10.1136/jnnp.71.3.371; Incrocci L, 2001, INT J RADIAT ONCOL, V51, P1190, DOI 10.1016/S0360-3016(01)01767-9; Incrocci L, 2006, INT J RADIAT ONCOL, V66, P439, DOI 10.1016/j.ijrobp.2006.04.047; Ishii N, 2006, INT J UROL, V13, P1066, DOI 10.1111/j.1442-2042.2006.01480.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Johannes CB, 2000, J UROLOGY, V163, P460, DOI 10.1016/S0022-5347(05)67900-1; JOHNSON AR, 1992, J UROLOGY, V147, P1542, DOI 10.1016/S0022-5347(17)37620-6; Jones LA, 2008, J SEX MED, V5, P1955, DOI 10.1111/j.1743-6109.2008.00879.x; Kadioglu A, 2008, J SEX MED, V5, P726, DOI 10.1111/j.1743-6109.2007.00701.x; Katz SD, 2005, AM J CARDIOL, V95, P36, DOI 10.1016/j.amjcard.2004.08.060; Klotz T, 2001, WORLD J UROL, V19, P32, DOI 10.1007/s003450000168; Kohler Tobias S, 2008, Urology, V71, P693, DOI 10.1016/j.urology.2007.11.073; Kongkanand Apichat, 2003, J Med Assoc Thai, V86, P195; Koulikov D, 2007, J UROLOGY, V177, P2267, DOI 10.1016/j.juro.2007.01.123; Kupelian V, 2006, J UROLOGY, V176, P2584, DOI 10.1016/j.juro.2006.08.020; Levinson IP, 2003, INT J IMPOT RES, V15, pS25, DOI 10.1038/sj.ijir.3900970; Light R. J., 1984, SUMMING SCI REV RES; Lindsey I, 2002, DIS COLON RECTUM, V45, P727, DOI 10.1007/s10350-004-6287-9; LOW WY, 2006, J MENS HLTH GEND, V3, P263; Lue TF, 1998, CAMPBELLS UROLOGY, P1181; Mahon A, 2005, AM J KIDNEY DIS, V45, P381, DOI 10.1053/j.ajkd.2004.10.012; Makhlouf AA, 2008, INT J IMPOT RES, V20, P157, DOI 10.1038/sj.ijir.3901576; Margo CE, 2007, AM J OPHTHALMOL, V143, P538, DOI 10.1016/j.ajo.2006.10.006; Martin-Morales A, 2007, J SEX MED, V4, P440, DOI 10.1111/j.1743-6109.2006.00426.x; Martinez-Jabaloyas JM, 2006, BJU INT, V97, P1278, DOI 10.1111/j.1464-410X.2006.06154.x; Mazo E, 2006, INT J IMPOT RES, V18, P464, DOI 10.1038/sj.ijir.3901454; McCullough AR, 2008, INT J IMPOT RES, V20, P388, DOI 10.1038/ijir.2008.21; McCullough AR, 2008, UROLOGY, V71, P686, DOI 10.1016/j.urology.2007.12.025; McCullough AR, 2008, J SEX MED, V5, P476, DOI 10.1111/j.1743-6109.2007.00700.x; MCEVOY GK, 2008, ATENOLOL AHFS DRUG I; McMahon C, 2005, J SEX MED, V2, P415, DOI 10.1111/j.1743-6109.2005.20360.x; McMahon CG, 2005, INT J CLIN PRACT, V59, P143, DOI 10.1111/j.1742-1241.2005.00451.x; McNicholas TA, 2003, BJU INT, V91, P69, DOI 10.1046/j.1464-410X.2003.04016.x; McVary KT, 2007, J UROLOGY, V177, P1401, DOI 10.1016/j.juro.2006.11.037; McVary KT, 2007, J UROLOGY, V177, P1071, DOI 10.1016/j.juro.2006.10.055; Merza Z, 2006, INT J ANDROL, V29, P381, DOI 10.1111/j.1365-2605.2005.00612.x; Meuleman E, 2001, BJU INT, V87, P75, DOI 10.1046/j.1464-410x.2001.00998.x; Miller TA, 2000, AM FAM PHYSICIAN, V61, P95; Miner M, 2008, J SEX MED, V5, P1455, DOI 10.1111/j.1743-6109.2008.00820.x; Mirone V, 2005, EUR UROL, V47, P846, DOI 10.1016/j.eururo.2005.02.019; Moher D, 2001, ANN INTERN MED, V134, P657, DOI 10.7326/0003-4819-134-8-200104170-00011; Montague DK, 2005, J UROLOGY, V174, P230, DOI 10.1097/01.ju.0000164463.19239.19; Montorsi F, 2004, J UROLOGY, V172, P1036, DOI 10.1097/01.ju.0000136448.71773.2b; Montorsi F, 1999, UROLOGY, V53, P1011, DOI 10.1016/S0090-4295(98)00643-8; Montorsi F, 2000, UROLOGY, V56, P906, DOI 10.1016/S0090-4295(00)00841-4; Montorsi F, 2008, EUR UROL, V54, P924, DOI 10.1016/j.eururo.2008.06.083; Montorsi F, 2004, J SEX MED, V1, P168, DOI 10.1111/j.1743-6109.2004.04025.x; Morano S, 2007, EUR UROL, V52, P1768, DOI 10.1016/j.eururo.2007.04.042; Morelli A, 2004, ENDOCRINOLOGY, V145, P2253, DOI 10.1210/en.2003-1699; Muezzinoglu T, 2007, YONSEI MED J, V48, P1015, DOI 10.3349/ymj.2007.48.6.1015; Nagao K, 2004, INT J UROL, V11, P515, DOI 10.1111/j.1442-2042.2004.00833.x; Nagao K, 2006, UROLOGY, V68, P845, DOI 10.1016/j.urology.2006.05.001; Nehra A, 2005, J UROLOGY, V173, P2067, DOI 10.1097/01.ju.0000158456.41788.93; Netto Junior N R, 1993, Rev Paul Med, V111, P454; NOLDUS J, 1994, UROLOGE A, V33, P73; Nurnberg HG, 2003, JAMA-J AM MED ASSOC, V289, P56, DOI 10.1001/jama.289.1.56; O'Leary MP, 2006, J UROLOGY, V175, P1058, DOI 10.1016/S0022-5347(05)00418-0; Olsson AM, 2001, INT J CLIN PRACT, V55, P171; Olsson AM, 2000, INT J CLIN PRACT, V54, P561; Orr G, 2006, J CLIN PSYCHOPHARM, V26, P426, DOI 10.1097/01.jcp.0000227701.33999.b3; Padma-Nathan H, 2003, UROLOGY, V62, P400, DOI 10.1016/S0090-4295(03)00567-3; Padma-Nathan H, 1998, INT J CLIN PRACT, V52, P375; Paick JS, 2008, J SEX MED, V5, P2672, DOI 10.1111/j.1743-6109.2008.00945.x; Paick JS, 2008, ASIAN J ANDROL, V10, P791, DOI 10.1111/j.1745-7262.2008.00422.x; Paick JS, 2008, J SEX MED, V5, P946, DOI 10.1111/j.1743-6109.2007.00723.x; Palmer JS, 2000, J UROLOGY, V164, P958, DOI 10.1016/S0022-5347(05)67225-4; Pepin S, 2008, J NEURO-OPHTHALMOL, V28, P76, DOI 10.1097/WNO.0b013e31816743da; *PFIZ, 2006, PFIZ ANN REP 2005; Pickering TG, 2004, AM J HYPERTENS, V17, P1135, DOI 10.1016/j.amjhyper.2004.07.004; Pomeranz HD, 2005, J NEURO-OPHTHALMOL, V25, P9, DOI 10.1097/00041327-200503000-00003; Pomeranz HD, 2002, OPHTHALMOLOGY, V109, P584, DOI 10.1016/S0161-6420(01)00976-9; Porst H, 2001, INT J IMPOT RES, V13, P192, DOI 10.1038/sj.ijir.3900713; Porst H, 1996, J UROLOGY, V155, P802, DOI 10.1016/S0022-5347(01)66315-8; Porst H, 2003, UROLOGY, V62, P121, DOI 10.1016/S0090-4295(03)00359-5; Porst H, 2006, EUR UROL, V50, P1086, DOI 10.1016/j.eururo.2006.05.036; Price DE, 1998, DIABETIC MED, V15, P821, DOI 10.1002/(SICI)1096-9136(199810)15:10<821::AID-DIA697>3.0.CO;2-P; Rabkin JG, 2000, ARCH GEN PSYCHIAT, V57, P141, DOI 10.1001/archpsyc.57.2.141; Rajfer J, 2007, INT J IMPOT RES, V19, P95, DOI 10.1038/sj.ijir.3901496; Ralph D, 2007, BJU INT, V100, P130, DOI 10.1111/j.1464-410X.2007.06900.x; Rendell MS, 1999, JAMA-J AM MED ASSOC, V281, P421, DOI 10.1001/jama.281.5.421; Reyes-Vallejo L, 2007, J SEX MED, V4, P1757, DOI 10.1111/j.1743-6109.2006.00381.x; Rhoden EL, 2002, INT J IMPOT RES, V14, P167, DOI 10.1038/sj.ijir.3900852; Rhoden EL, 2002, J UROLOGY, V167, P1745, DOI 10.1016/S0022-5347(05)65191-9; Tolra JR, 2006, J SEX MED, V3, P901, DOI 10.1111/j.1743-6109.2006.00297.x; Rosanoa GMC, 2005, EUR UROL, V47, P214, DOI 10.1016/j.eururo.2004.10.002; Rosen R, 2006, AM J PSYCHIAT, V163, P79, DOI 10.1176/appi.ajp.163.1.79; Rosen RC, 2004, J SEX MED, V1, P193, DOI 10.1111/j.1743-6109.2004.04028.x; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; Safarinejad MR, 2009, J UROLOGY, V181, P252, DOI 10.1016/j.juro.2008.09.003; Safarinejad MR, 2004, J DIABETES COMPLICAT, V18, P205, DOI 10.1016/S1056-8727(03)00056-4; Saylan M, 2006, INT J CLIN PRACT, V60, P812, DOI 10.1111/j.1742-1241.2006.00993.x; Schiavi RC, 1997, ARCH SEX BEHAV, V26, P231, DOI 10.1023/A:1024518730222; Schulz KF, 2002, LANCET, V359, P614, DOI 10.1016/S0140-6736(02)07750-4; Seftel AD, 2004, J UROLOGY, V172, P652, DOI 10.1097/01.ju.0000132857.39680.ce; Seftel AD, 2004, J ANDROL, V25, P963; Seibel I, 2002, J AM SOC NEPHROL, V13, P2770, DOI 10.1097/01.ASN.0000034201.97937.3E; Seidman SN, 2006, J SEX MARITAL THER, V32, P267, DOI 10.1080/00926230600575355; Seidman SN, 2001, AM J PSYCHIAT, V158, P1623, DOI 10.1176/appi.ajp.158.10.1623; Shabsigh R, 2004, J UROLOGY, V172, P658, DOI 10.1097/01.ju.0000132389.97804.d7; Shamloul R, 2005, J SEX MED, V2, P559, DOI 10.1111/j.1743-6109.2005.00071.x; Sharma RK, 2006, AM J KIDNEY DIS, V48, P128, DOI 10.1053/j.ajkd.2006.04.061; Sinha S, 2004, EYE, V18, P446, DOI 10.1038/sj.eye.6700697; Skoumal R, 2004, EUR UROL, V46, P362, DOI 10.1016/j.eururo.2004.04.026; Sommer F, 2007, ASIAN J ANDROL, V9, P134, DOI 10.1111/j.1745-7262.2007.00233.x; Staab A, 2004, PHARM RES-DORDR, V21, P1463, DOI 10.1023/B:PHAM.0000036922.03519.40; Stark S, 2001, EUR UROL, V40, P181, DOI 10.1159/000049770; Stief C, 2004, INT J CLIN PRACT, V58, P230, DOI 10.1111/j.1368-5031.2004.00128.x; Stuckey BGA, 2003, DIABETES CARE, V26, P279, DOI 10.2337/diacare.26.2.279; Su DHW, 2008, J NEURO-OPHTHALMOL, V28, P75, DOI 10.1097/WNO.0b013e318167554a; Swerdloff RS, 2004, BEST PRACT RES CL EN, V18, P349, DOI 10.1016/j.beem.2004.03.011; Tan HM, 2000, UROLOGY, V56, P635, DOI 10.1016/S0090-4295(00)00688-9; Tan HM, 2008, ASIAN J ANDROL, V10, P495, DOI 10.1111/j.1745-7262.2008.00388.x; Tignol J, 2004, INT CLIN PSYCHOPHARM, V19, P191, DOI 10.1097/01.yic.0000117902.43995.b0; Tsertsvadze A, 2009, EVID REP TECHNOL ASS, V171, P98; Tsujimura A, 2005, INT J IMPOT RES, V17, P259, DOI 10.1038/sj.ijir.3901300; Umrani Dhananjay N., 1999, Indian Journal of Physiology and Pharmacology, V43, P160; Valiquette L, 2005, MAYO CLIN PROC, V80, P1291, DOI 10.4065/80.10.1291; van Ahlen H, 2005, J SEX MED, V2, P856, DOI 10.1111/j.1743-6109.2005.00150.x; Virag R, 1999, UROLOGY, V54, P1073, DOI 10.1016/S0090-4295(99)00310-6; von Keitz A, 2004, EUR UROL, V45, P499, DOI 10.1016/j.eururo.2003.11.030; Wang C, 2000, J CLIN ENDOCR METAB, V85, P2839, DOI 10.1210/jc.85.8.2839; Warburton I, 2004, J SEX MED, V1, P179, DOI 10.1111/j.1743-6109.2004.04026.x; Webster LJ, 2004, ARCH INTERN MED, V164, P514, DOI 10.1001/archinte.164.5.514; Wespes E, 2006, EUR UROL, V49, P806, DOI 10.1016/j.eururo.2006.01.028; Wessells H, 2007, J UROLOGY, V177, P1675, DOI 10.1016/j.juro.2007.01.057; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Yassin AA, 2006, ANDROLOGIA, V38, P61, DOI 10.1111/j.1439-0272.2006.00712.x; Yip WCA, 2006, ASIAN J ANDROL, V8, P685, DOI 10.1111/j.1745-7262.2006.00213.x; Young JM, 2005, J ANDROL, V26, P310, DOI 10.2164/jandrol.04126; Young JM, 2002, UROLOGY, V60, P39, DOI 10.1016/S0090-4295(02)01689-8; Ziegler D, 2006, J SEX MED, V3, P883, DOI 10.1111/j.1743-6109.2006.00295.x; Zinner N, 2007, J SEX MED, V4, P137, DOI 10.1111/j.1743-6109.2006.00400.x; Zohdy W, 2007, J SEX MED, V4, P797, DOI 10.1111/j.1743-6109.2007.00499.x; Zumbe J, 2008, EUR UROL, V54, P204, DOI 10.1016/j.eururo.2008.03.056; 1993, JAMA, V270, P83	226	113	121	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 3	2009	151	9					650	W218		10.7326/0003-4819-151-9-200911030-00150	http://dx.doi.org/10.7326/0003-4819-151-9-200911030-00150			22	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	514IM	19884626				2023-01-03	WOS:000271387700007
J	Wald, R; Quinn, RR; Luo, J; Li, P; Scales, DC; Mamdani, MM; Ray, JG				Wald, Ron; Quinn, Robert R.; Luo, Jin; Li, Ping; Scales, Damon C.; Mamdani, Muhammad M.; Ray, Joel G.		Univ Toronto Acute Kidney Injury R	Chronic Dialysis and Death Among Survivors of Acute Kidney Injury Requiring Dialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE-RENAL-FAILURE; CRITICALLY-ILL PATIENTS; INTENSIVE-CARE-UNIT; REPLACEMENT THERAPY; HOSPITALIZED-PATIENTS; ELDERLY-PATIENTS; RECOVERY; OUTCOMES; RISK; EPIDEMIOLOGY	Context Severe acute kidney injury among hospitalized patients often necessitates initiation of short-term dialysis. Little is known about the long-term outcome of those who survive to hospital discharge. Objective To assess the risk of chronic dialysis and all-cause mortality in individuals who experience an episode of acute kidney injury requiring dialysis. Design, Setting, and Participants We conducted a population-based cohort study of all adult patients in Ontario, Canada, with acute kidney injury who required in-hospital dialysis and survived free of dialysis for at least 30 days after discharge between July 1, 1996, and December 31, 2006. These individuals were matched with patients without acute kidney injury or dialysis during their index hospitalization. Matching was by age plus or minus 5 years, sex, history of chronic kidney disease, receipt of mechanical ventilation during the index hospitalization, and a propensity score for developing acute kidney injury requiring dialysis. Patients were followed up until March 31, 2007. Main Outcome Measures The primary end point was the need for chronic dialysis and the secondary outcome was all-cause mortality. Results We identified 3769 adults with acute kidney injury requiring in-hospital dialysis and 13 598 matched controls. The mean age was 62 years and median follow-up was 3 years. The incidence rate of chronic dialysis was 2.63 per 100 personyears among individuals with acute kidney injury requiring dialysis, and 0.91 per 100 person-years among control participants (adjusted hazard ratio, 3.23; 95% confidence interval, 2.70-3.86). All-cause mortality rates were 10.10 and 10.85 per 100 person-years, respectively (adjusted hazard ratio, 0.95; 95% confidence interval, 0.891.02). Conclusions Acute kidney injury necessitating in-hospital dialysis was associated with an increased risk of chronic dialysis but not all-cause mortality. JAMA. 2009; 302(11): 1179-1185	[Wald, Ron] St Michaels Hosp, Div Nephrol, Toronto, ON M5C 2T2, Canada; [Ray, Joel G.] St Michaels Hosp, Div Gen Internal Med, Toronto, ON M5C 2T2, Canada; [Wald, Ron; Mamdani, Muhammad M.; Ray, Joel G.] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Wald, Ron; Scales, Damon C.; Mamdani, Muhammad M.; Ray, Joel G.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Quinn, Robert R.] Sunnybrook Hlth Sci Ctr, Div Nephrol, Toronto, ON M4N 3M5, Canada; [Scales, Damon C.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Luo, Jin; Li, Ping; Scales, Damon C.; Mamdani, Muhammad M.; Ray, Joel G.] Inst Clin Evaluat Sci, Toronto, ON, Canada; [Mamdani, Muhammad M.] King Saud Univ, Fac Med, Riyadh, Saudi Arabia	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; King Saud University	Wald, R (corresponding author), St Michaels Hosp, Div Nephrol, 61 Queen St E,9-140, Toronto, ON M5C 2T2, Canada.	waldr@smh.toronto.on.ca	Li, Ping/GYV-4914-2022; Lapinsky, Stephen/C-4624-2015; Quinn, Robert R/E-7017-2011	Lapinsky, Stephen/0000-0002-6930-0306; Friedrich, Jan/0000-0001-7248-2350	Ontario Ministry of Health and Long-Term Care; University of Toronto Faculty of Medicine; Canadian Institutes of Health Research New Investigator Award; Canadian Institutes of Health Research; Amgen; Canadian Institutes of Health Research Institute of Health Services and Policy Research Fellowship	Ontario Ministry of Health and Long-Term Care(Ministry of Health and Long-Term Care, Ontario); University of Toronto Faculty of Medicine(University of Toronto); Canadian Institutes of Health Research New Investigator Award(Canadian Institutes of Health Research (CIHR)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Amgen(Amgen); Canadian Institutes of Health Research Institute of Health Services and Policy Research Fellowship(Canadian Institutes of Health Research (CIHR))	Funding/Support: This study was supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care; and a New Staff Dean's Grant from the University of Toronto Faculty of Medicine. Dr Scales reports support from a Canadian Institutes of Health Research New Investigator Award. Dr Wald reports receipt of an RCT Mentoring Program Award from the Canadian Institutes of Health Research and an unrestricted grant from Amgen. Dr Quinn reports support from a Canadian Institutes of Health Research Institute of Health Services and Policy Research Fellowship. Dr Ray reports support from a Canadian Institutes of Health Research New Investigator Award.	Ahlstrom A, 2005, INTENS CARE MED, V31, P1222, DOI 10.1007/s00134-005-2681-6; Bagshaw SM, 2005, CRIT CARE, V9, pR700, DOI 10.1186/cc3879; Basile DP, 2001, AM J PHYSIOL-RENAL, V281, pF887, DOI 10.1152/ajprenal.0050.2001; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chertow GM, 2005, J AM SOC NEPHROL, V16, P3365, DOI 10.1681/ASN.2004090740; de Mendonca A, 2000, INTENS CARE MED, V26, P915, DOI 10.1007/s001340051281; Ishani A, 2009, J AM SOC NEPHROL, V20, P223, DOI 10.1681/ASN.2007080837; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; Ko DT, 2004, JAMA-J AM MED ASSOC, V291, P1864, DOI 10.1001/jama.291.15.1864; Liangos O, 2006, CLIN J AM SOC NEPHRO, V1, P43, DOI 10.2215/CJN.00220605; McCarthy JT, 1996, MAYO CLIN PROC, V71, P117, DOI 10.4065/71.2.117; Mehta RL, 2004, KIDNEY INT, V66, P1613, DOI 10.1111/j.1523-1755.2004.00927.x; Metnitz PGH, 2002, CRIT CARE MED, V30, P2051, DOI 10.1097/00003246-200209000-00016; Morgera S, 2002, AM J KIDNEY DIS, V40, P275, DOI 10.1053/ajkd.2002.34505; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Redelmeier DA, 2005, BRIT MED J, V331, P932, DOI 10.1136/bmj.38603.746944.3A; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Scales DC, 2006, J CLIN EPIDEMIOL, V59, P802, DOI 10.1016/j.jclinepi.2005.11.015; Schiffl H, 2006, NEPHROL DIAL TRANSPL, V21, P1248, DOI 10.1093/ndt/gfk069; Schiffl H, 2008, NEPHROL DIAL TRANSPL, V23, P2235, DOI 10.1093/ndt/gfn182; Silvester W, 2001, CRIT CARE MED, V29, P1910, DOI 10.1097/00003246-200110000-00010; Spurgeon KR, 2005, AM J PHYSIOL-RENAL, V288, pF568, DOI 10.1152/ajprenal.00330.2004; Uchino S, 2005, JAMA-J AM MED ASSOC, V294, P813, DOI 10.1001/jama.294.7.813; Waikar SS, 2006, J AM SOC NEPHROL, V17, P1688, DOI 10.1681/ASN.2006010073	25	519	540	1	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	2009	302	11					1179	1185		10.1001/jama.2009.1322	http://dx.doi.org/10.1001/jama.2009.1322			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	494FR	19755696	Bronze			2023-01-03	WOS:000269797600027
J	Kessler, D; Lewis, G; Kaur, S; Wiles, N; King, M; Weich, S; Sharp, DJ; Araya, R; Hollinghurst, S; Peters, TJ				Kessler, David; Lewis, Glyn; Kaur, Surinder; Wiles, Nicola; King, Michael; Weich, Scott; Sharp, Debbie J.; Araya, Ricardo; Hollinghurst, Sandra; Peters, Tim J.			Therapist-delivered internet psychotherapy for depression in primary care: a randomised controlled trial	LANCET			English	Article							COGNITIVE-BEHAVIORAL THERAPY; CLINICAL-TRIALS; BENEFITS; DISORDER	Background Despite strong evidence for its effectiveness, cognitive-behavioural therapy (CBT) remains difficult to access. Computerised programs have been developed to improve accessibility, but whether these interventions are responsive to individual needs is unknown. We investigated the effectiveness of CBT delivered online in real time by a therapist for patients with depression in primary care. Methods in this multicentre, randomised controlled trial, 297 individuals with a score of 14 or more on the Beck depression inventory (BDI) and a confirmed diagnosis of depression were recruited from 55 general practices in Bristol, London, and Warwickshire, UK. Participants were randomly assigned, by a computer-generated code, to online CRT in addition to usual care (intervention; n=149) or to usual care from their general practitioner while on an 8-month waiting list for online CBT (control; n=148). Participants, researchers involved in recruitment, and therapists were masked in advance to allocation. The primary outcome was recovery from depression (BDI score <10) at 4 months. Analysis was by intention to treat. This trial is registered, number ISRCTN 45444578. Findings 113 participants in the intervention group and 97 in the control group completed 4-month follow-up. 43 (38%) patients recovered from depression (BDI score <10) in the intervention group versus 23 (24%) in the control group at 4 months (odds ratio 2.39, 95% CI 1.23-4.67; p=0.011), and 46 (42%) versus 26 (26%) at 8 months (2.07,1.11-3.87; p=0.023). Interpretation CBT seems to be effective when delivered online in real time by a therapist, with benefits maintained over 8 months. This method of delivery could broaden access to CBT.	[Kessler, David; Kaur, Surinder; Sharp, Debbie J.; Hollinghurst, Sandra; Peters, Tim J.] Univ Bristol, Acad Unit Primary Hlth Care, NIHR Natl Sch Primary Care Res, Dept Community Based Med, Bristol BS8 2AA, Avon, England; [Lewis, Glyn; Wiles, Nicola; Araya, Ricardo] Univ Bristol, Dept Community Based Med, Acad Unit Psychiat, Bristol BS8 2AA, Avon, England; [King, Michael] Dept Mental Hlth Sci, London, England; [Weich, Scott] Univ Warwick, Hlth Sci Res Inst, Coventry CV4 7AL, W Midlands, England	University of Bristol; University of Bristol; University of London; University College London; University of Warwick	Kessler, D (corresponding author), Univ Bristol, Acad Unit Primary Hlth Care, NIHR Natl Sch Primary Care Res, Dept Community Based Med, 25 Belgrave Rd, Bristol BS8 2AA, Avon, England.	david.kessler@bristol.ac.uk	Lewis, Glyn/E-9944-2012; Burls, Amanda J.E./D-7641-2011; Araya, Ricardo/S-3144-2019; King, Michael B/D-7477-2011; Kessler, david/ABB-6489-2021	Lewis, Glyn/0000-0001-5205-8245; Araya, Ricardo/0000-0002-0420-5148; King, Michael B/0000-0003-4715-7171; Wiles, Nicola/0000-0002-5250-3553; Peters, Tim/0000-0003-2881-4180; sharp, deborah/0000-0003-3071-9860; Weich, Scott/0000-0002-7552-7697	BUPA Foundation; MRC [G0800800] Funding Source: UKRI; Medical Research Council [G0800800] Funding Source: researchfish	BUPA Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the BUPA Foundation. We thank all the practices and study participants; Harbinder Sandhu and Nick Green for assistance with data collection; and Nadine Field and Sue Wright from PsychologyOnline for facilitating the involvement of this organisation in the trial.	Beattie A, 2009, HEALTH EXPECT, V12, P45, DOI 10.1111/j.1369-7625.2008.00531.x; Beck A.T., 1987, MANUAL BECK DEPRESSI; Blackburn IM, 2001, BEHAV COGN PSYCHOTH, V29, P431, DOI 10.1017/S1352465801004040; Christensen H, 2006, PSYCHOL MED, V36, P1737, DOI 10.1017/S0033291706008695; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Churchill R, 2001, Health Technol Assess, V5, P1; Department of Health, IMPR ACC PSYCH THER; DeRubeis RJ, 2005, ARCH GEN PSYCHIAT, V62, P409, DOI 10.1001/archpsyc.62.4.409; Dunn G, 2005, STAT METHODS MED RES, V14, P369, DOI 10.1191/0962280205sm403oa; Hollinghurst S, 2005, BRIT MED J, V330, P999, DOI 10.1136/bmj.38377.715799.F7; Jenkinson C, 1997, J Health Serv Res Policy, V2, P14; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kirsch I, 2008, PLOS MED, V5, P260, DOI 10.1371/journal.pmed.0050045; LEWIS G, 1992, PSYCHOL MED, V22, P465, DOI 10.1017/S0033291700030415; Little RJ, 2000, ANNU REV PUBL HEALTH, V21, P121, DOI 10.1146/annurev.publhealth.21.1.121; *MED HEALTHC PROD, SEL SER REUPT INH SS; Pennebaker JW, 1999, J CLIN PSYCHOL, V55, P1243, DOI 10.1002/(SICI)1097-4679(199910)55:10<1243::AID-JCLP6>3.0.CO;2-N; Proudfoot J, 2004, BRIT J PSYCHIAT, V185, P46, DOI 10.1192/bjp.185.1.46; Roberts C, 2005, CLIN TRIALS, V2, P152, DOI 10.1191/1740774505cn076oa; Simon GE, 2004, JAMA-J AM MED ASSOC, V292, P935, DOI 10.1001/jama.292.8.935; TAYLOR EB, 1989, COGNITIVE THER RES, V13, P1, DOI 10.1007/BF01178485; Teasdale JD, 2002, J CONSULT CLIN PSYCH, V70, P275, DOI 10.1037//0022-006X.70.2.275; VANSCHAIK DJF, 2002, TIJDSCHR PSYCHIAT, V44, P609; Ward E, 2000, BRIT MED J, V321, P1383, DOI 10.1136/bmj.321.7273.1383; WHO, 2010, INT STAT CLASS DIS R; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	26	244	250	0	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	2009	374	9690					628	634		10.1016/S0140-6736(09)61257-5	http://dx.doi.org/10.1016/S0140-6736(09)61257-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	486TU	19700005				2023-01-03	WOS:000269222600023
J	Yu, AL; Gilman, AL; Ozkaynak, MF; London, WB; Kreissman, SG; Chen, HX; Smith, M; Anderson, B; Villablanca, JG; Matthay, KK; Shimada, H; Grupp, SA; Seeger, R; Reynolds, CP; Buxton, A; Reisfeld, RA; Gillies, SD; Cohn, SL; Maris, JM; Sondel, PM				Yu, Alice L.; Gilman, Andrew L.; Ozkaynak, M. Fevzi; London, Wendy B.; Kreissman, Susan G.; Chen, Helen X.; Smith, Malcolm; Anderson, Barry; Villablanca, Judith G.; Matthay, Katherine K.; Shimada, Hiro; Grupp, Stephan A.; Seeger, Robert; Reynolds, C. Patrick; Buxton, Allen; Reisfeld, Ralph A.; Gillies, Steven D.; Cohn, Susan L.; Maris, John M.; Sondel, Paul M.		Children's Oncology Grp	Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHILDRENS ONCOLOGY GROUP; HIGH-RISK NEUROBLASTOMA; ANTIGANGLIOSIDE GD2 ANTIBODY; BONE-MARROW-TRANSPLANTATION; COLONY-STIMULATING FACTOR; C-RECEPTOR POLYMORPHISMS; PHASE-I; RECOMBINANT INTERLEUKIN-2; REFRACTORY NEUROBLASTOMA; 13-CIS-RETINOIC ACID	Background: Preclinical and preliminary clinical data indicate that ch14.18, a monoclonal antibody against the tumor-associated disialoganglioside GD2, has activity against neuroblastoma and that such activity is enhanced when ch14.18 is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin-2. We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma. Methods: Patients with high-risk neuroblastoma who had a response to induction therapy and stem-cell transplantation were randomly assigned, in a 1:1 ratio, to receive standard therapy (six cycles of isotretinoin) or immunotherapy (six cycles of isotretinoin and five concomitant cycles of ch14.18 in combination with alternating GM-csf and interleukin-2). Event-free survival and overall survival were compared between the immunotherapy group and the standard-therapy group, on an intention-to-treat basis. Results: A total of 226 eligible patients were randomly assigned to a treatment group. In the immunotherapy group, a total of 52% of patients had pain of grade 3, 4, or 5, and 23% and 25% of patients had capillary leak syndrome and hypersensitivity reactions, respectively. With 61% of the number of expected events observed, the study met the criteria for early stopping owing to efficacy. The median duration of follow-up was 2.1 years. Immunotherapy was superior to standard therapy with regard to rates of event-free survival (66+/-5% vs. 46+/-5% at 2 years, P=0.01) and overall survival (86+/-4% vs. 75+/-5% at 2 years, P=0.02 without adjustment for interim analyses). Conclusions: Immunotherapy with ch14.18, GM-CSF, and interleukin-2 was associated with a significantly improved outcome as compared with standard therapy in patients with high-risk neuroblastoma. (Funded by the National Institutes of Health and the Food and Drug Administration; ClinicalTrials.gov number, NCT00026312.) N Engl J Med 2010;363:1324-34.	[Yu, Alice L.] Univ Calif San Diego, San Diego, CA 92103 USA; [Yu, Alice L.] Moores Canc Ctr, San Diego, CA 92103 USA; [Yu, Alice L.] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Gilman, Andrew L.] Levine Childrens Hosp, Charlotte, NC USA; [Kreissman, Susan G.] Duke Univ, Med Ctr, Durham, NC USA; [Ozkaynak, M. Fevzi] New York Med Coll, Valhalla, NY 10595 USA; [London, Wendy B.] Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA; [London, Wendy B.] Childrens Oncol Grp Stat & Data Ctr, Boston, MA USA; [Chen, Helen X.; Smith, Malcolm; Anderson, Barry] NCI, Bethesda, MD 20892 USA; [Villablanca, Judith G.; Shimada, Hiro; Seeger, Robert] Univ So Calif, Childrens Hosp Los Angeles, Los Angeles, CA USA; [Matthay, Katherine K.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA; [Matthay, Katherine K.] Univ Calif San Francisco, Childrens Hosp, San Francisco, CA 94143 USA; [Grupp, Stephan A.; Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Grupp, Stephan A.; Maris, John M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Reynolds, C. Patrick] Texas Tech Univ, Hlth Sci Ctr, Sch Med, Lubbock, TX 79430 USA; [Buxton, Allen] Childrens Oncol Grp Stat & Data Ctr, Arcadia, CA USA; [Reisfeld, Ralph A.] Scripps Res Inst, La Jolla, CA 92037 USA; [Gillies, Steven D.] Provenance Biopharmaceut, Waltham, MA USA; [Cohn, Susan L.] Univ Chicago, Chicago, IL 60637 USA; [Sondel, Paul M.] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA	University of California System; University of California San Diego; Academia Sinica - Taiwan; Duke University; New York Medical College; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Children's Oncology Group (COG); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Children's Hospital Los Angeles; University of Southern California; University of California System; University of California San Francisco; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Children's Oncology Group (COG); Scripps Research Institute; University of Chicago; University of Wisconsin System; University of Wisconsin Madison	Yu, AL (corresponding author), Univ Calif San Diego, 200 W Arbor Dr, San Diego, CA 92103 USA.	aliceyu@ucsd.edu	London, Wendy/ABD-4624-2021; London, Wendy Beth/ABA-8948-2021; Cohn, Susan/AAB-6010-2021	London, Wendy Beth/0000-0003-3571-6538; Cohn, Susan/0000-0001-5749-7650; Reynolds, C. Patrick/0000-0002-2827-8536; yu, alice/0000-0003-2444-0505	National Institutes of Health [U10-CA98543, U10-CA98413, U10-CA29139]; Food and Drug Administration [FD-R-002319]; FOOD AND DRUG ADMINISTRATION [R01FD002319] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U10CA098543, U10CA098413, R01CA032685, U10CA029139] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Food and Drug Administration(United States Department of Health & Human Services); FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants from the National Institutes of Health (U10-CA98543, U10-CA98413, and U10-CA29139) and the Food and Drug Administration (FD-R-002319).	Albertini MR, 1997, CLIN CANCER RES, V3, P1277; BARKER E, 1993, CANCER RES, V53, P362; BARKER E, 1991, CANCER RES, V51, P144; CHEUNG NKV, 1987, J CLIN ONCOL, V5, P1430, DOI 10.1200/JCO.1987.5.9.1430; DALLEGRI F, 1989, CLIN EXP IMMUNOL, V77, P58; Dutcher J, 2001, MED ONCOL, V18, P209, DOI 10.1385/MO:18:3:209; Frost JD, 1997, CANCER, V80, P317, DOI 10.1002/(SICI)1097-0142(19970715)80:2<317::AID-CNCR21>3.0.CO;2-W; Garaventa A, 2009, EUR J CANCER, V45, P2835, DOI 10.1016/j.ejca.2009.06.010; GILLIES SD, 1989, J IMMUNOL METHODS, V125, P191, DOI 10.1016/0022-1759(89)90093-8; Gilman AL, 2009, J CLIN ONCOL, V27, P85, DOI 10.1200/JCO.2006.10.3564; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; HANDGRETINGER R, 1995, EUR J CANCER, V31A, P261, DOI 10.1016/0959-8049(94)00413-Y; HANK JA, 1990, CANCER RES, V50, P5234; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kendra K, 1999, J IMMUNOTHER, V22, P423, DOI 10.1097/00002371-199909000-00006; Khan KD, 2006, CLIN CANCER RES, V12, P7046, DOI 10.1158/1078-0432.CCR-06-1571; KUSHNER BH, 1992, BLOOD, V79, P1484; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Leidi M, 2009, J IMMUNOL, V182, P4415, DOI 10.4049/jimmunol.0713732; Mani A, 2009, BREAST CANCER RES TR, V117, P83, DOI 10.1007/s10549-008-0251-7; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601; MUELLER BM, 1990, J IMMUNOL, V144, P1382; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Neal ZC, 2004, CLIN CANCER RES, V10, P4839, DOI 10.1158/1078-0432.CCR-03-0799; Osenga KL, 2006, CLIN CANCER RES, V12, P1750, DOI 10.1158/1078-0432.CCR-05-2000; Ozkaynak MF, 2000, J CLIN ONCOL, V18, P4077, DOI 10.1200/JCO.2000.18.24.4077; Rosenberg SA, 2009, CURR OPIN IMMUNOL, V21, P233, DOI 10.1016/j.coi.2009.03.002; SCHULZ G, 1984, CANCER RES, V44, P5914; Simon T, 2004, J CLIN ONCOL, V22, P3549, DOI 10.1200/JCO.2004.08.143; Simon T, 2009, PEDIATR BLOOD CANCER, V53, P708; Slart R, 1997, PAIN, V69, P119, DOI 10.1016/S0304-3959(96)03247-2; Surveillance Epidemiology and End Results (SEER) Program, 1969, SEER STAT MORT DAT T; SVENNERHOLM L, 1994, BBA-LIPID LIPID MET, V1214, P115, DOI 10.1016/0005-2760(94)90034-5; Taylor RJ, 2009, CANCER IMMUNOL IMMUN, V58, P997, DOI 10.1007/s00262-008-0613-3; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Xiao WH, 1997, PAIN, V69, P145, DOI 10.1016/S0304-3959(96)03280-0; Yu AL, 1998, J CLIN ONCOL, V16, P2169, DOI 10.1200/JCO.1998.16.6.2169; Yu AL, 1997, P AN M AM SOC CLIN, V6, P1846	40	1079	1162	3	86	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1324	1334		10.1056/NEJMoa0911123	http://dx.doi.org/10.1056/NEJMoa0911123			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879881	Green Accepted			2023-01-03	WOS:000282271500006
J	Petit-Zeman, S; Firkins, L; Scadding, JW				Petit-Zeman, Sophie; Firkins, Lester; Scadding, John W.			The James Lind Alliance: tackling research mismatches	LANCET			English	Editorial Material									[Petit-Zeman, Sophie] Assoc Med Res Charities, London WC1X 8TL, England; [Firkins, Lester] James Lind Initiat, James Lind Alliance Secretariat, Oxford, England; [Scadding, John W.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Petit-Zeman, S (corresponding author), Assoc Med Res Charities, London WC1X 8TL, England.							*ASS MED RES CHANT, 2009, AMRC JLA NAT VOIC IN; *ASS MED RES CHART, PAT PUBL INV NAT GRO; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; FENTON M, 2006, DEV DATABASE UNCERTA; *J LIND ALL, UR INC WORK PARTN; *J LIND ALL, ASTHM WORK PARTN; *NIHR HLTH TECHN A, ANN REP 2008; Oliver S, 2006, BIBLIO RES REPORTS P; Partridge N, 2004, LANCET, V364, P1923, DOI 10.1016/S0140-6736(04)17494-1; STALEY K, 2008, J LIND ALLIANCE SCOP; Stewart R, 2008, SYSTEMATIC MAP STUDI; UK DUETS RESOURCE MA	12	57	57	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2010	376	9742					667	669		10.1016/S0140-6736(10)60712-X	http://dx.doi.org/10.1016/S0140-6736(10)60712-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	646YW	20801389				2023-01-03	WOS:000281582900009
J	Hajdin, K; D'Alessandro, V; Niggli, FK; Schafer, BW; Bernasconi, M				Hajdin, Katarina; D'Alessandro, Valentina; Niggli, Felix K.; Schaefer, Beat W.; Bernasconi, Michele			Furin Targeted Drug Delivery for Treatment of Rhabdomyosarcoma in a Mouse Model	PLOS ONE			English	Article							PROPROTEIN CONVERTASES FURIN; PRO-PROTEIN CONVERTASES; CANCER-THERAPY; PHAGE DISPLAY; MONOCLONAL-ANTIBODIES; HOMING PEPTIDE; TUMOR-CELLS; HUMAN HEAD; GROWTH; INHIBITION	Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Improvement of treatment efficacy and decreased side effects through tumor-targeted drug delivery would be desirable. By panning with a phage-displayed cyclic random peptide library we selected a peptide with strong affinity for RMS in vitro and in vivo. The peptide minimal binding motif Arg-X-(Arg/Lys)(Arg/Lys) identified by alanine-scan, suggested the target receptor to be a proprotein convertase (PC). Expression profiling of all PCs in RMS biopsies and cell lines revealed consistent high expression levels for the membrane-bound furin and PC7. Direct binding of RMS-P3 peptide to furin was demonstrated by affinity chromatography and supported by activity and colocalization studies. Treatment of RMS in mice with doxorubicin coupled to the targeting peptide resulted in a two-fold increase in therapeutic efficacy compared to doxorubicin treatment alone. Our findings indicate surface-furin binding as novel mechanism for therapeutic cell penetration which needs to be further investigated. Furthermore, this work demonstrates that specific targeting of membrane-bound furin in tumors is possible for and suggests that RMS and other tumors might benefit from proprotein convertases targeted drug delivery.	[Hajdin, Katarina; D'Alessandro, Valentina; Niggli, Felix K.; Schaefer, Beat W.; Bernasconi, Michele] Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland	University Children's Hospital Zurich	Hajdin, K (corresponding author), Univ Childrens Hosp Zurich, Dept Oncol, Zurich, Switzerland.	michele.bernasconi@kispi.uzh.ch	Bernasconi, Michele/GOH-1815-2022; Bernasconi, Michele/CAG-2492-2022; Bernasconi, Michele/C-6734-2008; Niggli, Felix/L-6547-2017	Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Bernasconi, Michele/0000-0002-5746-8806; Niggli, Felix/0000-0002-7553-3712; Schafer, Beat/0000-0001-5988-2915	Swiss Bridge Foundation; Schweizer Forschungstiftung Kind und Krebs	Swiss Bridge Foundation; Schweizer Forschungstiftung Kind und Krebs	This work was supported by the Swiss Bridge Foundation, the Schweizer Forschungstiftung Kind und Krebs (http://www.kindundkrebs.ch/) and the Zurcher Krebsliga (http://www.krebsliga-zh.ch). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams GP, 2005, NAT BIOTECHNOL, V23, P1147, DOI 10.1038/nbt1137; AINA O, 2007, MOL PHARM; Aina OH, 2002, BIOPOLYMERS, V66, P184, DOI 10.1002/bip.10257; Basak A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007700; Bassi DE, 2005, MOL CARCINOGEN, V44, P151, DOI 10.1002/mc.20134; Bassi DE, 2003, AM J PATHOL, V162, P439, DOI 10.1016/S0002-9440(10)63838-2; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; Bassi DE, 2001, MOL CARCINOGEN, V31, P224, DOI 10.1002/mc.1057; Bergeron E, 2003, BIOCHEM J, V373, P475, DOI 10.1042/BJ20021630; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Breitfeld PP, 2005, ONCOLOGIST, V10, P518, DOI 10.1634/theoncologist.10-7-518; Chretien M, 2008, EXPERT OPIN THER TAR, V12, P1289, DOI 10.1517/14728222.12.10.1289 ; Christian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132; Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935; De Giovanni C, 2009, FUTURE ONCOL, V5, P1449, DOI 10.2217/fon.09.97; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; Dubois CM, 2001, AM J PATHOL, V158, P305, DOI 10.1016/S0002-9440(10)63970-3; Enback J, 2007, BIOCHEM SOC T, V35, P780, DOI 10.1042/BST0350780; Fogal V, 2008, CANCER RES, V68, P7210, DOI 10.1158/0008-5472.CAN-07-6752; Fugere M, 2005, TRENDS PHARMACOL SCI, V26, P294, DOI 10.1016/j.tips.2005.04.006; Futaki S, 2006, BIOPOLYMERS, V84, P241, DOI 10.1002/bip.20421; HOFFMAN JA, 2004, PHAGE DISPLAY PRACTI, P169; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Joyce JA, 2003, CANCER CELL, V4, P393, DOI 10.1016/S1535-6108(03)00271-X; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; KIDO H, 1993, J BIOL CHEM, V268, P13406; KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Lapierre M, 2007, CANCER RES, V67, P9030, DOI 10.1158/0008-5472.CAN-07-0807; Laprise MH, 2002, BLOOD, V100, P3578, DOI 10.1182/blood.V100.10.3578; Levene AP, 2005, J ROY SOC MED, V98, P146, DOI 10.1258/jrsm.98.4.146; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; McColl BK, 2007, FASEB J, V21, P1088, DOI 10.1096/fj.06-7060com; Mercapide J, 2002, CLIN CANCER RES, V8, P1740; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NELSEN SM, 2009, J BIOL CHEM; NISHIMURA S, 2008, J BIOL CHEM; Oh P, 2004, NATURE, V429, P629, DOI 10.1038/nature02580; REMACLE AG, 2010, INT J BIOCH CELL BIO; Ruoslahti E, 2004, BIOCHEM SOC T, V32, P397, DOI 10.1042/BST0320397; Scamuffa N, 2008, J CLIN INVEST, V118, P352, DOI 10.1172/JCI32040; Scholl FA, 2000, BRIT J CANCER, V82, P1239; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Siegfried G, 2003, J CLIN INVEST, V111, P1723, DOI 10.1172/JCI200317220; Srour N, 2003, FEBS LETT, V554, P275, DOI 10.1016/S0014-5793(03)01159-1; Stawowy P, 2004, BIOCHEM BIOPH RES CO, V321, P531, DOI 10.1016/j.bbrc.2004.07.001; Stern M, 2005, CRIT REV ONCOL HEMAT, V54, P11, DOI 10.1016/j.critrevonc.2004.10.011; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; Sun XW, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-73; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Thomas G, 2002, NAT REV MOL CELL BIO, V3, P753, DOI 10.1038/nrm934; Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wick W, 2004, J NEUROCHEM, V91, P1275, DOI 10.1111/j.1471-4159.2004.02806.x; Witt H, 2009, INT J CANCER, V124, P2026, DOI 10.1002/ijc.24170; Zurita AJ, 2003, J CONTROL RELEASE, V91, P183, DOI 10.1016/S0168-3659(03)00236-0	58	26	27	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2010	5	5							e10445	10.1371/journal.pone.0010445	http://dx.doi.org/10.1371/journal.pone.0010445			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	590PW	20454619	gold, Green Published, Green Submitted			2023-01-03	WOS:000277240300020
J	Deamer, DW				Deamer, David W.			From "Banghasomes" to liposomes: A memoir of Alec Bangham, 1921-2010	FASEB JOURNAL			English	Biographical-Item									Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Deamer, DW (corresponding author), Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.	deamer@soe.ucsc.edu							0	69	71	1	27	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2010	24	5					1308	1310		10.1096/fj.10-0503	http://dx.doi.org/10.1096/fj.10-0503			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20430797				2023-01-03	WOS:000277158900003
J	Cooke, M				Cooke, Molly			Cost Consciousness in Patient Care -- What is Medical Education's Responsibility?.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH-CARE		Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Cooke, M (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.							Abbo ED, 2006, AM J BIOETHICS, V6, P33, DOI 10.1080/15265160600755540; Beach MC, 2005, ANN FAM MED, V3, P53, DOI 10.1370/afm.257; Blumenthal D, 2001, NEW ENGL J MED, V344, P766, DOI 10.1056/NEJM200103083441012; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; Shortell SM, 1998, JAMA-J AM MED ASSOC, V280, P1102, DOI 10.1001/jama.280.12.1102	5	118	119	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 8	2010	362	14					1253	1255		10.1056/NEJMp0911502	http://dx.doi.org/10.1056/NEJMp0911502			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	579SN	20357275				2023-01-03	WOS:000276393700001
J	Barkun, AN; Bardou, M; Kuipers, EJ; Sung, J; Hunt, RH; Martel, M; Sinclair, P				Barkun, Alan N.; Bardou, Marc; Kuipers, Ernst J.; Sung, Joseph; Hunt, Richard H.; Martel, Myriam; Sinclair, Paul		Int Consensus Upper Gastrointestin	International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding	ANNALS OF INTERNAL MEDICINE			English	Review							HELICOBACTER-PYLORI INFECTION; PROTON-PUMP INHIBITORS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; TRANSCATHETER ARTERIAL EMBOLIZATION; DOSE OMEPRAZOLE INFUSION; RAPID UREASE TEST; LOW-RISK PATIENTS; ENDOSCOPIC INJECTION THERAPY; NONBLEEDING VISIBLE VESSELS; COST-EFFECTIVENESS ANALYSIS	Description: A multidisciplinary group of 34 experts from 15 countries developed this update and expansion of the recommendations on the management of acute nonvariceal upper gastrointestinal bleeding (UGIB) from 2003. ethods: The Appraisal of Guidelines for Research and Evaluation (AGREE) process and independent ethics protocols were used. Sources of data included original and published systematic reviews; randomized, controlled trials; and abstracts up to October 2008. Quality of evidence and strength of recommendations have been rated by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. Recommendations: Recommendations emphasize early risk stratification, by using validated prognostic scales, and early endoscopy (within 24 hours). Endoscopic hemostasis remains indicated for high-risk lesions, whereas data support attempts to dislodge clots with hemostatic, pharmacologic, or combination treatment of the underlying stigmata. Clips or thermocoagulation, alone or with epinephrine injection, are effective methods; epinephrine injection alone is not recommended. Second-look endoscopy may be useful in selected high-risk patients but is not routinely recommended. Preendoscopy proton-pump inhibitor (PPI) therapy may downstage the lesion; intravenous high-dose PPI therapy after successful endoscopic hemostasis decreases both rebleeding and mortality in patients with high-risk stigmata. Although selected patients can be discharged promptly after endoscopy, high-risk patients should be hospitalized for at least 72 hours after endoscopic hemostasis. For patients with UGIB who require a nonsteroidal anti-inflammatory drug, a PPI with a cyclooxygenase-2 inhibitor is preferred to reduce rebleeding. Patients with UGIB who require secondary cardiovascular prophylaxis should start receiving acetylsalicylic acid (ASA) again as soon as cardiovascular risks outweigh gastrointestinal risks (usually within 7 days); ASA plus PPI therapy is preferred over clopidogrel alone to reduce rebleeding.	[Barkun, Alan N.] McGill Univ, Ctr Hlth, Montreal Gen Hosp Site, Div Gastroenterol, Montreal, PQ H3G 1A4, Canada; Ctr Hosp Univ Dijon, Serv Pharmacol, F-21004 Dijon, France; Ctr Hosp Univ Dijon, CIC P 803, INSERM, F-21004 Dijon, France; Erasmus MC Univ Med Ctr, Rotterdam, Netherlands; Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China; McMaster Univ, Hlth Sci Ctr, Hamilton, ON, Canada; Canadian Assoc Gastroenterol, Oakville, ON, Canada	McGill University; CHU Dijon Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Erasmus University Rotterdam; Erasmus MC; Chinese University of Hong Kong; McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba	Barkun, AN (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp Site, Div Gastroenterol, 1650 Cedar Ave,Room D7-148, Montreal, PQ H3G 1A4, Canada.		Calvet, Xavier/H-3288-2019; Kuipers, Ernst J/H-3293-2019; Moayyedi, Paul/M-6178-2014; Martel, Myriam/ABB-3862-2020; Sung, Joseph J. Y./R-3203-2018	Calvet, Xavier/0000-0002-6278-9663; Kuipers, Ernst J/0000-0002-0633-3098; Moayyedi, Paul/0000-0002-3616-9292; Sung, Joseph J. Y./0000-0003-3125-5199; Romagnuolo, Joseph/0000-0002-5630-3022; Calvet, Xavier/0000-0002-4413-4209; QUENOT, Jean-Pierre/0000-0003-2351-682X	Canadian Association of Gastroenterology; European Association for Gastroenterology and Endoscopy; Asian Pacific Society of Digestive Endoscopy; Canadian Institutes of Health Research; AstraZeneca Molndal; Abbott Canada; Olympus Canada	Canadian Association of Gastroenterology; European Association for Gastroenterology and Endoscopy; Asian Pacific Society of Digestive Endoscopy; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); AstraZeneca Molndal(AstraZeneca); Abbott Canada(Abbott Laboratories); Olympus Canada	Grant Support: By the Canadian Association of Gastroenterology; European Association for Gastroenterology and Endoscopy; Asian Pacific Society of Digestive Endoscopy; and Institute of Diabetes, Metabolism, and Nutrition ( of the Canadian Institutes of Health Research), and at-arms-length contributions to these societies from AstraZeneca Molndal, Abbott Canada, and Olympus Canada.	*ACC, 2008, JOINT COMM STUD REG; Adamopoulos AB, 2003, EUR J GASTROEN HEPAT, V15, P381, DOI 10.1097/00042737-200304000-00008; Aguejouf O, 2009, CLIN APPL THROMB-HEM, V15, P523, DOI 10.1177/1076029608319945; Al-Sabah S, 2008, CLIN GASTROENTEROL H, V6, P418, DOI 10.1016/j.cgh.2007.12.037; Almela P, 2004, GASTROINTEST ENDOSC, V59, P772, DOI 10.1016/S0016-5107(04)00362-1; *AM ACCR COUNC CON, 2007, ACCME STAND COMM SUP; Amer Soc Anesthesiologists Task Fo, 2006, ANESTHESIOLOGY, V105, P198; Ananthakrishnan AN, 2009, CLIN GASTROENTEROL H, V7, P296, DOI 10.1016/j.cgh.2008.08.013; Archimandritis A, 2000, J GASTROEN HEPATOL, V15, P369, DOI 10.1046/j.1440-1746.2000.02171.x; Armstrong D, 2005, CAN J GASTROENTEROL, V19, P15, DOI 10.1155/2005/836030; Aseeri M, 2008, AM J GASTROENTEROL, V103, P2308, DOI 10.1111/j.1572-0241.2008.01975.x; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bajaj JS, 2007, DIGEST DIS SCI, V52, P2190, DOI 10.1007/s10620-006-9282-2; Baradarian R, 2004, AM J GASTROENTEROL, V99, P619, DOI 10.1111/j.1572-0241.2004.04073.x; Barkun A, 2003, ANN INTERN MED, V139, P843, DOI 10.7326/0003-4819-139-10-200311180-00012; Barkun A, 2004, AM J GASTROENTEROL, V99, P1238, DOI 10.1111/j.1572-0241.2004.30272.x; BARKUN A, 2006, CAN J GASTROENTEROL, V20, pA80; BARKUN A, 2009, GASTROENTEROLOGY, V134; Barkun AN, 2008, GASTROINTEST ENDOSC, V67, P1064, DOI 10.1016/j.gie.2008.02.040; Barkun A, 2008, GASTROENTEROLOGY, V134, pA167; Barkun AN, 2009, GASTROINTEST ENDOSC, V69, P786, DOI 10.1016/j.gie.2008.05.031; Barkun AN, 2004, ALIMENT PHARM THER, V19, P591, DOI 10.1046/j.1365-2036.2004.01808.x; Bellotto F, 2005, AM J MED, V118, P548, DOI 10.1016/j.amjmed.2005.01.026; Bensoussan K, 2005, CAN J GASTROENTEROL, V19, P487, DOI 10.1155/2005/198387; Bhatt DL, 2008, CIRCULATION, V118, P1894, DOI 10.1161/CIRCULATIONAHA.108.191087; Biondi-Zoccai GGL, 2006, EUR HEART J, V27, P2667, DOI 10.1093/eurheartj/ehl334; Bjorkman DJ, 2004, GASTROINTEST ENDOSC, V60, P1, DOI 10.1016/S0016-5107(04)01287-8; Blatchford O, 2000, LANCET, V356, P1318, DOI 10.1016/S0140-6736(00)02816-6; Bleau BL, 2002, GASTROINTEST ENDOSC, V56, P1, DOI 10.1067/mge.2002.125365; Bracey AW, 1999, TRANSFUSION, V39, P1070, DOI 10.1046/j.1537-2995.1999.39101070.x; Brullet E, 2004, GASTROINTEST ENDOSC, V60, P15, DOI 10.1016/S0016-5107(04)01314-8; Brullet E, 1996, GUT, V39, P155, DOI 10.1136/gut.39.2.155; Burger W, 2005, J INTERN MED, V257, P399, DOI 10.1111/j.1365-2796.2005.01477.x; Calvet X, 2004, GASTROENTEROLOGY, V126, P441, DOI 10.1053/j.gastro.2003.11.006; CALVET X, 2009, GASTROENTEROLOGY, V134; Camellini L, 2004, DIGEST LIVER DIS, V36, P271, DOI 10.1016/j.dld.2003.10.017; *CAN ASS GASTR, POL APPL IMPL CLIN P; *CAN MED ASS, 2007, GUID PHYS INT IND; Carbonell N, 2006, AM J GASTROENTEROL, V101, P1211, DOI 10.1111/j.1572-0241.2006.00582.x; Castro-Fernandez M, 2004, REV ESP ENFERM DIG, V96, P395; Chan AT, 2008, GASTROENTEROLOGY, V134, pA113; Chan FKL, 2005, NEW ENGL J MED, V352, P238, DOI 10.1056/NEJMoa042087; Chan FKL, 2004, GASTROENTEROLOGY, V127, P1038, DOI 10.1053/j.gastro.2004.07.010; Chan FKL, 2002, NEW ENGL J MED, V347, P2104, DOI 10.1056/NEJMoa021907; Chan FKL, 2008, AM J GASTROENTEROL, V103, P2908, DOI 10.1111/j.1572-0241.2008.02200.x; Chan FKL, 2007, LANCET, V369, P1621, DOI 10.1016/S0140-6736(07)60749-1; Chen GC, 2007, AM J EMERG MED, V25, P774, DOI 10.1016/j.ajem.2006.12.024; Chiu PW, 2006, GASTROENTEROLOGY, V130, pA121; Chiu PWY, 2009, CLIN GASTROENTEROL H, V7, P311, DOI 10.1016/j.cgh.2008.08.044; Chiu PW, 2009, CLIN GASTROENTEROL H, V7, P253; Chiu PWY, 2003, GUT, V52, P1403, DOI 10.1136/gut.52.10.1403; CHIU PWY, 2003, ANN COLL SURG HONG K, V7, P106; Chong E, 2003, PHARMACOTHERAPY, V23, P460, DOI 10.1592/phco.23.4.460.32128; CHOUDARI CP, 1994, GUT, V35, P464, DOI 10.1136/gut.35.4.464; Chung Il-Kwun, 2001, Korean Journal of Internal Medicine, V16, P147; CHUNG SCS, 1991, GASTROENTEROLOGY, V100, P33, DOI 10.1016/0016-5085(91)90579-A; Church NI, 2006, GASTROINTEST ENDOSC, V63, P606, DOI 10.1016/j.gie.2005.06.042; Cipolletta L, 2002, GASTROINTEST ENDOSC, V55, P1, DOI 10.1067/mge.2002.119219; Coffin B, 2002, GASTROINTEST ENDOSC, V56, P174, DOI 10.1067/mge.2002.126135; Colin R, 2000, GASTROEN CLIN BIOL, V24, P31; Cook DJ, 1997, ANN INTERN MED, V127, P210, DOI 10.7326/0003-4819-127-3-199708010-00006; Cooper GS, 2009, GASTROINTEST ENDOSC, V70, P229, DOI 10.1016/j.gie.2008.10.052; Cooper GS, 2009, GASTROENTEROLOGY, V136, P108, DOI 10.1053/j.gastro.2008.09.030; DALKEY N, 1969, FUTURES, V1, P408, DOI 10.1016/S0016-3287(69)80025-X; DALTON D, 2007, UK COMP AUDIT UPPER; Defreyne L, 2001, RADIOLOGY, V218, P739, DOI 10.1148/radiology.218.3.r01mr05739; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Demiray E, 2006, WORLD J GASTROENTERO, V12, P4206, DOI 10.3748/wjg.v12.i26.4206; Dial S, 2005, JAMA-J AM MED ASSOC, V294, P2989, DOI 10.1001/jama.294.23.2989; Dial S, 2004, CAN MED ASSOC J, V171, P33, DOI 10.1503/cmaj.1040876; Dorward S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005415.pub2; Dunn SP, 2008, CIRCULATION, V118, pS815; El-Serag HB, 2002, ARCH INTERN MED, V162, P2105, DOI 10.1001/archinte.162.18.2105; Ell C, 1998, GASTROINTEST ENDOSC, V47, pAB83; Elmunzer BJ, 2008, AM J GASTROENTEROL, V103, P2625, DOI 10.1111/j.1572-0241.2008.02070.x; Enns RA, 2006, WORLD J GASTROENTERO, V12, P7779, DOI 10.3748/wjg.v12.i48.7779; Erstad BL, 2004, CRIT CARE MED, V32, P1277, DOI 10.1097/01.CCM.0000127261.09066.6E; Focareta R, 2004, DIGEST LIVER DIS, V36, pS250; Frossard JL, 2002, GASTROENTEROLOGY, V123, P17, DOI 10.1053/gast.2002.34230; Gevers AM, 2002, GASTROINTEST ENDOSC, V55, P466, DOI 10.1067/mge.2002.112613; Gilard M, 2008, J AM COLL CARDIOL, V51, P256, DOI 10.1016/j.jacc.2007.06.064; Gisbert JP, 2007, HELICOBACTER, V12, P231, DOI 10.1111/j.1523-5378.2007.00492.x; Gisbert JP, 2006, AM J GASTROENTEROL, V101, P848, DOI 10.1111/j.1572-0241.2006.00528.x; Gisbert JP, 2006, J CLIN GASTROENTEROL, V40, P129, DOI 10.1097/01.mcg.0000196187.19426.03; Gisbert JP, 2004, ALIMENT PHARM THER, V19, P617, DOI 10.1111/j.1365-2036.2004.01898.x; Gisbert JP, 2004, ALIMENT PHARM THER, V19, P923, DOI 10.1111/j.1365-2036.2004.01932.x; Gralnek IM, 2008, NEW ENGL J MED, V359, P928, DOI 10.1056/NEJMra0706113; Grino P, 2003, EUR J GASTROEN HEPAT, V15, P525, DOI [10.1097/00042737-200305000-00011, 10.1097/01.meg.0000059114.41030.a9]; Grino P, 2001, SCAND J GASTROENTERO, V36, P1254, DOI 10.1080/003655201317097083; Guell M, 2006, ALIMENT PHARM THER, V23, P53, DOI 10.1111/j.1365-2036.2006.02726.x; Guyatt GH, 2008, CHEST, V133, p123S, DOI 10.1378/chest.08-0654; Habashi SL, 2007, AM J GASTROENTEROL, V102, pS526, DOI 10.14309/00000434-200709002-01114; Hanvivatvong Orrawadee, 2006, J Med Assoc Thai, V89 Suppl 3, pS98; Hay JA, 1997, JAMA-J AM MED ASSOC, V278, P2151, DOI 10.1001/jama.278.24.2151; HAYES S, 2007, AM COLL GASTR ANN M; HEARNSHAW S, 2009, GUT IN PRESS; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Ho PM, 2009, JAMA-J AM MED ASSOC, V301, P937, DOI 10.1001/jama.2009.261; Holme JB, 2006, ACTA RADIOL, V47, P244, DOI 10.1080/02841850600550690; HSU PI, 1994, GUT, V35, P746, DOI 10.1136/gut.35.6.746; Hsu PI, 1996, GASTROINTEST ENDOSC, V44, P382, DOI 10.1016/S0016-5107(96)70085-8; Hsu PI, 2004, WORLD J GASTROENTERO, V10, P3666, DOI 10.3748/wjg.v10.i24.3666; Imperiale TF, 2007, ARCH INTERN MED, V167, P1291, DOI 10.1001/archinte.167.12.1291; Jang JY, 2006, GASTROENTEROLOGY, V130, pA467; Jensen DM, 2006, AM J GASTROENTEROL, V101, P1991, DOI 10.1111/j.1572-0241.2006.00773.x; Jensen DM, 2002, GASTROENTEROLOGY, V123, P407, DOI 10.1053/gast.2002.34782; JENSEN DM, 2006, AM J GASTROENTEROL, V101, P2170; Juurlink DN, 2009, CAN MED ASSOC J, V180, P713, DOI 10.1503/cmaj.082001; Kahi CJ, 2005, GASTROENTEROLOGY, V129, P855, DOI 10.1053/j.gastro.2005.06.070; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; Khoshbaten M, 2006, BMC GASTROENTEROL, V6, DOI 10.1186/1471-230X-6-2; Kim SK, 2005, TECH GASTROINTEST EN, V7, P148, DOI 10.1016/j.tgie.2005.04.012; Klok RM, 2003, ALIMENT PHARM THER, V17, P1237, DOI 10.1046/j.1365-2036.2003.01562.x; Lai KC, 2006, CLIN GASTROENTEROL H, V4, P860, DOI 10.1016/j.cgh.2006.04.019; Lai KC, 2005, AM J MED, V118, P1271, DOI 10.1016/j.amjmed.2005.04.031; Lai KC, 1997, GASTROINTEST ENDOSC, V45, P26, DOI 10.1016/S0016-5107(97)70299-2; LAI KC, 1996, GASTROENTEROLOGY S, V110, pA167; LAI KH, 1994, ENDOSCOPY, V26, P338, DOI 10.1055/s-2007-1008987; Laine L, 2005, GASTROENTEROLOGY, V129, P2127, DOI 10.1053/j.gastro.2005.10.039; Laine L, 1996, GASTROINTEST ENDOSC, V43, P107, DOI 10.1016/S0016-5107(06)80109-4; Laine L, 2007, LANCET, V369, P465, DOI 10.1016/S0140-6736(07)60234-7; Laine L, 2009, CLIN GASTROENTEROL H, V7, P33, DOI 10.1016/j.cgh.2008.08.016; Lanas A, 2009, AM J GASTROENTEROL, V104, P1633, DOI 10.1038/ajg.2009.164; Lassen A, 2006, AM J GASTROENTEROL, V101, P945, DOI 10.1111/j.1572-0241.2006.00518.x; Lau JY, 2007, NEW ENGL J MED, V356, P1631, DOI 10.1056/NEJMoa065703; Lau JYW, 2000, NEW ENGL J MED, V343, P310, DOI 10.1056/NEJM200008033430501; Lau JYW, 1999, NEW ENGL J MED, V340, P751, DOI 10.1056/NEJM199903113401002; Lau JYW, 1998, ENDOSCOPY, V30, P513, DOI 10.1055/s-2007-1001336; Lee JG, 1999, GASTROINTEST ENDOSC, V50, P755, DOI 10.1016/S0016-5107(99)70154-9; Lee JM, 2000, AM J GASTROENTEROL, V95, P1166, DOI 10.1111/j.1572-0241.2000.02004.x; Lee KKC, 2003, GASTROINTEST ENDOSC, V57, P160, DOI 10.1067/mge.2003.74; Lee SY, 2005, GASTROENTEROLOGY, V128, pA639; LEONTIADIS G, 2009, GASTROENTEROLOGY, V134; Leontiadis GI, 2007, HEALTH TECHNOL ASSES, V11, P1; Leontiadis GI, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002094.pub3; Lewis JD, 2002, AM J GASTROENTEROL, V97, P2540; Liao CC, 2003, CHINESE MED J-PEKING, V116, P1821; Liao CC, 2001, GUT, V49, pA102; Lin CK, 1996, GASTROENTEROLOGY, V110, pA177; Lin HJ, 1998, ARCH INTERN MED, V158, P54, DOI 10.1001/archinte.158.1.54; Lin HJ, 1996, GASTROINTEST ENDOSC, V43, P470; Lin HJ, 2006, AM J GASTROENTEROL, V101, P500, DOI 10.1111/j.1572-0241.2006.00399.x; LIN HJ, 1994, GUT, V35, P1389, DOI 10.1136/gut.35.10.1389; Lin HJ, 2004, HELICOBACTER, V9, P663, DOI 10.1111/j.1083-4389.2004.00276.x; Lin HJ, 1996, J CLIN GASTROENTEROL, V22, P267, DOI 10.1097/00004836-199606000-00005; Ljungdahl M, 2002, EUR J SURG, V168, P384, DOI 10.1080/110241502320789050; Lo CC, 2005, WORLD J GASTROENTERO, V11, P3909; Loffroy R, 2008, J CLIN GASTROENTEROL, V42, P361, DOI 10.1097/MCG.0b013e3180319177; Longstreth GF, 1998, GASTROINTEST ENDOSC, V47, P219, DOI 10.1016/S0016-5107(98)70316-5; Maetzel A, 2003, ARTHRIT RHEUM-ARTHR, V49, P283, DOI 10.1002/art.11121; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; Marmo R, 2003, GASTROINTEST ENDOSC, V57, P62, DOI 10.1067/mge.2003.48; Marmo R, 2007, AM J GASTROENTEROL, V102, P469; Marmo R, 2007, AM J GASTROENTEROL, V102, P279, DOI 10.1111/j.1572-0241.2006.01023.x; Masaoka T, 2007, J GASTROEN HEPATOL, V22, P1404, DOI 10.1111/j.1440-1746.2006.04762.x; Messmann H, 1998, ENDOSCOPY, V30, P583, DOI 10.1055/s-2007-1001360; Moayyedi P, 2009, CAN J GASTROENTEROL, V23, P251, DOI 10.1155/2009/868946; Moreno P, 1998, AM J MED, V105, P176, DOI 10.1016/S0002-9343(98)00243-5; Naumovski-Mihalic S, 2005, GASTROENTEROLOGY, V128, pA641; NAUMOVSKIMIHALI.S, 2007, GUT, V56, pA234; Ng FH, 2004, ALIMENT PHARM THER, V19, P359, DOI 10.1111/j.1365-2036.2004.01857.x; O'Donoghue ML, 2009, LANCET, V374, P989, DOI 10.1016/S0140-6736(09)61525-7; Oei TT, 2002, AM J GASTROENTEROL, V97, P2271; Okazaki K, 2002, GUT, V51, P1, DOI 10.1136/gut.51.1.1; Palda VA, 2007, CAN MED ASSOC J, V177, P1221, DOI 10.1503/cmaj.070880; Peitz U, 2003, ALIMENT PHARM THER, V17, P1075, DOI 10.1046/j.1365-2036.2003.01548.x; Poultsides GA, 2008, ARCH SURG-CHICAGO, V143, P457, DOI 10.1001/archsurg.143.5.457; Rahme E, 2007, ARTHRIT RHEUM-ARTHR, V57, P748, DOI 10.1002/art.22764; Ripoll C, 2004, J VASC INTERV RADIOL, V15, P447; Robins GG, 2007, POSTGRAD MED J, V83, P768, DOI 10.1136/pgmj.2007.061614; Rockall TA, 1996, LANCET, V347, P1138, DOI 10.1016/S0140-6736(96)90607-8; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; Romagnuolo J, 2005, INT J QUAL HEALTH C, V17, P249, DOI 10.1093/intqhc/mzi023; Romagnuolo J, 2004, CAN J GASTROENTEROL, V18, P401, DOI 10.1155/2004/454252; Romagnuolo J, 2007, ARCH INTERN MED, V167, P265, DOI 10.1001/archinte.167.3.265; Rostom A, 2009, ALIMENT PHARM THER, V29, P481, DOI 10.1111/j.1365-2036.2008.03905.x; Rostom A, 2007, ANN INTERN MED, V146, P376, DOI 10.7326/0003-4819-146-5-200703060-00010; Roughead EE, 2009, MED J AUSTRALIA, V190, P114, DOI 10.5694/j.1326-5377.2009.tb02307.x; Rutgeerts P, 1997, LANCET, V350, P692, DOI 10.1016/S0140-6736(97)03233-9; SADOWSKI DC, 2009, PROTON PUMP INHIBITO; Saeed ZA, 1996, ENDOSCOPY, V28, P288, DOI 10.1055/s-2007-1005455; Schacher GM, 2005, ENDOSCOPY, V37, P324, DOI 10.1055/s-2004-826237; Scheiman JM, 2006, AM J GASTROENTEROL, V101, P701, DOI 10.1111/j.1572-0241.2006.00499.x; Schilling D, 2003, DIGEST LIVER DIS, V35, P217, DOI 10.1016/S1590-8658(03)00058-6; Shi SJ, 2008, EUR J CLIN PHARMACOL, V64, P935, DOI 10.1007/s00228-008-0538-y; Sibon I, 2004, NEUROLOGY, V62, P1187, DOI 10.1212/01.WNL.0000118288.04483.02; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Small DS, 2008, J CLIN PHARMACOL, V48, P475, DOI 10.1177/0091270008315310; Soncini M, 2007, EUR J GASTROEN HEPAT, V19, P543, DOI 10.1097/MEG.0b013e3281532b89; Spiegel BMR, 2005, ARTHRIT RHEUM-ARTHR, V53, P185, DOI 10.1002/art.21065; Spiegel BMR, 2003, AM J GASTROENTEROL, V98, P86; Spiegel BMR, 2001, ARCH INTERN MED, V161, P1393, DOI 10.1001/archinte.161.11.1393; SREEDHARAN A, 2009, GASTROENTEROLOGY, V134; Stanley AJ, 2009, LANCET, V373, P42, DOI 10.1016/S0140-6736(08)61769-9; SUNG J, 2007, GUT, V56, pA27; Sung JJY, 2003, ANN INTERN MED, V139, P237, DOI 10.7326/0003-4819-139-4-200308190-00005; Sung JJY, 2007, GUT, V56, P1364, DOI 10.1136/gut.2007.123976; Sung JJY, 2009, ANN INTERN MED, V150, P455, DOI 10.7326/0003-4819-150-7-200904070-00105; Sussman DA., 2008, GASTROINTEST ENDOSC, V67, pAB247; Tai CM, 2007, AM J EMERG MED, V25, P273, DOI 10.1016/j.ajem.2006.07.014; Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330; Targownik LE, 2008, GASTROENTEROLOGY, V134, P937, DOI 10.1053/j.gastro.2008.01.010; Targownik LE, 2007, CAN J GASTROENTEROL, V21, P425, DOI 10.1155/2007/636032; Targownik LE, 2006, CLIN GASTROENTEROL H, V4, P1459, DOI 10.1016/j.cgh.2006.08.018; The AGREE Collaboration, 2001, APPR GUID RES EV AGR; TOYODA H, 1995, ENDOSCOPY, V27, P304, DOI 10.1055/s-2007-1005697; Tripodi A, 2007, ALIMENT PHARM THERAP, V26, P141, DOI 10.1111/j.1365-2036.2007.03369.x; TSOI K, 2008, GUT, V57, pA355; Tsoi KKF, 2008, GASTROINTEST ENDOSC, V67, P1056, DOI 10.1016/j.gie.2007.11.056; Tu TC, 1999, GASTROINTEST ENDOSC, V49, P302, DOI 10.1016/S0016-5107(99)70005-2; US FDA, 2009, PLAV CLOP BIS 75 MG; van Leerdam ME, 2003, AM J GASTROENTEROL, V98, P1494, DOI 10.1016/S0002-9270(03)00299-5; van Leerdam ME, 2003, AM J GASTROENTEROL, V98, P798, DOI [10.1016/S0002-9270(03)00051-0, 10.1111/j.1572-0241.2003.07387.x]; Vergara M, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005584.pub2; VILLANUEVA C, 1994, GASTROINTEST ENDOSC, V40, P34, DOI 10.1016/S0016-5107(94)70006-0; VILLANUEVA C, 1993, DIGEST DIS SCI, V38, P2062, DOI 10.1007/BF01297086; Viviane A, 2008, VALUE HEALTH, V11, P1, DOI 10.1111/j.1524-4733.2007.00208.x; Vreeburg EM, 1999, GUT, V44, P331, DOI 10.1136/gut.44.3.331; Wei KL, 2007, J GASTROEN HEPATOL, V22, P43, DOI 10.1111/j.1440-1746.2006.04354.x; Wildner-Christensen M, 2002, DIGESTION, V66, P9, DOI 10.1159/000064421; Winiarski M, 2003, J CLIN GASTROENTEROL, V37, P34, DOI 10.1097/00004836-200307000-00010; Winstead NS, 2007, ALIMENT PHARM THERAP, V26, P1371, DOI 10.1111/j.1365-2036.2007.03516.x; Wolf AT, 2007, AM J GASTROENTEROL, V102, P290, DOI 10.1111/j.1572-0241.2006.00969.x; Yuan Y, 2008, GASTROINTEST ENDOSC, V68, P339, DOI 10.1016/j.gie.2008.03.1122; Zargar SA, 2006, J GASTROEN HEPATOL, V21, P716, DOI 10.1111/j.1440-1746.2006.04292.x	225	749	831	3	76	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 19	2010	152	2					101	+		10.7326/0003-4819-152-2-201001190-00009	http://dx.doi.org/10.7326/0003-4819-152-2-201001190-00009			21	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548IE	20083829				2023-01-03	WOS:000273953000005
J	Raine, R; Wong, W; Scholes, S; Ashton, C; Obichere, A; Ambler, G				Raine, Rosalind; Wong, Wun; Scholes, Shaun; Ashton, Charlotte; Obichere, Austin; Ambler, Gareth			Social variations in access to hospital care for patients with colorectal, breast, and lung cancer between 1999 and 2006: retrospective analysis of hospital episode statistics	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SOUTH EAST ENGLAND; CALMAN-HINE REPORT; SOCIOECONOMIC DEPRIVATION; RESECTION RATE; SURVIVAL; INEQUALITIES; MANAGEMENT; SURGERY; WOMEN; STAGE	Objectives To determine the extent to which type of hospital admission (emergency compared with elective) and surgical procedure varied by socioeconomic circumstances, age, sex, and year of admission for colorectal, breast, and lung cancer. Design Repeated cross sectional study with data from individual patients, 1 April 1999 to 31 March 2006. Setting Hospital episode statistics (HES) dataset. Participants 564 821 patients aged 50 and over admitted with a diagnosis of colorectal, breast, or lung cancer. Main outcome measures Proportion of patients admitted as emergencies, and the proportion receiving the recommended surgical treatment. Results Patients from deprived areas, older people, and women were more likely to be admitted as emergencies. For example, the adjusted odds ratio for patients with breast cancer in the least compared with most deprived fifth of deprivation was 0.63 (95% confidence interval 0.60 to 0.66) and the adjusted odds ratio for patients with lung cancer aged 80-89 compared with those aged 50-59 was 3.13 (2.93 to 3.34). There were some improvements in disparities between age groups but not for patients living in deprived areas over time. Patients from deprived areas were less likely to receive preferred procedures for rectal, breast, and lung cancer. These findings did not improve with time. For example, 67.4% (3529/5237) of patients in the most deprived fifth of deprivation had anterior resection for rectal cancer compared with 75.5% (4497/5959) of patients in the least deprived fifth (1.34, 1.22 to 1.47). Over half (54.0%, 11256/20849) of patients in the most deprived fifth of deprivation had breast conserving surgery compared with 63.7% (18445/28960) of patients in the least deprived fifth (1.21, 1.16 to 1.26). Men were less likely than women to undergo anterior resection and lung cancer resection and older people were less likely to receive breast conserving surgery and lung cancer resection. For example, the adjusted odds ratio for lung cancer patients aged 80-89 compared with those aged 50-59 was 0.52 (0.46 to 0.59). Conclusions Despite the implementation of the NHS Cancer Plan, social factors still strongly influence access to and the provision of care.	[Raine, Rosalind; Ashton, Charlotte] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; [Obichere, Austin] Univ Coll London Hosp, London NW1 2PG, England; [Ambler, Gareth] UCL, Dept Stat Sci, London WC1E 6BT, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; University College London; University of London; University College London	Raine, R (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	r.raine@ucl.ac.uk		Raine, Rosalind/0000-0003-0904-749X	National Institute for Health; National Institute for Health Research University College London Hospital/University College London Comprehensive Biomedical Research Centre; Legal and General Group; CRUK; Institute of Actuaries in England and Wales and the Faculty of Actuaries in Scotland	National Institute for Health; National Institute for Health Research University College London Hospital/University College London Comprehensive Biomedical Research Centre(National Institute for Health Research (NIHR)); Legal and General Group; CRUK(Cancer Research UK); Institute of Actuaries in England and Wales and the Faculty of Actuaries in Scotland	RR is partly funded by a National Institute for Health Research public health career scientist award and by the National Institute for Health Research University College London Hospital/University College London Comprehensive Biomedical Research Centre. WW and SS are funded by Legal and General Group. AO is partly funded by CRUK. The research was funded in part by the actuarial profession (Institute of Actuaries in England and Wales and the Faculty of Actuaries in Scotland). The authors' work was independent of the funders.	Battersby J, 2004, J EPIDEMIOL COMMUN H, V58, P623, DOI 10.1136/jech.2003.013391; Berrino F, 2007, LANCET ONCOL, V8, P773, DOI 10.1016/S1470-2045(07)70245-0; Brown SBF, 2007, BREAST CANCER RES TR, V103, P233, DOI 10.1007/s10549-006-9361-2; *CANC RES UK, 2009, UK LUNG CANC INC STA; Coleman MP, 2004, BRIT J CANCER, V90, P1367, DOI 10.1038/sj.bjc.6601696; Collins ED, 2009, J CLIN ONCOL, V27, P519, DOI 10.1200/JCO.2008.16.6215; Cooper ZN, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3264; Damhuis RAM, 1996, EUR RESPIR J, V9, P7, DOI 10.1183/09031936.96.09010007; *DEP HLTH, 1997, GUID COMM CANC SERV; *DEP HLTH, 2003, NHS CANC PLAN 3 YEAR; Department of Health, 2000, NHS CANC PLAN PLAN I; Devbhandari Mohan P, 2007, Interact Cardiovasc Thorac Surg, V6, P712, DOI 10.1510/icvts.2007.157289; Dixon J, 1998, J PUBLIC HEALTH MED, V20, P63, DOI 10.1093/oxfordjournals.pubmed.a024721; Downing A, 2007, BRIT J CANCER, V96, P836, DOI 10.1038/sj.bjc.6603622; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Garout M, 2008, INT J COLORECTAL DIS, V23, P155, DOI 10.1007/s00384-007-0390-z; Graham H, 2004, J SOC POLICY, V33, P115, DOI 10.1017/S0047279403007220; Gulliford M, 2003, ACCESS HLTH CARE; Harris AR, 2009, BRIT J SURG, V96, P763, DOI 10.1002/bjs.6621; health W., 2008, STAT INJ DEATHS RIS; Henley NC, 2005, BRIT J CANCER, V92, P631, DOI 10.1038/sj.bjc.6602390; *HES ONL, 2009, HES US GUID; Hole DJ, 2002, BRIT J SURG, V89, P586, DOI 10.1046/j.1365-2168.2002.02073.x; Imperatori A, 2006, THORAX, V61, P232, DOI 10.1136/thx.2005.040477; Jack RH, 2003, BRIT J CANCER, V88, P1025, DOI 10.1038/sj.bjc.6600831; Jack RH, 2006, J EVAL CLIN PRACT, V12, P573, DOI 10.1111/j.1365-2753.2006.00644.x; Janssen-Heijnen MLG, 1998, EUR J CANCER, V34, P2191, DOI 10.1016/S0959-8049(98)00312-8; Katz JN, 2001, JAMA-J AM MED ASSOC, V286, P1506, DOI 10.1001/jama.286.12.1506; Laroche C, 1998, THORAX, V53, P445, DOI 10.1136/thx.53.6.445; Martin-Ucar AE, 2004, LUNG CANCER, V46, P227, DOI 10.1016/j.lungcan.2004.03.010; McCarthy M, 2008, J EPIDEMIOL COMMUN H, V62, P650, DOI 10.1136/jech.2007.066258; Morris E, 2008, GUT, V57, P1690, DOI 10.1136/gut.2007.137877; Morris E, 2008, ANN ONCOL, V19, P284, DOI 10.1093/annonc/mdm432; Morris E, 2006, BRIT J CANCER, V95, P979, DOI 10.1038/sj.bjc.6603372; Myrdal G, 2009, LUNG CANCER, V63, P16, DOI 10.1016/j.lungcan.2008.05.011; *NAT I HLTH CLIN E, 2005, LUNG CANC DIAGN TREA; National Audit Office, 2005, NHS CANC PLAN PROGR; National Institute for Clinical Excellence, 2004, GUID CANC SERV IMPR; National Institute of Health and Clinical Excellence, 2002, GUID CANC SERV IMPR; Neal RD, 2005, BRIT J CANCER, V92, P1971, DOI 10.1038/sj.bjc.6602623; *NHS INF CTR HLTH, 2009, NAT LUNG CANC AUD; NOBLE M, 2009, ENGLISH INDICES DEPR; NUR U, 2008, CANC SURVIVAL ENGLAN; *OFF NAT STAT, 2008, CANC STAT REG; Office of Population Censuses and Surveys, 1990, TAB LIST CLASS SURG; Peake MD, 2003, AGE AGEING, V32, P171, DOI 10.1093/ageing/32.2.171; Pollock AM, 1998, BMJ-BRIT MED J, V317, P245, DOI 10.1136/bmj.317.7153.245; Rachet B, 2009, LANCET ONCOL, V10, P351, DOI 10.1016/S1470-2045(09)70028-2; Richards M, 2009, LANCET ONCOL, V10, P311, DOI 10.1016/S1470-2045(09)70086-5; *ROYAL COLL SURG E, 2008, 1 ROYAL COLL SURG EN; Sant M, 2003, ANN ONCOL, V14, pV61, DOI 10.1093/annonc/mdg754; SCHRIJVERS CTM, 1995, INT J CANCER, V63, P324, DOI 10.1002/ijc.2910630303; Snijders T, 1999, MULTILEVEL ANAL; Taylor A, 2003, J PUBLIC HEALTH MED, V25, P228, DOI 10.1093/pubmed/fdg072; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S; Tilney HS, 2008, ANN SURG, V247, P77, DOI 10.1097/SLA.0b013e31816076c3; Verdecchia A, 2007, LANCET ONCOL, V8, P784, DOI 10.1016/S1470-2045(07)70246-2; Wyld L, 2004, BRIT J CANCER, V90, P1486, DOI 10.1038/sj.bjc.6601742; Wyld L, 2007, EUR J CANCER, V43, P2253, DOI 10.1016/j.ejca.2007.07.035	59	74	76	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 14	2010	340								b5479	10.1136/bmj.b5479	http://dx.doi.org/10.1136/bmj.b5479			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	545DC	20075152	Green Published, hybrid			2023-01-03	WOS:000273711700004
J	Lacomba, MT; Sanchez, MJY; Goni, AZ; Merino, DP; del Moral, OM; Tellez, EC; Mogollon, EM				Lacomba, Maria Torres; Yuste Sanchez, Maria Jose; Zapico Goni, Alvaro; Merino, David Prieto; Mayoral del Moral, Orlando; Cerezo Tellez, Ester; Minayo Mogollon, Elena			Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AXILLARY WEB SYNDROME; QUALITY-OF-LIFE; EARLY REHABILITATION; CONSERVING THERAPY; NODE DISSECTION; ARM MORBIDITY; SURVIVORS; RELIABILITY; DIAGNOSIS; VALIDITY	Objective To determine the effectiveness of early physiotherapy in reducing the risk of secondary lymphoedema after surgery for breast cancer. Design Randomised, single blinded, clinical trial. Setting University hospital in Alcala de Henares, Madrid, Spain. Participants 120 women who had breast surgery involving dissection of axillary lymph nodes between May 2005 and June 2007. Intervention The early physiotherapy group was treated by a physiotherapist with a physiotherapy programme including manual lymph drainage, massage of scar tissue, and progressive active and action assisted shoulder exercises. This group also received an educational strategy. The control group received the educational strategy only. Main outcome measure Incidence of clinically significant secondary lymphoedema (>2 cm increase in arm circumference measured at two adjacent points compared with the non-affected arm). Results 116 women completed the one year follow-up. Of these, 18 developed secondary lymphoedema (16%): 14 in the control group (25%) and four in the intervention group (7%). The difference was significant (P=0.01); risk ratio 0.28 (95% confidence interval 0.10 to 0.79). A survival analysis showed a significant difference, with secondary lymphoedema being diagnosed four times earlier in the control group than in the intervention group (intervention/control, hazard ratio 0.26, 95% confidence interval 0.09 to 0.79). Conclusion Early physiotherapy could be an effective intervention in the prevention of secondary lymphoedema in women for at least one year after surgery for breast cancer involving dissection of axillary lymph nodes.	[Lacomba, Maria Torres; Yuste Sanchez, Maria Jose; Zapico Goni, Alvaro] Univ Alcala de Henares, Sch Physiotherapy, Physiotherapy Dept, E-28871 Madrid, Spain; [Zapico Goni, Alvaro] Principe Asturias Univ Hosp, Madrid, Spain; [Merino, David Prieto] London Sch Hyg & Trop Med, Med Stat Unit, Dept Epidemiol & Populat Hlth, London WC1, England; [Mayoral del Moral, Orlando] Prov Hosp, Physiotherapy Dept, Toledo, Spain	Universidad de Alcala; Prince of Asturias University Hospital; University of London; London School of Hygiene & Tropical Medicine	Lacomba, MT (corresponding author), Univ Alcala de Henares, Sch Physiotherapy, Physiotherapy Dept, E-28871 Madrid, Spain.	maria.torres@uah.es	Torres-Lacomba, María/A-5896-2017	Torres-Lacomba, María/0000-0002-7051-3130; Yuste Sanchez, Maria Jose/0000-0002-0059-4991; Cerezo-Tellez, Ester/0000-0001-8197-1420; Prieto-Merino, David/0000-0001-5001-0061; Mayoral del Moral, Orlando/0000-0001-5329-3415	Spanish Health Ministry [PI071124]	Spanish Health Ministry(Instituto de Salud Carlos IIISpanish Government)	This study was funded by the Health Institute Carlos III (Protocol PI071124) of the Spanish Health Ministry.	ADLER SS, 2002, FACILITACION NEUROMU; Armer Jane M., 2005, Lymphatic Research and Biology, V3, P208, DOI 10.1089/lrb.2005.3.208; Bani HA, 2007, PATIENT EDUC COUNS, V66, P311, DOI 10.1016/j.pec.2007.01.004; Batiston AP, 2005, FISIOTER PESQUI, V12, P30; Beaulac SM, 2002, ARCH SURG-CHICAGO, V137, P1253, DOI 10.1001/archsurg.137.11.1253; Box RC, 2002, BREAST CANCER RES TR, V75, P51, DOI 10.1023/A:1016591121762; Chen YW, 2008, AM J PHYS MED REHAB, V87, P33, DOI 10.1097/PHM.0b013e31815b6199; Cheville AL, 2003, SEMIN RADIAT ONCOL, V13, P214, DOI 10.1016/S1053-4296(03)00038-9; Cheville AL, 2007, J SURG ONCOL, V95, P409, DOI 10.1002/jso.20782; Cinar N, 2008, CANCER NURS, V31, P160, DOI 10.1097/01.NCC.0000305696.12873.0e; CORUNA A, 2006, XUNTA GALLCIA; FERRANDEZ J, 2006, REEDUCATION CANC SEI; FERRANDEZ J, 1999, ANN KINESITHER, V26, P265; Ferrandez JC, 1996, B CANCER, V83, P989; FERRANDEZ JC, 2005, ONCOLOGIE, V7, P316; FERRANDEZ JC, 2008, CUEST FISIOTER, V37, P187; FERRANDEZ JC, 1995, ANN KINESITHER, V22, P253; FERRANDEZ JC, 2007, CANC SEIN TRAITE MED, P119; FOLDI E, 1989, ANN PLAS SURG, V22, P505; Foldi M., 2005, PRINCIPES DRAINAGE L; Gergich NLS, 2008, CANCER-AM CANCER SOC, V112, P2809, DOI 10.1002/cncr.23494; Hack TF, 1999, J CLIN ONCOL, V17, P143, DOI 10.1200/JCO.1999.17.1.143; Harris SR, 2001, CAN MED ASSOC J, V164, P191; Hayes S, 2005, BREAST CANCER RES TR, V94, P1, DOI 10.1007/s10549-005-5991-z; Hayes S, 2005, BREAST CANCER RES TR, V89, P221, DOI 10.1007/s10549-004-2045-x; Johansson K, 2002, LYMPHOLOGY, V35, P59; Karges JR, 2003, PHYS THER, V83, P134, DOI 10.1093/ptj/83.2.134; KILBREATH SL, 2006, REHABIL ONCOL, V24, P9; Kitamura Yuko, 2005, Breast Cancer, V12, P130, DOI 10.2325/jbcs.12.130; KOAK Z, 2000, ACTA ONCOL, V39, P389; Kosir MA, 2001, J SURG RES, V95, P147, DOI 10.1006/jsre.2000.6021; Kwan W, 2002, J CLIN ONCOL, V20, P4242, DOI 10.1200/JCO.2002.09.018; LACOMBA MT, 2008, KINESITHER SCI, V494, P25; Leidenius M, 2003, AM J SURG, V185, P127, DOI 10.1016/S0002-9610(02)01214-X; LeVu B, 1997, B CANCER, V84, P957; Liu NF, 2004, LYMPHOLOGY, V37, P6; MARTINEZ I, 1999, 98267 U CAST MANCH J; MASMOUDI A, 2004, DERMATOLOGY ONLINE J, V12; McTiernan A, 2005, ONCOLOGY-NY, V19, P871; MEESKE K, 2008, BREAST CANC RES TREA, V14, P982; MORTIMER P, 1998, PROGR LYMPHOLOGY, P36; Moskovitz AH, 2001, AM J SURG, V181, P434, DOI 10.1016/S0002-9610(01)00602-X; Na YM, 1999, YONSEI MED J, V40, P1; Nardone Luigia, 2005, Rays, V30, P149; NEIGER H, 1998, ESTIRAMIENTOS ANALIT; Nesvold IL, 2008, ACTA ONCOL, V47, P835, DOI 10.1080/02841860801961257; Ocana A, 2006, J CLIN ONCOL, V24, P1477, DOI 10.1200/JCO.2005.01.8473; Ozaslan C, 2004, AM J SURG, V187, P69, DOI 10.1016/j.amjsurg.2002.12.003; Petrek JA, 1998, CANCER-AM CANCER SOC, V83, P2776, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2776::AID-CNCR25>3.0.CO;2-V; POURQUIER H, 2007, CANC SEIN TRAITE MED, P46; Powell SN, 2003, INT J RADIAT ONCOL, V55, P1209, DOI 10.1016/S0360-3016(02)04273-6; Ridner SH, 2006, PATIENT EDUC COUNS, V61, P72, DOI 10.1016/j.pec.2005.02.009; Rietman J, 2004, DISABIL REHABIL, V26, P78, DOI 10.1080/09638280310001629642; ROMAY H, 2006, GUIA MASOTERAPIA FIS, P311; RUNOWICK C, 1998, AM CANC SOC LYMPH WO, P2874; SALVAT I, 2006, GUIA MASOTERAPIA DIS, P152; SANDER AP, 2005, Q J MED, V98, P343; Shamley DR, 2005, BREAST CANCER RES TR, V90, P263, DOI 10.1007/s10549-004-4727-9; Shih YCT, 2009, J CLIN ONCOL, V27, P2007, DOI 10.1200/JCO.2008.18.3517; Soerjomataram I, 2008, BREAST CANCER RES TR, V107, P309, DOI 10.1007/s10549-007-9556-1; *STATACORP, 2008, STATA SOFTW 10 0 VER; Taylor R, 2006, PHYS THER, V86, P205, DOI 10.1093/ptj/86.2.205; Tengrup I, 2000, ACTA ONCOL, V39, P393, DOI 10.1080/028418600750013177; Tobbia D, 2009, J VASC RES, V46, P426, DOI 10.1159/000194273; Todd J, 2008, PHYSIOTHERAPY, V94, P265, DOI 10.1016/j.physio.2008.09.005; Lacomba MT, 2009, BREAST CANCER RES TR, V117, P625, DOI 10.1007/s10549-009-0371-8; TORRES M, 2009, CUEST FISIOTER, V38, P170; TORRES M, 2006, GUIA MASOTERAPIA DIS, P239; TORRES M, 2006, GUIA MASOTERAPIA FIS, P337; TORRES M, 2010, CUEST FISIO IN PRESS, V39; Weir HK, 2003, JNCI-J NATL CANCER I, V95, P1276, DOI 10.1093/jnci/djg040	71	222	228	4	49	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 12	2010	340								b5396	10.1136/bmj.b5396	http://dx.doi.org/10.1136/bmj.b5396			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	545CZ	20068255	Green Published, hybrid, Green Accepted			2023-01-03	WOS:000273711400002
J	Whetten, K; Ostermann, J; Whetten, RA; Pence, BW; O'Donnell, K; Messer, LC; Thielman, NM				Whetten, Kathryn; Ostermann, Jan; Whetten, Rachel A.; Pence, Brian W.; O'Donnell, Karen; Messer, Lynne C.; Thielman, Nathan M.		Positive Outcomes Orphans (POFO)	A Comparison of the Wellbeing of Orphans and Abandoned Children Ages 6-12 in Institutional and Community-Based Care Settings in 5 Less Wealthy Nations	PLOS ONE			English	Article							DIFFICULTIES QUESTIONNAIRE; STRENGTHS; ATTACHMENT; MODELS; ERITREA; ROMANIA; AFRICA; MALAWI; AIDS	Background: Leaders are struggling to care for the estimated 143,000,000 orphans and millions more abandoned children worldwide. Global policy makers are advocating that institution-living orphans and abandoned children (OAC) be moved as quickly as possible to a residential family setting and that institutional care be used as a last resort. This analysis tests the hypothesis that institutional care for OAC aged 6-12 is associated with worse health and wellbeing than community residential care using conservative two-tail tests. Methodology: The Positive Outcomes for Orphans (POFO) study employed two-stage random sampling survey methodology in 6 sites across 5 countries to identify 1,357 institution-living and 1,480 community-living OAC ages 6-12, 658 of whom were double-orphans or abandoned by both biological parents. Survey analytic techniques were used to compare cognitive functioning, emotion, behavior, physical health, and growth. Linear mixed-effects models were used to estimate the proportion of variability in child outcomes attributable to the study site, care setting, and child levels and institutional versus community care settings. Conservative analyses limited the community living children to double-orphans or abandoned children. Principal Findings: Health, emotional and cognitive functioning, and physical growth were no worse for institution-living than community-living OAC, and generally better than for community-living OAC cared for by persons other than a biological parent. Differences between study sites explained 2-23% of the total variability in child outcomes, while differences between care settings within sites explained 8-21%. Differences among children within care settings explained 64-87%. After adjusting for sites, age, and gender, institution vs. community-living explained only 0.3-7% of the variability in child outcomes. Conclusion: This study does not support the hypothesis that institutional care is systematically associated with poorer wellbeing than community care for OAC aged 6-12 in those countries facing the greatest OAC burden. Much greater variability among children within care settings was observed than among care settings type. Methodologically rigorous studies must be conducted in those countries facing the new OAC epidemic in order to understand which characteristics of care promote child wellbeing. Such characteristics may transcend the structural definitions of institutions or family homes.	[Whetten, Kathryn; Ostermann, Jan; Whetten, Rachel A.; Pence, Brian W.; O'Donnell, Karen; Messer, Lynne C.; Thielman, Nathan M.] Duke Univ, Ctr Hlth Policy, Duke Global Hlth Inst, Durham, NC 27710 USA; [Whetten, Kathryn] Duke Univ, Terry Sanford Inst Publ Policy, Durham, NC USA; [O'Donnell, Karen] Duke Univ, Med Ctr, Dept Psychiat, Durham, NC 27710 USA; [O'Donnell, Karen] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [O'Donnell, Karen] Duke Univ, Ctr Child & Family Hlth, Durham, NC USA; [Whetten, Kathryn; Pence, Brian W.] Duke Univ, Dept Community & Family Med, Durham, NC USA; [Thielman, Nathan M.] Duke Univ, Dept Med, Div Infect Dis & Int Hlth, Durham, NC USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; Duke University	Whetten, K (corresponding author), Duke Univ, Ctr Hlth Policy, Duke Global Hlth Inst, Durham, NC 27710 USA.	katewhetten@gmail.com	Thielman, Nathan/R-5142-2019; Ostermann, Jan/GQB-4743-2022; Whetten, Kathryn/C-8572-2009	Thielman, Nathan/0000-0001-8152-2879; Whetten, Kathryn/0000-0002-4841-7695; Ostermann, Jan/0000-0002-8236-9500	National Institute of Child Health and Development (NICHD) [5R01HD046345-04]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD046345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R25MH080916] Funding Source: NIH RePORTER	National Institute of Child Health and Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the National Institute of Child Health and Development (NICHD), grant No. 5R01HD046345-04. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*ABTH, 2003, COND SHELT RIO JAN; Atwine B, 2005, SOC SCI MED, V61, P555, DOI 10.1016/j.socscimed.2004.12.018; BEEGLE K, 2006, AM J AGR EC, V88; *BETT CAR NETW, FAM COMM BAS CAR; Case A, 2004, DEMOGRAPHY, V41, P483, DOI 10.1353/dem.2004.0019; Cluver Lucie, 2006, Ann Gen Psychiatry, V5, P8, DOI 10.1186/1744-859X-5-8; Crampin AC, 2003, AIDS, V17, P389, DOI 10.1097/00002030-200302140-00013; DEBBAS A, 2008, STRATEGIC APPROACH C; Delis D.C., 1987, CALIFORNIA VERBAL LE; *DEPSOS, 2008, UNICEF SOM MATT QUAL; Foster C, 2000, AIDS, V14, pS275; Foster G., 2000, PSYCHOL HEALTH MED, V5, P55, DOI DOI 10.1080/135485000106007; Goodman R, 1998, EUR CHILD ADOLES PSY, V7, P125, DOI 10.1007/s007870050057; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Goodman R, 1999, J ABNORM CHILD PSYCH, V27, P17, DOI 10.1023/A:1022658222914; INTERNATIONAL H, 2003, FORGOTTEN FAMILIES O, P24; KAUFMAN AS, 2003, KAUFMAN ASSESSMENT B; Kaufman AS., 1983, KAUFMAN ASSESSMENT B; McKenzie R., 1997, CHILD YOUTH CARE, V26, P87, DOI DOI 10.1007/BF02589359; McKenzie R. B., 1999, NEW DEMOCRAT    0101; Miller G. R., 1997, ANOVA BASICS APPL ST; MULLICK MSI, 2001, SOCIAL PSYCHIAT PSYC, V36, P1337; Muris P, 2004, CHILD PSYCHIAT HUM D, V34, P317; Nyambedha Erick O, 2003, J Cross Cult Gerontol, V18, P33, DOI 10.1023/A:1024826528476; Panpanich R, 1999, ANN TROP PAEDIATR, V19, P279, DOI 10.1080/02724939992374; Powell G, 2004, CHILDREN RESIDENTIAL; Rabe-Hesketh S, 2005, J ECONOMETRICS, V128, P301, DOI 10.1016/j.jeconom.2004.08.017; RICHARDMACKENZI, RETHINKING ORPHANAGE; Richter L., 2008, CHILDREN THRIVE FAMI; Sachs SE, 2004, LANCET, V364, P1404, DOI 10.1016/S0140-6736(04)17220-6; Sengendo J, 1997, Health Transit Rev, V7 Suppl, P105; Singer JD, 1998, J EDUC BEHAV STAT, V23, P323; Smyke AT, 2007, J CHILD PSYCHOL PSYC, V48, P210, DOI 10.1111/j.1469-7610.2006.01694.x; Smyke AT, 2002, J AM ACAD CHILD PSY, V41, DOI 10.1097/00004583-200208000-00016; StataCorp L, 2007, STAT DAT AN STAT SOF; TIZARD B, 1978, J CHILD PSYCHOL PSYC, V19, P99, DOI 10.1111/j.1469-7610.1978.tb00453.x; TIZARD B, 1975, J CHILD PSYCHOL PSYC, V16, P61, DOI 10.1111/j.1469-7610.1975.tb01872.x; TORITSYN A, 2007, DEV INTEGRATED SOCIA; *UN, 2007, DRAFT UN GUID APPR U; *UN DEV PROGR, HUM DEV IND STAT UPD; UNICEF, 2007, PROTECTING THE WORLD'S CHILDREN: IMPACT OF THE CONVENTION ON THE RIGHTS OF THE CHILD IN DIVERSE LEGAL SYSTEMS, P1; *UNICEF, 2004, CHILDR BRINK JOINT R; UNICEF, FACTS CHILDR; UNICEF UNAIDS Irish AID, 2008, COMM 4 GLOB PARTN FO; van Ijzendoorn MH, 2008, MERRILL PALMER QUART, V54, P341; Wareing PW, 2001, INT J FOOD SCI TECH, V36, P1, DOI 10.1046/j.1365-2621.2001.00419.x; *WHO, 2006, WHO CLIN GROWTH STAN; Wolff PH, 2005, AM J ORTHOPSYCHIAT, V75, P475, DOI 10.1037/0002-9432.75.4.475; WOLFF PH, 1995, SOC SCI MED, V40, P1133, DOI 10.1016/0277-9536(94)00168-S; Wolff PH, 1998, AM J PSYCHIAT, V155, P1319, DOI 10.1176/ajp.155.10.1319; World Health Organization, 2007, WORLD HLTH REP 2007; Xu RH, 2003, STAT MED, V22, P3527, DOI 10.1002/sim.1572; Zeanah CH, 2005, CHILD DEV, V76, P1015, DOI 10.1111/j.1467-8624.2005.00894.x	54	84	84	1	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 18	2009	4	12							e8169	10.1371/journal.pone.0008169	http://dx.doi.org/10.1371/journal.pone.0008169			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	534BN	20020037	Green Published, Green Submitted, gold			2023-01-03	WOS:000272870600001
J	Taccone, P; Pesenti, A; Latini, R; Polli, F; Vagginelli, F; Mietto, C; Caspani, L; Raimondi, F; Bordone, G; Iapichino, G; Mancebo, J; Guerin, C; Ayzac, L; Blanch, L; Fumagalli, R; Tognoni, G; Gattinoni, L				Taccone, Paolo; Pesenti, Antonio; Latini, Roberto; Polli, Federico; Vagginelli, Federica; Mietto, Cristina; Caspani, Luisa; Raimondi, Ferdinando; Bordone, Giovanni; Iapichino, Gaetano; Mancebo, Jordi; Guerin, Claude; Ayzac, Louis; Blanch, Lluis; Fumagalli, Roberto; Tognoni, Gianni; Gattinoni, Luciano		Prone-Supine II Study Grp	Prone Positioning in Patients With Moderate and Severe Acute Respiratory Distress Syndrome A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUCED LUNG INJURY; MECHANICAL VENTILATION; CLINICAL-TRIALS; FAILURE; METAANALYSIS; MULTICENTER; GUIDELINES; OUTCOMES; SEPSIS; STRAIN	Context Post hoc analysis of a previous trial has suggested that prone positioning may improve survival in patients with severe hypoxemia and with acute respiratory distress syndrome (ARDS). Objective To assess possible outcome benefits of prone positioning in patients with moderate and severe hypoxemia who are affected by ARDS. Design, Setting, and Patients The Prone-Supine II Study, a multicenter, unblinded, randomized controlled trial conducted in 23 centers in Italy and 2 in Spain. Patients were 342 adults with ARDS receiving mechanical ventilation, enrolled from February 2004 through June 2008 and prospectively stratified into subgroups with moderate (n=192) and severe (n=150) hypoxemia. Interventions Patients were randomized to undergo supine (n=174) or prone (20 hours per day; n=168) positioning during ventilation. Main Outcome Measures The primary outcome was 28-day all-cause mortality. Secondary outcomes were 6-month mortality and mortality at intensive care unit discharge, organ dysfunctions, and the complication rate related to prone positioning. Results Prone and supine patients from the entire study population had similar 28-day (31.0% vs 32.8%; relative risk [RR], 0.97; 95% confidence interval [CI], 0.84-1.13; P=.72) and 6-month (47.0% vs 52.3%; RR, 0.90; 95% CI, 0.73-1.11; P=.33) mortality rates, despite significantly higher complication rates in the prone group. Outcomes were also similar for patients with moderate hypoxemia in the prone and supine groups at 28 days (25.5% vs 22.5%; RR, 1.04; 95% CI, 0.89-1.22; P=.62) and at 6 months (42.6% vs 43.9%; RR, 0.98; 95% CI, 0.76-1.25; P=.85). The 28-day mortality of patients with severe hypoxemia was 37.8% in the prone and 46.1% in the supine group (RR, 0.87; 95% CI, 0.66-1.14; P=.31), while their 6-month mortality was 52.7% and 63.2%, respectively (RR, 0.78; 95% CI, 0.53-1.14; P=.19). Conclusion Data from this study indicate that prone positioning does not provide significant survival benefit in patients with ARDS or in subgroups of patients with moderate and severe hypoxemia. Trial Registration clinicaltrials.gov Identifier: NCT00159939 JAMA. 2009;302(18):1977-1984	[Taccone, Paolo; Vagginelli, Federica; Caspani, Luisa; Gattinoni, Luciano] Fdn IRCCS Osped Maggiore Policlin Mangiagalli Reg, Dipartimento Anestesia & Rianimaz, I-20122 Milan, Italy; [Pesenti, Antonio; Fumagalli, Roberto] Azienda Osped San Gerardo Monza, Dipartimento Med Perioperatoria & Terapie Intens, Monza, Italy; [Latini, Roberto] Ist Ric Farmacol Mario Negri, Dept Cardiovasc Res, Milan, Italy; [Polli, Federico; Mietto, Cristina; Iapichino, Gaetano; Gattinoni, Luciano] Univ Milan, Ist Anestesiol & Rianimaz, Milan, Italy; [Iapichino, Gaetano] Azienda Osped Polo Univ San Paolo, UO Anestesia & Rianimaz, Milan, Italy; [Pesenti, Antonio; Fumagalli, Roberto] Univ Milano Bicocca, Dipartimento Med Sperimentale, Milan, Italy; [Raimondi, Ferdinando] Polo Univ Luigi Sacco, UO Anestesia & Rianimaz, Milan, Italy; [Bordone, Giovanni] Ist Clin Humanitas, Dipartimento Anestesia & Rianimaz Gen, Rozzano, Italy; [Mancebo, Jordi] Hosp Sant Pau, Serv Med Intens, Barcelona, Spain; [Guerin, Claude] Hop Croix Rousse, Serv Reanimat Med & Assistance Resp, F-69317 Lyon, France; [Ayzac, Louis] Hosp Henry Gabrielle, Ctr Coordinat Lutte Infect Nosocomi Sud Est, St Genis Laval, France; [Blanch, Lluis] Univ Autonoma Barcelona, Crit Care Ctr, CIBER Enfermedades Resp, Corp Sanitaria Parc Tauli, Sabadell, Spain; [Tognoni, Gianni] Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, I-66030 Santa Maria Imbaro, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; University of Milano-Bicocca; IRCCS Humanitas Research Hospital; Hospital of Santa Creu i Sant Pau; CHU Lyon; CHU Lyon; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Gattinoni, L (corresponding author), Fdn IRCCS Osped Maggiore Policlin Mangiagalli Reg, Dipartimento Anestesia & Rianimaz, Via F Sforza 35, I-20122 Milan, Italy.	gattinon@policlinico.mi.it	Fumagalli, Roberto/AAB-9746-2019; Rialp, Gemma/I-3353-2016; Latini, Roberto/AAB-1410-2020; Polli, Federico/AAB-9868-2022; guerin, claude/H-5692-2014; Rossi, Sandra/AHH-8015-2022; Pesenti, Antonio/H-7483-2012	Fumagalli, Roberto/0000-0003-0398-1329; Rialp, Gemma/0000-0003-3614-3639; Latini, Roberto/0000-0002-3729-4650; guerin, claude/0000-0003-4700-6672; Rossi, Sandra/0000-0002-9963-8121; Pesenti, Antonio/0000-0003-2593-729X; Gattinoni, Luciano/0000-0001-5380-2494				Abroug F, 2008, INTENS CARE MED, V34, P1002, DOI 10.1007/s00134-008-1062-3; Alsaghir AH, 2008, CRIT CARE MED, V36, P603, DOI 10.1097/01.CCM.0000299739.98236.05; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Broccard A, 2000, CRIT CARE MED, V28, P295, DOI 10.1097/00003246-200002000-00001; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Chiumello D, 2008, AM J RESP CRIT CARE, V178, P346, DOI 10.1164/rccm.200710-1589OC; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Mancebo J, 2006, AM J RESP CRIT CARE, V173, P1233, DOI 10.1164/rccm.200503-353OC; Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC; PIEHL MA, 1976, CRIT CARE MED, V4, P13, DOI 10.1097/00003246-197601000-00003; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Slutsky AS, 2001, NEW ENGL J MED, V345, P610, DOI 10.1056/NEJM200108233450811; Sud S, 2008, CAN MED ASSOC J, V178, P1153, DOI 10.1503/cmaj.071802; Valenza F, 2005, CRIT CARE MED, V33, P361, DOI 10.1097/01.CCM.0000150660.45376.7C; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	20	317	362	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 11	2009	302	18					1977	1984		10.1001/jama.2009.1614	http://dx.doi.org/10.1001/jama.2009.1614			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	517MY	19903918	Bronze			2023-01-03	WOS:000271619700024
J	Eippert, F; Finsterbusch, J; Bingel, U; Buchel, C				Eippert, Falk; Finsterbusch, Juergen; Bingel, Ulrike; Buechel, Christian			Direct Evidence for Spinal Cord Involvement in Placebo Analgesia	SCIENCE			English	Article							MECHANISMS		[Eippert, Falk; Finsterbusch, Juergen; Buechel, Christian] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, D-20246 Hamburg, Germany; [Bingel, Ulrike] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Eippert, F (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci, D-20246 Hamburg, Germany.	f.eippert@uke.uni-hamburg.de	Finsterbusch, Jürgen/M-2969-2016; Eippert, Falk/M-6188-2013	Eippert, Falk/0000-0002-3986-1719				Benedetti F, 2005, J NEUROSCI, V25, P10390, DOI 10.1523/JNEUROSCI.3458-05.2005; Fields HL, 2006, WALL MELZACKS TXB PA, P125; Lilja J, 2006, J NEUROSCI, V26, P6330, DOI 10.1523/JNEUROSCI.0626-06.2006; Matre D, 2006, J NEUROSCI, V26, P559, DOI 10.1523/JNEUROSCI.4218-05.2006; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176	6	298	304	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	2009	326	5951					404	404		10.1126/science.1180142	http://dx.doi.org/10.1126/science.1180142			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	506ZM	19833962				2023-01-03	WOS:000270818600046
J	Richards, H				Richards, Helen			Personal View We must defend personal continuity in primary care	BRITISH MEDICAL JOURNAL			English	Editorial Material												Helen.cowan3@btinternet.com						2007, BRIT MED J, V335, P941	1	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 6	2009	339								b3923	10.1136/bmj.b3923	http://dx.doi.org/10.1136/bmj.b3923			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	505TF	19808748				2023-01-03	WOS:000270719100005
J	Azzopardi, DV; Strohm, B; Edwards, AD; Dyet, L; Halliday, HL; Juszczak, E; Kapellou, O; Levene, M; Marlow, N; Porter, E; Thoresen, M; Whitelaw, A; Brocklehurst, P				Azzopardi, Denis V.; Strohm, Brenda; Edwards, A. David; Dyet, Leigh; Halliday, Henry L.; Juszczak, Edmund; Kapellou, Olga; Levene, Malcolm; Marlow, Neil; Porter, Emma; Thoresen, Marianne; Whitelaw, Andrew; Brocklehurst, Peter		TOBY Study Grp	Moderate Hypothermia to Treat Perinatal Asphyxial Encephalopathy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; WHOLE-BODY HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; MILD HYPOTHERMIA; NEWBORN PIGLET; OUTCOMES; INFANTS; SAFETY; MODEL; TRIAL	Background: Whether hypothermic therapy improves neurodevelopmental outcomes in newborn infants with asphyxial encephalopathy is uncertain. Methods: We performed a randomized trial of infants who were less than 6 hours of age and had a gestational age of at least 36 weeks and perinatal asphyxial encephalopathy. We compared intensive care plus cooling of the body to 33.5 degreesC for 72 hours and intensive care alone. The primary outcome was death or severe disability at 18 months of age. Prespecified secondary outcomes included 12 neurologic outcomes and 14 other adverse outcomes. Results: Of 325 infants enrolled, 163 underwent intensive care with cooling, and 162 underwent intensive care alone. In the cooled group, 42 infants died and 32 survived but had severe neurodevelopmental disability, whereas in the noncooled group, 44 infants died and 42 had severe disability (relative risk for either outcome, 0.86; 95% confidence interval [CI], 0.68 to 1.07; P=0.17). Infants in the cooled group had an increased rate of survival without neurologic abnormality (relative risk, 1.57; 95% CI, 1.16 to 2.12; P=0.003). Among survivors, cooling resulted in reduced risks of cerebral palsy (relative risk, 0.67; 95% CI, 0.47 to 0.96; P=0.03) and improved scores on the Mental Developmental Index and Psychomotor Developmental Index of the Bayley Scales of Infant Development II (P=0.03 for each) and the Gross Motor Function Classification System (P=0.01). Improvements in other neurologic outcomes in the cooled group were not significant. Adverse events were mostly minor and not associated with cooling. Conclusions: Induction of moderate hypothermia for 72 hours in infants who had perinatal asphyxia did not significantly reduce the combined rate of death or severe disability but resulted in improved neurologic outcomes in survivors. (Current Controlled Trials number, ISRCTN89547571.) N Engl J Med 2009;361:1349-58.	[Azzopardi, Denis V.; Edwards, A. David; Dyet, Leigh; Kapellou, Olga; Porter, Emma] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Clin Sci, London W12 0NN, England; [Azzopardi, Denis V.; Edwards, A. David; Dyet, Leigh; Kapellou, Olga; Porter, Emma] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, MRC, Ctr Clin Sci, London W12 0NN, England; [Strohm, Brenda; Juszczak, Edmund; Brocklehurst, Peter] Univ Oxford, Natl Perinatal Epidemiol Unit, Oxford, England; [Halliday, Henry L.] Queens Univ Belfast, Dept Child Hlth, Belfast BT7 1NN, Antrim, North Ireland; [Halliday, Henry L.] Royal Matern Hosp, Dept Perinatal Med, Belfast, Antrim, North Ireland; [Levene, Malcolm] Univ Leeds, Leeds, W Yorkshire, England; [Levene, Malcolm] Leeds Gen Infirm, Leeds, W Yorkshire, England; [Marlow, Neil] Queens Med Ctr, Acad Div Child Hlth, Nottingham NG7 2UH, England; [Thoresen, Marianne] Univ Bristol, St Michaels Hosp, Dept Clin Sci, Bristol, Avon, England; [Whitelaw, Andrew] Southmead Hosp, Bristol, Avon, England	Imperial College London; Imperial College London; University of Oxford; Queens University Belfast; University of Leeds; Leeds General Infirmary; University of Leeds; University of Nottingham; University of Bristol; Southmead Hospital	Azzopardi, DV (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Div Clin Sci, Du Cane Rd, London W12 0NN, England.	d.azzopardi@imperial.ac.uk	Dore, Caroline J/J-4716-2012; Marlow, Neil/D-2918-2009; Brocklehurst, Peter/B-5804-2011; Edwards, Anthony/HCI-9626-2022; Ramenghi, Luca/AAB-4067-2020; Petrou, Stavros/ABD-8323-2021	Dore, Caroline J/0000-0001-9796-4970; Marlow, Neil/0000-0001-5890-2953; Ramenghi, Luca/0000-0003-0065-762X; Hubbard, Marie/0000-0003-0388-4983; Petrou, Stavros/0000-0003-3121-6050; Edwards, Anthony David/0000-0003-4801-7066; Blennow, Mats/0000-0001-9517-0261; Halliday, Henry/0000-0001-7978-4992	U. K. Medical Research Council; U. K. Department of Health; MRC [G0501681, MC_U120081323, G0100126, G0200270] Funding Source: UKRI; Medical Research Council [G0501681, MC_U120081323, G0100126, G0200270] Funding Source: researchfish	U. K. Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); U. K. Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	Supported by grants from the U. K. Medical Research Council and the U. K. Department of Health.	al Naqeeb N, 1999, PEDIATRICS, V103, P1263, DOI 10.1542/peds.103.6.1263; Allmark P, 2006, J MED ETHICS, V32, P439, DOI 10.1136/jme.2005.013722; Amess PN, 1997, PEDIATR RES, V41, P803, DOI 10.1203/00006450-199706000-00002; Azzopardi D, 2000, PEDIATRICS, V106, P684, DOI 10.1542/peds.106.4.684; Barks JDE, 2008, SEMIN FETAL NEONAT M, V13, P30, DOI 10.1016/j.siny.2007.09.004; Barnett AL, 2004, ARCH DIS CHILD, V89, P637, DOI 10.1136/adc.2002.019349; Bayley N., 2006, BAYLEY SCALES INFANT, V3rd; Bona E, 1998, PEDIATR RES, V43, P738, DOI 10.1203/00006450-199806000-00005; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Edwards AD, 1995, BIOCHEM BIOPH RES CO, V217, P1193, DOI 10.1006/bbrc.1995.2895; Eicher DJ, 2005, PEDIATR NEUROL, V32, P18, DOI 10.1016/j.pediatrneurol.2004.06.015; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; Haataja L, 1999, J PEDIATR-US, V135, P153, DOI 10.1016/S0022-3476(99)70016-8; Higgins RD, 2006, J PEDIATR-US, V148, P170, DOI 10.1016/j.jpeds.2005.12.009; JACOBS S, 2007, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003311.PUB2; Kirpalani H, 2007, PEDIATRICS, V120, P1126, DOI 10.1542/peds.2006-2776; Palisano RJ, 2000, PHYS THER, V80, P974, DOI 10.1093/ptj/80.10.974; Schulzke Sven M, 2007, BMC Pediatr, V7, P30; Shah PS, 2007, ARCH PEDIAT ADOL MED, V161, P951, DOI 10.1001/archpedi.161.10.951; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Shankaran S, 2008, PEDIATRICS, V122, pE791, DOI 10.1542/peds.2008-0456; Sirimanne ES, 1996, PEDIATR RES, V39, P591, DOI 10.1203/00006450-199604000-00005; THORESEN M, 1995, PEDIATR RES, V37, P667, DOI 10.1203/00006450-199505000-00019; Voss W, 2007, ACTA PAEDIATR, V96, P342, DOI 10.1111/j.1651-2227.2006.00130.x; Wyatt JS, 2007, PEDIATRICS, V119, P912, DOI 10.1542/peds.2006-2839	26	1153	1188	0	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 1	2009	361	14					1349	1358		10.1056/NEJMoa0900854	http://dx.doi.org/10.1056/NEJMoa0900854			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	500KZ	19797281	Green Published			2023-01-03	WOS:000270300000009
J	Ichiyama, R; Potuzak, M; Balak, M; Kalderon, N; Edgerton, VR				Ichiyama, Ronaldo; Potuzak, Melissa; Balak, Marissa; Kalderon, Nurit; Edgerton, V. Reggie			Enhanced Motor Function by Training in Spinal Cord Contused Rats Following Radiation Therapy	PLOS ONE			English	Article								Weight-bearing stepping, without supraspinal re-connectivity, can be attained by treadmill training in an animal whose spinal cord has been completely transected at the lower thoracic level. Repair of damaged tissue and of supraspinal connectivity/circuitry following spinal cord injury in rat can be achieved by specific cell elimination with radiation therapy of the lesion site delivered within a critical time window, 2-3 weeks postinjury. Here we examined the effects of training in the repaired spinal cord following clinical radiation therapy. Studies were performed in a severe rat spinal cord contusion injury model, one similar to fracture/crush injuries in humans; the injury was at the lower thoracic level and the training was a combined hindlimb standing and stepping protocol. Radiotherapy, in a similar manner to that reported previously, resulted in a significant level of tissue repair/preservation at the lesion site. Training in the irradiated group, as determined by limb kinematics tests, resulted in functional improvements that were significant for standing and stepping capacity, and yielded a significant direct correlation between standing and stepping performance. In contrast, the training in the unirradiated group resulted in no apparent beneficial effects, and yielded an inverse correlation between standing and stepping performance, e. g., subject with good standing showed poor stepping capacity. Further, without any training, a differential functional change was observed in the irradiated group; standing capacity was significantly inhibited while stepping showed a slight trend of improvement compared with the unirradiated group. These data suggest that following repair by radiation therapy the spinal circuitries which control posture and locomotor were modified, and that the beneficial functional modulation of these circuitries is use dependent. Further, for restoring beneficial motor function following radiotherapy, training seems to be crucial.			Ichiyama, R (corresponding author), Univ Leeds, Fac Biol Sci, Inst Membrane & Syst Biol, Leeds, W Yorkshire, England.	kalderon@spinalcordcure.org; vre@ucla.edu	Ichiyama, Ronaldo/B-7856-2009; 慧, 胡/C-5968-2009	Ichiyama, Ronaldo/0000-0002-7640-8032	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039375, P01NS016333] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS016333, NS16333, R01 NS039375, NS39375] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Belanger M, 1996, J NEUROPHYSIOL, V76, P471, DOI 10.1152/jn.1996.76.1.471; CAJAL SRY, 1928, DEGENERATION REGENER, V2, P482; Conta AC, 2004, J COMP NEUROL, V479, P347, DOI 10.1002/cne.20319; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329, DOI 10.1152/jn.1998.79.3.1329; de Leon RD, 2002, PROG BRAIN RES, V137, P141; de Leon RD, 1999, J NEUROPHYSIOL, V81, P85, DOI 10.1152/jn.1999.81.1.85; de Leon RD, 1998, J NEUROPHYSIOL, V80, P83; de Leon RD, 1999, PROG BRAIN RES, V123, P341, DOI 10.1016/S0079-6123(08)62869-1; Edgerton V R, 1997, Adv Neurol, V72, P233; Edgerton VR, 2004, ANNU REV NEUROSCI, V27, P145, DOI 10.1146/annurev.neuro.27.070203.144308; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797, DOI 10.1152/jn.1997.77.2.797; Heng C, 2009, EXP NEUROL, V216, P139, DOI 10.1016/j.expneurol.2008.11.023; HODGSON JA, 1994, MED SCI SPORT EXER, V26, P1491; Hutchinson KJ, 2004, BRAIN, V127, P1403, DOI 10.1093/brain/awh160; KAKULAS BA, 1987, PARAPLEGIA, V25, P212, DOI 10.1038/sc.1987.37; Kalderon N, 1996, P NATL ACAD SCI USA, V93, P11185, DOI 10.1073/pnas.93.20.11185; Kalderon N, 2005, CURR PHARM DESIGN, V11, P1237, DOI 10.2174/1381612053507477; Kalderon N, 2001, BRAIN RES, V904, P199, DOI 10.1016/S0006-8993(01)02402-7; KALDERON N, 1996, P NATL ACAD SCI USA, V93, P10079; Kalderon N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000565; LOVELY RG, 1990, BRAIN RES, V514, P206, DOI 10.1016/0006-8993(90)91417-F; LOVELY RG, 1986, EXP NEUROL, V92, P421, DOI 10.1016/0014-4886(86)90094-4; PRATT CA, 1994, J NEUROPHYSIOL, V71, P1981, DOI 10.1152/jn.1994.71.5.1981; Qi HX, 2004, SOMATOSENS MOT RES, V21, P229, DOI 10.1080/08990220400012588; Stokes BT, 2002, SPINAL CORD, V40, P101, DOI 10.1038/sj.sc.3101254; Tator CH, 1997, J NEUROSURG, V86, P483, DOI 10.3171/jns.1997.86.3.0483; Timoszyk WK, 2002, J NEUROPHYSIOL, V88, P3108, DOI 10.1152/jn.01050.2001; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61; Wu CWH, 2000, NEURON, V28, P967, DOI 10.1016/S0896-6273(00)00167-7	33	20	20	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 31	2009	4	8							e6862	10.1371/journal.pone.0006862	http://dx.doi.org/10.1371/journal.pone.0006862			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	489JH	19718437	Green Published, Green Submitted, gold			2023-01-03	WOS:000269415900025
J	Selbo, PK; Rosenblum, MG; Cheung, LH; Zhang, W; Berg, K				Selbo, Pal K.; Rosenblum, Michael G.; Cheung, Lawrence H.; Zhang, Wendy; Berg, Kristian			Multi-Modality Therapeutics with Potent Anti-Tumor Effects: Photochemical Internalization Enhances Delivery of the Fusion Toxin scFvMEL/rGel	PLOS ONE			English	Article								Background: There is a need for drug delivery systems (DDS) that can enhance cytosolic delivery of anti-cancer drugs trapped in the endo-lysosomal compartments. Exposure of cells to specific photosensitizers followed by light exposure (photochemical internalization, PCI) results in transfer of agents from the endocytic compartment into the cytosol. Methodology and Principal Findings: The recombinant single-chain fusion construct scFvMEL/rGel is composed of an antibody targeting the progenitor marker HMW-MAA/NG2/MGP/gp240 and the highly effective toxin gelonin (rGel). Here we demonstrate enhanced tumor cell selectivity, cytosolic delivery and anti-tumor activity by applying PCI of scFvMEL/rGel. PCI performed by light activation of cells co-incubated with scFvMEL/rGel and the endo-lysosomal targeting photosensitizers AlPcS2a or TPPS2a resulted in enhanced cytotoxic effects against antigen-positive cell lines, while no differences in cytotoxicity between the scFvMEL/rGel and rGel were observed in antigen-negative cells. Mice bearing well-developed melanoma (A-375) xenografts (50-100 mm(3)) were treated with PCI of scFvMEL/rGel. By 30 days after injection, similar to 100% of mice in the control groups had tumors>800 mm(3). In contrast, by day 40, 50% of mice in the PCI of scFvMEL/rGel combination group had tumors<800 mm(3) with no increase in tumor size up to 110 days. PCI of scFvMEL/rGel resulted in a synergistic effect (p<0.05) and complete regression (CR) in 33% of tumor-bearing mice (n = 12). Conclusions/Significance: This is a unique demonstration that a non-invasive multi-modality approach combining a recombinant, targeted therapeutic such as scFvMEL/rGel and PCI act in concert to provide potent in vivo efficacy without sacrificing selectivity or enhancing toxicity. The present DDS warrants further evaluation of its clinical potential.			Selbo, PK (corresponding author), Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Oslo, Norway.	selbo@rr-research.no	Selbo, Pål Kristian/B-4638-2009	Selbo, Pål Kristian/0000-0002-5310-057X; Berg, Kristian/0000-0002-7816-7543				Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Bababeygy SR, 2008, STEM CELLS DEV, V17, P11, DOI 10.1089/scd.2007.0117; Baumstark-Khan C, 1999, J FLUORESC, V9, P37, DOI 10.1023/A:1020583623407; Belachew S, 2003, J CELL BIOL, V161, P169, DOI 10.1083/jcb.200210110; Berg K, 1999, CANCER RES, V59, P1180; BERG K, 1994, INT J CANCER, V59, P814, DOI 10.1002/ijc.2910590618; Berg K, 2005, CLIN CANCER RES, V11, P8476, DOI 10.1158/1078-0432.CCR-05-1245; Berg K., 2006, MED LASER APPL, V21, P239; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Chekenya M, 2008, ONCOGENE, V27, P5182, DOI 10.1038/onc.2008.157; Chetty NC, 2008, CLIN EXP DERMATOL, V33, P204, DOI 10.1111/j.1365-2230.2007.02600.x; Dell'Erba L, 2001, ANTICANCER RES, V21, P925; Dietrich J, 2008, NAT CLIN PRACT ONCOL, V5, P393, DOI 10.1038/ncponc1132; Dietze A, 2005, BRIT J CANCER, V92, P2004, DOI 10.1038/sj.bjc.6602600; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; Girotti AW, 2001, J PHOTOCH PHOTOBIO B, V63, P103, DOI 10.1016/S1011-1344(01)00207-X; Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200; Grichnik JM, 2006, J INVEST DERMATOL, V126, P142, DOI 10.1038/sj.jid.5700017; Hassan R, 2007, CLIN CANCER RES, V13, P5144, DOI 10.1158/1078-0432.CCR-07-0869; Hogset A, 2004, ADV DRUG DELIVER REV, V56, P95, DOI 10.1016/j.addr.2003.08.016; Hopper C, 2000, Lancet Oncol, V1, P212; Jones AT, 2003, ADV DRUG DELIVER REV, V55, P1353, DOI 10.1016/j.addr.2003.07.002; Liu YY, 2006, NEOPLASIA, V8, P384, DOI 10.1593/neo.06121; Liu YY, 2006, NEOPLASIA, V8, P125, DOI 10.1593/neo.05556; Lu YJ, 2006, AAPS J, V8, pE466, DOI 10.1208/aapsj080355; Luo W, 2006, J IMMUNOL, V176, P6046, DOI 10.4049/jimmunol.176.10.6046; Ndoye A, 2006, MOL THER, V13, P1156, DOI 10.1016/j.ymthe.2006.02.003; NETTI PA, 1995, CANCER RES, V55, P5451; Nishiyama N, 2005, NAT MATER, V4, P934, DOI 10.1038/nmat1524; Oliveira S, 2008, CURR PHARM DESIGN, V14, P3686, DOI 10.2174/138161208786898789; Prasmickaite L, 2002, BRIT J CANCER, V86, P652, DOI 10.1038/sj.bjc.6600138; Riesenberg R, 1996, EUR J CANCER, V32A, P328, DOI 10.1016/0959-8049(95)00548-X; ROSENBLUM MG, 1987, CANCER CHEMOTH PHARM, V20, P41; Rosenblum MG, 2003, CANCER RES, V63, P3995; Rye PD, 1996, INT J CANCER, V68, P682, DOI 10.1002/(SICI)1097-0215(19961127)68:5<682::AID-IJC20>3.0.CO;2-2; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Selbo PK, 2006, J PHARMACOL EXP THER, V319, P604, DOI 10.1124/jpet.106.109165; Selbo PK, 2001, INT J CANCER, V92, P761, DOI 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4; Smith FO, 1996, BLOOD, V87, P1123, DOI 10.1182/blood.V87.3.1123.bloodjournal8731123; Steff AM, 2001, CYTOMETRY, V45, P237, DOI 10.1002/1097-0320(20011201)45:4<237::AID-CYTO10024>3.0.CO;2-J; Thong PSP, 2007, LANCET ONCOL, V8, P950, DOI 10.1016/S1470-2045(07)70318-2; Ulukaya E, 2004, CHEMOTHERAPY, V50, P43, DOI 10.1159/000077285; Veenendaal LM, 2002, P NATL ACAD SCI USA, V99, P7866, DOI [10.1073/pnas.122157899, 10.1073/pnas.162346299]; Weyergang A, 2006, J CONTROL RELEASE, V111, P165, DOI 10.1016/j.jconrel.2005.12.002; Weyergang A, 2009, MOL PHARMACEUT, V6, P255, DOI 10.1021/mp800156e; Weyeyang A, 2007, BIOCHEM PHARMACOL, V74, P226, DOI 10.1016/j.bcp.2007.04.018; Wiranowska M, 2006, BRAIN CELL BIOL, V35, P159, DOI 10.1007/s11068-007-9009-0; Yip WL, 2007, MOL PHARM, V4, P241, DOI 10.1021/mp060105u	50	44	47	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2009	4	8							e6691	10.1371/journal.pone.0006691	http://dx.doi.org/10.1371/journal.pone.0006691			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	487IY	19690617	gold, Green Submitted, Green Published			2023-01-03	WOS:000269267300009
J	Kerr, DJ; Midgley, R				Kerr, David J.; Midgley, Rachel			Can We Treat Cancer for a Dollar a Day? Guidelines for Low-Income Countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Kerr, David J.] Sidra Med & Res Ctr, Doha, Qatar; [Midgley, Rachel] Univ Oxford, Dept Clin Pharmacol, Oxford, England	Sidra Medical & Research Center; University of Oxford	Kerr, DJ (corresponding author), Sidra Med & Res Ctr, Doha, Qatar.			Kerr, Rachel/0000-0002-7240-3269				CanTreat Int, 2010, ANN ONCOL, V21, P680, DOI 10.1093/annonc/mdq055; Groot MT, 2006, BREAST J, V12, pS81, DOI 10.1111/j.1075-122X.2006.00206.x; Kerr F, 2006, ANN ONCOL, V17, P1730, DOI 10.1093/annonc/mdl442; Lingwood RJ, 2008, NAT REV CANCER, V8, P398, DOI 10.1038/nrc2372; Tan-Torres ET, 2003, MAKING CHOICES HLTH	5	43	44	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 26	2010	363	9					801	803		10.1056/NEJMp1002812	http://dx.doi.org/10.1056/NEJMp1002812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	642HG	20818843				2023-01-03	WOS:000281196600001
J	Witlox, J; Eurelings, LSM; de Jonghe, JFM; Kalisvaart, KJ; Eikelenboom, P; van Gool, WA				Witlox, Joost; Eurelings, Lisa S. M.; de Jonghe, Jos F. M.; Kalisvaart, Kees J.; Eikelenboom, Piet; van Gool, Willem A.			Delirium in Elderly Patients and the Risk of Postdischarge Mortality, Institutionalization, and Dementia A Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIP FRACTURE PATIENTS; POSTOPERATIVE DELIRIUM; OLDER PATIENTS; PROGNOSTIC-SIGNIFICANCE; PUBLICATION BIAS; OUTCOMES; REHABILITATION; PREDICTORS; PEOPLE; DEATH	Context Delirium is a common and serious complication in elderly patients. Evidence suggests that delirium is associated with long-term poor outcome but delirium often occurs in individuals with more severe underlying disease. Objective To assess the association between delirium in elderly patients and long-term poor outcome, defined as mortality, institutionalization, or dementia, while controlling for important confounders. Data Sources Asystematic search of studies published between January 1981 and April 2010 was conducted using the databases of MEDLINE, EMBASE, PsycINFO, and CINAHL. Study Selection Observational studies of elderly patients with delirium as a study variable and data on mortality, institutionalization, or dementia after a minimum follow-up of 3 months, and published in the English or Dutch language. Titles, abstracts, and articles were reviewed independently by 2 of the authors. Of 2939 references in the original search, 51 relevant articles were identified. Data Extraction Information on study design, characteristics of the study population, and outcome were extracted. Quality of studies was assessed based on elements of the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for cohort studies. Data Synthesis The primary analyses included only high-quality studies with statistical control for age, sex, comorbid illness or illness severity, and baseline dementia. Pooled-effect estimates were calculated with random-effects models. The primary analysis with adjusted hazard ratios (HRs) showed that delirium is associated with an increased risk of death compared with controls after an average follow-up of 22.7 months (7 studies; 271/714 patients [38.0%] with delirium, 616/2243 controls [27.5%]; HR, 1.95 [95% confidence interval {CI}, 1.51-2.52]; I-2, 44.0%). Moreover, patients who had experienced delirium were also at increased risk of institutionalization (7 studies; average follow-up, 14.6 months; 176/527 patients [33.4%] with delirium and 219/2052 controls [10.7%]; odds ratio [OR], 2.41 [95% CI, 1.77-3.29]; I-2, 0%) and dementia (2 studies; average follow-up, 4.1 years; 35/56 patients [62.5%] with delirium and 15/185 controls [8.1%]; OR, 12.52 [95% CI, 1.86-84.21]; I-2, 52.4%). The sensitivity, trim-and-fill, and secondary analyses with unadjusted high-quality risk estimates stratified according to the study characteristics confirmed the robustness of these results. Conclusion This meta-analysis provides evidence that delirium in elderly patients is associated with poor outcome independent of important confounders, such as age, sex, comorbid illness or illness severity, and baseline dementia. JAMA. 2010; 304(4): 443-451	[Eurelings, Lisa S. M.; Eikelenboom, Piet; van Gool, Willem A.] Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands; [Witlox, Joost; de Jonghe, Jos F. M.] Med Ctr Alkmaar, Dept Geriatr Med, Alkmaar, Netherlands; [Kalisvaart, Kees J.] Kennemer Gasthuis, Dept Geriatr Med, Haarlem, Netherlands; [Eikelenboom, Piet] GGZinGeest, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Medical Center Of Alkmaar; Spaarne Hospital	van Gool, WA (corresponding author), Acad Med Ctr, Dept Neurol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	w.a.vangool@amc.uva.nl	Van Gool, Willem A/G-5985-2012; Eikelenboom, Piet/AAF-6359-2020	Van Gool, Willem/0000-0003-3174-8233; Kalisvaart, Kees/0000-0002-7027-490X				Adamis D, 2007, AGE AGEING, V36, P644, DOI 10.1093/ageing/afm094; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, DOI DOI 10.1176/APPI.BOOKS.9780890425596; Bellelli G, 2008, AGE AGEING, V37, P353, DOI 10.1093/ageing/afn056; Bellelli G, 2007, J GERONTOL A-BIOL, V62, P1306, DOI 10.1093/gerona/62.11.1306; Bellelli G, 2008, J AM MED DIR ASSOC, V9, P55, DOI 10.1016/j.jamda.2007.09.009; BERGGREN D, 1987, ANESTH ANALG, V66, P497; Bickel H, 2008, DEMENT GERIATR COGN, V26, P26, DOI 10.1159/000140804; Bland JM, 2000, BRIT MED J, V320, P1468, DOI 10.1136/bmj.320.7247.1468; Borenstein M., 2009, INTRO META ANAL, P59, DOI [10.1002/9780470743386.ch13, DOI 10.1002/9780470743386.CH13]; Bouffard R, 2003, CAN J PSYCHIAT, V48, P546, DOI 10.1177/070674370304800806; Brannstrom B, 1989, Scand J Caring Sci, V3, P27; Cole MG, 2009, AGE AGEING, V38, P19, DOI 10.1093/ageing/afn253; Curyto KJ, 2001, AM J GERIAT PSYCHIAT, V9, P141, DOI 10.1176/appi.ajgp.9.2.141; Dasgupta M, 2006, J AM GERIATR SOC, V54, P1578, DOI 10.1111/j.1532-5415.2006.00893.x; de Rooij S E, 2007, Ned Tijdschr Geneeskd, V151, P1987; Dolan MM, 2000, J GERONTOL A-BIOL, V55, pM527, DOI 10.1093/gerona/55.9.M527; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Edelstein DM, 2004, CLIN ORTHOP RELAT R, P195, DOI 10.1097/01.blo.0000128649.59959.0c; Edlund A, 2001, J AM GERIATR SOC, V49, P1335, DOI 10.1046/j.1532-5415.2001.49261.x; Edlund A, 1999, DEMENT GERIATR COGN, V10, P325, DOI 10.1159/000017163; Edlund A, 2006, J GERIATR PSYCH NEUR, V19, P83, DOI 10.1177/0891988706286509; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; FRANCIS J, 1992, J AM GERIATR SOC, V40, P601, DOI 10.1111/j.1532-5415.1992.tb02111.x; Furlaneto ME, 2007, CLINICS, V62, P545, DOI 10.1590/S1807-59322007000500003; George J, 1997, AGE AGEING, V26, P423, DOI 10.1093/ageing/26.6.423; Giusti A, 2006, ARCH PHYS MED REHAB, V87, P826, DOI 10.1016/j.apmr.2006.02.018; Gonzalez M, 2005, EUR J PSYCHIAT, V19, P165, DOI 10.4321/s0213-61632005000300005; Gonzalez M, 2009, PSYCHOSOMATICS, V50, P234, DOI 10.1176/appi.psy.50.3.234; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Harjola VP, 2010, EUR J HEART FAIL, V12, P239, DOI 10.1093/eurjhf/hfq002; Heijmeriks JA, 2000, CLIN CARDIOL, V23, P540, DOI 10.1002/clc.4960230714; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Holroyd-Leduc JM, 2010, CAN MED ASSOC J, V182, P465, DOI 10.1503/cmaj.080519; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Inouye SK, 1998, J GEN INTERN MED, V13, P234, DOI 10.1046/j.1525-1497.1998.00073.x; Isaia G, 2009, AGE, V31, P109, DOI 10.1007/s11357-009-9086-3; Iwata M, 2006, GERONTOLOGY, V52, P92, DOI 10.1159/000090954; Juliebo V, 2009, J AM GERIATR SOC, V57, P1354, DOI 10.1111/j.1532-5415.2009.02377.x; Kakuma R, 2003, J AM GERIATR SOC, V51, P443, DOI 10.1046/j.1532-5415.2003.51151.x; Kat MG, 2008, DEMENT GERIATR COGN, V26, P1, DOI 10.1159/000140611; Koster S, 2009, ANN THORAC SURG, V87, P1469, DOI 10.1016/j.athoracsur.2009.02.080; Leslie DL, 2005, ARCH INTERN MED, V165, P1657, DOI 10.1001/archinte.165.14.1657; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; LEWIS LM, 1995, AM J EMERG MED, V13, P142, DOI 10.1016/0735-6757(95)90080-2; Loponen P, 2008, SCAND CARDIOVASC J, V42, P337, DOI 10.1080/14017430801939217; Lundstrom M, 2003, J AM GERIATR SOC, V51, P1002, DOI 10.1046/j.1365-2389.2003.51315.x; MacLullich AMJ, 2008, J PSYCHOSOM RES, V65, P229, DOI 10.1016/j.jpsychores.2008.05.019; Marcantonio ER, 2005, J AM GERIATR SOC, V53, P963, DOI 10.1111/j.1532-5415.2005.53305.x; Marcantonio ER, 2000, J AM GERIATR SOC, V48, P618, DOI 10.1111/j.1532-5415.2000.tb04718.x; McAvay GJ, 2006, J AM GERIATR SOC, V54, P1245, DOI 10.1111/j.1532-5415.2006.00815.x; McCusker J, 2002, ARCH INTERN MED, V162, P457, DOI 10.1001/archinte.162.4.457; Milisen K, 2001, J AM GERIATR SOC, V49, P523, DOI 10.1046/j.1532-5415.2001.49109.x; Minden SL, 2005, GEN HOSP PSYCHIAT, V27, P209, DOI 10.1016/j.genhosppsych.2004.12.004; Mittal VA, 2011, PSYCHIAT RES, V189, P158, DOI 10.1016/j.psychres.2011.06.006; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Morandi A, 2009, INT REV PSYCHIATR, V21, P43, DOI 10.1080/09540260802675296; Nightingale S, 2001, LANCET, V357, P1264, DOI 10.1016/S0140-6736(00)04421-4; OKeeffe S, 1997, J AM GERIATR SOC, V45, P174, DOI 10.1111/j.1532-5415.1997.tb04503.x; Olofsson B, 2005, SCAND J CARING SCI, V19, P119, DOI 10.1111/j.1471-6712.2005.00324.x; Pitkala KH, 2006, J GERONTOL A-BIOL, V61, P176, DOI 10.1093/gerona/61.2.176; Pitkala KH, 2005, DEMENT GERIATR COGN, V19, P158, DOI 10.1159/000082888; POMPEI P, 1994, J AM GERIATR SOC, V42, P809, DOI 10.1111/j.1532-5415.1994.tb06551.x; POOR G, 1995, CLIN ORTHOP RELAT R, P260; Rockwood K, 1999, AGE AGEING, V28, P551, DOI 10.1093/ageing/28.6.551; Rudolph JL, 2008, ANAESTHESIA, V63, P941, DOI 10.1111/j.1365-2044.2008.05523.x; Satish S, 1996, J AM GERIATR SOC, V44, P914, DOI 10.1111/j.1532-5415.1996.tb01860.x; Siddiqi N, 2006, AGE AGEING, V35, P350, DOI 10.1093/ageing/afl005; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Sutton AJ, 2000, BMJ-BRIT MED J, V320, P1574, DOI 10.1136/bmj.320.7249.1574; van Gool WA, 2010, LANCET, V375, P773, DOI 10.1016/S0140-6736(09)61158-2; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wacker P, 2006, DEMENT GERIATR COGN, V21, P221, DOI 10.1159/000091022; Young J, 2007, BMJ-BRIT MED J, V334, P842, DOI 10.1136/bmj.39169.706574.AD; Zakriya K, 2004, ANESTH ANALG, V98, P1798, DOI 10.1213/01.ANE.0000117145.50236.90	76	1104	1145	1	126	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	2010	304	4					443	451		10.1001/jama.2010.1013	http://dx.doi.org/10.1001/jama.2010.1013			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	631MA	20664045				2023-01-03	WOS:000280350100028
J	Mooney, P				Mooney, Paul			China cracks down on counterfeiters	NATURE MEDICINE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					360	360		10.1038/nm0410-360a	http://dx.doi.org/10.1038/nm0410-360a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376025	Bronze			2023-01-03	WOS:000276446800016
J	Hsieh, YH; Chen, KF; Gaydos, CA; Rothman, RE; Kelen, GD				Hsieh, Yu-Hsiang; Chen, Kuan-Fu; Gaydos, Charlotte A.; Rothman, Richard E.; Kelen, Gabor D.			Antiviral Prescriptions to US Ambulatory Care Visits with a Diagnosis of Influenza before and after High Level of Adamantane Resistance 2005-06 Season	PLOS ONE			English	Article							FOR-DISEASE-CONTROL; ORDER-ENTRY; INFECTIONS; RECOMMENDATIONS; VIRUS; RATES	Background: Rapid emergence of influenza A viruses resistance to anti-influenza drugs has been observed in the past five years. Our objective was to compare antiviral prescription patterns of ambulatory care providers to patients with a diagnosis of influenza before and after the 2005-2006 influenza season, which was temporally concordant with the emergence of adamantane resistance. We also determined providers' adherence to Centers for Disease Control and Prevention (CDC) 2006 interim treatment guidelines for influenza after the dissemination of guidelines. Methodology/Principal Findings: We conducted a multi-year cross-sectional analysis using 2002-2006 data from the national representative ambulatory care surveys, National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey. Our main outcome measure was prescription of any anti-influenza pharmaceutical medication, including amantadine, rimantadine, oseltamivir, and zanamivir. Analyses were performed using procedures taking into account the multi-stage survey design and weighted sampling probabilities of the data source. Overall, there were 941 visits to U. S. ambulatory care providers for which the diagnosis of influenza was made, representing 12,140,727 visits nationally. Antiviral drugs were prescribed in 21.7% of visits. Even though prescription rates were not significantly different by influenza season (2001-02: 26.4%; 2002-03: 11.2%; 2003-04: 16.5%; 2004-05: 18.0%; 2005-06: 35.8%; 2006-07: 46.5%, p = 0.061), significantly higher prescription rates were observed in the high adamantane resistance period (18.7% versus 37.0%, p = 0.023), and after the announcement of the 2006 guidelines (18.5% versus 38.8%, p = 0.032). Use of adamantanes decreased over time, in that they were commonly used during influenza seasons 2001-03 (60.1%), but used much less frequently during seasons 2003-05 (31.9%), and used rarely after high adamantane resistance emerged (2.2%) (p<0.001). Adherence to 2006 guidelines was 97.7%. After March 2006, no prescriptions for adamantanes were given to patients with a diagnosis of influenza. Conclusions/Significance: In this nationally representative study of U. S. ambulatory care visits, we found a complete absence of the use of adamantanes in all ambulatory care settings after March 2006, closely corresponding to release of the 2006 CDC interim guidelines. Adherence to such practice is an essential element for control and prevention of influenza, especially during the era of emergence of resistance to anti-viral drugs.	[Hsieh, Yu-Hsiang; Chen, Kuan-Fu; Rothman, Richard E.; Kelen, Gabor D.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21218 USA; [Gaydos, Charlotte A.; Rothman, Richard E.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Chen, Kuan-Fu] Chang Gung Mem Hosp, Dept Emergency Med, Taipei 10591, Taiwan	Johns Hopkins University; Johns Hopkins University; Chang Gung Memorial Hospital	Hsieh, YH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD 21218 USA.	yhsieh1@jhmi.edu	Gaydos, Charlotte A./E-9937-2010	Rothman, Richard/0000-0002-1017-9505; Kelen, Gabor/0000-0002-3236-8286; Chen, Kuan-Fu/0000-0001-7287-9497	United States Department of Homeland Security [N00014-D6-1-0991]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD042854] Funding Source: NIH RePORTER	United States Department of Homeland Security(United States Department of Homeland Security (DHS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	Dr. Hsieh, Dr. Gaydos, Dr. Rothman and Dr. Kelen are supported in part by a grant from the United States Department of Homeland Security (Grant Number N00014-D6-1-0991). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asaro PV, 2006, ACAD EMERG MED, V13, P452, DOI 10.1197/j.aem.2005.09.015; Bright RA, 2006, JAMA-J AM MED ASSOC, V295, P891, DOI 10.1001/jama.295.8.joc60020; Bright RA, 2005, LANCET, V366, P1175, DOI 10.1016/S0140-6736(05)67338-2; *CDCP, 2008, INT REC US INFL ANT; Centers for Disease Control and Prevention (CDC), 2006, MMWR Morb Mortal Wkly Rep, V55, P44; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P433; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; Dharan NJ, 2009, JAMA-J AM MED ASSOC, V301, P1034, DOI 10.1001/jama.2009.294; Grijalva CG, 2009, JAMA-J AM MED ASSOC, V302, P758, DOI 10.1001/jama.2009.1163; *HLTH AL NETW, 2006, CDC REC US AM RIM TR; Hsieh YH, 2008, AIDS, V22, P2127, DOI 10.1097/QAD.0b013e328310e066; Kane BG, 2004, ACAD EMERG MED, V11, P371, DOI 10.1197/j.aem.2003.11.016; Linder JA, 2005, PHARMACOEPIDEM DR S, V14, P531, DOI 10.1002/pds.1067; Magid DJ, 2003, SEX TRANSM DIS, V30, P30, DOI 10.1097/00007435-200301000-00007; MCCAIG L, 2006, ANAL DATA NAMCS NHAM; *NAT CTR HLTH STAT, 2007, NAT AMB MED CAR SURV; Ozdas A, 2006, J AM MED INFORM ASSN, V13, P188, DOI 10.1197/jamia.M1656; Tracy CR, 2009, WORLD J UROL, V27, P259, DOI 10.1007/s00345-008-0338-0; Vanderweil SG, 2007, ACAD EMERG MED, V14, P366, DOI 10.1197/j.aem.2006.10.096; WHO (World Health Organization), 2009, ANT US RISK DRUG RES	20	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2010	5	1							e8945	10.1371/journal.pone.0008945	http://dx.doi.org/10.1371/journal.pone.0008945			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	550OR	20126611	Green Published, gold, Green Submitted			2023-01-03	WOS:000274138000020
J	Sheridan, RL; Goldstein, MA; Stoddard, FJ; Walker, TG				Sheridan, Robert L.; Goldstein, Mark A.; Stoddard, Frederick J., Jr.; Walker, T. Gregory			A Boy with Hypothermia and Frostbite Stage 3 hypothermia. Stage 3 frostbite with diffuse distal small-vessel thrombosis and impending limb loss	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALCOHOL-USE; ACCIDENTAL HYPOTHERMIA; ADOLESCENTS; INJURY; BEHAVIORS; AGE; INVOLVEMENT; DISORDERS; DRINKING; ONSET		[Sheridan, Robert L.; Stoddard, Frederick J., Jr.] Massachusetts Gen Hosp, Dept Surg, Burns Serv, Boston, MA 02114 USA; [Goldstein, Mark A.] Massachusetts Gen Hosp, Div Adolescent & Young Adult Med, Dept Pediat, Boston, MA 02114 USA; [Stoddard, Frederick J., Jr.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Walker, T. Gregory] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Sheridan, Robert L.] Harvard Univ, Sch Med, Dept Surg, Cambridge, MA 02138 USA; [Goldstein, Mark A.] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; [Stoddard, Frederick J., Jr.] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA; [Walker, T. Gregory] Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University	Sheridan, RL (corresponding author), Massachusetts Gen Hosp, Dept Surg, Burns Serv, Boston, MA 02114 USA.							*AM MED ASS, 1997, GUID AD PREV SERV GA; [Anonymous], NIH PUBLICATION; Ary DV, 1999, BEHAV RES THER, V37, P217, DOI 10.1016/S0005-7967(98)00133-8; Biederman J, 2000, PEDIATRICS, V106, P792, DOI 10.1542/peds.106.4.792; Braaten JV, 1997, THROMB HAEMOSTASIS, V78, P1063; Bruen KJ, 2007, ARCH SURG-CHICAGO, V142, P546, DOI 10.1001/archsurg.142.6.546; Bruen KJ, 2009, J HAND SURG-AM, V34A, P553, DOI 10.1016/j.jhsa.2009.01.012; Cohen J. A., 2006, TREATING TRAUMA TRAU; Costello EJ, 2007, DRUG ALCOHOL DEPEN, V88, pS50, DOI 10.1016/j.drugalcdep.2006.12.009; de Mesones AR, 2002, HIGH ALT MED BIOL, V3, P395, DOI 10.1089/15270290260512873; de Souza D, 2007, J ELECTROCARDIOL, V40, P47, DOI 10.1016/j.jelectrocard.2006.08.094; DeWit DJ, 2000, AM J PSYCHIAT, V157, P745, DOI 10.1176/appi.ajp.157.5.745; DiClemente RJ, 2001, PEDIATRICS, V107, P1363, DOI 10.1542/peds.107.6.1363; Faden Vivian B, 2004, Alcohol Res Health, V28, P107; Grueskin J, 2007, WILD ENVIRON MED, V18, P133, DOI 10.1580/06-WEME-BR-034R1.1; Hanewinkel R, 2009, PEDIATRICS, V123, P989, DOI 10.1542/peds.2008-1465; Hingson R, 2001, PEDIATRICS, V108, P872, DOI 10.1542/peds.108.4.872; Hingson RW, 2000, JAMA-J AM MED ASSOC, V284, P1527, DOI 10.1001/jama.284.12.1527; Johnston L. D., 2008, NIH PUBLICATION, VI; Jurkovich GJ, 2007, SURG CLIN N AM, V87, P247, DOI 10.1016/j.suc.2006.10.003; Krantz MJ, 2005, NEW ENGL J MED, V352, P184, DOI 10.1056/NEJMicm030851; Nash SG, 2005, J ADOLESCENT HEALTH, V37, P19, DOI 10.1016/j.jadohealth.2004.06.004; O'keeffe K M, 1977, JACEP, V6, P491, DOI 10.1016/S0361-1124(77)80387-0; OSBORN JJ, 1953, AM J PHYSIOL, V175, P389, DOI 10.1152/ajplegacy.1953.175.3.389; Petrone P, 2003, EMERG MED CLIN N AM, V21, P1165, DOI 10.1016/S0733-8627(03)00074-9; RANKIN AC, 1984, BRIT MED J, V289, P874, DOI 10.1136/bmj.289.6449.874; Sieving RE, 2000, J ADOLESCENT HEALTH, V26, P27, DOI 10.1016/S1054-139X(99)00056-7; Silfvast T, 2003, RESUSCITATION, V59, P285, DOI 10.1016/S0300-9572(03)00237-5; Simantov E, 2000, ARCH PEDIAT ADOL MED, V154, P1025, DOI 10.1001/archpedi.154.10.1025; Stoddard FJ, 2002, J BURN CARE REHABIL, V23, P135, DOI 10.1097/00004630-200203000-00012; Stoddard FJ, 2001, J AM ACAD CHILD PSY, V40, P1128, DOI 10.1097/00004583-200110000-00007; TOWNE WD, 1972, NEW ENGL J MED, V287, P1135, DOI 10.1056/NEJM197211302872210; Twomey JA, 2005, J TRAUMA, V59, P1350, DOI 10.1097/01.ta.0000195517.50778.2e; WONG KC, 1983, WESTERN J MED, V138, P227	34	34	34	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	2009	361	27					2654	2662		10.1056/NEJMcpc0910088	http://dx.doi.org/10.1056/NEJMcpc0910088			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	538JV	20042758				2023-01-03	WOS:000273181300015
J	Graves, N; Courtney, M; Edwards, H; Chang, A; Parker, A; Finlayson, K				Graves, Nicholas; Courtney, Mary; Edwards, Helen; Chang, Anne; Parker, Anthony; Finlayson, Kathleen			Cost-Effectiveness of an Intervention to Reduce Emergency Re-Admissions to Hospital among Older Patients	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; CHRONIC HEART-FAILURE; EFFECTIVENESS ACCEPTABILITY CURVES; HEALTH-CARE; ECONOMIC-EVALUATION; TECHNOLOGY-ASSESSMENT; MANAGEMENT PROGRAM; EFFICIENCY; EQUITY; VALUES	Background: The objective is to estimate the cost-effectiveness of an intervention that reduces hospital re-admission among older people at high risk. A cost-effectiveness model to estimate the costs and health benefits of the intervention was implemented. Methodology/Principal Findings: The model used data from a randomised controlled trial conducted in an Australian tertiary metropolitan hospital. Participants were acute medical admissions aged >65 years with at least one risk factor for re-admission: multiple comorbidities,impaired functionality, aged >75 years, recent multiple admissions, poor social support, history of depression. The intervention was a comprehensive nursing and physiotherapy assessment and an individually tailored program of exercise strategies and nurse home visits with telephone follow-up; commencing in hospital and continuing following discharge for 24 weeks. The change to cost outcomes, including the costs of implementing the intervention and all subsequent use of health care services, and, the change to health benefits, represented by quality adjusted life years, were estimated for the intervention as compared to existing practice. The mean change to total costs and quality adjusted life years for an average individual over 24 weeks participating in the intervention were: cost savings of $333 (95% Bayesian credible interval $-1,932: 1,282) and 0.118 extra quality adjusted life years ( 95% Bayesian credible interval 0.1:0.136). The mean net-monetary-benefit per individual for the intervention group compared to the usual care condition was $7,907 (95% Bayesian credible interval $5,959:$9,995) for the 24 week period. Conclusions/Significance: The estimation model that describes this intervention predicts cost savings and improved health outcomes. A decision to remain with existing practices causes unnecessary costs and reduced health. Decision makers should consider adopting this program for elderly hospitalised patients.			Graves, N (corresponding author), Queensland Univ Technol, Inst Hlth & Biomed Innovat, Sch Publ Hlth, Brisbane, Qld 4001, Australia.	n.graves@qut.edu.au	Chang, Anne M/A-3425-2009; Edwards, Helen E/I-9554-2012; Finlayson, Kathleen/D-1108-2012; Edwards, Helen/GPX-3511-2022; Graves, Nicholas/A-3052-2011	Chang, Anne M/0000-0003-3409-874X; Finlayson, Kathleen/0000-0002-5743-2731; Edwards, Helen/0000-0002-4451-0577; Graves, Nicholas/0000-0002-5559-3267				*AIHW, 2004, RES AG CAR AUSTR 200; Australian Institute of Health and Welfare, 2006, AUSTR HOSP STAT 2004; Australian Institute of Health & Welfare, 2007, AUSTR HOSP STAT 2005; BIRCH S, 1992, J HEALTH ECON, V11, P279, DOI 10.1016/0167-6296(92)90004-K; Brazier J, 1999, HLTH TECHNOL ASSESS, V3; Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003; Briggs AH, 2001, HEALTH ECON, V10, P179, DOI 10.1002/hec.584; Capomolla S, 2002, J AM COLL CARDIOL, V40, P1259, DOI 10.1016/S0735-1097(02)02140-X; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Coast J, 2004, BRIT MED J, V329, P1233, DOI 10.1136/bmj.329.7476.1233; Cookson R, 2003, HEALTH ECON, V12, P891, DOI 10.1002/hec.847; Courtney M, 2009, J AM GERIATR SOC, V57, P395, DOI 10.1111/j.1532-5415.2009.02138.x; Del Sindaco D, 2007, J CARDIOVASC MED, V8, P324, DOI 10.2459/JCM.0b013e32801164cb; *DEP HLTH AG, 2007, COMPL MED BEN SCHED; Donaldson C, 2002, BRIT MED J, V325, P891, DOI 10.1136/bmj.325.7369.891; Drummond MF., 2005, METHODS EC EVALUATIO, P55; Elixhauser A, 2000, AHRQ PUBLICATION; Epstein DM, 2007, MED DECIS MAKING, V27, P128, DOI 10.1177/0272989X06297396; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Gray AM, 2006, MED DECIS MAKING, V26, P18, DOI 10.1177/0272989X05284108; Ho YL, 2007, J FORMOS MED ASSOC, V106, P313, DOI 10.1016/S0929-6646(09)60258-8; Hoch JS, 2002, HEALTH ECON, V11, P415, DOI 10.1002/hec.678; Jackson TJ, 2007, MED J AUSTRALIA, V187, P262, DOI 10.5694/j.1326-5377.2007.tb01238.x; Karmel R., 2007, B AUSTR I HLTH WELFA, V53; Krupnick A.J., 2004, VALUING HLTH OUTCOME; Kwok T, 2008, J CLIN NURS, V17, P109, DOI 10.1111/j.1365-2702.2007.01978.x; Latour CHM, 2007, J PSYCHOSOM RES, V62, P363, DOI 10.1016/j.jpsychores.2006.10.016; Layard R., 1994, COST BENEFIT ANAL; Mistiaen P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004510.pub3; *NAT HLTH SERV, 2006, HES ONL HOSP EP STAT; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Parker S. G., 2005, DO CURRENT DISCHARGE; Phillips CO, 2004, JAMA-J AM MED ASSOC, V291, P1358, DOI 10.1001/jama.291.11.1358; Rawlins MD, 2004, BRIT MED J, V329, P224, DOI 10.1136/bmj.329.7459.224; Ryan M, 2001, Health Technol Assess, V5, P1; Sampietro-Colom L, 2004, INT J TECHNOL ASSESS, V20, P145, DOI 10.1017/S0266462304000923; Shepperd S, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000313.pub4; SHIROIWA T, 2009, HLTH EC; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; Stinnett AA, 1996, J HEALTH ECON, V15, P641, DOI 10.1016/S0167-6296(96)00493-6; Sugden R., 1978, PRINCIPLES PRACTICAL; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; Trueman P, 2001, PHARMACOECONOMICS, V19, P609, DOI 10.2165/00019053-200119060-00001; WAGSTAFF A, 1991, J HEALTH ECON, V10, P21, DOI 10.1016/0167-6296(91)90015-F	45	21	21	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 14	2009	4	10							e7455	10.1371/journal.pone.0007455	http://dx.doi.org/10.1371/journal.pone.0007455			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	506WT	19829702	Green Published, gold, Green Submitted			2023-01-03	WOS:000270808700015
J	Ding, XQ; Quiambao, AB; Fitzgerald, JB; Cooper, MJ; Conley, SM; Naash, MI				Ding, Xi-Qin; Quiambao, Alexander B.; Fitzgerald, J. Browning; Cooper, Mark J.; Conley, Shannon M.; Naash, Muna I.			Ocular Delivery of Compacted DNA-Nanoparticles Does Not Elicit Toxicity in the Mouse Retina	PLOS ONE			English	Article								Subretinal delivery of polyethylene glycol-substituted lysine peptide (CK30PEG)-compacted DNA nanoparticles results in efficient gene expression in retinal cells. This work evaluates the ocular safety of compacted DNA nanoparticles. CK30PEG-compacted nanoparticles containing an EGFP expression plasmid were subretinally injected in adult mice (1 mu l at 0.3, 1.0 and 3.0 mu g/mu l). Retinas were examined for signs of inflammation at 1, 2, 4 and 7 days post-injection. Neither infiltration of polymorphonuclear neutrophils or lymphocytes was detected in retinas. In addition, elevation of macrophage marker F4/80 or myeloid marker myeloperoxidase was not detected in the injected eyes. The chemokine KC mRNA increased 3-4 fold in eyes injected with either nanoparticles or saline at 1 day post-injection, but returned to control levels at 2 days post-injection. No elevation of KC protein was observed in these mice. The monocyte chemotactic protein-1, increased 3-4 fold at 1 day post-injection for both nanoparticle and saline injected eyes, but also returned to control levels at 2 days. No elevations of tumor necrosis factor alpha mRNA or protein were detected. These investigations show no signs of local inflammatory responses associated with subretinal injection of compacted DNA nanoparticles, indicating that the retina may be a suitable target for clinical nanoparticle-based interventions.			Ding, XQ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK USA.	xi-qin-ding@ouhsc.edu			NEI NIH HHS [R01 EY018656-01, EY018656, R21 EY017031, R01 EY018656, EY-017031] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY018656, R21EY017031] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008; Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; Alexander JJ, 2007, NAT MED, V13, P685, DOI 10.1038/nm1596; Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268; Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649; Cai X, 2008, VISION RES, V48, P319, DOI 10.1016/j.visres.2007.07.012; Cai X, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005290; Chen X, 2008, MOL THER, V16, P333, DOI 10.1038/sj.mt.6300365; Chintakuntlawar AV, 2007, INVEST OPHTH VIS SCI, V48, P781, DOI 10.1167/iovs.06-1036; Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105; Dai H, 2006, INT J NANOMED, V1, P507, DOI 10.2147/nano.2006.1.4.507; Davies M, 2006, MOL VIS, V12, P467; Dezawa M, 2002, MICRON, V33, P1, DOI 10.1016/S0968-4328(01)00002-6; Elner VM, 1997, EXP EYE RES, V65, P781, DOI 10.1006/exer.1997.0380; Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038; Farjo R, 2006, J CELL BIOL, V173, P59, DOI 10.1083/jcb.200509036; Farjo R, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000038; Fink TL, 2006, GENE THER, V13, P1048, DOI 10.1038/sj.gt.3302761; Giese MJ, 1998, INVEST OPHTH VIS SCI, V39, P2785; Hantzschel N, 2007, LANGMUIR, V23, P10793, DOI 10.1021/la701691g; Halbert CL, 2006, HUM GENE THER, V17, P440, DOI 10.1089/hum.2006.17.440; Heinecke JW, 1997, BIOFACTORS, V6, P145, DOI 10.1002/biof.5520060208; Holtkamp GM, 1999, CLIN EXP IMMUNOL, V118, P35; Jan E, 2008, ACS NANO, V2, P928, DOI 10.1021/nn7004393; JO N, 2003, INVEST OPHTHALMOL VI, V44; Jun AS, 2003, EYE, V17, P906, DOI 10.1038/sj.eye.6700565; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; Konstan MW, 2004, HUM GENE THER, V15, P1255, DOI 10.1089/hum.2004.15.1255; Kowalczyk TH, 2003, MOL THER, V7, pS375; Lee J, 2009, SMALL, V5, P1213, DOI 10.1002/smll.200801788; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; Liaw J, 2001, GENE THER, V8, P999, DOI 10.1038/sj.gt.3301485; Limb GA, 1996, BRIT J OPHTHALMOL, V80, P168, DOI 10.1136/bjo.80.2.168; Limb GA, 2001, INVEST OPHTH VIS SCI, V42, P1586; Liu G, 2003, J BIOL CHEM, V278, P32578, DOI 10.1074/jbc.M305776200; Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315; Moyer AL, 2009, INVEST OPHTH VIS SCI, V50, P3783, DOI 10.1167/iovs.08-3051; Nakazawa T, 2006, MOL VIS, V12, P867; Nour M, 2003, INVEST OPHTH VIS SCI, V44, P4505, DOI 10.1167/iovs.03-0453; Oshitari T, 2006, DIABETES, V55, P86, DOI 10.2337/diabetes.55.1.86; Ott MG, 2006, NAT MED, V12, P401, DOI 10.1038/nm1393; Portillo JAC, 2008, J IMMUNOL, V181, P8719, DOI 10.4049/jimmunol.181.12.8719; Powers MR, 2005, CURR EYE RES, V30, P299, DOI 10.1080/02713680590923276; Ramadan RT, 2008, INVEST OPHTH VIS SCI, V49, P4482, DOI 10.1167/iovs.08-2085; Ramadan RT, 2006, CURR EYE RES, V31, P955, DOI 10.1080/02713680600976925; RAUSCH PG, 1978, NEW ENGL J MED, V298, P693, DOI 10.1056/NEJM197803302981301; Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103; Stieger K, 2008, MOL THER, V16, P916, DOI 10.1038/mt.2008.41; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410; Thomas CE, 2003, NAT REV GENET, V4, P346, DOI 10.1038/nrg1066; Uchida E, 2002, BIOL PHARM BULL, V25, P891, DOI 10.1248/bpb.25.891; Yoshida S, 2003, J LEUKOCYTE BIOL, V73, P137, DOI 10.1189/jlb.0302117; Yurek DM, 2009, MOL THER, V17, P641, DOI 10.1038/mt.2009.2; Ziady AG, 2003, MOL THER, V8, P936, DOI 10.1016/j.ymthe.2003.07.007; Ziady AG, 2003, MOL THER, V8, P948, DOI 10.1016/j.ymthe.2003.09.002	55	56	59	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2009	4	10							e7410	10.1371/journal.pone.0007410	http://dx.doi.org/10.1371/journal.pone.0007410			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	505VX	19823583	Green Published, gold, Green Submitted			2023-01-03	WOS:000270728500011
J	Ferreri, AJM; Reni, M; Foppoli, M; Martelli, M; Pangalis, GA; Frezzato, M; Cabras, MG; Fabbri, A; Corazzelli, G; Ilariucci, F; Rossi, G; Soffietti, R; Stelitano, C; Vallisa, D; Zaja, F; Zoppegno, L; Aondio, GM; Avvisati, G; Balzarotti, M; Brandes, AA; Fajardo, J; Gomez, H; Guarini, A; Pinotti, G; Rigacci, L; Uhlmann, C; Picozzi, P; Vezzulli, P; Ponzoni, M; Zucca, E; Caligaris-Cappio, F; Cavalli, F				Ferreri, Andres J. M.; Reni, Michele; Foppoli, Marco; Martelli, Maurizio; Pangalis, Gerasimus A.; Frezzato, Maurizio; Cabras, Maria Giuseppina; Fabbri, Alberto; Corazzelli, Gaetano; Ilariucci, Fiorella; Rossi, Giuseppe; Soffietti, Riccardo; Stelitano, Caterina; Vallisa, Daniele; Zaja, Francesco; Zoppegno, Lucia; Aondio, Gian Marco; Avvisati, Giuseppe; Balzarotti, Monica; Brandes, Alba A.; Fajardo, Jose; Gomez, Henry; Guarini, Attilio; Pinotti, Graziella; Rigacci, Luigi; Uhlmann, Catrina; Picozzi, Piero; Vezzulli, Paolo; Ponzoni, Maurilio; Zucca, Emanuele; Caligaris-Cappio, Federico; Cavalli, Franco		IELSG	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial	LANCET			English	Article							CENTRAL-NERVOUS-SYSTEM; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; CONSOLIDATING RADIOTHERAPY; INTERNATIONAL WORKSHOP; DEFERRED RADIOTHERAPY; EUROPEAN ORGANIZATION; CEREBROSPINAL-FLUID; RESPONSE CRITERIA; INITIAL TREATMENT	Background Chemotherapy with high-dose methotrexate is the conventional approach to treat primary CNS lymphomas, but superiority of polychemotherapy compared with high-dose methotrexate alone is unproven. We assessed the effect of adding high-dose cytarabine to methotrexate in patients with newly diagnosed primary CNS lymphoma. Methods This open, randomised, phase 2 trial was undertaken in 24 centres in six countries. 79 patients with non-Hodgkin lymphoma exclusively localised into the CNS, cranial nerves, or eyes, aged 18-75 years, and with Eastern Cooperative Oncology Group performance status of 3 or lower and measurable disease were centrally randomly assigned by computer to receive four courses of either methotrexate 3.5 g/m(2) on day 1 (n=40) or methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2) twice a day on days 2-3 (n=39). Both regimens were administered every 3 weeks and were followed by whole-brain irradiation. The primary endpoint was complete remission rate after chemotherapy. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00210314. Findings All randomly assigned participants were analysed. After chemotherapy, seven patients given methotrexate and 18 given methotrexate plus cytarabine achieved a complete remission, with a complete remission rate of 18% (95% CI 6-30) and 46% (31-61), respectively, (p=0.006). Nine patients receiving methotrexate and nine receiving methotrexate plus cytarabine achieved a partial response, with an overall response rate of 40% (25-55) and 69% (55-83), respectively, (p=0.009). Grade 3-4 haematological toxicity was more common in the methotrexate plus cytarabine group than in the methotrexate group (36 [92%] vs six [15%]). Four patients died of toxic effects (three vs one). Interpretation In patients aged 75 years and younger with primary CNS lymphoma, the addition of high-dose cytarabine to high-dose methotrexate provides improved outcome with acceptable toxicity compared with high-dose methotrexate alone.	[Ferreri, Andres J. M.] Ist Sci San Raffaele, Med Oncol Unit, Dept Oncol, I-20132 Milan, Italy; [Ferreri, Andres J. M.; Foppoli, Marco; Ponzoni, Maurilio; Caligaris-Cappio, Federico] Ist Sci San Raffaele, Unit Lymphoid Malignancies, I-20132 Milan, Italy; [Foppoli, Marco; Caligaris-Cappio, Federico] Ist Sci San Raffaele, Internal Med Unit, I-20132 Milan, Italy; [Picozzi, Piero] Ist Sci San Raffaele, Dept Oncol, Neurosurg Unit, I-20132 Milan, Italy; [Vezzulli, Paolo] Ist Sci San Raffaele, Neuroradiol Unit, I-20132 Milan, Italy; [Ponzoni, Maurilio] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy; [Caligaris-Cappio, Federico] Univ Vita & Salute, San Raffaele Sci Inst, Milan, Italy; [Martelli, Maurizio] Univ Roma La Sapienza, Dept Haematol, Rome, Italy; [Pangalis, Gerasimus A.] Univ Athens, Dept Haematol, Athens, Greece; [Frezzato, Maurizio] San Bortolo Hosp, Div Haematol, Vicenza, Italy; [Cabras, Maria Giuseppina] Hosp Businco, Div Haematol, Cagliari, Italy; [Fabbri, Alberto] Policlin Le Scotte, Div Haematol, Siena, Italy; [Corazzelli, Gaetano] Ist Pascale, Div Haematol, Naples, Italy; [Ilariucci, Fiorella] Azienda Osped Reggio Emilia, Div Haematol, Reggio Emilia, Italy; [Rossi, Giuseppe] Spedali Civil Brescia, Dept Haematol, I-25125 Brescia, Italy; [Soffietti, Riccardo] Azienda Osped San Giovanni Battista, Div Neurol, Turin, Italy; [Stelitano, Caterina] Azienda Osped Reggio Calabria, Div Haematol, Reggio Di Calabria, Italy; [Vallisa, Daniele] Osped Civile, Div Haematol, Piacenza, Italy; [Zaja, Francesco] Univ Udine, Clin Haematol, I-33100 Udine, Italy; [Zoppegno, Lucia] HIGA San Martin, La Plata, Argentina; [Aondio, Gian Marco] Azienda Osped Gravedona, Div Haematol, Gravedona, Italy; [Avvisati, Giuseppe] Univ Campus Biomed Roma, Div Haematol, Rome, Italy; [Balzarotti, Monica] Ist Clin Humanitas, Dept Haematol & Oncol, Rozzano, Italy; [Brandes, Alba A.] AUSL Bologna, Bellaria Hosp, Div Oncol, Bologna, Italy; [Fajardo, Jose] Hosp Santa Maria, Div Haematol, Lisbon, Portugal; [Gomez, Henry] Inst Nacl Enfermedades Neoplas, Lima, Peru; [Guarini, Attilio] Azienda Osped Bari, Div Haematol, Bari, Italy; [Pinotti, Graziella] Fdn Macchi, Osped Circolo, Med Oncol Unit, Varese, Italy; [Rigacci, Luigi] Azienda Osped Univ Careggi, Div Haematol, Florence, Italy; [Uhlmann, Catrina] Kantonospital, Aarau, Switzerland; [Zucca, Emanuele; Cavalli, Franco] Oncol Inst So Switzerland, Lymphoma Unit, Bellinzona, Switzerland	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Sapienza University Rome; National & Kapodistrian University of Athens; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of Siena; IRCCS Fondazione Pascale; IRCCS Arcispedale S. Maria Nuova; Hospital Spedali Civili Brescia; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Udine; University Campus Bio-Medico - Rome Italy; IRCCS Humanitas Research Hospital; AUSL di Bologna; Universidade de Lisboa; Hospital Santa Maria; Instituto Nacional de Enfermedades Neoplasicas; Ospedale Circolo & Fondazione Macchi; University of Florence; Azienda Ospedaliero Universitaria Careggi; Kantonsspital Aarau AG (KSA); Institute of Oncology Research (IOR)	Ferreri, AJM (corresponding author), Ist Sci San Raffaele, Med Oncol Unit, Dept Oncol, Via Olgettina 60, I-20132 Milan, Italy.	andres.ferreri@hsr.it	Balzarotti, Monica/ABG-4444-2021; Rossi, Giuseppe/K-3376-2016; ilariucci, fiorella/AAA-8256-2019; Rigacci, Luigi/K-4454-2018; Reni, Michele/J-8296-2016; Ferreri, Andrés J. M./A-6662-2013; Guarini, Attilio/AAK-3156-2020; rigacci, luigi/AAJ-3193-2020; Soffietti, Riccardo/AAA-7965-2022	Balzarotti, Monica/0000-0003-4666-5115; Rossi, Giuseppe/0000-0001-8377-2898; ilariucci, fiorella/0000-0002-4279-3358; Rigacci, Luigi/0000-0002-9320-9334; Reni, Michele/0000-0002-6463-0293; Ferreri, Andrés J. M./0000-0001-9606-6124; Guarini, Attilio/0000-0002-9304-6651; rigacci, luigi/0000-0002-9320-9334; Soffietti, Riccardo/0000-0002-9204-7038; Fabbri, Alberto/0000-0003-2603-9715; Vezzulli, Paolo/0000-0002-3568-4946; Picozzi, Piero/0000-0002-1743-4732; Zaja, Francesco/0000-0003-3995-8817; Zucca, Emanuele/0000-0002-5522-6109; Vallisa, Daniele/0000-0002-3130-1979; Brandes, Alba/0000-0002-2503-9089; Avvisati, Giuseppe/0000-0002-5027-5868; Gomez, Henry/0000-0003-2660-1843	Oncosuisse (Swiss Cancer League [ICP OCS-1356-03-2003]	Oncosuisse (Swiss Cancer League	We thank Valter Torri (Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy) for the relevant contribution to the trial design and statistical considerations; Cristina Morinini, Oxanna Lopez, Monica Bertini, and Elena Porro (The International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) for assistance; and Stefania Dell'Oro (San Raffaele Scientific institute, Milan, Italy) and Annarita Conconi (The International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) for their sustained scientific collaboration. The sponsor of this study was The International Extranodal Lymphoma Study Group, who has received an unrestricted grant from Oncosuisse (Swiss Cancer League; grant number ICP OCS-1356-03-2003).	Abrey LE, 2005, J CLIN ONCOL, V23, P5034, DOI 10.1200/JCO.2005.13.524; Abrey LE, 1998, J CLIN ONCOL, V16, P859, DOI 10.1200/JCO.1998.16.3.859; Abrey LE, 2000, J CLIN ONCOL, V18, P3144, DOI 10.1200/JCO.2000.18.17.3144; Batchelor T, 2003, J CLIN ONCOL, V21, P1044, DOI 10.1200/JCO.2003.03.036; Bessell EM, 1996, J CLIN ONCOL, V14, P945, DOI 10.1200/JCO.1996.14.3.945; BLAY JY, 1995, BLOOD, V86, P2922; Brada M, 1998, INT J RADIAT ONCOL, V40, P1157, DOI 10.1016/S0360-3016(98)00002-9; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Coiffier B, 2005, J CLIN ONCOL, V23, P6387, DOI 10.1200/JCO.2005.05.015; DeAngelis LM, 2002, J CLIN ONCOL, V20, P4643, DOI 10.1200/JCO.2002.11.013; Ferreri AJM, 2000, ANN ONCOL, V11, P927, DOI 10.1023/A:1008376412784; Ferreri AJM, 2006, NEUROLOGY, V66, P1435, DOI 10.1212/01.wnl.0000210464.94122.e1; Ferreri AJM, 2003, J CLIN ONCOL, V21, P2407, DOI 10.1200/JCO.2003.01.135; Ferreri AJM, 2003, J CLIN ONCOL, V21, P266, DOI 10.1200/JCO.2003.09.139; Ferreri AJM, 2002, NEUROLOGY, V58, P1513, DOI 10.1212/WNL.58.10.1513; Ferreri AJM, 2008, LEUKEMIA LYMPHOMA, V49, P2042, DOI 10.1080/10428190802381238; Feugier P, 2004, ANN ONCOL, V15, P129, DOI 10.1093/annonc/mdh013; GLASS J, 1994, J NEUROSURG, V81, P188, DOI 10.3171/jns.1994.81.2.0188; Guha-Thakurta N, 1999, J NEURO-ONCOL, V43, P259, DOI 10.1023/A:1006210703827; Harjunpaa A, 2001, LEUKEMIA LYMPHOMA, V42, P731, DOI 10.3109/10428190109099335; Herrlinger U, 2005, ANN NEUROL, V57, P843, DOI 10.1002/ana.20495; Hiraga S, 1999, J NEUROSURG, V91, P221, DOI 10.3171/jns.1999.91.2.0221; Hoang-Xuan K, 2003, J CLIN ONCOL, V21, P2726, DOI 10.1200/JCO.2003.11.036; HRYNIUK WM, 1990, J CLIN ONCOL, V8, P1935, DOI 10.1200/JCO.1990.8.12.1935; Illerhaus G, 2007, HAEMATOLOGICA, V93, P147, DOI 10.3324/haematol.11771; Korfel A, 1998, LEUKEMIA LYMPHOMA, V30, P609, DOI 10.3109/10428199809057573; Mead GM, 2000, CANCER, V89, P1359, DOI 10.1002/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9; O'Brien PC, 2006, INT J RADIAT ONCOL, V64, P408, DOI 10.1016/j.ijrobp.2005.07.958; Pels H, 2003, J CLIN ONCOL, V21, P4489, DOI 10.1200/JCO.2003.04.056; Poortmans PMP, 2003, J CLIN ONCOL, V21, P4483, DOI 10.1200/JCO.2003.03.108; Reni M, 2001, INT J RADIAT ONCOL, V51, P419, DOI 10.1016/S0360-3016(01)01639-X; Rubinstein LV, 2005, J CLIN ONCOL, V23, P7199, DOI 10.1200/JCO.2005.01.149; Shah GD, 2007, J CLIN ONCOL, V25, P4730, DOI 10.1200/JCO.2007.12.5062; SHAPIRO WR, 1975, NEW ENGL J MED, V293, P161, DOI 10.1056/NEJM197507242930402; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6	35	440	469	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2009	374	9700					1512	1520		10.1016/S0140-6736(09)61416-1	http://dx.doi.org/10.1016/S0140-6736(09)61416-1			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	517CS	19767089	Green Submitted			2023-01-03	WOS:000271591300030
J	Melekhin, VV; Shepherd, BE; Stinnette, SE; Rebeiro, PF; Barkanic, G; Raffanti, SP; Sterling, TR				Melekhin, Vlada V.; Shepherd, Bryan E.; Stinnette, Samuel E.; Rebeiro, Peter F.; Barkanic, Gema; Raffanti, Stephen P.; Sterling, Timothy R.			Antiretroviral Therapy Initiation Before, During, or After Pregnancy in HIV-1-Infected Women: Maternal Virologic, Immunologic, and Clinical Response	PLOS ONE			English	Article								Background: Pregnancy has been associated with a decreased risk of HIV disease progression in the highly active antiretroviral therapy (HAART) era. The effect of timing of HAART initiation relative to pregnancy on maternal virologic, immunologic and clinical outcomes has not been assessed. Methods: We conducted a retrospective cohort study from 1997-2005 among 112 pregnant HIV-infected women who started HAART before (N=12), during (N=70) or after pregnancy (N=30). Results: Women initiating HAART before pregnancy had lower CD4+ nadir and higher baseline HIV-1 RNA. Women initiating HAART after pregnancy were more likely to receive triple-nucleoside reverse transcriptase inhibitors. Multivariable analyses adjusted for baseline CD4+ lymphocytes, baseline HIV-1 RNA, age, race, CD4+ lymphocyte count nadir, history of ADE, prior use of non-HAART ART, type of HAART regimen, prior pregnancies, and date of HAART start. In these models, women initiating HAART during pregnancy had better 6-month HIV-1 RNA and CD4+ changes than those initiating HAART after pregnancy (-0.35 vs. 0.10 log(10) copies/mL, P=0.03 and 183.8 vs. -70.8 cells/mm(3), P=0.03, respectively) but similar to those initiating HAART before pregnancy (-0.32 log(10) copies/mL, P=0.96 and 155.8 cells/mm(3), P=0.81, respectively). There were 3 (25%) AIDS-defining events or deaths in women initiating HAART before pregnancy, 3 (4%) in those initiating HAART during pregnancy, and 5 (17%) in those initiating after pregnancy (P=0.01). There were no statistical differences in rates of HIV disease progression between groups. Conclusions: HAART initiation during pregnancy was associated with better immunologic and virologic responses than initiation after pregnancy.			Melekhin, VV (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37212 USA.	vlada.melekhin@vanderbilt.edu		Rebeiro, Peter/0000-0003-1951-9104	NIAID NIH HHS [P30 AI054999, P30 AI54999, T32 AI07474-10, T32 AI007474] Funding Source: Medline; PHS HHS [K24 A1065298] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007474, P30AI054999] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alliegro MB, 1997, ARCH INTERN MED, V157, P2585, DOI 10.1001/archinte.157.22.2585; Arnsten JH, 2001, CLIN INFECT DIS, V33, P1417, DOI 10.1086/323201; Arrive E, 2007, INT J EPIDEMIOL, V36, P1009, DOI 10.1093/ije/dym104; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015; Bardeguez AD, 2003, JAIDS-J ACQ IMM DEF, V32, P170, DOI 10.1097/00126334-200302010-00009; Bardeguez AD, 2008, JAIDS-J ACQ IMM DEF, V48, P408, DOI 10.1097/QAI.0b013e31817bbe80; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Bessinger R, 1998, AM J EPIDEMIOL, V147, P434, DOI 10.1093/oxfordjournals.aje.a009468; BIGGAR RJ, 1989, AM J OBSTET GYNECOL, V161, P1239, DOI 10.1016/0002-9378(89)90674-1; Brocklehurst P, 1998, BRIT J OBSTET GYNAEC, V105, P836, DOI 10.1111/j.1471-0528.1998.tb10227.x; Centers for Disease Control and Prevention, 1992, MMWR RECOMM REP, V41, P1; Chaix ML, 2006, J INFECT DIS, V193, P482, DOI 10.1086/499966; Cheng DM, 2007, ALCOHOL CLIN EXP RES, V31, P829, DOI 10.1111/j.1530-0277.2007.00381.x; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; DESCHAMPS MM, 1993, J ACQ IMMUN DEF SYND, V6, P446; Dietz PM, 2007, PAEDIATR PERINAT EP, V21, P62, DOI 10.1111/j.1365-3016.2007.00862.x; Dronda F, 2004, AIDS, V18, P2210, DOI 10.1097/00002030-200411050-00018; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; Ebrahim SH, 2000, JAMA-J AM MED ASSOC, V283, P361, DOI 10.1001/jama.283.3.361; Effros RB, 2003, CURR HIV RES, V1, P153, DOI 10.2174/1570162033485348; Ekpini RA, 2002, AIDS, V16, P625, DOI 10.1097/00002030-200203080-00015; FINGERHUT LA, 1990, AM J PUBLIC HEALTH, V80, P541, DOI 10.2105/AJPH.80.5.541; Giuliano M, 2003, AIDS, V17, P1570, DOI 10.1097/00002030-200307040-00022; Golub ET, 2008, CLIN INFECT DIS, V46, P305, DOI 10.1086/524752; HOCKE C, 1995, OBSTET GYNECOL, V86, P886, DOI 10.1016/0029-7844(95)00257-R; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Kakehasi FM, 2007, AIDS RES HUM RETROV, V23, P1515, DOI 10.1089/aid.2007.0025; Kaufmann GR, 2000, AIDS, V14, P959, DOI 10.1097/00002030-200005260-00007; Kramer MS, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.2.e35; Kully C, 1999, J INFECT DIS, V179, P705, DOI 10.1086/314615; KUMAR RM, 1995, INT J GYNECOL OBSTET, V49, P137, DOI 10.1016/0020-7292(95)02356-H; Kuritzkes DR, 2007, J INFECT DIS, V195, P1169, DOI 10.1086/512619; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lucas GM, 2002, AIDS, V16, P767, DOI 10.1097/00002030-200203290-00012; Mellins CA, 2008, AIDS CARE, V20, P958, DOI 10.1080/09540120701767208; MINKOFF H, 1987, OBSTET GYNECOL, V69, P285; Modjarrad K, 2008, AIDS, V22, P2179, DOI 10.1097/QAD.0b013e328312c756; Mofenson L., 2006, Morbidity and Mortality Weekly Report, V55, P592; *PAN ANT GUID ADU, 2008, GUID US ANT AG HIV 1; *PER HIV GUID GROU, 2008, PUBL HLTH SERV TASK; Perez-Elias MJ, 2005, HIV CLIN TRIALS, V6, P312, DOI 10.1310/B3NK-V5XQ-6VX9-5DEK; Polanczyk MJ, 2004, J IMMUNOL, V173, P2227, DOI 10.4049/jimmunol.173.4.2227; Vaz MJR, 2007, INT J STD AIDS, V18, P28, DOI 10.1258/095646207779949808; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Saada M, 2000, AIDS, V14, P2355, DOI 10.1097/00002030-200010200-00017; Sanchez-Ramon S, 2005, IMMUNOL LETT, V96, P195, DOI 10.1016/j.imlet.2004.09.004; Savitz DA, 2002, AM J OBSTET GYNECOL, V187, P1660, DOI 10.1067/mob.2002.127601; SCOTT GB, 1985, JAMA-J AM MED ASSOC, V253, P363, DOI 10.1001/jama.253.3.363; Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x; Tai JH, 2007, J INFECT DIS, V196, P1044, DOI 10.1086/520814; Thea DM, 1997, AIDS, V11, P437, DOI 10.1097/00002030-199704000-00006; *UN JOINT PROGR HI, 2008, 2007 AIDS EP UPD; Waller DK, 2000, PAEDIATR PERINAT EP, V14, P263, DOI 10.1046/j.1365-3016.2000.00275.x; Weisser M, 1998, J ACQ IMMUN DEF SYND, V17, P404, DOI 10.1097/00042560-199804150-00004; Welles SL, 2000, AIDS, V14, P263, DOI 10.1097/00002030-200002180-00008	56	13	13	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2009	4	9							e6961	10.1371/journal.pone.0006961	http://dx.doi.org/10.1371/journal.pone.0006961			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	491ZI	19742315	gold, Green Published, Green Submitted			2023-01-03	WOS:000269622500022
J	Federoff, HJ; Gostin, LO				Federoff, Howard J.; Gostin, Lawrence O.			Evolving From Reductionism to Holism Is There a Future for Systems Medicine?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GENOMEWIDE ASSOCIATION; DISEASE; BIOLOGY		[Federoff, Howard J.] Georgetown Univ, Med Ctr, Washington, DC 20057 USA; [Gostin, Lawrence O.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global & Hlth Law, Washington, DC USA	Georgetown University; Georgetown University	Federoff, HJ (corresponding author), Georgetown Univ, Med Ctr, Bldg D,4000 Reservoir Rd NW, Washington, DC 20057 USA.	hjf8@georgetown.edu						Burja AM, 2003, TRENDS BIOTECHNOL, V21, P504, DOI 10.1016/j.tibtech.2003.08.008; Clayton EW, 2003, NEW ENGL J MED, V349, P562, DOI 10.1056/NEJMra012577; Flexner A., 1910, MEDICAL ED US CANADA; Gostin LO, 2009, JAMA-J AM MED ASSOC, V301, P1373, DOI 10.1001/jama.2009.424; GOTTLIEB S, 2000, BRIT MED J, V321, pD1040; Hardy J, 2009, NEW ENGL J MED, V360, P1759, DOI 10.1056/NEJMra0808700; Hirschhorn JN, 2009, NEW ENGL J MED, V360, P1699, DOI 10.1056/NEJMp0808934; Pollard HB, 2000, ANAT REC, V259; Smyth DJ, 2008, NEW ENGL J MED, V359, P2767, DOI 10.1056/NEJMoa0807917; Yuan JS, 2008, TRENDS PLANT SCI, V13, P165, DOI 10.1016/j.tplants.2008.02.003	10	58	61	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	2009	302	9					994	996		10.1001/jama.2009.1264	http://dx.doi.org/10.1001/jama.2009.1264			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489TF	19724047				2023-01-03	WOS:000269444900025
J	Porco, TC; Gebre, T; Ayele, B; House, J; Keenan, J; Zhou, ZX; Hong, KC; Stoller, N; Ray, KJ; Emerson, P; Gaynor, BD; Lietman, TM				Porco, Travis C.; Gebre, Teshome; Ayele, Berhan; House, Jenafir; Keenan, Jeremy; Zhou, Zhaoxia; Hong, Kevin Cyrus; Stoller, Nicole; Ray, Kathryn J.; Emerson, Paul; Gaynor, Bruce D.; Lietman, Thomas M.			Effect of Mass Distribution of Azithromycin for Trachoma Control on Overall Mortality in Ethiopian Children A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OCULAR CHLAMYDIA-TRACHOMATIS; PLASMODIUM-VIVAX MALARIA; SINGLE-DOSE AZITHROMYCIN; INFECTIOUS TRACHOMA; STREPTOCOCCUS-PNEUMONIAE; CHILDHOOD MORTALITY; ORAL AZITHROMYCIN; GAMBIAN CHILDREN; DOUBLE-BLIND; ADDIS-ABABA	Context Mass oral azithromycin distribution to affected communities is a cornerstone of the World Health Organization's trachoma elimination program. Antibiotics are provided to target the ocular strains of chlamydia that cause trachoma, but may also be efficacious against respiratory disease, diarrhea, and malaria-frequent causes of childhood mortality in trachoma-endemic areas. Objective To compare mortality rates of participants aged 1 to 9 years in treated communities with those in untreated communities. Design, Setting, and Participants We conducted a cluster-randomized clinical trial of mass azithromycin administration for trachoma control. Forty-eight communities (known as subkebeles) were randomized into 1 of 3 treatment schedules (annual treatment of all residents [15 902 participants], biannual treatment of all residents [17 288 participants], or quarterly treatment of children only [14 716 participants]) or into 1 group for which treatment was delayed by 1 year (control, 18 498 participants). Twelve subkebeles were randomized to each of the 4 schedules with all children in each of the 3 communities being eligible for treatment. The trial was conducted in a field setting in rural Ethiopia, May 2006 to May 2007. Interventions A single dose of oral azithromycin (adults, 1 g; children, 20 mg/kg) was administered for treatment of ocular Chlamydia trachomatis infection. Antibiotic coverage levels for children aged 1 to 9 years exceeded 80% at all visits. Main Outcome Measure The main outcome measure was the community-specific mortality risk for children aged 1 to 9 years over the course of 1 year. Mortality was measured by enumerative census at baseline and again after 1 year. Comparison of the risk of mortality was a prespecified outcome for the clinical trial. Results The odds ratio for childhood mortality in the intervention communities was 0.51 (95% confidence interval, 0.29-0.90; P=.02; clustered logistic regression) compared with the control group. In the treated communities, the estimated overall mortality rate during this period for children aged 1 to 9 years in the untreated group was 8.3 per 1000 person-years (95% confidence interval, 5.3-13.1), while among the treated communities, the estimated overall mortality rate was 4.1 per 1000 person-years (95% confidence interval, 3.0-5.7) for children aged 1 to 9 years. Conclusion In a trachoma-endemic area, mass distribution of oral azithromycin was associated with reduced mortality in children. Trial Registration clinicaltrials.gov Identifier: NCT00322972 JAMA. 2009;302(9):962-968 www.jama.com	[Lietman, Thomas M.] Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94143 USA; [Porco, Travis C.; House, Jenafir; Keenan, Jeremy; Zhou, Zhaoxia; Hong, Kevin Cyrus; Stoller, Nicole; Ray, Kathryn J.; Gaynor, Bruce D.; Lietman, Thomas M.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; [Porco, Travis C.; Keenan, Jeremy; Zhou, Zhaoxia; Gaynor, Bruce D.; Lietman, Thomas M.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA; [Porco, Travis C.; Lietman, Thomas M.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lietman, TM (corresponding author), Univ Calif San Francisco, Inst Global Hlth, 513 Parnassus Ave,Room S309 Med Sci, San Francisco, CA 94143 USA.	tom.lietman@ucsf.edu	Keenan, Jeremy David/AAO-5882-2020; Gebre, Teshome/F-2973-2011	Keenan, Jeremy David/0000-0002-7118-1457; Gebre, Teshome/0000-0002-9884-0344; Emerson, Paul/0000-0002-6478-8816	The National Eye Institute of the National Institutes of Health [U10 EY016214]; Pfizer International (New York, New York); Bernard Osher Foundation; That Man May See; Peierls Foundation; Bodri Foundation; Harper Inglis Trust; South Asia Research Fund; Research to Prevent Blindness; Clinical & Translational Science Institute-Strategic Opportunities; NATIONAL EYE INSTITUTE [U10EY016214] Funding Source: NIH RePORTER	The National Eye Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); Pfizer International (New York, New York); Bernard Osher Foundation; That Man May See; Peierls Foundation; Bodri Foundation; Harper Inglis Trust; South Asia Research Fund; Research to Prevent Blindness(Research to Prevent Blindness (RPB)); Clinical & Translational Science Institute-Strategic Opportunities; NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	The National Eye Institute of the National Institutes of Health (the TANA study, U10 EY016214) was the primary supporter of this trial. Pfizer International (New York, New York) and the International Trachoma Initiative provided the azithromycin. Donations were also provided by the Bernard Osher Foundation, That Man May See, the Peierls Foundation, the Bodri Foundation, the Harper Inglis Trust, the South Asia Research Fund, and Research to Prevent Blindness. Dr Lietman gratefully acknowledges support from the Clinical & Translational Science Institute-Strategic Opportunities Support program sabbatical grant.	ADEGBOLA RA, 1995, PEDIATR INFECT DIS J, V14, P335, DOI 10.1097/00006454-199504000-00024; Ali M, 2005, B WORLD HEALTH ORGAN, V83, P27; Atik B, 2006, JAMA-J AM MED ASSOC, V296, P1488, DOI 10.1001/jama.296.12.1488; BAILEY RL, 1993, LANCET, V342, P453, DOI 10.1016/0140-6736(93)91591-9; Batt SL, 2003, ANTIMICROB AGENTS CH, V47, P2765, DOI 10.1128/AAC.47.9.2765-2769.2003; Chidambaram JD, 2006, JAMA-J AM MED ASSOC, V295, P1142, DOI 10.1001/jama.295.10.1142; Dunne MW, 2005, AM J TROP MED HYG, V73, P1108; Eisenberg JNS, 2003, EPIDEMIOLOGY, V14, P442, DOI 10.1097/01.ede.0000071411.19255.4c; Fleiss J.L., 2003, STAT METHODS RATES P; Fry AM, 2002, CLIN INFECT DIS, V35, P395, DOI 10.1086/341414; Geerligs PDP, 2003, B WORLD HEALTH ORGAN, V81, P205; Gill DA, 2008, CLIN INFECT DIS, V46, P564, DOI 10.1086/526777; Guchev IA, 2004, CLIN INFECT DIS, V38, P1095, DOI 10.1086/382879; Heppner DG, 2005, AM J TROP MED HYG, V73, P842; House JI, 2009, LANCET, V373, P1111, DOI 10.1016/S0140-6736(09)60323-8; Leach AJ, 1997, CLIN INFECT DIS, V24, P356, DOI 10.1093/clinids/24.3.356; Lietman T, 1999, NAT MED, V5, P572, DOI 10.1038/8451; Maher MJ, 1996, ACCIDENT ANAL PREV, V28, P281, DOI 10.1016/0001-4575(95)00059-3; Mariotti SP, 2004, NEW ENGL J MED, V351, P2004, DOI 10.1056/NEJMe048205; Melese M, 2004, JAMA-J AM MED ASSOC, V292, P721, DOI 10.1001/jama.292.6.721; Melese M, 2008, JAMA-J AM MED ASSOC, V299, P778, DOI 10.1001/jama.299.7.778; MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L; Mohammed E, 2000, ETHIOPIAN MED J, V38, P165; SADIQ ST, 1995, LANCET, V346, P881, DOI 10.1016/S0140-6736(95)92712-3; Schachter J, 1999, LANCET, V354, P630, DOI 10.1016/S0140-6736(98)12387-5; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; Solomon AW, 2005, ANTIMICROB AGENTS CH, V49, P4804, DOI 10.1128/AAC.49.11.4804-4806.2005; Solomon AW, 2004, NEW ENGL J MED, V351, P1962, DOI 10.1056/NEJMoa040979; SOMMER A, 1986, LANCET, V1, P1169; Taye A, 2007, ANN TROP MED PARASIT, V101, P441, DOI 10.1179/136485907X176544; THOREN A, 1982, J TROP PEDIATRICS, V28, P127, DOI 10.1093/tropej/28.3.127; Whitty CJM, 1999, PEDIATR INFECT DIS J, V18, P955, DOI 10.1097/00006454-199911000-00003; *WHO, 2004, NAT CHILD SURV C APR	33	137	137	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	2009	302	9					962	968		10.1001/jama.2009.1266	http://dx.doi.org/10.1001/jama.2009.1266			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489TF	19724043	Bronze			2023-01-03	WOS:000269444900021
J	Deahl, M				Deahl, Martin			Service personnel move to NHS mental health inpatient care	LANCET			English	Editorial Material									S Staffordshire & Shropshire NHS Fdn Trust, Stafford ST16 3AG, England		Deahl, M (corresponding author), S Staffordshire & Shropshire NHS Fdn Trust, Stafford ST16 3AG, England.	martindeahl@doctors.org.uk						*CAR QUAL COMM, 2009, MENT HLTH SERV AC IN; Crisp AH, 2000, BRIT J PSYCHIAT, V177, P4, DOI 10.1192/bjp.177.1.4; Iversen A, 2005, BRIT J PSYCHIAT, V186, P480, DOI 10.1192/bjp.186.6.480; *MENT HLTH FDN, 2010, MIL MENT HLTH; *NAT ARCH, DEF NEWS INP ME 1118; *NHS CONF, 2009, DEAL DOWNT GREAT EV; PALMER C, 2010, 2010 MOD PATIENT SAT	7	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 20	2010	376	9754					1717	1719		10.1016/S0140-6736(10)61190-7	http://dx.doi.org/10.1016/S0140-6736(10)61190-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690EI	20850177				2023-01-03	WOS:000284984900007
J	Zenvirt, S; Kravchenko-Balasha, N; Levitzki, A				Zenvirt, S.; Kravchenko-Balasha, N.; Levitzki, A.			Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents	ONCOGENE			English	Article						CHK1; checkpoint; cancer; p53	DNA-DAMAGE; S-PHASE; CHECKPOINT KINASES; MITOTIC CATASTROPHE; G(2)/M TRANSITION; PATHWAY; THERAPY; ARREST; ABROGATION; ATM	DNA damage checkpoints cause cell cycle arrest, allowing DNA repair before resumption of the cell cycle. These checkpoints can be activated through several signaling pathways. Checkpoint activators include p53, checkpoint kinase 1 (CHK1), checkpoint kinase 2 and/or MAPKAP kinase 2 (MK2). Many cancer cells lack p53 activity and, therefore, depend on alternative checkpoint activators to arrest the cell cycle following DNA damage. Inhibition of these pathways is expected to specifically sensitize these p53-deficient cells to DNA damage caused by chemotherapy. Using isogenic p53-proficient and p53-deficient cancer cell lines, we show that inactivation of CHK1, but not MK2, abrogates cell cycle arrest following chemotherapy, specifically in p53-deficient cells. However, we show that CHK1 is required to maintain genome integrity and cell viability, and that p53-proficient cells are no less sensitive than p53-deficient cells to CHK1 inhibition in the presence of DNA damage. Thus, combining CHK1 inhibition with DNA damage does not lead to preferential killing of p53-deficient over p53-proficient cells, and inhibiting CHK1 does not appear to be a promising approach for potentiation of cancer chemotherapy. Oncogene (2010) 29, 6149-6159; doi:10.1038/onc.2010.343; published online 23 August 2010	[Zenvirt, S.; Kravchenko-Balasha, N.; Levitzki, A.] Hebrew Univ Jerusalem, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.	Levitzki@vms.huji.ac.il	Kravchenko-Balasha, Nataly/D-7683-2016	Kravchenko-Balasha, Nataly/0000-0001-6943-7479	Lady Davis Fellowship Trust; Algen Biopharmaceuticals, Ltd.	Lady Davis Fellowship Trust; Algen Biopharmaceuticals, Ltd.	We would like to thank Dr Shoshana Klein for discussions and editing. This work was partially supported by the Lady Davis Fellowship Trust and by Algen Biopharmaceuticals, Ltd.	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ashwell S, 2008, EXPERT OPIN INV DRUG, V17, P1331, DOI [10.1517/13543784.17.9.1331, 10.1517/13543784.17.9.1331 ]; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen ZH, 2006, INT J CANCER, V119, P2784, DOI 10.1002/ijc.22198; Cho SH, 2005, CELL CYCLE, V4, P131, DOI 10.4161/cc.4.1.1299; Dai J, 2005, GENE DEV, V19, P472, DOI 10.1101/gad.1267105; DENT MF, 1995, CYTOTECHNOLOGY, V17, P27, DOI 10.1007/BF00749218; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hirose Y, 2001, CANCER RES, V61, P5843; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Kawabe T, 2004, MOL CANCER THER, V3, P513; Kravchenko-Balasha N, 2009, J BIOL CHEM, V284, P11717, DOI 10.1074/jbc.M900217200; Levesque AA, 2008, MOL CANCER THER, V7, P252, DOI 10.1158/1535-7163.MCT-07-2066; Lieberman HB, 2008, CURR MED CHEM, V15, P360, DOI 10.2174/092986708783497328; Manke IA, 2005, MOL CELL, V17, P37, DOI 10.1016/j.molcel.2004.11.021; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; O'Connor MJ, 2007, ONCOGENE, V26, P7816, DOI 10.1038/sj.onc.1210879; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Petermann E, 2006, CELL CYCLE, V5, P2203, DOI 10.4161/cc.5.19.3256; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Senderowicz AM, 2003, CANCER CHEMOTH PHARM, V52, pS61, DOI 10.1007/s00280-003-0624-x; Shao RG, 1997, CANCER RES, V57, P4029; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stark GR, 2006, MOL BIOTECHNOL, V32, P227, DOI 10.1385/MB:32:3:227; Tao YG, 2009, CELL CYCLE, V8, P1196, DOI 10.4161/cc.8.8.8203; Tse AN, 2004, CANCER RES, V64, P6635, DOI 10.1158/0008-5472.CAN-04-0841; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Xiao Z, 2006, MOL CANCER THER, V5, P1935, DOI 10.1158/1535-7163.MCT-06-0077; Zhang WH, 2008, CELL CYCLE, V7, P1668, DOI 10.4161/cc.7.11.5982; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zhou BBS, 2003, CANCER BIOL THER, V2, pS16; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	42	45	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6149	6159		10.1038/onc.2010.343	http://dx.doi.org/10.1038/onc.2010.343			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729914	Bronze			2023-01-03	WOS:000284356500007
J	Burd, NA; West, DWD; Staples, AW; Atherton, PJ; Baker, JM; Moore, DR; Holwerda, AM; Parise, G; Rennie, MJ; Baker, SK; Phillips, SM				Burd, Nicholas A.; West, Daniel W. D.; Staples, Aaron W.; Atherton, Philip J.; Baker, Jeff M.; Moore, Daniel R.; Holwerda, Andrew M.; Parise, Gianni; Rennie, Michael J.; Baker, Steven K.; Phillips, Stuart M.			Low-Load High Volume Resistance Exercise Stimulates Muscle Protein Synthesis More Than High-Load Low Volume Resistance Exercise in Young Men	PLOS ONE			English	Article							HUMAN SKELETAL-MUSCLE; P70 S6 KINASE; LENGTHENING CONTRACTIONS; AMINO-ACIDS; BLOOD-FLOW; PHOSPHORYLATION; MYOFIBRILLAR; INTENSITY; INCREASE; CONSUMPTION	Background: We aimed to determine the effect of resistance exercise intensity (% 1 repetition maximum- 1RM) and volume on muscle protein synthesis, anabolic signaling, and myogenic gene expression. Methodology/Principal Findings: Fifteen men (21 +/- 1 years; BMI = 24.1 +/- 0.8 kg/m(2)) performed 4 sets of unilateral leg extension exercise at different exercise loads and/or volumes: 90% of repetition maximum (1RM) until volitional failure (90FAIL), 30% 1RM work-matched to 90% FAIL (30WM), or 30% 1RM performed until volitional failure (30FAIL). Infusion of [ring-C-13(6)] phenylalanine with biopsies was used to measure rates of mixed (MIX), myofibrillar (MYO), and sarcoplasmic (SARC) protein synthesis at rest, and 4 h and 24 h after exercise. Exercise at 30WM induced a significant increase above rest in MIX (121%) and MYO (87%) protein synthesis at 4 h post-exercise and but at 24 h in the MIX only. The increase in the rate of protein synthesis in MIX and MYO at 4 h post-exercise with 90FAIL and 30FAIL was greater than 30WM, with no difference between these conditions; however, MYO remained elevated (199%) above rest at 24 h only in 30FAIL. There was a significant increase in Akt(Ser473) at 24h in all conditions (P = 0.023) and mTOR(Ser2448) phosphorylation at 4 h post-exercise (P = 0.025). Phosporylation of Erk1/2(Tyr202/204), p70S6K(Thr389), and 4E-BP1(Thr37/46) increased significantly (P<0.05) only in the 30FAIL condition at 4 h post-exercise, whereas, 4E-BP1(Thr37/46) phosphorylation was greater 24 h after exercise than at rest in both 90FAIL (237%) and 30FAIL (312%) conditions. Pax7 mRNA expression increased at 24 h post-exercise (P = 0.02) regardless of condition. The mRNA expression of MyoD and myogenin were consistently elevated in the 30FAIL condition. Conclusions/Significance: These results suggest that low-load high volume resistance exercise is more effective in inducing acute muscle anabolism than high-load low volume or work matched resistance exercise modes.	[Burd, Nicholas A.; West, Daniel W. D.; Staples, Aaron W.; Baker, Jeff M.; Moore, Daniel R.; Holwerda, Andrew M.; Parise, Gianni; Phillips, Stuart M.] McMaster Univ, Dept Kinesiol, Exercise Metab Res Grp, Hamilton, ON, Canada; [Atherton, Philip J.; Rennie, Michael J.] Univ Nottingham, City Hosp, Sch Grad Entry Med & Hlth, Derby, England; [Parise, Gianni] McMaster Univ, Dept Med Phys & Appl Radiat Sci, Hamilton, ON, Canada; [Baker, Steven K.] McMaster Univ, Michael G DeGroote Sch Med, Dept Neurol, Hamilton, ON, Canada	McMaster University; University of Nottingham; McMaster University; McMaster University	Burd, NA (corresponding author), McMaster Univ, Dept Kinesiol, Exercise Metab Res Grp, Hamilton, ON, Canada.	phillis@mcmaster.ca	Phillips, Stuart/B-2343-2009	Phillips, Stuart/0000-0002-1956-4098; Atherton, Philip/0000-0002-7286-046X; Burd, Nicholas/0000-0001-5581-3154; Holwerda, Andrew/0000-0002-7926-4863; Moore, Daniel/0000-0001-5865-4398	Natural Sciences and Engineering Research Council of Canada	Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This work was supported by the Natural Sciences and Engineering Research Council of Canada (http://www.nserc-crsng.gc.ca/index_eng.asp). The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.	Abe T, 2006, J APPL PHYSIOL, V100, P1460, DOI 10.1152/japplphysiol.01267.2005; ALWAY SE, 1990, EUR J APPL PHYSIOL O, V60, P346, DOI 10.1007/BF00713497; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V272, pE45, DOI 10.1152/ajpendo.1997.272.1.E45; BURD NA, 2010, J PHYSL; CAMERA DM, 2010, MED SCI SPORTS EXERC; Coffey VG, 2005, FASEB J, V19, P190, DOI 10.1096/fj.05-4809fje; Creer A, 2005, J APPL PHYSIOL, V99, P950, DOI 10.1152/japplphysiol.00110.2005; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; Cuthbertson DJ, 2006, AM J PHYSIOL-ENDOC M, V290, pE731, DOI 10.1152/ajpendo.00415.2005; Deldicque L, 2008, EUR J APPL PHYSIOL, V104, P57, DOI 10.1007/s00421-008-0786-7; Dreyer HC, 2006, J PHYSIOL-LONDON, V576, P613, DOI 10.1113/jphysiol.2006.113175; Drummond MJ, 2009, J PHYSIOL-LONDON, V587, P1535, DOI 10.1113/jphysiol.2008.163816; Eliasson J, 2006, AM J PHYSIOL-ENDOC M, V291, pE1197, DOI 10.1152/ajpendo.00141.2006; FRY CS, J APPL PHYSL; Fujita S, 2007, J APPL PHYSIOL, V103, P903, DOI 10.1152/japplphysiol.00195.2007; Fujita S, 2007, J PHYSIOL-LONDON, V582, P813, DOI 10.1113/jphysiol.2007.134593; Glover EI, 2008, AM J PHYSIOL-REG I, V295, pR604, DOI 10.1152/ajpregu.00097.2008; Greenhaff PL, 2008, AM J PHYSIOL-ENDOC M, V295, pE595, DOI 10.1152/ajpendo.90411.2008; Hartman JW, 2007, AM J CLIN NUTR, V86, P373, DOI 10.1093/ajcn/86.2.373; HENNEMAN E, 1957, SCIENCE, V126, P1345, DOI 10.1126/science.126.3287.1345; HEYS SD, 1990, BIOMED ENVIRON MASS, V19, P176, DOI 10.1002/bms.1200190314; HOLM L, 2009, AM J PHYSL ENDOCRINO; Holterman CE, 2005, SEMIN CELL DEV BIOL, V16, P575, DOI 10.1016/j.semcdb.2005.07.004; Karlsson HKR, 2004, AM J PHYSIOL-ENDOC M, V287, pE1, DOI 10.1152/ajpendo.00430.2003; Kim PL, 2005, J PHYSIOL-LONDON, V568, P283, DOI 10.1113/jphysiol.2005.093708; KUMAR V, 2009, P PHYSL SOC, V15, pC38; KUMAR V, 2008, J PHYSL; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Louis M, 2003, AM J PHYSIOL-ENDOC M, V285, pE1089, DOI 10.1152/ajpendo.00195.2003; MacDougall J D, 1995, Can J Appl Physiol, V20, P480; Mascher H, 2008, AM J PHYSIOL-ENDOC M, V294, pE43, DOI 10.1152/ajpendo.00504.2007; McKay BR, 2008, J PHYSIOL-LONDON, V586, P5549, DOI 10.1113/jphysiol.2008.160176; Miller BF, 2005, J PHYSIOL-LONDON, V567, P1021, DOI 10.1113/jphysiol.2005.093690; Mittendorfer B, 2005, J PHYSIOL-LONDON, V563, P203, DOI 10.1113/jphysiol.2004.077180; Moore DR, 2009, J PHYSIOL-LONDON, V587, P897, DOI 10.1113/jphysiol.2008.164087; Moore DR, 2009, AM J CLIN NUTR, V89, P161, DOI 10.3945/ajcn.2008.26401; Moore DR, 2005, AM J PHYSIOL-ENDOC M, V288, pE1153, DOI 10.1152/ajpendo.00387.2004; Moore DR, 2004, EUR J APPL PHYSIOL, V92, P399, DOI 10.1007/s00421-004-1072-y; Nakshabendi IM, 1995, AM J PHYSIOL-ENDOC M, V269, pE996, DOI 10.1152/ajpendo.1995.269.6.E996; Petrella JK, 2006, AM J PHYSIOL-ENDOC M, V291, pE937, DOI 10.1152/ajpendo.00190.2006; PHILLIPS SM, 1997, AM J PHYSIOL, V273, P99; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Takarada Y, 2002, EUR J APPL PHYSIOL, V86, P308, DOI 10.1007/s00421-001-0561-5; VILLAREAL DT, 2010, OBESITY SILVER SPRIN; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; West DWD, 2010, J APPL PHYSIOL, V108, P60, DOI 10.1152/japplphysiol.01147.2009; West DWD, 2009, J PHYSIOL-LONDON, V587, P5239, DOI 10.1113/jphysiol.2009.177220; Wilborn CD, 2009, J STRENGTH COND RES, V23, P2179, DOI 10.1519/JSC.0b013e3181bab493; Wilkinson SB, 2008, J PHYSIOL-LONDON, V586, P3701, DOI 10.1113/jphysiol.2008.153916; Wilkinson SB, 2007, AM J CLIN NUTR, V85, P1031, DOI 10.1093/ajcn/85.4.1031; Williamson D, 2003, J PHYSIOL-LONDON, V547, P977, DOI 10.1113/jphysiol.2002.036673	52	338	347	1	70	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 9	2010	5	8							e12033	10.1371/journal.pone.0012033	http://dx.doi.org/10.1371/journal.pone.0012033			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	636XC	20711498	Green Published, gold, Green Submitted			2023-01-03	WOS:000280776800015
J	Jouvet, P; Lacroix, J				Jouvet, Philippe; Lacroix, Jacques			Improving interhospital paediatric transport	LANCET			English	Editorial Material							INTENSIVE-CARE; CRITICALLY-ILL; RETRIEVAL TEAM; REDUCTION; CHILDREN; MORBIDITY; SEVERITY; OUTCOMES; ILLNESS; SYSTEM		[Jouvet, Philippe; Lacroix, Jacques] Univ Montreal, St Justine Hosp, Dept Paediat, Div Paediat Crit Care Med, Montreal, PQ H3T 1C5, Canada	Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine	Lacroix, J (corresponding author), Univ Montreal, St Justine Hosp, Dept Paediat, Div Paediat Crit Care Med, Montreal, PQ H3T 1C5, Canada.		Jouvet, Philippe A/H-3293-2018	Jouvet, Philippe A/0000-0001-5684-3398				BRITTO J, 1995, BRIT MED J, V311, P836, DOI 10.1136/bmj.311.7009.836; Duncan H, 2006, J CRIT CARE, V21, P271, DOI 10.1016/j.jcrc.2006.06.007; EDGE WE, 1994, CRIT CARE MED, V22, P1186, DOI 10.1097/00003246-199407000-00023; Gregory CJ, 2008, PEDIATRICS, V121, pE906, DOI 10.1542/peds.2007-2089; Hanson CC, 2009, QUAL SAF HEALTH CARE, V18, P500, DOI 10.1136/qshc.2007.026054; Odetola FO, 2008, PEDIATR CRIT CARE ME, V9, P20, DOI 10.1097/01.PCC.0000298642.11872.29; Orr RA, 2009, PEDIATRICS, V124, P40, DOI 10.1542/peds.2008-0515; Ramnarayan P, 2010, LANCET, V376, P698, DOI 10.1016/S0140-6736(10)61113-0; Shann F, 1997, INTENS CARE MED, V23, P201, DOI 10.1007/s001340050317; Tibballs J, 2005, ARCH DIS CHILD, V90, P1148, DOI 10.1136/adc.2004.069401; Vos GD, 2004, INTENS CARE MED, V30, P302, DOI 10.1007/s00134-003-2066-7; Warren J, 2004, CRIT CARE MED, V32, P256, DOI 10.1097/01.CCM.0000104917.39204.0A	12	3	4	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG-SEP	2010	376	9742					660	661		10.1016/S0140-6736(10)61110-5	http://dx.doi.org/10.1016/S0140-6736(10)61110-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646YW	20708257				2023-01-03	WOS:000281582900005
J	Rothberg, MB; Pekow, PS; Lahti, M; Brody, O; Skiest, DJ; Lindenauer, PK				Rothberg, Michael B.; Pekow, Penelope S.; Lahti, Maureen; Brody, Oren; Skiest, Daniel J.; Lindenauer, Peter K.			Antibiotic Therapy and Treatment Failure in Patients Hospitalized for Acute Exacerbations of Chronic Obstructive Pulmonary Disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MANAGEMENT; DIAGNOSIS; COPD	Context Guidelines recommend antibiotic therapy for acute exacerbations of chronic obstructive pulmonary disease (COPD), but the evidence is based on small, heterogeneous trials, few of which include hospitalized patients. Objective To compare the outcomes of patients treated with antibiotics in the first 2 hospital days with those treated later or not at all. Design, Setting, and Patients Retrospective cohort of patients aged 40 years or older who were hospitalized from January 1, 2006, through December 31, 2007, for acute exacerbations of COPD at 413 acute care facilities throughout the United States. Main Outcome Measures A composite measure of treatment failure, defined as the initiation of mechanical ventilation after the second hospital day, inpatient mortality, or readmission for acute exacerbations of COPD within 30 days of discharge; length of stay, and hospital costs. Results Of 84 621 patients, 79% received at least 2 consecutive days of antibiotic treatment. Treated patients were less likely than nontreated patients to receive mechanical ventilation after the second hospital day (1.07%; 95% confidence interval [CI], 1.06%-1.08% vs 1.80%; 95% CI, 1.78%-1.82%), had lower rates of inpatient mortality (1.04%; 95% CI, 1.03%-1.05% vs 1.59%; 95% CI, 1.57%-1.61%), and had lower rates of readmission for acute exacerbations of COPD (7.91%; 95% CI, 7.89%-7.94% vs 8.79%; 95% CI, 8.74%-8.83%). Patients treated with antibiotic agents had a higher rate of readmissions for Clostridium difficile (0.19%; 95% CI, 0.187%-0.193%) than those who were not treated (0.09%; 95% CI, 0.086%-0.094%). After multivariable adjustment, including the propensity for antibiotic treatment, the risk of treatment failure was lower in antibiotic-treated patients (odds ratio, 0.87; 95% CI, 0.82-0.92). A grouped treatment approach and hierarchical modeling to account for potential confounding of hospital effects yielded similar results. Analysis stratified by risk of treatment failure found similar magnitudes of benefit across all subgroups. Conclusion Early antibiotic administration was associated with improved outcomes among patients hospitalized for acute exacerbations of COPD regardless of the risk of treatment failure. JAMA. 2010;303(20):2035-2042 www.jama.com	[Rothberg, Michael B.; Brody, Oren] Baystate Med Ctr, Div Gen Med & Geriatr, Springfield, MA 01199 USA; [Rothberg, Michael B.; Pekow, Penelope S.; Lindenauer, Peter K.] Baystate Med Ctr, Ctr Qual Care Res, Springfield, MA 01199 USA; [Skiest, Daniel J.] Baystate Med Ctr, Div Infect Dis, Springfield, MA 01199 USA; [Rothberg, Michael B.; Brody, Oren; Lindenauer, Peter K.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Pekow, Penelope S.; Lahti, Maureen] Univ Massachusetts, Sch Publ Hlth, Amherst, MA 01003 USA	Baystate Medical Center; Baystate Medical Center; Baystate Medical Center; Tufts University; University of Massachusetts System; University of Massachusetts Amherst	Rothberg, MB (corresponding author), Baystate Med Ctr, Div Gen Med & Geriatr, 759 Chestnut St, Springfield, MA 01199 USA.	michael.rothberg@bhs.org						ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Daniels JMA, 2010, AM J RESP CRIT CARE, V181, P150, DOI 10.1164/rccm.200906-0837OC; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Groenewegen KH, 2003, RESP MED, V97, P770, DOI 10.1016/S0954-6111(03)00026-X; Johnston SC, 2002, AM J EPIDEMIOL, V156, P753, DOI 10.1093/aje/kwf095; Lieberman D, 2001, DIAGN MICR INFEC DIS, V40, P95, DOI 10.1016/S0732-8893(01)00255-3; Lindenauer PK, 2006, ANN INTERN MED, V144, P894, DOI 10.7326/0003-4819-144-12-200606200-00006; Moody A, 2004, THORAX, V59, P1; *NAT HEART LUNG BL, TAK 1 STEP BREATH BE; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Nouira S, 2001, LANCET, V358, P2020, DOI 10.1016/S0140-6736(01)07097-0; O'Donnell DE, 2008, CAN RESPIR J, V15, p1A, DOI 10.1155/2008/641965; Parsons L, 2001, REDUCING BIAS PROPEN; Patil SP, 2003, ARCH INTERN MED, V163, P1180, DOI 10.1001/archinte.163.10.1180; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Ram FSF, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004403.pub2; Rosell A, 2005, ARCH INTERN MED, V165, P891, DOI 10.1001/archinte.165.8.891; SACHS APE, 1995, THORAX, V50, P758, DOI 10.1136/thx.50.7.758; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi S, 2008, AM J RESP CRIT CARE, V177, P491, DOI 10.1164/rccm.200708-1234OC; Snow V, 2001, ANN INTERN MED, V134, P595, DOI 10.7326/0003-4819-134-7-200104030-00015; Stolz D, 2007, CHEST, V131, P9, DOI 10.1378/chest.06-1500; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278	25	149	159	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 26	2010	303	20					2035	2042		10.1001/jama.2010.672	http://dx.doi.org/10.1001/jama.2010.672			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	600VY	20501925	Bronze			2023-01-03	WOS:000278018200027
J	Green, SM; Mason, KP				Green, Steven M.; Mason, Keira P.			Reformulation of the Sedation Continuum	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROCEDURAL SEDATION; ANALGESIA		[Green, Steven M.] Loma Linda Univ, Med Ctr, Dept Emergency Med, Loma Linda, CA 92354 USA; [Green, Steven M.] Childrens Hosp, Loma Linda, CA USA; [Mason, Keira P.] Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA; [Mason, Keira P.] Harvard Univ, Sch Med, Boston, MA USA	Loma Linda University; Children's Hospital Los Angeles; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Green, SM (corresponding author), Loma Linda Univ, Med Ctr, Dept Emergency Med, A-108,11234 Anderson St, Loma Linda, CA 92354 USA.	steve@viridissimo.com	Mason, Keira/AAS-4734-2020; Mason, Keira/GZN-2525-2022	Mason, Keira/0000-0002-9375-7816; 				[Anonymous], 1985, PEDIATRICS, V76, P317; BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V254, P1073; Casamassimo P, 2006, PEDIATRICS, V118, P2587, DOI 10.1542/peds.2006-2780; Cravero JP, 2004, ANESTH ANALG, V99, P1355, DOI 10.1213/01.ANE.0000134810.60270.E8; Green SM, 2008, ANN EMERG MED, V52, P392, DOI 10.1016/j.annemergmed.2007.12.002; Green SM, 2008, ANN EMERG MED, V52, P9, DOI 10.1016/j.annemergmed.2007.12.001; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; *JOINT COMM, SED AN CAR STAND; Krauss B, 2008, PEDIATR ANESTH, V18, P30, DOI 10.1111/j.1460-9592.2007.02406.x; Krauss B, 2007, ANN EMERG MED, V50, P172, DOI 10.1016/j.annemergmed.2006.10.016	10	20	21	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2010	303	9					876	877		10.1001/jama.2010.217	http://dx.doi.org/10.1001/jama.2010.217			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562NU	20197535				2023-01-03	WOS:000275059500022
J	Libster, R; Bugna, J; Coviello, S; Hijano, DR; Dunaiewsky, M; Reynoso, N; Cavalieri, ML; Guglielmo, MC; Areso, MS; Gilligan, T; Santucho, F; Cabral, G; Gregorio, GL; Moreno, R; Lutz, MI; Panigasi, AL; Saligari, L; Caballero, MT; Almeida, RME; Meyer, MEG; Neder, MD; Davenport, MC; Del Valle, MP; Santidrian, VS; Mosca, G; Dominguez, MG; Alvarez, L; Landa, P; Pota, A; Bolonati, N; Dalamon, R; Mercol, VIS; Espinoza, M; Peuchot, JC; Karolinski, A; Bruno, M; Borsa, A; Ferrero, F; Bonina, A; Ramonet, M; Albano, LC; Luedicke, N; Alterman, E; Savy, V; Baumeister, E; Chappell, JD; Edwards, KM; Melendi, GA; Polack, FP				Libster, Romina; Bugna, Jimena; Coviello, Silvina; Hijano, Diego R.; Dunaiewsky, Mariana; Reynoso, Natalia; Cavalieri, Maria L.; Guglielmo, Maria C.; Soledad Areso, M.; Gilligan, Tomas; Santucho, Fernanda; Cabral, Graciela; Gregorio, Gabriela L.; Moreno, Rina; Lutz, Maria I.; Panigasi, Alicia L.; Saligari, Liliana; Caballero, Mauricio T.; Eguees Almeida, Rodrigo M.; Gutierrez Meyer, Maria E.; Neder, Maria D.; Davenport, Maria C.; Del Valle, Maria P.; Santidrian, Valeria S.; Mosca, Guillermina; Garcia Dominguez, Mercedes; Alvarez, Liliana; Landa, Patricia; Pota, Ana; Bolonati, Norma; Dalamon, Ricardo; Sanchez Mercol, Victoria I.; Espinoza, Marco; Carlos Peuchot, Juan; Karolinski, Ariel; Bruno, Miriam; Borsa, Ana; Ferrero, Fernando; Bonina, Angel; Ramonet, Margarita; Albano, Lidia C.; Luedicke, Nora; Alterman, Elias; Savy, Vilma; Baumeister, Elsa; Chappell, James D.; Edwards, Kathryn M.; Melendi, Guillermina A.; Polack, Fernando P.			Pediatric Hospitalizations Associated with 2009 Pandemic Influenza A (H1N1) in Argentina	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNITED-STATES; CHILDREN; VIRUS; INFECTION; MORTALITY; ILLNESS; WAVE	BACKGROUND While the Northern Hemisphere experiences the effects of the 2009 pandemic influenza A (H1N1) virus, data from the recent influenza season in the Southern Hemisphere can provide important information on the burden of disease in children. METHODS We conducted a retrospective case series involving children with acute infection of the lower respiratory tract or fever in whom 2009 H1N1 influenza was diagnosed on reverse-transcriptase polymerase-chain-reaction assay and who were admitted to one of six pediatric hospitals serving a catchment area of 1.2 million children. We compared rates of admission and death with those among age-matched children who had been infected with seasonal influenza strains in previous years. RESULTS Between May and July 2009, a total of 251 children were hospitalized with 2009 H1N1 influenza. Rates of hospitalization were double those for seasonal influenza in 2008. Of the children who were hospitalized, 47 (19%) were admitted to an intensive care unit, 42 (17%) required mechanical ventilation, and 13 (5%) died. The overall rate of death was 1.1 per 100,000 children, as compared with 0.1 per 100,000 children for seasonal influenza in 2007. (No pediatric deaths associated with seasonal influenza were reported in 2008.) Most deaths were caused by refractory hypoxemia in infants under 1 year of age (death rate, 7.6 per 100,000). CONCLUSIONS Pandemic 2009 H1N1 influenza was associated with pediatric death rates that were 10 times the rates for seasonal influenza in previous years.	[Polack, Fernando P.] Vanderbilt Univ, Dept Pediat, Vanderbilt Vaccine Ctr, Nashville, TN 37232 USA; [Libster, Romina; Bugna, Jimena; Coviello, Silvina; Espinoza, Marco; Alterman, Elias; Melendi, Guillermina A.; Polack, Fernando P.] Fdn INFANT, Buenos Aires, DF, Argentina; [Hijano, Diego R.] Hosp Ninos Sor Ludovica La Plata, Inst Desarrollo & Invest Pediat, Buenos Aires, DF, Argentina; [Hijano, Diego R.; Dunaiewsky, Mariana; Reynoso, Natalia; Cavalieri, Maria L.; Guglielmo, Maria C.; Soledad Areso, M.; Caballero, Mauricio T.; Eguees Almeida, Rodrigo M.; Gutierrez Meyer, Maria E.; Mosca, Guillermina; Sanchez Mercol, Victoria I.] Minist Ciencia Tecn & Innovac Prod, Programa INFANT, Buenos Aires, DF, Argentina; [Dunaiewsky, Mariana; Guglielmo, Maria C.; Neder, Maria D.; Davenport, Maria C.; Del Valle, Maria P.; Santidrian, Valeria S.; Ferrero, Fernando; Bonina, Angel] Hosp Ninos Pedro de Elizalde, Buenos Aires, DF, Argentina; [Reynoso, Natalia; Mosca, Guillermina; Garcia Dominguez, Mercedes; Luedicke, Nora] Hosp Materno Infantil Dr Carlos Gianantonio, Buenos Aires, DF, Argentina; [Cavalieri, Maria L.; Soledad Areso, M.; Sanchez Mercol, Victoria I.; Carlos Peuchot, Juan] Hosp Eva Peron, Buenos Aires, DF, Argentina; [Gilligan, Tomas; Santucho, Fernanda; Saligari, Liliana; Landa, Patricia; Pota, Ana; Bolonati, Norma; Dalamon, Ricardo; Karolinski, Ariel; Bruno, Miriam] Hosp Durand, Buenos Aires, DF, Argentina; [Cabral, Graciela; Gregorio, Gabriela L.; Moreno, Rina; Lutz, Maria I.; Panigasi, Alicia L.; Saligari, Liliana; Ramonet, Margarita; Albano, Lidia C.] Hosp Posadas, Buenos Aires, DF, Argentina; [Caballero, Mauricio T.; Eguees Almeida, Rodrigo M.; Gutierrez Meyer, Maria E.; Borsa, Ana] Hosp Ninos Sor Maria Ludovica, Buenos Aires, DF, Argentina; [Savy, Vilma; Baumeister, Elsa] Dr Carlos G Malbran Inst, Buenos Aires, DF, Argentina; [Chappell, James D.] Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA	Vanderbilt University; University of Buenos Aires; University of Buenos Aires; Vanderbilt University	Polack, FP (corresponding author), Vanderbilt Univ, Dept Pediat, Vanderbilt Vaccine Ctr, 1161 21st Ave,D-7235 MCN, Nashville, TN 37232 USA.	fernando.p.polack@vanderbilt.edu	Ferrero, Fernando/AAE-1886-2020; Hijano, Diego/N-2665-2018	Ferrero, Fernando/0000-0001-6335-0102; Hijano, Diego/0000-0002-2903-666X; Davenport, Maria Carolina/0000-0002-6675-8813	Fundacion INFANT 2008 Fundraising Campaign; National Institute of Environmental Health Sciences; Argentine National Ministry of Health; Thrasher Research Fund; Fogarty International Center Clinical Research Fellow Program at Vanderbilt University	Fundacion INFANT 2008 Fundraising Campaign; National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Argentine National Ministry of Health; Thrasher Research Fund; Fogarty International Center Clinical Research Fellow Program at Vanderbilt University(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	Supported by the Fundacion INFANT 2008 Fundraising Campaign and the Director's Challenge Award from the National Institute of Environmental Health Sciences (to Dr. Polack); the Carrillo - Onativia Scholarship, Argentine National Ministry of Health (to Dr. Bugna); and an Early Career Thrasher Award from the Thrasher Research Fund and the Fogarty International Center Clinical Research Fellow Program at Vanderbilt University (to Dr. Melendi).	Andreasen V, 2008, J INFECT DIS, V197, P270, DOI 10.1086/524065; Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721; Chowell G, 2009, NEW ENGL J MED, V361, P674, DOI 10.1056/NEJMoa0904023; Cordova-Villalobos Jose A, 2009, Health Res Policy Syst, V7, P21, DOI 10.1186/1478-4505-7-21; Freymuth F, 2006, J MED VIROL, V78, P1498, DOI 10.1002/jmv.20725; Hackett S, 2009, LANCET, V374, P605, DOI 10.1016/S0140-6736(09)61511-7; Hancock K, 2009, NEW ENGL J MED, V361, P1945, DOI 10.1056/NEJMoa0906453; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0; Laham FR, 2004, J INFECT DIS, V189, P2047, DOI 10.1086/383350; Lister P, 2009, LANCET, V374, P605, DOI [10.1016/S0140-6736(09)61512-9, 10.1016/S0140-6736(09)61513-0]; Martinez FD, 2001, J ALLERGY CLIN IMMUN, V107, pS449, DOI 10.1067/mai.2001.114993; *MIN SAL, IN PAND INFL 2009; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Olson DR, 2005, P NATL ACAD SCI USA, V102, P11059, DOI 10.1073/pnas.0408290102; Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Rahman M, 2008, DIAGN MICR INFEC DIS, V62, P162, DOI 10.1016/j.diagmicrobio.2007.10.012; Simonsen L, 1998, J INFECT DIS, V178, P53, DOI 10.1086/515616; Simonsen L, 2005, THREAT PANDEMIC INFL, P89, DOI DOI 10.2105/AJPH.2007.119933; *SOC ARG PED, CAL VAC; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; RESULTADOS PROVINCIA; GEOGRAPHIC SPREAD IN; 2009, MMWR MORB MORTAL WKL, V58, P521; 2009, SITUACION INFLUENZA; 2009 H1N1 VACCINATIO; H1N1 FLU CLIN PUBLIC; CASES HUMAN INFECT P; SWINE INFLUENZA CASE	30	314	335	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	2010	362	1					45	55		10.1056/NEJMoa0907673	http://dx.doi.org/10.1056/NEJMoa0907673			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	540PA	20032320				2023-01-03	WOS:000273345500008
J	Pasternak, AO; Jurriaans, S; Bakker, M; Prins, JM; Berkhout, B; Lukashov, VV				Pasternak, Alexander O.; Jurriaans, Suzanne; Bakker, Margreet; Prins, Jan M.; Berkhout, Ben; Lukashov, Vladimir V.			Cellular Levels of HIV Unspliced RNA from Patients on Combination Antiretroviral Therapy with Undetectable Plasma Viremia Predict the Therapy Outcome	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; LOAD LESS-THAN-50 COPIES/ML; CD4(+) T-LYMPHOCYTES; RESIDUAL VIREMIA; LATENT RESERVOIR; VIRAL LOAD; PERIPHERAL-BLOOD; DRUG-RESISTANCE; IN-VIVO; REPLICATION	Background: Combination antiretroviral therapy (cART), the standard of care for HIV-1 infection, is considered to be successful when plasma viremia remains below the detection limit of commercial assays. Yet, cART fails in a substantial proportion of patients after the apparent success. No laboratory markers are known that are predictive of cART outcome in initial responders during the period of undetectable plasma viremia. Methodology/Principal Findings: Here, we report the results of a retrospective longitudinal study of twenty-six HIV-infected individuals who initially responded to cART by having plasma viremia suppressed to <50 copies/ml. Eleven of these patients remained virologically suppressed, whereas fifteen experienced subsequent cART failure. Using sensitive methods based on seminested real-time PCR, we measured the levels of HIV-1 proviral (pr) DNA, unspliced ( us) RNA, and multiply spliced RNA in the peripheral blood mononuclear cells (PBMC) of these patients at multiple time points during the period of undetectable plasma viremia on cART. Median under-therapy level of usRNA was significantly higher (0.43 log(10) difference, P = 0.0015) in patients who experienced subsequent cART failure than in successfully treated patients. In multivariate analysis, adjusted for baseline CD4(+) counts, prior ART experience, and particular cART regimens, the maximal usRNA level under therapy was the best independent predictor of subsequent therapy failure ( adjusted odds ratio [95% CI], 24.4 [1.5-389.5], P = 0.024). The only other factor significantly associated with cART failure was prior ART experience ( adjusted odds ratio [ 95% CI], 12.3 [1.1-138.4], P = 0.042). Levels of usRNA under cART inversely correlated with baseline CD4(+) counts ( P = 0.0003), but did not correlate with either baseline usRNA levels or levels of prDNA under therapy. Conclusion: Our data demonstrate that the level of HIV-1 usRNA in PBMC, measured in cART-treated patients with undetectable plasma viremia, is a strong predictive marker for the outcome of therapy.	[Pasternak, Alexander O.; Bakker, Margreet; Berkhout, Ben; Lukashov, Vladimir V.] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Lab Expt Virol,CINIMA, NL-1105 AZ Amsterdam, Netherlands; [Jurriaans, Suzanne] Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Lab Clin Virol, NL-1105 AZ Amsterdam, Netherlands; [Prins, Jan M.] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Pasternak, AO (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med Microbiol, Lab Expt Virol,CINIMA, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	v.lukashov@amc.uva.nl	Prins, Jan M./AAF-4945-2020; Pasternak, Alexander/P-2067-2017	Pasternak, Alexander/0000-0002-4097-4251	Dutch AIDS Fonds [2004045]; The Netherlands National Institute for Public Health and the Environment	Dutch AIDS Fonds; The Netherlands National Institute for Public Health and the Environment	The study was financially supported by the Dutch AIDS Fonds (http://www.aidsfonds.nl/), grant 2004045. The Amsterdam Cohort Studies are financially supported by The Netherlands National Institute for Public Health and the Environment. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagnarelli P, 1996, J VIROL, V70, P7603, DOI 10.1128/JVI.70.11.7603-7613.1996; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; Chun TW, 2005, J CLIN INVEST, V115, P3250, DOI 10.1172/JCI26197; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fischer M, 2002, ANTIVIR THER, V7, P91; Fischer M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-107; Frenkel LM, 2003, J VIROL, V77, P5721, DOI 10.1128/JVI.77.10.5721-5730.2003; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gallant JE, 2007, CLIN INFECT DIS, V44, P453, DOI 10.1086/510752; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hatzakis AE, 2004, AIDS, V18, P2261, DOI 10.1097/00002030-200411190-00006; Havlir DV, 2003, J VIROL, V77, P11212, DOI 10.1128/JVI.77.20.11212-11219.2003; Hermankova M, 2003, J VIROL, V77, P7383, DOI 10.1128/JVI.77.13.7383-7392.2003; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; Hockett RD, 1999, J EXP MED, V189, P1545, DOI 10.1084/jem.189.10.1545; Joos B, 2008, P NATL ACAD SCI USA, V105, P16725, DOI 10.1073/pnas.0804192105; Kupfer B, 2007, J MED VIROL, V79, P1440, DOI 10.1002/jmv.20993; Le Moing V, 2002, AIDS, V16, P21, DOI 10.1097/00002030-200201040-00004; Lewin SR, 1999, J VIROL, V73, P6099, DOI 10.1128/JVI.73.7.6099-6103.1999; Maldarelli F, 2007, PLOS PATHOG, V3, P484, DOI 10.1371/journal.ppat.0030046; Miller V, 1999, J INFECT DIS, V180, P530, DOI 10.1086/314890; Mocroft A, 2003, AIDS, V17, P1741, DOI 10.1097/00002030-200308150-00003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Pasternak AO, 2008, J CLIN MICROBIOL, V46, P2206, DOI 10.1128/JCM.00055-08; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Persaud D, 2000, J CLIN INVEST, V105, P995, DOI 10.1172/JCI9006; Phillips AN, 2004, AIDS, V18, P1795, DOI 10.1097/00002030-200409030-00008; Phillips AN, 2002, J INFECT DIS, V186, P1086, DOI 10.1086/343801; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Shen L, 2008, J ALLERGY CLIN IMMUN, V122, P22, DOI 10.1016/j.jaci.2008.05.033; Shiu C, 2009, J VIROL, V83, P9731, DOI 10.1128/JVI.00570-09; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Smith CJ, 2009, HIV MED, V10, P19, DOI 10.1111/j.1468-1293.2008.00650.x; Smith CJ, 2005, J INFECT DIS, V192, P1387, DOI 10.1086/466534; Tobin NH, 2005, J VIROL, V79, P9625, DOI 10.1128/JVI.79.15.9625-9634.2005; Vitoria M, 2006, ANTIRETROVIRAL THERA; Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; Yerly S, 2000, AIDS, V14, P2805, DOI 10.1097/00002030-200012220-00001; Zanchetta M, 2006, J INFECT DIS, V193, P1718, DOI 10.1086/504264; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	46	66	66	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 31	2009	4	12							e8490	10.1371/journal.pone.0008490	http://dx.doi.org/10.1371/journal.pone.0008490			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	538JK	20046870	Green Published, Green Submitted, gold			2023-01-03	WOS:000273180200004
J	Louie, JK; Acosta, M; Winter, K; Jean, C; Gavali, S; Schechter, R; Vugia, D; Harriman, K; Matyas, B; Glaser, CA; Samuel, MC; Rosenberg, J; Talarico, J; Hatch, D				Louie, Janice K.; Acosta, Meileen; Winter, Kathleen; Jean, Cynthia; Gavali, Shilpa; Schechter, Robert; Vugia, Duc; Harriman, Kathleen; Matyas, Bela; Glaser, Carol A.; Samuel, Michael C.; Rosenberg, Jon; Talarico, John; Hatch, Douglas		Calif Pandemic (H1N1) Working Grp	Factors Associated With Death or Hospitalization Due to Pandemic 2009 Influenza A(H1N1) Infection in California	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEASONAL INFLUENZA; OBESE-PATIENTS; OUTCOMES; COMPLICATIONS; EPIDEMIOLOGY; MANAGEMENT; DIAGNOSIS; MORTALITY; CHILDREN; INFANTS	Context Pandemic influenza A(H1N1) emerged rapidly in California in April 2009. Preliminary comparisons with seasonal influenza suggest that pandemic 2009 influenza A(H1N1) disproportionately affects younger ages and causes generally mild disease. Objective To describe the clinical and epidemiologic features of pandemic 2009 influenza A(H1N1) cases that led to hospitalization or death. Design, Setting, and Participants Statewide enhanced public health surveillance of California residents who were hospitalized or died with laboratory evidence of pandemic 2009 influenza A(H1N1) infection reported to the California Department of Public Health between April 23 and August 11, 2009. Main Outcome Measure Characteristics of hospitalized and fatal cases. Results During the study period there were 1088 cases of hospitalization or death due to pandemic 2009 influenza A(H1N1) infection reported in California. The median age was 27 years (range, <1-92 years) and 68% (741/1088) had risk factors for seasonal influenza complications. Sixty-six percent (547/833) of those with chest radiographs performed had infiltrates and 31% (340/1088) required intensive care. Rapid antigen tests were falsely negative in 34% (208/618) of cases evaluated. Secondary bacterial infection was identified in 4% (46/1088). Twenty-one percent (183/884) received no antiviral treatment. Overall fatality was 11% (118/1088) and was highest (18%-20%) in persons aged 50 years or older. The most common causes of death were viral pneumonia and acute respiratory distress syndrome. Conclusions In the first 16 weeks of the current pandemic, the median age of hospitalized infected cases was younger than is common with seasonal influenza. Infants had the highest hospitalization rates and persons aged 50 years or older had the highest mortality rates once hospitalized. Most cases had established risk factors for complications of seasonal influenza. JAMA. 2009;302(17):1896-1902	[Louie, Janice K.; Acosta, Meileen; Winter, Kathleen; Jean, Cynthia; Gavali, Shilpa; Schechter, Robert; Vugia, Duc; Harriman, Kathleen; Matyas, Bela; Glaser, Carol A.; Samuel, Michael C.; Rosenberg, Jon; Talarico, John; Hatch, Douglas; Calif Pandemic (H1N1) Working Grp] Calif Dept Publ Hlth, Richmond, CA 94804 USA	California Department of Public Health	Louie, JK (corresponding author), Calif Dept Publ Hlth, 850 Marina Bay Pkwy, Richmond, CA 94804 USA.	Janice.Louie@cdph.ca.gov		Pan, Chao-Yang/0000-0003-1584-4233	CDPH	CDPH	This study was fully sponsored by the CDPH.	Akinnusi ME, 2008, CRIT CARE MED, V36, P151, DOI 10.1097/01.CCM.0000297885.60037.6E; Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475; [Anonymous], UPD INT REC US ANT M; Balish A., 2009, Morbidity and Mortality Weekly Report, V58, P826; Battegay M, 2020, SWISS MED WKLY, V150, DOI [10.4414/smw.w20203, 10.4414/smw.2020.20203]; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P536; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P521; Duarte AG, 2007, CRIT CARE MED, V35, P732, DOI 10.1097/01.CCM.0000256842.39767.41; El-Solh A, 2001, CHEST, V120, P1989, DOI 10.1378/chest.120.6.1989; Englund J., 2009, Morbidity and Mortality Weekly Report, V58, P893; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.293.15.1861; Ginsberg M., 2009, Morbidity and Mortality Weekly Report, V58, P400; Napolitano L. M., 2009, Morbidity and Mortality Weekly Report, V58, P749; Harper SA, 2009, CLIN INFECT DIS, V48, P1003, DOI 10.1086/598513; Ho YC, 2009, J INFECTION, V58, P439, DOI 10.1016/j.jinf.2009.03.007; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0; Koenig SM, 2001, AM J MED SCI, V321, P249, DOI 10.1097/00000441-200104000-00006; McGeer A, 2007, CLIN INFECT DIS, V45, P1568, DOI 10.1086/523584; Morris AE, 2007, CHEST, V131, P342, DOI 10.1378/chest.06-1709; Mullooly JP, 2007, VACCINE, V25, P846, DOI 10.1016/j.vaccine.2006.09.041; O'Brien MA, 2004, PEDIATRICS, V113, P585, DOI 10.1542/peds.113.3.585; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869; Poirier P, 2009, CIRCULATION, V120, P86, DOI 10.1161/CIRCULATIONAHA.109.192575; Ritger K. A., 2009, Morbidity and Mortality Weekly Report, V58, P913; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Vaillant L, 2009, EUROSURVEILLANCE, V14, P2; Vasoo S, 2009, CLIN INFECT DIS, V49, P1090, DOI 10.1086/644743; VGONTZAS AN, 1994, ARCH INTERN MED, V154, P1705, DOI 10.1001/archinte.154.15.1705; World Health Organization, 2010, GLOB AL RESP PAND H1; World Health Organization, 2009, WKLY EPIDEMIOL REC, V84, P301	33	772	825	0	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 4	2009	302	17					1896	1902		10.1001/jama.2009.1583	http://dx.doi.org/10.1001/jama.2009.1583			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	514DU	19887665	Bronze			2023-01-03	WOS:000271375300021
J	Ganti, AK				Ganti, Apar Kishor			Another nail in the coffin for hormone-replacement therapy?	LANCET			English	Editorial Material							CELL LUNG-CANCER; ESTROGEN PLUS PROGESTIN; WOMEN; SURVIVAL; RECEPTOR; RISK; EXPRESSION		[Ganti, Apar Kishor] Univ Nebraska Med Ctr, Dept Internal Med, Hematol Oncol Sect, Omaha, NE 68198 USA; [Ganti, Apar Kishor] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	Ganti, AK (corresponding author), Univ Nebraska Med Ctr, Dept Internal Med, Hematol Oncol Sect, Omaha, NE 68198 USA.	aganti@unmc.edu	Ganti, Apar Kishor/D-5498-2015	Ganti, Apar Kishor/0000-0003-3724-2671				Chlebowski RT, 2009, LANCET, V374, P1243, DOI 10.1016/S0140-6736(09)61526-9; Ettinger B, 1996, OBSTET GYNECOL, V87, P6, DOI 10.1016/0029-7844(95)00358-4; Ganti AK, 2006, J CLIN ONCOL, V24, P59, DOI 10.1200/JCO.2005.02.9827; Hays J, 2003, NEW ENGL J MED, V348, P1839, DOI 10.1056/NEJMoa030311; Huang B, 2009, CANCER, V115, P4167, DOI 10.1002/cncr.24475; Ishibashi H, 2005, CANCER RES, V65, P6450, DOI 10.1158/0008-5472.CAN-04-3087; Manson JE, 2003, NEW ENGL J MED, V349, P523, DOI 10.1056/NEJMoa030808; Marquez-Garban DC, 2009, ANN NY ACAD SCI, V1155, P194, DOI 10.1111/j.1749-6632.2009.04116.x; Moore KA, 2003, ANN THORAC SURG, V76, P1789, DOI 10.1016/S0003-4975(03)01024-5; Omoto Y, 2001, BIOCHEM BIOPH RES CO, V285, P340, DOI 10.1006/bbrc.2001.5158; Schabath MB, 2004, CLIN CANCER RES, V10, P113, DOI 10.1158/1078-0432.CCR-0911-3; Schwartz AG, 2007, J CLIN ONCOL, V25, P5785, DOI 10.1200/JCO.2007.13.3975	12	9	9	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 10	2009	374	9697					1217	1218		10.1016/S0140-6736(09)61571-3	http://dx.doi.org/10.1016/S0140-6736(09)61571-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	507KQ	19767095				2023-01-03	WOS:000270852500005
J	Sukkar, E				Sukkar, Elizabeth			International Aid The cost of donated drugs	BRITISH MEDICAL JOURNAL			English	Editorial Material												Elizabeth.Sukkar@informa.com						Hogerzeil HV, 1997, BRIT MED J, V314, P737, DOI 10.1136/bmj.314.7082.737; Pharmaciens Sans Frontieres, 2005, IOP C SERIES EARTH E; WHO, 1999, GUID SAF DISP UNW PH; World Health Organization, 1999, GUID DRUG DON	4	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 2	2009	339								b3830	10.1136/bmj.b3830	http://dx.doi.org/10.1136/bmj.b3830			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	502LD	19801381				2023-01-03	WOS:000270460200001
J	Holzer, M				Holzer, Michael			Targeted Temperature Management for Comatose Survivors of Cardiac Arrest	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNATIONAL LIAISON COMMITTEE; MILD THERAPEUTIC HYPOTHERMIA; INTENSIVE-CARE-UNIT; CEREBRAL-ISCHEMIA; POSTISCHEMIC HYPOTHERMIA; BRAIN TEMPERATURE; IN-VIVO; REPERFUSION; CARDIOPULMONARY; RESUSCITATION	A 62-year-old man collapses on the street, and emergency medical personnel who are called to the scene find that he is not breathing and that he has no pulse. The first recorded cardiac rhythm is ventricular fibrillation. Advanced cardiac life-support measures, including intubation, a total dose of 2 mg of epinephrine, and six defibrillation attempts, restore spontaneous circulation 22 minutes after the onset of the event. On admission to the emergency department, his condition is hemodynamically stable and he has adequate oxygenation and ventilation, but he is still comatose. A neurologic examination reveals reactive pupils and a positive cough reflex. The core body temperature is 35.5 degrees C. A diagnosis of the post-cardiac arrest syndrome with coma is made. An intensive care specialist evaluates the patient and recommends the immediate initiation of targeted temperature management.	Med Univ Vienna, Dept Emergency Med, A-1090 Vienna, Austria	Medical University of Vienna	Holzer, M (corresponding author), Med Univ Vienna, Dept Emergency Med, Wahringer Gurtel 18-20-6D, A-1090 Vienna, Austria.	michael.holzer@meduniwien.ac.at			KCI Medical; EMCOOLS; Medivance; Life Recovery Systems; Velomedix	KCI Medical; EMCOOLS; Medivance; Life Recovery Systems; Velomedix	Dr. Holzer reports receiving fees for board membership from KCI Medical, consulting fees from EMCOOLS, and lecture fees from KCI Medical and Medivance. The Department of Emergency Medicine at the Medical University of Vienna received research grants from KCI Medical, Life Recovery Systems, and Velomedix on behalf of Dr. Holzer. No other potential conflict of interest relevant to this article was reported.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Arrich J, 2007, CRIT CARE MED, V35, P1041, DOI 10.1097/01.CCM.0000259383.48324.35; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bokesch PM, 1996, ANESTHESIOLOGY, V85, P1439, DOI 10.1097/00000542-199612000-00026; Chamorro C, 2010, ANESTH ANALG, V110, P1328, DOI 10.1213/ANE.0b013e3181d8cacf; COLBOURNE F, 1994, BRAIN RES, V654, P265, DOI 10.1016/0006-8993(94)90488-X; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; D'Cruz BJ, 2002, J CEREBR BLOOD F MET, V22, P843, DOI 10.1097/00004647-200207000-00009; De Jonghe B, 2002, JAMA-J AM MED ASSOC, V288, P2859, DOI 10.1001/jama.288.22.2859; Eberspacher E, 2005, ACTA ANAESTH SCAND, V49, P477, DOI 10.1111/j.1399-6576.2005.00649.x; ERNSTER L, 1988, CRIT CARE MED, V16, P947, DOI 10.1097/00003246-198810000-00005; *EUR RES COUNC, 2005, RESUSCITATION, V67, pS1, DOI DOI 10.1016/J.RESUSCITATION.2005.10.001; Falkenbach P, 2009, RESUSCITATION, V80, P990, DOI 10.1016/j.resuscitation.2009.04.044; Frank SM, 1997, JAMA-J AM MED ASSOC, V277, P1127, DOI 10.1001/jama.277.14.1127; Fukuoka N, 2004, RESUSCITATION, V60, P225, DOI 10.1016/j.resuscitation.2003.09.017; Greer DM, 2006, SEMIN NEUROL, V26, P373, DOI 10.1055/s-2006-948317; Hachimi-Idrissi S, 2001, RESUSCITATION, V51, P275, DOI 10.1016/S0300-9572(01)00412-9; Hachimi-Idrissi S, 2004, BRAIN RES, V1019, P217, DOI 10.1016/j.brainres.2004.06.013; Hoesch RE, 2008, CRIT CARE CLIN, V24, P25, DOI 10.1016/j.ccc.2007.11.003; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jarnum H, 2009, RESUSCITATION, V80, P425, DOI 10.1016/j.resuscitation.2009.01.004; JENNETT B, 1975, LANCET, V1, P480; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; Kim F, 2007, CIRCULATION, V115, P3064, DOI 10.1161/CIRCULATIONAHA.106.655480; KUBOYAMA K, 1993, CRIT CARE MED, V21, P1348, DOI 10.1097/00003246-199309000-00019; LANIER WL, 1995, J NEUROSURG ANESTH, V7, P216, DOI 10.1097/00008506-199507000-00021; LAPTOOK AR, 1995, PEDIATR RES, V38, P919, DOI 10.1203/00006450-199512000-00015; Laurent I, 2005, J AM COLL CARDIOL, V46, P432, DOI 10.1016/j.jacc.2005.04.039; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; Leithner C, 2010, NEUROLOGY, V74, P965, DOI 10.1212/WNL.0b013e3181d5a631; Logue ES, 2007, ACAD EMERG MED, V14, P293, DOI 10.1197/j.aem.2006.10.097; Losert H, 2008, RESUSCITATION, V76, P214, DOI 10.1016/j.resuscitation.2007.08.003; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; McCullough JN, 1999, ANN THORAC SURG, V67, P1895, DOI 10.1016/S0003-4975(99)00441-5; Merchant RM, 2009, CIRC-CARDIOVASC QUAL, V2, P421, DOI 10.1161/CIRCOUTCOMES.108.839605; MICHELSON AD, 1994, THROMB HAEMOSTASIS, V71, P633; NICHOL G, 2008, JAMA-J AM MED ASSOC, V300, P1763; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nielsen N, 2009, ACTA ANAESTH SCAND, V53, P926, DOI 10.1111/j.1399-6576.2009.02021.x; Nolan JP, 2008, RESUSCITATION, V79, P350, DOI 10.1016/j.resuscitation.2008.09.017; Nolan JP, 2003, RESUSCITATION, V57, P231, DOI 10.1016/S0300-9572(03)00184-9; Oddo M, 2006, CRIT CARE MED, V34, P1865, DOI 10.1097/01.CCM.0000221922.08878.49; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2001, J NEUROSURG, V94, P697, DOI 10.3171/jns.2001.94.5.0697; Rea TD, 2004, AM J CARDIOL, V93, P1455, DOI 10.1016/j.amjcard.2004.03.002; REDMOND JM, 1994, J THORAC CARDIOV SUR, V107, P776; Rundgren M, 2006, INTENS CARE MED, V32, P836, DOI 10.1007/s00134-006-0178-6; Schulman SP, 2006, NEUROL CLIN, V24, P41, DOI 10.1016/j.ncl.2005.11.002; Seder DB, 2009, CRIT CARE MED, V37, pS211, DOI 10.1097/CCM.0b013e3181aa5bad; Skulec R, 2008, ACTA ANAESTH SCAND, V52, P188, DOI 10.1111/j.1399-6576.2007.01510.x; STERZ F, 1992, RESUSCITATION, V24, P27, DOI 10.1016/0300-9572(92)90171-8; STONE JG, 1995, ANESTHESIOLOGY, V82, P344, DOI 10.1097/00000542-199502000-00004; Straus SMJM, 2004, J CLIN EPIDEMIOL, V57, P98, DOI 10.1016/S0895-4356(03)00210-5; Sunde K, 2006, RESUSCITATION, V69, P29, DOI 10.1016/j.resuscitation.2005.12.003; Szydlowska K, 2010, CELL CALCIUM, V47, P122, DOI 10.1016/j.ceca.2010.01.003; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Webster CM, 2009, NEUROBIOL DIS, V33, P301, DOI 10.1016/j.nbd.2008.11.001; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Wong CHY, 2008, CURR MED CHEM, V15, P1; Young GB, 2009, NEW ENGL J MED, V361, P605, DOI 10.1056/NEJMcp0903466; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	62	156	166	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	2010	363	13					1256	1264		10.1056/NEJMct1002402	http://dx.doi.org/10.1056/NEJMct1002402			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652ZA	20860507				2023-01-03	WOS:000282050000009
J	Neoptolemos, JP; Stocken, DD; Bassi, C; Ghaneh, P; Cunningham, D; Goldstein, D; Padbury, R; Moore, MJ; Gallinger, S; Mariette, C; Wente, MN; Izbicki, JR; Friess, H; Lerch, MM; Dervenis, C; Olah, A; Butturini, G; Doi, R; Lind, PA; Smith, D; Valle, JW; Palmer, DH; Buckels, JA; Thompson, J; McKay, CJ; Rawcliffe, CL; Buchler, MW				Neoptolemos, John P.; Stocken, Deborah D.; Bassi, Claudio; Ghaneh, Paula; Cunningham, David; Goldstein, David; Padbury, Robert; Moore, Malcolm J.; Gallinger, Steven; Mariette, Christophe; Wente, Moritz N.; Izbicki, Jakob R.; Friess, Helmut; Lerch, Markus M.; Dervenis, Christos; Olah, Attila; Butturini, Giovanni; Doi, Ryuichiro; Lind, Pehr A.; Smith, David; Valle, Juan W.; Palmer, Daniel H.; Buckels, John A.; Thompson, Joyce; McKay, Colin J.; Rawcliffe, Charlotte L.; Buechler, Markus W.		European Study Grp Pancreatic Canc	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CURATIVE RESECTION; CHEMORADIATION; SURVIVAL; THERAPY; CHEMORADIOTHERAPY; CARCINOMA	Context Adjuvant fluorouracil has been shown to be of benefit for patients with resected pancreatic cancer. Gemcitabine is known to be the most effective agent in advanced disease as well as an effective agent in patients with resected pancreatic cancer. Objective To determine whether fluorouracil or gemcitabine is superior in terms of overall survival as adjuvant treatment following resection of pancreatic cancer. Design, Setting, and Patients The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada. Included in ESPAC-3 version 2 were 1088 patients with pancreatic ductal adenocarcinoma who had undergone cancer resection; patients were randomized between July 2000 and January 2007 and underwent at least 2 years of follow-up. Interventions Patients received either fluorouracil plus folinic acid (folinic acid, 20 mg/m(2), intravenous bolus injection, followed by fluorouracil, 425 mg/m(2) intravenous bolus injection given 1-5 days every 28 days) (n=551) or gemcitabine (1000 mg/m2 intravenous infusion once a week for 3 of every 4 weeks) (n=537) for 6 months. Main Outcome Measures Primary outcome measure was overall survival; secondary measures were toxicity, progression-free survival, and quality of life. Results Final analysis was carried out on an intention-to-treat basis after a median of 34.2 (interquartile range, 27.1-43.4) months' follow-up after 753 deaths (69%). Median survival was 23.0 (95% confidence interval [CI], 21.1-25.0) months for patients treated with fluorouracil plus folinic acid and 23.6 (95% CI, 21.4-26.4) months for those treated with gemcitabine (chi(2)(1) = 0.7; P = .39; hazard ratio, 0.94 [95% CI, 0.81-1.08]). Seventy-seven patients (14%) receiving fluorouracil plus folinic acid had 97 treatment-related serious adverse events, compared with 40 patients (7.5%) receiving gemcitabine, who had 52 events (P<.001). There were no significant differences in either progression-free survival or global quality-of-life scores between the treatment groups. Conclusion Compared with the use of fluorouracil plus folinic acid, gemcitabine did not result in improved overall survival in patients with completely resected pancreatic cancer.	[Neoptolemos, John P.; Ghaneh, Paula; Rawcliffe, Charlotte L.] Univ Liverpool, Liverpool Canc Res UK Canc Trials Unit, Liverpool Canc Res UK Ctr, Liverpool L69 3GA, Merseyside, England; [Stocken, Deborah D.] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England; [Bassi, Claudio; Butturini, Giovanni] Univ Verona, Dept Surg, I-37100 Verona, Italy; [Cunningham, David] Royal Marsden Natl Hlth Serv Fdn Trust, London, England; [Cunningham, David] Royal Marsden Natl Hlth Serv Fdn Trust, Surrey, England; [Goldstein, David; Padbury, Robert] Australasian Gastrointestinal Trials Grp, Camperdown, NSW, Australia; [Moore, Malcolm J.] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada; [Gallinger, Steven] Univ Toronto, Fac Med, Dept Surg, Univ Hlth Network, Toronto, ON M5S 1A1, Canada; [Mariette, Christophe] Univ Hosp Claude Huriez, Dept Digest & Oncol Surg, Lille, France; [Wente, Moritz N.; Buechler, Markus W.] Heidelberg Univ, Dept Surg, D-6900 Heidelberg, Germany; [Izbicki, Jakob R.] Univ Hamburg, Dept Gen Visceral & Thorac Surg, Hamburg, Germany; [Friess, Helmut] Tech Univ Munich, Dept Surg, Munich, Germany; [Lerch, Markus M.] Univ Greifswald, Dept Med A, Greifswald, Germany; [Dervenis, Christos] Agia Olga Hosp, Athens, Greece; [Olah, Attila] Petz Aladar Hosp, Gyor, Hungary; [Doi, Ryuichiro] Kyoto Univ, Dept Surg, Kyoto, Japan; [Lind, Pehr A.] Karolinska Stockholm Soder Hosp, Dept Oncol, Stockholm, Sweden; [Smith, David] Clatterbridge Ctr Oncol, Bebington, Merseyside, England; [Valle, Juan W.] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England; [Palmer, Daniel H.; Buckels, John A.] Univ Hosp Birmingham Natl Hlth Serv Fdn Trust, Queen Elizabeth Hosp, Birmingham, W Midlands, England; [Thompson, Joyce] Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; [McKay, Colin J.] Glasgow Royal Infirm, Lister Dept Surg, Glasgow G4 0SF, Lanark, Scotland	University of Liverpool; Cancer Research UK; University of Birmingham; University of Verona; Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Universite de Lille - ISITE; CHU Lille; Ruprecht Karls University Heidelberg; University of Hamburg; Technical University of Munich; Ernst Moritz Arndt Universitat Greifswald; General Hospital of N. Ionia Agia Olga; Kyoto University; Karolinska Institutet; Karolinska University Hospital; Clatterbridge Cancer Centre; Christie NHS Foundation Trust; University of Birmingham; Heart of England NHS Foundation Trust; University of Birmingham; University of Glasgow	Neoptolemos, JP (corresponding author), Univ Liverpool, Liverpool Canc Res UK Canc Trials Unit, Canc Res UK Ctr, 5th Floor,UCD Bldg,Daulby St, Liverpool L69 3GA, Merseyside, England.	j.p.neoptolemos@liverpool.ac.uk	Sutton, Robert/I-3587-2016; Butturini, Giovanni/B-5567-2017; Lerch, Markus M./E-2206-2016; Vickers, Michael M/E-4095-2010; Valle, Juan W/J-3571-2015; Gallinger, Steven/E-4575-2013; Neoptolemos, John/HGU-7742-2022; Wyld, David/B-8893-2015; Kleeff, Jorg/B-2124-2009	Sutton, Robert/0000-0001-6600-562X; Butturini, Giovanni/0000-0002-9172-4885; Lerch, Markus M./0000-0002-9643-8263; Valle, Juan W/0000-0002-1999-0863; Wyld, David/0000-0001-9523-4333; Cunningham, David/0000-0001-5158-1069; Neoptolemos, John/0000-0002-6201-7399; SALVIA, Roberto/0000-0002-3514-8473; Dousset, Bertrand/0000-0003-2526-7345; Madhusudan, Srinivasan/0000-0002-5354-5480; Stocken, Deborah/0000-0001-8031-1738; Katsourakis, Anastasios/0000-0002-5151-9449; Kleeff, Jorg/0000-0003-3432-6669; Naredi, Peter/0000-0002-5652-0422; Spry, Nigel/0000-0001-8659-5065; Segersvard, Ralf/0000-0002-5702-7971; Doi, Ryuichiro/0000-0002-7298-2301	Cancer Research UK; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales; Cancer Council of Queensland; Cancer Council of Victoria; Cancer Council of South Australia; National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital; Cancer Research UK [11883, 8968] Funding Source: researchfish; National Institute for Health Research [NF-SI-0507-10154, 08/29/02] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia; Cancer Council of New South Wales(Cancer Council New South Wales); Cancer Council of Queensland(Cancer Council Queensland); Cancer Council of Victoria(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); Cancer Council of South Australia(Cancer Council South Australia); National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital(Royal Society of New ZealandMarsden Fund (NZ)); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	This study was supported by Cancer Research UK; National Cancer Institute of Canada, Canadian Cancer Society; Fonds de Recherche de la Societe Nationale Francaise de Gastroenterologie; Fondazioone Italiana Malattie del Pancreas; Health and Medical Research Council of Australia, Cancer Councils of New South Wales, Queensland, Victoria, and South Australia. Dr Cunningham's work is funded in part by the National Institute for Health Research Biomedical Research Centre at the Royal Marsden Hospital.	BAKKEVOLD KE, 1993, EUR J CANCER, V29A, P698, DOI 10.1016/S0959-8049(05)80349-1; Berger AC, 2008, J CLIN ONCOL, V26, P5918, DOI 10.1200/JCO.2008.18.6288; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Butturini G, 2008, ARCH SURG-CHICAGO, V143, P75, DOI 10.1001/archsurg.2007.17; Carter R, 2009, INT J CANCER, V124, P2960, DOI 10.1002/ijc.24270; COX DR, 1972, J R STAT SOC B, V187, P220; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; KALSER MH, 1985, ARCH SURG-CHICAGO, V120, P899; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kosuge T, 2006, JPN J CLIN ONCOL, V36, P159, DOI 10.1093/jjco/hyi234; *NAT CANC I, 1999, COMM TOX CRIT CTC VE; Neoptolemos JP, 2001, LANCET, V358, P1576, DOI 10.1016/S0140-6736(01)06651-X; Neoptolemos JP, 2004, NEW ENGL J MED, V350, P1200, DOI 10.1056/NEJMoa032295; Oettle H, 2007, JAMA-J AM MED ASSOC, V297, P267, DOI 10.1001/jama.297.3.267; Pedrazzoli Sergio, 1999, Digestive Surgery, V16, P337, DOI 10.1159/000018744; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Regine WF, 2008, JAMA-J AM MED ASSOC, V299, P1019, DOI 10.1001/jama.299.9.1019; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Smeenk HG, 2007, ANN SURG, V246, P734, DOI 10.1097/SLA.0b013e318156eef3; Takada T, 2002, CANCER, V95, P1685, DOI 10.1002/cncr.10831; Twombly R, 2008, J NATL CANCER I, V100, P1670, DOI 10.1093/jnci/djn428; Ueno H, 2009, BRIT J CANCER, V101, P908, DOI 10.1038/sj.bjc.6605256; Wagner M, 2004, BRIT J SURG, V91, P586, DOI 10.1002/bjs.4484	24	958	982	0	61	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2010	304	10					1073	1081		10.1001/jama.2010.1275	http://dx.doi.org/10.1001/jama.2010.1275			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	646RM	20823433	Bronze			2023-01-03	WOS:000281559800017
J	Mroz, P; Huang, YY; Szokalska, A; Zhiyentayev, T; Janjua, S; Nifli, AP; Sherwood, ME; Ruzie, C; Borbas, KE; Fan, DZ; Krayer, M; Balasubramanian, T; Yang, E; Kee, HL; Kirmaier, C; Diers, JR; Bocian, DF; Holten, D; Lindsey, JS; Hamblin, MR				Mroz, Pawel; Huang, Ying-Ying; Szokalska, Angelika; Zhiyentayev, Timur; Janjua, Sahar; Nifli, Artemissia-Phoebe; Sherwood, Margaret E.; Ruzie, Christian; Borbas, K. Eszter; Fan, Dazhong; Krayer, Michael; Balasubramanian, Thiagarajan; Yang, Eunkyung; Kee, Hooi Ling; Kirmaier, Christine; Diers, James R.; Bocian, David F.; Holten, Dewey; Lindsey, Jonathan S.; Hamblin, Michael R.			Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy	FASEB JOURNAL			English	Article						multidrug resistance; melanosomes; electron microscopy	OVARIAN-CARCINOMA CELLS; MALIGNANT-MELANOMA; ANTITUMOR IMMUNITY; MELANOGENESIS; PHOTOSENSITIZERS; CANCER; OXYGEN; CYCLOPHOSPHAMIDE; SUBSTITUENTS; MELANOCYTES	Cutaneous malignant melanoma remains a therapeutic challenge, and patients with advanced disease have limited survival. Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and it may show promise as an antimelanoma modality. However, high melanin levels in melanomas can adversely affect PDT effectiveness. Herein the extent of melanin contribution to melanoma resistance to PDT was investigated in a set of melanoma cell lines that markedly differ in the levels of pigmentation; 3 new bacteriochlorins successfully overcame the resistance. Cell killing studies determined that bacteriochlorins are superior at (LD50 approximate to 0.1 mu M) when compared with controls such as the FDA-approved Photofrin (LD50 approximate to 10 mu M) and clinically tested LuTex (LD50 approximate to 1 mu M). The melanin content affects PDT effectiveness, but the degree of reduction is significantly lower for bacteriochlorins than for Photofrin. Microscopy reveals that the least effective bacteriochlorin localizes predominantly in lysosomes, while the most effective one preferentially accumulates in mitochondria. Interestingly all bacteriochlorins accumulate in melanosomes, and subsequent illumination leads to melanosomal damage shown by electron microscopy. Fluorescent probes show that the most effective bacteriochlorin produces significantly higher levels of hydroxyl radicals, and this is consistent with the redox properties suggested by molecular-orbital calculations. The best in vitro performing bacteriochlorin was tested in vivo in a mouse melanoma model using spectrally resolved fluorescence imaging and provided significant survival advantage with 20% of cures (P<0.01).-Mroz, P., Huang, Y.-Y., Szokalska, A., Zhiyentayev, T., Janjua, S., Nifli, A.-P., Sherwood, M. E., Ruzie, C., Borbas, K. E., Fan, D., Krayer, M., Balasubramanian, T., Yang, E., Kee, H. L., Kirmaier, C., Diers, J. R., Bocian, D. F., Holten, D., Lindsey, J. S., Hamblin, M. R. Stable synthetic bacteriochlorins overcome the resistance of melanoma to photodynamic therapy. FASEB J. 24, 3160-3170 (2010). www.fasebj.org	[Mroz, Pawel; Huang, Ying-Ying; Szokalska, Angelika; Zhiyentayev, Timur; Janjua, Sahar; Nifli, Artemissia-Phoebe; Sherwood, Margaret E.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Mroz, Pawel; Huang, Ying-Ying; Nifli, Artemissia-Phoebe; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Szokalska, Angelika] Med Univ Warsaw, Dept Immunol, Ctr Biostruct, Warsaw, Poland; [Zhiyentayev, Timur] MIT, Dept Chem, Cambridge, MA 02139 USA; [Janjua, Sahar] Aga Khan Med Coll, Karachi, Pakistan; [Ruzie, Christian; Borbas, K. Eszter; Fan, Dazhong; Krayer, Michael; Lindsey, Jonathan S.] N Carolina State Univ, Dept Chem, Raleigh, NC 27695 USA; [Balasubramanian, Thiagarajan] NIRvana Pharmaceut Inc, Raleigh, NC USA; [Yang, Eunkyung; Kee, Hooi Ling; Kirmaier, Christine; Holten, Dewey] Washington Univ, Dept Chem, St Louis, MO 63130 USA; [Diers, James R.; Bocian, David F.] Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Guangxi Medical University; Medical University of Warsaw; Massachusetts Institute of Technology (MIT); University of North Carolina; North Carolina State University; Washington University (WUSTL); University of California System; University of California Riverside; Harvard University; Massachusetts Institute of Technology (MIT)	Hamblin, MR (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Mike/AAB-2511-2022; Nifli, Artemissia-Phoebe/H-6171-2019; Mroz, Pawel/P-1258-2019; Muchowicz, Angelika/J-7494-2012; Huang, yingying/J-7329-2012; Huang, Ying-ying/G-3153-2011; Hamblin, Michael R/H-2758-2019; Lindsey, Jonathan S/J-7761-2012	Nifli, Artemissia-Phoebe/0000-0002-8829-7894; Muchowicz, Angelika/0000-0003-4707-1722; Huang, yingying/0000-0002-4038-0277; Huang, Ying-ying/0000-0003-3066-6981; Hamblin, Michael R/0000-0001-6431-4605; Mroz, Pawel/0000-0003-3838-4743; Krayer, Michael/0000-0002-1945-1181	NIH [R01GM36238, R01AI050875]; Burroughs-Wellcome fellowship; Jimmy V. NCSU Cancer Therapeutics Training Program; National Institute of Allergy and Infectious Diseases [R41AI072854]; Genzyme-Partners Translational Research; Foundation for Polish Science; International Union against Cancer; European Structural Fund; Division of Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences of the U.S. Department of Energy [DE-FG02-05ER15660, DE-FG02-05ER15661]; NATIONAL CANCER INSTITUTE [R01CA083882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050875, R41AI072854] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036238] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs-Wellcome fellowship(Burroughs Wellcome Fund); Jimmy V. NCSU Cancer Therapeutics Training Program; National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Genzyme-Partners Translational Research; Foundation for Polish Science(Foundation for Polish ScienceEuropean Commission); International Union against Cancer; European Structural Fund; Division of Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences of the U.S. Department of Energy(United States Department of Energy (DOE)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the NIH (R01GM36238 to J.S.L. and R01AI050875 to M. R. H.), a Burroughs-Wellcome fellowship (to M. K.), and the Jimmy V. NCSU Cancer Therapeutics Training Program. P. M. and T. B. were supported by a grant (R41AI072854) from the National Institute of Allergy and Infectious Diseases to NIRvana Pharmaceuticals. P. M. was partly supported by Genzyme-Partners Translational Research Grant. A. S. was supported by the Foundation for Polish Science, the International Union against Cancer, and the European Structural Fund: Mazowieckie Stypendium Doktoranckie. Characterization of the photophysical and redox properties of the bacteriochlorins described herein was initially motivated by solar-energy studies and supported by grants from the Division of Chemical Sciences, Geosciences and Biosciences Division, Office of Basic Energy Sciences of the U.S. Department of Energy to D. F. B. (DE-FG02-05ER15660) and D. H. (DE-FG02-05ER15661). The authors thank Pharmacyclics (Sunnyvale, CA, USA) for the gift of LuTex and loan of 730-nm laser and QLT (Vancouver, BC, Canada) for the gift of Photofrin.	Ashur I, 2009, J PHYS CHEM A, V113, P8027, DOI 10.1021/jp900580e; Biolo R, 1996, PHOTOCHEM PHOTOBIOL, V63, P224, DOI 10.1111/j.1751-1097.1996.tb03018.x; Borbas KE, 2008, ORG LETT, V10, P1931, DOI 10.1021/ol800436u; Brozyna AA, 2008, INT J CANCER, V123, P1448, DOI 10.1002/ijc.23664; Busetti A, 1999, BRIT J CANCER, V79, P821, DOI 10.1038/sj.bjc.6690131; Carlson JA, 2005, J AM ACAD DERMATOL, V52, P743, DOI 10.1016/j.jaad.2004.08.034; Castano AP, 2008, P NATL ACAD SCI USA, V105, P5495, DOI 10.1073/pnas.0709256105; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Castano AP, 2004, PHOTODIAGN PHOTODYN, V1, P279, DOI 10.1016/S1572-1000(05)00007-4; Chang SK, 2008, CLIN CANCER RES, V14, P4146, DOI 10.1158/1078-0432.CCR-07-4536; Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103; Chen KG, 2009, PIGM CELL MELANOMA R, V22, P740, DOI 10.1111/j.1755-148X.2009.00630.x; Cummins DL, 2006, MAYO CLIN PROC, V81, P500, DOI 10.4065/81.4.500; Dellian M, 1996, INT J CANCER, V65, P246; Fan DZ, 2007, J ORG CHEM, V72, P5350, DOI 10.1021/jo070785s; GRADYUSHKO AT, 1970, PHOTOCHEM PHOTOBIOL, V11, P387, DOI 10.1111/j.1751-1097.1970.tb06011.x; HOLTEN D, 1976, PHOTOCHEM PHOTOBIOL, V23, P415, DOI 10.1111/j.1751-1097.1976.tb07275.x; Hong L, 2006, PHOTOCHEM PHOTOBIOL, V82, P1475, DOI 10.1562/2006-03-14-RA-846; Kee HL, 2007, PHOTOCHEM PHOTOBIOL, V83, P1125, DOI 10.1111/j.1751-1097.2007.00151.x; Kee HL, 2008, J PHOTOCH PHOTOBIO A, V200, P346, DOI 10.1016/j.jphotochem.2008.08.006; Kim HJ, 2005, J ORG CHEM, V70, P5475, DOI 10.1021/jo050467y; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; Kuroda TS, 2005, METHOD ENZYMOL, V403, P419, DOI 10.1016/S0076-6879(05)03037-5; Lapouge K, 1999, BIOCHEMISTRY-US, V38, P11115, DOI 10.1021/bi990723z; Liu WG, 2007, CLIN CANCER RES, V13, P2463, DOI 10.1158/1078-0432.CCR-06-1599; Liu Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P135, DOI 10.1562/2004-08-03-RA-259.1; Mazor O, 2005, PHOTOCHEM PHOTOBIOL, V81, P342, DOI 10.1562/2004-06-14-RA-199.1; Mennel S, 2007, OPHTHALMOLOGICA, V221, P216, DOI 10.1159/000101922; MROZ P, 2009, P SPIE, V7380; Mroz P, 2009, CANCER LETT, V282, P63, DOI 10.1016/j.canlet.2009.02.054; NAKAYASU M, 1977, J CELL PHYSIOL, V92, P49, DOI 10.1002/jcp.1040920107; *NAT COMPR CANC NE, 2009, NCCN CLIN PRACT GUID; Naylor MF, 2006, BRIT J DERMATOL, V155, P1287, DOI 10.1111/j.1365-2133.2006.07514.x; ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291; ORLOW SJ, 1993, J INVEST DERMATOL, V100, P55, DOI 10.1111/1523-1747.ep12354138; Price M, 2009, PHOTOCHEM PHOTOBIOL, V85, P1177, DOI 10.1111/j.1751-1097.2009.00555.x; Riley PA, 2003, PIGM CELL RES, V16, P548, DOI 10.1034/j.1600-0749.2003.00069.x; Ruzie C, 2008, J ORG CHEM, V73, P5806, DOI 10.1021/jo800736c; Safaei R, 2005, MOL CANCER THER, V4, P1595, DOI 10.1158/1535-7163.MCT-05-0102; Safaei R, 2005, CLIN CANCER RES, V11, P756; Sapan CV, 1999, BIOTECHNOL APPL BIOC, V29, P99; Setsukinai K, 2003, J BIOL CHEM, V278, P3170, DOI 10.1074/jbc.M209264200; Shao Y, 2006, PHYS CHEM CHEM PHYS, V8, P3172, DOI 10.1039/b517914a; Sheleg SV, 2004, PHOTODERMATOL PHOTO, V20, P21, DOI 10.1111/j.1600-0781.2004.00078.x; Simon JD, 2009, PIGM CELL MELANOMA R, V22, P563, DOI 10.1111/j.1755-148X.2009.00610.x; SLOMINSKI A, 1993, J THEOR BIOL, V164, P103, DOI 10.1006/jtbi.1993.1142; Slominski A, 2004, PHYSIOL REV, V84, P1155, DOI 10.1152/physrev.00044.2003; Slominski A, 2001, ARCH PATHOL LAB MED, V125, P1295; Slominski A, 2009, INT J CANCER, V124, P1470, DOI 10.1002/ijc.24005; SOLCA FF, 1993, FEBS LETT, V322, P177, DOI 10.1016/0014-5793(93)81563-F; Su JF, 2008, J NANOSCI NANOTECHNO, V8, P1174, DOI 10.1166/jnn.2008.317; Suzuki I, 1996, ENDOCRINOLOGY, V137, P1627, DOI 10.1210/en.137.5.1627; Szakacs G, 2004, MOL INTERV, V4, P323, DOI 10.1124/mi.4.6.5; Taniguchi M, 2008, NEW J CHEM, V32, P947, DOI 10.1039/b717803d; Trachtenberg J, 2008, BJU INT, V102, P556, DOI 10.1111/j.1464-410X.2008.07753.x; WEBER G, 1957, T FARADAY SOC, V53, P646, DOI 10.1039/tf9575300646; Woodburn KW, 1998, J INVEST DERMATOL, V110, P746, DOI 10.1046/j.1523-1747.1998.00182.x; Yeung P F, 2001, IDrugs, V4, P351	58	78	80	0	49	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2010	24	9					3160	3170		10.1096/fj.09-152587	http://dx.doi.org/10.1096/fj.09-152587			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	645IK	20385618	Green Published			2023-01-03	WOS:000281446400006
J	Temel, JS; Greer, JA; Muzikansky, A; Gallagher, ER; Admane, S; Jackson, VA; Dahlin, CM; Blinderman, CD; Jacobsen, J; Pirl, WF; Billings, JA; Lynch, TJ				Temel, Jennifer S.; Greer, Joseph A.; Muzikansky, Alona; Gallagher, Emily R.; Admane, Sonal; Jackson, Vicki A.; Dahlin, Constance M.; Blinderman, Craig D.; Jacobsen, Juliet; Pirl, William F.; Billings, J. Andrew; Lynch, Thomas J.			Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							QUALITY-OF-LIFE; FUNCTIONAL ASSESSMENT; ELDERLY-PATIENTS; SUPPORTIVE CARE; THERAPY-LUNG; DEPRESSION; SURVIVAL; CISPLATIN; TRIAL; INTERVENTION	BACKGROUND Patients with metastatic non-small-cell lung cancer have a substantial symptom burden and may receive aggressive care at the end of life. We examined the effect of introducing palliative care early after diagnosis on patient-reported outcomes and end-of-life care among ambulatory patients with newly diagnosed disease. METHODS We randomly assigned patients with newly diagnosed metastatic non-small-cell lung cancer to receive either early palliative care integrated with standard oncologic care or standard oncologic care alone. Quality of life and mood were assessed at baseline and at 12 weeks with the use of the Functional Assessment of Cancer Therapy-Lung (FACT-L) scale and the Hospital Anxiety and Depression Scale, respectively. The primary outcome was the change in the quality of life at 12 weeks. Data on end-of-life care were collected from electronic medical records. RESULTS Of the 151 patients who underwent randomization, 27 died by 12 weeks and 107 (86% of the remaining patients) completed assessments. Patients assigned to early palliative care had a better quality of life than did patients assigned to standard care (mean score on the FACT-L scale [in which scores range from 0 to 136, with higher scores indicating better quality of life], 98.0 vs. 91.5; P = 0.03). In addition, fewer patients in the palliative care group than in the standard care group had depressive symptoms (16% vs. 38%, P = 0.01). Despite the fact that fewer patients in the early palliative care group than in the standard care group received aggressive end-of-life care (33% vs. 54%, P = 0.05), median survival was longer among patients receiving early palliative care (11.6 months vs. 8.9 months, P = 0.02). CONCLUSIONS Among patients with metastatic non-small-cell lung cancer, early palliative care led to significant improvements in both quality of life and mood. As compared with patients receiving standard care, patients receiving early palliative care had less aggressive care at the end of life but longer survival. (Funded by an American Society of Clinical Oncology Career Development Award and philanthropic gifts; ClinicalTrials.gov number, NCT01038271.)	[Temel, Jennifer S.; Greer, Joseph A.; Muzikansky, Alona; Gallagher, Emily R.; Jackson, Vicki A.; Dahlin, Constance M.; Jacobsen, Juliet; Pirl, William F.; Billings, J. Andrew] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Admane, Sonal] SUNY Buffalo, Buffalo, NY 14260 USA; [Blinderman, Craig D.] Columbia Univ, Med Ctr, Dept Anesthesiol, New York, NY USA; [Lynch, Thomas J.] Yale Univ, New Haven, CT USA	Harvard University; Massachusetts General Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Columbia University; Yale University	Temel, JS (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA.	jtemel@partners.org	Admane, Sonal/K-7486-2019	Pirl, William/0000-0001-5226-9886; admane, sonal/0000-0002-1616-5462	American Society of Clinical Oncology; Joanne Hill Monahan Cancer Fund and Golf Fights Cancer; Roche; Boehringer Ingelheim; Merck; AstraZeneca; Bristol-Myers Squibb; Sanofi-Aventis	American Society of Clinical Oncology; Joanne Hill Monahan Cancer Fund and Golf Fights Cancer; Roche(Roche Holding); Boehringer Ingelheim(Boehringer Ingelheim); Merck(Merck & Company); AstraZeneca(AstraZeneca); Bristol-Myers Squibb(Bristol-Myers Squibb); Sanofi-Aventis(Sanofi-Aventis)	Supported by an American Society of Clinical Oncology Career Development Award and philanthropic gifts from the Joanne Hill Monahan Cancer Fund and Golf Fights Cancer.; Dr. Temel reports receiving payment for developing continuing medical education (CME) programs from InforMEDical; and Dr. Lynch, serving on the board of Infinity Pharmaceuticals, receiving consulting fees from Roche, Boehringer Ingelheim, Merck, AstraZeneca, Bristol-Myers Squibb, and Sanofi-Aventis, royalties from Partners HealthCare, and payment for developing CME programs from InforMEDical. No other potential conflict of interest relevant to this article was reported.	ALBERTI W, 1995, BRIT MED J, V311, P899; *AM SOC CLIN ONC Q, 2009, ASCO QOPI SUMM MEAS; Bakitas M, 2009, JAMA-J AM MED ASSOC, V302, P741, DOI 10.1001/jama.2009.1198; Bonomi P, 2000, J CLIN ONCOL, V18, P623, DOI 10.1200/JCO.2000.18.3.623; Brown J, 2005, J CLIN ONCOL, V23, P7417, DOI 10.1200/JCO.2005.09.158; Cella D, 2004, SEMIN ONCOL, V31, P11, DOI 10.1053/j.seminoncol.2004.04.008; Cella D, 2002, J CLIN EPIDEMIOL, V55, P285, DOI 10.1016/S0895-4356(01)00477-2; CELLA DF, 1995, LUNG CANCER-J IASLC, V12, P199, DOI 10.1016/0169-5002(95)00450-F; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Emanuel EJ, 2002, ARCH INTERN MED, V162, P1722, DOI 10.1001/archinte.162.15.1722; Ferris FD, 2009, J CLIN ONCOL, V27, P3052, DOI 10.1200/JCO.2008.20.1558; Follwell M, 2009, J CLIN ONCOL, V27, P206, DOI 10.1200/JCO.2008.17.7568; HOPWOOD P, 1995, BRIT J CANCER, V71, P633, DOI 10.1038/bjc.1995.124; Hopwood P, 2000, J CLIN ONCOL, V18, P893, DOI 10.1200/JCO.2000.18.4.893; JACKSON VA, 2009, J CLIN ONCOL S, V27, P20635; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jordhoy MS, 2001, J CLIN ONCOL, V19, P3884, DOI 10.1200/JCO.2001.19.18.3884; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Langer CJ, 2002, JNCI-J NATL CANCER I, V94, P173; Levy MH, 2009, J NATL COMPR CANC NE, V7, P436, DOI 10.6004/jnccn.2009.0031; Lutz S, 2001, J Palliat Med, V4, P157, DOI 10.1089/109662101750290191; Maione P, 2005, J CLIN ONCOL, V23, P6865, DOI 10.1200/JCO.2005.02.527; Mongan JJ, 2008, NEW ENGL J MED, V358, P1509, DOI 10.1056/NEJMsb0707912; Morita T, 2005, J CLIN ONCOL, V23, P2637, DOI 10.1200/JCO.2005.12.107; Movsas B, 2009, J CLIN ONCOL, V27, P5816, DOI 10.1200/JCO.2009.23.7420; National Consensus Project, 2009, CLIN PRACT GUID QUAL; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Pirl WF, 2008, PSYCHOSOMATICS, V49, P218, DOI 10.1176/appi.psy.49.3.218; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Rummans TA, 2006, J CLIN ONCOL, V24, P635, DOI 10.1200/JCO.2006.06.209; Sandler AB, 2000, J CLIN ONCOL, V18, P122, DOI 10.1200/JCO.2000.18.1.122; Spiro SG, 2004, THORAX, V59, P828, DOI 10.1136/thx.2003.020164; Tang ST, 2009, J CLIN ONCOL, V27, P4613, DOI 10.1200/JCO.2008.20.5096; Temel JS, 2007, J CLIN ONCOL, V25, P2377, DOI 10.1200/JCO.2006.09.2627; Temel JS, 2010, J GEN INTERN MED, V25, P150, DOI 10.1007/s11606-009-1161-z; Walling A, 2008, J CLIN ONCOL, V26, P3896, DOI 10.1200/JCO.2007.15.9509; Weinstein MC, 2010, NEW ENGL J MED, V362, P460, DOI 10.1056/NEJMsb0911104; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zimmermann C, 2008, JAMA-J AM MED ASSOC, V299, P1698, DOI 10.1001/jama.299.14.1698	39	4503	4560	12	456	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	2010	363	8					733	742		10.1056/NEJMoa1000678	http://dx.doi.org/10.1056/NEJMoa1000678			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	639TE	20818875				2023-01-03	WOS:000280996600007
J	Harper, JM; Wilkinson, JE; Miller, RA				Harper, James M.; Wilkinson, J. Erby; Miller, Richard A.			Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction	FASEB JOURNAL			English	Article						MIF; CR; life span; cancer; inflammation	AUGSBURG CASE-COHORT; FACTOR MIF; LIFE-SPAN; FACTOR GENE; RHEUMATOID-ARTHRITIS; PROSTATE-CANCER; GROWTH; INFLAMMATION; EXPRESSION; GLUCOSE	Macrophage migration inhibitory factor (MIF) affects inflammation, glucose homeostasis, and cellular proliferation in mammals. Previously, we found that MIF was significantly elevated in multiple long-lived mouse models, including calorie restriction (CR), which led us to hypothesize that MIF might be important in the control of mammalian life span and be necessary for the life-extending effects of CR. To test this hypothesis, we examined the life span of mice with a targeted deletion of the Mif gene on a segregating B6 x 129/Sv background (MIF-KO) under ad libitum (AL) feeding and CR conditions. Control mice were generated by mating C57BL/6J females with 129/SvJ males to make an F1 hybrid, and crossing F1 males to F1 females to produce segregating F2 mice homozygous for the normal MIF allele. Not only did MIF-KO mice show a life span extension in response to CR, they were, unexpectedly, longer lived than controls under standard AL conditions. MIF-KO mice were significantly protected against lethal hemangiosarcoma, but more likely than controls to die of disseminated amyloid, an age-related inflammatory syndrome. Overall, these data refute the suggestion that MIF is required for the CR effect on life span, but raise the possibility that MIF may limit life span in normal mice.-Harper, J.M., Wilkinson, J.E., Miller, R.A. Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. FASEB J. 24, 2436-2442 (2010). www.fasebj.org	[Harper, James M.; Miller, Richard A.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Harper, James M.; Miller, Richard A.] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA; [Wilkinson, J. Erby] Univ Michigan, Unit Lab Anim Med, Ann Arbor, MI 48109 USA; [Miller, Richard A.] Ann Arbor Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System	Harper, JM (corresponding author), Rm 3005,BSRB,Box 2200,109 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	jmharper@umich.edu		Harper, James/0000-0003-0765-8828	U.S. National Institutes of Health [AG023122, AG024824, AG013283]; NATIONAL INSTITUTE ON AGING [P30AG013283, U19AG023122, P30AG024824] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Melissa Burns, Maggie Lauderdale, and Jessica Sewald for technical assistance. The work was supported by U.S. National Institutes of Health grants AG023122, AG024824, and AG013283. The authors report no conflict of interest.	Al-Regaiey KA, 2007, J GERONTOL A-BIOL, V62, P18, DOI 10.1093/gerona/62.1.18; Anahara R, 2006, REPROD TOXICOL, V21, P167, DOI 10.1016/j.reprotox.2005.08.001; Awandare GA, 2009, J INFECT DIS, V200, P629, DOI 10.1086/600894; Bach JP, 2008, ONCOLOGY-BASEL, V75, P127, DOI 10.1159/000155223; Bacher M, 1997, AM J PATHOL, V150, P235; Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Bell EL, 2007, MOL CELL BIOL, V27, P5737, DOI 10.1128/MCB.02265-06; Bocheva A., 2008, Autonomic & Autacoid Pharmacology, V28, P117, DOI 10.1111/j.1474-8673.2008.00425.x; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Bucala R, 1996, FASEB J, V10, P1607, DOI 10.1096/fasebj.10.14.9002552; Burger-Kentischer A, 2002, CIRCULATION, V105, P1561, DOI 10.1161/01.CIR.0000012942.49244.82; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Cavigelli SA, 2003, P NATL ACAD SCI USA, V100, P16131, DOI 10.1073/pnas.2535721100; Cavigelli SA, 2006, HORM BEHAV, V50, P454, DOI 10.1016/j.yhbeh.2006.06.001; Cvetkovic I, 2006, INT IMMUNOPHARMACOL, V6, P1527, DOI 10.1016/j.intimp.2006.06.009; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Denz A, 2010, J SURG RES, V160, P29, DOI 10.1016/j.jss.2009.03.048; Ding GX, 2009, J SURG ONCOL, V100, P106, DOI 10.1002/jso.21304; Fingerle-Rowson G, 2003, AM J PATHOL, V162, P47, DOI 10.1016/S0002-9440(10)63797-2; Fingerle-Rowson GR, 2001, IMMUNOL CELL BIOL, V79, P368, DOI 10.1046/j.1440-1711.2001.01024.x; Fingerle-Rowson G, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-22; Flaster H, 2007, MOL ENDOCRINOL, V21, P1267, DOI 10.1210/me.2007-0065; GANGULY R, 1986, ALLERGOL IMMUNOPATH, V14, P1; GANGULY R, 1985, Allergie und Immunologie (Leipzig), V31, P203; Hagemann T, 2007, MOL CANCER THER, V6, P1993, DOI 10.1158/1535-7163.MCT-07-0118; Hardman MJ, 2005, AM J PATHOL, V167, P1561, DOI 10.1016/S0002-9440(10)61241-2; Herder C, 2008, DIABETOLOGIA, V51, P276, DOI 10.1007/s00125-007-0800-3; Herder C, 2006, DIABETES CARE, V29, P368, DOI 10.2337/diacare.29.02.06.dc05-1474; HOGENESCH H, 1993, VIRCHOWS ARCH B, V64, P37, DOI 10.1007/BF02915094; Honda A, 2009, CARCINOGENESIS, V30, P1597, DOI 10.1093/carcin/bgp160; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; HUAXIANG XH, 2009, CANCER, V115, P5441; Koska J, 2009, INT J OBESITY, V33, P842, DOI 10.1038/ijo.2009.106; Magalhaes ES, 2009, FASEB J, V23, P1262, DOI 10.1096/fj.08-124248; Martin J, 2009, FASEB J, V23, P720, DOI 10.1096/fj.08-119628; Masternak MM, 2006, EXP GERONTOL, V41, P417, DOI 10.1016/j.exger.2006.01.009; Mehta R, 2009, SCIENCE, V324, P1196, DOI 10.1126/science.1173507; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Miller RA, 2005, AGING CELL, V4, P119, DOI 10.1111/j.1474-9726.2005.00152.x; Miller RA, 2002, MOL ENDOCRINOL, V16, P2657, DOI 10.1210/me.2002-0142; Mitchell RA, 2004, CELL SIGNAL, V16, P13, DOI 10.1016/j.cellsig.2003.07.002; Mizue Y, 2000, INT J MOL MED, V5, P397; Morand EF, 2006, NAT REV DRUG DISCOV, V5, P399, DOI 10.1038/nrd2029; Morand EF, 2005, INTERN MED J, V35, P419, DOI 10.1111/j.1445-5994.2005.00853.x; Nemajerova A, 2007, EMBO J, V26, P987, DOI 10.1038/sj.emboj.7601564; Ohkawara T, 2008, SCAND J GASTROENTERO, V43, P1497, DOI 10.1080/00365520802273017; Paiva CN, 2009, J LEUKOCYTE BIOL, V85, P855, DOI 10.1189/jlb.0108009; Pan JH, 2004, CIRCULATION, V109, P3149, DOI 10.1161/01.CIR.0000134704.84454.D2; RACHELLE D, 2002, ARTHRITIS RHEUM, V46, P2402; Radstake TRDJ, 2005, ARTHRITIS RHEUM, V52, P3020, DOI 10.1002/art.21285; Rendon BE, 2009, EXP MOL PATHOL, V86, P180, DOI 10.1016/j.yexmp.2009.01.001; Rohrbach S, 2008, BIOGERONTOLOGY, V9, P169, DOI 10.1007/s10522-008-9126-x; Satoskar AR, 2001, INFECT IMMUN, V69, P906, DOI 10.1128/IAI.69.2.906-911.2001; Simpson EM, 1997, NAT GENET, V16, P19, DOI 10.1038/ng0597-19; Stosic-Grujicic S, 2008, J CELL PHYSIOL, V215, P665, DOI 10.1002/jcp.21346; Stosic-Grujicic S, 2009, AUTOIMMUN REV, V8, P244, DOI 10.1016/j.autrev.2008.07.037; Taylor JA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-135; Thorand B, 2007, DIABETES CARE, V30, P854, DOI 10.2337/dc06-1693; Toso C, 2008, DIABETOLOGIA, V51, P1937, DOI 10.1007/s00125-008-1063-3; Turturro A, 2002, J GERONTOL A-BIOL, V57, pB379, DOI 10.1093/gerona/57.11.B379; Verschuren L, 2009, CIRC RES, V105, P99, DOI 10.1161/CIRCRESAHA.109.199166; Wang CX, 2004, MECH AGEING DEV, V125, P629, DOI 10.1016/j.mad.2004.07.003; Weindruch R., 1988, RETARDATION AGING DI; Welford SM, 2006, GENE DEV, V20, P3366, DOI 10.1101/gad.1471106; Wilson JM, 2005, GASTROENTEROLOGY, V129, P1485, DOI 10.1053/j.gastro.2005.07.061; Winner M, 2008, CANCER RES, V68, P7253, DOI 10.1158/0008-5472.CAN-07-6227; Xu XD, 2008, CANCER LETT, V261, P147, DOI 10.1016/j.canlet.2007.11.028; Yabunaka N, 2000, DIABETES CARE, V23, P256, DOI 10.2337/diacare.23.2.256; Yee JR, 2008, PSYCHOSOM MED, V70, P1050, DOI 10.1097/PSY.0b013e31818425fb; YOSHITAKA S, 2003, GASTROENTEROLOGY, V124, P725; Zhang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006348	71	50	52	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2010	24	7					2436	2442		10.1096/fj.09-152223	http://dx.doi.org/10.1096/fj.09-152223			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	618HV	20219983	Green Submitted, Green Published			2023-01-03	WOS:000279343600030
J	Sacks, FM; Campos, H				Sacks, Frank M.; Campos, Hannia			Dietary Therapy in Hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDITERRANEAN-STYLE DIET; BLOOD-PRESSURE; WEIGHT-LOSS; STOP HYPERTENSION; DASH DIET; ENDOTHELIAL FUNCTION; CARDIOVASCULAR MORTALITY; MICROVASCULAR FUNCTION; SODIUM REDUCTION; UNITED-STATES	A 57-year-old woman presents to an outpatient clinic for evaluation of hypertension. She has no history or symptoms of cardiovascular disease and reports having gained 15 kg over the past 30 years. Her blood pressure is 155/95 mm Hg, her weight 86 kg, her height 165 cm, her body-mass index (BMI, the weight in kilograms divided by the square of the height in meters) 31, and her waist circumference 98 cm. Her serum triglyceride level is 175 mg per deciliter (2.0 mmol per liter), high-density lipoprotein cholesterol 42 mg per deciliter (1.1 mmol per liter), low-density lipoprotein cholesterol 110 mg per deciliter (2.8 mmol per liter), and glucose 85 mg per deciliter (4.7 mmol per liter). Her clinical profile is thus consistent with the metabolic syndrome. 1 She is a nonsmoker, is sedentary, and eats a diet that is high in white bread, processed meats, and snacks and drinks containing sugars and sodium and is low in fruits and vegetables. She is interested in adopting a healthier lifestyle.	[Sacks, Frank M.; Campos, Hannia] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Sacks, Frank M.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Sacks, Frank M.] Brigham & Womens Hosp, Dept Med, Div Cardiol, Boston, MA 02115 USA; [Sacks, Frank M.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sacks, FM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, Bldg 1,2nd Fl, Boston, MA 02115 USA.	fsacks@hsph.harvard.edu						Adrogue HJ, 2007, NEW ENGL J MED, V356, P1966, DOI 10.1056/NEJMra064486; Akita S, 2003, HYPERTENSION, V42, P8, DOI 10.1161/01.HYP.0000074668.08704.6E; Al-Solaiman Y, 2009, J HUM HYPERTENS, V23, P826, DOI 10.1038/jhh.2009.32; American Heart Association, 2005, NO FAD DIET PERS PLA; Appel LJ, 2006, HYPERTENSION, V47, P296, DOI 10.1161/01.HYP.0000202568.01167.B6; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455; BERK BC, 2004, BRENNER RECTORS KIDN, V2, P1999; Blacher J, 2005, NAT CLIN PRACT CARD, V2, P450, DOI 10.1038/ncpcardio0307; Blanck Heidi Michels, 2008, Prev Chronic Dis, V5, pA35; Blumenthal JA, 2010, ARCH INTERN MED, V170, P126, DOI 10.1001/archinternmed.2009.470; Bray GA, 2010, AM J CARDIOL, V105, P579, DOI 10.1016/j.amjcard.2009.10.002; Bray GA, 2004, AM J CARDIOL, V94, P222, DOI 10.1016/j.amjcard.2004.03.070; Chang HY, 2006, AM J CLIN NUTR, V83, P1289, DOI 10.1093/ajcn/83.6.1289; Chen J, 2009, LANCET, V373, P829, DOI 10.1016/S0140-6736(09)60144-6; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Conlin PR, 2003, AM J HYPERTENS, V16, P337, DOI 10.1016/S0895-7061(03)00056-6; Cook NR, 2007, BMJ-BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55; CTR. FOR STRATEGIC & INT'L STUD, 2008, SEL DEV APPR, P1; de Jongh RT, 2007, J HYPERTENS, V25, P1887, DOI 10.1097/HJH.0b013e32825e1db7; Elliott, 1997, BRIT MED J, V315, P458; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; Engeli S, 2005, HYPERTENSION, V45, P356, DOI 10.1161/01.HYP.0000154361.47683.d3; EPSTEIN FREDERICK H., 1967, P155; Eriksson MK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005195; Esler M, 2006, HYPERTENSION, V48, P787, DOI 10.1161/01.HYP.0000242642.42177.49; Esposito K, 2009, ANN INTERN MED, V151, P591, DOI 10.7326/0003-4819-151-8-200910200-00026; Esposito K, 2004, JAMA-J AM MED ASSOC, V292, P1440, DOI 10.1001/jama.292.12.1440; Esposito K, 2009, ANN INTERN MED, V151, P306, DOI 10.7326/0003-4819-151-5-200909010-00004; Ezzati M, 2008, CIRCULATION, V117, P905, DOI 10.1161/CIRCULATIONAHA.107.732131; Feldstein C, 2009, J AM SOC HYPERTENS, V3, P353, DOI 10.1016/j.jash.2009.10.001; Gates PE, 2009, EXP PHYSIOL, V94, P311, DOI 10.1113/expphysiol.2008.043349; Goff DC, 2001, ANN EPIDEMIOL, V11, P271, DOI 10.1016/S1047-2797(00)00224-6; Grimes CA, 2009, APPETITE, V53, P189, DOI 10.1016/j.appet.2009.06.007; Hajjar I, 2006, ANNU REV PUBL HEALTH, V27, P465, DOI 10.1146/annurev.publhealth.27.021405.102132; Hall JE, 2001, AM J HYPERTENS, V14, p103S, DOI 10.1016/S0895-7061(01)02077-5; Hall JE, 2003, HYPERTENSION, V41, P625, DOI 10.1161/01.HYP.0000052314.95497.78; Ho JT, 2007, HORM METAB RES, V39, P694, DOI 10.1055/s-2007-985354; Hsieh YC, 2009, PUBLIC HEALTH NUTR, V12, P570, DOI 10.1017/S1368980008002875; Kaplan N., 2006, KAPLANS CLIN HYPERTE, V9th, P50; Karanja N, 2007, J AM DIET ASSOC, V107, P1530, DOI 10.1016/j.jada.2007.06.013; KATZEN M, 2006, EAT DRINK WEIGH LESS; Kokkinos Peter, 2005, J Clin Hypertens (Greenwich), V7, P165, DOI 10.1111/j.1524-6175.2005.04079.x; LANDSBERG L, 1981, INT J OBESITY, V5, P79; Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8; LEE MA, 1993, CIRCULATION, V87, P7; Lichtenstein A, 2006, CIRCULATION, V114, pE629, DOI 10.1161/CIRCULATIONAHA.106.180281; *MAYOCLINIC COM, DASH DIET REC; McCall DO, 2009, CIRCULATION, V119, P2153, DOI 10.1161/CIRCULATIONAHA.108.831297; Mellen PB, 2008, ARCH INTERN MED, V168, P308, DOI 10.1001/archinternmed.2007.119; MOORE T, 2001, DASH DIET HYPERTENSI, P1; National Heart Lung and Blood Institute & National Heart Lung and Blood Institute, 2006, YOUR GUID LOW YOUR B, V1st; O'Shaughnessy KM, 2006, ANNU REV NUTR, V26, P343, DOI 10.1146/annurev.nutr.26.061505.111316; Obarzanek E, 2003, HYPERTENSION, V42, P459, DOI 10.1161/01.HYP.0000091267.39066.72; Okosun IS, 1999, J HUM HYPERTENS, V13, P425, DOI 10.1038/sj.jhh.1000862; PEAR RNEW, 2010, NY TIMES        0405, pA10; Pierce GL, 2008, HYPERTENSION, V52, P72, DOI 10.1161/HYPERTENSIONAHA.108.111427; Pimenta E, 2009, HYPERTENSION, V54, P475, DOI 10.1161/HYPERTENSIONAHA.109.131235; Rallidis LS, 2009, AM J CLIN NUTR, V90, P263, DOI 10.3945/ajcn.2008.27290; Rankins J, 2005, J NUTR EDUC BEHAV, V37, P259, DOI 10.1016/S1499-4046(06)60281-9; Rao MV, 2008, AM J KIDNEY DIS, V51, pS30, DOI 10.1053/j.ajkd.2007.12.012; Re RN, 2004, NAT CLIN PRACT CARD, V1, P42, DOI 10.1038/ncpcardio0012; ROCCHINI AP, 1989, NEW ENGL J MED, V321, P580, DOI 10.1056/NEJM198908313210905; RODRIGUEZ BL, 1994, HYPERTENSION, V24, P779, DOI 10.1161/01.HYP.24.6.779; SACKS FM, 1988, AM J CLIN NUTR, V48, P795, DOI 10.1093/ajcn/48.3.795; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; SACKS FM, 1974, AM J EPIDEMIOL, V100, P390, DOI 10.1093/oxfordjournals.aje.a112050; Sacks Frank M., 1995, Annals of Epidemiology, V5, P108, DOI 10.1016/1047-2797(94)00055-X; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Safar ME, 2009, HYPERTENSION, V54, P203, DOI 10.1161/HYPERTENSIONAHA.109.129585; SAILE F, 1930, MED KLIN, V25, P929; SEALEY JE, 1988, J HYPERTENS, V6, P763, DOI 10.1097/00004872-198811000-00001; Seals DR, 2006, EXP GERONTOL, V41, P501, DOI 10.1016/j.exger.2006.01.001; Sokka T, 2008, CLIN EXP RHEUMATOL, V26, pS35, DOI 10.1161/CIRCULATIONAHA.109.192644; Straznicky NE, 2005, J CLIN ENDOCR METAB, V90, P5998, DOI 10.1210/jc.2005-0961; Straznicky NE, 2010, DIABETES, V59, P71, DOI 10.2337/db09-0934; Svetkey LP, 2008, JAMA-J AM MED ASSOC, V299, P1139, DOI 10.1001/jama.299.10.1139; Swain JF, 2008, J AM DIET ASSOC, V108, P257, DOI 10.1016/j.jada.2007.10.040; Trichopoulou A, 2001, Nutr Metab Cardiovasc Dis, V11, P1; Uzu T, 2006, J HYPERTENS, V24, P1627, DOI 10.1097/01.hjh.0000239299.71001.77; Victor RG, 2008, CURR HYPERTENS REP, V10, P241, DOI 10.1007/s11906-008-0045-7; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; Williamson DA, 2010, J BEHAV MED, V33, P35, DOI 10.1007/s10865-009-9230-7; Wood DA, 2008, LANCET, V371, P1999, DOI 10.1016/S0140-6736(08)60868-5; Young CM, 2008, J CLIN HYPERTENS, V10, P603, DOI 10.1111/j.1751-7176.2008.08199.x; Zandi-Nejad K, 2006, HYPERTENSION, V47, P502, DOI 10.1161/01.HYP.0000198544.09909.1a	86	147	154	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 3	2010	362	22					2102	2112		10.1056/NEJMct0911013	http://dx.doi.org/10.1056/NEJMct0911013			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	603XU	20519681				2023-01-03	WOS:000278242200009
J	Lo, AC; Guarino, PD; Richards, LG; Haselkorn, JK; Wittenberg, GF; Federman, DG; Ringer, RJ; Wagner, TH; Krebs, HI; Volpe, BT; Bever, CT; Bravata, DM; Duncan, PW; Corn, BH; Maffucci, AD; Nadeau, SE; Conroy, SS; Powell, JM; Huang, GD; Peduzzi, P				Lo, Albert C.; Guarino, Peter D.; Richards, Lorie G.; Haselkorn, Jodie K.; Wittenberg, George F.; Federman, Daniel G.; Ringer, Robert J.; Wagner, Todd H.; Krebs, Hermano I.; Volpe, Bruce T.; Bever, Christopher T., Jr.; Bravata, Dawn M.; Duncan, Pamela W.; Corn, Barbara H.; Maffucci, Alysia D.; Nadeau, Stephen E.; Conroy, Susan S.; Powell, Janet M.; Huang, Grant D.; Peduzzi, Peter			Robot-Assisted Therapy for Long-Term Upper-Limb Impairment after Stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONSTRAINT-INDUCED MOVEMENT; RANDOMIZED CONTROLLED-TRIAL; CLINICAL-TRIALS; UPPER EXTREMITY; SINGLE-BLIND; FORCED USE; REHABILITATION; INFORMATION; RECOVERY; IMPACT	BACKGROUND Effective rehabilitative therapies are needed for patients with long-term deficits after stroke. METHODS In this multicenter, randomized, controlled trial involving 127 patients with moderate-to-severe upper-limb impairment 6 months or more after a stroke, we randomly assigned 49 patients to receive intensive robot-assisted therapy, 50 to receive intensive comparison therapy, and 28 to receive usual care. Therapy consisted of 36 1-hour sessions over a period of 12 weeks. The primary outcome was a change in motor function, as measured on the Fugl-Meyer Assessment of Sensorimotor Recovery after Stroke, at 12 weeks. Secondary outcomes were scores on the Wolf Motor Function Test and the Stroke Impact Scale. Secondary analyses assessed the treatment effect at 36 weeks. RESULTS At 12 weeks, the mean Fugl-Meyer score for patients receiving robot-assisted therapy was better than that for patients receiving usual care (difference, 2.17 points; 95% confidence interval [CI], -0.23 to 4.58) and worse than that for patients receiving intensive comparison therapy (difference, -0.14 points; 95% CI, -2.94 to 2.65), but the differences were not significant. The results on the Stroke Impact Scale were significantly better for patients receiving robot-assisted therapy than for those receiving usual care (difference, 7.64 points; 95% CI, 2.03 to 13.24). No other treatment comparisons were significant at 12 weeks. Secondary analyses showed that at 36 weeks, robot-assisted therapy significantly improved the Fugl-Meyer score (difference, 2.88 points; 95% CI, 0.57 to 5.18) and the time on the Wolf Motor Function Test (difference, -8.10 seconds; 95% CI, -13.61 to -2.60) as compared with usual care but not with intensive therapy. No serious adverse events were reported. CONCLUSIONS In patients with long-term upper-limb deficits after stroke, robot-assisted therapy did not significantly improve motor function at 12 weeks, as compared with usual care or intensive therapy. In secondary analyses, robot-assisted therapy improved outcomes over 36 weeks as compared with usual care but not with intensive therapy. (ClinicalTrials.gov number, NCT00372411.)	[Lo, Albert C.] Brown Univ, Providence Vet Affairs Med Ctr, Providence, RI 02909 USA; [Lo, Albert C.] Brown Univ, Ctr Restorat & Regenerat Med, VA Res & Dev Ctr Excellence, Providence, RI 02909 USA; [Guarino, Peter D.; Corn, Barbara H.; Maffucci, Alysia D.; Peduzzi, Peter] VA Cooperat Studies Program Coordinating Ctr, West Haven, CT USA; [Federman, Daniel G.] VA Connecticut Healthcare Syst, West Haven, CT USA; [Federman, Daniel G.] Yale Univ, New Haven, CT USA; [Richards, Lorie G.; Nadeau, Stephen E.] N Florida S Georgia Vet Hlth Syst, Gainesville, FL USA; [Richards, Lorie G.; Nadeau, Stephen E.] Univ Florida, Gainesville, FL USA; [Haselkorn, Jodie K.; Powell, Janet M.] VA Puget Sound Healthcare Syst, Seattle, WA USA; [Haselkorn, Jodie K.; Powell, Janet M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Wittenberg, George F.] VAMC Baltimore Geriatr Res Educ & Clin Ctr, Baltimore, MD USA; [Wittenberg, George F.; Bever, Christopher T., Jr.] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA; [Bever, Christopher T., Jr.] VA Maryland Healthcare Syst, Res Serv, Baltimore, MD USA; [Conroy, Susan S.] VAMC, Baltimore, MD USA; [Ringer, Robert J.] Clin Res Pharm Coordinating Ctr, VA Cooperat Studies Program, Albuquerque, NM USA; [Wagner, Todd H.] VA Palo Alto Healthcare Syst, Hlth Econ Resource Ctr, Menlo Pk, CA USA; [Krebs, Hermano I.] MIT, Cambridge, MA 02139 USA; [Volpe, Bruce T.] Cornell Univ, Weill Med Coll, Burke Med Res Inst, White Plains, NY USA; [Bravata, Dawn M.] Richard L Roudebush VAMC, Indianapolis, IN USA; [Duncan, Pamela W.] Duke Univ, Doctor Phys Therapy Program, Duke Div, Durham, NC USA; [Huang, Grant D.] VA Off Res & Dev Serv, Cooperat Studies Program Cent Off, Washington, DC USA	Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Brown University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; State University System of Florida; University of Florida; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; Geriatric Research Education & Clinical Center; University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Massachusetts Institute of Technology (MIT); Cornell University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; Duke University	Lo, AC (corresponding author), Brown Univ, Providence Vet Affairs Med Ctr, 830 Chalkstone Ave,111N, Providence, RI 02909 USA.	albert.lo@va.gov	volpe, b/U-8409-2019; Wittenberg, George F/J-8698-2015; Wittenberg, George/AAM-3428-2020	Wittenberg, George/0000-0001-5603-1197; Duncan, Pamela/0000-0002-4838-3253; Wagner, Todd/0000-0001-7625-3504; Lo, Albert/0000-0002-6508-1361; Volpe, Bruce/0000-0002-1098-1848	Veterans Affairs Cooperative Studies Program and Rehabilitation Research and Development Service; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD045343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028747, P30AG028740] Funding Source: NIH RePORTER	Veterans Affairs Cooperative Studies Program and Rehabilitation Research and Development Service; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by the Veterans Affairs Cooperative Studies Program and Rehabilitation Research and Development Service.	Atteya Abdul-Alim A, 2004, Neurosciences (Riyadh), V9, P24; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Broeks JG, 1999, DISABIL REHABIL, V21, P357; Dromerick AW, 2009, NEUROLOGY, V73, P195, DOI 10.1212/WNL.0b013e3181ab2b27; Dromerick AW, 2000, STROKE, V31, P2984, DOI 10.1161/01.STR.31.12.2984; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Fasoli SE, 2003, ARCH PHYS MED REHAB, V84, P477, DOI 10.1053/apmr.2003.50110; Ferraro M, 2003, NEUROLOGY, V61, P1604, DOI 10.1212/01.WNL.0000095963.00970.68; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; JENNISON C, 1997, J AM STAT ASSOC, V92, P1330; Jennison C, 1999, GROUP SEQUENTIAL MET; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; Krebs H I, 1998, IEEE Trans Rehabil Eng, V6, P75, DOI 10.1109/86.662623; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LAN KKG, 1993, STAT MED, V12, P753, DOI 10.1002/sim.4780120804; Lang CE, 2009, ARCH PHYS MED REHAB, V90, P1692, DOI 10.1016/j.apmr.2009.04.005; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Lo AC, 2009, NEUROREHAB NEURAL RE, V23, P775, DOI 10.1177/1545968309338195; Mehta CR, 2001, DRUG INF J, V35, P1095, DOI 10.1177/009286150103500407; Page SJ, 2004, ARCH PHYS MED REHAB, V85, P14, DOI 10.1016/S0003-9993(03)00481-7; Page SJ, 2008, PHYS THER, V88, P333, DOI 10.2522/ptj.20060029; Rigler SK, 2002, CLIN REHABIL, V16, P420, DOI 10.1191/0269215502cr515oa; Scharfstein DO, 1997, J AM STAT ASSOC, V92, P1342, DOI 10.2307/2965404; Studenski SA, 2004, AGE AGEING, V33, P195, DOI 10.1093/ageing/afh056; Suputtitada Areerat, 2004, Journal of the Medical Association of Thailand, V87, P1482; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; Volpe BT, 2008, NEUROREHAB NEURAL RE, V22, P305, DOI 10.1177/1545968307311102; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095	32	838	889	11	275	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 13	2010	362	19					1772	1783		10.1056/NEJMoa0911341	http://dx.doi.org/10.1056/NEJMoa0911341			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	594RQ	20400552	Green Accepted			2023-01-03	WOS:000277555500004
J	Bachmann, S; Finger, C; Huss, A; Egger, M; Stuck, AE; Clough-Gorr, KM				Bachmann, Stefan; Finger, Christoph; Huss, Anke; Egger, Matthias; Stuck, Andreas E.; Clough-Gorr, Kerri M.			Inpatient rehabilitation specifically designed for geriatric patients: systematic review and meta-analysis of randomised controlled trials	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIP FRACTURE; ELDERLY-PEOPLE; OLDER-PEOPLE; FUNCTIONAL DECLINE; CLINICAL-TRIAL; HEALTH-CARE; INTERNATIONAL CLASSIFICATION; CONCEPTUAL DESCRIPTION; COMMUNITY HOSPITALS; EVALUATION UNIT	Objective To assess the effects of inpatient rehabilitation specifically designed for geriatric patients compared with usual care on functional status, admissions to nursing homes, and mortality. Design Systematic review and meta-analysis. Data sources Medline, Embase, Cochrane database, and reference lists from published literature. Review methods Only randomised controlled trials were included. Trials had to report on inpatient rehabilitation and report at least one of functional improvement, admission to nursing homes, or mortality. Trials of consultation or outpatient services, trials including patients aged <55, trials of non-multidisciplinary rehabilitation, and trials without a control group receiving usual care were excluded. Data were double extracted. Odds ratios and relative risks with 95% confidence intervals were calculated. Results 17 trials with 4780 people comparing the effects of general or orthopaedic geriatric rehabilitation programmes with usual care were included. Metaanalyses of effects indicated an overall benefit in outcomes at discharge (odds ratio 1.75 (95% confidence interval 1.31 to 2.35) for function, relative risk 0.64 (0.51 to 0.81) for nursing home admission, relative risk 0.72 (0.55 to 0.95) for mortality) and at end of follow-up (1.36 (1.07 to 1.71), 0.84 (0.72 to 0.99), 0.87 (0.77 to 0.97), respectively). Limited data were available on impact on health care or cost. Compared with those in control groups, weighted mean length of hospital stay after randomisation was longer in patients allocated to general geriatric rehabilitation (24.5 v 15.1 days) and shorter in patients allocated to orthopaedic rehabilitation (24.6 v 28.9 days). Conclusion Inpatient rehabilitation specifically designed for geriatric patients has the potential to improve outcomes related to function, admission to nursing homes, and mortality. Insufficient data are available for defining characteristics and cost effectiveness of successful programmes.	[Bachmann, Stefan; Stuck, Andreas E.] Univ Hosp Bern, Inselspital, Dept Geriatr, Robert Bosch Fdn, CH-3010 Bern, Switzerland; [Bachmann, Stefan] Rehabil Ctr Klin Valens, CH-7317 Valens, Switzerland; [Huss, Anke; Egger, Matthias; Clough-Gorr, Kerri M.] Univ Bern, Inst Social & Prevent Med, CH-3012 Bern, Switzerland; [Huss, Anke] Netherlands Utrecht Univ, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; [Egger, Matthias] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; [Clough-Gorr, Kerri M.] Boston Univ, Med Ctr, Sect Geriatr, Boston, MA 02118 USA	University of Bern; University Hospital of Bern; University of Bern; Utrecht University; University of Bristol; Boston University	Stuck, AE (corresponding author), Univ Hosp Bern, Inselspital, Dept Geriatr, Robert Bosch Fdn, Freiburgstr 10, CH-3010 Bern, Switzerland.	andreas.stuck@spitalnetzbern.ch	Bachmann, Stefan/AAE-8947-2022	Huss, Anke/0000-0001-9268-1867	Robert Bosch Foundation, Stuttgart, Germany [32.5.1141.0021.0]	Robert Bosch Foundation, Stuttgart, Germany	SB was supported by a Forschungskolleg Geriatrie Grant from the Robert Bosch Foundation, Stuttgart, Germany (grant No 32.5.1141.0021.0).	APPLEGATE WB, 1991, AM J PUBLIC HEALTH, V81, P1302, DOI 10.2105/AJPH.81.10.1302; APPLEGATE WB, 1990, NEW ENGL J MED, V322, P1572, DOI 10.1056/NEJM199005313222205; Baztan JJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b50; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Beswick AD, 2008, LANCET, V371, P725, DOI 10.1016/S0140-6736(08)60342-6; Cameron I D, 1993, Disabil Rehabil, V15, P29; Chinn S, 2000, STAT MED, V19, P3127, DOI 10.1002/1097-0258(20001130)19:22<3127::AID-SIM784>3.0.CO;2-M; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ellis G, 2004, BRIT MED BULL, V71, P45, DOI 10.1093/bmb/ldh033; Fleming SA, 2004, AGE AGEING, V33, P384, DOI 10.1093/ageing/afh126; Gaugler Joseph E, 2007, BMC Geriatr, V7, P13, DOI 10.1186/1471-2318-7-13; GILCHRIST WJ, 1988, BRIT MED J, V297, P1116, DOI 10.1136/bmj.297.6656.1116; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; Green J, 2005, BMJ-BRIT MED J, V331, P317, DOI 10.1136/bmj.38498.387569.8F; Harbord RM, 2006, STAT MED, V25, P3443, DOI 10.1002/sim.2380; HASSELBLAD V, 1995, PSYCHOL BULL, V117, P167, DOI 10.1037/0033-2909.117.1.167; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Huss A, 2008, J GERONTOL A-BIOL, V63, P298, DOI 10.1093/gerona/63.3.298; Huusko TM, 2002, ACTA ORTHOP SCAND, V73, P425, DOI 10.1080/00016470216324; Huusko TM, 2000, BRIT MED J, V321, P1107, DOI 10.1136/bmj.321.7269.1107; Juni P, 2001, BMJ-BRIT MED J, V323, P42, DOI 10.1136/bmj.323.7303.42; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; KARPPI P, 1995, AGING-CLIN EXP RES, V7, P207, DOI 10.1007/BF03324317; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KENNIE DC, 1988, BRIT MED J, V297, P1083, DOI 10.1136/bmj.297.6656.1083; MAHONEY F I, 1965, Md State Med J, V14, P61; Naglie G, 2002, CAN MED ASSOC J, V167, P25; O'Reilly J, 2008, AGE AGEING, V37, P513, DOI 10.1093/ageing/afn120; Ottenbacher KJ, 2004, JAMA-J AM MED ASSOC, V292, P1687, DOI 10.1001/jama.292.14.1687; Phibbs CS, 2006, MED CARE, V44, P91, DOI 10.1097/01.mlr.0000188981.06522.e0; REID J, 1989, BRIT MED J, V299, P25, DOI 10.1136/bmj.299.6690.25-a; RUBENSTEIN LZ, 1988, J CLIN EPIDEMIOL, V41, P441, DOI 10.1016/0895-4356(88)90045-5; RUBENSTEIN LZ, 1995, AGING-CLIN EXP RES, V7, P212, DOI 10.1007/BF03324318; RUBENSTEIN LZ, 1984, NEW ENGL J MED, V311, P1664, DOI 10.1056/NEJM198412273112604; Saltvedt I, 2004, AGING CLIN EXP RES, V16, P300; Saltvedt I, 2002, J AM GERIATR SOC, V50, P792, DOI 10.1046/j.1532-5415.2002.50202.x; Saltvedt I, 2006, GERONTOLOGY, V52, P223, DOI 10.1159/000093654; Shyu YIL, 2005, J AM GERIATR SOC, V53, P811, DOI 10.1111/j.1532-5415.2005.53253.x; Stenvall M, 2007, J REHABIL MED, V39, P232, DOI 10.2340/16501977-0045; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Stettler C, 2006, AM HEART J, V152, P27, DOI 10.1016/j.ahj.2005.09.015; Stuck AE, 2002, JAMA-J AM MED ASSOC, V287, P1022, DOI 10.1001/jama.287.8.1022; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Stucki G, 2003, DISABIL REHABIL, V25, P628, DOI 10.1080/09638280110070221; Stucki G, 2007, J REHABIL MED, V39, P279, DOI 10.2340/16501977-0041; Stucki G, 2007, J REHABIL MED, V39, P286, DOI 10.2340/16501977-0044; Swanson CE, 1998, MED J AUSTRALIA, V169, P515, DOI 10.5694/j.1326-5377.1998.tb123397.x; Vidan M, 2005, J AM GERIATR SOC, V53, P1476, DOI 10.1111/j.1532-5415.2005.53466.x; Wells JL, 2003, ARCH PHYS MED REHAB, V84, P890, DOI 10.1016/S0003-9993(02)04929-8; White S J, 1994, J Tenn Med Assoc, V87, P425; WHO, 1981, WHO TECH REP SER, V668, P1; Young J, 2007, J AM GERIATR SOC, V55, P1995, DOI 10.1111/j.1532-5415.2007.01456.x	54	188	194	1	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 20	2010	340								c1718	10.1136/bmj.c1718	http://dx.doi.org/10.1136/bmj.c1718			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	589HM	20406866	Green Published, Green Submitted			2023-01-03	WOS:000277137700004
J	Ishizuka, T; Fujimori, I; Kato, M; Noji-Sakikawa, C; Saito, M; Yoshigae, Y; Kubota, K; Kurihara, A; Izumi, T; Ikeda, T; Okazaki, O				Ishizuka, Tomoko; Fujimori, Izumi; Kato, Mitsunori; Noji-Sakikawa, Chisa; Saito, Motoko; Yoshigae, Yasushi; Kubota, Kazuishi; Kurihara, Atsushi; Izumi, Takashi; Ikeda, Toshihiko; Okazaki, Osamu			Human Carboxymethylenebutenolidase as a Bioactivating Hydrolase of Olmesartan Medoxomil in Liver and Intestine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIENELACTONE HYDROLASE; CARBOXYLESTERASE ISOZYMES; HUMAN VALACYCLOVIRASE; CATALYTIC-PROPERTIES; PRODRUG; ACTIVATION; PROTEIN; IDENTIFICATION; HYDROLYSIS; STABILITY	Olmesartan medoxomil (OM) is a prodrug type angiotensin II type 1 receptor antagonist widely prescribed as an antihypertensive agent. Herein, we describe the identification and characterization of the OM bioactivating enzyme that hydrolyzes the prodrug and converts to its pharmacologically active metabolite olmesartan in human liver and intestine. The protein was purified from human liver cytosol by successive column chromatography and was identified by mass spectrometry to be a carboxymethylenebutenolidase (CMBL) homolog. Human CMBL, whose endogenous function has still not been reported, is a human homolog of Pseudomonas dienelactone hydrolase involved in the bacterial halocatechol degradation pathway. The ubiquitous expression of human CMBL gene transcript in various tissues was observed. The recombinant human CMBL expressed in mammalian cells was clearly shown to activate OM. By comparing the enzyme kinetics and chemical inhibition properties between the recombinant protein and human tissue preparations, CMBL was demonstrated to be the primary OM bioactivating enzyme in the liver and intestine. The recombinant CMBL also converted other prodrugs having the same ester structure as OM, faropenem medoxomil and lenampicillin, to their active metabolites. CMBL exhibited a unique sensitivity to chemical inhibitors, thus, being distinguishable from other known esterases. Site-directed mutagenesis on the putative active residue Cys(132) of the recombinant CMBL caused a drastic reduction of the OM-hydrolyzing activity. We report for the first time that CMBL serves as a key enzyme in the bioactivation of OM, hydrolyzing the ester bond of the prodrug type xenobiotics.	[Ishizuka, Tomoko; Kurihara, Atsushi; Izumi, Takashi; Okazaki, Osamu] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, Tokyo 1408710, Japan; [Fujimori, Izumi] Daiichi Sankyo Co Ltd, R&D Operat Dept, Tokyo 1408710, Japan; [Ikeda, Toshihiko] Yokohama Coll Pharm, Kanagawa 2450066, Japan; [Kato, Mitsunori; Noji-Sakikawa, Chisa; Kubota, Kazuishi] Daiichi Sankyo Co Ltd, Translat Med & Clin Pharmacol Dept, Tokyo 1408710, Japan	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Ishizuka, T (corresponding author), Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Shinagawa Ku, 1-2-58 Hiromachi, Tokyo 1408710, Japan.	ishizuka.tomoko.xx@daiichisankyo.co.jp						Beaumont K, 2003, CURR DRUG METAB, V4, P461, DOI 10.2174/1389200033489253; BEVERIDGE AJ, 1995, PROTEIN ENG, V8, P135, DOI 10.1093/protein/8.2.135; Carr PD, 2009, PROTEIN PEPTIDE LETT, V16, P1137; CHEAH E, 1993, PROTEINS, V16, P64, DOI 10.1002/prot.340160108; Chrysant SG, 2008, DRUG TODAY, V44, P443, DOI [10.1358/dot.2008.44.6.1223895, 10.1358/dot.2008.44.6.1219543]; Draganov DI, 2004, N-S ARCH PHARMACOL, V369, P78, DOI 10.1007/s00210-003-0833-1; Easthope SE, 2002, DRUGS, V62, P1253, DOI 10.2165/00003495-200262080-00016; Ettmayer P, 2004, J MED CHEM, V47, P2393, DOI 10.1021/jm0303812; Ewing RM, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100134; Finn RD, 2008, NUCLEIC ACIDS RES, V36, pD281, DOI 10.1093/nar/gkm960; Hosokawa M, 2008, MOLECULES, V13, P412, DOI 10.3390/molecules13020412; Imai T, 2006, DRUG METAB PHARMACOK, V21, P173, DOI 10.2133/dmpk.21.173; James RW, 2004, FREE RADICAL BIO MED, V37, P1986, DOI 10.1016/j.freeradbiomed.2004.08.012; Kim I, 2003, J BIOL CHEM, V278, P25348, DOI 10.1074/jbc.M302055200; Kubota K, 2003, PROTEOMICS, V3, P616, DOI 10.1002/pmic.200300410; Laeis Petra, 2001, Journal of Hypertension, V19, pS21; Lai LS, 2008, J BIOL CHEM, V283, P9318, DOI 10.1074/jbc.M709530200; Liederer BM, 2006, J PHARM SCI-US, V95, P1177, DOI 10.1002/jps.20542; Ma SF, 2005, DRUG METAB DISPOS, V33, P1911, DOI 10.1124/dmd.105.006163; NGAI KL, 1987, J BACTERIOL, V169, P699, DOI 10.1128/jb.169.2.699-703.1987; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PATHAK D, 1988, J MOL BIOL, V204, P435, DOI 10.1016/0022-2836(88)90587-6; PATHAK D, 1990, J MOL BIOL, V214, P497, DOI 10.1016/0022-2836(90)90196-S; PATHAK D, 1991, PROTEINS, V9, P267, DOI 10.1002/prot.340090405; Pieper U, 2006, NUCLEIC ACIDS RES, V34, pD291, DOI 10.1093/nar/gkj059; Redon Josep, 2009, J Renin Angiotensin Aldosterone Syst, V10, P147, DOI 10.1177/1470320309342735; Reyns T, 2008, J CHROMATOGR B, V861, P108, DOI 10.1016/j.jchromb.2007.11.007; SAARI WS, 1984, J MED CHEM, V27, P713, DOI 10.1021/jm00372a002; SAITO A, 1986, ANTIMICROB AGENTS CH, V29, P948, DOI 10.1128/AAC.29.5.948; SAKAMOTO F, 1984, CHEM PHARM BULL, V32, P2241; Satoh T, 2006, CHEM-BIOL INTERACT, V162, P195, DOI 10.1016/j.cbi.2006.07.001; Satoh Tetsuo, 2005, Toxicol Appl Pharmacol, V207, P11, DOI 10.1016/j.taap.2005.01.046; SCHMIDT E, 1980, BIOCHEM J, V192, P339, DOI 10.1042/bj1920339; Schurek KN, 2007, EXPERT REV ANTI-INFE, V5, P185, DOI 10.1586/14787210.5.2.185; Scott LJ, 2008, DRUGS, V68, P1239, DOI 10.2165/00003495-200868090-00005; TAYLOR P, 1991, J BIOL CHEM, V266, P4025; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; Testa B, 2004, BIOCHEM PHARMACOL, V68, P2097, DOI 10.1016/j.bcp.2004.07.005; TESTA B, 2003, HYDROLYSIS DRUG PROD, P1; Tougou K, 1998, DRUG METAB DISPOS, V26, P355	40	41	43	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 16	2010	285	16					11892	11902		10.1074/jbc.M109.072629	http://dx.doi.org/10.1074/jbc.M109.072629			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	584XI	20177059	Green Published, hybrid			2023-01-03	WOS:000276787100017
J	Kitchener, H; Powell, M				Kitchener, Henry; Powell, Melanie			Radiotherapy for endometrial cancer: a key piece in the jigsaw	LANCET			English	Editorial Material							RANDOMIZED-TRIAL; CARCINOMA; SURGERY		[Kitchener, Henry] Univ Manchester, Acad Hlth Sci Ctr, Cent Manchester Univ Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, Manchester M13 9WL, Lancs, England; [Powell, Melanie] Barts & London NHS Trust, Dept Radiotherapy, London, England	University of Manchester; Barts Health NHS Trust	Kitchener, H (corresponding author), Univ Manchester, Acad Hlth Sci Ctr, Cent Manchester Univ Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, Manchester M13 9WL, Lancs, England.	henry.kitchener@manchester.ac.uk						AALDERS J, 1980, OBSTET GYNECOL, V56, P419; Blake P, 2009, LANCET, V373, P137, DOI 10.1016/S0140-6736(08)61767-5; *CANC RES UK, UK UT WOMB CANC INC; Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5; Creutzberg CL, 2003, GYNECOL ONCOL, V89, P201, DOI 10.1016/S0090-8258(03)00126-4; CREUTZBERG CL, 2009, RANDOMIZED PHASE 3 T; Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048; Nout RA, 2010, LANCET, V375, P816, DOI 10.1016/S0140-6736(09)62163-2; Nout RA, 2009, J CLIN ONCOL, V27, P3547, DOI 10.1200/JCO.2008.20.2424	9	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 6	2010	375	9717					781	782		10.1016/S0140-6736(10)60099-2	http://dx.doi.org/10.1016/S0140-6736(10)60099-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	570MO	20206759				2023-01-03	WOS:000275682600005
J	Mouro-Chanteloup, I; Cochet, S; Chami, M; Genetet, S; Zidi-Yahiaoui, N; Engel, A; Colin, Y; Bertrand, O; Ripoche, P				Mouro-Chanteloup, Isabelle; Cochet, Sylvie; Chami, Mohamed; Genetet, Sandrine; Zidi-Yahiaoui, Nedjma; Engel, Andreas; Colin, Yves; Bertrand, Olivier; Ripoche, Pierre			Functional Reconstitution into Liposomes of Purified Human RhCG Ammonia Channel	PLOS ONE			English	Article							RED-BLOOD-CELLS; NITROSOMONAS-EUROPAEA; TRANSPORT; PROTEINS; GLYCOPROTEIN; EXPRESSION; MEMBRANE; KIDNEY; WATER; RHBG	Background: Rh glycoproteins (RhAG, RhBG, RhCG) are members of the Amt/Mep/Rh family which facilitate movement of ammonium across plasma membranes. Changes in ammonium transport activity following expression of Rh glycoproteins have been described in different heterologous systems such as yeasts, oocytes and eukaryotic cell lines. However, in these complex systems, a potential contribution of endogenous proteins to this function cannot be excluded. To demonstrate that Rh glycoproteins by themselves transport NH(3), human RhCG was purified to homogeneity and reconstituted into liposomes, giving new insights into its channel functional properties. Methodology/Principal Findings: An HA-tag introduced in the second extracellular loop of RhCG was used to purify to homogeneity the HA-tagged RhCG glycoprotein from detergent-solubilized recombinant HEK293E cells. Electron microscopy analysis of negatively stained purified RhCG-HA revealed, after image processing, homogeneous particles of 9 nm diameter with a trimeric protein structure. Reconstitution was performed with sphingomyelin, phosphatidylcholine and phosphatidic acid lipids in the presence of the C(12)E(8) detergent which was subsequently removed by Biobeads. Control of protein incorporation was carried out by freeze-fracture electron microscopy. Particle density in liposomes was a function of the Lipid/Protein ratio. When compared to empty liposomes, ammonium permeability was increased two and three fold in RhCG-proteoliposomes, depending on the Lipid/Protein ratio (1/300 and 1/150, respectively). This strong NH(3) transport was reversibly inhibited by mercuric and copper salts and exhibited a low Arrhenius activation energy. Conclusions/Significance: This study allowed the determination of ammonia permeability per RhCG monomer, showing that the apparent Punit(NH3) (around 1 x 10(-3) mu m(3).s(-1)) is close to the permeability measured in HEK293E cells expressing a recombinant human RhCG (1.60 x 10(-3) mu m(3).s(-1)), and in human red blood cells endogenously expressing RhAG (2.18 x 10(-3) mu m(3).s(-1)). The major finding of this study is that RhCG protein is active as an NH(3) channel and that this function does not require any protein partner.	[Mouro-Chanteloup, Isabelle; Cochet, Sylvie; Genetet, Sandrine; Zidi-Yahiaoui, Nedjma; Colin, Yves; Bertrand, Olivier; Ripoche, Pierre] INSERM, UMR S 665, Paris, France; [Mouro-Chanteloup, Isabelle; Cochet, Sylvie; Genetet, Sandrine; Zidi-Yahiaoui, Nedjma; Colin, Yves; Bertrand, Olivier; Ripoche, Pierre] Univ Paris Diderot Paris 7, Paris, France; [Mouro-Chanteloup, Isabelle; Cochet, Sylvie; Genetet, Sandrine; Zidi-Yahiaoui, Nedjma; Colin, Yves; Bertrand, Olivier; Ripoche, Pierre] Inst Natl Transfus Sanguine, F-75015 Paris, France; [Chami, Mohamed; Engel, Andreas] Univ Basel, Biozentrum, E Muller Inst Struct Biol, Ctr Imaging & Nanoanalyt,C CINA, Basel, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Basel	Mouro-Chanteloup, I (corresponding author), INSERM, UMR S 665, Paris, France.	isabelle.mouro-chanteloup@inserm.fr	colin, yves/O-1910-2017; Isabelle, Mouro-Chanteloup/M-9750-2018	colin, yves/0000-0001-5196-4254; Isabelle, Mouro-Chanteloup/0000-0002-6368-9904; GENETET, Sandrine/0000-0001-8497-0087	Institut National de la Transfusion Sanguine, Paris; INSERM, Paris; Societe Francaise d'Hematologie; Societe Francaise de Nephrologie; Fondation pour la Recherche Medicale	Institut National de la Transfusion Sanguine, Paris; INSERM, Paris(Institut National de la Sante et de la Recherche Medicale (Inserm)); Societe Francaise d'Hematologie; Societe Francaise de Nephrologie; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale)	This work was supported by the Institut National de la Transfusion Sanguine, Paris and INSERM, Paris. N.Z.-Y. acknowledges the financial support of the Societe Francaise d'Hematologie, of the Societe Francaise de Nephrologie and of the Fondation pour la Recherche Medicale. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bakouh N, 2004, J BIOL CHEM, V279, P15975, DOI 10.1074/jbc.M308528200; Benjelloun F, 2005, PFLUG ARCH EUR J PHY, V450, P155, DOI 10.1007/s00424-005-1381-y; Biver S, 2008, NATURE, V456, P339, DOI 10.1038/nature07518; Bruce LJ, 2009, BLOOD, V113, P1350, DOI 10.1182/blood-2008-07-171140; Bruce LJ, 2003, BLOOD, V101, P4180, DOI 10.1182/blood-2002-09-2824; Butterworth RF, 2003, ALCOHOL RES HEALTH, V27, P143; Callebaut I, 2006, TRANSFUS CLIN BIOL, V13, P70, DOI 10.1016/j.tracli.2006.02.001; Cartron JP, 1999, BEST PRACT RES CL HA, V12, P655, DOI 10.1053/beha.1999.0047; Eladari D, 2002, J AM SOC NEPHROL, V13, P1999, DOI 10.1097/01.ASN.0000025280.02386.9D; Han KH, 2009, AM J PHYSIOL-LUNG C, V297, pL153, DOI 10.1152/ajplung.90524.2008; HODAK M, 2009, P NATL ACAD SCI US; Huang CH, 2005, P NATL ACAD SCI USA, V102, P15512, DOI 10.1073/pnas.0507886102; Javelle A, 2007, J STRUCT BIOL, V158, P472, DOI 10.1016/j.jsb.2007.01.004; Juge N, 2006, J BIOL CHEM, V281, P39499, DOI 10.1074/jbc.M607670200; Kaufmann TC, 2006, BIOPHYS J, V90, P310, DOI 10.1529/biophysj.105.070193; Khademi S, 2004, SCIENCE, V305, P1587, DOI 10.1126/science.1101952; Lee SY, 2009, J MOL BIOL, V387, P1055, DOI 10.1016/j.jmb.2009.02.034; Li X, 2007, P NATL ACAD SCI USA, V104, P19279, DOI 10.1073/pnas.0709710104; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Lupo D, 2007, P NATL ACAD SCI USA, V104, P19303, DOI 10.1073/pnas.0706563104; Mak DOD, 2006, AM J PHYSIOL-RENAL, V290, pF297, DOI 10.1152/ajprenal.00147.2005; Marini AM, 1997, TRENDS BIOCHEM SCI, V22, P460, DOI 10.1016/S0968-0004(97)01132-8; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Mayer M, 2006, J GEN PHYSIOL, V127, P133, DOI 10.1085/jgp.200509369; Nakhoul NL, 2005, AM J PHYSIOL-RENAL, V288, pF170, DOI 10.1152/ajprenal.00419.2003; Nicolas V, 2003, J BIOL CHEM, V278, P25526, DOI 10.1074/jbc.M302816200; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; Quentin F, 2003, J AM SOC NEPHROL, V14, P545, DOI 10.1097/01.ASN.0000050413.43662.55; Rigaud JL, 2003, METHOD ENZYMOL, V372, P65; Ripoche P, 2004, P NATL ACAD SCI USA, V101, P17222, DOI 10.1073/pnas.0403704101; Stewart GS, 2006, AM J PHYSIOL-RENAL, V290, pF1437, DOI 10.1152/ajprenal.00449.2005; VANHEESWIJK MPE, 1986, J MEMBRANE BIOL, V92, P183, DOI 10.1007/BF01870707; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; Verlander JW, 2003, AM J PHYSIOL-RENAL, V284, pF323, DOI 10.1152/ajprenal.00050.2002; Weidinger K, 2007, FEMS MICROBIOL LETT, V273, P260, DOI 10.1111/j.1574-6968.2007.00805.x; Weiner ID, 2007, ANNU REV PHYSIOL, V69, P317, DOI 10.1146/annurev.physiol.69.040705.142215; Weiner ID, 2006, TRANSFUS CLIN BIOL, V13, P159, DOI 10.1016/j.tracli.2006.02.002; Westhoff CM, 2002, J BIOL CHEM, V277, P12499, DOI 10.1074/jbc.C200060200; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002; Zheng L, 2004, P NATL ACAD SCI USA, V101, P17090, DOI 10.1073/pnas.0406475101; Zidi-Yahiaoui N, 2005, BIOCHEM J, V391, P33, DOI 10.1042/BJ20050657; ZIDIYAHIAOUI N, 2009, AM J PHYSL CELL PHYS	43	38	40	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2010	5	1							e8921	10.1371/journal.pone.0008921	http://dx.doi.org/10.1371/journal.pone.0008921			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	550OR	20126667	Green Published, gold, Green Submitted			2023-01-03	WOS:000274138000004
J	Olasveengen, TM; Sunde, K; Brunborg, C; Thowsen, J; Steen, PA; Wik, L				Olasveengen, Theresa M.; Sunde, Kjetil; Brunborg, Cathrine; Thowsen, Jon; Steen, Petter A.; Wik, Lars			Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNATIONAL LIAISON COMMITTEE; EUROPEAN-RESUSCITATION-COUNCIL; AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY-RESUSCITATION; LIFE-SUPPORT; VENTRICULAR-FIBRILLATION; ADRENALINE EPINEPHRINE; CHEST COMPRESSIONS; QUALITY; VASOPRESSIN	Context Intravenous access and drug administration are included in advanced cardiac life support (ACLS) guidelines despite a lack of evidence for improved outcomes. Epinephrine was an independent predictor of poor outcome in a large epidemiological study, possibly due to toxicity of the drug or cardiopulmonary resuscitation (CPR) interruptions secondary to establishing an intravenous line and drug administration. Objective To determine whether removing intravenous drug administration from an ACLS protocol would improve survival to hospital discharge after out-of-hospital cardiac arrest. Design, Setting, and Patients Prospective, randomized controlled trial of consecutive adult patients with out-of-hospital nontraumatic cardiac arrest treated within the emergency medical service system in Oslo, Norway, between May 1, 2003, and April 28, 2008. Interventions Advanced cardiac life support with intravenous drug administration or ACLS without access to intravenous drug administration. Main Outcome Measures The primary outcome was survival to hospital discharge. The secondary outcomes were 1-year survival, survival with favorable neurological outcome, hospital admission with return of spontaneous circulation, and quality of CPR (chest compression rate, pauses, and ventilation rate). Results Of 1183 patients for whom resuscitation was attempted, 851 were included; 418 patients were in the ACLS with intravenous drug administration group and 433 were in the ACLS with no access to intravenous drug administration group. The rate of survival to hospital discharge was 10.5% for the intravenous drug administration group and 9.2% for the no intravenous drug administration group (P=.61), 32% vs 21%, respectively, (P<.001) for hospital admission with return of spontaneous circulation, 9.8% vs 8.1% (P=.45) for survival with favorable neurological outcome, and 10% vs 8%(P=.53) for survival at 1 year. The quality of CPR was comparable and within guideline recommendations for both groups. After adjustment for ventricular fibrillation, response interval, witnessed arrest, or arrest in a public location, there was no significant difference in survival to hospital discharge for the intravenous group vs the no intravenous group (adjusted odds ratio, 1.15; 95% confidence interval, 0.69-1.91). Conclusion Compared with patients who received ACLS without intravenous drug administration following out-of-hospital cardiac arrest, patients with intravenous access and drug administration had higher rates of short-term survival with no statistically significant improvement in survival to hospital discharge, quality of CPR, or long-term survival. Trial Registration clinicaltrials.gov Identifier: NCT00121524 JAMA. 2009; 302(20): 2222-2229	[Olasveengen, Theresa M.; Wik, Lars] Oslo Univ Hosp, Expt Med Res Inst, N-0407 Oslo, Norway; [Brunborg, Cathrine] Oslo Univ Hosp, Clin Res Ctr, N-0407 Oslo, Norway; [Wik, Lars] Oslo Univ Hosp, Natl Competence Ctr Emergency Med, N-0407 Oslo, Norway; [Olasveengen, Theresa M.] Oslo Univ Hosp, Dept Anesthesiol, N-0407 Oslo, Norway; [Thowsen, Jon; Steen, Petter A.] Oslo Univ Hosp, Dept Ambulance, N-0407 Oslo, Norway; [Sunde, Kjetil] Oslo Univ Hosp, Surg Intens Care Unit, N-0407 Oslo, Norway; [Steen, Petter A.] Oslo Univ Hosp, Fac Div UUH, N-0407 Oslo, Norway	University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo; University of Oslo	Olasveengen, TM (corresponding author), Oslo Univ Hosp, Expt Med Res Inst, N-0407 Oslo, Norway.	t.m.olasveengen@medisin.uio.no			Eastern Norway Regional Health Authority; Oslo University Hospital; Norwegian Air Ambulance Foundation; Laerdal Foundation for Acute Medicine; Anders Jahres Fund	Eastern Norway Regional Health Authority; Oslo University Hospital; Norwegian Air Ambulance Foundation; Laerdal Foundation for Acute Medicine; Anders Jahres Fund	Funding/Support: The study was supported by grants from the Eastern Norway Regional Health Authority, Oslo University Hospital, Norwegian Air Ambulance Foundation, Laerdal Foundation for Acute Medicine, and the Anders Jahres Fund.	*2005 AM HEART ASS, 2005, CIRCULATION, V112, P58, DOI DOI 10.1161/CIRCULATIONAHA.105.16657; American Heart Association, 2000, CIRCULATION, V102, P1, DOI [10.1161/circ.102.suppl_1.I-1, DOI 10.1161/CIRC.102.SUPPL_1.I-1]; Angelos MG, 2008, RESUSCITATION, V77, P101, DOI 10.1016/j.resuscitation.2007.10.017; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Birks EJ, 2006, NEW ENGL J MED, V355, P1873, DOI 10.1056/NEJMoa053063; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P32; Chen YS, 2008, LANCET, V372, P554, DOI 10.1016/S0140-6736(08)60958-7; Ewy GA, 2009, J AM COLL CARDIOL, V53, P149, DOI 10.1016/j.jacc.2008.05.066; Gazmuri RJ, 2007, RESUSCITATION, V75, P400, DOI 10.1016/j.resuscitation.2007.09.008; Grogaard HK, 2007, J AM COLL CARDIOL, V50, P1093, DOI 10.1016/j.jacc.2007.05.028; Holmberg M, 2002, RESUSCITATION, V54, P37, DOI 10.1016/S0300-9572(02)00048-5; Holzer M, 2002, NEW ENGL J MED, V346, P549; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; Morris DC, 2008, NEW ENGL J MED, V359, P1624, DOI 10.1056/NEJMc081591; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Odegaard S, 2007, RESUSCITATION, V74, P127, DOI 10.1016/j.resuscitation.2006.12.006; OTTO CW, 1984, ANN EMERG MED, V13, P840, DOI 10.1016/S0196-0644(84)80455-2; PEARSON JW, 1963, AM HEART J, V66, P210, DOI 10.1016/0002-8703(63)90036-X; Pocock S. J., 1983, CLIN TRIALS PRACTICA, P123; Pytte M, 2006, RESUSCITATION, V71, P369, DOI 10.1016/j.resuscitation.2006.05.003; Ristagno G, 2007, CRIT CARE MED, V35, P2145, DOI 10.1097/01.CCM.0000280427.76175.D2; SILFVAST T, 1991, J INTERN MED, V229, P331, DOI 10.1111/j.1365-2796.1991.tb00355.x; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; Stiell IG, 2004, NEW ENGL J MED, V351, P647, DOI 10.1056/NEJMoa040325; STUEVEN HA, 1984, ANN EMERG MED, V13, P815, DOI 10.1016/S0196-0644(84)80447-3; Sunde K, 2007, RESUSCITATION, V73, P29, DOI 10.1016/j.resuscitation.2006.08.016; TANG WC, 1995, CIRCULATION, V92, P3089, DOI 10.1161/01.CIR.92.10.3089; Vandycke C, 2000, RESUSCITATION, V45, P161, DOI 10.1016/S0300-9572(00)00188-X; Virkkunen I, 2008, RESUSCITATION, V77, P207, DOI 10.1016/j.resuscitation.2007.12.006; Wenzel V, 2004, NEW ENGL J MED, V350, P105, DOI 10.1056/NEJMoa025431; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389	36	336	345	0	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	2009	302	20					2222	2229		10.1001/jama.2009.1729	http://dx.doi.org/10.1001/jama.2009.1729			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	523NI	19934423				2023-01-03	WOS:000272080500026
J	Bidon, C; Lachuer, J; Molgo, J; Wierinckx, A; de la Porte, S; Pignol, B; Christen, Y; Meloni, R; Koenig, H; Faucon-Biguet, N; Mallet, J				Bidon, Caroline; Lachuer, Joel; Molgo, Jordi; Wierinckx, Anne; de la Porte, Sabine; Pignol, Bernadette; Christen, Yves; Meloni, Rolando; Koenig, Herbert; Faucon-Biguet, Nicole; Mallet, Jacques			The Extract of Ginkgo biloba EGb 761 Reactivates a Juvenile Profile in the Skeletal Muscle of Sarcopenic Rats by Transcriptional Reprogramming	PLOS ONE			English	Article							FATTY-ACID OXIDATION; GENE-EXPRESSION; CALORIC RESTRICTION; LIFE-SPAN; BETA; COLLAGEN; GLUCOSE; REGENERATION; METABOLISM; RESISTANCE	Background: Sarcopenia is a major public health problem in industrialized nations, placing an increasing burden on public healthcare systems because the loss of skeletal muscle mass and strength that characterizes this affection increases the dependence and the risk of injury caused by sudden falls in elderly people. Albeit exercise and caloric restriction improve sarcopenia-associated decline of the muscular performances, a more suitable and focused pharmacological treatment is still lacking. Methodology/Principal Findings: In order to evaluate such a possible treatment, we investigated the effects of EGb 761, a Ginkgo biloba extract used in chronic age-dependent neurological disorders, on the function of the soleus muscle in aged rats. EGb 761 induced a gain in muscular mass that was associated with an improvement of the muscular performances as assessed by biochemical and electrophysiological tests. DNA microarray analysis shows that these modifications are accompanied by the transcriptional reprogramming of genes related to myogenesis through the TGF beta signaling pathway and to energy production via fatty acids and glucose oxidation. EGb 761 restored a more juvenile gene expression pattern by regenerating the aged muscle and reversing the age-related metabolic shift from lipids to glucose utilization. Conclusions/Significance: Thus, EGb 761 may represent a novel treatment for sarcopenia both more manageable and less cumbersome than exercise and caloric restriction.	[Bidon, Caroline; Meloni, Rolando; Koenig, Herbert; Faucon-Biguet, Nicole; Mallet, Jacques] Hop La Pitie Salpetriere, CNRS, Biotechnol & Biotherapie UMR 7225, Paris, France; [Bidon, Caroline; Meloni, Rolando; Koenig, Herbert; Faucon-Biguet, Nicole; Mallet, Jacques] Hop La Pitie Salpetriere, INSERM, CRICM UMR S 975, Paris, France; [Bidon, Caroline; Meloni, Rolando; Koenig, Herbert; Faucon-Biguet, Nicole; Mallet, Jacques] UPMC Univ Paris 06, Paris, France; [Lachuer, Joel; Wierinckx, Anne] INSERM, Lab Neurooncol & Neuroinflammat U842, F-69008 Lyon, France; [Lachuer, Joel] ProfileXpert, IFR19, Bron, France; [Lachuer, Joel] Univ Lyon 1, UMR S842, F-69365 Lyon, France; [Molgo, Jordi; de la Porte, Sabine] CNRS, Inst Neurobiol Alfred Fessard, Cellular & Mol Neurobiol Lab, UPR9040, Gif Sur Yvette, France; [Christen, Yves] Ipsen, Boulogne Billancourt, France; [Pignol, Bernadette] Ipsen Res Labs, Les Ulis, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Ipsen	Bidon, C (corresponding author), Hop La Pitie Salpetriere, CNRS, Biotechnol & Biotherapie UMR 7225, Paris, France.	jacques.mallet@upmc.fr	de la PORTE, Sabine/AAE-4208-2022; de la Porte, Sabine/N-5275-2018; Wierinckx, Anne/AAF-5233-2021; Meloni, Rolando/GOJ-7446-2022	de la PORTE, Sabine/0000-0002-7725-8646; Wierinckx, Anne/0000-0002-0186-6645; Meloni, Rolando/0000-0002-6464-8469; lachuer, joel/0000-0002-5209-5094	IPSEN; Beaufour-Ipsen; C.N.R.S.	IPSEN(Ipsen); Beaufour-Ipsen(Ipsen); C.N.R.S.(Centre National de la Recherche Scientifique (CNRS)European Commission)	This work was partly financed by IPSEN ("Institut des produits de synthese et d'extraction naturelle'') http://web2.ipsen.com/. CB was the recipient of a thesis bursary from IPSEN. BP and YC are employed by IPSEN. This work was supported by Beaufour-Ipsen and the C.N.R.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahlemeyer B, 2003, PHARMACOPSYCHIATRY, V36, pS8; Ahtikoski AM, 2003, ACTA PHYSIOL SCAND, V177, P473, DOI 10.1046/j.1365-201X.2003.01061.x; Armand AS, 2003, DEV DYNAM, V227, P256, DOI 10.1002/dvdy.10306; Bezaire V, 2007, FASEB J, V21, P312, DOI 10.1096/fj.06-6966rev; Blaak EE, 1999, J CLIN ENDOCR METAB, V84, P3764, DOI 10.1210/jc.84.10.3764; Bruce CR, 2006, AM J PHYSIOL-ENDOC M, V291, pE99, DOI 10.1152/ajpendo.00587.2005; CHRISTEN Y, 2004, OXIDAT STRESS DIS, P145; Criscuolo F, 2005, P ROY SOC B-BIOL SCI, V272, P803, DOI 10.1098/rspb.2004.3044; Dardevet D, 2002, J NUTR, V132, P95, DOI 10.1093/jn/132.1.95; Faulkner JA, 1995, ADV EXP MED BIOL, V384, P471; Fontaniere S, 2006, ENDOCR-RELAT CANCER, V13, P1223, DOI 10.1677/erc.1.01294; HANSON AN, 1983, ANAL BIOCHEM, V130, P32, DOI 10.1016/0003-2697(83)90646-2; HEPPLE RT, 2003, SCI AGING KNOWLEDGE, V46, pPE31; Huijing PA, 1999, J BIOMECH, V32, P329, DOI 10.1016/S0021-9290(98)00186-9; Ibrahimi A, 1999, J BIOL CHEM, V274, P26761, DOI 10.1074/jbc.274.38.26761; Ker RF, 2002, COMP BIOCHEM PHYS A, V133, P987, DOI 10.1016/S1095-6433(02)00171-X; Kollias HD, 2008, J APPL PHYSIOL, V104, P579, DOI 10.1152/japplphysiol.01091.2007; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lynch Gordon S, 2004, Expert Opin Emerg Drugs, V9, P345, DOI 10.1517/14728214.9.2.345; Marzetti E, 2008, FREE RADICAL BIO MED, V44, P160, DOI 10.1016/j.freeradbiomed.2007.05.028; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; McLennan IS, 2002, INT J DEV BIOL, V46, P559; Navarro A, 2001, FRONT BIOSCI-LANDMRK, V6, pD26, DOI 10.2741/Navarro; Nguyen-Huu T, 2005, ANESTHESIOLOGY, V103, P788, DOI 10.1097/00000542-200510000-00017; Oh KS, 2007, EXP MOL MED, V39, P385, DOI 10.1038/emm.2007.43; Park SK, 2005, CARDIOVASC RES, V66, P205, DOI 10.1016/j.cardiores.2005.01.005; Pattison JS, 2003, PHYSIOL GENOMICS, V15, P34, DOI 10.1152/physiolgenomics.00040.2003; Perez CF, 2005, AM J PHYSIOL-CELL PH, V288, pC640, DOI 10.1152/ajpcell.00407.2004; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; ROSENBERG IH, 1989, AM J CLIN NUTR, V50, P1231, DOI 10.1093/ajcn/50.5.1231; Sastre J, 2002, CELL MOL BIOL, V48, P685; Sekiya T, 2004, BIOCHEM BIOPH RES CO, V320, P680, DOI 10.1016/j.bbrc.2004.06.017; Selman C, 2006, PHYSIOL GENOMICS, V27, P187, DOI 10.1152/physiolgenomics.00084.2006; Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x; Toth MJ, 2000, EUR J CLIN NUTR, V54, pS121, DOI 10.1038/sj.ejcn.1601033; Vianna CR, 2001, PHYSIOL GENOMICS, V5, P137, DOI 10.1152/physiolgenomics.2001.5.3.137; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; WHALEN RG, 1990, DEV BIOL, V141, P24, DOI 10.1016/0012-1606(90)90099-5; Winter JC, 1998, PHYSIOL BEHAV, V63, P425, DOI 10.1016/S0031-9384(97)00464-2; Wu ZX, 2002, CELL MOL BIOL, V48, P725; Yamaza H, 2002, MICROSC RES TECHNIQ, V59, P325, DOI 10.1002/jemt.10212; Yarasheski K E, 2002, J Nutr Health Aging, V6, P343	42	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2009	4	11							e7998	10.1371/journal.pone.0007998	http://dx.doi.org/10.1371/journal.pone.0007998			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	533MH	19956636	gold, Green Submitted, Green Published			2023-01-03	WOS:000272827500025
J	van Linschoten, R; van Middelkoop, M; Berger, MY; Heintjes, EM; Verhaar, JAN; Willemsen, SP; Koes, BW; Bierma-Zeinstra, SM				van Linschoten, R.; van Middelkoop, M.; Berger, M. Y.; Heintjes, E. M.; Verhaar, J. A. N.; Willemsen, S. P.; Koes, B. W.; Bierma-Zeinstra, S. M.			Supervised exercise therapy versus usual care for patellofemoral pain syndrome: an open label randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTERIOR KNEE PAIN; CLOSED KINETIC CHAIN; CLINICAL-TRIAL; PHYSIOTHERAPY; MANAGEMENT; DISORDERS; TESTS	Objective To assess the effectiveness of supervised exercise therapy compared with usual care with respect to recovery, pain, and function in patients with patellofemoral pain syndrome. Design Open label randomised controlled trial. Setting General practice and sport physician practice. Participants Patients with a new episode of patellofemoral pain syndrome recruited by their general practitioner or sport physician. Interventions The intervention group received a standardised exercise programme for 6 weeks tailored to individual performance and supervised by a physical therapist, and were instructed to practise the tailored exercises at home for 3 months. The control group were assigned usual care, which comprised a "wait and see" approach of rest during periods of pain and refraining from pain provoking activities. Both the intervention group and the control group received written information about patellofemoral pain syndrome and general instructions for home exercises. Main outcome measures The primary outcomes were self reported recovery (7 point Likert scale), pain at rest and pain on activity (0-10 point numerical rating scale), and function (0-100 point Kujala patellofemoral score) at 3 months and 12 months follow-up. Results A total of 131 participants were included in the study: 65 in the intervention group and 66 in the control group. After 3 months, the intervention group showed better outcomes than the control group with regard to pain at rest (adjusted difference -1.07, 95% confidence interval -1.92 to -0.22; effect size 0.47), pain on activity (-1.00, -1.91 to -0.08; 0.45), and function (4.92, 0.14 to 9.72; 0.34). At 12 months, the intervention group continued to show better outcomes than the control group with regard to pain (adjusted difference in pain at rest -1.29, -2.16 to -0.42; effect size 0.56; pain on activity -1.19, -2.22 to -0.16; effect size 0.54), but not function (4.52, -0.73 to 9.76). A higher proportion of patients in the exercise group than in the control group reported recovery (41.9% v 35.0% at 3 months and 62.1% v 50.8% at 12 months), although the differences in self reported recovery between the two groups were not statistically significant. Predefined subgroup analyses revealed that patients recruited by sport physicians (n=30) did not benefit from the intervention, whereas those recruited by general practitioners (n=101) showed significant and clinically relevant differences in pain and function in favour of the intervention group. Conclusion Supervised exercise therapy resulted in less pain and better function at short term and long term follow-up compared with usual care in patients with patellofemoral pain syndrome in general practice. Exercise therapy did not produce a significant difference in the rate of self reported recovery.	[van Linschoten, R.; van Middelkoop, M.; Berger, M. Y.; Willemsen, S. P.; Koes, B. W.; Bierma-Zeinstra, S. M.] Erasmus Univ, Med Ctr, Dept Gen Practice, Rotterdam, Netherlands; [Verhaar, J. A. N.] Erasmus Univ, Med Ctr, Dept Orthopaed, Rotterdam, Netherlands; [Willemsen, S. P.] Erasmus Univ, Med Ctr, Dept Epidemiol & Biostat, Rotterdam, Netherlands; [Heintjes, E. M.] PHARMO Inst, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Linschoten, R (corresponding author), Erasmus Univ, Med Ctr, Dept Gen Practice, Rotterdam, Netherlands.	r.v.linschoten@hccnet.nl	Bierma-Zeinstra, Sita/AAF-2122-2019; Koes, Bart w/K-4614-2016; Verhaar, Jan/AAH-1372-2020	Koes, Bart w/0000-0002-0450-9969; Verhaar, Jan/0000-0003-3016-9600; van Middelkoop, Marienke/0000-0001-6926-0618	ZON-MW (The Netherlands organisation for health research and development)	ZON-MW (The Netherlands organisation for health research and development)(Netherlands Organization for Health Research and Development)	This study was supported by ZON-MW (The Netherlands organisation for health research and development).	Bizzini M, 2003, J ORTHOP SPORT PHYS, V33, P4, DOI 10.2519/jospt.2003.33.1.4; CIRKEL JW, 1998, HUISARTS WET, V41, P246; Clark DI, 2000, ANN RHEUM DIS, V59, P700, DOI 10.1136/ard.59.9.700; Collins N, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1735; Crossley K, 2002, AM J SPORT MED, V30, P857, DOI 10.1177/03635465020300061701; Crossley KM, 2004, ARCH PHYS MED REHAB, V85, P815, DOI 10.1016/S0003-9993(03)00613-0; Cutbill JW, 1997, CLIN J SPORT MED, V7, P40, DOI 10.1097/00042752-199701000-00008; Dehaven K E, 1979, Am J Sports Med, V7, P5, DOI 10.1177/036354657900700102; DENHERTOG PC, 2003, ONGEVALLEN BEWEGEN N; Dixit S, 2007, AM FAM PHYSICIAN, V75, P194; DOWNIE WW, 1978, ANN RHEUM DIS, V37, P378, DOI 10.1136/ard.37.4.378; Dursun N, 2001, ARCH PHYS MED REHAB, V82, P1692, DOI 10.1053/apmr.2001.26253; GOBELET C, 1992, REV RHUM, V59, P23; Hartung J., 2008, STAT METAANALYSIS AP; Heintjes EM, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003472, DOI 10.1002/14651858.CD003472]; KUJALA UM, 1993, ARTHROSCOPY, V9, P159, DOI 10.1016/S0749-8063(05)80366-4; Lun VMY, 2005, CLIN J SPORT MED, V15, P233; Malanga GA, 2003, ARCH PHYS MED REHAB, V84, P592, DOI 10.1053/apmr.2003.50026; Mayo E., 1949, HAWTHORNE W ELECT CO; McConnell J, 2002, CLIN SPORT MED, V21, P363, DOI 10.1016/S0278-5919(02)00027-3; Nijs J, 2006, MANUAL THER, V11, P69, DOI 10.1016/j.math.2005.04.002; Nimon G, 1998, J PEDIATR ORTHOPED, V18, P118, DOI 10.1097/00004694-199801000-00021; SANCHISALFONSO V, 2006, ANTERIOR KNEE PAIN P; Stiene HA, 1996, J ORTHOP SPORT PHYS, V24, P136, DOI 10.2519/jospt.1996.24.3.136; Taunton JE, 2002, BRIT J SPORT MED, V36, P95, DOI 10.1136/bjsm.36.2.95; Thomee R, 1999, SPORTS MED, V28, P245, DOI 10.2165/00007256-199928040-00003; Timm KE, 1998, MED SCI SPORT EXER, V30, P665, DOI 10.1097/00005768-199805000-00004; van der Velden J, 1991, NATL STUDIE NAAR ZIE; van Linschoten R, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-31; WHITELAW GP, 1989, CLIN ORTHOP RELAT R, P234; Witvrouw E, 2000, AM J SPORT MED, V28, P687, DOI 10.1177/03635465000280051201; Witvrouw E, 2005, KNEE SURG SPORT TR A, V13, P122, DOI 10.1007/s00167-004-0577-6; Witvrouw E, 2004, AM J SPORT MED, V32, P1122, DOI 10.1177/0363546503262187	33	90	92	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 20	2009	339								b4074	10.1136/bmj.b4074	http://dx.doi.org/10.1136/bmj.b4074			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	510PJ	19843565	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000271102100003
J	Sissoko, MS; Dabo, A; Traore, H; Diallo, M; Traore, B; Konate, D; Niare, B; Diakite, M; Kamate, B; Traore, A; Bathily, A; Tapily, A; Toure, OB; Cauwenbergh, S; Jansen, HF; Doumbo, OK				Sissoko, Mahamadou S.; Dabo, Abdoulaye; Traore, Hamidou; Diallo, Mouctar; Traore, Boubacar; Konate, Drissa; Niare, Boubacar; Diakite, Moussa; Kamate, Bourama; Traore, Abdrahamane; Bathily, Aboudramane; Tapily, Amadou; Toure, Ousmane B.; Cauwenbergh, Sarah; Jansen, Herwig F.; Doumbo, Ogobara K.			Efficacy of Artesunate plus Sulfamethoxypyrazine/Pyrimethamine versus Praziquantel in the Treatment of Schistosoma haematobium in Children	PLOS ONE			English	Article							ARTEMETHER-LUMEFANTRINE; FALCIPARUM-MALARIA; MANSONI FOCUS; PYRIMETHAMINE; COMBINATION; INFECTION; COMMUNITY; PATHOLOGY; BLADDER; KIDNEY	Background: This study was conducted to determine the efficacy of the antimalarial artemisinin-based combination therapy (ACT) artesunate + sulfamethoxypyrazine/pyrimethamine (As+SMP), administered in doses used for malaria, to treat Schistosoma haematobium in school aged children. Methodology/Principal Findings: The study was conducted in Djalakorodji, a peri-urban area of Bamako, Mali, using a double blind setup in which As+SMP was compared with praziquantel (PZQ). Urine samples were examined for Schistosoma haematobium on days -1, 0, 28 and 29. Detection of haematuria, and haematological and biochemical exams were conducted on day 0 and day 28. Clinical exams were performed on days 0, 1, 2, and 28. A total of 800 children were included in the trial. The cure rate obtained without viability testing was 43.9% in the As+SMP group versus 53% in the PZQ group (Chi(2) = 6.44, p = 0.011). Egg reduction rates were 95.6% with PZQ in comparison with 92.8% with As+SMP, p = 0.096. The proportion of participants who experienced adverse events related to the medication was 0.5% (2/400) in As+SMP treated children compared to 2.3% (9/399) in the PZQ group (p = 0.033). Abdominal pain and vomiting were the most frequent adverse events in both treatment arms. All adverse events were categorized as mild. Conclusions/Significance: The study demonstrates that PZQ was more effective than As+SMP for treating Schistosoma haematobium. However, the safety and tolerability profile of As+SMP was similar to that seen with PZQ. Our findings suggest that further investigations seem justifiable to determine the dose/efficacy/safety pattern of As+SMP in the treatment of Schistosoma infections.			Sissoko, MS (corresponding author), Univ Bamako, Malaria Res & Training Ctr, Fac Med Pharm & Odontostomatol, Dept Epidemiol Parasit Dis, Bamako, Mali.	mssissoko@mrtcbko.org						Adam I, 2008, ANN TROP MED PARASIT, V102, P39, DOI 10.1179/136485908X252214; BERTE N, 1999, ACTA TROP, V72, P53; Boulanger D, 2007, T ROY SOC TROP MED H, V101, P113, DOI 10.1016/j.trstmh.2006.03.003; Brouwer KC, 2003, ACTA TROP, V85, P339, DOI 10.1016/S0001-706X(02)00262-0; CLERCQ D, 2002, ACTA TROP, V82, P61; Danso-Appiah A, 2009, PARASITOLOGY, V136, P1837, DOI 10.1017/S0031182009005939; DANSOAPPIAH A, 2008, COCHRANE DB SYST REV, V16; DOUMENGUE JP, 1987, ATLAS GLOBAL DISTRIB; Gryseels B, 2001, TROP MED INT HEALTH, V6, P864, DOI 10.1046/j.1365-3156.2001.00811.x; GRYSEELS B, 1987, T ROY SOC TROP MED H, V81, P641, DOI 10.1016/0035-9203(87)90439-1; Guisse F, 1997, AM J TROP MED HYG, V56, P511, DOI 10.4269/ajtmh.1997.56.511; Inyang-Etoh PC, 2004, ANN TROP MED PARASIT, V98, P491, DOI 10.1179/000349804225003460; Jaoko WG, 1996, E AFR MED J, V73, P499; Kabatereine NB, 2003, T ROY SOC TROP MED H, V97, P599, DOI 10.1016/S0035-9203(03)80044-5; Kimura Eisaku, 1992, Tropical Medicine, V34, P91; KIRSTEN E, 2005, AM J TROP MED HYG, V73, P1124; KLAYMAN DL, 1985, SCIENCE, V228, P1049, DOI 10.1126/science.3887571; Kouriba B, 2005, J INFECT DIS, V192, P2152, DOI 10.1086/498214; MCCARTHY JJ, 2001, INTERGOVERNMENTAL PA; Midzi N, 2008, T ROY SOC TROP MED H, V102, P759, DOI 10.1016/j.trstmh.2008.03.010; Nmorsi O. P. G., 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P32; Raso G, 2004, T ROY SOC TROP MED H, V98, P18, DOI 10.1016/S0035-9203(03)00003-8; Sagara I, 2006, AM J TROP MED HYG, V75, P630, DOI 10.4269/ajtmh.2006.75.630; Sagara I, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-63; SHUHUA X, 1989, ANTIMICROB AGENTS CH, V33, P1557, DOI 10.1128/AAC.33.9.1557; SISSOKO K, 2005, THESIS; STELMA FF, 1995, AM J TROP MED HYG, V53, P167, DOI 10.4269/ajtmh.1995.53.167; Utzinger J, 2003, ANTIMICROB AGENTS CH, V47, P1487, DOI 10.1128/AAC.47.5.1487-1495.2003; Utzinger J, 2001, ACTA TROP, V80, P9, DOI 10.1016/S0001-706X(01)00138-3; Utzinger J, 2007, CURR OPIN INVEST DR, V8, P105; WEGNER DHG, 1984, ARZNEIMITTEL-FORSCH, V34-2, P1132; *WHO, 2005, WHOTDRSWG07; *WHO, 2002, WHOCDCCPEPVC20024; World Health Organization, 1993, WHO TECHN REP SER; Xiao SH, 2006, INT J PARASITOL, V36, P957, DOI 10.1016/j.ijpara.2006.03.007	35	33	38	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 5	2009	4	10							e6732	10.1371/journal.pone.0006732	http://dx.doi.org/10.1371/journal.pone.0006732			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	504DG	19802383	Green Submitted, gold, Green Published			2023-01-03	WOS:000270593600001
J	Dawson, R; Condos, R; Tse, D; Huie, ML; Ress, S; Tseng, CH; Brauns, C; Weiden, M; Hoshino, Y; Bateman, E; Rom, WN				Dawson, Rod; Condos, Rany; Tse, Doris; Huie, Maryann L.; Ress, Stanley; Tseng, Chi-Hong; Brauns, Clint; Weiden, Michael; Hoshino, Yoshihiko; Bateman, Eric; Rom, William N.			Immunomodulation with Recombinant Interferon-gamma 1b in Pulmonary Tuberculosis	PLOS ONE			English	Article								Background: Current treatment regimens for pulmonary tuberculosis require at least 6 months of therapy. Immune adjuvant therapy with recombinant interferon-gamma 1b (rIFN-gamma b) may reduce pulmonary inflammation and reduce the period of infectivity by promoting earlier sputum clearance. Methodology/Principal Findings: We performed a randomized, controlled clinical trial of directly observed therapy (DOTS) versus DOTS supplemented with nebulized or subcutaneously administered rIFN-gamma 1b over 4 months to 89 patients with cavitary pulmonary tuberculosis. Bronchoalveolar lavage (BAL) and blood were sampled at 0 and 4 months. There was a significant decline in levels of inflammatory cytokines IL-1 beta, IL-6, IL-8, and IL-10 in 24-hour BAL supernatants only in the nebulized rIFN-gamma 1b group from baseline to week 16. Both rIFN-gamma 1b groups showed significant 3-fold increases in CD4+ lymphocyte response to PPD at 4 weeks. There was a significant (p = 0.03) difference in the rate of clearance of Mtb from the sputum smear at 4 weeks for the nebulized rIFN-gamma 1b adjuvant group compared to DOTS or DOTS with subcutaneous rIFN-gamma 1b. In addition, there was significant reduction in the prevalence of fever, wheeze, and night sweats at 4 weeks among patients receiving rFN-gamma 1b versus DOTS alone. Conclusion: Recombinant interferon-gamma 1b adjuvant therapy plus DOTS in cavitary pulmonary tuberculosis can reduce inflammatory cytokines at the site of disease, improve clearance of Mtb from the sputum, and improve constitutional symptoms.			Dawson, R (corresponding author), Univ Cape Town, Dept Med, Fac Hlth Sci, Div Pulmonol, ZA-7925 Cape Town, South Africa.	William.Rom@nyumc.edu	Hoshino, Yoshihiko/B-5159-2019	Hoshino, Yoshihiko/0000-0002-3132-0715; Rom, William/0000-0002-8793-7028	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059832, R01HL057879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007267] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR000096, MO1 RR00096] Funding Source: Medline; NHLBI NIH HHS [R01 HL059832-10, R01 HL059832, R01 HL057879, HL57879, HL59832] Funding Source: Medline; NIEHS NIH HHS [T32 ES007267] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bai XY, 2004, TUBERCULOSIS, V84, P375, DOI 10.1016/j.tube.2004.05.001; Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8; Bonecini-Almeida MG, 2004, INFECT IMMUN, V72, P2628, DOI 10.1128/IAI.72.5.2628-2634.2004; Condos R, 1997, LANCET, V349, P1513, DOI 10.1016/S0140-6736(96)12273-X; Condos R, 2003, INFECT IMMUN, V71, P2058, DOI 10.1128/IAI.71.4.2058-2064.2003; Dheda K, 2007, TUBERCULOSIS, V87, P237, DOI 10.1016/j.tube.2006.11.001; Dorman SE, 2004, LANCET, V364, P2113, DOI 10.1016/S0140-6736(04)17552-1; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; Giosue S, 1998, AM J RESP CRIT CARE, V158, P1156, DOI 10.1164/ajrccm.158.4.9803065; Gold JA, 2004, INFECT IMMUN, V72, P645, DOI 10.1128/IAI.72.2.645-650.2004; Grassi M, 2006, CLIN IMMUNOL, V121, P100, DOI 10.1016/j.clim.2006.06.008; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hirsch CS, 1999, J INFECT DIS, V180, P2069, DOI 10.1086/315114; Hougardy JM, 2007, AM J RESP CRIT CARE, V176, P409, DOI 10.1164/rccm.200701-084OC; JAFFE HA, 1991, J CLIN INVEST, V88, P297, DOI 10.1172/JCI115291; Johnson JL, 2003, AM J RESP CRIT CARE, V168, P185, DOI 10.1164/rccm.200211-1359OC; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6; Maartens G, 2007, LANCET, V370, P2030, DOI 10.1016/S0140-6736(07)61262-8; MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063; Marchant A, 2001, AM J RESP CELL MOL, V24, P187, DOI 10.1165/ajrcmb.24.2.4274; Martineau AR, 2007, J CLIN INVEST, V117, P1988, DOI 10.1172/JCI31097; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; Seneviratne SL, 2007, THORAX, V62, P97, DOI 10.1136/thx.2005.051649; Suarez-Mendez R, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-44; Toossi Zahra, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P513; TRAMONTANA JM, 1995, MOL MED, V1, P384, DOI 10.1007/BF03401576; van der Wel N, 2007, CELL, V129, P1287, DOI 10.1016/j.cell.2007.05.059; Young DB, 2008, J CLIN INVEST, V118, P1255, DOI 10.1172/JCI34614; ZHANG YH, 1995, J CLIN INVEST, V95, P586, DOI 10.1172/JCI117702	30	75	77	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2009	4	9							e6984	10.1371/journal.pone.0006984	http://dx.doi.org/10.1371/journal.pone.0006984			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	494FO	19753300	gold, Green Published, Green Submitted			2023-01-03	WOS:000269796500001
J	Mok, TS; Wu, YL; Thongprasert, S; Yang, CH; Chu, DT; Saijo, N; Sunpaweravong, P; Han, BH; Margono, B; Ichinose, Y; Nishiwaki, Y; Ohe, Y; Yang, JJ; Chewaskulyong, B; Jiang, HY; Duffield, EL; Watkins, CL; Armour, AA; Fukuoka, M				Mok, Tony S.; Wu, Yi-Long; Thongprasert, Sumitra; Yang, Chih-Hsin; Chu, Da-Tong; Saijo, Nagahiro; Sunpaweravong, Patrapim; Han, Baohui; Margono, Benjamin; Ichinose, Yukito; Nishiwaki, Yutaka; Ohe, Yuichiro; Yang, Jin-Ji; Chewaskulyong, Busyamas; Jiang, Haiyi; Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.; Fukuoka, Masahiro			Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL LUNG-CANCER; FACTOR-RECEPTOR GENE; PROSPECTIVE PHASE-II; FUNCTIONAL ASSESSMENT; 1ST-LINE GEFITINIB; TREATED PATIENTS; EGFR MUTATIONS; THERAPY; MULTICENTER; ERLOTINIB	Background: Previous, uncontrolled studies have suggested that first-line treatment with gefitinib would be efficacious in selected patients with non-small-cell lung cancer. Methods: In this phase 3, open-label study, we randomly assigned previously untreated patients in East Asia who had advanced pulmonary adenocarcinoma and who were nonsmokers or former light smokers to receive gefitinib (250 mg per day) (609 patients) or carboplatin (at a dose calculated to produce an area under the curve of 5 or 6 mg per milliliter per minute) plus paclitaxel (200 mg per square meter of body-surface area) (608 patients). The primary end point was progression-free survival. Results: The 12-month rates of progression-free survival were 24.9% with gefitinib and 6.7% with carboplatin-paclitaxel. The study met its primary objective of showing the noninferiority of gefitinib and also showed its superiority, as compared with carboplatin-paclitaxel, with respect to progression-free survival in the intention-to-treat population (hazard ratio for progression or death, 0.74; 95% confidence interval [CI], 0.65 to 0.85; P<0.001). In the subgroup of 261 patients who were positive for the epidermal growth factor receptor gene (EGFR) mutation, progression-free survival was significantly longer among those who received gefitinib than among those who received carboplatin-paclitaxel (hazard ratio for progression or death, 0.48; 95% CI, 0.36 to 0.64; P<0.001), whereas in the subgroup of 176 patients who were negative for the mutation, progression-free survival was significantly longer among those who received carboplatin-paclitaxel (hazard ratio for progression or death with gefitinib, 2.85; 95% CI, 2.05 to 3.98; P<0.001). The most common adverse events were rash or acne (in 66.2% of patients) and diarrhea (46.6%) in the gefitinib group and neurotoxic effects (69.9%), neutropenia (67.1%), and alopecia (58.4%) in the carboplatin-paclitaxel group. Conclusions: Gefitinib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia. The presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib. (ClinicalTrials.gov number, NCT00322452.) N Engl J Med 2009;361:947-57.	[Mok, Tony S.] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China; [Wu, Yi-Long; Yang, Jin-Ji] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China; [Chu, Da-Tong] Chinese Acad Med Sci, Canc Hosp, Beijing 100037, Peoples R China; [Han, Baohui] Shanghai Chest Hosp, Shanghai, Peoples R China; [Thongprasert, Sumitra; Chewaskulyong, Busyamas] Chiang Mai Univ, Maharaj Nakorn Chiang Mai Hosp, Chiang Mai 50000, Thailand; [Sunpaweravong, Patrapim] Prince Songkla Univ, Hat Yai, Thailand; [Yang, Chih-Hsin] Natl Taiwan Univ Hosp, Taipei, Taiwan; [Saijo, Nagahiro; Nishiwaki, Yutaka] Natl Canc Ctr Hosp E, Chiba, Japan; [Ichinose, Yukito] Kyushu Natl Canc Ctr, Fukuoka, Japan; [Ohe, Yuichiro] Natl Canc Ctr, Tokyo, Japan; [Jiang, Haiyi] AstraZeneca, Osaka, Japan; [Fukuoka, Masahiro] Kinki Univ, Sch Med, Osaka 589, Japan; [Margono, Benjamin] Dr Soetomo Hosp, Surabaya, Indonesia; [Duffield, Emma L.; Watkins, Claire L.; Armour, Alison A.] AstraZeneca, Macclesfield, Cheshire, England	Chinese University of Hong Kong; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Shanghai Jiao Tong University; Chiang Mai University; Prince of Songkla University; National Taiwan University; National Taiwan University Hospital; National Cancer Center - Japan; National Cancer Center - Japan; AstraZeneca; Kindai University (Kinki University); Dr Soetomo General Hospital Surabaya; AstraZeneca	Mok, TS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Shatin, Hong Kong, Peoples R China.	tony@clo.cuhk.edu.hk	Wu, Yi-Long/AAW-9832-2020; Wu, Yi-Long/AAB-9137-2022; Wu, Yi-Long/C-3396-2008; Mok, Tony Shu Kam/B-2310-2019; Wu, Yi-Long/GRJ-9238-2022; Yang, James Chih-Hsin/W-1587-2019	Wu, Yi-Long/0000-0002-3611-0258; Mok, Tony Shu Kam/0000-0002-8251-0551; Wu, Yi-Long/0000-0002-3611-0258; Yang, James Chih-Hsin/0000-0002-5586-5138	AstraZeneca	AstraZeneca(AstraZeneca)	We thank the patients and investigators for their participation in this study and Annette Smith, Ph. D., from Complete Medical Communications, who provided editing support funded by AstraZeneca.	Cella D, 2002, J CLIN EPIDEMIOL, V55, P285, DOI 10.1016/S0895-4356(01)00477-2; CELLA DF, 1995, LUNG CANCER-J IASLC, V12, P199, DOI 10.1016/0169-5002(95)00450-F; Chang GC, 2005, INVEST NEW DRUG, V23, P73, DOI 10.1023/B:DRUG.0000047108.39129.7c; Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Hirsch FR, 2006, J CLIN ONCOL, V24, P5034, DOI 10.1200/JCO.2006.06.3958; Inoue A, 2006, J CLIN ONCOL, V24, P3340, DOI 10.1200/JCO.2005.05.4692; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Kimura H, 2006, J THORAC ONCOL, V1, P260, DOI 10.1016/S1556-0864(15)31577-X; Kosaka T, 2004, CANCER RES, V64, P8919, DOI 10.1158/0008-5472.CAN-04-2818; Lee DH, 2005, CLIN CANCER RES, V11, P3032, DOI 10.1158/1078-0432.CCR-04-2149; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668; Morikawa T, 1995, J Biopharm Stat, V5, P297, DOI 10.1080/10543409508835115; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Park K, 2006, CURR MED RES OPIN, V22, P561, DOI 10.1185/030079906X89847; Pfister DG, 2004, J CLIN ONCOL, V22, P330, DOI 10.1200/JCO.2004.09.053; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Sequist, 2008, J CLIN ONCOL, V26, P3472, DOI 10.1200/JCO.2008.18.4747; Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Tamura K, 2008, BRIT J CANCER, V98, P907, DOI 10.1038/sj.bjc.6604249; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Westfall P.H., 1993, RESAMPLING BASED MUL; Whitcombe D, 1999, NAT BIOTECHNOL, V17, P804, DOI 10.1038/11751; Yang CH, 2008, J CLIN ONCOL, V26, P2745, DOI 10.1200/JCO.2007.15.6695; Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924	32	6231	6663	13	637	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	2009	361	10					947	957		10.1056/NEJMoa0810699	http://dx.doi.org/10.1056/NEJMoa0810699			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	490EI	19692680	Bronze			2023-01-03	WOS:000269480400004
J	O'Donnell, MR; Jarand, J; Loveday, M; Padayatchi, N; Zelnick, J; Werner, L; Naidoo, K; Master, I; Osburn, G; Kvasnovsky, C; Shean, K; Pai, M; Van der Walt, M; Horsburgh, CR; Dheda, K				O'Donnell, Max R.; Jarand, Julie; Loveday, Marian; Padayatchi, Nesri; Zelnick, Jennifer; Werner, Lise; Naidoo, Kasavan; Master, Iqbal; Osburn, Garth; Kvasnovsky, Charlotte; Shean, Karen; Pai, Madhukar; Van der Walt, Martie; Horsburgh, Charles R.; Dheda, Keertan			High Incidence of Hospital Admissions With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Among South African Health Care Workers	ANNALS OF INTERNAL MEDICINE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; RISK; HIV; INFECTION; TB	Background: Nosocomial transmission has been described in extensively drug-resistant tuberculosis (XDR-TB) and HIV co-infected patients in South Africa. However, little is known about the rates of drug-resistant tuberculosis among health care workers in countries with high tuberculosis and HIV burden. Objective: To estimate rates of multidrug-resistant tuberculosis (MDR-TB) and XDR-TB hospitalizations among health care workers in KwaZulu-Natal, South Africa. Design: Retrospective study of patients with drug-resistant tuberculosis who were admitted from 2003 to 2008 for the initiation of drug-resistant tuberculosis therapy. Setting: A public tuberculosis referral hospital in KwaZulu-Natal, South Africa. Participants: 231 health care workers and 4151 non-health care workers admitted for initiation of MDR-TB or XDR-TB treatment. Measurements: Hospital admission rates and hospital admission incidence rate ratios. Results: Estimated incidence of MDR-TB hospitalization was 64.8 per 100 000 health care workers versus 11.9 per 100 000 non-health care workers (incidence rate ratio, 5.46 [95% CI, 4.75 to 6.28]). Estimated incidence of XDR-TB hospitalizations was 7.2 per 100 000 health care workers versus 1.1 per 100 000 non-health care workers (incidence rate ratio, 6.69 [CI, 4.38 to 10.20]). A higher percentage of health care workers than non-health care workers with MDR-TB or XDR-TB were women (78% vs. 47%; P < 0.001), and health care workers were less likely to report previous tuberculosis treatment (41% vs. 92%; P < 0.001). HIV infection did not differ between health care workers and nonhealth care workers (55% vs. 57%); however, among HIV-infected patients, a higher percentage of health care workers were receiving antiretroviral medications (63% vs. 47%; P < 0.001). Limitation: The study had an observational retrospective design, is subject to referral bias, and had no information on type of health care work or duration of occupational exposure to tuberculosis. Conclusion: Health care workers in this HIV-endemic area were substantially more likely to be hospitalized with either MDR-TB or XDR-TB than were non-health care workers. The increased risk may be explained by occupational exposure, underlining the urgent need for tuberculosis infection-control programs.	Boston Univ, Sch Med, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Univ KwaZulu Natal, Ctr AIDS Programme Res S Africa, Durban, South Africa; Univ Calgary, Calgary, AB, Canada; MRC, Cape Town, South Africa; Salem State Coll, Sch Social Work, Salem, MA 01970 USA; King George V Mem Hosp, Sydenham, South Africa; Emory Univ, Sch Med, Atlanta, GA USA; Rollins Sch Publ Hlth, Atlanta, GA USA; UCL, London, England; McGill Univ, Montreal, PQ, Canada	Boston University; Boston University; University of Kwazulu Natal; University of Calgary; Massachusetts System of Public Higher Education; Salem State University; Emory University; Emory University; Rollins School Public Health; University of London; University College London; McGill University	O'Donnell, MR (corresponding author), Albert Einstein Coll Med, Div Pulm Med, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	max.odonnell@einstein.yu.edu	van der Walt, Martie/CAH-0101-2022; Pai, Madhukar/AAX-9901-2021; PAL, MRINAL/ABG-9676-2020; padayatchi, nesri/Q-2780-2019; Loveday, Marian/M-8016-2013; Mitchell, Ellen/H-5475-2013	van der Walt, Martie/0000-0001-9987-3167; Pai, Madhukar/0000-0003-3667-4536; PAL, MRINAL/0000-0002-1032-272X; padayatchi, nesri/0000-0003-2543-9071; Loveday, Marian/0000-0001-9205-9314; Horsburgh, C./0000-0001-6838-7895; Naidoo, Kogieleum/0000-0002-8874-6661	National Institutes of Health, National Institutes of Allergy and Infectious Diseases [T32 AI52074]; American Thoracic Society; Centre for AIDS Programme of Research; National Institutes of Health; U.S. Department of Health and Human Services the Centre for AIDS Programme of Research [A1069469]; Fogarty International Center, National Institutes of Health [D43TW00231]; Canadian Institutes of Health Research; FOGARTY INTERNATIONAL CENTER [D43TW000231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI052074, U01AI069469] Funding Source: NIH RePORTER	National Institutes of Health, National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); American Thoracic Society; Centre for AIDS Programme of Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Health and Human Services the Centre for AIDS Programme of Research; Fogarty International Center, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Dr. O'Donnell was supported by the National Institutes of Health (T32 AI52074; National Institutes of Allergy and Infectious Diseases) and an American Thoracic Society Career Development Award. In addition, Drs. O'Donnell and Padayatchi were supported by the Centre for AIDS Programme of Research. The National Institutes of Health and the U.S. Department of Health and Human Services funds the Centre for AIDS Programme of Research (A1069469). Dr. Padayatchi was also supported by Columbia University-Southern African Fogarty AIDS International Training and Research Programme funded by the Fogarty International Center, National Institutes of Health (D43TW00231). Dr. Pai is supported by a New Investigator Award from the Canadian Institutes of Health Research. These funding sources played no role in the study design or data analysis.	Askew GL, 1997, PEDIATRICS, V100, P19, DOI 10.1542/peds.100.1.19; Basu S, 2008, EPIDEMIOL INFECT, V136, P1585, DOI 10.1017/S0950268808000964; Basu S, 2007, LANCET, V370, P1500, DOI 10.1016/S0140-6736(07)61636-5; BUTHELEZI S, 2008, 2 GLOB XDR TB TASK F; *CDCP, 2006, MMWR-MORBID MORTAL W, V55, P1176; CLEVELAND JL, 1995, INFECT CONT HOSP EP, V16, P7; Dheda K, 2010, LANCET, V375, P1798, DOI 10.1016/S0140-6736(10)60492-8; Dimitrova B, 2005, INT J TUBERC LUNG D, V9, P43; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; Galgalo T, 2008, INT J TUBERC LUNG D, V12, P949; Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1; Gandhi NR, 2010, AM J RESP CRIT CARE, V181, P80, DOI 10.1164/rccm.200907-0989OC; GANDHI NR, 2006, JAMA-J AM MED ASSOC, V296, P2927; GANDHI NR, 2008, J CLIN EPIDEMIOL, V61, P344; *HLTH SYST TRUST, 2007, S AFR HLTH REV; James P, 2009, INT J TUBERC LUNG D, V13, P795; Joshi R, 2006, PLOS MED, V3, P2376, DOI 10.1371/journal.pmed.0030494; Karim QA, 2002, INT J EPIDEMIOL, V31, P37, DOI 10.1093/ije/31.1.37; Karim SSA, 2009, LANCET, V374, P921, DOI 10.1016/S0140-6736(09)60916-8; Menzies D, 2007, INT J TUBERC LUNG D, V11, P593; Naidoo S, 2006, INT J TUBERC LUNG D, V10, P676; O'Donnell MR, 2009, INT J TUBERC LUNG D, V13, P855; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; Raviglione MC, 2007, NEW ENGL J MED, V356, P656, DOI 10.1056/NEJMp068273; REISNER BS, 1995, DIAGN MICR INFEC DIS, V22, P325, DOI 10.1016/0732-8893(95)00147-7; Rusch-Gerdes S, 2006, J CLIN MICROBIOL, V44, P688, DOI 10.1128/JCM.44.3.688-692.2006; Sotgiu G, 2008, INT J TUBERC LUNG D, V12, P606; *STAT S AFR, 2007, S AFR COMM SURV; *STAT S AFR, 2001, S AFR NAT POP CENS; Wells CD, 2007, J INFECT DIS, V196, pS86, DOI 10.1086/518665; World Health Organization, 2009, WHO POL TB INF CONTR; World Health Organization, 2008, GLOB TUB CONTR SURV; Zelnick J, 2005, J PUBLIC HEALTH POL, V26, P163, DOI 10.1057/palgrave.jphp.3200021	33	146	151	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 19	2010	153	8					516	522		10.7326/0003-4819-153-8-201010190-00008	http://dx.doi.org/10.7326/0003-4819-153-8-201010190-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	665SA	20956708	Green Accepted			2023-01-03	WOS:000283054600004
J	Morris, RT; Monk, BJ				Morris, Robert T.; Monk, Bradley J.			Ovarian cancer: relevant therapy, not timing, is paramount	LANCET			English	Editorial Material							PEGYLATED LIPOSOMAL DOXORUBICIN; TRIAL; CARCINOMA		[Morris, Robert T.] Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA; [Morris, Robert T.] St John Hosp & Med Ctr, Detroit, MI USA; [Monk, Bradley J.] Creighton Univ, Sch Med, Dept Obstet & Gynecol, St Josephs Hosp & Med Ctr,Div Gynecol Oncol, Phoenix, AZ USA	Wayne State University; St. John Hospital & Medical Center; Creighton University; St. Joseph's Hospital and Medical Center	Morris, RT (corresponding author), Wayne State Univ, Dept Obstet & Gynecol, Detroit, MI 48201 USA.	rmorris@med.wayne.edu						Burger RA, 2007, J CLIN ONCOL, V25, P5165, DOI 10.1200/JCO.2007.11.5345; Chi DS, 2000, GYNECOL ONCOL, V77, P227, DOI 10.1006/gyno.2000.5749; Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312; Monk BJ, 2010, J CLIN ONCOL, V28, P3107, DOI 10.1200/JCO.2009.25.4037; Monk BJ, 2009, INT J GYNECOL CANCER, V19, pS63, DOI 10.1111/IGC.0b013e3181c104fa; Munkarah A, 2001, GYNECOL ONCOL, V81, P237, DOI 10.1006/gyno.2001.6143; Parmar MKB, 2003, LANCET, V361, P2099; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Pujade-Lauraine E, 2010, J CLIN ONCOL, V28, P3323, DOI 10.1200/JCO.2009.25.7519; Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8	10	14	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 2	2010	376	9747					1120	1122		10.1016/S0140-6736(10)61515-2	http://dx.doi.org/10.1016/S0140-6736(10)61515-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888975				2023-01-03	WOS:000282915700005
J	Denzler, KL; Waters, R; Jacobs, BL; Rochon, Y; Langland, JO				Denzler, Karen L.; Waters, Robert; Jacobs, Bertram L.; Rochon, Yvan; Langland, Jeffrey O.			Regulation of Inflammatory Gene Expression in PBMCs by Immunostimulatory Botanicals	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; NF-KAPPA-B; ASTRAGALUS-MEMBRANACEUS; ALTERNATIVE MEDICINE; GLYCYRRHIZA-GLABRA; IN-VITRO; COMPLEMENTARY MEDICINE; BACTERIAL ENDOPHYTES; ECHINACEA-PURPUREA; RADIX-ASTRAGALI	Many hundreds of botanicals are used in complementary and alternative medicine for therapeutic use as antimicrobials and immune stimulators. While there exists many centuries of anecdotal evidence and few clinical studies on the activity and efficacy of these botanicals, limited scientific evidence exists on the ability of these botanicals to modulate the immune and inflammatory responses. Using botanogenomics (or herbogenomics), this study provides novel insight into inflammatory genes which are induced in peripheral blood mononuclear cells following treatment with immunomodulatory botanical extracts. These results may suggest putative genes involved in the physiological responses thought to occur following administration of these botanical extracts. Using extracts from immunostimulatory herbs (Astragalus membranaceus, Sambucus cerulea, Andrographis paniculata) and an immunosuppressive herb (Urtica dioica), the data presented supports previous cytokine studies on these herbs as well as identifying additional genes which may be involved in immune cell activation and migration and various inflammatory responses, including wound healing, angiogenesis, and blood pressure modulation. Additionally, we report the presence of lipopolysaccharide in medicinally prepared extracts of these herbs which is theorized to be a natural and active component of the immunostimulatory herbal extracts. The data presented provides a more extensive picture on how these herbs may be mediating their biological effects on the immune and inflammatory responses.	[Denzler, Karen L.; Waters, Robert; Jacobs, Bertram L.; Langland, Jeffrey O.] Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA; [Waters, Robert; Rochon, Yvan; Langland, Jeffrey O.] SW Coll Naturopath Med, Dept Naturopath Res, Tempe, AZ USA; [Rochon, Yvan] Herbal Vital Inc, Sedona, AZ USA	Arizona State University; Arizona State University-Tempe	Denzler, KL (corresponding author), Arizona State Univ, Biodesign Inst, Tempe, AZ 85287 USA.	Jeffrey.Langland@asu.edu			Arizona State University Biodesign Institute; Southwest College of Naturopathic Medicine	Arizona State University Biodesign Institute; Southwest College of Naturopathic Medicine	Funding was provided by the Arizona State University Biodesign Institute and the Southwest College of Naturopathic Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Barak V, 2001, EUR CYTOKINE NETW, V12, P290; BARAK V, 2004, ISR MED ASSOC J, V4, P919; Barnes Patricia M, 2004, Adv Data, P1; Barrios-Rodiles M, 1998, J IMMUNOL, V161, P2441; Bergner P., 2005, MED HERBALISM, V14, P1; Bezugla Y, 2006, PROSTAG OTH LIPID M, V79, P93, DOI 10.1016/j.prostaglandins.2005.11.001; Block Keith I, 2003, Integr Cancer Ther, V2, P247, DOI 10.1177/1534735403256419; Brush J, 2006, PHYTOTHER RES, V20, P687, DOI 10.1002/ptr.1938; Caroff M, 2002, MICROBES INFECT, V4, P915, DOI 10.1016/S1286-4579(02)01612-X; Chen W, 2008, EXP CLIN ENDOCR DIAB, V116, P468, DOI 10.1055/s-2008-1058081; Cho WCS, 2007, CANCER LETT, V252, P43, DOI 10.1016/j.canlet.2006.12.001; Cho WCS, 2007, J ETHNOPHARMACOL, V113, P132, DOI 10.1016/j.jep.2007.05.020; Chomarat P, 2000, NAT IMMUNOL, V1, P510, DOI 10.1038/82763; Dong Jing, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P872; Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; Fleming LW, 1999, SCOT MED J, V44, P176, DOI 10.1177/003693309904400609; Fontanarosa PB, 1998, JAMA-J AM MED ASSOC, V280, P1618, DOI 10.1001/jama.280.18.1618; Freudenberg MA, 2008, IMMUNOBIOLOGY, V213, P193, DOI 10.1016/j.imbio.2007.11.008; Fu PP, 2009, J ENVIRON SCI HEAL C, V27, P91, DOI 10.1080/10590500902885676; Ganguly T, 2001, PHYTOMEDICINE, V8, P348, DOI 10.1078/0944-7113-00055; GESSANI S, 1993, J IMMUNOL, V151, P3758; Girard R, 2003, J CELL SCI, V116, P293, DOI 10.1242/jcs.00212; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Hallemeesch MM, 2003, AM J PHYSIOL-ENDOC M, V285, pE871, DOI 10.1152/ajpendo.00004.2002; Han DO, 2009, METHOD FIND EXP CLIN, V31, P95, DOI 10.1358/mf.2009.31.2.1353846; Han SJ, 2002, J BIOL CHEM, V277, P44715, DOI 10.1074/jbc.M202524200; HIKINO H, 1976, PLANTA MED, V30, P297, DOI 10.1055/s-0028-1097733; Hmama Z, 1999, J BIOL CHEM, V274, P1050, DOI 10.1074/jbc.274.2.1050; HONG H, 1986, ORIENTAL MATERIA MED; Kang YJ, 2008, EXP BIOL MED, V233, P1059, DOI 10.3181/0802-MR-47; KAWAGUCHI H, 1995, RES COMMUN MOL PATH, V89, P317; Kumar RA, 2004, J ETHNOPHARMACOL, V92, P291, DOI 10.1016/j.jep.2004.03.004; Kusum Mayura, 2004, Journal of the Medical Association of Thailand, V87, P1065; Langland JO, 2006, J VIROL, V80, P10083, DOI 10.1128/JVI.00607-06; Lee KY, 2005, INT IMMUNOPHARMACOL, V5, P1225, DOI 10.1016/j.intimp.2005.02.020; Lei Yan, 2003, Zhongguo Zhongyao Zazhi, V28, P876; Liu J.P., 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003711.PUB2; Mao Su-ping, 2004, Zhongguo Zhong Xi Yi Jie He Za Zhi, V24, P121; Martin KW, 2003, ANTIVIR THER, V8, P77; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; Matkovic Z, 2010, PHYTOTHER RES, V24, P175, DOI [10.1002/ptr.2877, 10.1002/ptr.3062]; Mechtcheriakova D, 2007, CELL SIGNAL, V19, P748, DOI 10.1016/j.cellsig.2006.09.004; Mietus-Snyder M, 1998, ARTERIOSCL THROM VAS, V18, P1440, DOI 10.1161/01.ATV.18.9.1440; Moeenrezakhanlou A, 2008, J LEUKOCYTE BIOL, V84, P519, DOI 10.1189/jlb.1207833; Nose M, 1998, BIOL PHARM BULL, V21, P1110, DOI 10.1248/bpb.21.1110; Peng Tianqing, 1995, Chinese Medical Sciences Journal, V10, P146; Pernerstorfer T, 1999, CIRCULATION, V100, P2485, DOI 10.1161/01.CIR.100.25.2485; Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288; PURI A, 1993, J NAT PROD, V56, P995, DOI 10.1021/np50097a002; Qi ZH, 2006, HYPERTENSION, V48, P323, DOI 10.1161/01.HYP.0000231934.67549.b7; Ragupathi G, 2008, VACCINE, V26, P4860, DOI 10.1016/j.vaccine.2008.06.098; Ramanathan M, 2007, MOL BIOL CELL, V18, P14, DOI 10.1091/mbc.E06-07-0596; Riehemann K, 1999, FEBS LETT, V442, P89, DOI 10.1016/S0014-5793(98)01622-6; Rios JL, 1997, PHYTOTHER RES, V11, P411, DOI 10.1002/(SICI)1099-1573(199709)11:6<411::AID-PTR132>3.0.CO;2-6; Ritchie MR, 2007, P NUTR SOC, V66, P479, DOI 10.1017/S0029665107005794; Rosenblueth M, 2006, MOL PLANT MICROBE IN, V19, P827, DOI 10.1094/MPMI-19-0827; Ryan RP, 2008, FEMS MICROBIOL LETT, V278, P1, DOI 10.1111/j.1574-6968.2007.00918.x; Setty AR, 2005, SEMIN ARTHRITIS RHEU, V34, P773, DOI 10.1016/j.semarthrit.2005.01.011; Sharif O, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-1; Shi CS, 2008, BLOOD, V112, P3661, DOI 10.1182/blood-2008-03-142760; Shon YH, 2002, BIOL PHARM BULL, V25, P77, DOI 10.1248/bpb.25.77; Sinclair S, 1998, Altern Med Rev, V3, P338; Spelman K, 2006, ALTERN MED REV, V11, P128; Storey JD, 2007, AM J HUM GENET, V80, P502, DOI 10.1086/512017; Strobel G, 2003, MICROBIOL MOL BIOL R, V67, P491, DOI 10.1128/MMBR.67.4.491-502.2003; SUN Y, 2004, YI JUN YI XUE XUE BA, V24, P57; Tan BKH, 2004, CURR MED CHEM, V11, P1423, DOI 10.2174/0929867043365161; Teucher T, 1996, ARZNEIMITTEL-FORSCH, V46, P906; Thomas KJ, 2001, COMPLEMENT THER MED, V9, P2, DOI 10.1054/ctim.2000.0407; THORNE, 2005, ALTERN MED REV, V10, P51; WANG F, 2008, ZHONGGUO ZHONG XI YI, V28; Wei GH, 2003, INT J SYST EVOL MICR, V53, P1575, DOI 10.1099/ijs.0.02031-0; Wei HM, 2003, ONCOL REP, V10, P1507; Yang XY, 2010, VACCINE, V28, P737, DOI 10.1016/j.vaccine.2009.10.065; Yesilada E, 2005, J ETHNOPHARMACOL, V96, P71, DOI 10.1016/j.jep.2004.08.036; YIN X, 2010, BIOCH BIOPHYS RES CO; Yu SY, 2007, J ETHNOPHARMACOL, V110, P352, DOI 10.1016/j.jep.2006.09.024; Zaks-Zilberman M, 1998, INFECT IMMUN, V66, P4669, DOI 10.1128/IAI.66.10.4669-4675.1998; ZHAO HY, 1991, CHINESE MED J-PEKING, V104, P770; Zhu XL, 2007, PHYTOTHER RES, V21, P663, DOI 10.1002/ptr.2144; Zwickey H, 2007, PHYTOTHER RES, V21, P1109, DOI 10.1002/ptr.2207	84	23	26	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2010	5	9							e12561	10.1371/journal.pone.0012561	http://dx.doi.org/10.1371/journal.pone.0012561			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	647OL	20838436	Green Submitted, gold, Green Published			2023-01-03	WOS:000281627700014
J	Yu, XR; Huang, YG; Qu, G; Xu, JY; Hui, SY				Yu, Xuerong; Huang, Yuguang; Qu, Ge; Xu, Jiaying; Hui, Shangyi			Safety and current status of blood transfusion in China	LANCET			English	Editorial Material									[Yu, Xuerong; Huang, Yuguang; Qu, Ge; Xu, Jiaying; Hui, Shangyi] Beijing Union Med Coll Hosp, Dept Anaesthesiol, Beijing 100730, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Huang, YG (corresponding author), Beijing Union Med Coll Hosp, Dept Anaesthesiol, 1 Shuaifuyuan, Beijing 100730, Peoples R China.	pumchhyg@yahoo.com.cn	xu, jia/GSD-6347-2022					FENG Z, 2005, CHINA DAILY BEI 1201, P92502; JUAN S, 2007, CHINA DAILY BEI 0901, P92502; MINGYAN W, 2009, EVENING PAPER B 0122, P92502; MINYI C, 2007, NEWS NET CHINES 1204, P92502; QI B, BEIJING BUREAU HLTH, P92502; QI L, 1999, REGULATION BLOOD DON, P92502; The Ministry of Health of the People's Republic of China Joint United Nations Programme on HIV/AIDS and World Health Organization, 2006, 2005 UPD HIV AIDS EP; United States Department of Health and Human Services, 2007 NAT BLOOD COLL; YUGUI L, 2008, BEIJING EVENING 1006, P92502	9	25	28	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 24	2010	375	9724					1420	1421		10.1016/S0140-6736(10)60003-7	http://dx.doi.org/10.1016/S0140-6736(10)60003-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	590FL	20347128				2023-01-03	WOS:000277210000011
J	Wearden, AJ; Dowrick, C; Chew-Graham, C; Bentall, RP; Morriss, RK; Peters, S; Riste, L; Richardson, G; Lovell, K; Dunn, G				Wearden, Alison J.; Dowrick, Christopher; Chew-Graham, Carolyn; Bentall, Richard P.; Morriss, Richard K.; Peters, Sarah; Riste, Lisa; Richardson, Gerry; Lovell, Karina; Dunn, Graham		FINE Trial Writing Grp; FINE Trial Grp	Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COGNITIVE-BEHAVIOR THERAPY; GRADED-EXERCISE; HEALTH-CARE; INTERVENTIONS	Objective To evaluate the effectiveness of home delivered pragmatic rehabilitation-a programme of gradually increasing activity designed collaboratively by the patient and the therapist-and supportive listening-an approach based on non-directive counselling-for patients in primary care with chronic fatigue syndrome/myalgic encephalomyelitis or encephalitis (CFS/ME). Design Single blind, randomised, controlled trial. Setting 186 general practices across the north west of England between February 2005 and May 2007. Participants 296 patients aged 18 or over with CFS/ME (median illness duration seven years) diagnosed using the Oxford criteria. Interventions Participants were randomly allocated to pragmatic rehabilitation, supportive listening, or general practitioner treatment as usual. Both therapies were delivered at home in 10 sessions over 18 weeks by one of three adult specialty general nurses who had received four months' training, including supervised practice, in each of the interventions. GP treatment as usual was unconstrained except that patients were not to be referred for systematic psychological therapies during the treatment period. Main outcome measures The primary clinical outcomes were fatigue and physical functioning at the end of treatment (20 weeks) and 70 weeks from recruitment compared with GP treatment as usual. Lower fatigue scores and higher physical functioning scores denote better outcomes. Results A total of 257 (87%) of the 296 patients who entered the trial were assessed at 70 weeks, the primary outcome point. Analysis was on an intention to treat basis, with robust treatment effects estimated after adjustment for missing data using probability weights. Immediately after treatment (at 20 weeks), patients allocated to pragmatic rehabilitation (n=95) had significantly improved fatigue (effect estimate -1.18, 95% confidence interval -2.18 to -0.18; P=0.021) but not physical functioning (-0.18, 95% CI -5.88 to +5.52; P=0.950) compared with patients allocated to treatment as usual (n=100). At one year after finishing treatment (70 weeks), there were no statistically significant differences in fatigue or physical functioning between patients allocated to pragmatic rehabilitation and those on treatment as usual (-1.00, 95% CI -2.10 to +0.11; P=0.076 and +2.57, 95% CI 3.90 to +9.03; P=0.435). At 20 weeks, patients allocated to supportive listening (n=101) had poorer physical functioning than those allocated to treatment as usual (-7.54, 95% CI -12.76 to -2.33; P=0.005) and no difference in fatigue. At 70 weeks, patients allocated to supportive listening did not differ significantly from those allocated to treatment as usual on either primary outcome. Conclusions For patients with CFS/ME in primary care, pragmatic rehabilitation delivered by trained nurse therapists improves fatigue in the short term compared with unconstrained GP treatment as usual, but the effect is small and not statistically significant at one year follow-up. Supportive listening delivered by trained nurse therapists is not an effective treatment for CFS/ME.	[Wearden, Alison J.; Peters, Sarah; Riste, Lisa] Univ Manchester, Sch Psychol Sci, Manchester M13 9PL, Lancs, England; [Dowrick, Christopher] Univ Liverpool, Sch Populat Community & Behav Sci, Liverpool L69 3BX, Merseyside, England; [Chew-Graham, Carolyn; Dunn, Graham] Univ Manchester, Sch Community Based Med, Manchester M13 9PL, Lancs, England; [Bentall, Richard P.] Univ Bangor, Sch Psychol, Bangor, Gwynedd, Wales; [Morriss, Richard K.] Univ Nottingham, Inst Mental Hlth, Sch Community Hlth Sci, Nottingham NG7 2RD, England; [Richardson, Gerry] Univ York, Ctr Hlth Econ, York YO10 5DD, N Yorkshire, England; [Richardson, Gerry] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England; [Lovell, Karina] Univ Manchester, Sch Nursing Midwifery & Social Work, Manchester M13 9PL, Lancs, England	University of Manchester; University of Liverpool; University of Manchester; Bangor University; University of Nottingham; University of York - UK; University of Hull; University of York - UK; University of Manchester	Wearden, AJ (corresponding author), Univ Manchester, Sch Psychol Sci, Manchester M13 9PL, Lancs, England.	alison.wearden@manchester.ac.uk	Lovell, Karina S E/E-6410-2012	Lovell, Karina S E/0000-0001-8821-895X; Riste, Lisa/0000-0003-2606-0717; Morriss, Richard/0000-0003-2910-4121	UK Medical Research Council [G200212]; UK Department of Health; University of Manchester; MRC [G0200212] Funding Source: UKRI; Medical Research Council [G0200212] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department of Health; University of Manchester; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The UK Medical Research Council (G200212) and the UK Department of Health funded the trial. The study was sponsored by the University of Manchester. The sponsor and the funder of the study had no role in the study design, data collection and analysis, interpretation or reporting of this work, or the decision to submit the work for publication. All authors are independent of the funding source.	Bombardier CH, 1996, MED CARE, V34, P924, DOI 10.1097/00005650-199609000-00005; Boutron I, 2008, ANN INTERN MED, V148, P295, DOI 10.7326/0003-4819-148-4-200802190-00008; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Chambers D, 2006, J ROY SOC MED, V99, P506, DOI 10.1258/jrsm.99.10.506; Darbishire L, 2003, BRIT J GEN PRACT, V53, P441; *DEP H6TH, 2002, REP CFS ME WORK GROU; Edmonds M, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003200.PUB2; Euba R, 1996, BRIT J PSYCHIAT, V168, P121, DOI 10.1192/bjp.168.1.121; Everitt B. S., 2004, STAT ASPECTS DESIGN; FIRST MB, 1995, J PERS DISORD, V9, P83, DOI 10.1521/pedi.1995.9.2.83; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; HEYTING A, 1992, STAT MED, V11, P2043, DOI 10.1002/sim.4780111603; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Komaroff AL, 1996, AM J MED, V101, P281, DOI 10.1016/S0002-9343(96)00174-X; Little R. J., 2019, STAT ANAL MISSING DA, V793; McCrone P, 2003, PSYCHOL MED, V33, P253, DOI 10.1017/S0033291702006980; MELLORCLARK J, 2001, 79 ROYAL COLL GEN PR; *NAT I HLTH CLIN E, 2007, CG53 NIFHACECG NICE; *NAT TASK FORC CHO, 1994, REP NAT TASK FORC CH; Powell P, 2001, BMJ-BRIT MED J, V322, P387, DOI 10.1136/bmj.322.7283.387; Price JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001027.pub2; Prins JB, 2001, LANCET, V357, P841, DOI 10.1016/S0140-6736(00)04198-2; Raine R, 2002, BMJ-BRIT MED J, V325, P1082, DOI 10.1136/bmj.325.7372.1082; Ridsdale L, 2001, BRIT J GEN PRACT, V51, P19; RISTE L, 2009, PATIENTS REPORTS MAN; Scheeres K, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-175; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; TOWNSEND P, 1987, J SOC POLICY, V16, P125, DOI 10.1017/S0047279400020341; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wearden AJ, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-9; Williams J.B.W., 2002, STRUCTURED CLIN INTE; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	68	68	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 23	2010	340								c1777	10.1136/bmj.c1777	http://dx.doi.org/10.1136/bmj.c1777			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	589HR	20418251	hybrid, Green Published			2023-01-03	WOS:000277138300001
J	Baliki, MN; Geha, PY; Fields, HL; Apkarian, AV				Baliki, Marwan N.; Geha, Paul Y.; Fields, Howard L.; Apkarian, A. Vania			Predicting Value of Pain and Analgesia: Nucleus Accumbens Response to Noxious Stimuli Changes in the Presence of Chronic Pain	NEURON			English	Article							VENTRAL TEGMENTAL AREA; MIDBRAIN DOPAMINERGIC-NEURONS; AVERSIVE STIMULI; HUMAN BRAIN; POSITIVE REINFORCEMENT; SUBSTANTIA-NIGRA; REWARD; ACTIVATION; PERCEPTION; INHIBITION	We compared brain activations in response to acute noxious thermal stimuli in controls and chronic back pain (CBP) patients. Pain perception and related cortical activation patterns were similar in the two groups. However, nucleus accumbens (NAc) activity differentiated the groups at a very high accuracy, exhibiting phasic and tonic responses with distinct properties. Positive phasic NAc activations at stimulus onset and offset tracked stimulus salience and, in normal subjects, predicted reward (pain relief) magnitude at stimulus offset. In CBP, NAc activity correlated with different cortical circuitry from that of normals and phasic activity at stimulus offset was negative in polarity, suggesting that the acute pain relieves the ongoing back pain. The relieving effect was confirmed in a separate psychophysical study in CBP. Therefore, in contrast to somatosensory pathways, which reflect sensory properties of acute noxious stimuli, NAc activity in humans encodes its predicted value and anticipates its analgesic potential on chronic pain.	[Baliki, Marwan N.; Geha, Paul Y.; Apkarian, A. Vania] Northwestern Univ, Feinberg Sch Med, Dept Physiol, Chicago, IL 60611 USA; [Apkarian, A. Vania] Northwestern Univ, Feinberg Sch Med, Dept Anesthesia, Chicago, IL 60611 USA; [Apkarian, A. Vania] Northwestern Univ, Feinberg Sch Med, Dept Surg, Chicago, IL 60611 USA; [Apkarian, A. Vania] Northwestern Univ, Feinberg Sch Med, Rehabil Inst Chicago, Chicago, IL 60611 USA; [Fields, Howard L.] Univ Calif San Francisco, Dept Neurol, Emeryville, CA 94608 USA; [Fields, Howard L.] Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Emeryville, CA 94608 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Shirley Ryan AbilityLab; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center	Apkarian, AV (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Physiol, 303 E Chicago Ave,Ward 4-334, Chicago, IL 60611 USA.	a-apkarian@northwestern.edu	Fields, Howard/ABG-9073-2020	Apkarian, A. Vania/0000-0002-9788-7458; Geha, Paul/0000-0002-0537-7216	NIH, NINDS [NS 35115]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035115] Funding Source: NIH RePORTER	NIH, NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to dedicate this study to the memory of Prof. Oscar Calvo who recently passed away. He made these experiments possible by building the thermal stimulator as well as parts of the finger-span device. We also thank all patients and healthy subjects for volunteering their time for this study. We are grateful for the technical help provided by Maria Virginia Centeno, Rami Jabakhanji, and Prof. Dante Chialvo. The study was funded by an NIH grant, NINDS NS 35115.	Ambroggi F, 2008, NEURON, V59, P648, DOI 10.1016/j.neuron.2008.07.004; Apkarian AV, 2009, PROG NEUROBIOL, V87, P81, DOI 10.1016/j.pneurobio.2008.09.018; Apkarian AV, 2008, CURR OPIN NEUROBIOL, V18, P464, DOI 10.1016/j.conb.2008.09.012; Apkarian AV, 2005, EUR J PAIN, V9, P463, DOI 10.1016/j.ejpain.2004.11.001; Baliki MN, 2009, J NEUROPHYSIOL, V101, P875, DOI 10.1152/jn.91100.2008; Baliki MN, 2008, J NEUROSCI, V28, P1398, DOI 10.1523/JNEUROSCI.4123-07.2008; Baliki MN, 2006, J NEUROSCI, V26, P12165, DOI 10.1523/JNEUROSCI.3576-06.2006; Bassareo V, 2002, J NEUROSCI, V22, P4709, DOI 10.1523/JNEUROSCI.22-11-04709.2002; Becerra L, 2001, NEURON, V32, P927, DOI 10.1016/S0896-6273(01)00533-5; Becerra L, 2008, EUR J PAIN, V12, P866, DOI 10.1016/j.ejpain.2007.12.007; Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x; Brischoux F, 2009, P NATL ACAD SCI USA, V106, P4894, DOI 10.1073/pnas.0811507106; Carlezon WA, 2009, NEUROPHARMACOLOGY, V56, P122, DOI 10.1016/j.neuropharm.2008.06.075; Coizet V, 2006, NEUROSCIENCE, V139, P1479, DOI 10.1016/j.neuroscience.2006.01.030; Delgado MR, 2008, PHILOS T R SOC B, V363, P3787, DOI 10.1098/rstb.2008.0161; Fields H, 2004, NAT REV NEUROSCI, V5, P565, DOI 10.1038/nrn1431; Fields H., 2006, P 11 WORLD C PAIN SE, P449; Fields HL, 2007, ANNU REV NEUROSCI, V30, P289, DOI 10.1146/annurev.neuro.30.051606.094341; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; Glimcher PW, 2009, NEUROECONOMICS: DECISION MAKING AND THE BRAIN, P1; Glimcher PW, 2003, BRADFORD BOOKS, P1; GOEDERS NE, 1983, SCIENCE, V221, P773, DOI 10.1126/science.6879176; Harris RE, 2007, J NEUROSCI, V27, P10000, DOI 10.1523/JNEUROSCI.2849-07.2007; Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1; Jensen J, 2003, NEURON, V40, P1251, DOI 10.1016/S0896-6273(03)00724-4; Jensen J, 2007, HUM BRAIN MAPP, V28, P294, DOI 10.1002/hbm.20274; Johansen JP, 2004, NAT NEUROSCI, V7, P398, DOI 10.1038/nn1207; Joshua M, 2008, J NEUROSCI, V28, P11673, DOI 10.1523/JNEUROSCI.3839-08.2008; KALIVAS PW, 1995, BRAIN RES, V675, P325, DOI 10.1016/0006-8993(95)00013-G; Kriegeskorte N, 2009, NAT NEUROSCI, V12, P535, DOI 10.1038/nn.2303; Liu ZH, 2008, NEUROPSYCHOPHARMACOL, V33, P3010, DOI 10.1038/npp.2008.4; MAEDA H, 1982, BRAIN RES BULL, V8, P7, DOI 10.1016/0361-9230(82)90021-1; MEYER RA, 2006, PERIPHERAL MECH CUTA; MILLER G, 2009, SCIENCE, V324, P335; MILNER PM, 1991, CAN J PSYCHOL, V45, P1, DOI 10.1037/h0084275; Mirenowicz J, 1996, NATURE, V379, P449, DOI 10.1038/379449a0; Montague PR, 2006, ANNU REV NEUROSCI, V29, P417, DOI 10.1146/annurev.neuro.29.051605.112903; Montague PR, 2002, NEURON, V36, P265, DOI 10.1016/S0896-6273(02)00974-1; Montague PR, 1996, J NEUROSCI, V16, P1936, DOI 10.1523/jneurosci.16-05-01936.1996; Niva Y, 2007, ANN NY ACAD SCI, V1104, P357, DOI 10.1196/annals.1390.018; O'Doherty JP, 2004, CURR OPIN NEUROBIOL, V14, P769, DOI 10.1016/j.conb.2004.10.016; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775; Platt ML, 2008, NAT NEUROSCI, V11, P398, DOI 10.1038/nn2062; Poldrack RA, 2009, SOC COGN AFFECT NEUR, V4, P208, DOI 10.1093/scan/nsp011; Rolls E. T., 2005, EMOTION EXPLAINED; Salamone JD, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.013.2009; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCHULTZ W, 1990, J NEUROPHYSIOL, V63, P607, DOI 10.1152/jn.1990.63.3.607; Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229; SCHULTZ W, 1987, J NEUROPHYSIOL, V57, P201, DOI 10.1152/jn.1987.57.1.201; Schultz W, 2007, ANNU REV NEUROSCI, V30, P259, DOI 10.1146/annurev.neuro.28.061604.135722; Scott DJ, 2007, NEURON, V55, P325, DOI 10.1016/j.neuron.2007.06.028; Scott DJ, 2006, J NEUROSCI, V26, P10789, DOI 10.1523/JNEUROSCI.2577-06.2006; Seymour B, 2004, NATURE, V429, P664, DOI 10.1038/nature02581; Seymour B, 2005, NAT NEUROSCI, V8, P1234, DOI 10.1038/nn1527; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; TSAI CT, 1980, BRAIN RES, V195, P299, DOI 10.1016/0006-8993(80)90066-9; Ungless MA, 2004, SCIENCE, V303, P2040, DOI 10.1126/science.1093360; YOUNG AMJ, 1993, NEUROSCIENCE, V54, P5, DOI 10.1016/0306-4522(93)90378-S; Zubieta JK, 2005, J NEUROSCI, V25, P7754, DOI 10.1523/JNEUROSCI.0439-05.2005	61	371	378	0	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	APR 15	2010	66	1					149	160		10.1016/j.neuron.2010.03.002	http://dx.doi.org/10.1016/j.neuron.2010.03.002			12	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	587TP	20399736	Green Accepted, Bronze			2023-01-03	WOS:000277016200016
J	Fendel, R; Brandts, C; Rudat, A; Kreidenweiss, A; Steur, C; Appelmann, I; Ruehe, B; Schroder, P; Berdel, WE; Kremsner, PG; Mordmuller, B				Fendel, Rolf; Brandts, Christian; Rudat, Annika; Kreidenweiss, Andrea; Steur, Claudia; Appelmann, Iris; Ruehe, Bettina; Schroeder, Paul; Berdel, Wolfgang E.; Kremsner, Peter G.; Mordmueller, Benjamin			Hemolysis Is Associated with Low Reticulocyte Production Index and Predicts Blood Transfusion in Severe Malarial Anemia	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM MALARIA; AFRICAN CHILDREN; INFECTED ERYTHROCYTES; CELL DEFORMABILITY; OXIDATIVE STRESS; RED-CELLS; PHAGOCYTOSIS; ERYTHROPOIESIS; CLEARANCE; ERYTHROPHAGOCYTOSIS	Background: Falciparum Malaria, an infectious disease caused by the apicomplexan parasite Plasmodium falciparum, is among the leading causes of death and morbidity attributable to infectious diseases worldwide. In Gabon, Central Africa, one out of four inpatients have severe malarial anemia (SMA), a life-threatening complication if left untreated. Emerging drug resistant parasites might aggravate the situation. This case control study investigates biomarkers of enhanced hemolysis in hospitalized children with either SMA or mild malaria (MM). Methods and Findings: Ninety-one children were included, thereof 39 SMA patients. Strict inclusion criteria were chosen to exclude other causes of anemia. At diagnosis, erythrophagocytosis (a direct marker for extravascular hemolysis, EVH) was enhanced in SMA compared to MM patients (5.0 arbitrary units (AU) (interquartile range (IR): 2.2-9.6) vs. 2.1 AU (IR: 1.3-3.9), p<0.01). Furthermore, indirect markers for EVH, (i.e. serum neopterin levels, spleen size enlargement and monocyte pigment) were significantly increased in SMA patients. Markers for erythrocyte ageing, such as CD35 (complement receptor 1), CD55 (decay acceleration factor) and phosphatidylserine exposure (annexin-V-binding) were investigated by flow cytometry. In SMA patients, levels of CD35 and CD55 on the red blood cell surface were decreased and erythrocyte removal markers were increased when compared to MM or reconvalescent patients. Additionally, intravascular hemolysis (IVH) was quantified using several indirect markers (LDH, alpha-HBDH, haptoglobin and hemopexin), which all showed elevated IVH in SMA. The presence of both IVH and EVH predicted the need for blood transfusion during antimalarial treatment (odds ratio 61.5, 95% confidence interval (CI): 8.9-427). Interestingly, this subpopulation is characterized by a significantly lowered reticulocyte production index (RPI, p<0.05). Conclusions: Our results show the multifactorial pathophysiology of SMA, whereby EVH and IVH play a particularly important role. We propose a model where removal of infected and non-infected erythrocytes of all ages (including reticulocytes) by EVH and IVH is a main mechanism of SMA. Further studies are underway to investigate the mechanism and extent of reticulocyte removal to identify possible interventions to reduce the risk of SMA development.	[Fendel, Rolf; Brandts, Christian; Rudat, Annika; Kreidenweiss, Andrea; Steur, Claudia; Appelmann, Iris; Ruehe, Bettina; Schroeder, Paul; Kremsner, Peter G.; Mordmueller, Benjamin] Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon; [Fendel, Rolf; Kreidenweiss, Andrea; Kremsner, Peter G.; Mordmueller, Benjamin] Univ Tubingen, Inst Trop Med, Tubingen, Germany; [Fendel, Rolf] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA; [Brandts, Christian; Rudat, Annika; Appelmann, Iris; Berdel, Wolfgang E.] Univ Munster, Dept Med, Munster, Germany; [Brandts, Christian] Goethe Univ Frankfurt, Dept Med, Frankfurt, Germany	Eberhard Karls University of Tubingen; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Munster; Goethe University Frankfurt	Fendel, R (corresponding author), Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon.	benjamin.mordmueller@uni-tuebingen.de	Mordmüller, Benjamin/A-5749-2010; Fendel, Rolf/K-3985-2013	Mordmüller, Benjamin/0000-0001-9101-2768; Fendel, Rolf/0000-0003-4716-0311; Kreidenweiss, Andrea/0000-0002-5025-7221; Brandts, Christian H./0000-0003-1732-2535	Deutsche Forschungsgemeinschaft [DFG MO 1071/4-1, BR 1945/6-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	The study was supported by a grant (DFG MO 1071/4-1 and BR 1945/6-1) from the Deutsche Forschungsgemeinschaft (http://www.dfg.de/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akech SO, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-256; [Anonymous], 2008, WORLD MAL REP 2008; Ayi K, 2005, INFECT IMMUN, V73, P2559, DOI 10.1128/IAI.73.4.2559-2563.2005; Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Bouyou-Akotet MK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-300; Casals-Pascual C, 2006, CURR MOL MED, V6, P155, DOI 10.2174/156652406776055159; Casals-Pascual C, 2006, BLOOD, V108, P2569, DOI 10.1182/blood-2006-05-018697; Ceesay SJ, 2008, LANCET, V372, P1545, DOI 10.1016/S0140-6736(08)61654-2; Chang KH, 2004, INT J PARASITOL, V34, P1501, DOI 10.1016/j.ijpara.2004.10.008; COLEBUNDERS R, 1991, J INFECT DIS, V164, P450, DOI 10.1093/infdis/164.3.450; CONNOR J, 1994, J BIOL CHEM, V269, P2399; Craig ML, 2005, J IMMUNOL, V174, P3059, DOI 10.4049/jimmunol.174.5.3059; DAVIS TME, 1990, J CLIN INVEST, V86, P793, DOI 10.1172/JCI114776; Dondorp AM, 1999, AM J TROP MED HYG, V60, P733, DOI 10.4269/ajtmh.1999.60.733; Dondorp AM, 2003, REDOX REP, V8, P292, DOI 10.1179/135100003225002934; Dzeing-Ella A, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-1; Fendel R, 2007, CYTOM PART A, V71A, P258, DOI 10.1002/cyto.a.20360; Griffiths MJ, 2001, BRIT J HAEMATOL, V113, P486, DOI 10.1046/j.1365-2141.2001.02758.x; Guinovart C, 2006, CURR MOL MED, V6, P137, DOI 10.2174/156652406776055131; Helbok R, 2006, AM J TROP MED HYG, V75, P443, DOI 10.4269/ajtmh.2006.75.443; Helegbe GK, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-165; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; Issifou S, 2007, AM J TROP MED HYG, V77, P1015, DOI 10.4269/ajtmh.2007.77.1015; Kremsner PG, 2009, J INFECT DIS, V199, P142, DOI 10.1086/595295; KREMSNER PG, 1995, ANTIMICROB AGENTS CH, V39, P1603, DOI 10.1128/AAC.39.7.1603; Kremsner PG, 2000, LANCET, V355, P40, DOI 10.1016/S0140-6736(99)04761-3; Lamikanra AA, 2007, BLOOD, V110, P18, DOI 10.1182/blood-2006-09-018069; Mahaffy JM, 1998, J THEOR BIOL, V190, P135, DOI 10.1006/jtbi.1997.0537; Mandal D, 2002, FEBS LETT, V513, P184, DOI 10.1016/S0014-5793(02)02294-9; McGilvray ID, 2000, BLOOD, V96, P3231, DOI 10.1182/blood.V96.9.3231; McQueen PG, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000149; Metzger WG, 1995, T ROY SOC TROP MED H, V89, P637, DOI 10.1016/0035-9203(95)90423-9; Moore A, 2001, LANCET, V358, P657, DOI 10.1016/S0140-6736(01)05783-X; Mordmuller B, 1998, CLIN INFECT DIS, V26, P850, DOI 10.1086/513926; Mordmuller BG, 1997, EUR CYTOKINE NETW, V8, P29; NEWTON CRJC, 1992, LANCET, V340, P917, DOI 10.1016/0140-6736(92)93334-J; Nuchsongsin F, 2007, AM J TROP MED HYG, V77, P617, DOI 10.4269/ajtmh.2007.77.617; Nyakoe NK, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-7; Owuor B, 2008, MOL MED, V14, P89, DOI 10.2119/2007-00093.Owuor; OYAKHIROME S, 2010, AM J TROP M IN PRESS; Price RN, 2001, AM J TROP MED HYG, V65, P614, DOI 10.4269/ajtmh.2001.65.614; Riley RS, 2001, J CLIN LAB ANAL, V15, P267, DOI 10.1002/jcla.1039; Safeukui I, 2008, BLOOD, V112, P2520, DOI 10.1182/blood-2008-03-146779; Team R. D. C R Development Core Team R, 2019, R LANG ENV STAT COMP; Waitumbi JN, 2004, J INFECT DIS, V190, P1183, DOI 10.1086/423140; Waitumbi JN, 2000, BLOOD, V95, P1481, DOI 10.1182/blood.V95.4.1481.004k15_1481_1486; Wiesner J, 1997, EUR J IMMUNOL, V27, P2708, DOI 10.1002/eji.1830271034	47	37	38	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2010	5	3							e10038	10.1371/journal.pone.0010038	http://dx.doi.org/10.1371/journal.pone.0010038			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	580BA	20386613	Green Submitted, Green Published, gold			2023-01-03	WOS:000276420400010
J	Goldfine, AB; Fonseca, V; Jablonski, KA; Pyle, L; Staten, MA; Shoelson, SE				Goldfine, Allison B.; Fonseca, Vivian; Jablonski, Kathleen A.; Pyle, Laura; Staten, Myrlene A.; Shoelson, Steven E.		TINSAL-T2D Targeting Inflammation	The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							NF-KAPPA-B; GLOMERULAR-FILTRATION-RATE; INDUCED INSULIN-RESISTANCE; SODIUM-SALICYLATE; IKK-BETA; NONACETYLATED SALICYLATE; CYSTATIN-C; URIC-ACID; ASPIRIN; INFLAMMATION	Background: Salsalate, a nonacetylated prodrug of salicylate, has been shown to decrease blood glucose concentration in small studies. Objective: To compare the efficacy and safety of salsalate at different doses in patients with type 2 diabetes. Design: Parallel randomized trial with computer-generated randomization and centralized allocation. Patients and investigators, including those assessing outcomes and performing analyses, were masked to group assignment. (ClinicalTrials.gov registration number: NCT00392678) Setting: 3 private practices and 14 universities in the United States. Patients: Persons aged 18 to 75 years with fasting plasma glucose concentrations of 12.5 mmol/L or less (<= 225 mg/dL) and hemoglobin A(1c) (HbA(1c)) levels of 7.0% to 9.5% treated by diet, exercise, and oral medication at stable doses for at least 8 weeks. Intervention: After a 4-week, single-masked run-in period, patients were randomly assigned to receive placebo or salsalate in dosages of 3.0, 3.5, or 4.0 g/d for 14 weeks (27 patients each) in addition to their current therapy. Measurements: Change in HbA(1c) was the primary outcome. Adverse effects and changes in measures of coronary risk and renal function were secondary outcomes. Results: Higher proportions of patients in the 3 salsalate treatment groups experienced decreases in HbA(1c) levels of 0.5% or more from baseline (P = 0.009). Mean HbA(1c) changes were -0.36% (P = 0.02) at 3.0 g/d, -0.34% (P = 0.02) at 3.5 g/d, and -0.49% (P = 0.001) at 4.0 g/d compared with placebo. Other markers of glycemic control also improved in the 3 salsalate groups, as did circulating triglyceride and adiponectin concentrations. Mild hypoglycemia was more common with salsalate; documented events occurred only in patients taking sulfonylureas. Urine albumin concentrations increased in all salsalate groups compared with placebo. The drug was otherwise well tolerated. Limitation: The number of patients studied and the trial duration were insufficient to warrant recommending the use of salsalate for type 2 diabetes at this time. Conclusion: Salsalate lowers HbA(1c) levels and improves other markers of glycemic control in patients with type 2 diabetes and may therefore provide a new avenue for treatment. Renal and cardiac safety of the drug require further evaluation.	[Shoelson, Steven E.] Joslin Diabet Ctr, Boston, MA 02215 USA; Tulane Univ, New Orleans, LA 70118 USA; George Washington Univ, Rockville, MD USA; NIDDKD, Washington, DC USA	Harvard University; Joslin Diabetes Center, Inc.; Tulane University; George Washington University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Shoelson, SE (corresponding author), Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.	steven.shoelson@joslin.harvard.edu	Pyle, Laura/I-8733-2019	Pyle, Laura/0000-0001-5577-8221; Goldfine, Allison/0000-0002-0345-1048	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; National Institutes of Health [U01 DK74556, P50 HL83813]; National Institutes of Health General Clinical Research Center; Clinical and Translational Science; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000454] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032, M01RR002635, UL1RR025008] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL083813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK074556] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health General Clinical Research Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Clinical and Translational Science; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.; By National Institutes of Health grants U01 DK74556 and P50 HL83813, National Institutes of Health General Clinical Research Center and Clinical and Translational Science Award grants at multiple sites, and the Tullis-Tulane (Dr. Fonseca) and Helen and Morton Adler (Dr. Shoelson) Chairs. Caraco Pharmaceuticals (Detroit, Michigan) supplied drug and placebo, Lifescan (Miltipas, California; a division of Johnson & Johnson) supplied home glucose-monitoring kits, and Mercodia (Uppsala, Sweden) supplied insulin assay kits.	APRIL P, 1990, SEMIN ARTHRITIS RHEU, V19, P20; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Coll E, 2000, AM J KIDNEY DIS, V36, P29, DOI 10.1053/ajkd.2000.8237; Ebstein W, 1876, BERLINER KLIN WOCHEN, V13, P337; EDMAR D, 1971, ACTA RADIOL DIAGN, V11, P57, DOI 10.1177/028418517101100107; Feig DI, 2008, NEW ENGL J MED, V359, P1811, DOI 10.1056/NEJMra0800885; Fernandez-Real JM, 2008, J CLIN ENDOCR METAB, V93, P2523, DOI 10.1210/jc.2007-1212; Fleischman A, 2008, DIABETES CARE, V31, P289, DOI 10.2337/dc07-1338; FRANTZ B, 1995, SCIENCE, V270, P2017, DOI 10.1126/science.270.5244.2017; GILGORE SG, 1960, DIABETES, V9, P392, DOI 10.2337/diab.9.5.392; Goldfine AB, 2008, CTS-CLIN TRANSL SCI, V1, P36, DOI 10.1111/j.1752-8062.2008.00026.x; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; HOLM S, 1979, SCAND J STAT, V6, P65; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hundal RS, 2002, J CLIN INVEST, V109, P1321, DOI 10.1172/JCI200214955; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Koska J, 2009, DIABETOLOGIA, V52, P385, DOI 10.1007/s00125-008-1239-x; LANZA F, 1989, J RHEUMATOL, V16, P1570; LIMA MAS, 1985, ARCH INTERN MED, V145, P1139, DOI 10.1001/archinte.1985.00360060207035; LOLL PJ, 1995, NAT STRUCT BIOL, V2, P637, DOI 10.1038/nsb0895-637; MacIsaac RJ, 2006, DIABETOLOGIA, V49, P1686, DOI 10.1007/s00125-006-0275-7; MORRIS HG, 1985, THER DRUG MONIT, V7, P435, DOI 10.1097/00007691-198512000-00012; Pierce GL, 2009, CIRCULATION, V119, P1284, DOI 10.1161/CIRCULATIONAHA.108.804294; Pierce JW, 1996, J IMMUNOL, V156, P3961; REID J, 1957, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5053.1071; Rosolowsky ET, 2008, CLIN J AM SOC NEPHRO, V3, P706, DOI 10.2215/CJN.04271007; ROTH S, 1990, SEMIN ARTHRITIS RHEU, V19, P11; Shoelson SE, 2006, J CLIN INVEST, V116, P1793, DOI 10.1172/JCI29069; Stevens LA, 2007, J AM SOC NEPHROL, V18, P2749, DOI 10.1681/ASN.2007020199; SWEENEY JD, 1991, THROMB RES, V61, P23, DOI 10.1016/0049-3848(91)90165-S; Wagner JA, 2009, CLIN PHARMACOL THER, V86, P619, DOI 10.1038/clpt.2009.88; Williamson RT, 1901, BRIT MED J, V1901, P760, DOI 10.1136/bmj.1.2100.760; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	37	283	286	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 16	2010	152	6					346	+		10.7326/0003-4819-152-6-201003160-00004	http://dx.doi.org/10.7326/0003-4819-152-6-201003160-00004			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	573IF	20231565	Green Accepted			2023-01-03	WOS:000275905200002
J	Briel, M; Meade, M; Mercat, A; Brower, RG; Talmor, D; Walter, SD; Slutsky, AS; Pullenayegum, E; Zhou, Q; Cook, D; Brochard, L; Richard, JCM; Lamontagne, F; Bhatnagar, N; Stewart, TE; Guyatt, G				Briel, Matthias; Meade, Maureen; Mercat, Alain; Brower, Roy G.; Talmor, Daniel; Walter, Stephen D.; Slutsky, Arthur S.; Pullenayegum, Eleanor; Zhou, Qi; Cook, Deborah; Brochard, Laurent; Richard, Jean-Christophe M.; Lamontagne, Francois; Bhatnagar, Neera; Stewart, Thomas E.; Guyatt, Gordon			Higher vs Lower Positive End-Expiratory Pressure in Patients With Acute Lung Injury and Acute Respiratory Distress Syndrome Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECHANICAL VENTILATION; RANDOMIZED-TRIALS; TIDAL VOLUME; APACHE-II; RECRUITMENT; STRATEGY; OUTCOMES; MORTALITY; MODELS	Context Trials comparing higher vs lower levels of positive end-expiratory pressure (PEEP) in adults with acute lung injury or acute respiratory distress syndrome ( ARDS) have been underpowered to detect small but potentially important effects on mortality or to explore subgroup differences. Objectives To evaluate the association of higher vs lower PEEP with patient-important outcomes in adults with acute lung injury or ARDS who are receiving ventilation with low tidal volumes and to investigate whether these associations differ across prespecified subgroups. Data Sources Search of MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials (1996-January 2010) plus a hand search of conference proceedings (2004-January 2010). Study Selection Two reviewers independently screened articles to identify studies randomly assigning adults with acute lung injury or ARDS to treatment with higher vs lower PEEP ( with low tidal volume ventilation) and also reporting mortality. Data Extraction Data from 2299 individual patients in 3 trials were analyzed using uniform outcome definitions. Prespecified effect modifiers were tested using multivariable hierarchical regression, adjusting for important prognostic factors and clustering effects. Results There were 374 hospital deaths in 1136 patients (32.9%) assigned to treatment with higher PEEP and 409 hospital deaths in 1163 patients (35.2%) assigned to lower PEEP ( adjusted relative risk [RR], 0.94; 95% confidence interval [CI], 0.86-1.04; P=.25). Treatment effects varied with the presence or absence of ARDS, defined by a value of 200 mm Hg or less for the ratio of partial pressure of oxygen to fraction of inspired oxygen concentration (P=.02 for interaction). In patients with ARDS (n=1892), there were 324 hospital deaths (34.1%) in the higher PEEP group and 368 (39.1%) in the lower PEEP group ( adjusted RR, 0.90; 95% CI, 0.81-1.00; P=.049); in patients without ARDS (n=404), there were 50 hospital deaths (27.2%) in the higher PEEP group and 44 (19.4%) in the lower PEEP group (adjusted RR, 1.37; 95% CI, 0.98-1.92; P=.07). Rates of pneumothorax and vasopressor use were similar. Conclusions Treatment with higher vs lower levels of PEEP was not associated with improved hospital survival. However, higher levels were associated with improved survival among the subgroup of patients with ARDS. JAMA. 2010; 303(9):865-873 www.jama.com	[Briel, Matthias; Meade, Maureen; Walter, Stephen D.; Pullenayegum, Eleanor; Zhou, Qi; Cook, Deborah; Lamontagne, Francois; Bhatnagar, Neera; Guyatt, Gordon] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; [Briel, Matthias] Univ Basel Hosp, Basel Inst Clin Epidemiol, CH-4031 Basel, Switzerland; [Mercat, Alain] Univ Hosp Angers, Angers, France; [Brower, Roy G.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Baltimore, MD USA; [Talmor, Daniel] Beth Israel Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02215 USA; [Talmor, Daniel] Harvard Univ, Sch Med, Boston, MA USA; [Slutsky, Arthur S.; Stewart, Thomas E.] Univ Toronto, Toronto, ON, Canada; [Brochard, Laurent] Univ Hosp Albert Chenevier Henri Mondor, INSERM, Unit 955, Med ICU, Creteil, France; [Brochard, Laurent] Univ Paris Est, Creteil, France; [Richard, Jean-Christophe M.] Univ Hosp Charles Nicolle, Rouen, France; [Richard, Jean-Christophe M.] UPRES EA Unit 3830, Rouen, France; [Lamontagne, Francois] Univ Sherbrooke, Sherbrooke, PQ J1K 2R1, Canada	McMaster University; University of Basel; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Toronto; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHU de Rouen; University of Sherbrooke	Meade, M (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, Room 2C12,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	meadema@hhsc.ca	Briel, Matthias/AAT-9284-2021; Mercat, Alain/AFU-4426-2022; Pullenayegum, Eleanor/AAT-1712-2020; Bhatnagar, Neera/B-8004-2013; Zhou, Qi/GSM-9583-2022; Walter, Stephen/AAB-5548-2022; Slutsky, Arthur/M-3325-2019	Pullenayegum, Eleanor/0000-0003-4265-1330; Bhatnagar, Neera/0000-0002-5060-5257; Walter, Stephen/0000-0003-4157-8928; Briel, Matthias/0000-0002-2070-5230	Canadian Intensive Care Foundation; Swiss National Science Foundation [PASMA-112951/1]; Roche Research Foundation	Canadian Intensive Care Foundation; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Roche Research Foundation	The study was funded in part by a grant from the Canadian Intensive Care Foundation. Dr Briel is supported by a scholarship from the Swiss National Science Foundation (PASMA-112951/1) and the Roche Research Foundation. Dr Cook is a Canada Research Chair of the Canadian Institutes for Health Research.	Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Babyak MA, 2004, PSYCHOSOM MED, V66, P411, DOI 10.1097/01.psy.0000127692.23278.a9; Beck DH, 2003, INTENS CARE MED, V29, P249, DOI 10.1007/s00134-002-1607-9; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bernard GR, 1997, SEPSIS, V1, P43, DOI DOI 10.1023/A:1009711301483; Brower RG, 2004, NEW ENGL J MED, V351, P327; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Gattinoni L, 2006, NEW ENGL J MED, V354, P1775, DOI 10.1056/NEJMoa052052; Gattinoni L, 2008, JAMA-J AM MED ASSOC, V299, P691, DOI 10.1001/jama.299.6.691; Gordo-Vidal F, 2008, MED INTENSIVA, V32, P316, DOI 10.1016/S0210-5691(08)70962-8; Gordo-Vidal F., 2007, Med. Intensiva, V31, P491; Guyatt G, 2008, USERS GUIDES MED LIT; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Guyatt GH, 2008, PLOS MED, V5, P3, DOI 10.1371/journal.pmed.0050004; Halter JM, 2007, CRIT CARE, V11, DOI 10.1186/cc5695; Hopewell S, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.MR000001.pub2, 10.1002/14651858.MR000011.pub2]; Koopman L, 2007, J CLIN EPIDEMIOL, V60, P1002, DOI 10.1016/j.jclinepi.2007.01.018; Kumar A, 1973, Crit Care Med, V1, P181, DOI 10.1097/00003246-197307000-00001; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Phoenix SI, 2009, ANESTHESIOLOGY, V110, P1098, DOI 10.1097/ALN.0b013e31819fae06; Pinsky MR, 1997, INTENS CARE MED, V23, P493, DOI 10.1007/s001340050364; Putensen C, 2009, ANN INTERN MED, V151, P566, DOI 10.7326/0003-4819-151-8-200910200-00011; RUBIN DB, 2002, STAT ANAL MISSING DA, P35; Simmonds MC, 2005, CLIN TRIALS, V2, P209, DOI 10.1191/1740774505cn087oa; Snijders T.A., 1999, MULTILEVEL ANAL INTR, P41; Suistomaa M, 2002, INTENS CARE MED, V28, P479, DOI 10.1007/s00134-002-1214-9; Talmor D, 2008, NEW ENGL J MED, V359, P2095, DOI 10.1056/NEJMoa0708638; Toth I, 2007, CRIT CARE MED, V35, P787, DOI 10.1097/01.CCM.0000257330.54882.BE; Tremblay LN, 2006, INTENS CARE MED, V32, P24, DOI 10.1007/s00134-005-2817-8; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01; Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC; Warn DE, 2002, STAT MED, V21, P1601, DOI 10.1002/sim.1189	37	902	964	3	59	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 3	2010	303	9					865	873		10.1001/jama.2010.218	http://dx.doi.org/10.1001/jama.2010.218			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	562NU	20197533	Bronze			2023-01-03	WOS:000275059500020
J	Yu, YB; Dosanjh, L; Lao, LX; Tan, M; Shim, BS; Luo, Y				Yu, Young-Beob; Dosanjh, Laura; Lao, Lixing; Tan, Ming; Shim, Bum Sang; Luo, Yuan			Cinnamomum cassia Bark in Two Herbal Formulas Increases Life Span in Caenorhabditis elegans via Insulin Signaling and Stress Response Pathways	PLOS ONE			English	Article							BILOBA EXTRACT EGB-761; JUZEN-TAIHO-TO; POSTPRANDIAL BLOOD-GLUCOSE; EXPRESSION; MEDICINE; RESISTANCE; MICE; BEHAVIORS; TOLERANCE; INGESTION	Background: Proving the efficacy and corresponding mode of action of herbal supplements is a difficult challenge for evidence-based herbal therapy. A major hurdle is the complexity of herbal preparations, many of which combine multiple herbs, particularly when the combination is assumed to be vitally important to the effectiveness of the herbal therapy. This issue may be addressed through the use of contemporary methodology and validated animal models. Methods and Principal Findings: In this study, two commonly used traditional herbal formulas, Shi Quan Da Bu Tang (SQDB) and Huo Luo Xiao Ling Dan (HLXL) were evaluated using a survival assay and oxidative stress biomarkers in a well-established C. elegans model of aging. HLXL is an eleven herb formula modified from a top-selling traditional herbal formula for the treatment of arthritic joint pain. SQDB consists of ten herbs often used for fatigue and energy, particularly in the aged. We demonstrate here that SQDB significantly extend life span in a C. elegans model of aging. Among all individual herbs tested, two herbs Cinnamomum cassia bark (Chinese pharmaceutical name: Cinnamomi Cortex, CIN) and Panax ginseng root (Chinese pharmaceutical name: Ginseng Radix, GS) significantly extended life span in C. elegans. CIN in both SQDB and HLXL formula extended life span via modulation of multiple longevity assurance genes, including genes involved in insulin signaling and stress response pathways. All the life-span-extending herbs (SQDB, CIN and GS) also attenuated levels of H2O2 and enhanced small heat shock protein expression. Furthermore, the life span-extending herbs significantly delayed human amyloid beta (A beta)-induced toxicity in transgenic C. elegans expressing human A beta. Conclusion/Significance: These results validate an invertebrate model for rapid, systematic evaluation of commonly used Chinese herbal formulations and may provide insight for designing future evidence-based herbal therapy(s).	[Yu, Young-Beob; Dosanjh, Laura; Luo, Yuan] Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; [Lao, Lixing; Luo, Yuan] Univ Maryland, Sch Med, Ctr Integrat Med, Baltimore, MD 21201 USA; [Tan, Ming] Univ Maryland, Sch Med, Div Biostat, Baltimore, MD 21201 USA; [Yu, Young-Beob] Korea Inst Oriental Med, Brain Dis Res Ctr, Taejon, South Korea; [Yu, Young-Beob] Nambu Univ, Dept Med Plant Resources, Kwangju, South Korea; [Shim, Bum Sang] Kyung Hee Univ, Coll Oriental Med, Seoul, South Korea	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Korea Institute of Oriental Medicine (KIOM); Nambu University; Kyung Hee University	Yu, YB (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.	yluo@rx.umaryland.edu	Shim, Bum-sang/AAH-9081-2020; Lao, Lixing/I-7979-2013; Lao, Lixing/P-9107-2019	Lao, Lixing/0000-0003-0198-9714; Yu, Young-Bob/0000-0001-7785-5988	NIH [AT001928]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001928] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	NIH AT001928 http://nccam.nih.gov/. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin KA, 2009, INT J CLIN EXP MED, V2, P254; Antebi A, 2007, NATURE, V447, P536, DOI 10.1038/447536a; Artal-Sanz Marto, 2006, Biotechnology Journal, V1, P1405, DOI 10.1002/biot.200600176; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Blumenthal M, 2000, HERBAL MED; Boyd-Kimball D, 2006, NEUROBIOL AGING, V27, P1239, DOI 10.1016/j.neurobiolaging.2005.07.001; Brown MK, 2006, PHARMACOL BIOCHEM BE, V85, P620, DOI 10.1016/j.pbb.2006.10.017; Brown MK, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-62; BURNS JJ, 2009, TOXICOLOGY      1007; Cao ZM, 2007, J GERONTOL A-BIOL, V62, P1337, DOI 10.1093/gerona/62.12.1337; Cohen E, 2006, SCIENCE, V313, P1604, DOI 10.1126/science.1124646; Collins JJ, 2006, EXP GERONTOL, V41, P1032, DOI 10.1016/j.exger.2006.06.038; DOSANJH LE, 2009, J ALZHEIMERS DI 1105; Dragland S, 2003, J NUTR, V133, P1286; Drake J, 2003, NEUROBIOL AGING, V24, P415, DOI 10.1016/S0197-4580(02)00225-7; DUDONNE S, 2009, J AGR FOOD CHEM; Dugasani S, 2010, J ETHNOPHARMACOL, V127, P515, DOI 10.1016/j.jep.2009.10.004; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Farooqui T, 2009, MECH AGEING DEV, V130, P203, DOI 10.1016/j.mad.2008.11.006; HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124; Hasani-Ranjbar Shirin, 2009, Inflammation & Allergy Drug Targets, V8, P2; Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2; Hlebowicz J, 2007, AM J CLIN NUTR, V85, P1552, DOI 10.1093/ajcn/85.6.1552; Hlebowicz J, 2009, AM J CLIN NUTR, V89, P815, DOI 10.3945/ajcn.2008.26807; HU Y, 2009, IMMUNOPHARMACOL IMMU; Jitomir J, 2009, J MED FOOD, V12, P467, DOI 10.1089/jmf.2008.0128; Kamiyama H, 2005, BIOL PHARM BULL, V28, P2111, DOI 10.1248/bpb.28.2111; Kato M, 2007, WORLD J GASTROENTERO, V13, P2289, DOI 10.3748/wjg.v13.i16.2289; Kim SH, 2006, J ETHNOPHARMACOL, V104, P119, DOI 10.1016/j.jep.2005.08.059; Kirkham S, 2009, DIABETES OBES METAB, V11, P1100, DOI 10.1111/j.1463-1326.2009.01094.x; Kogure T, 2005, PHYTOMEDICINE, V12, P327, DOI 10.1016/j.phymed.2004.05.002; Kwon HK, 2009, CANCER LETT, V278, P174, DOI 10.1016/j.canlet.2009.01.015; Lao LX, 2006, AM J CHINESE MED, V34, P833, DOI 10.1142/S0192415X06004326; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LINK CD, 1995, P NATL ACAD SCI USA, V92, P9368, DOI 10.1073/pnas.92.20.9368; Link CD, 2001, NEUROBIOL AGING, V22, P217, DOI 10.1016/S0197-4580(00)00237-2; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Luo Y., 2003, Current Topics in Nutraceutical Research, V1, P49; Luo Y, 2004, REDOX REP, V9, P65, DOI 10.1179/135100004225004733; Mettler S, 2009, NUTR RES, V29, P723, DOI 10.1016/j.nutres.2009.10.002; Morimoto RI, 2006, NEW ENGL J MED, V355, P2254, DOI 10.1056/NEJMcibr065573; Panickar KS, 2009, EXP NEUROL, V216, P420, DOI 10.1016/j.expneurol.2008.12.024; Peterson DW, 2009, J ALZHEIMERS DIS, V17, P585, DOI 10.3233/JAD-2009-1083; Petrascheck M, 2007, NATURE, V450, P553, DOI 10.1038/nature05991; Pinkston JM, 2006, SCIENCE, V313, P971, DOI 10.1126/science.1121908; Qin B, 2009, HORM METAB RES, V41, P516, DOI 10.1055/s-0029-1202813; QIN B, 2009, HORM METAB RES; Qin BL, 2003, DIABETES RES CLIN PR, V62, P139, DOI 10.1016/S0168-8227(03)00173-6; Qin BL, 2009, J NUTR BIOCHEM, V20, P901, DOI 10.1016/j.jnutbio.2008.08.005; Rajaiah R, 2009, J ETHNOPHARMACOL, V123, P40, DOI 10.1016/j.jep.2009.02.032; Riedlinger JE, 2001, ANN PHARMACOTHER, V35, P228, DOI 10.1345/aph.10122; Satoh H, 2002, J ALTERN COMPLEM MED, V8, P107, DOI 10.1089/107555302317371370; SMITH JV, 2003, J ALZ DIS, V4; Solomon TPJ, 2007, DIABETES OBES METAB, V9, P895, DOI 10.1111/j.1463-1326.2006.00694.x; Solomon TPJ, 2009, EUR J APPL PHYSIOL, V105, P969, DOI 10.1007/s00421-009-0986-9; Srivastava D, 2008, BIOGERONTOLOGY, V9, P309, DOI 10.1007/s10522-008-9139-5; Strayer A, 2003, FASEB J, V17, P2305, DOI 10.1096/fj.03-0376fje; Tagami K, 2004, BIOL PHARM BULL, V27, P156, DOI 10.1248/bpb.27.156; Tsuchiya M, 2008, INT J CANCER, V123, P2503, DOI 10.1002/ijc.23828; Tsunemi A, 2005, NEUROCHEM RES, V30, P75, DOI 10.1007/s11064-004-9688-1; Vijg J, 2008, NATURE, V454, P1065, DOI 10.1038/nature07216; Wilson MA, 2006, AGING CELL, V5, P59, DOI 10.1111/j.1474-9726.2006.00192.x; Wilson Mark A., 2008, BMC Pharmacology, V8, P15, DOI 10.1186/1471-2210-8-15; Wolkow CA, 2000, SCIENCE, V290, P147, DOI 10.1126/science.290.5489.147; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; WU Y, 2008, NEUROBIOL AGING, V10, P1016; Wu YJ, 2006, J NEUROSCI, V26, P13102, DOI 10.1523/JNEUROSCI.3448-06.2006; Wu ZX, 2002, CELL MOL BIOL, V48, P725; Yang M, 2010, J ETHNOPHARMACOL, V127, P264, DOI 10.1016/j.jep.2009.11.010; YAO CJ, 2009, EVID BASED COMP 1123; Zarse K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004062; Zee-Cheng Robert K.-Y, 1992, Methods and Findings in Experimental and Clinical Pharmacology, V14, P725; Zhang LZ, 2009, FREE RADICAL BIO MED, V46, P414, DOI 10.1016/j.freeradbiomed.2008.10.041; Zhang RX, 2009, J ETHNOPHARMACOL, V121, P366, DOI 10.1016/j.jep.2008.11.018	74	50	54	1	30	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2010	5	2							e9339	10.1371/journal.pone.0009339	http://dx.doi.org/10.1371/journal.pone.0009339			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	560SU	20179756	Green Submitted, Green Published, gold			2023-01-03	WOS:000274923900008
J	Hill, J; Treasure, T				Hill, Jennifer; Treasure, Tom		Natl Clinical Guideline Ctr Acute	Guidelines Reducing the risk of venous thromboembolism in patients admitted to hospital: summary of NICE guidance	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HIP		[Hill, Jennifer] Royal Coll Physicians, Natl Clin Guideline Ctr Acute & Chron Condit, London NW1 4LE, England; [Treasure, Tom] UCL, Clin Operat Res Unit, Guideline Dev Grp, London WC1H 0BT, England	Royal College of Physicians; University of London; University College London	Hill, J (corresponding author), Royal Coll Physicians, Natl Clin Guideline Ctr Acute & Chron Condit, London NW1 4LE, England.	tom.treasure@gmail.com		Stansby, Gerard/0000-0001-5539-3049; Wonderling, David/0000-0003-0315-6273	National Institute for Health and Clinical Excellence	National Institute for Health and Clinical Excellence	The National Clinical Guideline Centre for Acute and Chronic Conditions was commissioned and funded by the National Institute for Health and Clinical Excellence to write this summary.	Choudhry NK, 2006, BMJ-BRIT MED J, V332, P141, DOI 10.1136/bmj.38698.709572.55; Cohen AT, 2007, THROMB HAEMOSTASIS, V98, P756, DOI 10.1160/TH07-03-0212; Department of Health, 2007, REP IND EXP WORK GRO; Department of Health, RISK ASS VEN THROMB; Eikelboom JW, 2009, CHEST, V135, P513, DOI 10.1378/chest.08-2655; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Haas SB, 2008, J BONE JOINT SURG AM, V90A, P2764; Hill J, 2007, BMJ-BRIT MED J, V334, P1053, DOI 10.1136/bmj.39174.678032.AD; House of Commons Health Select Committee, 2005, PREV VEN THROMB HOSP; Hunt BJ, 2008, ARTERIOSCL THROM VAS, V28, P398, DOI 10.1161/ATVBAHA.108.162586; *NAT I HLTH CLIN E, 2008, STROK DIAGN MAN AC S; Sharrock NE, 2008, CLIN ORTHOP RELAT R, V466, P714, DOI 10.1007/s11999-007-0092-4	12	56	71	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 27	2010	340								c95	10.1136/bmj.c95	http://dx.doi.org/10.1136/bmj.c95			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YB	20106897				2023-01-03	WOS:000274089300016
J	Ruskin, DN; Kawamura, M; Masino, SA				Ruskin, David N.; Kawamura, Masahito, Jr.; Masino, Susan A.			Reduced Pain and Inflammation in Juvenile and Adult Rats Fed a Ketogenic Diet	PLOS ONE			English	Article							ACTIVATED-RECEPTOR-ALPHA; CALORIE RESTRICTION; PROTEIN RESTRICTION; LOW-CARBOHYDRATE; KETONE-BODIES; ADENOSINE; METABOLISM; CHILDREN; BRAIN; EXPRESSION	The ketogenic diet is a high-fat, low-carbohydrate regimen that forces ketone-based rather than glucose-based cellular metabolism. Clinically, maintenance on a ketogenic diet has been proven effective in treating pediatric epilepsy and type II diabetes, and recent basic research provides evidence that ketogenic strategies offer promise in reducing brain injury. Cellular mechanisms hypothesized to be mobilized by ketone metabolism and underlying the success of ketogenic diet therapy, such as reduced reactive oxygen species and increased central adenosine, suggest that the ketolytic metabolism induced by the diet could reduce pain and inflammation. To test the effects of a ketone-based metabolism on pain and inflammation directly, we fed juvenile and adult rats a control diet (standard rodent chow) or ketogenic diet (79% fat) ad libitum for 3-4 weeks. We then quantified hindpaw thermal nociception as a pain measure and complete Freund's adjuvant-induced local hindpaw swelling and plasma extravasation (fluid movement from the vasculature) as inflammation measures. Independent of age, maintenance on a ketogenic diet reduced the peripheral inflammatory response significantly as measured by paw swelling and plasma extravasation. The ketogenic diet also induced significant thermal hypoalgesia independent of age, shown by increased hindpaw withdrawal latency in the hotplate nociception test. Anti-inflammatory and hypoalgesic diet effects were generally more robust in juveniles. The ketogenic diet elevated plasma ketones similarly in both age groups, but caused slowed body growth only in juveniles. These data suggest that applying a ketogenic diet or exploiting cellular mechanisms associated with ketone-based metabolism offers new therapeutic opportunities for controlling pain and peripheral inflammation, and that such a metabolic strategy may offer significant benefits for children and adults.	[Ruskin, David N.; Kawamura, Masahito, Jr.; Masino, Susan A.] Trinity Coll, Dept Psychol, Hartford, CT 06106 USA; [Ruskin, David N.; Kawamura, Masahito, Jr.; Masino, Susan A.] Trinity Coll, Neurosci Program, Hartford, CT 06106 USA; [Kawamura, Masahito, Jr.] Jikei Univ, Sch Med, Dept Pharmacol, Minato Ku, Tokyo, Japan	Trinity College; Trinity College; Jikei University	Ruskin, DN (corresponding author), Trinity Coll, Dept Psychol, Hartford, CT 06106 USA.	susan.masino@trincoll.edu			National Institutes of Health [061290]; National Science Foundation [IOS-0843585]; CHDI; Trinity College; Division Of Integrative Organismal Systems [0843585] Funding Source: National Science Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R15NS061290] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation(National Science Foundation (NSF)); CHDI; Trinity College; Division Of Integrative Organismal Systems(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Supported by the National Institutes of Health (061290), National Science Foundation (IOS-0843585), CHDI (www.highqfoundation.org) and Trinity College (www.trincoll.edu). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baranano Kristin W, 2008, Curr Treat Options Neurol, V10, P410, DOI 10.1007/s11940-008-0043-8; Becker N, 1997, PAIN, V73, P393, DOI 10.1016/S0304-3959(97)00126-7; Bough KJ, 2003, EPILEPSIA, V44, P752, DOI 10.1046/j.1528-1157.2003.55502.x; Bough KJ, 1999, EPILEPSY RES, V35, P21, DOI 10.1016/S0920-1211(98)00125-9; COLLINS JE, 1985, HUM NUTR-APPL NUTR, V39A, P255; Cullingford TE, 2004, PROSTAG LEUKOTR ESS, V70, P253, DOI 10.1016/j.plefa.2003.09.008; Cullingford T, 2008, EPILEPSIA, V49, P70, DOI 10.1111/j.1528-1167.2008.01840.x; Dickenson AH, 2000, CNS DRUGS, V13, P77, DOI 10.2165/00023210-200013020-00001; EDDY AA, 1994, AM J PHYSIOL, V266, pF884, DOI 10.1152/ajprenal.1994.266.6.F884; Fragasso G, 2008, CURR PHARM DESIGN, V14, P2582, DOI 10.2174/138161208786071245; Giordano M, 2008, DIABETOLOGIA, V51, P21, DOI 10.1007/s00125-007-0874-y; Gureje O, 1998, JAMA-J AM MED ASSOC, V280, P147, DOI 10.1001/jama.280.2.147; HAAS RH, 1986, AM J MED GENET, V24, P225; Hallbook T, 2007, EPILEPSY RES, V77, P134, DOI 10.1016/j.eplepsyres.2007.09.008; Hemingway C, 2001, PEDIATRICS, V108, P898, DOI 10.1542/peds.108.4.898; Hori A, 1997, EPILEPSIA, V38, P750, DOI 10.1111/j.1528-1157.1997.tb01461.x; Iughetti L, 2007, J ENDOCRINOL INVEST, V30, P700; Kim DY, 2007, J NEUROCHEM, V101, P1316, DOI 10.1111/j.1471-4159.2007.04483.x; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee HT, 2004, AM J PHYSIOL-RENAL, V286, pF298, DOI 10.1152/ajprenal.00185.2003; Liu YMC, 2003, J AM DIET ASSOC, V103, P707, DOI 10.1053/jada.2003.50136; LoVerme J, 2006, J PHARMACOL EXP THER, V319, P1051, DOI 10.1124/jpet.106.111385; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; Malan TP, 2002, ANESTHESIOLOGY, V96, P1161, DOI 10.1097/00000542-200205000-00020; Mantis JG, 2009, EPILEPSY BEHAV, V15, P133, DOI 10.1016/j.yebeh.2009.02.038; Martinez-Dominguez E, 2001, INFLAMM RES, V50, P102, DOI 10.1007/s000110050731; MASINO SA, 2009, CURR NEUROP IN PRESS; Masino SA, 2008, TRENDS NEUROSCI, V31, P273, DOI 10.1016/j.tins.2008.02.009; Navab M, 2008, CURR OPIN CLIN NUTR, V11, P459, DOI 10.1097/MCO.0b013e32830460c2; Neal EG, 2008, LANCET NEUROL, V7, P500, DOI 10.1016/S1474-4422(08)70092-9; Poon A, 1999, EUR J PHARMACOL, V384, P123, DOI 10.1016/S0014-2999(99)00626-3; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Rodriguez-Enriquez S, 2009, MOL NUTR FOOD RES, V53, P29, DOI 10.1002/mnfr.200700470; SAWYNOK J, 1982, NEUROPHARMACOLOGY, V21, P397, DOI 10.1016/0028-3908(82)90022-3; Seyfried Thomas N, 2005, Nutr Metab (Lond), V2, P30, DOI 10.1186/1743-7075-2-30; Shibolet O, 2002, CLIN IMMUNOL, V105, P48, DOI 10.1006/clim.2002.5260; Silva MC, 2005, NUTR NEUROSCI, V8, P259, DOI 10.1080/10284150500475032; Sorkin LS, 2003, EXP NEUROL, V184, P162, DOI 10.1016/S0014-4886(03)00102-X; Sullivan PG, 2004, ANN NEUROL, V55, P576, DOI 10.1002/ana.20062; Tendler D, 2007, DIGEST DIS SCI, V52, P589, DOI 10.1007/s10620-006-9433-5; Thio LL, 2006, PEDIATR RES, V60, P413, DOI 10.1203/01.pdr.0000238244.54610.27; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; Westman EC, 2008, NUTR METAB, V5, DOI 10.1186/1743-7075-5-36; WINYARD PG, 1999, FREE RADICALS INFLAM; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Yudkoff M, 2007, ANNU REV NUTR, V27, P415, DOI 10.1146/annurev.nutr.27.061406.093722; Ziegler DR, 2005, PHYSIOL BEHAV, V84, P421, DOI 10.1016/j.physbeh.2005.01.003	48	108	111	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 23	2009	4	12							e8349	10.1371/journal.pone.0008349	http://dx.doi.org/10.1371/journal.pone.0008349			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	535UT	20041135	gold, Green Published			2023-01-03	WOS:000272998100005
J	Tamura, MK; Covinsky, KE; Chertow, GM; Yaffe, K; Landefeld, CS; McCulloch, CE				Tamura, Manjula Kurella; Covinsky, Kenneth E.; Chertow, Glenn M.; Yaffe, Kristine; Landefeld, C. Seth; McCulloch, Charles E.			Functional Status of Elderly Adults before and after Initiation of Dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPREHENSIVE GERIATRIC ASSESSMENT; CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; MINIMUM DATA SET; CARDIAC REHABILITATION; HEMODIALYSIS; SURVIVAL; OCTOGENARIANS; INTERVENTION; VALIDATION	BACKGROUND It is unclear whether functional status before dialysis is maintained after the initiation of this therapy in elderly patients with end-stage renal disease (ESRD). METHODS Using a national registry of patients undergoing dialysis, which was linked to a national registry of nursing home residents, we identified all 3702 nursing home residents in the United States who were starting treatment with dialysis between June 1998 and October 2000 and for whom at least one measurement of functional status was available before the initiation of dialysis. Functional status was measured by assessing the degree of dependence in seven activities of daily living (on the Minimum Data Set-Activities of Daily Living [MDS-ADL] scale of 0 to 28 points, with higher scores indication greater functional difficulty). RESULTS The median MDS-ADL score increased from 12 during the 3 months before the initiation of dialysis to 16 during the 3 months after the initiation of dialysis. Three months after the initiation of dialysis, functional status had been maintained in 39% of nursing home residents, but by 12 months after the initiation of dialysis, 58% had died and predialysis functional status had been maintained in only 13%. In a random-effects model, the initiation of dialysis was associated with a sharp declin in functional status, indicated by an increase of 2.8 points in the MDS-ADL score (95% confidence interval [CI], 2.5 to 3.0); this decline was independent of age, sex, race, and functional-status trajectory before the initiation of dialysis. The decline in functional status associated with the initiation of dialysis remained substantial (1.7 points; 95% CI, 1.4 to 2.1), even after adjustment for the presence or absence of an accelerated functional decline during the 3-month period before the initiation of dialysis. CONCLUSIONS Among nursing home residents with ESRD, the initiation of dialysis is associated with a substantial and sustained decline in functional status.	[Tamura, Manjula Kurella; Chertow, Glenn M.] Stanford Univ, Sch Med, Div Nephrol, Dept Med, Palo Alto, CA 94304 USA; [Covinsky, Kenneth E.; Landefeld, C. Seth] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat & Neurol, San Francisco, CA 94143 USA; [Yaffe, Kristine; McCulloch, Charles E.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Covinsky, Kenneth E.; Yaffe, Kristine; Landefeld, C. Seth] San Francisco VA Med Ctr, San Francisco, CA USA	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Tamura, MK (corresponding author), Stanford Univ, Sch Med, Div Nephrol, Dept Med, 780 Welch Rd,Suite 106, Palo Alto, CA 94304 USA.	mktamura@stanford.edu	Tamura, Manjula Kurella/C-8284-2014	Tamura, Manjula Kurella/0000-0001-5227-2479; Chertow, Glenn/0000-0002-7599-0534	National Institute of Aging [K23AG028952]; National Center for Research Resources [KL2RR024130]; National Institute of Diabetes and Digestive and Kidney Diseases [N01DK12450]; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K24AG029812, K23AG028952] Funding Source: NIH RePORTER	National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by a Paul B. Beeson Career Development Award in Aging (K23AG028952, to Dr. Kurella Tamura) from the National Institute of Aging and grants from the National Center for Research Resources (KL2RR024130) and the National Institute of Diabetes and Digestive and Kidney Diseases (N01DK12450).	ANDERSON JE, 1993, AM J KIDNEY DIS, V21, P619, DOI 10.1016/S0272-6386(12)80034-5; Brunori G, 2007, AM J KIDNEY DIS, V49, P569, DOI 10.1053/j.ajkd.2007.02.278; Caplan GA, 2004, J AM GERIATR SOC, V52, P1417, DOI 10.1111/j.1532-5415.2004.52401.x; Carey EC, 2004, J GEN INTERN MED, V19, P1027, DOI 10.1111/j.1525-1497.2004.40016.x; Collins AJ, 2005, AM J KIDNEY DIS, V45, pV, DOI 10.1053/j.ajkd.2004.10.009; Cook WL, 2008, KIDNEY INT, V73, P1289, DOI 10.1038/ki.2008.62; DeOreo PB, 1997, AM J KIDNEY DIS, V30, P204, DOI 10.1016/S0272-6386(97)90053-6; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; HAWES C, 1995, GERONTOLOGIST, V35, P172, DOI 10.1093/geront/35.2.172; Huang YJ, 2008, KIDNEY INT, V74, P1079, DOI 10.1038/ki.2008.381; IFUDU O, 1994, JAMA-J AM MED ASSOC, V271, P29, DOI 10.1001/jama.271.1.29; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; Joly D, 2003, J AM SOC NEPHROL, V14, P1012, DOI 10.1097/01.ASN.0000054493.04151.80; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Kutner NG, 2006, J AM SOC NEPHROL, V17, P1175, DOI 10.1681/ASN.2005101027; Lawton MP, 1998, J AM GERIATR SOC, V46, P736, DOI 10.1111/j.1532-5415.1998.tb03809.x; Li M, 2007, AM J KIDNEY DIS, V50, P90, DOI 10.1053/j.ajkd.2007.04.011; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; Reddy NC, 2007, NEPHROL DIAL TRANSPL, V22, P1399, DOI 10.1093/ndt/gfl809; Reuben DB, 1999, J AM GERIATR SOC, V47, P269, DOI 10.1111/j.1532-5415.1999.tb02988.x; Smith C, 2003, NEPHRON CLIN PRACT, V95, pC40, DOI 10.1159/000073708; Snowden M, 1999, J AM GERIATR SOC, V47, P1000, DOI 10.1111/j.1532-5415.1999.tb01297.x; Winkelmayer WC, 2005, AM J KIDNEY DIS, V46, P225, DOI 10.1053/j.ajkd.2005.04.029	25	666	687	2	47	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	2009	361	16					1539	1547		10.1056/NEJMoa0904655	http://dx.doi.org/10.1056/NEJMoa0904655			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	506LT	19828531	Green Accepted			2023-01-03	WOS:000270777000007
J	Jaddoe, VWV				Jaddoe, Vincent W. V.			Antenatal education programmes: do they work?	LANCET			English	Editorial Material							CHILDBIRTH; RATES		[Jaddoe, Vincent W. V.] Erasmus Univ, Med Ctr, Dept Epidemiol, Generat R Study Grp, NL-3000 CA Rotterdam, Netherlands; [Jaddoe, Vincent W. V.] Erasmus Univ, Med Ctr, Dept Paediat, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Jaddoe, VWV (corresponding author), Erasmus Univ, Med Ctr, Dept Epidemiol, Generat R Study Grp, NL-3000 CA Rotterdam, Netherlands.	v.jaddoe@erasmusmc.nl						Bergstrom M, 2009, BJOG-INT J OBSTET GY, V116, P1167, DOI 10.1111/j.1471-0528.2009.02144.x; Carroli G, 2001, LANCET, V357, P1565, DOI 10.1016/S0140-6736(00)04723-1; Cyna Allan M, 2006, BMC Pregnancy Childbirth, V6, P5, DOI 10.1186/1471-2393-6-5; Deave Toity, 2008, BMC Pregnancy Childbirth, V8, P30, DOI 10.1186/1471-2393-8-30; Dick-Read Grantly, 1944, CHILDBIRTH FEAR PRIN; Fabian HM, 2005, ACTA OBSTET GYN SCAN, V84, P436, DOI 10.1111/j.0001-6349.2005.00732.x; Gagnon AJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002869.pub2; Lamaze F., 1958, PAINLESS CHILDBIRTH; Su LL, 2007, BMJ-BRIT MED J, V335, P596, DOI 10.1136/bmj.39279.656343.55	9	17	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2009	374	9693					863	864		10.1016/S0140-6736(09)61610-X	http://dx.doi.org/10.1016/S0140-6736(09)61610-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	496BN	19748386				2023-01-03	WOS:000269943100010
J	Baker, DL; Schmidt, ML; Cohn, SL; Maris, JM; London, WB; Buxton, A; Stram, D; Castleberry, RP; Shimada, H; Sandler, A; Shamberger, RC; Look, AT; Reynolds, CP; Seeger, RC; Matthay, KK				Baker, David L.; Schmidt, Mary L.; Cohn, Susan L.; Maris, John M.; London, Wendy B.; Buxton, Allen; Stram, Daniel; Castleberry, Robert P.; Shimada, Hiroyuki; Sandler, Anthony; Shamberger, Robert C.; Look, A. Thomas; Reynolds, C. Patrick; Seeger, Robert C.; Matthay, Katherine K.		Children's Oncology Grp	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYC GENE AMPLIFICATION; TUMOR-CELL PLOIDY; N-MYC; CHROMOSOME 1P; UNRESECTABLE NEUROBLASTOMA; LOCALIZED NEUROBLASTOMA; INFANTS; THERAPY; CLASSIFICATION; PREDICTOR	Background: The survival rate among patients with intermediate-risk neuroblastoma who receive dose-intensive chemotherapy is excellent, but the survival rate among patients who receive reduced doses of chemotherapy for shorter periods of time is not known. Methods: We conducted a prospective, phase 3, nonrandomized trial to determine whether a 3-year estimated overall survival of more than 90% could be maintained with reductions in the duration of therapy and drug doses, using a tumor biology-based therapy assignment. Eligible patients had newly diagnosed, intermediate-risk neuroblastoma without MYCN amplification; these patients included infants (<365 days of age) who had stage 3 or 4 disease, children (greater/equal 365 days of age) who had stage 3 tumors with favorable histopathological features, and infants who had stage 4S disease with a diploid DNA index or unfavorable histopathological features. Patients who had disease with favorable histopathological features and hyperdiploidy were assigned to four cycles of chemotherapy, and those with an incomplete response or either unfavorable feature were assigned to eight cycles. Results: Between 1997 and 2005, a total of 479 eligible patients were enrolled in this trial (270 patients with stage 3 disease, 178 with stage 4 disease, and 31 with stage 4S disease). A total of 323 patients had tumors with favorable biologic features, and 141 had tumors with unfavorable biologic features. Ploidy, but not histopathological features, was significantly predictive of the outcome. Severe adverse events without disease progression occurred in 10 patients (2.1%), including secondary leukemia (in 3 patients), death from infection (in 3 patients), and death at surgery (in 4 patients). The 3-year estimate (+/-SE) of overall survival for the entire group was 96+/-1%, with an overall survival rate of 98+/-1% among patients who had tumors with favorable biologic features and 93+/-2% among patients who had tumors with unfavorable biologic features. Conclusions: A very high rate of survival among patients with intermediate-risk neuroblastoma was achieved with a biologically based treatment assignment involving a substantially reduced duration of chemotherapy and reduced doses of chemotherapeutic agents as compared with the regimens used in earlier trials. These data provide support for further reduction in chemotherapy with more refined risk stratification. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00003093.) N Engl J Med 2010;363:1313-23.	[Matthay, Katherine K.] Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; [Baker, David L.] Princess Margaret Hosp Children, Perth, WA, Australia; [Schmidt, Mary L.] Univ Illinois, Coll Med, Chicago, IL USA; [Cohn, Susan L.] Comer Childrens Hosp, Chicago, IL USA; [Cohn, Susan L.] Univ Chicago, Chicago, IL 60637 USA; [Maris, John M.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Maris, John M.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [London, Wendy B.; Shamberger, Robert C.] Childrens Hosp, Boston, MA 02115 USA; [London, Wendy B.; Shamberger, Robert C.] Harvard Univ, Sch Med, Boston, MA USA; [Buxton, Allen] Childrens Oncol Grp Stat & Data Ctr, Arcadia, CA USA; [Stram, Daniel; Shimada, Hiroyuki; Seeger, Robert C.] Univ So Calif, Childrens Hosp Los Angeles, Los Angeles, CA USA; [Castleberry, Robert P.] Univ Alabama Birmingham, Birmingham, AL USA; [Sandler, Anthony] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Sandler, Anthony] George Washington Univ, Med Ctr, Washington, DC 20037 USA; [Look, A. Thomas] St Jude Childrens Res Hosp, Memphis, TN USA; [Reynolds, C. Patrick] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA; [Matthay, Katherine K.] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Western Australia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Chicago; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Children's Oncology Group (COG); Children's Hospital Los Angeles; University of Southern California; University of Alabama System; University of Alabama Birmingham; Children's National Health System; George Washington University; St Jude Children's Research Hospital; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of California System; University of California San Francisco	Matthay, KK (corresponding author), Univ Calif San Francisco, Sch Med, Dept Pediat, 505 Parnassus Ave,Rm M 647, San Francisco, CA 94143 USA.	matthayk@peds.ucsf.edu	London, Wendy/ABD-4624-2021; Irving, Helen/J-5158-2013; Cohn, Susan/AAB-6010-2021; London, Wendy Beth/ABA-8948-2021; Mascarenhas, Leo/M-1801-2019	London, Wendy Beth/0000-0003-3571-6538; Mascarenhas, Leo/0000-0001-7790-0777; Cohn, Susan/0000-0001-5749-7650; Sandler, Anthony/0000-0001-9440-2964; Reynolds, C. Patrick/0000-0002-2827-8536; Kanwar, Vikramjit/0000-0001-6054-1579; Razzouk, Bassem/0000-0003-0536-6135	National Cancer Institute of the National Institutes of Health [UIO-CA98543, UIO-CA98413, UIO-CA29139]; NATIONAL CANCER INSTITUTE [U10CA017829, U10CA098543, U10CA098413, U10CA029139] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants (UIO-CA98543, UIO-CA98413, and UIO-CA29139) from the National Cancer Institute of the National Institutes of Health.	Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; ATTIYEH EF, 2007, J CLIN ONCOL S, V25, pS18; Bagatell R, 2005, J CLIN ONCOL, V23, P8819, DOI 10.1200/JCO.2004.00.2931; Bergeron C, 2005, PEDIATR BLOOD CANCER, V45, P32, DOI 10.1002/pbc.20379; Bowman LC, 1997, J NATL CANCER I, V89, P373, DOI 10.1093/jnci/89.5.373; BROCK PR, 1992, BRIT J CANCER, V66, pS36; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Brodeur GM, 2002, PRINCIPLES PRACTICE, P895; Caron H, 1996, NEW ENGL J MED, V334, P225, DOI 10.1056/NEJM199601253340404; Cecchetto G, 2005, J CLIN ONCOL, V23, P8483, DOI 10.1200/JCO.2005.02.4661; Cohn SL, 2009, J CLIN ONCOL, V27, P289, DOI 10.1200/JCO.2008.16.6785; De Bernardi B, 2009, J CLIN ONCOL, V27, P1034, DOI 10.1200/JCO.2008.17.5877; DEBERNARDI B, 1995, J CLIN ONCOL, V13, P884, DOI 10.1200/JCO.1995.13.4.884; English MW, 1999, BRIT J CANCER, V81, P336, DOI 10.1038/sj.bjc.6690697; Greenwood M., 1926, REPORTS PUBLIC HLTH, V33, P1; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Gurney JG, 2007, PEDIATRICS, V120, pE1229, DOI 10.1542/peds.2007-0178; Hero B, 2008, J CLIN ONCOL, V26, P1504, DOI 10.1200/JCO.2007.12.3349; Janoueix-Lerosey I, 2009, J CLIN ONCOL, V27, P1026, DOI 10.1200/JCO.2008.16.0630; Katzenstein HM, 1998, J CLIN ONCOL, V16, P2007, DOI 10.1200/JCO.1998.16.6.2007; KIELY EM, 1994, J PEDIATR SURG, V29, P128, DOI 10.1016/0022-3468(94)90307-7; LOOK AT, 1984, NEW ENGL J MED, V311, P231, DOI 10.1056/NEJM198407263110405; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; MARIS JM, 1995, CANCER RES, V55, P4664; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Matthay KK, 2010, BRIT J CANCER, V102, P1319, DOI 10.1038/sj.bjc.6605621; Matthay KK, 1998, J CLIN ONCOL, V16, P1256, DOI 10.1200/JCO.1998.16.4.1256; Monclair T, 2009, J CLIN ONCOL, V27, P298, DOI 10.1200/JCO.2008.16.6876; Nickerson HJ, 2000, J CLIN ONCOL, V18, P477, DOI 10.1200/JCO.2000.18.3.477; NITSCHKE R, 1991, J CLIN ONCOL, V9, P1181, DOI 10.1200/JCO.1991.9.7.1181; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Paulino AC, 2002, INT J RADIAT ONCOL, V52, P1025, DOI 10.1016/S0360-3016(01)02713-4; Rubie H, 2001, MED PEDIATR ONCOL, V36, P247, DOI 10.1002/1096-911X(20010101)36:1<247::AID-MPO1061>3.0.CO;2-Z; Schmidt ML, 2000, J CLIN ONCOL, V18, P1260, DOI 10.1200/JCO.2000.18.6.1260; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; SHIMADA H, 1984, J NATL CANCER I, V73, P405, DOI 10.1093/jnci/73.2.405; Shimada H, 2001, CANCER, V92, P2451, DOI 10.1002/1097-0142(20011101)92:9<2451::AID-CNCR1595>3.0.CO;2-S; Simon T, 2008, PEDIATR BLOOD CANCER, V50, P965, DOI 10.1002/pbc.21343; SKINNER R, 1992, BRIT J CANCER, V66, pS30; SMITH MA, 1994, MED PEDIATR ONCOL, V23, P86, DOI 10.1002/mpo.2950230205; STEINHERZ LJ, 1992, PEDIATRICS, V89, P942; Strother D, 1997, EUR J CANCER, V33, P2121, DOI 10.1016/S0959-8049(97)00293-1; STROTHER D, 1995, J PEDIAT HEMATOL ONC, V17, P254, DOI 10.1097/00043426-199508000-00007	47	186	194	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	2010	363	14					1313	1323		10.1056/NEJMoa1001527	http://dx.doi.org/10.1056/NEJMoa1001527			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	655TD	20879880	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000282271500005
J	Vadhan-Raj, S; Trent, J; Patel, S; Zhou, X; Johnson, MM; Araujo, D; Ludwig, JA; O'Roark, S; Gillenwater, AM; Bueso-Ramos, C; El-Naggar, AK; Benjamin, RS				Vadhan-Raj, Saroj; Trent, Jonathan; Patel, Shreyaskumar; Zhou, Xiao; Johnson, Marcella M.; Araujo, Dejka; Ludwig, Joseph A.; O'Roark, Shana; Gillenwater, Ann M.; Bueso-Ramos, Carlos; El-Naggar, Adel K.; Benjamin, Robert S.			Single-Dose Palifermin Prevents Severe Oral Mucositis During Multicycle Chemotherapy in Patients With Cancer A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							KERATINOCYTE GROWTH-FACTOR; STEM-CELL TRANSPLANTATION; COMPETING RISK; THERAPY; RADIOTHERAPY; PATHOGENESIS; PROPHYLAXIS; MANAGEMENT; INJURY; MODEL	Background: Mucositis can be a serious complication of cancer treatment. Palifermin reduces mucositis when given in multiple doses to patients undergoing hematopoietic stem-cell transplantation. Objective: To evaluate the efficacy of palifermin given as a single dose before each cycle in patients receiving multicycle chemotherapy. Design: Randomized, double-blind, placebo-controlled trial. (Clinical Trials.gov registration number: NCT00267046) Setting: The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Patients: 48 patients with sarcoma were randomly assigned in a 2: 1 ratio to receive palifermin or placebo. All patients received doxorubicin-based chemotherapy (90 mg per m(2) of body surface area over 3 days, by infusion). Intervention: Palifermin (180 mu g per kg of body weight) or placebo was administered intravenously as a single dose 3 days before each chemotherapy cycle (maximum, 6 cycles). Patients who had severe mucositis received open-label palifermin in subsequent cycles. Measurements: Oral assessment of mucositis by using World Health Organization (WHO) oral toxicity scale (grades 0 to 4), with moderate to severe mucositis (grades 2 to 4) as the main outcomes; patient-reported outcome questionnaire; and daily symptom record diary. Results: A median of 6 blinded cycles (range, 1 to 6) were completed by the palifermin group and 2 (range, 1 to 6) by the placebo group. Compared with placebo, palifermin reduced the cumulative incidence of moderate to severe (grade 2 or higher) mucositis (44% vs. 88%; P < 0.001; difference, -44 percentage points [95% CI, -71 to -16 percentage points) and severe (grade 3 or 4) mucositis (13% vs. 51%; P = 0.002; difference, -38 percentage points [CI, -67 to -9 percentage points]). The main adverse effects were thickening of oral mucosa (72% in the palifermin group vs. 31% in the placebo group; P = 0.007) and altered taste. Seven of the 8 patients who had severe mucositis in the placebo group received open-label palifermin. None of these patients had severe mucositis in the subsequent cycles (a total of 17) with open-label palifermin. Limitations: Study limitations include smaller sample size for the control group, inclusion of only patients with sarcoma, and perceived unblinding of the treatment because of notable differences between the biologic effects of palifermin and placebo. Conclusion: A single dose of palifermin before each cycle reduced the incidence and severity of mucositis. The drug was generally well tolerated, but most patients experienced thickening of oral mucosa. Further investigation is needed to determine whether palifermin use will facilitate greater adherence to chemotherapy regimens by reducing mucositis.	[Vadhan-Raj, Saroj] Univ Texas MD Anderson Canc Ctr, Sect Cytokines & Support Oncol, Dept Sarcoma Med Oncol, Houston, TX 77230 USA	University of Texas System; UTMD Anderson Cancer Center	Vadhan-Raj, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Sect Cytokines & Support Oncol, Dept Sarcoma Med Oncol, 1515 Holcombe Blvd,Unit 450,Box 301402, Houston, TX 77230 USA.	svadhanr@mdanderson.org	Trent, Jonathan/AAR-7113-2021	Trent, Jonathan/0000-0001-6169-5238; Gillenwater, Ann/0000-0002-0935-0037	Amgen	Amgen(Amgen)	By Amgen.	Bartek J, 2001, SCIENCE, V294, P66, DOI 10.1126/science.1066237; Borges L, 2006, INT J RADIAT ONCOL, V66, P254, DOI 10.1016/j.ijrobp.2006.05.025; Dorr W, 2005, INT J RADIAT BIOL, V81, P557, DOI 10.1080/09553000500196136; Epstein Joel B, 2006, Expert Opin Emerg Drugs, V11, P353, DOI 10.1517/14728214.11.2.353; Farrell CL, 1999, INT J RADIAT BIOL, V75, P609; Farrell CL, 1998, CANCER RES, V58, P933; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Gray R, 2010, CMPRSK SUBDISTRIBUTI; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; Keefe DM, 2007, CANCER-AM CANCER SOC, V109, P820, DOI 10.1002/cncr.22484; Lalla RV, 2006, CANCER J, V12, P348, DOI 10.1097/00130404-200609000-00004; Lee JJ, 2000, AM STAT, V54, P63, DOI 10.2307/2685614; Lewis IJ, 2007, JNCI-J NATL CANCER I, V99, P112, DOI 10.1093/jnci/djk015; Mead GM, 2002, LANCET, V359, P815, DOI 10.1016/S0140-6736(02)07960-6; Meropol NJ, 2003, J CLIN ONCOL, V21, P1452, DOI 10.1200/JCO.2003.10.079; Neganova I, 2008, J ANAT, V213, P30, DOI 10.1111/j.1469-7580.2008.00931.x; Papas AS, 2003, BONE MARROW TRANSPL, V31, P705, DOI 10.1038/sj.bmt.1703870; Patel SR, 1998, AM J CLIN ONCOL-CANC, V21, P317, DOI 10.1097/00000421-199806000-00025; Potting CMJ, 2006, EUR J CANCER CARE, V15, P431, DOI 10.1111/j.1365-2354.2006.00684.x; Rosen LS, 2006, J CLIN ONCOL, V24, P5194, DOI 10.1200/JCO.2005.04.1152; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Scully C, 2003, HEAD NECK-J SCI SPEC, V25, P1057, DOI 10.1002/hed.10318; Sonis ST, 2004, CANCER-AM CANCER SOC, V100, P1995, DOI 10.1002/cncr.20162; Sorensen JB, 2008, CANCER-AM CANCER SOC, V112, P1600, DOI 10.1002/cncr.23328; Spielberger R, 2004, NEW ENGL J MED, V351, P2590, DOI 10.1056/NEJMoa040125; Stiff PJ, 2006, J CLIN ONCOL, V24, P5186, DOI 10.1200/JCO.2005.02.8340; Stiff PJ, 2006, BONE MARROW TRANSPL, V37, P393, DOI 10.1038/sj.bmt.1705250; VADHANRAJ S, 1992, J CLIN ONCOL, V10, P1266, DOI 10.1200/JCO.1992.10.8.1266; Worthington HV, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000978.pub3	29	42	42	1	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 21	2010	153	6					358	367		10.7326/0003-4819-153-6-201009210-00003	http://dx.doi.org/10.7326/0003-4819-153-6-201009210-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	652WY	20855800				2023-01-03	WOS:000282043100002
J	Barclay, S; Maher, J				Barclay, Stephen; Maher, Jane			Spotlight: Palliative Care Beyond Cancer Having the difficult conversations about the end of life	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; GOOD DOCTOR; DEATH; COMMUNICATION; ONCOLOGISTS; PREFERENCES; FAMILIES; ILLNESS; DIE		[Barclay, Stephen] Inst Publ Hlth, Gen Pract & Primary Care Res Unit,, Cambridge CB2 2SR, England; [Maher, Jane] Mt Vernon Canc Ctr, London, England	University of Cambridge; Mount Vernon Cancer Centre	Barclay, S (corresponding author), Inst Publ Hlth, Gen Pract & Primary Care Res Unit,, Cambridge CB2 2SR, England.	sigb2@medschl.cam.ac.uk		Barclay, Stephen/0000-0002-4505-7743				[Anonymous], 2005, MORT STAT; Barclay S, 2009, BRIT J GEN PRACT, V59, P642, DOI 10.3399/bjgp09X454052; Berry SR, 2008, J CLIN ONCOL, V26, P157, DOI 10.1200/JCO.2007.12.3224; BUCKMAN R, 1992, BREAK BAD NEWS; Christakis N A, 1998, Hosp J, V13, P71; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Cleland John G F, 2002, Heart Fail Rev, V7, P229, DOI 10.1023/A:1020024122726; Coulter A, 2002, BRIT MED J, V325, P668, DOI 10.1136/bmj.325.7366.668; Dale J, 2009, QUAL SAF HEALTH CARE, V18, P174, DOI 10.1136/qshc.2007.024836; Ellershaw JE, 2003, CARE DYING PATHWAY E; FORD S, 1994, BRIT J CANCER, V70, P767, DOI 10.1038/bjc.1994.393; Gattellari M, 2002, J CLIN ONCOL, V20, P503, DOI 10.1200/JCO.20.2.503; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Heffner JE, 2000, CHEST, V117, P1474, DOI 10.1378/chest.117.5.1474; Hurwitz B, 2002, BMJ-BRIT MED J, V325, P667, DOI 10.1136/bmj.325.7366.667; Kirk P, 2004, BMJ-BRIT MED J, V328, P1343, DOI 10.1136/bmj.38103.423576.55; Koedoot CG, 2004, EUR J CANCER, V40, P225, DOI 10.1016/j.ejca.2003.10.008; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; *MACM CANC SUPP, 2004, UNCL MILL; Maltoni M, 2002, HEMATOL ONCOL CLIN N, V16, P715, DOI 10.1016/S0889-8588(02)00024-2; Murray SA, 2005, BRIT MED J, V330, P611, DOI 10.1136/bmj.330.7492.611; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murtagh FEM, 2004, CLIN MED, V4, P39, DOI 10.7861/clinmedicine.4-1-39; Quirt CF, 1997, LUNG CANCER-J IASLC, V18, P1, DOI 10.1016/S0169-5002(97)00048-2; TODD CJ, 1984, SOC SCI MED, V18, P667, DOI 10.1016/0277-9536(84)90295-8; Wenrich MD, 2001, ARCH INTERN MED, V161, P868, DOI 10.1001/archinte.161.6.868; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	29	28	29	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 16	2010	341								c4862	10.1136/bmj.c4862	http://dx.doi.org/10.1136/bmj.c4862			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	653MO	20847022				2023-01-03	WOS:000282095800006
J	Antczak, P; Ortega, F; Chipman, JK; Falciani, F				Antczak, Philipp; Ortega, Fernando; Chipman, J. Kevin; Falciani, Francesco			Mapping Drug Physico-Chemical Features to Pathway Activity Reveals Molecular Networks Linked to Toxicity Outcome	PLOS ONE			English	Article							EXPRESSION; SELECTION	The identification of predictive biomarkers is at the core of modern toxicology. So far, a number of approaches have been proposed. These rely on statistical inference of toxicity response from either compound features (i.e., QSAR), in vitro cell based assays or molecular profiling of target tissues (i.e., expression profiling). Although these approaches have already shown the potential of predictive toxicology, we still do not have a systematic approach to model the interaction between chemical features, molecular networks and toxicity outcome. Here, we describe a computational strategy designed to address this important need. Its application to a model of renal tubular degeneration has revealed a link between physicochemical features and signalling components controlling cell communication pathways, which in turn are differentially modulated in response to toxic chemicals. Overall, our findings are consistent with the existence of a general toxicity mechanism operating in synergy with more specific single-target based mode of actions (MOAs) and provide a general framework for the development of an integrative approach to predictive toxicology.	[Antczak, Philipp; Ortega, Fernando; Chipman, J. Kevin; Falciani, Francesco] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England	University of Birmingham	Falciani, F (corresponding author), Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England.	f.falciani@bham.ac.uk	Ortega, Fernando/G-2129-2015; Falciani, Francesco/F-3490-2010; Antczak, Philipp/L-5879-2019	Ortega, Fernando/0000-0002-3172-2095; Antczak, Philipp/0000-0001-9600-7757	Biotechnology and Biological Sciences Research Council (BBSRC); United Kingdom Natural Environment Research Council (NERC) [NE/C507661/1]; NERC [NE/D000793/1] Funding Source: UKRI; Natural Environment Research Council [NE/D000793/1, NE/C507661/1] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); United Kingdom Natural Environment Research Council (NERC)(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	This work has been partially supported by a Biotechnology and Biological Sciences Research Council (BBSRC) PhD studentship to PA and by the United Kingdom Natural Environment Research Council (NERC) Post-Genomic and Proteomic Programme grant NE/C507661/1. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amin RP, 2002, TOXICOLOGY, V181, P555, DOI 10.1016/S0300-483X(02)00481-X; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bushel PR, 2002, J BIOMED INFORM, V35, P160, DOI 10.1016/S1532-0464(02)00525-7; Cariello NF, 2002, MUTAGENESIS, V17, P321, DOI 10.1093/mutage/17.4.321; Chipman JK, 2003, TOXICOL SCI, V71, P146, DOI 10.1093/toxsci/71.2.146; Conesa A, 2008, GENOMICS, V92, P373, DOI 10.1016/j.ygeno.2008.05.015; Dieterle F, 2008, CURR OPIN DRUG DISC, V11, P60; Dix DJ, 2007, TOXICOL SCI, V95, P5, DOI 10.1093/toxsci/kfl103; Doi AM, 2007, TOXICOL PATHOL, V35, P533, DOI 10.1080/01926230701338941; Fielden MR, 2005, TOXICOL PATHOL, V33, P675, DOI 10.1080/01926230500321213; Freeman JW, 2004, FRONT BIOSCI-LANDMRK, V9, P1889, DOI 10.2741/1388; Geng H, 2009, AM J PATHOL, V174, P1291, DOI 10.2353/ajpath.2009.080295; GOWER JC, 1966, BIOMETRIKA, V53, P325, DOI 10.1093/biomet/53.3-4.325; Judson R, 2009, ENVIRON HEALTH PERSP, V117, P685, DOI 10.1289/ehp.0800168; KLAASSEN C, 1993, J OCCUPATIONAL ENV M, V35, P76; Kong SW, 2006, BIOINFORMATICS, V22, P2373, DOI 10.1093/bioinformatics/btl401; Lobenhofer EK, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-6-r100; Mayr LM, 2009, CURR OPIN PHARMACOL, V9, P580, DOI 10.1016/j.coph.2009.08.004; Merlot C, 2010, DRUG DISCOV TODAY, V15, P16, DOI 10.1016/j.drudis.2009.09.010; Pereira CV, 2009, CURR DRUG SAF, V4, P34, DOI 10.2174/157488609787354440; RAYCHAUDHURI S, 2000, PAC S BIOC PAC S BIO; Sameith K, 2008, BIOINFORMATICS, V24, P2602, DOI 10.1093/bioinformatics/btn489; SCHOEPPE W, 1977, P ROY SOC MED, V70, P36, DOI 10.1177/00359157770700S207; SONG S, 2006, PRINCIPAL COORDINATE; Song S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-502; Steiner G, 2004, ENVIRON HEALTH PERSP, V112, P1236, DOI 10.1289/txg.7036; TEAM RDC, 2005, R LANGUAGE ENV STAT; Tetko IV, 2005, J COMPUT AID MOL DES, V19, P453, DOI 10.1007/s10822-005-8694-y; Thomas RS, 2001, MOL PHARMACOL, V60, P1189, DOI 10.1124/mol.60.6.1189; Trevino V, 2006, BIOINFORMATICS, V22, P1154, DOI 10.1093/bioinformatics/btl074; Vayer P, 2009, M S-MED SCI, V25, P871, DOI 10.1051/medsci/20092510871; Vedani A, 2006, BASIC CLIN PHARMACOL, V99, P195, DOI 10.1111/j.1742-7843.2006.pto_471.x; Waring JF, 2002, TOXICOLOGY, V181, P537, DOI 10.1016/S0300-483X(02)00477-8	33	11	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2010	5	8							e12385	10.1371/journal.pone.0012385	http://dx.doi.org/10.1371/journal.pone.0012385			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	643MT	20811577	Green Submitted, Green Published, gold			2023-01-03	WOS:000281301500004
J	Sasson, C; Keirns, CC; Smith, D; Sayre, M; Macy, M; Meurer, W; McNally, BF; Kellermann, AL; Iwashyna, TJ				Sasson, Comilla; Keirns, Carla C.; Smith, Dylan; Sayre, Michael; Macy, Michelle; Meurer, William; McNally, Bryan F.; Kellermann, Arthur L.; Iwashyna, Theodore J.		Cardiac Arrest Registry Enhance Su	Small Area Variations in Out-of-Hospital Cardiac Arrest: Does the Neighborhood Matter?	ANNALS OF INTERNAL MEDICINE			English	Article							RESUSCITATION	Background: The incidence and outcomes of out-of-hospital cardiac arrest vary widely across cities. It is unknown whether similar differences exist at the neighborhood level. Objective: To determine the extent to which neighborhoods have persistently high rates of cardiac arrest but low rates of bystander cardiopulmonary resuscitation (CPR). Design: Multilevel Poisson regression of 1108 cardiac arrests from 161 census tracts as captured by the Cardiac Arrest Registry to Enhance Survival (CARES). Setting: Fulton County, Georgia, between 1 October 2005 to 30 November 2008. Measurements: Incidence of cardiac arrest, by census tract and year and by rates of bystander CPR. Results: Adjusted rates of cardiac arrest varied across neighborhoods (interquartile range [IQR], 0.57 to 0.73 per 1000 persons; mean, 0.64 per 1000 persons [SD, 0.11]) but were stable from year to year (intraclass correlation, 0.36 [95% CI, 0.26 to 0.50]; P < 0.001). Adjusted bystander CPR rates also varied by census tract (IQR, 19% to 29%; mean, 25% [SD, 10%]). Limitation: Analysis was based on data from a single county. Conclusion: Surveillance data can identify neighborhoods with a persistently high incidence of cardiac arrest and low rates of bystander CPR. These neighborhoods are promising targets for community-based interventions.	Univ Michigan, Ann Arbor, MI 48109 USA; SUNY Stony Brook, Med Ctr, Stony Brook, NY 11794 USA; Ohio State Univ, Columbus, OH 43210 USA; Emory Univ, Sch Med, Atlanta, GA USA	University of Michigan System; University of Michigan; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University System of Ohio; Ohio State University; Emory University	Sasson, C (corresponding author), Robert Wood Johnson Fdn, Clin Scholars Program, 1150 W Med Ctr Dr,6312 Med Sci Bldg 1,Campus Box, Ann Arbor, MI 48109 USA.	comilla@umich.edu	Meurer, William J/A-7547-2010; Keirns, Carla/AAT-9384-2020; Sayre, Michael R/E-8383-2017; Macy, Michelle/AAV-7528-2020; McNally, Bryan/AAE-9332-2020	Meurer, William J/0000-0002-1158-5302; Sayre, Michael R/0000-0003-0322-3181; Macy, Michelle/0000-0003-4401-7384; Iwashyna, Theodore/0000-0002-4226-9310	Robert Wood Johnson Foundation; National Institutes of Health [K08 HL091249]; Centers for Disease Control and Prevention [MM-0917-05/05]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL091249] Funding Source: NIH RePORTER	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	By the Robert Wood Johnson Foundation Clinical Scholars Program, National Institutes of Health (grant K08 HL091249), and Centers for Disease Control and Prevention (grant MM-0917-05/05).	*CARD ARR REG ENH, IRB APPR MOD; Eisenberg MS, 2001, NEW ENGL J MED, V344, P1304, DOI 10.1056/NEJM200104263441707; Hayward RA, 2007, HEALTH SERV RES, V42, P1718, DOI 10.1111/j.1475-6773.2006.00661.x; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Lerner EB, 2005, ACAD EMERG MED, V12, P81, DOI 10.1197/j.aem.2004.08.044; McCarthy M, 2000, Rev Environ Health, V15, P97; McNally B, 2009, ANN EMERG MED, V54, P674, DOI 10.1016/j.annemergmed.2009.03.018; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Rabe-Hesketh Sophia, 2008, MULTILEVEL LONGITUDI; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Sasson C, 2008, JAMA-J AM MED ASSOC, V300, P1432, DOI 10.1001/jama.300.12.1432; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576	12	66	67	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2010	153	1					19	W12		10.7326/0003-4819-153-1-201007060-00255	http://dx.doi.org/10.7326/0003-4819-153-1-201007060-00255			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	620GS	20516307	Green Accepted			2023-01-03	WOS:000279487700003
J	Frost, PJ; Leadbeatter, S; Wise, MP				Frost, Paul J.; Leadbeatter, Stephen; Wise, Matt P.			The Competent Novice Managing sudden death in hospital	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							LIFE CARE; CERTIFICATION; MEDICINE; AUDIT; NEWS; END; BAD		[Frost, Paul J.; Wise, Matt P.] Univ Wales Hosp, Crit Care Directorate, Cardiff CF14 4XW, Wales; [Frost, Paul J.] Cardiff Univ, Schoool Med, Univ Wales Hosp, Cardiff, Wales; [Leadbeatter, Stephen] Univ Wales Hosp, Dept Med Genet Pathol & Haematol, Cardiff CF14 4XW, Wales	Cardiff University; Cardiff University; Cardiff University	Frost, PJ (corresponding author), Univ Wales Hosp, Crit Care Directorate, Cardiff CF14 4XW, Wales.	Paul.Frost@CardiffandVale.Wales.nhs.uk		Wise, Matt/0000-0002-2763-4316				Academy of Medical Royal Colleges, 2008, COD PRACT DIAGN CONF; AWOONORRENNER S, 1991, BRIT MED J, V302, P356, DOI 10.1136/bmj.302.6772.356; Baker JN, 2007, J PALLIAT MED, V10, P420, DOI 10.1089/jpm.2006.0135; Cave J, 2008, BRIT MED J, V336, P326, DOI 10.1136/bmj.39455.639340.AD; Department of Health, 2005, PAT DIES ADV DEV BER; Edmonds P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5048; Ellershaw J, 2007, PALLIATIVE MED, V21, P365, DOI 10.1177/0269216307081117; Fallowfield L, 2004, LANCET, V363, P312, DOI 10.1016/S0140-6736(03)15392-5; *HOSP EP STAT, 2009, HEADL FIG 2008 9; Iversen A, 2009, BMJ-BRIT MED J, V338, P1139; JAMES DS, 1995, J ROY COLL PHYS LOND, V29, P424; Jurkovich GJ, 2000, J TRAUMA, V48, P865, DOI 10.1097/00005373-200005000-00009; LEADBEATTER S, 1986, J ROY COLL PHYS LOND, V20, P273; LEADBEATTER S, 1986, J ROY COLL PHYS LOND, V20, P129; LEASH RM, 1994, DEATH NOTIFICATION; Lserson KV, 2000, ANN EMERG MED, V36, P75, DOI 10.1067/mem.2000.107664; *M CUR PALL CAR I, LIV LIV CAR PATHW 20; Moores TS, 2007, MED EDUC, V41, P942, DOI 10.1111/j.1365-2923.2007.02836.x; National Council for Hospice and Specialist Palliative Care Services, 2003, BREAK BAD NEWS REG G; NEVILLE RG, 1987, J ROY COLL GEN PRACT, V37, P496; Office for National Statistics, MORT STAT DEATHS REG; Redinbaugh EM, 2003, BMJ-BRIT MED J, V327, P185, DOI 10.1136/bmj.327.7408.185; Selinger CP, 2007, POSTGRAD MED J, V83, P285, DOI 10.1136/pgmj.2006.054833; Swift B, 2002, J CLIN PATHOL, V55, P275, DOI 10.1136/jcp.55.4.275; Treloar AJ, 2008, BRIT MED J, V336, P905, DOI 10.1136/bmj.39556.400370.80; *UK TRANSPL, 2003, UK HOSP POL ORG TISS	26	1	1	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	2010	340								c962	10.1136/bmj.c962	http://dx.doi.org/10.1136/bmj.c962			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	586JZ	20388691				2023-01-03	WOS:000276904800021
J	de Jager, DJ; Grootendorst, DC; Jager, KJ; van Dijk, PC; Tomas, LMJ; Ansell, D; Collart, F; Finne, P; Heaf, JG; De Meester, J; Wetzels, JFM; Rosendaal, FR; Dekker, FW				de Jager, Dinanda J.; Grootendorst, Diana C.; Jager, Kitty J.; van Dijk, Paul C.; Tomas, Lonneke M. J.; Ansell, David; Collart, Frederic; Finne, Patrik; Heaf, James G.; De Meester, Johan; Wetzels, Jack F. M.; Rosendaal, Frits R.; Dekker, Friedo W.			Cardiovascular and Noncardiovascular Mortality Among Patients Starting Dialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; RISK-FACTOR; HEMODIALYSIS; DEATH; DYSFUNCTION; PREVALENCE; REGISTRY; FRAILTY; GENDER	Context Cardiovascular mortality is considered the main cause of death in patients receiving dialysis and is 10 to 20 times higher in such patients than in the general population. Objective To evaluate if high overall mortality in patients starting dialysis is a consequence of increased cardiovascular mortality risk only or whether noncardiovascular mortality is equally increased. Design, Setting, and Patients Using data from between January 1, 1994, and January 1, 2007, age-stratified mortality in a European cohort of adults starting dialysis and receiving follow-up for a mean of 1.8 (SD, 1.1) years ( European Renal Association-European Dialysis and Transplant Association [ERA-EDTA] Registry [N=123 407]) was compared with the European general population (Eurostat). Main Outcome Measures Cause of death was recorded by ERA-EDTA codes in patients and matching International Statistical Classification of Diseases, 10th Revision codes in the general population. Standardized cardiovascular and noncardiovascular mortality rates, their ratio, difference, and relative excess of cardiovascular over noncardiovascular mortality were calculated. Results Overall all-cause mortality rates in patients and the general population were 192 per 1000 person-years (95% confidence interval [CI], 190-193) and 12.055 per 1000 person-years ( 95% CI, 12.05-12.06), respectively. Cause of death was known for 90% of the patients and 99% of the general population. In patients, 16 654 deaths (39%) were cardiovascular and 21 654 (51%) were noncardiovascular. In the general population, 7 041 747 deaths (40%) were cardiovascular and 10 183 322 (58%) were noncardiovascular. Cardiovascular and noncardiovascular mortality rates in patients were respectively 38.1 per 1000 person-years ( 95% CI, 37.2-39.0) and 50.1 per 1000 person-years ( 95% CI, 48.9-51.2) higher than in the general population. On a relative scale, standardized cardiovascular and noncardiovascular mortality were respectively 8.8 ( 95% CI, 8.6-9.0) and 8.1 ( 95% CI, 7.9-8.3) times higher than in the general population. The ratio of these rates, ie, relative excess of cardiovascular over noncardiovascular mortality in patients starting dialysis compared with the general population, was 1.09 ( 95% CI, 1.06-1.12). Relative excess in a sensitivity analysis in which unknown/missing causes of death were regarded either as noncardiovascular or cardiovascular varied between 0.90 ( 95% CI, 0.88-0.93) and 1.39 ( 95% CI, 1.35-1.43). Conclusion Patients starting dialysis have a generally increased risk of death that is not specifically caused by excess cardiovascular mortality. JAMA. 2009; 302(16):1782-1789 www.jama.com	[de Jager, Dinanda J.; Grootendorst, Diana C.; Tomas, Lonneke M. J.; Rosendaal, Frits R.; Dekker, Friedo W.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands; [Jager, Kitty J.; van Dijk, Paul C.] Univ Amsterdam, Acad Med Ctr, ERA EDTA Registry, Dept Med Informat, NL-1105 AZ Amsterdam, Netherlands; [Ansell, David] United Kingdom Renal Registry, Bristol, Avon, England; [Collart, Frederic] French Speaking Belgium ESRD Registry, Brussels, Belgium; [Finne, Patrik] Finnish Registry Kidney Dis, Helsinki, Finland; [Heaf, James G.] Copenhagen Univ Hosp, Dept Nephrol, Herlev, Denmark; [De Meester, Johan] AZ Nikolaas, Dept Nephrol Dialysis & Hypertens, St Niklaas, Belgium; [Wetzels, Jack F. M.] Radboud Univ Nijmegen, Med Ctr, Dept Nephrol, NL-6525 ED Nijmegen, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam; Academic Medical Center Amsterdam; Universite Libre de Bruxelles; University of Copenhagen; Radboud University Nijmegen	de Jager, DJ (corresponding author), Leiden Univ, Med Ctr, Dept Clin Epidemiol, C7-104,POB 9600, NL-2300 RC Leiden, Netherlands.	d.j.de_jager@lumc.nl	Dekker, Friedo W/B-6452-2011; Rosendaal, Frits/Q-3842-2017; Wetzels, Jack F.M./A-1720-2014	Dekker, Friedo W/0000-0002-2433-2494; Rosendaal, Frits/0000-0003-2558-7496; Wetzels, Jack F.M./0000-0002-0650-6921; Collart, Frederic/0000-0003-1673-5450; Ansell, David/0000-0001-9575-1509	European Renal Association-European Dialysis and Transplant Association (ERA-EDTA)	European Renal Association-European Dialysis and Transplant Association (ERA-EDTA)	The ERA-EDTA Registry is funded by the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA).	Anavekar NS, 2004, NEW ENGL J MED, V351, P1285, DOI 10.1056/NEJMoa041365; Aucella F, 2009, ATHEROSCLEROSIS, V207, P541, DOI 10.1016/j.atherosclerosis.2009.05.011; BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; Cheung AK, 2004, KIDNEY INT, V65, P2380, DOI 10.1111/j.1523-1755.2004.00657.x; Cheung AK, 2000, KIDNEY INT, V58, P353, DOI 10.1046/j.1523-1755.2000.00173.x; den Elzen WPJ, 2006, NEPHROL DIAL TRANSPL, V21, P1588, DOI 10.1093/ndt/gfk092; *ERA EDTA REG, 2007, ERA EDTA REG 2006 AN, P129; *EUR COMM, CAUS DEATH ABS NUMB; *EUR COMM, POP 1 JAN SEX AG 199; Foley RN, 1998, J AM SOC NEPHROL, V9, P267; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; FOLEY RN, 1995, KIDNEY INT, V47, P186, DOI 10.1038/ki.1995.22; Foley RN, 2006, ADV CHRONIC KIDNEY D, V13, P205, DOI 10.1053/j.ackd.2006.04.006; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Garg AX, 2002, KIDNEY INT, V61, P1486, DOI 10.1046/j.1523-1755.2002.00270.x; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Havekes B, 2006, AM J KIDNEY DIS, V47, P823, DOI 10.1053/j.ajkd.2006.01.019; Hermans MMH, 2007, KIDNEY INT, V72, P202, DOI 10.1038/sj.ki.5002178; Herzog CA, 1998, NEW ENGL J MED, V339, P799, DOI 10.1056/NEJM199809173391203; Jager KJ, 2000, PERITON DIALYSIS INT, V20, pS118; Johansen KL, 2007, J AM SOC NEPHROL, V18, P2960, DOI 10.1681/ASN.2007020221; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Ketteler M, 2006, KIDNEY INT, V70, pS5, DOI 10.1038/sj.ki.5001996; Kielstein JT, 2005, AM J KIDNEY DIS, V46, P186, DOI 10.1053/j.ajkd.2005.05.009; Langman CB, 2005, AM J KIDNEY DIS, V46, pS6, DOI 10.1053/j.ajkd.2005.07.024; Lastra G, 2006, ADV CHRONIC KIDNEY D, V13, P365, DOI 10.1053/j.ackd.2006.07.011; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; Locatelli F, 2001, NEPHROL DIAL TRANSPL, V16, P459, DOI 10.1093/ndt/16.3.459; Maisonneuve P, 1999, LANCET, V354, P93, DOI 10.1016/S0140-6736(99)06154-1; Shanahan CM, 2005, CURR OPIN NEPHROL HY, V14, P361, DOI 10.1097/01.mnh.0000172723.52499.38; Stack AG, 2001, J AM SOC NEPHROL, V12, P1516, DOI 10.1681/ASN.V1271516; Stel VS, 2005, NEPHROL DIAL TRANSPL, V20, P2803, DOI 10.1093/ndt/gfi099; Stenvinkel P, 2007, J INTERN MED, V261, P488, DOI 10.1111/j.1365-2796.2007.01777.x; Stompor T, 2007, PERITON DIALYSIS INT, V27, pS215; US Renal Data System, USRDS 2008 ANN DAT R; van Dijk PCW, 2001, NEPHROL DIAL TRANSPL, V16, P1120, DOI 10.1093/ndt/16.6.1120; Villar E, 2007, J AM SOC NEPHROL, V18, P2125, DOI 10.1681/ASN.2006091048; Weiner DE, 2004, J AM SOC NEPHROL, V15, P1307, DOI 10.1097/01.ASN.0000123691.46138.E2; World Health Organization, 1992, INT STAT CLASS DIS 1; 1992, AM J KIDNEY DIS S2, V20, P32	40	505	518	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	2009	302	16					1782	1789		10.1001/jama.2009.1488	http://dx.doi.org/10.1001/jama.2009.1488			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	511FW	19861670	Bronze			2023-01-03	WOS:000271150300021
J	Meybohm, P; Gruenewald, M; Albrecht, M; Zacharowski, KD; Lucius, R; Zitta, K; Koch, A; Tran, N; Scholz, J; Bein, B				Meybohm, Patrick; Gruenewald, Matthias; Albrecht, Martin; Zacharowski, Kai D.; Lucius, Ralph; Zitta, Karina; Koch, Alexander; Tran, Nguyen; Scholz, Jens; Bein, Berthold			Hypothermia and Postconditioning after Cardiopulmonary Resuscitation Reduce Cardiac Dysfunction by Modulating Inflammation, Apoptosis and Remodeling	PLOS ONE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; MYOCARDIAL ISCHEMIA-REPERFUSION; AMERICAN-HEART-ASSOCIATION; COMATOSE SURVIVORS; STROKE FOUNDATION; CRITICAL-CARE; ARREST; INFARCTION; MODEL; CARDIOLOGY	Background: Mild therapeutic hypothermia following cardiac arrest is neuroprotective, but its effect on myocardial dysfunction that is a critical issue following resuscitation is not clear. This study sought to examine whether hypothermia and the combination of hypothermia and pharmacological postconditioning are cardioprotective in a model of cardiopulmonary resuscitation following acute myocardial ischemia. Methodology/Principal Findings: Thirty pigs (28-34 kg) were subjected to cardiac arrest following left anterior descending coronary artery ischemia. After 7 minutes of ventricular fibrillation and 2 minutes of basic life support, advanced cardiac life support was started according to the current AHA guidelines. After successful return of spontaneous circulation (n = 21), coronary perfusion was reestablished after 60 minutes of occlusion, and animals were randomized to either normothermia at 38 degrees C, hypothermia at 33 degrees C or hypothermia at 33 degrees C combined with sevoflurane (each group n = 7) for 24 hours. The effects on cardiac damage especially on inflammation, apoptosis, and remodeling were studied using cellular and molecular approaches. Five animals were sham operated. Animals treated with hypothermia had lower troponin T levels (p<0.01), reduced infarct size (34 +/- 7 versus 57 +/- 12%; p<0.05) and improved left ventricular function compared to normothermia (p<0.05). Hypothermia was associated with a reduction in: (i) immune cell infiltration, (ii) apoptosis, (iii) IL-1 beta and IL-6 mRNA up-regulation, and (iv) IL-1 beta protein expression (p<0.05). Moreover, decreased matrix metalloproteinase-9 activity was detected in the ischemic myocardium after treatment with mild hypothermia. Sevoflurane conferred additional protective effects although statistic significance was not reached. Conclusions/Significance: Hypothermia reduced myocardial damage and dysfunction after cardiopulmonary resuscitation possible via a reduced rate of apoptosis and pro-inflammatory cytokine expression.			Meybohm, P (corresponding author), Univ Hosp Schleswig Holstein, Dept Anaesthesiol & Intens Care Med, Kiel, Germany.	meybohm@anaesthesie.uni-kiel.de	Albrecht, Martin/AAW-9303-2021; Lucius, Ralph/B-1614-2010; Meybohm, Patrick/K-4066-2017; Gruenewald, Matthias/F-9485-2012	Albrecht, Martin/0000-0003-2580-768X; Meybohm, Patrick/0000-0002-2666-8696; 				Abbate A, 2002, J CELL PHYSIOL, V193, P145, DOI 10.1002/jcp.10174; Abbate A, 2008, CIRCULATION, V117, P2670, DOI 10.1161/CIRCULATIONAHA.107.740233; Adrie C, 2002, CIRCULATION, V106, P562, DOI 10.1161/01.CIR.0000023891.80661.AD; Bein B, 2005, ANESTH ANALG, V100, P610, DOI 10.1213/01.ANE.0000145012.27484.A7; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bolli R, 2004, CIRC RES, V95, P125, DOI 10.1161/01.RES.0000137171.97172.d7; Bujak M, 2008, AM J PATHOL, V173, P57, DOI 10.2353/ajpath.2008.070974; deVreedeSwagemakers JJM, 1997, J AM COLL CARDIOL, V30, P1500, DOI 10.1016/S0735-1097(97)00355-0; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Hale SL, 1997, BASIC RES CARDIOL, V92, P351, DOI 10.1007/BF00788947; Holzer M, 2005, CRIT CARE MED, V33, P414, DOI 10.1097/01.CCM.0000153410.87750.53; Holzer M, 2008, BEST PRACT RES-CLIN, V22, P711, DOI 10.1016/j.bpa.2008.02.001; Idris AH, 1996, CIRCULATION, V94, P2324, DOI 10.1161/01.CIR.94.9.2324; KELLEY KW, 1973, J ANIM SCI, V36, P927; KERN KB, 1990, AM HEART J, V120, P324, DOI 10.1016/0002-8703(90)90076-A; KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186; Koreny M, 2009, RESUSCITATION, V80, P56, DOI 10.1016/j.resuscitation.2008.08.019; Lange M, 2009, ANESTHESIOLOGY, V110, P516, DOI 10.1097/ALN.0b013e318197ff62; Laurent I, 2002, J AM COLL CARDIOL, V40, P2110, DOI 10.1016/S0735-1097(02)02594-9; Ly HQ, 2005, AM HEART J, V150, DOI 10.1016/j.ahj.200502.049; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Oddo M, 2008, CRIT CARE MED, V36, P2296, DOI 10.1097/CCM.0b013e3181802599; Pell JP, 2003, HEART, V89, P839, DOI 10.1136/heart.89.8.839; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Ren Guofeng, 2003, Current Drug Targets - Inflammation and Allergy, V2, P242, DOI 10.2174/1568010033484098; Riess ML, 2002, ANESTH ANALG, V95, P1540, DOI 10.1097/00000539-200212000-00013; Roesner JP, 2007, CRIT CARE MED, V35, P1730, DOI 10.1097/01.CCM.0000269035.30231.76; Spinale FG, 2007, PHYSIOL REV, V87, P1285, DOI 10.1152/physrev.00012.2007; Stangl V, 2002, CARDIOVASC RES, V53, P12, DOI 10.1016/S0008-6363(01)00420-5; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Tsai MS, 2008, J AM COLL CARDIOL, V51, P1988, DOI 10.1016/j.jacc.2007.12.057; von Bismarck P, 2007, CRIT CARE MED, V35, P2309, DOI 10.1097/01.CCM.0000281472.47067.45; Weber NC, 2005, BEST PRACT RES-CLIN, V19, P429, DOI 10.1016/j.bpa.2005.02.003; Wolfrum S, 2008, CRIT CARE MED, V36, P1780, DOI 10.1097/CCM.0b013e31817437ca; Xu TY, 2008, RESUSCITATION, V76, P103, DOI 10.1016/j.resuscitation.2007.06.004; Zhao ZQ, 2003, AM J PHYSIOL-HEART C, V285, pH579, DOI 10.1152/ajpheart.01064.2002	36	59	68	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2009	4	10							e7588	10.1371/journal.pone.0007588	http://dx.doi.org/10.1371/journal.pone.0007588			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	511ER	19855846	Green Published, gold, Green Submitted			2023-01-03	WOS:000271147200011
J	Sudore, RL				Sudore, Rebecca L.			Can We Agree to Disagree?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												rsucsf@yahoo.com	Sudore, Rebecca/AAF-1635-2021						0	12	12	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	2009	302	15					1629	1630		10.1001/jama.2009.1422	http://dx.doi.org/10.1001/jama.2009.1422			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	508NX	19843890				2023-01-03	WOS:000270941200001
J	Danovaro, R; Umani, SF; Pusceddu, A				Danovaro, Roberto; Umani, Serena Fonda; Pusceddu, Antonio			Climate Change and the Potential Spreading of Marine Mucilage and Microbial Pathogens in the Mediterranean Sea	PLOS ONE			English	Article								Background: Marine snow (small amorphous aggregates with colloidal properties) is present in all oceans of the world. Surface water warming and the consequent increase of water column stability can favour the coalescence of marine snow into marine mucilage, large marine aggregates representing an ephemeral and extreme habitat. Marine mucilage characterize aquatic systems with altered environmental conditions. Methodology/Principal Findings: We investigated, by means of molecular techniques, viruses and prokaryotes within the mucilage and in surrounding seawater to examine the potential of mucilage to host new microbial diversity and/or spread marine diseases. We found that marine mucilage contained a large and unexpectedly exclusive microbial biodiversity and hosted pathogenic species that were absent in surrounding seawater. We also investigated the relationship between climate change and the frequency of mucilage in the Mediterranean Sea over the last 200 years and found that the number of mucilage outbreaks increased almost exponentially in the last 20 years. The increasing frequency of mucilage outbreaks is closely associated with the temperature anomalies. Conclusions/Significance: We conclude that the spreading of mucilage in the Mediterranean Sea is linked to climate-driven sea surface warming. The mucilage can act as a controlling factor of microbial diversity across wide oceanic regions and could have the potential to act as a carrier of specific microorganisms, thereby increasing the spread of pathogenic bacteria.			Danovaro, R (corresponding author), Polytech Univ Marche, Dept Marine Sci, Ancona, Italy.	r.danovaro@univpm.it	Fonda, Serena/H-6753-2012					Aktan Y., 2008, Harmful Algae News, V36, P1; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; Azam F, 2001, NATURE, V414, P495, DOI 10.1038/35107174; Azam F, 1999, Ann Ist Super Sanita, V35, P411; Baldi F, 1997, MAR ECOL PROG SER, V153, P45, DOI 10.3354/meps153045; Beaumont NJ, 2007, MAR POLLUT BULL, V54, P253, DOI 10.1016/j.marpolbul.2006.12.003; Bongiorni L, 2007, AQUAT MICROB ECOL, V49, P15, DOI 10.3354/ame01126; Carlton JT, 1998, CONSERV BIOL, V12, P1165, DOI 10.1046/j.1523-1739.1998.0120061165.x; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Corinaldesi C, 2005, APPL ENVIRON MICROB, V71, P46, DOI 10.1128/AEM.71.1.46-50.2005; Corinaldesi C, 2003, APPL ENVIRON MICROB, V69, P2664, DOI 10.1128/AEM.69.5.2664-2673.2003; Danovaro R, 2006, APPL ENVIRON MICROB, V72, P5982, DOI 10.1128/AEM.01361-06; Danovaro R, 2005, SCI TOTAL ENVIRON, V353, P189, DOI 10.1016/j.scitotenv.2005.09.029; Danovaro R, 2003, MAR POLLUT BULL, V46, P301, DOI 10.1016/S0025-326X(02)00461-7; Danovaro R, 2001, TRENDS ECOL EVOL, V16, P505, DOI 10.1016/S0169-5347(01)02215-7; Danovaro R, 2008, NATURE, V454, P1084, DOI 10.1038/nature07268; Danovaro R, 2008, ENVIRON HEALTH PERSP, V116, P441, DOI 10.1289/ehp.10966; DEGOBBIS D, 1995, SCI TOTAL ENVIRON, V165, P43, DOI 10.1016/0048-9697(95)04542-9; Del Negro P, 2005, SCI TOTAL ENVIRON, V353, P258, DOI 10.1016/j.scitotenv.2005.09.018; Flander-Putrle V, 2008, HARMFUL ALGAE, V7, P752, DOI 10.1016/j.hal.2008.02.009; FOGG GE, 1995, SCI TOTAL ENVIRON, V165, P59, DOI 10.1016/0048-9697(95)04543-A; Fonda Umani S., 1989, EPISODI MARE SPORCO, P178; GIANI M, 1992, SCIENCE OF THE TOTAL ENVIRONMENT, SUPPLEMENT 1992, P539; Heissenberger A, 1996, MAR ECOL PROG SER, V135, P299, DOI 10.3354/meps135299; HEISSENBERGER A, 1994, MARINE ECOLOGY PROGR, V111, P128; Herndl Gerhard J., 1992, Marine Microbial Food Webs, V6, P149; HERNDL GJ, 1988, PSZNI MAR ECOL, V9, P79; KALTENBOCK E, 1992, MAR ECOL PROG SER, V87, P147, DOI 10.3354/meps087147; KOKELJ F, 1994, CONTACT DERMATITIS, V31, P257, DOI 10.1111/j.1600-0536.1994.tb01999.x; LEPPARD GG, 1995, SCI TOTAL ENVIRON, V165, P103, DOI 10.1016/0048-9697(95)04546-D; Luna GM, 2007, ENVIRON MICROBIOL, V9, P1851, DOI 10.1111/j.1462-2920.2007.01287.x; MacKenzie L, 2002, HARMFUL ALGAE, V1, P295, DOI 10.1016/S1568-9883(02)00006-9; MALEJ A, 1993, MAR ECOL PROG SER, V96, P33, DOI 10.3354/meps096033; MONTI M, 1995, SCI TOTAL ENVIRON, V165, P145, DOI 10.1016/0048-9697(95)04548-F; MULLERNIKLAS G, 1994, LIMNOL OCEANOGR, V39, P58; MYKLESTAD S, 1977, J EXP MAR BIOL ECOL, V29, P161, DOI 10.1016/0022-0981(77)90046-6; OBERNOSTERER I, 1995, MAR ECOL PROG SER, V116, P247, DOI 10.3354/meps116247; Pachauri Rajendra, 2007, AR4 CLIMATE CHANGE 2; Pajdak-Stos A, 2001, AQUAT MICROB ECOL, V23, P237, DOI 10.3354/ame023237; Patz JA, 2005, NATURE, V438, P310, DOI 10.1038/nature04188; Pauly D, 1998, SCIENCE, V279, P860, DOI 10.1126/science.279.5352.860; PEDUZZI P, 1993, LIMNOL OCEANOGR, V38, P1562, DOI 10.4319/lo.1993.38.7.1562; POSEDEL N, 1991, MAR ECOL PROG SER, V77, P135, DOI 10.3354/meps077135; Precali R, 2005, SCI TOTAL ENVIRON, V353, P10, DOI 10.1016/j.scitotenv.2005.09.066; Pusceddu A, 2005, CONT SHELF RES, V25, P2491, DOI 10.1016/j.csr.2005.08.013; Rath J, 1998, AQUAT MICROB ECOL, V14, P261, DOI 10.3354/ame014261; Richardson LL, 1998, TRENDS ECOL EVOL, V13, P438, DOI 10.1016/S0169-5347(98)01460-8; RINALDI A, 1995, SCI TOTAL ENVIRON, V165, P165, DOI 10.1016/0048-9697(95)04550-K; Roether W, 1996, SCIENCE, V271, P333, DOI 10.1126/science.271.5247.333; SCHUSTER S, 1995, MAR ECOL PROG SER, V124, P227, DOI 10.3354/meps124227; Sellner KG, 1999, COAST ESTUAR STUD, V55, P173; SHIBATA A, 2007, MARINE ECOLOGY PROGR, V155, P303; Simon M, 2002, AQUAT MICROB ECOL, V28, P175, DOI 10.3354/ame028175; Umani SF, 2007, AQUAT MICROB ECOL, V46, P163; Umani SF, 2005, SCI TOTAL ENVIRON, V353, P218, DOI 10.1016/j.scitotenv.2005.09.016; WEINBAUER MG, 1995, J PLANKTON RES, V17, P1851, DOI 10.1093/plankt/17.9.1851; WEINBAUER MG, 1995, MICROBIAL ECOL, V30, P25, DOI 10.1007/BF00184511; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000	58	87	100	2	40	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2009	4	9							e7006	10.1371/journal.pone.0007006	http://dx.doi.org/10.1371/journal.pone.0007006			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	496KE	19759910	gold, Green Published, Green Submitted			2023-01-03	WOS:000269970000008
J	Virtanen, A; Joutsensaari, J; Koop, T; Kannosto, J; Yli-Pirila, P; Leskinen, J; Makela, JM; Holopainen, JK; Poschl, U; Kulmala, M; Worsnop, DR; Laaksonen, A				Virtanen, Annele; Joutsensaari, Jorma; Koop, Thomas; Kannosto, Jonna; Yli-Pirila, Pasi; Leskinen, Jani; Makela, Jyrki M.; Holopainen, Jarmo K.; Poeschl, Ulrich; Kulmala, Markku; Worsnop, Douglas R.; Laaksonen, Ari			An amorphous solid state of biogenic secondary organic aerosol particles	NATURE			English	Article							ATMOSPHERIC PARTICLES; OLEIC-ACID; MODEL; OXIDATION; CLIMATE; CHEMISTRY; DIFFUSION; EMISSIONS; PRODUCTS; FORESTS	Secondary organic aerosol (SOA) particles are formed in the atmosphere from condensable oxidation products of anthropogenic and biogenic volatile organic compounds (VOCs)(1-7). On a global scale, biogenic VOCs account for about 90% of VOC emissions(1,8) and of SOA formation (90 billion kilograms of carbon per year)(1-4). SOA particles can scatter radiation and act as cloud condensation or ice nuclei, and thereby influence the Earth's radiation balance and climate(1,2,5,9,10). They consist of a myriad of different compounds with varying physicochemical properties, and little information is available on the phase state of SOA particles. Gas-particle partitioning models usually assume that SOA particles are liquid(1,5,11), but here we present experimental evidence that they can be solid under ambient conditions. We investigated biogenic SOA particles formed from oxidation products of VOCs in plant chamber experiments and in boreal forests within a few hours after atmospheric nucleation events. On the basis of observed particle bouncing in an aerosol impactor and of electron microscopy we conclude that biogenic SOA particles can adopt an amorphous solid-most probably glassy-state. This amorphous solid state should provoke a rethinking of SOA processes because it may influence the partitioning of semi-volatile compounds, reduce the rate of heterogeneous chemical reactions, affect the particles' ability to accommodate water and act as cloud condensation or ice nuclei, and change the atmospheric lifetime of the particles(12-15). Thus, the results of this study challenge traditional views of the kinetics and thermodynamics of SOA formation and transformation in the atmosphere and their implications for air quality and climate.	[Virtanen, Annele; Kannosto, Jonna; Makela, Jyrki M.] Tampere Univ Technol, Dept Phys, FIN-33101 Tampere, Finland; [Joutsensaari, Jorma; Worsnop, Douglas R.; Laaksonen, Ari] Univ Eastern Finland, Dept Math & Phys, Kuopio 70211, Finland; [Koop, Thomas] Univ Bielefeld, Dept Chem, D-33615 Bielefeld, Germany; [Yli-Pirila, Pasi; Leskinen, Jani; Holopainen, Jarmo K.] Univ Eastern Finland, Dept Environm Sci, Kuopio 70211, Finland; [Poeschl, Ulrich] Max Planck Inst Chem, Biogeochem Dept, D-55128 Mainz, Germany; [Kulmala, Markku; Worsnop, Douglas R.] Univ Helsinki, Dept Phys, Helsinki 00014, Finland; [Kulmala, Markku] Stockholm Univ, Dept Appl Environm Sci, S-10691 Stockholm, Sweden; [Worsnop, Douglas R.] Aerodyne Res Inc, Billerica, MA 01821 USA; [Worsnop, Douglas R.; Laaksonen, Ari] Finnish Meteorol Inst, FIN-00101 Helsinki, Finland	Tampere University; University of Eastern Finland; University of Bielefeld; University of Eastern Finland; Max Planck Society; University of Helsinki; Stockholm University; Aerodyne Research; Finnish Meteorological Institute	Virtanen, A (corresponding author), Tampere Univ Technol, Dept Phys, POB 692, FIN-33101 Tampere, Finland.	annele.virtanen@tut.fi; thomas.koop@uni-bielefeld.de	Laaksonen, Ari/B-5094-2011; Kulmala, Markku T/I-7671-2016; Mäkelä, Jyrki/G-4223-2014; Worsnop, Douglas R/D-2817-2009; Virtanen, Annele/E-7699-2010; Pöschl, Ulrich/A-6263-2010; Koop, Thomas/B-7861-2008; Holopainen, Jarmo K./B-1656-2008	Laaksonen, Ari/0000-0002-1657-2383; Kulmala, Markku T/0000-0003-3464-7825; Worsnop, Douglas R/0000-0002-8928-8017; Virtanen, Annele/0000-0002-2917-5344; Pöschl, Ulrich/0000-0003-1412-3557; Koop, Thomas/0000-0002-7571-3684; Holopainen, Jarmo K./0000-0001-5026-3245; Makela, Jyrki Mikael/0000-0002-6757-3589	Academy of Finland [110763, 111543, 131019, 218115]; Maj and Tor Nessling foundation	Academy of Finland(Academy of Finland); Maj and Tor Nessling foundation	We acknowledge support by the Academy of Finland (decision numbers 110763, 111543, 131019, 218115 and Centre of Excellence Programme) and the Maj and Tor Nessling foundation. We also acknowledge J. Keskinen and A. Arffman for fruitful discussions concerning impactor performance, H. Kuuluvainen for his help in bounce factor measurements, K. Rissa for SEM imaging, L. Hao, P. Tiitta, A. Kortelainen and P. Miettinen for aerosol mass spectrometer analyses and their help during experiments, J. Jokiniemi, U. Tapper and J. Lyyranen (VTT Technical Research Centre of Finland) for the development of SEM sample collection and image analysis methods, A. Diekmann for the differential scanning calorimeter measurements and T. Wagner for providing polystyrene samples.	Bahreini R, 2005, ENVIRON SCI TECHNOL, V39, P5674, DOI 10.1021/es048061a; Claeys M, 2004, SCIENCE, V303, P1173, DOI 10.1126/science.1092805; DAHNEKE B, 1971, J COLLOID INTERF SCI, V37, P342, DOI 10.1016/0021-9797(71)90302-X; Ehn M, 2007, ATMOS CHEM PHYS, V7, P211, DOI 10.5194/acp-7-211-2007; Fuzzi S, 2006, ATMOS CHEM PHYS, V6, P2017, DOI 10.5194/acp-6-2017-2006; GUENTHER A, 1995, J GEOPHYS RES-ATMOS, V100, P8873, DOI 10.1029/94JD02950; Hallquist M, 2009, ATMOS CHEM PHYS, V9, P5155, DOI 10.5194/acp-9-5155-2009; HAMERI K, 2000, REP SER AEROSOL SCI, V47, P47; Hari P, 2005, BOREAL ENVIRON RES, V10, P315; *IPCC, 2007, CLIM CHANG 2007 PHYS, P161; Jimenez JL, 2009, SCIENCE, V326, P1525, DOI 10.1126/science.1180353; Joutsensaari J, 2005, ATMOS CHEM PHYS, V5, P1489, DOI 10.5194/acp-5-1489-2005; Kalberer M, 2004, SCIENCE, V303, P1659, DOI 10.1126/science.1092185; Kanakidou M, 2005, ATMOS CHEM PHYS, V5, P1053, DOI 10.5194/acp-5-1053-2005; Kavouras IG, 1998, NATURE, V395, P683, DOI 10.1038/27179; Laaksonen A, 2008, ATMOS CHEM PHYS, V8, P2657, DOI 10.5194/acp-8-2657-2008; Marcolli C, 2004, J PHYS CHEM A, V108, P2216, DOI [10.1021/jp036080l, 10.1021/jp0360801]; Maria SF, 2004, SCIENCE, V306, P1921, DOI 10.1126/science.1103491; Mentel TF, 2009, ATMOS CHEM PHYS, V9, P4387, DOI 10.5194/acp-9-4387-2009; Mikhailov E, 2009, ATMOS CHEM PHYS, V9, P9491, DOI 10.5194/acp-9-9491-2009; Murray BJ, 2008, ATMOS CHEM PHYS, V8, P5423, DOI 10.5194/acp-8-5423-2008; PANKOW JF, 1994, ATMOS ENVIRON, V28, P189, DOI 10.1016/1352-2310(94)90094-9; PANKOW JF, 1987, ATMOS ENVIRON, V21, P2275, DOI 10.1016/0004-6981(87)90363-5; PARKER R, 1995, CARBOHYD RES, V273, P147, DOI 10.1016/0008-6215(95)00120-I; Shiraiwa M, 2010, ATMOS CHEM PHYS, V10, P3673, DOI 10.5194/acp-10-3673-2010; STEIN SW, 1994, ATMOS ENVIRON, V28, P1739, DOI 10.1016/1352-2310(94)90136-8; Tunved P, 2006, SCIENCE, V312, P261, DOI 10.1126/science.1123052; Zahardis J, 2007, ATMOS CHEM PHYS, V7, P1237, DOI 10.5194/acp-7-1237-2007; Zobrist B, 2008, ATMOS CHEM PHYS, V8, P5221, DOI 10.5194/acp-8-5221-2008	29	553	557	12	559	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 14	2010	467	7317					824	827		10.1038/nature09455	http://dx.doi.org/10.1038/nature09455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	663PB	20944744				2023-01-03	WOS:000282898700063
J	Heazell, AE				Heazell, Alexander E.			Personal View Towards an end to stillbirths	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Manchester, Manchester M13 9PL, Lancs, England	University of Manchester	Heazell, AE (corresponding author), Univ Manchester, Manchester M13 9PL, Lancs, England.	alexander.heazell@manchester.ac.uk		Heazell, Alexander/0000-0002-4303-7845	National Institute for Health Research [CL-2009-06-002] Funding Source: researchfish	National Institute for Health Research(National Institute for Health Research (NIHR))		Ahman E, 2007, NEONATAL PERINATAL M; [Anonymous], 2009, STUD STILLB CLAIMS; *CONF ENQ STILLB D, 1998, 5 ANN REP CONF ENQ S; *CONF ENQ STILLB D, 2001, 8 ANN REP CONF ENQ S; Confidential Enquiry into Maternal and Child Health, 2009, PER MORT 2007 ENGL W; Guildea ZES, 2001, ARCH DIS CHILD, V84, P307, DOI 10.1136/adc.84.4.307; Haws RA, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S5; Henley A, 2008, SEMIN FETAL NEONAT M, V13, P325, DOI 10.1016/j.siny.2008.03.003; *NAT I HLTH RES, 2008, TRANSF HLTH RES 1 2; Scott J, 2009, SAVING BABIES LIVES	10	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 6	2010	341								c5070	10.1136/bmj.c5070	http://dx.doi.org/10.1136/bmj.c5070			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	663JE	20926491				2023-01-03	WOS:000282879400015
J	Rustin, GJS; van der Burg, MEL; Griffin, CL; Guthrie, D; Lamont, A; Jayson, GC; Kristensen, G; Mediola, C; Coens, C; Qian, WD; Parmar, MKB; Swart, AM				Rustin, Gordon J. S.; van der Burg, Maria E. L.; Griffin, Clare L.; Guthrie, David; Lamont, Alan; Jayson, Gordon C.; Kristensen, Gunnar; Mediola, Cesar; Coens, Corneel; Qian, Wendi; Parmar, Mahesh K. B.; Swart, Ann Marie		MRC OV05 Investigator; EORTC 55955 Investigator	Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial	LANCET			English	Article							FOLLOW-UP; EUROPEAN-ORGANIZATION; CA-125; PROGRESSION; IMMEDIATE; CEA	Background Serum CA125 concentration often rises several months before clinical or symptomatic relapse in women with ovarian cancer. In the MRC OV05/EORTC 55955 collaborative trial, we aimed to establish the benefits of early treatment on the basis of increased CA125 concentrations compared with delayed treatment on the basis of clinical recurrence. Methods Women with ovarian cancer in complete remission after first-line platinum-based chemotherapy and a normal CA125 concentration were registered for this randomised controlled trial. Clinical examination and CA125 measurement were done every 3 months. Patients and investigators were masked to CA125 results, which were monitored by coordinating centres. If CA125 concentration exceeded twice the upper limit of normal, patients were randomly assigned (1:1) by minimisation to early or delayed chemotherapy. Patients and clinical sites were informed of allocation to early treatment, and treatment was started as soon as possible within 28 days of the increased CA125 measurement. Patients assigned to delayed treatment continued masked CA125 measurements, with treatment commencing at clinical or symptomatic relapse. All patients were treated according to standard local practice. The primary outcome was overall survival. Analysis was by intention to treat. This study is registered, ISRCTN87786644. Findings 1442 patients were registered for the trial, of whom 529 were randomly assigned to treatment groups and were included in our analysis (265 early, 264 delayed). With a median follow-up of 56.9 months (IQR 37.4-81.8) from randomisation and 370 deaths (186 early, 184 delayed), there was no evidence of a difference in overall survival between early and delayed treatment (HR 0.98, 95% CI 0.80-1.20, p=0.85). Median survival from randomisation was 25.7 months (95% CI 23.0-27.9) for patients on early treatment and 27.1 months (22.8-30.9) for those on delayed treatment. Interpretation Our findings showed no evidence of a survival benefit with early treatment of relapse on the basis of a raised CA125 concentration alone, and therefore the value of routine measurement of CA125 in the follow-up of patients with ovarian cancer who attain a complete response after first-line treatment is not proven.	[Griffin, Clare L.; Qian, Wendi; Swart, Ann Marie] MRC, Clin Trials Unit, London NW1 2DA, England; [Rustin, Gordon J. S.] Mt Vernon Canc Ctr, Northwood, Middx, England; [van der Burg, Maria E. L.] Erasmus MC Univ Med Ctr, Rotterdam, Netherlands; [Guthrie, David] Derbyshire Royal Infirm, Derby DE1 2QY, England; [Lamont, Alan] Colchester Hosp Univ NHS Fdn Trust, Colchester, Essex, England; [Jayson, Gordon C.] Christie Hosp, Manchester, Lancs, England; [Jayson, Gordon C.] Univ Manchester, Manchester, Lancs, England; [Kristensen, Gunnar] Norwegian Radium Hosp, Oslo Univ Hosp, Oslo, Norway; [Mediola, Cesar] Hosp Univ 12 Octubre, Madrid, Spain; [Coens, Corneel] European Org Res & Treatment Canc Headquarters, Brussels, Belgium	Medical Research Council Clinical Trials Unit; Mount Vernon Cancer Centre; Erasmus University Rotterdam; Erasmus MC; Christie NHS Foundation Trust; Christie Hospital; University of Manchester; University of Oslo; Hospital Universitario 12 de Octubre; European Organisation for Research & Treatment of Cancer	Swart, AM (corresponding author), MRC, Clin Trials Unit, 222 Euston Rd, London NW1 2DA, England.	ams@ctu.mrc.ac.uk	Ottevanger, Petronella Beatrix/N-3577-2014; Jayson, Gordon C/O-8224-2015; Massuger, Leon F.A.G./H-8072-2014; Sydes, Matthew/C-3373-2008; de Barros Lopes, Alberto/B-2116-2018; Rustin, Gordon J. S./J-9763-2019	Ottevanger, Petronella Beatrix/0000-0001-8209-487X; Jayson, Gordon C/0000-0002-8515-8944; Sydes, Matthew/0000-0002-9323-1371; de Barros Lopes, Alberto/0000-0002-8796-3891; Gabra, Hani/0000-0002-3322-4399; Dorum, Anne/0000-0002-6274-2398	UK Medical Research Council; National Cancer Research Network; EORTC Charitable Trust; MRC [MC_U122861379, G0601746] Funding Source: UKRI; Medical Research Council [G0601746, MC_U122861379] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Cancer Research Network; EORTC Charitable Trust; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	OV05 was funded by the UK Medical Research Council and supported by the National Cancer Research Network. EORTC 55955 was supported by a donation from the EORTC Charitable Trust. We thank Claire Vale (Meta-analysis Group, M RC Clinical Trials Unit), who helped with the systematic review, and all women who participated in the trials.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Ardeshna KM, 2003, LANCET, V362, P516, DOI 10.1016/S0140-6736(03)14110-4; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; Bristow RE, 2009, GYNECOL ONCOL, V112, P1, DOI 10.1016/j.ygyno.2008.10.002; Falk SJ, 2002, BRIT MED J, V325, P465, DOI 10.1136/bmj.325.7362.465; GLIMELIUS B, 1992, J CLIN ONCOL, V10, P904, DOI 10.1200/JCO.1992.10.6.904; Goonewardene TI, 2007, LANCET ONCOL, V8, P813, DOI 10.1016/S1470-2045(07)70273-5; Harter P, 2006, ANN SURG ONCOL, V13, P1702, DOI 10.1245/s10434-006-9058-0; Higgins J., 2009, COCHRANE HDB SYSTEMA; Liu PY, 2007, J CLIN ONCOL, V25, P3615, DOI 10.1200/JCO.2006.09.4540; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NAIK R, 2006, COCHRANE DB SYST REV, V3; NORTHOVER J, 1994, JAMA-J AM MED ASSOC, V272, P31, DOI 10.1001/jama.1994.03520010041025; O'Brien MER, 2006, ANN ONCOL, V17, P270, DOI 10.1093/annonc/mdj073; Parmar MKB, 2003, LANCET, V361, P2099; Pecorelli S, 2009, J CLIN ONCOL, V27, P4642, DOI 10.1200/JCO.2009.21.9691; Rustin GJS, 2001, J CLIN ONCOL, V19, P4054, DOI 10.1200/JCO.2001.19.20.4054; Rustin GJS, 1996, ANN ONCOL, V7, P361; Schroder FH, 2009, EUR UROL, V55, P14, DOI 10.1016/j.eururo.2008.09.008; VANDERBURG MEL, 1990, ANN ONCOL, V1, P301, DOI 10.1093/oxfordjournals.annonc.a057754; Vergote I, 2000, J NATL CANCER I, V92, P1534, DOI 10.1093/jnci/92.18.1534; Wong SSL, 2006, J MED LIBR ASSOC, V94, P41	22	360	380	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 2	2010	376	9747					1155	1163		10.1016/S0140-6736(10)61268-8	http://dx.doi.org/10.1016/S0140-6736(10)61268-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	663UN	20888993				2023-01-03	WOS:000282915700032
J	Engert, A; Plutschow, A; Eich, HT; Lohri, A; Dorken, B; Borchmann, P; Berger, B; Greil, R; Willborn, KC; Wilhelm, M; Debus, J; Eble, MJ; Sokler, M; Ho, A; Rank, A; Ganser, A; Trumper, L; Bokemeyer, C; Kirchner, H; Schubert, J; Kral, Z; Fuchs, M; Muller-Hermelink, HK; Muller, RP; Diehl, V				Engert, Andreas; Pluetschow, Annette; Eich, Hans Theodor; Lohri, Andreas; Doerken, Bernd; Borchmann, Peter; Berger, Bernhard; Greil, Richard; Willborn, Kay C.; Wilhelm, Martin; Debus, Juergen; Eble, Michael J.; Soekler, Martin; Ho, Antony; Rank, Andreas; Ganser, Arnold; Truemper, Lorenz; Bokemeyer, Carsten; Kirchner, Hartmut; Schubert, Joerg; Kral, Zdenek; Fuchs, Michael; Mueller-Hermelink, Hans-Konrad; Mueller, Rolf-Peter; Diehl, Volker			Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITRON-EMISSION-TOMOGRAPHY; INVOLVED-FIELD RADIOTHERAPY; COMBINED-MODALITY THERAPY; RADIATION-THERAPY; PROGNOSTIC SCORE; 2ND MALIGNANCY; CLINICAL-TRIAL; 2 CYCLES; CHEMOTHERAPY; DISEASE	BACKGROUND Whether it is possible to reduce the intensity of treatment in early (stage I or II) Hodgkin's lymphoma with a favorable prognosis remains unclear. We therefore conducted a multicenter, randomized trial comparing four treatment groups consisting of a combination chemotherapy regimen of two different intensities followed by involved-field radiation therapy at two different dose levels. METHODS We randomly assigned 1370 patients with newly diagnosed early-stage Hodgkin's lymphoma with a favorable prognosis to one of four treatment groups: four cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by 30 Gy of radiation therapy (group 1), four cycles of ABVD followed by 20 Gy of radiation therapy (group 2), two cycles of ABVD followed by 30 Gy of radiation therapy (group 3), or two cycles of ABVD followed by 20 Gy of radiation therapy (group 4). The primary end point was freedom from treatment failure; secondary end points included efficacy and toxicity of treatment. RESULTS The two chemotherapy regimens did not differ significantly with respect to freedom from treatment failure (P = 0.39) or overall survival (P = 0.61). At 5 years, the rates of freedom from treatment failure were 93.0% (95% confidence interval [CI], 90.5 to 94.8) with the four-cycle ABVD regimen and 91.1% (95% CI, 88.3 to 93.2) with the two-cycle regimen. When the effects of 20-Gy and 30-Gy doses of radiation therapy were compared, there were also no significant differences in freedom from treatment failure (P = 1.00) or overall survival (P = 0.61). Adverse events and acute toxic effects of treatment were most common in the patients who received four cycles of ABVD and 30 Gy of radiation therapy (group 1). CONCLUSIONS In patients with early-stage Hodgkin's lymphoma and a favorable prognosis, treatment with two cycles of ABVD followed by 20 Gy of involved-field radiation therapy is as effective as, and less toxic than, four cycles of ABVD followed by 30 Gy of involved-field radiation therapy. Long-term effects of these treatments have not yet been fully assessed. (Funded by the Deutsche Krebshilfe and the Swiss Federal Government; ClinicalTrials.gov number, NCT00265018.)	[Engert, Andreas; Pluetschow, Annette; Borchmann, Peter; Fuchs, Michael; Diehl, Volker] Univ Cologne, Dept Internal Med, German Hodgkin Study Grp, Cologne, Germany; [Eich, Hans Theodor; Mueller, Rolf-Peter] Univ Cologne, Dept Radiat Oncol, Cologne, Germany; [Doerken, Bernd] Charite, Dept Hematol & Oncol, D-13353 Berlin, Germany; [Berger, Bernhard] Univ Tubingen, Dept Radiat Oncol, Tubingen, Germany; [Soekler, Martin] Univ Tubingen, Dept Internal Med 2, Tubingen, Germany; [Willborn, Kay C.] Pius Hosp Oldenburg, Klin Strahlentherapie & Internist Onkol, Oldenburg, Germany; [Wilhelm, Martin] Schwerpunkt Hamatol Onkol, Med Klin 5, Klinikum Nurnberg Nord, Nurnberg, Germany; [Debus, Juergen] Heidelberg Univ, Dept Radiat Oncol, Heidelberg, Germany; [Ho, Antony] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany; [Eble, Michael J.] Rhein Westfal TH Aachen, Dept Radiotherapy, Aachen, Germany; [Rank, Andreas] Univ Munich, Univ Hosp Grosshadern, Dept Internal Med 3, Munich, Germany; [Ganser, Arnold] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, D-3000 Hannover, Germany; [Truemper, Lorenz] Univ Gottingen, Dept Hematol & Oncol, Gottingen, Germany; [Bokemeyer, Carsten] Univ Med Ctr Hamburg, Dept Oncol Hematol & Bone Marrow Transplantat, Hamburg, Germany; [Kirchner, Hartmut] Siloah Clin, Dept Hematol Oncol, Hannover, Germany; [Schubert, Joerg] Evangel Krankenhaus Hamm, Med Klin, Abt Hamatoonkol, Hamm, Germany; [Mueller-Hermelink, Hans-Konrad] Univ Wurzburg, Inst Pathol, D-8700 Wurzburg, Germany; [Lohri, Andreas] Swiss Grp Clin Canc Res, Bern, Switzerland; [Greil, Richard] Salzburg Univ, Dept Med 3, A-5020 Salzburg, Austria; [Kral, Zdenek] Univ Hosp, Dept Internal Med Hematooncol, Brno, Czech Republic; [Kral, Zdenek] Masaryk Univ, Fac Med, Brno, Czech Republic	University of Cologne; University of Cologne; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Pius-Hospital Oldenburg; Klinikum Nurnberg Nord; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; RWTH Aachen University; University of Munich; Hannover Medical School; University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Wurzburg; Swiss Group for Clinical Cancer Research (SAKK); Salzburg University; University Hospital Brno; Masaryk University Brno	Engert, A (corresponding author), Kerpenerstr 62, D-50937 Cologne, Germany.	a.engert@uni-koeln.de	Greil, Richard F/C-7673-2017; Wilhelm, Martin/J-3964-2014	Greil, Richard F/0000-0002-4462-3694; 	Deutsche Krebshilfe; Swiss Federal Government	Deutsche Krebshilfe(Deutsche Krebshilfe); Swiss Federal Government	Supported by grants from the Deutsche Krebshilfe and the Swiss Federal Government.	Aviles A, 1998, CLIN LAB HAEMATOL, V20, P95, DOI 10.1046/j.1365-2257.1998.00096.x; BLOOMFIELD CD, 1982, CANCER TREAT REP, V66, P835; BOIVIN JF, 1995, JNCI-J NATL CANCER I, V87, P732, DOI 10.1093/jnci/87.10.732; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; Canellos GP, 2005, J CLIN ONCOL, V23, P4574, DOI 10.1200/JCO.2005.01.911; CARDE P, 1988, J CLIN ONCOL, V6, P239, DOI 10.1200/JCO.1988.6.2.239; Connors JM, 2005, J CLIN ONCOL, V23, P6400, DOI 10.1200/JCO.2005.05.016; Eghbali H, 2005, BLOOD, V106, p240A; Engert A, 2003, J CLIN ONCOL, V21, P3601, DOI 10.1200/JCO.2003.03.023; Engert A, 2007, J CLIN ONCOL, V25, P3495, DOI 10.1200/JCO.2006.07.0482; Ferme C, 2007, NEW ENGL J MED, V357, P1916, DOI 10.1056/NEJMoa064601; Franklin J, 2006, ANN ONCOL, V17, P1749, DOI 10.1093/annonc/mdl302; Gallamini A, 2007, J CLIN ONCOL, V25, P3746, DOI 10.1200/JCO.2007.11.6525; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Hutchings M, 2006, BLOOD, V107, P52, DOI 10.1182/blood-2005-06-2252; Kobe C, 2008, BLOOD, V112, P3989, DOI 10.1182/blood-2008-06-155820; Mauch P, 1999, HODGKINS DIS; Meyer RM, 2005, J CLIN ONCOL, V23, P4634, DOI 10.1200/JCO.2005.09.085; Nachman JB, 2002, J CLIN ONCOL, V20, P3765, DOI 10.1200/JCO.2002.12.007; National Comprehensive Cancer Network, 2008, NCCN CLIN PRACT GUID; Ng AK, 2002, J CLIN ONCOL, V20, P2101, DOI 10.1200/JCO.2002.08.021; Noordijk EM, 2006, J CLIN ONCOL, V24, P3128, DOI 10.1200/JCO.2005.05.2746; PAVLOVSKY S, 1988, JNCI-J NATL CANCER I, V80, P1466, DOI 10.1093/jnci/80.18.1466; Spaepen K, 2001, BRIT J HAEMATOL, V115, P272, DOI 10.1046/j.1365-2141.2001.03169.x; Specht L, 1998, J CLIN ONCOL, V16, P830, DOI 10.1200/JCO.1998.16.3.830; Specht L, 2003, BLOOD, V102, p637A; Straus DJ, 2004, BLOOD, V104, P3483, DOI 10.1182/blood-2004-04-1311; van Leeuwen FE, 2000, J CLIN ONCOL, V18, P487, DOI 10.1200/JCO.2000.18.3.487; Yahalom J, 2006, J CLIN ONCOL, V24, P544, DOI 10.1200/JCO.2005.04.4396; Zinzani PL, 2006, ANN ONCOL, V17, P1296, DOI 10.1093/annonc/mdl122	30	606	624	2	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	2010	363	7					640	652		10.1056/NEJMoa1000067	http://dx.doi.org/10.1056/NEJMoa1000067			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	636TN	20818855	Bronze, Green Accepted			2023-01-03	WOS:000280764600007
J	Chatterjee, A; Adak, A; Singh, AK; Srivastava, MK; Ghosh, SK; Tiwari, S; Devara, PCS; Raha, S				Chatterjee, Abhijit; Adak, Anandamay; Singh, Ajay K.; Srivastava, Manoj K.; Ghosh, Sanjay K.; Tiwari, Suresh; Devara, Panuganti C. S.; Raha, Sibaji			Aerosol Chemistry over a High Altitude Station at Northeastern Himalayas, India	PLOS ONE			English	Article							CHEMICAL-COMPOSITION; ATMOSPHERIC AEROSOL; SIZE DISTRIBUTIONS; TIBETAN PLATEAU; NEPAL HIMALAYA; DRY DEPOSITION; BOUNDARY-LAYER; PARTICLE-SIZE; WESTERN INDIA; MINERAL DUST	Background: There is an urgent need for an improved understanding of the sources, distributions and properties of atmospheric aerosol in order to control the atmospheric pollution over northeastern Himalayas where rising anthropogenic interferences from rapid urbanization and development is becoming an increasing concern. Methodology/Principal Findings: An extensive aerosol sampling program was conducted in Darjeeling (altitude,2200 meter above sea level (masl), latitude 27 degrees 01'N and longitude 88 degrees 15'E), a high altitude station in northeastern Himalayas, during January-December 2005. Samples were collected using a respirable dust sampler and a fine dust sampler simultaneously. Ion chromatograph was used to analyze the water soluble ionic species of aerosol. The average concentrations of fine and coarse mode aerosol were found to be 29.5 +/- 20.8 mu g m(-3) and 19.6 +/- 11.1 mu g m(-3) respectively. Fine mode aerosol dominated during dry seasons and coarse mode aerosol dominated during monsoon. Nitrate existed as NH4NO3 in fine mode aerosol during winter and as NaNO3 in coarse mode aerosol during monsoon. Gas phase photochemical oxidation of SO2 during premonsoon and aqueous phase oxidation during winter and postmonsoon were the major pathways for the formation of SO42- in the atmosphere. Long range transport of dust aerosol from arid regions of western India was observed during premonsoon. The acidity of fine mode aerosol was higher in dry seasons compared to monsoon whereas the coarse mode acidity was higher in monsoon compared to dry seasons. Biomass burning, vehicular emissions and dust particles were the major types of aerosol from local and continental regions whereas sea salt particles were the major types of aerosol from marine source regions. Conclusions/Significance: The year-long data presented in this paper provide substantial improvements to the heretofore poor knowledge regarding aerosol chemistry over northeastern Himalayas, and should be useful to policy makers in making control strategies.	[Chatterjee, Abhijit; Adak, Anandamay; Raha, Sibaji] Bose Inst, Environm Sci Sect, Kolkata, India; [Singh, Ajay K.; Ghosh, Sanjay K.; Raha, Sibaji] Bose Inst, Ctr Astroparticle Phys & Space Sci, Kolkata, India; [Singh, Ajay K.; Ghosh, Sanjay K.; Raha, Sibaji] Bose Inst, Ctr Astroparticle Phys & Space Sci, Darjeeling, India; [Srivastava, Manoj K.] Banaras Hindu Univ, Dept Geophys, Varanasi 221005, Uttar Pradesh, India; [Ghosh, Sanjay K.; Raha, Sibaji] Bose Inst, Dept Phys, Kolkata, India; [Tiwari, Suresh] Indian Inst Trop Meteorol, New Delhi, India; [Devara, Panuganti C. S.] Indian Inst Trop Meteorol, Pune, Maharashtra, India	Department of Science & Technology (India); Bose Institute; Department of Science & Technology (India); Bose Institute; Banaras Hindu University (BHU); Department of Science & Technology (India); Bose Institute; Ministry of Earth Sciences (MoES) - India; Indian Institute of Tropical Meteorology (IITM); Ministry of Earth Sciences (MoES) - India; Indian Institute of Tropical Meteorology (IITM)	Chatterjee, A (corresponding author), Bose Inst, Environm Sci Sect, Kolkata, India.	sibajiraha@bic.boseinst.ernet.in	Singh, Ajay/AAF-4414-2020	Srivastava, Manoj Kumar/0000-0002-1035-8220	Science & Engineering Research Council, Department of Science & Technology, Government of India [IR/S2/PF-01/2003]	Science & Engineering Research Council, Department of Science & Technology, Government of India(Department of Science & Technology (India))	This study was supported through a grant (No. IR/S2/PF-01/2003) of the Science & Engineering Research Council, Department of Science & Technology, Government of India under the IRHPA (Intensification of Research in High Priority Areas) scheme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ASHISH A, 2006, NATURE SCI, V4, P53; Carrico CM, 2003, ATMOS ENVIRON, V37, P2811, DOI 10.1016/S1352-2310(03)00197-3; Chatterjee A, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2006JD007144; Dasgupta PK, 2007, ATMOS ENVIRON, V41, P4242, DOI 10.1016/j.atmosenv.2006.09.054; DECESARI S, 2009, ATMOS CHEM PHYS DISC, V9, P25522; Duce RA, 1991, GLOBAL BIOGEOCHEM CY, V5, P193, DOI 10.1029/91GB01778; Gajananda K, 2005, ATMOS ENVIRON, V39, P4817, DOI 10.1016/j.atmosenv.2005.01.038; Gautam R, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL037641; Gautam R, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036967; Giuliacci M., 1988, PHYS DYNAMICAL CLIMA; IPCC Apndice, 2007, AR4 CLIMATE CHANGE 2; Kaupp H, 1999, ATMOS ENVIRON, V33, P85, DOI 10.1016/S1352-2310(98)00129-0; Kim HS, 2007, ATMOS ENVIRON, V41, P6762, DOI 10.1016/j.atmosenv.2007.04.060; Kulshrestha MJ, 2003, ATMOS ENVIRON, V37, P3057, DOI 10.1016/S1352-2310(03)00290-5; Kulshrestha UC, 1998, J ATMOS CHEM, V29, P109, DOI 10.1023/A:1005796400044; Kumar A, 2008, ATMOS ENVIRON, V42, P5169, DOI 10.1016/j.atmosenv.2008.03.004; Lau KM, 2006, CLIM DYNAM, V26, P855, DOI 10.1007/s00382-006-0114-2; Lippmann M, 2000, Appl Occup Environ Hyg, V15, P57; MAENHAUT W, 1987, Journal of Trace and Microprobe Techniques, V5, P135; MAYEWSKI PA, 1979, ARCTIC ALPINE RES, V11, P267, DOI 10.2307/1550417; MCINNES LM, 1994, J GEOPHYS RES-ATMOS, V99, P8257, DOI 10.1029/93JD03453; Momin GA, 1999, CURR SCI INDIA, V76, P985; MOZURKEWICH M, 1993, ATMOS ENVIRON A-GEN, V27, P261, DOI 10.1016/0960-1686(93)90356-4; OHTA S, 1990, ATMOS ENVIRON A-GEN, V24, P815, DOI 10.1016/0960-1686(90)90282-R; Pakkanen TA, 1996, ATMOS ENVIRON, V30, P2475, DOI 10.1016/1352-2310(95)00492-0; Pathak RK, 2004, ATMOS ENVIRON, V38, P2965, DOI 10.1016/j.atmosenv.2004.02.044; Ramanathan V, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008124; Rastogi N, 2007, J ATMOS CHEM, V56, P149, DOI 10.1007/s10874-006-9047-5; Rastogi N, 2005, ATMOS ENVIRON, V39, P5541, DOI 10.1016/j.atmosenv.2005.06.011; Rastogi N, 2009, ATMOS ENVIRON, V43, P3481, DOI 10.1016/j.atmosenv.2009.04.030; Rengarajan R, 2007, J GEOPHYS RES-ATMOS, V112, DOI 10.1029/2006JD008150; Safai P.D., 1995, IASTA B, pS1; Seinfeld JH, 1986, ENV POL SUS DEV, V40, P26; Shrestha AB, 1997, ATMOS ENVIRON, V31, P2815, DOI 10.1016/S1352-2310(97)00047-2; Shrestha AB, 2000, ATMOS ENVIRON, V34, P3349, DOI 10.1016/S1352-2310(99)00366-0; *SPSS INC, 2003, ADV STAT MAN SPSS PC; Venkataraman C, 2002, ATMOS ENVIRON, V36, P1979, DOI 10.1016/S1352-2310(02)00167-X; VONSTROCH, 1999, STAT ANAL CLIMATE RE; WAKE CP, 1994, ATMOS ENVIRON, V28, P695, DOI 10.1016/1352-2310(94)90046-9; Wang Y, 2005, ATMOS ENVIRON, V39, P3771, DOI 10.1016/j.atmosenv.2005.03.013; Xiu GL, 2004, ATMOS ENVIRON, V38, P227, DOI 10.1016/j.atmosenv.2003.09.053; ZELENKA MP, 1994, ATMOS ENVIRON, V28, P1425, DOI 10.1016/1352-2310(94)90205-4; Zhuang H, 1999, ATMOS ENVIRON, V33, P843, DOI 10.1016/S1352-2310(98)00305-7	43	57	58	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2010	5	6							e11122	10.1371/journal.pone.0011122	http://dx.doi.org/10.1371/journal.pone.0011122			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	612GZ	20585397	Green Submitted, Green Published, gold			2023-01-03	WOS:000278886100008
J	Parad, RB				Parad, Richard B.			HFOV in preterms: an individual patients' data meta-analysis	LANCET			English	Editorial Material									Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Newborn Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Parad, RB (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Newborn Med, Boston, MA 02115 USA.	rparad@partners.org	Parad, Richard B/AGX-7702-2022; Parad, Richard/E-8559-2010	Parad, Richard B/0000-0002-4326-0609; 				BARRINGTON KJ, 2007, COCHRANE DB SYST REV, V3; COOLS F, 2010, LANCET, DOI DOI 10.1056/S0140-6736(10)60278-4; COOLS F, 2009, BMC PEDIATR, V16, P9; Cools F, 2009, COCHRANE DB SYST REV, V3; Courtney SE, 2003, CRIT CARE, V7, P423, DOI 10.1186/cc2178; FITZHARDINGE PM, 1990, J PEDIATR-US, V117, P939; Reade MC, 2010, INTENS CARE MED, V36, P11, DOI 10.1007/s00134-009-1650-x; STEWART LA, 1993, LANCET, V341, P418, DOI 10.1016/0140-6736(93)93004-K	8	1	1	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 12	2010	375	9731					2054	2055		10.1016/S0140-6736(10)60756-8	http://dx.doi.org/10.1016/S0140-6736(10)60756-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	614OK	20549868				2023-01-03	WOS:000279069300005
J	Rodriguez-Noriega, E; Gonzalez-Diaz, E; Morfin-Otero, R; Gomez-Abundis, GF; Briseno-Ramirez, J; Perez-Gomez, HR; Lopez-Gatell, H; Alpuche-Aranda, CM; Ramirez, E; Lopez, I; Iguala, M; Chapela, IB; Zavala, EP; Hernandez, M; Stuart, TL; Villarino, ME; Widdowson, MA; Waterman, S; Uyeki, T; Azziz-Baumgartner, E				Rodriguez-Noriega, Eduardo; Gonzalez-Diaz, Esteban; Morfin-Otero, Rayo; Gomez-Abundis, Gerardo F.; Briseno-Ramirez, Jaime; Raul Perez-Gomez, Hector; Lopez-Gatell, Hugo; Alpuche-Aranda, Celia M.; Ramirez, Ernesto; Lopez, Irma; Iguala, Miguel; Bojorquez Chapela, Ietza; Palacios Zavala, Ethel; Hernandez, Mauricio; Stuart, Tammy L.; Villarino, Margarita Elsa; Widdowson, Marc-Alain; Waterman, Steve; Uyeki, Timothy; Azziz-Baumgartner, Eduardo		Hosp Civil Guadalajara	Hospital Triage System for Adult Patients Using an Influenza-Like Illness Scoring System during the 2009 Pandemic-Mexico	PLOS ONE			English	Article							A H1N1 VIRUS; SURGE CAPACITY; UNITED-STATES; CRITICAL-CARE; PNEUMONIA; DISASTER	Background: Pandemic influenza A (H1N1) virus emerged during 2009. To help clinicians triage adults with acute respiratory illness, a scoring system for influenza-like illness (ILI) was implemented at Hospital Civil de Guadalajara, Mexico. Methods: A medical history, laboratory and radiology results were collected on emergency room (ER) patients with acute respiratory illness to calculate an ILI-score. Patients were evaluated for admission by their ILI-score and clinicians' assessment of risk for developing complications. Nasal and throat swabs were collected from intermediate and high-risk patients for influenza testing by RT-PCR. The disposition and ILI-score of those oseltamivir-treated versus untreated, clinical characteristics of 2009 pandemic influenza A (H1N1) patients versus test-negative patients were compared by Pearson's X(2), Fisher's Exact, and Wilcoxon rank-sum tests. Results: Of 1840 ER patients, 230 were initially hospitalized (mean ILI-score = 15), and the rest were discharged, including 286 ambulatory patients given oseltamivir (median ILI-score = 11), and 1324 untreated (median ILI-score = 5). Fourteen (1%) untreated patients returned, and 3 were hospitalized on oseltamivir (median ILI-score = 19). Of 371 patients tested by RTPCR, 104 (28%) had pandemic influenza and 42 (11%) had seasonal influenza A detected. Twenty (91%) of 22 imaged hospitalized pandemic influenza patients had bilateral infiltrates compared to 23 (38%) of 61 imaged hospital test-negative patients (p<0.001). One patient with confirmed pandemic influenza presented 6 days after symptom onset, required mechanical ventilation, and died. Conclusions: The triaging system that used an ILI-score complimented clinicians' judgment of who needed oseltamivir and inpatient care and helped hospital staff manage a surge in demand for services.	[Rodriguez-Noriega, Eduardo; Gonzalez-Diaz, Esteban; Morfin-Otero, Rayo; Briseno-Ramirez, Jaime; Raul Perez-Gomez, Hector] Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico; [Rodriguez-Noriega, Eduardo; Morfin-Otero, Rayo; Gomez-Abundis, Gerardo F.; Briseno-Ramirez, Jaime; Raul Perez-Gomez, Hector] Univ Guadalajara, Inst Patol Infecciosa & Expt, Ctr Univ Ciencias Salud, Guadalajara 44430, Jalisco, Mexico; [Lopez-Gatell, Hugo; Bojorquez Chapela, Ietza; Palacios Zavala, Ethel; Hernandez, Mauricio] Mexico Minist Hlth, Direcc Gen Epidemiol, Mexico City, DF, Mexico; [Alpuche-Aranda, Celia M.; Ramirez, Ernesto; Lopez, Irma; Iguala, Miguel] Natl Publ Hlth Lab, Mexico City, DF, Mexico; [Stuart, Tammy L.] Publ Hlth Agcy Canada, Winnipeg, MB, Canada; [Villarino, Margarita Elsa; Widdowson, Marc-Alain; Waterman, Steve; Uyeki, Timothy; Azziz-Baumgartner, Eduardo] US Ctr Dis Control & Prevent, Atlanta, GA USA	Universidad de Guadalajara; Public Health Agency of Canada; Centers for Disease Control & Prevention - USA	Rodriguez-Noriega, E (corresponding author), Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico.	eha9@cdc.gov	Morfín-Otero, Rayo/AAR-8027-2021; Gonzalez-Diaz, Esteban/GVU-0915-2022	Morfín-Otero, Rayo/0000-0001-9576-1950; Gonzalez-Diaz, Esteban/0000-0002-9743-3739; Widdowson, Marc-Alain/0000-0002-0682-6933; RAMIREZ-GONZALEZ, JOSE ERNESTO/0000-0003-0477-2211; Rodriguez-Noriega, Eduardo/0000-0002-1386-4815				Azziz-Baumgartner E, 2009, INFLUENZA OTHER RESP, V3, P189, DOI 10.1111/j.1750-2659.2009.00091.x; *CDC, 2009, INT GUID ANT REC PAT; Chowell G, 2009, NEW ENGL J MED, V361, P674, DOI 10.1056/NEJMoa0904023; Christian MD, 2006, CAN MED ASSOC J, V175, P1377, DOI 10.1503/cmaj.060911; Cordova J. A., 2009, Morbidity and Mortality Weekly Report, V58, P585; Dawood FS, 2009, NEW ENGL J MED, V360, P2605, DOI 10.1056/NEJMoa0903810; *DEP HLTH BRIT INF, 2007, THORAX, V62, pS1; Glaser CA, 2002, EMERG INFECT DIS, V8, P569, DOI 10.3201/eid0806.010370; Hak E, 2004, J INFECT DIS, V189, P450, DOI 10.1086/381165; HANCOCK K, 2009, NEW ENGL J MED, V361, P1; Ho Y-S., 2009, J ENV PROTECTION SCI, V3, P111; Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0; Nguyen-Van-Tam JS, 2003, VACCINE, V21, P1762, DOI 10.1016/S0264-410X(03)00069-0; Olson DR, 2007, PLOS MED, V4, P1349, DOI 10.1371/journal.pmed.0040247; Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252; Powell T, 2008, DISASTER MED PUBLIC, V2, P20, DOI 10.1097/DMP.0b013e3181620794; *PUBL HLTH AG CAN, 2008, CAN INFL PLAN HLTH S; Rubinson L, 2008, CHEST, V133, p32S, DOI 10.1378/chest.07-2691; Schull MJ, 2006, ACAD EMERG MED, V13, P1228, DOI [10.1197/j.aem.2006.04.011, 10.1111/j.1553-2712.2006.tb01653.x]; Singanayagam A, 2009, QJM-INT J MED, V102, P379, DOI 10.1093/qjmed/hcp027; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; *US DEP HHS, HHS PAND INFL PLA S5; WHO Global Influenza Programme & World Health Organization, 2009, PAND INFL PREP RESP; [No title captured]	25	16	17	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 14	2010	5	5							e10658	10.1371/journal.pone.0010658	http://dx.doi.org/10.1371/journal.pone.0010658			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	597PU	20498718	Green Submitted, Green Published, gold			2023-01-03	WOS:000277771600019
J	Li, YY; Liu, L; Tollefsbol, TO				Li, Yuanyuan; Liu, Liang; Tollefsbol, Trygve O.			Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression	FASEB JOURNAL			English	Article						cancer; DNA methylation; histone modification; E2F-1; longevity	TELOMERASE ACTIVITY; CANCER-CELLS; TUMOR-CELLS; CALORIC RESTRICTION; GENETIC ELEMENTS; MECHANISMS; DISEASE; CARCINOMA; IMMORTALIZATION; INHIBITION	Cancer cells metabolize glucose at elevated rates and have a higher sensitivity to glucose reduction. However, the precise molecular mechanisms leading to different responses to glucose restriction between normal and cancer cells are not fully understood. We analyzed normal WI-38 and immortalized WI-38/S fetal lung fibroblasts and found that glucose restriction resulted in growth inhibition and apoptosis in WI-38/S cells, whereas it induced lifespan extension in WI-38 cells. Moreover, in WI-38/S cells glucose restriction decreased expression of hTERT (human telomerase reverse transcriptase) and increased expression of p16(INK4a). Opposite effects were found in the gene expression of hTERT and p16 in WI-38 cells in response to glucose restriction. The altered gene expression was partly due to glucose restriction-induced DNA methylation changes and chromatin remodeling of the hTERT and p16 promoters in normal and immortalized WI-38 cells. Furthermore, glucose restriction resulted in altered hTERT and p16 expression in response to epigenetic regulators in WI-38 rather than WI-38/S cells, suggesting that energy stress-induced differential epigenetic regulation may lead to different cellular fates in normal and precancerous cells. Collectively, these results provide new insights into the epigenetic mechanisms of a nutrient control strategy that may contribute to cancer therapy as well as antiaging approaches.-Li, Y., Liu, L., Tollefsbol, T. O. Glucose restriction can extend normal cell lifespan and impair precancerous cell growth through epigenetic control of hTERT and p16 expression. FASEB J. 24, 1442-1453 (2010). www.fasebj.org	[Li, Yuanyuan; Tollefsbol, Trygve O.] Univ Alabama, Dept Biol, Birmingham, AL 35294 USA; [Liu, Liang; Tollefsbol, Trygve O.] Univ Alabama, Ctr Aging, Birmingham, AL USA; [Liu, Liang] Univ Alabama, Dept Med, Birmingham, AL 35294 USA; [Tollefsbol, Trygve O.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA; [Tollefsbol, Trygve O.] Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL USA; [Tollefsbol, Trygve O.] Univ Alabama, Comprehens Diabet Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Tollefsbol, TO (corresponding author), CH 175,1300 Univ Blvd, Birmingham, AL 35294 USA.	trygve@uab.edu		Tollefsbol, Trygve/0000-0002-0284-1511	Imperial Cancer Research Fund Laboratories, London, UK; NATIONAL CANCER INSTITUTE [R01CA129415] Funding Source: NIH RePORTER	Imperial Cancer Research Fund Laboratories, London, UK; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Dr. Gordon Peters (Imperial Cancer Research Fund Laboratories, London, UK) and Dr. Silvia Bacchetti (Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada) for kindly providing the luciferase constructs used in this investigation.	Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Casillas MA, 2003, GENE, V316, P57, DOI 10.1016/S0378-1119(03)00739-X; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Cuezva JM, 2002, CANCER RES, V62, P6674; Del Bufalo D, 2005, CELL DEATH DIFFER, V12, P1429, DOI 10.1038/sj.cdd.4401670; Dhahbi JM, 2004, P NATL ACAD SCI USA, V101, P5524, DOI 10.1073/pnas.0305300101; Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625; Garber K, 2006, SCIENCE, V312, P1158, DOI 10.1126/science.312.5777.1158; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gupta AK, 1997, MOL CELL BIOCHEM, V170, P23, DOI 10.1023/A:1006890316102; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Hara E, 1996, MOL CELL BIOL, V16, P859; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Kanaya T, 1998, INT J CANCER, V78, P539, DOI 10.1002/(SICI)1097-0215(19981123)78:5<539::AID-IJC2>3.0.CO;2-I; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Leibiger IB, 2006, NAT MED, V12, P34, DOI 10.1038/nm0106-34; Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; RACKER E, AM SCI, V60, P56; Rohren EM, 2004, RADIOLOGY, V231, P305, DOI 10.1148/radiol.2312021185; Shin JY, 2000, CANCER RES, V60, P262; Thompson CB, 2005, COLD SH Q B, V70, P357, DOI 10.1101/sqb.2005.70.011; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Willcox BJ, 2007, ANN NY ACAD SCI, V1114, P434, DOI 10.1196/annals.1396.037; Zhu Z, 2007, CANCER RES, V67, P12018, DOI 10.1158/0008-5472.CAN-07-2834	36	89	95	1	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1442	1453		10.1096/fj.09-149328	http://dx.doi.org/10.1096/fj.09-149328			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	20019239	Green Published			2023-01-03	WOS:000277158900017
J	Solberg, R; Enot, D; Deigner, HP; Koal, T; Scholl-Burgi, S; Saugstad, OD; Keller, M				Solberg, Ronnaug; Enot, David; Deigner, Hans-Peter; Koal, Therese; Scholl-Buergi, Sabine; Saugstad, Ola D.; Keller, Matthias			Metabolomic Analyses of Plasma Reveals New Insights into Asphyxia and Resuscitation in Pigs	PLOS ONE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; ROOM-AIR RESUSCITATION; 100-PERCENT OXYGEN; L-CARNITINE; NEWBORN-INFANTS; NEONATAL ENCEPHALOPATHY; TERM INFANTS; BRAIN-INJURY; METAANALYSIS; CHOLESTEROL	Background: Currently, a limited range of biochemical tests for hypoxia are in clinical use. Early diagnostic and functional biomarkers that mirror cellular metabolism and recovery during resuscitation are lacking. We hypothesized that the quantification of metabolites after hypoxia and resuscitation would enable the detection of markers of hypoxia as well as markers enabling the monitoring and evaluation of resuscitation strategies. Methods and Findings: Hypoxemia of different durations was induced in newborn piglets before randomization for resuscitation with 21% or 100% oxygen for 15 min or prolonged hyperoxia. Metabolites were measured in plasma taken before and after hypoxia as well as after resuscitation. Lactate, pH and base deficit did not correlate with the duration of hypoxia. In contrast to these, we detected the ratios of alanine to branched chained amino acids (Ala/BCAA; R-2. adj = 0.58, qvalue, 0.001) and of glycine to BCAA (Gly/BCAA; R-2.adj = 0.45, q-value, 0.005), which were highly correlated with the duration of hypoxia. Combinations of metabolites and ratios increased the correlation to R-2 adjust = 0.92. Reoxygenation with 100% oxygen delayed cellular metabolic recovery. Reoxygenation with different concentrations of oxygen reduced lactate levels to a similar extent. In contrast, metabolites of the Krebs cycle (which is directly linked to mitochondrial function) including alpha keto-glutarate, succinate and fumarate were significantly reduced at different rates depending on the resuscitation, showing a delay in recovery in the 100% reoxygenation groups. Additional metabolites showing different responses to reoxygenation include oxysterols and acylcarnitines (n = 8-11, q<0.001). Conclusions: This study provides a novel strategy and set of biomarkers. It provides biochemical in vivo data that resuscitation with 100% oxygen delays cellular recovery. In addition, the oxysterol increase raises concerns about the safety of 100% O-2 resuscitation. Our biomarkers can be used in a broad clinical setting for evaluation or the prediction of damage in conditions associated with low tissue oxygenation in both infancy and adulthood. These findings have to be validated in human trials.	[Solberg, Ronnaug; Saugstad, Ola D.] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Pediat Res, N-0316 Oslo, Norway; [Solberg, Ronnaug] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Surg Res, N-0316 Oslo, Norway; [Enot, David; Deigner, Hans-Peter; Koal, Therese] BIOCRATES Life Sci AG, Innsbruck, Austria; [Scholl-Buergi, Sabine] Innsbruck Med Univ, Dept Pediat 4, Div Neuropediatr & Inherited Metab Disorders, Innsbruck, Austria; [Keller, Matthias] Univ Essen Gesamthsch, Dept Pediat 1, Essen, Germany	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Medical University of Innsbruck; University of Duisburg Essen	Solberg, R (corresponding author), Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Pediat Res, N-0316 Oslo, Norway.	Matthias.Keller@uk-essen.de	Saugstad, Ola/AAS-9041-2021	Saugstad, Ola/0000-0002-3166-5254; Scholl-Burgi, Sabine/0000-0002-2529-4231	South-Eastern Norway Regional Health Authority; Norwegian SIDS; Stillbirth Society	South-Eastern Norway Regional Health Authority; Norwegian SIDS; Stillbirth Society	Financial support was provided by the South-Eastern Norway Regional Health Authority and the Norwegian SIDS and Stillbirth Society. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bayes R, 2001, EARLY HUM DEV, V65, pS103, DOI 10.1016/S0378-3782(01)00212-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Binienda ZK, 2003, ANN NY ACAD SCI, V993, P289, DOI 10.1111/j.1749-6632.2003.tb07536.x; Bjorkhem I, 1997, J BIOL CHEM, V272, P30178, DOI 10.1074/jbc.272.48.30178; Bretillon L, 2000, NEUROSCI LETT, V293, P87, DOI 10.1016/S0304-3940(00)01466-X; Briddon A, 1996, ANN CLIN BIOCHEM, V33, P227, DOI 10.1177/000456329603300309; Cai C, 2008, J HUAZHONG U SCI-MED, V28, P207, DOI 10.1007/s11596-008-0224-4; Cam H, 2005, J TROP PEDIATRICS, V51, P106, DOI 10.1093/tropej/fmh089; Chace DH, 2003, PEDIATR RES, V53, P823, DOI 10.1203/01.PDR.0000059220.39578.3D; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Davis PG, 2004, LANCET, V364, P1329, DOI 10.1016/S0140-6736(04)17189-4; DE V, 1990, BIOL NEONATE S, V58, P54; GEHRKE I, 1990, LUNG, V168, P79, DOI 10.1007/BF02719678; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Groenendaal F, 2000, Semin Neonatol, V5, P17, DOI 10.1053/siny.1999.0119; Hastie T., 2013, ELEMENTS STAT LEARNI, DOI DOI 10.1007/978-0-387-84858-7_16; HELLSTROMWESTAS L, 1995, ARCH DIS CHILD-FETAL, V72, pF34, DOI 10.1136/fn.72.1.F34; Helton E, 2000, PEDIATRICS, V105, P1260; International Liaison Committee on Resuscitation, 2005, Resuscitation, V67, P293; Jacobs S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003311.pub2; Kim H, 2005, BIOINFORMATICS, V21, P187, DOI 10.1093/bioinformatics/bth499; Li J, 2004, FREE RADICAL BIO MED, V36, P1460, DOI 10.1016/j.freeradbiomed.2004.03.005; Markham EA, 2007, STAND, V7, P62; Marlow N, 2005, ARCH DIS CHILD-FETAL, V90, pF380, DOI 10.1136/adc.2004.067520; McGuire William, 2006, Clin Evid, P511; Meyburg J, 2001, PEDIATR RES, V49, P125, DOI 10.1203/00006450-200101000-00024; Odd DE, 2009, LANCET, V373, P1615, DOI 10.1016/S0140-6736(09)60244-0; Oka T, 2008, CIRC J, V72, P1359, DOI 10.1253/circj.72.1359; Rabi Y, 2007, RESUSCITATION, V72, P353, DOI 10.1016/j.resuscitation.2006.06.134; Rebouche CJ, 2004, ANN NY ACAD SCI, V1033, P30, DOI 10.1196/annals.1320.003; REZNICK AZ, 1992, ARCH BIOCHEM BIOPHYS, V296, P394, DOI 10.1016/0003-9861(92)90589-O; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Saugstad OD, 2003, PEDIATRICS, V112, P296, DOI 10.1542/peds.112.2.296; Saugstad OD, 2008, NEONATOLOGY, V94, P176, DOI 10.1159/000143397; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Smith J, 2000, BRIT J OBSTET GYNAEC, V107, P461, DOI 10.1111/j.1471-0528.2000.tb13262.x; Spiekerkoetter U, 2009, J INHERIT METAB DIS, V32, P498, DOI 10.1007/s10545-009-1126-8; Swindle M M, 1988, J Invest Surg, V1, P65, DOI 10.3109/08941938809141077; Thoresen M, 2000, Semin Neonatol, V5, P61, DOI 10.1053/siny.1999.0118; TODO G, 1986, INVEST RADIOL, V21, P689, DOI 10.1097/00004424-198609000-00003; Touma EH, 2001, ARCH DIS CHILD, V84, P58, DOI 10.1136/adc.84.1.58; Vance JE, 2005, SEMIN CELL DEV BIOL, V16, P193, DOI 10.1016/j.semcdb.2005.01.005; Vanier MT, 2003, CLIN GENET, V64, P269, DOI 10.1034/j.1399-0004.2003.00147.x; VANNUCCI RC, 1990, PEDIATRICS, V85, P961; Vento M, 2005, AM J RESP CRIT CARE, V172, P1393, DOI 10.1164/rccm.200412-1740OC; Wainwright MS, 2006, STROKE, V37, P524, DOI 10.1161/01.STR.0000198892.15269.f7; Wainwright MS, 2003, PEDIATR RES, V54, P688, DOI 10.1203/01.PDR.0000085036.07561.9C; Waterham HR, 2006, FEBS LETT, V580, P5442, DOI 10.1016/j.febslet.2006.07.027; *WHO, 2005, WORLD HTLH REP 2005; Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1	50	92	100	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2010	5	3							e9606	10.1371/journal.pone.0009606	http://dx.doi.org/10.1371/journal.pone.0009606			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565XA	20231903	Green Published, Green Submitted, gold			2023-01-03	WOS:000275328300019
J	Gustafson, WC; Weiss, WA				Gustafson, W. C.; Weiss, W. A.			Myc proteins as therapeutic targets	ONCOGENE			English	Review						myc; mycn; neuroblastoma; N-myc; mTor; PI3K	ANAPLASTIC LYMPHOMA KINASE; INITIAL TESTING STAGE-1; ARF TUMOR-SUPPRESSOR; C-MYC; N-MYC; GENE-EXPRESSION; DNA-BINDING; CELL-LINES; TRANSCRIPTIONAL CONTROL; MALIGNANT PROGRESSION	Myc proteins (c-myc, Mycn and Mycl) target proliferative and apoptotic pathways vital for progression in cancer. Amplification of the MYCN gene has emerged as one of the clearest indicators of aggressive and chemotherapy-refractory disease in children with neuroblastoma, the most common extracranial solid tumor of childhood. Phosphorylation and ubiquitin-mediated modulation of Myc protein influence stability and represent potential targets for therapeutic intervention. Phosphorylation of Myc proteins is controlled in-part by the receptor tyrosine kinase/phosphatidylinositol 3-kinase/Akt/mTOR signaling, with additional contributions from Aurora A kinase. Myc proteins regulate apoptosis in part through interactions with the p53/Mdm2/Arf signaling pathway. Mutation in p53 is commonly observed in patients with relapsed neuroblastoma, contributing to both biology and therapeutic resistance. This review examines Myc function and regulation in neuroblastoma, and discusses emerging therapies that target Mycn. Oncogene (2010) 29, 1249-1259; doi:10.1038/onc.2009.512; published online 25 January 2010	[Gustafson, W. C.; Weiss, W. A.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA; [Gustafson, W. C.] Univ Calif San Francisco, Div Pediat Hematol Oncol, San Francisco, CA 94143 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Weiss, W. A.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Gustafson, WC (corresponding author), Univ Calif San Francisco, Dept Pediat, Helen Diller Family Canc Res Bldg,1450 3rd St, San Francisco, CA 94158 USA.	GustafsonC@peds.ucsf.edu		Weiss, William/0000-0003-2230-9132	NIH [CA133091, NS055750, CA102321, CA097257, CA128583]; Burroughs Wellcome Fund; American Brain Tumor Association; Brain Tumor Society; Accelerate Brain Cancer Cure; Alex's Lemonade Stand Foundation; Children's National Brain Tumor Foundation; Wallace H. Coulter Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Samuel G Waxman Foundation; V Foundation; NATIONAL CANCER INSTITUTE [R01CA102321, R01CA133091, R01CA148699, P01CA081403, T32CA128583, P50CA097257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055750] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund(Burroughs Wellcome Fund); American Brain Tumor Association; Brain Tumor Society; Accelerate Brain Cancer Cure; Alex's Lemonade Stand Foundation; Children's National Brain Tumor Foundation; Wallace H. Coulter Foundation; Katie Dougherty Foundation; Pediatric Brain Tumor Foundation; Samuel G Waxman Foundation; V Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Chris Hackett and Theo Nicolaides for critical review. We acknowledge support from NIH grants CA133091, NS055750, CA102321, CA097257, CA128583; Burroughs Wellcome Fund, American Brain Tumor Association, The Brain Tumor Society, Accelerate Brain Cancer Cure; Alex's Lemonade Stand, Children's National Brain Tumor, Wallace H. Coulter, Katie Dougherty, Pediatric Brain Tumor, Samuel G Waxman and V Foundations.	Alaminos M, 2003, CANCER RES, V63, P4538; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; Amente S, 2007, FEBS LETT, V581, P821, DOI 10.1016/j.febslet.2007.01.062; ARMSTRONG BC, 1992, CELL GROWTH DIFFER, V3, P385; Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; ASKEW DS, 1991, ONCOGENE, V6, P1915; Attiyeh EF, 2005, NEW ENGL J MED, V353, P2243, DOI 10.1056/NEJMoa052399; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Barbieri E, 2006, MOL CANCER THER, V5, P2358, DOI 10.1158/1535-7163.MCT-06-0305; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Bell E, 2007, CELL CYCLE, V6, P1249, DOI 10.4161/cc.6.10.4222; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; Berg T, 2008, CURR OPIN CHEM BIOL, V12, P464, DOI 10.1016/j.cbpa.2008.07.023; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Bown N, 1999, NEW ENGL J MED, V340, P1954, DOI 10.1056/NEJM199906243402504; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Brooks TA, 2009, NAT REV CANCER, V9, P849, DOI 10.1038/nrc2733; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Chan HSL, 1997, CLIN CANCER RES, V3, P1699; Chen QR, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-70; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chen ZW, 2009, NEOPLASIA, V11, P753, DOI 10.1593/neo.09466; Cheng AJ, 2007, EUR J CANCER, V43, P1467, DOI 10.1016/j.ejca.2007.03.008; Chesler L, 2008, NEOPLASIA, V10, P1268, DOI 10.1593/neo.08778; Chesler L, 2007, CANCER RES, V67, P9435, DOI 10.1158/0008-5472.CAN-07-1316; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Chiarle R, 2008, NAT REV CANCER, V8, P11, DOI 10.1038/nrc2291; CLAUSEN N, 1989, ACTA PAEDIATR SCAND, V78, P736, DOI 10.1111/j.1651-2227.1989.tb11135.x; Cobbold LC, 2008, MOL CELL BIOL, V28, P40, DOI 10.1128/MCB.01298-07; Cohn SL, 2000, J CLIN ONCOL, V18, P3604, DOI 10.1200/JCO.2000.18.21.3604; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; Cotterman R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005799; Coutts AS, 2009, DNA REPAIR, V8, P483, DOI 10.1016/j.dnarep.2009.01.008; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; DOWNS KM, 1989, GENE DEV, V3, P860, DOI 10.1101/gad.3.6.860; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fulda S, 1999, ONCOGENE, V18, P1479, DOI 10.1038/sj.onc.1202435; Fulda S, 2009, CURR CANCER DRUG TAR, V9, P729, DOI 10.2174/156800909789271521; Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; Gingras AC, 2001, GENE DEV, V15, P2852; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434; Guo C, 1999, ONCOGENE, V18, P4948, DOI 10.1038/sj.onc.1202887; Hackett CS, 2003, CANCER RES, V63, P5266; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640; HIRNING U, 1991, MECH DEVELOP, V33, P119, DOI 10.1016/0925-4773(91)90078-K; HIRVONEN H, 1990, ONCOGENE, V5, P1787; Ho R, 2002, CANCER RES, V62, P6462; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hossain MS, 2008, ONCOGENE, V27, P6075, DOI 10.1038/onc.2008.200; Houghton PJ, 2008, PEDIATR BLOOD CANCER, V50, P799, DOI 10.1002/pbc.21296; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Ikegaki N, 2007, CLIN CANCER RES, V13, P6001, DOI 10.1158/1078-0432.CCR-07-0071; Inge TH, 2002, SURGERY, V132, P232, DOI 10.1067/msy.2002.125387; Jacobs JFM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-239; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kanemaru KK, 2008, PEDIATR BLOOD CANCER, V50, P806, DOI 10.1002/pbc.21273; Kang J, 2008, ONCOGENE, V27, P3999, DOI 10.1038/onc.2008.15; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Keshelava N, 1998, CANCER RES, V58, P5396; Keshelava N, 1997, EUR J CANCER, V33, P2002, DOI 10.1016/S0959-8049(97)00213-X; Keshelava N, 2000, MED PEDIATR ONCOL, V35, P563, DOI 10.1002/1096-911X(20001201)35:6<563::AID-MPO15>3.0.CO;2-J; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koppen A, 2007, CANCER LETT, V256, P218, DOI 10.1016/j.canlet.2007.06.011; Kramps C, 2004, J BIOL CHEM, V279, P5110, DOI 10.1074/jbc.M304758200; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; Li RS, 2008, MED RES REV, V28, P372, DOI 10.1002/med.20109; Li ZL, 2009, CELL CYCLE, V8, P2703, DOI 10.4161/cc.8.17.9418; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu T, 2009, EUR J CANCER, V45, P1846, DOI 10.1016/j.ejca.2009.03.002; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1999, J CELL BIOCHEM, V72, P483, DOI 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Manohar CF, 2004, ONCOGENE, V23, P753, DOI 10.1038/sj.onc.1207151; Mao DYL, 2003, CURR BIOL, V13, P882, DOI 10.1016/S0960-9822(03)00297-5; Maris JM, 2008, PEDIATR BLOOD CANCER, V51, P42, DOI 10.1002/pbc.21535; Maris JM, 2008, NEW ENGL J MED, V358, P2585, DOI 10.1056/NEJMoa0708698; Maris JM, 2009, CANCER CELL, V15, P5, DOI 10.1016/j.ccr.2008.12.008; Marques M, 2008, MOL CELL BIOL, V28, P2803, DOI 10.1128/MCB.01786-07; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Martins RAP, 2008, GENE DEV, V22, P179, DOI 10.1101/gad.1608008; Marzec M, 2007, ONCOGENE, V26, P5606, DOI 10.1038/sj.onc.1210346; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Mill P, 2005, DEV CELL, V9, P293, DOI 10.1016/j.devcel.2005.05.009; Moore HC, 2008, J CLIN PATHOL, V61, P1098, DOI 10.1136/jcp.2007.054627; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Mosse YP, 2009, CLIN CANCER RES, V15, P5609, DOI 10.1158/1078-0432.CCR-08-2762; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Norris MD, 2000, MED PEDIATR ONCOL, V35, P585, DOI 10.1002/1096-911X(20001201)35:6<585::AID-MPO20>3.3.CO;2-G; Oberthuer A, 2006, J CLIN ONCOL, V24, P5070, DOI 10.1200/JCO.2006.06.1879; Ohira M, 2005, CANCER CELL, V7, P337, DOI 10.1016/j.ccr.2005.03.019; Okubo T, 2005, DEVELOPMENT, V132, P1363, DOI 10.1242/dev.01678; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Ota S, 2007, DEVELOPMENT, V134, P1583, DOI 10.1242/dev.000703; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Paffhausen T, 2007, CANCER LETT, V250, P17, DOI 10.1016/j.canlet.2006.09.010; Park JR, 2008, PEDIATR CLIN N AM, V55, P97, DOI 10.1016/j.pcl.2007.10.014; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PULVERER BJ, 1994, ONCOGENE, V9, P59; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; Raabe EH, 2008, ONCOGENE, V27, P469, DOI 10.1038/sj.onc.1210659; Riley RD, 2004, CLIN CANCER RES, V10, P4, DOI 10.1158/1078-0432.CCR-1051-2; Rohrer T, 2002, PEDIATR PULM, V33, P71, DOI 10.1002/ppul.10031; Ruggero D, 2009, CANCER RES, V69, P8839, DOI 10.1158/0008-5472.CAN-09-1970; SAKSELA K, 1992, ONCOGENE, V7, P347; Schramm A, 2005, ONCOGENE, V24, P7902, DOI 10.1038/sj.onc.1208936; Schramm A, 2009, CANCER LETT, V282, P55, DOI 10.1016/j.canlet.2009.02.052; Schulte JH, 2009, CANCER LETT, V274, P10, DOI 10.1016/j.canlet.2008.06.010; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shang XY, 2009, MOL CANCER THER, V8, P2461, DOI 10.1158/1535-7163.MCT-08-0857; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Slack A, 2005, CANCER LETT, V228, P21, DOI 10.1016/j.canlet.2005.01.050; Slack A, 2005, P NATL ACAD SCI USA, V102, P731, DOI 10.1073/pnas.0405495102; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Stupack DG, 2006, NATURE, V439, P95, DOI 10.1038/nature04323; Tang XX, 2006, CANCER RES, V66, P2826, DOI 10.1158/0008-5472.CAN-05-0854; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; Trochet D, 2005, AM J HUM GENET, V76, P421, DOI 10.1086/428366; Tweddle DA, 2001, CANCER RES, V61, P8; Ushmorov A, 2008, ONCOGENE, V27, P3424, DOI 10.1038/sj.onc.1211017; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Van Maerken T, 2009, CELL DEATH DIFFER, V16, P1563, DOI 10.1038/cdd.2009.138; Van Maerken T, 2009, JNCI-J NATL CANCER I, V101, P1562, DOI 10.1093/jnci/djp355; Vermeulen J, 2009, LANCET ONCOL, V10, P663, DOI 10.1016/S1470-2045(09)70154-8; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; VOGAN K, 1993, CANCER RES, V53, P5269; Wagner LM, 2009, J CELL BIOCHEM, V107, P46, DOI 10.1002/jcb.22094; Walkley CR, 2005, NAT CELL BIOL, V7, P172, DOI 10.1038/ncb1214; Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weiss WA, 2000, CANCER RES, V60, P2483; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Westermann F, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r150; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Witt O, 2009, CURR PHARM DESIGN, V15, P436, DOI 10.2174/138161209787315774; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Xue C, 2007, CANCER RES, V67, P10351, DOI 10.1158/0008-5472.CAN-06-4345; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Yu K, 2009, CANCER RES, V69, P6232, DOI 10.1158/0008-5472.CAN-09-0299; Zask A, 2009, J MED CHEM, V52, P5013, DOI 10.1021/jm900851f; Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	199	148	154	1	38	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2010	29	9					1249	1259		10.1038/onc.2009.512	http://dx.doi.org/10.1038/onc.2009.512			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	20101214	Green Accepted			2023-01-03	WOS:000275170600001
J	Humbert, M; Casteran, N; Letard, S; Hanssens, K; Iovanna, J; Finetti, P; Bertucci, F; Bader, T; Mansfield, CD; Moussy, A; Hermine, O; Dubreuil, P				Humbert, Martine; Casteran, Nathalie; Letard, Sebastien; Hanssens, Katia; Iovanna, Juan; Finetti, Pascal; Bertucci, Francois; Bader, Thomas; Mansfield, Colin D.; Moussy, Alain; Hermine, Olivier; Dubreuil, Patrice			Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model	PLOS ONE			English	Article							CANCER; INHIBITION; EXPRESSION; CARCINOMA; GROWTH; PROGRESSION; METASTASIS; SURVIVAL; THERAPY	Background: Tyrosine kinases are attractive targets for pancreatic cancer therapy because several are over-expressed, including PDGFR alpha/beta, FAK, Src and Lyn. A critical role of mast cells in the development of pancreatic cancer has also been reported. Masitinib is a tyrosine kinase inhibitor that selectively targets c-Kit, PDGFR alpha/beta, Lyn, and to a lesser extent the FAK pathway, without inhibiting kinases of known toxicities. Masitinib is particularly efficient in controlling the proliferation, differentiation and degranulation of mast cells. This study evaluates the therapeutic potential of masitinib in pancreatic cancer, as a single agent and in combination with gemcitabine. Methodology/Findings: Proof-of-concept studies were performed in vitro on human pancreatic tumour cell lines and then in vivo using a mouse model of human pancreatic cancer. Molecular mechanisms were investigated via gene expression profiling. Masitinib as a single agent had no significant antiproliferative activity while the masitinib/gemcitabine combination showed synergy in vitro on proliferation of gemcitabine-refractory cell lines Mia Paca2 and Panc1, and to a lesser extent in vivo on Mia Paca2 cell tumour growth. Specifically, masitinib at 10 mu M strongly sensitised Mia Paca2 cells to gemcitabine (> 400-fold reduction in IC50); and moderately sensitised Panc1 cells (10-fold reduction). Transcriptional analysis identified the Wnt/beta-catenin signalling pathway as down-regulated in the cell lines resensitised by the masitinib/gemcitabine combination. Conclusions: These data establish proof-of-concept that masitinib can sensitise gemcitabine-refractory pancreatic cancer cell lines and warrant further in vivo investigation. Indeed, such an effect has been recently observed in a phase 2 clinical study of patients with pancreatic cancer who received a masitinib/gemcitabine combination.	[Humbert, Martine; Casteran, Nathalie; Hanssens, Katia; Bader, Thomas; Mansfield, Colin D.; Moussy, Alain] AB Sci SA, Paris, France; [Letard, Sebastien; Dubreuil, Patrice] Ctr Reference Mastocytoses, Ctr Rech Cancerol Marseille Signalisat Hematopoie, INSERM, U891, Marseille, France; [Letard, Sebastien; Finetti, Pascal; Bertucci, Francois; Dubreuil, Patrice] Univ Mediterranee, Marseille, France; [Iovanna, Juan] INSERM, U624, F-13258 Marseille, France; [Finetti, Pascal; Bertucci, Francois] Inst J Paoli I Calmettes, Dept Med Oncol, Dept Mol Oncol, Ctr Rech Cancerol Marseille,INSERM,U891, F-13009 Marseille, France; [Hermine, Olivier] Univ Paris 05, CNRS, UMR 8147, Ctr Reference Mastocytoses,Serv Hematol,Hop Necke, F-75270 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Humbert, M (corresponding author), AB Sci SA, Paris, France.	olivier.hermine@nck.aphp.fr; patrice.dubreuil@inserm.fr	Hermine, Olivier/Q-7072-2018; Dubreuil, Patrice/V-4816-2019; Iovanna, Juan/M-9805-2017; dubreuil, patrice/F-5346-2011; Finetti, Pascal/O-8669-2017	Dubreuil, Patrice/0000-0003-1155-1150; Iovanna, Juan/0000-0003-1822-2237; dubreuil, patrice/0000-0003-1155-1150; Bertucci, Francois/0000-0002-0157-0959; Hermine, Olivier/0000-0003-2574-3874; LETARD, Sebastien/0000-0002-6508-7376; Finetti, Pascal/0000-0002-2674-3123	la Ligue Nationale Contre le Cancer; equipe labellisee; INCa; Institut National du Cancer; Agence Nationale pour la Recherche; AB Science, S. A., Paris, France	la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); equipe labellisee; INCa(Institut National du Cancer (INCA) France); Institut National du Cancer(Institut National du Cancer (INCA) France); Agence Nationale pour la Recherche(French National Research Agency (ANR)); AB Science, S. A., Paris, France	This work was supported in part by funds from: INSERM (Institut National de la Sante de la Recherche Medicale), la Ligue Nationale Contre le Cancer, equipe labellisee (P. D. and J. I.); INCa (Institut National du Cancer - PACA in PACA project), Institut National du Cancer (O. H. and P. D.); and the Agence Nationale pour la Recherche, RIB project (P. D.). This study was financially supported by AB Science, S. A., Paris, France. The sponsor was involved in the study design, data analysis and interpretation, manuscript preparation and in the decision to submit the manuscript.	Bertucci F, 2006, CANCER RES, V66, P4636, DOI 10.1158/0008-5472.CAN-06-0031; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Chen J, 2006, CANCER LETT, V233, P328, DOI 10.1016/j.canlet.2005.03.027; Dubreuil P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007258; Duxbury MS, 2004, J AM COLL SURGEONS, V198, P953, DOI 10.1016/j.jamcollsurg.2004.01.037; Duxbury MS, 2003, BIOCHEM BIOPH RES CO, V311, P786, DOI 10.1016/j.bbrc.2003.10.060; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; Force T, 2007, NAT REV CANCER, V7, P332, DOI 10.1038/nrc2106; Giroux V, 2006, CLIN CANCER RES, V12, P235, DOI 10.1158/1078-0432.CCR-05-1700; Hahn KA, 2008, J VET INTERN MED, V22, P1301, DOI 10.1111/j.1939-1676.2008.0190.x; Hammel P, 2009, J CLIN ONCOL, V27; Hammond JR, 1999, J PHARMACOL EXP THER, V288, P1185; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Murtaugh L Charles, 2008, Organogenesis, V4, P81; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Ozawa F, 2001, TERATOGEN CARCIN MUT, V21, P27, DOI 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9; Saif MW, 2006, J PANCREAS, V7, P337; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; Sultana A, 2007, BRIT J CANCER, V96, P1183, DOI 10.1038/sj.bjc.6603719; Sultana A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-192; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tebib J, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2740; Trevino JG, 2006, AM J PATHOL, V168, P962, DOI 10.2353/ajpath.2006.050570; Yasuda A, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-46; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yokoi K, 2005, CANCER RES, V65, P10371, DOI 10.1158/0008-5472.CAN-05-1698	30	57	59	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 4	2010	5	3							e9430	10.1371/journal.pone.0009430	http://dx.doi.org/10.1371/journal.pone.0009430			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	564EW	20209107	gold, Green Published, Green Submitted			2023-01-03	WOS:000275197100002
J	Mtove, G; Amos, B; von Seidlein, L; Hendriksen, I; Mwambuli, A; Kimera, J; Mallahiyo, R; Kim, DR; Ochiai, RL; Clemens, JD; Reyburn, H; Magesa, S; Deen, JL				Mtove, George; Amos, Ben; von Seidlein, Lorenz; Hendriksen, Ilse; Mwambuli, Abraham; Kimera, Juma; Mallahiyo, Rajabu; Kim, Deok Ryun; Ochiai, R. Leon; Clemens, John D.; Reyburn, Hugh; Magesa, Stephen; Deen, Jacqueline L.			Invasive Salmonellosis among Children Admitted to a Rural Tanzanian Hospital and a Comparison with Previous Studies	PLOS ONE			English	Article							COMMUNITY-ACQUIRED BACTEREMIA; NON-TYPHOIDAL SALMONELLA; MALAWIAN CHILDREN; MALARIA TRANSMISSION; AFRICAN CHILDREN; FEVER; INFECTIONS; DISEASE; KENYA; PNEUMONIA	Background: The importance of invasive salmonellosis in African children is well recognized but there is inadequate information on these infections. We conducted a fever surveillance study in a Tanzanian rural hospital to estimate the case fraction of invasive salmonellosis among pediatric admissions, examine associations with common co-morbidities and describe its clinical features. We compared our main findings with those from previous studies among children in sub-Saharan Africa. Methodology/Principal Findings: From 1 March 2008 to 28 Feb 2009, 1,502 children were enrolled into the study. We collected clinical information and blood for point of care tests, culture, and diagnosis of malaria and HIV. We analyzed the clinical features on admission and outcome by laboratory-confirmed diagnosis. Pathogenic bacteria were isolated from the blood of 156 (10%) children, of which 14 (9%) were S. typhi, 45 (29%) were NTS and 97 (62%) were other pathogenic bacteria. Invasive salmonellosis accounted for 59/156 (38%) bacteremic children. Children with typhoid fever were significantly older and presented with a longer duration of fever. NTS infections were significantly associated with prior antimalarial treatment, malarial complications and with a high risk for death. Conclusions/Significance: Invasive salmonellosis, particularly NTS infection, is an important cause of febrile disease among hospitalized children in our rural Tanzanian setting. Previous studies showed considerable variation in the case fraction of S. typhi and NTS infections. Certain suggestive clinical features (such as older age and long duration of fever for typhoid whereas concomitant malaria, anemia, jaundice and hypoglycemia for NTS infection) may be used to distinguish invasive salmonellosis from other severe febrile illness.	[Mtove, George; Magesa, Stephen] Natl Inst Med Res, Amani Ctr, Tanga, Tanzania; [Mtove, George; Amos, Ben; von Seidlein, Lorenz; Hendriksen, Ilse; Mwambuli, Abraham; Kimera, Juma; Reyburn, Hugh; Magesa, Stephen; Deen, Jacqueline L.] Joint Malaria Programme, Moshi, Tanzania; [Amos, Ben; Kimera, Juma; Mallahiyo, Rajabu] Hosp Teule, Muheza, Tanga, Tanzania; [von Seidlein, Lorenz; Kim, Deok Ryun; Ochiai, R. Leon; Clemens, John D.; Deen, Jacqueline L.] Int Vaccine Inst, Seoul, South Korea; [Hendriksen, Ilse] Mahidol Oxford Res Unit, Bangkok, Thailand; [Reyburn, Hugh] London Sch Hyg & Trop Med, London WC1, England	International Vaccine Institute; Mahidol Oxford Tropical Medicine Research Unit (MORU); University of London; London School of Hygiene & Tropical Medicine	Mtove, G (corresponding author), Natl Inst Med Res, Amani Ctr, Tanga, Tanzania.	mtoveg2002@yahoo.co.uk	Amos, Ben/AAG-6934-2022; Amos, Ben/AFL-6820-2022	Amos, Ben/0000-0002-8569-1650; Amos, Ben/0000-0002-8569-1650; Ochiai, Leon/0000-0002-5079-6786; Mtove, George/0000-0001-5173-0829	Korean International Cooperation Agency through the International Vaccine Institute	Korean International Cooperation Agency through the International Vaccine Institute	This work was funded by a grant from the Korean International Cooperation Agency through the International Vaccine Institute (http://www.ivi.org/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachou H, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-160; Bahwere P, 2001, Int J Infect Dis, V5, P180, DOI 10.1016/S1201-9712(01)90067-0; Berkley J, 1999, T ROY SOC TROP MED H, V93, P283, DOI 10.1016/S0035-9203(99)90024-X; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Brent AJ, 2006, PEDIATR INFECT DIS J, V25, P230, DOI 10.1097/01.inf.0000202066.02212.ff; Brent AJ, 2006, LANCET, V367, P482, DOI 10.1016/S0140-6736(06)68180-4; Bronzan RN, 2007, J INFECT DIS, V195, P895, DOI 10.1086/511437; Cheesbrough JS, 1997, PEDIATR INFECT DIS J, V16, P277, DOI 10.1097/00006454-199703000-00005; DUGGAN MB, 1975, ARCH DIS CHILD, V50, P67, DOI 10.1136/adc.50.1.67; Edmonds S, 2009, HIV MED, V10, P26; Enwere G, 2006, PEDIATR INFECT DIS J, V25, P700, DOI 10.1097/01.inf.0000226839.30925.a5; Giglioli G, 1929, Proc R Soc Med, V23, P165; Graham SM, 2000, T ROY SOC TROP MED H, V94, P310, DOI 10.1016/S0035-9203(00)90337-7; Graham SM, 2002, CURR OPIN INFECT DIS, V15, P507, DOI 10.1097/00001432-200210000-00009; Graham SM, 2000, PEDIATR INFECT DIS J, V19, P1189, DOI 10.1097/00006454-200012000-00016; GREEN SDR, 1993, ANN TROP PAEDIATR, V13, P45, DOI 10.1080/02724936.1993.11747624; LEPAGE P, 1987, LANCET, V1, P1458; MABEY DCW, 1987, J INFECT DIS, V155, P1319, DOI 10.1093/infdis/155.6.1319; Mandomando I, 2009, TROP MED INT HEALTH, V14, P1467, DOI 10.1111/j.1365-3156.2009.02399.x; Maxwell CA, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-28; Morpeth SC, 2009, CLIN INFECT DIS, V49, P606, DOI 10.1086/603553; Mweu E, 2008, TROP MED INT HEALTH, V13, P532, DOI 10.1111/j.1365-3156.2008.02031.x; *NACP, 2007, UN REP TANZ; O'Meara WP, 2008, LANCET, V372, P1555, DOI 10.1016/S0140-6736(08)61655-4; Ochiai RL, 2008, B WORLD HEALTH ORGAN, V86, P260, DOI 10.2471/BLT.06.039818; ODEMPSEY TJD, 1994, PEDIATR INFECT DIS J, V13, P122, DOI 10.1097/00006454-199402000-00009; Samarasekera U, 2008, LANCET INFECT DIS, V8, P408, DOI 10.1016/S1473-3099(08)70136-1; Sigauque B, 2009, PEDIATR INFECT DIS J, V28, P108, DOI 10.1097/INF.0b013e318187a87d; Sinha A, 1999, LANCET, V354, P734, DOI 10.1016/S0140-6736(98)09001-1; *STAT NBO, 2002, UN REP TANZ NAT CENS; Walsh AL, 2000, PEDIATR INFECT DIS J, V19, P312, DOI 10.1097/00006454-200004000-00010; Williams TN, 2009, LANCET, V374, P1364, DOI 10.1016/S0140-6736(09)61374-X; World Health Organization, 2005, POCK HOSP CAR CHILDR	34	59	59	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2010	5	2							e9244	10.1371/journal.pone.0009244	http://dx.doi.org/10.1371/journal.pone.0009244			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	556KT	20168998	gold, Green Accepted, Green Published			2023-01-03	WOS:000274590500022
J	Singh, AK; Kumar, RP; Pandey, N; Singh, N; Sinha, M; Bhushan, A; Kaur, P; Sharma, S; Singh, TP				Singh, Amit K.; Kumar, Ramasamy P.; Pandey, Nisha; Singh, Nagendra; Sinha, Mau; Bhushan, Asha; Kaur, Punit; Sharma, Sujata; Singh, Tej P.			Mode of Binding of the Tuberculosis Prodrug Isoniazid to Heme Peroxidases BINDING STUDIES AND CRYSTAL STRUCTURE OF BOVINE LACTOPEROXIDASE WITH ISONIAZID AT 2.7 angstrom RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTHROMYCES-RAMOSUS PEROXIDASE; ISONICOTINIC-ACID HYDRAZIDE; X-RAY CRYSTALLOGRAPHY; MYCOBACTERIUM-TUBERCULOSIS; SALICYLHYDROXAMIC-ACID; HORSERADISH-PEROXIDASE; HUMAN MYELOPEROXIDASE; CATALASE-PEROXIDASE; BENZHYDROXAMIC ACID; OXIDATIVE STRESS	Isoniazid (INH) is an anti-tuberculosis prodrug that is activated by mammalian lactoperoxidase and Mycobacterium tuberculosis catalase peroxidase (MtCP). We report here binding studies, an enzyme assay involving INH, and the crystal structure of the complex of bovine lactoperoxidase (LPO) with INH to illuminate binding properties and INH activation as well as the mode of diffusion and interactions together with a detailed structural and functional comparison with MtCP. The structure determination shows that isoniazid binds to LPO at the substrate binding site on the distal heme side. The substrate binding site is connected to the protein surface through a long hydrophobic channel. The acyl hydrazide moiety of isoniazid interacts with Phe(422) O, Gln(423) O-epsilon 1, and Phe(254) O. In this arrangement, pyridinyl nitrogen forms a hydrogen bond with a water molecule, W-1, which in turn forms three hydrogen bonds with Fe3+, His(109) N epsilon 2, and Gln(105) N-epsilon 2. The remaining two sides of isoniazid form hydrophobic interactions with the atoms of heme pyrrole ring A, C-beta and C-gamma atoms of Glu(258), and C-gamma and C-delta atoms of Arg(255). The binding studies indicate that INH binds to LPO with a value of 0.9 x 10(-6) M for the dissociation constant. The nitro blue tetrazolium reduction assay shows that INH is activated by the reaction of LPO-H2O2 with INH. This suggests that LPO can be used for INH activation. It also indicates that the conversion of INH into isonicotinoyl radical by LPO may be the cause of INH toxicity.	[Singh, Amit K.; Kumar, Ramasamy P.; Pandey, Nisha; Singh, Nagendra; Sinha, Mau; Bhushan, Asha; Kaur, Punit; Sharma, Sujata; Singh, Tej P.] All India Inst Med Sci, Dept Biophys, New Delhi 110029, India	All India Institute of Medical Sciences (AIIMS) New Delhi	Singh, TP (corresponding author), All India Inst Med Sci, Dept Biophys, Ansari Nagar, New Delhi 110029, India.	tpsingh.aiims@gmail.com	Ramasamy, Prem Kumar/I-6801-2019	Ramasamy, Prem Kumar/0000-0002-6555-8289; SINHA, MAU/0000-0003-3011-9160				Bertrand T, 2004, J BIOL CHEM, V279, P38991, DOI 10.1074/jbc.M402382200; BHAT TN, 1974, ACTA CRYSTALLOGR B, V30, P2921, DOI 10.1107/S0567740874008521; Blair-Johnson M, 2001, BIOCHEMISTRY-US, V40, P13990, DOI 10.1021/bi0111808; BORS W, 1978, PHOTOCHEM PHOTOBIOL, V28, P629, DOI 10.1111/j.1751-1097.1978.tb06982.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CHARLAND MB, 1995, SIGMAPLOT SCI; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; Delano W.L, 2002, DELANO SCI; DEVI BG, 1975, BIOCHEM J, V149, P187, DOI 10.1042/bj1490187; DOERGE DR, 1994, CHEM RES TOXICOL, V7, P164, DOI 10.1021/tx00038a008; FERRARI RP, 1993, SPECTROCHIM ACTA A, V49, P1261, DOI 10.1016/0584-8539(93)80034-8; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Gerson C, 2000, AM J RESP CELL MOL, V22, P665, DOI 10.1165/ajrcmb.22.6.3980; Ghibaudi EM, 2000, REDOX REP, V5, P229, DOI 10.1179/135100000101535672; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; IKEDASAITO M, 1991, J BIOL CHEM, V266, P3611; Itakura H, 1997, FEBS LETT, V412, P107, DOI 10.1016/S0014-5793(97)00751-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Metcalfe C, 2008, J BIOL CHEM, V283, P6193, DOI 10.1074/jbc.M707412200; METODIEWA D, 1989, BIOCHEM BIOPH RES CO, V160, P1183, DOI 10.1016/S0006-291X(89)80128-7; METODIEWA D, 1989, ARCH BIOCHEM BIOPHYS, V274, P601, DOI 10.1016/0003-9861(89)90475-X; Monzani E, 1997, BIOCHEMISTRY-US, V36, P1918, DOI 10.1021/bi961868y; Oakley GG, 1996, CHEM RES TOXICOL, V9, P1285, DOI 10.1021/tx960103o; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pierattelli R, 2004, J BIOL CHEM, V279, P39000, DOI 10.1074/jbc.M402384200; POULOS TL, 1980, J BIOL CHEM, V255, P575; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMAKRISHNA NVS, 1993, CHEM RES TOXICOL, V6, P837, DOI 10.1021/tx00036a013; Sawatdee S, 2006, MALAYS J PHARM SCI, V4, P43; Sharp KH, 2003, NAT STRUCT BIOL, V10, P303, DOI 10.1038/nsb913; Sheikh IA, 2009, J BIOL CHEM, V284, P14849, DOI 10.1074/jbc.M807644200; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; Singh AK, 2009, BIOPHYS J, V96, P646, DOI 10.1016/j.bpj.2008.09.019; Singh AK, 2009, J BIOL CHEM, V284, P20311, DOI 10.1074/jbc.M109.010280; Singh AK, 2008, J MOL BIOL, V376, P1060, DOI 10.1016/j.jmb.2007.12.012; SIPE HJ, 1994, CARCINOGENESIS, V15, P2637, DOI 10.1093/carcin/15.11.2637; STEVENS FJ, 1987, MOL IMMUNOL, V24, P1055, DOI 10.1016/0161-5890(87)90073-3; Tsukamoto K, 1999, BIOCHEMISTRY-US, V38, P12558, DOI 10.1021/bi982925l; Welinder K.G., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; Wijkstrom-Frei C, 2003, AM J RESP CELL MOL, V29, P206, DOI 10.1165/rcmb.2002-0152OC; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5; ZHANG HC, 1993, CAN J CHEM, V71, P1990, DOI 10.1139/v93-248; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; Zhao XB, 2007, BIOCHEMISTRY-US, V46, P3161, DOI 10.1021/bi062218p	49	36	36	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 8	2010	285	2					1569	1576		10.1074/jbc.M109.060327	http://dx.doi.org/10.1074/jbc.M109.060327			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539MH	19907057	Green Published, hybrid			2023-01-03	WOS:000273258200075
J	Gianni, L; Eiermann, W; Semiglazov, V; Manikhas, A; Lluch, A; Tjulandin, S; Zambetti, M; Vazquez, F; Byakhow, M; Lichinitser, M; Climent, MA; Ciruelos, E; Ojeda, B; Mansutti, M; Bozhok, A; Baronio, R; Feyereislova, A; Barton, C; Valagussa, P; Baselga, J				Gianni, Luca; Eiermann, Wolfgang; Semiglazov, Vladimir; Manikhas, Alexey; Lluch, Ana; Tjulandin, Sergey; Zambetti, Milvia; Vazquez, Federico; Byakhow, Mikhail; Lichinitser, Mikhail; Angel Climent, Miguel; Ciruelos, Eva; Ojeda, Belen; Mansutti, Mauro; Bozhok, Alla; Baronio, Roberta; Feyereislova, Andrea; Barton, Claire; Valagussa, Pinuccia; Baselga, Jose			Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort	LANCET			English	Article							COMPARING DOXORUBICIN; MONOCLONAL-ANTIBODY; PHASE-II; CYCLOPHOSPHAMIDE; PACLITAXEL; EFFICACY; RECEPTOR; THERAPY; SAFETY; PLUS	Background The monoclonal antibody trastuzumab has survival benefit when given with chemotherapy to patients with early, operable, and metastatic breast cancer that has HER2 (also known as ERBB2) overexpression or amplification. We aimed to assess event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer receiving neoadjuvant chemotherapy with or without 1 year of trastuzumab. Methods We compared I year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment; n=117) with no trastuzumab (118), in women with HER2-positive locally advanced or inflammatory breast cancer treated with a neoadjuvant chemotherapy regimen consisting of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and fluorouracil. Randomisation was done with a computer program and minimisation technique, taking account of geographical area, disease stage, and hormone receptor status. investigators were informed of treatment allocation. A parallel cohort of 99 patients with HER2-negative disease was included and treated with the same chemotherapy regimen. Primary endpoint was event-free survival. Analysis was by intention to treat. This study is registered, number ISRCTN86043495. Findings Trastuzumab significantly improved event-free survival in patients with HER2-positive breast cancer (3-year event-free survival, 71% [95% CI 61-78; n=36 events] with trastuzumab, vs 56% [46-65; n=51 events] without; hazard ratio 0.59 [95% CI 0.38-0.90]; p=0.013). Trastuzumab was well tolerated and, despite concurrent administration with doxorubicin, only two patients (2%) developed symptomatic cardiac failure. Both responded to cardiac drugs. Interpretation The addition of neoadjuvant and adjuvant trastuzumab to neoadjuvant chemotherapy should be considered for women with HER2-positive locally advanced or inflammatory breast cancer to improve event-free survival, survival, and clinical and pathological turnout responses.	[Gianni, Luca; Zambetti, Milvia] Fdn IRCCS Ist Nazl Tumori, I-20133 Milan, Italy; [Eiermann, Wolfgang] Frauenklin vom Roten Kreuz, Munich, Germany; [Semiglazov, Vladimir; Bozhok, Alla] NN Petrov Oncol Res Inst, St Petersburg, Russia; [Manikhas, Alexey] City Oncol Hosp, St Petersburg, Russia; [Lluch, Ana] Hosp Clin Univ Valencia, Valencia, Spain; [Tjulandin, Sergey; Lichinitser, Mikhail] NN Blokhin Russian Canc Ctr, Moscow, Russia; [Vazquez, Federico; Baselga, Jose] Vall dHebron Univ Hosp, Barcelona, Spain; [Byakhow, Mikhail] Cent Clin Hosp, Moscow, Russia; [Angel Climent, Miguel] Ist Valenciano Oncol, Valencia, Spain; [Ciruelos, Eva] Hosp Univ 12 Octubre, Madrid, Spain; [Ojeda, Belen] Hosp San Pau, Barcelona, Spain; [Mansutti, Mauro] Osped S Maria Misericordia, Udine, Italy; [Baronio, Roberta; Valagussa, Pinuccia] Fdn Michelangelo, Milan, Italy; [Feyereislova, Andrea; Barton, Claire] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland	Fondazione IRCCS Istituto Nazionale Tumori Milan; N.N. Petrov Research Institute of Oncology; Hospital Clinic Universitari de Valencia; N.N. Blokhin Russian Cancer Research Center; Hospital Universitari Vall d'Hebron; Instituto Valenciano De Oncologia; Hospital Universitario 12 de Octubre; Hospital Santa Maria della Misericordia; Roche Holding	Gianni, L (corresponding author), Fdn IRCCS Ist Nazl Tumori, 1 Via Venezian, I-20133 Milan, Italy.	luca.gianni@istitutotumori.mi.it	Lluch, Ana/R-5493-2019; Manikhas, Alexey/ABI-7193-2020; Mieszkowska, Magdalena/O-6753-2017	Lluch, Ana/0000-0003-2766-407X; Semiglazov, Vladimir/0000-0003-0077-9619; Ciruelos, Eva/0000-0002-2796-1042; GIANNI, LUCA/0000-0002-2372-9625; Manikhas, Alexey/0000-0001-9616-6635; Valagussa, Pinuccia/0000-0003-3590-7916	GlaxoSmithKline; F Hoffmann-La Roche	GlaxoSmithKline(GlaxoSmithKline); F Hoffmann-La Roche(Hoffmann-La Roche)	LG has served on scientific advisory boards for Roche, Genentech, GlaxoSimthKline, Wyeth, Novartis, Millennium, Biogenldec, and Eisai. I B has had consultant or advisory roles for Exelixis, Merck, Novartis, and Roche, and has received research Funding from GlaxoSmithKline. AF is employed by Roche. CB has been employed by Roche, has held consultancies for ONO Pharma, Cellact, Acacia, Michelangelo, BTG Ltd, Kuros Biosurgery, Micromet AG, Bioenvision, Norgine, and Piramed, and has field stock in GlaxoSmithKline. WE, VS, AM, AL, ST MZ, FV, MB, ML, MAC, EC, BO, MM, AB, RB, and PV declare that they have no conflicts of interest.; F Hoffmann-La Roche provided trasnizurnalk and financial support. We thank all the patients who have participated in our trial, the many associates, in particular medical oncologists, surgeons, radiation therapists, pathologists, research nurses, and data managers for their cooperation, and Alberto Berti, Lidia Mariani, and Claudia Tomezzoli from the Michelangelo operations office and Viviana Beritata from SOLTI for study coordination and data management. Data from this trial have previously been presented at international conferences (Baselga et al, ECCO 2007; Eiermann et al, EBCC7 2008; Semiglazov et al, EBCC7 2008).	Baselga J, 2007, EJC SUPPL, V5, P193, DOI 10.1016/S1359-6349(07)70792-9; Baselga J, 2005, J CLIN ONCOL, V23, P2162, DOI 10.1200/JCO.2005.01.014; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Bianchi G, 2003, CLIN CANCER RES, V9, P5944; Bonadonna G, 1998, J CLIN ONCOL, V16, P93, DOI 10.1200/JCO.1998.16.1.93; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Chia S, 2008, J CLIN ONCOL, V26, P786, DOI 10.1200/JCO.2008.15.0243; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Collett D., 1994, MODELLING SURVIVAL D; Eiermann W, 2008, EJC SUPPL, V6, P115, DOI 10.1016/S1359-6349(08)70544-5; Gianni L, 2001, ANN ONCOL, V12, P1067, DOI 10.1023/A:1011655503511; Gianni L, 2007, J CLIN ONCOL, V25, P3389, DOI 10.1200/JCO.2007.10.9504; Gianni L, 2009, J CLIN ONCOL, V27, P2474, DOI 10.1200/JCO.2008.19.2567; Gluck Stefan, 2008, Int J Med Sci, V5, P341; Hance KW, 2005, JNCI-J NATL CANCER I, V97, P966, DOI 10.1093/jnci/dji172; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; *NAT CANC I, COMM TOX CRIT VERS 2; Perez EA, 2008, J CLIN ONCOL, V26, P1231, DOI 10.1200/JCO.2007.13.5467; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Ross JS, 2009, ONCOLOGIST, V14, P320, DOI 10.1634/theoncologist.2008-0230; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sant M, 2004, CANCER-AM CANCER SOC, V100, P715, DOI 10.1002/cncr.20038; SEMINGLAZOV V, 2008, EJC SUPPL, V6, P115; Shaye OS, 2007, J CLIN ONCOL, V25; Slamon D, 2005, BREAST CANCER RES TR, V94, pS5; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Tan-Chiu E, 2005, J CLIN ONCOL, V23, P7811, DOI 10.1200/JCO.2005.02.4091; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Untch M, 2008, 6 EUR BREAST CANC C; Zell JA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2225	32	846	902	3	78	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2010	375	9712					377	384		10.1016/S0140-6736(09)61964-4	http://dx.doi.org/10.1016/S0140-6736(09)61964-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	552PK	20113825				2023-01-03	WOS:000274305500025
J	Paulden, M; Palmer, S; Hewitt, C; Gilbody, S				Paulden, Mike; Palmer, Stephen; Hewitt, Catherine; Gilbody, Simon			Screening for postnatal depression in primary care: cost effectiveness analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPECIFICITY; IMPACT; METAANALYSIS; SENSITIVITY	Objective To evaluate the cost effectiveness of routine screening for postnatal depression in primary care. Design Cost effectiveness analysis with a decision model of alternative methods of screening for depression, including standardised postnatal depression and generic depression instruments. The performance of screening instruments was derived from a systematic review and bivariate meta-analysis at a range of instrument cut points; estimates of other relevant parameters were derived from literature sources and relevant databases. A decision tree considered the full treatment pathway from the possible onset of postnatal depression through identification, treatment, and possible relapse. Setting Primary care. Participants A hypothetical population of women assessed for postnatal depression either via routine care only or supplemented by use of formal identification methods six weeks postnatally, as recommended in recent guidelines. Main outcome measures Costs expressed in 2006-7 prices and impact on health outcomes expressed in terms of quality adjusted life years (QALYs). The time horizon of the analysis was one year. Results The routine application of either postnatal or general depression questionnaires did not seem to be cost effective compared with routine care only. The Edinburgh postnatal depression scale (at a cut point of 16) had an incremental cost effectiveness ratio (ICER) of 41 pound 103 ((sic)45 398, $67 130) per QALY compared with routine care only. The ICER for all other strategies ranged from 49 pound 928 to 272 pound 463 per QALY versus routine care only, while the probability that no formal identification strategy was cost effective was 88% (59%) at a cost effectiveness threshold of 20 pound 000 (30 pound 000) per QALY. While sensitivity analysis indicated that the cost of managing incorrectly identified depression (false positive result) was an important driver of the model, formal identification approaches did not seem to be cost effective at any feasible estimate of this cost. Conclusions Formal identification methods for postnatal depression do not seem to represent value for money for the NHS. The major determinant of cost effectiveness seems to be the potential additional costs of managing women incorrectly diagnosed as depressed. Formal identification methods for postnatal depression do not currently satisfy the National Screening Committee's criteria for the adoption of a screening strategy as part of national health policy.	[Gilbody, Simon] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England	University of York - UK	Paulden, M (corresponding author), Univ Toronto, Toronto Hlth Econ & Technol Assessment THETA Coll, Leslie Dan Pharm Bldg,144 Coll St, Toronto, ON M5S 3M2, Canada.	mike.paulden@theta.utoronto.ca	Paulden, Michael/E-2061-2016; Gilbody, Simon/E-6543-2010; Gilbody, Simon/AAY-3720-2021	Gilbody, Simon/0000-0002-8236-6983; Hewitt, Catherine Elizabeth/0000-0002-0415-3536; Paulden, Mike/0000-0002-0381-5980	NIHR Health Technology Assessment (HTA) Programme [05/39/06]; National Institute for Health Research [05/39/06] Funding Source: researchfish	NIHR Health Technology Assessment (HTA) Programme; National Institute for Health Research(National Institute for Health Research (NIHR))	This study was funded by the NIHR Health Technology Assessment (HTA) Programme (HTA project grant 05/39/06). The funding source had no role in study design, conduct, data collection, data analysis, or data interpretation or in the decision to submit the manuscript for publication.	Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; [Anonymous], 2005, PERINATAL DEPRESSION; Arroll B, 2005, BRIT MED J, V331, P884, DOI 10.1136/bmj.38607.464537.7C; Briggs A, 2006, DECISION MODELLING H; Chisholm D, 1997, SOC PSYCH PSYCH EPID, V32, P68, DOI 10.1007/BF00788923; Chu HT, 2006, J CLIN EPIDEMIOL, V59, P1331, DOI 10.1016/j.jclinepi.2006.06.011; COGILL SR, 1986, BMJ-BRIT MED J, V292, P1165, DOI 10.1136/bmj.292.6529.1165; Cox J.L., 1998, J REPROD INFANT PSYC, V16, P199, DOI DOI 10.1080/02646839808404568; CURTIS K, 2007, UNIT COSTS HLTH SOCI; Hearn G, 1998, BRIT J GEN PRACT, V48, P1064; Hendrick V, 2003, BRIT MED J, V327, P1003, DOI 10.1136/bmj.327.7422.1003; Henshaw C., 2005, SCREENING PERINATAL; Hewitt CE, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13360; Higgins JPT, 2009, J R STAT SOC A STAT, V172, P137, DOI 10.1111/j.1467-985X.2008.00552.x; JOHANNESSON M, 1995, HEALTH POLICY, V31, P225, DOI 10.1016/0168-8510(95)98130-T; Kessler D, 2002, BRIT MED J, V325, P1016, DOI 10.1136/bmj.325.7371.1016; LOVESTONE S, 1993, BRIT J PSYCHIAT, V163, P210, DOI 10.1192/bjp.163.2.210; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Murray L, 1999, J CHILD PSYCHOL PSYC, V40, P1259, DOI 10.1111/1469-7610.00542; Murray L, 1996, CHILD DEV, V67, P2512, DOI 10.2307/1131637; National Institute for Health and Clinical Excellence (NICE), 2008, GUID METH TECHN APPR; National Screening Committee, 2003, UK NAT SCREEN COMM C; NICE, 2007, ANT POSTN MENT HLTH; *PEARS, BECK DEPR INV 2 BDI; Reitsma JB, 2005, J CLIN EPIDEMIOL, V58, P982, DOI 10.1016/j.jclinepi.2005.02.022; Revicki DA, 1998, J AFFECT DISORDERS, V48, P25, DOI 10.1016/S0165-0327(97)00117-1; Shakespeare J., 2005, SCREENING PERINATAL, P21; *UK NAT SCREEN COM, 2009, CRIT APR VIAB EFF AP	28	88	88	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 22	2009	339								b5203	10.1136/bmj.b5203	http://dx.doi.org/10.1136/bmj.b5203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	536ZJ	20028779	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000273082200006
J	Er, F; Nia, AM; Gassanov, N; Caglayan, E; Erdmann, E; Hoppe, UC				Er, Fikret; Nia, Amir M.; Gassanov, Natig; Caglayan, Evren; Erdmann, Erland; Hoppe, Uta C.			Impact of Rescue-Thrombolysis during Cardiopulmonary Resuscitation in Patients with Pulmonary Embolism	PLOS ONE			English	Article							CARDIAC-ARREST; MANAGEMENT; GUIDELINES; ECHOCARDIOGRAPHY; DIAGNOSIS; REGISTRY	Background: Cardiac arrest in patients with pulmonary embolism (PE) is associated with high morbidity and mortality. Thrombolysis is expected to improve the outcome in these patients. However studies evaluating rescue-thrombolysis in patients with PE are missing, mainly due to the difficulties of clinical diagnosis of PE. We aimed to determine the success influencing factors of thrombolysis during resuscitation in patients with PE. Methodology/Principal Findings: We analyzed retrospectively the outcome of 104 consecutive patients with confirmed (n = 63) or highly suspected (n = 41) PE and monitored cardiac arrest. In all patients rtPA was administrated for thrombolysis during cardiopulmonary resuscitation. In 40 of the 104 patients (38.5%) a return of spontaneous circulation (ROSC) could be achieved successfully. Patients with ROSC received thrombolysis significantly earlier after CPR onset compared to patients without ROSC (13.6+/-1.2 min versus 24.6+/-0.8 min; p<0.001). 19 patients (47.5%) out of the 40 patients with initially successful resuscitation survived to hospital discharge. In patients with hospital discharge thrombolysis therapy was begun with a significantly shorter delay after cardiac arrest compared to all other patients (11.0+/-1.3 vs. 22.5+/-0.9 min; p<0.001). Conclusion: Rescue-thrombolysis should be considered and started in patients with PE and cardiac arrest, as soon as possible after cardiac arrest onset.	[Er, Fikret; Nia, Amir M.; Gassanov, Natig; Caglayan, Evren; Erdmann, Erland; Hoppe, Uta C.] Univ Cologne, Dept Internal Med 2, Cologne, Germany; [Hoppe, Uta C.] Univ Cologne, Ctr Mol Med, CMMC, Cologne, Germany	University of Cologne; University of Cologne	Er, F (corresponding author), Univ Cologne, Dept Internal Med 2, Cologne, Germany.	Fikret.Er@uk-koeln.de	Caglayan, Evren/ABB-8674-2020		Center for Molecular Medicine Cologne, Cologne, Germany	Center for Molecular Medicine Cologne, Cologne, Germany	The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding source: Center for Molecular Medicine Cologne, Cologne, Germany.	Abu-Laban RB, 2002, NEW ENGL J MED, V346, P1522, DOI 10.1056/NEJMoa012885; Aklog L, 2002, CIRCULATION, V105, P1416, DOI 10.1161/01.CIR.0000012526.21603.25; Bailen MR, 2001, CRIT CARE MED, V29, P2211, DOI 10.1097/00003246-200111000-00027; Bottiger BW, 2008, NEW ENGL J MED, V359, P2651, DOI 10.1056/NEJMoa070570; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; Goran KP, 2008, EUR HEART J, V29, P3066, DOI 10.1093/eurheartj/ehn474; HOFFMANN B, 2009, THROMB RES; Jardin F, 1997, CHEST, V111, P209, DOI 10.1378/chest.111.1.209; JARDIN F, 1991, PRESSE MED, V20, P2085; JENNETT B, 1975, LANCET, V1, P480; Kasper W, 1997, J AM COLL CARDIOL, V30, P1165, DOI 10.1016/S0735-1097(97)00319-7; LUALDI JC, 1995, AM HEART J, V130, P1276, DOI 10.1016/0002-8703(95)90155-8; SOLOFF LA, 1967, AM HEART J, V74, P710, DOI 10.1016/0002-8703(67)90510-8; Torbicki A, 2008, EUR HEART J, V29, P2276, DOI 10.1093/eurheartj/ehn310; vanderWouw PA, 1997, J AM COLL CARDIOL, V30, P780, DOI 10.1016/S0735-1097(97)00218-0; Wells PS, 1998, ANN INTERN MED, V129, P997, DOI 10.7326/0003-4819-129-12-199812150-00002; 2000, EUR HEART J, V21, P1301	17	24	27	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 15	2009	4	12							e8323	10.1371/journal.pone.0008323	http://dx.doi.org/10.1371/journal.pone.0008323			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	533ON	20016808	Green Submitted, Green Published, gold			2023-01-03	WOS:000272833800017
J	Vedula, SS; Bero, L; Scherer, RW; Dickersin, K				Vedula, S. Swaroop; Bero, Lisa; Scherer, Roberta W.; Dickersin, Kay			Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PAINFUL DIABETIC-NEUROPATHY; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; CLINICAL-TRIALS; PHARMACEUTICAL-INDUSTRY; MIGRAINE PROPHYLAXIS; BIPOLAR DISORDER; PUBLICATION; REGISTRATION	Background: There is good evidence of selective outcome reporting in published reports of randomized trials. Methods: We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (prophylaxis against migraine and treatment of bipolar disorders, neuropathic pain, and nociceptive pain), comparing internal company documents with published reports. Results: We identified 20 clinical trials for which internal documents were available from Pfizer and Parke-Davis; of these trials, 12 were reported in publications. For 8 of the 12 reported trials, the primary outcome defined in the published report differed from that described in the protocol. Sources of disagreement included the introduction of a new primary outcome (in the case of 6 trials), failure to distinguish between primary and secondary outcomes (2 trials), relegation of primary outcomes to secondary outcomes (2 trials), and failure to report one or more protocol-defined primary outcomes (5 trials). Trials that presented findings that were not significant (P greater/equal 0.05) for the protocol-defined primary outcome in the internal documents either were not reported in full or were reported with a changed primary outcome. The primary outcome was changed in the case of 5 of 8 published trials for which statistically significant differences favoring gabapentin were reported. Of the 21 primary outcomes described in the protocols of the published trials, 6 were not reported at all and 4 were reported as secondary outcomes. Of 28 primary outcomes described in the published reports, 12 were newly introduced. Conclusions: We identified selective outcome reporting for trials of off-label use of gabapentin. This practice threatens the validity of evidence for the effectiveness of off-label interventions. N Engl J Med 2009;361:1963-71.	[Vedula, S. Swaroop; Scherer, Roberta W.; Dickersin, Kay] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Clin Trials, Dept Epidemiol, Baltimore, MD USA; [Bero, Lisa] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA; [Bero, Lisa] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vedula, SS (corresponding author), 615 N Wolfe St, Baltimore, MD 21205 USA.	svedula@jhsph.edu		Bero, Lisa/0000-0003-1893-6651				Backonja M, 1998, JAMA-J AM MED ASSOC, V280, P1831, DOI 10.1001/jama.280.21.1831; Backonja M, 2003, CLIN THER, V25, P81, DOI 10.1016/S0149-2918(03)90011-7; BACKONJA M, 2002, EUR J NEUROL S2, V9, P191; BACKONJA M, 1997, 16 ANN SCI M AM PAIN; Caraceni A, 2004, J CLIN ONCOL, V22, P2909, DOI 10.1200/jco.2004.08.141; Chan AW, 2004, CAN MED ASSOC J, V171, P735, DOI 10.1503/cmaj.1041086; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Dallocchio C, 2000, J PAIN SYMPTOM MANAG, V20, P280, DOI 10.1016/S0885-3924(00)00181-0; De Angelis C, 2004, ANN INTERN MED, V141, P477, DOI 10.7326/0003-4819-141-6-200409210-00109; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; Dickersin K, 2003, JAMA-J AM MED ASSOC, V290, P516, DOI 10.1001/jama.290.4.516; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; Dickersin K, 2005, PUBLICATION BIAS IN META-ANALYSIS: PREVENTION, ASSESSMENT AND ADJUSTMENTS, P11; Djulbegovic B, 2000, LANCET, V356, P635, DOI 10.1016/S0140-6736(00)02605-2; Evans Scott, 2007, PLoS Clin Trials, V2, pe18, DOI 10.1371/journal.pctr.0020018; FRIEDMAN LM, 1998, FUNDAMENTALS CLIN TR, P284; Gomez-Perez FJ, 2004, BRIT J DIABETES VASC, V4, P173; GOMEZPEREZ FJ, 2002, 5 INT C MECH TREATM; GORDH TE, 2002, 10 WORLD C PAIN SAN; Gordh TE, 2008, PAIN, V138, P255, DOI 10.1016/j.pain.2007.12.011; Gorson KC, 1999, J NEUROL NEUROSUR PS, V66, P251, DOI 10.1136/jnnp.66.2.251; Gorson KC, 1998, NEUROLOGY, V50, pA103; Gulmezoglu AM, 2005, LANCET, V365, P1829, DOI 10.1016/S0140-6736(05)66589-0; Hill KP, 2008, ANN INTERN MED, V149, P251, DOI 10.7326/0003-4819-149-4-200808190-00006; Jureidini JN, 2008, INT J RISK SAF MED, V29, P73, DOI DOI 10.3233/JRS-2008-0426; Krleza-Jeric K, 2005, BMJ-BRIT MED J, V330, P956, DOI 10.1136/bmj.330.7497.956; Krleza-Jeric K, 2005, BMJ-BRIT MED J, V330, P1258; Lee K, 2008, PLOS MED, V5, P1348, DOI 10.1371/journal.pmed.0050191; Lexchin J, 2003, BMJ-BRIT MED J, V326, P1167, DOI 10.1136/bmj.326.7400.1167; Mathew NT, 1999, CEPHALALGIA, V19, P380; Mathew NT, 2001, HEADACHE, V41, P119, DOI 10.1046/j.1526-4610.2001.111006119.x; MATHEW NT, 1998, 17 ANN SCI M AM PAIN; Melander H, 2003, BMJ-BRIT MED J, V326, P1171, DOI 10.1136/bmj.326.7400.1171; Nissen SE, 2007, NEW ENGL J MED, V357, P100; Olson CM, 2002, JAMA-J AM MED ASSOC, V287, P2825, DOI 10.1001/jama.287.21.2825; Pande AC, 2000, BIPOLAR DISORD, V2, P249, DOI 10.1034/j.1399-5618.2000.20305.x; Psaty BM, 2008, JAMA-J AM MED ASSOC, V299, P1949, DOI 10.1001/jama.299.16.1949; Psaty BM, 2008, JAMA-J AM MED ASSOC, V299, P1813, DOI 10.1001/jama.299.15.1813; Rising K, 2009, PLOS MED, V6, P117, DOI 10.1371/journal.pmed.1000017; Rising K, 2008, PLOS MED, V5, P1561, DOI 10.1371/journal.pmed.0050217; Serpell MG, 2002, PAIN, V99, P557, DOI 10.1016/S0304-3959(02)00255-5; SERPELL MG, 2002, 5 INT C MECH TREATM; Sismondo S, 2008, CONTEMP CLIN TRIALS, V29, P109, DOI 10.1016/j.cct.2007.08.001; Steinman MA, 2006, ANN INTERN MED, V145, P284, DOI 10.7326/0003-4819-145-4-200608150-00008; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779; Vieta E, 2006, J CLIN PSYCHIAT, V67, P473, DOI 10.4088/JCP.v67n0320; Wang PW, 2002, BIPOLAR DISORD, V4, P296, DOI 10.1034/j.1399-5618.2002.01211.x; Wessely P, 1987, CEPHALALGIA, V7, P477; Wiffen PJ, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD005452, 10.1002/14651858.CD005451]	49	232	235	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 12	2009	361	20					1963	1971		10.1056/NEJMsa0906126	http://dx.doi.org/10.1056/NEJMsa0906126			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	518AI	19907043	Bronze			2023-01-03	WOS:000271660500010
J	Klein, MB; Kramer, CB; Nelson, J; Rivara, FP; Gibran, NS; Concannon, T				Klein, Matthew B.; Kramer, C. Bradley; Nelson, Jason; Rivara, Frederick P.; Gibran, Nicole S.; Concannon, Thomas			Geographic Access to Burn Center Hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMA; TRANSPORT; CARE; RESUSCITATION; INJURIES; TIMES	Context The delivery of burn care is a resource-intensive endeavor that requires specialized personnel and equipment. The optimal geographic distribution of burn centers has long been debated; however, the current distribution of centers relative to geographic area and population is unknown. Objective To estimate the proportion of the US population living within 1 and 2 hours by rotary air transport ( helicopter) or ground transport of a burn care facility. Design and Setting A cross-sectional analysis of geographic access to US burn centers utilizing the 2000 US census, road and speed limit data, the Atlas and Database of Air Medical Services database, and the 2008 American Burn Association Directory. Main Outcome Measure The proportion of state, regional, and national population living within 1 and 2 hours by air transport or ground transport of a burn care facility. Results In 2008, there were 128 self-reported burn centers in the United States including 51 American Burn Association-verified centers. An estimated 25.1% and 46.3% of the US population live within 1 and 2 hours by ground transport, respectively, of a verified burn center. By air, 53.9% and 79.0% of the population live within 1 and 2 hours, respectively, of a verified center. There was significant regional variation in access to verified burn centers by both ground and rotary air transport. The greatest proportion of the population with access was highest in the northeast region and lowest in the southern United States. Conclusion Nearly 80% of the US population lives within 2 hours by ground or rotary air transport of a verified burn center; however, there is both state and regional variation in geographic access to these centers. JAMA. 2009; 302( 16):1774-1781 www.jama.com	[Klein, Matthew B.; Kramer, C. Bradley; Gibran, Nicole S.] Univ Washington, Burn Ctr, Seattle, WA 98195 USA; [Klein, Matthew B.] Univ Washington, Div Plast Surg, Seattle, WA 98195 USA; [Rivara, Frederick P.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Rivara, Frederick P.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Nelson, Jason; Concannon, Thomas] Tufts Univ, Sch Med, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA; [Nelson, Jason; Concannon, Thomas] Tufts Med Ctr, Boston, MA USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Tufts University; Tufts Medical Center	Klein, MB (corresponding author), Harborview Med Ctr, UW Burn Ctr, 325 Ninth Ave,POB 359796, Seattle, WA 98104 USA.	mbklein@u.washington.edu	Concannon, Thomas/A-1610-2013		National Center for Research Resources [1KL2RR025015-01]; Centers for Disease Control and Prevention [R49/CE000197]; David and Nancy Auth-Washington Research Foundation Endowment; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000423] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL [R49CE000197] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025015] Funding Source: NIH RePORTER	National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); David and Nancy Auth-Washington Research Foundation Endowment; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by the National Center for Research Resources grant 1KL2RR025015-01, Harborview Injury Prevention and Research Center (HIPRC) grant R49/CE000197 from the Centers for Disease Control and Prevention, and by the David and Nancy Auth-Washington Research Foundation Endowment.	*AM BURN ASS, BURN CAR FAC US; American Burn Association, BURN INC TREATM US 2; Berkebile B L, 1986, J Burn Care Rehabil, V7, P411, DOI 10.1097/00004630-198609000-00007; Branas CC, 2000, HEALTH SERV RES, V35, P489; Branas Charles C, 2005, LDI Issue Brief, V11, P1; Carr BG, 2006, PREHOSP EMERG CARE, V10, P198, DOI 10.1080/10903120500541324; *CTR TRANSP INJ RE, 2006, ATL DAT AIR MED SERV; Diaz MA, 2005, J TRAUMA, V58, P148, DOI 10.1097/01.TA.0000124264.43941.41; Falcone R E, 1998, Air Med J, V17, P161, DOI 10.1016/S1067-991X(98)90043-8; Faucher LD, 2004, J BURN CARE REHABIL, V25, P464, DOI 10.1097/01.BCR.0000144534.93523.DC; HAMMOND JS, 1987, J TRAUMA, V27, P1161, DOI 10.1097/00005373-198710000-00011; Ivy ME, 2000, J TRAUMA, V49, P387, DOI 10.1097/00005373-200009000-00001; KEARNEY PA, 1991, ANN EMERG MED, V20, P882, DOI 10.1016/S0196-0644(05)81431-3; Klein MB, 2006, BURNS, V32, P940, DOI 10.1016/j.burns.2006.04.001; Klein MB, 2007, J BURN CARE RES, V28, P49, DOI 10.1097/BCR.0B013E31802C894B; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; O'Mara MS, 2005, J TRAUMA, V58, P1011, DOI 10.1097/01.TA.0000162732.39083.15; PALMER JH, 1987, INJURY, V18, P250, DOI 10.1016/0020-1383(87)90008-8; Pruitt B A Jr, 1979, J Trauma, V19, P868; Pruitt BA, 2000, J TRAUMA, V49, P567, DOI 10.1097/00005373-200009000-00030; Rogers FB, 1999, J TRAUMA, V46, P328, DOI 10.1097/00005373-199902000-00022; Saffle JR, 2004, J TRAUMA, V57, P57, DOI 10.1097/01.TA.0000103992.21727.8F; Sheridan R, 1999, J BURN CARE REHABIL, V20, P347, DOI 10.1097/00004630-199909000-00002; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; The American College of Surgeons, 2006, RES OPT CAR INJ PAT; Warden GD, 2003, J BURN CARE REHABIL, V24, P173, DOI 10.1097/01.BCR.0000066784.94077.C6; Wong K, 2004, ANZ J SURG, V74, P318, DOI 10.1111/j.1445-1433.2003.02738.x; Young JS, 1998, AM SURGEON, V64, P88; ZONIES D, 2009, J BURN CARE RES, V30, pS85, DOI DOI 10.1097/BCR0B013E3181998FC2	29	84	84	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	2009	302	16					1774	1781		10.1001/jama.2009.1548	http://dx.doi.org/10.1001/jama.2009.1548			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	511FW	19861669	Bronze, Green Accepted			2023-01-03	WOS:000271150300020
J	Saxena, S; Bottle, A; Gilbert, R; Sharland, M				Saxena, Sonia; Bottle, Alex; Gilbert, Ruth; Sharland, Mike			Increasing Short-Stay Unplanned Hospital Admissions among Children in England; Time Trends Analysis '97-'06	PLOS ONE			English	Article							PRESCHOOL-CHILDREN; HEALTH-SERVICES; UNITED-STATES; ACUTELY ILL; CARE; CONTINUITY; PARENTS; CHILDHOOD; PROVIDER; QUALITY	Background: Timely care by general practitioners in the community keeps children out of hospital and provides better continuity of care. Yet in the UK, access to primary care has diminished since 2004 when changes in general practitioners' contracts enabled them to 'opt out' of providing out-of-hours care and since then unplanned pediatric hospital admission rates have escalated, particularly through emergency departments. We hypothesised that any increase in isolated short stay admissions for childhood illness might reflect failure to manage these cases in the community over a 10 year period spanning these changes. Methods and Findings: We conducted a population based time trends study of major causes of hospital admission in children <10 years using the Hospital Episode Statistics database, which records all admissions to all NHS hospitals in England using ICD10 codes. Outcomes measures were total and isolated short stay unplanned hospital admissions (lasting less than 2 days without readmission within 28 days) from 1997 to 2006. Over the period annual unplanned admission rates in children aged <10 years rose by 22% (from 73.6/1000 to 89.5/1000 child years) with larger increases of 41% in isolated short stay admissions (from 42.7/1000 to 60.2/1000 child years). There was a smaller fall of 12% in admissions with length of stay of >2 days. By 2006, 67.3% of all unplanned admissions were isolated short stays,2 days. The increases in admission rates were greater for common non-infectious than infectious causes of admissions. Conclusions: Short stay unplanned hospital admission rates in young children in England have increased substantially in recent years and are not accounted for by reductions in length of in-hospital stay. The majority are isolated short stay admissions for minor illness episodes that could be better managed by primary care in the community and may be evidence of a failure of primary care services.			Saxena, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Primary Care & Social Med, London, England.	s.saxena@imperial.ac.uk	Saxena, Sonia K/G-4821-2013; Saxena, Sonia/ABD-7737-2021	Saxena, Sonia K/0000-0003-3787-2083; Saxena, Sonia/0000-0003-3787-2083; sharland, mike/0000-0001-8626-8291; Bottle, Alex/0000-0001-9978-2011; Gilbert, Ruth/0000-0001-9347-2709	Department of Health [PDA/02/06/076] Funding Source: Medline; Medical Research Council [G0400546B] Funding Source: researchfish; National Institute for Health Research [PDA/02/06/076] Funding Source: researchfish	Department of Health; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))		Agency for Healthcare Research and Quality, 2008, CLIN CLASS SOFTW CCS; Chief Nursing Officer's Directorate Children Families and Maternity Analysis, 2008, TRENDS CHILDR YOUNG; Christakis DA, 2001, PEDIATRICS, V107, P524, DOI 10.1542/peds.107.3.524; *DEP HLTH, 2008, EV CHILD MATT; *DEP HLTH, 2009, HLTH LIV BRIGH FUT S; *DEP HLTH, 1998, HES BOOK; Dixon J, 1998, J PUBLIC HEALTH MED, V20, P63, DOI 10.1093/oxfordjournals.pubmed.a024721; Flores G, 2003, PEDIATRICS, V112, P1021, DOI 10.1542/peds.112.5.1021; Gadomski A, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e1; Gill JM, 1998, ARCH FAM MED, V7, P352, DOI 10.1001/archfami.7.4.352; Hargreaves S, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-153; *HEALTHC COMM, 2005, NHS PERF RAT 2004 20; Hippisley-Cox J, 2007, TRENDS CONSULTATION; Horton R, 2008, LANCET, V372, P3, DOI 10.1016/S0140-6736(08)60963-0; Inkelas M, 2004, PEDIATRICS, V113, P1917; Kai J, 1996, BRIT MED J, V313, P987; Kai J, 1996, BRIT MED J, V313, P983; Kmietowicz Z, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1207; Lachman P, 2004, BRIT MED J, V329, P693, DOI 10.1136/bmj.329.7468.693; Leibowitz R, 2003, FAM PRACT, V20, P311, DOI 10.1093/fampra/cmg313; MacFaul R, 2001, ARCH DIS CHILD, V85, P203, DOI 10.1136/adc.85.3.203; McDonald KM, 2008, PEDIATRICS, V122, pE416, DOI 10.1542/peds.2007-2477; National Collaborating Centre for Women's and Children's Health, 2007, FEV ILLN CHILDR ASS; *NHS CONF, 2003, INV GEN PRACT NEW GE; NHS Institute for Innovation and Improvement, 2008, FOC EM URG CAR PATHW; *OFF NAT STAT, 2009, MID 1997 POP EST ENG; Ogilvie D, 2005, ARCH DIS CHILD, V90, P138, DOI 10.1136/adc.2003.035543; *ORG EC COOP DEV, 2001, HLTH GLANC; Roland M, 2008, NEW ENGL J MED, V359, P2087, DOI 10.1056/NEJMp0805633; Royal College of Paediatrics and Child Health, 2008, MOD FUT; Salisbury C, 2000, BRIT MED J, V320, P618, DOI 10.1136/bmj.320.7235.618; Saxena S, 1999, BRIT MED J, V318, P642, DOI 10.1136/bmj.318.7184.642; Saxena S, 2002, BMJ-BRIT MED J, V325, P520, DOI 10.1136/bmj.325.7363.520; Starfield B., 1992, PRIMARY CARE CONCEPT; Stephenson T, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1783; Stewart M, 1998, ARCH DIS CHILD, V79, P219, DOI 10.1136/adc.79.3.219; Wise PH, 2007, J PEDIATR-US, V151, pS6, DOI 10.1016/j.jpeds.2007.08.013; Wise PH, 2004, HEALTH AFFAIR, V23, P9, DOI 10.1377/hlthaff.23.5.9	38	68	68	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 15	2009	4	10							e7484	10.1371/journal.pone.0007484	http://dx.doi.org/10.1371/journal.pone.0007484			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	507JB	19829695	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000270847800017
J	Roos, AK; Eriksson, F; Timmons, JA; Gerhardt, J; Nyman, U; Gudmundsdotter, L; Brave, A; Wahren, B; Pisa, P				Roos, Anna-Karin; Eriksson, Fredrik; Timmons, James A.; Gerhardt, Josefine; Nyman, Ulrika; Gudmundsdotter, Lindvi; Brave, Andreas; Wahren, Britta; Pisa, Pavel			Skin Electroporation: Effects on Transgene Expression, DNA Persistence and Local Tissue Environment	PLOS ONE			English	Article							IN-VIVO ELECTROPORATION; GENE-EXPRESSION; PLASMID DNA; SKELETAL-MUSCLE; IMMUNE-RESPONSES; VACCINE DELIVERY; INTRAMUSCULAR INJECTION; FIREFLY LUCIFERASE; NAKED DNA; IMMUNOGENICITY	Background: Electrical pulses have been used to enhance uptake of molecules into living cells for decades. This technique, often referred to as electroporation, has become an increasingly popular method to enhance in vivo DNA delivery for both gene therapy applications as well as for delivery of vaccines against both infectious diseases and cancer. In vivo electrovaccination (gene delivery followed by electroporation) is currently being investigated in several clinical trials, including DNA delivery to healthy volunteers. However, the mode of action at molecular level is not yet fully understood. Methodology/Principal Findings: This study investigates intradermal DNA electrovaccination in detail and describes the effects on expression of the vaccine antigen, plasmid persistence and the local tissue environment. Gene profiling of the vaccination site showed that the combination of DNA and electroporation induced a significant up-regulation of proinflammatory genes. In vivo imaging of luciferase activity after electrovaccination demonstrated a rapid onset (minutes) and a long duration (months) of transgene expression. However, when the more immunogenic prostate specific antigen (PSA) was co-administered, PSA-specific T cells were induced and concurrently the luciferase expression became undetectable. Electroporation did not affect the long-term persistence of the PSA-expressing plasmid. Conclusions/Significance: This study provides important insights to how DNA delivery by intradermal electrovaccination affects the local immunological responses of the skin, transgene expression and clearance of the plasmid. As the described vaccination approach is currently being evaluated in clinical trials, the data provided will be of high significance.			Roos, AK (corresponding author), Karolinska Inst, Sci Pk, Solna, Sweden.	roos.anki@gmail.com	Timmons, James A/J-4698-2014; Timmons, James A/M-6350-2019; Nyman, Ulrika/D-3708-2013	Timmons, James A/0000-0002-2255-1220; Timmons, James A/0000-0002-2255-1220; Eriksson, Fredrik/0000-0001-9548-3276				Ahlen G, 2007, J IMMUNOL, V179, P4741, DOI 10.4049/jimmunol.179.7.4741; Babiuk S, 2004, J BIOTECHNOL, V110, P1, DOI 10.1016/j.jbiotec.2004.01.015; Babiuk S, 2003, MOL THER, V8, P992, DOI 10.1016/j.ymthe.2003.09.008; Babiuk S, 2002, VACCINE, V20, P3399, DOI 10.1016/S0264-410X(02)00269-4; Barouch DH, 2004, IMMUNOL REV, V202, P266, DOI 10.1111/j.0105-2896.2004.00200.x; Bergman PJ, 2003, CLIN CANCER RES, V9, P1284; Bins AD, 2005, NAT MED, V11, P899, DOI 10.1038/nm1264; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Chen Z, 2002, BIOCHEM BIOPH RES CO, V290, P66, DOI 10.1006/bbrc.2001.6147; Chiarella P, 2008, EXPERT OPIN BIOL TH, V8, P1645, DOI [10.1517/14712598.8.11.1645, 10.1517/14712598.8.11.1645 ]; Contag CH, 2000, NEOPLASIA, V2, P41, DOI 10.1038/sj.neo.7900079; Daud AI, 2008, J CLIN ONCOL, V26, P3235, DOI 10.1200/JCO.2007.13.9048; Doh SG, 1997, GENE THER, V4, P648, DOI 10.1038/sj.gt.3300460; Drabick JJ, 2001, MOL THER, V3, P249, DOI 10.1006/mthe.2000.0257; Dupuis M, 2000, J IMMUNOL, V165, P2850, DOI 10.4049/jimmunol.165.5.2850; Durieux AC, 2004, J GENE MED, V6, P809, DOI 10.1002/jgm.534; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; Greenland JR, 2007, J IMMUNOL, V178, P5652, DOI 10.4049/jimmunol.178.9.5652; Greenland JR, 2007, VACCINE, V25, P3731, DOI 10.1016/j.vaccine.2007.01.120; Gronevik E, 2005, J GENE MED, V7, P1246, DOI 10.1002/jgm.760; Guevara-Patino JA, 2003, ADV CANCER RES, V90, P157, DOI 10.1016/S0065-230X(03)90005-4; Hakamata Y, 2006, TRANSPLANTATION, V81, P1179, DOI 10.1097/01.tp.0000203137.06587.4a; Hirao LA, 2008, VACCINE, V26, P440, DOI 10.1016/j.vaccine.2007.10.041; Hooper JW, 2007, VACCINE, V25, P1814, DOI 10.1016/j.vaccine.2006.11.017; Jeon YH, 2006, VACCINE, V24, P3057, DOI 10.1016/j.vaccine.2006.01.033; Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luckay A, 2007, J VIROL, V81, P5257, DOI 10.1128/JVI.00055-07; Luxembourg A, 2007, EXPERT OPIN BIOL TH, V7, P1647, DOI 10.1517/14712598.7.11.1647; Maruyama H, 2001, GENE THER, V8, P1808, DOI 10.1038/sj.gt.3301604; Medi BM, 2005, INT J PHARMACEUT, V294, P53, DOI 10.1016/j.ijpharm.2004.12.014; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Prud'homme GJ, 2006, CURR GENE THER, V6, P243, DOI 10.2174/156652306776359504; Rice J, 2008, NAT REV CANCER, V8, P108, DOI 10.1038/nrc2326; Rizzuto G, 1999, P NATL ACAD SCI USA, V96, P6417, DOI 10.1073/pnas.96.11.6417; Roos AK, 2006, MOL THER, V13, P320, DOI 10.1016/j.ymthe.2005.08.005; Sandstrom E, 2008, J INFECT DIS, V198, P1482, DOI 10.1086/592507; SCHIRRMACHER V, 2008, 2 INT C CANC VACC AD; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; Tollefsen S, 2003, SCAND J IMMUNOL, V57, P229, DOI 10.1046/j.1365-3083.2003.01218.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Ulmer JB, 2006, TRENDS MOL MED, V12, P216, DOI 10.1016/j.molmed.2006.03.007; Wang Z, 2004, GENE THER, V11, P711, DOI 10.1038/sj.gt.3302213; Widera G, 2000, J IMMUNOL, V164, P4635, DOI 10.4049/jimmunol.164.9.4635; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Zhang L, 2002, BBA-GEN SUBJECTS, V1572, P1, DOI 10.1016/S0304-4165(02)00270-2; Zhu DL, 2002, CURR OPIN MOL THER, V4, P41	48	112	118	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 30	2009	4	9							e7226	10.1371/journal.pone.0007226	http://dx.doi.org/10.1371/journal.pone.0007226			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	501BO	19789652	gold, Green Published, Green Submitted			2023-01-03	WOS:000270354100002
J	Salvage, AV; Quinn, B				Salvage, Ann V.; Quinn, Barry			Practice A Patient's Journey Cancer and chemotherapy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Quinn, Barry] Univ London St Georges Hosp, London SW17 0QT, England	St Georges University London	Quinn, B (corresponding author), Univ London St Georges Hosp, London SW17 0QT, England.	barry.quinn@stgeorges.nhs.uk							0	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 24	2009	339								b2875	10.1136/bmj.b2875	http://dx.doi.org/10.1136/bmj.b2875			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	489AP	19703923				2023-01-03	WOS:000269392100001
J	Schastak, S; Ziganshyna, S; Gitter, B; Wiedemann, P; Claudepierre, T				Schastak, Stanislaw; Ziganshyna, Svitlana; Gitter, Burkhard; Wiedemann, Peter; Claudepierre, Thomas			Efficient Photodynamic Therapy against Gram-Positive and Gram-Negative Bacteria Using THPTS, a Cationic Photosensitizer Excited by Infrared Wavelength	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ANTIMICROBIAL RESISTANCE; PSEUDOMONAS-AERUGINOSA; PORPHYRIN DERIVATIVES; ESCHERICHIA-COLI; BASIC PRINCIPLES; PHOTOINACTIVATION; INFECTIONS; SUSCEPTIBILITY; EPIDEMIOLOGY	The worldwide rise in the rates of antibiotic resistance of bacteria underlines the need for alternative antibacterial agents. A promising approach to kill antibiotic-resistant bacteria uses light in combination with a photosensitizer to induce a phototoxic reaction. Concentrations of 1, 10 and 100 mu M of tetrahydroporphyrin-tetratosylat (THPTS) and different incubation times (30, 90 and 180min) were used to measure photodynamic efficiency against two Gram-positive strains of S. aureus (MSSA and MRSA), and two Gram-negative strains of E. coli and P. aeruginosa. We found that phototoxicity of the drug is independent of the antibiotic resistance pattern when incubated in PBS for the investigated strains. Also, an incubation with 100 mu M THPTS followed by illumination, yielded a 6lg (>= 99.999%) decrease in the viable numbers of all bacteria strains tested, indicating that the THPTS drug has a high degree of photodynamic inactivation. We then modulated incubation time, photosensitizer concentration and monitored the effect of serum on the THPTS activity. In doing so, we established the conditions to obtain the strongest bactericidal effect. Our results suggest that this new and highly pure synthetic compound should improve the efficiency of photodynamic therapy against multiresistant bacteria and has a significant potential for clinical applications in the treatment of nosocomial infections.	[Schastak, Stanislaw; Wiedemann, Peter; Claudepierre, Thomas] Univ Leipzig, Fac Med, Dept Ophthalmol, Leipzig, Germany; [Ziganshyna, Svitlana] Univ Leipzig, Fac Med, Dept Anaesthesia & Intens Care Med, Leipzig, Germany; [Gitter, Burkhard] Biolitec AG, Res & Dev, Jena, Germany	Leipzig University; Leipzig University; Biolitec AG	Schastak, S (corresponding author), Univ Leipzig, Fac Med, Dept Ophthalmol, Leipzig, Germany.	stas@medizin.uni-leipzig.de		Claudepierre, Thomas/0000-0001-6968-8518	Biolitec AG; Ophthalmology Department at the Faculty of Medicine of the University of Leipzig; Novartis-Pharma Germany; French Foundation "Gueules Cassees"; Stiferverbrand fur die Deutsche Wissenchaft	Biolitec AG; Ophthalmology Department at the Faculty of Medicine of the University of Leipzig; Novartis-Pharma Germany; French Foundation "Gueules Cassees"; Stiferverbrand fur die Deutsche Wissenchaft	This work was funded by Biolitec AG and by the Ophthalmology Department at the Faculty of Medicine of the University of Leipzig. T. C. is supported by grants from Novartis-Pharma Germany, from the French Foundation "Gueules Cassees" and from the "Stiferverbrand fur die Deutsche Wissenchaft". Other than the input of the authors in the wording of the manuscript, and in providing materials and approving permission to publish freely, Biolitec AG as a funder had no direct role in the conception of the method, the study design, data collection, or analysis. Novartis Pharma-Germany, Foundation "Gueules Cassees", "Stiferverbrand fur die Deutsche Wissenchaft" and the Ophthalmology Department as funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alves E, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-70; Banfi S, 2006, J PHOTOCH PHOTOBIO B, V85, P28, DOI 10.1016/j.jphotobiol.2006.04.003; Boucher HW, 2008, CLIN INFECT DIS, V46, pS344, DOI 10.1086/533590; Caminos DA, 2006, PHOTOCH PHOTOBIO SCI, V5, P56, DOI 10.1039/b513511g; Cardo D, 2004, AM J INFECT CONTROL, V32, P470, DOI 10.1016/j.ajic.2004.10.001; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P565; Costa L, 2008, PHOTOCH PHOTOBIO SCI, V7, P415, DOI 10.1039/b712749a; Diekema DJ, 2004, CLIN INFECT DIS, V38, P78, DOI 10.1086/380457; Engelmann FM, 2007, J BIOENERG BIOMEMBR, V39, P175, DOI 10.1007/s10863-007-9075-0; Felmingham D, 2005, J ANTIMICROB CHEMOTH, V56, P3, DOI 10.1093/jac/dki297; Ferro S, 2007, INT J BIOCHEM CELL B, V39, P1026, DOI 10.1016/j.biocel.2007.02.001; Fotinos N, 2008, ANTIMICROB AGENTS CH, V52, P1366, DOI 10.1128/AAC.01372-07; Fridkin SK, 2001, CLIN INFECT DIS, V32, P108, DOI 10.1086/317542; Gillham MI, 2009, J ANTIMICROB CHEMOTH, V63, P728, DOI 10.1093/jac/dkp007; Gupta MR, 2009, TRANSPL INFECT DIS, V11, P424, DOI 10.1111/j.1399-3062.2009.00422.x; Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a; Hamblin MR, 2003, J INFECT DIS, V187, P1717, DOI 10.1086/375244; Jenkins TC, 2009, INFECT CONT HOSP EP, V30, P233, DOI 10.1086/595963; JEVONS MP, 1963, LANCET, V1, P904; Jones RN, 2003, SEMIN RESP CRIT CARE, V24, P121, DOI 10.1055/s-2003-37923; Jori G, 2006, J ENVIRON PATHOL TOX, V25, P505, DOI 10.1615/JEnvironPatholToxicolOncol.v25.i1-2.320; Jori G, 2006, LASER SURG MED, V38, P468, DOI 10.1002/lsm.20361; Lazzeri D, 2004, PHOTOCHEM PHOTOBIOL, V80, P286, DOI 10.1562/2004-03-08-RA-105.1; Lin YM, 2010, J BIOL CHEM, V285, P8985, DOI 10.1074/jbc.M109.078725; MacDonald IJ, 2001, J PORPHYR PHTHALOCYA, V5, P105, DOI 10.1002/jpp.328; MacKenzie FM, 2006, CLIN MICROBIOL INFEC, V12, P1185, DOI 10.1111/j.1469-0691.2006.01549.x; Maisch T, 2007, PHOTOCH PHOTOBIO SCI, V6, P545, DOI 10.1039/b614770d; Maisch T, 2005, ANTIMICROB AGENTS CH, V49, P1542, DOI 10.1128/AAC.49.4.1542-1552.2005; Maisch T, 2007, LASER MED SCI, V22, P83, DOI 10.1007/s10103-006-0409-7; Moet GJ, 2007, DIAGN MICR INFEC DIS, V57, P7, DOI 10.1016/j.diagmicrobio.2006.05.009; NITZAN Y, 1983, CURR MICROBIOL, V8, P279, DOI 10.1007/BF01577728; Raab O, 1900, Z BIOL-MUNICH, V39, P524; Rammelkamp CH, 1942, P SOC EXP BIOL MED, V51, P386, DOI 10.3181/00379727-51-13986; Schastak S, 2008, METHOD FIND EXP CLIN, V30, P129, DOI 10.1358/mf.2008.30.2.1165448; Seaton RA, 2008, J ANTIMICROB CHEMOTH, V62, P15, DOI 10.1093/jac/dkn368; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Tappeiner H.v., 1904, DEUT ARCH KLIN MED, V80, P427; Tappeiner H.V., 1904, DMW DTSCH MED WOCHEN, V30, P579, DOI [10.1055/s-0029-1187467, DOI 10.1055/S-0029-1187467]; Wainwright M, 2004, INT BIODETER BIODEGR, V53, P119, DOI 10.1016/j.ibiod.2003.11.006; Witte W, 2007, ZBL CHIR, V132, P124, DOI 10.1055/s-2007-960652; Zolfaghari PS, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-27; EARSS EUROPEAN ANTIM, P21	42	69	72	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2010	5	7							e11674	10.1371/journal.pone.0011674	http://dx.doi.org/10.1371/journal.pone.0011674			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	628II	20652031	gold, Green Submitted, Green Published			2023-01-03	WOS:000280109700007
J	Renoux, C; Dell'Aniello, S; Garbe, E; Suissa, S				Renoux, Christel; Dell'Aniello, Sophie; Garbe, Edeltraut; Suissa, Samy			Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRACTICE RESEARCH DATABASE; POSTMENOPAUSAL WOMEN; VENOUS THROMBOEMBOLISM; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; CONTROLLED-TRIAL; EQUINE ESTROGEN; METAANALYSIS; ASSOCIATION; IMPACT	Objectives To determine the risk of stroke associated with oral and transdermal routes of administration of hormone replacement therapy. Design Population based nested case-control study. Setting About 400 general practices in the United Kingdom contributing to the General Practice Research Database. Participants Cohort of all women in the database aged 50-79 years between 1 January 1987 and 31 October 2006 who were members of a practice that fulfilled predefined quality criteria and without a diagnosis of stroke before cohort entry. For each case of stroke occurring during follow-up, up to four controls were selected from among the cohort members in the risk sets defined by the case. Exposure to hormone replacement therapy (HRT) was categorised into oestrogens only, oestrogens plus progestogen, progestogen only, and tibolone. Oestrogens were further subdivided according to the route of administration (oral v transdermal) and dose (high v low). Main outcome measures Rate ratio of stroke associated with current use of oral and transdermal HRT compared with no use. Current use was considered as a prescription whose duration included the index date. Results There were 15 710 cases of stroke matched to 59 958 controls. The rate of stroke in the cohort was 2.85 per 1000 per year. The adjusted rate ratio of stroke associated with current use of transdermal HRT was 0.95 (95% CI 0.75 to 1.20) relative to no use. The risk of stroke was not increased with use of low oestrogen dose patches (rate ratio 0.81(0.62 to 1.05)) compared with no use, whereas the risk was increased with high dose patches (rate ratio 1.89 (1.15 to 3.11)). Current users of oral HRT had a higher rate of stroke than non-users (rate ratio 1.28 (1.15 to 1.42)) with both low dose and high dose. Conclusions The use of transdermal HRT containing low doses of oestrogen does not seem to increase the risk of stroke. The presence of residual confounding, however, cannot be entirely excluded in the interpretation of this finding.	[Renoux, Christel; Dell'Aniello, Sophie; Suissa, Samy] McGill Univ, Jewish Gen Hosp, Ctr Clin Epidemiol, McGill Pharmacoepidemiol Res Unit, Montreal, PQ H3T 1E2, Canada; [Renoux, Christel; Dell'Aniello, Sophie; Suissa, Samy] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3T 1E2, Canada; [Renoux, Christel; Dell'Aniello, Sophie; Suissa, Samy] McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; [Garbe, Edeltraut] Univ Bremen, Dept Clin Epidemiol, Bremen Inst Prevent Res & Social Med, D-28359 Bremen, Germany	McGill University; McGill University; McGill University; Leibniz Institute for Prevention Research & Epidemiology (BIPS); University of Bremen	Suissa, S (corresponding author), McGill Univ, Jewish Gen Hosp, Ctr Clin Epidemiol, McGill Pharmacoepidemiol Res Unit, Montreal, PQ H3T 1E2, Canada.	samy.suissa@mcgill.ca			Canadian Institutes of Health Research (CIHR); Canadian Foundation for Innovation; Organon; Multiple Sclerosis Society of Canada	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Organon; Multiple Sclerosis Society of Canada	Funding: This research was funded by grants from the Canadian Institutes of Health Research (CIHR), the Canadian Foundation for Innovation, and Organon. SS is the recipient of a distinguished investigator award from the CIHR. CR is the recipient of a postdoctoral fellowship from the Multiple Sclerosis Society of Canada	Andersohn F, 2006, STROKE, V37, P1725, DOI 10.1161/01.STR.0000226642.55207.94; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Arana A, 2006, MENOPAUSE, V13, P730, DOI 10.1097/01.gme.0000233494.28335.71; Archer DF, 2003, MENOPAUSE, V10, P516, DOI 10.1097/01.GME.0000070526.74726.8A; Bath PMW, 2005, BRIT MED J, V330, P342, DOI 10.1136/bmj.38331.655347.8F; Canonico M, 2006, J THROMB HAEMOST, V4, P1259, DOI 10.1111/j.1538-7836.2006.01933.x; Canonico M, 2008, BMJ-BRIT MED J, V336, P1227, DOI 10.1136/bmj.39555.441944.BE; Canonico M, 2007, CIRCULATION, V115, P840, DOI 10.1161/CIRCULATIONAHA.106.642280; Cherry N, 2002, LANCET, V360, P2001; Clarke SC, 2002, BJOG-INT J OBSTET GY, V109, P1056, DOI 10.1111/j.1471-0528.2002.01544.x; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; de Vries CS, 2006, MATURITAS, V53, P343, DOI 10.1016/j.maturitas.2005.06.004; Gutthann SP, 1997, BMJ-BRIT MED J, V314, P796, DOI 10.1136/bmj.314.7083.796; Hall GC, 2004, NEUROLOGY, V62, P563, DOI 10.1212/01.WNL.0000110312.36809.7F; Hemelaar M, 2008, FERTIL STERIL, V90, P642, DOI 10.1016/j.fertnstert.2007.07.1298; Hendrix SL, 2006, CIRCULATION, V113, P2425, DOI 10.1161/CIRCULATIONAHA.105.594077; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; Magliano DJ, 2006, BJOG-INT J OBSTET GY, V113, P5, DOI 10.1111/j.1471-0528.2005.00797.x; Modena MG, 2005, MATURITAS, V52, P1, DOI 10.1016/j.maturitas.2005.05.003; PLACE VA, 1985, AM J OBSTET GYNECOL, V152, P1092, DOI 10.1016/0002-9378(85)90568-X; Renoux C, 2008, MATURITAS, V61, P305, DOI 10.1016/j.maturitas.2008.09.020; Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419; Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465; Sare GM, 2008, EUR HEART J, V29, P2031, DOI 10.1093/eurheartj/ehn299; Scarabin PY, 2003, LANCET, V362, P428, DOI 10.1016/S0140-6736(03)14066-4; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Straczek C, 2005, CIRCULATION, V112, P3495, DOI 10.1161/CIRCULATIONAHA.105.565556; Varas-Lorenzo C, 2000, CIRCULATION, V101, P2572, DOI 10.1161/01.CIR.101.22.2572; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673	32	183	185	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 3	2010	340								c2519	10.1136/bmj.c2519	http://dx.doi.org/10.1136/bmj.c2519			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	608BM	20525678	hybrid			2023-01-03	WOS:000278556500005
J	Hernandez, AF; Greiner, MA; Fonarow, GC; Hammill, BG; Heidenreich, PA; Yancy, CW; Peterson, ED; Curtis, LH				Hernandez, Adrian F.; Greiner, Melissa A.; Fonarow, Gregg C.; Hammill, Bradley G.; Heidenreich, Paul A.; Yancy, Clyde W.; Peterson, Eric D.; Curtis, Lesley H.			Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-CARE; TRANSITIONAL CARE; OPTIMIZE-HF; INPATIENT; OPPORTUNITIES; CHALLENGES; OUTPATIENT; PROGRAM	Context Readmission after hospitalization for heart failure is common. Early outpatient follow-up after hospitalization has been proposed as a means of reducing readmission rates. However, there are limited data describing patterns of follow-up after heart failure hospitalization and its association with readmission rates. Objective To examine associations between outpatient follow-up within 7 days after discharge from a heart failure hospitalization and readmission within 30 days. Design, Setting, and Patients Observational analysis of patients 65 years or older with heart failure and discharged to home from hospitals participating in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure and the Get With the Guidelines-Heart Failure quality improvement program from January 1, 2003, through December 31, 2006. Main Outcome Measure All-cause readmission within 30 days after discharge. Results The study population included 30 136 patients from 225 hospitals. Median length of stay was 4 days (interquartile range, 2-6) and 21.3% of patients were readmitted within 30 days. At the hospital level, the median percentage of patients who had early follow-up after discharge from the index hospitalization was 38.3% (interquartile range, 32.4%-44.5%). Compared with patients whose index admission was in a hospital in the lowest quartile of early follow-up (30-day readmission rate, 23.3%), the rates of 30-day readmission were 20.5% among patients in the second quartile (riskadjusted hazard ratio [HR], 0.85; 95% confidence interval [CI], 0.78-0.93), 20.5% among patients in the third quartile (risk-adjusted HR, 0.87; 95% CI, 0.78-0.96), and 20.9% among patients in the fourth quartile (risk-adjusted HR, 0.91; 95% CI, 0.83-1.00). Conclusions Among patients who are hospitalized for heart failure, substantial variation exists in hospital-level rates of early outpatient follow-up after discharge. Patients who are discharged from hospitals that have higher early follow-up rates have a lower risk of 30-day readmission.	[Hernandez, Adrian F.; Greiner, Melissa A.; Hammill, Bradley G.; Peterson, Eric D.; Curtis, Lesley H.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27715 USA; [Hernandez, Adrian F.; Peterson, Eric D.; Curtis, Lesley H.] Duke Univ, Sch Med, Dept Med, Durham, NC 27715 USA; [Heidenreich, Paul A.] Palo Alto VA Med Ctr, Palo Alto, CA USA; [Fonarow, Gregg C.] Ahmanson UCLA Cardiomyopathy Ctr, Los Angeles, CA USA; [Yancy, Clyde W.] Baylor Heart & Vasc Inst, Dallas, TX USA	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Hernandez, AF (corresponding author), Duke Univ, Sch Med, Duke Clin Res Inst, POB 17969, Durham, NC 27715 USA.	adrian.hernandez@duke.edu	Peterson, Eric David/ABF-5033-2021; Heidenreich, Paul/AAU-6864-2021; Hernandez, Adrian F/A-7818-2016; Fonarow, Gregg C/D-5988-2014	Heidenreich, Paul/0000-0001-7730-8490; Hernandez, Adrian F/0000-0003-3387-9616; Fonarow, Gregg C/0000-0002-3192-8093	GlaxoSmithKline; Medtronic; American Heart Association Pharmaceutical Round-table Outcomes Center [087512N]; American Heart Association Pharmaceutical Roundtable [0675060N]; Agency for Healthcare Research and Quality [U18HS016964]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS016964] Funding Source: NIH RePORTER	GlaxoSmithKline(GlaxoSmithKline); Medtronic(Medtronic); American Heart Association Pharmaceutical Round-table Outcomes Center; American Heart Association Pharmaceutical Roundtable(American Heart Association); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Get With the Guidelines-Heart Failure is a program of the American Heart Association and is supported in part by an unrestricted educational grant from GlaxoSmithKline and Medtronic. OPTIMIZE-HF was supported by GlaxoSmithKline. This study was supported by American Heart Association Pharmaceutical Round-table Outcomes Center grant 087512N. Dr Hernandez was supported by American Heart Association Pharmaceutical Roundtable grant 0675060N. Drs Peterson and Curtis were supported by grant U18HS016964 from the Agency for Healthcare Research and Quality.	Adams KF, 2006, J CARD FAIL, V12, P10, DOI 10.1016/j.cardfail.2005.12.001; *AM COLL CARD I HE, HOSP HOM H2H; *AM HOSP ASS, 2008, AHA ANN SURV DAT 200; Bodenheimer T, 2008, NEW ENGL J MED, V358, P1064, DOI 10.1056/NEJMhpr0706165; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; *CTR MED MED SERV, 2007, CTR MED MED SERV M S; Curtis LH, 2009, CIRC-CARDIOVASC QUAL, V2, P377, DOI 10.1161/CIRCOUTCOMES.108.822692; Ezekowitz JA, 2005, CAN MED ASSOC J, V172, P189, DOI 10.1503/cmaj.1032017; Fonarow GC, 2004, AM HEART J, V148, P43, DOI 10.1016/j.ahj.2004.03.004; Hammill BG, 2009, AM HEART J, V157, P995, DOI 10.1016/j.ahj.2009.04.002; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jessup M, 2009, CIRCULATION, V119, P1977, DOI 10.1161/CIRCULATIONAHA.109.192064; Jha AK, 2009, NEW ENGL J MED, V361, P2637, DOI 10.1056/NEJMsa0904859; *JOINT COMM, 2006, JOINT COMM SPEC MAN; Jong P, 2003, CIRCULATION, V108, P184, DOI 10.1161/01.CIR.0000080290.39027.48; Kuo Y, 2009, NEW ENGL J MED, V360, P1102, DOI 10.1056/NEJMsa0802381; Leendertse AJ, 2008, ARCH INTERN MED, V168, P1890, DOI 10.1001/archinternmed.2008.3; Peikes D, 2009, JAMA-J AM MED ASSOC, V301, P603, DOI 10.1001/jama.2009.126; Pham HH, 2008, HEALTH AFFAIR, V27, P1315, DOI 10.1377/hlthaff.27.5.1315; Romano PS, 2005, NEW ENGL J MED, V353, P302, DOI 10.1056/NEJMe058150; Sharma G, 2009, JAMA-J AM MED ASSOC, V301, P1671, DOI 10.1001/jama.2009.517	22	723	732	2	39	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 5	2010	303	17					1716	1722		10.1001/jama.2010.533	http://dx.doi.org/10.1001/jama.2010.533			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	591CR	20442387	Bronze			2023-01-03	WOS:000277276600024
J	Volkow, ND; Montaner, J				Volkow, Nora D.; Montaner, Julio			Enhanced HIV Testing, Treatment, and Support for HIV-Infected Substance Users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; INJECTION-DRUG USERS; EPIDEMIC; CARE		[Volkow, Nora D.] NIDA, NIH, Bethesda, MD 20892 USA; [Montaner, Julio] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada; [Montaner, Julio] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Montaner, Julio] Int AIDS Soc, Geneva, Switzerland	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); B.C. Centre for Excellence in HIV/AIDS; University of British Columbia	Volkow, ND (corresponding author), 6001 Execut Blvd,Room 5274,MSC 9581, Bethesda, MD 20892 USA.	nvolkow@nida.nih.gov	Montaner, Julio/K-7621-2012		NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [DP1DA026182] Funding Source: NIH RePORTER; CIHR Funding Source: Medline; NIDA NIH HHS [DP1 DA026182] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); CIHR(Canadian Institutes of Health Research (CIHR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bruce RD, 2007, INFECT DIS CLIN N AM, V21, P149, DOI 10.1016/j.idc.2007.03.009; Hall HI, 2008, JAMA-J AM MED ASSOC, V300, P520, DOI 10.1001/jama.300.5.520; Lert F, 2007, INT J DRUG POLICY, V18, P255, DOI 10.1016/j.drugpo.2007.05.002; Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9; Spaulding AC, 2009, PLOS ONE, V4, pA16, DOI 10.1371/journal.pone.0007558; *SUBST AB MENT HLT, RES 2008 NAT SURV DR; Wood E, 2005, AIDS, V19, P1189, DOI 10.1097/01.aids.0000176219.48484.f1; Wood E, 2008, JAMA-J AM MED ASSOC, V300, P550, DOI 10.1001/jama.300.5.550; Wood E, 2006, DRUG ALCOHOL REV, V25, P451, DOI 10.1080/09595230600883313; Wood E, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1649	10	50	50	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	2010	303	14					1423	1424		10.1001/jama.2010.421	http://dx.doi.org/10.1001/jama.2010.421			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	582KX	20388900	Green Accepted			2023-01-03	WOS:000276597300029
J	Mullard, A				Mullard, Asher			The anticounterfeiter's technological tool kit	NATURE MEDICINE			English	News Item																			0	23	23	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					361	361		10.1038/nm0410-361a	http://dx.doi.org/10.1038/nm0410-361a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376027	Bronze			2023-01-03	WOS:000276446800018
J	Silveira, MJ; Kim, SYH; Langa, KM				Silveira, Maria J.; Kim, Scott Y. H.; Langa, Kenneth M.			Advance Directives and Outcomes of Surrogate Decision Making before Death.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OF-LIFE CARE; CRITICALLY-ILL; LIVING WILL; END; HEALTH; PLACE	Background: Recent discussions about health care reform have raised questions regarding the value of advance directives. Methods: We used data from survey proxies in the Health and Retirement Study involving adults 60 years of age or older who had died between 2000 and 2006 to determine the prevalence of the need for decision making and lost decision-making capacity and to test the association between preferences documented in advance directives and outcomes of surrogate decision making. Results: Of 3746 subjects, 42.5% required decision making, of whom 70.3% lacked decision-making capacity and 67.6% of those subjects, in turn, had advance directives. Subjects who had living wills were more likely to want limited care (92.7%) or comfort care (96.2%) than all care possible (1.9%); 83.2% of subjects who requested limited care and 97.1% of subjects who requested comfort care received care consistent with their preferences. Among the 10 subjects who requested all care possible, only 5 received it; however, subjects who requested all care possible were far more likely to receive aggressive care as compared with those who did not request it (adjusted odds ratio, 22.62; 95% confidence interval [CI], 4.45 to 115.00). Subjects with living wills were less likely to receive all care possible (adjusted odds ratio, 0.33; 95% CI, 0.19 to 0.56) than were subjects without living wills. Subjects who had assigned a durable power of attorney for health care were less likely to die in a hospital (adjusted odds ratio, 0.72; 95% CI, 0.55 to 0.93) or receive all care possible (adjusted odds ratio, 0.54; 95% CI, 0.34 to 0.86) than were subjects who had not assigned a durable power of attorney for health care. Conclusions: Between 2000 and 2006, many elderly Americans needed decision making near the end of life at a time when most lacked the capacity to make decisions. Patients who had prepared advance directives received care that was strongly associated with their preferences. These findings support the continued use of advance directives. N Engl J Med 2010;362:1211-8.	[Silveira, Maria J.; Langa, Kenneth M.] Univ Michigan, Vet Affairs Ctr Clin Management Res, Ann Arbor, MI 48109 USA; [Silveira, Maria J.; Langa, Kenneth M.] Univ Michigan, Div Gen Med, Ann Arbor, MI 48109 USA; [Silveira, Maria J.; Kim, Scott Y. H.] Univ Michigan, Bioeth Program, Ann Arbor, MI 48109 USA; [Langa, Kenneth M.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA; [Kim, Scott Y. H.] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [Kim, Scott Y. H.] Univ Michigan, Ctr Behav & Decis Sci Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Silveira, MJ (corresponding author), 300 N Ingalls Bldg,Rm 7C27,Box 5429, Ann Arbor, MI 48901 USA.	mariajs@umich.edu		Silveira, Maria/0000-0002-6600-8633; Langa, Kenneth/0000-0002-2798-1836	Ann Arbor Veterans Affairs Center for Clinical Management Research; Division of General Medicine at the University of Michigan; National Institute on Aging [R01 AG027010, U01 AG09740]; Greenwall Faculty Scholarship in Bioethics; NATIONAL INSTITUTE ON AGING [R01AG027010, U01AG009740] Funding Source: NIH RePORTER	Ann Arbor Veterans Affairs Center for Clinical Management Research; Division of General Medicine at the University of Michigan; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Greenwall Faculty Scholarship in Bioethics; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by core funds from the Ann Arbor Veterans Affairs Center for Clinical Management Research and the Division of General Medicine at the University of Michigan (to Dr. Silveira); a grant (R01 AG027010) from the National Institute on Aging and a Paul Beeson Physician Faculty Scholars in Aging Research award (to Dr. Langa); a grant (U01 AG09740) from the National Institute on Aging for the Health and Retirement Study, which was performed at the Survey Research Center, Institute for Social Research, University of Michigan; and a Greenwall Faculty Scholarship in Bioethics (to Dr. Kim).	Brown Barbara A, 2003, J Gerontol Nurs, V29, P4; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; Degenholtz HB, 2004, ANN INTERN MED, V141, P113, DOI 10.7326/0003-4819-141-2-200407200-00009; EDINGER W, 1992, J FAM PRACTICE, V35, P650; Fagerlin A, 2004, HASTINGS CENT REP, V34, P30, DOI 10.2307/3527683; Goodman MD, 1998, CRIT CARE MED, V26, P701, DOI 10.1097/00003246-199804000-00018; Juster FT, 1995, J HUM RESOUR, V30, pS7, DOI 10.2307/146277; LO B, 1985, ARCH INTERN MED, V145, P1115, DOI 10.1001/archinte.145.6.1115; O'Brien M, 2009, HILL            0813; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; Smucker W D, 1993, J Am Board Fam Pract, V6, P473; Soldo BJ, 1997, J GERONTOL B-PSYCHOL, V52, P1, DOI 10.1093/geronb/52B.Special_Issue.1; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; TENO JM, 1994, J CLIN ETHIC, V5, P23; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2007, J AM GERIATR SOC, V55, P189, DOI 10.1111/j.1532-5415.2007.01045.x	18	842	860	3	84	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 1	2010	362	13					1211	1218		10.1056/NEJMsa0907901	http://dx.doi.org/10.1056/NEJMsa0907901			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	577QQ	20357283	Green Accepted			2023-01-03	WOS:000276239500011
J	Jones, AE; Shapiro, NI; Trzeciak, S; Arnold, RC; Claremont, HA; Kline, JA				Jones, Alan E.; Shapiro, Nathan I.; Trzeciak, Stephen; Arnold, Ryan C.; Claremont, Heather A.; Kline, Jeffrey A.		Emergency Med Shock Res Network	Lactate Clearance vs Central Venous Oxygen Saturation as Goals of Early Sepsis Therapy A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BENCH-TO-BEDSIDE; DIRECTED THERAPY; SEPTIC SHOCK; TRANSLATING RESEARCH; UNITED-STATES; ORGAN FAILURE; RESUSCITATION; GUIDELINES; SCORE; IMPLEMENTATION	Context Goal-directed resuscitation for severe sepsis and septic shock has been reported to reduce mortality when applied in the emergency department. Objective To test the hypothesis of noninferiority between lactate clearance and central venous oxygen saturation (ScvO(2)) as goals of early sepsis resuscitation. Design, Setting, and Patients Multicenter randomized, noninferiority trial involving patients with severe sepsis and evidence of hypoperfusion or septic shock who were admitted to the emergency department from January 2007 to January 2009 at 1 of 3 participating US urban hospitals. Interventions We randomly assigned patients to 1 of 2 resuscitation protocols. The ScvO(2) group was resuscitated to normalize central venous pressure, mean arterial pressure, and ScvO(2) of at least 70%; and the lactate clearance group was resuscitated to normalize central venous pressure, mean arterial pressure, and lactate clearance of at least 10%. The study protocol was continued until all goals were achieved or for up to 6 hours. Clinicians who subsequently assumed the care of the patients were blinded to the treatment assignment. Main Outcome Measure The primary outcome was absolute in-hospital mortality rate; the noninferiority threshold was set at Delta equal to -10%. Results Of the 300 patients enrolled, 150 were assigned to each group and patients were well matched by demographic, comorbidities, and physiological features. There were no differences in treatments administered during the initial 72 hours of hospitalization. Thirty-four patients (23%) in the ScvO(2) group died while in the hospital (95% confidence interval [CI], 17%-30%) compared with 25 (17%; 95% CI, 11%-24%) in the lactate clearance group. This observed difference between mortality rates did not reach the predefined -10% threshold (intent-to-treat analysis: 95% CI for the 6% difference, -3% to 15%). There were no differences in treatment-related adverse events between the groups. Conclusion Among patients with septic shock who were treated to normalize central venous and mean arterial pressure, additional management to normalize lactate clearance compared with management to normalize ScvO(2) did not result in significantly different in-hospital mortality.	[Jones, Alan E.; Claremont, Heather A.; Kline, Jeffrey A.] Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28203 USA; [Shapiro, Nathan I.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Shapiro, Nathan I.] Beth Israel Deaconess Med Ctr, Vasc Biol Res Ctr, Boston, MA 02215 USA; [Trzeciak, Stephen] Cooper Univ Hosp, Dept Med, Div Crit Care Med, Camden, NJ USA; [Trzeciak, Stephen; Arnold, Ryan C.] Cooper Univ Hosp, Dept Emergency Med, Camden, NJ USA	Carolinas Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Cooper University Hospital; Cooper University Hospital	Kline, JA (corresponding author), Carolinas Med Ctr, Dept Emergency Med, 1000 Blythe Blvd,MEB 304, Charlotte, NC 28203 USA.	jkline@carolinas.org	Shapiro, Nathan/F-1718-2016		National Institutes of Health (NIH) [GM76652, GM83211, HL091757, GM076659]; National Institute of General Medical Sciences; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM076652, P50GM076659, K23GM083211] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funding/Support: This project was supported by grant GM76652 from the National Institutes of Health (NIH), National Institute of General Medical Sciences (Dr Jones). Dr Trzeciak was supported by grant GM83211 from the NIH. Dr Shapiro was supported by grants HL091757 and GM076659 from the NIH.	Agency for Healthcare Research Quality, AG HEALTHC RES QUAL; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Arnold RC, 2009, SHOCK, V32, P35, DOI 10.1097/SHK.0b013e3181971d47; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Carlbom DJ, 2007, CRIT CARE MED, V35, P2525, DOI 10.1097/01.ccm.0000298122.49245.d7; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Dombrovskiy VY, 2007, CRIT CARE MED, V35, P1244, DOI 10.1097/01.CCM.0000261890.41311.E9; Ho BCH, 2006, CRIT CARE, V10, DOI 10.1186/cc4918; Hollenberg SM, 2004, CRIT CARE MED, V32, P1928, DOI 10.1097/01.CCM.0000139761.05492.D6; Jones AE, 2008, CRIT CARE MED, V36, P2734, DOI 10.1097/CCM.0b013e318186f839; Jones AE, 2007, ACAD EMERG MED, V14, P1072, DOI 10.1197/j.aem.2007.04.014; Jones AE, 2007, CHEST, V132, P425, DOI 10.1378/chest.07-0234; Jones Alan E, 2005, Crit Care Med, V33, P1888, DOI 10.1097/01.CCM.0000166872.78449.B1; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Nguyen HB, 2007, CRIT CARE MED, V35, P1105, DOI 10.1097/01.CCM.0000259463.33848.3D; Nguyen HB, 2004, CRIT CARE MED, V32, P1637, DOI 10.1097/01.CCM.0000132904.35713.A7; Peake S, 2007, CRIT CARE MED, V35, P994, DOI 10.1097/01.CCM.0000257481.37623.3B; Perel A, 2008, CRIT CARE, V12, DOI 10.1186/cc6979; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Shapiro NI, 2010, J EMERG MED, V39, P89, DOI 10.1016/j.jemermed.2009.07.021; Shapiro NI, 2003, CRIT CARE MED, V31, P670, DOI 10.1097/01.CCM.0000054867.01688.D1; Shapiro NI, 2006, CRIT CARE MED, V34, P1025, DOI 10.1097/01.CCM.0000206104.18647.A8; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; Trzeciak S, 2006, CHEST, V129, P225, DOI 10.1378/chest.129.2.225; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wang HE, 2007, CRIT CARE MED, V35, P1928, DOI 10.1097/01.CCM.0000277043.85378.C1; Watts JA, 2003, ACAD EMERG MED, V10, P985, DOI 10.1197/S1069-6563(03)00319-1; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989	29	707	801	2	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	2010	303	8					739	746		10.1001/jama.2010.158	http://dx.doi.org/10.1001/jama.2010.158			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	559DD	20179283	Green Accepted, Bronze			2023-01-03	WOS:000274800000025
J	Sack, RL				Sack, Robert L.			Jet Lag	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE RESPONSE CURVE; LIGHT MELATONIN ONSET; CIRCADIAN-RHYTHMS; WESTWARD FLIGHT; BRIGHT LIGHT; SLEEP; SHIFT; ALLEVIATION; ADAPTATION; CAFFEINE	A 55-year-old physician is planning a trip from Los Angeles to London to attend a scientific conference. His previous trip to Europe was complicated by sleepiness during meetings and difficulty falling asleep and remaining asleep at night. He wants to know what he can do to avoid jet lag. What would you advise?	Oregon Hlth & Sci Univ, Dept Psychiat, Sleep Disorders Med Program, Portland, OR 97201 USA	Oregon Health & Science University	Sack, RL (corresponding author), Oregon Hlth & Sci Univ, Dept Psychiat, Sleep Disorders Med Program, Mail Code CR139,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	sackr@ohsu.edu			Takeda Pharmaceuticals North America; Mini Mitter	Takeda Pharmaceuticals North America(Takeda Pharmaceutical Company Ltd); Mini Mitter	Dr. Sack reports receiving consulting fees from Takeda Pharmaceuticals North America and Mini Mitter, a subsidiary of Philips Respironics. No other potential conflict of interest relevant to this article was reported.	American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS; ARENDT J, 1986, BRIT MED J, V292, P1170, DOI 10.1136/bmj.292.6529.1170; Arendt J., 1988, ANN REV CHRONOPHARMA, V5, P53; ASCHOFF J, 1975, CHRONOBIOLOGIA, V2, P23; Baehr EK, 1999, AM J PHYSIOL-REG I, V277, pR1598, DOI 10.1152/ajpregu.1999.277.6.R1598; Beaumont M, 2004, J APPL PHYSIOL, V96, P50, DOI 10.1152/japplphysiol.00940.2002; BOGAN R, 2009, 23 ANN M ASS PROF SL; Burgess HJ, 2008, J PHYSIOL-LONDON, V586, P639, DOI 10.1113/jphysiol.2007.143180; Buxton OM, 2000, SLEEP, V23, P915; Buxton OM, 2003, AM J PHYSIOL-REG I, V284, pR714, DOI 10.1152/ajpregu.00355.2002; CLAUSTRAT B, 1992, BIOL PSYCHIAT, V32, P705, DOI 10.1016/0006-3223(92)90300-O; DAAN S, 1984, PSYCHOPHARMACOL BULL, V20, P566; Daurat A, 2000, PSYCHOPHARMACOLOGY, V149, P241, DOI 10.1007/s002139900367; Dolder CR, 2008, CNS DRUGS, V22, P1021, DOI 10.2165/0023210-200822120-00005; Dubocovich ML, 1996, BEHAV BRAIN RES, V73, P141; DWARDS BJ, 2000, ERGONOMICS, V43, P1501; Eastman CI, 2009, SLEEP MED CLIN, V4, P241, DOI 10.1016/j.jsmc.2009.02.006; Herxheimer A, 2002, COCHRANE DB SYST REV, V2, DOI [10.1002/14651858.CD001520, DOI 10.1002/14651858.CD001520]; Jamieson AO, 2001, SLEEP MED, V2, P423, DOI 10.1016/S1389-9457(00)00073-3; Khalsa SBS, 2003, J PHYSIOL-LONDON, V549, P945, DOI 10.1113/jphysiol.2003.040477; LAVIE P, 1990, PSYCHOPHARMACOLOGY, V101, P250, DOI 10.1007/BF02244135; Lewy AJ, 1998, CHRONOBIOL INT, V15, P71, DOI 10.3109/07420529808998671; LEWY AJ, 1989, CHRONOBIOL INT, V6, P93, DOI 10.3109/07420528909059144; Lowden A, 1998, CHRONOBIOL INT, V15, P365, DOI 10.3109/07420529808998696; Morgenthaler TI, 2007, SLEEP, V30, P1445, DOI 10.1093/sleep/30.11.1445; MORRIS HH, 1987, JAMA-J AM MED ASSOC, V258, P945, DOI 10.1001/jama.258.7.945; Nickelsen T, 2002, CHRONOBIOL INT, V19, P915, DOI 10.1081/CBI-120014108; NICKELSEN T, 1991, ADV PINEAL, V5, P303; Pandi-Perumal SR, 2007, PROG NEURO-PSYCHOPH, V31, P1, DOI 10.1016/j.pnpbp.2006.06.020; PETRIE K, 1989, BRIT MED J, V298, P705, DOI 10.1136/bmj.298.6675.705; PETRIE K, 1993, BIOL PSYCHIAT, V33, P526, DOI 10.1016/0006-3223(93)90007-Z; Pierard C, 2001, EUR J APPL PHYSIOL, V85, P144, DOI 10.1007/s004210100418; Rajaratnam SMW, 2009, LANCET, V373, P482, DOI 10.1016/S0140-6736(08)61812-7; Reilly T, 2001, INT J SPORTS MED, V22, P166, DOI 10.1055/s-2001-16379; Reynolds NC, 2002, MIL MED, V167, P451, DOI 10.1093/milmed/167.6.451; Sack RL, 2007, SLEEP, V30, P1460, DOI 10.1093/sleep/30.11.1460; Silverman D, 2009, LANCET, V373, P2067, DOI 10.1016/S0140-6736(09)60209-9; Smith MR, 2008, PHYSIOL BEHAV, V95, P449, DOI 10.1016/j.physbeh.2008.07.012; Spitzer RL, 1999, AM J PSYCHIAT, V156, P1392; Suhner A, 2001, AVIAT SPACE ENVIR MD, V72, P638; Suhner A, 1998, CHRONOBIOL INT, V15, P655, DOI 10.3109/07420529808993201; Takahashi T, 2002, PSYCHIAT CLIN NEUROS, V56, P301, DOI 10.1046/j.1440-1819.2002.00988.x; Takahashi T, 1999, PSYCHIAT CLIN NEUROS, V53, P257, DOI 10.1046/j.1440-1819.1999.00537.x; Waterhouse J, 2007, LANCET, V369, P1117, DOI 10.1016/S0140-6736(07)60529-7; PROFILE US RESIDENT	45	90	95	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 4	2010	362	5					440	447		10.1056/NEJMcp0909838	http://dx.doi.org/10.1056/NEJMcp0909838			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	551FV	20130253				2023-01-03	WOS:000274193300009
J	Hasegawa, T; Mikoda, N; Kitazawa, M; LaFerla, FM				Hasegawa, Tohru; Mikoda, Nobuyuki; Kitazawa, Masashi; LaFerla, Frank M.			Treatment of Alzheimer's Disease with Anti-Homocysteic Acid Antibody in 3xTg-AD Male Mice	PLOS ONE			English	Article							IMMATURE RATS; A-BETA; RECEPTOR; RELEASE; INHIBITION; METHIONINE; CULTURES; STRESS	Alzheimer's disease (AD) is an age-associated progressive neurodegenerative disorder with dementia, the exact pathogenic mechanisms of which remain unknown. We previously reported that homocysteic acid (HA) may be one of the pathological biomarkers in the brain with AD and that the increased levels of HA may induce the accumulation of intraneuronal amyloid-beta (A beta) peptides. In this study, we further investigated the pathological role of HA in a mouse model of AD. Four-monthold prepathological 3xTg-AD mice exhibited higher levels of HA in the hippocampus than did age-matched nontransgenic mice, suggesting that HA accumulation may precede both A beta and tau pathologies. We then fed 3-month-old 3xTg-AD mice with vitamin B6-deficient food for 3 weeks to increase the HA levels in the brain. Concomitantly, mice received either saline or anti-HA antibody intraventricularly via a guide cannula every 3 days during the course of the B6-deficient diet. We found that mice that received anti-HA antibody significantly resisted cognitive impairment induced by vitamin B6 deficiency and that AD-related pathological changes in their brains was attenuated compared with the saline-injected control group. A similar neuroprotective effect was observed in 12-month-old 3xTg-AD mice that received anti-HA antibody injections while receiving the regular diet. We conclude that increased brain HA triggers memory impairment and that this condition deteriorates with amyloid and leads to subsequent neurodegeneration in mouse models of AD.	[Hasegawa, Tohru] Saga Womens Jr Coll, Saga, Japan; [Mikoda, Nobuyuki] Kyudo Ltd, Tosu, Saga, Japan; [Kitazawa, Masashi; LaFerla, Frank M.] Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA USA	University of California System; University of California Irvine	Hasegawa, T (corresponding author), Saga Womens Jr Coll, Saga, Japan.	hasegawa@yumekobo-shizuka.com	Kitazawa, Masashi/AAI-1721-2021	Kitazawa, Masashi/0000-0003-2165-8197; MIKODA, NOBUYUKI/0000-0002-0708-4329	Arfresa Pharmcology	Arfresa Pharmcology	This experiment was supported by Arfresa Pharmcology (http://www.alfresa-pharma.co.jp/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akbari Y, 2004, BIOCHEM BIOPH RES CO, V322, P1145, DOI 10.1016/j.bbrc.2004.07.136; ALSPECTOR E, RELATIONSHIP NEUROGE; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Chwatko G, 2007, FASEB J, V21, P1707, DOI 10.1096/fj.06-7435com; DO KQ, 1988, J NEURAL TRANSM, V72, P185, DOI 10.1007/BF01243418; Do KQ, 1997, J NEUROCHEM, V68, P2386, DOI 10.1046/j.1471-4159.1997.68062386.x; Folbergrova J, 2007, EXP NEUROL, V204, P597, DOI 10.1016/j.expneurol.2006.12.010; Hasegawa T, 2005, J NEUROSCI RES, V80, P869, DOI 10.1002/jnr.20514; Hasegawa T, 2007, MED HYPOTHESES, V69, P1135, DOI 10.1016/j.mehy.2007.02.034; Kluska MM, 2005, NEUROSCIENCE, V135, P723, DOI 10.1016/j.neuroscience.2005.06.082; Langmeier M, 2003, EPILEPSIA, V44, P299, DOI 10.1046/j.1528-1157.2003.31702.x; LIEBERMA.M, 1965, BIOCHEM J, V97, P449, DOI 10.1042/bj0970449; Lockhart B, 2000, BRAIN RES, V855, P292, DOI 10.1016/S0006-8993(99)02372-0; McMahon JA, 2006, NEW ENGL J MED, V354, P2764, DOI 10.1056/NEJMoa054025; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; OHMORI S, 1975, H-S Z PHYSIOL CHEM, V356, P1369, DOI 10.1515/bchm2.1975.356.2.1369; Qu K, 2008, NEUROCHEM INT, V52, P155, DOI 10.1016/j.neuint.2007.05.016; Shankar GM, 2007, J NEUROSCI, V27, P2866, DOI 10.1523/JNEUROSCI.4970-06.2007; Sommer S, 2004, J PROTEOME RES, V3, P572, DOI 10.1021/pr034115o	19	24	24	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 20	2010	5	1							e8593	10.1371/journal.pone.0008593	http://dx.doi.org/10.1371/journal.pone.0008593			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546AI	20098691	gold, Green Published			2023-01-03	WOS:000273779000003
J	Peltzer, K				Peltzer, Karl			Traditional health practitioners in South Africa	LANCET			English	Editorial Material							HEALERS; MEDICINE		[Peltzer, Karl] Human Sci Res Council, ZA-0001 Pretoria, Gauteng Prov, South Africa; [Peltzer, Karl] Univ Free State, Dept Psychol, Bloemfontein, Free State Prov, South Africa	Human Sciences Research Council-South Africa; University of the Free State	Peltzer, K (corresponding author), Human Sci Res Council, ZA-0001 Pretoria, Gauteng Prov, South Africa.	kpeltzer@hsrc.ac.za	Peltzer, Karl/Q-7334-2019	Peltzer, Karl/0000-0002-5980-0876				Colvin M, 2003, INT J TUBERC LUNG D, V7, pS86; Devenish A, 2005, SOC DYNAMICS, V31, P243, DOI 10.1080/02533950508628715; Ensink K., 1999, TRANSCULT PSYCHIATRY, V36, P23, DOI [DOI 10.1177/13634615990, 10.1177/136346159903600102, DOI 10.1177/136346159903600102]; Gqaleni N., 2007, S AFR HLTH REV, V2007, P175; Kahn M.S., 2001, TRANSCULT PSYCHIATRY, V38, P35, DOI DOI 10.1177/136346150103800104; Meissner O, 2004, SAMJ S AFR MED J, V94, P901; Owira PMO, 2009, PHYTOTHER RES, V23, P147, DOI 10.1002/ptr.2595; PELTZER K, 2006, S AFRI J OBSTET GYNA, V16, P74; Peltzer K, 2006, AIDS BEHAV, V10, P683, DOI 10.1007/s10461-006-9110-x; Peltzer K, 2009, AFR J TRADIT COMPLEM, V6, P175; Sorsdahl K, 2009, J NERV MENT DIS, V197, P434, DOI 10.1097/NMD.0b013e3181a61dbc; 2008, GOVT GAZETTE    0110	12	25	26	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 19	2009	374	9694					956	957		10.1016/S0140-6736(09)61261-7	http://dx.doi.org/10.1016/S0140-6736(09)61261-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	498PK	19709734				2023-01-03	WOS:000270154100007
J	Bakitas, M; Lyons, KD; Hegel, MT; Balan, S; Brokaw, FC; Seville, J; Hull, JG; Li, ZZ; Tosteson, TD; Byock, IR; Ahles, TA				Bakitas, Marie; Lyons, Kathleen Doyle; Hegel, Mark T.; Balan, Stefan; Brokaw, Frances C.; Seville, Janette; Hull, Jay G.; Li, Zhongze; Tosteson, Tor D.; Byock, Ira R.; Ahles, Tim A.			Effects of a Palliative Care Intervention on Clinical Outcomes in Patients With Advanced Cancer The Project ENABLE II Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; CHRONIC ILLNESS CARE; END; MANAGEMENT; HEALTH; CONSULTATION; MEANINGFUL; DEPRESSION; PROVIDERS; FAMILIES	Context There are few randomized controlled trials on the effectiveness of palliative care interventions to improve the care of patients with advanced cancer. Objective To determine the effect of a nursing-led intervention on quality of life, symptom intensity, mood, and resource use in patients with advanced cancer. Design, Setting, and Participants Randomized controlled trial conducted from November 2003 through May 2008 of 322 patients with advanced cancer in a rural, National Cancer Institute-designated comprehensive cancer center in New Hampshire and affiliated outreach clinics and a VA medical center in Vermont. Interventions A multicomponent, psychoeducational intervention (Project ENABLE [Educate, Nurture, Advise, Before Life Ends]) conducted by advanced practice nurses consisting of 4 weekly educational sessions and monthly follow-up sessions until death or study completion (n = 161) vs usual care (n = 161). Main Outcome Measures Quality of life was measured by the Functional Assessment of Chronic Illness Therapy for Palliative Care (score range, 0-184). Symptom intensity was measured by the Edmonton Symptom Assessment Scale (score range, 0-900). Mood was measured by the Center for Epidemiological Studies Depression Scale (range, 0-60). These measures were assessed at baseline, 1 month, and every 3 months until death or study completion. Intensity of service was measured as the number of days in the hospital and in the intensive care unit (ICU) and the number of emergency department visits recorded in the electronic medical record. Results A total of 322 participants with cancer of the gastrointestinal tract (41%; 67 in the usual care group vs 66 in the intervention group), lung (36%; 58 vs 59), genitourinary tract (12%; 20 vs 19), and breast (10%; 16 vs 17) were randomized. The estimated treatment effects (intervention minus usual care) for all participants were a mean (SE) of 4.6 (2) for quality of life (P = .02), -27.8 (15) for symptom intensity (P = .06), and -1.8 (0.81) for depressed mood (P = .02). The estimated treatment effects in participants who died during the study were a mean (SE) of 8.6 (3.6) for quality of life (P = .02), -24.2 (20.5) for symptom intensity (P = .24), and -2.7 (1.2) for depressed mood (P = .03). Intensity of service did not differ between the 2 groups. Conclusion Compared with participants receiving usual oncology care, those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood, but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits. Trial Registration clinicaltrials.gov Identifier: NCT00253383 JAMA. 2009;302(7):741-749	[Bakitas, Marie; Brokaw, Frances C.; Byock, Ira R.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Anesthesiol, Sect Palliat Med, Lebanon, NH 03756 USA; [Lyons, Kathleen Doyle; Hegel, Mark T.; Seville, Janette; Ahles, Tim A.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Psychiat, Lebanon, NH 03756 USA; [Balan, Stefan; Brokaw, Frances C.] Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Med, Lebanon, NH 03756 USA; [Hull, Jay G.] Dartmouth Coll, Dept Psychol & Brain Sci, Hanover, NH 03755 USA; [Bakitas, Marie] Yale Univ, Sch Nursing, New Haven, CT 06536 USA; [Balan, Stefan] White River Junct VA Med Ctr, White River Jct, VT USA; [Li, Zhongze; Tosteson, Tor D.] Norris Cotton Canc Ctr, Lebanon, NH USA; [Ahles, Tim A.] Mem Sloan Kettering Canc Ctr, Dept Psychiat, New York, NY 10021 USA	Dartmouth College; Dartmouth College; Dartmouth College; Dartmouth College; Yale University; Norris Cotton Cancer Center; Memorial Sloan Kettering Cancer Center	Bakitas, M (corresponding author), Dartmouth Hitchcock Med Ctr, Dartmouth Med Sch, Dept Anesthesiol, Sect Palliat Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	marie.bakitas@dartmouth.edu	Lyons, Kathleen/ABA-2433-2020	Bakitas, Marie/0000-0002-2913-2053; Lyons, Kathleen/0000-0002-8895-4612	Department of Defense Clinical Nurse Researcher award; American Cancer Society Doctoral Scholarship; National Institutes of Health/National Institute of Nursing Research [T32NR008346]; National Cancer Institute [R01 CA101704]; NATIONAL CANCER INSTITUTE [P30CA023108, R01CA101704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [T32NR008346, R01NR011871] Funding Source: NIH RePORTER	Department of Defense Clinical Nurse Researcher award(United States Department of Defense); American Cancer Society Doctoral Scholarship(American Cancer Society); National Institutes of Health/National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	Dr Bakitas is a recipient of a Department of Defense Clinical Nurse Researcher award, an American Cancer Society Doctoral Scholarship, and a postdoctoral fellowship at Yale University's School of Nursing (National Institutes of Health/National Institute of Nursing Research grant T32NR008346). This study was supported by National Cancer Institute grant R01 CA101704.	Ahles TA, 2001, J PAIN SYMPTOM MANAG, V22, P584, DOI 10.1016/S0885-3924(01)00301-3; *AM CANC SOC, 2007, CANC FACTS FIG 2007; [Anonymous], 2002, STAT ANAL MISSING DA; Bakitas MA, 2006, J PAIN SYMPTOM MANAG, V31, P270, DOI 10.1016/j.jpainsymman.2005.07.011; Bakitas M, 2008, CANCER-AM CANCER SOC, V112, P1854, DOI 10.1002/cncr.23381; Bakitas Marie, 2004, J Palliat Med, V7, P363, DOI 10.1089/109662104773709530; Bakitas Marie, 2009, Palliat Support Care, V7, P75, DOI 10.1017/S1478951509000108; Bee PE, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-60; Berkman LF, 2003, JAMA-J AM MED ASSOC, V289, P3106; Brady M J, 1999, Cancer Treat Res, V100, P203; Bruera E, 1991, J Palliat Care, V7, P6; Byock I, 2006, J PALLIAT MED, V9, P137, DOI 10.1089/jpm.2006.9.137; Cella D, 2002, QUAL LIFE RES, V11, P207, DOI 10.1023/A:1015276414526; de Vet HC, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-54; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Epstein RM, 2007, NIH PUBLICATION; FERGUSON R, 2003, GROUP SHARED MED APP, V2; Ferris FD, 2002, MODEL GUIDE HOSPICE; Field MJ, 1997, APPROACHING DEATH IM; Foley KM, 2001, IMPROVING PALLIATIVE; Follwell M, 2009, J CLIN ONCOL, V27, P206, DOI 10.1200/JCO.2008.17.7568; Glasgow RE, 2006, HEALTH PROMOT INT, V21, P245, DOI 10.1093/heapro/dal017; Greisinger AJ, 1997, CANCER PRACT, V5, P147; Hays RD, 2000, PHARMACOECONOMICS, V18, P419, DOI 10.2165/00019053-200018050-00001; Hegel M. T., 2000, FAMILIES SYSTEMS HLT, V18, P423, DOI DOI 10.1037/H0091866; Hibbard JH, 2004, HEALTH SERV RES, V39, P1005, DOI 10.1111/j.1475-6773.2004.00269.x; Holland J C, 2001, Cancer Control, V8, P88; Holland JC, 1999, ONCOLOGY-NY, V13, P459; Jakobsson U, 2007, J CLIN NURS, V16, P95, DOI 10.1111/j.1365-2702.2006.01584.x; Lyons KD, 2009, J PAIN SYMPTOM MANAG, V37, P23, DOI 10.1016/j.jpainsymman.2007.12.015; McNiff KK, 2008, J CLIN ONCOL, V26, P3832, DOI 10.1200/JCO.2008.16.8674; Meier Diane E, 2004, J Palliat Med, V7, P119, DOI 10.1089/109662104322737395; Morrison RS, 2008, ARCH INTERN MED, V168, P1783, DOI 10.1001/archinte.168.16.1783; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Mularski RA, 2007, J PAIN SYMPTOM MANAG, V34, pS7, DOI 10.1016/j.jpainsymman.2007.04.004; *NAT COMPR CANC NE, 2006, PALL CAR V 1 2006 NC; National Consensus Project, 2009, CLIN PRACT GUID QUAL; Nelson EL, 2008, CLIN CANCER RES, V14, P2111, DOI 10.1158/1078-0432.CCR-07-1632; Noffsinger EB, 2000, GROUP PRACT J, V48, P46; Okun A, 1996, PSYCHOL REP, V79, P1059, DOI 10.2466/pr0.1996.79.3.1059; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ringash J, 2007, CANCER-AM CANCER SOC, V110, P196, DOI 10.1002/cncr.22799; ROCCAFORTE WH, 1992, J AM GERIATR SOC, V40, P697, DOI 10.1111/j.1532-5415.1992.tb01962.x; Schild SE, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.8076; Schnipper L, 1998, J CLIN ONCOL, V16, P1986; Skalla KA, 2004, ONCOL NURS FORUM, V31, P313, DOI 10.1188/04.ONF.313-319; Smith Thomas J, 2003, J Palliat Med, V6, P699, DOI 10.1089/109662103322515202; Sohl SJ, 2007, PREV MED, V45, P252, DOI 10.1016/j.ypmed.2007.06.009; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; Sweeney L, 2007, AM J MANAG CARE, V13, P84; Tan AD, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.9515; Temel JS, 2007, J CLIN ONCOL, V25, P2377, DOI 10.1200/JCO.2006.09.2627; Wagner E H, 1998, Eff Clin Pract, V1, P2; Wagner EH, 2001, HEALTH AFFAIR, V20, P64, DOI 10.1377/hlthaff.20.6.64; Wagner EH, 2005, J ALTERN COMPLEM MED, V11, pS7, DOI 10.1089/acm.2005.11.s-7; Wasson J H, 1998, Jt Comm J Qual Improv, V24, P513; Wennberg JE, 2004, BMJ-BRIT MED J, V328, P607, DOI 10.1136/bmj.328.7440.607; Wennberg JE, 2006, CARE PATIENTS SEVERE; who, WHO DEF PALL CAR; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Zimmermann C, 2008, JAMA-J AM MED ASSOC, V299, P1698, DOI 10.1001/jama.299.14.1698	64	1118	1122	5	171	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	2009	302	7					741	749		10.1001/jama.2009.1198	http://dx.doi.org/10.1001/jama.2009.1198			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	484UT	19690306	Green Accepted, Bronze			2023-01-03	WOS:000269073800022
J	Van Goietsenoven, G; Hutton, J; Becker, JP; Lallemand, B; Robert, F; Lefranc, F; Pirker, C; Vandenbussche, G; Van Antwerpen, P; Evidente, A; Berger, W; Prevost, M; Pelletier, J; Kiss, R; Kinzy, TG; Kornienko, A; Mathieu, V				Van Goietsenoven, Gwendoline; Hutton, Jenna; Becker, Jean-Paul; Lallemand, Benjamin; Robert, Francis; Lefranc, Florence; Pirker, Christine; Vandenbussche, Guy; Van Antwerpen, Pierre; Evidente, Antonio; Berger, Walter; Prevost, Martine; Pelletier, Jerry; Kiss, Robert; Kinzy, Terri Goss; Kornienko, Alexander; Mathieu, Veronique			Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas	FASEB JOURNAL			English	Article						narciclasine; growth inhibition; apoptosis resistance; actin	ACTIN-BINDING PROTEIN; ELONGATION-FACTOR 1A; CANCER-CELLS; TRANSLATION ELONGATION; APOPTOSIS; NARCICLASINE; CYTOSKELETON; MITOCHONDRIA; RESISTANCE; LYCORINE	Melanomas display poor response rates to adjuvant therapies because of their intrinsic resistance to proapoptotic stimuli. This study indicates that such resistance can be overcome, at least partly, through the targeting of eEF1A elongation factor with narciclasine, an Amaryllidaceae isocarbostyril controlling plant growth. Narciclasine displays IC50 growth inhibitory values between 30-100 nM in melanoma cell lines, irrespective of their levels of resistance to proapoptotic stimuli. Normal noncancerous cell lines are much less affected. At nontoxic doses, narciclasine also significantly improves (P=0.004) the survival of mice bearing metastatic apoptosis-resistant melanoma xeno-grafts in their brain. The eEF1A targeting with narciclasine (50 nM) leads to 1) marked actin cytoskeleton disorganization, resulting in cytokinesis impairment, and 2) protein synthesis impairment (elongation and initiation steps), whereas apoptosis is induced at higher doses only (>= 200 nM). In addition to molecular docking validation and identification of potential binding sites, we biochemically confirmed that narciclasine directly binds to human recombinant and yeast-purified eEF1A in a nanomolar range, but not to actin or elongation factor 2, and that 5 nM narciclasine is sufficient to impair eEF1A-related actin bundling activity. eEF1A is thus a potential target to combat melanomas regardless of their apoptosis-sensitivity, and this finding reconciles the pleiotropic cytostatic of narciclasine.-Van Goietsenoven, G., Hutton, J., Becker, J.-P., Lallemand, B., Robert, F., Lefranc, F., Pirker, C., Vandenbussche, G., Van Antwerpen, P., Evidente, A., Berger, W., Prevost, M., Pelletier, J., Kiss, R., Goss Kinzy, T., Kornienko, A., Mathieu, V. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J. 24, 4575-4584 (2010). www.fasebj.org	[Kiss, Robert] Univ Libre Bruxelles, Inst Pharm, Toxicol Lab, B-1050 Brussels, Belgium; [Lallemand, Benjamin] Univ Libre Bruxelles, Lab Bioanalyt Chem Toxicol & Appl Chem, B-1050 Brussels, Belgium; [Van Antwerpen, Pierre] Univ Libre Bruxelles, Inst Pharm, Lab Pharmaceut Chem, B-1050 Brussels, Belgium; [Becker, Jean-Paul; Vandenbussche, Guy; Prevost, Martine] Univ Libre Bruxelles, Lab Struct & Funct Biol Membranes, Ctr Struct Biol & Bioinformat, B-1050 Brussels, Belgium; [Hutton, Jenna; Kinzy, Terri Goss] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA; [Robert, Francis; Pelletier, Jerry] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Lefranc, Florence] Erasme Univ Hosp, Dept Neurosurg, B-1070 Brussels, Belgium; [Pirker, Christine; Berger, Walter] Med Univ Vienna, Inst Canc Res, Dept Med 1, Vienna, Austria; [Evidente, Antonio] Univ Naples Federico II, Dipartimento Sci Suolo Pianta Ambiente & Prod Ani, Portici, Italy; [Kornienko, Alexander] New Mexico Inst Min & Technol, Dept Chem, Socorro, NM 87801 USA	Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Rutgers State University New Brunswick; Rutgers State University Medical Center; McGill University; Universite Libre de Bruxelles; Medical University of Vienna; University of Naples Federico II; New Mexico Institute of Mining Technology	Kiss, R (corresponding author), Univ Libre Bruxelles, Inst Pharm, Toxicol Lab, Campus Plaine,Blvd Triomphe, B-1050 Brussels, Belgium.	rkiss@ulb.ac.be	Evidente, Antonio/N-9357-2013; Kornienko, Alexander/AAE-1870-2020	Evidente, Antonio/0000-0001-9110-1656; Kornienko, Alexander/0000-0003-2041-7367; Pirker, Christine/0000-0001-7104-4404; Kinzy, Terri/0000-0003-1394-9226; Van Antwerpen, Pierre/0000-0002-4934-8863; Vandenbussche, Guy/0000-0001-9592-2304; Berger, Walter/0000-0003-0014-1658	Fonds Yvonne Boel (Brussels, Belgium); Fonds National de la Recherche Scientifique (FNRS; Brussels, Belgium); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057483] Funding Source: NIH RePORTER	Fonds Yvonne Boel (Brussels, Belgium); Fonds National de la Recherche Scientifique (FNRS; Brussels, Belgium)(Fonds de la Recherche Scientifique - FNRS); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors thank Jean-Francois Gaussin and Sebastien Sauvage for the in vivo experiment. The present work has been supported partly by grants awarded by the Fonds Yvonne Boel (Brussels, Belgium) and by the Fonds National de la Recherche Scientifique (FNRS; Brussels, Belgium). F.L. is a clinical research fellow, V.M. is a senior research assistant, and R.K. is a director of research with the FNRS.	Atallah Ehab, 2005, Curr Treat Options Oncol, V6, P185; Berger W, 1997, INT J CANCER, V71, P108, DOI 10.1002/(SICI)1097-0215(19970328)71:1<108::AID-IJC18>3.0.CO;2-E; Bi YR, 2003, J PLANT PHYSIOL, V160, P1041, DOI 10.1078/0176-1617-00911; Boldogh IR, 2006, BBA-MOL CELL RES, V1763, P450, DOI 10.1016/j.bbamcr.2006.02.014; CARRASCO L, 1975, FEBS LETT, V52, P236, DOI 10.1016/0014-5793(75)80813-1; CERIOTTI G, 1967, NATURE, V213, P595, DOI 10.1038/213595a0; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; de Heredia ML, 2004, CURR OPIN CELL BIOL, V16, P80, DOI 10.1016/j.ceb.2003.11.002; Dumont P, 2007, NEOPLASIA, V9, P766, DOI 10.1593/neo.07535; Duttaroy A, 1998, EXP CELL RES, V238, P168, DOI 10.1006/excr.1997.3819; Eberle J, 2007, DRUG RESIST UPDATE, V10, P218, DOI 10.1016/j.drup.2007.09.001; Edmonds BT, 1996, J CELL SCI, V109, P2705; EVIDENTE A, 1991, PLANTA MED, V57, P293, DOI 10.1055/s-2006-960098; Franklin-Tong VE, 2008, BIOCHEM J, V413, P389, DOI 10.1042/BJ20080320; Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o; Gerweck LE, 1996, CANCER RES, V56, P1194; GHEORGHUI A, 1962, ANN PHARM FR, V20, P531; Grassi G, 2007, BIOCHIMIE, V89, P1544, DOI 10.1016/j.biochi.2007.07.007; Gross SR, 2005, NAT STRUCT MOL BIOL, V12, P772, DOI 10.1038/nsmb979; Gross SR, 2007, MOL CELL BIOL, V27, P1974, DOI 10.1128/MCB.00832-06; Hamm C, 2008, CANCER TREAT REV, V34, P145, DOI 10.1016/j.ctrv.2007.10.003; Hayot C, 2006, TOXICOL APPL PHARM, V211, P30, DOI 10.1016/j.taap.2005.06.006; Ingrassia L, 2009, J MED CHEM, V52, P1100, DOI 10.1021/jm8013585; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; JIMENEZ A, 1976, BIOCHIM BIOPHYS ACTA, V425, P342, DOI 10.1016/0005-2787(76)90261-6; Kornienko A, 2008, CHEM REV, V108, P1982, DOI 10.1021/cr078198u; La Porta CAM, 2007, CURR MED CHEM, V14, P387; Lamoral-Theys D, 2009, J MED CHEM, V52, P6244, DOI 10.1021/jm901031h; Lefranc F, 2009, MOL CANCER THER, V8, P1739, DOI 10.1158/1535-7163.MCT-08-0932; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Liu J, 2007, BIOMED PHARMACOTHER, V61, P229, DOI 10.1016/j.biopha.2007.01.003; Liu XS, 2009, CANCER LETT, V274, P16, DOI 10.1016/j.canlet.2008.08.029; Mathieu V, 2009, J CELL MOL MED, V13, P3960, DOI 10.1111/j.1582-4934.2009.00708.x; McLachlan A, 2005, APOPTOSIS, V10, P619, DOI 10.1007/s10495-005-1896-x; Murray JW, 1996, J CELL BIOL, V135, P1309, DOI 10.1083/jcb.135.5.1309; Noble CG, 2008, CELL MOL LIFE SCI, V65, P1335, DOI 10.1007/s00018-008-7495-6; Pelletier CL, 2007, CANCER RES, V67, P1609, DOI 10.1158/0008-5472.CAN-06-2875; Pettit GR, 2009, J NAT PROD, V72, P1279, DOI 10.1021/np9001948; PETTIT GR, 1986, J NAT PROD, V49, P995, DOI 10.1021/np50048a005; Pinke DE, 2008, GYNECOL ONCOL, V108, P561, DOI 10.1016/j.ygyno.2007.11.019; Pittman YR, 2009, J BIOL CHEM, V284, P4739, DOI 10.1074/jbc.M807945200; SADOWSKI J, 1993, CHEM REV, V93, P2567, DOI 10.1021/cr00023a012; Siedlakowski P, 2008, CANCER BIOL THER, V7, P376, DOI 10.4161/cbt.7.3.5364; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Wang CH, 2008, J CELL SCI, V121, P2913, DOI 10.1242/jcs.023911; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0	48	99	99	0	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2010	24	11					4575	4584		10.1096/fj.10-162263	http://dx.doi.org/10.1096/fj.10-162263			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	675UA	20643906	Green Published			2023-01-03	WOS:000283861100042
J	Adhikari, NKJ; Fowler, RA; Bhagwanjee, S; Rubenfeld, GD				Adhikari, Neill K. J.; Fowler, Robert A.; Bhagwanjee, Satish; Rubenfeld, Gordon D.			Critical Care 1 Critical care and the global burden of critical illness in adults	LANCET			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; INTENSIVE-CARE; UNITED-STATES; MECHANICAL VENTILATION; SEVERE SEPSIS; NATIONAL-AUDIT; ILL PATIENTS; SOUTH-AFRICA; OF-LIFE	Critical care has evolved from treatment of poliomyelitis victims with respiratory failure in an intensive care unit to treatment of severely ill patients irrespective of location or specific technology. Population-based studies in the developed world suggest that the burden of critical illness is higher than generally appreciated and will increase as the population ages. Critical care capacity has long been needed in the developing world, and efforts to improve the care of the critically ill in these settings are starting to occur. Expansion of critical care to handle the consequences of an ageing population, natural disasters, conflict, inadequate primary care, and higher-risk medical therapies will be challenged by high costs at a time of economic constraint. To meet this challenge, investigators in this discipline will need to measure the global burden of critical illness and available critical-care resources, and develop both preventive and therapeutic interventions that are generalisable across countries.	[Adhikari, Neill K. J.; Fowler, Robert A.; Rubenfeld, Gordon D.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Adhikari, Neill K. J.; Fowler, Robert A.; Rubenfeld, Gordon D.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Bhagwanjee, Satish] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Washington; University of Washington Seattle	Rubenfeld, GD (corresponding author), Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	gordon.rubenfeld@sunnybrook.ca						*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Anand S, 2004, LANCET, V364, P1603, DOI 10.1016/S0140-6736(04)17313-3; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Angus DC, 2004, CRIT CARE MED, V32, P638, DOI 10.1097/01.CCM.0000114816.62331.08; Angus Derek C., 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P207; Annane D, 2003, AM J RESP CRIT CARE, V168, P165, DOI 10.1164/rccm.2201087; [Anonymous], COCHRANE DATABASE SY; Barrett H, 2006, INTENS CARE MED, V32, P1371, DOI 10.1007/s00134-006-0215-5; Barrett H, 2005, INTENS CARE MED, V31, P553, DOI 10.1007/s00134-005-2583-7; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; Bhagwanjee S, 2007, SAMJ S AFR MED J, V97, P1311; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Breslow MJ, 2007, J CRIT CARE, V22, P66, DOI 10.1016/j.jcrc.2007.01.006; Burnham G, 2006, LANCET, V368, P1421, DOI 10.1016/S0140-6736(06)69491-9; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; CARSON SS, 2006, J INTENSIVE CARE MED, V2, P173; Celis E, 2002, CRIT CARE, V6, P405; Cheng AC, 2008, PLOS MED, V5, P1173, DOI 10.1371/journal.pmed.0050175; *COBATRICE COLL, 2009, INTENS CARE MED, DOI DOI 10.1007/S00134-009-1514-4; Coghlan B, 2006, LANCET, V367, P44, DOI 10.1016/S0140-6736(06)67923-3; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; Cuthbertson BH, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3723; Davydow DS, 2008, PSYCHOSOM MED, V70, P512, DOI 10.1097/PSY.0b013e31816aa0dd; Degoricija V, 2002, CROAT MED J, V43, P713; Devereaux A, 2008, CHEST, V133, p1S, DOI 10.1378/chest.08-0649; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Dowdy DW, 2005, INTENS CARE MED, V31, P611, DOI 10.1007/s00134-005-2592-6; DRENNAN K, 2008, INTENSIVE CARE RESOU; Du B, 2010, CRIT CARE, V14, DOI 10.1186/cc8222; Dunser MW, 2006, CRIT CARE MED, V34, P1234, DOI 10.1097/01.CCM.0000208360.70835.87; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Engelhardt HT, 1998, J MED PHILOS, V23, P643; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Fowler RA, 2003, JAMA-J AM MED ASSOC, V290, P367, DOI 10.1001/jama.290.3.367; Gao HY, 2007, INTENS CARE MED, V33, P667, DOI 10.1007/s00134-007-0532-3; Garrard C, 1998, BMJ-BRIT MED J, V316, P1841; Granger CB, 2003, ARCH INTERN MED, V163, P2345, DOI 10.1001/archinte.163.19.2345; Grenvik A, 2009, CRIT CARE CLIN, V25, P239, DOI 10.1016/j.ccc.2008.11.001; Halpern NA, 2004, CRIT CARE MED, V32, P1254, DOI 10.1097/01.CCM.0000128577.31689.4C; Hariharan S, 2007, W INDIAN MED J, V56, P144; Harrison DA, 2006, CRIT CARE, V10, DOI 10.1186/cc4854; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Haynes Alex B, 2009, N Engl J Med, V360, P491, DOI 10.1056/NEJMsa0810119; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Horton R, 2009, LANCET, V373, P355, DOI 10.1016/S0140-6736(09)60116-1; IBSEN B, 1954, P ROY SOC MED, V47, P72, DOI 10.1177/003591575404700120; Jackson Richard, 2008, GRAYING GREAT POWERS; Jochberger S, 2008, ANESTH ANALG, V106, P942, DOI 10.1213/ane.0b013e318166ecb8; Jonsen A R, 1986, Law Med Health Care, V14, P172; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kahn JM, 2009, CRIT CARE MED, V37, P2149, DOI 10.1097/CCM.0b013e3181a009d0; Kelley MA, 2004, CHEST, V125, P1514, DOI 10.1378/chest.125.4.1514; KELLEY MA, 1988, NEW ENGL J MED, V318, P1613, DOI 10.1056/NEJM198806163182410; Kirigia Joses M, 2006, Afr J Health Sci, V13, P86; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Lazongas C, 2008, AM J RESP CRIT CARE, V177, pA41; Levy MM, 2008, ANN INTERN MED, V148, P801, DOI 10.7326/0003-4819-148-11-200806030-00002; Linde-Zwirble WT, 2004, CRIT CARE, V8, P222, DOI 10.1186/cc2917; Lott JP, 2009, AM J RESP CRIT CARE, V179, P676, DOI 10.1164/rccm.200808-1281OC; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849, DOI 10.1164/ajrccm.159.6.9808136; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6; Moran JL, 2008, CRIT CARE MED, V36, P46, DOI 10.1097/01.CCM.0000295313.08084.58; Mullan F, 2005, NEW ENGL J MED, V353, P1810, DOI 10.1056/NEJMsa050004; Needham DM, 2005, CRIT CARE MED, V33, P574, DOI [10.1097/01.CCM.0000155992.21174.31, 10.1097/01.ccm.0000155992.21174.31]; Needham DM, 2004, CRIT CARE MED, V32, P1504, DOI 10.1097/01.CCM.0000129972.31533.37; Phua J, 2009, AM J RESP CRIT CARE, V179, P220, DOI 10.1164/rccm.200805-722OC; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Razzak JA, 2002, B WORLD HEALTH ORGAN, V80, P900; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Robnett MK, 2006, CRIT CARE MED, V34, pS25, DOI 10.1097/01.CCM.0000203087.42439.53; Rosenthal VD, 2008, AM J INFECT CONTROL, V36, P627, DOI [10.1016/j.ajic.2008.03.003, 10.1016/j.ajic.2008.10.009, 10.1016/j.ajic.2008.06.003]; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; Rubenfeld GD, 2004, CRIT CARE MED, V32, P1289, DOI 10.1097/01.CCM.0000127266.39560.96; Rubenfeld GD, 2003, CRIT CARE MED, V31, pS276, DOI 10.1097/01.CCM.0000057904.62683.2B; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Scribante J, 2007, SAMJ S AFR MED J, V97, P1315; Sprung CL, 2003, JAMA-J AM MED ASSOC, V290, P790, DOI 10.1001/jama.290.6.790; Tsang KW, 2003, NEW ENGL J MED, V348, P1977, DOI 10.1056/NEJMoa030666; Tu JV, 2009, CAN MED ASSOC J, V180, pE118, DOI 10.1503/cmaj.081197; Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233; Villar J, 2007, AM J RESP CRIT CARE, V176, P795, DOI 10.1164/rccm.200610-1534OC; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; WALTHER SM, 2004, LAKARTIDNINGEN, V101, P3771; Walther Sten M, 2004, Lakartidningen, V101, P3771; Ward NS, 2008, CRIT CARE MED, V36, P471, DOI 10.1097/CCM.0B013E3181629511; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; Weinert CR, 2003, AM J RESP CRIT CARE, V167, P1304, DOI 10.1164/rccm.200205-478OC; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8; Winters BD, 2007, CRIT CARE MED, V35, P1238, DOI 10.1097/01.CCM.0000262388.85669.68; Wunsch H, 2005, J CRIT CARE, V20, P264, DOI 10.1016/j.jcrc.2005.08.002; Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8; Wunsch H, 2009, AM J RESP CRIT CARE, V180, P875, DOI 10.1164/rccm.200902-0201OC; Yatawatte A B, 2004, Ceylon Med J, V49, P51	100	686	719	5	69	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 16	2010	376	9749					1339	1346		10.1016/S0140-6736(10)60446-1	http://dx.doi.org/10.1016/S0140-6736(10)60446-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	671RX	20934212	Bronze, Green Published			2023-01-03	WOS:000283528600037
J	Noguchi, Y; Nishikata, N; Shikata, N; Kimura, Y; Aleman, JO; Young, JD; Koyama, N; Kelleher, JK; Takahashi, M; Stephanopoulos, G				Noguchi, Yasushi; Nishikata, Natsumi; Shikata, Nahoko; Kimura, Yoshiko; Aleman, Jose O.; Young, Jamey D.; Koyama, Naoto; Kelleher, Joanne K.; Takahashi, Michio; Stephanopoulos, Gregory			Ketogenic Essential Amino Acids Modulate Lipid Synthetic Pathways and Prevent Hepatic Steatosis in Mice	PLOS ONE			English	Article							INDUCED INSULIN-RESISTANCE; ACTIVATED PROTEIN-KINASE; REGULATES FOOD-INTAKE; FATTY LIVER-DISEASE; UNCOUPLING PROTEIN-3; ENERGY-EXPENDITURE; IMPROVES GLUCOSE; DE-NOVO; MUSCLE; RAT	Background: Although dietary ketogenic essential amino acid (KAA) content modifies accumulation of hepatic lipids, the molecular interactions between KAAs and lipid metabolism are yet to be fully elucidated. Methodology/Principal Findings: We designed a diet with a high ratio (E/N) of essential amino acids (EAAs) to non-EAAs by partially replacing dietary protein with 5 major free KAAs (Leu, Ile, Val, Lys and Thr) without altering carbohydrate and fat content. This high-KAA diet was assessed for its preventive effects on diet-induced hepatic steatosis and whole-animal insulin resistance. C57B6 mice were fed with a high-fat diet, and hyperinsulinemic ob/ob mice were fed with a high-fat or high-sucrose diet. The high-KAA diet improved hepatic steatosis with decreased de novo lipogensis (DNL) fluxes as well as reduced expressions of lipogenic genes. In C57B6 mice, the high-KAA diet lowered postprandial insulin secretion and improved glucose tolerance, in association with restored expression of muscle insulin signaling proteins repressed by the high-fat diet. Lipotoxic metabolites and their synthetic fluxes were also evaluated with reference to insulin resistance. The high-KAA diet lowered muscle and liver ceramides, both by reducing dietary lipid incorporation into muscular ceramides and preventing incorporation of DNL-derived fatty acids into hepatic ceramides. Conclusion: Our results indicate that dietary KAA intake improves hepatic steatosis and insulin resistance by modulating lipid synthetic pathways.	[Noguchi, Yasushi; Aleman, Jose O.; Young, Jamey D.; Kelleher, Joanne K.; Stephanopoulos, Gregory] MIT, Dept Chem Engn, Cambridge, MA 02139 USA; [Kelleher, Joanne K.] Massachusetts Gen Hosp, Shriners Burn Hosp, Boston, MA 02114 USA; [Noguchi, Yasushi; Nishikata, Natsumi; Shikata, Nahoko; Kimura, Yoshiko; Koyama, Naoto; Takahashi, Michio] Ajinomoto Co Inc, Res Inst Hlth Fundamentals, Kanagawa, Japan	Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Ajinomoto Co Inc	Noguchi, Y (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	gregstep@mit.edu	Young, Jamey/A-5857-2012	Koyama, Naoto/0000-0003-2005-915X; Aleman, Jose/0000-0003-3753-6717	National Institutes of Health (NIH) Bioengineering Research Partnership [DK58533]; NIH Metabolomics Roadmap Initiative [DK070291]; NIH [DK072856]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK072856, R33DK070291, R01DK058533] Funding Source: NIH RePORTER	National Institutes of Health (NIH) Bioengineering Research Partnership(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Metabolomics Roadmap Initiative; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Institutes of Health (NIH) Bioengineering Research Partnership Grant DK58533 and NIH Metabolomics Roadmap Initiative DK070291. J.D.Y. was supported by NIH grant DK072856. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bassilian S, 2002, AM J PHYSIOL-ENDOC M, V282, pE507, DOI 10.1152/ajpendo.00211.2001; Bernstein AM, 2007, J AM DIET ASSOC, V107, P644, DOI 10.1016/j.jada.2007.01.002; Blazquez C, 2001, FEBS LETT, V489, P149, DOI 10.1016/S0014-5793(01)02089-0; Blouet C, 2009, J NEUROSCI, V29, P8302, DOI 10.1523/JNEUROSCI.1668-09.2009; Carmiel-Haggai M, 2004, FASEB J, V18, P136, DOI 10.1096/fj.04-2291fje; Chao LC, 2009, DIABETES, V58, P2788, DOI 10.2337/db09-0763; Chibalin AV, 2008, CELL, V132, P375, DOI 10.1016/j.cell.2007.12.035; Choi CS, 2007, J CLIN INVEST, V117, P1995, DOI 10.1172/JCI13579; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Eisenstein J, 2002, NUTR REV, V60, P189, DOI 10.1301/00296640260184264; Guo FF, 2007, CELL METAB, V5, P103, DOI 10.1016/j.cmet.2007.01.001; Hasty AH, 1999, J LIPID RES, V40, P1529; Hinault C, 2004, FASEB J, V18, P1894, DOI 10.1096/fj.03-1409fje; Holland WL, 2007, CELL METAB, V5, P167, DOI 10.1016/j.cmet.2007.01.002; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Klaus S, 2005, J NUTR, V135, P1854, DOI 10.1093/jn/135.8.1854; Krebs M, 2005, EUR J CLIN INVEST, V35, P351, DOI 10.1111/j.1365-2362.2005.01506.x; Krebs M, 2002, DIABETES, V51, P599, DOI 10.2337/diabetes.51.3.599; Lee WNP, 2000, AM J PHYSIOL-ENDOC M, V279, pE425, DOI 10.1152/ajpendo.2000.279.2.E425; Lowenstein J M, 1975, Methods Enzymol, V35, P279, DOI 10.1016/0076-6879(75)35165-3; Monetti M, 2007, CELL METAB, V6, P69, DOI 10.1016/j.cmet.2007.05.005; Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002; Noguchi Y, 2006, AM J CLIN NUTR, V83, p513S; Noguchi Y, 2009, J BIOL CHEM, V284, P33425, DOI 10.1074/jbc.M109.049478; Noguchi Y, 2008, PHYSIOL GENOMICS, V34, P315, DOI 10.1152/physiolgenomics.00007.2008; PELLETT P L, 1984, American Journal of Clinical Nutrition, V40, P718, DOI 10.1093/ajcn/40.3.718; PENG Y, 1973, J NUTR, V103, P608, DOI 10.1093/jn/103.4.608; Postic C, 2008, J CLIN INVEST, V118, P829, DOI 10.1172/JCI34275; Putman CT, 2003, J PHYSIOL-LONDON, V551, P169, DOI 10.1113/jphysiol.2003.04069; RAO PBR, 1960, J NUTR, V71, P327, DOI 10.1093/jn/71.3.327; Sanyal AJ, 2005, NAT CLIN PRACT GASTR, V2, P46, DOI 10.1038/ncpgasthep0084; She P, 2007, CELL METAB, V6, P181, DOI 10.1016/j.cmet.2007.08.003; SINGAL SA, 1953, J BIOL CHEM, V200, P867; Solerte SB, 2004, AM J CARDIOL, V93, p23A, DOI 10.1016/i.amjcard.2003.11.006; Stoeckman AK, 2002, J BIOL CHEM, V277, P27029, DOI 10.1074/jbc.M202638200; Styczynski MP, 2007, ANAL CHEM, V79, P966, DOI 10.1021/ac0614846; Tilg H, 2005, NAT CLIN PRACT GASTR, V2, P148, DOI 10.1038/ncpgasthep0116; Tremblay F, 2005, DIABETES, V54, P2674, DOI 10.2337/diabetes.54.9.2674; Tserng KY, 2003, ANAL BIOCHEM, V323, P84, DOI 10.1016/j.ab.2003.08.026; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003; Vieu C, 2002, J LIPID RES, V43, P510; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Watanabe M, 2006, NATURE, V439, P484, DOI 10.1038/nature04330; WILLIAMS JN, 1963, NATURE, V200, P472, DOI 10.1038/200472a0; Winzell MS, 2004, DIABETES, V53, pS215, DOI 10.2337/diabetes.53.suppl_3.S215; Wu Y, 2007, J BIOL CHEM, V282, P9777, DOI 10.1074/jbc.M608310200; Yu CL, 2002, J BIOL CHEM, V277, P50230, DOI 10.1074/jbc.M200958200; Zhang YY, 2007, DIABETES, V56, P1647, DOI 10.2337/db07-0123	49	44	53	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2010	5	8							e12057	10.1371/journal.pone.0012057	http://dx.doi.org/10.1371/journal.pone.0012057			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	637IW	20706589	gold, Green Published, Green Submitted			2023-01-03	WOS:000280811900015
J	Robbins, D; Gu, X; Shi, RH; Liu, JF; Wang, F; Ponville, J; McCord, JM; Zhao, YF				Robbins, Delira; Gu, Xin; Shi, Runhua; Liu, Jianfeng; Wang, Fei; Ponville, Jacqulyne; McCord, Joe M.; Zhao, Yunfeng			The Chemopreventive Effects of Protandim: Modulation of p53 Mitochondrial Translocation and Apoptosis during Skin Carcinogenesis	PLOS ONE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; IMMUNODEFICIENT MICE; CANCER-CELLS; 12-O-TETRADECANOYLPHORBOL-13-ACETATE; PATHWAY; MODEL; COMBINATION; ACTIVATION; EXTRACT; MOUSE	Protandim, a well defined dietary combination of 5 well-established medicinal plants, is known to induce endogenous antioxidant enzymes, such as manganese superoxide dismutase (MnSOD). Our previous studies have shown through the induction of various antioxidant enzymes, products of oxidative damage can be decreased. In addition, we have shown that tumor multiplicity and incidence can be decreased through the dietary administration of Protandim in the two-stage skin carcinogenesis mouse model. It has been demonstrated that cell proliferation is accommodated by cell death during DMBA/TPA treatment in the two-stage skin carcinogenesis model. Therefore, we investigated the effects of the Protandim diet on apoptosis; and proposed a novel mechanism of chemoprevention utilized by the Protandim dietary combination. Interestingly, Protandim suppressed DMBA/TPA induced cutaneous apoptosis. Recently, more attention has been focused on transcription-independent mechanisms of the tumor suppressor, p53, that mediate apoptosis. It is known that cytoplasmic p53 rapidly translocates to the mitochondria in response to pro-apoptotic stress. Our results showed that Protandim suppressed the mitochondrial translocation of p53 and mitochondrial outer membrane proteins such as Bax. We examined the levels of p53 and MnSOD expression/activity in murine skin JB6 promotion sensitive (P+) and promotion-resistant (P-) epidermal cells. Interestingly, p53 was induced only in P+ cells, not P- cells; whereas MnSOD is highly expressed in P- cells when compared to P+ cells. In addition, wild-type p53 was transfected into JB6 P-cells. We found that the introduction of wild-type p53 promoted transformation in JB6 P- cells. Our results suggest that suppression of p53 and induction of MnSOD may play an important role in the tumor suppressive activity of Protandim.	[Robbins, Delira; Zhao, Yunfeng] Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA 71105 USA; [Gu, Xin] Louisiana State Univ, Hlth Sci Ctr, Dept Pathol, Shreveport, LA 71105 USA; [Wang, Fei] Jilin Univ, Coll Life Sci, Changchun 130023, Jilin Province, Peoples R China; [Ponville, Jacqulyne] Nicholls State Univ, Dept Chem, Thibodaux, LA 70310 USA; [McCord, Joe M.] Univ Colorado Denver, Dept Med, Aurora, CO USA; [McCord, Joe M.] Hlth Sci Ctr, Aurora, CO USA; [Shi, Runhua] Louisiana State Univ, Hlth Sci Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71105 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Jilin University; University of Louisiana System; Nicholls State University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Robbins, D (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol Toxicol & Neurosci, Shreveport, LA 71105 USA.	yzhao1@lsuhsc.edu	McCord, Joe/GWU-8607-2022	Robichaux, Jacqulyne/0000-0001-8812-7054				Avila GE, 2005, J PHARMACOL EXP THER, V315, P170, DOI 10.1124/jpet.105.087585; BOWDEN GT, 1995, MOL MECH INVOLVED SK, P99; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Chaurasia SS, 2000, PHARMACOL RES, V41, P663, DOI 10.1006/phrs.1999.0634; Chen J, 2006, APOPTOSIS, V11, P943, DOI 10.1007/s10495-006-6715-5; Dhar SK, 2006, J BIOL CHEM, V281, P21698, DOI 10.1074/jbc.M601083200; Hota SK, 2009, NEUROBIOL DIS, V34, P23, DOI 10.1016/j.nbd.2008.12.006; Katiyar SK, 2005, MOL CANCER THER, V4, P207; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Liu JF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005284; Manna SK, 1999, J IMMUNOL, V163, P6800; MARCHENKO ND, 2005, J BIOL CHEM, V280, P19166; Nelson SK, 2006, FREE RADICAL BIO MED, V40, P341, DOI 10.1016/j.freeradbiomed.2005.08.043; Pani G, 2004, CURR MED CHEM, V11, P1299, DOI 10.2174/0929867043365297; Pani G, 2009, INT J BIOCHEM CELL B, V41, P1002, DOI 10.1016/j.biocel.2008.10.011; POLYAK K, 1997, NATURE, V389, P237; Potapovich AI, 2003, BIOCHEMISTRY-MOSCOW+, V68, P514, DOI 10.1023/A:1023947424341; Tang XW, 2007, J CLIN INVEST, V117, P3753, DOI 10.1172/JCI32481; Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005; Zhang XP, 2007, CLIN CANCER RES, V13, P7181, DOI 10.1158/1078-0432.CCR-07-1133; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835; Zhao YF, 2002, ONCOGENE, V21, P3836, DOI 10.1038/sj.onc.1205477; Zhao Yunfeng, 2003, Methods Mol Biol, V218, P177; Zheng X, 2006, CLIN CANCER RES, V12, P3444, DOI 10.1158/1078-0432.CCR-05-2823	26	24	26	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2010	5	7							e11902	10.1371/journal.pone.0011902	http://dx.doi.org/10.1371/journal.pone.0011902			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	633QZ	20689586	Green Published, gold			2023-01-03	WOS:000280520300017
J	Kahn, JM; Benson, NM; Appleby, D; Carson, SS; Iwashyna, TJ				Kahn, Jeremy M.; Benson, Nicole M.; Appleby, Dina; Carson, Shannon S.; Iwashyna, Theodore J.			Long-term Acute Care Hospital Utilization After Critical Illness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MECHANICAL VENTILATION; RACIAL VARIATION; UNITED-STATES; SEVERE SEPSIS; OUTCOMES; MEDICARE; MORTALITY; PATIENT; COSTS; EPIDEMIOLOGY	Context Long-term acute care hospitals have emerged as a novel approach for the care of patients recovering from severe acute illness, but the extent and increases in their activity at the national level are unknown. Objective To examine temporal trends in long-term acute care hospital utilization after an episode of critical illness among fee-for-service Medicare beneficiaries aged 65 years or older. Design, Setting, and Patients Retrospective cohort study using the Medicare Provider Analysis and Review files from 1997 to 2006. We included all Medicare hospitalizations involving admission to an intensive care unit of an acute care, nonfederal hospital within the continental United States. Main Outcome Measures Overall long-term acute care utilization, associated costs, and survival following transfer. Results The number of long-term acute care hospitals in the United States increased at a mean rate of 8.8% per year, from 192 in 1997 to 408 in 2006. During that time, the annual number of long-term acute care admissions after critical illness increased from 13 732 to 40 353, with annual costs increasing from $484 million to $1.325 billion. The age-standardized population incidence of long-term acute care utilization after critical illness increased from 38.1 per 100 000 in 1997 to 99.7 per 100 000 in 2006, with greater use among male individuals and black individuals in all periods. Over time, transferred patients had higher numbers of comorbidities (5.0 in 19972000 vs 5.8 in 2004-2006, P<.001) and were more likely to receive mechanical ventilation at the long-term acute care hospital (16.4% in 1997-2000 vs 29.8% in 20042006, P<.001). One-year mortality after long-term acute care hospital admission was high throughout the study period: 50.7% in 1997-2000 and 52.2% in 2004-2006. Conclusions Long-term acute care hospital utilization after critical illness is common and increasing. Survival among Medicare beneficiaries transferred to long-term acute care after critical illness is poor. JAMA. 2010; 303(22): 2253-2259	[Kahn, Jeremy M.] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Div Pulm Allergy & Crit Care, Philadelphia, PA 19104 USA; [Kahn, Jeremy M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Carson, Shannon S.] Univ N Carolina, Sch Med, Div Pulm & Crit Care, Chapel Hill, NC USA; [Iwashyna, Theodore J.] Univ Michigan, Sch Med, Div Pulm & Crit Care, Ann Arbor, MI USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Michigan System; University of Michigan	Kahn, JM (corresponding author), Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Div Pulm Allergy & Crit Care, Blockley Hall 723,423 Guardian Dr, Philadelphia, PA 19104 USA.	jmkahn@mail.med.upenn.edu		Iwashyna, Theodore/0000-0002-4226-9310; Kahn, Jeremy/0000-0001-9688-5576; Benson, Nicole/0000-0001-5361-4311	National Institutes of Health (NIH) [R01HL096651, K08HL091249]; Pennsylvania Department of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL096651, K08HL091249] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pennsylvania Department of Health; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by grant R01HL096651 from the National Institutes of Health (NIH) (Dr Kahn). Dr Iwashyna is supported by NIH grant K08HL091249. This project was also funded, in part, under a grant from the Pennsylvania Department of Health, which specifically disclaims responsibility for any analyses, interpretations, or conclusions.	AIKEN LH, 2002, JAMA-J AM MED ASSOC, V288, P1987, DOI [DOI 10.1001/JAMA.288.16.1987, 10.1001/jama.288.16.1987]; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; [Anonymous], CLIN CLASS SOFTW ICD; Barnato AE, 2008, AM J RESP CRIT CARE, V177, P279, DOI 10.1164/rccm.200703-480OC; Barnato AE, 2007, J GEN INTERN MED, V22, P338, DOI 10.1007/s11606-006-0088-x; BLUSTEIN J, 1994, AM J PUBLIC HEALTH, V84, P1018, DOI 10.2105/AJPH.84.6.1018; Carson SS, 2008, CRIT CARE MED, V36, P2061, DOI 10.1097/CCM.0b013e31817b8925; Carson SS, 2007, CHEST, V131, P2, DOI 10.1378/chest.06-2513; Carson SS, 1999, AM J RESP CRIT CARE, V159, P1568, DOI 10.1164/ajrccm.159.5.9809002; Carson SS, 2002, CRIT CARE CLIN, V18, P461, DOI 10.1016/S0749-0704(02)00015-5; Combes A, 2003, CRIT CARE MED, V31, P1373, DOI 10.1097/01.CCM.0000065188.87029.C3; Cox CE, 2009, CRIT CARE MED, V37, P2888, DOI 10.1097/CCM.0b013e3181ab86ed; Diringer MN, 2001, CRIT CARE MED, V29, P1792, DOI 10.1097/00003246-200109000-00023; Engoren M, 2004, CHEST, V125, P220, DOI 10.1378/chest.125.1.220; Halpern NA, 2010, CRIT CARE MED, V38, P65, DOI 10.1097/CCM.0b013e3181b090d0; Horwitz JR, 2009, J HEALTH ECON, V28, P924, DOI 10.1016/j.jhealeco.2009.06.008; Horwitz LI, 2008, ARCH INTERN MED, V168, P1755, DOI 10.1001/archinte.168.16.1755; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; Iglehart JK, 2005, NEW ENGL J MED, V352, P78, DOI 10.1056/NEJMhpr043631; Iwashyna TJ, 2009, MED CARE, V47, P787, DOI 10.1097/MLR.0b013e318197b1f5; Kahn JM, 2007, CURR OPIN CRIT CARE, V13, P514, DOI 10.1097/MCC.0b013e3282efb7c9; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Kahn JM, 2010, INTENS CARE MED, V36, P8, DOI 10.1007/s00134-009-1672-4; LAUDERDALE DS, 1993, EPIDEMIOL REV, V15, P319, DOI 10.1093/oxfordjournals.epirev.a036123; Liu K, 2001, HEALTH CARE FINANC R, V23, P1; MacIntyre NR, 2005, CHEST, V128, P3937, DOI 10.1378/chest.128.6.3937; Medicare Payment Advisory Commission, 2004, REP C NEW APPR MED; Medicare Payment Advisory Commission, 2010, REP C MED PAYM POL; Pilcher DV, 2005, THORAX, V60, P187, DOI 10.1136/thx.2004.026500; Quan H, 2004, MED CARE, V42, P801, DOI 10.1097/01.mlr.0000132391.59713.0d; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Riley GF, 2009, MED CARE, V47, pS51, DOI 10.1097/MLR.0b013e31819c95aa; Scales DC, 2006, J CLIN EPIDEMIOL, V59, P802, DOI 10.1016/j.jclinepi.2005.11.015; Scheinhorn DJ, 2007, CHEST, V131, P85, DOI 10.1378/chest.06-1081; Scheinhorn DJ, 2007, CHEST, V131, P76, DOI 10.1378/chest.06-1079; Schonhofer B, 2002, INTENS CARE MED, V28, P908, DOI 10.1007/s00134-002-1287-5; Seneff MG, 2000, CRIT CARE MED, V28, P342, DOI 10.1097/00003246-200002000-00009; Shepardson LB, 1999, J GEN INTERN MED, V14, P15, DOI 10.1046/j.1525-1497.1999.00275.x; Taira DA, 2003, AM HEART J, V145, P452, DOI 10.1067/mhj.2003.3; Thygeson M, 2008, HEALTH AFFAIR, V27, P1283, DOI 10.1377/hlthaff.27.5.1283; Wunsch H, 2010, JAMA-J AM MED ASSOC, V303, P849, DOI 10.1001/jama.2010.216	41	209	214	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	2010	303	22					2253	2259		10.1001/jama.2010.761	http://dx.doi.org/10.1001/jama.2010.761			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	607IY	20530778	Green Submitted, Green Accepted, Bronze			2023-01-03	WOS:000278496800023
J	Bennell, K; Wee, E; Coburn, S; Green, S; Harris, A; Staples, M; Forbes, A; Buchbinder, R				Bennell, Kim; Wee, Elin; Coburn, Sally; Green, Sally; Harris, Anthony; Staples, Margaret; Forbes, Andrew; Buchbinder, Rachelle			Efficacy of standardised manual therapy and home exercise programme for chronic rotator cuff disease: randomised placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SHOULDER IMPINGEMENT SYNDROME; QUALITY-OF-LIFE; SUBACROMIAL IMPINGEMENT; PHYSICAL-THERAPY; CLINICAL-TRIALS; DOUBLE-BLIND; EPIDEMIOLOGIC SURVEILLANCE; MUSCULOSKELETAL DISORDERS; COST-EFFECTIVENESS; GENERAL HEALTH	Objective To investigate the efficacy of a programme of manual therapy and exercise treatment compared with placebo treatment delivered by physiotherapists for people with chronic rotator cuff disease. Design Randomised, participant and single assessor blinded, placebo controlled trial. Setting Metropolitan region of Melbourne, Victoria, Australia. Participants 120 participants with chronic (>3 months) rotator cuff disease recruited through medical practitioners and from the community. Interventions The active treatment comprised a manual therapy and home exercise programme; the placebo treatment comprised inactive ultrasound therapy and application of an inert gel. Participants in both groups received 10 sessions of individual standardised treatment over 10 weeks. For the following 12 weeks, the active group continued the home exercise programme and the placebo group received no treatment. Main outcome measures The primary outcomes were pain and function measured by the shoulder pain and disability index, average pain on movement measured on an 11 point numerical rating scale, and participants' perceived global rating of overall change. Results 112 (93%) participants completed the 22 week trial. At 11 weeks no difference was found between groups for change in shoulder pain and disability index (3.6, 95% confidence interval -2.1 to 9.4) or change in pain (0.7, -0.1 to 1.5); both groups showed significant improvements. More participants in the active group reported a successful outcome (defined as "much better"), although the difference was not statistically significant: 42% (24/57) of active participants and 30% (18/61) of placebo participants (relative risk 1.43, 0.87 to 2.34). The active group showed a significantly greater improvement in shoulder pain and disability index than did the placebo group at 22 weeks (between group difference 7.1, 0.3 to 13.9), although no significant difference existed between groups for change in pain (0.9, -0.03 to 1.7) or for the percentage of participants reporting a successful treatment outcome (relative risk 1.39, 0.94 to 2.03). Several secondary outcomes favoured the active group, including shoulder pain and disability index function score, muscle strength, interference with activity, and quality of life. Conclusion A standardised programme of manual therapy and home exercise did not confer additional immediate benefits for pain and function compared with a realistic placebo treatment that controlled for therapists' contact in middle aged to older adults with chronic rotator cuff disease. However, greater improvements were apparent at follow-up, particularly in shoulder function and strength, suggesting that benefits with active treatment take longer to manifest.	[Bennell, Kim; Wee, Elin; Coburn, Sally] Univ Melbourne, Sch Hlth Sci, Ctr Hlth Exercise & Sports Med, Dept Physiotherapy, Parkville, Vic 3010, Australia; [Coburn, Sally] Royal Melbourne Hosp, Dept Physiotherapy, Melbourne, Vic, Australia; [Green, Sally] Monash Univ, Monash Inst Hlth Serv Res, Melbourne, Vic, Australia; [Harris, Anthony] Monash Univ, Ctr Hlth Econ, Clayton, Vic 3800, Australia; [Staples, Margaret; Buchbinder, Rachelle] Cabrini Hosp, Monash Dept Clin Epidemiol, Melbourne, Vic, Australia; [Staples, Margaret; Forbes, Andrew; Buchbinder, Rachelle] Monash Univ, Dept Epidemiol & Prevent Med, Sch Publ Hlth & Prevent Med, Clayton, Vic 3800, Australia	University of Melbourne; Royal Melbourne Hospital; Monash University; Monash University; Cabrini Health; Monash University; Monash University	Bennell, K (corresponding author), Univ Melbourne, Sch Hlth Sci, Ctr Hlth Exercise & Sports Med, Dept Physiotherapy, Parkville, Vic 3010, Australia.	k.bennell@unimelb.edu.au	Buchbinder, Rachelle/G-2952-2011; Zmistowski, Ben/AAI-7901-2020; Bennell, Kim/C-7022-2014	Buchbinder, Rachelle/0000-0002-0597-0933; Green, Sally Elizabeth/0000-0002-9564-9050; Bennell, Kim/0000-0003-4982-5639; Harris, Anthony/0000-0003-1641-3320; Coburn, Sally/0000-0002-2233-0006; Forbes, Andrew/0000-0003-4269-914X	Australian Research Council; Australian National Health and Medical Research Council; National Health and Medical Research Council [299840]; ANZ Trustees; Department of Physiotherapy Royal Melbourne Hospital; Royal Melbourne Hospital; School of Physiotherapy, University of Melbourne	Australian Research Council(Australian Research Council); Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); ANZ Trustees; Department of Physiotherapy Royal Melbourne Hospital; Royal Melbourne Hospital; School of Physiotherapy, University of Melbourne(University of Melbourne)	KB is funded in part by an Australian Research Council future fellowship. RB is funded in part by an Australian National Health and Medical Research Council practitioner fellowship. This work was funded by the National Health and Medical Research Council (project grant #299840). Pilot funds were provided by ANZ Trustees, Department of Physiotherapy and Victor Hurley Grant Royal Melbourne Hospital and the School of Physiotherapy, University of Melbourne. The study sponsors had no role in the design; in the collection, analysis, and interpretation of the data; or in the writing of the article and the decision to submit it for publication.	BADLEY EM, 1992, ANN RHEUM DIS, V51, P366, DOI 10.1136/ard.51.3.366; Bang MD, 2000, J ORTHOP SPORT PHYS, V30, P126, DOI 10.2519/jospt.2000.30.3.126; Barnett AG, 2005, INT J EPIDEMIOL, V34, P215, DOI 10.1093/ije/dyh299; BARTOLOZZI A, 1994, CLIN ORTHOP RELAT R, P90; Bennell K, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-86; Bennell KL, 2005, ANN RHEUM DIS, V64, P906, DOI 10.1136/ard.2004.026526; Bridges-Webb C., 1992, MED J AUST S, V157, pS1; BROX JI, 1993, BMJ-BRIT MED J, V307, P899, DOI 10.1136/bmj.307.6909.899; Buchbinder R, 2007, ARTHRIT RHEUM-ARTHR, V57, P1027, DOI 10.1002/art.22892; Buchsbaum D J, 1996, Recent Results Cancer Res, V141, P9; CHARD MD, 1991, ARTHRITIS RHEUM-US, V34, P766, DOI 10.1002/art.1780340619; COBURN S, 2008, THESIS U MELBOURNE; Conroy DE, 1998, J ORTHOP SPORT PHYS, V28, P3, DOI 10.2519/jospt.1998.28.1.3; Cothran Roger Lee Jr, 2006, J Surg Orthop Adv, V15, P132; Crossley K, 2002, AM J SPORT MED, V30, P857, DOI 10.1177/03635465020300061701; Crow R., 1999, HEALTH TECHNOL ASSES, V3, P1, DOI [DOI 10.3310/HTA3030, DOI 10.3310/hta3030]; Cullen DM, 2007, AUSTRALAS RADIOL, V51, P226, DOI 10.1111/j.1440-1673.2007.01685.x; Dickens VA, 2005, PHYSIOTHERAPY, V91, P159, DOI 10.1016/j.physio.2004.10.008; Ekeberg OM, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3112; Faber E, 2006, J OCCUP REHABIL, V16, P7, DOI 10.1007/s10926-005-9003-2; Gartsman GM, 1998, J SHOULDER ELB SURG, V7, P228, DOI 10.1016/S1058-2746(98)90050-7; Glazier RH, 1998, CAN MED ASSOC J, V158, P1037; Green S, 2003, Cochrane Database Syst Rev, pCD004258; Haahr JP, 2005, ANN RHEUM DIS, V64, P760, DOI 10.1136/ard.2004.021188; HAWKINS RJ, 1980, AM J SPORT MED, V8, P151, DOI 10.1177/036354658000800302; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Heald SL, 1997, PHYS THER, V77, P1079, DOI 10.1093/ptj/77.10.1079; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; James KE, 1996, STAT MED, V15, P1421; Ketola S, 2009, J BONE JOINT SURG BR, V91B, P1326, DOI 10.1302/0301-620X.91B10.22094; Krogsboll LT, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-1; Kuhn JE, 2009, J SHOULDER ELB SURG, V18, P138, DOI 10.1016/j.jse.2008.06.004; Kuijpers T, 2004, PAIN, V109, P420, DOI 10.1016/j.pain.2004.02.017; Lombardi I, 2008, ARTHRIT RHEUM-ARTHR, V59, P615, DOI 10.1002/art.23576; Ludewig PM, 2009, J ORTHOP SPORT PHYS, V39, P90, DOI 10.2519/jospt.2009.2808; Ludewig PM, 2003, OCCUP ENVIRON MED, V60, P841, DOI 10.1136/oem.60.11.841; Maitland GD, 2001, VERTEBRAL MANIPULATI; May S, 2008, AUST J PHYSIOTHER, V54, P261, DOI 10.1016/S0004-9514(08)70005-9; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Michener LA, 2003, CLIN BIOMECH, V18, P369, DOI 10.1016/S0268-0033(03)00047-0; Mintken PE, 2009, J SHOULDER ELB SURG, V18, P920, DOI 10.1016/j.jse.2008.12.015; Moosmayer S, 2007, J CLIN ULTRASOUND, V35, P20, DOI 10.1002/jcu.20286; Morton V, 2005, J EVAL CLIN PRACT, V11, P59, DOI 10.1111/j.1365-2753.2004.00505.x; Osborne RH, 2003, J CLIN EPIDEMIOL, V56, P138, DOI 10.1016/S0895-4356(02)00601-7; Ostor AJK, 2005, RHEUMATOLOGY, V44, P800, DOI 10.1093/rheumatology/keh598; Paterson C, 2005, BMJ-BRIT MED J, V330, P1202, DOI 10.1136/bmj.330.7501.1202; PETERS D, 1994, BRIT J GEN PRACT, V44, P25; Roach K E, 1991, Arthritis Care Res, V4, P143, DOI 10.1002/art.1790040403; Roquelaure Y, 2002, OCCUP ENVIRON MED, V59, P452, DOI 10.1136/oem.59.7.452; Roquelaure Y, 2006, ARTHRIT RHEUM-ARTHR, V55, P765, DOI 10.1002/art.22222; Roy JS, 2009, ARTHRIT RHEUM-ARTHR, V61, P623, DOI 10.1002/art.24396; Senbursa G, 2007, KNEE SURG SPORT TR A, V15, P915, DOI 10.1007/s00167-007-0288-x; Smith KL, 2000, J SHOULDER ELB SURG, V9, P395, DOI 10.1067/mse.2000.108962; Sterne Jonathan A C, 2009, BMJ, V338, pb2393, DOI 10.1136/bmj.b2393; ten Klooster PM, 2006, PAIN, V121, P151, DOI 10.1016/j.pain.2005.12.021; Thomas E, 2005, ANN RHEUM DIS, V64, P1056, DOI 10.1136/ard.2004.029959; Trampas A, 2006, PHYS THER REV, V11, P125, DOI 10.1179/108331906X99065; Walters SJ, 2001, AGE AGEING, V30, P337, DOI 10.1093/ageing/30.4.337; Walther M, 2004, J SHOULDER ELB SURG, V13, P417, DOI 10.1016/j.jse.2004.02.002; Whitfield K, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-19; WILLIAMS JW, 1995, J RHEUMATOL, V22, P727	61	114	115	2	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2010	340								c2756	10.1136/bmj.c2756	http://dx.doi.org/10.1136/bmj.c2756			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	611MB	20530557	Green Published, hybrid			2023-01-03	WOS:000278818300003
J	Sugahara, KN; Teesalu, T; Karmali, PP; Kotamraju, VR; Agemy, L; Greenwald, DR; Ruoslahti, E				Sugahara, Kazuki N.; Teesalu, Tambet; Karmali, Priya Prakash; Kotamraju, Venkata Ramana; Agemy, Lilach; Greenwald, Daniel R.; Ruoslahti, Erkki			Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; PHAGE DISPLAY; MOUSE MODEL; IN-VIVO; NANOPARTICLES; DOXORUBICIN; CELL; INTEGRINS; DELIVERY	Poor penetration of anticancer drugs into tumors can be an important factor limiting their efficacy. We studied mouse tumor models to show that a previously characterized tumor-penetrating peptide, iRGD, increased vascular and tissue permeability in a tumor-specific and neuropilin-1-dependent manner, allowing coadministered drugs to penetrate into extravascular tumor tissue. Importantly, this effect did not require the drugs to be chemically conjugated to the peptide. Systemic injection with iRGD improved the therapeutic index of drugs of various compositions, including a small molecule (doxorubicin), nanoparticles (nab-paclitaxel and doxorubicin liposomes), and a monoclonal antibody (trastuzumab). Thus, coadministration of iRGD may be a valuable way to enhance the efficacy of anticancer drugs while reducing their side effects, a primary goal of cancer therapy research.	[Sugahara, Kazuki N.; Teesalu, Tambet; Kotamraju, Venkata Ramana; Agemy, Lilach; Ruoslahti, Erkki] Univ Calif Santa Barbara, Vasc Mapping Lab, Ctr Nanomed, Sanford Burnham Med Res Inst, Santa Barbara, CA 93106 USA; [Karmali, Priya Prakash; Ruoslahti, Erkki] Sanford Burnham Med Res Inst, Canc Res Ctr, La Jolla, CA 92037 USA; [Greenwald, Daniel R.] Canc Ctr Santa Barbara, Santa Barbara Hematol Oncol Med Grp, Santa Barbara, CA 93105 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Santa Barbara; Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Vasc Mapping Lab, Ctr Nanomed, Sanford Burnham Med Res Inst, Biol 2 Bldg, Santa Barbara, CA 93106 USA.	ruoslahti@burnham.org	Teesalu, Tambet/J-1802-2015		National Cancer Institute of the NIH [CA104898, CA119414, CA119335, CA124427, CA115410, CA30199]; U.S. Department of Defense [BC076050, BC08544]; NATIONAL CANCER INSTITUTE [U54CA119335, R01CA119414, R01CA124427, R01CA115410, P01CA104898, P30CA030199] Funding Source: NIH RePORTER	National Cancer Institute of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank D. Hanahan for transgenic mice, R. M. Hoffman for the GFP-PC-3 cell line, M. J. Sailor and J.-H. Park for advice on the synthesis of iron oxide nanoworms, and E. Engvall for comments on the manuscript. This work was supported by grants CA104898, CA119414, CA119335, CA124427, CA115410, and CA30199 from the National Cancer Institute of the NIH and grants BC076050 and BC08544 from the U.S. Department of Defense. The authors and their institutions have patents on methods and compositions related to peptides and proteins with C-terminal elements and related to internalizing RGD peptides.	Acevedo LM, 2008, BLOOD, V111, P2674, DOI 10.1182/blood-2007-08-110205; Arola OJ, 2000, CANCER RES, V60, P1789; Black Keith L, 2004, Cancer Control, V11, P165; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; FENDLY BM, 1990, CANCER RES, V50, P1550; Hambley TW, 2009, CANCER RES, V69, P1259, DOI 10.1158/0008-5472.CAN-08-3786; Hoffman JA, 2003, CANCER CELL, V4, P383, DOI 10.1016/S1535-6108(03)00273-3; Jia HY, 2006, J BIOL CHEM, V281, P13493, DOI 10.1074/jbc.M512121200; Joyce JA, 2003, CANCER CELL, V4, P393, DOI 10.1016/S1535-6108(03)00271-X; Karmali PP, 2009, NANOMED-NANOTECHNOL, V5, P73, DOI 10.1016/j.nano.2008.07.007; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Maeda H, 2003, INT IMMUNOPHARMACOL, V3, P319, DOI 10.1016/S1567-5769(02)00271-0; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Monsky WL, 1999, CANCER RES, V59, P4129; Murohara T, 1998, CIRCULATION, V97, P99, DOI 10.1161/01.CIR.97.1.99; Murphy EA, 2008, P NATL ACAD SCI USA, V105, P9343, DOI 10.1073/pnas.0803728105; Park JH, 2009, SMALL, V5, P694, DOI 10.1002/smll.200801789; Pastorino F, 2008, CLIN CANCER RES, V14, P7320, DOI 10.1158/1078-0432.CCR-08-0804; Pellet-Many C, 2008, BIOCHEM J, V411, P211, DOI 10.1042/BJ20071639; Petrioli R, 2008, CANCER TREAT REV, V34, P710, DOI 10.1016/j.ctrv.2008.05.004; Porkka K, 2002, P NATL ACAD SCI USA, V99, P7444, DOI 10.1073/pnas.062189599; Primeau T, 2005, IMMUNOL RES, V32, P109, DOI 10.1385/IR:32:1-3:109; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013; Tagle Danilo A., 1992, Human Molecular Genetics, V1, P121, DOI 10.1093/hmg/1.2.121; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; YUAN F, 1995, CANCER RES, V55, P3752	32	816	861	14	566	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	2010	328	5981					1031	1035		10.1126/science.1183057	http://dx.doi.org/10.1126/science.1183057			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	598YW	20378772	Green Accepted			2023-01-03	WOS:000277877100042
J	Charurat, M; Oyegunle, M; Benjamin, R; Habib, A; Eze, E; Ele, P; Ibanga, I; Ajayi, S; Eng, M; Mondal, P; Gebi, U; Iwu, E; Etiebet, MA; Abimiku, A; Dakum, P; Farley, J; Blattner, W				Charurat, Man; Oyegunle, Modupe; Benjamin, Renata; Habib, Abdulrazaq; Eze, Emeka; Ele, Prince; Ibanga, Iquo; Ajayi, Samuel; Eng, Maria; Mondal, Prosanta; Gebi, Usman; Iwu, Emilia; Etiebet, Mary-Ann; Abimiku, Alash'le; Dakum, Patrick; Farley, John; Blattner, William			Patient Retention and Adherence to Antiretrovirals in a Large Antiretroviral Therapy Program in Nigeria: A Longitudinal Analysis for Risk Factors	PLOS ONE			English	Article							HIV-INFECTED ADULTS; FOLLOW-UP; SOUTH-AFRICA; HIV-1-INFECTED PATIENTS; IMPROVE ADHERENCE; INCOME COUNTRIES; LACTIC-ACIDOSIS; 1ST YEAR; STAVUDINE; UGANDA	Background: Substantial resources and patient commitment are required to successfully scale-up antiretroviral therapy (ART) and provide appropriate HIV management in resource-limited settings. We used pharmacy refill records to evaluate risk factors for loss to follow-up (LTFU) and non-adherence to ART in a large treatment cohort in Nigeria. Methods and Findings: We reviewed clinic records of adult patients initiating ART between March 2005 and July 2006 at five health facilities. Patients were classified as LTFU if they did not return > 60 days from their expected visit. Pharmacy refill rates were calculated and used to assess non-adherence. We identified risk factors associated with LTFU and non-adherence using Cox and Generalized Estimating Equation (GEE) regressions, respectively. Of 5,760 patients initiating ART, 26% were LTFU. Female gender (p < 0.001), post-secondary education (p = 0.03), and initiating treatment with zidovudine-containing (p = 0.004) or tenofovir-containing (p = 0.05) regimens were associated with decreased risk of LTFU, while patients with only primary education (p = 0.02) and those with baseline CD4 counts (cell/ml(3)) > 350 and < 100 were at a higher risk of LTFU compared to patients with baseline CD4 counts of 100-200. The adjusted GEE analysis showed that patients aged < 35 years (p = 0.005), who traveled for > 2 hours to the clinic (p = 0.03), had total ART duration of > 6 months (p < 0.001), and CD4 counts > 200 at ART initiation were at a higher risk of non-adherence. Patients who disclosed their HIV status to spouse/family (p = 0.01) and were treated with tenofovir-containing regimens (p < 0.001) were more likely to be adherent. Conclusions: These findings formed the basis for implementing multiple pre-treatment visit preparation that promote disclosure and active community outreaching to support retention and adherence. Expansion of treatment access points of care to communities to diminish travel time may have a positive impact on adherence.	[Charurat, Man; Oyegunle, Modupe; Benjamin, Renata; Eng, Maria; Mondal, Prosanta; Etiebet, Mary-Ann; Abimiku, Alash'le; Dakum, Patrick; Farley, John; Blattner, William] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA; [Habib, Abdulrazaq] Aminu Kano Teaching Hosp, Kano, Nigeria; [Eze, Emeka] Univ Benin, Teaching Hosp, Benin, Edo State, Nigeria; [Ele, Prince] Nnamdi Azikwe Univ, Teaching Hosp, Nnewi, Anambra State, Nigeria; [Ibanga, Iquo] Univ Calabar, Teaching Hosp, Calabar, Cross River Sta, Nigeria; [Ajayi, Samuel] Univ Abuja, Teaching Hosp, Abuja, Federal Capital, Nigeria; [Gebi, Usman; Iwu, Emilia; Etiebet, Mary-Ann; Dakum, Patrick] Inst Human Virol Nigeria, Abuja, Federal Capital, Nigeria; [Iwu, Emilia] Univ Maryland, Sch Nursing, Dept Family & Community Hlth, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University of Benin; University of Calabar; University System of Maryland; University of Maryland Baltimore	Charurat, M (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.	mcharurat@ihv.umaryland.edu		Gebi, Usman/0000-0002-1395-4650; Benjamin, Renata/0000-0001-6406-4247	U.S. Centers for Disease Control and Prevention [PS000651]; The U.S. National Institutes of Health's Fogarty AIDS International Training Research Program [D43 TW001041]; International Epidemiologic Database to evaluate AIDS [U01AI069919]; FOGARTY INTERNATIONAL CENTER [D43TW001041] Funding Source: NIH RePORTER; NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION [U2GPS000651] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069919] Funding Source: NIH RePORTER	U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); The U.S. National Institutes of Health's Fogarty AIDS International Training Research Program; International Epidemiologic Database to evaluate AIDS; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR HIV, VIRAL HEPATITIS, STDS AND TB PREVENTION(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	The AIDS Care and Treatment in Nigeria (ACTION) project is supported by the U.S. Centers for Disease Control and Prevention (Cooperative Agreement No. PS000651). This publication content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC. This on-going project is jointly implemented by the Institute of Human Virology of the University of Maryland School of Medicine, Institute of Human Virology Nigeria, the Nigerian Federal Ministry of Health, and local partner treatment facilities. The U.S. National Institutes of Health's Fogarty AIDS International Training Research Program (AITRP, D43 TW001041) and the International Epidemiologic Database to evaluate AIDS (IeDEA, U01AI069919) provided research training support for this analysis.	[Anonymous], 2008, EP FACT SHEET HIV AI; Bajunirwe Francis, 2009, J Int Assoc Physicians AIDS Care (Chic), V8, P139, DOI 10.1177/1545109709332470; Bell DJ, 2007, JAIDS-J ACQ IMM DEF, V45, P560, DOI 10.1097/QAI.0b013e3180decadb; Birbeck GL, 2009, AM J TROP MED HYG, V80, P669, DOI 10.4269/ajtmh.2009.80.669; Bisson GP, 2008, PLOS MED, V5, P777, DOI 10.1371/journal.pmed.0050109; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; Braitstein P, 2008, J WOMENS HEALTH, V17, P47, DOI 10.1089/jwh.2007.0353; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; Brinkhof MWG, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000066; Chi BH, 2009, INT J EPIDEMIOL, V38, P746, DOI 10.1093/ije/dyp004; Crane JT, 2006, AIDS BEHAV, V10, P437, DOI 10.1007/s10461-006-9080-z; Cui J, 2009, AM J EPIDEMIOL, V169, P113, DOI 10.1093/aje/kwn292; Dalal RP, 2008, JAIDS-J ACQ IMM DEF, V47, P101, DOI 10.1097/QAI.0b013e31815b833a; FARLEY J, 2007, ADHERENCE ASSESSMENT; *FMOH, 2005, GUID US ANT DRUGS NI; Grossberg Robert, 2007, Curr HIV/AIDS Rep, V4, P187, DOI 10.1007/s11904-007-0027-4; Horton NJ, 1999, STAT MED, V18, P213, DOI 10.1002/(SICI)1097-0258(19990130)18:2<213::AID-SIM999>3.0.CO;2-E; Idoko JA, 2007, INT J STD AIDS, V18, P760, DOI 10.1258/095646207782212252; Joly V, 2002, AIDS, V16, P2447, DOI 10.1097/00002030-200212060-00010; Karcher H, 2007, TROP MED INT HEALTH, V12, P687, DOI 10.1111/j.1365-3156.2007.01830.x; Keiser O, 2008, TROP MED INT HEALTH, V13, P870, DOI 10.1111/j.1365-3156.2008.02078.x; Krebs DW, 2008, AIDS CARE, V20, P311, DOI 10.1080/09540120701594776; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Lawn SD, 2006, CLIN INFECT DIS, V43, P770, DOI 10.1086/507095; LIANG KY, 1993, ANNU REV PUBL HEALTH, V14, P43, DOI 10.1146/annurev.pu.14.050193.000355; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Miller KD, 2000, ANN INTERN MED, V133, P192, DOI 10.7326/0003-4819-133-3-200008010-00010; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Mokrzycki MH, 2000, CLIN INFECT DIS, V30, P198, DOI 10.1086/313594; Muyingo SK, 2008, JAIDS-J ACQ IMM DEF, V48, P468, DOI 10.1097/QAI.0b013e31817dc3fd; Nachega JB, 2004, AIDS RES HUM RETROV, V20, P1053, DOI 10.1089/aid.2004.20.1053; Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, pS127, DOI 10.1097/01.qai.0000248349.25630.3d; Nachega Jean B, 2009, Curr HIV/AIDS Rep, V6, P121, DOI 10.1007/s11904-009-0017-9; Nacher M, 2006, AM J TROP MED HYG, V74, P915, DOI 10.4269/ajtmh.2006.74.915; Navario P, 2009, LANCET, V374, P184, DOI 10.1016/S0140-6736(09)61312-X; Oyugi JH, 2007, AIDS, V21, P965, DOI 10.1097/QAD.0b013e32802e6bfa; Pearson CR, 2007, JAIDS-J ACQ IMM DEF, V46, P238, DOI 10.1097/QAI.0b013e318153f7ba; Reliquet V, 2001, HIV Med, V2, P92, DOI 10.1046/j.1468-1293.2001.00066.x; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Scarsella A, 2002, ADV THER, V19, P1, DOI 10.1007/BF02850013; SCHOENFELD DA, 1983, BIOMETRICS, V39, P499, DOI 10.2307/2531021; Unge C, 2009, JAIDS-J ACQ IMM DEF, V50, P397, DOI 10.1097/QAI.0b013e318194618e; van Griensven J, 2007, T ROY SOC TROP MED H, V101, P793, DOI 10.1016/j.trstmh.2007.02.020; Vriesendorp R, 2007, EUR J CLIN PHARMACOL, V63, P1115, DOI 10.1007/s00228-007-0369-2; Weidle PJ, 2006, LANCET, V368, P1587, DOI 10.1016/S0140-6736(06)69118-6; Weiser S, 2003, JAIDS-J ACQ IMM DEF, V34, P281, DOI 10.1097/00126334-200311010-00004; Williams AB, 2006, JAIDS-J ACQ IMM DEF, V42, P314, DOI 10.1097/01.qai.0000221681.60187.88; World Health Organization, 2006, ANT THER HIV INF AD; Wouters E, 2009, AIDS PATIENT CARE ST, V23, P357, DOI 10.1089/apc.2008.0201	49	98	98	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 11	2010	5	5							e10584	10.1371/journal.pone.0010584	http://dx.doi.org/10.1371/journal.pone.0010584			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	594UB	20485670	Green Published, Green Submitted, gold			2023-01-03	WOS:000277563200017
J	Weng, CL; Zhao, YT; Liu, QH; Fu, CJ; Sun, F; Ma, YL; Chen, YW; He, QY				Weng, Cui-Lian; Zhao, Yun-Tao; Liu, Qing-Hua; Fu, Chang-Jun; Sun, Feng; Ma, Yan-Liang; Chen, Yan-Wen; He, Quan-Ying			Meta-analysis: Noninvasive Ventilation in Acute Cardiogenic Pulmonary Edema	ANNALS OF INTERNAL MEDICINE			English	Review							POSITIVE AIRWAY PRESSURE; EMERGENCY-DEPARTMENT PATIENTS; RANDOMIZED CONTROLLED-TRIAL; SUPPORT VENTILATION; MYOCARDIAL-INFARCTION; FACE MASK; OXYGEN-THERAPY; BILEVEL; FAILURE; MORTALITY	Background: Noninvasive ventilation (NIV) is commonly used to treat patients with acute cardiogenic pulmonary edema (ACPE), but the findings of a recent large clinical trial suggest that NIV may be less effective for ACPE than previously thought. Purpose: To provide an estimate of the effect of NIV on clinical outcomes in patients with ACPE that incorporates recent trial evidence and explore ways to interpret that evidence in the context of preceding evidence that favors NIV. Data Sources: PubMed and EMBASE from 1966 to December 2009, Cochrane Central Register of Controlled Trials and conference proceedings through December 2009, and reference lists, without language restriction. Study Selection: Randomized trials that compared continuous positive airway pressure and bilevel ventilation with standard therapy or each other. Data Extraction: Two independent reviewers extracted data. Outcomes examined were mortality, intubation rate, and incidence of new myocardial infarction (MI). Data Synthesis: Compared with standard therapy, continuous positive airway pressure reduced mortality (relative risk [RR], 0.64 [95% CI, 0.44 to 0.92]) and need for intubation (RR, 0.44 [CI, 0.32 to 0.60]) but not incidence of new MI (RR, 1.07 [CI, 0.84 to 1.37]). The effect was more prominent in trials in which myocardial ischemia or infarction caused ACPE in higher proportions of patients (RR, 0.92 [CI, 0.76 to 1.10] when 10% of patients had ischemia or MI vs. 0.43 [CI, 0.17 to 1.07] when 50% had ischemia or MI). Bilevel ventilation reduced the need for intubation (RR, 0.54 [CI, 0.33 to 0.86]) but did not reduce mortality or new MI. No differences were detected between continuous positive airway pressure and bilevel ventilation on any clinical outcomes for which they were directly compared. Limitations: The quality of the evidence base was limited. Definitions, cause, and severity of ACPE differed among the trials, as did patient characteristics and clinical settings. Conclusion: Although a recent large trial contradicts results from previous studies, the evidence in aggregate still supports the use of NIV for patients with ACPE. Continuous positive airway pressure reduces mortality more in patients with ACPE secondary to acute myocardial ischemia or infarction.	[Weng, Cui-Lian] Capital Med Univ, Beijing Chaoyang Hosp Affiliate, Peking Univ, Peking Univ Peoples Hosp, Beijing 100044, Peoples R China; Tsinghua Univ, Beijing 100084, Peoples R China; Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China	Capital Medical University; Peking University; Tsinghua University; Xiamen University	Zhao, YT (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp Affiliate, Peking Univ, Peking Univ Peoples Hosp, 11 Xizhimen S St, Beijing 100044, Peoples R China.		Sun, Feng/AGF-7912-2022; Sun, Feng/E-8859-2010	Sun, Feng/0000-0003-4334-6805; Sun, Feng/0000-0001-9212-0496				Bellone A, 2005, INTENS CARE MED, V31, P807, DOI 10.1007/s00134-005-2649-6; Bellone A, 2004, CRIT CARE MED, V32, P1860, DOI 10.1097/01.CCM.0000139694.47326.B6; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; Bhogal SK, 2005, J CLIN EPIDEMIOL, V58, P668, DOI 10.1016/j.jclinepi.2005.01.002; BOLLAERT PE, 2002, AM J RESP CRIT CARE, V165, pA387; Collins SP, 2006, ANN EMERG MED, V48, P260, DOI 10.1016/j.annemergmed.2006.01.038; Crane SD, 2004, EMERG MED J, V21, P155, DOI 10.1136/emj.2003.005413; Cross AM, 2003, EMERG MED J, V20, P531, DOI 10.1136/emj.20.6.531; Delclaux C, 2000, JAMA-J AM MED ASSOC, V284, P2352, DOI 10.1001/jama.284.18.2352; DUCROS C, 2007, CONTINUOUS POSITIVE; Felker GM, 2003, AM HEART J, V145, pS18, DOI 10.1067/mhj.2003.150; FERRARI G, 2009, J EMERG MED; FERRARI G, 2006, J EMERGENCY MED, V30, P246; Ferrari G, 2007, CHEST, V132, P1804, DOI 10.1378/chest.07-1058; Ferrer M, 2003, AM J RESP CRIT CARE, V168, P1438, DOI 10.1164/rccm.200301-072OC; GHANEM MK, 2009, NONINVASIVE MECH VEN; Gray AJ, 2009, HEALTH TECHNOL ASSES, V13, P1, DOI 10.3310/hta13330; Gray A, 2008, NEW ENGL J MED, V359, P142, DOI 10.1056/NEJMoa0707992; [赫朝霞 Hao Chaoxia], 2002, [江西医学院学报, Acta Academiae Medicinae Jiangxi], V42, P48; Ho KM, 2006, CRIT CARE, V10, DOI 10.1186/cc4861; Kelly CA, 2002, EUR HEART J, V23, P1379, DOI 10.1053/euhj.2001.3156; L'Her E, 2004, INTENS CARE MED, V30, P882, DOI 10.1007/s00134-004-2183-y; Levitt MA, 2001, J EMERG MED, V21, P363, DOI 10.1016/S0736-4679(01)00385-7; LIESCHING TN, 2003, AM J RESP CRIT CARE, V167, pA864; LIN M, 1995, CHEST, V107, P1379, DOI 10.1378/chest.107.5.1379; MARTINBERMUDEZ R, 2002, INTENS CARE MED, V28, pA255; Masip J, 2005, JAMA-J AM MED ASSOC, V294, P3124, DOI 10.1001/jama.294.24.3124; Masip J, 2000, LANCET, V356, P2126, DOI 10.1016/S0140-6736(00)03492-9; Masip J, 2008, NEW ENGL J MED, V359, P2068; Mehta S, 1997, CRIT CARE MED, V25, P620, DOI 10.1097/00003246-199704000-00011; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moritz F, 2007, ANN EMERG MED, V50, P666, DOI 10.1016/j.annemergmed.2007.06.488; Nava S, 2003, AM J RESP CRIT CARE, V168, P1432, DOI 10.1164/rccm.200211-1270OC; Park M, 2004, CRIT CARE MED, V32, P2407, DOI 10.1097/01.CCM.0000147770.20400.10; Park M, 2001, Arq Bras Cardiol, V76, P221; Peter JV, 2006, LANCET, V367, P1155, DOI 10.1016/S0140-6736(06)68506-1; Plaisance P, 2007, EUR HEART J, V28, P2895, DOI 10.1093/eurheartj/ehm502; Poppas A, 2002, AM J RESP CRIT CARE, V165, P4, DOI 10.1164/ajrccm.165.1.2102075; Potts JM, 2009, POL ARCH MED WEWN, V119, P349, DOI 10.20452/pamw.705; RASANEN J, 1985, AM J CARDIOL, V55, P296, DOI 10.1016/0002-9149(85)90364-9; Schmid CH, 1998, STAT MED, V17, P1923, DOI 10.1002/(SICI)1097-0258(19980915)17:17<1923::AID-SIM874>3.0.CO;2-6; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; Takeda S, 1997, ANESTH ANALG, V84, P1091, DOI 10.1097/00000539-199705000-00025; Takeda S, 1998, JPN CIRC J, V62, P553, DOI 10.1253/jcj.62.553; Thompson SG, 2002, STAT MED, V21, P1559, DOI 10.1002/sim.1187; THYS FC, 2006, HERMES STUDY STUDY F; Vital FMR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005351.pub2; Weitz G, 2007, EUR J EMERG MED, V14, P276, DOI 10.1097/MEJ.0b013e32826fb377; Winck JC, 2006, CRIT CARE, V10, DOI 10.1186/cc4905	49	133	149	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 4	2010	152	9					590	+		10.7326/0003-4819-152-9-201005040-00009	http://dx.doi.org/10.7326/0003-4819-152-9-201005040-00009			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	595IN	20439577				2023-01-03	WOS:000277604000006
J	Torres, C				Torres, Christian			Counterfeiting goes cinematic in public campaigns	NATURE MEDICINE			English	News Item																			0	2	2	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					363	363		10.1038/nm0410-363a	http://dx.doi.org/10.1038/nm0410-363a			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376032				2023-01-03	WOS:000276446800023
J	Sawka, AM; Ismaila, N; Cranney, A; Thabane, L; Kastner, M; Gafni, A; Woodhouse, LJ; Crilly, R; Cheung, AM; Adachi, JD; Josse, RG; Papaioannou, A				Sawka, Anna M.; Ismaila, Nofisat; Cranney, Ann; Thabane, Lehana; Kastner, Monika; Gafni, Amiram; Woodhouse, Linda J.; Crilly, Richard; Cheung, Angela M.; Adachi, Jonathan D.; Josse, Robert G.; Papaioannou, Alexandra			A Scoping Review of Strategies for the Prevention of Hip Fracture in Elderly Nursing Home Residents	PLOS ONE			English	Review							VITAMIN-D SUPPLEMENTATION; BONE-MINERAL DENSITY; LONG-TERM-CARE; OLDER-PEOPLE; RISK-FACTORS; PROTECTORS DECREASE; ALZHEIMERS-DISEASE; SUNLIGHT EXPOSURE; HYPOVITAMINOSIS-D; CONTROLLED-TRIAL	Background: Elderly nursing home residents are at increased risk of hip fracture; however, the efficacy of fracture prevention strategies in this population is unclear. Objective: We performed a scoping review of randomized controlled trials of interventions tested in the long-term care (LTC) setting, examining hip fracture outcomes. Methods: We searched for citations in 6 respective electronic searches, supplemented by hand searches. Two reviewers independently reviewed all citations and full-text papers; consensus was achieved on final inclusion. Data was abstracted in duplicate. Findings: We reviewed 22,349 abstracts or citations and 949 full-text papers. Data from 20 trials were included: 7-vitamin D (n = 12,875 participants), 2-sunlight exposure (n = 522), 1-alendronate (n = 327), 1-fluoride (n = 460), 4-exercise or multimodal interventions (n = 8,165), and 5-hip protectors (n = 2,594). Vitamin D, particularly vitamin D-3 >= 800 IU orally daily, reduced hip fracture risk. Hip protectors reduced hip fractures in included studies, although a recent large study not meeting inclusion criteria was negative. Fluoride and sunlight exposure did not significantly reduce hip fractures. Falls were reduced in three studies of exercise or multimodal interventions, with one study suggesting reduced hip fractures in a secondary analysis. A staff education and risk assessment strategy did not significantly reduce falls or hip fractures. In a study underpowered for fracture outcomes, alendronate did not significantly reduce hip fractures in LTC. Conclusions: The intervention with the strongest evidence for reduction of hip fractures in LTC is Vitamin D supplementation; more research on other interventions is needed.	[Sawka, Anna M.; Ismaila, Nofisat; Cheung, Angela M.] Univ Hlth Network, Dept Med, Div Endocrinol, Toronto, ON, Canada; [Sawka, Anna M.; Cheung, Angela M.; Josse, Robert G.] Univ Toronto, Dept Med, Div Endocrinol, Toronto, ON, Canada; [Cranney, Ann] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada; [Thabane, Lehana; Gafni, Amiram] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Kastner, Monika] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Woodhouse, Linda J.] McMaster Univ, Sch Rehabil Sci, Hamilton, ON, Canada; [Woodhouse, Linda J.] Sunnybrook Hlth Sci Ctr, Holland Orthopaed & Arthrit Hosp, Dept Surg, Toronto, ON M4N 3M5, Canada; [Crilly, Richard] Univ Western Ontario, Dept Med, Div Geriatr, London, ON, Canada; [Cheung, Angela M.] Univ Hlth Network, Dept Med, Div Gen Internal Med, Toronto, ON, Canada; [Adachi, Jonathan D.] St Josephs Healthcare, Dept Med, Div Rheumatol, Hamilton, ON, Canada; [Adachi, Jonathan D.] McMaster Univ, Dept Med, Div Rheumatol, Hamilton, ON, Canada; [Josse, Robert G.] St Michaels Hosp, Dept Med, Div Endocrinol, Toronto, ON M5B 1W8, Canada; [Papaioannou, Alexandra] Hamilton Hlth Sci, Dept Med, Div Geriatr, Hamilton, ON, Canada; [Papaioannou, Alexandra] McMaster Univ, Dept Med, Div Geriatr, Hamilton, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Ottawa; Ottawa Hospital Research Institute; McMaster University; University of Toronto; McMaster University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; McMaster University; McMaster University	Sawka, AM (corresponding author), Univ Hlth Network, Dept Med, Div Endocrinol, Toronto, ON, Canada.	sawkaam@yahoo.com	Ismaila, Nofisat/HGC-3899-2022; Sawka, Anna/AAA-4336-2020; Woodhouse, Linda J/AAV-7090-2020	Cheung, Angela M./0000-0001-8332-0744; Woodhouse, Linda J/0000-0002-1615-8895	Canadian Institutes of Health Research [FRN 82616]; Ontario Ministry of Health	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario)	This work was funded by the Canadian Institutes of Health Research (Knowledge Translation - Research Synthesis Competition, FRN 82616) as well as, in part, by the Osteoporosis Strategy Program of the Ontario Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barton BA, 2008, CLIN TRIALS, V5, P347, DOI 10.1177/1740774508095120; Beaupre LA, 2007, J GERONTOL A-BIOL, V62, P1127, DOI 10.1093/gerona/62.10.1127; Becker C, 2003, J AM GERIATR SOC, V51, P306, DOI 10.1046/j.1532-5415.2003.51103.x; Berry SD, 2008, J AM GERIATR SOC, V56, P1887, DOI 10.1111/j.1532-5415.2008.01918.x; Bischoff-Ferrari HA, 2005, JAMA-J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257; Bischoff-Ferrari HA, 2009, ARCH INTERN MED, V169, P551, DOI 10.1001/archinternmed.2008.600; Brennan J, 2003, OSTEOPOROSIS INT, V14, P515, DOI 10.1007/s00198-003-1404-5; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; Butler M, 1996, AGE AGEING, V25, P381, DOI 10.1093/ageing/25.5.381; Chandler JM, 2000, JAMA-J AM MED ASSOC, V284, P972, DOI 10.1001/jama.284.8.972; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; Chapuy MC, 2002, OSTEOPOROSIS INT, V13, P257, DOI 10.1007/s001980200023; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; Cox H, 2008, AGE AGEING, V37, P167, DOI 10.1093/ageing/afm168; Crotty M, 2000, J Qual Clin Pract, V20, P167, DOI 10.1046/j.1440-1762.2000.00385.x; Cumming RG, 1996, AM J EPIDEMIOL, V143, P1191; Ekman A, 1997, LANCET, V350, P563, DOI 10.1016/S0140-6736(05)63140-6; Flicker L, 2005, J AM GERIATR SOC, V53, P1881, DOI 10.1111/j.1532-5415.2005.00468.x; Greenspan SL, 2002, ANN INTERN MED, V136, P742, DOI 10.7326/0003-4819-136-10-200205210-00009; Harada A, 2001, OSTEOPOROSIS INT, V12, P215, DOI 10.1007/s001980170132; INKOVAARA J, 1975, BMJ-BRIT MED J, V3, P73, DOI 10.1136/bmj.3.5975.73; Jantti PO, 1998, AGE AGEING, V27, P758, DOI 10.1093/ageing/27.6.758; Jensen J, 2002, ANN INTERN MED, V136, P733, DOI 10.7326/0003-4819-136-10-200205210-00008; Jorgensen EB, 2008, KAIS, V2021, P1, DOI [DOI 10.1002/14651858.CD001155.PUB2, 10.1002/mp.15257]; Kiel DP, 2007, JAMA-J AM MED ASSOC, V298, P413, DOI 10.1001/jama.298.4.413; Koike T, 2009, OSTEOPOROSIS INT, V20, P1613, DOI 10.1007/s00198-008-0824-7; KOMAR L, 1993, J AM GERIATR SOC, V41, P1057, DOI 10.1111/j.1532-5415.1993.tb06452.x; Lauritzen JB, 1997, DAN MED BULL, V44, P155; Law M, 2006, AGE AGEING, V35, P482, DOI 10.1093/ageing/afj080; Lyons RA, 2007, OSTEOPOROSIS INT, V18, P811, DOI 10.1007/s00198-006-0309-5; Maggio D, 2001, CALCIFIED TISSUE INT, V68, P337, DOI 10.1007/s002230001212; Meyer G, 2003, BRIT MED J, V326, P76, DOI 10.1136/bmj.326.7380.76; Meyer HE, 2002, J BONE MINER RES, V17, P709, DOI 10.1359/jbmr.2002.17.4.709; MORRIS JC, 1987, J GERONTOL, V42, P412, DOI 10.1093/geronj/42.4.412; Norton R, 1999, AGE AGEING, V28, P135, DOI 10.1093/ageing/28.2.135; OOMS ME, 1994, OSTEOPOROSIS INT, V4, P6, DOI 10.1007/BF02352254; Papadimitropoulos E, 2000, J SOC OBSTET GYNAECO, V22, P591; Rapp K, 2008, J BONE MINER RES, V23, P1825, DOI [10.1359/jbmr.080702, 10.1359/JBMR.080702]; Sakamoto K, 2006, J ORTHOP SCI, V11, P467, DOI 10.1007/s00776-006-1057-2; Sato Y, 2005, J BONE MINER RES, V20, P1327, DOI 10.1359/JBMR.050402; Sato Y, 2005, CEREBROVASC DIS, V20, P187, DOI 10.1159/000087203; Sato Y, 2003, NEUROLOGY, V61, P338, DOI 10.1212/01.WNL.0000078892.24356.90; Sawka AM, 2005, OSTEOPOROSIS INT, V16, P1461, DOI 10.1007/s00198-005-1932-2; Sawka AM, 2007, J CLIN EPIDEMIOL, V60, P336, DOI 10.1016/j.jclinepi.2006.07.006; Singh S, 2004, J RHEUMATOL, V31, P1607; Vu Man Quang, 2004, J Am Med Dir Assoc, V5, P401, DOI 10.1016/S1525-8610(04)70009-2; Weller I, 2004, ANN EPIDEMIOL, V14, P319, DOI 10.1016/j.annepidem.2003.08.005; Wiktorowicz ME, 2001, OSTEOPOROSIS INT, V12, P271, DOI 10.1007/s001980170116; Zimmerman SI, 1999, OSTEOPOROSIS INT, V9, P151	49	28	30	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2010	5	3							e9515	10.1371/journal.pone.0009515	http://dx.doi.org/10.1371/journal.pone.0009515			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	562OZ	20209088	Green Published, Green Submitted, gold			2023-01-03	WOS:000275063400020
J	Smith, SR				Smith, Steven R.			A Look at the Low-Carbohydrate Diet	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Florida Hosp, Burnham Inst, Translat Res Inst, Orlando, FL USA	Adventist Health Services; AdventHealth	Smith, SR (corresponding author), Florida Hosp, Burnham Inst, Translat Res Inst, Orlando, FL USA.		Smith, Steven/HDM-9496-2022	Smith, Steven/0000-0002-5098-8147				FOO SY, 2009, P NATL ACAD SCI 0824; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; Sacks FM, 2009, NEW ENGL J MED, V360, P859, DOI 10.1056/NEJMoa0804748; Smith SR, 2006, J CLIN ENDOCR METAB, V91, P2506, DOI 10.1210/jc.2006-1018; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953	5	16	16	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 3	2009	361	23					2286	2288		10.1056/NEJMcibr0908756	http://dx.doi.org/10.1056/NEJMcibr0908756			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	525ZM	19955530				2023-01-03	WOS:000272257100016
J	Howell, MD				Howell, Michael D.			A 37-Year-Old Man Trying to Choose a High-Quality Hospital Review of Hospital Quality Indicators	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; PRIMARY-CARE PHYSICIANS; PAY-FOR-PERFORMANCE; OF-CARE; HEALTH-CARE; UNITED-STATES; MEDICARE PATIENTS; PATIENT-OUTCOMES; CARDIAC-SURGERY	Mr A, a previously healthy 37-year-old man, was diagnosed as having Prinzmetal angina and a hypercoagulable state 3 years ago after an ST-elevation myocardial infarction. Now, his cardiologist is moving and Mr A must select a new physician and health system. Geographic relocation, insurance changes, and other events force millions in the United States to change physicians and hospitals every year. Mr A should begin by choosing a primary care physician, since continuity and coordination of care improves outcomes. Evidence for evaluating specific physicians is less robust, though a variety of sources are available. A broad range of detailed quality information, such as Medicare's Hospital Compare (http://www.hospitalcompare.hhs.gov/), is available for selecting a hospital. However, the relationship of these metrics to patient outcomes is variable, and different Web sites provide meaningfully different rankings and data interpretations. For Mr A in particular, a warfarin management team, the hospital's location, and a cardiologist with whom he feels comfortable and who can communicate with his primary care physician are important factors. Nevertheless, hospital quality information and metrics are an important component of the strategy Mr A should take to solve this challenging problem. JAMA. 2009;302(21):2353-2360	[Howell, Michael D.] Beth Israel Deaconess Med Ctr, Silverman Inst Hlth Care Qual & Safety, Boston, MA 02215 USA; [Howell, Michael D.] Beth Israel Deaconess Med Ctr, Div Pulm Crit Care & Sleep Med, Boston, MA 02215 USA; [Howell, Michael D.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Howell, MD (corresponding author), Beth Israel Deaconess Med Ctr, Silverman Inst Hlth Care Qual & Safety, 330 Brookline Ave, Boston, MA 02215 USA.	mhowell@bidmc.harvard.edu	Howell, Michael/B-8065-2009	Howell, Michael/0000-0001-7003-6971	Robert Wood Johnson Foundation	Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	Dr Howell reports that he receives grant support from the Robert Wood Johnson Foundation's Advancing the Science of Continuous Quality Improvement and Physician Faculty Scholars Program.	[Anonymous], 2008, US NEWS WORLD REP, V145, P76; [Anonymous], 2008, US NEWS WORLD REP, V145, P78; Atherly A, 2005, INQUIRY-J HEALTH CAR, V42, P255, DOI 10.5034/inquiryjrnl_42.3.255; Aujesky D, 2008, CAN MED ASSOC J, V178, P27, DOI 10.1503/cmaj.070743; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Bradley EH, 2006, JAMA-J AM MED ASSOC, V296, P72, DOI 10.1001/jama.296.1.72; *BUR LAB STAT, EMPL SIT SUMM MAY 20; Cabana MD, 2004, J FAM PRACTICE, V53, P974; Campbell RJ, 2003, FAM MED, V35, P60; Casalino LP, 2007, HEALTH AFFAIR, V26, P492, DOI 10.1377/hlthaff.26.2.492; Casalino LP, 2007, HEALTH AFFAIR, V26, pW405, DOI 10.1377/hlthaff.26.3.w405; Chen J, 2006, J GEN INTERN MED, V21, P238, DOI 10.1111/j.1525-1497.2006.00326.x; Chen J, 2003, HEALTH AFFAIR, V22, P243, DOI 10.1377/hlthaff.22.2.243; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; Chiquette E, 1998, ARCH INTERN MED, V158, P1641, DOI 10.1001/archinte.158.15.1641; Christian CK, 2005, WORLD J SURG, V29, P1241, DOI 10.1007/s00268-005-7993-8; COLEMAN J, 1957, SOCIOMETRY, V20, P253, DOI 10.2307/2785979; COMAROW A, 2008, US NEWSS BEST HOSP C; Cunningham PJ, 2000, HEALTH AFFAIR, V19, P158, DOI 10.1377/hlthaff.19.3.158; de Jong JD, 2006, HEALTH SERV RES, V41, P374, DOI 10.1111/j.1475-6773.2005.00486.x; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Durairaj L, 2005, CHEST, V128, P1682, DOI 10.1378/chest.128.3.1682; Esserman L, 2002, JNCI-J NATL CANCER I, V94, P369; Ezekowitz JA, 2005, CAN MED ASSOC J, V172, P189, DOI 10.1503/cmaj.1032017; Faber M, 2009, MED CARE, V47, P1, DOI 10.1097/MLR.0b013e3181808bb5; *FAM US, 2009, UN UN AM; Forrest CB, 2002, J FAM PRACTICE, V51, P215; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Gorey KM, 2009, CANCER-AM CANCER SOC, V115, P3563, DOI 10.1002/cncr.24401; Gosden T, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002215; Graber ML, 2005, ARCH INTERN MED, V165, P1493, DOI 10.1001/archinte.165.13.1493; Gruen RL, 2009, CA-CANCER J CLIN, V59, P192, DOI 10.3322/caac.20018; Halm EA, 2002, ANN INTERN MED, V137, P511, DOI 10.7326/0003-4819-137-6-200209170-00012; *HEALTHGRADES, 2009, 3 ANN HEALTHGRADES A; Hibbard JH, 2008, ANN INTERN MED, V148, P160, DOI 10.7326/0003-4819-148-2-200801150-00011; Hofer TP, 1999, JAMA-J AM MED ASSOC, V281, P2098, DOI 10.1001/jama.281.22.2098; Holmboe ES, 2008, ARCH INTERN MED, V168, P1396, DOI 10.1001/archinte.168.13.1396; HUNINK MG, 2001, DECISION MAKING HLTH, P364; Iezzoni LI, 1997, JAMA-J AM MED ASSOC, V278, P1600, DOI 10.1001/jama.278.19.1600; Institute of Medicine (IOM), 2001, CROSS QUAL CHASM NEW; Jha AK, 2008, NEW ENGL J MED, V359, P1921, DOI 10.1056/NEJMsa0804116; Jha AK, 2008, JT COMM J QUAL PATIE, V34, P318, DOI 10.1016/S1553-7250(08)34040-9; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; *KAIS FAM FDN AG H, 2006 UPD CONS VIEWS; Kellum JA, 2009, JAMA-J AM MED ASSOC, V301, P2496, DOI 10.1001/jama.2009.850; Kernisan LP, 2009, JAMA-J AM MED ASSOC, V301, P1341, DOI 10.1001/jama.2009.422; Ketcham JD, 2007, HEALTH AFFAIR, V26, P195, DOI 10.1377/hlthaff.26.1.195; Khuri SF, 1999, ANN SURG, V230, P414, DOI 10.1097/00000658-199909000-00014; KIMMEL SE, 1995, JAMA-J AM MED ASSOC, V274, P1137, DOI 10.1001/jama.274.14.1137; KLEIN MW, 1961, J HEALTH HUM BEHAV, V2, P138, DOI 10.2307/2948811; Kostopoulou O, 2008, FAM PRACT, V25, P400, DOI 10.1093/fampra/cmn071; Krumholz HM, 2002, JAMA-J AM MED ASSOC, V287, P1277, DOI 10.1001/jama.287.10.1277; Landon BE, 2003, JAMA-J AM MED ASSOC, V290, P1183, DOI 10.1001/jama.290.9.1183; Landon BE, 2008, ANN INTERN MED, V148, P353, DOI 10.7326/0003-4819-148-5-200803040-00006; Lavarreda SA, 2008, MED CARE, V46, P1055, DOI 10.1097/MLR.0b013e318187d8db; *LEAPFR GROUP, LEAPFR HOSP SURV RES; Leonardi MJ, 2007, ARCH SURG-CHICAGO, V142, P863, DOI 10.1001/archsurg.142.9.863; Macinko J, 2007, INT J HEALTH SERV, V37, P111, DOI 10.2190/3431-G6T7-37M8-P224; O'Malley AS, 2005, ARCH INTERN MED, V165, P2129, DOI 10.1001/archinte.165.18.2129; Peterson ED, 2004, JAMA-J AM MED ASSOC, V291, P195, DOI 10.1001/jama.291.2.195; Pham HH, 2009, ANN INTERN MED, V150, P236, DOI 10.7326/0003-4819-150-4-200902170-00004; Reed M C, 2000, Data Bull (Cent Stud Health Syst Change), P1; Reis SE, 1997, J AM COLL CARDIOL, V30, P733, DOI 10.1016/S0735-1097(97)00214-3; ROAN S, 2008, LOS ANGELES TIM 0519; Roetzheim RG, 2001, J FAM PRACTICE, V50, P1027; Rosenblatt RA, 1998, JAMA-J AM MED ASSOC, V279, P1364, DOI 10.1001/jama.279.17.1364; ROTHBERG MB, 2009, J HOSP MED, DOI DOI 10.1002/JHM.481; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; Scholle SH, 2008, AM J MANAG CARE, V14, P829; Schull MJ, 2006, ANN EMERG MED, V48, P647, DOI 10.1016/j.annemergmed.2006.03.025; Schwartz LM, 2005, BMJ-BRIT MED J, V331, P821, DOI 10.1136/bmj.38614.449016.DE; Shahian DM, 2005, ANN THORAC SURG, V80, P2106, DOI 10.1016/j.athoracsur.2005.06.078; Shahian DM, 2001, ANN THORAC SURG, V72, P2155, DOI 10.1016/S0003-4975(01)03222-2; Sharp LK, 2002, ACAD MED, V77, P534, DOI 10.1097/00001888-200206000-00011; SHI LY, 1994, INT J HEALTH SERV, V24, P431, DOI 10.2190/BDUU-J0JD-BVEX-N90B; Sofaer S, 2005, HEALTH SERV RES, V40, P2018, DOI 10.1111/j.1475-6773.2005.00473.x; Song HK, 2009, J THORAC CARDIOV SUR, V137, P65, DOI 10.1016/j.jtcvs.2008.09.053; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; Staiger DO, 2009, MED CARE, V47, P226, DOI 10.1097/MLR.0b013e3181847574; Stukel TA, 2005, JAMA-J AM MED ASSOC, V293, P1329, DOI 10.1001/jama.293.11.1329; *THOMS REUT, 100 TOP HOSP NAT BEN; Trivedi AN, 2006, JAMA-J AM MED ASSOC, V296, P1998, DOI 10.1001/jama.296.16.1998; Trivedi AN, 2005, NEW ENGL J MED, V353, P692, DOI 10.1056/NEJMsa051207; *UCOMPAREHEALTHCAR, METH; *US BUR CENS, DET TABL GEOGR MOB 2; Wang OJ, 2007, ARCH INTERN MED, V167, P1345, DOI 10.1001/archinte.167.13.1345; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694; Williams SC, 2006, CIRCULATION, V114, P558, DOI 10.1161/CIRCULATIONAHA.105.600973; Wilson CT, 2007, ARCH SURG-CHICAGO, V142, P242, DOI 10.1001/archsurg.142.3.242; Yarnall KSH, 2003, AM J PUBLIC HEALTH, V93, P635, DOI 10.2105/AJPH.93.4.635; 2008, US NEWS WORLD REP, V145, P74	92	8	8	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 2	2009	302	21					2353	2360		10.1001/jama.2009.1684	http://dx.doi.org/10.1001/jama.2009.1684			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	525TK	19887653				2023-01-03	WOS:000272239000024
J	Myers, JE; Tsiouris, SJ				Myers, Julie E.; Tsiouris, Simon J.			Is there a place for directly observed therapy in HAART?	LANCET			English	Editorial Material							ANTIRETROVIRAL THERAPY; ADHERENCE; HIV		[Tsiouris, Simon J.] Columbia Univ, Div Infect Dis, Coll Phys & Surg, New York, NY 10032 USA; Columbia Univ, Ctr Infect Dis Epidemiol Res, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY 10032 USA	Columbia University; Columbia University	Tsiouris, SJ (corresponding author), Columbia Univ, Div Infect Dis, Coll Phys & Surg, New York, NY 10032 USA.	st326@columbia.edu						Ford N, 2009, LANCET, V374, P2064, DOI 10.1016/S0140-6736(09)61671-8; Frieden TR, 2007, B WORLD HEALTH ORGAN, V85, P407, DOI 10.2471/BLT.06.038927; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Gordon CM, 2006, JAIDS-J ACQ IMM DEF, V43, pS36, DOI 10.1097/01.qai.0000248347.87512.ba; Gross R, 2009, ARCH INTERN MED, V169, P1224, DOI 10.1001/archinternmed.2009.172; Harries AD, 2004, T ROY SOC TROP MED H, V98, P695, DOI 10.1016/j.trstmh.2004.05.002; Mills EJ, 2006, JAMA-J AM MED ASSOC, V296, P679, DOI 10.1001/jama.296.6.679; Simoni Jane M, 2008, Curr Infect Dis Rep, V10, P515, DOI 10.1007/s11908-008-0083-y; Volmink J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003510.pub2; [WHO UNAIDS UNICEF], 2009, UN ACC SCAL PRIOR HI; *WHO STOP TB PARTN, STOP TB STRAT BUILD	11	2	2	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC-JAN	2009	374	9707					2030	2032		10.1016/S0140-6736(09)61991-7	http://dx.doi.org/10.1016/S0140-6736(09)61991-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	537OO	19954831				2023-01-03	WOS:000273122900005
J	Quaranta, A; Bellantuono, V; Cassano, G; Lippe, C				Quaranta, Angelo; Bellantuono, Vito; Cassano, Giuseppe; Lippe, Claudio			Why Amphibians Are More Sensitive than Mammals to Xenobiotics	PLOS ONE			English	Article							PIG EAR SKIN; ANURAN AMPHIBIANS; ATRAZINE; EXTINCTION; ABSORPTION; EXPOSURE; PENETRATION; HERBICIDE; TRANSPORT; JUNCTIONS	Dramatic declines in amphibian populations have been described all over the world since the 1980s. The evidence that the sensitivity to environmental threats is greater in amphibians than in mammals has been generally linked to the observation that amphibians are characterized by a rather permeable skin. Nevertheless, a numerical comparison of data of percutaneous (through the skin) passage between amphibians and mammals is lacking. Therefore, in this investigation we have measured the percutaneous passage of two test molecules (mannitol and antipyrine) and three heavily used herbicides (atrazine, paraquat and glyphosate) in the skin of the frog Rana esculenta ( amphibians) and of the pig ear (mammals), by using the same experimental protocol and a simple apparatus which minimizes the edge effect, occurring when the tissue is clamped in the usually used experimental device. The percutaneous passage (P) of each substance is much greater in frog than in pig. LogP is linearly related to logK(ow) (logarithm of the octanol-water partition coefficient). The measured P value of atrazine was about 134 times larger than that of glyphosate in frog skin, but only 12 times in pig ear skin. The FoD value (P(frog)/P(pig)) was 302 for atrazine, 120 for antipyrine, 66 for mannitol, 29 for paraquat, and 26 for glyphosate. The differences in structure and composition of the skin between amphibians and mammals are discussed.			Quaranta, A (corresponding author), Univ Bari, Dept Anim Prod, I-70121 Bari, Italy.	a.quaranta@veterinaria.uniba.it		Quaranta, Angelo/0000-0001-7835-2485; CASSANO, Giuseppe/0000-0003-3698-3355				Anderson JM, 2001, NEWS PHYSIOL SCI, V16, P126; BirdLife International, 2004, STAT WORLDS BIRDS IN; BLAUSTEIN AR, 1990, TRENDS ECOL EVOL, V5, P203, DOI 10.1016/0169-5347(90)90129-2; Boone MD, 2003, ENVIRON TOXICOL CHEM, V22, P2695, DOI 10.1897/02-401; Carrer DC, 2008, J CONTROL RELEASE, V132, P12, DOI 10.1016/j.jconrel.2008.08.006; Cassano G, 2006, ENVIRON TOXICOL CHEM, V25, P509, DOI 10.1897/05-141R.1; Dalton R, 2002, NATURE, V416, P665, DOI 10.1038/416665a; DICK IP, 1992, J PHARM PHARMACOL, V44, P640, DOI 10.1111/j.2042-7158.1992.tb05485.x; FARQUHAR MG, 1965, J CELL BIOL, V26, P263, DOI 10.1083/jcb.26.1.263; HADLEY NF, 1991, ADV LIPID RES, V24, P303; Hansch C., 1995, J AM CHEM SOC; HELMAN SI, 1974, AM J PHYSIOL, V226, P1198, DOI 10.1152/ajplegacy.1974.226.5.1198; Herkenne C, 2006, PHARM RES-DORDR, V23, P1850, DOI 10.1007/s11095-006-9011-8; IUCN - The World Conservation Union, 2001, IUCN RED LIST CAT CR; IUCN - World Conservation Union, 2003, IUCN RED LIST THREAT; Langerveld AJ, 2009, ENVIRON RES, V109, P379, DOI 10.1016/j.envres.2009.01.006; Lillywhite HB, 2006, J EXP BIOL, V209, P202, DOI 10.1242/jeb.02007; LILLYWHITE HB, 2007, KOSMETISCHE MED, V5, P220; Moody RP, 2000, TOXICOL IN VITRO, V14, P467, DOI 10.1016/S0887-2333(00)00038-2; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; Nielsen JB, 2000, OCCUP ENVIRON MED, V57, P734, DOI 10.1136/oem.57.11.734; OECD, 2004, OECD GUID TEST CHEM; Pimm SL, 2000, NATURE, V403, P843, DOI 10.1038/35002708; Rowe CL, 2003, AMPHIBIAN DECLINE: AN INTEGRATED ANALYSIS OF MULTIPLE STRESSOR EFFECTS, P9; Sangster J, 2006, LOGKOW DATABANK EVAL; Schaefer H., 1996, SKIN BARRIER PRINCIP, P118; Sodhi NS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001636; Stuart SN, 2004, SCIENCE, V306, P1783, DOI 10.1126/science.1103538; Suzawa M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002117; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Uchiyama M, 2006, GEN COMP ENDOCR, V147, P54, DOI 10.1016/j.ygcen.2005.12.018; Vallet V, 2007, TOXICOL IN VITRO, V21, P1182, DOI 10.1016/j.tiv.2007.03.007; Willens S, 2006, ENVIRON TOXICOL PHAR, V22, P255, DOI 10.1016/j.etap.2006.04.010; WITHERS PC, 1984, J EXP ZOOL, V232, P11, DOI 10.1002/jez.1402320103; Young BE, 2001, CONSERV BIOL, V15, P1213, DOI 10.1046/j.1523-1739.2001.00218.x	35	85	89	7	64	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2009	4	11							e7699	10.1371/journal.pone.0007699	http://dx.doi.org/10.1371/journal.pone.0007699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	514RZ	19888346	Green Published, Green Submitted, gold			2023-01-03	WOS:000271414600007
J	Qaseem, A; Snow, V; Denberg, TD; Casey, DE; Forciea, MA; Owens, DK; Shekelle, P				Qaseem, Amir; Snow, Vincenza; Denberg, Thomas D.; Casey, Donald E., Jr.; Forciea, Mary Ann; Owens, Douglas K.; Shekelle, Paul		Amer Coll Phys	Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							SILDENAFIL CITRATE VIAGRA((R)); PLACEBO-CONTROLLED TRIAL; RANDOMIZED DOUBLE-BLIND; URINARY-TRACT SYMPTOMS; ON-DEMAND TADALAFIL; PHOSPHODIESTERASE TYPE-5 INHIBITOR; SPARING RADICAL PROSTATECTOMY; INCREASES PENILE RIGIDITY; SERUM TESTOSTERONE LEVELS; FLEXIBLE-DOSE VARDENAFIL	Description: The American College of Physicians developed this guideline to present the available evidence on hormonal testing in and pharmacologic management of erectile dysfunction. Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, vardenafil, tadalafil, mirodenafil, and udenafil, and hormonal treatment. Methods: Published literature on this topic was identified by using MEDLINE (1966 to May 2007), EMBASE (1980 to week 22 of 2007), Cochrane Central Register of Controlled Trials (second quarter of 2007), PsycINFO (1985 to June 2007), AMED (1985 to June 2007), and SCOPUS (2006). The literature search was updated by searching for articles in MEDLINE and EMBASE published between May 2007 and April 2009. Searches were limited to English-language publications. This guideline grades the evidence and recommendations by using the American College of Physicians' clinical practice guidelines grading system. Recommendation 1: The American College of Physicians recommends that clinicians initiate therapy with a PDE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindication to PDE-5 inhibitor use (Grade: strong recommendation; high-quality evidence). Recommendation 2: The American College of Physicians recommends that clinicians base the choice of a specific PDE-5 inhibitor on the individual preferences of men with erectile dysfunction, including ease of use, cost of medication, and adverse effects profile (Grade: weak recommendation; low-quality evidence). Recommendation 3: The American College of Physicians does not recommend for or against routine use of hormonal blood tests or hormonal treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to determine net benefits and harms).	[Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19104 USA; Univ Penn, Philadelphia, PA 19104 USA; Univ Colorado, Aurora, CO USA; Atlantic Hlth, Morristown, NJ USA; Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA; Stanford Univ, Stanford, CA 94305 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA	American College of Physicians; University of Pennsylvania; University of Colorado System; University of Colorado Anschutz Medical Campus; Atlantic Health System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19104 USA.	aqaseem@acponline.org	Casey, Donald/AFM-6658-2022	Casey, Donald/0000-0002-3820-598X	American College of Physicians' operating budget	American College of Physicians' operating budget	Financial support for the development of this guideline comes exclusively from the American College of Physicians' operating budget.	Abdel-Naser MB, 2004, INT J IMPOT RES, V16, P552, DOI 10.1038/sj.ijir.3901245; Acar D, 2004, ARCH ANDROLOGY, V50, P247, DOI 10.1080/01485010490448769; AKPUNONU BE, 1994, J GEN INTERN MED, V9, P336, DOI 10.1007/BF02599183; Albuquerque Denilson C., 2005, Int. braz j urol., V31, P342, DOI 10.1590/S1677-55382005000400008; Althof SE, 2006, J SEX MED, V3, P521, DOI 10.1111/j.1743-6109.2006.00234.x; Araujo AB, 2007, J CLIN ENDOCR METAB, V92, P4241, DOI 10.1210/jc.2007-1245; Aversa A, 2007, INT J IMPOT RES, V19, P200, DOI 10.1038/sj.ijir.3901513; Aversa A, 2003, CLIN ENDOCRINOL, V58, P632, DOI 10.1046/j.1365-2265.2003.01764.x; Aytac IA, 1999, BJU INT, V84, P50; Bank AJ, 2006, VASC MED, V11, P251, DOI 10.1177/1358863x06072221; Bannowsky A, 2008, BJU INT, V101, P1279, DOI 10.1111/j.1464-410X.2008.07515.x; Becher E, 2002, INT J IMPOT RES, V14, pS33, DOI 10.1038/sj.ijir.3900896; Bocchio M, 2008, ATHEROSCLEROSIS, V196, P313, DOI 10.1016/j.atherosclerosis.2006.09.035; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; Boulton AJM, 2001, DIABETOLOGIA, V44, P1296, DOI 10.1007/s001250100656; Boyanov M A, 2003, Aging Male, V6, P1; Bunch T J, 2002, Aging Male, V5, P38, DOI 10.1080/713604648; Buranakitjaroen Peera, 2007, Journal of the Medical Association of Thailand, V90, P1100; Burnett AL, 2009, J UROLOGY, V181, P245, DOI 10.1016/j.juro.2008.09.005; Buvat J, 1997, J UROLOGY, V158, P1764, DOI 10.1016/S0022-5347(01)64123-5; Buvat J, 2008, BJU INT, V102, P1645, DOI 10.1111/j.1464-410X.2008.07908.x; Cappelleri JC, 2000, UROLOGY, V56, P477, DOI 10.1016/S0090-4295(00)00697-X; Carrier S, 2005, J SEX MED, V2, P685, DOI 10.1111/j.1743-6109.2005.00097.x; Carson C, 2005, UROLOGY, V65, P353, DOI 10.1016/j.urology.2004.09.056; Carson CC, 2004, BJU INT, V94, P1301, DOI 10.1111/j.1464-410X.2004.05161.x; Cavallini G, 2005, UROLOGY, V66, P1080, DOI 10.1016/j.urology.2005.05.014; Cavallini G, 2004, UROLOGY, V63, P641, DOI 10.1016/j.urology.2003.11.009; Chen KK, 2001, INT J IMPOT RES, V13, P221, DOI 10.1038/sj.ijir.3900685; Chen KK, 2004, J SEX MED, V1, P201, DOI 10.1111/j.1743-6109.2004.04029.x; Chiang HS, 2007, INT J IMPOT RES, V19, P411, DOI 10.1038/sj.ijir.3901562; Choi HK, 2003, INT J IMPOT RES, V15, P80, DOI 10.1038/sj.ijir.3900944; CHOI HK, 2006, TAEHAN PINYOGIKWA HA, V47, P852; Choppin A, 2001, INT J IMPOT RES, V13, P157, DOI 10.1038/sj.ijir.3900653; Christiansen E, 2000, INT J IMPOT RES, V12, P177, DOI 10.1038/sj.ijir.3900527; Citron JT, 1996, J UROLOGY, V155, P529, DOI 10.1016/S0022-5347(01)66441-3; CLOPPER RR, 1993, PSYCHONEUROENDOCRINO, V18, P149, DOI 10.1016/0306-4530(93)90066-T; Corona G, 2008, J SEX MED, V5, P2454, DOI 10.1111/j.1743-6109.2008.00856.x; De Rose AF, 2005, INT J IMPOT RES, V17, P76, DOI 10.1038/sj.ijir.3901265; de Tejada IS, 2002, DIABETES CARE, V25, P2159; DeBusk RF, 2004, AM J CARDIOL, V93, P147, DOI 10.1016/j.amjcard.2003.09.030; Demir E, 2006, TRANSPL P, V38, P1379, DOI 10.1016/j.transproceed.2006.02.076; Diamond LE, 2005, UROLOGY, V65, P755, DOI 10.1016/j.urology.2004.10.060; Dinsmore WW, 1999, UROLOGY, V53, P800, DOI 10.1016/S0090-4295(98)00586-X; DRINKA PJ, 1993, SOUTHERN MED J, V86, P1264, DOI 10.1097/00007611-199311000-00017; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; Dunzendorfer U, 2002, IN VIVO, V16, P345; Eardley I, 2002, BRIT J CLIN PHARMACO, V53, p61S, DOI 10.1046/j.0306-5251.2001.00034.x; Eardley I, 2005, BJU INT, V96, P1323, DOI 10.1111/j.1464-410X.2005.05892.x; Eardley I, 2004, BJU INT, V94, P871, DOI 10.1111/j.1464-410X.2004.05049.x; Eardley I, 2004, BJU INT, V93, P1271, DOI 10.1111/j.1464-410X.2004.04816.x; Eardley I, 2001, BRIT J PSYCHIAT, V178, P325, DOI 10.1192/bjp.178.4.325; Earle CM, 2003, UROLOGY, V62, P727, DOI 10.1016/S0090-4295(03)00508-9; Edwards D, 2006, J SEX MED, V3, P1028, DOI 10.1111/j.1743-6109.2006.00329.x; El-Sakka AI, 2007, J SEX MED, V4, P1691, DOI 10.1111/j.1743-6109.2006.00342.x; El-Sakka AI, 2006, J UROLOGY, V176, P2589, DOI 10.1016/j.juro.2006.08.005; El-Sakka AI, 2005, J SEX MED, V2, P551, DOI 10.1111/j.1743-6109.2005.00082.x; Fahmy AK, 1999, BJU INT, V84, P482; Fava M, 2006, J CLIN PSYCHIAT, V67, P240, DOI 10.4088/JCP.v67n0210; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; FORSBERG L, 1990, SCAND J UROL NEPHROL, V24, P83, DOI 10.3109/00365599009180368; Fowler CJ, 2005, J NEUROL NEUROSUR PS, V76, P700, DOI 10.1136/jnnp.2004.038695; Gentile V, 2004, CURR MED RES OPIN, V20, P1377, DOI 10.1185/030079904x2394; GLINA S, 2001, BRAZ J UROL, V27, P148; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Goldstein I, 2005, J SEX MED, V2, P819, DOI 10.1111/j.1743-6109.2005.00147.x; Goldstein I, 2003, DIABETES CARE, V26, P777, DOI 10.2337/diacare.26.3.777; GOMAA AA, 2006, J MENS HLTH GEND, V3, P47; Gomez F, 2002, INT J IMPOT RES, V14, pS42, DOI 10.1038/sj.ijir.3900897; Gopalakrishnan R, 2006, AM J PSYCHIAT, V163, P494, DOI 10.1176/appi.ajp.163.3.494; Govier F, 2003, CLIN THER, V25, P2709, DOI 10.1016/S0149-2918(03)80328-4; Guay A, 2007, J SEX MED, V4, P1046, DOI 10.1111/j.1743-6109.2007.00530.x; GUAY AT, 1991, UROLOGY, V38, P317, DOI 10.1016/0090-4295(91)80143-U; Guo YL, 2006, INT J UROL, V13, P721, DOI 10.1111/j.1442-2042.2006.01393.x; Haren M, 2005, AGE AGEING, V34, P125, DOI 10.1093/ageing/afi003; Hatzichristou D, 2004, EUR UROL, V45, P634, DOI 10.1016/j.eururo.2004.01.014; Hatzichristou D, 2008, DIABETIC MED, V25, P138, DOI 10.1111/j.1464-5491.2007.02338.x; Hatzichristou D, 2002, J UROLOGY, V168, P615, DOI 10.1016/S0022-5347(05)64690-3; Heiman JR, 2007, BJOG-INT J OBSTET GY, V114, P437, DOI 10.1111/j.1471-0528.2006.01228.x; Hellstrom WJG, 2002, J ANDROL, V23, P763; Herrmann HC, 2006, J SEX MED, V3, P303, DOI 10.1111/j.1743-6109.2005.00156.x; Hong SK, 2007, J UROLOGY, V178, P613, DOI 10.1016/j.juro.2007.03.132; Hundertmark J, 2007, J SEX MED, V4, P1126, DOI 10.1111/j.1743-6109.2007.00536.x; Hussain IF, 2001, J NEUROL NEUROSUR PS, V71, P371, DOI 10.1136/jnnp.71.3.371; Incrocci L, 2001, INT J RADIAT ONCOL, V51, P1190, DOI 10.1016/S0360-3016(01)01767-9; Incrocci L, 2006, INT J RADIAT ONCOL, V66, P439, DOI 10.1016/j.ijrobp.2006.04.047; Ishii N, 2006, INT J UROL, V13, P1066, DOI 10.1111/j.1442-2042.2006.01480.x; Johannes CB, 2000, J UROLOGY, V163, P460, DOI 10.1016/S0022-5347(05)67900-1; JOHNSON AR, 1992, J UROLOGY, V147, P1542, DOI 10.1016/S0022-5347(17)37620-6; Jones LA, 2008, J SEX MED, V5, P1955, DOI 10.1111/j.1743-6109.2008.00879.x; Kadioglu A, 2008, J SEX MED, V5, P726, DOI 10.1111/j.1743-6109.2007.00701.x; Kaplan SA, 2007, EUR UROL, V51, P1717, DOI 10.1016/j.eururo.2007.01.033; Katz SD, 2005, AM J CARDIOL, V95, P36, DOI 10.1016/j.amjcard.2004.08.060; Klotz T, 2001, WORLD J UROL, V19, P32, DOI 10.1007/s003450000168; Kohler Tobias S, 2008, Urology, V71, P693, DOI 10.1016/j.urology.2007.11.073; Kongkanand Apichat, 2003, J Med Assoc Thai, V86, P195; Koulikov D, 2007, J UROLOGY, V177, P2267, DOI 10.1016/j.juro.2007.01.123; Kupelian V, 2006, J UROLOGY, V176, P2584, DOI 10.1016/j.juro.2006.08.020; Levinson IP, 2003, INT J IMPOT RES, V15, pS25, DOI 10.1038/sj.ijir.3900970; Lindsey I, 2002, DIS COLON RECTUM, V45, P727, DOI 10.1007/s10350-004-6287-9; LOW WY, 2006, J MENS HLTH GEND, V3, P263; Mahon A, 2005, AM J KIDNEY DIS, V45, P381, DOI 10.1053/j.ajkd.2004.10.012; Makhlouf AA, 2008, INT J IMPOT RES, V20, P157, DOI 10.1038/sj.ijir.3901576; Margo CE, 2007, AM J OPHTHALMOL, V143, P538, DOI 10.1016/j.ajo.2006.10.006; Martin-Morales A, 2007, J SEX MED, V4, P440, DOI 10.1111/j.1743-6109.2006.00426.x; Mazo E, 2006, INT J IMPOT RES, V18, P464, DOI 10.1038/sj.ijir.3901454; McCullough AR, 2008, INT J IMPOT RES, V20, P388, DOI 10.1038/ijir.2008.21; McCullough AR, 2008, UROLOGY, V71, P686, DOI 10.1016/j.urology.2007.12.025; McCullough AR, 2008, J SEX MED, V5, P476, DOI 10.1111/j.1743-6109.2007.00700.x; MCEVOY GK, 2008, AHFS DRUG INFORM; McMahon C, 2005, J SEX MED, V2, P415, DOI 10.1111/j.1743-6109.2005.20360.x; McMahon CG, 2005, INT J CLIN PRACT, V59, P143, DOI 10.1111/j.1742-1241.2005.00451.x; McVary KT, 2007, J UROLOGY, V177, P1401, DOI 10.1016/j.juro.2006.11.037; McVary KT, 2007, J UROLOGY, V177, P1071, DOI 10.1016/j.juro.2006.10.055; Melnik T, 2005, J SEX MARITAL THER, V31, P243, DOI 10.1080/00926230590513465; Merza Z, 2006, INT J ANDROL, V29, P381, DOI 10.1111/j.1365-2605.2005.00612.x; Meuleman E, 2001, BJU INT, V87, P75, DOI 10.1046/j.1464-410x.2001.00998.x; Miner M, 2008, J SEX MED, V5, P1455, DOI 10.1111/j.1743-6109.2008.00820.x; Mirone V, 2005, EUR UROL, V47, P846, DOI 10.1016/j.eururo.2005.02.019; Montorsi F, 2004, J UROLOGY, V172, P1036, DOI 10.1097/01.ju.0000136448.71773.2b; Montorsi F, 1999, UROLOGY, V53, P1011, DOI 10.1016/S0090-4295(98)00643-8; Montorsi F, 2000, UROLOGY, V56, P906, DOI 10.1016/S0090-4295(00)00841-4; Montorsi F, 2008, EUR UROL, V54, P924, DOI 10.1016/j.eururo.2008.06.083; Montorsi F, 2004, J SEX MED, V1, P168, DOI 10.1111/j.1743-6109.2004.04025.x; Morano S, 2007, EUR UROL, V52, P1768, DOI 10.1016/j.eururo.2007.04.042; Muezzinoglu T, 2007, YONSEI MED J, V48, P1015, DOI 10.3349/ymj.2007.48.6.1015; Nagao K, 2004, INT J UROL, V11, P515, DOI 10.1111/j.1442-2042.2004.00833.x; Nagao K, 2006, UROLOGY, V68, P845, DOI 10.1016/j.urology.2006.05.001; Nehra A, 2005, J UROLOGY, V173, P2067, DOI 10.1097/01.ju.0000158456.41788.93; Netto Junior N R, 1993, Rev Paul Med, V111, P454; Nurnberg HG, 2003, JAMA-J AM MED ASSOC, V289, P56, DOI 10.1001/jama.289.1.56; O'Leary MP, 2006, J UROLOGY, V175, P1058, DOI 10.1016/S0022-5347(05)00418-0; Olsson AM, 2001, INT J CLIN PRACT, V55, P171; Olsson AM, 2000, INT J CLIN PRACT, V54, P561; Orr G, 2006, J CLIN PSYCHOPHARM, V26, P426, DOI 10.1097/01.jcp.0000227701.33999.b3; Padma-Nathan H, 2003, UROLOGY, V62, P400, DOI 10.1016/S0090-4295(03)00567-3; Padma-Nathan H, 1998, INT J CLIN PRACT, V52, P375; Paick JS, 2008, J SEX MED, V5, P2672, DOI 10.1111/j.1743-6109.2008.00945.x; Paick JS, 2008, ASIAN J ANDROL, V10, P791, DOI 10.1111/j.1745-7262.2008.00422.x; Paick JS, 2008, J SEX MED, V5, P946, DOI 10.1111/j.1743-6109.2007.00723.x; Palmer JS, 2000, J UROLOGY, V164, P958, DOI 10.1016/S0022-5347(05)67225-4; Pavone C, 2004, J UROLOGY, V172, P2347, DOI 10.1097/01.ju.0000144032.39336.28; Perimenis P, 2004, ANDROLOGIA, V36, P106, DOI 10.1111/j.1439-0272.2004.00614.x; Perimenis P, 2004, INT J IMPOT RES, V16, P2, DOI 10.1038/sj.ijir.3901119; Perimenis P, 2007, ASIAN J ANDROL, V9, P259, DOI 10.1111/j.1745-7262.2007.00085.x; Pickering TG, 2004, AM J HYPERTENS, V17, P1135, DOI 10.1016/j.amjhyper.2004.07.004; Porst H, 2001, INT J IMPOT RES, V13, P192, DOI 10.1038/sj.ijir.3900713; Porst H, 2007, EUR J MED RES, V12, P61; Porst H, 2003, UROLOGY, V62, P121, DOI 10.1016/S0090-4295(03)00359-5; Porst H, 2006, EUR UROL, V50, P1086, DOI 10.1016/j.eururo.2006.05.036; Price DE, 1998, DIABETIC MED, V15, P821, DOI 10.1002/(SICI)1096-9136(199810)15:10<821::AID-DIA697>3.0.CO;2-P; Rabkin JG, 2000, ARCH GEN PSYCHIAT, V57, P141, DOI 10.1001/archpsyc.57.2.141; Rajfer J, 2007, INT J IMPOT RES, V19, P95, DOI 10.1038/sj.ijir.3901496; Ralph D, 2007, BJU INT, V100, P130, DOI 10.1111/j.1464-410X.2007.06900.x; Rendell MS, 1999, JAMA-J AM MED ASSOC, V281, P421, DOI 10.1001/jama.281.5.421; Reyes-Vallejo L, 2007, J SEX MED, V4, P1757, DOI 10.1111/j.1743-6109.2006.00381.x; Rhoden EL, 2002, INT J IMPOT RES, V14, P167, DOI 10.1038/sj.ijir.3900852; Rhoden EL, 2002, J UROLOGY, V167, P1745, DOI 10.1016/S0022-5347(05)65191-9; Tolra JR, 2006, J SEX MED, V3, P901, DOI 10.1111/j.1743-6109.2006.00297.x; Rosanoa GMC, 2005, EUR UROL, V47, P214, DOI 10.1016/j.eururo.2004.10.002; Rosen R, 2006, AM J PSYCHIAT, V163, P79, DOI 10.1176/appi.ajp.163.1.79; Rosen RC, 2004, J SEX MED, V1, P193, DOI 10.1111/j.1743-6109.2004.04028.x; Safarinejad MR, 2006, INT J IMPOT RES, V18, P550, DOI 10.1038/sj.ijir.3901476; Safarinejad MR, 2009, J UROLOGY, V181, P252, DOI 10.1016/j.juro.2008.09.003; Safarinejad MR, 2004, J DIABETES COMPLICAT, V18, P205, DOI 10.1016/S1056-8727(03)00056-4; Saylan M, 2006, INT J CLIN PRACT, V60, P812, DOI 10.1111/j.1742-1241.2006.00993.x; Schiavi RC, 1997, ARCH SEX BEHAV, V26, P231, DOI 10.1023/A:1024518730222; Seftel AD, 2004, J UROLOGY, V172, P652, DOI 10.1097/01.ju.0000132857.39680.ce; Seftel AD, 2004, J ANDROL, V25, P963; Seibel I, 2002, J AM SOC NEPHROL, V13, P2770, DOI 10.1097/01.ASN.0000034201.97937.3E; Seidman SN, 2006, J SEX MARITAL THER, V32, P267, DOI 10.1080/00926230600575355; Seidman SN, 2001, AM J PSYCHIAT, V158, P1623, DOI 10.1176/appi.ajp.158.10.1623; Shabsigh R, 2004, J UROLOGY, V172, P658, DOI 10.1097/01.ju.0000132389.97804.d7; Shamloul R, 2005, J SEX MED, V2, P559, DOI 10.1111/j.1743-6109.2005.00071.x; Sharma RK, 2006, AM J KIDNEY DIS, V48, P128, DOI 10.1053/j.ajkd.2006.04.061; Skoumal R, 2004, EUR UROL, V46, P362, DOI 10.1016/j.eururo.2004.04.026; Sommer F, 2007, ASIAN J ANDROL, V9, P134, DOI 10.1111/j.1745-7262.2007.00233.x; Staab A, 2004, PHARM RES-DORDR, V21, P1463, DOI 10.1023/B:PHAM.0000036922.03519.40; Stark S, 2001, EUR UROL, V40, P181, DOI 10.1159/000049770; Stief C, 2004, INT J CLIN PRACT, V58, P230, DOI 10.1111/j.1368-5031.2004.00128.x; Stuckey BGA, 2003, DIABETES CARE, V26, P279, DOI 10.2337/diacare.26.2.279; Tan HM, 2000, UROLOGY, V56, P635, DOI 10.1016/S0090-4295(00)00688-9; Tan HM, 2008, ASIAN J ANDROL, V10, P495, DOI 10.1111/j.1745-7262.2008.00388.x; Tignol J, 2004, INT CLIN PSYCHOPHARM, V19, P191, DOI 10.1097/01.yic.0000117902.43995.b0; Tsertsvadze A, 2009, EVID REP TECHNOL ASS, V171, P98; Tsertsvadze A, 2009, ANN INTERN MED, V151, P650, DOI 10.7326/0003-4819-151-9-200911030-00150; Tsujimura A, 2005, INT J IMPOT RES, V17, P259, DOI 10.1038/sj.ijir.3901300; Ugarte F, 2002, INT J IMPOT RES, V14, pS48, DOI 10.1038/sj.ijir.3900898; Valiquette L, 2005, MAYO CLIN PROC, V80, P1291, DOI 10.4065/80.10.1291; van Ahlen H, 2005, J SEX MED, V2, P856, DOI 10.1111/j.1743-6109.2005.00150.x; Virag R, 1999, UROLOGY, V54, P1073, DOI 10.1016/S0090-4295(99)00310-6; von Keitz A, 2004, EUR UROL, V45, P499, DOI 10.1016/j.eururo.2003.11.030; Warburton I, 2004, J SEX MED, V1, P179, DOI 10.1111/j.1743-6109.2004.04026.x; Webster LJ, 2004, ARCH INTERN MED, V164, P514, DOI 10.1001/archinte.164.5.514; Wessells H, 2007, J UROLOGY, V177, P1675, DOI 10.1016/j.juro.2007.01.057; Yassin AA, 2006, ANDROLOGIA, V38, P61, DOI 10.1111/j.1439-0272.2006.00712.x; Yip WCA, 2006, ASIAN J ANDROL, V8, P685, DOI 10.1111/j.1745-7262.2006.00213.x; Young JM, 2005, J ANDROL, V26, P310, DOI 10.2164/jandrol.04126; Young JM, 2002, UROLOGY, V60, P39, DOI 10.1016/S0090-4295(02)01689-8; Ziegler D, 2006, J SEX MED, V3, P883, DOI 10.1111/j.1743-6109.2006.00295.x; Zinner N, 2007, J SEX MED, V4, P137, DOI 10.1111/j.1743-6109.2006.00400.x; Zohdy W, 2007, J SEX MED, V4, P797, DOI 10.1111/j.1743-6109.2007.00499.x; Zumbe J, 2008, EUR UROL, V54, P204, DOI 10.1016/j.eururo.2008.03.056	202	53	54	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 3	2009	151	9					639	W208		10.7326/0003-4819-151-9-200911030-00151	http://dx.doi.org/10.7326/0003-4819-151-9-200911030-00151			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	514IM	19884625				2023-01-03	WOS:000271387700006
J	Atkinson, P; Chesters, A; Heinz, P				Atkinson, Paul; Chesters, Adam; Heinz, Peter			Pain management and sedation for children in the emergency department	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIAL; INTRAVENOUS CANNULATION; VAPOCOOLANT SPRAY; ANALGESIA		[Atkinson, Paul; Chesters, Adam; Heinz, Peter] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Emergency Dept, Cambridge CB2 0QQ, England	Addenbrooke's Hospital; University of Cambridge	Atkinson, P (corresponding author), Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Emergency Dept, Cambridge CB2 0QQ, England.	Paul.atkinson@addenbrookes.nhs.uk		Atkinson, Paul/0000-0001-9900-4594				ATKINSON P, 2010, EMERGENCY MED ILLUST, P32; Atkinson PRT, 2006, EMERG MED J, V23, P503, DOI 10.1136/emj.2005.028456; Bauchner H, 1996, PEDIATRICS, V98, P861; Borland M, 2007, ANN EMERG MED, V49, P335, DOI 10.1016/j.annemergmed.2006.06.016; Buttner W, 2000, PAEDIATR ANAESTH, V10, P303, DOI 10.1046/j.1460-9592.2000.00530.x; *COLL EM MED CLIN, 2004, MAN PAIN CHILDR; Costello M, 2006, CLIN PEDIATR, V45, P628, DOI 10.1177/0009922806291013; Ekbom K, 2005, ARCH DIS CHILD, V90, P1073, DOI 10.1136/adc.2004.060319; Farion KJ, 2008, CAN MED ASSOC J, V179, P31, DOI 10.1503/cmaj.070874; Ferguson C, 2005, EMERG MED J, V22, P507, DOI 10.1136/emj.2005.026575; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; GREEN SM, 2009, ANN EMERG MED; Harrop JE, 2007, ARCH DIS CHILDHOOD-E, V92, pEP101, DOI 10.1136/adc.2006.109447; Horwitz N, 2002, ARCH DIS CHILD, V87, P80, DOI 10.1136/adc.87.1.80; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Lander JA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004236.pub2; MCGRATH PJ, 1985, ADV PAIN RES THER, V9, P395; Merkel S I, 1997, Pediatr Nurs, V23, P293; O'Donnell JJ, 2002, EMERG MED J, V19, P195, DOI 10.1136/emj.19.3.195; Quinn J, 1998, ANN EMERG MED, V32, P645, DOI 10.1016/S0196-0644(98)70061-7; *SCOTT INT GUID NE, 2004, SAF SED CHILDR UND D; Spagrud LJ, 2003, AM J NURS, V103, P62, DOI 10.1097/00000446-200312000-00020; Treston Greg, 2004, Emerg Med Australas, V16, P145, DOI 10.1111/j.1742-6723.2004.00583.x; Uman LS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005179; Wong D L, 1988, Pediatr Nurs, V14, P9	25	23	23	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 30	2009	339								b4234	10.1136/bmj.b4234	http://dx.doi.org/10.1136/bmj.b4234			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	514AQ	19880530				2023-01-03	WOS:000271366100003
J	Smith, LFP; Ewings, PD; Quinlan, C				Smith, Lindsay F. P.; Ewings, Paul D.; Quinlan, Catherine			Incidence of pregnancy after expectant, medical, or surgical management of spontaneous first trimester miscarriage: long term follow-up of miscarriage treatment (MIST) randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SPONTANEOUS-ABORTION; MISSED ABORTION; FERTILITY	Objectives To compare fertility rates after the three methods of managing early miscarriage in women recruited to the MIST (miscarriage treatment) randomised controlled trial. Setting Early pregnancy clinics of acute hospitals in the south west region of England. Participants 1199 women who had had an early miscarriage (<13 weeks) confirmed by scan. Intervention Expectant, medical, or surgical management. Main outcome measures Self reported pregnancy rates and live birth rates. Results Of 1199 women recruited to the trial, 1128 consented to follow-up. Of these, 762 women replied giving pregnancy details (68% response rate). Respondents were representative of the trial participants. The live birth rate five years after the index miscarriage was similar in the three management groups: 177/224 (79%, 95% confidence interval 73% to 84%) in the expectant management group, 181/230 ( 79%, 73% to 84%) in the medical group, and 192/235 (82%, 76% to 86%) in the surgical group. There was also no significant difference according to previous birth history. Older women and those with previous miscarriages were significantly less likely to subsequently give birth. Conclusion Method of miscarriage management does not affect subsequent pregnancy rates with around four in five women giving birth within five years of the index miscarriage. Women can be reassured that long term fertility concerns need not affect their choice of miscarriage management. Trial registration National Research Register N0467011677/N0467073587.	[Smith, Lindsay F. P.; Quinlan, Catherine] E Somerset Res Consortium, W Coker BA22 9AH, Somerset, England; [Ewings, Paul D.] Taunton & Somerset Hosp, Res & Dev Support Unit, Taunton TA1 5DA, Somerset, England		Smith, LFP (corresponding author), E Somerset Res Consortium, W Coker BA22 9AH, Somerset, England.	research@esrec.nhs.uk			BMA Claire Wand Fund	BMA Claire Wand Fund	This study was funded by the BMA Claire Wand Fund. All authors are independent from the body providing funding for this research. Sponsorship and research governance management for this study was provided by East Somerset Research Consortium.	ANKUM WM, 1995, LANCET, V345, P1179, DOI 10.1016/S0140-6736(95)91010-7; Blohm F, 1997, LANCET, V349, P995, DOI 10.1016/S0140-6736(97)24014-6; Chipchase J, 1997, BRIT J OBSTET GYNAEC, V104, P840, DOI 10.1111/j.1471-0528.1997.tb12030.x; Chung TKH, 1999, FERTIL STERIL, V71, P1054, DOI 10.1016/S0015-0282(99)00128-4; CLAYTON SG, 1989, GYNAECOLOGY 10 TEACH; DAVID TJ, 1980, BRIT MED J, V280, P447, DOI 10.1136/bmj.280.6212.447-a; DICKEY RP, 1993, BRIT MED J, V307, P259, DOI 10.1136/bmj.307.6898.259-b; ELREFAEY H, 1992, BRIT MED J, V305, P1399, DOI 10.1136/bmj.305.6866.1399; FORBES K, 1995, BRIT MED J, V310, P1426, DOI 10.1136/bmj.310.6992.1426; Geyman J P, 1999, J Am Board Fam Pract, V12, P55; HENSHAW R, 1993, BRIT MED J, V306, P8944; Johnson N, 1997, EUR J OBSTET GYN R B, V72, P213, DOI 10.1016/S0301-2115(96)02668-1; Kaplan B, 1996, HUM REPROD, V11, P92; LEVIN S, 1979, ACTA OBSTET GYN SCAN, V58, P371, DOI 10.3109/00016347909154598; Nielsen S, 1999, BRIT J OBSTET GYNAEC, V106, P804, DOI 10.1111/j.1471-0528.1999.tb08401.x; NIELSEN S, 1995, LANCET, V345, P84, DOI 10.1016/S0140-6736(95)90060-8; Petrou S, 2006, BJOG-INT J OBSTET GY, V113, P879, DOI 10.1111/j.1471-0528.2006.00998.x; *ROYAL COLL OBST G, 2003, GREEN TOP GUID ROYAL, V17; Smith LF, 2006, BRIT J GEN PRACT, V56, P198; SMITH LFP, 1993, BRIT MED J, V306, P1540, DOI 10.1136/bmj.306.6891.1540-c; Trinder J, 2006, BMJ-BRIT MED J, V332, P1235, DOI 10.1136/bmj.38828.593125.55	21	39	39	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 8	2009	339								b3827	10.1136/bmj.b3827	http://dx.doi.org/10.1136/bmj.b3827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	505TH	19815581	Green Published, hybrid			2023-01-03	WOS:000270719300001
J	O'Brien, PC; Seymour, JF				O'Brien, Peter C.; Seymour, John F.			Progress in primary CNS lymphoma	LANCET			English	Editorial Material							NERVOUS-SYSTEM LYMPHOMA; HIGH-DOSE METHOTREXATE; RADIOTHERAPY; CHEMOTHERAPY; TRIAL; MULTICENTER; SURVIVAL; BRAIN		[O'Brien, Peter C.] Calvary Mater Newcastle, Dept Radiat Oncol, Newcastle, NSW 2310, Australia	Calvary Mater Newcastle Hospital	O'Brien, PC (corresponding author), Calvary Mater Newcastle, Dept Radiat Oncol, Newcastle, NSW 2310, Australia.	peter.obrien@mater.health.nsw.gov.au	Seymour, John/K-7326-2019	Seymour, John/0000-0003-2188-6835				Abrey LE, 2005, J CLIN ONCOL, V23, P5034, DOI 10.1200/JCO.2005.13.524; Abrey LE, 1998, J CLIN ONCOL, V16, P859, DOI 10.1200/JCO.1998.16.3.859; Batchelor T, 2003, J CLIN ONCOL, V21, P1044, DOI 10.1200/JCO.2003.03.036; ERVIN T, 1980, CANCER, V45, P1556, DOI 10.1002/1097-0142(19800401)45:7<1556::AID-CNCR2820450707>3.0.CO;2-B; Ferreri AJM, 2002, NEUROLOGY, V58, P1513, DOI 10.1212/WNL.58.10.1513; Ferreri AJM, 2009, LANCET, V374, P1512, DOI 10.1016/S0140-6736(09)61416-1; Herrlinger U, 2002, ANN NEUROL, V51, P247, DOI 10.1002/ana.10102; Mead GM, 2000, CANCER, V89, P1359, DOI 10.1002/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9; NELSON DF, 1992, INT J RADIAT ONCOL, V23, P9, DOI 10.1016/0360-3016(92)90538-S; OTT RJ, 1991, EUR J CANCER, V27, P1356, DOI 10.1016/0277-5379(91)90009-3; Poortmans PMP, 2003, J CLIN ONCOL, V21, P4483, DOI 10.1200/JCO.2003.03.108; Reni M, 2004, J CLIN ONCOL, V22, P1165, DOI 10.1200/JCO.2004.99.259; Shenkier TN, 2005, CANCER, V103, P1008, DOI 10.1002/cncr.20868; Steensma DP, 2009, J CLIN ONCOL, V27, P1737, DOI 10.1200/JCO.2008.20.6292	14	12	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2009	374	9700					1477	1478		10.1016/S0140-6736(09)61488-4	http://dx.doi.org/10.1016/S0140-6736(09)61488-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	517CS	19767091				2023-01-03	WOS:000271591300005
J	Gram, GJ; Karlsson, I; Agger, EM; Andersen, P; Fomsgaard, A				Gram, Gregers Jacob; Karlsson, Ingrid; Agger, Else Marie; Andersen, Peter; Fomsgaard, Anders			A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8(+) Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice	PLOS ONE			English	Article								Background: Specific cellular cytotoxic immune responses (CTL) are important in combating viral diseases and a highly desirable feature in the development of targeted HIV vaccines. Adjuvants are key components in vaccines and may assist the HIV immunogens in inducing the desired CTL responses. In search for appropriate adjuvants for CD8(+) T cells it is important to measure the necessary immunological features e. g. functional cell killing/lysis in addition to immunological markers that can be monitored by simple immunological laboratory methods. Methodology/Principal Findings: We tested the ability of a novel two component adjuvant, CAF01, consisting of the immune stimulating synthetic glycolipid TDB (Trehalose-Dibehenate) incorporated into cationic DDA (Dimethyldioctadecylammonium bromide) liposomes to induce CD8(+) T-cell restricted cellular immune responses towards subdominant minimal HLA-A0201-restricted CTL epitopes from HIV-1 proteins in HLA-A*0201 transgenic HHD mice. CAF01 has an acceptable safety profile and is used in preclinical development of vaccines against HIV-1, malaria and tuberculosis. Conclusions/Significance: We found that CAF01 induced cellular immune responses against HIV-1 minimal CTL epitopes in HLA-A*0201 transgenic mice to levels comparable with that of incomplete Freund's adjuvant.			Gram, GJ (corresponding author), Statens Serum Inst, Dept Virol, DK-2300 Copenhagen, Denmark.	afo@ssi.dk		Andersen, Peter/0000-0002-5869-2551; Fomsgaard, Anders/0000-0003-4304-0603				ALEXANDER J, 1994, IMMUNITY, V1, P751, DOI 10.1016/S1074-7613(94)80017-0; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Christensen D, 2007, EXPERT REV VACCINES, V6, P785, DOI 10.1586/14760584.6.5.785; Corbet S, 2003, J GEN VIROL, V84, P2409, DOI 10.1099/vir.0.19152-0; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Kloverpris H, 2009, AIDS, V23, P1329, DOI 10.1097/QAD.0b013e32832d9b00; Korsholm KS, 2007, IMMUNOLOGY, V121, P216, DOI 10.1111/j.1365-2567.2007.02560.x; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Malhotra U, 2003, J VIROL, V77, P2663, DOI 10.1128/JVI.77.4.2663-2674.2003; Pascolo S, 1997, J EXP MED, V185, P2043, DOI 10.1084/jem.185.12.2043; Thorn M, 2007, APMIS, V115, P757, DOI 10.1111/j.1600-0463.2007.apm_595.x; Vangala A, 2006, J PHARM PHARMACOL, V58, P787, DOI 10.1211/jpp.58.6.0009; Wilson CC, 2001, J VIROL, V75, P4195, DOI 10.1128/JVI.75.9.4195-4207.2001	15	37	37	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2009	4	9							e6950	10.1371/journal.pone.0006950	http://dx.doi.org/10.1371/journal.pone.0006950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	492XS	19759892	gold, Green Published, Green Submitted			2023-01-03	WOS:000269696600005
J	Bobrow, BJ; Spaite, DW; Berg, RA; Stolz, U; Sanders, AB; Kern, KB; Vadeboncoeur, TF; Clark, LL; Gallagher, JV; Stapczynski, JS; LoVecchio, F; Mullins, TJ; Humble, WO; Ewy, GA				Bobrow, Bentley J.; Spaite, Daniel W.; Berg, Robert A.; Stolz, Uwe; Sanders, Arthur B.; Kern, Karl B.; Vadeboncoeur, Tyler F.; Clark, Lani L.; Gallagher, John V.; Stapczynski, J. Stephan; LoVecchio, Frank; Mullins, Terry J.; Humble, Will O.; Ewy, Gordon A.			Chest Compression-Only CPR by Lay Rescuers and Survival From Out-of-Hospital Cardiac Arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BYSTANDER CARDIOPULMONARY-RESUSCITATION; AMERICAN-HEART-ASSOCIATION; HEALTH-CARE PROFESSIONALS; BASIC LIFE-SUPPORT; VENTRICULAR-FIBRILLATION; STROKE-FOUNDATION; TASK-FORCE; STATEMENT; VENTILATION; COMMITTEE	Context Chest compression-only bystander cardiopulmonary resuscitation (CPR) may be as effective as conventional CPR with rescue breathing for out-of-hospital cardiac arrest. Objective To investigate the survival of patients with out-of-hospital cardiac arrest using compression-only CPR (COCPR) compared with conventional CPR. Design, Setting, and Patients A 5-year prospective observational cohort study of survival in patients at least 18 years old with out-of-hospital cardiac arrest between January 1, 2005, and December 31, 2009, in Arizona. The relationship between layperson bystander CPR and survival to hospital discharge was evaluated using multivariable logistic regression. Main Outcome Measure Survival to hospital discharge. Results Among 5272 adults with out-of-hospital cardiac arrest of cardiac etiology not observed by responding emergency medical personnel, 779 were excluded because bystander CPR was provided by a health care professional or the arrest occurred in a medical facility. A total of 4415 met all inclusion criteria for analysis, including 2900 who received no bystander CPR, 666 who received conventional CPR, and 849 who received COCPR. Rates of survival to hospital discharge were 5.2% (95% confidence interval [CI], 4.4%-6.0%) for the no bystander CPR group, 7.8% (95% CI, 5.8%-9.8%) for conventional CPR, and 13.3% (95% CI, 11.0%-15.6%) for COCPR. The adjusted odds ratio (AOR) for survival for conventional CPR vs no CPR was 0.99 (95% CI, 0.69-1.43), for COCPR vs no CPR, 1.59 (95% CI, 1.18-2.13), and for COCPR vs conventional CPR, 1.60 (95% CI, 1.08-2.35). From 2005 to 2009, lay rescuer CPR increased from 28.2% (95% CI, 24.6%-31.8%) to 39.9% (95% CI, 36.8%-42.9%; P<.001); the proportion of CPR that was COCPR increased from 19.6% (95% CI, 13.6%-25.7%) to 75.9% (95% CI, 71.7%-80.1%; P<.001). Overall survival increased from 3.7% (95% CI, 2.2%-5.2%) to 9.8% (95% CI, 8.0%-11.6%; P<.001). Conclusion Among patients with out-of-hospital cardiac arrest, layperson compression-only CPR was associated with increased survival compared with conventional CPR and no bystander CPR in this setting with public endorsement of chest compression-only CPR. JAMA. 2010; 304(13): 1447-1454	[Bobrow, Bentley J.; Mullins, Terry J.; Humble, Will O.] Arizona Dept Hlth Serv, 150 N 18th Ave,Ste 540, Phoenix, AZ 85007 USA; [Bobrow, Bentley J.; Spaite, Daniel W.; Stolz, Uwe] Univ Arizona, Dept Emergency Med, Arizona Emergency Med Res Ctr, Tucson, AZ USA; [Bobrow, Bentley J.; Sanders, Arthur B.; Kern, Karl B.; Clark, Lani L.; Ewy, Gordon A.] Univ Arizona, Sarver Heart Ctr, Tucson, AZ USA; [Berg, Robert A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Vadeboncoeur, Tyler F.] Mayo Clin, Jacksonville, FL 32224 USA; [Gallagher, John V.] Phoenix Fire Dept, Phoenix, AZ USA; [Bobrow, Bentley J.; Stapczynski, J. Stephan; LoVecchio, Frank] Maricopa Cty Gen Hosp, Dept Emergency Med, Phoenix, AZ USA	Arizona Department of Health Services; University of Arizona; University of Arizona; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Mayo Clinic; Maricopa County General Hospital	Bobrow, BJ (corresponding author), Arizona Dept Hlth Serv, 150 N 18th Ave,Ste 540, Phoenix, AZ 85007 USA.	bobrowb@azdhs.gov		Spaite, Daniel/0000-0003-2601-6476	Medtronic Foundation; American Heart Association	Medtronic Foundation; American Heart Association(American Heart Association)	Drs Bobrow, Ewy, and Spaite reported that the University of Arizona has received support from the Medtronic Foundation involving community-based translation of resuscitation science. Dr Bobrow reported being a member of the American Heart Association Basic Life Support Committee and in the past having received a grant from the American Heart Association to study ultrabrief CPR video training. No other disclosures were reported.	[Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Assar D, 2000, RESUSCITATION, V45, P7, DOI 10.1016/S0300-9572(00)00152-0; Aufderheide TP, 2004, CIRCULATION, V109, P1960, DOI 10.1161/01.CIR.0000126594.79136.61; Becker LB, 1997, CIRCULATION, V96, P2102, DOI 10.1161/01.CIR.96.6.2102; BERG RA, 1993, CIRCULATION, V88, P1907, DOI 10.1161/01.CIR.88.4.1907; Berg RA, 1997, CIRCULATION, V96, P4364; Berg RA, 2001, CIRCULATION, V104, P2465, DOI 10.1161/hc4501.098926; Bobrow BJ, 2008, PREHOSP EMERG CARE, V12, P381, DOI 10.1080/10903120802100670; Bobrow BJ, 2008, JAMA-J AM MED ASSOC, V299, P1158, DOI 10.1001/jama.299.10.1158; Bobrow BJ, 2009, ANN EMERG MED, V54, P656, DOI 10.1016/j.annemergmed.2009.06.011; Bobrow BJ, 2009, ANN EMERG MED, V54, pe1; Coons SJ, 2009, RESUSCITATION, V80, P334, DOI 10.1016/j.resuscitation.2008.11.024; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; GALLAGHER EJ, 1995, JAMA-J AM MED ASSOC, V274, P1922, DOI 10.1001/jama.274.24.1922; Hallstrom A, 2000, NEW ENGL J MED, V342, P1546, DOI 10.1056/NEJM200005253422101; Heidenreich JW, 2004, RESUSCITATION, V62, P283, DOI 10.1016/j.resuscitation.2004.05.013; Iwami T, 2007, CIRCULATION, V116, P2900, DOI 10.1161/CIRCULATIONAHA.107.723411; Jacobs I, 2004, CIRCULATION, V110, P3385, DOI 10.1161/01.CIR.0000147236.85306.15; Kellum MJ, 2008, ANN EMERG MED, V52, P244, DOI 10.1016/j.annemergmed.2008.02.006; Kern KB, 1998, RESUSCITATION, V39, P179, DOI 10.1016/S0300-9572(98)00141-5; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; LOCKE CJ, 1995, ARCH INTERN MED, V155, P938, DOI 10.1001/archinte.155.9.938; Nagao K, 2007, LANCET, V369, P920; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Rea TD, 2010, NEW ENGL J MED, V363, P423, DOI 10.1056/NEJMoa0908993; SANDERS AB, 1985, J AM COLL CARDIOL, V6, P113, DOI 10.1016/S0735-1097(85)80261-8; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Sayre MR, 2008, CIRCULATION, V117, P2162, DOI 10.1161/CIRCULATIONAHA.107.189380; Stiell IG, 1999, ANN EMERG MED, V33, P44, DOI 10.1016/S0196-0644(99)70415-4; Svensson L, 2010, NEW ENGL J MED, V363, P434, DOI 10.1056/NEJMoa0908991; *US BUR CENS, AR QUICKFACTS; Vadeboncoeur T, 2007, RESUSCITATION, V75, P68, DOI 10.1016/j.resuscitation.2007.02.015; Vaillancourt C, 2008, CAN J EMERG MED, V10, P51, DOI 10.1017/S1481803500010010; Weisfeldt ML, 2002, JAMA-J AM MED ASSOC, V288, P3035, DOI 10.1001/jama.288.23.3035; Wik L, 2003, JAMA-J AM MED ASSOC, V289, P1389, DOI 10.1001/jama.289.11.1389; Willerson JT, 2000, CIRCULATION, V102, P1	37	327	349	1	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2010	304	13					1447	1454		10.1001/jama.2010.1392	http://dx.doi.org/10.1001/jama.2010.1392			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	658SO	20924010				2023-01-03	WOS:000282509900020
J	von Ungern-Sternberg, BS; Boda, K; Chambers, NA; Rebmann, C; Johnson, C; Sly, PD; Habre, W				von Ungern-Sternberg, Britta S.; Boda, Krisztina; Chambers, Neil A.; Rebmann, Claudia; Johnson, Chris; Sly, Peter D.; Habre, Walid			Risk assessment for respiratory complications in paediatric anaesthesia: a prospective cohort study	LANCET			English	Article							LARYNGEAL MASK AIRWAY; TRACT INFECTIONS; REFLEX BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS; INTRAVENOUS LIDOCAINE; TRACHEAL INTUBATION; ADVERSE EVENTS; LUNG-FUNCTION; CHILDREN; ASTHMA	Background Perioperative respiratory adverse events in children are one of the major causes of morbidity and mortality during paediatric anaesthesia. We aimed to identify associations between family history, anaesthesia management, and occurrence of perioperative respiratory adverse events. Methods We prospectively included all children who had general anaesthesia for surgical or medical interventions, elective or urgent procedures at Princess Margaret Hospital for Children, Perth, Australia, from Feb 1,2007, to Jan 31, 2008. On the day of surgery, anaesthetists in charge of paediatric patients completed an adapted version of the International Study Group for Asthma and Allergies in Childhood questionnaire. We collected data on family medical history of asthma, atopy, allergy, upper respiratory tract infection, and passive smoking. Anaesthesia management and all perioperative respiratory adverse events were recorded. Findings 9297 questionnaires were available for analysis. A positive respiratory history (nocturnal dry cough, wheezing during exercise, wheezing more than three times in the past 12 months, or a history of present or past eczema) was associated with an increased risk for bronchospasm (relative risk [RR] 8.46, 95% Cl 6.18-11.59; p<0.0001), laryngospasm (4.13, 3.37-5.08; p<0.0001), and perioperative cough, desaturation, or airway obstruction (3.05, 2.76-3.37; p<0.0001). Upper respiratory tract infection was associated with an increased risk for perioperative respiratory adverse events only when symptoms were present (RR 2.05, 95% CI 1.82-2.31; p<0.0001) or less than 2 weeks before the procedure (2.34, 2.07-2.66; p<0.0001), whereas symptoms of upper respiratory tract infection 2-4 weeks before the procedure significantly lowered the incidence of perioperative respiratory adverse events (0.66, 0.53-0.81; p<0.0001). A history of at least two family members having asthma, atopy, or smoking increased the risk for perioperative respiratory adverse events (all p<0.0001). Risk was lower with intravenous induction compared with inhalational induction (all p<0.0001), inhalational compared with intravenous maintenance of anaesthesia (all p<0.0001), airway management by a specialist paediatric anaesthetist compared with a registrar (all p<0.0001), and use of face mask compared with tracheal intubation (all p<0.0001). Interpretation Children at high risk for perioperative respiratory adverse events could be systematically identified at the preanaesthetic assessment and thus can benefit from a specifically targeted anaesthesia management.	[von Ungern-Sternberg, Britta S.; Chambers, Neil A.; Rebmann, Claudia; Johnson, Chris] Princess Margaret Hosp Children, Dept Anaesthesia, Perth, WA, Australia; [von Ungern-Sternberg, Britta S.; Sly, Peter D.] Univ Western Australia, Telethon Inst Child Hlth Res, Div Clin Sci, Perth, WA 6009, Australia; [von Ungern-Sternberg, Britta S.; Sly, Peter D.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia; [von Ungern-Sternberg, Britta S.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; [Boda, Krisztina] Univ Szeged, Dept Med Informat, Szeged, Hungary; [Habre, Walid] Univ Geneva, Geneva Childrens Hosp, Paediat Anaesthesia Unit, Geneva, Switzerland	University of Western Australia; Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia; Szeged University; University of Geneva	von Ungern-Sternberg, BS (corresponding author), Princess Margaret Hosp Children, Dept Anaesthesia, Roberts Rd, Subiaco, WA 6008, Australia.	bvonungern@uhbs.ch	von Ungern-Sternberg, Britta/S-5532-2019; von Ungern-Sternberg, Britta/CAG-9904-2022; Sly, Peter D/F-1486-2010	von Ungern-Sternberg, Britta/0000-0002-8043-8541; Sly, Peter D/0000-0001-6305-2201; Boda, Krisztina/0000-0002-9937-0460	Department of Anaesthesia, Princess Margaret Hospital for Children; Swiss Foundation for Grants in Biology and Medicine; Swiss National Science Foundation; Voluntary Academic Society Basel, Switzerland	Department of Anaesthesia, Princess Margaret Hospital for Children; Swiss Foundation for Grants in Biology and Medicine; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Voluntary Academic Society Basel, Switzerland	This study was supported by the Department of Anaesthesia, Princess Margaret Hospital for Children, a grant of the Swiss Foundation for Grants in Biology and Medicine in cooperation with the Swiss National Science Foundation, and by the Voluntary Academic Society Basel, Switzerland. We thank all staff members of the Department of Anaesthesia and the nurses in postanaesthetic care unit, Princess Margaret Hospital for Children, Perth, Australia, for their tremendous support with this study.	Adamzik M, 2007, ANESTH ANALG, V104, P168, DOI 10.1213/01.ane.0000247884.94119.d5; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Backlund AB, 2006, ALLERGY, V61, P549, DOI 10.1111/j.1398-9995.2006.01027.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bhananker SM, 2007, ANESTH ANALG, V105, P344, DOI 10.1213/01.ane.0000268712.00756.dd; Bjerg A, 2007, PEDIATRICS, V120, P741, DOI 10.1542/peds.2006-3742; Bordet F, 2002, PAEDIATR ANAESTH, V12, P762, DOI 10.1046/j.1460-9592.2002.00987.x; BUCKNER CK, 1985, AM REV RESPIR DIS, V132, P305; Chang HYS, 2007, ANESTH ANALG, V104, P1109, DOI 10.1213/01.ane.0000260638.57139.87; COHEN MM, 1991, ANESTH ANALG, V72, P282; Forastiere F, 1996, AM J RESP CRIT CARE, V153, P1098, DOI 10.1164/ajrccm.153.3.8630551; Groeben H, 1996, ANESTHESIOLOGY, V84, P533, DOI 10.1097/00000542-199603000-00007; Groeben H, 1999, AM J RESP CRIT CARE, V159, P530, DOI 10.1164/ajrccm.159.2.9806102; Groeben H, 2000, CHEST, V118, P509, DOI 10.1378/chest.118.2.509; Habre W, 1996, BRIT J ANAESTH, V77, P739, DOI 10.1093/bja/77.6.739; Harnett M, 2000, CAN J ANAESTH, V47, P315, DOI 10.1007/BF03020944; Homer JR, 2007, PEDIATR ANESTH, V17, P154, DOI 10.1111/j.1460-9592.2006.02059.x; Jones DT, 2006, OTOLARYNG HEAD NECK, V135, P12, DOI 10.1016/j.otohns.2006.03.011; Joos GF, 2003, EUR RESPIR J, V21, P1050, DOI 10.1183/09031936.03.00008403; Joseph-Bowen J, 2004, AM J RESP CRIT CARE, V169, P850, DOI 10.1164/rccm.200304-556OC; Lakshmipathy N, 1996, ANESTH ANALG, V82, P724, DOI 10.1097/00000539-199604000-00008; Mamie C, 2004, PEDIATR ANESTH, V14, P218, DOI 10.1111/j.1460-9592.2004.01169.x; Murat I, 2004, PAEDIATR ANAESTH, V14, P158, DOI 10.1111/j.1460-9592.2004.01167.x; Parnis SJ, 2001, PAEDIATR ANAESTH, V11, P29, DOI 10.1046/j.1460-9592.2001.00607.x; Rooke GA, 1997, ANESTHESIOLOGY, V86, P1294, DOI 10.1097/00000542-199706000-00010; Schreiner MS, 1996, ANESTHESIOLOGY, V85, P475, DOI 10.1097/00000542-199609000-00005; Schutz N, 2004, BRIT J ANAESTH, V92, P254, DOI 10.1093/bja/aeh049; Skolnick ET, 1998, ANESTHESIOLOGY, V88, P1144, DOI 10.1097/00000542-199805000-00003; Tait AR, 1998, ANESTH ANALG, V86, P706, DOI 10.1097/00000539-199804000-00006; Tait AR, 2005, ANESTH ANALG, V100, P59, DOI 10.1213/01.ANE.0000139653.53618.91; Tait AR, 2001, ANESTHESIOLOGY, V95, P299, DOI 10.1097/00000542-200108000-00008; Tay CLM, 2001, PAEDIATR ANAESTH, V11, P711, DOI 10.1046/j.1460-9592.2001.00767.x; Varughese AM, 2006, PEDIATR ANESTH, V16, P723, DOI 10.1111/j.1460-9592.2006.01856.x; Von Ungern-Stemberg BS, 2007, ANESTHESIOLOGY, V107, P714, DOI 10.1097/01.anes.0000286925.25272.b5; von Ungern-Sternberg BS, 2008, ANESTHESIOLOGY, V108, P216, DOI 10.1097/01.anes.0000299430.90352.d5	35	287	293	1	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 4	2010	376	9743					773	783		10.1016/S0140-6736(10)61193-2	http://dx.doi.org/10.1016/S0140-6736(10)61193-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	650EC	20816545				2023-01-03	WOS:000281831000028
J	Farrell, AM; Brazier, M				Farrell, Anne-Maree; Brazier, Margaret			Consent for blood transfusion	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Farrell, Anne-Maree; Brazier, Margaret] Univ Manchester, Sch Law, Inst Sci Eth & Innovat, Ctr Social Eth & Policy, Manchester M13 9PL, Lancs, England	University of Manchester	Farrell, AM (corresponding author), Univ Manchester, Sch Law, Inst Sci Eth & Innovat, Ctr Social Eth & Policy, Manchester M13 9PL, Lancs, England.	a.m.farrell@manchester.ac.uk		Farrell, Anne-Maree/0000-0001-9522-6528	Wellcome Trust [087439] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		*ADV COMM SAF BLOO, 2010, PAT CONS BLOOD TRANS; *CMO NAT BLOOD TRA, 2008, BETT BLOOD TRANSF HS; CONNON W, 2007, COMMUNICATION   0316; General Medical Council, 2008, CONS PAT DOCT MAK DE; HEWITT B, 1997, BRIT MED J, V316, P397; Killion DF, 2007, TRANSFUSION, V47, P557, DOI 10.1111/j.1537-2995.2007.01185.x; MCCLELLAND D, 2007, HDB BLOOD TRANSFUSIO; Murphy MF, 1997, TRANSFUSION MED, V7, P287, DOI 10.1046/j.1365-3148.1997.d01-41.x; Re T, 1992, ALL ER, V4, P649; *SER HAZ TRANSF, ANN REP 2008 SUMM; Williams FG, 1997, BRIT MED J, V315, P380, DOI 10.1136/bmj.315.7105.380	11	8	8	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	AUG 24	2010	341								c4336	10.1136/bmj.c4336	http://dx.doi.org/10.1136/bmj.c4336			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	645IG	20736271	Green Submitted			2023-01-03	WOS:000281445900006
J	Gillett, M; Dallosso, HM; Dixon, S; Brennan, A; Carey, ME; Campbell, MJ; Heller, S; Khunti, K; Skinner, TC; Davies, MJ				Gillett, M.; Dallosso, H. M.; Dixon, S.; Brennan, A.; Carey, M. E.; Campbell, M. J.; Heller, S.; Khunti, K.; Skinner, T. C.; Davies, M. J.			Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLUSTER RANDOMIZED-TRIALS; QUALITY-OF-LIFE; UKPDS; MODEL; WEIGHT; IMPACT; STYLE; RISK	Objectives To assess the long term clinical and cost effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) intervention compared with usual care in people with newly diagnosed type 2 diabetes. Design We undertook a cost-utility analysis that used data from a 12 month, multicentre, cluster randomised controlled trial and, using the Sheffield type 2 diabetes model, modelled long term outcomes in terms of use of therapies, incidence of complications, mortality, and associated effect on costs and health related quality of life. A further cost-utility analysis was also conducted using current "real world" costs of delivering the intervention estimated for a hypothetical primary care trust. Setting Primary care trusts in the United Kingdom. Participants Patients with newly diagnosed type 2 diabetes. Intervention A six hour structured group education programme delivered in the community by two professional healthcare educators. Main outcome measures Incremental costs and quality adjusted life years (QALYs) gained. Results On the basis of the data in the trial, the estimated mean incremental lifetime cost per person receiving the DESMOND intervention is 209 pound (95% confidence interval -704 pound to 1137; pound (sic)251, -(sic)844 to (sic)1363; $326, -$1098 to $1773), the incremental gain in QALYs per person is 0.0392 (-0.0813 to 0.1786), and the mean incremental cost per QALY is 5387 pound. Using "real world" intervention costs, the lifetime incremental cost of the DESMOND intervention is 82 pound (-831 pound to 1010) pound and the mean incremental cost per QALY gained is 2092 pound. A probabilistic sensitivity analysis indicated that the likelihood that the DESMOND programme is cost effective at a threshold of 20 pound 000 per QALY is 66% using trial based intervention costs and 70% using "real world" costs. Results from a one way sensitivity analysis suggest that the DESMOND intervention is cost effective even under more modest assumptions that include the effects of the intervention being lost after one year. Conclusion Our results suggest that the DESMOND intervention is likely to be cost effective compared with usual care, especially with respect to the real world cost of the intervention to primary care trusts, with reductions in weight and smoking being the main benefits delivered.	[Gillett, M.; Dixon, S.; Brennan, A.; Campbell, M. J.] Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England; [Dallosso, H. M.; Carey, M. E.] Univ Hosp Leicester NHS Trust, DESMOND Project Off, Leicester, Leics, England; [Heller, S.] Univ Sheffield, Sch Med & Biomed Sci, Acad Unit Diabet Endocrinol & Metab, Sheffield, S Yorkshire, England; [Khunti, K.] Univ Leicester, Dept Hlth Sci, Leicester, Leics, England; [Skinner, T. C.] Combined Univ Ctr Rural Hlth, Geraldton, Australia; [Davies, M. J.] Univ Leicester, Leicester Royal Infirm, Dept Cardiovasc Med, Leicester, Leics, England	University of Sheffield; University Hospitals of Leicester NHS Trust; University of Leicester; University of Sheffield; University of Leicester; University of Western Australia; University of Leicester	Gillett, M (corresponding author), Univ Sheffield, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England.	m.gillett@sheffield.ac.uk	Campbell, Michael J/I-4253-2014; Davies, Michael/AGX-9184-2022; /ABC-9527-2021; Skinner, Timothy/G-2865-2010; Skinner, Timothy C/N-2221-2013; Davies, Michael/GWV-2527-2022	Campbell, Michael J/0000-0003-3529-2739; Davies, Michael/0000-0002-5196-6919; Skinner, Timothy C/0000-0002-0018-6963; Davies, Melanie/0000-0002-9987-9371; Brennan, Alan/0000-0002-1025-312X; Heller, Simon/0000-0002-2425-9565; Khunti, Kamlesh/0000-0003-2343-7099	Diabetes UK	Diabetes UK(Diabetes UK)	The study was funded by a grant from Diabetes UK secured by the University Hospitals of Leicester NHS Trust. The analysis was independently designed and undertaken by the University of Sheffield School of Health and Related Research and collaborators. Researchers worked independently from the funders. Similarly the writing of the report and the decision to submit the article for publication was entirely independent of the funder. The study funder had no input into the study design or analysis, nor the interpretation of data.	[Anonymous], 2008, GUID METH TECHN APPR; Brennan A, 2006, HEALTH ECON, V15, P1295, DOI 10.1002/hec.1148; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; Campbell MJ, 2007, STAT MED, V26, P2, DOI 10.1002/sim.2731; Campbell MJ, 2000, STAT METHODS MED RES, V9, P81, DOI 10.1191/096228000676246354; Clarke P, 2003, DIABETIC MED, V20, P442, DOI 10.1046/j.1464-5491.2003.00972.x; Clarke P, 2002, MED DECIS MAKING, V22, P340, DOI 10.1177/027298902400448902; Clarke PM, 2004, DIABETOLOGIA, V47, P1747, DOI 10.1007/s00125-004-1527-z; Coffey JT, 2002, DIABETES CARE, V25, P2238, DOI 10.2337/diacare.25.12.2238; CURTIS L, 2007, PERSONAL SOCIAL SERV; Davies MJ, 2008, BMJ-BRIT MED J, V336, P491, DOI 10.1136/bmj.39474.922025.BE; Deakin TA, 2006, DIABETIC MED, V23, P944, DOI 10.1111/j.1464-5491.2006.01906.x; Dennett SL, 2008, VALUE HEALTH, V11, P478, DOI 10.1111/j.1524-4733.2007.00260.x; Dinneen SF, 2008, BMJ-BRIT MED J, V336, P459, DOI 10.1136/bmj.39478.693715.80; Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002; HARRELL FE, 1998, STAT MED, V90, P144; HAWKINS J, 2007, THESIS U SHEFFIELD; Holman RR, 2008, NEW ENGL J MED, V359, P1577, DOI 10.1056/NEJMoa0806470; *INT DIAB FED, 2007, IDF DIAB ATL PREV ES; Khunti K, 2008, DIABETIC MED, V25, P1454, DOI 10.1111/j.1464-5491.2008.02620.x; Kothari V, 2002, STROKE, V33, P1776, DOI 10.1161/01.STR.0000020091.07144.C7; Lindstrom J, 2005, P NUTR SOC, V64, P81, DOI 10.1079/PNS2004412; LOVEMAN E, 2008, HEALTH TECHNOL ASSES, V1, P116; Massi-Benedetti M, 2002, DIABETOLOGIA, V45, pS1, DOI 10.1007/s00125-002-0860-3; Morris AD, 2002, DIABETES-METAB RES, V18, pS32, DOI 10.1002/dmrr.295; *NAT I HLTH CLIN E, 2009, 87 NICE; Nathan DM, 2009, DIABETES CARE, V32, P193, DOI 10.2337/dc08-9025; National Institute for Clinical Excellence, 2003, 60 NICE, V60; *NHS INF CTR HLTH, 2008, PRESCR COSL AN ENGL; O'Hagan A, 2007, HEALTH ECON, V16, P1009, DOI 10.1002/hec.1199; O'Meara S, 2002, Health Technol Assess, V6, P1; Skinner TC, 2006, PATIENT EDUC COUNS, V64, P369, DOI 10.1016/j.pec.2006.04.007; Stevens RJ, 2001, CLIN SCI, V101, P671, DOI 10.1042/CS20000335; Trento M, 2004, DIABETES CARE, V27, P670, DOI 10.2337/diacare.27.3.670; URBANSKI P, 2008, J AM DIET ASS S1, V108, P6; Warren E, 2004, MED DECIS MAKING, V24, P9, DOI 10.1177/0272989X03261565	36	117	120	0	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 20	2010	341								c4093	10.1136/bmj.c4093	http://dx.doi.org/10.1136/bmj.c4093			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	642KY	20729270	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000281213600001
J	Pasupathy, D; Wood, AM; Pell, JP; Fleming, M; Smith, GCS				Pasupathy, Dharmintra; Wood, Angela M.; Pell, Jill P.; Fleming, Michael; Smith, Gordon C. S.			Time of birth and risk of neonatal death at term: retrospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERINATAL DEATH; CESAREAN DELIVERY; UNITED-STATES; MORTALITY; STILLBIRTH; INTRAPARTUM; ASPHYXIA; SCOTLAND; INFANTS; WALES	Objective To determine the effect of time and day of birth on the risk of neonatal death at term. Design Population based retrospective cohort study. Setting Data from the linked Scottish morbidity records, Stillbirth and Infant Death Survey, and birth certificate database of live births in Scotland, 1985-2004. Subjects Liveborn term singletons with cephalic presentation. Perinatal deaths from congenital anomalies excluded. Final sample comprised 1 039 560 live births. Main outcome measure All neonatal deaths (in the first four weeks of life) unrelated to congenital abnormality, plus a subgroup of deaths ascribed to intrapartum anoxia. Results The risk of neonatal death was 4.2 per 10 000 during the normal working week (Monday to Friday, 09001700) and 5.6 per 10 000 at all other times (out of hours) (unadjusted odds ratio 1.3, 95% confidence interval 1.1 to 1.6). Adjustment for maternal characteristics had no material effect. The higher rate of death out of hours was because of an increased risk of death ascribed to intrapartum anoxia (adjusted odds ratio 1.7, 1.2 to 2.3). Though exclusion of elective caesarean deliveries attenuated the association between death ascribed to anoxia and delivery out of hours, a significant association persisted (adjusted odds ratio 1.5, 1.1 to 2.0). The attributable fraction of neonatal deaths ascribed to intrapartum anoxia associated with delivery out of hours was 26% (95% confidence interval 5% to 42%). Conclusions Delivering an infant outside the normal working week was associated with an increased risk of neonatal death at term ascribed to intrapartum anoxia.	[Pasupathy, Dharmintra; Smith, Gordon C. S.] Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 2SW, England; [Pasupathy, Dharmintra; Smith, Gordon C. S.] NIHR Cambridge Comprehens Biomed Res Ctr, Cambridge CB2 2SW, England; [Wood, Angela M.] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England; [Pell, Jill P.] Univ Glasgow, Publ Hlth Sect, Glasgow G12 8TA, Lanark, Scotland; [Fleming, Michael] NHS Natl Serv Scotland, Informat Serv Div, Paisley PA3 2SJ, Renfrew, Scotland	University of Cambridge; University of Cambridge; University of Glasgow; NHS National Services Scotland	Smith, GCS (corresponding author), Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 2SW, England.	gcss2@cam.ac.uk	Wood, Angela/GZA-5762-2022; Smith, Gordon/A-8070-2008; Pasupathy, Dharmintra/N-9586-2019	Wood, Angela/0000-0002-7937-304X; Smith, Gordon/0000-0003-2124-0997; Pasupathy, Dharmintra/0000-0002-6722-1006; fleming, michael/0000-0002-2185-4502; Pell, Jill/0000-0002-8898-7035	Medical Research Council; Royal College of Obstetricians and Gynaecologists; MRC [G0600469] Funding Source: UKRI; British Heart Foundation [RG/08/014/24067] Funding Source: researchfish; Medical Research Council [G0600469] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Royal College of Obstetricians and Gynaecologists; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	DP was supported by the Medical Research Council and the Royal College of Obstetricians and Gynaecologists (Florence and William-Blair Bell Memorial Fellowship Fund) clinical research fellowship. His current affiliation is clinical lecturer in Maternal and Fetal Medicine in the Academic Department of Women's Health, King's College London. The funding source had no involvement in the design of the study and collection, analysis, and interpretation of the data.	COLE SK, 1980, PERINATAL AUDIT SURV, P39; Cutler DM, 2006, NEW ENGL J MED, V355, P920, DOI 10.1056/NEJMsa054744; Gould JB, 2005, OBSTET GYNECOL, V106, P352, DOI 10.1097/01.AOG.0000168627.33566.3c; Gould JB, 2003, JAMA-J AM MED ASSOC, V289, P2958, DOI 10.1001/jama.289.22.2958; Heller G, 2000, BRIT MED J, V321, P274, DOI 10.1136/bmj.321.7256.274; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; *INF STAT DIV NAT, 2000, SCOTT PER INF MORT M; Landon MB, 2004, NEW ENGL J MED, V351, P2581, DOI 10.1056/NEJMoa040405; Little R, 2008, STAT ANAL MISSING DA; Luo ZC, 2004, CAN MED ASSOC J, V170, P337; Luo ZC, 2001, BRIT MED J, V323, P1327, DOI 10.1136/bmj.323.7325.1327; MACFARLANE A, 1978, BRIT MED J, V2, P1670, DOI 10.1136/bmj.2.6153.1670; MANGOLD WD, 1981, AM J PUBLIC HEALTH, V71, P601, DOI 10.2105/AJPH.71.6.601; MATHERS CD, 1983, J EPIDEMIOL COMMUN H, V37, P57, DOI 10.1136/jech.37.1.57; MCILWAINE GM, 1985, BRIT J OBSTET GYNAEC, V92, P9, DOI 10.1111/j.1471-0528.1985.tb01041.x; PACCAUD F, 1988, LANCET, V1, P340, DOI 10.1016/S0140-6736(88)91130-0; Pasupathy D, 2009, JAMA-J AM MED ASSOC, V302, P660, DOI 10.1001/jama.2009.1111; Pasupathy D, 2009, INT J EPIDEMIOL, V38, P490, DOI 10.1093/ije/dyn225; RUFFIEUX C, 1992, AM J EPIDEMIOL, V135, P936, DOI 10.1093/oxfordjournals.aje.a116389; Slickers JE, 2008, AM J EPIDEMIOL, V168, P1259, DOI 10.1093/aje/kwn248; Smith GCS, 2003, LANCET, V362, P1779, DOI 10.1016/S0140-6736(03)14896-9; Smith GCS, 2002, JAMA-J AM MED ASSOC, V287, P2684, DOI 10.1001/jama.287.20.2684; Smith GCS, 2007, LANCET, V370, P1715, DOI 10.1016/S0140-6736(07)61723-1; Stephansson O, 2003, EPIDEMIOLOGY, V14, P218, DOI 10.1097/00001648-200303000-00017; Stewart JH, 1998, BRIT MED J, V316, P657, DOI 10.1136/bmj.316.7132.657; Tomashek KM, 2007, J PEDIATR-US, V151, P450, DOI 10.1016/j.jpeds.2007.05.002	26	66	69	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 15	2010	341								c3498	10.1136/bmj.c3498	http://dx.doi.org/10.1136/bmj.c3498			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	628XD	20634347	Green Published, Green Accepted, hybrid			2023-01-03	WOS:000280156800004
J	Shakur, H; Roberts, I; Bautista, R; Caballero, J; Coats, T; Dewan, Y; El-Sayed, H; Gogichaishvili, T; Gupta, S; Herrera, J; Hunt, B; Iribhogbe, P; Izurieta, M; Khamis, H; Komolafe, E; Marrero, MA; Mejia-Mantilla, J; Miranda, J; Morales, C; Olaomi, O; Dashi, F; Perel, P; Peto, R; Ramana, PV; Ravi, RR; Yutthalcasemsunt, S; Dakubo, J; Gogichaishvili, T; Golden, N; Izurieta, M; Khamis, H; Komolafe, E; Loria-Castellanos, J; Mejia-Mantilla, J; Miranda, J; Munoz, A; Mutiso, V; Olcwen, P; Ortiz, Z; Pascual, M; Ravi, R; Roslani, A; Trenkler, S; Volpi, A; Yutthakasemsunt, S; Roberts, I; Shakur, H; Perel, P; Bametson, L; Ramos, M; Cook, L; Kawahara, T; Balogun, E; Berle, M; Barrow, C; Brady, T; Rubery, C; Wayte, J; To, C; Franklin, I; Chaudhry, B; Coats, T; Deakin, C; Goodacre, S; Hunt, B; Meddings, D; Peto, R; Roberts, I; Sandercock, P; Roberts, I; Shakur, H; Coats, T; Edwards, P; Hunt, B; Ramos, M; Collins, R; Grant, A; Myburgh, J; Baxter, A				Shakur, Haleema; Roberts, Ian; Bautista, Raul; Caballero, Jose; Coats, Tim; Dewan, Yashbir; El-Sayed, Hesham; Gogichaishvili, Tamar; Gupta, Sanjay; Herrera, Jorge; Hunt, Beverley; Iribhogbe, Pius; Izurieta, Mario; Khamis, Hussein; Komolafe, Edward; Marrero, Maria-Acelia; Mejia-Mantilla, Jorge; Miranda, Jaime; Morales, Carlos; Olaomi, Oluwole; Dashi, Fatos; Perel, Pablo; Peto, Richard; Ramana, P. V.; Ravi, R. R.; Yutthalcasemsunt, Surakrant; Dakubo, Jonathan; Gogichaishvili, Tamar; Golden, Nyoman; Izurieta, Mario; Khamis, Hussein; Komolafe, Edward; Loria-Castellanos, Jorge; Mejia-Mantilla, Jorge; Miranda, Jaime; Munoz, Angeles; Mutiso, Vincent; Olcwen, Patrick; Ortiz, Zulma; Pascual, Maria; Ravi, R.; Roslani, April; Trenkler, Stefan; Volpi, Annalisa; Yutthakasemsunt, Surakrant; Roberts, Ian; Shakur, Haleema; Perel, Pablo; Bametson, Lin; Ramos, Maria; Cook, Lisa; Kawahara, Taemi; Balogun, Eni; Berle, Matthew; Barrow, Collette; Brady, Tony; Rubery, Chris; Wayte, Jackie; To, Cynthia; Franklin, Ian; Chaudhry, Brigitte; Coats, Tim; Deakin, Charles; Goodacre, Steve; Hunt, Beverley; Meddings, David; Peto, Richard; Roberts, Ian; Sandercock, Peter; Roberts, Ian; Shakur, Haleema; Coats, Tim; Edwards, Phil; Hunt, Beverley; Ramos, Maria; Collins, Rory; Grant, Adrian; Myburgh, John; Baxter, Alex		Crash 2 Trial Collaborators	Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial	LANCET			English	Article							BRAIN-INJURY; EPIDEMIOLOGY	Background Tranexamic acid can reduce bleeding in patients undergoing elective surgery. We assessed the effects of early administration of a short course of tranexamic acid on death, vascular occlusive events, and the receipt of blood transfusion in trauma patients. Methods This randomised controlled trial was undertaken in 274 hospitals in 40 countries. 20 211 adult trauma patients with, or at risk of, significant bleeding were randomly assigned within 8 h of injury to either tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h) or matching placebo. Randomisation was balanced by centre, with an allocation sequence based on a block size of eight, generated with a computer random number generator. Both participants and study staff (site investigators and trial coordinating centre staff) were masked to treatment allocation. The primary outcome was death in hospital within 4 weeks of injury, and was described with the following categories: bleeding, vascular occlusion (myocardial infarction, stroke and pulmonary embolism), multiorgan failure, head injury, and other. All analyses were by intention to treat. This study is registered as ISRCTN86750102, Clinicaltrials.gov NCT00375258, and South African Clinical Trial Register DOH-27-0607-1919. Findings 10 096 patients were allocated to tranexamic acid and 10 115 to placebo, of whom 10 060 and 10 067, respectively, were analysed. All-cause mortality was significantly reduced with tranexamic acid (1463 [14.5%] tranexamic acid group vs 1613 [16.0%] placebo group; relative risk 0.91, 95% CI 0.85-0.97; p=0.0035). The risk of death due to bleeding was significantly reduced (489 [4.9%] vs 574 [5.7%]; relative risk 0.85, 95% CI 0.76-0.96; p=0.0077). Interpretation Tranexamic acid safely reduced the risk of death in bleeding trauma patients in this study. On the basis of these results, tranexamic acid should be considered for use in bleeding trauma patients.	[Shakur, Haleema] Univ London London Sch Hyg & Trop Med, Clin Trials Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Shakur, H (corresponding author), Univ London London Sch Hyg & Trop Med, Clin Trials Unit, Keppel St, London WC1E 7HT, England.	crash@lshtm.ac.uk	Roslani, April Camilla/B-8245-2010; Trochez, Adolfo Leon/Z-1749-2019; Volpi, Annalisa/AHH-5394-2022; Balogh, Zsolt/A-2002-2010; Mohammad, Bassim Irheim/G-3715-2019; LORIA-CASTELLANOS, JORGE/J-2410-2016; Dewan, Yashbir/C-6503-2013; Mbuagbaw, Lawrence/D-9381-2015; Nottidge, Timothy/ACH-9894-2022; Miranda, J. Jaime/A-8482-2008; Dharap, Satish/AAE-8565-2020; Collins, Rory/ABA-8487-2020; Mohammad, Bassim/AAE-3715-2020; LORIA-CASTELLANOS, JORGE/N-2363-2019; Coats, Timothy/AAW-1254-2021; Anyanwu, Stanley/W-2514-2019	Roslani, April Camilla/0000-0003-2458-965X; Trochez, Adolfo Leon/0000-0002-3621-6036; Volpi, Annalisa/0000-0001-5337-9155; Balogh, Zsolt/0000-0002-0277-4822; LORIA-CASTELLANOS, JORGE/0000-0001-9269-0034; Dewan, Yashbir/0000-0002-7154-1301; Mbuagbaw, Lawrence/0000-0001-5855-5461; Nottidge, Timothy/0000-0002-5245-8115; Miranda, J. Jaime/0000-0002-4738-5468; Dharap, Satish/0000-0002-9304-9617; LORIA-CASTELLANOS, JORGE/0000-0001-9269-0034; Coats, Timothy/0000-0003-2736-2784; Sandercock, Peter/0000-0001-8484-0135; Mankar, Dr. Sushil/0000-0002-7432-2761; ABUBAKAR, MUHAMMAD LAWAL/0000-0002-5536-873X; Wallis, Lee/0000-0003-2711-3139; Mohammad, Bassim/0000-0001-6732-5940; YUSUF, AYODEJI SALMAN/0000-0002-6002-8641; Moradi, Ehsan/0000-0002-1403-0150; RAMANA, P V/0000-0003-4654-0590; Soto, Alonso/0000-0001-8648-8032; Goodacre, Steve/0000-0003-0803-8444; Hokkam, Emad/0000-0003-1532-6655; Aminu Balarabe, Muhammad/0000-0001-5607-5480; Ochoa-Parra, Marcelo/0000-0003-0432-8962; amini, afshin/0000-0001-8928-8212; Wattanakrai, Kamol/0000-0003-4383-0795; komolafe, edward/0000-0003-1261-3501; Okwen, Patrick/0000-0002-9017-7496; Pangi, Ashok/0000-0002-3417-3976; RUBIANO ESCOBAR, ANDRES MARIANO/0000-0001-8931-3254; /0000-0002-2342-301X; Kumar, Dinesh/0000-0003-3602-4023; Chaudhuri, pratyush/0000-0001-9766-728X; Caballero-Alvarado, Jose/0000-0001-8297-6901; Shakur-Still, Haleema/0000-0002-6511-109X; JAMALUDDIN, SABARIAH/0000-0002-3788-7915	UK NIHR Health Technology; Pfizer; BUPA Foundation; J P Moulton Charitable Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008315] Funding Source: NIH RePORTER; National Institute for Health Research [06/303/20] Funding Source: researchfish	UK NIHR Health Technology; Pfizer(Pfizer); BUPA Foundation; J P Moulton Charitable Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institute for Health Research(National Institute for Health Research (NIHR))	Funding UK NIHR Health Technology Assessment programme, Pfizer, BUPA Foundation, and J P Moulton Charitable Foundation.	Baigent C, 2010, OXFORD TXB MED, P31; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; COATS T, 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD004896; Duley L, 2008, CLIN TRIALS, V5, P40, DOI 10.1177/1740774507087704; Ekback G, 2000, ANESTH ANALG, V91, P1124; Ferrer P, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-29; Fiechtner BK, 2001, ANESTH ANALG, V92, P1131; Gosselin RA, 2009, B WORLD HEALTH ORGAN, V87, P246, DOI 10.2471/BLT.08.052290; Henry DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub2; Hogan MC, 2010, LANCET, V375, P1609, DOI 10.1016/S0140-6736(10)60518-1; HORROW JC, 1995, ANESTHESIOLOGY, V82, P383, DOI 10.1097/00000542-199502000-00009; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Lawson JH, 2004, SEMIN HEMATOL, V41, P55, DOI 10.1053/j.seminhematol.2003.11.012; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mock CN, 1998, J TRAUMA, V44, P804, DOI 10.1097/00005373-199805000-00011; *MRC CRASH TRIAL C, 2008, BMJ-BRIT MED J, V12, P12; Okamoto S, 1997, SEMIN THROMB HEMOST, V23, P493, DOI 10.1055/s-2007-996127; Peden M, 2002, INJURY CHART BOOK GR; PEREL P, 2008, EMC MED RES METHODOL, V8, P72; Perel P, 2009, BMC EMERG MED, V9, DOI 10.1186/1471-227X-9-15; RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Shakur H, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-40; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; WYATT J, 1995, BRIT MED J, V310, P1502, DOI 10.1136/bmj.310.6993.1502	25	1778	1842	2	103	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2010	376	9734					23	32		10.1016/S0140-6736(10)60835-5	http://dx.doi.org/10.1016/S0140-6736(10)60835-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	624SR	20554319				2023-01-03	WOS:000279841600021
J	Spence, D				Spence, Des			From the Frontline Medicalisation of ageing: plastic people	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	0	0	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 30	2010	340								c3494	10.1136/bmj.c3494	http://dx.doi.org/10.1136/bmj.c3494			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	621NT	20591946				2023-01-03	WOS:000279586300016
J	Shepherd, M				Shepherd, Marv			Beef up international cooperation on counterfeits	NATURE MEDICINE			English	Editorial Material								Counterfeit drugs are a menacing and deadly problem worldwide. The proliferation of fake drugs is astounding, with over 100 countries reporting incidents of fake drugs, according to a 2008 report from the Pharmaceutical Security Institute. And incidents of drug counterfeiting show no evidence of declining: some industry insiders suggest that the number of counterfeit medicines on the market has increased as much as 25% each year over the past several years.	[Shepherd, Marv] Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA; [Shepherd, Marv] A Vienna, Vienna, Austria	University of Texas System; University of Texas Austin	Shepherd, M (corresponding author), Univ Texas Austin, Coll Pharm, Austin, TX 78712 USA.								0	13	13	0	9	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2010	16	4					366	366		10.1038/nm0410-366	http://dx.doi.org/10.1038/nm0410-366			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	580KJ	20376036				2023-01-03	WOS:000276446800028
J	Venter, JC				Venter, J. Craig			Multiple personal genomes await	NATURE			English	Editorial Material							SEQUENCE		J Craig Venter Inst, La Jolla, CA 92121 USA	J. Craig Venter Institute	Venter, JC (corresponding author), J Craig Venter Inst, La Jolla, CA 92121 USA.	jcventer@jcvi.org						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Levy S, 2007, PLOS BIOL, V5, P2113, DOI 10.1371/journal.pbio.0050254; Peterson J, 2009, GENOME RES, V19, P2317, DOI 10.1101/gr.096651.109; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	7	89	97	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	2010	464	7289					676	677		10.1038/464676a	http://dx.doi.org/10.1038/464676a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	577EO	20360717	Bronze			2023-01-03	WOS:000276205000019
J	Teno, JM; Mitchell, SL; Gozalo, PL; Dosa, D; Hsu, A; Intrator, O; Mor, V				Teno, Joan M.; Mitchell, Susan L.; Gozalo, Pedro L.; Dosa, David; Hsu, Amy; Intrator, Orna; Mor, Vincent			Hospital Characteristics Associated With Feeding Tube Placement in Nursing Home Residents With Advanced Cognitive Impairment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED CONTROLLED-TRIAL; ADVANCED DEMENTIA; CARE; LIFE; END	Context Tube-feeding is of questionable benefit for nursing home residents with advanced dementia. Approximately two-thirds of US nursing home residents who are tube fed had their feeding tube inserted during an acute care hospitalization. Objective To identify US hospital characteristics associated with higher rates of feeding tube insertion in nursing home residents with advanced cognitive impairment. Design, Setting, and Patients The sample included nursing home residents aged 66 years or older with advanced cognitive impairment admitted to acute care hospitals between 2000 and 2007. Rate of feeding tube placement was based on a 20% sample of all Medicare Claims files and was assessed in hospitals with at least 30 such admissions during the 8-year period. A multivariable model with the unit of the analysis being the hospital admission identified hospital-level factors independently associated with feeding tube insertion rates, including bed size, ownership, urban location, and medical school affiliation. Measures of each hospital's care practices for all patients with serious chronic illnesses were evaluated, including intensive care unit (ICU) use in the last 6 months of life, the use of hospice services, and the ratio of specialist to primary care physicians. Patient-level characteristics were also considered. Main Outcome Measure Endoscopic or surgical insertion of a gastrostomy tube during a hospitalization. Results In 2797 acute care hospitals with 280 869 admissions among 163 022 nursing home residents with advanced cognitive impairment, the rate of feeding tube insertion varied from 0 to 38.9 per 100 hospitalizations (mean [SD], 6.5 [5.3]; median [interquartile range], 5.3 [2.6-9.3]). The mean rate of feeding tube insertions per 100 admissions was 7.9 in 2000, decreasing to 6.2 in 2007. Higher insertion rates were associated with the following hospital features: for-profit ownership vs government owned (8.5 vs 5.5 insertions per 100 hospitalizations; adjusted odds ratio [AOR], 1.33; 95% confidence interval [CI], 1.21-1.46), larger size (>310 beds vs <101 beds: 8.0 vs 4.3 insertions per 100 hospitalizations; AOR, 1.48; 95% CI, 1.35-1.63), and greater ICU use in the last 6 months of life (highest vs lowest decile: 10.1 vs 2.9 insertions per 100 hospitalizations; AOR, 2.60; 95% CI, 2.20-3.06). These differences persisted after controlling for patient characteristics. Specialist to primary care ratio and hospice use were weakly or not associated with feeding tube placement. Conclusion Among nursing home residents with advanced cognitive impairment admitted to acute care hospitals, for-profit ownership, larger hospital size, and greater ICU use was associated with increased rates of feeding tube insertion, even after adjusting for patient-level characteristics. JAMA. 2010; 303(6): 544-550	[Teno, Joan M.; Gozalo, Pedro L.; Dosa, David; Hsu, Amy; Intrator, Orna; Mor, Vincent] Brown Univ, Warren Alpert Sch Med, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; [Mitchell, Susan L.] Harvard Univ, Sch Med, Inst Aging Res, Boston, MA USA; [Dosa, David; Intrator, Orna] Providence Vet Affairs Med Ctr, Providence, RI USA	Brown University; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Teno, JM (corresponding author), Brown Univ, Warren Alpert Sch Med, Ctr Gerontol & Hlth Care Res, 121 S Main St, Providence, RI 02912 USA.	joan_teno@brown.edu			National Institute on Aging [RC1AG036418, P01AG027296, K24AG033640]; NATIONAL INSTITUTE ON AGING [K24AG033640, P01AG027296, RC1AG036418] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was funded by grants RC1AG036418 and P01AG027296 from the National Institute on Aging. Dr Mitchell is supported by grant K24AG033640 from the National Institute on Aging.	Ahronheim JC, 2001, J AM GERIATR SOC, V49, P148, DOI 10.1046/j.1532-5415.2001.49035.x; [Anonymous], ICD 9 PROV DIAGN COD; Braun UK, 2005, J AM GERIATR SOC, V53, P242, DOI 10.1111/j.1532-5415.2005.53109.x; Duszak R, 2003, J VASC INTERV RADIOL, V14, P1031; Finucane TE, 1999, JAMA-J AM MED ASSOC, V282, P1365, DOI 10.1001/jama.282.14.1365; Gessert CE, 2000, J AM GERIATR SOC, V48, P1593, DOI 10.1111/j.1532-5415.2000.tb03869.x; Gessert CE, 2006, J AM GERIATR SOC, V54, P1199, DOI 10.1111/j.1532-5415.2006.00824.x; Gillick MR, 2000, NEW ENGL J MED, V342, P206, DOI 10.1056/NEJM200001203420312; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Kuo S, 2009, J AM MED DIR ASSOC, V10, P264, DOI 10.1016/j.jamda.2008.10.010; Lin CY, 2009, MED CARE, V47, P524, DOI 10.1097/MLR.0b013e31819261bd; Mebane-Sims I, 2009, ALZHEIMERS DEMENT, V5, P234, DOI 10.1016/j.jalz.2009.03.001; Meier DE, 2001, ARCH INTERN MED, V161, P594, DOI 10.1001/archinte.161.4.594; Mitchell SL, 1997, ARCH INTERN MED, V157, P327, DOI 10.1001/archinte.157.3.327; Mitchell SL, 2003, JAMA-J AM MED ASSOC, V290, P73, DOI 10.1001/jama.290.1.73; Mitchell SL, 2007, JAMA-J AM MED ASSOC, V298, P2527, DOI 10.1001/jama.298.17.jrr70001; Mitchell SL, 2007, J AM GERIATR SOC, V55, P432, DOI 10.1111/j.1532-5415.2007.01086.x; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; OBrien LA, 1997, J GEN INTERN MED, V12, P364, DOI 10.1046/j.1525-1497.1997.00061.x; Rhodes R, 2009, J CLIN ONCOL, V27, P5496, DOI 10.1200/JCO.2009.24.2206; Rich SE, 2009, J AM GERIATR SOC, V57, P146, DOI 10.1111/j.1532-5415.2008.02090.x; Teno JM, 2009, J PALLIAT MED, V12, P359, DOI 10.1089/jpm.2008.0168; Volandes AE, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2159; Wennberg JE, 2008, TRACKING CARE PATIEN	25	99	101	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 10	2010	303	6					544	550		10.1001/jama.2010.79	http://dx.doi.org/10.1001/jama.2010.79			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	553PG	20145231	Green Accepted, Bronze			2023-01-03	WOS:000274378700026
J	Kutner, JS				Kutner, Jean S.			An 86-Year-Old Woman With Cardiac Cachexia Contemplating the End of Her Life Review of Hospice Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SERIOUSLY ILL PATIENTS; ADVANCED HEART-FAILURE; IMPLANTABLE DEFIBRILLATORS; PALLIATIVE CARE; DECISION-MAKING; MEDICARE PROGRAM; TERMINAL CARE; NEAR-DEATH; FAMILIES; PREFERENCES	Mrs H is an 86-year-old woman with progressive congestive heart failure and multiple chronic conditions who is experiencing worsening function and quality of life despite maximum medical therapies. She seeks advice regarding control over the circumstances of the end of her life, be it by suicide or under hospice care. Typical of US populations older than 65 years with multiple chronic health conditions and functional decline who are facing the end of life, Mrs H's concerns are particularly about quality of life, not being a burden on loved ones, and maintaining control. As she demonstrates, psychological, existential, and social factors, particularly fear of being a burden, are more common reasons for desiring hastened death than those related directly to physical symptoms. Hospice, which provides a multidisciplinary approach to care at the end of life, can assist Mrs H and her family in making decisions that are consistent with her goals. JAMA. 2010;303(4):349-356	Univ Colorado Denver, Sch Med, Dept Med, Div Gen Internal Med, Aurora, CO 80045 USA	Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus	Kutner, JS (corresponding author), Univ Colorado Denver, Sch Med, Dept Med, Div Gen Internal Med, Acad Off 1,Box B180,12631 E 17th Ave, Aurora, CO 80045 USA.	jean.kutner@ucdenver.edu			NIA NIH HHS [1K07 AG030337-01A2] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K07AG030337] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alla F, 2000, AM HEART J, V139, P895, DOI 10.1016/S0002-8703(00)90023-1; American Heart Association, 2009, HEART DIS STROK STAT; [Anonymous], DARTMOUTH ATLAS HLTH; Braun TC, 1999, J PAIN SYMPTOM MANAG, V18, P126, DOI 10.1016/S0885-3924(99)00038-X; Campbell DE, 2004, ANN INTERN MED, V140, P269, DOI 10.7326/0003-4819-140-4-200402170-00009; Carlson MDA, 2008, J PAIN SYMPTOM MANAG, V36, P107, DOI 10.1016/j.jpainsymman.2007.09.014; Carlson MDA, 2007, HEALTH SERV RES, V42, P1672, DOI 10.1111/j.1475-6773.2006.00685.x; CARPENTER S, 2009, NY TIMES        0330; Casarett D, 2006, J AM GERIATR SOC, V54, P472, DOI 10.1111/j.1532-5415.2005.00628.x; Casarett D, 2005, J AM GERIATR SOC, V53, P249, DOI 10.1111/j.1532-5415.2005.53110.x; Casarett David J, 2003, Am J Hosp Palliat Care, V20, P205, DOI 10.1177/104990910302000309; Casarett DJ, 2004, J AM GERIATR SOC, V52, P1923, DOI 10.1111/j.1532-5415.2004.52520.x; Christakis NA, 2003, SOC SCI MED, V57, P465, DOI 10.1016/S0277-9536(02)00370-2; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Connor SR, 2004, J PAIN SYMPTOM MANAG, V28, P316, DOI 10.1016/j.jpainsymman.2004.07.003; Connor SR, 2007, J PAIN SYMPTOM MANAG, V33, P238, DOI 10.1016/j.jpainsymman.2006.10.010; Currow DC, 2007, J AM GERIATR SOC, V55, P590, DOI 10.1111/j.1532-5415.2007.01124.x; Dougherty CM, 2007, J CARDIOVASC NURS, V22, P480, DOI 10.1097/01.JCN.0000297384.36873.52; Downey L, 2009, J PAIN SYMPTOM MANAG, V37, P175, DOI 10.1016/j.jpainsymman.2008.02.012; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Ezekowitz JA, 2008, AM J CARDIOL, V102, P79, DOI 10.1016/j.amjcard.2008.02.102; Formiga F, 2004, QJM-INT J MED, V97, P803, DOI 10.1093/qjmed/hch135; Fox E, 1999, JAMA-J AM MED ASSOC, V282, P1638, DOI 10.1001/jama.282.17.1638; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Fried TR, 1999, ANN INTERN MED, V131, P109, DOI 10.7326/0003-4819-131-2-199907200-00006; Ganzini L, 2003, NEW ENGL J MED, V349, P359, DOI 10.1056/NEJMsa035086; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Goldstein N, 2009, J AM COLL CARDIOL, V54, P371, DOI 10.1016/j.jacc.2009.04.030; Goldstein NE, 2008, J GEN INTERN MED, V23, P7, DOI 10.1007/s11606-007-0239-8; Goldstein NE, 2008, J GEN INTERN MED, V23, P2, DOI 10.1007/s11606-007-0237-x; Goldstein NE, 2004, ANN INTERN MED, V141, P835, DOI 10.7326/0003-4819-141-11-200412070-00006; Goodlin SJ, 2004, J CARD FAIL, V10, P200, DOI 10.1016/j.cardfail.2003.09.006; Hanchate A, 2009, ARCH INTERN MED, V169, P493, DOI 10.1001/archinternmed.2008.616; Heidenreich PA, 2006, J AM COLL CARDIOL, V47, P752, DOI 10.1016/j.jacc.2005.11.021; Hudson PL, 2006, PALLIATIVE MED, V20, P693, DOI 10.1177/0269216306071799; Huynh BC, 2008, J AM GERIATR SOC, V56, P1111, DOI 10.1111/j.1532-5415.2008.01756.x; Huynh BC, 2006, ARCH INTERN MED, V166, P1892, DOI 10.1001/archinte.166.17.1892; Jong P, 2002, ARCH INTERN MED, V162, P1689, DOI 10.1001/archinte.162.15.1689; Kellett J, 2008, EUR J INTERN MED, V19, P155, DOI 10.1016/j.ejim.2007.09.002; Kronman AC, 2008, J GEN INTERN MED, V23, P1330, DOI 10.1007/s11606-008-0638-5; Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1; Lee DS, 2003, JAMA-J AM MED ASSOC, V290, P2581, DOI 10.1001/jama.290.19.2581; Levenson JW, 2000, J AM GERIATR SOC, V48, pS101, DOI 10.1111/j.1532-5415.2000.tb03119.x; Levy WC, 2006, CIRCULATION, V113, P1424, DOI 10.1161/CIRCULATIONAHA.105.584102; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Medicare Payment Advisory Commission, 2002, REP C MED BEN ACC HO; Morss S, 2008, J AM GERIATR SOC, V56, P124, DOI 10.1111/j.1532-5415.2007.01507.x; Mueller PS, 2008, PACE, V31, P560, DOI 10.1111/j.1540-8159.2008.01041.x; *NAT HOSP FDN, 2008, HOSP CAR CONS GUID S; *NAT HOSP PALL CAR, 2009, NHPCO FACTS FIG HOSP; National Consensus Project, 2009, CLIN PRACT GUID QUAL; *OR DEP HUM SERV, 2006, 8 ANN REP OR DEATH D; Quill TE, 2004, NEW ENGL J MED, V350, P2029, DOI 10.1056/NEJMp038216; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; Rhodes RL, 2008, J PAIN SYMPTOM MANAG, V35, P365, DOI 10.1016/j.jpainsymman.2007.12.004; Rosenfeld KE, 2000, J GEN INTERN MED, V15, P620, DOI 10.1046/j.1525-1497.2000.06289.x; Schockett ER, 2005, J PAIN SYMPTOM MANAG, V30, P400, DOI 10.1016/j.jpainsymman.2005.04.013; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Smith MA, 2008, GERONTOLOGIST, V48, P25, DOI 10.1093/geront/48.1.25; Steinbrook R, 2008, NEW ENGL J MED, V359, P2513, DOI 10.1056/NEJMp0809394; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Stevenson J, 2004, BMJ-BRIT MED J, V329, P909, DOI 10.1136/bmj.329.7471.909; Taylor DH, 2007, SOC SCI MED, V65, P1466, DOI 10.1016/j.socscimed.2007.05.028; Teno J M, 2001, J Palliat Med, V4, P457, DOI 10.1089/109662101753381593; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Teno JM, 2007, J PAIN SYMPTOM MANAG, V34, P120, DOI 10.1016/j.jpainsymman.2007.04.014; Teno JM, 2009, JAMA-J AM MED ASSOC, V301, P651, DOI 10.1001/jama.2009.109; Tsevat J, 1998, JAMA-J AM MED ASSOC, V279, P371, DOI 10.1001/jama.279.5.371; *US BUR CENS, US CENS DAT; US Department of Health and Human Services Centers for Medicare and Medicaid Services, 2008, FED REG, V73, P32087; Virnig BA, 2004, J AM GERIATR SOC, V52, P731, DOI 10.1111/j.1532-5415.2004.52213.x; Virnig BA, 2006, J PALLIAT MED, V9, P1292, DOI 10.1089/jpm.2006.9.1292; Weissman DE, 2004, JAMA-J AM MED ASSOC, V292, P1738, DOI 10.1001/jama.292.14.1738; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665	75	11	11	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 27	2010	303	4					349	356		10.1001/jama.2009.2015	http://dx.doi.org/10.1001/jama.2009.2015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548IC	20051558				2023-01-03	WOS:000273952800023
J	Lettieri, CJ; Shah, AA; Holley, AB; Kelly, WF; Chang, AS; Roop, SA				Lettieri, Christopher J.; Shah, Anita A.; Holley, Aaron B.; Kelly, William F.; Chang, Audrey S.; Roop, Stuart A.		CPAP ASAP Trial	Effects of a Short Course of Eszopiclone on Continuous Positive Airway Pressure Adherence A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							OBSTRUCTIVE SLEEP-APNEA; NASAL CPAP THERAPY; QUALITY-OF-LIFE; 1ST 3 MONTHS; APNOEA/HYPOPNOEA SYNDROME; APNEA/HYPOPNEA SYNDROME; PATIENT COMPLIANCE; HYPERTENSION; ASSOCIATION; VARIABILITY	Background: Adherence to short-term continuous positive airway pressure (CPAP) may predict long-term use. Unfortunately, initial CPAP intolerance may lead to poor adherence or abandonment of therapy. Objective: To determine whether a short course of eszopiclone at the onset of therapy improves long-term CPAP adherence more than placebo in adults with obstructive sleep apnea. Design: Parallel randomized, placebo-controlled trial from March 2007 to December 2008. Randomization, maintained and concealed centrally by pharmacy personnel, was computer-generated using fixed blocks of 10. Referring physicians, investigators, and patients were blinded to the treatment assignment until after the final data were collected. (ClinicalTrials.gov registration number: NCT00612157) Setting: Academic sleep disorder center. Patients: 160 adults (mean age, 45.7 years [SD, 7.3]; mean apnea-hypopnea index, 36.9 events/h [ SD, 23]) with newly diagnosed obstructive sleep apnea initiating CPAP. Intervention: Eszopiclone, 3 mg (n = 76), or matching placebo (n = 78) for the first 14 nights of CPAP. Measurements: Use of CPAP was measured weekly for 24 weeks. Adherence to CPAP (primary outcome) and the rate of CPAP discontinuation and improvements in symptoms (secondary outcomes) were compared. Follow-up at 1, 3, and 6 months was completed by 150, 136, and 120 patients, respectively. Results: Patients in the eszopiclone group used CPAP for 20.8% more nights (95% CI, 7.2% to 34.4%; P = 0.003), 1.3 more hours per night for all nights (CI, 0.4 to 2.2 hours; P = 0.005), and 1.1 more hours per night of CPAP use (CI, 0.2 to 2.1 hours; P = 0.019). The hazard ratio for discontinuation of CPAP was 1.90 (CI, 1.1 to 3.4; P = 0.033) times higher in the placebo group. Side effects were reported in 7.1% of patients and did not differ between groups. Limitations: Patients had severe obstructive sleep apnea treated at a specialized sleep center with frequent follow-up; results may not be generalizable to different settings. Patients' tolerance to CPAP and their reasons for discontinuation were not assessed. Conclusion: Compared with placebo, a short course of eszopiclone during the first 2 weeks of CPAP improved adherence and led to fewer patients discontinuing therapy.	[Lettieri, Christopher J.] Walter Reed Army Med Ctr, Washington, DC 20307 USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA	Lettieri, CJ (corresponding author), Walter Reed Army Med Ctr, 6900 Georgia Ave,NW, Washington, DC 20307 USA.	christopher.lettieri@us.army.mil		Lettieri, Christopher/0000-0001-7950-2908	Henry M. Jackson Foundation for the Advancement of Military Medicine	Henry M. Jackson Foundation for the Advancement of Military Medicine	By Sepracor to the Henry M. Jackson Foundation for the Advancement of Military Medicine.	Aloia MS, 2005, J CLIN SLEEP MED, V1, P346; Aloia Mark S, 2007, Behav Sleep Med, V5, P229; Anstead M, 1998, Curr Opin Pulm Med, V4, P351, DOI 10.1097/00063198-199811000-00008; Bradshaw DA, 2006, CHEST, V130, P1369, DOI 10.1378/chest.130.5.1369; Budhiraja R, 2007, SLEEP, V30, P320; Chervin RD, 1997, SLEEP, V20, P284, DOI 10.1093/sleep/20.4.284; Collen J, 2009, CHEST, V135, P704, DOI 10.1378/chest.08-2182; EDINGER JD, 1994, PERCEPT MOTOR SKILL, V78, P1116, DOI 10.2466/pms.1994.78.3c.1116; ENGLEMAN HM, 1994, THORAX, V49, P263, DOI 10.1136/thx.49.3.263; Engleman HM, 2003, SLEEP MED REV, V7, P81, DOI 10.1053/smrv.2001.0197; HOFFSTEIN V, 1992, AM REV RESPIR DIS, V145, P841, DOI 10.1164/ajrccm/145.4_Pt_1.841; Howard ME, 2004, AM J RESP CRIT CARE, V170, P1014, DOI 10.1164/rccm.200312-1782oc; Hoy CJ, 1999, AM J RESP CRIT CARE, V159, P1096, DOI 10.1164/ajrccm.159.4.9808008; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; Kryger M, 2007, SLEEP BREATH, V11, P159, DOI 10.1007/s11325-006-0096-4; Kushida CA, 2005, SLEEP, V28, P499, DOI 10.1093/sleep/28.4.499; Likar LL, 1997, CHEST, V111, P1273, DOI 10.1378/chest.111.5.1273; McArdle N, 1999, AM J RESP CRIT CARE, V159, P1108, DOI 10.1164/ajrccm.159.4.9807111; Meslier N, 1998, EUR RESPIR J, V12, P185, DOI 10.1183/09031936.98.12010185; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Noseda A, 2004, CHEST, V126, P31, DOI 10.1378/chest.126.1.31; Pelayo R, 2007, CHEST, V131, P1616, DOI 10.1378/chest.06-3036; Pepin JL, 1999, AM J RESP CRIT CARE, V160, P1124, DOI 10.1164/ajrccm.160.4.9802027; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; REEVESHOCHE MK, 1994, AM J RESP CRIT CARE, V149, P149, DOI 10.1164/ajrccm.149.1.8111574; Rosenberg R, 2007, SLEEP MED, V8, P464, DOI 10.1016/j.sleep.2006.10.007; SHEPARD JW, 1992, CLIN CHEST MED, V13, P437; Stephane BA, 2002, CR PHYS, V3, P239, DOI 10.1016/S1631-0705(02)01303-8; Stepnowsky CJ, 2002, SLEEP, V25, P758, DOI 10.1093/sleep/25.7.758; Veale D, 2002, QUAL LIFE RES, V11, P389, DOI 10.1023/A:1015599326110; Weaver TE, 1997, SLEEP, V20, P278, DOI 10.1093/sleep/20.4.278; Weaver TE, 1997, SLEEP, V20, P835; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG	33	86	92	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2009	151	10					696	W225		10.7326/0003-4819-151-10-200911170-00006	http://dx.doi.org/10.7326/0003-4819-151-10-200911170-00006			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	524LP	19920270				2023-01-03	WOS:000272145100003
J	Patel, A; Buszewicz, M; Beecham, J; Griffin, M; Rait, G; Nazareth, I; Atkinson, A; Barlow, J; Haines, A				Patel, Anita; Buszewicz, Marta; Beecham, Jennifer; Griffin, Mark; Rait, Greta; Nazareth, Irwin; Atkinson, Angela; Barlow, Julie; Haines, Andy			Economic evaluation of arthritis self management in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; CHRONIC DISEASE; HEALTH-STATUS; PROGRAM; TRIAL	Objective To assess the cost effectiveness of a self management programme plus education booklet for arthritis in primary care. Design Cost effectiveness and cost utility analysis from health and social care and societal perspectives alongside a randomised controlled trial. Setting 74 general practices in the United Kingdom. Participants 812 patients aged 50 or more with osteoarthritis of the hips or knees, or both, and pain or disability, or both. Interventions Randomisation to either six sessions of an arthritis self management programme plus an education booklet (intervention group) or the education booklet alone (standard care control group). Main outcome measures Total health and social care costs and total societal costs at 12 months; cost effectiveness (incremental cost effectiveness ratios and cost effectiveness acceptability curves) on basis of quality of life (SF-36, primary outcome measure), EuroQol visual analogue scale, and quality adjusted life years (QALYs). Results At 12 months health and social care costs in the intervention group were 101 pound higher (95% confidence interval 3 pound to 176) pound than those in the control group because the additional costs of the arthritis self management programme did not seem to be fully offset by savings elsewhere. There were no significant differences in societal costs (which were up to 13 times the size of health and social care costs) or any of the outcomes. From the health and social care perspective the intervention was dominated by the control on the basis of QALYs (which were non-significantly lower in the intervention group) and had incremental cost effectiveness ratios between 279 pound and 13 pound 473 for the other outcomes. From the societal perspective the intervention seemed superior to the control owing to non-significantly lower costs and non-significantly better outcomes on all measures except QALYs. Probabilities of the arthritis self management programme's cost effectiveness ranged between 12% and 97% (for thresholds ranging 0 pound to 1000) pound based on one point improvements in SF-36 outcomes, but the clinical significance of this is debatable. Probabilities of cost effectiveness on the basis of the visual analogue scale and QALYs were low. Conclusions Cost effectiveness of an arthritis self management programme is not suggested on the basis of current National Institute for Health and Clinical Excellence cost perspectives and QALY thresholds. The probability of cost effectiveness is greater when broader costs and other quality of life outcomes are considered. These results suggest that the cost effectiveness of the Department of Health's expert patients programme cannot be assumed across all clinical conditions and that further rigorous evaluations for other conditions may be needed.	[Patel, Anita] Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London SE5 8AF, England; [Buszewicz, Marta; Griffin, Mark; Rait, Greta; Nazareth, Irwin] UCL, Sch Life & Med Sci, Res Dept Primary Care & Populat Hlth, London WC1E 6BT, England; [Beecham, Jennifer] Univ Kent, Personal Social Serv Res Unit, Canterbury, Kent, England; [Rait, Greta; Nazareth, Irwin] MRC Gen Practice Res Framework, London, England; [Atkinson, Angela] James Cook Univ Hosp, NE Stroke Res Network, Middlesbrough, Cleveland, England; [Barlow, Julie] Coventry Univ, Fac Hlth & Life Sci, Appl Res Ctr Hlth & Lifestyle Intervent, Self Management Programme, Coventry, W Midlands, England; [Haines, Andy] London Sch Hyg & Trop Med, London, England	University of London; King's College London; University of London; University College London; University of Kent; James Cook University Hospital; Coventry University; University of London; London School of Hygiene & Tropical Medicine	Patel, A (corresponding author), Kings Coll London, Inst Psychiat, Ctr Econ Mental Hlth, London SE5 8AF, England.	anita.patel@iop.kcl.ac.uk	Patel, Anita/F-9832-2010; Beecham, Jennifer K/E-7836-2010; Griffin, Mark/C-1827-2008	Beecham, Jennifer K/0000-0001-5147-3383; Rait, Greta/0000-0002-7216-7294; Haines, Andy/0000-0002-8053-4605; Nazareth, Irwin/0000-0003-2146-9628; Patel, Anita/0000-0003-0769-1732	UK Medical Research Council [G9900306]; MRC [MC_U122797163, MC_U122797165] Funding Source: UKRI; Medical Research Council [MC_U122797163, MC_U122797165] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This trial was funded by the UK Medical Research Council (grant No G9900306). The trial was initially funded to run for three years, from 1 June 2000 to 31 May 2003. A supplement and extension extended the trial completion date to 31 May 2004. The UK Medical Research Council funded the trial, peer reviewed the protocol, and was represented on the trial steering committee. The funders had no role in the study design or management, data collection, analysis and interpretation, writing of the report, or preparation of the manuscript.	*ARTHR CAR, 2007, ARTHR CAR FACT SHEET; Beecham J., 2001, MEASURING MENTAL HLT; BEECHAM J, 2002, MEASURING MENTAL HLT; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469; Buszewicz M, 2006, BMJ-BRIT MED J, V333, P879, DOI 10.1136/bmj.38965.375718.80; Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3; Curtis, 2003, UNIT COSTS HLTH SOCI; Department of Health (UK), 1999, CAR CAR NAT STRAT CA; DOLAN P, 1995, 138 U YORK; Drummond MJ, 2008, BMJ-BRIT MED J, V337, P770; Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635; Griffiths C, 2007, BMJ-BRIT MED J, V334, P1254, DOI 10.1136/bmj.39227.698785.47; Kennedy A, 2007, J EPIDEMIOL COMMUN H, V61, P254, DOI 10.1136/jech.2006.053538; Kruger JMS, 1998, ARCH INTERN MED, V158, P1245, DOI 10.1001/archinte.158.11.1245; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008; Manca A, 2005, HEALTH ECON, V14, P487, DOI 10.1002/hec.944; RAFTERY J, 1995, EC EVALUATION MENTAL; Richardson G, 2008, J EPIDEMIOL COMMUN H, V62, P361, DOI 10.1136/jech.2006.057430; Richardson G, 2005, INT J TECHNOL ASSESS, V21, P423, DOI 10.1017/S0266462305050592; RICHARDSON J, 2001, 126 MON U; Solomon DH, 2002, J RHEUMATOL, V29, P362; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLIAMS A, 1990, HEALTH POLICY, V16, P199	26	29	30	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 22	2009	339								b3532	10.1136/bmj.b3532	http://dx.doi.org/10.1136/bmj.b3532			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	499OE	19773329	Green Published, Green Accepted, hybrid, Green Submitted			2023-01-03	WOS:000270231500006
J	Kelly, CJ; Mir, FA				Kelly, Christopher J.; Mir, Fraz A.			Economics of biological therapies	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							FOLLOW-ON BIOLOGICS; DRUGS; NICE		[Mir, Fraz A.] Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 0QQ, England; [Kelly, Christopher J.] Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge CB2 0QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Kelly, CJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 0QQ, England.	fam31@cam.ac.uk		Kelly, Christopher/0000-0002-1246-844X				Aggarwal S, 2007, NAT BIOTECHNOL, V25, P1097, DOI 10.1038/nbt1007-1097; [Anonymous], 2007, PHARM PRIC REG SCHEM; BERNDT E, 2007, DO AUTHORIZED GENERI; Claxton K, 2008, BMJ-BRIT MED J, V336, P251, DOI 10.1136/bmj.39434.500185.25; Covic A, 2007, INT UROL NEPHROL, V39, P261, DOI 10.1007/s11255-006-9167-5; CROW JM, 2008, CHEM WORLD      0424; *DAT, BIOG 2005 NEW LEV CO; *EUR MED AG, 2006, QUEST ANS REC REF MA; European Medicenes Agency, 2005, GUID SIM BIOL MED PR; *FED TRAD COMM, 2009, EM HLTH CAR ISS; Frank RG, 2007, NEW ENGL J MED, V357, P841, DOI 10.1056/NEJMp078095; Grabowski H, 2006, HEALTH AFFAIR, V25, P1291, DOI 10.1377/hlthaff.25.5.1291; JUDLOWE S, 2008, PROPOSED LEGISLATION; *LA MER BUS INT, TOP 20 BIOL 2007; Muller M, 2006, WIEN KLIN WOCHENSCHR, V118, P508, DOI 10.1007/s00508-006-0670-6; MUNDY A, 2009, WALL STREET J   0225; Raftery J, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b67; ROYSTON J, 2008, BIOTECHNOL PROGR, V21, P11; SHAPIRO R, 2008, GENERIC BIOL TREATME; SHENOUDA M, 2008, POLITICAL UPDATE E S; Sikora K, 2007, J ROY SOC MED, V100, P166, DOI 10.1258/jrsm.100.4.166; Sleijfer S, 2009, CLIN PHARMACOL THER, V85, P136, DOI 10.1038/clpt.2008.245; Steinbrook R, 2008, NEW ENGL J MED, V359, P1977, DOI 10.1056/NEJMp0806862; *TUCK BIOG PAN, 2008, CAP MARK PERSP; U. S. Food and Drug Administration, FREQ ASK QUEST THER; *UBS INV BANK EQ R, 2005, INTR PHARM BIOT IND; Webb DJ, 2007, LANCET, V369, P1415, DOI 10.1016/S0140-6736(07)60648-5; Wright E, 2007, CHIM OGGI, V25, P4; YAKATAN S, 2005, BIOEXECUTIVE INT, V1, P2; 2008, PHARMA TIMES    0410; 2009, BBC NEWS        0616; 2009, BIOPHARMA TODAY 0519	32	21	21	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 21	2009	339								b3276	10.1136/bmj.b3276	http://dx.doi.org/10.1136/bmj.b3276			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	486SE	19700510				2023-01-03	WOS:000269217200005
J	Huang, HR; Xie, CQ; Sun, X; Ritchie, RP; Zhang, JF; Chen, YE				Huang, Huarong; Xie, Changqing; Sun, Xuan; Ritchie, Raquel P.; Zhang, Jifeng; Chen, Y. Eugene			miR-10a Contributes to Retinoid Acid-induced Smooth Muscle Cell Differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC STEM-CELLS; NF-KAPPA-B; SERUM RESPONSE FACTOR; NEOINTIMAL LESION FORMATION; HISTONE DEACETYLASES; GENE-EXPRESSION; MYELOID-LEUKEMIA; DOWN-REGULATION; MICRORNA; GROWTH	MicroRNAs (miRs) have been reported to play a critical role in muscle differentiation and function. The purpose of this study is to determine the role of miRs during smooth muscle cell (SMC) differentiation from embryonic stem cells (ESCs). MicroRNA profiling showed that miR-10a expression is steadily increased during in vitro differentiation of mouse ESCs into SMCs. Loss-of-function approaches using miR-10a inhibitors uncovered that miR-10a is a critical mediator for SMC lineage determination in our retinoic acid-induced ESC/SMC differentiation system. In addition, we have documented for the first time that histone deacetylase 4 is a novel target of miR-10a and mediates miR-10a function during ESC/SMC differentiation. To determine the molecular mechanism through which retinoic acid induced miR-10a expression, a consensus NF-kappa B element was identified in the miR-10a gene promoter by bioinformatics analysis, and chromatin immunoprecipitation assay confirmed that NF-kappa B could bind to this element. Finally, inhibition of NF-kappa B nuclear translocation repressed miR-10a expression and decreased SMC differentiation from ESCs. Our data demonstrate for the first time that miR-10a is a novel regulator in SMC differentiation from ESCs. These studies suggest that miR-10a may play important roles in vascular biology and have implications for the diagnosis and treatment of vascular diseases.	[Huang, Huarong; Xie, Changqing; Sun, Xuan; Ritchie, Raquel P.; Zhang, Jifeng; Chen, Y. Eugene] Univ Michigan, Ctr Cardiovasc, Dept Internal Med, Med Ctr, Ann Arbor, MI 48109 USA; [Sun, Xuan] Cent S Univ, Inst Reprod & Stem Cell Engn, Changsha 410078, Hunan, Peoples R China	University of Michigan System; University of Michigan; Central South University	Chen, YE (corresponding author), 1150 W Med Ctr Dr,MSRB 3,7301E, Ann Arbor, MI 48109 USA.	echenum@umich.edu		Striepen, Boris/0000-0002-7426-432X	National Institutes of Health [HL092421, HL068878, HL89544]; American Heart Association [0825837G, 09SDG2260023, 0835237N, 0840025N]; American Heart Association National Scientific Development [09SDG2260023, 0835237N, 0840025N]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089544, R01HL068878, R21HL092421] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); American Heart Association National Scientific Development; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported, in whole or in part, by National Institutes of Health Grants HL092421, HL068878, and HL89544 (to Y.E.C.).; Supported by American Heart Association Postdoctoral Fellowship 0825837G.; Supported by American Heart Association National Scientific Development Grant 09SDG2260023.; Supported by a National Institutes of Health Research Supplement to Promote Diversity.; Supported by American Heart Association National Scientific Development Grant 0835237N.; An American Heart Association established investigator (Grant 0840025N).	Agirre X, 2008, MOL CANCER RES, V6, P1830, DOI 10.1158/1541-7786.MCR-08-0167; Bai G, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-15; Boettger T, 2009, J CLIN INVEST, V119, P2634, DOI 10.1172/JCI38864; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; Cao DS, 2005, MOL CELL BIOL, V25, P364, DOI 10.1128/MCB.25.1.364-376.2005; Chen CF, 2007, MAMM GENOME, V18, P316, DOI 10.1007/s00335-007-9032-6; Cheng YH, 2009, CIRC RES, V105, P158, DOI 10.1161/CIRCRESAHA.109.197517; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Davis BN, 2009, J BIOL CHEM, V284, P3728, DOI 10.1074/jbc.M808788200; Davis FJ, 2003, J BIOL CHEM, V278, P20047, DOI 10.1074/jbc.M209998200; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Drab M, 1997, FASEB J, V11, P905, DOI 10.1096/fasebj.11.11.9285489; Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749; Gu P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002548; Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hirschi KK, 2002, J BIOL CHEM, V277, P6287, DOI 10.1074/jbc.M106649200; Huang HR, 2006, BIOCHEM BIOPH RES CO, V351, P321, DOI 10.1016/j.bbrc.2006.09.171; Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015; Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986; Jin P, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-39; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Levenberg S, 2002, P NATL ACAD SCI USA, V99, P4391, DOI 10.1073/pnas.032074999; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Liu XJ, 2009, CIRC RES, V104, P476, DOI 10.1161/CIRCRESAHA.108.185363; Loots GG, 2004, NUCLEIC ACIDS RES, V32, pW217, DOI 10.1093/nar/gkh383; Magness ST, 2004, J IMMUNOL, V173, P1561, DOI 10.4049/jimmunol.173.3.1561; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; Marson A, 2008, CELL, V134, P521, DOI 10.1016/j.cell.2008.07.020; McDonald OG, 2007, CIRC RES, V100, P1428, DOI 10.1161/01.RES.0000266448.30370.a0; Murry CE, 2008, CELL, V132, P661, DOI 10.1016/j.cell.2008.02.008; NARAYANAN R, 1993, MOL CELL BIOL, V13, P3802, DOI 10.1128/MCB.13.6.3802; Neppl RL, 2009, CELL STEM CELL, V5, P130, DOI 10.1016/j.stem.2009.07.004; Orom UA, 2008, MOL CELL, V30, P460, DOI 10.1016/j.molcel.2008.05.001; Ovcharenko D, 2007, CANCER RES, V67, P10782, DOI 10.1158/0008-5472.CAN-07-1484; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Qiu P, 2002, CIRC RES, V90, P858, DOI 10.1161/01.RES.0000016504.08608.B9; Ruby JG, 2006, CELL, V127, P1193, DOI 10.1016/j.cell.2006.10.040; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; Sinha Sanjay, 2009, V482, P345, DOI 10.1007/978-1-59745-060-7_22; Torres J, 2008, NAT CELL BIOL, V10, P194, DOI 10.1038/ncb1680; Tzur G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003726; Varnholt H, 2008, HEPATOLOGY, V47, P1223, DOI 10.1002/hep.22158; Veerla S, 2009, INT J CANCER, V124, P2236, DOI 10.1002/ijc.24183; Walsh K, 2001, Z Kardiol, V90 Suppl 3, P12; Widera D, 2006, INT J DEV NEUROSCI, V24, P91, DOI 10.1016/j.ijdevneu.2005.11.017; Woltering JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001396; Xiao QZ, 2007, AM J PHYSIOL-CELL PH, V292, pC342, DOI 10.1152/ajpcell.00341.2006; Xie CQ, 2007, ARTERIOSCL THROM VAS, V27, pE311, DOI 10.1161/ATVBAHA.107.154260; Xie CQ, 2009, STEM CELLS DEV, V18, P741, DOI 10.1089/scd.2008.0179; Xin M, 2009, GENE DEV, V23, P2166, DOI 10.1101/gad.1842409; Yoshida T, 2007, AM J PHYSIOL-CELL PH, V292, pC886, DOI 10.1152/ajpcell.00449.2006; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	55	118	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 26	2010	285	13					9383	9389		10.1074/jbc.M109.095612	http://dx.doi.org/10.1074/jbc.M109.095612			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	576RP	20231284	Green Published, hybrid			2023-01-03	WOS:000276165900010
J	Padayatty, SJ; Sun, AY; Chen, Q; Espey, MG; Drisko, J; Levine, M				Padayatty, Sebastian J.; Sun, Andrew Y.; Chen, Qi; Espey, Michael Graham; Drisko, Jeanne; Levine, Mark			Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects	PLOS ONE			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; RECOMMENDED DIETARY ALLOWANCE; ACUTE OXALATE NEPHROPATHY; ACID-INDUCED HEMOLYSIS; TERMINAL HUMAN CANCER; ASCORBIC-ACID; EXPERIMENTAL POLIOMYELITIS; SUPPLEMENTAL ASCORBATE; SUPPORTIVE TREATMENT; HYDROGEN-PEROXIDE	Background: Anecdotal information and case reports suggest that intravenously administered vitamin C is used by Complementary and Alternate Medicine (CAM) practitioners. The scale of such use in the U. S. and associated side effects are unknown. Methods and Findings: We surveyed attendees at annual CAM Conferences in 2006 and 2008, and determined sales of intravenous vitamin C by major U. S. manufacturers/distributors. We also queried practitioners for side effects, compiled published cases, and analyzed FDA's Adverse Events Database. Of 199 survey respondents (out of 550), 172 practitioners administered IV vitamin C to 11,233 patients in 2006 and 8876 patients in 2008. Average dose was 28 grams every 4 days, with 22 total treatments per patient. Estimated yearly doses used (as 25g/50ml vials) were 318,539 in 2006 and 354,647 in 2008. Manufacturers' yearly sales were 750,000 and 855,000 vials, respectively. Common reasons for treatment included infection, cancer, and fatigue. Of 9,328 patients for whom data is available, 101 had side effects, mostly minor, including lethargy/fatigue in 59 patients, change in mental status in 21 patients and vein irritation/phlebitis in 6 patients. Publications documented serious adverse events, including 2 deaths in patients known to be at risk for IV vitamin C. Due to confounding causes, the FDA Adverse Events Database was uninformative. Total numbers of patients treated in the US with high dose vitamin C cannot be accurately estimated from this study. Conclusions: High dose IV vitamin C is in unexpectedly wide use by CAM practitioners. Other than the known complications of IV vitamin C in those with renal impairment or glucose 6 phosphate dehydrogenase deficiency, high dose intravenous vitamin C appears to be remarkably safe. Physicians should inquire about IV vitamin C use in patients with cancer, chronic, untreatable, or intractable conditions and be observant of unexpected harm, drug interactions, or benefit.	[Padayatty, Sebastian J.; Sun, Andrew Y.; Espey, Michael Graham; Levine, Mark] NIDDK, Mol & Clin Nutr Sect, NIH, Bethesda, MD 20892 USA; [Chen, Qi; Drisko, Jeanne] Univ Kansas, Med Ctr, Program Integrat Med, Kansas City, KS 66103 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Kansas; University of Kansas Medical Center	Padayatty, SJ (corresponding author), NIDDK, Mol & Clin Nutr Sect, NIH, Bethesda, MD 20892 USA.	MarkL@intra.niddk.nih.gov	Chen, Qi/D-8278-2015; Levine, Mark/HIZ-8652-2022; Ganapathy, Suthakar/C-1266-2013; Padayatty, Sebastian J/A-8581-2012	Chen, Qi/0000-0002-7173-8411; Levine, Mark/0000-0001-6297-4650; Ganapathy, Suthakar/0000-0003-3828-5382; Padayatty, Sebastian J/0000-0001-8758-3170; Sun, Andrew/0000-0002-7925-6580	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health	National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported in part by the Intramural Research Program, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali A, 2009, J ALTERN COMPLEM MED, V15, P247, DOI 10.1089/acm.2008.0410; Barnes Patricia M, 2004, Adv Data, P1; Bromley J, 2005, ANN PHARMACOTHER, V39, P1566, DOI 10.1345/aph.1E634; CALLEJA H B, 1960, Ohio State Med J, V56, P821; CAMERON E, 1976, P NATL ACAD SCI USA, V73, P3685, DOI 10.1073/pnas.73.10.3685; CAMERON E, 1972, LANCET, V1, P542; CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538; CAMPBELL GD, 1975, ANN INTERN MED, V82, P810, DOI 10.7326/0003-4819-82-6-810_1; Canavese C, 2005, AM J KIDNEY DIS, V45, P540, DOI 10.1053/j.ajkd.2004.10.025; CATHCART RF, 1981, MED HYPOTHESES, V7, P1359, DOI 10.1016/0306-9877(81)90126-2; Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102; Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105; Chen Q, 2007, P NATL ACAD SCI USA, V104, P8749, DOI 10.1073/pnas.0702854104; CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303; DL VP, 2004, JPEN J PARENTER ENTE, V28, P435; Gaby Alan R, 2002, Altern Med Rev, V7, P389; Gonzalez Michael J, 2005, Integr Cancer Ther, V4, P32, DOI 10.1177/1534735404273861; Heaney ML, 2008, CANCER RES, V68, P8031, DOI 10.1158/0008-5472.CAN-08-1490; Hoffer LJ, 2008, ANN ONCOL, V19, P1969, DOI 10.1093/annonc/mdn377; IWAMOTO N, 1994, AM J HEMATOL, V47, P337, DOI 10.1002/ajh.2830470426; IWAMOTO N, 1994, LANCET, V343, P357, DOI 10.1016/S0140-6736(94)91195-9; Jungeblut CW, 1937, J EXP MED, V66, P459, DOI 10.1084/jem.66.4.459; Jungeblut CW, 1939, J EXP MED, V70, P315, DOI 10.1084/jem.70.3.315; Jungeblut CW, 1935, J EXP MED, V62, P517, DOI 10.1084/jem.62.4.517; KLENNER F R, 1949, South Med Surg, V111, P209; KLENNER F R, 1951, South Med Surg, V113, P101; KLENNER FR, 1971, J APPL NUTR, V23, P61; LAWTON JM, 1985, ARCH INTERN MED, V145, P950, DOI 10.1001/archinte.145.5.950; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; Levine M, 1999, JAMA-J AM MED ASSOC, V281, P1415, DOI 10.1001/jama.281.15.1415; Levine M, 2009, FREE RADICAL BIO MED, V47, P27, DOI 10.1016/j.freeradbiomed.2009.04.001; Levy T E, 2002, VITAMIN C INFECT DIS; MCALLISTER CJ, 1984, JAMA-J AM MED ASSOC, V252, P1684, DOI 10.1001/jama.1984.03350130016019; McCORMICK W J, 1954, Arch Pediatr, V71, P313; MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301; Padayatty SJ, 2006, NEW ENGL J MED, V355, P1065; Padayatty SJ, 2000, J AM COLL NUTR, V19, P423, DOI 10.1080/07315724.2000.10718941; Padayatty SJ, 2004, ANN INTERN MED, V140, P533, DOI 10.7326/0003-4819-140-7-200404060-00010; PATTERSON JW, 1951, AM J PHYSIOL, V165, P61, DOI 10.1152/ajplegacy.1951.165.1.61; PATTERSON JW, 1950, J BIOL CHEM, V183, P81; Pauling L., 1976, VITAMIN C COMMON COL; REES DC, 1993, BRIT MED J, V306, P841, DOI 10.1136/bmj.306.6881.841; Riordan HD, 1990, J ORTHOMOL MED, V5, P5; RIORDAN NH, 1995, MED HYPOTHESES, V44, P207, DOI 10.1016/0306-9877(95)90137-X; Riordan NH, 2000, J ORTHOMOL MED, V15, P201; Sabin AB, 1939, J EXP MED, V69, P507, DOI 10.1084/jem.69.4.507; Verrax J, 2009, FREE RADICAL BIO MED, V47, P32, DOI 10.1016/j.freeradbiomed.2009.02.016; WITTES RE, 1985, NEW ENGL J MED, V312, P178, DOI 10.1056/NEJM198501173120310; WONG K, 1994, AUST NZ J MED, V24, P410, DOI 10.1111/j.1445-5994.1994.tb01477.x; 2008, NUTR BUSINESS J	51	231	242	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2010	5	7							e11414	10.1371/journal.pone.0011414	http://dx.doi.org/10.1371/journal.pone.0011414			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	621OQ	21179458	Green Published, gold, Green Submitted			2023-01-03	WOS:000279589300002
J	Tang, YQ; Jaganath, IB; Sekaran, SD				Tang, Yin-Quan; Jaganath, Indu Bala; Sekaran, Shamala Devi			Phyllanthus spp. Induces Selective Growth Inhibition of PC-3 and MeWo Human Cancer Cells through Modulation of Cell Cycle and Induction of Apoptosis	PLOS ONE			English	Article							PROSTATE-CANCER; AMARUS; EXPRESSION; ACID; EXTRACT; PLANTS	Background: Phyllanthus is a traditional medicinal plant that has been used in the treatment of many diseases including hepatitis and diabetes. The main aim of the present work was to investigate the potential cytotoxic effects of aqueous and methanolic extracts of four Phyllanthus species (P. amarus, P. niruri, P. urinaria and P. watsonii) against skin melanoma and prostate cancer cells. Methodology/Principal Findings: Phyllanthus plant appears to possess cytotoxic properties with half-maximal inhibitory concentration (IC50) values of 150-300 mu g/ml for aqueous extract and 50-150 mu g/ml for methanolic extract that were determined using the MTS reduction assay. In comparison, the plant extracts did not show any significant cytotoxicity on normal human skin (CCD-1127Sk) and prostate (RWPE-1) cells. The extracts appeared to act by causing the formation of a clear "ladder'' fragmentation of apoptotic DNA on agarose gel, displayed TUNEL-positive cells with an elevation of caspase-3 and -7 activities. The Lactate Dehydrogenase (LDH) level was lower than 15% in Phyllanthus treated-cancer cells. These indicate that Phyllanthus extracts have the ability to induce apoptosis with minimal necrotic effects. Furthermore, cell cycle analysis revealed that Phyllanthus induced a Go/G1-phase arrest on PC-3 cells and a S-phase arrest on MeWo cells and these were accompanied by accumulation of cells in the Sub-G1 (apoptosis) phase. The cytotoxic properties may be due to the presence of polyphenol compounds such as ellagitannins, gallotannins, flavonoids and phenolic acids found both in the water and methanol extract of the plants. Conclusions/Significance: Phyllanthus plant exerts its growth inhibition effect in a selective manner towards cancer cells through the modulation of cell cycle and induction of apoptosis via caspases activation in melanoma and prostate cancer cells. Hence, Phyllanthus may be sourced for the development of a potent apoptosis-inducing anticancer agent.	[Tang, Yin-Quan; Sekaran, Shamala Devi] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia; [Jaganath, Indu Bala] MARDI, Ctr Biotechnol, Serdang, Malaysia	Universiti Malaya; Institute Penyelidikan Dan Kemajuan Pertanian	Tang, YQ (corresponding author), Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia.	shamalamy@yahoo.com	tang, yin/GXZ-6989-2022; Devi, Shamala Devi/B-9735-2010; Tang, Yin-Quan/J-5859-2013; Sekaran, Shamala Devi/B-8482-2008; Tang, Yin-Quan/K-5725-2017	Devi, Shamala Devi/0000-0002-0478-0425; Sekaran, Shamala Devi/0000-0002-0478-0425; Tang, Yin-Quan/0000-0001-7327-2830; Jaganath, Indu/0000-0002-3272-9598	University Malaya [UM PS183/2009B]; Malaysian Agricultural and Research Development Institute (MARDI) [53-02-03-1002]	University Malaya(Universiti Malaya); Malaysian Agricultural and Research Development Institute (MARDI)	This study was funded by the Postgraduate Research Grant, University Malaya (UM PS183/2009B)(www.um.edu.my) and Malaysian Agricultural and Research Development Institute (MARDI) (53-02-03-1002)(www.mardi.gov.my). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AM CANC SOC, 2009, CANC FACTS FIG 2009, P19; Asha VV, 2007, FITOTERAPIA, V78, P134, DOI 10.1016/j.fitote.2006.10.009; Baek SJ, 2004, CARCINOGENESIS, V25, P2425, DOI 10.1093/carcin/bgh255; BLUMBERG BS, 1990, VACCINE, V8, pS86, DOI 10.1016/0264-410X(90)90225-B; *CANC RES UK, 2010, SKIN CANC UK INC STA; Che XH, 2010, BASIC CLIN PHARMACOL, V106, P30, DOI 10.1111/j.1742-7843.2009.00465.x; Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011; CRAGG GM, 2007, BIOACTIVE NATURAL PR; Deichmann M, 1999, J CLIN ONCOL, V17, P1891, DOI 10.1200/JCO.1999.17.6.1891; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Faried A, 2007, INT J ONCOL, V30, P605; Guchelaar H J, 1992, Clin Oncol (R Coll Radiol), V4, P388, DOI 10.1016/S0936-6555(05)81134-3; Hastak K, 2005, FASEB J, V19, P789, DOI 10.1096/fj.04-2226fje; Huang ST, 2004, LIFE SCI, V75, P339, DOI 10.1016/j.lfs.2003.12.013; Jeena KJ, 1999, CANCER LETT, V136, P11, DOI 10.1016/S0304-3835(98)00294-8; Ji BC, 2009, J AGR FOOD CHEM, V57, P7596, DOI 10.1021/jf901308p; Jin UH, 2005, LIFE SCI, V77, P2760, DOI 10.1016/j.lfs.2005.02.028; Kasibhatla S, 2003, MOL CANCER THER, V2, P573; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim SJ, 2006, BIOCHEM BIOPH RES CO, V339, P463, DOI 10.1016/j.bbrc.2005.11.040; Kloucek P, 2005, J ETHNOPHARMACOL, V99, P309, DOI 10.1016/j.jep.2005.01.062; Lansky EP, 2005, INVEST NEW DRUG, V23, P11, DOI 10.1023/B:DRUG.0000047101.02178.07; Lee CD, 1996, EUR J CLIN INVEST, V26, P1069, DOI 10.1046/j.1365-2362.1996.410595.x; Madson JG, 2009, AM J PATHOL, V174, P2357, DOI 10.2353/ajpath.2009.080638; Maecker HL, 2000, CANCER RES, V60, P4638; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailloux A, 2001, EUR J CELL BIOL, V80, P442, DOI 10.1078/0171-9335-00171; Mazumder A, 2006, NAT PROD RES, V20, P323, DOI 10.1080/14786410600650404; Mazunder UK, 2005, EURO B DRUG RES, V13, P15; Molinari M, 2000, EMBO REP, V1, P71, DOI 10.1093/embo-reports/kvd018; Ott M, 1997, EUR J CLIN INVEST, V27, P908, DOI 10.1046/j.1365-2362.1997.2020749.x; Prakash A, 1995, PHYTOTHER RES, V9, P594, DOI 10.1002/ptr.2650090813; Puri N, 2004, FASEB J, V18, P1373, DOI 10.1096/fj.04-1774com; Rajeshkumar NV, 2000, J ETHNOPHARMACOL, V73, P215, DOI 10.1016/S0378-8741(00)00311-1; Rajeshkumar NV, 2002, J ETHNOPHARMACOL, V81, P17, DOI 10.1016/S0378-8741(01)00419-6; RAPHAEL KR, 2002, J EXP BIOL, V40, P905; Ren WY, 2003, MED RES REV, V23, P519, DOI 10.1002/med.10033; Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594; Shoeb M., 2006, BANGL J PHARMACOL, V1, P35, DOI [10.3329/bjp.v1i2.486, DOI 10.3329/BJP.V1I2.486]; Soini Y, 1998, AM J PATHOL, V153, P1041, DOI 10.1016/S0002-9440(10)65649-0; Sun J, 2006, CANCER LETT, V241, P124, DOI 10.1016/j.canlet.2005.10.027; VARMA A, 2009, ECAM IN PRESS; VENKATESWARAN PS, 1997, P NATL ACAD SCI USA, V84, P274; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zhou MX, 2002, J PHARMACOL EXP THER, V303, P124, DOI 10.1124/jpet.102.037192; Zhou S, 1997, Zhongguo Zhong Yao Za Zhi, V22, P109	47	105	108	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2010	5	9							e12644	10.1371/journal.pone.0012644	http://dx.doi.org/10.1371/journal.pone.0012644			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	648IV	20838625	Green Published, gold, Green Submitted			2023-01-03	WOS:000281687100013
